# ==============================================================================
# List of protein-ligand complexes with known binding data in PDBbind v.2020
# 19443 protein-ligand complexes in total, sorted by their release year.
# Latest update: July 2021
# PDB code, resolution, release year, binding data, reference, ligand name
# ==============================================================================
2tpi  2.10  1982  Kd=49uM       // 2tpi.pdf (2-mer)
5tln  2.30  1982  Ki=0.43uM     // 5tln.pdf (BAN) incomplete ligand structure
4tln  2.30  1982  Ki=190uM      // 4tln.pdf (LNO)
4cts  2.90  1984  Kd<10uM       // 4cts.pdf (OAA)
6rsa   NMR  1986  Ki=40uM       // 6rsa.pdf (UVC)
1rnt  1.90  1987  Kd=6.5uM      // 1rnt.pdf (2GP)
6cha  1.80  1987  Ki=40uM       // 6cha.pdf (PBA) covalent complex
4ts1  2.50  1989  Kd=11.6uM     // 4ts1.pdf (TYR)
4tmn  1.70  1989  Ki=0.068nM    // 4tmn.pdf (0PK)
2tmn  1.60  1989  Ki=1.3uM      // 2tmn.pdf (0FA)
1tlp  2.30  1989  Ki=28nM       // 1tlp.pdf (RDF)
1tmn  1.90  1989  Ki=50nM       // 1tmn.pdf (0ZN)
5tmn  1.60  1989  Ki=9.1nM      // 5tmn.pdf (0PJ)
4fab  2.70  1990  Kd=8.8nM      // 4fab.pdf (FLU)
1p01  2.00  1990  Ki=0.35nM     // 1p01.pdf (0EG) covalent complex
3at1  2.80  1990  Ki=0.66mM     // 3at1.pdf (PCT)
1p05  2.10  1990  Ki=1100nM     // 1p05.pdf (5-mer) incomplete ligand structure
1p10  2.25  1990  Ki=200nM      // 1p10.pdf (5-mer) incomplete ligand structure
6gch  2.10  1990  Ki=20uM       // 6gch.pdf (APF) covalent complex
7gch  1.80  1990  Ki=2uM        // 7gch.pdf (LPF) covalent complex
1p04  2.55  1990  Ki=40nM       // 1p04.pdf (5-mer) incomplete ligand structure
1p06  2.34  1990  Ki=540nM      // 1p06.pdf (5-mer) incomplete ligand structure
1p03  2.15  1990  Ki=6.4nM      // 1p03.pdf (5-mer) incomplete ligand structure
1p02  2.00  1990  Ki=67nM       // 1p02.pdf (5-mer) incomplete ligand structure
8abp  1.49  1991  Kd=0.010uM    // 8abp.pdf (GLA/GLB) isomer
1rbp  2.00  1991  Kd=0.19uM     // 1rbp.pdf (RTL)
7abp  1.67  1991  Kd=0.35uM     // 7abp.pdf (FCA/FCB) isomer
6abp  1.67  1991  Kd=0.44uM     // 6abp.pdf (ARA/ARB) isomer
1fkf  1.70  1991  Kd=0.4nM      // 1fkf.pdf (FK5)
9icd  2.50  1991  Kd=125uM      // 9icd.pdf (NAP)
6apr  2.50  1991  Ki<=17nM      // 6apr.pdf (6-mer)
4er1  2.00  1991  Ki=0.242uM    // 4er1.pdf (0ZP)
5er2  1.80  1991  Ki=0.27uM     // 5er2.pdf (0EK)
4er2  2.00  1991  Ki=0.5nM      // 4er2.pdf (6-mer)
2ypi  2.50  1991  Ki=15uM       // 2ypi.pdf (PGA)
4er4  2.10  1991  Ki=160nM      // 4er4.pdf (10-mer) incomplete ligand
5apr  2.10  1991  Ki=17nM       // 5apr.pdf (9-mer) incomplete ligand structure
3er5  1.80  1991  Ki=1nM        // 3er5.pdf (10-mer)
4apr  2.50  1991  Ki=200nM      // 4apr.pdf (8-mer) incomplete ligand structure
5hvp  2.00  1991  Ki=20nM       // 5hvp.pdf (6-mer)
6cpa  2.00  1991  Ki=3pM        // 6cpa.pdf (ZAF)
2er9  2.20  1991  Ki=40nM       // 2er9.pdf (8-mer) incomplete ligand
2er0  3.00  1991  Ki=420nM      // 2er0.pdf (8-mer)
4sga  1.80  1991  Ki=50nM       // 4sga.pdf (5-mer)
2er6  2.00  1991  Ki=60nM       // 2er6.pdf (7-mer) redundant to 1gvx
3er3  2.00  1991  Ki=81nM       // 3er3.pdf (0EL) incomplete ligand structure
5er1  2.00  1991  Ki=960nM      // 5er1.pdf (0HT)
9abp  1.97  1992  Kd=0.01uM     // 9abp.pdf (GLA/GLB) isomer
1bap  1.75  1992  Kd=0.14uM     // 1bap.pdf (ARA/ARB) isomer
5abp  1.80  1992  Kd=0.23uM     // 5abp.pdf (GLA/GLB) isomer
8gpb  2.20  1992  Kd=0.25mM     // 8gpb.pdf (AMP) Kd=0.25-0.7mM
1apb  1.76  1992  Kd=1.51uM     // 1apb.pdf (FCA/FCB) isomer
7gpb  2.90  1992  Kd=3uM        // 7gpb.pdf (AMP)
1stp  2.60  1992  Kd=40fM       // 1stp.pdf (BTN)
5est  2.09  1992  Ki=0.3uM      // 5est.pdf (0P2) covalent complex
6tim  2.20  1992  Ki=0.61mM     // 6tim.pdf (G3P)
6gpb  2.86  1992  Ki=14uM       // 6gpb.pdf (H2P)
9hvp  2.80  1992  Ki=4.5nM      // 9hvp.pdf (0E9)
4tim  2.40  1992  Ki=6.9mM      // 4tim.pdf (2PG)
4est  1.78  1992  Ki=9.5uM      // 4est.pdf (5-mer) covalent complex
2mip  2.20  1993  IC50<=3.5nM   // 2mip.pdf (7-mer)
4phv  2.10  1993  IC50=0.67nM   // 4phv.pdf (VAC)
1rne  2.40  1993  IC50=2nM      // 1rne.pdf (C60)
1ind  2.20  1993  Kd=0.09nM     // 1ind.pdf (EOT) Kd for In-EOT
1igj  2.50  1993  Kd=0.1nM      // 1igj.pdf (DGX)
1fkb  1.70  1993  Kd=0.2nM      // 1fkb.pdf (RAP)
1gca  1.70  1993  Kd=0.2uM      // 1gca.pdf (GAL)
1l83  1.70  1993  Kd=0.40mM     // 1l83.pdf (BNZ)
2avi  3.00  1993  Kd=0.6fM      // 2avi.pdf (BTN)
1rin  2.60  1993  Kd=0.7mM      // 1rin.pdf (MAN)
1dmb  1.80  1993  Kd=1.80uM     // 1dmb.pdf (BCD)
1atr  2.34  1993  Kd=110nM      // 1atr.pdf (ADP) Kd by filter binding assay
1dbb  2.70  1993  Kd=1nM        // 1dbb.pdf (STR)
1pop  2.10  1993  Kd=1nM        // 1pop.pdf (4-mer) covalent complex
1gpy  2.40  1993  Kd=20uM       // 1gpy.pdf (G6P) Kd=20-30uM
1abf  1.90  1993  Kd=3.8uM      // 1abf.pdf (FCA/FCB) isomer
1rgl  2.00  1993  Kd=37uM       // 1rgl.pdf (2GP)
6rnt  1.80  1993  Kd=4.3mM      // 6rnt.pdf (2AM)
1rgk  1.87  1993  Kd=49.1uM     // 1rgk.pdf (2AM)
1hiv  2.00  1993  Ki<1.0nM      // 1hiv.pdf (1ZK)
1pip  1.70  1993  Ki<10uM       // 1pip.pdf (7-mer)
8hvp  2.50  1993  Ki<1nM        // 8hvp.pdf (7-mer)
3gst  1.90  1993  Ki=0.19uM     // 3gst.pdf (GPR)
1cps  2.25  1993  Ki=0.22uM     // 1cps.pdf (CPM)
7hvp  2.40  1993  Ki=0.24nM     // 7hvp.pdf (6-mer)
2gst  1.80  1993  Ki=0.85uM     // 2gst.pdf (GPS)
2lpr  2.25  1993  Ki=1.3nM      // 2lpr.pdf (5-mer) incomplete ligand structure; covalent complex
3lpr  2.15  1993  Ki=1100nM     // 3lpr.pdf (5-mer) incomplete ligand structure; covalent complex
1ppm  1.70  1993  Ki=1600nM     // 1ppm.pdf (0P1)
1hos  2.30  1993  Ki=2.8nM      // 1hos.pdf (PHP)
1ppl  1.70  1993  Ki=2.8nM      // 1ppl.pdf (1Z7)
9lpr  2.20  1993  Ki=2000nM     // 9lpr.pdf (5-mer) incomplete ligand structure; covalent complex
8lpr  2.25  1993  Ki=240nM      // 8lpr.pdf (5-mer) incomplete ligand structure; covalent complex
5lpr  2.13  1993  Ki=270nM      // 5lpr.pdf (5-mer) incomplete ligand structure; covalent complex
1bcd  1.90  1993  Ki=2nM        // 1bcd.pdf (FMS)
1ivp  2.50  1993  Ki=30nM       // 1ivp.pdf (1ZK)
1trd  2.50  1993  Ki=4uM        // 1trd.pdf (PGH)
6lpr  2.10  1993  Ki=50nM       // 6lpr.pdf (5-mer) incomplete ligand structure; covalent complex
7lpr  2.05  1993  Ki=66nM       // 7lpr.pdf (5-mer) incomplete ligand structure; covalent complex
1mns  2.00  1993  Ki=67uM       // 1mns.pdf (APG) covalent complex
1ths  2.20  1994  IC50=0.029uM  // 1ths.pdf (11-mer)
1htf  2.20  1994  IC50=148nM    // 1htf.pdf (G26)
2hmb  2.10  1994  IC50=2.6uM    // 2hmb.pdf (PLM) ligand is PALMITIC ACID
1him  2.90  1994  IC50=20nM     // 1him.pdf (10-mer) incomplete ligand
1dbj  2.70  1994  IC50=21nM     // 1dbj.pdf (AE2)
1hte  2.80  1994  IC50=2265nM   // 1hte.pdf (G23)
2dbl  2.90  1994  IC50=2nM      // 2dbl.pdf (S5H)
1htg  2.00  1994  IC50=3.8nM    // 1htg.pdf (G37)
1thr  2.30  1994  IC50=4.2uM    // 1thr.pdf (13-mer) X-ray(human thrombin); IC50=4.2uM(bovine thrombin)
1acj  2.80  1994  IC50=8.2nM    // 1acj.pdf (THA) ligand is compound tacrine
1dbk  3.00  1994  IC50=8nM      // 1dbk.pdf (ANO)
1hsl  1.89  1994  Kd=0.064uM    // 1hsl.pdf (HIS)
2drc  1.90  1994  Kd=0.13nM     // 2drc.pdf (MTX)
1sre  1.78  1994  Kd=0.14mM     // 1sre.pdf (HAB)
1sri  1.65  1994  Kd=0.83uM     // 1sri.pdf (DMB)
1tka  2.70  1994  Kd=0.8uM      // 1tka.pdf (N3T)
1abt   NMR  1994  Kd=1.4uM      // 1abt.pdf (12-mer) incomplete ligand
1lst  1.80  1994  Kd=14nM       // 1lst.pdf (LYS)
1tkc  2.70  1994  Kd=14uM       // 1tkc.pdf (M6T)
1avd  2.70  1994  Kd=1fM        // 1avd.pdf (BTN)
1ctr  2.45  1994  Kd=1uM        // 1ctr.pdf (TFP) Kd in 1-8uM range for the CaM-TFP complex with two, four, and seven TFP molecules bound to CaM
1hgi  2.70  1994  Kd=2.1mM      // 1hgi.pdf (ANA)
1hgj  2.70  1994  Kd=22mM       // 1hgj.pdf (AMN)
1dhj  1.80  1994  Kd=281nM      // 1dhj.pdf (MTX)
1tys  1.80  1994  Kd=3.27uM     // 1tys.pdf (TMP)
1sps  2.70  1994  Kd=3nM        // 1sps.pdf (11-mer) incomplete ligand structure
1pyg  2.87  1994  Kd=3uM        // 1pyg.pdf (AMP)
1adl  1.60  1994  Kd=4.4uM      // 1adl.pdf (ACD)
1mfd  2.10  1994  Kd=4.9uM      // 1mfd.pdf (3-mer)
1hge  2.60  1994  Kd=5.4mM      // 1hge.pdf (MNA)
2cgr  2.20  1994  Kd=53nM       // 2cgr.pdf (GAS)
1dhi  1.90  1994  Kd=55nM       // 1dhi.pdf (MTX)
1srg  1.80  1994  Kd=5uM        // 1srg.pdf (MHB)
1erb  1.90  1994  Kd=8nM        // 1erb.pdf (ETR) Kd=93nM in phosphate buffer; Kd=8nM in crystallization buffer
1mfa  1.70  1994  Kd=9.1uM      // 1mfa.pdf (3-mer)
1tni  1.90  1994  Ki=0.10mM     // 1tni.pdf (PBN)
2ctc  1.40  1994  Ki=0.13mM     // 2ctc.pdf (HFA)
1add  2.40  1994  Ki=0.18uM     // 1add.pdf (1DA)
1tmb  2.30  1994  Ki=0.18uM     // 1tmb.pdf (5-mer)
1elc  1.75  1994  Ki=0.22uM     // 1elc.pdf (0Z3)
1wht  2.00  1994  Ki=0.2mM      // 1wht.pdf (BZS)
1tsi  2.84  1994  Ki=0.33mM     // 1tsi.pdf (4PB)
1cil  1.60  1994  Ki=0.37nM     // 1cil.pdf (ETS)
2sim  1.60  1994  Ki=0.38mM     // 2sim.pdf (DAN)
1thl  1.70  1994  Ki=0.38uM     // 1thl.pdf (0DB)
1tnh  1.80  1994  Ki=0.43mM     // 1tnh.pdf (FBA)
1ela  2.00  1994  Ki=0.44uM     // 1ela.pdf (0Z1)
1cbx  2.00  1994  Ki=0.45uM     // 1cbx.pdf (BZS)
1inc  1.94  1994  Ki=0.46nM     // 1inc.pdf (ICL) covalent complex
1ppc  1.80  1994  Ki=0.69uM     // 1ppc.pdf (MID)
1hps  2.30  1994  Ki=0.6nM      // 1hps.pdf (RUN)
1fig  3.00  1994  Ki=0.6uM      // 1fig.pdf (TSA)
1tet  2.30  1994  Ki=0.83uM     // 1tet.pdf (15-mer) incomplete ligand structure
1azm  2.00  1994  Ki=0.8uM      // 1azm.pdf (AZM) ligand is compound 2
1rpa  3.00  1994  Ki=1.0uM      // 1rpa.pdf (TAR)
1tng  1.80  1994  Ki=1.17mM     // 1tng.pdf (AMC)
1pph  1.90  1994  Ki=1.2uM      // 1pph.pdf (0ZG)
1ett  2.50  1994  Ki=1.3uM      // 1ett.pdf (4QQ) X-ray(epsilon-thrombin); Ki(alpha-thrombin)
1cim  2.10  1994  Ki=1.52nM     // 1cim.pdf (PTS)
1csi  1.70  1994  Ki=1.6nM      // 1csi.pdf (CMX)
1cin  2.10  1994  Ki=1.88nM     // 1cin.pdf (MTS)
1fki  2.20  1994  Ki=100nM      // 1fki.pdf (SB1)
1rpf  2.20  1994  Ki=103uM      // 1rpf.pdf (C3P) ligand is compound 3'-CMP
1gbt  2.00  1994  Ki=10mM       // 1gbt.pdf (GBS)
1apw  1.80  1994  Ki=10nM       // 1apw.pdf (5-mer)
1fkg  2.00  1994  Ki=10nM       // 1fkg.pdf (SB3)
1tkb  2.30  1994  Ki=10nM       // 1tkb.pdf (N1T)
1nnb  2.80  1994  Ki=10uM       // 1nnb.pdf (DAN)
1tnj  1.80  1994  Ki=11.0mM     // 1tnj.pdf (PEA)
1ent  1.90  1994  Ki=110nM      // 1ent.pdf (0EM) redundant to 1gvw
1hvl  1.80  1994  Ki=112pM      // 1hvl.pdf (A76) Ki=112pM (cryst, pH=6.2); Ki=1000pM (soln, pH=4.7)
7cpa  2.00  1994  Ki=11fM       // 7cpa.pdf (FVF)
1epo  2.00  1994  Ki=11nM       // 1epo.pdf (2Z3)
1hvk  1.80  1994  Ki=11pM       // 1hvk.pdf (A79) Ki=11pM (cryst, pH=6.2); Ki=77pM (soln, pH=4.7)
1hvi  1.80  1994  Ki=12pM       // 1hvi.pdf (A77) Ki=12pM (cryst, pH=6.2); Ki=84pM (soln, pH=4.7)
1tnl  1.90  1994  Ki=13.3mM     // 1tnl.pdf (TPA)
1bra  2.20  1994  Ki=15000uM    // 1bra.pdf (BEN)
1hgt  2.20  1994  Ki=150nM      // 1hgt.pdf (12-mer) incomplete ligand structure
1els  2.40  1994  Ki=15pM       // 1els.pdf (PAH) redundant to 1ebg
1eed  2.00  1994  Ki=16.2uM     // 1eed.pdf (0EO) incomplete ligand structure
1heg  2.20  1994  Ki=18nM       // 1heg.pdf (PSI)
1sbg  2.30  1994  Ki=18nM       // 1sbg.pdf (IM1)
1apv  1.80  1994  Ki=1nM        // 1apv.pdf (5-mer)
1hef  2.20  1994  Ki=1nM        // 1hef.pdf (5-mer)
1agm  2.30  1994  Ki=1pM        // 1agm.pdf (ACR)
1ppk  1.80  1994  Ki=22nM       // 1ppk.pdf (IVV)
1csh  1.65  1994  Ki=28nM       // 1csh.pdf (AMX)
1iht  2.10  1994  Ki=3.5nM      // 1iht.pdf (14-mer) incomplete ligand
1lyb  2.50  1994  Ki=3.8pM      // 1lyb.pdf (6-mer)
1tnk  1.80  1994  Ki=32.5mM     // 1tnk.pdf (PRA)
1dwc  3.00  1994  Ki=39nM       // 1dwc.pdf (MIT)
2cht  2.20  1994  Ki=3uM        // 2cht.pdf (BAR)
1aaq  2.50  1994  Ki=4.0nM      // 1aaq.pdf (PSI)
1hvj  2.00  1994  Ki=4pM        // 1hvj.pdf (A78) Ki=4pM (cryst, pH=6.2); Ki=35pM (soln, pH=4.7)
1epq  1.90  1994  Ki=6.5nM      // 1epq.pdf (0QF) incomplete ligand structure
1dwd  3.00  1994  Ki=6.6nM      // 1dwd.pdf (MID)
1epp  1.90  1994  Ki=69nM       // 1epp.pdf (1Z1) incomplete ligand structure
1ets  2.30  1994  Ki=6nM        // 1ets.pdf (MID) X-ray(epsilon-thrombin) while Ki(alpha-thrombin)
1elb  2.10  1994  Ki=70nM       // 1elb.pdf (0Z4)
8cpa  2.00  1994  Ki=710pM      // 8cpa.pdf (AGF)
1fkh  1.95  1994  Ki=7nM        // 1fkh.pdf (SBX)
1siv  2.50  1994  Ki=8.4nM      // 1siv.pdf (PSI)
1ida  1.70  1995  IC50<=2.0nM   // 1ida.pdf (0PO)
1mnc  2.10  1995  IC50=0.046nM  // 1mnc.pdf (PLH) ligand is compound 2a
1fta  2.30  1995  IC50=0.44uM   // 1fta.pdf (AMP)
1shd  2.00  1995  IC50=0.67uM   // 1shd.pdf (5-mer)
1tps  1.90  1995  IC50=10nM     // 1tps.pdf (8-mer)
1idb  2.20  1995  IC50=11nM     // 1idb.pdf (0DO)
1hrn  1.80  1995  IC50=9nM      // 1hrn.pdf (03D)
1gsf  2.70  1995  IC50~10uM     // 1gsf.pdf (EAA)
1drj  2.50  1995  Kd=0.040uM    // 1drj.pdf (RIP)
2dri  1.60  1995  Kd=0.13uM     // 2dri.pdf (RIP)
1drk  2.00  1995  Kd=0.15uM     // 1drk.pdf (RIP)
1flr  1.85  1995  Kd=0.1nM      // 1flr.pdf (FLU)
1tyr  1.80  1995  Kd=0.1uM      // 1tyr.pdf (REA)
1hmr  1.40  1995  Kd=0.28uM     // 1hmr.pdf (ELA)
1hms  1.40  1995  Kd=0.43uM     // 1hms.pdf (OLA)
1cbr  2.90  1995  Kd=0.4nM      // 1cbr.pdf (REA) ligand is (all-E)-RA
1hmt  1.40  1995  Kd=1.64uM     // 1hmt.pdf (STE)
1cka  1.50  1995  Kd=1.9uM      // 1cka.pdf (10-mer) incomplete ligand structure
1utr   NMR  1995  Kd=10nM       // 1utr.pdf (PCB)
1ahx  2.00  1995  Kd=120uM      // 1ahx.pdf (HCI)
1cny  2.30  1995  Kd=14nM       // 1cny.pdf (EG3)
1laf  2.06  1995  Kd=14nM       // 1laf.pdf (ARG)
186l  1.80  1995  Kd=14uM       // 186l.pdf (N4B) ligand is compound 38
1cnw  2.00  1995  Kd=19nM       // 1cnw.pdf (EG1)
184l  1.80  1995  Kd=19uM       // 184l.pdf (I4B) ligand is compound 39
1lcj  1.80  1995  Kd=1nM        // 1lcj.pdf (11-mer)
1yda  2.10  1995  Kd=280nM      // 1yda.pdf (AZM)
185l  1.80  1995  Kd=290uM      // 185l.pdf (IND) ligand is compound 15
1pgp  2.50  1995  Kd=2uM        // 1pgp.pdf (6PG)
1lah  2.06  1995  Kd=30nM       // 1lah.pdf (ORN)
187l  1.80  1995  Kd=422uM      // 187l.pdf (PXY) ligand is compound 18
1cnx  1.90  1995  Kd=43nM       // 1cnx.pdf (EG2)
1ahy  2.30  1995  Kd=440uM      // 1ahy.pdf (MAE)
188l  1.80  1995  Kd=470uM      // 188l.pdf (OXE) ligand is compound 4
1ckb  1.90  1995  Kd=5.2uM      // 1ckb.pdf (10-mer) incomplete ligand structure
1ydb  1.90  1995  Kd=5.8nM      // 1ydb.pdf (AZM)
1lag  2.06  1995  Kd=500nM      // 1lag.pdf (HIS)
1prl   NMR  1995  Kd=59uM       // 1prl.pdf (9-mer)
1prm   NMR  1995  Kd=59uM       // 1prm.pdf (9-mer) redundant to 1prl
1rlp   NMR  1995  Kd=8.0uM      // 1rlp.pdf (9-mer)
1rlq   NMR  1995  Kd=8.0uM      // 1rlq.pdf (9-mer) redundant to 1rlp
1ydd  2.10  1995  Kd=86nM       // 1ydd.pdf (AZM)
1dis   NMR  1995  Ki<0.01nM     // 1dis.pdf (BDM)
2gyi  1.60  1995  Ki<=100nM     // 2gyi.pdf (HYA)
1cgl  2.40  1995  Ki=0.135uM    // 1cgl.pdf (0ED)
1ele  2.00  1995  Ki=0.14uM     // 1ele.pdf (0QN)
2ada  2.40  1995  Ki=0.1pM      // 2ada.pdf (HPR)
1fpc  2.30  1995  Ki=0.1uM      // 1fpc.pdf (0ZI)
1eld  2.00  1995  Ki=0.20uM     // 1eld.pdf (0Z0)
1lcp  1.65  1995  Ki=0.23uM     // 1lcp.pdf (PLU)
2srt   NMR  1995  Ki=0.23uM     // 2srt.pdf (INH)
1pdz  2.20  1995  Ki=0.2mM      // 1pdz.pdf (PGA)
1tyn  2.00  1995  Ki=0.2nM      // 1tyn.pdf (CTA) covalent complex
1hvr  1.80  1995  Ki=0.31nM     // 1hvr.pdf (XK2) IC50=0.22uM
1atl  1.80  1995  Ki=0.52uM     // 1atl.pdf (SLE-TYR)
1tpw  1.90  1995  Ki=0.5mM      // 1tpw.pdf (PGH)
1hpv  1.90  1995  Ki=0.60nM     // 1hpv.pdf (478)
1css  1.70  1995  Ki=0.8uM      // 1css.pdf (FCX)
1ctu  2.30  1995  Ki=1.2pM      // 1ctu.pdf (ZEB)
1gar  1.96  1995  Ki=100pM      // 1gar.pdf (U89)
1eat  2.00  1995  Ki=15nM       // 1eat.pdf (TFI) covalent complex
1ebg  2.10  1995  Ki=15pM       // 1ebg.pdf (PAH) redundant to 2ptz
1hdt  2.60  1995  Ki=17.2nM     // 1hdt.pdf (0E7)
1bty  1.50  1995  Ki=18.4uM     // 1bty.pdf (BEN) ligand is TPB7
1eas  1.80  1995  Ki=18nM       // 1eas.pdf (TFK) covalent complex
1ibg  2.70  1995  Ki=2.8nM      // 1ibg.pdf (OBN)
1fiv  2.00  1995  Ki=260nM      // 1fiv.pdf (5-mer)
1bma  1.80  1995  Ki=26uM       // 1bma.pdf (0QH)
1ctt  2.20  1995  Ki=30uM       // 1ctt.pdf (DHZ)
1csr  1.70  1995  Ki=42nM       // 1csr.pdf (FAM)
1hbv  2.30  1995  Ki=430nM      // 1hbv.pdf (GAN)
1std  2.90  1995  Ki=47pM       // 1std.pdf (BFS) ligand is compound 2
1qca  2.20  1995  Ki=5.4uM      // 1qca.pdf (FUA)
1hvs  2.25  1995  Ki=50pM       // 1hvs.pdf (A77)
1hii  2.30  1995  Ki=53nM       // 1hii.pdf (C20)
1lan  1.90  1995  Ki=60nM       // 1lan.pdf (LEU)
1hti  2.80  1995  Ki=7.4uM      // 1hti.pdf (PGA)
1ppi  2.20  1995  Ki=9.7uM      // 1ppi.pdf (4-mer)
1hih  2.20  1995  Ki=9nM        // 1hih.pdf (C20)
1vrt  2.20  1996  IC50=0.08uM   // 1vrt.pdf (NVP)
1vru  2.40  1996  IC50=0.1uM    // 1vru.pdf (AAP)
1rth  2.20  1996  IC50=0.4uM    // 1rth.pdf (U05)
1bil  2.40  1996  IC50=0.5nM    // 1bil.pdf (0IU)
1pig  2.20  1996  IC50=0.7nM    // 1pig.pdf (8-mer) incomplete ligand structure
1bim  2.80  1996  IC50=1.2nM    // 1bim.pdf (0QB)
1fpi  2.30  1996  IC50=1.3uM    // 1fpi.pdf (AMP) ligand is AMP
1inf  2.40  1996  IC50=10uM     // 1inf.pdf (ST4)
1cwc  1.86  1996  IC50=16.0nM   // 1cwc.pdf (11-mer)
1rti  3.00  1996  IC50=17uM     // 1rti.pdf (HEF)
1gym  2.20  1996  IC50=2mM      // 1gym.pdf (MYG)
1cpi  2.05  1996  IC50=39nM     // 1cpi.pdf (5-mer)
1mik  1.76  1996  IC50=450nM    // 1mik.pdf (11-mer)
1inh  2.40  1996  IC50=5mM      // 1inh.pdf (ST6) compound 111
1ing  2.40  1996  IC50>10mM     // 1ing.pdf (ST5)
1qwf   NMR  1996  Kd=0.45uM     // 1qwf.pdf (12-mer)
1nja  2.50  1996  Kd=0.49uM     // 1nja.pdf (DCM)
1qwe   NMR  1996  Kd=1.2uM      // 1qwe.pdf (12-mer)
1njb  2.74  1996  Kd=1.6uM      // 1njb.pdf (UMP)
1gaf  1.95  1996  Kd=10nM       // 1gaf.pdf (NPE)
1sts  1.95  1996  Kd=10uM       // 1sts.pdf (7-mer) Kd for monomer; incomplete ligand
1tsy  2.20  1996  Kd=11.0uM     // 1tsy.pdf (UMP)
1cea  2.06  1996  Kd=11uM       // 1cea.pdf (ACA)
1dar  2.40  1996  Kd=11uM       // 1dar.pdf (GDP)
1slg  1.76  1996  Kd=125uM      // 1slg.pdf (7-mer) incomplete ligand
1lkk  1.00  1996  Kd=140nM      // 1lkk.pdf (4-mer)
1lkl  1.80  1996  Kd=1540nM     // 1lkl.pdf (4-mer)
1tsv  2.90  1996  Kd=16.0uM     // 1tsv.pdf (UMP)
1nje  2.30  1996  Kd=160uM      // 1nje.pdf (DCM)
1str  1.80  1996  Kd=17uM       // 1str.pdf (6-mer) Kd for monomer
1ceb  2.07  1996  Kd=1uM        // 1ceb.pdf (AMH)
1njd  2.20  1996  Kd=2.7uM      // 1njd.pdf (UMP)
1njc  2.50  1996  Kd=2.8uM      // 1njc.pdf (DCM)
1mai  1.90  1996  Kd=210nM      // 1mai.pdf (I3P)
1zsb  2.00  1996  Kd=250mM      // 1zsb.pdf (AZM)
1sld  2.50  1996  Kd=270nM      // 1sld.pdf (6-mer)
2olb  1.40  1996  Kd=2900nM     // 2olb.pdf (3-mer)
1pot  1.80  1996  Kd=3.2uM      // 1pot.pdf (SPD)
1btn  2.00  1996  Kd=40uM       // 1btn.pdf (I3P) Kd measured on GPIns(4, 5)P2
1det  1.80  1996  Kd=50uM       // 1det.pdf (2GP)
1kel  1.90  1996  Kd=52nM       // 1kel.pdf (AAH)
1sle  2.00  1996  Kd=670nM      // 1sle.pdf (8-mer)
1swi  2.60  1996  Kd=800uM      // 1swi.pdf (BNZ)
1cyn  1.85  1996  Ki<21nM       // 1cyn.pdf (11-mer)
1mmq  1.90  1996  Ki=0.03uM     // 1mmq.pdf (RRS)
2upj  3.00  1996  Ki=0.041uM    // 2upj.pdf (U02)
1lhc  1.95  1996  Ki=0.04nM     // 1lhc.pdf (DP7) covalent complex
2csm  2.80  1996  Ki=0.05mM     // 2csm.pdf (TYR)
1grp  2.50  1996  Ki=0.189mM    // 1grp.pdf (ICT)
1fmb  1.80  1996  Ki=0.1nM      // 1fmb.pdf (HYB) X-ray(EIAV I54G)while Ki(EIAV wild type)
1sln  2.27  1996  Ki=0.23uM     // 1sln.pdf (INH)
1lhd  2.35  1996  Ki=0.24nM     // 1lhd.pdf (DI2) covalent complex
1lhe  2.25  1996  Ki=0.29nM     // 1lhe.pdf (DI3) covalent complex
1hsg  2.00  1996  Ki=0.38nM     // 1hsg.pdf (MK1) redundant to 1hsh but in lower resoluation
1hsh  1.90  1996  Ki=0.38nM     // 1hsh.pdf (MK1)
1igb  2.30  1996  Ki=0.4uM      // 1igb.pdf (IPO)
1jrs  1.80  1996  Ki=0.4uM      // 1jrs.pdf (3-mer) covalent complex
1aht  1.60  1996  Ki=0.62uM     // 1aht.pdf (APA) covalent complex
1mmp  2.30  1996  Ki=0.85uM     // 1mmp.pdf (RSS)
1pbk  2.50  1996  Ki=0.9nM      // 1pbk.pdf (RAP)
1jao  2.40  1996  Ki=1.2uM      // 1jao.pdf (0D3)
1gai  1.70  1996  Ki=10nM       // 1gai.pdf (GAC)
1tcx  2.30  1996  Ki=112nM      // 1tcx.pdf (IM1)
1cwb  2.20  1996  Ki=13nM       // 1cwb.pdf (11-mer)
1rdn  1.80  1996  Ki=14.4mM     // 1rdn.pdf (MAG)
1amn  2.80  1996  Ki=15fM       // 1amn.pdf (NAF) covalent complex
1dud  2.30  1996  Ki=15uM       // 1dud.pdf (DUD)
1gah  2.00  1996  Ki=1pM        // 1gah.pdf (ACR)
1gno  2.30  1996  Ki=20nM       // 1gno.pdf (U0E)
1rdj  1.80  1996  Ki=21.7mM     // 1rdj.pdf (MFB)
1gnn  2.30  1996  Ki=2100nM     // 1gnn.pdf (U0E)
1dif  1.70  1996  Ki=22pM       // 1dif.pdf (A85)
1bmn  2.80  1996  Ki=3.6nM      // 1bmn.pdf (BM9)
1rev  2.60  1996  Ki=33nM       // 1rev.pdf (TB9)
1jaq  2.40  1996  Ki=33uM       // 1jaq.pdf (01S)
2csn  2.50  1996  Ki=39uM       // 2csn.pdf (CKI)
1mmr  2.40  1996  Ki=4.0uM      // 1mmr.pdf (SRS)
1mtr  1.75  1996  Ki=4nM        // 1mtr.pdf (PI6)
1hpx  2.00  1996  Ki=5.5pM      // 1hpx.pdf (KNI)
1rdl  1.70  1996  Ki=5.7mM      // 1rdl.pdf (MMA)
1gnm  2.30  1996  Ki=560nM      // 1gnm.pdf (U0E)
1pro  1.80  1996  Ki=5pM        // 1pro.pdf (A88)
1noi  2.50  1996  Ki=700uM      // 1noi.pdf (NTZ) redundant to 1noj
1noj  2.40  1996  Ki=700uM      // 1noj.pdf (NTZ)
1nok  2.40  1996  Ki=700uM      // 1nok.pdf (NTZ) redundant to 1noj
1bmm  2.60  1996  Ki=79nM       // 1bmm.pdf (BM2)
1lhg  2.25  1996  Ki=79nM       // 1lhg.pdf (DI5) covalent complex
1lhf  2.40  1996  Ki=8.1nM      // 1lhf.pdf (DI4) covalent complex
1rdi  1.80  1996  Ki=8.8mM      // 1rdi.pdf (MFU)
1mdl  1.85  1996  Ki=810uM      // 1mdl.pdf (RMN) ligand is compound (R)-Mandelate
1rnm  2.00  1996  Ki=844.2uM    // 1rnm.pdf (C5P) ligand is compound 5'-CMP; Ki measured at pH=6.0
1tcw  2.40  1996  Ki=960nM      // 1tcw.pdf (IM1)
1fkw  2.40  1996  Ki=9uM        // 1fkw.pdf (PUR)
1kvo  2.00  1997  IC50=0.013uM  // 1kvo.pdf (OAP)
1tze  2.10  1997  IC50=0.148uM  // 1tze.pdf (7-mer)
1lt6  2.20  1997  IC50=0.5mM    // 1lt6.pdf (GAA)
1jlx  2.20  1997  IC50=1.6uM    // 1jlx.pdf (3-mer)
1bkm  2.00  1997  IC50=1.8uM    // 1bkm.pdf (1C5)
2rox  2.00  1997  IC50=10.5uM   // 2rox.pdf (T44) ligand is thyroxine (T4)
1jld  2.50  1997  IC50=185nM    // 1jld.pdf (0PP)
1lt5  1.70  1997  IC50=2mM      // 1lt5.pdf (TDG)
1tvr  3.00  1997  IC50=33nM     // 1tvr.pdf (TB9)
1uwb  3.20  1997  IC50=4.6nM    // 1uwb.pdf (TBO)
1dth  2.00  1997  IC50=6nM      // 1dth.pdf (BAT)
1rt2  2.55  1997  IC50=6nM      // 1rt2.pdf (TNK)
1aq1  2.00  1997  IC50=7nM      // 1aq1.pdf (STU)
1rt1  2.55  1997  IC50=8nM      // 1rt1.pdf (MKC)
1avn  2.00  1997  Kd=0.125mM    // 1avn.pdf (HSM)
1rbo  2.30  1997  Kd=0.19pM     // 1rbo.pdf (CAP)
1drv  2.20  1997  Kd=0.29uM     // 1drv.pdf (A3D) ligand is 3-Ac-NADH; Kd=0.29+/-0.05uM
1aqj  2.60  1997  Kd=0.34uM     // 1aqj.pdf (SFG)
1bxl   NMR  1997  Kd=0.34uM     // 1bxl.pdf (16-mer) Kd=0.34+/-0.03uM
1okl  2.10  1997  Kd=0.93uM     // 1okl.pdf (MNS)
1ao0  2.80  1997  Kd=11.0uM     // 1ao0.pdf (ADP)
1nlp   NMR  1997  Kd=11uM       // 1nlp.pdf (8-mer)
1avp  2.60  1997  Kd=12nM       // 1avp.pdf (11-mer) covalent complex
1jev  1.30  1997  Kd=130nM      // 1jev.pdf (3-mer)
1aj7  2.10  1997  Kd=135uM      // 1aj7.pdf (NPE)
1jeu  1.25  1997  Kd=150nM      // 1jeu.pdf (3-mer)
1ag9  1.80  1997  Kd=1nM        // 1ag9.pdf (FMN)
1ado  1.90  1997  Kd=1uM        // 1ado.pdf (13P)
2adm  2.60  1997  Kd=2.0uM      // 2adm.pdf (SAM)
1aqi  2.60  1997  Kd=2.4uM      // 1aqi.pdf (SAH)
2h4n  1.90  1997  Kd=2nM        // 2h4n.pdf (AZM)
1nlo   NMR  1997  Kd=3.4uM      // 1nlo.pdf (9-mer)
1gbq   NMR  1997  Kd=3.5mM      // 1gbq.pdf (10-mer)
3gbq   NMR  1997  Kd=3.5uM      // 2gbq.pdf (10-mer) minimized averaged structure
2mas  2.30  1997  Kd=30nM       // 2mas.pdf (PIR)
1rst  1.70  1997  Kd=37uM       // 1rst.pdf (9-mer)
1aqc  2.30  1997  Kd=4.56uM     // 1aqc.pdf (10-mer)
1shc   NMR  1997  Kd=53nM       // 1shc.pdf (12-mer)
1jet  1.20  1997  Kd=56nM       // 1jet.pdf (3-mer)
2hrp  2.20  1997  Kd=5nM        // 2hrp.pdf (10-mer) Kd measured on full length HIV-1 protease
2aac  1.60  1997  Kd=6mM        // 2aac.pdf (FCB)
1irs   NMR  1997  Kd=6uM        // 1irs.pdf (11-mer)
1mpa  2.60  1997  Kd=9.1nM      // 1mpa.pdf (9-mer)
1nox  1.59  1997  Kd=90nM       // 1nox.pdf (FMN)
1lfo  2.30  1997  Kd~0.2uM      // 1lfo.pdf (OLA) Kd=0.009-0.2uM for site 1; Kd=0.06-4.0uM for site 2
1uvt  2.50  1997  Ki=0.023uM    // 1uvt.pdf (I48)
1qbt  2.10  1997  Ki=0.024nM    // 1qbt.pdf (146)
1qbr  1.80  1997  Ki=0.027nM    // 1qbr.pdf (XV6)
1ajq  2.05  1997  Ki=0.049mM    // 1ajq.pdf (SPA)
1qbu  1.80  1997  Ki=0.058nM    // 1qbu.pdf (846)
1ai7  2.50  1997  Ki=0.082mM    // 1ai7.pdf (IPH)
1ai6  2.55  1997  Ki=0.107mM    // 1ai6.pdf (4HP)
4vgc  2.10  1997  Ki=0.127uM    // 4vgc.pdf (SRD) covalent complex
1hxb  2.30  1997  Ki=0.12nM     // 1hxb.pdf (ROC)
1sqc  2.85  1997  Ki=0.14uM     // 1sqc.pdf (LDA)
3mbp  1.70  1997  Ki=0.16uM     // 3mbp.pdf (3-mer)
1ai5  2.36  1997  Ki=0.189mM    // 1ai5.pdf (MNP)
1ad8  2.00  1997  Ki=0.25uM     // 1ad8.pdf (MDL) covalent complex
1dmp  2.00  1997  Ki=0.28nM     // 1dmp.pdf (DMQ) IC50=76nM
1qbs  1.80  1997  Ki=0.34nM     // 1qbs.pdf (DMP)
1pau  2.50  1997  Ki=0.35nM     // 1pau.pdf (5-mer) covalent complex
2kce  2.20  1997  Ki=0.67uM     // 2kce.pdf (D16)
1hpo  2.50  1997  Ki=0.6nM      // 1hpo.pdf (UNI)
1af2  2.30  1997  Ki=0.8mM      // 1af2.pdf (__U)
1vgc  1.90  1997  Ki=1.20uM     // 1vgc.pdf (V36) covalent complex
1yds  2.20  1997  Ki=1.2uM      // 1yds.pdf (IQS)
3gss  1.90  1997  Ki=1.5uM      // 3gss.pdf (2-mer)
1dub  2.50  1997  Ki=1.6uM      // 1dub.pdf (CAA)
1uvu  2.80  1997  Ki=10uM       // 1uvu.pdf (DCH) incomplete ligand structure
2gss  1.90  1997  Ki=11.5uM     // 2gss.pdf (EAA)
1ajx  2.00  1997  Ki=12.2nM     // 1ajx.pdf (AH1)
2rkm  1.80  1997  Ki=125uM      // 2rkm.pdf (2-mer)
1h4n  2.00  1997  Ki=12uM       // 1h4n.pdf (TRS)
3aid  2.50  1997  Ki=137nM      // 3aid.pdf (ARQ)
1aid  2.20  1997  Ki=15uM       // 1aid.pdf (THK)
1al7  2.60  1997  Ki=16nM       // 1al7.pdf (HST)
1ajv  2.00  1997  Ki=19.1nM     // 1ajv.pdf (NMB)
1ajn  2.36  1997  Ki=2.32mM     // 1ajn.pdf (AAN)
1fwe  2.00  1997  Ki=2.5uM      // 1fwa.pdf (HAE) Ki=1.3mM, total Ki=2.5uM
1vfn  2.15  1997  Ki=2.5uM      // 1vfn.pdf (HPA)
1juy  2.50  1997  Ki=22nM       // 1juy.pdf (H5P)
1vot  2.50  1997  Ki=250nM      // 1vot.pdf (HUP) redundant to 1gpk
1ydr  2.20  1997  Ki=3.0uM      // 1ydr.pdf (IQP)
3vgc  1.67  1997  Ki=3.11uM     // 3vgc.pdf (SRB) covalent complex
1ai4  2.35  1997  Ki=3.13mM     // 1ai4.pdf (DHY)
7upj  2.00  1997  Ki=3.2nM      // 7upj.pdf (INU)
1anf  1.67  1997  Ki=3.5uM      // 1anf.pdf (GLC-GLC)
1al8  2.20  1997  Ki=4.8uM      // 1al8.pdf (DHP)
1fax  3.00  1997  Ki=41nM       // 1fax.pdf (DX9)
6upj  2.34  1997  Ki=480nM      // 6upj.pdf (NIU)
1ydt  2.30  1997  Ki=48nM       // 1ydt.pdf (IQB)
1uvs  2.80  1997  Ki=4uM        // 1uvs.pdf (I11)
2vgc  1.80  1997  Ki=5.76uM     // 2vgc.pdf (V35) covalent complex
1ajp  2.31  1997  Ki=5.85mM     // 1ajp.pdf (OMD)
1amk  1.83  1997  Ki=50uM       // 1amk.pdf (PGA) Ki=0.050+/-0.003mM
1ml1  2.60  1997  Ki=52uM       // 1ml1.pdf (PGA)
1tom  1.80  1997  Ki=5nM        // 1tom.pdf (MIN)
1sme  2.70  1997  Ki=6pM        // 1sme.pdf (6-mer)
5upj  2.30  1997  Ki=75nM       // 5upj.pdf (UIN)
2jxr  2.40  1997  Ki=90nM       // 2jxr.pdf (2Z3)
1rtf  2.30  1997  Ki=910uM      // 1rtf.pdf (BEN)
1bm2  2.10  1998  IC50=0.11uM   // 1bm2.pdf (7-mer)
2pax  2.40  1998  IC50=0.18uM   // 2pax.pdf (4AN)
1vik  2.40  1998  IC50=0.3nM    // 1vik.pdf (BAY) redundant to 1vij
4aig  2.00  1998  IC50=0.3uM    // 4aig.pdf (FLX)
4pax  2.80  1998  IC50=0.4uM    // 4pax.pdf (NU1)
1a2c  2.10  1998  IC50=0.5uM    // 1a2c.pdf (4-mer)
1bmb  1.80  1998  IC50=0.7uM    // 1bmb.pdf (9-mer)
1aq7  2.20  1998  IC50=0.9uM    // 1aq7.pdf (4-mer)
1bl4  1.90  1998  IC50=1.8nM    // 1bl4.pdf (AP1)
1fgi  2.50  1998  IC50=10uM     // 1fgi.pdf (SU1) IC50=10-20uM
2aig  2.60  1998  IC50=10uM     // 2aig.pdf (0GR)
3pax  2.40  1998  IC50=10uM     // 3pax.pdf (3MB)
3aig  2.80  1998  IC50=1uM      // 3aig.pdf (0ZC)
1agw  2.40  1998  IC50=20uM     // 1agw.pdf (SU2) IC50=20-40uM
2qwg  1.80  1998  IC50=230uM    // 2qwg.pdf (G28)
1bji  2.00  1998  IC50=2nM      // 1bji.pdf (DPC)
1bmq  2.50  1998  IC50=38nM     // 1bmq.pdf (MNO) covalent complex
1ao8   NMR  1998  IC50=6nM      // 1ao8.pdf (MTX) ligand is methotrexate
1skj  2.00  1998  IC50=7.0uM    // 1skj.pdf (UR2)
1err  2.60  1998  IC50=7.7nM    // 1err.pdf (RAL) ligand is compound 2, RALOXIFENE
1a5v  1.90  1998  IC50=800uM    // 1a5v.pdf (_Y3)
1akv  2.00  1998  Kd=0.0026nM   // 1akv.pdf (FMN sq)
1b7h  2.00  1998  Kd=0.0095uM   // 1b7h.pdf (3-mer)
1b6h  1.80  1998  Kd=0.015uM    // 1b6h.pdf (3-mer)
1a4k  2.40  1998  Kd=0.01uM     // 1a4k.pdf (FRA)
3pcj  2.13  1998  Kd=0.06uM     // 3pcj.pdf (INO)
1b1h  1.80  1998  Kd=0.093uM    // 1b1h.pdf (3-mer)
1ax2  1.95  1998  Kd=0.103mM    // 1ax2.pdf (NAG-GAL)
1b39  2.10  1998  Kd=0.120uM    // 1b39.pdf (ATP) redundant to 1b38
1bcj  2.10  1998  Kd=0.20mM     // 1bcj.pdf (NGA)
1b0h  1.90  1998  Kd=0.20uM     // 1b0h.pdf (3-mer)
1b38  2.00  1998  Kd=0.254uM    // 1b38.pdf (ATP)
1a7x  2.00  1998  Kd=0.2nM      // 1a7x.pdf (FKA)
1a09  2.00  1998  Kd=0.2uM      // 1a09.pdf (4-mer) covalent complex
3pck  2.13  1998  Kd=0.2uM      // 3pck.pdf (NNO)
1x11  2.50  1998  Kd=0.32uM     // 1x11.pdf (14-mer) incomplete ligand structure
220l  1.85  1998  Kd=0.4mM      // 220l.pdf (BNZ) redundant to 1l83
223l  1.90  1998  Kd=0.4mM      // 223l.pdf (BNZ) redundant to 1l83
1a07  2.20  1998  Kd=0.4uM      // 1a07.pdf (4-mer) incomplete ligand structure
1a1b  2.20  1998  Kd=0.4uM      // 1a1b.pdf (3-mer)
1a1c  2.40  1998  Kd=0.4uM      // 1a1c.pdf (3-mer)
1ax1  1.95  1998  Kd=0.515mM    // 1ax1.pdf (GLC-GAL)
1bcu  2.00  1998  Kd=0.53mM     // 1bcu.pdf (PRL) Kd=0.53mM in crystal; Kd=10uM in solution
2nmb   NMR  1998  Kd=0.53uM     // 2nmb.pdf (7-mer)
1wdn  1.94  1998  Kd=0.5uM      // 1wdn.pdf (GLN)
1b3h  2.00  1998  Kd=0.62uM     // 1b3h.pdf (3-mer)
1axz  1.95  1998  Kd=0.637mM    // 1axz.pdf (GAL)
1a9q  2.00  1998  Kd=0.68uM     // 1a9q.pdf (HPA) ligand is hypoxanthine
1ax0  1.90  1998  Kd=0.746mM    // 1ax0.pdf (A2G)
1akq  1.90  1998  Kd=0.79nM     // 1akq.pdf (FMN ox)
1akr  1.58  1998  Kd=0.82nM     // 1akr.pdf (FMN ox)
1jmg  2.20  1998  Kd=0.85uM     // 1jmg.pdf (UMP)
1jmi  2.50  1998  Kd=0.87uM     // 1jmi.pdf (UMP) redundant to 1jmg
1b5h  1.90  1998  Kd=0.97uM     // 1b5h.pdf (3-mer)
1a4h  2.50  1998  Kd=1.2uM      // 1a4h.pdf (GDM) redundant to 1yet
1aj6  2.30  1998  Kd=1.2uM      // 1aj6.pdf (NOV) Kd measured at 300K
1lvk  1.90  1998  Kd=1.2uM      // 1lvk.pdf (MNT-BEF)
1yet  1.90  1998  Kd=1.2uM      // 1yet.pdf (GDM) ligand is compound 34(geldanamycin)
1bbz  1.65  1998  Kd=1.5uM      // 1bbz.pdf (11-mer)
1vwn  1.85  1998  Kd=1.5uM      // 1vwn.pdf (7-mer) incomplete ligand structure
1jmf  2.50  1998  Kd=1.7uM      // 1jmf.pdf (UMP)
1gux  1.85  1998  Kd=110nM      // 1gux.pdf (9-mer)
1b3l  2.00  1998  Kd=1300nM     // 1b3l.pdf (3-mer)
1b3f  1.80  1998  Kd=130nM      // 1b3f.pdf (3-mer)
1af6  2.40  1998  Kd=15mM       // 1af6.pdf (GLC-FRU)
1azg   NMR  1998  Kd=16uM       // 1a0n.pdf (14-mer) minimized averaged structure; Kd1=16uM(ITC); Kd2=50uM(NMR); Kd3=28uM(CD);
1axs  2.60  1998  Kd=17nM       // 1axs.pdf (HOP)
1br8  2.90  1998  Kd=18uM       // 1br8.pdf (12-mer)
1a1e  2.20  1998  Kd=1uM        // 1a1e.pdf (4-mer)
2izl  1.48  1998  Kd=1uM        // 2izl.pdf (IMI)
1vwl  1.45  1998  Kd=2.33uM     // 1vwl.pdf (9-mer)
1azl  1.80  1998  Kd=2.4nM      // 1azl.pdf (FMN ox)
1a08  2.20  1998  Kd=2.4uM      // 1a08.pdf (4-mer)
1akw  1.75  1998  Kd=2.6nM      // 1akw.pdf (FMN ox)
1b3g  2.00  1998  Kd=200nM      // 1b3g.pdf (3-mer)
4tmk  1.98  1998  Kd=20nM       // 4tmk.pdf (T5A)
3pcn  2.40  1998  Kd=220uM      // 3pcn.pdf (DHY)
1amw  1.85  1998  Kd=29uM       // 1amw.pdf (ADP)
1b2h  1.90  1998  Kd=29uM       // 1b2h.pdf (3-mer)
1a99  2.20  1998  Kd=2uM        // 1a99.pdf (PUT)
1akt  1.80  1998  Kd=3.2nM      // 1akt.pdf (FMN ox)
1b4h  1.90  1998  Kd=3.44uM     // 1b4h.pdf (3-mer)
1a3e  1.85  1998  Kd=3.5nM      // 1a3e.pdf (18-mer) incomplete ligand structure
1bm7  2.00  1998  Kd=30nM       // 1bm7.pdf (FLF)
1vwf  1.92  1998  Kd=310nM      // 1vwf.pdf (9-mer) Kd for ligand in cyclized form
5tmp  1.98  1998  Kd=34nM       // 5tmp.pdf (Z5A)
1bhf  1.80  1998  Kd=42uM       // 1bhf.pdf (5-mer)
1swg  1.80  1998  Kd=43.9nM     // 1swg.pdf (BTN)
4rsk  2.10  1998  Kd=47.4uM     // 4rsk.pdf (U3P) Ki=47.4uM (with 0.018M Na+); Ki=153.6uM (with 0.142M Na+)
1a0t  2.40  1998  Kd=50mM       // 1a0t.pdf (SUC)
1at5  1.80  1998  Kd=64uM       // 1at5.pdf (3-mer)
1aku  1.90  1998  Kd=746nM      // 1aku.pdf (FMN hq)
1b05  2.00  1998  Kd=75nM       // 1b05.pdf (3-mer)
1b32  1.75  1998  Kd=79nM       // 1b32.pdf (3-mer)
1at6  1.80  1998  Kd=85uM       // 1at6.pdf (3-mer)
1awi  2.20  1998  Kd=90uM       // 1awi.pdf (10-mer)
1usn  1.80  1998  Ki=0.018uM    // 1usn.pdf (IN9)
2qwe  2.00  1998  Ki=0.033uM    // 2qwe.pdf (GNA)
1bv7  2.00  1998  Ki=0.05nM     // 1bv7.pdf (XV6) complex between HIV-1 PR (I84V mutant) with XV638; Ki mutant/wt ratio=0.5; Ki(wt)=0.1nM
1a5g  2.06  1998  Ki=0.071nM    // 1a5g.pdf (00L) covalent complex
1xug  1.50  1998  Ki=0.09uM     // 1xug.pdf (BAB)
1bxo  0.95  1998  Ki=0.10nM     // 1bxo.pdf (PP7)
1bv9  2.00  1998  Ki=0.11nM     // 1bv9.pdf (XV6)
1a52  2.80  1998  Ki=0.138nM    // 1a52.pdf (EST) ligand is compound Estradiol (E2)
1bhx  2.30  1998  Ki=0.145uM    // 1bhx.pdf (R56)
1tbz  2.30  1998  Ki=0.16nM     // 1tbz.pdf (00Q) covalent complex
1bdr  2.80  1998  Ki=0.21uM     // 1bdr.pdf (IM1)
2usn  2.20  1998  Ki=0.31uM     // 2usn.pdf (IN8)
1moq  1.57  1998  Ki=0.35mM     // 1moq.pdf (GLP)
1alw  2.03  1998  Ki=0.3uM      // 1alw.pdf (ISA)
1bdq  2.50  1998  Ki=0.46uM     // 1bdq.pdf (IM1)
1met  1.90  1998  Ki=0.4nM      // 1met.pdf (DMP)
10gs  2.20  1998  Ki=0.4uM      // 10gs.pdf (VWW)
1br6  2.30  1998  Ki=0.6mM      // 1br6.pdf (PT1)
1ayu  2.20  1998  Ki=0.7nM      // 1ayu.pdf (INA) covalent complex
1tsl  2.50  1998  Ki=0.7uM      // 1tsl.pdf (A15)
1awh  3.00  1998  Ki=0.83uM     // 1awh.pdf (GR3) covalent complex
1meu  1.90  1998  Ki=0.8uM      // 1meu.pdf (DMP)
2wed  1.50  1998  Ki=0.8uM      // 2wed.pdf (PP6)
1awf  2.20  1998  Ki=0.97uM     // 1awf.pdf (GR4) covalent complex
3pcf  2.15  1998  Ki=0.9uM      // 3pcf.pdf (FHB)
1tsm  3.00  1998  Ki=1.0uM      // 1tsm.pdf (MR2)
2pri  2.30  1998  Ki=1.23mM     // 2pri.pdf (D6G)
1a4w  1.80  1998  Ki=1.2uM      // 1a4w.pdf (QWE)
1bdl  2.80  1998  Ki=1.41uM     // 1bdl.pdf (IM1)
3tlh  2.00  1998  Ki=1.5nM      // 3tlh.pdf (3TL)
2amv  2.30  1998  Ki=1.6nM      // 2amv.pdf (BIN)
1a8t  2.55  1998  Ki=1.6uM      // 1a8t.pdf (061)
3pce  2.06  1998  Ki=10mM       // 3pce.pdf (3HP)
1ayv  2.30  1998  Ki=10nM       // 1ayv.pdf (IN6) covalent complex
1b5g  2.07  1998  Ki=10nM       // 1b5g.pdf (0ZE) covalent complex
1mem  1.80  1998  Ki=11.5nM     // 1mem.pdf (0D6) covalent complex
2wec  1.50  1998  Ki=110uM      // 2wec.pdf (PP5)
1a9m  2.30  1998  Ki=119nM      // 1a9m.pdf (U0E)
1hvh  1.80  1998  Ki=11nM       // 1hvh.pdf (Q82)
1au2  2.60  1998  Ki=13nM       // 1au2.pdf (POS) covalent complex
1ilq   NMR  1998  Ki=13uM       // 1ilp.pdf (19-mer) minimized mean structure; Ki=20uM(CXCR-1 and IL-8)
2qwd  2.00  1998  Ki=14uM       // 2qwd.pdf (4AM)
1b4d  2.00  1998  Ki=15.6uM     // 1b4d.pdf (CRA)
1hxw  1.80  1998  Ki=15pM       // 1hxw.pdf (RIT)
1bju  1.80  1998  Ki=16uM       // 1bju.pdf (GP6) Ki=16+/-2.8uM for ACPU
2qwb  2.00  1998  Ki=1820uM     // 2qwb.pdf (SIA)
6cgt  2.60  1998  Ki=1uM        // 6cgt.pdf (6-mer)
2qwf  1.90  1998  Ki=2.160uM    // 2qwf.pdf (G20)
4mbp  1.70  1998  Ki=2.3uM      // 4mbp.pdf (4-mer)
1a61  2.20  1998  Ki=2.4nM      // 1a61.pdf (00N) covalent complex
1bwa  1.90  1998  Ki=2.5nM      // 1bwa.pdf (XV6)
1bjv  1.80  1998  Ki=2.9uM      // 1bju.pdf (GP8) Ki=2.9+/-0.1uM for APPU
1a46  2.12  1998  Ki=2000nM     // 1a46.pdf (00K) covalent complex
1b0f  3.00  1998  Ki=20nM       // 1b0f.pdf (SEI) covalent complex
1mes  1.90  1998  Ki=20nM       // 1mes.pdf (DMP)
1bjr  2.44  1998  Ki=21nM       // 1bjr.pdf (10-mer) covalent complex
1au0  2.60  1998  Ki=22nM       // 1au0.pdf (SDK) covalent complex
5fiv  1.90  1998  Ki=22nM       // 5fiv.pdf (3TL)
1a7t  1.85  1998  Ki=23mM       // 1a7t.pdf (MES)
1afk  1.70  1998  Ki=240nM      // 1afk.pdf (PAP)
3pcc  1.98  1998  Ki=240uM      // 3pcc.pdf (PHB)
3jdw  2.40  1998  Ki=253uM      // 3jdw.pdf (ORN)
2hpa  2.90  1998  Ki=25uM       // 2hpa.pdf (PT3)
2qwc  1.60  1998  Ki=280uM      // 2qwc.pdf (DAN)
1hfs  1.70  1998  Ki=2nM        // 1hfs.pdf (L04)
1ohr  2.10  1998  Ki=2nM        // 1ohr.pdf (1UN)
1a8i  1.78  1998  Ki=3.0uM      // 1a8i.pdf (GLS)
1bwb  1.80  1998  Ki=3.8nM      // 1bwb.pdf (146)
2prj  2.30  1998  Ki=32uM       // 2prj.pdf (NBG)
1lox  2.40  1998  Ki=3uM        // 1lox.pdf (RS7)
1b11  1.90  1998  Ki=41nM       // 1b11.pdf (3TL)
1bxq  1.41  1998  Ki=42nM       // 1bxq.pdf (PP8)
3pcb  2.19  1998  Ki=4mM        // 3pcb.pdf (3HB)
1bq3  2.70  1998  Ki=4uM        // 1bq3.pdf (IHP)
3pch  2.05  1998  Ki=4uM        // 3pch.pdf (CHB)
1a28  1.80  1998  Ki=5.1nM      // 1a28.pdf (STR) ligand is progesterone
1auj  2.10  1998  Ki=5.6nM      // 1auj.pdf (PPB) covalent complex
1a30  2.00  1998  Ki=50uM       // 1a30.pdf (3-mer)
1afl  1.70  1998  Ki=520nM      // 1afl.pdf (ATR)
1axr  2.30  1998  Ki=540uM      // 1axr.pdf (HTP)
1ibc  2.73  1998  Ki=56pM       // 1ibc.pdf (4-mer) covalent complex
3pcg  1.96  1998  Ki=5mM        // 3pcg.pdf (4HP)
1a69  2.10  1998  Ki=5uM        // 1a69.pdf (FMB)
16pk  1.60  1998  Ki=6uM        // 16pk.pdf (BIS) X-ray(Trypanosoma brucei PGK) while Ki(yeast PGK)
1bq4  2.50  1998  Ki=6uM        // 1bq4.pdf (BHC)
3bls  2.30  1998  Ki=7.3uM      // 3bls.pdf (APB) covalent complex
2web  1.50  1998  Ki=7.6uM      // 2web.pdf (PP4)
6fiv  1.90  1998  Ki=8.3nM      // 6fiv.pdf (3TL)
1aw1  2.70  1998  Ki=89mM       // 1aw1.pdf (PGA)
1stc  2.30  1998  Ki=8nM        // 1stc.pdf (STU)
1jfh  2.03  1998  Ki=9mM        // 1jfh.pdf (MA2-MA3)
1br5  2.50  1998  Ki>2mM        // 1br5.pdf (NEO)
1a4m  1.95  1998  Ki~0.1pM      // 1a4m.pdf (PRH)
1a4g  2.20  1999  IC50=0.004uM  // 1a4g.pdf (ZMR)
1bl7  2.50  1999  IC50=0.019uM  // 1bl7.pdf (SB4)
1bmk  2.40  1999  IC50=0.025uM  // 1bmk.pdf (SB5)
1qf5  2.00  1999  IC50=0.043uM  // 1qf5.pdf (RPL)
1bqm  3.10  1999  IC50=0.045uM  // 1bqm.pdf (HBY)
1a9u  2.50  1999  IC50=0.048uM  // 1a9u.pdf (SB2) redundant to 2ewa
1db4  2.20  1999  IC50=0.057uM  // 1db4.pdf (8IN) ligand is compound 13d
1db5  2.80  1999  IC50=0.152uM  // 1db5.pdf (6IN) ligand is compound 7g
1bl6  2.50  1999  IC50=0.16uM   // 1bl6.pdf (SB6)
1qfs  2.00  1999  IC50=0.33nM   // 1qfs.pdf (ZPR) ligand is compound 59, Z-PRO-PROLINAL
1qti  2.50  1999  IC50=0.36uM   // 1qti.pdf (GNT)
1vij  2.40  1999  IC50=0.3nM    // 1vij.pdf (BAY)
1c3r  2.00  1999  IC50=0.4uM    // 1c3r.pdf (TSN)
1bqn  3.30  1999  IC50=0.60uM   // 1bqn.pdf (HBY)
1qf4  2.20  1999  IC50=0.665uM  // 1qf4.pdf (RPD)
1cj1  3.00  1999  IC50=1.6nM    // 1cj1.pdf (C78)
1a86  2.00  1999  IC50=101uM    // 1a86.pdf (0ZB)
1biw  2.50  1999  IC50=104nM    // 1biw.pdf (S80)
5prc  2.35  1999  IC50=13uM     // 5prc.pdf (ATZ)
2cbr  2.80  1999  IC50=140nM    // 2cbr.pdf (A80)
1cx9  2.30  1999  IC50=178nM    // 1cx9.pdf (NHP)
6prc  2.30  1999  IC50=17uM     // 5prc.pdf (CEB) in Complex with the Herbicide Atrazine S(-) enantiomer
1bqo  2.30  1999  IC50=18.4nM   // 1bqo.pdf (N25)
3erk  2.10  1999  IC50=18uM     // 3erk.pdf (SB4)
1qs4  2.10  1999  IC50=2.3uM    // 1qs4.pdf (100)
1bio  1.50  1999  IC50=2.9uM    // 1bio.pdf (SOA)
1b9v  2.35  1999  IC50=224uM    // 1b9v.pdf (RA2)
1zfp  1.80  1999  IC50=26nM     // 1zfp.pdf (6-mer)
1qpf  2.50  1999  IC50=27nM     // 1qpf.pdf (858)
4erk  2.20  1999  IC50=27uM     // 4erk.pdf (OLO)
1czq  1.50  1999  IC50=29uM     // 1czq.pdf (17-mer) IC50=46uM(D10-p1-2k; Syncytia); IC50=85uM(D10-p1-2k, Viral Entry).
1qpl  2.90  1999  IC50=3.1nM    // 1qpl.pdf (587)
1b2i   NMR  1999  IC50=3.1uM    // 1b2i.pdf (AMH) ligand is compound TXA, Clot-Lysis Buffer and Plasma assay
1a4q  1.90  1999  IC50=3.6uM    // 1a4q.pdf (DPC)
1a85  2.00  1999  IC50=30uM     // 1a85.pdf (0DY)
1c50  2.30  1999  IC50=334nM    // 1c50.pdf (CHI)
1bug  2.70  1999  IC50=43uM     // 1bug.pdf (URS)
3znc  2.80  1999  IC50=45.3nM   // 3znc.pdf (BZ1)
1c9d  2.30  1999  IC50=499nM    // 1c9d.pdf (HF1)
1eve  2.50  1999  IC50=5.7nM    // 1eve.pdf (E20)
3cbs  2.00  1999  IC50=58nM     // 3cbs.pdf (R12)
7prc  2.65  1999  IC50=6.2uM    // 5prc.pdf (CET) in complex with the Herbicide Atrazine R(+) enantiomer
2cbs  2.10  1999  IC50=6nM      // 2cbs.pdf (R13)
1cw2  2.00  1999  IC50=715nM    // 1cw2.pdf (HSP)
1c5f  2.47  1999  IC50=860nM    // 1c5f.pdf (11-mer)
1b9t  2.40  1999  IC50=8uM      // 1b9t.pdf (RAI)
1tc1  1.41  1999  IC50>2mM      // 1tc1.pdf (FMB) incomplete ligand structure
1b9s  2.50  1999  IC50>667uM    // 1b9s.pdf (FDI)
1a7c  1.95  1999  Kd<=100uM     // 1a7c.pdf (6-mer) Kd<=100uM for site 1; Kd=700uM for site 2
1bnm  2.60  1999  Kd=0.10nM     // 1bnm.pdf (AL8)
1bnn  2.30  1999  Kd=0.10nM     // 1bnn.pdf (AL1)
1d3v  1.70  1999  Kd=0.11uM     // 1d3v.pdf (ABH)
1swr  1.90  1999  Kd=0.12uM     // 1swr.pdf (BTN)
1a42  2.25  1999  Kd=0.13nM     // 1a42.pdf (BZU)
1bn3  2.20  1999  Kd=0.13nM     // 1bn3.pdf (AL6)
1bnt  2.15  1999  Kd=0.16nM     // 1bnt.pdf (AL2)
1bkj  1.80  1999  Kd=0.17uM     // 1bkj.pdf (FMN)
1b2m  2.00  1999  Kd=0.185mM    // 1b2m.pdf (2-mer)
5fwg  2.00  1999  Kd=0.19uM     // 5fwg.pdf (GPR) structure is GST mutant; Kd measured on GST wild type
2a2g  2.90  1999  Kd=0.1uM      // 2a2g.pdf (LEO)
1bnu  2.15  1999  Kd=0.20nM     // 1bnu.pdf (AL3)
1a4r  2.50  1999  Kd=0.22uM     // 1a4r.pdf (GNH) Kd=9.4pM for GDP
2ay3  2.40  1999  Kd=0.28mM     // 2ay3.pdf (MPP)
1a50  2.30  1999  Kd=0.2uM      // 1a50.pdf (FIP) Kd=0.2-0.5uM
1bnq  2.40  1999  Kd=0.32nM     // 1bnq.pdf (AL4)
1rpj  1.80  1999  Kd=0.33uM     // 1rpj.pdf (ALL)
1ct8  2.20  1999  Kd=0.3uM      // 1ct8.pdf (TAA)
1bn1  2.10  1999  Kd=0.46nM     // 1bn1.pdf (AL5)
1bn4  2.10  1999  Kd=0.49nM     // 1bn4.pdf (AL9)
1azx  2.90  1999  Kd=0.4nM      // 1azx.pdf (NTP)
1d4p  2.07  1999  Kd=0.5uM      // 1d4p.pdf (BPP)
1czl  1.80  1999  Kd=0.71nM     // 1czl.pdf (FMN sq)
2ay6  2.20  1999  Kd=0.78mM     // 2ay6.pdf (3IB)
1bnw  2.25  1999  Kd=0.83nM     // 1bnw.pdf (TPD)
1czr  1.90  1999  Kd=1.0nM      // 1czr.pdf (FMN ox)
2ay4  2.20  1999  Kd=1.24mM     // 2ay4.pdf (PPT)
2ans  2.50  1999  Kd=1.2uM      // 2ans.pdf (2AN)
1ork  2.40  1999  Kd=1.56nM     // 1ork.pdf (ATC)
1bnv  2.40  1999  Kd=1.70nM     // 1bnv.pdf (AL7)
1c12  2.60  1999  Kd=1.9nM      // 1c12.pdf (TRZ)
2bow  2.80  1999  Kd=100uM      // 2bow.pdf (P4P)
1fpp  2.75  1999  Kd=10nM       // 1fpp.pdf (FPP) Kd measured on protein from human
1b9j  1.80  1999  Kd=1100nM     // 1b9j.pdf (3-mer)
1qka  1.80  1999  Kd=1200nM     // 1qka.pdf (3-mer)
1a37  3.60  1999  Kd=120nM      // 1a37.pdf (15-mer) incomplete ligand
1d4w  1.80  1999  Kd=120nM      // 1d4t.pdf (11-mer) fluorescence polarization binding constant=120nM, data not shown; incomplete ligand
1vr1  1.90  1999  Kd=128nM      // 1vr1.pdf (10-mer) Kd measured on thrombin (S195A, VR1tPA)
2ay2  2.40  1999  Kd=13.1mM     // 2ay2.pdf (CXP)
3tmk  2.00  1999  Kd=135nM      // 3tmk.pdf (T5A)
1bky  2.00  1999  Kd=144uM      // 1bky.pdf (1MC) X-ray(wild type) while Kd(VP39-F180W)
1bux  2.80  1999  Kd=14uM       // 1bux.pdf (PPS)
1mxl   NMR  1999  Kd=154uM      // 1mxl.pdf (17-mer) Kd=154+/-10uM
1d2e  1.94  1999  Kd=1uM        // 1d2e.pdf (GDP)
2ay5  2.40  1999  Kd=2.6mM      // 2ay5.pdf (IOP)
1bgq  2.50  1999  Kd=2.7nM      // 1bgq.pdf (RDC)
3kiv  1.80  1999  Kd=20uM       // 3kiv.pdf (ACA)
1qsc  2.40  1999  Kd=210uM      // 1qsc.pdf (7-mer)
1sm3  1.95  1999  Kd=24uM       // 1sm3.pdf (13-mer) incomplete ligand structure
1d7i  1.90  1999  Kd=250uM      // 1d7i.pdf (DSS)
5a3h  1.82  1999  Kd=26.7uM     // 5a3h.pdf (FFC) covalent complex
1b58  1.80  1999  Kd=260nM      // 1b58.pdf (3-mer)
1d04  1.85  1999  Kd=26uM       // 1d04.pdf (FMN hq)
1czo  1.85  1999  Kd=28uM       // 1czo.pdf (FMN hq)
2pcp  2.20  1999  Kd=2nM        // 2pcp.pdf (1PC)
1bt6  2.40  1999  Kd=2uM        // 1bt6.pdf (14-mer) Kd = 2uM for free annexin II; Kd <10 nM when (annexin II)2(p11)2 the complex is formed; incomplete ligand
1yei  1.90  1999  Kd=35nM       // 1yei.pdf (PGG)
1yej  1.85  1999  Kd=35nM       // 1yej.pdf (PNF)
1b5j  1.80  1999  Kd=37nM       // 1b5j.pdf (3-mer)
1bzy  2.00  1999  Kd=4.6nM      // 1bzy.pdf (IMU)
1b55  2.40  1999  Kd=40nM       // 1b55.pdf (4IP)
1qja  2.00  1999  Kd=416nM      // 1qja.pdf (8-mer)
1b51  1.80  1999  Kd=43nM       // 1b51.pdf (3-mer)
1qkb  1.80  1999  Kd=45nM       // 1qkb.pdf (3-mer)
2ay7  2.40  1999  Kd=5.0mM      // 2ay7.pdf (CLT)
2ay1  2.20  1999  Kd=5.14mM     // 2ay1.pdf (AHC)
1clu  1.70  1999  Kd=5.4nM      // 1clu.pdf (DBG)
2ay8  2.20  1999  Kd=5.8mM      // 2ay8.pdf (4TB)
1d7j  1.85  1999  Kd=500uM      // 1d7j.pdf (BUQ)
1b46  1.80  1999  Kd=5200nM     // 1b46.pdf (3-mer)
1b40  2.20  1999  Kd=53nM       // 1b40.pdf (3-mer)
1b4z  1.75  1999  Kd=5900nM     // 1b4z.pdf (3-mer)
1bzf   NMR  1999  Kd=5nM        // 1bzf.pdf (TMQ)
2ay9  2.50  1999  Kd=6.9mM      // 2ay9.pdf (5PV)
1evh  1.80  1999  Kd=602uM      // 1evh.pdf (7-mer) incomplete ligand structure
1aze   NMR  1999  Kd=60uM       // 1aze.pdf (10-mer)
1qk4  1.90  1999  Kd=61uM       // 1qk4.pdf (IMP)
1d4t  1.10  1999  Kd=650nM      // 1d4t.pdf (11-mer) Kd=650nM (FP)
1qk3  1.65  1999  Kd=7.1uM      // 1qk3.pdf (5GP)
1qaw  2.50  1999  Kd=7.5uM      // 1qaw.pdf (TRP)
1b52  2.30  1999  Kd=76nM       // 1b52.pdf (3-mer)
3mct  2.00  1999  Kd=85.5uM     // 3mct.pdf (3MC) X-ray(VP39 wild type) while Kd(VP39 F180W)
3mag  1.80  1999  Kd=86uM       // 3mag.pdf (3MA) X-ray(VP39 wild type) while Kd(VP39 F180W)
1bwn  2.10  1999  Kd=87nM       // 1bwn.pdf (4IP)
1m6p  1.80  1999  Kd=8uM        // 1m6p.pdf (M6P)
2mpa  2.60  1999  Kd=9.1nM      // 2mpa.pdf (9-mer)
1b5i  1.90  1999  Kd=90nM       // 1b5i.pdf (3-mer)
1b42  2.20  1999  Kd=97.9uM     // 1b42.pdf (M1A) X-ray(wild type) while Kd(VP39-F180W)
1swp  2.00  1999  Kd~10pM       // 1swp.pdf (BTN)
1swk  2.00  1999  Kd~1pM        // 1swk.pdf (BTN)
1swn  2.20  1999  Kd~1pM        // 1swn.pdf (BTN)
1d4y  1.97  1999  Ki=0.008nM    // 1d4y.pdf (TPV)
3erd  2.03  1999  Ki=0.126nM    // 3erd.pdf (DES) ligand is diethylstilbestrol, affinity in Human Breast Cancer
2std  2.10  1999  Ki=0.14nM     // 2std.pdf (CRP)
456c  2.40  1999  Ki=0.17nM     // 456c.pdf (CBP)
1bzh  2.10  1999  Ki=0.17uM     // 1bzh.pdf (7-mer)
1sfi  1.65  1999  Ki=0.1nM      // 1sfi.pdf (14-mer)
1ch8  2.50  1999  Ki=0.1uM      // 1ch8.pdf (GPX)
1oth  1.85  1999  Ki=0.1uM      // 1oth.pdf (PAO) Ki measured at pH=7.0, temp=37C
3ert  1.90  1999  Ki=0.249nM    // 3ert.pdf (OHT) ligand is 4-OH-Tamoxifen, affinity in human breast cancer
1bo5  3.20  1999  Ki=0.25mM     // 1bo5.pdf (FBP)
1dfo  2.40  1999  Ki=0.2uM      // 1dfo.pdf (FFO) Ki=0.2~0.5uM
1ca8  2.10  1999  Ki=0.32nM     // 1ca8.pdf (0KV) covalent complex
4yas  2.00  1999  Ki=0.39mM     // 4yas.pdf (CLX) covalent complex
1bxr  2.10  1999  Ki=0.4mM      // 1bxr.pdf (ANP)
1pme  2.00  1999  Ki=0.4nM      // 1pme.pdf (SB2)
2bpx  2.80  1999  Ki=0.4nM      // 2bpx.pdf (MK1)
830c  1.60  1999  Ki=0.52nM     // 830c.pdf (RS1)
5yas  2.20  1999  Ki=0.55mM     // 5yas.pdf (FAC)
1a5h  2.90  1999  Ki=0.5uM      // 1a5h.pdf (BBA) Ki measured on full lenghth sc-tPA
1ba8  1.80  1999  Ki=1.0nM      // 1ba8.pdf (0IT) covalent complex
1ekb  2.30  1999  Ki=1.0uM      // 1ekb.pdf (7-mer) incomplete ligand structure; covalent complex
1cet  2.05  1999  Ki=1.3mM      // 1cet.pdf (CLQ)
2bza  1.90  1999  Ki=1.58mM     // 2bza.pdf (ABN)
11gs  2.30  1999  Ki=1.5uM      // 11gs.pdf (2-mer) redundant to 3gss
1dg9  1.90  1999  Ki=1.8mM      // 1dg9.pdf (EPE)
3amv  2.10  1999  Ki=10.8nM     // 3amv.pdf (BIN)
1qin  2.00  1999  Ki=10nM       // 1qin.pdf (GIP)
1cp6  1.90  1999  Ki=10uM       // 1cp6.pdf (BUB) incomplete ligand structure
1qf2  2.06  1999  Ki=1200nM     // 1qf2.pdf (TI3)
1bzc  2.35  1999  Ki=12uM       // 1bzc.pdf (TPI)
1xka  2.30  1999  Ki=131nM      // 1xka.pdf (4PP) IC50=272nM
1bm6   NMR  1999  Ki=13nM       // 1bm6.pdf (3-mer)
1a94  2.00  1999  Ki=14nM       // 1a94.pdf (0Q4)
1b8y  2.00  1999  Ki=14nM       // 1b8y.pdf (IN7)
1d5r  2.10  1999  Ki=15mM       // 1d5r.pdf (TLA)
1ce5  1.90  1999  Ki=18.4uM     // 1ce5.pdf (BEN) redundant to 3gy7
1caq  1.80  1999  Ki=19nM       // 1caq.pdf (DPS) redundant to 1ciz
7std  1.80  1999  Ki=19pM       // 7std.pdf (CRP)
6std  1.80  1999  Ki=2.3nM      // 6std.pdf (MS2)
1mfi  1.80  1999  Ki=2.6uM      // 1mfi.pdf (FHC)
2sfp  1.90  1999  Ki=20mM       // 2sfp.pdf (PPI)
1bai  2.40  1999  Ki=20nM       // 1bai.pdf (0Q4)
2bpv  1.90  1999  Ki=21.2nM     // 2bpv.pdf (1IN)
1c3x  2.40  1999  Ki=210uM      // 1c3x.pdf (8IG)
1bzj  2.25  1999  Ki=22uM       // 1bzj.pdf (PIC)
966c  1.90  1999  Ki=23nM       // 966c.pdf (RS2)
1b8o  1.50  1999  Ki=23pM       // 1b8o.pdf (IMH)
13gs  1.90  1999  Ki=24uM       // 13gs.pdf (SAS)
1upf  2.30  1999  Ki=25uM       // 1upf.pdf (URF)
1c3e  2.10  1999  Ki=260nM      // 1c3e.pdf (NHR)
1a0q  2.30  1999  Ki=27nM       // 1a0q.pdf (HEP)
1c3b  2.25  1999  Ki=27nM       // 1c3b.pdf (BZB) covalent complex
1qhc  1.70  1999  Ki=27nM       // 1qhc.pdf (PUA)
2tsr  2.60  1999  Ki=29nM       // 2tsr.pdf (D16)
2fmb  1.80  1999  Ki=2nM        // 2fmb.pdf (LP1)
1cr6  2.80  1999  Ki=3.1nM      // 1cr6.pdf (CPU)
1bgo  2.30  1999  Ki=3.5nM      // 1bgo.pdf (I10) covalent complex
4fiv  1.80  1999  Ki=300nM      // 4fiv.pdf (LP1)
1qcp  1.80  1999  Ki=30nM       // 1qcp.pdf (RWJ) covalent complex
1b8n  2.00  1999  Ki=30pM       // 1b8n.pdf (IMG)
1d6n  2.70  1999  Ki=31.5uM     // 1d6n.pdf (PPO) Ki measured on HGPRTase wt
5std  1.95  1999  Ki=32pM       // 5std.pdf (UNN)
1ciz  1.64  1999  Ki=36nM       // 1ciz.pdf (DPS)
2bpy  1.90  1999  Ki=39.8nM     // 2bpy.pdf (3IN)
1bb0  2.10  1999  Ki=4.4nM      // 1bb0.pdf (0IV) covalent complex
1hwr  1.80  1999  Ki=4.70nM     // 1hwr.pdf (216)
7kme  2.10  1999  Ki=40uM       // 7kme.pdf (7-mer) incomplete ligand structure
1qbv  1.80  1999  Ki=4100nM     // 1qbv.pdf (PPX)
1qjb  2.00  1999  Ki=416nM      // 1qjb.pdf (8-mer) Ki for structure mode 2
1qf0  2.20  1999  Ki=42nM       // 1qf0.pdf (TI2)
2fgi  2.50  1999  Ki=45.2nM     // 2fgi.pdf (PD1)
4std  2.15  1999  Ki=47pM       // 4std.pdf (BFS)
1qf1  2.00  1999  Ki=48nM       // 1qf1.pdf (TI1)
1qbq  2.40  1999  Ki=5nM        // 1qbq.pdf (HFP)
1icj  1.90  1999  Ki=6mM        // 1icj.pdf (PGO)
3std  1.65  1999  Ki=7.7pM      // 3std.pdf (MQ0)
4prg  2.90  1999  Ki=70nM       // 4prg.pdf (072)
2toh  2.30  1999  Ki=70uM       // 2toh.pdf (HBI)
3usn   NMR  1999  Ki=710nM      // 3usn.pdf (ATT)
1zzz  1.90  1999  Ki=7300nM     // 1zzz.pdf (0IV) incomplete ligand structure; covalent complex
1b56  2.05  1999  Ki=802nM      // 1b56.pdf (PLM) binding data for E.coli FABP, not human
1yyy  2.10  1999  Ki=8100nM     // 1yyy.pdf (0KV) incomplete ligand structure; covalent complex
1ody  2.00  1999  Ki=8nM        // 1ody.pdf (LP1)
1qr3  1.60  2000  IC50=0.26uM   // 1qr3.pdf (8-mer)
1eei  2.00  2000  IC50=0.7mM    // 1eei.pdf (GAA)
1d5j  2.60  2000  IC50=0.7nM    // 1d5j.pdf (MM3)
1e02  2.15  2000  IC50=0.7uM    // 1e02.pdf (UNA)
1e00  1.83  2000  IC50=0.8uM    // 1e00.pdf (DHM)
1eef  1.80  2000  IC50=1.2mM    // 1eef.pdf (2-mer) ligand is GAL-I06
1dzj  2.00  2000  IC50=1.3uM    // 1dzj.pdf (SES)
1c3i  1.83  2000  IC50=1.6uM    // 1c3i.pdf (TR1)
1bzs  1.70  2000  IC50=10nM     // 1bzs.pdf (BSI)
1fv9  3.00  2000  IC50=10uM     // 1fv9.pdf (172)
1efi  1.60  2000  IC50=12mM     // 1efi.pdf (GAT)
1qhr  2.20  2000  IC50=130nM    // 1qhr.pdf (157) covalent complex
1ftk  1.60  2000  IC50=14.5uM   // 1ftk.pdf (KAI) IC50 measured on S1S2J
1fd7  1.80  2000  IC50=14mM     // 1fd7.pdf (AI1)
1d8f  2.40  2000  IC50=18nM     // 1d8f.pdf (SPI)
1qj6  2.20  2000  IC50=18nM     // 1qj6.pdf (167) covalent complex
1c8k  1.76  2000  IC50=1uM      // 1c8k.pdf (CPB)
1di8  2.20  2000  IC50=1uM      // 1di8.pdf (DTQ)
1cqp  2.60  2000  IC50=2.4uM    // 1cqp.pdf (803)
1fyr  2.40  2000  IC50=2.4uM    // 1fyr.pdf (5-mer)
1e06  2.12  2000  IC50=2.5uM    // 1e06.pdf (IPB)
1e1y  2.23  2000  IC50=2.5uM    // 1e1y.pdf (CPB)
1qpe  2.00  2000  IC50=20nM     // 1qpe.pdf (PP2)
1d8e  3.00  2000  IC50=250nM    // 1d8e.pdf (6-mer) FTase complexed with the FPP(FII) anolog and 11-mer KKKSKTKCVIM, IC50 for 11-mer is 50nM. IC50 for TKCVIM 6-mer is 250nM
1dmt  2.10  2000  IC50=2nM      // 1dmt.pdf (RDF) ligand is Phospho-ramidon
1d8m  2.44  2000  IC50=3.1nM    // 1d8m.pdf (BBH)
1qkn  2.25  2000  IC50=3.4nM    // 1qkn.pdf (RAL) ligand is compound 1, RALOXIFENE
1dzp  1.83  2000  IC50=3.6uM    // 1dzp.pdf (BZQ)
1dzm  1.93  2000  IC50=3.9uM    // 1dzm.pdf (BZM)
1d7x  2.00  2000  IC50=3nM      // 1d7x.pdf (SPC)
3gwx  2.40  2000  IC50=4.0uM    // 3gwx.pdf (EPA)
1exv  2.40  2000  IC50=45nM     // 1exv.pdf (700)
1c29  2.30  2000  IC50=472nM    // 1c29.pdf (HE1) redundant to 1c8v
1c8v  2.20  2000  IC50=472nM    // 1c8v.pdf (HE1)
1qtn  1.20  2000  IC50=50nM     // 1qtn.pdf (5-mer) covalent complex
1ezf  2.15  2000  IC50=56nM     // 1ezf.pdf (IN0)
1dtt  3.00  2000  IC50=5nM      // 1dtt.pdf (FTC)
1di9  2.60  2000  IC50=5uM      // 1di9.pdf (MSQ)
1c8l  2.30  2000  IC50=6.9nM    // 1c8l.pdf (BIN)
1dx6  2.30  2000  IC50=652nM    // 1dx6.pdf (GNT)
1dtq  2.80  2000  IC50=6nM      // 1dtq.pdf (FPT)
1em6  2.20  2000  IC50=6nM      // 1em6.pdf (CP4)
1dm2  2.10  2000  IC50=70nM     // 1dm2.pdf (HMD)
1ftj  1.90  2000  IC50=821nM    // 1ftj.pdf (GLU)
1qj7  2.20  2000  IC50=8nM      // 1qj7.pdf (GR1) covalent complex
1fsg  1.05  2000  IC50=9.5uM    // 1fsg.pdf (9DG)
1ftl  1.80  2000  IC50=998nM    // 1ftl.pdf (DNQ)
1qj1  2.00  2000  IC50=9nM      // 1qj1.pdf (166) covalent complex
1fao  1.80  2000  Kd=0.043uM    // 1fao.pdf (4IP)
1fl3  2.45  2000  Kd=0.16uM     // 1fl3.pdf (SPB)
1d2s  1.55  2000  Kd=0.182nM    // 1d2s.pdf (DHT) ligand is compound 1, 5-ALPHA-DIHYDROTESTOSTERONE, pKd=9.74
1df8  1.51  2000  Kd=0.20nM     // 1df8.pdf (BTN)
1qku  3.20  2000  Kd=0.26nM     // 1qku.pdf (EST) WT Kd=0.26+/-0.05nM
1g52  1.80  2000  Kd=0.29nM     // 1g52.pdf (F2B)
1d3q  2.90  2000  Kd=0.29uM     // 1d3q.pdf (BT2)
1c7f  2.00  2000  Kd=0.30nM     // 1c7f.pdf (FMN ox)
1dl7  2.35  2000  Kd=0.32uM     // 1dl7.pdf (NCH)
1g1d  2.04  2000  Kd=0.36nM     // 1g1d.pdf (FSB)
1flm  1.30  2000  Kd=0.43nM     // 1flm.pdf (FMN)
1e03  2.90  2000  Kd=0.4nM      // 1e03.pdf (NTP)
1db1  1.80  2000  Kd=0.55nM     // 1db1.pdf (VDX)
1fcz  1.38  2000  Kd=0.6nM      // 1fcz.pdf (156)
1fbm  2.70  2000  Kd=0.6uM      // 1fbm.pdf (RTL)
1d3d  2.04  2000  Kd=0.81nM     // 1d3d.pdf (BZT)
1f4y  2.80  2000  Kd=0.83uM     // 1f4y.pdf (MGU)
1dzk  1.48  2000  Kd=0.8uM      // 1dzk.pdf (PRZ)
1g53  1.94  2000  Kd=0.91nM     // 1g53.pdf (F6B)
1qkt  2.20  2000  Kd=0.92nM     // 1qkt.pdf (EST)
1czc  2.50  2000  Kd=1.5mM      // 1czc.pdf (GUA)
1czk  1.90  2000  Kd=1.5nM      // 1czk.pdf (FMN ox)
1g54  1.86  2000  Kd=1.5nM      // 1g54.pdf (FFB)
1g46  1.84  2000  Kd=1.6nM      // 1g46.pdf (F2B)
1duv  1.70  2000  Kd=1.6pM      // 1duv.pdf (PSQ)
1ggd  1.50  2000  Kd=1.6uM      // 1ggd.pdf (FAF) covalent complex
1qft  1.25  2000  Kd=1.7nM      // 1qft.pdf (HSM)
1ddm   NMR  2000  Kd=1.7uM      // 1ddm.pdf (11-mer)
1fhr   NMR  2000  Kd=100uM      // 1fhr.pdf (7-mer)
1f8a  1.84  2000  Kd=10uM       // 1f8a.pdf (7-mer)
1ql7  2.10  2000  Kd=10uM       // 1ql7.pdf (ZEN) Kd=10~20uM
1c5c  1.61  2000  Kd=110nM      // 1c5c.pdf (TK4)
1elr  1.90  2000  Kd=11uM       // 1elr.pdf (6-mer)
1ff1   NMR  2000  Kd=12uM       // 1f8h.pdf (11-mer) Kd=12+/-2uM; incomplete ligand
1qng  2.10  2000  Kd=13nM       // 1qng.pdf (11-mer)
1qiw  2.30  2000  Kd=18nM       // 1qiw.pdf (DPD)
1dpu   NMR  2000  Kd=1uM        // 1dpu.pdf (16-mer) Kd<1uM; Kd=5uM(binding affinity of RPA32172-270 for XPA1-98)
1f40   NMR  2000  Kd=1uM        // 1f40.pdf (GPI)
1g4j  1.84  2000  Kd=2.0nM      // 1g4j.pdf (FFB)
1dkd  2.10  2000  Kd=2.0uM      // 1dkd.pdf (12-mer) incomplete ligand
1e8h  2.60  2000  Kd=2.1uM      // 1e8h.pdf (ADP)
1g45  1.83  2000  Kd=2.3nM      // 1g45.pdf (FSB)
1cze  2.40  2000  Kd=2.4mM      // 1cze.pdf (SIN)
1f4x  2.30  2000  Kd=2.6uM      // 1f4x.pdf (MGS)
1fo0  2.50  2000  Kd=2.6uM      // 1fo0.pdf (8-mer)
1om2   NMR  2000  Kd=20uM       // 1om2.pdf (11-mer)
1e5a  1.80  2000  Kd=23nM       // 1e5a.pdf (TBP)
1ftm  1.70  2000  Kd=24.8nM     // 1ftm.pdf (AMQ)
1fzq  1.70  2000  Kd=24nM       // 1fzq.pdf (GDP)
1fj4  2.35  2000  Kd=26uM       // 1fj4.pdf (TLM) redundant to 2vb8
1g1e   NMR  2000  Kd=29nM       // 1g1e.pdf (16-mer) Kd=15nM(binding affinity of Mad1 1-35 and Sin3)
1e4h  1.80  2000  Kd=3.9nM      // 1e4h.pdf (PBR)
1g48  1.86  2000  Kd=3.9nM      // 1g48.pdf (F6B)
1fcy  1.30  2000  Kd=3nM        // 1fcy.pdf (564)
1bp0  2.40  2000  Kd=4.0uM      // 1bp0.pdf (UMP)
1d3p  2.10  2000  Kd=41nM       // 1d3p.pdf (BT3)
1qpb  2.40  2000  Kd=44mM       // 1qpb.pdf (PYM)
1g4o  1.96  2000  Kd=5.6nM      // 1g4o.pdf (BSB)
1c7e  2.25  2000  Kd=505nM      // 1c7e.pdf (FMN hq)
1ej4  2.25  2000  Kd=50nM       // 1ej4.pdf (17-mer) incomplete ligand structure
1g6g  1.60  2000  Kd=530nM      // 1g6g.pdf (13-mer) incomplete ligand structure
1g6r  2.80  2000  Kd=54uM       // 1g6r.pdf (8-mer)
1etz  2.60  2000  Kd=58nM       // 1etz.pdf (GAS)
1f3j  3.10  2000  Kd=6.0uM      // 1f3j.pdf (14-mer) HEL(11-25) peptide and I-Ag7 complex, Kd=6.0+/-0.7uM
1fcx  1.47  2000  Kd=64nM       // 1fcx.pdf (184)
1d6v  2.00  2000  Kd=670nM      // 1d6v.pdf (HOP)
1fch  2.20  2000  Kd=70nM       // 1fch.pdf (5-mer)
1d6s  2.30  2000  Kd=78uM       // 1d6s.pdf (PLP) Kd measured on OASS wt
1dva  3.00  2000  Kd=8.5nM      // 1dva.pdf (19-mer) incomplete ligan structure
1qnh  2.10  2000  Kd=872nM      // 1qnh.pdf (11-mer)
1c1u  1.75  2000  Ki=0.0056uM   // 1c1u.pdf (BAI)
1c4v  2.10  2000  Ki=0.016nM    // 1c4v.pdf (IH2)
1b57  2.00  2000  Ki=0.01uM     // 1b57.pdf (PGH) ligand is phosphoglycolohydroxamic acid (PGH)
1c1r  1.37  2000  Ki=0.0235uM   // 1c1r.pdf (BAI)
1c1v  1.98  2000  Ki=0.023uM    // 1c1v.pdf (BAB)
1f7b  1.80  2000  Ki=0.025mM    // 1f7b.pdf (NAV) covalent complex
1c4u  2.10  2000  Ki=0.043nM    // 1c4u.pdf (IH1)
1c70  2.50  2000  Ki=0.05nM     // 1c70.pdf (L75)
1fjs  1.92  2000  Ki=0.11nM     // 1fjs.pdf (Z34)
1fh8  1.95  2000  Ki=0.13uM     // 1fh8.pdf (2-mer) ligand is XYP-XIF
1fhd  1.90  2000  Ki=0.15uM     // 1fhd.pdf (2-mer) ligand is XYP-XIM
1gfz  2.30  2000  Ki=0.1mM      // 1gfz.pdf (CFF) Ki=0.1-0.2mM
1e37  1.75  2000  Ki=0.20mM     // 1e37.pdf (TPY) covalent complex
1c5x  1.75  2000  Ki=0.21uM     // 1c5x.pdf (ESI)
1d1p  2.20  2000  Ki=0.25mM     // 1d1p.pdf (EPE)
1f3e  1.85  2000  Ki=0.2uM      // 1f3e.pdf (DPZ)
1c6y  2.50  2000  Ki=0.31nM     // 1c6y.pdf (MK1) X-ray(HIV-1 protease with 9 mutations) while Ki(wild type)
1fh9  1.72  2000  Ki=0.37uM     // 1fh9.pdf (2-mer) ligand is XYP-LOX
1c5q  1.43  2000  Ki=0.44uM     // 1c5q.pdf (ESI)
1e6s  1.35  2000  Ki=0.6mM      // 1e6s.pdf (GOX)
1d4k  1.85  2000  Ki=0.6nM      // 1d4k.pdf (PI8)
1d9i  2.30  2000  Ki=0.78nM     // 1d9i.pdf (00P)
1ec9  2.00  2000  Ki=0.8mM      // 1ec9.pdf (XYH)
1fq8  2.80  2000  Ki=0.94uM     // 1fq8.pdf (2Y4)
1f74  1.60  2000  Ki=0.9mM      // 1f74.pdf (NAY)
1ezq  2.20  2000  Ki=0.9nM      // 1ezq.pdf (RPR)
1eoc  2.25  2000  Ki=0.9uM      // 1eoc.pdf (4NC)
1qon  2.72  2000  Ki=1.09nM     // 1qon.pdf (I40) Ki measured on AChE (Musca domestica)
1ecq  2.00  2000  Ki=1.0mM      // 1ecq.pdf (DXG)
1c5s  1.36  2000  Ki=1.0uM      // 1c5s.pdf (ESX)
1f4e  1.90  2000  Ki=1.1mM      // 1f4e.pdf (TPR)
1doj  1.70  2000  Ki=1.1nM      // 1doj.pdf (1Z0) covalent complex
1e34  1.80  2000  Ki=1.32mM     // 1e34.pdf (TPX) covalent complex
1qm5  2.00  2000  Ki=1.5uM      // 1qm5.pdf (5-mer)
1fkn  1.90  2000  Ki=1.6nM      // 1fkn.pdf (7-mer)
1d4l  1.75  2000  Ki=1.7nM      // 1d4l.pdf (PI9)
1b6k  1.85  2000  Ki=1.8nM      // 1b6k.pdf (PI5)
1f0t  1.80  2000  Ki=1000nM     // 1f0t.pdf (PR1)
1dqn  1.75  2000  Ki=10nM       // 1dqn.pdf (IMU)
1e2k  1.70  2000  Ki=11.4uM     // 1e2k.pdf (TMC)
1d6w  2.00  2000  Ki=1100nM     // 1d6w.pdf (00R)
1exw  2.40  2000  Ki=125uM      // 1exw.pdf (HDS) covalent complex
1b6j  1.85  2000  Ki=12nM       // 1b6j.pdf (5-mer)
1c4y  2.70  2000  Ki=12nM       // 1c4y.pdf (IH3)
1fq6  2.70  2000  Ki=13.7nM     // 1fq6.pdf (0QF)
1erq  1.90  2000  Ki=13nM       // 1erq.pdf (BJH) covalent complex
1qbn  1.80  2000  Ki=1400nM     // 1qbn.pdf (688)
1c83  1.80  2000  Ki=14uM       // 1c83.pdf (OAI)
1ecv  1.95  2000  Ki=14uM       // 1ecv.pdf (878)
1qji  2.14  2000  Ki=14uM       // 1qji.pdf (PKF)
1gfw  2.80  2000  Ki=15nM       // 1gfw.pdf (MSI) covalent complex
1qb1  1.80  2000  Ki=170nM      // 1qb1.pdf (974)
1eoj  2.10  2000  Ki=17fM       // 1eoj.pdf (14-mer)
1ek1  3.10  2000  Ki=17nM       // 1ek1.pdf (CIU)
1f0s  2.10  2000  Ki=18nM       // 1f0s.pdf (PR2)
1qbo  1.80  2000  Ki=18nM       // 1qbo.pdf (711)
1qaq  2.80  2000  Ki=18uM       // 1qaq.pdf (SFG)
1ylv  2.15  2000  Ki=2.0mM      // 1ylv.pdf (SHF) covalent complex
1f57  1.75  2000  Ki=2.3uM      // 1f57.pdf (DCY)
1hlf  2.26  2000  Ki=2.3uM      // 1hlf.pdf (GL4) Ki measured with phosphate
1ejn  1.80  2000  Ki=2.4uM      // 1ejn.pdf (AGB)
1c5n  1.50  2000  Ki=20uM       // 1c5n.pdf (ESI)
1c86  2.30  2000  Ki=20uM       // 1c86.pdf (OPA)
1c5p  1.43  2000  Ki=21uM       // 1c5p.pdf (BAM)
1f0r  2.10  2000  Ki=22nM       // 1f0r.pdf (815)
1c85  2.72  2000  Ki=23uM       // 1c85.pdf (OBA)
1f4f  2.00  2000  Ki=24uM       // 1f4f.pdf (TP3)
1c2t  2.10  2000  Ki=260nM      // 1c2t.pdf (NHS) redundant to 1c3e
1d09  2.10  2000  Ki=27nM       // 1d09.pdf (PAL) ATCase in complex with PALA
1egh  2.00  2000  Ki=2uM        // 1egh.pdf (PGA)
1ggn  2.36  2000  Ki=3.1uM      // 1ggn.pdf (GLS)
1fq7  2.80  2000  Ki=3.74uM     // 1fq7.pdf (2Y3)
1c5o  1.90  2000  Ki=320uM      // 1c5o.pdf (BAM)
1f4g  1.75  2000  Ki=330nM      // 1f4g.pdf (TP4)
1qan  2.40  2000  Ki=33uM       // 1qan.pdf (SAH)
1fw0  1.90  2000  Ki=3690nM     // 1fw0.pdf (KAI) ligand is kainate
1qb9  1.80  2000  Ki=36nM       // 1qb9.pdf (806)
1eol  2.10  2000  Ki=38fM       // 1eol.pdf (15-mer)
1fq4  2.70  2000  Ki=398.0nM    // 1fq4.pdf (2Y2)
1b6p  2.00  2000  Ki=3nM        // 1b6p.pdf (PI7) incomplete ligand structure
1fq5  2.40  2000  Ki=4.0nM      // 1fq5.pdf (0GM)
1f73  1.95  2000  Ki=4.1mM      // 1f73.pdf (HMN)
1ql9  2.30  2000  Ki=4.45uM     // 1ql9.pdf (ZEN)
1qi0  2.10  2000  Ki=4.5mM      // 1qi0.pdf (CBI)
1dy4  1.90  2000  Ki=44uM       // 1dy4.pdf (SNP)
1b6m  1.85  2000  Ki=4nM        // 1b6m.pdf (PI6) redundant to 1mtr
1c88  1.80  2000  Ki=5.1uM      // 1c88.pdf (OTA)
1fh7  1.82  2000  Ki=5.8uM      // 1fh7.pdf (2-mer) ligand is XYP-XDN
1ero  2.10  2000  Ki=5.9nM      // 1ero.pdf (BJP) covalent complex
1b74  2.30  2000  Ki=50mM       // 1b74.pdf (DGN)
1qm4  2.66  2000  Ki=50uM       // 1qm4.pdf (AMB)
1e2l  2.40  2000  Ki=51.5uM     // 1e2l.pdf (TMC)
1b6l  1.75  2000  Ki=5nM        // 1b6l.pdf (PI4)
1ek2  3.00  2000  Ki=6.3nM      // 1ek2.pdf (CDU)
1ft7  2.20  2000  Ki=6.6uM      // 1ft7.pdf (PLU) Ki measured at pH=8.0
1c5y  1.65  2000  Ki=63uM       // 1c5y.pdf (ESP)
1c87  2.10  2000  Ki=63uM       // 1c87.pdf (OPA)
1f0u  1.90  2000  Ki=69nM       // 1f0u.pdf (RPR)
1bsk  3.00  2000  Ki=76uM       // 1bsk.pdf (MLN)
1e55  2.00  2000  Ki=76uM       // 1e55.pdf (2-mer) ligand is BGC-DHR; Ki measured on Glu1 wt
1gfy  2.13  2000  Ki=8.32uM     // 1gfy.pdf (COL) ligand is compound 29; -logKi=5.08
1enu  1.95  2000  Ki=8.3uM      // 1enu.pdf (APZ)
1qq9  1.53  2000  Ki=8.7mM      // 1qq9.pdf (MET)
1eix  2.50  2000  Ki=8.8pM      // 1eix.pdf (BMQ) redundant to 1x1z
1dgm  1.80  2000  Ki=8.9uM      // 1dgm.pdf (ADN) ligand is adenosine
1c5t  1.37  2000  Ki=80uM       // 1c5t.pdf (ESP)
1qb6  1.80  2000  Ki=870nM      // 1qb6.pdf (623)
8a3h  0.97  2000  Ki=88uM       // 8a3h.pdf (IDC)
1c84  2.35  2000  Ki=9.9uM      // 1c84.pdf (761)
1ci7  2.60  2000  Ki=90nM       // 1ci7.pdf (CB3)
1c5z  1.85  2000  Ki=97uM       // 1c5z.pdf (BAM)
1dqx  2.40  2000  Ki=9pM        // 1dqx.pdf (BMP) redundant to 1x1z
1jlq  3.00  2001  IC50=0.007uM  // 1jlq.pdf (SBN)
1h8y  2.00  2001  IC50=0.02uM   // 1h8y.pdf (MER)
1joj  3.00  2001  IC50=0.06mM   // 1joj.pdf (7-mer)
1jbd   NMR  2001  IC50=0.12uM   // 1hoy.pdf (14-mer) lowest-energy structure
1g37  2.00  2001  IC50=0.1nM    // 1g37.pdf (110) covalent complex
1i7m  2.24  2001  IC50=0.23nM   // 1i7m.pdf (_CG)
1ft4  2.90  2001  IC50=0.27uM   // 1ft4.pdf (703)
1hvy  1.90  2001  IC50=0.29uM   // 1hvy.pdf (D16) ligand is Raltitrexed
1jik  2.80  2001  IC50=0.2nM    // 1jik.pdf (545)
1fo3  1.75  2001  IC50=0.2uM    // 1fo3.pdf (KIF)
1jq3  1.80  2001  IC50=0.2uM    // 1jq3.pdf (AAT)
1i7c  2.40  2001  IC50=0.4uM    // 1i7c.pdf (MGB)
1k2i  1.80  2001  IC50=0.78mM   // 1k2i.pdf (SN1) covalent complex
1i91  2.00  2001  IC50=1.15nM   // 1i91.pdf (INQ)
1i8z  1.93  2001  IC50=1.27nM   // 1i8z.pdf (INL)
1i90  2.00  2001  IC50=1.28nM   // 1i90.pdf (INM)
1jvp  1.53  2001  IC50=1.6uM    // 1jvp.pdf (LIG)
1jj9  2.00  2001  IC50=1.7uM    // 1jj9.pdf (BBT)
1hc9  1.80  2001  IC50=1.9nM    // 1hc9.pdf (13-mer)
1iep  2.10  2001  IC50=100nM    // 1iep.pdf (STI)
1fvv  2.80  2001  IC50=10nM     // 1fvv.pdf (107)
1g2a  1.75  2001  IC50=10nM     // 1g2a.pdf (BB2)
1k1p  1.90  2001  IC50=11.9nM   // 1k1p.pdf (MEL) ligand is compound Melagatran
1g49  1.90  2001  IC50=16nM     // 1g49.pdf (111)
1h5u  1.76  2001  IC50=178nM    // 1h5u.pdf (CHI) IC50=334nM without glucose
1jii  3.20  2001  IC50=1nM      // 1jii.pdf (383)
1f0q  2.63  2001  IC50=1uM      // 1f0q.pdf (EMO)
1g4k  2.00  2001  IC50=2.0uM    // 1g4k.pdf (HQQ)
1ikw  3.00  2001  IC50=2.5nM    // 1ikw.pdf (EFZ)
1cs4  2.50  2001  IC50=2.7uM    // 1cs4.pdf (101)
1fo2  2.38  2001  IC50=20uM     // 1fo2.pdf (DMJ)
1haa   NMR  2001  IC50=2nM      // 1haa.pdf (13-mer)
1i32  2.60  2001  IC50=2uM      // 1i32.pdf (NMD)
1hbj  2.50  2001  IC50=3.0nM    // 1hbj.pdf (FBQ) covalent complex
1g05  2.45  2001  IC50=3.1nM    // 1g05.pdf (BBH)
1jje  1.80  2001  IC50=3.7nM    // 1jje.pdf (BYS)
1fls   NMR  2001  IC50=33nM     // 1fls.pdf (WAY)
1e9h  2.50  2001  IC50=35nM     // 1e9h.pdf (INR)
1hyz  2.30  2001  IC50=380uM    // 1hyz.pdf (TTO) incomplete ligand structure
1i8j  1.90  2001  IC50=39uM     // 1i8j.pdf (DSB)
1jij  3.20  2001  IC50=3nM      // 1jij.pdf (629)
1jk7  1.90  2001  IC50=3nM      // 1jk7.pdf (OKA)
1hs6  1.95  2001  IC50=4.2uM    // 1hs6.pdf (BES)
1g5s  2.61  2001  IC50=48nM     // 1g5s.pdf (I17)
1jil  2.20  2001  IC50=4nM      // 1jil.pdf (485)
1iky  3.00  2001  IC50=5.5nM    // 1iky.pdf (MSD)
1ikv  3.00  2001  IC50=520nM    // 1ikv.pdf (EFZ)
1i72  2.00  2001  IC50=55nM     // 1i72.pdf (MAO) ligand is compound 5
1fvt  2.20  2001  IC50=60nM     // 1fvt.pdf (106)
1ikx  2.80  2001  IC50=7.0nM    // 1ikx.pdf (PNU)
1i33  3.00  2001  IC50=75uM     // 1i33.pdf (TND)
1g27  2.10  2001  IC50=7nM      // 1g27.pdf (BB1)
1jjt  1.80  2001  IC50=9nM      // 1jjt.pdf (BDS)
1hyv  1.70  2001  IC50>5mM      // 1hyv.pdf (TTA)
1i5d  2.90  2001  Kd<0.010uM    // 1i5d.pdf (128)
1j7z  2.25  2001  Kd=0.02uM     // 1j7z.pdf (15-mer) X-ray(2M sarcosine); Kd=4.21uM(6.5 Kd=3.38uM(10     Kd=2.00uM(20     Kd=1.30uM(30     Kd=0.70uM(40     Kd=0.38uM(50     Kd=0.18uM(55     Kd=0.02uM(60
1jd6  2.70  2001  Kd=0.041uM    // 1jd6.pdf (10-mer)
1ie9  1.40  2001  Kd=0.065nM    // 1ie9.pdf (VDX) ligand is 1,25(OH)2 vitamin D3
1j81  2.20  2001  Kd=0.08uM     // 1j7z.pdf (15-mer) Kd=0.53uM(10     Kd=0.30uM(20     Kd=0.08uM(30
1hn4  1.50  2001  Kd=0.15mM     // 1hn4.pdf (MJI)
1fwv  2.20  2001  Kd=0.19mM     // 1fwv.pdf (3-mer)
1fwu  1.90  2001  Kd=0.20mM     // 1fwu.pdf (3-mer)
1jd5  1.90  2001  Kd=0.24uM     // 1jd5.pdf (10-mer)
1j4q   NMR  2001  Kd=0.36uM     // 1j4q.pdf (13-mer)
1i80  2.00  2001  Kd=0.39uM     // 1i80.pdf (9HX)
1j80  2.10  2001  Kd=0.3uM      // 1j7z.pdf (15-mer) Kd=0.88uM; Kd=0.30uM
1k3q   NMR  2001  Kd=0.3uM      // 1k3n.pdf (13-mer)
1g3f   NMR  2001  Kd=0.43uM     // 1g3f.pdf (9-mer)
1ex8  1.85  2001  Kd=0.47uM     // 1ex8.pdf (A4P) Kd=0.47uM (with Mg2+); Kd=1.93uM (without Mg2+)
1g7v  2.40  2001  Kd=0.4uM      // 1g7v.pdf (PAI)
1i7z  2.30  2001  Kd=0.4uM      // 1i7z.pdf (COC)
1ka7   NMR  2001  Kd=0.60uM     // 1ka7.pdf (12-mer)
1h6e  3.60  2001  Kd=0.7uM      // 1h6e.pdf (11-mer) incomplete ligand
1hiy  2.60  2001  Kd=0.83mM     // 1hiy.pdf (3AN)
1e3g  2.40  2001  Kd=0.99nM     // 1e3g.pdf (R18) ligand is compound 3 (RU1881)
1hn2  1.80  2001  Kd=1.0uM      // 1hn2.pdf (ANC)
1h8s  2.40  2001  Kd=1.54uM     // 1h8s.pdf (AIC)
1j4p   NMR  2001  Kd=10.2uM     // 1j4p.pdf (13-mer)
1k3n   NMR  2001  Kd=10.2uM     // 1k3n.pdf (13-mer)
1j4k   NMR  2001  Kd=100uM      // 1j4k.pdf (7-mer) redundant to 1fhr
1ih0   NMR  2001  Kd=10uM       // 1ih0.pdf (EMD)
1f90  2.60  2001  Kd=11.9nM     // 1f90.pdf (9-mer)
1k1l  2.50  2001  Kd=125nM      // 1k1l.pdf (FD3)
1fzo  1.80  2001  Kd=13nM       // 1fzo.pdf (9-mer)
1h61  1.40  2001  Kd=13uM       // 1h61.pdf (PDN)
1k1n  2.00  2001  Kd=153nM      // 1k1n.pdf (CCR)
1h62  1.90  2001  Kd=17uM       // 1h62.pdf (ANB)
1k03  2.70  2001  Kd=1uM        // 1k03.pdf (HBA)
1hq5  2.30  2001  Kd=2.22uM     // 1hq5.pdf (S2C)
1i9n  1.86  2001  Kd=2.2nM      // 1i9n.pdf (IOA)
1ha2  2.50  2001  Kd=2.9uM      // 1ha2.pdf (SWF)
1fzm  1.80  2001  Kd=20nM       // 1fzm.pdf (8-mer)
1h60  1.60  2001  Kd=20uM       // 1h60.pdf (STR)
1f47  1.95  2001  Kd=21.6uM     // 1f47.pdf (17-mer) Kd=21.6uM(binding to immobilized ZipA/M185); Kd=0.2uM(binding to soluble ZipA).
1if8  1.94  2001  Kd=230pM      // 1if8.pdf (SBS)
1ii5  1.60  2001  Kd=240nM      // 1ii5.pdf (GLU)
1joc  2.20  2001  Kd=24uM       // 1joc.pdf (ITP)
1k1i  2.20  2001  Kd=264nM      // 1k1i.pdf (FD1)
1k1j  2.20  2001  Kd=28nM       // 1k1j.pdf (FD2)
1i8h   NMR  2001  Kd=29uM       // 1i8h.pdf (13-mer)
1jgl  2.15  2001  Kd=2nM        // 1jgl.pdf (EST)
1i9l  1.93  2001  Kd=3.3nM      // 1i9l.pdf (INV)
1i9m  1.84  2001  Kd=3.3nM      // 1i9m.pdf (INW)
1i9o  1.86  2001  Kd=3.8nM      // 1i9o.pdf (IOC)
1h9z  2.50  2001  Kd=3.8uM      // 1h9z.pdf (RWF)
1i9p  1.92  2001  Kd=3.9nM      // 1i9p.pdf (IOE)
1i9q  1.80  2001  Kd=3.9nM      // 1i9q.pdf (IOF)
1imx  1.82  2001  Kd=300uM      // 1imx.pdf (CPQ)
1if7  1.98  2001  Kd=30pM       // 1if7.pdf (SBR)
1ewj  2.50  2001  Kd=32nM       // 1ewj.pdf (BLM)
1iq1  2.80  2001  Kd=35nM       // 1iq1.pdf (11-mer)
1fl6  2.80  2001  Kd=37nM       // 1fl6.pdf (AAH)
1ikt  1.75  2001  Kd=400uM      // 1ikt.pdf (OXN)
1k1m  2.20  2001  Kd=40nM       // 1k1m.pdf (FD4)
1jmq   NMR  2001  Kd=40uM       // 1jmq.pdf (10-mer)
1ilh  2.76  2001  Kd=41nM       // 1ilh.pdf (SRL)
1e3v  2.00  2001  Kd=45.74uM    // 1e3v.pdf (DXC)
1fe3  2.80  2001  Kd=46.7nM     // 1fe3.pdf (OLA)
1fzk  1.70  2001  Kd=4nM        // 1fzk.pdf (9-mer)
1h6h  1.70  2001  Kd=5.0uM      // 1h6h.pdf (PIB)
1k9r   NMR  2001  Kd=500uM      // 1k9r.pdf (6-mer)
1fdq  2.10  2001  Kd=53.4nM     // 1fdq.pdf (HXA)
1i5h   NMR  2001  Kd=53uM       // 1i5h.pdf (17-mer) Kd=53+/-8uM(150 mM KCl, 10 mM potassium phosphate, pH 7.4); Kd=21+/-3uM(10 mM sodium phosphate, pH 7.4).
1idg   NMR  2001  Kd=65nM       // 1idg.pdf (19-mer) incomplete ligand structure
1k9q   NMR  2001  Kd=700uM      // 1k9q.pdf (5-mer)
1gny  1.63  2001  Kd=73uM       // 1gny.pdf (5-mer)
1g6s  1.50  2001  Kd=7uM        // 1g6s.pdf (S3P) ligand is SHIKIMATE-3-PHOSPHATE (S3P)
1fzj  1.90  2001  Kd=8nM        // 1fzj.pdf (8-mer)
1i1e  2.50  2001  Kd=9.4uM      // 1i1e.pdf (DM2)
1j4r  1.80  2001  Ki=0.019uM    // 1j4r.pdf (001)
1f8c  1.70  2001  Ki=0.04uM     // 1f8c.pdf (4AM)
1e66  2.10  2001  Ki=0.13nM     // 1e66.pdf (HUX)
1fsy  1.75  2001  Ki=0.15uM     // 1fsy.pdf (105) covalent complex
1g7g  2.20  2001  Ki=0.25uM     // 1g7g.pdf (INX)
1jzs  2.50  2001  Ki=0.25uM     // 1jzs.pdf (MRC)
1i37  2.00  2001  Ki=0.27nM     // 1i37.pdf (DHT)
1hp0  2.10  2001  Ki=0.2uM      // 1hp0.pdf (AD3)
1k9s  2.00  2001  Ki=0.30uM     // 1k9s.pdf (FM2)
1fsw  1.90  2001  Ki=0.32uM     // 1fsw.pdf (CTB) covalent complex
1i00  2.50  2001  Ki=0.46uM     // 1i00.pdf (D16)
1hnn  2.40  2001  Ki=0.58uM     // 1hnn.pdf (SKF)
1hqh  2.80  2001  Ki=0.5uM      // 1hqh.pdf (NNH)
1f92  2.60  2001  Ki=0.64uM     // 1f92.pdf (UKP)
1e72  1.60  2001  Ki=0.6mM      // 1e72.pdf (GOX)
1jp5  2.70  2001  Ki=0.6nM      // 1jp5.pdf (9-mer) Ki measured on full length HIV-1 protease; incomplete ligand structure
1h9l  1.67  2001  Ki=0.76mM     // 1h9l.pdf (5-mer) incomplete ligand structure; covalent complex
1e6q  1.35  2001  Ki=0.7mM      // 1e6q.pdf (NTZ)
1g42  1.80  2001  Ki=0.97mM     // 1g42.pdf (CP2) Ki=0.97+/-0.085mM, ligand is 1, 2-DCP
1hqg  2.00  2001  Ki=1.0mM      // 1hqg.pdf (ORN) Ki=880mM for URE
1iih  2.20  2001  Ki=1.3mM      // 1iih.pdf (3PG)
1e1x  1.85  2001  Ki=1.3uM      // 1e1x.pdf (NW1)
1hdq  2.30  2001  Ki=1.5uM      // 1hdq.pdf (INF)
1f1j  2.35  2001  Ki=1.6nM      // 1f1j.pdf (5-mer) covalent complex
1g3c  1.80  2001  Ki=1.6uM      // 1g3c.pdf (109)
1g3b  1.80  2001  Ki=1.8uM      // 1g3b.pdf (108) Ki for Mg-108
1eub   NMR  2001  Ki=1.9nM      // 1eub.pdf (3-mer)
1e5j  1.85  2001  Ki=100uM      // 1e5j.pdf (4-mer)
1juj  3.00  2001  Ki=109nM      // 1juj.pdf (LYA)
1hlk  2.50  2001  Ki=10uM       // 1hlk.pdf (113) IC50=29uM
1hqf  2.90  2001  Ki=10uM       // 1hqf.pdf (HAR) Ki=10-42uM
1i6v  3.30  2001  Ki=10uM       // 1i6v.pdf (RFP)
1g2k  1.95  2001  Ki=11nM       // 1g2k.pdf (NM1)
1f2o  1.70  2001  Ki=12.4mM     // 1f2o.pdf (LEU) Ki measured with Ca2+
1f2p  1.80  2001  Ki=12.7mM     // 1f2p.pdf (PHE) Ki measured with Ca2+
1e1v  1.95  2001  Ki=12uM       // 1e1v.pdf (CMG)
1g30  2.00  2001  Ki=140nM      // 1g30.pdf (T87)
1f8e  1.40  2001  Ki=15uM       // 1f8e.pdf (49A)
1ga8  2.00  2001  Ki=16mM       // 1ga8.pdf (DEL)
1f28  1.90  2001  Ki=16nM       // 1f28.pdf (F89)
1f5k  1.80  2001  Ki=180uM      // 1f5k.pdf (BAM)
1fm9  2.10  2001  Ki=1nM        // 1fm9.pdf (570)
1fpy  2.89  2001  Ki=1uM        // 1fpy.pdf (PPQ)
1i48  3.25  2001  Ki=2.0uM      // 1i48.pdf (CCO)
1g5f  1.80  2001  Ki=2.31mM     // 1g5f.pdf (DCE)
1jak  1.75  2001  Ki=2.7uM      // 1jak.pdf (IFG)
1g3d  1.80  2001  Ki=2.8uM      // 1g3d.pdf (108) Ki for Cu-108
1i43  3.10  2001  Ki=200uM      // 1i43.pdf (PMC)
1iem  2.30  2001  Ki=20nM       // 1iem.pdf (CB4) covalent complex
1iew  2.55  2001  Ki=25.50uM    // 1iew.pdf (G2F) covalent complex
1iig  2.60  2001  Ki=27mM       // 1iig.pdf (3PP)
1dxp  2.40  2001  Ki=27nM       // 1dxp.pdf (16-mer) Ki=27-67nM; PDBcode:1dy9(binding with inhibitor I; PDBcode:1dy8(binding with inhibitor II); incomplete ligand
1i41  3.20  2001  Ki=27uM       // 1i41.pdf (HEN)
1hp5  2.10  2001  Ki=280nM      // 1hp5.pdf (NGT)
1g2o  1.75  2001  Ki=28pM       // 1g2o.pdf (IMH)
1f9e  2.90  2001  Ki=2nM        // 1f9e.pdf (5-mer) covalent complex
1g98  1.90  2001  Ki=2uM        // 1g98.pdf (PA5)
1g9r  2.00  2001  Ki=2uM        // 1g9r.pdf (UPF)
1jsv  1.96  2001  Ki=2uM        // 1jsv.pdf (U55)
1g7f  1.80  2001  Ki=3.4uM      // 1g7f.pdf (INZ)
1hi4  1.80  2001  Ki=32uM       // 1hi4.pdf (A3P)
1ik4  2.00  2001  Ki=39nM       // 1ik4.pdf (PGH)
1f8b  1.80  2001  Ki=4.0uM      // 1f8b.pdf (DAN)
1g3e  1.80  2001  Ki=4.2uM      // 1g3e.pdf (109) Ki for Cu-109
1hee  1.75  2001  Ki=4.6uM      // 1hee.pdf (LHY)
1k06  1.80  2001  Ki=4.6uM      // 1k06.pdf (BZD)
1k08  2.26  2001  Ki=4.6uM      // 1k08.pdf (BZD) redundant to 1k06
1f8d  1.40  2001  Ki=400uM      // 1f8d.pdf (9AM)
1g2m  3.02  2001  Ki=40nM       // 1g2m.pdf (R11)
1jh1  2.70  2001  Ki=41uM       // 1jh1.pdf (JST)
1jut  2.70  2001  Ki=47.7nM     // 1jut.pdf (LYD) Ki measured on human TS
1f5l  2.10  2001  Ki=5.3uM      // 1f5l.pdf (AMR)
1jd0  1.50  2001  Ki=5.7nM      // 1jd0.pdf (AZM) redundant to 1ydb
1f9g  2.00  2001  Ki=53mM       // 1f9g.pdf (ASC)
1g2l  1.90  2001  Ki=57nM       // 1g2l.pdf (T87)
1hv5  2.60  2001  Ki=5nM        // 1hv5.pdf (RXP)
1hi3  1.80  2001  Ki=64uM       // 1hi3.pdf (A2P)
1k1o  2.00  2001  Ki=675nM      // 1k1o.pdf (IGN)
1g36  1.90  2001  Ki=67nM       // 1g36.pdf (R11)
1efy  2.20  2001  Ki=6nM        // 1efy.pdf (BZC)
1jr1  2.60  2001  Ki=6nM        // 1jr1.pdf (MOA) Ki=6-10nM measured on IMPDH human type II
1g35  1.80  2001  Ki=7.3nM      // 1g35.pdf (AHF)
1gcz  1.90  2001  Ki=7.4uM      // 1gcz.pdf (YZ9)
1gag  2.70  2001  Ki=750nM      // 1gag.pdf (13-mer) incomplete ligand structure
1g32  1.90  2001  Ki=780nM      // 1g32.pdf (R11)
1jtq  2.50  2001  Ki=8.5nM      // 1jtq.pdf (LY3) Ki measured on LY3/TS (human)
1jjk  3.00  2001  Ki=8.8pM      // 1jjk.pdf (BMP) PH6.0
1iau  2.00  2001  Ki=80nM       // 1iau.pdf (5-mer) covalent complex
1ga9  2.10  2001  Ki=83nM       // 1ga9.pdf (ETP) covalent complex
1hyo  1.30  2001  Ki=84.8uM     // 1hyo.pdf (HBU)
1hi5  1.80  2001  Ki=92uM       // 1hi5.pdf (ADP)
1l6y  1.90  2002  IC50=0.22mM   // 1l6y.pdf (4OX) IC50=0.57mM(94min); IC50=0.22mM(16h)
1kkq  3.00  2002  IC50=0.24uM   // 1kkq.pdf (471)
1i7i  2.35  2002  IC50=0.2uM    // 1i7i.pdf (AZ2) IC50 measured on mPPAR-gamma
1il9  3.10  2002  IC50=0.40mM   // 1il9.pdf (MOG)
1m5c  1.65  2002  IC50=0.5uM    // 1m5c.pdf (BRH)
1kz8  2.00  2002  IC50=0.83uM   // 1kz8.pdf (PFE)
1gzg  1.66  2002  IC50=0.9mM    // 1gzg.pdf (LAF)
1h1q  2.50  2002  IC50=1.0uM    // 1h1q.pdf (2A6)
1i7g  2.20  2002  IC50=1.0uM    // 1i7g.pdf (AZ2)
1kat   NMR  2002  IC50=1.0uM    // 1kat.pdf (19-mer) IC50=0.3uM(VEGF1-109/v107)
1ld7  2.00  2002  IC50=1.1nM    // 1ld7.pdf (U66)
1il4  2.60  2002  IC50=1.4mM    // 1il4.pdf (9DG)
1ktt  2.10  2002  IC50=1.5uM    // 1ktt.pdf (C02)
1jyi  2.75  2002  IC50=100uM    // 1jyi.pdf (12-mer)
1kmv  1.05  2002  IC50=112nM    // 1kmv.pdf (LII) IC50 measured on rat liver DHFR
1klg  2.40  2002  IC50=13nM     // 1klg.pdf (15-mer) mutant TPI23-37(T28I) peptide/HLA-DR1 complexes, IC50=13nM
1m5f  1.95  2002  IC50=14.8nM   // 1m5f.pdf (AM1)
1juf  2.00  2002  IC50=1400nM   // 1juf.pdf (9-mer)
1iyl  3.20  2002  IC50=1nM      // 1iyl.pdf (R64)
1ke8  2.00  2002  IC50=1uM      // 1ke8.pdf (LS4)
1jiz  2.60  2002  IC50=2.0nM    // 1jiz.pdf (CGS) IC50 measured on mouse MMP-12
1il5  2.80  2002  IC50=2.2mM    // 1il5.pdf (DDP)
1h1r  2.00  2002  IC50=2.3uM    // 1h1r.pdf (6CP)
1lev  2.15  2002  IC50=2.5uM    // 1lev.pdf (CLI) IC50 measured on human F16Bpase
1m7q  2.40  2002  IC50=2.6nM    // 1m7q.pdf (DQO)
1il3  2.80  2002  IC50=2.8mM    // 1il3.pdf (7DG)
1m5e  1.46  2002  IC50=20.1nM   // 1m5e.pdf (AM1)
1hww  1.87  2002  IC50=20nM     // 1hww.pdf (SWA)
1klu  1.93  2002  IC50=25nM     // 1klg.pdf (15-mer) wild-type TPI23-37 peptide/HLA-DR1 complexes, IC50=25nM
1kak  2.50  2002  IC50=26uM     // 1kak.pdf (FNP)
1ld8  1.80  2002  IC50=3.5nM    // 1ld8.pdf (U49)
1ijr  2.20  2002  IC50=3.6uM    // 1ijr.pdf (CC0) IC50 measured on Src SH2
1eou  2.10  2002  IC50=36nM     // 1eou.pdf (SMS)
1l6s  1.70  2002  IC50=39uM     // 1l6s.pdf (DSB)
1hy7  1.50  2002  IC50=4.09uM   // 1hy7.pdf (MBS)
1kyn  3.50  2002  IC50=4.1uM    // 1kyn.pdf (KTP)
1hxk  1.50  2002  IC50=400uM    // 1hxk.pdf (DMJ)
1hty  1.40  2002  IC50=40mM     // 1hty.pdf (TRS) tris inhibit dGMII, IC50=40mM
1gmy  1.90  2002  IC50=45nM     // 1gmy.pdf (3-mer) covalent complex
1nd5  2.90  2002  IC50=4nM      // 1nd5.pdf (2BF)
1jg0  2.00  2002  IC50=5.0uM    // 1jg0.pdf (DDT)
1ke6  2.00  2002  IC50=5.7nM    // 1ke6.pdf (LS2)
1inq  2.20  2002  IC50=539nM    // 1inq.pdf (9-mer)
1ke5  2.20  2002  IC50=560nM    // 1ke5.pdf (LS1)
1jdj  2.20  2002  IC50=5mM      // 1jdj.pdf (CFP)
1lqf  2.50  2002  IC50=5nM      // 1lqf.pdf (BGD)
1g9a  2.10  2002  IC50=5uM      // 1g9a.pdf (BAB) IC50=5-10uM
1g9b  2.00  2002  IC50=5uM      // 1g9b.pdf (BAB) IC50=5-10uM
1g9c  2.35  2002  IC50=5uM      // 1g9c.pdf (BAB) IC50=5-10uM
1g9d  2.20  2002  IC50=5uM      // 1g9d.pdf (BAB) IC50=5-10uM
1k3t  1.95  2002  IC50=64uM     // 1k3t.pdf (BRZ)
1ke9  2.00  2002  IC50=660nM    // 1ke9.pdf (LS5)
1mzs  2.10  2002  IC50=7.0uM    // 1mzs.pdf (669)
1ljt  2.00  2002  IC50=7uM      // 1ljt.pdf (HDI) IC50 measured on MIF dopachrome tautomerase
1ke7  2.00  2002  IC50=8.9nM    // 1ke7.pdf (LS3)
1m5d  1.73  2002  IC50=9.2uM    // 1m5d.pdf (BRH)
1m5b  1.85  2002  IC50=9.7nM    // 1m5b.pdf (BN1)
1llb  1.72  2002  IC50=900nM    // 1llb.pdf (PCN) covalent complex
1m7y  1.60  2002  Kd=0.011nM    // 1m7y.pdf (PPG)
1lbf  2.05  2002  Kd=0.014uM    // 1lbf.pdf (137)
1jyc  2.75  2002  Kd=0.046mM    // 1jyc.pdf (15-mer) Kd rang between 0.046 and 0.23 mM (Oldenberg et al., 1992; Kaur  et  al.,  1997).
1n4k  2.20  2002  Kd=0.09nM     // 1n4k.pdf (I3P)
1lrh  1.90  2002  Kd=0.15uM     // 1lrh.pdf (NLA)
1li6  2.00  2002  Kd=0.16mM     // 1li6.pdf (5MP)
1kv2  2.80  2002  Kd=0.1nM      // 1kv2.pdf (B96)
1is0  1.90  2002  Kd=0.1uM      // 1is0.pdf (4-mer)
1gz9  1.70  2002  Kd=0.31mM     // 1gz9.pdf (FUC-LAT)
1gzc  1.58  2002  Kd=0.32mM     // 1gzc.pdf (LAT)
1esz  2.00  2002  Kd=0.3uM      // 1esz.pdf (CPO)
1gx8  2.40  2002  Kd=0.43uM     // 1gx8.pdf (RTL) compound retinoids 1, chance of additional binding site in the cases of 1
1m83  2.20  2002  Kd=0.4mM      // 1m83.pdf (ATP)
1g50  2.90  2002  Kd=0.53uM     // 1g50.pdf (EST)
1gui  1.90  2002  Kd=0.53uM     // 1gui.pdf (6-mer)
1lhw  1.75  2002  Kd=0.832nM    // 1lhw.pdf (ESM) ligand is compound 12, pKd=9.08
1lgt  1.70  2002  Kd=0.8uM      // 1lgt.pdf (BP3) Ki=2.75mM is for steady-state kinetic parameter for DHBD for chlorinated DHBs
1kdk  1.70  2002  Kd=0.9nM      // 1kdk.pdf (DHT)
1kl5  1.80  2002  Kd=1.02uM     // 1kl5.pdf (9-mer) incomplete ligand structure
1kv1  2.50  2002  Kd=1.16uM     // 1kv1.pdf (BMU)
1lhv  2.00  2002  Kd=1.23nM     // 1lhv.pdf (NOG) ligand is D-NORGESTREL, pKd=8.91
1kzn  2.30  2002  Kd=1.2nM      // 1kzn.pdf (CBN)
1kyv  2.40  2002  Kd=1.2uM      // 1kyv.pdf (RBF)
1kl3  1.70  2002  Kd=1.37uM     // 1kl3.pdf (9-mer) incomplete ligand structure
1lek  2.15  2002  Kd=1.3nM      // 1lek.pdf (8-mer)
1lhu  1.80  2002  Kd=1.48nM     // 1lhu.pdf (EST) ligand is compound 20; -logKd=8.83
1guw   NMR  2002  Kd=1.9uM      // 1guw.pdf (18-mer) Kd=0.7(HP1/Lys-9-methylated peptide)
1m74  3.00  2002  Kd=100nM      // 1m74.pdf (ADP) Kd for Mg-ADP
1lgw  1.85  2002  Kd=100uM      // 1lgw.pdf (1AN)
1l5q  2.25  2002  Kd=108uM      // 1l5q.pdf (CFF)
1jm4   NMR  2002  Kd=10uM       // 1jm4.pdf (11-mer) Tat AcK50
1jpl  2.40  2002  Kd=10uM       // 1jpl.pdf (12-mer) incomplete ligand structure
1leg  1.75  2002  Kd=11.1nM     // 1leg.pdf (8-mer)
1k6v  2.00  2002  Kd=120nM      // 1k6v.pdf (XN2)
1mwt  2.45  2002  Kd=13.3mM     // 1mwt.pdf (PNM) ligand is penicillin G
1h2t  2.15  2002  Kd=13nM       // 1h2t.pdf (GDP-7MG)
1h2u  2.40  2002  Kd=13nM       // 1h2u.pdf (GDP-7MG) redundant to 1h2t
1h79  2.90  2002  Kd=13uM       // 1h79.pdf (TTP)
1l5r  2.10  2002  Kd=17uM       // 1l5r.pdf (RBF)
1h7a  2.75  2002  Kd=19uM       // 1h7a.pdf (DTP)
1lvc  3.60  2002  Kd=1uM        // 1lvc.pdf (DOT)
1kne  2.40  2002  Kd=2.5uM      // 1kne.pdf (15-mer) incomplete ligand structure
1kf0  2.50  2002  Kd=2.80mM     // 1kf0.pdf (ACP) Kd for Mg-ACP
1mwn   NMR  2002  Kd=200nM      // 1mwn.pdf (12-mer) Kd=200-300nM
1l2z   NMR  2002  Kd=203uM      // 1l2z.pdf (11-mer)
1i8i  2.40  2002  Kd=22nM       // 1i8i.pdf (12-mer) DSFV MR1 binds to EGFRVIII peptide, Kd=22nM measured at room temperature; incomplete ligand
1l0a  2.90  2002  Kd=23.9uM     // 1kzz.pdf (18-mer)
1j5i   NMR  2002  Kd=230uM      // 1j5i.pdf (NCZ)
1k6t  2.25  2002  Kd=24nM       // 1k6t.pdf (XN1)
1gwr  2.40  2002  Kd=250nM      // 1gwr.pdf (12-mer) incomplete ligand structure
1mq1   NMR  2002  Kd=260nM      // 1mq1.pdf (12-mer)
1jyq  2.00  2002  Kd=2nM        // 1jyq.pdf (4-mer)
1g85  1.80  2002  Kd=3.3uM      // 1g85.pdf (3OL)
1jq9  1.80  2002  Kd=3.57nM     // 1jq9.pdf (5-mer)
1lf8  2.30  2002  Kd=3.5uM      // 1lf8.pdf (12-mer) incomplete ligand structure
1h0a  1.70  2002  Kd=3.6uM      // 1h0a.pdf (I3P)
1k6c  2.20  2002  Kd=33nM       // 1k6c.pdf (MK1)
1k2v  1.97  2002  Kd=36uM       // 1k2v.pdf (DEF)
1k6p  2.20  2002  Kd=44nM       // 1k6p.pdf (XN3)
1n5z  2.70  2002  Kd=44uM       // 1n5z.pdf (14-mer) Kd=36uM(Pex13p SH3 domain/Pex5p); incomplete ligand
1jlr  2.45  2002  Kd=465uM      // 1jlr.pdf (GTP)
1gu3  2.30  2002  Kd=47.6uM     // 1gu3.pdf (5-mer)
1fd0  1.38  2002  Kd=4nM        // 1fd0.pdf (254)
1l5s  2.10  2002  Kd=550uM      // 1l5s.pdf (URC)
1juq  2.20  2002  Kd=56uM       // 1juq.pdf (13-mer) incomplete ligand structure
1li3  1.85  2002  Kd=56uM       // 1li3.pdf (3CH)
1kll  1.50  2002  Kd=6.3uM      // 1kll.pdf (_MC)
1jif  1.60  2002  Kd=630nM      // 1jif.pdf (BLM)
1lxh   NMR  2002  Kd=65nM       // 1lxg.pdf (19-mer) the minimized average structure; incomplete ligand
1lbk  1.86  2002  Kd=668uM      // 1lbk.pdf (GSH)
1lkx  3.00  2002  Kd=7.1uM      // 1lkx.pdf (ADP)
1gwq  2.45  2002  Kd=76nM       // 1gwq.pdf (9-mer) incomplete ligand structure
1kna  2.10  2002  Kd=7uM        // 1kna.pdf (15-mer) incomplete ligand structure
1m48  1.95  2002  Kd=8.2uM      // 1m48.pdf (FRG)
1gni  2.40  2002  Kd=8.5nM      // 1gni.pdf (OLA)
1lxf   NMR  2002  Kd=80uM       // 1lxf.pdf (BEP) Kd=550uM for 17-mer
1lb6  1.80  2002  Kd=84uM       // 1lb6.pdf (9-mer)
1g7q  1.60  2002  Kd=877nM      // 1g7q.pdf (8-mer)
1ez9  1.90  2002  Kd=8uM        // 1ez9.pdf (4-mer)
1kmy  2.00  2002  Kd=8uM        // 1kmy.pdf (BPY)
1g7p  1.50  2002  Kd=90nM       // 1g7p.pdf (9-mer)
1gnj  2.60  2002  Kd=91nM       // 1gnj.pdf (ACD) Kd for the first ACD
1li2  2.00  2002  Kd=91uM       // 1li2.pdf (IPH)
1l7x  2.30  2002  Kd=92uM       // 1l7x.pdf (CFF)
1kc5  2.50  2002  Kd~0.1uM      // 1kc5.pdf (15-mer) Kd is not exact value
1kcs  2.50  2002  Kd~0.1uM      // 1kc5.pdf (15-mer) Kd is not exact value
1m21  1.80  2002  Ki<0.3uM      // 1m21.pdf (4-mer)
1ghy  1.85  2002  Ki=0.008uM    // 1ghy.pdf (121) Ki for Zn-121
1gj7  1.50  2002  Ki=0.013uM    // 1gj7.pdf (132)
1izh  1.90  2002  Ki=0.02uM     // 1izh.pdf (Q50)
1gi4  1.37  2002  Ki=0.065uM    // 1gi4.pdf (122) Ki for Zn-122
1d4h  1.81  2002  Ki=0.10nM     // 1d4h.pdf (BEH)
1ec2  2.00  2002  Ki=0.10nM     // 1ec2.pdf (BEJ)
1gj6  1.50  2002  Ki=0.10uM     // 1gj6.pdf (132)
1gj8  1.64  2002  Ki=0.11uM     // 1gj8.pdf (133)
1mto  3.20  2002  Ki=0.11uM     // 1mto.pdf (F6P)
1kuk  1.45  2002  Ki=0.124mM    // 1kuk.pdf (3-mer)
1m0q  2.00  2002  Ki=0.13mM     // 1m0q.pdf (EPC)
1kug  1.37  2002  Ki=0.160mM    // 1kug.pdf (3-mer)
1kui  1.50  2002  Ki=0.169mM    // 1kui.pdf (3-mer)
1h1b  2.00  2002  Ki=0.16nM     // 1h1b.pdf (151) covalent complex
1ihy  3.00  2002  Ki=0.18mM     // 1ihy.pdf (APR)
1kqb  1.80  2002  Ki=0.1mM      // 1kqb.pdf (BEZ)
1eby  2.29  2002  Ki=0.20nM     // 1eby.pdf (BEB)
1ke3  2.15  2002  Ki=0.20uM     // 1ke3.pdf (BDB) covalent complex
1izi  2.15  2002  Ki=0.26uM     // 1izi.pdf (Q50)
1gzv  3.51  2002  Ki=0.27uM     // 1gzv.pdf (PA5)
1gz4  2.20  2002  Ki=0.2mM      // 1gz4.pdf (ATP)
1loq  1.50  2002  Ki=0.2mM      // 1loq.pdf (U)
1kf6  2.70  2002  Ki=0.2uM      // 1kf6.pdf (HQO) E. coli Quinol-Fumarate Reductase with HQNO, Ki=0.2uM
1koj  1.90  2002  Ki=0.2uM      // 1koj.pdf (PAN)
1gpn  2.35  2002  Ki=0.334uM    // 1gpn.pdf (HUB)
1j01  2.00  2002  Ki=0.34uM     // 1j01.pdf (XIL)
1jqe  1.91  2002  Ki=0.36uM     // 1jqe.pdf (QUN) Ki=9.0uM for SAH
1m4h  2.10  2002  Ki=0.3nM      // 1m4h.pdf (7-mer)
1ebz  2.01  2002  Ki=0.40nM     // 1ebz.pdf (BEC)
1lol  1.90  2002  Ki=0.41uM     // 1lol.pdf (XMP)
1gjb  1.90  2002  Ki=0.45uM     // 1gjb.pdf (130) redundant to 1gjc
1gjc  1.73  2002  Ki=0.45uM     // 1gjc.pdf (130)
1ksn  2.10  2002  Ki=0.4nM      // 1ksn.pdf (FXV)
1gqs  3.00  2002  Ki=0.5uM      // 1gqs.pdf (SAF)
1gi6  1.49  2002  Ki=0.60uM     // 1gi6.pdf (124)
1ew9  2.00  2002  Ki=0.6mM      // 1ew9.pdf (MMQ)
1l8g  2.50  2002  Ki=0.6uM      // 1l8g.pdf (DBD) ligand is compound f1; protein is PTPN1
1gvk  0.94  2002  Ki=0.89mM     // 1gvk.pdf (4-mer) covalent complex
1h22  2.15  2002  Ki=0.8nM      // 1h22.pdf (E10)
1ebw  1.81  2002  Ki=0.90nM     // 1ebw.pdf (BEI)
1ec3  1.80  2002  Ki=0.92nM     // 1ec3.pdf (MS3)
1jq8  2.00  2002  Ki=1.01uM     // 1jq8.pdf (5-mer)
1fv0  1.70  2002  Ki=1.18uM     // 1fv0.pdf (9AR)
1ec1  2.10  2002  Ki=1.20nM     // 1ec1.pdf (BEE)
1h2k  2.15  2002  Ki=1.2mM      // 1h2k.pdf (OGA) ligand is compound 31
1mui  2.80  2002  Ki=1.3pM      // 1mui.pdf (AB1)
1d4i  1.81  2002  Ki=1.40nM     // 1d4i.pdf (BEG)
1k4g  1.70  2002  Ki=1.4uM      // 1k4g.pdf (AIQ)
1kpm  1.80  2002  Ki=1.59uM     // 1kpm.pdf (VIT)
1kav  2.35  2002  Ki=1.5uM      // 1kav.pdf (FEP)
1kds  2.15  2002  Ki=1.7uM      // 1kds.pdf (NPB) covalent complex
1lf3  2.70  2002  Ki=100nM      // 1lf3.pdf (EH5)
1gvw  1.00  2002  Ki=110nM      // 1gvw.pdf (0EM)
1h5v  1.10  2002  Ki=117uM      // 1h5v.pdf (5-mer)
1gj5  1.73  2002  Ki=11uM       // 1gj5.pdf (130)
1km3  1.50  2002  Ki=12.4uM     // 1km3.pdf (UP6) ligand is compound 3
1h1p  2.10  2002  Ki=12uM       // 1h1p.pdf (CMG) redundant to 1e1v
1jqy  2.14  2002  Ki=12uM       // 1jqy.pdf (A32)
1j15  2.00  2002  Ki=143uM      // 1j15.pdf (BEN) redundant to 1j16
1j16  1.60  2002  Ki=143uM      // 1j16.pdf (BEN)
1me4  1.20  2002  Ki=146nM      // 1me4.pdf (T10)
1jwt  2.50  2002  Ki=14nM       // 1jwt.pdf (BLI)
1nde  3.00  2002  Ki=15nM       // 1nde.pdf (MON)
1ghz  1.39  2002  Ki=16uM       // 1ghz.pdf (120)
1lee  1.90  2002  Ki=18nM       // 1lee.pdf (R36)
1gvu  0.94  2002  Ki=1nM        // 1gvu.pdf (10-mer) incomplete ligand structure
1iup  1.60  2002  Ki=2.9mM      // 1iup.pdf (ALQ) X-ray(Cumd S103A) while Ki(CumD wild type)
1kdw  2.28  2002  Ki=2.9uM      // 1kdw.pdf (4CB) covalent complex
1h4w  1.70  2002  Ki=22uM       // 1h4w.pdf (BEN)
1m1b  2.25  2002  Ki=22uM       // 1m1b.pdf (SPV)
1gyy  1.35  2002  Ki=230uM      // 1gyy.pdf (FHC)
1g9s  2.80  2002  Ki=247uM      // 1g9s.pdf (IMP)
1l2s  1.94  2002  Ki=26uM       // 1l2s.pdf (STC)
1n1m  2.50  2002  Ki=2uM        // 1n1m.pdf (A3M)
1ec0  1.79  2002  Ki=3.2nM      // 1ec0.pdf (BED)
1gyx  1.35  2002  Ki=3.3mM      // 1gyx.pdf (BEZ) Ki=13.9mM for EPE
1gi1  1.42  2002  Ki=3.4uM      // 1gi1.pdf (BMZ) Ki measured at pH=7.72
1gja  1.56  2002  Ki=3.8uM      // 1gja.pdf (135)
1jys  1.90  2002  Ki=300uM      // 1jys.pdf (ADE)
1lf2  1.80  2002  Ki=30nM       // 1lf2.pdf (R37)
1gu1  1.80  2002  Ki=30uM       // 1gu1.pdf (FA1)
1gi7  1.79  2002  Ki=31uM       // 1gi7.pdf (120)
1j14  2.40  2002  Ki=32.2uM     // 1j14.pdf (BEN)
1iiq  1.83  2002  Ki=33nM       // 1iiq.pdf (0ZR)
1h8l  2.60  2002  Ki=34nM       // 1h8l.pdf (GEM)
1kti  1.97  2002  Ki=370uM      // 1kti.pdf (AZC)
1eb1  1.80  2002  Ki=37pM       // 1eb1.pdf (10-mer)
1kc7  2.20  2002  Ki=3uM        // 1kc7.pdf (PPR)
1it6  2.00  2002  Ki=4.1nM      // 1it6.pdf (CYU) incomplete ligand structure
1k21  1.86  2002  Ki=4.2nM      // 1k21.pdf (IGN)
1ke0  2.30  2002  Ki=4.2uM      // 1ke0.pdf (CVB) covalent complex
1gpk  2.10  2002  Ki=4.3uM      // 1gpk.pdf (HUP)
1d4j  1.81  2002  Ki=4.40nM     // 1d4j.pdf (MSC)
1h23  2.15  2002  Ki=4.5nM      // 1h23.pdf (E12)
1m0o  2.40  2002  Ki=4.9mM      // 1m0o.pdf (MPM) Ki=0.5mM when preincubated with DGD for 30min
1kzk  1.09  2002  Ki=41pM       // 1kzk.pdf (JE2)
1mhw  1.90  2002  Ki=45nM       // 1mhw.pdf (5-mer)
1ghv  1.85  2002  Ki=45uM       // 1ghv.pdf (120)
1i2s  1.70  2002  Ki=490uM      // 1i2s.pdf (CIT) ligand is citrate
1k22  1.93  2002  Ki=4nM        // 1k22.pdf (MEL)
1kfy  3.60  2002  Ki=5.2uM      // 1kfy.pdf (BRS)
1ew8  2.20  2002  Ki=5.5mM      // 1ew8.pdf (PAE)
1g9t  2.80  2002  Ki=526uM      // 1g9t.pdf (5GP)
1j17  2.00  2002  Ki=6.05uM     // 1j17.pdf (ZEN)
1m0n  2.20  2002  Ki=6.0mM      // 1m0n.pdf (HCP)
1gi9  1.80  2002  Ki=6.0uM      // 1gi9.pdf (123)
1gjd  1.75  2002  Ki=6.0uM      // 1gjd.pdf (136)
1jqd  2.28  2002  Ki=6.9uM      // 1jqd.pdf (SAH)
1gvx  1.00  2002  Ki=60nM       // 1gvx.pdf (6-mer)
1ll4  2.80  2002  Ki=60nM       // 1ll4.pdf (3-mer)
1kv5  1.65  2002  Ki=60uM       // 1kv5.pdf (PGA)
1ghw  1.75  2002  Ki=63uM       // 1ghw.pdf (BMZ)
1me3  1.20  2002  Ki=64.6nM     // 1me3.pdf (P10)
1los  1.90  2002  Ki=64nM       // 1los.pdf (UP6) X-ray(R203A) while Ki(wild type)
1h1s  2.00  2002  Ki=6nM        // 1h1s.pdf (4SP)
1h1h  2.00  2002  Ki=6uM        // 1h1h.pdf (A2P) Ki=6-7uM
1jcx  1.80  2002  Ki=7.0uM      // 1jcx.pdf (PAI)
1k4h  1.80  2002  Ki=7.7uM      // 1k4h.pdf (APQ)
1jvu  1.78  2002  Ki=7uM        // 1jvu.pdf (C2P) ligand is 2'-CMP
1lor  1.60  2002  Ki=8.8pM      // 1lor.pdf (BMP) redundant to 1x1z
1gi8  1.75  2002  Ki=8.9uM      // 1gi8.pdf (BMZ)
1gj4  1.81  2002  Ki=85uM       // 1gj4.pdf (132)
1eb2  2.00  2002  Ki=980nM      // 1eb2.pdf (BPO)
1oit  1.60  2003  IC50<0.003uM  // 1oit.pdf (HDT)
1nju  2.70  2003  IC50<0.05uM   // 1nju.pdf (0FP) covalent complex
1nkm  2.70  2003  IC50<0.05uM   // 1nkm.pdf (0FP) covalent complex; redundant to 1nju
1q6m  2.20  2003  IC50=0.013uM  // 1q6m.pdf (P27)
1q6j  2.20  2003  IC50=0.016uM  // 1q6j.pdf (335)
1q6n  2.10  2003  IC50=0.023uM  // 1q6n.pdf (P90)
1j1a  2.20  2003  IC50=0.029uM  // 1j1a.pdf (BHP)
1onp  2.50  2003  IC50=0.030uM  // 1onp.pdf (FOM)
1oir  1.91  2003  IC50=0.032uM  // 1oir.pdf (HDY)
1ogu  2.60  2003  IC50=0.034uM  // 1ogu.pdf (ST8)
1nq0  2.40  2003  IC50=0.048nM  // 1nq0.pdf (4HY) ligand is compound 2, -logIC50=10.32
1mzc  2.00  2003  IC50=0.06nM   // 1mzc.pdf (BNE)
1nyx  2.65  2003  IC50=0.092uM  // 1nyx.pdf (DRF)
1g3m  1.70  2003  IC50=0.10nM   // 1g3m.pdf (PCQ) IC50=0.10-0.19nM
1ouk  2.50  2003  IC50=0.13nM   // 1ouk.pdf (084)
1n7t   NMR  2003  IC50=0.15uM   // 1n7t.pdf (7-mer)
1okx  2.80  2003  IC50=0.16uM   // 1okx.pdf (8-mer)
1mqd  1.46  2003  IC50=0.17uM   // 1mqd.pdf (SHI) crystal without zinc
1ms7  1.97  2003  IC50=0.17uM   // 1ms7.pdf (SHI) crystal with zinc
1pqc  2.80  2003  IC50=0.1uM    // 1pqc.pdf (444) ligand is compound 2, T0901317. scintillation proximity ligand binding assay (SPA)
1kwr  2.25  2003  IC50=0.25uM   // 1kwr.pdf (SG2)
1mqh  1.80  2003  IC50=0.30uM   // 1mqh.pdf (BWD)
1q9m  2.30  2003  IC50=0.33uM   // 1q9m.pdf (ROL)
1nl4  2.70  2003  IC50=0.39nM   // 1nl4.pdf (FTL)
1mqg  2.15  2003  IC50=0.52uM   // 1mqg.pdf (IWD)
1ol2  2.60  2003  IC50=0.53uM   // 1ol2.pdf (6-mer) IC50=7.2uM for CDK2-cyclin A kinase activity
1oyn  2.00  2003  IC50=0.55uM   // 1oyn.pdf (ROL)
1kwq  2.60  2003  IC50=0.62nM   // 1kwq.pdf (SG1)
1okv  2.40  2003  IC50=0.68uM   // 1okv.pdf (6-mer) IC50=7.7uM for CDK2-cyclin A kinase activity
1ove  2.10  2003  IC50=0.74nM   // 1ove.pdf (358)
1pxl  2.50  2003  IC50=0.9uM    // 1pxl.pdf (CK4) IC50 for CDK2-cyclin E kinase inhibition
1n94  3.50  2003  IC50=1.1nM    // 1n94.pdf (TIN)
1n95  2.30  2003  IC50=1.2nM    // 1n95.pdf (FTH)
1o5m  2.30  2003  IC50=1.9nM    // 1o5m.pdf (336)
1nzq  2.18  2003  IC50=11nM     // 1nzq.pdf (162)
1n0t  2.10  2003  IC50=12.2uM   // 1n0t.pdf (AT1)
1p2a  2.50  2003  IC50=12nM     // 1p2a.pdf (5BN)
1q6s  2.20  2003  IC50=12nM     // 1q6s.pdf (214)
1h0w  2.10  2003  IC50=13uM     // 1h0w.pdf (207)
1pxj  2.30  2003  IC50=13uM     // 1pxj.pdf (CK2) IC50 for CDK2-cyclin E kinase inhibition
1h3b  2.80  2003  IC50=141nM    // 1h3b.pdf (R46)
1p5e  2.22  2003  IC50=15.6uM   // 1p5e.pdf (TBS) IC50 for TBS/CDK2
1pmv  2.50  2003  IC50=150nM    // 1pmv.pdf (537)
1q3d  2.20  2003  IC50=15nM     // 1q3d.pdf (STU)
1njt  2.50  2003  IC50=15uM     // 1njt.pdf (6-mer) covalent complex
1mkd  2.90  2003  IC50=160nM    // 1mkd.pdf (ZAR)
1pxi  1.95  2003  IC50=17uM     // 1pxi.pdf (CK1) IC50 for CDK2-cyclin E kinase inhibition
1m51  2.25  2003  IC50=18.8uM   // 1m51.pdf (TSX)
1o6h  2.80  2003  IC50=186nM    // 1o6h.pdf (W37)
1h36  2.80  2003  IC50=18nM     // 1h36.pdf (R88)
1urc  2.60  2003  IC50=19.2uM   // 1urc.pdf (6-mer)
1uom  2.28  2003  IC50=19nM     // 1uom.pdf (PTI) IC50 measured on full length ERalpha
1npw  2.00  2003  IC50=2.0nM    // 1npw.pdf (LGZ)
1nhx  2.10  2003  IC50=2.11uM   // 1nhx.pdf (FTB)
1n9a  3.20  2003  IC50=2.2nM    // 1n9a.pdf (FTI)
1pxk  2.80  2003  IC50=2.2uM    // 1pxk.pdf (CK3) IC50 for CDK2-cyclin E kinase inhibition
1oiq  2.31  2003  IC50=2.9uM    // 1oiq.pdf (HDU)
1mm6  2.15  2003  IC50=20nM     // 1mm6.pdf (QUS) crystal without zinc
1mm7  1.65  2003  IC50=20nM     // 1mm7.pdf (QUS) crystal with zinc
1pyw  2.10  2003  IC50=20nM     // 1pyw.pdf (10-mer)
1ol1  2.90  2003  IC50=21uM     // 1ol1.pdf (6-mer) IC50=37uM for CDK2-cyclin A kinase activity
1q41  2.10  2003  IC50=22nM     // 1q41.pdf (IXM)
1h01  1.79  2003  IC50=22uM     // 1h01.pdf (FAL) racemic ligand
1mqi  1.35  2003  IC50=23.53nM  // 1mqi.pdf (FWD)
1o6q  2.80  2003  IC50=23nM     // 1o6q.pdf (R17)
1h3a  2.85  2003  IC50=281nM    // 1h3a.pdf (R04)
1h39  2.80  2003  IC50=289nM    // 1h39.pdf (R03)
1h08  1.80  2003  IC50=28uM     // 1h08.pdf (BYP) racemic ligand BYP/BWP
1h35  2.80  2003  IC50=29nM     // 1h35.pdf (R01)
1nnk  1.85  2003  IC50=3.5uM    // 1nnk.pdf (CE2)
1h3c  2.90  2003  IC50=306nM    // 1h3c.pdf (R79)
1h00  1.60  2003  IC50=38uM     // 1h00.pdf (FCP/FAP) isomer
1q6p  2.30  2003  IC50=3nM      // 1q6p.pdf (213)
1h07  1.85  2003  IC50=3uM      // 1h07.pdf (MFP/MFQ) isomer
1mxu  1.80  2003  IC50=4.0uM    // 1mxu.pdf (BWD)
1my3  1.75  2003  IC50=4.0uM    // 1my3.pdf (BWD)
1ouy  2.50  2003  IC50=4.3nM    // 1ouy.pdf (094)
1mqj  1.65  2003  IC50=4.76uM   // 1mqj.pdf (HWD)
1rgj   NMR  2003  IC50=4.9nM    // 1rgj.pdf (13-mer)
1o79  2.80  2003  IC50=406nM    // 1o79.pdf (R23)
1q3w  2.30  2003  IC50=4nM      // 1q3w.pdf (ATU)
1okw  2.50  2003  IC50=5.6uM    // 1okw.pdf (7-mer) IC50=31uM for CDK2-cyclin A kinase activity
1nmk  2.10  2003  IC50=5.7nM    // 1nmk.pdf (SFM)
1npv  2.00  2003  IC50=5.7nM    // 1npv.pdf (L27)
1pmu  2.70  2003  IC50=590nM    // 1pmu.pdf (9HP)
1h37  2.80  2003  IC50=59nM     // 1h37.pdf (R02)
1q6t  2.30  2003  IC50=5nM      // 1q6t.pdf (600)
1o0d  2.44  2003  IC50=6.2nM    // 1o0d.pdf (163)
1onh  1.38  2003  IC50=6.2nM    // 1onh.pdf (WY4) covalent complex
1oe0  2.40  2003  IC50=6.9uM    // 1oe0.pdf (TTP)
1gsz  2.80  2003  IC50=61nM     // 1gsz.pdf (R71)
1pmn  2.20  2003  IC50=7.1nM    // 1pmn.pdf (984)
1pmx   NMR  2003  IC50=7.2uM    // 1pmx.pdf (16-mer) obtained for wild-type IGF-F1-1 displayed on the gene-3 coat protein (7.2 uM).
1pq6  2.40  2003  IC50=7.94nM   // 1pq6.pdf (965) ligand is compound 2, pIC50=8.1
1o6r  2.70  2003  IC50=80nM     // 1o6r.pdf (R19)
1ong  1.10  2003  IC50=9nM      // 1ong.pdf (WY4) covalent complex
1n1g  2.50  2003  IC50~5mM      // 1n1g.pdf (BCP)
1nfs  1.96  2003  Kd<0.12nM     // 1nfs.pdf (DED) Kd measured on IPP isomerase (claviceps purpurea)
1nf8  1.60  2003  Kd=0.015uM    // 1nf8.pdf (ISC)
1o7o  1.97  2003  Kd=0.032mM    // 1o7o.pdf (UDP)
1gx0  1.80  2003  Kd=0.060mM    // 1gx0.pdf (UDP) ligand is UDP-GAL
1nzl  1.90  2003  Kd=0.07uM     // 1nzl.pdf (8-mer)
1mv0   NMR  2003  Kd=0.0933mM   // 1mv0.pdf (14-mer) Kd=0.0933+/-0.0612mM
1oeb  1.76  2003  Kd=0.118uM    // 1oeb.pdf (13-mer) incomplete ligand
1q72  1.70  2003  Kd=0.14uM     // 1q72.pdf (COC)
1qyg  1.81  2003  Kd=0.14uM     // 1qyg.pdf (BCG)
1p1n  1.60  2003  Kd=0.16uM     // 1p1n.pdf (KAI)
1hk2  2.80  2003  Kd=0.17uM     // 1hk2.pdf (T44)
1usi  1.80  2003  Kd=0.18uM     // 1usi.pdf (PHE)
1ugy  2.40  2003  Kd=0.19mM     // 1ugy.pdf (GAL-GLC)
1n4m  2.20  2003  Kd=0.19uM     // 1n4m.pdf (18-mer) Kd=0.19+/-0.04uM
1ov3  1.80  2003  Kd=0.19uM     // 1ov3.pdf (18-mer) Kd=0.19uM(Isothermal Titration Calorimetry); Kd=0.4uM(Fluorescence Intensity Titrations); incomplete ligand
1o5p   NMR  2003  Kd=0.1nM      // 1o5p.pdf (CHR)
1gww  1.80  2003  Kd=0.258mM    // 1gww.pdf (UDP) ligand is UDP-GLC
1hk3  2.80  2003  Kd=0.26uM     // 1hk3.pdf (T44)
1mrw  2.00  2003  Kd=0.2nM      // 1mrw.pdf (K57)
1g74  1.70  2003  Kd=0.30uM     // 1g74.pdf (OLA)
1o9k  2.60  2003  Kd=0.34uM     // 1o9k.pdf (18-mer) Kd=0.34+/-0.02uM
1gt3  1.80  2003  Kd=0.35uM     // 1gt3.pdf (DHM)
1ms6  1.90  2003  Kd=0.3nM      // 1ms6.pdf (BLN) covalent complex
1gt4  2.10  2003  Kd=0.3uM      // 1gt4.pdf (UNA)
1h28  2.80  2003  Kd=0.3uM      // 1h25.pdf (11-mer) 11-Mer PEPTIDE of P107 bound to phospho-CDK2/cyclin A, Kd=0.3uM. Ligand in structure has 10-mer, GSAKRRLFGE. Kd(6-mer, RRLFGE)=2.4uM
1nzv  2.10  2003  Kd=0.40uM     // 1nzv.pdf (8-mer)
1usk  2.00  2003  Kd=0.40uM     // 1usk.pdf (LEU)
1m7d  2.30  2003  Kd=0.59uM     // 1m7d.pdf (3-mer)
1h24  2.50  2003  Kd=0.5uM      // 1h24.pdf (9-mer)
1mh5  2.10  2003  Kd=0.61nM     // 1mh5.pdf (HAL)
1njf  2.30  2003  Kd=0.62uM     // 1njf.pdf (AGS) Kd=1.03uM for ADP; Kd=1.36uM for ATP
1msn  2.00  2003  Kd=0.81nM     // 1msn.pdf (JE2)
1ogx  2.00  2003  Kd=0.81uM     // 1ogx.pdf (EQU)
1ugw  1.70  2003  Kd=0.82mM     // 1ugw.pdf (GAL)
1gt5  2.08  2003  Kd=0.8uM      // 1gt5.pdf (BZQ)
1ogd  1.95  2003  Kd=0.93mM     // 1ogd.pdf (RIP)
1n8u  1.80  2003  Kd=0.93uM     // 1n8u.pdf (BDD) redundant to 1n8v
1n8v  1.39  2003  Kd=0.93uM     // 1n8v.pdf (BDD)
1q8u  1.90  2003  Kd=1.1uM      // 1q8u.pdf (H52)
1ugx  1.60  2003  Kd=1.24uM     // 1ugx.pdf (GAL-MGC)
1ogz  2.30  2003  Kd=1.4uM      // 1ogz.pdf (EQU) Kd=1.4+/-0.1uM
1ols  1.85  2003  Kd=1.52uM     // 1ols.pdf (TDP)
1ntv  1.50  2003  Kd=1.5uM      // 1ntv.pdf (14-mer) incomplete ligand structure
1urg  1.80  2003  Kd=1.5uM      // 1urg.pdf (MAL)
1p1o  1.60  2003  Kd=1.74uM     // 1p1o.pdf (QUS)
1mjj  2.10  2003  Kd=1.83nM     // 1mjj.pdf (HAL)
1h25  2.50  2003  Kd=1.8uM      // 1h25.pdf (11-mer) 11-Mer PEPTIDE of RETINOBLASTOMA bound to phospho-CDK2/cyclin A, Kd=1.8uM. Ligand in structure has 10-mer, PKPLKKLRFD.Kd(6-mer, KKLRFD)=2.3uM; incomplete ligand
1n7m  1.80  2003  Kd=1.96uM     // 1n7m.pdf (NMP)
1obx  1.35  2003  Kd=1.9uM      // 1obx.pdf (8-mer) incomplete ligand
1r0p  1.80  2003  Kd=10nM       // 1r0p.pdf (KSA)
1oai  1.00  2003  Kd=10uM       // 1oai.pdf (9-mer)
1r2b  2.20  2003  Kd=11.4uM     // 1r2b.pdf (17-mer) Kd=11.4+/-1uM(ITC)
1n3w  2.60  2003  Kd=110nM      // 1n3w.pdf (MAL)
1p1q  2.00  2003  Kd=12.8uM     // 1p1q.pdf (AMQ)
1i3z  2.15  2003  Kd=131nM      // 1i3z.pdf (14-mer) incomplete ligand
1r0x  2.20  2003  Kd=149uM      // 1r0x.pdf (ATP)
1r10  3.00  2003  Kd=149uM      // 1r10.pdf (ATP)
1jws  2.60  2003  Kd=14uM       // 1jwm.pdf (13-mer) HLA-DR1(HA peptide 306-318) complex with SEC3 3B1, Kd=14uM
1j19  2.40  2003  Kd=16.4nM     // 1j19.pdf (16-mer)
1q8t  2.00  2003  Kd=17.5uM     // 1q8t.pdf (Y27)
1oif  2.12  2003  Kd=19nM       // 1oif.pdf (IFM)
1p93  2.70  2003  Kd=19nM       // 1p93.pdf (DEX) ligand is dexamethasone
1gt1  1.71  2003  Kd=1uM        // 1gt1.pdf (ANC) Kd=3.3uM for PRZ
1lnm  1.90  2003  Kd=2.0nM      // 1lnm.pdf (DTX)
1ow4  1.60  2003  Kd=2.1uM      // 1ow4.pdf (2AN)
1hk1  2.65  2003  Kd=2.3uM      // 1hk1.pdf (T44)
1h27  2.20  2003  Kd=2.5uM      // 1h25.pdf (11-mer) 11-Mer PEPTIDE of P27 bound to phospho-CDK2/cyclin A, Kd=0.9uM. Ligand in structure has 6-mer, RNLFGP, Kd(6-mer)=2.5uM; incomplete ligand
1o9d  2.30  2003  Kd=2.5uM      // 1o9d.pdf (5-mer)
1gwv  2.50  2003  Kd=2.68mM     // 1gwv.pdf (LAT)
1h26  2.24  2003  Kd=2.9uM      // 1h25.pdf (11-mer) 11-Mer PEPTIDE of P53 bound to phospho-CDK2/cyclin A, Kd=2.9uM.ligand in structure has 9-mer, SRHKKLMFK.Kd(6-mer, KKLMFK)=2.9uM; incomplete ligand
1ngw  2.60  2003  Kd=20.7nM     // 1ngw.pdf (MMP) Fab 7g12 complexed with N-methylmesoporphyrin, Kd=20.7nM
1oz0  2.50  2003  Kd=20nM       // 1oz0.pdf (MS1)
1h3h   NMR  2003  Kd=220nM      // 1h3h.pdf (11-mer) Kd=220+/-22nM
1ofz  1.50  2003  Kd=24.1uM     // 1ofz.pdf (FUL)
1mn9  2.90  2003  Kd=24uM       // 1mn9.pdf (RTP)
1q9d  2.35  2003  Kd=25uM       // 1q9d.pdf (OI1)
1nli  1.93  2003  Kd=260uM      // 1nli.pdf (ADE)
1jwm  2.70  2003  Kd=270uM      // 1jwm.pdf (13-mer) HLA-DR1(HA peptide 306-318) complex with SEC3 wt, Kd=270uM
1m13  2.15  2003  Kd=27nM       // 1m13.pdf (HYF)
1uj0  1.70  2003  Kd=27uM       // 1uj0.pdf (11-mer) incomplete ligand
1q4k  2.30  2003  Kd=280nM      // 1q4k.pdf (6-mer) incomplete ligand structure
1umw  1.90  2003  Kd=280nM      // 1umw.pdf (7-mer)
1oko  1.60  2003  Kd=29uM       // 1oko.pdf (GLB)
1uh1  2.80  2003  Kd=3.3uM      // 1uh1.pdf (NGA-AMG)
1lv8  2.30  2003  Kd=3.5uM      // 1lv8.pdf (9PP) redundant to 1lvu
1oba  2.45  2003  Kd=3.6mM      // 1oba.pdf (CHT)
1nu8  2.50  2003  Kd=3.8uM      // 1nu8.pdf (3-mer) covalent complex
1p28  1.70  2003  Kd=3.8uM      // 1p28.pdf (HBS/HBR) isomer
1lke  1.90  2003  Kd=30.2nM     // 1lke.pdf (DOG)
1osg  3.00  2003  Kd=30nM       // 1osg.pdf (12-mer) Kd=30+/-10nM (isothermal titration calorimetry); IC50=92nM
1ntk  2.60  2003  Kd=32pM       // 1ntk.pdf (AY1) bc1-antimycin A complex, Kd=32pM
1msm  2.00  2003  Kd=33pM       // 1msm.pdf (JE2)
1n0s  2.00  2003  Kd=35.2nM     // 1n0s.pdf (FLU)
1r17  1.86  2003  Kd=379nM      // 1r17.pdf (16-mer) Kd=380nM(Isothermal Titration Calorimetry); Kd=379nM(Fluorescence Intensity Titrations); incomplete ligand
1olu  1.90  2003  Kd=39.3uM     // 1olu.pdf (TDP)
1oe7  1.80  2003  Kd=3uM        // 1oe7.pdf (GSH) redundant to 1oe8
1oe8  1.65  2003  Kd=3uM        // 1oe8.pdf (GSH)
1m7i  2.50  2003  Kd=4.0uM      // 1m7i.pdf (5-mer)
1mj7  2.25  2003  Kd=4.50nM     // 1mj7.pdf (HAL)
1jwu  2.30  2003  Kd=4.6uM      // 1jwm.pdf (13-mer) HLA-DR1(HA peptide 306-318) complex with SEC3 3B2, Kd=4.6uM
1lvu  2.05  2003  Kd=4.8uM      // 1lvu.pdf (9PP)
1oim  2.15  2003  Kd=4.8uM      // 1oim.pdf (NOJ) redundant to 2j77
1hk4  2.40  2003  Kd=4.9uM      // 1hk4.pdf (T44)
1q4l  2.77  2003  Kd=40nM       // 1q4l.pdf (679)
1py1  2.60  2003  Kd=40uM       // 1py1.pdf (7-mer) incomplete ligand structure
1p7m   NMR  2003  Kd=42uM       // 1p7m.pdf (ADK)
1olx  2.25  2003  Kd=47.1uM     // 1olx.pdf (TDP)
1ow6  2.35  2003  Kd=4uM        // 1ow6.pdf (13-mer) incomplete ligand
1ow7  2.60  2003  Kd=4uM        // 1ow6.pdf (13-mer) incomplete ligand
1ow8  2.85  2003  Kd=4uM        // 1ow6.pdf (13-mer) incomplete ligand
1pz5  1.80  2003  Kd=4uM        // 1pz5.pdf (8-mer)
1hk5  2.70  2003  Kd=5.72uM     // 1hk5.pdf (T44)
1q8w  2.20  2003  Kd=5.7uM      // 1q8w.pdf (M77)
1oqp   NMR  2003  Kd=50nM       // 1oqp.pdf (19-mer)
1mfg  1.25  2003  Kd=50uM       // 1mfg.pdf (9-mer)
1ppx   NMR  2003  Kd=52nM       // 1ppx.pdf (8OG)
1pun   NMR  2003  Kd=52nM       // 1pun.pdf (8OG) redundant to 1ppx
1puq   NMR  2003  Kd=52nM       // 1puq.pdf (8OG) redundant to 1ppx
1pus   NMR  2003  Kd=52nM       // 1pus.pdf (8OG) redundant to 1ppx
1gx4  1.46  2003  Kd=53uM       // 1gx4.pdf (UDP) ternary complex; Kd of LacNAc(GAL-NAG) to enzyme-Mn2+-UDP complex is 0.58mM; Kd of UDP to emzyme is 53uM
1m5w  1.96  2003  Kd=54uM       // 1m5w.pdf (DXP)
1mrx  2.00  2003  Kd=55nM       // 1mrx.pdf (K57)
1mau  2.15  2003  Kd=5pM        // 1mau.pdf (ATP)
1p4u  2.20  2003  Kd=5uM        // 1p4u.pdf (13-mer) Kd=5+/-1uM; incomplete ligand
1pdq  1.76  2003  Kd=5uM        // 1pdq.pdf (18-mer) Kd=5+/-1uM; incomplete ligand
1ucn  2.00  2003  Kd=6.0uM      // 1ucn.pdf (ADP)
1ox9  2.90  2003  Kd=6.16uM     // 1ox9.pdf (11-mer) incomplete ligand structure
1nw5  2.05  2003  Kd=6.1uM      // 1nw5.pdf (SAM)
1q5l   NMR  2003  Kd=600uM      // 1q5l.pdf (7-mer)
1odi  2.40  2003  Kd=62uM       // 1odi.pdf (ADN)
1nu1  3.20  2003  Kd=64nM       // 1ntk.pdf (QNO) NQNO1 binds to bc1, Kd=64nM
1o9e  2.60  2003  Kd=66uM       // 1o9e.pdf (FSC)
1l6m  2.40  2003  Kd=7.9nM      // 1l6m.pdf (DBH) Kd for Fe-DBH
1om9  2.50  2003  Kd=70uM       // 1om9.pdf (15-mer) incomplete ligand
1nw7  2.10  2003  Kd=8.1uM      // 1nw7.pdf (SAH)
1iwq  2.00  2003  Kd=8.8nM      // 1iwq.pdf (19-mer) Kd=8.8+/-1.6nM; incomplete ligand
1maw  3.00  2003  Kd=80mM       // 1maw.pdf (ATP) Kd for the second ATP
1gwm  1.15  2003  Kd=80uM       // 1gwm.pdf (6-mer)
1odj  2.40  2003  Kd=80uM       // 1odj.pdf (GMP)
1jn2  1.90  2003  Kd=82uM       // 1jn2.pdf (SFP)
1onz  2.40  2003  Kd=8uM        // 1onz.pdf (968) Ki=17uM
1ndj  1.81  2003  Kd~0.69pM     // 1ndj.pdf (BTN)
1n9m  1.60  2003  Kd~11pM       // 1n9m.pdf (BTN)
1n43  1.89  2003  Kd~28pM       // 1n43.pdf (BTN)
1o3e  1.64  2003  Ki=0.011uM    // 1o3e.pdf (696) redundant to 1o3f
1o3f  1.55  2003  Ki=0.011uM    // 1o3f.pdf (696)
1o3g  1.55  2003  Ki=0.011uM    // 1o3g.pdf (696) redundant to 1o3f
1o2t  1.62  2003  Ki=0.014uM    // 1o2t.pdf (783) pH=7.48
1j07  2.35  2003  Ki=0.021uM    // 1j07.pdf (DCU) Ki measured on TcAChE
1o2q  1.50  2003  Ki=0.021uM    // 1o2q.pdf (991)
1lyx  1.90  2003  Ki=0.029mM    // 1lyx.pdf (PGA)
1lzo  2.80  2003  Ki=0.029mM    // 1lzo.pdf (PGA)
1pf8  2.51  2003  Ki=0.031uM    // 1pf8.pdf (SU9)
1n46  2.20  2003  Ki=0.03nM     // 1n46.pdf (PFA)
1oyt  1.67  2003  Ki=0.057uM    // 1oyt.pdf (FSN)
1nhg  2.43  2003  Ki=0.05uM     // 1nhg.pdf (TCL) Ki=0.05uM pfENR with Triclosan
1o3h  1.53  2003  Ki=0.05uM     // 1o3h.pdf (907) redundant to 1o3i
1o3i  1.51  2003  Ki=0.05uM     // 1o3i.pdf (907)
1o2h  1.77  2003  Ki=0.068uM    // 1o2h.pdf (CR3) Ki measured at pH=8.06
1o39  1.59  2003  Ki=0.074uM    // 1o39.pdf (780) redundant to 1o3d
1o3b  1.75  2003  Ki=0.074uM    // 1o3b.pdf (780) redundant to 1o3d
1o3c  1.64  2003  Ki=0.074uM    // 1o3c.pdf (780) redundant to 1o3d; pH=7.50
1o3d  1.33  2003  Ki=0.074uM    // 1o3d.pdf (780)
1nz7  2.40  2003  Ki=0.076uM    // 1nz7.pdf (901)
1nm6  1.80  2003  Ki=0.09nM     // 1nm6.pdf (L86)
1m9n  1.93  2003  Ki=0.12uM     // 1m9n.pdf (XMP)
1o2j  1.65  2003  Ki=0.12uM     // 1o2j.pdf (656)
1o2k  1.63  2003  Ki=0.12uM     // 1o2k.pdf (656)
1pvn  2.00  2003  Ki=0.15nM     // 1pvn.pdf (MZP)
1nnu  2.50  2003  Ki=0.15uM     // 1nhg.pdf (TCT) Ki=0.15uM pfENR with Triclosan Analogs 2
1o37  1.45  2003  Ki=0.15uM     // 1o37.pdf (653) redundant to 1o38
1o38  1.38  2003  Ki=0.15uM     // 1o38.pdf (653)
1nlj  2.40  2003  Ki=0.16nM     // 1nlj.pdf (2CA) covalent complex
1nq7  1.50  2003  Ki=0.16uM     // 1nq7.pdf (ARL)
1mpl  1.12  2003  Ki=0.17mM     // 1mpl.pdf (RE1) covalent complex
1o30  1.55  2003  Ki=0.17uM     // 1o30.pdf (693)
1o3j  1.40  2003  Ki=0.17uM     // 1o3j.pdf (334)
1o3k  1.43  2003  Ki=0.17uM     // 1o3k.pdf (334) redundant to 1o3j
1ony  2.15  2003  Ki=0.17uM     // 1ony.pdf (588)
1gz3  2.30  2003  Ki=0.20mM     // 1gz3.pdf (ATP) redundant to 1gz4
1o3p  1.81  2003  Ki=0.22uM     // 1o3p.pdf (655)
1n7i  2.80  2003  Ki=0.26uM     // 1n7i.pdf (LY1)
1o86  2.00  2003  Ki=0.27nM     // 1o86.pdf (LPR)
1n4h  2.10  2003  Ki=0.28uM     // 1n4h.pdf (REA)
1o3l  1.40  2003  Ki=0.29uM     // 1o3l.pdf (678)
1nms  1.70  2003  Ki=0.2uM      // 1nms.pdf (161) Ki for reversible ligand
1m2r  1.70  2003  Ki=0.35uM     // 1m2r.pdf (MNY)
1n7j  2.70  2003  Ki=0.37uM     // 1n7j.pdf (IDI)
1nax  2.70  2003  Ki=0.37uM     // 1nax.pdf (IH5) ligand is compound 8
1o2o  1.63  2003  Ki=0.44uM     // 1o2o.pdf (950)
1pbq  1.90  2003  Ki=0.54uM     // 1pbq.pdf (DK1)
1oxq  2.30  2003  Ki=0.5uM      // 1oxq.pdf (9-mer) incomplete ligand structure
1iy7  2.00  2003  Ki=0.64uM     // 1iy7.pdf (CXA)
1o6i  1.70  2003  Ki=0.65mM     // 1o6i.pdf (0HZ)
1k1y  2.40  2003  Ki=0.6mM      // 1k1y.pdf (ACR)
1qwu  2.03  2003  Ki=0.6mM      // 1qwu.pdf (GUL) covalent complex
1nc1  2.00  2003  Ki=0.75uM     // 1nc1.pdf (MTH)
1o2g  1.58  2003  Ki=0.76uM     // 1o2g.pdf (696)
1m2p  2.00  2003  Ki=0.78uM     // 1m2p.pdf (HNA)
1o2z  1.65  2003  Ki=0.78uM     // 1o2z.pdf (312)
1m2q  1.79  2003  Ki=0.80uM     // 1m2q.pdf (MNX)
1o2n  1.50  2003  Ki=0.81uM     // 1o2n.pdf (762)
1nhz  2.30  2003  Ki=0.84uM     // 1nhz.pdf (486) ligand is RU486
1pu7  1.93  2003  Ki=0.8mM      // 1pu7.pdf (39A)
1pu8  2.13  2003  Ki=0.8mM      // 1pu8.pdf (EA1)
1os0  2.10  2003  Ki=0.93uM     // 1os0.pdf (0PQ)
1k27  1.95  2003  Ki=1.0nM      // 1k27.pdf (MTM) Ki=26nM at initial rate; Ki=1.0nM at equilibrium
1p6d  2.00  2003  Ki=1.15mM     // 1p6d.pdf (3PC) X-ray(phospholipase C D55N) while Ki(wild type)
1j37  2.40  2003  Ki=1.1nM      // 1j37.pdf (X8Z)
1nfw  2.10  2003  Ki=1.1nM      // 1nfw.pdf (RRR)
1nl9  2.40  2003  Ki=1.1uM      // 1nl9.pdf (989)
1o36  1.70  2003  Ki=1.1uM      // 1o36.pdf (607)
1p6e  2.30  2003  Ki=1.21mM     // 1p6e.pdf (PC5) X-ray(phospholipase C D55N) while Ki(wild type)
1ms0  2.50  2003  Ki=1.23mM     // 1ms0.pdf (DAN) ligand is compound 1
1o0h  1.20  2003  Ki=1.2uM      // 1o0h.pdf (ADP)
1n3i  1.90  2003  Ki=1.3nM      // 1n3i.pdf (DIH) Ki*=42pM
1nfy  2.10  2003  Ki=1.3nM      // 1nfy.pdf (RTR)
1nt1  2.00  2003  Ki=1.3nM      // 1nt1.pdf (T76)
1ny0  1.75  2003  Ki=1.4uM      // 1ny0.pdf (NBF) covalent complex
1o2u  1.41  2003  Ki=1.4uM      // 1o2u.pdf (847) redundant to 1o2w
1o2v  1.50  2003  Ki=1.4uM      // 1o2v.pdf (847) redundant to 1o2w
1o2w  1.38  2003  Ki=1.4uM      // 1o2w.pdf (847)
1o2x  1.46  2003  Ki=1.4uM      // 1o2x.pdf (847) redundant to 1o2w
1o2y  1.45  2003  Ki=1.4uM      // 1o2y.pdf (847) redundant to 1o2w
1q54  1.93  2003  Ki=1.4uM      // 1q54.pdf (BHI)
1ny2  2.30  2003  Ki=1.75mM     // 1ny2.pdf (5-mer) incomplete ligand structure
1lq2  2.70  2003  Ki=1.7nM      // 1lq2.pdf (IDD) Ki measured on barley beta-d-glucan glucohydrolase
1pxh  2.15  2003  Ki=1.8nM      // 1pxh.pdf (SNA) incomplete ligand structure
1o32  1.78  2003  Ki=1.8uM      // 1o32.pdf (801) redundant to 1o33
1o33  1.46  2003  Ki=1.8uM      // 1o33.pdf (801)
1o34  1.50  2003  Ki=1.8uM      // 1o34.pdf (801) redundant to 1o33
1mf4  1.90  2003  Ki=10.2nM     // 1mf4.pdf (5-mer)
1p0y  2.55  2003  Ki=100.8mM    // 1p0y.pdf (MLZ)
1nu3  1.75  2003  Ki=100uM      // 1nu3.pdf (VPR)
1my4  1.90  2003  Ki=105nM      // 1my4.pdf (IWD) ligand is compound (S)-2e
1nc6  1.90  2003  Ki=10nM       // 1nc6.pdf (ABB) covalent complex
1kr3  2.50  2003  Ki=10uM       // 1kr3.pdf (113) redundant to 1hlk
1nc3  2.20  2003  Ki=10uM       // 1nc3.pdf (FMC)
1o35  1.41  2003  Ki=10uM       // 1o35.pdf (802)
1jn4  1.80  2003  Ki=11.3uM     // 1jn4.pdf (139)
1oyq  1.90  2003  Ki=110nM      // 1oyq.pdf (T87)
1mrs  2.00  2003  Ki=110uM      // 1mrs.pdf (5HU)
1ndv  2.30  2003  Ki=1200nM     // 1ndv.pdf (FR0)
1ph0  2.20  2003  Ki=120nM      // 1ph0.pdf (418) incomplete ligand structure
1pr5  2.50  2003  Ki=120uM      // 1pr5.pdf (TBN)
1npz  2.00  2003  Ki=13nM       // 1npz.pdf (C1P) covalent complex
1nhw  2.35  2003  Ki=14.3uM     // 1nhg.pdf (TCC) Ki=14.3uM pfENR with Triclosan Analogs 1
1n1t  1.60  2003  Ki=140uM      // 1n1t.pdf (DAN)
1n1v  2.10  2003  Ki=140uM      // 1n1v.pdf (DAN) redundant to 1n1t
1n51  2.30  2003  Ki=14uM       // 1n51.pdf (4-mer)
1o2p  1.47  2003  Ki=14uM       // 1o2p.pdf (972) Ki measured on human trypsin
1lqe  2.20  2003  Ki=1507nM     // 1lqe.pdf (IMA) incomplete ligand structure
1njs  1.98  2003  Ki=15nM       // 1njs.pdf (KEU)
1nvs  1.80  2003  Ki=15nM       // 1nvs.pdf (UCM)
1oss  1.93  2003  Ki=16.4uM     // 1oss.pdf (BEN)
1my2  1.80  2003  Ki=17nM       // 1my2.pdf (AMQ) ligand is compound 2, AMPA, data from ref.25
1j36  2.40  2003  Ki=18nM       // 1j36.pdf (LPR)
1nfu  2.05  2003  Ki=18nM       // 1nfu.pdf (RRP)
1mcz  2.80  2003  Ki=1mM        // 1mcz.pdf (RMN)
1mq5  2.10  2003  Ki=1nM        // 1mq5.pdf (XLC)
1mxo  1.83  2003  Ki=1nM        // 1mxo.pdf (SM2) covalent complex
1lf9  2.20  2003  Ki=1pM        // 1lf9.pdf (ACR)
1o8b  1.25  2003  Ki=2.1mM      // 1o8b.pdf (ABF)
1oxn  2.20  2003  Ki=2.1uM      // 1oxn.pdf (9-mer) incomplete ligand structure
1n5r  2.25  2003  Ki=2.2uM      // 1n5r.pdf (PRM)
1nhu  2.00  2003  Ki=2.2uM      // 1nhu.pdf (153)
1nhv  2.90  2003  Ki=2.2uM      // 1nhv.pdf (154)
1lrt  2.20  2003  Ki=2.3uM      // 1lrt.pdf (TAD)
1h0r  2.10  2003  Ki=200uM      // 1h0r.pdf (FA1) ligand is compound 3a
1nyy  1.90  2003  Ki=21uM       // 1nyy.pdf (105) covalent complex
1nny  2.40  2003  Ki=22nM       // 1nny.pdf (515)
1owk  2.80  2003  Ki=23.5nM     // 1owk.pdf (303)
1pb9  1.60  2003  Ki=241uM      // 1pb9.pdf (4AX)
1no9  1.90  2003  Ki=24nM       // 1no9.pdf (4ND) covalent complex
1orw  2.84  2003  Ki=25.1nM     // 1orw.pdf (2-mer) covalent complex
1lpz  2.40  2003  Ki=25nM       // 1lpz.pdf (CMB)
1nj1  2.55  2003  Ki=25nM       // 1nj1.pdf (5CA)
1pcg  2.70  2003  Ki=25nM       // 1pcg.pdf (9-mer) Ki for ligand in cyclized form
1pa9  2.00  2003  Ki=25uM       // 1pa9.pdf (CSN)
1h46  1.52  2003  Ki=270uM      // 1h46.pdf (RNP)
1np0  2.50  2003  Ki=270uM      // 1np0.pdf (NGT) ligand is compound 1a (NAG-thiazoline)
1owi  2.93  2003  Ki=28.0nM     // 1owi.pdf (426)
1lpk  2.20  2003  Ki=28nM       // 1lpk.pdf (CBB)
1i5r  1.60  2003  Ki=3.0nM      // 1i5r.pdf (HYC)
1nfx  2.15  2003  Ki=3.0nM      // 1nfx.pdf (RDR)
1pyn  2.20  2003  Ki=3.2uM      // 1pyn.pdf (941)
1o2s  1.65  2003  Ki=3.4uM      // 1o2s.pdf (CR4) redundant to 1gi1
1pq3  2.70  2003  Ki=30nM       // 1pq3.pdf (S2C)
1mrn  2.45  2003  Ki=30uM       // 1mrn.pdf (T5A)
1my8  1.72  2003  Ki=35nM       // 1my8.pdf (SM3) covalent complex
1ozv  2.65  2003  Ki=36.6mM     // 1ozv.pdf (LYS)
1no6  2.40  2003  Ki=39uM       // 1no6.pdf (794)
1nym  1.20  2003  Ki=4.0uM      // 1nym.pdf (CXB) covalent complex
1nwl  2.40  2003  Ki=4.1mM      // 1nwl.pdf (964)
1lzq  2.20  2003  Ki=4.1nM      // 1lzq.pdf (0ZQ)
1oy7  2.70  2003  Ki=4.4uM      // 1oy7.pdf (9-mer) incomplete ligand structure
1nl6  2.80  2003  Ki=4.8pM      // 1nl6.pdf (750) covalent complex
1jt1  1.78  2003  Ki=400uM      // 1jt1.pdf (MCO)
1owh  1.61  2003  Ki=40nM       // 1owh.pdf (239)
1ocn  1.31  2003  Ki=412nM      // 1ocn.pdf (2-mer) X-ray(CEL6A D416A) while Ki(CEL6A wild type)
1owj  3.10  2003  Ki=48.0nM     // 1owj.pdf (155)
1o1s  2.30  2003  Ki=49nM       // 1o1s.pdf (1NH)
1ps3  1.80  2003  Ki=5.2mM      // 1ps3.pdf (KIF)
1nvq  2.00  2003  Ki=5.6nM      // 1nvq.pdf (UCN)
1nj5  2.80  2003  Ki=50nM       // 1nj5.pdf (P5A)
1nqc  1.80  2003  Ki=50nM       // 1nqc.pdf (C4P) covalent complex
1ndw  2.00  2003  Ki=5900nM     // 1ndw.pdf (FR2)
1o0f  1.50  2003  Ki=5uM        // 1o0f.pdf (A3P)
1pr1  2.30  2003  Ki=5uM        // 1pr1.pdf (FMB) redundant to 1a69
1h1d  2.00  2003  Ki=6.0nM      // 1h1d.pdf (BIA)
1o2r  1.45  2003  Ki=6.1uM      // 1o2r.pdf (CR9)
1owd  2.32  2003  Ki=6.3nM      // 1owd.pdf (497)
1ocq  1.08  2003  Ki=6.5uM      // 1ocq.pdf (IFM-BGC)
1q1m  2.60  2003  Ki=6.9uM      // 1q1m.pdf (234)
1n3z  1.65  2003  Ki=63.2uM     // 1n3z.pdf (U3P) Ki measured at pH=6.0; redundant to 3djp
1owe  1.60  2003  Ki=631nM      // 1owe.pdf (675)
1nxy  1.60  2003  Ki=64nM       // 1nxy.pdf (SM2) covalent complex
1me7  2.15  2003  Ki=65nM       // 1me7.pdf (RVP)
1me8  1.90  2003  Ki=65nM       // 1me8.pdf (RVP)
1ndy  2.00  2003  Ki=680nM      // 1ndy.pdf (FR3)
1pb8  1.45  2003  Ki=7.02uM     // 1pb8.pdf (DSN)
1o0m  1.50  2003  Ki=7.1uM      // 1o0m.pdf (U2P)
1p2g  2.30  2003  Ki=7.4mM      // 1p2g.pdf (8-mer)
1qx1  1.30  2003  Ki=7.5mM      // 1qx1.pdf (FMF) covalent complex
1ndz  2.00  2003  Ki=7.7nM      // 1ndz.pdf (FR5)
1nvr  1.80  2003  Ki=7.8nM      // 1nvr.pdf (STU)
1m2x  1.50  2003  Ki=70uM       // 1m2x.pdf (MCO) Ki=70~100uM
1mq6  2.10  2003  Ki=7pM        // 1mq6.pdf (XLD)
1lpg  2.00  2003  Ki=82nM       // 1lpg.pdf (IMA)
1o0n  1.50  2003  Ki=82uM       // 1o0n.pdf (U3P)
1n2v  2.10  2003  Ki=83uM       // 1n2v.pdf (BDI) redundant to 2z1w
1ui0  1.50  2003  Ki=88nM       // 1ui0.pdf (URA)
1njj  2.45  2003  Ki=8mM        // 1njj.pdf (GET)
1o0o  1.20  2003  Ki=8uM        // 1o0o.pdf (A2P)
1od8  1.05  2003  Ki=8uM        // 1od8.pdf (XDL-XYP)
1qxk  2.30  2003  Ki=9.0uM      // 1qxk.pdf (429)
1lqd  2.70  2003  Ki=9nM        // 1lqd.pdf (CMI)
1mx1  2.40  2003  Ki>100uM      // 1mx1.pdf (THA)
1urw  1.60  2004  IC50<0.003uM  // 1urw.pdf (I1P)
1sqi  2.15  2004  IC50<20nM     // 1sqi.pdf (869)
1s17  1.95  2004  IC50<5nM      // 1s17.pdf (GNR) IC50 for GNR/PDF-Ni
1uv5  2.80  2004  IC50=0.005uM  // 1uv5.pdf (BRW) IC50 measured on gsk-3 a/b
1xom  1.55  2004  IC50=0.011uM  // 1xom.pdf (CIO)
1xbc  2.00  2004  IC50=0.012uM  // 1xbc.pdf (STU)
1vjb  3.20  2004  IC50=0.013uM  // 1vjb.pdf (OHT) ligand is compound 1, (4-OHT)
1xon  1.72  2004  IC50=0.021nM  // 1xon.pdf (PIL)
1vjy  2.00  2004  IC50=0.023uM  // 1vjy.pdf (460)
1xlx  2.19  2004  IC50=0.025uM  // 1xlx.pdf (CIO)
1q1y  1.90  2004  IC50=0.02uM   // 1q1y.pdf (BB2) ligand is actinonin, a hydroxamate peptidic compound, as a positive control was IC50=0.02uM
1r5g  2.00  2004  IC50=0.03uM   // 1r5g.pdf (AO1)
1xm4  2.31  2004  IC50=0.041nM  // 1xm4.pdf (PIL)
1xdg  2.10  2004  IC50=0.05uM   // 1xdg.pdf (AB8)
1rs4  2.70  2004  IC50=0.068uM  // 1rs4.pdf (45P)
1py2  2.80  2004  IC50=0.06uM   // 1py2.pdf (FRH)
1unh  2.35  2004  IC50=0.10uM   // 1unh.pdf (IXM)
1r58  1.90  2004  IC50=0.11uM   // 1r58.pdf (AO5)
1vj5  2.35  2004  IC50=0.12uM   // 1vj5.pdf (CIU)
1v0p  2.00  2004  IC50=0.13uM   // 1v0p.pdf (PVB)
1rv1  2.30  2004  IC50=0.14uM   // 1rv1.pdf (IMZ)
1ung  2.30  2004  IC50=0.16uM   // 1ung.pdf (ALH) IC50=0.16-0.20uM
1r5h  2.40  2004  IC50=0.18uM   // 1r5h.pdf (AO2)
1rwq  2.20  2004  IC50=0.1nM    // 1rwq.pdf (5AP)
1unl  2.20  2004  IC50=0.20uM   // 1unl.pdf (RRC) ligand is (R)-roscovitine
1oiu  2.00  2004  IC50=0.21uM   // 1oiu.pdf (N76)
1tkz  2.81  2004  IC50=0.24uM   // 1tkz.pdf (H16)
1xnz  1.52  2004  IC50=0.24uM   // 1xnz.pdf (FCD)
1o45  1.80  2004  IC50=0.25nM   // 1o45.pdf (687) covalent complex
1snk  2.40  2004  IC50=0.25nM   // 1snk.pdf (MYE) covalent complex
1so2  2.40  2004  IC50=0.27nM   // 1so2.pdf (666)
1xdd  2.20  2004  IC50=0.2uM    // 1xdd.pdf (AAY)
1rsd  2.50  2004  IC50=0.30uM   // 1rsd.pdf (PSB)
1pzj  1.46  2004  IC50=0.32mM   // 1pzj.pdf (15B)
1t46  1.60  2004  IC50=0.37uM   // 1t46.pdf (STI) ligand is compound imatinib
1tl1  2.90  2004  IC50=0.38uM   // 1tl1.pdf (H18)
1xor  1.54  2004  IC50=0.39uM   // 1xor.pdf (ZAR)
1o4d  1.85  2004  IC50=0.3mM    // 1o4d.pdf (262) covalent complex
1o4f  2.00  2004  IC50=0.3mM    // 1o4f.pdf (790)
1xm6  1.92  2004  IC50=0.42uM   // 1xm6.pdf (5RM)
1xp6  1.70  2004  IC50=0.4nM    // 1xp6.pdf (AIU)
1tow  2.00  2004  IC50=0.57uM   // 1tow.pdf (CRZ)
1xn0  2.31  2004  IC50=0.57uM   // 1xn0.pdf (ROL) racemic ligand
1o4e  2.00  2004  IC50=0.5mM    // 1o4e.pdf (299) covalent complex
1xp1  1.80  2004  IC50=0.5nM    // 1xp1.pdf (AIH)
1tl3  2.80  2004  IC50=0.63uM   // 1tl3.pdf (H20)
1x81  3.50  2004  IC50=0.65nM   // 1x81.pdf (JAN)
1xoq  1.83  2004  IC50=0.68nM   // 1xoq.pdf (ROF)
1tkt  2.60  2004  IC50=0.71uM   // 1tkt.pdf (H12)
1uu3  1.70  2004  IC50=0.75uM   // 1uu3.pdf (LY4)
1rhk  2.50  2004  IC50=0.771nM  // 1rhk.pdf (6-mer) covalent complex
1tu6  1.75  2004  IC50=0.83nM   // 1tu6.pdf (FSP) covalent complex
1xmu  2.30  2004  IC50=0.84nM   // 1xmu.pdf (ROF)
1sj0  1.90  2004  IC50=0.8nM    // 1sj0.pdf (E4D)
1ni1  2.30  2004  IC50=0.90nM   // 1ni1.pdf (2C5)
1xlz  2.06  2004  IC50=0.96uM   // 1xlz.pdf (FIL)
1o41  1.70  2004  IC50=0.9mM    // 1o41.pdf (300) covalent complex
1pum  2.30  2004  IC50=0.9mM    // 1pum.pdf (GLB)
1xp0  1.79  2004  IC50=1.0nM    // 1xp0.pdf (VDN)
1uze  1.82  2004  IC50=1.27nM   // 1uze.pdf (EAL) ligand is compound 12d, IC50 ref 20. -logIC50=8.4-9.4, +/-0.5 unit
1o4k  1.57  2004  IC50=1.2mM    // 1o4k.pdf (PSN) covalent complex
1xoz  1.37  2004  IC50=1.2nM    // 1xoz.pdf (CIA)
1xp9  1.80  2004  IC50=1.3nM    // 1xp9.pdf (AIJ)
1tqf  1.80  2004  IC50=1.4uM    // 1tqf.pdf (32P)
1utz  2.50  2004  IC50=1.4uM    // 1utz.pdf (PF3) IC50=1.4uM (no AH); IC50=14nM (with AH)
1rri  2.00  2004  IC50=1.5uM    // 1rri.pdf (A45)
1ros  2.00  2004  IC50=1.7nM    // 1ros.pdf (DEO)
1xpc  1.60  2004  IC50=1.7nM    // 1xpc.pdf (AIT)
1hkm  2.55  2004  IC50=1.9nM    // 1hkm.pdf (3-mer)
1s9v  2.22  2004  IC50=100uM    // 1s9v.pdf (11-mer) HLA-DQ2 complexed with deamidated gliadin peptide, IC50=100uM
1tlo  1.90  2004  IC50=100uM    // 1tlo.pdf (E64) covalent complex
1o46  2.00  2004  IC50=10nM     // 1o46.pdf (903)
1sqb  2.69  2004  IC50=11.2nM   // 1sqb.pdf (AZO) azoxystrobin, AZ to bovine bc1 IC50=11.2nM, yeast bc1 IC50=251nM
1o4a  1.50  2004  IC50=120nM    // 1o4a.pdf (197) covalent complex
1tg5  1.90  2004  IC50=12nM     // 1tg5.pdf (645)
1wdy  1.80  2004  IC50=13nM     // 1wdy.pdf (25A)
1uyh  2.20  2004  IC50=14.3uM   // 1uyh.pdf (PU0) IC50 measured on full length yeast HSP90-alpha
1uu7  1.90  2004  IC50=14uM     // 1uu7.pdf (BI2)
1uy9  2.00  2004  IC50=15.3uM   // 1uy9.pdf (PU6) IC50 measured on full length yeast HSP90-alpha
1qxy  1.04  2004  IC50=16uM     // 1qxy.pdf (M2C)
1uyk  2.00  2004  IC50=17.1uM   // 1uyk.pdf (PUX) IC50 measured on full length yeast HSP90-alpha
1rhq  3.00  2004  IC50=17.7nM   // 1rhq.pdf (0ZZ) covalent complex
1rhm  2.50  2004  IC50=1735nM   // 1rhm.pdf (NA4) covalent complex
1w22  2.50  2004  IC50=175.5nM  // 1w22.pdf (NHB)
1qxz  1.68  2004  IC50=19uM     // 1qxz.pdf (M3C)
1tou  2.00  2004  IC50=1uM      // 1tou.pdf (B1V)
1uvr  2.81  2004  IC50=1uM      // 1uvr.pdf (BI8)
1npa  2.00  2004  IC50=2.0nM    // 1npa.pdf (3NH)
1tve  3.00  2004  IC50=2.1uM    // 1tve.pdf (178)
1o43  1.50  2004  IC50=2.2uM    // 1o43.pdf (821) covalent complex
1o4i  1.75  2004  IC50=2.3mM    // 1o4i.pdf (219) covalent complex
1o4p  1.90  2004  IC50=2.5mM    // 1o4p.pdf (791)
1hkj  2.60  2004  IC50=2.6nM    // 1hkj.pdf (3-mer)
1rtl  2.75  2004  IC50=2.6uM    // 1rtl.pdf (CPX) covalent complex
1szm  2.50  2004  IC50=2.94uM   // 1szm.pdf (BI2)
1xos  2.28  2004  IC50=20uM     // 1xos.pdf (VIA)
1oq5  1.50  2004  IC50=21nM     // 1oq5.pdf (CEL)
1uwh  2.95  2004  IC50=22nM     // 1uwh.pdf (BAX) ligand is Sorafenib
1t49  1.90  2004  IC50=22uM     // 1t49.pdf (892)
1soj  2.90  2004  IC50=242nM    // 1soj.pdf (IBM)
1v3x  2.20  2004  IC50=24nM     // 1v3x.pdf (D76)
1q6k  2.10  2004  IC50=26nM     // 1q6k.pdf (TCO) covalent complex
1vcj  2.40  2004  IC50=26uM     // 1vcj.pdf (IBA)
1riw  2.04  2004  IC50=28nM     // 1riw.pdf (OSC)
1rrw  2.21  2004  IC50=28uM     // 1rrw.pdf (9MG)
1vyz  2.21  2004  IC50=290nM    // 1vyz.pdf (N5B)
1tkx  2.85  2004  IC50=29nM     // 1tkx.pdf (GWB)
1o4b  1.85  2004  IC50=2uM      // 1o4b.pdf (876)
1rhu  2.51  2004  IC50=3.00nM   // 1rhu.pdf (3CY) covalent complex
1tl9  1.80  2004  IC50=3.0uM    // 1tl9.pdf (4-mer) covalent complex
1xh3  1.48  2004  IC50=3.1uM    // 1xh3.pdf (14-mer) alt.M-CSF peptide binds to HLA-B*3501, IC50=3.1uM
1o4q  1.70  2004  IC50=3.2mM    // 1o4q.pdf (256)
1o4o  1.70  2004  IC50=3.5mM    // 1o4o.pdf (HPS)
1o4h  2.25  2004  IC50=3.6mM    // 1o4h.pdf (772)
1xot  2.34  2004  IC50=3.8uM    // 1xot.pdf (VDN)
1o4r  1.50  2004  IC50=3.9mM    // 1o4r.pdf (787)
1uyf  2.00  2004  IC50=30uM     // 1uyf.pdf (PU1) IC50 measured on full length yeast HSP90-alpha
1t48  2.20  2004  IC50=350uM    // 1t48.pdf (BB3)
1v1k  2.31  2004  IC50=35uM     // 1v1k.pdf (3FP)
1vyw  2.30  2004  IC50=37nM     // 1vyw.pdf (292)
1rsi  2.20  2004  IC50=38uM     // 1rsi.pdf (977)
1rq2  1.86  2004  IC50=3mM      // 1rq2.pdf (CIT)
1o44  1.70  2004  IC50=3nM      // 1o44.pdf (852)
1r78  2.00  2004  IC50=3nM      // 1r78.pdf (FMD)
1uyi  2.00  2004  IC50=4.1uM    // 1uyi.pdf (PUZ) IC50 measured on full length yeast HSP90-alpha
1o4j  1.70  2004  IC50=4.4mM    // 1o4j.pdf (IS2)
1hkk  1.85  2004  IC50=40nM     // 1hkk.pdf (3-mer)
1uyc  2.00  2004  IC50=41uM     // 1uyc.pdf (PU7) IC50 measured on full length yeast HSP90-alpha
1o49  1.70  2004  IC50=437nM    // 1o49.pdf (493)
1o48  1.55  2004  IC50=450nM    // 1o48.pdf (853)
1o47  1.80  2004  IC50=4nM      // 1o47.pdf (822)
1w4l  2.16  2004  IC50=4nM      // 1w4l.pdf (GL8)
1t1r  2.30  2004  IC50=4uM      // 1t1r.pdf (IMB)
1tv6  2.80  2004  IC50=4uM      // 1tv6.pdf (CP9)
1uu9  1.95  2004  IC50=4uM      // 1uu9.pdf (BI3)
1v0o  1.90  2004  IC50=5.50uM   // 1v0o.pdf (INR)
1xmy  2.40  2004  IC50=50.12nM  // 1xmy.pdf (ROL) ligand is compound (R)-Rolipram, pIC50=7.3
1w51  2.55  2004  IC50=500nM    // 1w51.pdf (L01) ligand is compound 1
1ppw  2.21  2004  IC50=50uM     // 1ppw.pdf (EIP)
1rs2  2.31  2004  IC50=50uM     // 1rs2.pdf (209)
1py5  2.30  2004  IC50=51nM     // 1py5.pdf (PY1)
1uyg  2.00  2004  IC50=53.5uM   // 1uyg.pdf (PU2) IC50 measured on full length yeast HSP90-alpha
1u59  2.30  2004  IC50=55.8nM   // 1u59.pdf (STU)
1okz  2.51  2004  IC50=5nM      // 1okz.pdf (UCN)
1v2h  2.70  2004  IC50=5uM      // 1v2h.pdf (GUN)
1oky  2.30  2004  IC50=6.5nM    // 1oky.pdf (STU)
1w6j  2.20  2004  IC50=6.5nM    // 1w6j.pdf (R71) ligand is compound 9
1q0b  1.90  2004  IC50=6.7uM    // 1q0b.pdf (NAT)
1uk1  3.00  2004  IC50=60nM     // 1uk1.pdf (FRQ)
1re1  2.50  2004  IC50=6117nM   // 1re1.pdf (NA3) covalent complex
1oiy  2.40  2004  IC50=64nM     // 1oiy.pdf (N41)
1oi9  2.10  2004  IC50=69nM     // 1oi9.pdf (N20)
1pw6  2.60  2004  IC50=6uM      // 1pw6.pdf (FRB)
1rhr  3.00  2004  IC50=7.95nM   // 1rhr.pdf (CNE) covalent complex
1w6r  2.05  2004  IC50=702nM    // 1w6r.pdf (GNT)
1w76  2.30  2004  IC50=702nM    // 1w76.pdf (GNT) redundant to 1w6r
1rxp  1.70  2004  IC50=72nM     // 1rxp.pdf (169) covalent complex
1uy8  1.98  2004  IC50=75uM     // 1uy8.pdf (PU5) IC50 measured on full length yeast HSP90-alpha
1pfy  1.93  2004  IC50=7nM      // 1pfy.pdf (MSP)
1tfz  1.80  2004  IC50=7nM      // 1tfz.pdf (869)
1qxw  1.67  2004  IC50=7uM      // 1qxw.pdf (M1C)
1t1s  2.40  2004  IC50=7uM      // 1t1s.pdf (CBQ)
1rry  2.70  2004  IC50=80uM     // 1rry.pdf (204)
1uk0  3.00  2004  IC50=8nM      // 1uk0.pdf (FRM) ligand is compound 4f
1t4j  2.70  2004  IC50=8uM      // 1t4j.pdf (FRJ)
1rhj  2.20  2004  IC50=9.17nM   // 1rhj.pdf (PZN) covalent complex
1u32  2.00  2004  IC50=97nM     // 1u32.pdf (OKA)
1o42  1.70  2004  IC50=9nM      // 1o42.pdf (843)
1uu8  2.50  2004  IC50=9uM      // 1uu8.pdf (BI1)
1utt  2.20  2004  IC50>100uM    // 1utt.pdf (CP8)
1uy6  1.90  2004  IC50>200uM    // 1uy6.pdf (PU3) IC50 measured on full length yeast HSP90-alpha
1uy7  1.90  2004  IC50>200uM    // 1uy7.pdf (PU4) IC50 measured on full length yeast HSP90-alpha
1uyd  2.00  2004  IC50>200uM    // 1uyd.pdf (PU8) IC50 measured on full length yeast HSP90-alpha
1uye  2.00  2004  IC50>200uM    // 1uye.pdf (PU9) IC50 measured on full length yeast HSP90-alpha
1o4l  1.65  2004  IC50>40mM     // 1o4l.pdf (CIT)
1o4m  1.60  2004  IC50>40mM     // 1o4m.pdf (MLA)
1o4n  1.60  2004  IC50>40mM     // 1o4n.pdf (OXD)
1ukt  2.20  2004  IC50>5600uM   // 1ukt.pdf (4-mer)
1o4g  1.55  2004  IC50>5mM      // 1o4g.pdf (I59)
1uym  2.45  2004  IC50~1uM      // 1uym.pdf (PU3) ligand is compound 19, PU3. IC50=1-2uM
1tfq   NMR  2004  Kd=0.012uM    // 1tfq.pdf (998)
1xsc   NMR  2004  Kd=0.05mM     // 1xsc.pdf (ATP)
1xzx  2.50  2004  Kd=0.06nM     // 1xzx.pdf (_T3)
1sr7  1.46  2004  Kd=0.08nM     // 1sr7.pdf (MOF)
1toi  1.90  2004  Kd=0.090mM    // 1toi.pdf (HCI)
1utj  1.83  2004  Kd=0.144mM    // 1utj.pdf (ABN)
1os5  2.20  2004  Kd=0.14uM     // 1os5.pdf (NH1) IC50=0.93uM
1oh4  1.35  2004  Kd=0.18mM     // 1oh4.pdf (7-mer)
1s3k  1.90  2004  Kd=0.24uM     // 1s3k.pdf (4-mer) Fab hu3S193 in complex with the Lewis Y tetrasaccharide, Kd=2.4E-7M
1vjc  2.10  2004  Kd=0.263mM    // 1vjc.pdf (ATP) Kd for Mg-ATP
1ujk  1.90  2004  Kd=0.27uM     // 1ujj.pdf (12-mer) Kd=0.27+/-0.17uM(SPR); Kd=40uM(ITC); incomplete ligand
1vjd  1.90  2004  Kd=0.286mM    // 1vjd.pdf (ATP)
1nki  0.95  2004  Kd=0.2uM      // 1nki.pdf (PPF) Ki=0.41uM
1s19  2.10  2004  Kd=0.31nM     // 1s19.pdf (MC9) ligand is MC903(calcipotriol)
1utn  1.15  2004  Kd=0.321mM    // 1utn.pdf (ABN)
1ru2  1.48  2004  Kd=0.32uM     // 1ru2.pdf (APC) Kd for Mg-APC
1q4x  2.80  2004  Kd=0.33nM     // 1q4x.pdf (G24)
1qy1  1.70  2004  Kd=0.3uM      // 1qy1.pdf (PRZ)
1toj  1.90  2004  Kd=0.41mM     // 1toj.pdf (HCI)
1ukh  2.35  2004  Kd=0.42uM     // 1ukh.pdf (11-mer) Kd=0.42+/-0.13uM; incomplete ligand
1sqn  1.45  2004  Kd=0.4nM      // 1sqn.pdf (NDR)
1xow  1.80  2004  Kd=0.52nM     // 1xow.pdf (R18)
1udt  2.30  2004  Kd=0.5nM      // 1udt.pdf (VIA) Kd=0.5~6.6nM
1tpz  2.00  2004  Kd=0.64uM     // 1tpz.pdf (GDP) redundant to 1tq4
1tq4  1.95  2004  Kd=0.64uM     // 1tq4.pdf (GDP)
1tog  2.31  2004  Kd=0.6mM      // 1tog.pdf (HCI)
1uho  2.50  2004  Kd=0.6nM      // 1uho.pdf (VDN) Kd=0.6~0.7nM
1xb7  2.50  2004  Kd=0.6uM      // 1xb7.pdf (12-mer) incomplete ligand
1uod  1.90  2004  Kd=0.78mM     // 1uod.pdf (G3H) covalent complex
1xxh  3.45  2004  Kd=0.78uM     // 1xxh.pdf (AGS)
1w9u  1.85  2004  Kd=0.81uM     // 1w9u.pdf (5-mer) IC50=0.5uM
1oj5  2.20  2004  Kd=0.8uM      // 1oj5.pdf (14-mer)
1ujj  2.60  2004  Kd=0.8uM      // 1ujj.pdf (12-mer) Kd=0.8+/-0.19uM(SPR); Kd=390uM(ITC); incomplete ligand
1t7d  2.47  2004  Kd=0.94uM     // 1t7d.pdf (ARY)
1utm  1.50  2004  Kd=0.972mM    // 1utm.pdf (PEA)
1udu  2.83  2004  Kd=0.9nM      // 1udu.pdf (CIA) Kd=0.9-6.7nM
1t29  2.30  2004  Kd=0.9uM      // 1t29.pdf (14-mer) incomplete ligand
1t7r  1.40  2004  Kd=1.1uM      // 1t7r.pdf (15-mer) incomplete ligand; Kd between AR LBD and FxxLF peptide
1oay  2.66  2004  Kd=1.2uM      // 1oay.pdf (FUR)
1ok7  1.65  2004  Kd=1.2uM      // 1ok7.pdf (16-mer) Kd=1.2uM(model1:inhibiton requires two occupied binding sites); Kd2=8.0uM (modle 2: inhibition occurs with only one occupied binding site); incomplete ligand
1ule  2.15  2004  Kd=1.2uM      // 1ule.pdf (3-mer)
1u1w  1.35  2004  Kd=1.4uM      // 1u1w.pdf (3HA)
1p17  2.70  2004  Kd=1.5mM      // 1p17.pdf (IMP)
1ryf  1.75  2004  Kd=1.6nM      // 1ryf.pdf (GDP) Kd for mant-GDP
1qy2  1.75  2004  Kd=1.8uM      // 1qy2.pdf (IPZ)
1t7f  1.60  2004  Kd=1.8uM      // 1t7f.pdf (15-mer) incomplete ligand structure
1v11  1.95  2004  Kd=104.8uM    // 1v11.pdf (TDP)
1rmz  1.34  2004  Kd=10nM       // 1rmz.pdf (NGH) Kd=8mM for AHA
1vyg  2.40  2004  Kd=10nM       // 1vyg.pdf (ACD)
1xws  1.80  2004  Kd=10nM       // 1xws.pdf (BI1)
1sbr  2.30  2004  Kd=10uM       // 1sbr.pdf (VIB)
1v1m  2.00  2004  Kd=115.0uM    // 1v1m.pdf (TDP)
1pg2  1.75  2004  Kd=11uM       // 1pg2.pdf (MET) Kd=43uM for MET/MetRS
1uz8  1.80  2004  Kd=11uM       // 1uz8.pdf (3-mer)
1nlt  2.70  2004  Kd=12uM       // 1nlt.pdf (7-mer)
1v16  1.90  2004  Kd=134.8uM    // 1v16.pdf (TDP)
1vkj  2.50  2004  Kd=14uM       // 1vkj.pdf (A3P)
1rd4  2.40  2004  Kd=18.3nM     // 1rd4.pdf (L08)
1ru1  1.40  2004  Kd=18uM       // 1ru1.pdf (APC) Kd=0.32uM for Mg-APC
1pfu  1.91  2004  Kd=1900uM     // 1pfu.pdf (MPJ)
1ux7  1.50  2004  Kd=1mM        // 1ux7.pdf (3-mer)
1xt3  2.40  2004  Kd=2.01uM     // 1xt3.pdf (6-mer)
1uti  1.50  2004  Kd=2.4uM      // 1uti.pdf (16-mer)
1q1g  2.02  2004  Kd=2.7nM      // 1q1g.pdf (MTI)
1r5w  2.90  2004  Kd=2.9uM      // 1r5v.pdf (13-mer) IC50=100+/-3nM; EC50=0.023nM
1oau  1.80  2004  Kd=20nM       // 1oau.pdf (SER-DNF)
1ryh  1.75  2004  Kd=27.6nM     // 1ryh.pdf (GNP) Kd for mant-GNP
1w80  1.90  2004  Kd=28.6uM     // 1w80.pdf (12-mer) incomplete ligand structure
1utc  2.30  2004  Kd=28uM       // 1utc.pdf (9-mer) incomplete ligand
1szd  1.50  2004  Kd=29.16uM    // 1szd.pdf (APR)
1xap  2.10  2004  Kd=2nM        // 1xap.pdf (TTB) Kd=2~9nM
1y0x  3.10  2004  Kd=2nM        // 1y0x.pdf (T44)
1xxi  4.10  2004  Kd=3.0uM      // 1xxi.pdf (ADP)
1t08  2.10  2004  Kd=3.1uM      // 1t08.pdf (15-mer) Kd=3.1+/-0.3uM(APC R3-    catenin); Kd=10+/-1.3nM(APC pR3-    catenin).
1uef  2.50  2004  Kd=3.2uM      // 1uef.pdf (13-mer) incomplete ligand
1utl  1.70  2004  Kd=3.41mM     // 1utl.pdf (PRA)
1tok  1.85  2004  Kd=3.4mM      // 1tok.pdf (MAE)
1r5n  2.90  2004  Kd=3.8uM      // 1r5n.pdf (GDP)
1u2r  2.60  2004  Kd=3.9uM      // 1u2r.pdf (GDP)
1vea  2.80  2004  Kd=30nM       // 1vea.pdf (HBN)
1xa5  2.12  2004  Kd=316nM      // 1xa5.pdf (KAR)
1osv  2.50  2004  Kd=330uM      // 1osv.pdf (13-mer) incomplete ligand structure; Kd for bile acid-activated FXR to coactivator peptide NID-3 (KENALLRYLLDKD)
1r5v  2.50  2004  Kd=33uM       // 1r5v.pdf (13-mer) IC50=90+/-2nM; EC50=0.13nM
1qvu  2.96  2004  Kd=35uM       // 1qvu.pdf (PRL) ternary complex of QacR with ethidium and proflavine; QacR bind to Pf with Kd=35uM in the presence of 75uM Et
1utp  1.30  2004  Kd=36mM       // 1utp.pdf (PBN)
1t2v  3.30  2004  Kd=400nM      // 1t2v.pdf (16-mer) incomplete ligand
1upk  1.85  2004  Kd=400nM      // 1upk.pdf (12-mer) incomplete ligand
1oar  2.22  2004  Kd=40nM       // 1oar.pdf (AZN)
1r6n  2.40  2004  Kd=40nM       // 1r6n.pdf (434)
1qvt  2.89  2004  Kd=42uM       // 1qvt.pdf (PRL)
1td7  2.50  2004  Kd=43uM       // 1td7.pdf (NFL) Ki=1.26uM
1uw6  2.20  2004  Kd=45.2nM     // 1uw6.pdf (NCT)
1ttm  1.95  2004  Kd=45nM       // 1ttm.pdf (667)
1sv3  1.35  2004  Kd=45uM       // 1sv3.pdf (ANN) Ki=18uM
1t37  2.60  2004  Kd=45uM       // 1t37.pdf (5-mer)
1w3j  2.00  2004  Kd=484nM      // 1w3j.pdf (OXZ)
1r9l  1.59  2004  Kd=4uM        // 1r9l.pdf (BET)
1s5q   NMR  2004  Kd=5.2uM      // 1s5q.pdf (16-mer) Kd=5.2+/-1.0uM
1uto  1.15  2004  Kd=5.32mM     // 1uto.pdf (PEA)
2bfr  2.50  2004  Kd=5.63uM     // 2bfr.pdf (ADP)
1opi   NMR  2004  Kd=50nM       // 1o0p.pdf (13-mer) Kd=50-100nM
1sw1  1.90  2004  Kd=50nM       // 1sw1.pdf (PBE)
1u8t  1.50  2004  Kd=55uM       // 1u8t.pdf (16-mer) incomplete ligand
1uxa  1.50  2004  Kd=5mM        // 1uxa.pdf (SIA-GAL)
1oxr  1.93  2004  Kd=6.4uM      // 1oxr.pdf (AIN)
1sw2  2.10  2004  Kd=60nM       // 1sw2.pdf (BET)
1pzi  1.99  2004  Kd=60uM       // 1pzi.pdf (1DM)
1ulg  2.20  2004  Kd=62.2uM     // 1ulg.pdf (GAL-NGA)
1q7a  1.60  2004  Kd=64nM       // 1q7a.pdf (OPB)
1sje  2.45  2004  Kd=6nM        // 1sje.pdf (16-mer) HLA-DR1 and Gag[PP16] peptide complex, IC50=29+/-1nM, Kd=6nM; incomplete ligand
1w2x  2.80  2004  Kd=7.2uM      // 1w2x.pdf (RCP)
1uv6  2.50  2004  Kd=7575nM     // 1uv6.pdf (CCE)
1p19  2.30  2004  Kd=76.8uM     // 1p19.pdf (IMP)
1uxb  1.75  2004  Kd=7mM        // 1uxb.pdf (SIA-GAL)
1rzx  2.10  2004  Kd=80uM       // 1rzx.pdf (7-mer)
1nw4  2.20  2004  Kd=860pM      // 1nw4.pdf (IMH)
1x8s  2.50  2004  Kd=8uM        // 1x8s.pdf (12-mer) incomplete ligand
1u9l  1.90  2004  Kd=9.6uM      // 1u9l.pdf (13-mer) incomplete ligand structure
1r4w  2.50  2004  Kd=90uM       // 1r4w.pdf (GSH)
1t79  1.80  2004  Kd=920nM      // 1t79.pdf (15-mer) incomplete ligand structure
1sjh  2.25  2004  Kd=9nM        // 1sje.pdf (13-mer) HLA-DR1 and Gag[PG13] peptide complex, IC50=28+/-3nM, Kd=9nM
1vyf  1.85  2004  Kd=9nM        // 1vyf.pdf (OLA)
1r6z  2.80  2004  Kd>10uM       // 1r6z.pdf (MAL)
1syo  2.20  2004  Kd~1nM        // 1syo.pdf (M6P)
1sz0  2.10  2004  Kd~1nM        // 1sz0.pdf (M6P)
1sm2  2.30  2004  Ki<10nM       // 1sm2.pdf (STU)
1rp7  2.09  2004  Ki=0.003uM    // 1rp7.pdf (TZD)
1vja  2.00  2004  Ki=0.020uM    // 1vja.pdf (7IN)
1w1g  1.45  2004  Ki=0.021uM    // 1w1g.pdf (4PT)
1oxg  2.20  2004  Ki=0.027nM    // 1oxg.pdf (14-mer) covalent complex; Ki=2.7+/-0.3    0-11M
1v0l  0.98  2004  Ki=0.028uM    // 1v0l.pdf (XIF-XYP)
1v0n  1.10  2004  Ki=0.028uM    // 1v0n.pdf (XIF-XYP) redundant to 1v0l
1vj9  2.40  2004  Ki=0.028uM    // 1vj9.pdf (5IN)
1sqo  1.84  2004  Ki=0.035uM    // 1sqo.pdf (UI2)
1sc8  2.40  2004  Ki=0.036uM    // 1sc8.pdf (2IN)
1ua4  1.90  2004  Ki=0.06mM     // 1ua4.pdf (AMP)
1pxm  2.53  2004  Ki=0.06uM     // 1pxm.pdf (CK5)
1xd0  2.00  2004  Ki=0.075uM    // 1xd0.pdf (ARE)
1pxn  2.50  2004  Ki=0.07uM     // 1pxn.pdf (CK6)
1sb1  1.90  2004  Ki=0.128uM    // 1sb1.pdf (165)
1pkx  1.90  2004  Ki=0.12uM     // 1pkx.pdf (XMP)
1vcu  2.85  2004  Ki=0.14mM     // 1vcu.pdf (DAN) ligand is compound 4, DANA
1om1  1.68  2004  Ki=0.17uM     // 1om1.pdf (IQA)
1nh0  1.03  2004  Ki=0.18nM     // 1nh0.pdf (5-mer)
1wc1  1.93  2004  Ki=0.1mM      // 1wc1.pdf (TAT)
1wc6  2.51  2004  Ki=0.1mM      // 1wc6.pdf (TAT)
1rjk  1.99  2004  Ki=0.1nM      // 1rjk.pdf (VDZ) ligand is compound 4
1pxp  2.30  2004  Ki=0.22uM     // 1pxp.pdf (CK8)
1qw7  1.90  2004  Ki=0.25mM     // 1qw7.pdf (EBP)
1uys  2.80  2004  Ki=0.25mM     // 1uys.pdf (H1L)
1w1d  1.50  2004  Ki=0.30uM     // 1w1d.pdf (4IP)
1s4d  2.70  2004  Ki=0.32uM     // 1s4d.pdf (SAH)
1xjd  2.00  2004  Ki=0.33nM     // 1xjd.pdf (STU)
1q4w  1.93  2004  Ki=0.35uM     // 1q4w.pdf (DQU) redundant to 1r5y
1r5y  1.20  2004  Ki=0.35uM     // 1r5y.pdf (DQU)
1o5a  1.68  2004  Ki=0.38uM     // 1o5a.pdf (696)
1re8  2.10  2004  Ki=0.3nM      // 1re8.pdf (BD2)
1t69  2.91  2004  Ki=0.48uM     // 1t69.pdf (SHH) ligand is compound SAHA
1w3l  1.04  2004  Ki=0.52uM     // 1w3l.pdf (3-mer)
1px4  1.60  2004  Ki=0.59mM     // 1px4.pdf (IPT)
1phw  2.36  2004  Ki=0.5mM      // 1phw.pdf (__N)
1pwp  2.90  2004  Ki=0.5uM      // 1pwp.pdf (NSC)
1w25  2.70  2004  Ki=0.5uM      // 1w25.pdf (C2E)
1wm1  2.10  2004  Ki=0.5uM      // 1wm1.pdf (PTB)
1sqa  2.00  2004  Ki=0.62nM     // 1sqa.pdf (UI1)
1sqt  1.90  2004  Ki=0.63uM     // 1sqt.pdf (UI3)
1v2k  2.00  2004  Ki=0.65uM     // 1v2k.pdf (ZEN)
1ta6  1.90  2004  Ki=0.74nM     // 1ta6.pdf (177)
1u0g  1.70  2004  Ki=0.7uM      // 1u0g.pdf (E4P)
1s26  3.00  2004  Ki=0.85mM     // 1s26.pdf (APC)
1o5f  1.78  2004  Ki=0.85uM     // 1o5f.pdf (CR9)
1uj5  2.00  2004  Ki=0.89mM     // 1uj5.pdf (5RP)
1uj6  1.74  2004  Ki=0.89mM     // 1uj6.pdf (A5P)
1xbo  2.50  2004  Ki=0.92uM     // 1xbo.pdf (IX1)
1s63  1.90  2004  Ki=0.9nM      // 1s63.pdf (778)
1uwu  1.95  2004  Ki=1.04uM     // 1uwu.pdf (GOX)
1uwt  1.95  2004  Ki=1.08uM     // 1uwt.pdf (GTL)
1mu8  2.00  2004  Ki=1.0nM      // 1mu8.pdf (CDB)
1v2n  1.80  2004  Ki=1.25uM     // 1v2n.pdf (BBA)
1r1h  1.95  2004  Ki=1.2nM      // 1r1h.pdf (BIR)
1u6q  2.02  2004  Ki=1.31uM     // 1u6q.pdf (745)
1ugp  1.63  2004  Ki=1.3mM      // 1ugp.pdf (BUA)
1sl3  1.81  2004  Ki=1.4pM      // 1sl3.pdf (170)
1q63  1.85  2004  Ki=1.4uM      // 1q63.pdf (AIQ) redundant to 1k4g
1m0b  2.45  2004  Ki=1.53nM     // 1m0b.pdf (0ZQ)
1w5w  1.80  2004  Ki=1.6nM      // 1w5w.pdf (BE4)
1rql  2.40  2004  Ki=1.79mM     // 1rql.pdf (VSO)
2bet  2.20  2004  Ki=1.7mM      // 2bet.pdf (DEZ)
1o5b  1.85  2004  Ki=1.7uM      // 1o5b.pdf (ESI)
1q66  1.75  2004  Ki=1.7uM      // 1q66.pdf (KMB)
1ur9  1.80  2004  Ki=1.7uM      // 1ur9.pdf (3-mer)
1o5e  1.75  2004  Ki=1.8uM      // 1o5e.pdf (132)
1u0h  2.90  2004  Ki=110nM      // 1u0h.pdf (ONM)
1qxl  2.25  2004  Ki=11nM       // 1qxl.pdf (FR8)
1o5g  1.75  2004  Ki=11uM       // 1o5g.pdf (CR9)
1pwq  3.52  2004  Ki=11uM       // 1pwq.pdf (SD2)
1t3t  1.90  2004  Ki=11uM       // 1t3t.pdf (ADP) X-ray(PurL) while Ki(PurM)
1tl7  2.80  2004  Ki=12nM       // 1tl7.pdf (ONM)
1uz1  2.00  2004  Ki=130nM      // 1uz1.pdf (IFL)
1v79  2.50  2004  Ki=13nM       // 1v79.pdf (FR7) Ki measured on human ADA
1xff  1.80  2004  Ki=15uM       // 1xff.pdf (GLU)
1v48  2.20  2004  Ki=16nM       // 1v48.pdf (HA1)
1pi5  1.49  2004  Ki=17nM       // 1pi5.pdf (SM2) covalent complex
1v2o  1.62  2004  Ki=18.45uM    // 1v2o.pdf (ANH)
1v2p  1.92  2004  Ki=18.45uM    // 1v2p.pdf (ANH) redundant to 1v2o
1sdv  1.40  2004  Ki=1810pM     // 1sdv.pdf (MK1)
1u2y  1.95  2004  Ki=18mM       // 1u2y.pdf (GOX)
1txr  2.00  2004  Ki=18nM       // 1txr.pdf (BES)
1v2t  1.90  2004  Ki=19.56uM    // 1v2t.pdf (ANH)
1rm8  1.80  2004  Ki=1nM        // 1rm8.pdf (BAT) X-ray(MMP-16) while Ki(MMP-1,-2,-3)
1ssq  1.85  2004  Ki=1uM        // 1ssq.pdf (CYS)
1pxo  1.96  2004  Ki=2.0nM      // 1pxo.pdf (CK7)
1pwu  2.70  2004  Ki=2.1uM      // 1pwu.pdf (GM6) Ki measured on LF wt
1mue  2.00  2004  Ki=2.3nM      // 1mue.pdf (CDD)
1r1j  2.35  2004  Ki=2.3nM      // 1r1j.pdf (OIR)
1r1i  2.60  2004  Ki=2.9nM      // 1r1i.pdf (TI1)
1rdt  2.40  2004  Ki=200nM      // 1rdt.pdf (L79)
1rek  2.30  2004  Ki=200nM      // 1rek.pdf (B8L)
1s39  1.95  2004  Ki=20nM       // 1s39.pdf (AQO) Ki=20~50nM
1uou  2.11  2004  Ki=20nM       // 1uou.pdf (CMU)
1v41  2.85  2004  Ki=20uM       // 1v41.pdf (AZG)
1xs7  2.80  2004  Ki=25.1nM     // 1xs7.pdf (MMI)
1w8m  1.65  2004  Ki=25mM       // 1w8m.pdf (E1P)
1u33  1.95  2004  Ki=25uM       // 1u33.pdf (LM2)
1v2r  1.70  2004  Ki=278.96uM   // 1v2r.pdf (ANH)
1pk0  3.30  2004  Ki=27nM       // 1pk0.pdf (EMA)
1q95  2.46  2004  Ki=27nM       // 1q95.pdf (PAL)
1w5y  1.90  2004  Ki=3.3nM      // 1w5y.pdf (BE6)
1q65  2.10  2004  Ki=3.5uM      // 1q65.pdf (BHB)
1t4s  2.80  2004  Ki=3.6mM      // 1t4s.pdf (VAL)
1xxe   NMR  2004  Ki=3.9uM      // 1xxe.pdf (TUX)
1uml  2.50  2004  Ki=30nM       // 1uml.pdf (FR4)
1w8l  1.80  2004  Ki=320mM      // 1w8l.pdf (1P3)
1ro6  2.00  2004  Ki=350nM      // 1ro6.pdf (ROL) Ki=350~400nM
1pi4  1.39  2004  Ki=37nM       // 1pi4.pdf (SM3) covalent complex
1pye  2.00  2004  Ki=386nM      // 1pye.pdf (PM1) IC50=0.32uM
1q5k  1.94  2004  Ki=38nM       // 1q5k.pdf (TMU) IC50=104nM
1ta2  2.30  2004  Ki=3nM        // 1ta2.pdf (176)
1xkk  2.40  2004  Ki=3nM        // 1xkk.pdf (FMM)
1w5x  1.90  2004  Ki=4.0nM      // 1w5x.pdf (BE5)
1mu6  1.99  2004  Ki=4.2nM      // 1mu6.pdf (CDA)
1uz4  1.71  2004  Ki=400uM      // 1uz4.pdf (IFL)
1p57  1.75  2004  Ki=40uM       // 1p57.pdf (CR4)
1q83  2.65  2004  Ki=410fM      // 1q83.pdf (TZ5)
1sgu  1.90  2004  Ki=4235nM     // 1sgu.pdf (MK1)
1v2u  1.80  2004  Ki=427uM      // 1v2u.pdf (BEN)
1v2v  1.80  2004  Ki=427uM      // 1v2v.pdf (BEN) redundant to 1v2u
1rwx  1.85  2004  Ki=43nM       // 1rww.pdf (YBH) IL-1 beta , compound 18b, EC50=12.4uM
1pzo  1.90  2004  Ki=480uM      // 1pzo.pdf (CBT)
1pzp  1.45  2004  Ki=490uM      // 1pzp.pdf (FTA)
1s64  2.55  2004  Ki=4nM        // 1s64.pdf (778) Ki in the presence of ATP
1xbb  1.57  2004  Ki=5.0uM      // 1xbb.pdf (STI)
1s89  2.22  2004  Ki=5.8uM      // 1s89.pdf (PGA)
1w3k  1.20  2004  Ki=50uM       // 1w3k.pdf (BGC-OXZ)
1v2l  1.60  2004  Ki=51uM       // 1v2l.pdf (BEN)
1v2m  1.65  2004  Ki=51uM       // 1v2m.pdf (BEN) redundant to 1v2l
1sdt  1.30  2004  Ki=540pM      // 1sdt.pdf (MK1)
1v2j  1.90  2004  Ki=566uM      // 1v2j.pdf (BEN)
2bes  2.10  2004  Ki=57uM       // 2bes.pdf (RES)
1rej  2.20  2004  Ki=5nM        // 1rej.pdf (B1L)
1rww  2.80  2004  Ki=5nM        // 1rww.pdf (OQB) compound 20b
1o5c  1.63  2004  Ki=6.0uM      // 1o5c.pdf (CR9)
1ogg  1.97  2004  Ki=6.4uM      // 1ogg.pdf (3-mer)
1ro7  1.80  2004  Ki=657uM      // 1ro7.pdf (CSF)
1v2s  1.72  2004  Ki=68uM       // 1v2s.pdf (BEN)
1pl0  2.60  2004  Ki=6nM        // 1pl0.pdf (BW2) incomplete ligand structure
1s38  1.81  2004  Ki=7.0uM      // 1s38.pdf (MAQ)
1w5v  1.80  2004  Ki=7.1nM      // 1w5v.pdf (BE3)
1thz  1.80  2004  Ki=7.1uM      // 1thz.pdf (326)
1o5r  2.35  2004  Ki=7.5nM      // 1o5r.pdf (FR9)
1q91  1.60  2004  Ki=70uM       // 1q91.pdf (DPB)
1pf7  2.60  2004  Ki=72pM       // 1pf7.pdf (IMH)
1v2q  2.30  2004  Ki=73.62uM    // 1v2q.pdf (ANH)
1sdu  1.25  2004  Ki=86pM       // 1sdu.pdf (MK1)
1q84  2.45  2004  Ki=8900fM     // 1q84.pdf (TZ4)
1tuf  2.40  2004  Ki=89uM       // 1tuf.pdf (AZ1)
1p4r  2.55  2004  Ki=8nM        // 1p4r.pdf (354)
1v0k  1.03  2004  Ki=8uM        // 1v0k.pdf (XDN-XYP)
1v0m  1.07  2004  Ki=8uM        // 1v0m.pdf (XDN-XYP) redundant to 1v0k
1v7a  2.50  2004  Ki=9.8nM      // 1v7a.pdf (FRC)
1pwy  2.80  2004  Ki=90uM       // 1pwy.pdf (AC2)
1sh9  2.50  2004  Ki=932nM      // 1sh9.pdf (RIT)
1v2w  1.75  2004  Ki=97.79uM    // 1v2w.pdf (ANH)
1yt9  3.00  2005  IC50=0.005uM  // 1yt9.pdf (OIS)
1tt1  1.93  2005  IC50=0.007uM  // 1tt1.pdf (KAI) ligand is KAINATE
2a5u  2.70  2005  IC50=0.008uM  // 2a5u.pdf (QYT)
1z6j  2.00  2005  IC50=0.0094uM  // 1z6j.pdf (PY3)
1waw  1.75  2005  IC50=0.013uM  // 1waw.pdf (5-mer)
1yhs  2.15  2005  IC50=0.01uM   // 1yhs.pdf (STU)
2b54  1.85  2005  IC50=0.020uM  // 2b54.pdf (D05)
1y2k  1.36  2005  IC50=0.021uM  // 1y2k.pdf (7DE)
1y2j  2.55  2005  IC50=0.033uM  // 1y2j.pdf (7DE)
1y2h  2.40  2005  IC50=0.056uM  // 1y2h.pdf (6DE)
1y91  2.15  2005  IC50=0.059uM  // 1y91.pdf (CT9)
1w83  2.50  2005  IC50=0.065uM  // 1w83.pdf (L11)
1z4u  2.80  2005  IC50=0.07uM   // 1z4u.pdf (PH9)
1yvf  2.50  2005  IC50=0.10uM   // 1yvf.pdf (PH7)
2a3x  3.00  2005  IC50=0.12uM   // 2a3x.pdf (CPK)
1yt7  2.30  2005  IC50=0.13nM   // 1yt7.pdf (3FC) covalent complex
1s9t  1.80  2005  IC50=0.15uM   // 1s9t.pdf (QUS) ligand is compound 4
1y2e  2.10  2005  IC50=0.16uM   // 1y2e.pdf (5DE)
2ai8  1.70  2005  IC50=0.16uM   // 2ai8.pdf (SB7)
1rw8  2.40  2005  IC50=0.175uM  // 1rw8.pdf (580)
2c1a  1.95  2005  IC50=0.17uM   // 2c1a.pdf (I5S)
2a4z  2.90  2005  IC50=0.250uM  // 2a4z.pdf (BYM)
2byh  1.90  2005  IC50=0.258uM  // 2byh.pdf (2D7)
1y2c  1.67  2005  IC50=0.27uM   // 1y2c.pdf (3DE)
2c6l  2.30  2005  IC50=0.27uM   // 2c6l.pdf (DT4)
1zz3  1.76  2005  IC50=0.290uM  // 1zz3.pdf (3YP)
1z6q  2.03  2005  IC50=0.2uM    // 1z6q.pdf (195)
1wbt  2.00  2005  IC50=0.34uM   // 1wbt.pdf (WBT)
1wbn  2.40  2005  IC50=0.35uM   // 1wbn.pdf (L09)
2c6m  1.90  2005  IC50=0.35uM   // 2c6m.pdf (DT5)
2c1b  2.00  2005  IC50=0.40uM   // 2c1b.pdf (CQP)
1z34  2.40  2005  IC50=0.42mM   // 1z34.pdf (2FD)
2byi  1.60  2005  IC50=0.461uM  // 2byi.pdf (2DD)
1xhm  2.70  2005  IC50=0.47uM   // 1xhm.pdf (15-mer) Peptide (SIGK) Bound to a G Protein Beta:Gamma Heterodimer, IC50=0.47uM; incomplete ligand
2ai7  2.00  2005  IC50=0.4uM    // 2ai7.pdf (SB7)
1wzy  2.50  2005  IC50=0.56uM   // 1wzy.pdf (F29)
1zh7  2.50  2005  IC50=0.5uM    // 1zh7.pdf (11-mer)
1r6g  3.00  2005  IC50=0.62nM   // 1r6g.pdf (442)
1wbs  1.80  2005  IC50=0.63uM   // 1wbs.pdf (LI2)
2b53  2.00  2005  IC50=0.6uM    // 2b53.pdf (D23)
2c6k  1.90  2005  IC50=0.73uM   // 2c6k.pdf (DT2)
2bz5  1.90  2005  IC50=0.7uM    // 2bz5.pdf (AB4)
1xo2  2.90  2005  IC50=0.85uM   // 1xo2.pdf (FSE)
1you  2.30  2005  IC50=0.87nM   // 1you.pdf (PFD)
2b5j  2.90  2005  IC50=0.8nM    // 2b5j.pdf (3AC)
1zz1  1.57  2005  IC50=0.95uM   // 1zz1.pdf (SHH)
1z6p  2.40  2005  IC50=0.9uM    // 1z6p.pdf (194)
2a3i  1.95  2005  IC50=0.9uM    // 2a3i.pdf (12-mer) MR bound to the SRC1-4 motif with a highest affinity IC50=0.9uM
1yc5  1.40  2005  IC50=1.0mM    // 1yc5.pdf (NCA)
2c4g  2.70  2005  IC50=1.15uM   // 2c4g.pdf (514)
1w1t  1.90  2005  IC50=1.1mM    // 1w1t.pdf (CHQ)
1u3s  2.50  2005  IC50=1.4nM    // 1u3s.pdf (797)
2bro  2.20  2005  IC50=1.4uM    // 2bro.pdf (DF2)
1zyj  2.00  2005  IC50=1.5uM    // 1zyj.pdf (BI5)
2bge  1.80  2005  IC50=1.6mM    // 2bge.pdf (T2D) ligand is compound 20
1wug   NMR  2005  IC50=1.6uM    // 1wug.pdf (NP1)
1zuc  2.00  2005  IC50=1.7nM    // 1zuc.pdf (T98)
2c68  1.95  2005  IC50=1.8uM    // 2c68.pdf (CT6)
1x76  2.20  2005  IC50=1.9nM    // 1x76.pdf (697)
1z3c  2.20  2005  IC50=100uM    // 1z3c.pdf (SA8)
1x7e  2.80  2005  IC50=1062.5nM  // 1x7e.pdf (244)
2c6i  1.80  2005  IC50=11uM     // 2c6i.pdf (DT1)
1zp5  1.80  2005  IC50=1200uM   // 1zp5.pdf (2NI)
1wqv  2.50  2005  IC50=130nM    // 1wqv.pdf (PSM)
2f6y  2.15  2005  IC50=134.8uM  // 2f6y.pdf (ENT)
1ywr  1.95  2005  IC50=13nM     // 1ywr.pdf (LI9) IC50 measured on TNF-alpha
1x78  2.30  2005  IC50=14.0nM   // 1x78.pdf (244)
1ymx  1.70  2005  IC50=14.0uM   // 1ymx.pdf (CFX) covalent complex
1yw2  2.01  2005  IC50=141nM    // 1yw2.pdf (PGJ) IC50 measured on TNF-alpha
1yhm  2.50  2005  IC50=147uM    // 1yhm.pdf (AHD)
2a3a  2.10  2005  IC50=1500uM   // 2a3a.pdf (TEP)
2b8l  1.70  2005  IC50=15nM     // 2b8l.pdf (5HA)
1ttv   NMR  2005  IC50=160nM    // 1ttv.pdf (IMY)
1wbv  2.00  2005  IC50=162uM    // 1wbv.pdf (LI3)
1y57  1.91  2005  IC50=1633nM   // 1y57.pdf (MPZ)
1xh8  1.60  2005  IC50=1700nM   // 1xh8.pdf (R55)
1wss  2.60  2005  IC50=17nM     // 1wss.pdf (3CB)
1x7q  1.45  2005  IC50=186nM    // 1x7q.pdf (9-mer)
1wu1  2.30  2005  IC50=18nM     // 1wu1.pdf (D91)
1x70  2.10  2005  IC50=18nM     // 1x70.pdf (715)
1w82  2.20  2005  IC50=196nM    // 1w82.pdf (L10)
1yk7  2.50  2005  IC50=19nM     // 1yk7.pdf (NBL) covalent complex
1wbg  2.20  2005  IC50=1mM      // 1wbg.pdf (L03)
1z9h  2.60  2005  IC50=1mM      // 1z9h.pdf (IMN)
2ban  2.95  2005  IC50=1nM      // 2ban.pdf (357)
1zgv  2.20  2005  IC50=1uM      // 1zgv.pdf (501)
1y2d  1.70  2005  IC50=2.0uM    // 1y2d.pdf (4DE)
2aie  1.70  2005  IC50=2.2uM    // 2aie.pdf (SB9)
1w1y  1.85  2005  IC50=2.4mM    // 1w1y.pdf (TYP)
2bbb  1.70  2005  IC50=2.4nM    // 2bbb.pdf (HH1)
2f71  1.55  2005  IC50=2.5uM    // 2f71.pdf (UN7)
1x0n   NMR  2005  IC50=20nM     // 1x0n.pdf (DTF) ligand is compound 4
2bts  1.99  2005  IC50=20nM     // 2bts.pdf (U32)
2brh  2.10  2005  IC50=22.9uM   // 2brh.pdf (DFW)
1y6a  2.10  2005  IC50=22nM     // 1y6a.pdf (AAZ)
2c69  2.10  2005  IC50=26uM     // 2c69.pdf (CT8)
2bmc  2.60  2005  IC50=27nM     // 2bmc.pdf (MPY)
1svg  2.02  2005  IC50=2nM      // 1svg.pdf (I04)
2be2  2.43  2005  IC50=2nM      // 2be2.pdf (R22)
2bpm  2.40  2005  IC50=2nM      // 2bpm.pdf (529)
2bw7  2.30  2005  IC50=2uM      // 2bw7.pdf (ECS)
1u3q  2.40  2005  IC50=3.5nM    // 1u3q.pdf (272)
1u9w  2.30  2005  IC50=3.5nM    // 1u9w.pdf (IHI) covalent complex
1ynd  1.60  2005  IC50=3.6nM    // 1ynd.pdf (SFA)
2a3w  2.20  2005  IC50=3.8uM    // 2a3w.pdf (CPJ)
2aia  1.70  2005  IC50=3.9uM    // 2aia.pdf (SB8)
1z5m  2.17  2005  IC50=30nM     // 1z5m.pdf (LI8)
1zkn  2.10  2005  IC50=31uM     // 1zkn.pdf (IBM)
2f70  2.12  2005  IC50=33.5uM   // 2f70.pdf (UN6)
1wok  3.00  2005  IC50=33nM     // 1wok.pdf (CNQ)
1wcc  2.20  2005  IC50=350uM    // 1wcc.pdf (CIG)
1w84  2.20  2005  IC50=35uM     // 1w84.pdf (L12)
1svh  2.30  2005  IC50=360nM    // 1svh.pdf (I08)
2f6v  1.70  2005  IC50=37uM     // 2f6v.pdf (SK2)
1y6b  2.10  2005  IC50=38nM     // 1y6b.pdf (AAX)
1veb  2.89  2005  IC50=39nM     // 1veb.pdf (I05)
1yi3  2.50  2005  IC50=4.0uM    // 1yi3.pdf (LY2)
1x7b  2.30  2005  IC50=4.1nM    // 1x7b.pdf (041)
1yvz  2.20  2005  IC50=4.4uM    // 1yvz.pdf (JPC)
1wb0  1.65  2005  IC50=4.5uM    // 1wb0.pdf (5-mer)
1u9q  2.30  2005  IC50=4.7nM    // 1u9q.pdf (186) covalent complex
2f6z  1.70  2005  IC50=4.8uM    // 2f6z.pdf (UN5)
1way  2.02  2005  IC50=400uM    // 1way.pdf (L02)
1xog  2.80  2005  IC50=410nM    // 1xog.pdf (ABW)
1xoe  2.20  2005  IC50=41nM     // 1xoe.pdf (ABX)
1wbw  2.41  2005  IC50=44uM     // 1wbw.pdf (LI4)
1yrs  2.50  2005  IC50=450nM    // 1yrs.pdf (L47) ternary complex of KSP-4-ADP(Mg2+), IC50 for inhibitor 4
2a3b  1.90  2005  IC50=469uM    // 2a3b.pdf (CFF)
1w1p  2.10  2005  IC50=5.0mM    // 1w1p.pdf (GIO)
1zzl  2.00  2005  IC50=5.0nM    // 1zzl.pdf (TZY)
1wum   NMR  2005  IC50=5.1uM    // 1wum.pdf (NP2)
2brn  2.80  2005  IC50=5.5uM    // 2brn.pdf (DF1)
1u9e  2.40  2005  IC50=5.7nM    // 1u9e.pdf (397)
1zrz  3.00  2005  IC50=5.8uM    // 1zrz.pdf (BI1)
1wv7  2.70  2005  IC50=55nM     // 1wv7.pdf (5PI)
1sve  2.49  2005  IC50=5nM      // 1sve.pdf (I01)
1u3r  2.21  2005  IC50=5nM      // 1u3r.pdf (338)
1w0x  2.20  2005  IC50=5uM      // 1w0x.pdf (OLO) ligand is compound 5, olomoucine
1zz2  2.00  2005  IC50=6.0uM    // 1zz2.pdf (B11)
2brg  2.10  2005  IC50=6.1uM    // 2brg.pdf (DFY)
1w1v  1.85  2005  IC50=6.3mM    // 1w1v.pdf (ALJ)
1sqp  2.70  2005  IC50=6.3nM    // 1sqb.pdf (MYX) myxothiazol to bovine and yeast bc1, similar IC50=6.3nM
1wun  2.40  2005  IC50=62nM     // 1wun.pdf (P5B)
1xqc  2.05  2005  IC50=63nM     // 1xqc.pdf (AEJ)
1xur  1.85  2005  IC50=6600nM   // 1xur.pdf (PB5)
1xuo  1.80  2005  IC50=69nM     // 1xuo.pdf (LA1)
1u9v  2.20  2005  IC50=6nM      // 1u9v.pdf (IHE) covalent complex
1xuc  1.70  2005  IC50=72nM     // 1xuc.pdf (PB3)
1u9x  2.10  2005  IC50=7nM      // 1u9x.pdf (IHJ) covalent complex
1yvx  2.00  2005  IC50=8.0uM    // 1yvx.pdf (IPC)
1zkl  1.67  2005  IC50=8.1uM    // 1zkl.pdf (IBM)
1wxz  2.80  2005  IC50=8.6nM    // 1wxz.pdf (FRL) IC50 measured on human ADA
1zgb  2.30  2005  IC50=8.8nM    // 1zgb.pdf (A1E) IC50 measured on rat AChE/A1E
2brc  1.60  2005  IC50=8.9uM    // 2brc.pdf (CT5)
1y2b  1.40  2005  IC50=82uM     // 1y2b.pdf (DEE)
1wax  2.20  2005  IC50=86uM     // 1wax.pdf (LO1)
1xud  1.80  2005  IC50=8nM      // 1xud.pdf (PB4)
1zxc  2.28  2005  IC50=8nM      // 1zxc.pdf (IH6)
2b52  1.88  2005  IC50=8nM      // 2b52.pdf (D42)
1zaj  1.89  2005  IC50=8uM      // 1zaj.pdf (M2P) ligand is Mannitol Bis-phosphate (MBP)
1wtg  2.20  2005  IC50=93nM     // 1wtg.pdf (3BP)
2btr  1.85  2005  IC50=95nM     // 2btr.pdf (U73)
2b55  1.85  2005  IC50=96nM     // 2b55.pdf (D31)
1x8b  1.81  2005  IC50=97nM     // 1x8b.pdf (824) ligand is compound 1
2b8v  1.80  2005  IC50=98nM     // 2b8v.pdf (3BN)
1x7r  2.00  2005  IC50=9nM      // 1x7r.pdf (GEN) IC50 measured on estrogen receptor beta
1zm7  2.20  2005  IC50>1000uM   // 1zm7.pdf (TTP)
1w7h  2.21  2005  IC50>1mM      // 1w7h.pdf (3IP)
1wbo  2.16  2005  IC50>1mM      // 1wbo.pdf (2CH)
2bgd  2.40  2005  Kd<10uM       // 2bgd.pdf (T1D) IC50=2.47uM
1tft   NMR  2005  Kd=0.005uM    // 1tft.pdf (997)
1t13  2.90  2005  Kd=0.042uM    // 1t13.pdf (INI)
2bfq  1.50  2005  Kd=0.13uM     // 2bfq.pdf (AR6)
1xt8  2.00  2005  Kd=0.14uM     // 1xt8.pdf (CYS)
1tr7  2.10  2005  Kd=0.15uM     // 1tr7.pdf (DEG) redundant to 1uwf
1uwf  1.69  2005  Kd=0.15uM     // 1uwf.pdf (DEG)
2f01  0.85  2005  Kd=0.1pM      // 2f01.pdf (BTN)
1tmm  1.25  2005  Kd=0.23uM     // 1tmm.pdf (APC) Kd for Mg-APC
1zub   NMR  2005  Kd=0.27uM     // 1zub.pdf (11-mer) incomplete ligand
2bmz  2.40  2005  Kd=0.2mM      // 2bmz.pdf (XLM)
1ysg   NMR  2005  Kd=0.30mM     // 1ysg.pdf (4FC)
2aa6  1.95  2005  Kd=0.39nM     // 2aa6.pdf (STR) ligand is Progesterone
2bys  2.05  2005  Kd=0.3nM      // 2bys.pdf (LOB)
1w9v  2.00  2005  Kd=0.46uM     // 1w9v.pdf (5-mer) IC50=1.1uM
1z2b  4.10  2005  Kd=0.4uM      // 1z2b.pdf (VLB)
2ao6  1.89  2005  Kd=0.52nM     // 2ao6.pdf (R18) redundant to 1xow but in lower resoltuion
1s5z  2.00  2005  Kd=0.62mM     // 1s5z.pdf (SON) Kd=0.62+/-0.05mM; Ki=1.3+/-0.2mM
2bt9  0.94  2005  Kd=0.64uM     // 2bt9.pdf (MFU)
1y8p  2.63  2005  Kd=0.84uM     // 1y8p.pdf (ATP)
1yy6  1.70  2005  Kd=0.86uM     // 1yy6.pdf (10-mer) incomplete ligand
2byp  2.07  2005  Kd=0.88nM     // 2byp.pdf (12-mer)
1kjr  1.55  2005  Kd=0.88uM     // 1kjr.pdf (3-mer)
1ws5  1.90  2005  Kd=0.926mM    // 1ws5.pdf (MAM)
1ws4  1.90  2005  Kd=1.00mM     // 1ws4.pdf (GYP)
2asu  1.85  2005  Kd=1.0nM      // 2asu.pdf (19-mer) covalent complex; incomplete ligand
1xk5  2.40  2005  Kd=1.0uM      // 1xk5.pdf (TPG)
1y8o  2.48  2005  Kd=1.30uM     // 1y8o.pdf (ADP)
1ydk  1.95  2005  Kd=1.3uM      // 1ydk.pdf (GTX)
2a29   NMR  2005  Kd=1.4mM      // 2a29.pdf (ANP)
1wdq  1.28  2005  Kd=10.45mM    // 1wdq.pdf (MAL)
1vyj  2.80  2005  Kd=100nM      // 1vyj.pdf (16-mer)
1ycm   NMR  2005  Kd=10nM       // 1ycm.pdf (NGH)
1z3j   NMR  2005  Kd=10nM       // 1z3j.pdf (NGH)
1yid  2.40  2005  Kd=10uM       // 1yid.pdf (ATP) Kd for Mg-ATP
1ykp  2.41  2005  Kd=1100uM     // 1ykp.pdf (DHB)
1x9d  1.41  2005  Kd=110uM      // 1x9d.pdf (SMD)
1z3t  1.70  2005  Kd=115uM      // 1z3t.pdf (CBI)
2a58  2.80  2005  Kd=12.0uM     // 2a58.pdf (RBF)
1y2f  2.00  2005  Kd=12uM       // 1y2f.pdf (WAI)
1xfv  3.35  2005  Kd=130uM      // 1xfv.pdf (3AT)
1xh7  2.47  2005  Kd=150nM      // 1xh7.pdf (R96) IC50=1900nM
1sqq  3.00  2005  Kd=15nM       // 1sqb.pdf (OST) MOAS to bovine bc1, Kd=15nM, to yeast bc1, Kd=2nM
1y3p  2.00  2005  Kd=15uM       // 1y3p.pdf (4-mer)
2a0t   NMR  2005  Kd=15uM       // 2a0t.pdf (10-mer) Kd by HSQC
1ywh  2.70  2005  Kd=16.4nM     // 1ywh.pdf (13-mer)
1u1b  2.00  2005  Kd=16nM       // 1u1b.pdf (PAX)
1y19  2.60  2005  Kd=170nM      // 1y19.pdf (14-mer) Kd=170+/-5nM(for phosphorylated peptide); Kd=271+/-0.6nM(for unphosphorylated peptide); incomplete ligand
1xh9  1.64  2005  Kd=17nM       // 1xh9.pdf (R69)
2b2v  2.65  2005  Kd=17uM       // 2b2v.pdf (16-mer) incomplete ligand
1y0l  2.50  2005  Kd=1nM        // 1y0l.pdf (HAN)
1t7j  2.20  2005  Kd=2.0nM      // 1t7j.pdf (478)
2bz8  2.00  2005  Kd=2.5uM      // 2bz8.pdf (11-mer) Kd=2.5+/-1.0uM
2byr  2.45  2005  Kd=2.8nM      // 2byr.pdf (MLK)
1y3n  1.60  2005  Kd=2.8uM      // 1y3n.pdf (2-mer) ligand is BEM-MAV
2c2l  3.30  2005  Kd=2.8uM      // 2c2l.pdf (10-mer) incomplete ligand structure
1xge  1.90  2005  Kd=20.8uM     // 1xge.pdf (DOR)
1xr8  2.30  2005  Kd=200nM      // 1xr8.pdf (9-mer)
1w70  1.46  2005  Kd=200uM      // 1w70.pdf (15-mer) incomplete ligand structure
2bjm  2.15  2005  Kd=200uM      // 2bjm.pdf (ANF)
2agv  2.40  2005  Kd=20nM       // 2agv.pdf (BHQ)
2arm  1.23  2005  Kd=21nM       // 2arm.pdf (OIN) Ki=7.4nM
2a25  2.20  2005  Kd=24uM       // 2a25.pdf (13-mer) Kd=24+/-4uM; incomplete ligand
2c3i  1.90  2005  Kd=25nM       // 2c3i.pdf (IYZ) ligand is compound imidazo[1,2-b]pyridazine 1
1wva  1.94  2005  Kd=270nM      // 1wva.pdf (S2C) B-containing
1yc4  1.81  2005  Kd=280nM      // 1yc4.pdf (43P)
1wdr  1.35  2005  Kd=3.05mM     // 1wdr.pdf (MAL)
1y98  2.50  2005  Kd=3.7uM      // 1y98.pdf (12-mer)
1w96  1.80  2005  Kd=3.9nM      // 1w96.pdf (S1A)
1y3a  2.50  2005  Kd=3.9uM      // 1y3a.pdf (16-mer) ligand is KB752 peptide, Kd=3.9+/-0.6uM, EC50 for GEF activity is 5.6+/-1.1 uM; incomplete ligand
1zhy  1.60  2005  Kd=300nM      // 1zhy.pdf (CLR)
1xz8  2.80  2005  Kd=30uM       // 1xz8.pdf (U5P)
2a4m  2.30  2005  Kd=30uM       // 2a4m.pdf (TRP)
2br8  2.40  2005  Kd=32.6nM     // 2br8.pdf (17-mer) Kd=32.6+/-8.5nM(ITC); IC50=28+/-6nM; EC50calc=21+/-7nM.
1zkk  1.45  2005  Kd=33uM       // 1zkk.pdf (10-mer) incomplete ligand structure
1xh5  2.05  2005  Kd=3400nM     // 1xh5.pdf (R68) IC50=2400nM
1xh4  2.45  2005  Kd=34nM       // 1xh4.pdf (R69) IC50=30nM
2bj4  2.00  2005  Kd=34uM       // 2bj4.pdf (11-mer) ER LBD with a 11-mer peptide corresponding to the alpha-II interaction motif (LTSRDFGSWYA)
1zhk  1.60  2005  Kd=35.2uM     // 1zhk.pdf (13-mer)
1ywi   NMR  2005  Kd=371uM      // 1ywi.pdf (10-mer) Kd=371+/-22uM; incomplete ligand
2bak  2.20  2005  Kd=37nM       // 2bak.pdf (AQZ)
1tjp  1.50  2005  Kd=38uM       // 1tjp.pdf (HPF)
2baj  2.25  2005  Kd=4.0nM      // 2baj.pdf (1PP)
1w6y  2.10  2005  Kd=4.4uM      // 1w6y.pdf (EQU)
1yvh  2.05  2005  Kd=43nM       // 1yvh.pdf (13-mer) incomplete ligand
1we2  2.30  2005  Kd=44uM       // 1we2.pdf (DHK)
1y2a  2.20  2005  Kd=45.8nM     // 1y2a.pdf (10-mer)
1xq0  1.76  2005  Kd=454nM      // 1xq0.pdf (4TR)
1zm6  2.60  2005  Kd=45uM       // 1zm6.pdf (5-mer)
1xh6  1.90  2005  Kd=48nM       // 1xh6.pdf (R94) IC50=400nM
2bal  2.10  2005  Kd=490nM      // 2bal.pdf (PQA)
2az5  2.10  2005  Kd=5.36uM     // 2az5.pdf (307) ligand is SPD304, Kd=5.36+/-0.21uM
1x07  2.20  2005  Kd=520uM      // 1x07.pdf (IPE) Kd for Mg-IPE
2f8i  1.54  2005  Kd=55nM       // 2f8i.pdf (205)
1rr6  2.50  2005  Kd=56pM       // 1rr6.pdf (IMH) Kd=860pM for PfPNP-IMH complex
2aeb  1.29  2005  Kd=5nM        // 2aeb.pdf (ABH)
1x8d  1.80  2005  Kd=6.16mM     // 1x8d.pdf (RNS) Kd=5.91mM measured with minor form of protein
1yc1  1.70  2005  Kd=680nM      // 1yc1.pdf (4BC)
1xr9  1.79  2005  Kd=70nM       // 1xr8.pdf (9-mer)
1z3v  1.61  2005  Kd=77uM       // 1z3v.pdf (LAT)
2c1n  2.00  2005  Kd=78.1uM     // 2c1j.pdf (8-mer) Kd=78.1+/-6.7uM, peptide(ALA-ARG-LYS-SEP-THR-GLY-GLY-LYS)
1t4e  2.60  2005  Kd=80nM       // 1t4e.pdf (DIZ)
2f7i  1.60  2005  Kd=80nM       // 2f7i.pdf (26C)
1y2g  1.90  2005  Kd=83.1uM     // 1y2g.pdf (CL3)
1xpz  2.02  2005  Kd=84nM       // 1xpz.pdf (4TZ)
1vj6   NMR  2005  Kd=8uM        // 1vj6.pdf (10-mer) PDZ2 complex with C-terminus of APC, Kd=8uM
1zhl  1.50  2005  Kd=9.9uM      // 1zhk.pdf (13-mer)
2b9a  1.54  2005  Kd=9nM        // 2b9a.pdf (FBC)
1w7x  1.80  2005  Ki=0.004uM    // 1w7x.pdf (413)
1wuq  2.00  2005  Ki=0.0054uM   // 1wuq.pdf (8GT)
2ajl  2.50  2005  Ki=0.013uM    // 2ajl.pdf (JNH) covalent complex
1yly  1.25  2005  Ki=0.015uM    // 1yly.pdf (CB4) covalent complex
1t4v  2.00  2005  Ki=0.021uM    // 1t4v.pdf (14A)
2c3k  2.60  2005  Ki=0.026uM    // 2c3k.pdf (ABO)
1ysi   NMR  2005  Ki=0.036uM    // 1ysi.pdf (N3B) ligand is compound 1, assay without human serum
1xn2  1.90  2005  Ki=0.03nM     // 1xn2.pdf (11-mer) incomplete ligand
1s50  1.65  2005  Ki=0.063uM    // 1s50.pdf (GLU)
1x8j  2.35  2005  Ki=0.11uM     // 1x8j.pdf (AOI) ligand is Androsterone
1tvo  2.50  2005  Ki=0.14uM     // 1tvo.pdf (FRZ)
2etk  2.96  2005  Ki=0.15uM     // 2etk.pdf (HFS)
2etr  2.60  2005  Ki=0.15uM     // 2etr.pdf (Y27)
1wur  1.82  2005  Ki=0.22uM     // 1wuq.pdf (8DG)
1w31  1.90  2005  Ki=0.25mM     // 1w31.pdf (SHO) Ki measured on ALAD (R. spheroides)
1ws1  2.00  2005  Ki=0.28nM     // 1ws1.pdf (BB2)
2bok  1.64  2005  Ki=0.28uM     // 2bok.pdf (784)
2a5s  1.70  2005  Ki=0.2uM      // 2a5s.pdf (GLU)
1w2k  3.00  2005  Ki=0.35uM     // 1w2k.pdf (380)
2b07  2.10  2005  Ki=0.37uM     // 2b07.pdf (598)
1w0y  2.50  2005  Ki=0.38uM     // 1w0y.pdf (771)
2ax9  1.65  2005  Ki=0.3nM      // 2ax9.pdf (BHM) ligand is compound R-3
1yys  2.75  2005  Ki=0.47uM     // 1yys.pdf (SAZ) Ki measured on Trichodiene Synthase wt
1yvm  1.60  2005  Ki=0.4uM      // 1yvm.pdf (TMG)
2ayr  1.90  2005  Ki=0.51nM     // 2ayr.pdf (L4G)
1yyr  2.50  2005  Ki=0.51uM     // 1yyr.pdf (SAZ) X-ray(Y305F) while Ki(Trichodiene Synthase wild type)
2ael  2.50  2005  Ki=0.51uM     // 2ael.pdf (SAZ) X-ray(R304K) while Ki(Trichodiene synthase wild type)
2esm  3.20  2005  Ki=0.53uM     // 2esm.pdf (M77)
1wcq  2.10  2005  Ki=0.55uM     // 1wcq.pdf (DAN)
1ym1  1.12  2005  Ki=0.578uM    // 1ym1.pdf (SM2) covalent complex
2b17  2.71  2005  Ki=0.62uM     // 2b17.pdf (DIF)
2c3j  2.10  2005  Ki=0.659uM    // 2c3j.pdf (DBQ)
1z71  1.80  2005  Ki=0.66nM     // 1z71.pdf (L17)
1x6u  2.70  2005  Ki=0.6mM      // 1x6u.pdf (DO8)
1x39  1.80  2005  Ki=0.6nM      // 1x39.pdf (IDE)
1z1r  1.85  2005  Ki=0.6nM      // 1z1r.pdf (HBH) Ki=0.6~12nM
1y1z  1.50  2005  Ki=0.831mM    // 1y1z.pdf (192)
1zxv  2.67  2005  Ki=0.8uM      // 1zxv.pdf (MFM)
1xgj  1.97  2005  Ki=1.0uM      // 1xgj.pdf (HTC)
2br6  1.70  2005  Ki=1.10mM     // 2br6.pdf (HSL)
1yms  1.60  2005  Ki=1.2uM      // 1yms.pdf (NBF) covalent complex
2brm  2.20  2005  Ki=1.3uM      // 2brm.pdf (DFZ)
1x38  1.70  2005  Ki=1.7nM      // 1x38.pdf (IDD)
1zp8  2.02  2005  Ki=1.7nM      // 1zp8.pdf (AB2) IC50=6nM
1zdp  1.70  2005  Ki=1.8uM      // 1zdp.pdf (TIO)
1zyr  3.00  2005  Ki=1.8uM      // 1zyr.pdf (STD)
1zoh  1.81  2005  Ki=100nM      // 1zoh.pdf (K44) IC50=740nM
1w2h  2.00  2005  Ki=10uM       // 1w2h.pdf (ATM)
2ad5  2.80  2005  Ki=110uM      // 2ad5.pdf (CTP)
2brb  2.10  2005  Ki=13.7uM     // 2brb.pdf (PFQ)
1x7a  2.90  2005  Ki=13nM       // 1x7a.pdf (187)
1z6f  1.60  2005  Ki=13uM       // 1z6f.pdf (BO9) covalent complex
1xk9  2.10  2005  Ki=140nM      // 1xk9.pdf (P34)
1xgi  1.96  2005  Ki=14uM       // 1xgi.pdf (NST)
1ya4  3.20  2005  Ki=15.2uM     // 1ya4.pdf (CTX)
1y1m  1.80  2005  Ki=15.3mM     // 1y1m.pdf (AC5)
1wkm  2.30  2005  Ki=150mM      // 1wkm.pdf (MET)
1v1j  2.20  2005  Ki=15uM       // 1v1j.pdf (FA3)
1y3w  1.80  2005  Ki=1680nM     // 1y3w.pdf (UIP)
1x8t  1.90  2005  Ki=16nM       // 1x8t.pdf (RC1)
1ybg  2.60  2005  Ki=16uM       // 1ybg.pdf (TAV)
2afw  1.56  2005  Ki=17uM       // 2afw.pdf (AHN)
2aou  2.30  2005  Ki=18.6nM     // 2aou.pdf (CQA)
1wvj  1.75  2005  Ki=185nM      // 1wvj.pdf (IBC)
2adu  1.90  2005  Ki=18nM       // 2adu.pdf (R20)
1w4p  1.69  2005  Ki=18uM       // 1w4p.pdf (UM3)
2bvd  1.60  2005  Ki=1uM        // 2bvd.pdf (ISX)
2a14  1.70  2005  Ki=2.0uM      // 2a14.pdf (SAH) ligand is compound SAH
2erz  2.20  2005  Ki=2.2uM      // 2erz.pdf (HFS)
1t31  1.90  2005  Ki=2.3nM      // 1t31.pdf (OHH)
1z9g  1.70  2005  Ki=2.3uM      // 1z9g.pdf (RRT)
1ze8  2.00  2005  Ki=21nM       // 1ze8.pdf (PIU)
1wn6  1.80  2005  Ki=21uM       // 1wn6.pdf (BST)
1y3v  1.60  2005  Ki=2300nM     // 1y3v.pdf (UIR)
1y3y  1.75  2005  Ki=2300nM     // 1y3y.pdf (UIR) redundant to 1y3v
2azr  2.00  2005  Ki=230uM      // 2azr.pdf (982)
2bo4  1.95  2005  Ki=24.6uM     // 2bo4.pdf (FLC)
1yqy  2.30  2005  Ki=24nM       // 1yqy.pdf (915)
1t5a  2.80  2005  Ki=24uM       // 1t5a.pdf (OXL)
2f6t  1.70  2005  Ki=24uM       // 2f6t.pdf (1C2) IC50=42.5uM
2bgr  2.00  2005  Ki=250uM      // 2bgr.pdf (9-mer) incomplete ligand structure
1tx7  1.75  2005  Ki=25uM       // 1tx7.pdf (4CM)
1u65  2.61  2005  Ki=26.4nM     // 1u65.pdf (CP0)
2ax6  1.50  2005  Ki=27nM       // 2ax6.pdf (HFT) ligand is compound 2b, Ki for hAR in Transiently-Transfected COS-1 Cells
1w2g  2.10  2005  Ki=27uM       // 1w2g.pdf (THM)
1y6q  2.20  2005  Ki=2pM        // 1y6q.pdf (TDI)
2bgn  3.15  2005  Ki=2uM        // 2bgn.pdf (9-mer) incomplete ligand structure
1z4n  1.97  2005  Ki=30uM       // 1z4n.pdf (GL1) redundant to 1z4o
1z4o  1.90  2005  Ki=30uM       // 1z4o.pdf (GL1)
1u71  2.20  2005  Ki=33nM       // 1u71.pdf (MXA) ligand is compound 4(PTX); Ki=0.025nM in J. Med. Chem., 1996, Vol.39, pp.892-903
1syi  2.10  2005  Ki=3590nM     // 1syi.pdf (CPW)
1wvc  2.50  2005  Ki=35uM       // 1wvc.pdf (CTP)
1vzq  1.54  2005  Ki=36nM       // 1vzq.pdf (SHY)
2a3c  2.07  2005  Ki=37uM       // 2a3c.pdf (PNX) IC50=126uM
2aow  2.97  2005  Ki=38.2nM     // 2aow.pdf (THA)
2aox  3.12  2005  Ki=38.2nM     // 2aox.pdf (THA) redundant to 2aox
1t32  1.85  2005  Ki=38nM       // 1t32.pdf (OHH)
1syh  1.80  2005  Ki=393nM      // 1syh.pdf (CPW)
1z6d  1.54  2005  Ki=4.6mM      // 1z6d.pdf (IMP)
1zgi  2.20  2005  Ki=4.6uM      // 1zgi.pdf (382)
1y20  1.40  2005  Ki=4.8uM      // 1y20.pdf (1AC)
1vyq  2.40  2005  Ki=4.98uM     // 1vyq.pdf (DUX)
1xn3  2.00  2005  Ki=40nM       // 1xn2.pdf (14-mer)
1zoe  1.77  2005  Ki=40nM       // 1zoe.pdf (K25)
1xnx  2.90  2005  Ki=416nM      // 1xnx.pdf (ATE) ligand is compound androstenol, pIC50=6.38
1yfz  2.20  2005  Ki=45uM       // 1yfz.pdf (IMP)
1z6s  1.50  2005  Ki=46uM       // 1z6s.pdf (AMP)
1z1h  1.85  2005  Ki=4nM        // 1z1h.pdf (HBB)
1zpa  2.02  2005  Ki=4nM        // 1zpa.pdf (A83)
2al5  1.65  2005  Ki=4nM        // 2al5.pdf (FWD) ligand is compound (S)-2b
1w4q  1.68  2005  Ki=5.5uM      // 1w4q.pdf (UMF)
2b7f  2.60  2005  Ki=50nM       // 2b7f.pdf (10-mer) Ki=50nM (high-salt buffer); Ki=2.3uM (low-salt buffer)
1rt9  2.30  2005  Ki=56pM       // 1rt9.pdf (IMH) ligand is compound 1, Immucillin-H
1y4z  2.00  2005  Ki=57nM       // 1y4z.pdf (PCI) competitive Ki=57+/-14nM, noncompetitive Ki=490+/-9nM
1yxd  2.00  2005  Ki=5uM        // 1yxd.pdf (LYS) Ki=5-50uM
1t5f  2.20  2005  Ki=60uM       // 1t5f.pdf (DHH)
1xhy  1.85  2005  Ki=662nM      // 1xhy.pdf (KAI)
2c6o  2.10  2005  Ki=6nM        // 2c6o.pdf (4SP) redundant to 1h1s
1w4o  1.60  2005  Ki=6uM        // 1w4o.pdf (UA3)
2afx  1.64  2005  Ki=7.1uM      // 2afx.pdf (1BN)
2br1  2.00  2005  Ki=7.2uM      // 2br1.pdf (PFP)
1yqj  2.00  2005  Ki=7.3nM      // 1yqj.pdf (6NP)
1zog  2.30  2005  Ki=70nM       // 1zog.pdf (K37) IC50=250nM
1y3x  1.70  2005  Ki=7315nM     // 1y3x.pdf (UIB)
1x8r  1.50  2005  Ki=750nM      // 1x8r.pdf (SC1)
1z95  1.80  2005  Ki=76nM       // 1z95.pdf (198)
1y6r  2.20  2005  Ki=77pM       // 1y6r.pdf (MTM)
2exm  1.80  2005  Ki=78uM       // 2exm.pdf (ZIP)
2c3l  2.35  2005  Ki=8.58uM     // 2c3l.pdf (IDZ)
1x1z  1.45  2005  Ki=8.8pM      // 1x1z.pdf (BMP)
1yq7  2.20  2005  Ki=82.2nM     // 1yq7.pdf (RIS) ligand is compound 8(risedronate); time-Dependent IC50 initial 452.9nM to final 5.7nM
2d06  2.30  2005  Ki=83.2uM     // 2d06.pdf (EST)
1yci  2.70  2005  Ki=83uM       // 1yci.pdf (NDF)
2aov  2.48  2005  Ki=91nM       // 2aov.pdf (C2M)
2bqv  2.10  2005  Ki=9nM        // 2bqv.pdf (A1A)
2buc  2.50  2006  IC50<100nM    // 2buc.pdf (008)
2bed  2.70  2006  IC50=0.007uM  // 2bed.pdf (736)
2bu5  2.35  2006  IC50=0.0165uM  // 2bu5.pdf (TF1) ligand is compound 3r
1ym2  2.05  2006  IC50=0.01uM   // 1ym2.pdf (6-mer)
1ym4  2.25  2006  IC50=0.039uM  // 1ym4.pdf (5-mer)
2f4b  2.07  2006  IC50=0.05uM   // 2f4b.pdf (EHA)
2nsx  2.11  2006  IC50=0.063uM  // 2nsx.pdf (IFM) ligand is compound D-Isofagomine
2bdf  2.10  2006  IC50=0.067uM  // 2bdf.pdf (24A)
2evo  1.70  2006  IC50=0.067uM  // 2evo.pdf (CT0)
2bcd  2.10  2006  IC50=0.06nM   // 2bcd.pdf (5-mer)
2ewp  2.30  2006  IC50=0.079uM  // 2ewp.pdf (TXF)
2fq6  1.78  2006  IC50=0.079uM  // 2fq6.pdf (P3F) compound 18, IC50=0.079+/-0.02uM, ligand is the product.
2g1y  2.50  2006  IC50=0.09uM   // 2g1y.pdf (5IG) ligand is compound 19
2h03  1.65  2006  IC50=0.09uM   // 2h03.pdf (3UN)
2gm1  2.30  2006  IC50=0.10uM   // 2gm1.pdf (2AZ)
2hha  2.35  2006  IC50=0.122uM  // 2hha.pdf (3TP)
2axi  1.40  2006  IC50=0.14uM   // 2axi.pdf (10-mer)
2iw6  2.30  2006  IC50=0.14uM   // 2iw6.pdf (QQ2)
2ath  2.28  2006  IC50=0.152uM  // 2ath.pdf (3EA)
2f3e  2.11  2006  IC50=0.156uM  // 2f3e.pdf (AXQ)
2f3f  2.30  2006  IC50=0.19uM   // 2f3f.pdf (AXF)
2ie4  2.60  2006  IC50=0.1nM    // 2ie3.pdf (OKA)
2etm  2.30  2006  IC50=0.212uM  // 2etm.pdf (7PY) ligand is compound 1
1zeo  2.50  2006  IC50=0.21uM   // 1zeo.pdf (C01)
2c5n  2.10  2006  IC50=0.22uM   // 2c5n.pdf (CK8)
2h96  3.00  2006  IC50=0.23uM   // 2h96.pdf (893)
2gtk  2.10  2006  IC50=0.251uM  // 2gtk.pdf (208)
1zpc  2.60  2006  IC50=0.254uM  // 1zpc.pdf (716) covalent complex
2c5x  2.90  2006  IC50=0.25uM   // 2c5x.pdf (MTW) redundant to 2c5y
2c5y  2.25  2006  IC50=0.25uM   // 2c5y.pdf (MTW)
2gg2  1.00  2006  IC50=0.25uM   // 2gg0.pdf (U12) compound 3
2gg5  2.12  2006  IC50=0.25uM   // 2gg0.pdf (U19) compound 4
2cv3  1.90  2006  IC50=0.27uM   // 2cv3.pdf (11-mer) MW>1000
2evc  1.60  2006  IC50=0.29uM   // 2evc.pdf (FC3)
2ggx  1.90  2006  IC50=0.32mM   // 2ggx.pdf (NPJ)
2h02  2.30  2006  IC50=0.32uM   // 2h02.pdf (2UN)
2auz  2.30  2006  IC50=0.35nM   // 2auz.pdf (CT2) covalent complex
2fyv  1.90  2006  IC50=0.3mM    // 2fyv.pdf (W72)
2gz7  1.86  2006  IC50=0.3uM    // 2gz7.pdf (D3F)
2bdj  2.50  2006  IC50=0.45nM   // 2bdj.pdf (HET)
2f2c  2.80  2006  IC50=0.45uM   // 2f2c.pdf (AP9)
2fm0  2.00  2006  IC50=0.4nM    // 2fm0.pdf (M98)
2a4l  2.40  2006  IC50=0.4uM    // 2a4l.pdf (RRC)
2fda  2.00  2006  IC50=0.502uM  // 2fda.pdf (682) covalent complex
2aux  2.40  2006  IC50=0.50nM   // 2aux.pdf (CT1) covalent complex
2hai  1.58  2006  IC50=0.53uM   // 2hai.pdf (PFI)
1ykr  1.80  2006  IC50=0.56uM   // 1ykr.pdf (628)
2fix  3.50  2006  IC50=0.57uM   // 2fix.pdf (870)
2gg3  1.45  2006  IC50=0.58uM   // 2gg0.pdf (U13) compound 7
2f3r  2.50  2006  IC50=0.5uM    // 2f3r.pdf (G5P)
2i5j  3.15  2006  IC50=0.5uM    // 2i5j.pdf (K05) 0.5+/-0.2, DHBNH inhibit RT-RNH
2evm  1.70  2006  IC50=0.693uM  // 2evm.pdf (FC2)
2g6p  1.90  2006  IC50=0.6uM    // 2g6p.pdf (HM2)
2ccu  2.70  2006  IC50=0.74uM   // 2ccu.pdf (2D9)
2fde  2.70  2006  IC50=0.7nM    // 2fde.pdf (385)
2ewy  3.10  2006  IC50=0.7uM    // 2ewy.pdf (DBO)
2gfs  1.75  2006  IC50=0.7uM    // 2gfs.pdf (PQB)
1zpb  2.10  2006  IC50=0.85uM   // 1zpb.pdf (995) covalent complex
2c6e  2.10  2006  IC50=0.8nM    // 2c6e.pdf (HPM) ligand is compound 2h, also is compound 13 in ref.21
2fum  2.89  2006  IC50=0.8uM    // 2fum.pdf (MIX)
2ggu  1.90  2006  IC50=0.94mM   // 2ggu.pdf (MLR)
2fes  2.42  2006  IC50=0.98nM   // 2fes.pdf (3SP)
2c0o  2.85  2006  IC50=1.22uM   // 2c0o.pdf (L2G)
2g01  3.50  2006  IC50=1.22uM   // 2g01.pdf (73Q)
2ew5  2.20  2006  IC50=1.25uM   // 2ew5.pdf (Y12)
2aa9  1.50  2006  IC50=1.2mM    // 2aa9.pdf (SKM) IC50=1.2mM (with Cl-); IC50=1.7mM (with HCO3-)
2aay  1.55  2006  IC50=1.2mM    // 2aay.pdf (SKM) redundant to 2aa9
2cm8  2.10  2006  IC50=1.35uM   // 2cm8.pdf (F16)
2feq  2.44  2006  IC50=1.39nM   // 2feq.pdf (34P)
1ztq  2.00  2006  IC50=1.3nM    // 1ztq.pdf (033)
2j9a  1.73  2006  IC50=1.3uM    // 2j9a.pdf (5-mer)
1yw7  1.85  2006  IC50=1.4uM    // 1yw7.pdf (A41) ligand is compound 4
2g19  1.70  2006  IC50=1.4uM    // 2g19.pdf (4HG) ligand is compound 1
2i40  2.80  2006  IC50=1.58uM   // 2i40.pdf (BLZ)
2ckm  2.15  2006  IC50=1.5nM    // 2ckm.pdf (AA7) X-ray(TcAChE); IC50(rat AChE)
2giu  2.20  2006  IC50=1.5nM    // 2giu.pdf (FBR)
2nq6  1.50  2006  IC50=1.5uM    // 2nq6.pdf (HM4)
2cmc  2.20  2006  IC50=1.75uM   // 2cmc.pdf (DFM)
2gg7  1.12  2006  IC50=1.75uM   // 2gg0.pdf (U14) compound 1, 2
2cne  1.80  2006  IC50=1.7nM    // 2cne.pdf (DFJ)
2j7x  2.10  2006  IC50=1.7nM    // 2j7x.pdf (EST) ligand is 17 beta-estradiol
2gg0  1.28  2006  IC50=1.7uM    // 2gg0.pdf (U11) compound 12
2h44  1.80  2006  IC50=1.7uM    // 2h44.pdf (7CA)
2anm  2.40  2006  IC50=1.8nM    // 2anm.pdf (CDO)
2ew6  2.20  2006  IC50=10.8uM   // 2ew6.pdf (Y13)
2f1b  1.45  2006  IC50=1000uM   // 2f18.pdf (GB3) compound 10
2brp  2.00  2006  IC50=100uM    // 2brp.pdf (SIE) IC50(SpnHyal)>100uM, IC50(SagHyal)=11uM
2c8y  2.20  2006  IC50=100uM    // 2c8y.pdf (C3M)
2iw8  2.30  2006  IC50=103nM    // 2iw8.pdf (4SP)
2fme  2.10  2006  IC50=104nM    // 2fme.pdf (3QC)
1yw8  2.65  2006  IC50=10nM     // 1yw8.pdf (A75)
2ama  1.90  2006  IC50=10nM     // 2ama.pdf (DHT) ligand is compound 2, dihydrotestosterone
2cng  1.90  2006  IC50=110nM    // 2cng.pdf (IZE)
2igy  2.60  2006  IC50=113nM    // 2igx.pdf (A2T) compound 18, IC50(PM-1)=1123nM, IC50(PM-6)=19440nM, IC50(red blood cell)=126nM
2hny  2.50  2006  IC50=1165nM   // 2hny.pdf (NVP)
2gga  1.70  2006  IC50=11mM     // 2gga.pdf (GPJ)
2irz  1.80  2006  IC50=12nM     // 2irz.pdf (I02)
2c93  2.20  2006  IC50=12uM     // 2c93.pdf (C4M)
2ggb  2.13  2006  IC50=12uM     // 2gg0.pdf (U17) compound 14
1zd5  2.60  2006  IC50=13.4uM   // 1zd5.pdf (NC7)
2cgu  2.50  2006  IC50=13.4uM   // 2cgu.pdf (3A3)
2f3k  1.60  2006  IC50=13nM     // 2f3k.pdf (RO1)
2j50  3.00  2006  IC50=13nM     // 2j50.pdf (627)
2fjm  2.10  2006  IC50=142nM    // 2fjm.pdf (073) IC50=142+/-41nM
2gnh  2.05  2006  IC50=149nM    // 2gnh.pdf (H52)
2j87  3.10  2006  IC50=14uM     // 2j87.pdf (TTP) IC50=14+/-4.0uM
2cgx  2.20  2006  IC50=15.6uM   // 2cgx.pdf (3D3)
2bdl  2.00  2006  IC50=15nM     // 2bdl.pdf (4PR) covalent complex
2euf  3.00  2006  IC50=15nM     // 2euf.pdf (LQQ)
2i0v  2.80  2006  IC50=160nM    // 2i0v.pdf (6C3) quinolone inhibits cFMS
2ggd  1.70  2006  IC50=160uM    // 2ggd.pdf (GPJ)
2chz  2.60  2006  IC50=16nM     // 2chw.pdf (093) HUMAN PI-3K GAMMA CATALYTIC SUBUNIT, how get IC50?
2cgw  2.20  2006  IC50=17.3uM   // 2cgw.pdf (3C3)
2bdy  1.61  2006  IC50=17nM     // 2bdy.pdf (UNB)
2chw  2.60  2006  IC50=17uM     // 2chw.pdf (039) HUMAN PI-3K GAMMA CATALYTIC SUBUNIT
2azc  2.01  2006  IC50=183nM    // 2azc.pdf (3TL)
2cma  2.30  2006  IC50=185nM    // 2cma.pdf (F20)
2chx  2.50  2006  IC50=18nM     // 2chw.pdf (090) HUMAN PI-3K GAMMA CATALYTIC SUBUNIT, how get IC50?
2b7a  2.00  2006  IC50=1nM      // 2b7a.pdf (IZA)
2am1  2.50  2006  IC50=1uM      // 2am1.pdf (1LG)
2fl2  2.50  2006  IC50=2.0nM    // 2fl2.pdf (N4T)
2ccs  1.79  2006  IC50=2.0uM    // 2ccs.pdf (4BH)
2gpp  2.60  2006  IC50=2.0uM    // 2gpp.pdf (1BA) complexed with Nuclear receptor-interacting protein 1
2hwh  2.30  2006  IC50=2.0uM    // 2hwh.pdf (RNA)
2bb7  1.70  2006  IC50=2.14uM   // 2bb7.pdf (QMS)
2gni  2.27  2006  IC50=2.28uM   // 2gni.pdf (M77)
2i47  1.90  2006  IC50=2.2nM    // 2i47.pdf (KGY)
2f4j  1.91  2006  IC50=2.2uM    // 2f4j.pdf (VX6)
2h42  2.30  2006  IC50=2.4nM    // 2h42.pdf (VIA)
1yy4  2.70  2006  IC50=2.52nM   // 1yy4.pdf (4NA)
2fky  2.30  2006  IC50=2.6nM    // 2fky.pdf (N2T)
2iit  2.35  2006  IC50=2.6nM    // 2iit.pdf (872)
1yye  2.03  2006  IC50=2.7nM    // 1yye.pdf (196)
2h8h  2.20  2006  IC50=2.7nM    // 2h8h.pdf (H8H)
2nq7  1.60  2006  IC50=2.9uM    // 2nq7.pdf (HM5)
2a2x  2.44  2006  IC50=20.2nM   // 2a2x.pdf (NA9)
2fwy  2.10  2006  IC50=200nM    // 2fwy.pdf (H64)
2is0  2.20  2006  IC50=200nM    // 2is0.pdf (I03)
1zaf  2.20  2006  IC50=20nM     // 1zaf.pdf (789)
2c4f  1.72  2006  IC50=20nM     // 2c4f.pdf (GIL)
2g1r  2.42  2006  IC50=20nM     // 2g1r.pdf (3IG) ligand is compound 34
2ica  1.56  2006  IC50=20nM     // 2ica.pdf (2IC)
2cm7  2.10  2006  IC50=210nM    // 2cm7.pdf (IZD)
2bve  2.20  2006  IC50=215uM    // 2bve.pdf (PH5) PROP compound
2cni  2.00  2006  IC50=21nM     // 2cni.pdf (IZF)
2g0h  2.30  2006  IC50=22.7nM   // 2g0h.pdf (SP3)
2c8x  2.17  2006  IC50=220nM    // 2c8x.pdf (C5M)
2az9  2.50  2006  IC50=22nM     // 2az9.pdf (3TL) incomplete structure
2fj0  2.70  2006  IC50=22nM     // 2fj0.pdf (TFC) covalent complex
2nyr  2.06  2006  IC50=22uM     // 2nyr.pdf (SVR)
2exc  2.75  2006  IC50=235nM    // 2exc.pdf (JNK) ligand is compound 12
2bkt  2.30  2006  IC50=23nM     // 2bkt.pdf (RPF)
2cnf  2.20  2006  IC50=240nM    // 2cnf.pdf (F32)
2i0y  1.90  2006  IC50=24nM     // 2i0v.pdf (5CN) arylamide inhibits cFMS
2i1m  1.80  2006  IC50=24nM     // 2i0v.pdf (5CN) arylamide inhibits cFMS
1zd4  2.70  2006  IC50=253uM    // 1zd4.pdf (NC6)
2gg8  1.80  2006  IC50=25uM     // 2gg0.pdf (U15) compound 15
2cgv  2.60  2006  IC50=27.3uM   // 2cgv.pdf (3B3)
2cmf  2.50  2006  IC50=28nM     // 2cmf.pdf (F11) X-ray(TcAChE); IC50(rat AChE)
2hwi  2.00  2006  IC50=3.0uM    // 2hwi.pdf (VRX)
2gc8  2.20  2006  IC50=3.1uM    // 2gc8.pdf (885)
2cn8  2.70  2006  IC50=3.5uM    // 2cn8.pdf (DBQ)
2fie  2.81  2006  IC50=3.5uM    // 2fie.pdf (A74)
2gg9  1.05  2006  IC50=3.5uM    // 2gg0.pdf (U16) compound 13
2c8w  1.96  2006  IC50=3.7nM    // 2c8w.pdf (C7M)
2am9  1.64  2006  IC50=3.9nM    // 2am9.pdf (TES)
1zom  2.25  2006  IC50=30nM     // 1zom.pdf (339) compound 36, mutations(S452A, T493A, K455A, C500S)
2c6c  2.00  2006  IC50=30nM     // 2c6c.pdf (24I)
2bua  2.56  2006  IC50=30uM     // 2bua.pdf (007)
2c90  2.25  2006  IC50=330uM    // 2c90.pdf (C1M)
2c9t  2.25  2006  IC50=33nM     // 2c9t.pdf (13-mer) IC50=33+/-5nM
2bks  2.20  2006  IC50=37nM     // 2bks.pdf (PZ1)
2fl6  2.50  2006  IC50=38nM     // 2fl6.pdf (N5T)
2fjn  2.20  2006  IC50=39nM     // 2fjm.pdf (073) IC50=39+/-10nM
2b1p  1.90  2006  IC50=3nM      // 2b1p.pdf (AIZ) ligand is compound 18
2hfp  2.00  2006  IC50=3nM      // 2hfp.pdf (NSI)
2gcd  2.55  2006  IC50=3uM      // 2gcd.pdf (STU)
2gz8  1.97  2006  IC50=3uM      // 2gz8.pdf (F3F)
2fjp  2.40  2006  IC50=4.3nM    // 2fjp.pdf (S14)
2dq7  2.80  2006  IC50=4.8nM    // 2dq7.pdf (STU)
2fdd  1.58  2006  IC50=4.8nM    // 2fdd.pdf (385)
2ddf  1.70  2006  IC50=41nM     // 2ddf.pdf (INN) IC50=41+/-3nM, mutation(S266A, V353G, Q452N), WT IC50=43+/-4nM
2c6g  2.20  2006  IC50=428uM    // 2c6g.pdf (GLU) ligand is glutamate, some cofactors in crystal
2np8  2.25  2006  IC50=42nM     // 2np8.pdf (CC3) compound 1
2fm5  2.03  2006  IC50=43nM     // 2fm5.pdf (M99)
2g1q  2.51  2006  IC50=44nM     // 2g1q.pdf (N9H)
2g9x  2.50  2006  IC50=45nM     // 2g9x.pdf (NU5)
2dxs  2.20  2006  IC50=46nM     // 2dxs.pdf (JTP)
2hk5  2.00  2006  IC50=46nM     // 2hk5.pdf (1BM) IC50(Src)=162nM, IC50(Lck)=3nM, IC50(IL-2)=0.549uM
2ank  2.46  2006  IC50=47.3nM   // 2ank.pdf (N12)
2boi  1.10  2006  IC50=48uM     // 2boi.pdf (MFU)
2g24  1.90  2006  IC50=4uM      // 2g24.pdf (7IG) ligand is compound 11
2chm  1.60  2006  IC50=5.5nM    // 2chm.pdf (3P4)
2aq7  2.30  2006  IC50=500uM    // 2aq7.pdf (TL5)
2aqb  2.19  2006  IC50=500uM    // 2aqb.pdf (TL6)
2hd1  2.23  2006  IC50=500uM    // 2hd1.pdf (IBM)
2a0c  1.95  2006  IC50=50nM     // 2a0c.pdf (CK9) ligand is olomoucine II
2fwz  2.10  2006  IC50=50nM     // 2fwz.pdf (H71)
2g0g  2.54  2006  IC50=512nM    // 2g0g.pdf (SP0)
2igx  1.70  2006  IC50=54nM     // 2igx.pdf (A1T) compound 22, ligand structure has some mistakes. IC50(PM-1)=711nM, IC50(PM-6)=3214nM
2gnl  2.60  2006  IC50=58nM     // 2gnl.pdf (H52)
2cnh  1.80  2006  IC50=59nM     // 2cnh.pdf (IZB)
2gv2  1.80  2006  IC50=5nM      // 2gv2.pdf (9-mer) MW>1000
2c5o  2.10  2006  IC50=6.50uM   // 2c5o.pdf (CK2)
2iiv  2.15  2006  IC50=6.6nM    // 2iiv.pdf (565)
2bv4  1.00  2006  IC50=600uM    // 2bv4.pdf (MMA)
2fv9  2.02  2006  IC50=60nM     // 2ddf.pdf (002) TACE V353G complexed with JMV 390, IC50=60+/-5nM, mutation(S266A, V353G, Q452N), WT IC50=65+/-4nM
2j83  2.00  2006  IC50=61uM     // 2j83.pdf (BAT)
2azb  2.03  2006  IC50=64nM     // 2azb.pdf (3TL) incomplete structure
2cmb  1.70  2006  IC50=65nM     // 2cmb.pdf (F17)
2j4z  2.00  2006  IC50=65nM     // 2j4z.pdf (626)
2a8h  2.30  2006  IC50=67nM     // 2a8h.pdf (4NH)
2az8  2.00  2006  IC50=6nM      // 2az8.pdf (3TL) incomplete structure
2gnf  2.28  2006  IC50=6uM      // 2gnf.pdf (Y27)
2gnj  2.28  2006  IC50=6uM      // 2gnj.pdf (Y27)
2d1x  1.90  2006  IC50=7.9uM    // 2d1x.pdf (15-mer) IC50=7.9+/-3.12uM; incomplete ligand
2alv  1.90  2006  IC50=70uM     // 2alv.pdf (CY6) covalent complex
2f1a  1.45  2006  IC50=720uM    // 2f18.pdf (GB2) compound 9
2gmx  3.50  2006  IC50=77nM     // 2gmx.pdf (877)
2b1z  1.78  2006  IC50=79nM     // 2b1z.pdf (17M) PBA(relative binding affinity)=8.1nM; EC50=5.3nM
2ayp  2.90  2006  IC50=7nM      // 2ayp.pdf (43A)
2bkz  2.60  2006  IC50=7nM      // 2bkz.pdf (SBC)
2go4  2.70  2006  IC50=7uM      // 2go4.pdf (TUX) X-ray(source=A.aeolicus); Ki=650nM(source=E.coli)
2i7c  1.71  2006  IC50=8.5uM    // 2i7c.pdf (AAT) IC50=8.5+/-0.3uM
2iw9  2.00  2006  IC50=8.9nM    // 2iw9.pdf (4SP)
2f18  1.30  2006  IC50=80uM     // 2f18.pdf (GB1) compound 8
2auc  2.60  2006  IC50=84uM     // 2auc.pdf (15-mer) incomplete ligand
2aei  2.52  2006  IC50=86nM     // 2aei.pdf (03R)
2hiw  2.20  2006  IC50=8nM      // 2hiw.pdf (7MP) IC50(dephosphorylated)=8nM, IC50(phosphorylated)=11nM
2am2  2.80  2006  IC50=8uM      // 2am2.pdf (2LG)
2cct  2.30  2006  IC50=9.5uM    // 2cct.pdf (2E1)
2i1r  2.20  2006  IC50=9.7uM    // 2i1r.pdf (VXR)
2bub  2.66  2006  IC50=90nM     // 2bub.pdf (FPB)
2i0h  2.00  2006  IC50=9nM      // 2i0h.pdf (222)
1zd2  3.00  2006  IC50>500uM    // 1zd2.pdf (NC3)
1zd3  2.30  2006  IC50>500uM    // 1zd3.pdf (NC4)
2fv5  2.10  2006  Kd<2pM        // 2fv5.pdf (541) X-ray(source=human); Ki=0.56nM(source=pig)
2f34  1.74  2006  Kd=0.13uM     // 2f34.pdf (UBA)
2c94  1.90  2006  Kd=0.15uM     // 2c94.pdf (TSF)
1ybo  2.30  2006  Kd=0.16mM     // 1ybo.pdf (17-mer) Kd=0.16+/-0.01mM; incomplete ligand
2fb8  2.90  2006  Kd=0.16nM     // 2fb8.pdf (215) ligand is compound SB-590885
2ceo  2.80  2006  Kd=0.1nM      // 2ceo.pdf (T44)
2gh7  1.00  2006  Kd=0.1pM      // 2gh7.pdf (BTN)
2iwx  1.50  2006  Kd=0.21uM     // 2cgf.pdf (M1S) Kd measured by ITC, compound 15h
2ews  2.05  2006  Kd=0.24uM     // 2ews.pdf (ANP)
2euk  1.85  2006  Kd=0.25uM     // 2euk.pdf (3-mer)
2fgh  2.80  2006  Kd=0.28uM     // 2fgh.pdf (ATP)
2h21  2.45  2006  Kd=0.29uM     // 2h21.pdf (SAM)
2eum  2.30  2006  Kd=0.2uM      // 2eum.pdf (3-mer)
2evl  2.20  2006  Kd=0.2uM      // 2evl.pdf (3-mer)
2cgf  2.20  2006  Kd=0.39uM     // 2cgf.pdf (P2N) Kd measured by ITC, compound 15a
2iws  2.70  2006  Kd=0.44uM     // 2cgf.pdf (NP4) ITC, compound 15f cis, ligand:cis
2c9d  2.80  2006  Kd=0.48uM     // 2c9d.pdf (PHR)
2izx  1.30  2006  Kd=0.4nM      // 2izx.pdf (DTD) Kd(AKAP-IS)=0.4nM
2hdx  2.35  2006  Kd=0.55uM     // 2hdx.pdf (11-mer) Kd=0.55+/-0.010uM; incomplete ligand
2f14  1.71  2006  Kd=0.64nM     // 2f14.pdf (FL1)
2fgu  2.00  2006  Kd=0.66nM     // 2fgu.pdf (5-mer)
1zc9  2.00  2006  Kd=0.6mM      // 1zc9.pdf (PMP)
2c97  2.00  2006  Kd=0.72uM     // 2c97.pdf (JCL)
2cvd  1.45  2006  Kd=0.8uM      // 2cvd.pdf (HQL)
2ivz  2.00  2006  Kd=0.92uM     // 2ivz.pdf (16-mer) Kd=0.92+/-0.03uM; incomplete ligand
2ce9  2.12  2006  Kd=0.93uM     // 2ce8.pdf (5-mer)
2df6  1.30  2006  Kd=1.05uM     // 2df6.pdf (18-mer) Kd=1.05+/-0.035uM; EC50=0.9+/-0.05uM
2j79  1.94  2006  Kd=1.1uM      // 2j79.pdf (GTL)
2fkf  2.00  2006  Kd=1.2mM      // 2fkf.pdf (G16)
2fw6  1.85  2006  Kd=1.2mM      // 2fw6.pdf (CIT)
2fwp  1.85  2006  Kd=1.2mM      // 2fwp.pdf (CIT) redundant to 2fw6
2iwu  2.80  2006  Kd=1.2uM      // 2cgf.pdf (NP5) ITC, compound 15f trans, ligand:trans
2g83  2.80  2006  Kd=1.2uM      // 2g83.pdf (GDP) Kd for GDP with AlF4-
2g6q  2.00  2006  Kd=1.5uM      // 2g6q.pdf (12-mer) Kd=1.5+/-1uM; incomplete ligand
2boj  1.80  2006  Kd=1.7uM      // 2boj.pdf (ARW)
2fl5  3.00  2006  Kd=1.8nM      // 2fl5.pdf (RBF)
2gfa  2.10  2006  Kd=10.4uM     // 2gfa.pdf (10-mer) incomplete ligand
2h2h  2.20  2006  Kd=10.5uM     // 2h2d.pdf (11-mer) Kd=10.5+/-1.4uM; incomplete ligand
2j7g  1.91  2006  Kd=100nM      // 2j7g.pdf (GI4)
2buv  1.80  2006  Kd=100uM      // 2bum.pdf (DHB)
2flh  1.20  2006  Kd=106uM      // 2flh.pdf (ZEA) Kd(ITC)=106+/-12uM, Kd(ADA)=148+/-14uM
2bmv  2.11  2006  Kd=10mM       // 2bmv.pdf (BEN) FMN calculated Kd=10mM, for holoflavodoxin and benzamidine
2ewa  2.10  2006  Kd=11.5nM     // 2ewa.pdf (SB2)
2h9n  2.00  2006  Kd=115uM      // 2h9m.pdf (11-mer) Kd=115+/-13uM; incomplete ligand
2a5b  2.49  2006  Kd=117uM      // 2a5b.pdf (8HG)
2cbz  1.50  2006  Kd=118uM      // 2cbz.pdf (ATP)
2j77  2.10  2006  Kd=12.9uM     // 2j77.pdf (NOJ)
2foy  1.55  2006  Kd=120nM      // 2foy.pdf (B30) Cu-containing
2haw  1.75  2006  Kd=12uM       // 2haw.pdf (2PN)
2clv  1.90  2006  Kd=13.2nM     // 2clv.pdf (8-mer) MW>1000
2g2r  2.75  2006  Kd=13nM       // 2g2r.pdf (TNS)
2g97  2.90  2006  Kd=152nM      // 2g97.pdf (DGB)
2hu6  1.32  2006  Kd=154uM      // 2hu6.pdf (37A)
2o4n  2.00  2006  Kd=15nM       // 2o4k.pdf (TPV)
2gl0  2.25  2006  Kd=15uM       // 2gl0.pdf (ADN)
2gzl  2.50  2006  Kd=15uM       // 2gzl.pdf (2AA) IC50=3mM
2ccc  1.70  2006  Kd=17.57nM    // 2ccc.pdf (LFN)
2fx9  2.10  2006  Kd=17nM       // 2fx7.pdf (14-mer) human fab 4e10 complex with a thioether-linked peptide on gp41, Kd=17nM
2b4l  2.00  2006  Kd=17uM       // 2b4l.pdf (BET)
2h9p  1.91  2006  Kd=192uM      // 2h9m.pdf (11-mer) Kd=192+/-26uM; incomplete ligand
2o4p  1.80  2006  Kd=19pM       // 2o4k.pdf (TPV) same as 6dif
2ha4  2.56  2006  Kd=2.0mM      // 2h9y.pdf (ACH) Kd=2.0+/-0.2mM, Kd(ambenonium kinetics)=2.0+/-0.2mM, Kd(direct titration)=1.7+/-0.7mM
2fr3  1.48  2006  Kd=2.0nM      // 2fr3.pdf (REA) wt Kd=2.0+/-1.2nM, Kd(F15W)=40+/-4nM
2c92  1.60  2006  Kd=2.11uM     // 2c92.pdf (TP6)
2cbu  1.85  2006  Kd=2.1uM      // 2cbu.pdf (CTS) Ki=2uM
2azm  2.41  2006  Kd=2.2uM      // 2azm.pdf (10-mer) incomplete ligand
2bmk  2.30  2006  Kd=2.4uM      // 2bmk.pdf (PDD)
2fuu   NMR  2006  Kd=2.7uM      // 2f6j.pdf (15-mer) NMR structure; Kd1=2.7uM (ITC); Kd2=1.6+/-1.0uM (FP)
2f6j  2.00  2006  Kd=2.7uM      // 2f6j.pdf (15-mer) X-ray structure; Kd1=2.7uM (ITC); Kd2=1.6+/-1.0uM (FP); incomplete ligand
2c9b  2.75  2006  Kd=2.88uM     // 2c9b.pdf (PUG)
2idk  2.55  2006  Kd=2.9uM      // 2idk.pdf (C2F)
2a8g  1.99  2006  Kd=205uM      // 2a8g.pdf (GNG)
2flu  1.50  2006  Kd=20nM       // 2flu.pdf (16-mer)
2fx7  1.76  2006  Kd=20nM       // 2fx7.pdf (16-mer) human fab 4e10 complex with a 16-residue peptide on gp41, Kd=20nM
2hmv  2.20  2006  Kd=20nM       // 2hmu.pdf (ADP) Kd=20~70nM
2hmw  3.00  2006  Kd=20nM       // 2hmu.pdf (ATP) 20-70, Kd is apparent dissociation constant
2hmu  2.25  2006  Kd=20nM       // 2hmu.pdf (ATP) Kd=20~70nM
2cex  2.20  2006  Kd=20uM       // 2cex.pdf (DAN)
2h23  2.45  2006  Kd=21.2uM     // 2h23.pdf (SAH) X-ray(pLSMT); Kd(aLSMT)
2fqw  1.71  2006  Kd=210nM      // 2fqw.pdf (NOS)
2aoj  1.60  2006  Kd=22.1uM     // 2aof.pdf (10-mer) Kd=22.1+/-2.8uM
2j75  1.85  2006  Kd=225nM      // 2j75.pdf (NOY)
2ca8  2.49  2006  Kd=22uM       // 2ca8.pdf (GSH)
2ha2  2.05  2006  Kd=22uM       // 2h9y.pdf (SCK) Kd=22+/-1uM, Ki=21+/-2uM, Kd(decidium kinetics)=22+/-1uM
2j7b  1.87  2006  Kd=240nM      // 2j7b.pdf (NTZ)
2a5c  2.50  2006  Kd=24uM       // 2a5c.pdf (8DA)
2fsv  2.30  2006  Kd=25uM       // 2fr8.pdf (NAD)
2fqy  1.90  2006  Kd=270nM      // 2fqy.pdf (ADN)
2aof  1.32  2006  Kd=28.2uM     // 2aof.pdf (11-mer) Kd=28.2+/-4.2uM
2fov  1.15  2006  Kd=28nM       // 2fov.pdf (B30) Cu-containing
2b4m  2.80  2006  Kd=295uM      // 2b4m.pdf (PBE)
2frd  3.20  2006  Kd=29uM       // 2fr8.pdf (NAD) Kd(dI.S138A.)2(dIII)1-NADH)=29uM
2h3e  2.30  2006  Kd=2uM        // 2h3e.pdf (6PR)
2g5u  1.80  2006  Kd=3.2nM      // 2g5u.pdf (PCQ)
2cbv  1.95  2006  Kd=3.3uM      // 2cbv.pdf (CGB) Ki=4uM
2co0  2.25  2006  Kd=3.3uM      // 2co0.pdf (15-mer) Kd=3.3+/-0.2uM; incomplete ligand
2hf8  2.10  2006  Kd=3.4uM      // 2hf8.pdf (GSP)
2f35  1.87  2006  Kd=3.94uM     // 2f35.pdf (UBC)
2fx8  2.20  2006  Kd=302nM      // 2fx7.pdf (12-mer) human fab 4e10 complex with an aib-induced peptide on gp41, Kd=302nM
2o4s  1.54  2006  Kd=31pM       // 2o4k.pdf (AB1) same as 6dj1
2nm1  2.15  2006  Kd=34nM       // 2nm1.pdf (17-mer) Kd=34nM(ITC titration at pH 5.7); binding affinity between HCB and the isolated Syt-II is independent of pH.
2ccb  1.65  2006  Kd=35.76nM    // 2ccb.pdf (RBF)
2iko  1.90  2006  Kd=3571nM     // 2iko.pdf (7IG) IC50=6560nM
2o4k  1.60  2006  Kd=35pM       // 2o4k.pdf (DR7)
2h9m  1.90  2006  Kd=35uM       // 2h9m.pdf (11-mer) Kd=35+/-8uM; incomplete ligand
2aoh  1.42  2006  Kd=36.3uM     // 2aof.pdf (10-mer) Kd=36.3+/-5.4uM
2amt  2.30  2006  Kd=36uM       // 2amt.pdf (1AA)
2cia  1.45  2006  Kd=370nM      // 2ci9.pdf (11-mer) incomplete ligand
2ha0  2.20  2006  Kd=37uM       // 2h9y.pdf (NWA) Kd=37+/-13uM, Ki=23+/-6uM, Kd(ambenonium kinetics)=37+/-13uM, Kd(decidium kinetics)=33+/-2uM. ligand structure, two hydroxyl groups, different from reference.
2j78  1.65  2006  Kd=384nM      // 2j78.pdf (GOX)
2ez5   NMR  2006  Kd=3uM        // 2ez5.pdf (11-mer)
2h6b  2.20  2006  Kd=4.1uM      // 2h6b.pdf (3C4)
2h2j  2.45  2006  Kd=4.2uM      // 2h2j.pdf (SFG) X-ray(pLSMT); Kd(aLSMT)
2h2d  1.70  2006  Kd=4.3uM      // 2h2d.pdf (18-mer) Kd=4.3+/-0.5uM; incomplete ligand
2fxv  2.05  2006  Kd=4.5uM      // 2fxv.pdf (5GP)
2h13  1.58  2006  Kd=4.5uM      // 2h13.pdf (10-mer) Kd=4.5+/-0.2uM; incomplete ligand
2c80  2.30  2006  Kd=4.7uM      // 2c80.pdf (GTX)
2ez7  2.00  2006  Kd=43.5uM     // 2ez7.pdf (DHI)
2ha7  2.66  2006  Kd=440uM      // 2h9y.pdf (BCH) Kd(ambenonium kinetics)=440+/-50uM, Kd(decidium kinetics)=760+/-320uM
2j7f  2.28  2006  Kd=445nM      // 2j7f.pdf (GI3)
2fys  2.50  2006  Kd=44uM       // 2fys.pdf (17-mer) incomplete ligand
2ha5  2.15  2006  Kd=46uM       // 2h9y.pdf (AT3) Kd(ambenonium kinetics)=46+/-23uM; Kd(decidium kinetics)=160+/-100uM
2j7e  2.19  2006  Kd=48nM       // 2j7e.pdf (GI2)
2ha6  2.25  2006  Kd=48uM       // 2h9y.pdf (SCK) Kd(ambenonium kinetics)=48+/-4uM
2c1p  2.00  2006  Kd=4uM        // 2c1p.pdf (FNZ) Kd=4~6uM
2fsa  1.90  2006  Kd=5.0uM      // 2f6j.pdf (15-mer) incomplete ligand
2a4w  1.50  2006  Kd=5.1nM      // 2a4w.pdf (BLM) Kd1=5.1nM; Kd2>1000nM; MW>1000
2g96  2.90  2006  Kd=52.8uM     // 2g96.pdf (NMN)
2ces  2.15  2006  Kd=56nM       // 2ces.pdf (GIM) Ki=138nM at pH=5.8
2gph  1.90  2006  Kd=5uM        // 2gph.pdf (16-mer) covalent complex
2gz2  2.10  2006  Kd=6.0uM      // 2gz2.pdf (A2P) Kd=6.0+/-1.0uM
2f5t  1.45  2006  Kd=6.8uM      // 2f5t.pdf (MAL)
2o4l  1.33  2006  Kd=608pM      // 2o4k.pdf (TPV)
2ci9  1.50  2006  Kd=60nM       // 2ci9.pdf (12-mer) incomplete ligand
2fo4  2.70  2006  Kd=60nM       // 2fo4.pdf (8-mer) Kd=160nM(4oC); Kd=60nM(23oC); Kd=300nM(37oC)
1yon  1.95  2006  Kd=61uM       // 1yon.pdf (A2R) 2P-ADP-ribose, Kd=61+/-8uM at pH=7.7, Kd=250+/-65uM at pH=4.5
2j7h  1.95  2006  Kd=65nM       // 2j7h.pdf (AZF)
2doo  2.43  2006  Kd=67nM       // 2doo.pdf (C4H) Kd=67+/-14nM; Ki=140+/-10nM; IC50=0.7+/-0.1uM
1zea  1.78  2006  Kd=6uM        // 1zea.pdf (9-mer)
2h6q  1.87  2006  Kd=7.8uM      // 2h6q.pdf (9-mer) incomplete ligand
2fr8  2.60  2006  Kd=700uM      // 2fr8.pdf (NAD) Kd(dI.R127A.-NADH)=700uM
2bba  1.65  2006  Kd=70nM       // 2bba.pdf (15-mer) IC50=15nM; incomplete ligand
2fci   NMR  2006  Kd=70nM       // 2fci.pdf (14-mer)
2hmh  2.00  2006  Kd=70nM       // 2hmh.pdf (11-mer)
2fqx  1.70  2006  Kd=71nM       // 2fqx.pdf (GMP)
2j7d  2.24  2006  Kd=74nM       // 2j7d.pdf (GI1)
2fgv  1.50  2006  Kd=760nM      // 2fgv.pdf (5-mer)
2o9k  1.90  2006  Kd=77uM       // 2h9m.pdf (11-mer) Kd=77+/-16uM; incomplete ligand
2iku  2.60  2006  Kd=79nM       // 2iku.pdf (LIY) IC50=58nM
2il2  2.24  2006  Kd=79nM       // 2il2.pdf (LIX) IC50=27nM
2fxu  1.35  2006  Kd=7nM        // 2fxu.pdf (BID)
2gtv   NMR  2006  Kd=7uM        // 2gtv.pdf (TSA) Kd(overall)=7uM
2h6k  1.89  2006  Kd=8.7uM      // 2h6k.pdf (8-mer) MW>1000
2fou  0.99  2006  Kd=80nM       // 2fou.pdf (B22) Cu-containing
2hnx  1.50  2006  Kd=83nM       // 2hnx.pdf (PLM) Kd=0.083uM for ALB2
1zsh  2.90  2006  Kd=85nM       // 1zsh.pdf (IHP)
2ate  1.80  2006  Kd=86nM       // 2ate.pdf (NIA) wt PurE with NO2-AIR; Kd=86+/-31nM
2h5a  1.72  2006  Kd=8uM        // 2h5a.pdf (X1P)
2h2g  1.63  2006  Kd=9.2uM      // 2h2d.pdf (11-mer) Kd=9.2+/-1.6uM; incomplete ligand
2d0k  1.90  2006  Kd=9.51uM     // 2d0k.pdf (FOL)
2cet  1.97  2006  Kd=9.6nM      // 2cet.pdf (PGI) Ki=7.5nM at pH=5.8
2cc7  1.80  2006  Kd=9.88nM     // 2cc7.pdf (LUM)
2fts  2.41  2006  Kd=90nM       // 2fts.pdf (13-mer) Kd=90-120nM
2ha3  2.25  2006  Kd=930uM      // 2h9y.pdf (CHT) Kd=930+/-120uM, Kd(ambenonium kinetics)=930+/-120uM, Ki=1.4+/-0.2mM
2aoi  1.40  2006  Kd=96.7uM     // 2aof.pdf (11-mer) Kd=96.7+/-12.3uM
2h2e  2.60  2006  Kd>1000uM     // 2h2e.pdf (SA8) X-ray(pLSMT); Kd(aLSMT)
2exg   NMR  2006  Kd~50uM       // 2exg.pdf (STF)
2cer  2.29  2006  Ki<=0.6nM     // 2cer.pdf (PGI)
2cf8  1.30  2006  Ki=0.008uM    // 2cf8.pdf (ESH)
2cf9  1.79  2006  Ki=0.015uM    // 2cf9.pdf (348)
2f0z  2.80  2006  Ki=0.017mM    // 2f0z.pdf (ZMR) ligand is Zanamivir (compd 1)
2aoe  1.54  2006  Ki=0.024uM    // 2aoe.pdf (0Q4)
2d1o  2.02  2006  Ki=0.02uM     // 2d1o.pdf (FA4)
2hh5  1.80  2006  Ki=0.032uM    // 2hh5.pdf (GNQ) redundant to 2hhn
2f7o  1.43  2006  Ki=0.036uM    // 2f7o.pdf (MSN)
2f81  1.25  2006  Ki=0.03nM     // 2f81.pdf (017)
2fzz  2.20  2006  Ki=0.03nM     // 2fzz.pdf (5QC)
2f9u  2.60  2006  Ki=0.041uM    // 2f9u.pdf (5NH) covalent complex
2i3h  1.62  2006  Ki=0.04uM     // 2i3h.pdf (4-mer)
2i3i  2.30  2006  Ki=0.05uM     // 2i3i.pdf (618)
2a4g  2.50  2006  Ki=0.066uM    // 2a4g.pdf (UNH) covalent complex
2a4q  2.45  2006  Ki=0.066uM    // 2a4q.pdf (FNH) covalent complex
2bq6  3.00  2006  Ki=0.07nM     // 2bq6.pdf (IIB)
2bz6  1.60  2006  Ki=0.081uM    // 2bz6.pdf (346)
1zsf  1.98  2006  Ki=0.12nM     // 1zsf.pdf (0ZS)
2d3u  2.00  2006  Ki=0.12uM     // 2d3u.pdf (CCT)
1zsr  2.06  2006  Ki=0.15nM     // 1zsr.pdf (0ZT) redundant to 1zsf
2b1i  2.02  2006  Ki=0.15uM     // 2b1g.pdf (93A) compound 3, include AICAR transformylase and IMP cyclohydrolase
2d41  2.10  2006  Ki=0.15uM     // 2d41.pdf (SNH)
2g00  2.10  2006  Ki=0.18nM     // 2g00.pdf (4QC)
1z6e  1.80  2006  Ki=0.19nM     // 1z6e.pdf (IK8)
2i0g  2.50  2006  Ki=0.19nM     // 2i0g.pdf (I0G)
2b1g  2.10  2006  Ki=0.23uM     // 2b1g.pdf (13A) compound 2, include AICAR transformylase and IMP cyclohydrolase
2d3z  1.80  2006  Ki=0.23uM     // 2d3z.pdf (FIH)
2f7p  1.28  2006  Ki=0.249uM    // 2f7p.pdf (2SK)
2hwg  2.70  2006  Ki=0.28mM     // 2hwg.pdf (OXL)
2jbj  2.19  2006  Ki=0.2nM      // 2jbj.pdf (G88)
2f10  2.90  2006  Ki=0.33mM     // 2f10.pdf (BCZ) ligand is compound 3, Peramivir
2bzz  0.98  2006  Ki=0.37uM     // 2bzz.pdf (AP5)
2fqo  1.87  2006  Ki=0.37uM     // 2fqo.pdf (HYI)
2g94  1.86  2006  Ki=0.3nM      // 2g94.pdf (ZPQ)
2gvj  2.10  2006  Ki=0.3nM      // 2gvj.pdf (DGB)
2hoc  2.10  2006  Ki=0.3nM      // 2hoc.pdf (1CN) ligand is compound 16
2f9b  2.54  2006  Ki=0.3uM      // 2f9b.pdf (N1H)
2h4g  2.50  2006  Ki=0.3uM      // 2h4g.pdf (694)
2aqu  2.00  2006  Ki=0.48nM     // 2aqu.pdf (DR7)
2jbk  2.99  2006  Ki=0.4uM      // 2jbj.pdf (QUS)
2aog  1.10  2006  Ki=0.53uM     // 2aog.pdf (2NC)
2avv  1.50  2006  Ki=0.55nM     // 2avv.pdf (MK1) redundant to 1sdt
1w6h  2.24  2006  Ki=0.5nM      // 1w6h.pdf (TIT) ligand is compound 5, TIT1330
1zvx  1.87  2006  Ki=0.6nM      // 1zvx.pdf (FIN)
2fqt  1.79  2006  Ki=0.72uM     // 2fqt.pdf (H1D)
2g5t  2.30  2006  Ki=0.82nM     // 2g5t.pdf (ACF) covalent complex
2i0d  1.95  2006  Ki=0.8pM      // 2i0d.pdf (MUT)
2ewb  1.85  2006  Ki=0.8uM      // 2ewb.pdf (ZED)
2i03  2.40  2006  Ki=1.0nM      // 2i03.pdf (AXD) covalent complex
2ien  1.30  2006  Ki=1.0nM      // 2ien.pdf (017) redundant to 3tkw; binding data so different from 3tkw
2fhy  2.95  2006  Ki=1.1uM      // 2fhy.pdf (A37) IC50=6.6uM
2h5i  1.69  2006  Ki=1.3nM      // 2h5i.pdf (5-mer) covalent complex
2idw  1.10  2006  Ki=1.3nM      // 2idw.pdf (017)
2avo  1.10  2006  Ki=1.40nM     // 2avo.pdf (MK1)
1yz3  2.40  2006  Ki=1.55nM     // 1yz3.pdf (SKA)
2b1v  1.80  2006  Ki=1.8uM      // 2b1v.pdf (458)
2flb  1.95  2006  Ki=1.8uM      // 2flb.pdf (6NH)
2d2v  2.50  2006  Ki=100mM      // 2b1q.pdf (MAL) maltose
2gvd  2.90  2006  Ki=100nM      // 2gvd.pdf (128) Ki=100+/-30nM, Ki=81+/-27nM in presence of G alpha s
2b1r  2.20  2006  Ki=101mM      // 2b1q.pdf (CBI) cellobiose
2g8r  1.70  2006  Ki=103uM      // 2g8r.pdf (N3E)
2hds  1.16  2006  Ki=10mM       // 2hds.pdf (4MB)
1ypg  1.80  2006  Ki=10nM       // 1ypg.pdf (UIR)
2anl  3.30  2006  Ki=110nM      // 2anl.pdf (JE2)
2fpz  2.00  2006  Ki=110uM      // 2fpz.pdf (270)
2e1w  2.50  2006  Ki=11nM       // 2e1w.pdf (FR6)
2h5j  2.00  2006  Ki=12.4nM     // 2h5j.pdf (5-mer) covalent complex
2gvv  1.73  2006  Ki=125uM      // 2gvv.pdf (DI9)
1zfk  1.56  2006  Ki=12nM       // 1zfk.pdf (NR2) ligand is compound 3
2gbf  3.10  2006  Ki=12nM       // 2gbf.pdf (AIA) covalent complex
2aoc  1.30  2006  Ki=13.0uM     // 2aoc.pdf (2NC)
2clx  1.80  2006  Ki=13.3uM     // 2clx.pdf (F18) IC50=3.5uM
2gvz  3.27  2006  Ki=130nM      // 2gvd.pdf (ONA) Ki=130+/-11nM, Ki=14+/-3.7nM in presence of G alpha s
2c6n  3.00  2006  Ki=131.5nM    // 2c6n.pdf (LPR) ligand is lisinopril
2gv7  2.20  2006  Ki=14nM       // 2gv7.pdf (672)
2a4r  2.40  2006  Ki=15nM       // 2a4r.pdf (BNH) covalent complex
2j34  2.01  2006  Ki=15nM       // 2j34.pdf (GS6)
2hb1  2.00  2006  Ki=160uM      // 2hb1.pdf (512)
2hd6  1.80  2006  Ki=16nM       // 2hd6.pdf (BOS)
2i19  2.28  2006  Ki=16nM       // 2i19.pdf (1BY)
2ajd  2.56  2006  Ki=16pM       // 2ajd.pdf (BPR) covalent complex; X-ray(porcine DPIV); Ki(human DPIV); B-containing
2dua  2.00  2006  Ki=17uM       // 2dua.pdf (OXL)
2bmg  2.70  2006  Ki=18nM       // 2bmg.pdf (I1H)
2am4  1.70  2006  Ki=190uM      // 2am4.pdf (U2F)
2f94  1.94  2006  Ki=195nM      // 2f94.pdf (BFQ) ligand is compound 6(ibandronate); time-Dependent IC50 initial 1052 nM to final 25.4 nM
2fzc  2.10  2006  Ki=1990uM     // 2fzc.pdf (EOP) IC50=200uM; Ki=2160uM (for substrate CP); Ki=1990uM (for substrate Asp)
2hdr  2.20  2006  Ki=19mM       // 2hdr.pdf (4A3)
2j4i  1.80  2006  Ki=1nM        // 2j4i.pdf (GSJ)
2f8g  1.22  2006  Ki=2.0nM      // 2f8g.pdf (017)
2avm  1.10  2006  Ki=2.0uM      // 2avm.pdf (2NC)
2nw4  3.00  2006  Ki=2.11nM     // 2nw4.pdf (8NH) Ki=2.11+/-0.16nM, EC50(C2C12)=0.44+/-0.03nM, EC50(PEC)=8.66+/-0.22nM
2aod  1.40  2006  Ki=2.17uM     // 2aod.pdf (2NC)
2an5  2.50  2006  Ki=2.1uM      // 2an5.pdf (TTL)
2c4v  2.50  2006  Ki=2.5mM      // 2c4v.pdf (CIT)
2i0j  2.90  2006  Ki=2.68nM     // 2i0j.pdf (I0G)
2iuz  1.95  2006  Ki=2.8uM      // 2iuz.pdf (D1H)
2bvr  1.25  2006  Ki=200uM      // 2bvr.pdf (4CP)
2fx6  1.57  2006  Ki=200uM      // 2fx6.pdf (270)
2c4w  1.55  2006  Ki=20uM       // 2c4w.pdf (GAJ)
2dw7  2.50  2006  Ki=20uM       // 2dw7.pdf (SRT)
2cn0  1.30  2006  Ki=22nM       // 2cn0.pdf (F25) Ki for racemic ligand
2fzk  2.50  2006  Ki=250uM      // 2fzk.pdf (EOZ) IC50=79uM; Ki=250uM (for substrate CP); Ki=310uM (for substrate Asp)
2fs8  2.50  2006  Ki=25nM       // 2fs8.pdf (C3A) covalent complex
2fxr  2.50  2006  Ki=25nM       // 2fxr.pdf (C3A) covalent complex
2gsu  2.00  2006  Ki=260uM      // 2gsu.pdf (AMP)
2b1q  2.20  2006  Ki=26mM       // 2b1q.pdf (TRE) trehalose
2fdp  2.50  2006  Ki=26nM       // 2fdp.pdf (FRP)
2avs  1.10  2006  Ki=27.0nM     // 2avs.pdf (MK1)
2i3v  2.40  2006  Ki=282nM      // 2i3v.pdf (GLU) redundant to 2xxr
2f1g  1.90  2006  Ki=29nM       // 2f1g.pdf (GNF)
2b7d  2.24  2006  Ki=2nM        // 2b7d.pdf (C1B)
2bvx  3.20  2006  Ki=2nM        // 2bvx.pdf (5CB) Structure of ligand is different from reference
2i0e  2.60  2006  Ki=2nM        // 2i0e.pdf (PDS) IC50=17nM
2i3z  2.90  2006  Ki=2nM        // 2i3z.pdf (LIR) Ki=2nM (0% plasma); Ki=600nM (18% plasma)
2f2h  1.95  2006  Ki=2uM        // 2f2h.pdf (XTG)
2ajb  2.75  2006  Ki=3.14uM     // 2ajb.pdf (0QG) covalent complex
2ieo  1.53  2006  Ki=3.2nM      // 2ieo.pdf (017) redundant to 2hs1
2ihq  2.00  2006  Ki=3.2nM      // 2ihq.pdf (LG7)
2h4k  2.30  2006  Ki=3.2uM      // 2h4k.pdf (509)
2ioa  2.80  2006  Ki=3.2uM      // 2ioa.pdf (GGA) Ki*=7.8nM
2hs1  0.84  2006  Ki=3.3nM      // 2hs1.pdf (017)
2aez  3.05  2006  Ki=3.5mM      // 2ade.pdf (DQR) for native 1-FEH IIa, Ki=5.9mM. for mutant Ki=3.5mM, data not shown
2g5p  2.40  2006  Ki=3.8nM      // 2g5p.pdf (ADF) covalent complex
2j47  1.98  2006  Ki=3.9uM      // 2j47.pdf (GDV)
1zfq  1.55  2006  Ki=30nM       // 1zfq.pdf (ZEC) ligand is compound 21
2f89  2.60  2006  Ki=331nM      // 2f89.pdf (210) ligand is compound 2, pamidronate. Time-Dependent Inhibition IC50 initial 1932 nM to final 353 nM
2c57  3.10  2006  Ki=370uM      // 2c57.pdf (FA1)
2ivu  2.50  2006  Ki=375nM      // 2ivu.pdf (ZD6)
2isw  1.75  2006  Ki=37nM       // 2isv.pdf (PGH) Ki=37+/-2nM
2isv  2.30  2006  Ki=37nM       // 2isv.pdf (PGH) Ki=37+/-2nM; redundant to 2isw
2cmo  2.65  2006  Ki=394nM      // 2cmo.pdf (M1L) X-ray(S-NS1209); Ki(RS-NS1209)
2boh  2.20  2006  Ki=3nM        // 2boh.pdf (IIA)
2bqw  2.95  2006  Ki=3nM        // 2bqw.pdf (IIE)
2bxt  1.83  2006  Ki=3nM        // 2bxt.pdf (C2D) ligand structure is different in reference
2fs9  2.30  2006  Ki=3nM        // 2fs9.pdf (C4A) covalent complex
2fvd  1.85  2006  Ki=3nM        // 2fvd.pdf (LIA)
2gbi  3.30  2006  Ki=3nM        // 2gbi.pdf (XIH)
2hb3  1.35  2006  Ki=4.5pM      // 2hb3.pdf (GRL)
2hs2  1.22  2006  Ki=4.9nM      // 2hs2.pdf (017) redundant to 2hs1
2hdq  2.10  2006  Ki=40mM       // 2hdq.pdf (C21)
1y3g  2.10  2006  Ki=40nM       // 1y3g.pdf (3-mer)
2j9h  2.40  2006  Ki=410uM      // 2j9h.pdf (GTX) Ki=410+/-26uM , Midpoint concentration 0.06+/-0.01M
2hzy  1.35  2006  Ki=41nM       // 2hzy.pdf (DHJ) ligand is compound 1; Ki=41+/-0.4nM
2avq  1.30  2006  Ki=41uM       // 2avq.pdf (2NC)
2fzg  2.25  2006  Ki=420uM      // 2fzg.pdf (EOB) IC50=86uM; Ki=420uM (for substrate CP); Ki=420uM (for substrate Asp)
2aw1  1.46  2006  Ki=43nM       // 2aw1.pdf (COX)
2gv6  2.10  2006  Ki=46nM       // 2gv6.pdf (730)
2j2u  1.90  2006  Ki=47nM       // 2j2u.pdf (GSQ)
2i0a  1.80  2006  Ki=4pM        // 2i0a.pdf (MUI)
2i80  2.19  2006  Ki=4uM        // 2i80.pdf (G1L)
2cbj  2.35  2006  Ki=5.4nM      // 2cbi.pdf (OAN) Ki(hOGA-OAN)=70nM for a homologue
1zge  1.65  2006  Ki=50nM       // 1zge.pdf (SDA) ligand is compound 9
2aq9  1.80  2006  Ki=50nM       // 2aq9.pdf (15-mer) IC50=60+/-9nM(1uM acyl-ACP); IC50=730+/-107nM(100uM acyl-ACP); incomplete ligand
2ceq  2.14  2006  Ki=53nM       // 2ceq.pdf (GIM)
1zky  2.25  2006  Ki=560nM      // 1zky.pdf (689)
2gbg  3.00  2006  Ki=56nM       // 2gbg.pdf (1AD) covalent complex
2fai  2.10  2006  Ki=570nM      // 2fai.pdf (459)
2gmk  1.65  2006  Ki=590uM      // 2gmk.pdf (AMP) Ki=590+/-20uM; IC50=2.5uM
2hdu  1.49  2006  Ki=5mM        // 2hdu.pdf (F12)
2ff1  2.07  2006  Ki=6.2nM      // 2ff1.pdf (IMH)
2ff2  2.20  2006  Ki=6.2nM      // 2ff2.pdf (IMH) redundant to 2ff1
2h5d  0.90  2006  Ki=6.4nM      // 2h5d.pdf (5-mer) B-containing
2h65  2.30  2006  Ki=6.5nM      // 2h65.pdf (6-mer) covalent complex
2f80  1.45  2006  Ki=6.6nM      // 2f80.pdf (017)
2g63  2.00  2006  Ki=6.7nM      // 2g63.pdf (AAF) covalent complex
2hnc  1.55  2006  Ki=60nM       // 2hnc.pdf (1SA) ligand is compound 13
2aj8  2.11  2006  Ki=638nM      // 2aj8.pdf (SC3)
2g8n  2.15  2006  Ki=63nM       // 2g8n.pdf (F83)
1z9y  1.66  2006  Ki=65nM       // 1z9y.pdf (FUN) ligand is compound 7
2cji  2.10  2006  Ki=6nM        // 2cji.pdf (GSK)
2hxm  1.30  2006  Ki=6uM        // 2hxm.pdf (302)
1zs0  1.56  2006  Ki=700nM      // 1zs0.pdf (EIN)
2bxu  2.80  2006  Ki=70nM       // 2bxu.pdf (C1D) in PDB database, not aromatic cycle
1yp9  2.10  2006  Ki=7700nM     // 1yp9.pdf (UIZ)
2d1n  2.37  2006  Ki=7nM        // 2d1n.pdf (FA4)
2fm2  2.70  2006  Ki=7nM        // 2fm2.pdf (3BC) covalent complex
2bvs  1.40  2006  Ki=80uM       // 2bvs.pdf (2CE)
2f9k  2.06  2006  Ki=85.9nM     // 2f9k.pdf (ZOL) ligand is compound 7(zoledronate); time-Dependent inhibition; Ki or IC50 increase 100 folds
2bq7  2.20  2006  Ki=89nM       // 2bq7.pdf (IID)
1ype  1.81  2006  Ki=8nM        // 1ype.pdf (UIP)
1w7g  1.65  2006  Ki=8uM        // 1w7g.pdf (MIU) Ki=8~18uM
2c02  2.00  2006  Ki=92uM       // 2c02.pdf (ADP) redundant to 1hi5
1ypj  1.78  2006  Ki=95nM       // 1ypj.pdf (UIB)
2fah  2.09  2006  Ki>50mM       // 2fah.pdf (MLA)
2in6  1.90  2007  IC50=0.023uM  // 2in6.pdf (839) compound 59
2j4a  2.20  2007  IC50=0.025nM  // 2j4a.pdf (OEF) ligand is compound 5, -logIC50=10.6
2io6  2.20  2007  IC50=0.030uM  // 2in6.pdf (330) compound 18
2uzn  2.30  2007  IC50=0.03uM   // 2uzb.pdf (C96)
2obj  2.50  2007  IC50=0.05uM   // 2obj.pdf (VRV)
2hwp  2.48  2007  IC50=0.073uM  // 2hwo.pdf (DJK) compound 2, S345C
2duv  2.20  2007  IC50=0.087uM  // 2duv.pdf (371) compound 15a
2hwo  2.50  2007  IC50=0.126uM  // 2hwo.pdf (RBS) compound 4, S345C
2p3g  3.80  2007  IC50=0.126uM  // 2p3g.pdf (F10)
2uzb  2.70  2007  IC50=0.12uM   // 2uzb.pdf (C75)
2r9s  2.40  2007  IC50=0.15uM   // 2r9s.pdf (255) compound 16a; IC50=0.15+/-0.02uM
2jdt  2.15  2007  IC50=0.17uM   // 2jdt.pdf (I5S) PKA-PKB-1, IC50 for PKB- beta -I5S complex is 0.23uM
2uzd  2.72  2007  IC50=0.18uM   // 2uzb.pdf (C85)
2rjp  2.80  2007  IC50=0.1uM    // 2rjp.pdf (886)
2va7  2.20  2007  IC50=0.20uM   // 2va5.pdf (C27) measured by FRET
2of2  2.00  2007  IC50=0.21uM   // 2of2.pdf (547)
2j7w  2.60  2007  IC50=0.22uM   // 2j7w.pdf (GTP)
2jdo  1.80  2007  IC50=0.23uM   // 2jdo.pdf (I5S) polymer2:GLYCOGEN SYNTHASE KINASE-3 BETA   EC.No.2.7.11.26
2pgj  1.71  2007  IC50=0.26mM   // 2pgj.pdf (N1C)
2pgl  1.76  2007  IC50=0.26mM   // 2pgj.pdf (N1C) incorrect data [protein in crystal is E226Q mutant]
2uw6  2.23  2007  IC50=0.28uM   // 2uw3.pdf (GVO) (S)-enantiomer IC50=0.28+/-0.03uM
3b8z  1.40  2007  IC50=0.29uM   // 3b8z.pdf (294)
1vsn  2.00  2007  IC50=0.2nM    // 1vsn.pdf (NFT) compound 23, ligand difference: CN -> CH2NH2
2ofv  2.00  2007  IC50=0.2nM    // 2ofv.pdf (242)
2gdo  3.00  2007  IC50=0.32nM   // 2gdo.pdf (12C) compound 11
2o64  2.44  2007  IC50=0.34uM   // 2o3p.pdf (MYU)
2ohv  2.50  2007  IC50=0.35uM   // 2ohv.pdf (NHL) IC50=0.1ug/mL, MW=287.31
2fw3  2.50  2007  IC50=0.38uM   // 2fw3.pdf (BUI) ligand is compound ST1326
2oj9  2.00  2007  IC50=0.39uM   // 2oj9.pdf (BMI)
2hog  1.90  2007  IC50=0.3nM    // 2hog.pdf (710) compound 21, IC50(Cdk7)=56nM, EC50(CEA)=690nM
2pvw  1.71  2007  IC50=0.3nM    // 2or4.pdf (G88)
2q6b  2.00  2007  IC50=0.3nM    // 2q6b.pdf (HR2)
2off  2.20  2007  IC50=0.3uM    // 2off.pdf (OFF)
2owb  2.10  2007  IC50=0.44uM   // 2ou7.pdf (626)
2qpj  2.05  2007  IC50=0.45uM   // 2qpj.pdf (I20)
2uyi  2.10  2007  IC50=0.48uM   // 2pg2.pdf (K02) ligand is in the KSP allosteric binding site
2v10  3.10  2007  IC50=0.4nM    // 2v0z.pdf (C61)
2e98  1.90  2007  IC50=0.59uM   // 2e8t.pdf (B29)
2og8  2.30  2007  IC50=0.5nM    // 2ofv.pdf (1N8)
2uzl  2.40  2007  IC50=0.61uM   // 2uzb.pdf (C94)
2gmv  2.30  2007  IC50=0.63uM   // 2gmv.pdf (UN8) compound 16, IC50=0.63+/-0.14uM
2p98  1.70  2007  IC50=0.64uM   // 2p98.pdf (YE7) IC50=0.64uM at 5uM Mn; IC50=4.31uM at 100uM Mn
2hy0  1.70  2007  IC50=0.65nM   // 2hxl.pdf (306) compound 22, IC50 is tested at 0.1mM ATP. EC50(cell)=97nM
2o65  2.85  2007  IC50=0.65uM   // 2o3p.pdf (MYF)
2ozr  2.30  2007  IC50=0.67nM   // 2ow9.pdf (GG1)
2va6  2.50  2007  IC50=0.67uM   // 2va5.pdf (H24) IC50=0.67 uM in SPR assay; IC50=0.38uM in FRET assay; IC50=0.28uM in IGEN assay
2e99  2.00  2007  IC50=0.69uM   // 2e8t.pdf (B08)
2v0z  2.20  2007  IC50=0.6nM    // 2v0z.pdf (C41)
3b2w  2.30  2007  IC50=0.6nM    // 3b2w.pdf (9NH)
2uue  2.06  2007  IC50=0.74uM   // 2uue.pdf (MTZ) superseded by 2uue
2o63  2.00  2007  IC50=0.78uM   // 2o3p.pdf (MYC)
2g9r  2.07  2007  IC50=0.84uM   // 2g9q.pdf (G27) IC50(rabbit muscle)=0.84+/-0.13uM
2g9u  2.15  2007  IC50=0.84uM   // 2g9u.pdf (G27) ligand is compound 8
2q1j  1.90  2007  IC50=0.8nM    // 2q1j.pdf (FXI)
2pzi  2.40  2007  IC50=0.8uM    // 2pzi.pdf (AXX)
2e9a  2.10  2007  IC50=0.91uM   // 2e8t.pdf (B28)
2o48  2.59  2007  IC50=0.97uM   // 2o48.pdf (AC6)
2i6a  2.20  2007  IC50=0.9nM    // 2i6a.pdf (5I5) compound 1, IC50=0.9+/-0.1nM
2v12  3.20  2007  IC50=0.9nM    // 2v0z.pdf (C39)
2r0u  1.90  2007  IC50=1.0nM    // 2r0u.pdf (M54)
2p99  1.80  2007  IC50=1.16uM   // 2p98.pdf (YE6)
2e9c  2.05  2007  IC50=1.1uM    // 2e8t.pdf (B75)
2o3p  2.24  2007  IC50=1.1uM    // 2o3p.pdf (QUE)
2o7v  2.30  2007  IC50=1.1uM    // 2o7r.pdf (DEP) Ligand structure has missing atoms (covalent inhibition)
2g9v  2.15  2007  IC50=1.21uM   // 2g9q.pdf (IFM) IC50(rabbit muscle)=1.21+/-0.18uM, phosphated of sites
2uzv  2.50  2007  IC50=1.36uM   // 2uzv.pdf (SS5) compound 13au, IC50=1360nM
2e9d  2.50  2007  IC50=1.3uM    // 2e8t.pdf (B76)
2jbl  2.40  2007  IC50=1.3uM    // 2jbl.pdf (SMA)
2ooh  1.85  2007  IC50=1.3uM    // 2ooh.pdf (OX3)
2ork  1.89  2007  IC50=1.4mM    // 2orj.pdf (IPD)
2ghg  3.50  2007  IC50=1.5nM    // 2ghg.pdf (A53) Z:E>98:1, MTT(F5.12-Akt)IC50=0.2nM. ligand: C=C->C-C
2r9m  1.97  2007  IC50=1.5nM    // 2r9m.pdf (Y11) ligand is compound 1
2qe5  2.60  2007  IC50=1.64uM   // 2qe2.pdf (617)
2q2y  2.50  2007  IC50=1.6nM    // 2q2y.pdf (MKR)
2q7m  4.25  2007  IC50=1.6nM    // 2q7m.pdf (2CS) ligand is compound MK-0591
2p3o  2.76  2007  IC50=1.7mM    // 2p3l.pdf (GTA) IC50=1.7mM for 7MeGpppAC4; IC50=2.52mM for 7MeGpppAC5
2pg2  1.85  2007  IC50=1.7uM    // 2pg2.pdf (K01) ligand is in the KSP allosteric binding site
2veu  2.40  2007  IC50=100nM    // 2veu.pdf (IZ1) pNPP enzyme assay. compound 4A
2ohr  2.25  2007  IC50=100uM    // 2ohp.pdf (8IP)
2qcg  1.75  2007  IC50=100uM    // 2qcd.pdf (5BU)
2p4i  2.50  2007  IC50=10nM     // 2p2h.pdf (MR9) Protein synonym: tyrosine-protein kinase receptor tie-2
2qcn  1.85  2007  IC50=10uM     // 2qcd.pdf (U5P)
2gh6  2.20  2007  IC50=11.19uM  // 2gh6.pdf (CF3) IC50=11.19+/-2.50uM
2ieh  2.70  2007  IC50=110nM    // 2ieh.pdf (MOY)
2ojf  2.10  2007  IC50=110nM    // 2oh0.pdf (4PY)
2hiz  2.50  2007  IC50=112nM    // 2hiz.pdf (LIJ) compound 32, IC50(Cat-D)=67nM
2e2b  2.20  2007  IC50=11nM     // 2e2b.pdf (406) compound 8 INNO-406
2oah  1.80  2007  IC50=11nM     // 2oah.pdf (QIN)
2p83  2.50  2007  IC50=11nM     // 2p83.pdf (MR0)
2qk8  2.40  2007  IC50=12.2nM   // 2qk8.pdf (MTX)
2q1l  2.05  2007  IC50=12.4nM   // 2q1l.pdf (882) there is a mistake in ref. (confusing compound 2 and 3)
2hxl  1.80  2007  IC50=12nM     // 2hxl.pdf (422)
2qd9  1.70  2007  IC50=13nM     // 2qd9.pdf (LGF)
2hxq  2.00  2007  IC50=144nM    // 2hxl.pdf (373)
2gfj  1.80  2007  IC50=150uM    // 2fu7.pdf (_VI)
2ou7  2.40  2007  IC50=155uM    // 2ou7.pdf (ANP)
2o5k  3.20  2007  IC50=15nM     // 2o5k.pdf (HBM)
2o7n  1.75  2007  IC50=15nM     // 2o7n.pdf (2O7) in vitro assay is at cellular level
3bi6  2.20  2007  IC50=15nM     // 3bi6.pdf (396) compound 24
2hb9  1.75  2007  IC50=15uM     // 2fu7.pdf (L13)
2ilp  1.90  2007  IC50=15uM     // 2ilp.pdf (GB5) 4-chlorocinnamic hydroxamate
2q6c  2.00  2007  IC50=16.7nM   // 2q6b.pdf (HR1)
2oph  2.40  2007  IC50=16nM     // 2oph.pdf (277) IC50=16nM (DPP-4, 0% HS); IC50=40nM (DPP-4, 50% HS)
2hyy  2.40  2007  IC50=170nM    // 2hyy.pdf (STI) IC50(WT-Abl)=170+/-23nM, IC50(Bcr-Abl)=231+/-43nM
2osc  2.80  2007  IC50=17nM     // 2oo8.pdf (MUH)
2qe2  2.90  2007  IC50=17nM     // 2qe2.pdf (452)
2vex  2.20  2007  IC50=180nM    // 2veu.pdf (IZ4) pNPP enzyme assay. compound 4H
2oh0  2.20  2007  IC50=18nM     // 2oh0.pdf (2PY)
2uw7  2.10  2007  IC50=18nM     // 2uw3.pdf (GVP) IC50=18+/-7nM
2pjl  2.30  2007  IC50=190nM    // 2pjl.pdf (047) ligand is compound 1a
2iok  2.40  2007  IC50=1nM      // 2iog.pdf (IOK) compound 1d, IC50(ER beta )=94nM
2ofu  2.00  2007  IC50=1nM      // 2ofu.pdf (1N9)
2oo8  2.20  2007  IC50=1nM      // 2oo8.pdf (RAJ)
2ow1  2.20  2007  IC50=1nM      // 2ovx.pdf (7MR) incorrect data [protein in crystal is E402Q mutant]
2r6n  1.95  2007  IC50=1nM      // 2r6n.pdf (CKE) covalent inhibition
2rgu  2.60  2007  IC50=1nM      // 2rgu.pdf (356)
2q72  1.70  2007  IC50=2.09mM   // 2q6h.pdf (IXX)
2q2z  3.00  2007  IC50=2.0nM    // 2q2y.pdf (MKK)
2v0c  1.85  2007  IC50=2.1uM    // 2v0c.pdf (ANZ) incorrect data [ligand in crystal is AMP-AN2690 adduct; IC50=2.1uM is for AN2690]
2r3c  1.73  2007  IC50=2.2uM    // 2r3c.pdf (17-mer) incomplete ligand
2qt9  2.10  2007  IC50=2.3nM    // 2qt9.pdf (524)
2gu8  2.20  2007  IC50=2.6nM    // 2gu8.pdf (796) compound 2aa, IC50(AKT1)=6nM, IC50(AKT2)=23nM
2j2i  1.90  2007  IC50=200nM    // 2j2i.pdf (LY4) ligand is LY333531
2ow0  2.00  2007  IC50=201nM    // 2ovx.pdf (6MR) incorrect data [protein in crystal is E402Q mutant]
2qoh  1.95  2007  IC50=20nM     // 2qoh.pdf (P3Y)
2uw0  2.00  2007  IC50=20nM     // 2uw0.pdf (GVK)
2h9t  2.40  2007  IC50=20uM     // 2h9t.pdf (SVR) Inhibition of alpha Thrombin-induced fibrinogen clotting by SVR, IC50=20uM
2jc0  2.20  2007  IC50=20uM     // 2jc0.pdf (699) filtermat assay using full length 1b enzyme
2rcu  1.78  2007  IC50=210nM    // 2rcu.pdf (BUJ)
2p8s  2.20  2007  IC50=21nM     // 2p8s.pdf (417)
2vcj  2.50  2007  IC50=21nM     // 2vci.pdf (2EQ)
2vci  2.00  2007  IC50=21nM     // 2vci.pdf (2GJ)
2oq6  2.00  2007  IC50=250uM    // 2oq6.pdf (OGA) ligand is compound 19
2q6h  1.85  2007  IC50=250uM    // 2q6h.pdf (CXX)
2qch  1.95  2007  IC50=250uM    // 2qcd.pdf (5IU)
2qoe  2.30  2007  IC50=25nM     // 2qoe.pdf (448)
2jaj  2.00  2007  IC50=25uM     // 2jaj.pdf (D20) NG-DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1 WITH L-257, IC50<25uM
2ohq  2.10  2007  IC50=25uM     // 2ohp.pdf (7IP)
2ph6  2.00  2007  IC50=27nM     // 2ph6.pdf (712)
2uzo  2.30  2007  IC50=27uM     // 2uzb.pdf (C62)
2hvx  2.60  2007  IC50=29nM     // 2hvx.pdf (DRX) compound 5f, IC50=29+/-9nM
2hm1  2.20  2007  IC50=2nM      // 2hm1.pdf (LIQ) compound 13, IC50(Cat-D)=474nM, IC50(HEKcell)=1nM
2ovx  2.00  2007  IC50=2nM      // 2ovx.pdf (4MR) incorrect data [protein in crystal is E402Q mutant]
2uym  2.11  2007  IC50=3.1uM    // 2pg2.pdf (K03) ligand is in the KSP allosteric binding site
2nww  3.20  2007  IC50=3.3uM    // 2nwl.pdf (TB1) IC50=3.3+/-1.5uM, mutations:D37H, K40H, K125H, K132H, K223H, K264H, K368H
2ds1  2.00  2007  IC50=3.4nM    // 2ds1.pdf (1CD) IC50(CDK1)=1.0nM, IC50(CDK4)=6.4nM, IC50(CDK6)=12nM
2oh4  2.05  2007  IC50=3.5nM    // 2oh4.pdf (GIG)
2vev  1.80  2007  IC50=300nM    // 2veu.pdf (IZ2) pNPP enzyme assay. compound 4B
2ow9  1.74  2007  IC50=30nM     // 2ow9.pdf (SP6)
2gfk  1.90  2007  IC50=30uM     // 2fu7.pdf (VII)
2h1h  2.40  2007  IC50=30uM     // 2h1f.pdf (AFH) ADP-2F-heptose inhibited WaaC with IC50 around 30uM
2ohm  2.70  2007  IC50=310uM    // 2of0.pdf (8AP)
2gj4  1.60  2007  IC50=319nM    // 2gj4.pdf (2TH) compound 17, both (+/-) conformations. IC50(cell)=3.6uM
2uw5  2.14  2007  IC50=31nM     // 2uw3.pdf (GVN) (R)-enantiomer IC50=34+/-11nM, (S)-enantiomer IC50=0.28+/-0.03uM
2qcf  1.22  2007  IC50=320uM    // 2qcd.pdf (5FU)
2fvc  2.00  2007  IC50=32nM     // 2fvc.pdf (888) analogue compound 2
2hz0  2.10  2007  IC50=330nM    // 2hyy.pdf (GIN) IC50(WT-Abl)=330+/-113nM, IC50(Bcr-Abl)=565+/-60nM
2nqg  2.04  2007  IC50=333nM    // 2nqg.pdf (NQG) IC50=333+/-95nM
2hz4  2.80  2007  IC50=3425nM   // 2hyy.pdf (4ST) IC50(WT-Abl)=3425+/-1075nM
2pzy  2.90  2007  IC50=34nM     // 2pzy.pdf (B18)
2p2i  2.40  2007  IC50=38nM     // 2p2h.pdf (608)
2poq  2.59  2007  IC50=38uM     // 2poq.pdf (ISD) monkey dimeric DD
2gd8  1.46  2007  IC50=39nM     // 2gd8.pdf (PO1) compound 21, IC50(steroid sulfatase)=39nM
2v11  3.10  2007  IC50=3nM      // 2v0z.pdf (C80)
2vf6  2.10  2007  IC50=3nM      // 2vf6.pdf (M0N) ligand is compound 4, MINODRONATE
2ga2  1.95  2007  IC50=3uM      // 2ga2.pdf (A19) ligand is  A193400, compound 1, HMVEC cell line growth inhibition
2ohu  2.35  2007  IC50=4.2uM    // 2ohp.pdf (IP7)
2vd7  2.25  2007  IC50=4.2uM    // 2vd7.pdf (PD2) ligand is compound 1
2gqn  1.80  2007  IC50=4.5uM    // 2fq6.pdf (BLP) compound 1, IC50=4.5+/-0.6uM, ligand is the product.
2qtb  2.25  2007  IC50=4.8nM    // 2qt9.pdf (474)
2jbu  3.00  2007  IC50=400uM    // 2jbu.pdf (12-mer) IC50=400+/-100uM; incomplete ligand
2q8i  2.60  2007  IC50=400uM    // 2q8g.pdf (RDC)
2qcd  2.03  2007  IC50=400uM    // 2qcd.pdf (U5P)
2o9i  2.80  2007  IC50=40nM     // 2o9i.pdf (444) ligand is Compound 1, T0901317, pIC50=7.4
2ohs  2.45  2007  IC50=40uM     // 2ohp.pdf (9IP)
2gm9  2.30  2007  IC50=41nM     // 2gj4.pdf (3TH) compound 15, both (+/-) conformations. IC50(cell)=0.69uM
2hzn  2.70  2007  IC50=41nM     // 2hyy.pdf (KIN) IC50(WT-Abl)=41nM, IC50(Bcr-Abl)>700nM
2q9n  2.20  2007  IC50=430nM    // 2q9m.pdf (LK5) covalent inhibition
2pvv  2.11  2007  IC50=438uM    // 2or4.pdf (OSE)
2vey  2.20  2007  IC50=43nM     // 2veu.pdf (IZ5) pNPP enzyme assay. compound 4I
2qcm  1.67  2007  IC50=450uM    // 2qcd.pdf (JW5)
2uze  2.40  2007  IC50=47uM     // 2uzb.pdf (C95)
2oic  2.40  2007  IC50=4nM      // 2oic.pdf (STU)
2pe2  2.13  2007  IC50=4nM      // 2pe2.pdf (464) PDK1 mediated AKT2 activation assay (cAKT2)
2uw4  2.00  2007  IC50=5.2uM    // 2uw3.pdf (L15) complex PKA-PKB-3, IC50=5.2+/-3.3uM
2os9  1.70  2007  IC50=5.7mM    // 2orj.pdf (INS)
2gde  2.00  2007  IC50=5.7nM    // 2gde.pdf (SN3)
2pix  2.40  2007  IC50=50uM     // 2pio.pdf (FLF) FP screening detects IC50~50uM for FLF
2p33  2.40  2007  IC50=57nM     // 2p33.pdf (J07)
2r8q  1.50  2007  IC50=580uM    // 2r8q.pdf (IBM)
3biz  2.20  2007  IC50=58nM     // 3bi6.pdf (61E) compound 14
2iqg  1.70  2007  IC50=5nM      // 2iqg.pdf (F2I) compound 6b
2nv7  2.10  2007  IC50=5nM      // 2nv7.pdf (555) IC50=5+/-2nM, polymer 2: Nuclear receptor coactivator 1, EC. No. 2.3.1.48
2pe1  2.14  2007  IC50=5nM      // 2pe0.pdf (517) PDK1 mediated AKT2 activation assay (cAKT2)
2rfn  2.50  2007  IC50=5nM      // 2rfn.pdf (AM7) IC50=17nM(phosphorylated c-Met); X-ray:unphosphorylated c-Met
2p9a  1.60  2007  IC50=6.56uM   // 2p98.pdf (YE6)
2imb  2.41  2007  IC50=60uM     // 2ilp.pdf (AHL) L-arginine hydroxamate
2q9m  2.05  2007  IC50=62nM     // 2q9m.pdf (LK7) covalent inhibition
2vew  2.00  2007  IC50=64nM     // 2veu.pdf (IZ3) pNPP enzyme assay. compound 3I
2p2h  1.95  2007  IC50=68nM     // 2p2h.pdf (994)
2ow2  2.90  2007  IC50=6nM      // 2ovx.pdf (8MR) incorrect data [protein in crystal is E402Q mutant]
2i5f  1.35  2007  IC50=7.5uM    // 2i5c.pdf (5IP) bound ligand to be Ins(1, 2, 3, 5, 6)P5, not IP6
2hzi  1.70  2007  IC50=70nM     // 2hyy.pdf (JIN) IC50(WT-Abl)=70+/-32nM, IC50(Bcr-Abl)=22+/-2nM
2p8h  1.80  2007  IC50=71nM     // 2p8h.pdf (MY9)
3bcn  2.85  2007  IC50=76.25nM  // 2pre.pdf (E64)
2uw8  2.00  2007  IC50=77uM     // 2uw3.pdf (GVQ) IC50=77+/-39.6uM
2nqi  2.04  2007  IC50=784nM    // 2nqg.pdf (NQI) IC50=784+/-130nM
2ywp  2.90  2007  IC50=7nM      // 2ywp.pdf (A42)
2o5d  2.20  2007  IC50=7uM      // 2o5d.pdf (VR1)
2ooz  1.80  2007  IC50=7uM      // 2ooz.pdf (OX5) ligand is compound OXIM6
2jbo  3.10  2007  IC50=8.5nM    // 2jbo.pdf (P4O) form-1, PH4.5
2jbp  3.31  2007  IC50=8.5nM    // 2jbo.pdf (P4O) form-2, PH7.5
2pe0  2.35  2007  IC50=80nM     // 2pe0.pdf (39Z) PDK1 mediated AKT2 activation assay (cAKT2)
2qju  2.90  2007  IC50=80uM     // 2qju.pdf (DSM)
2uw3  2.19  2007  IC50=80uM     // 2uw3.pdf (GVG) complex PKA-PKB-1, IC50=80+/-38uM
2of4  2.70  2007  IC50=81nM     // 2of2.pdf (979)
2ogz  2.10  2007  IC50=84nM     // 2ogz.pdf (U1N)
2va5  2.75  2007  IC50=86uM     // 2va5.pdf (C8C) IC50=86uM in SPR assay; IC50=130uM in FRET assay
2q8g  1.90  2007  IC50=87nM     // 2q8g.pdf (AZX)
2iog  1.60  2007  IC50=8nM      // 2iog.pdf (IOG) compound 11f, IC50(ER beta )=1231nM, IC50(MCF-7)=42.7nM
2oht  2.30  2007  IC50=9.1uM    // 2ohp.pdf (IP6)
2or4  1.62  2007  IC50=9.5uM    // 2or4.pdf (QUS)
2pcu  1.60  2007  IC50=910uM    // 2pcu.pdf (5-mer)
2ohp  2.25  2007  IC50=94uM     // 2ohp.pdf (6IP)
2no3  3.20  2007  IC50=9nM      // 2no3.pdf (859) JNK1 inhibitor 2b, T183E, Y183E
2z60  1.95  2007  IC50=9nM      // 2qoh.pdf (P3Y)
2ohk  2.20  2007  IC50~2000uM   // 2ohk.pdf (1SQ)
2v7a  2.50  2007  Kd=0.005uM    // 2v7a.pdf (627) IC50=25nM
2e7l  2.50  2007  Kd=0.029uM    // 2e7l.pdf (9-mer)
2gek  2.40  2007  Kd=0.03uM     // 2gej.pdf (GDP)
2nnv  1.10  2007  Kd=0.03uM     // 2nmx.pdf (M29) Kd=0.03+/-0.001uM, Ki=0.06+/-0.01uM
2uxi  2.50  2007  Kd=0.05uM     // 2uxh.pdf (G50) Kd=0.05+/-0.01uM; two independent binding sites
2pl0  2.80  2007  Kd=0.062uM    // 2pl0.pdf (STI) see ref. 8
2r5d  1.66  2007  Kd=0.07nM     // 2r3c.pdf (17-mer) IC50=0.25nM
2v8w  2.30  2007  Kd=0.15uM     // 2v8w.pdf (MGO)
2jdu  1.50  2007  Kd=0.19uM     // 2jdu.pdf (MFU) G24N/Me-alpha-Fuc; Kd=0.19+/-0.03uM
2c1q  2.10  2007  Kd=0.1pM      // 2c1q.pdf (BTN)
2p0d  1.81  2007  Kd=0.1uM      // 2p0d.pdf (I3P)
2v00  1.55  2007  Kd=0.22mM     // 2v00.pdf (V15)
2gej  2.60  2007  Kd=0.23uM     // 2gej.pdf (GDD) ligand is GDP-Man; Kd=0.23uM
2oi3   NMR  2007  Kd=0.23uM     // 2oi3.pdf (14-mer) Kd=0.23+/-0.03uM
2jdp  1.30  2007  Kd=0.25uM     // 2jdp.pdf (MFU) S23A/Me-alpha-Fuc; Kd=0.25+/-0.01uM
2jbv  1.86  2007  Kd=0.29mM     // 2jbv.pdf (FAO) Kd=0.29+/-0.01mM
2jdk  1.10  2007  Kd=0.29uM     // 2jdh.pdf (3-mer) ligand 14, Kd(FUC-NAG-T45)=0.29uM
2py4  1.49  2007  Kd=0.2uM      // 2py4.pdf (DUP) Kd=1.6uM for human dUTPase with DUP
2jdh  1.10  2007  Kd=0.31uM     // 2jdh.pdf (3-mer) ligand 11, Kd(FUC)=2.9uM, Kd(FUC-NAG-TA5)=0.31uM
2qki  2.40  2007  Kd=0.39uM     // 2qki.pdf (13-mer)
2nn7  1.85  2007  Kd=0.3uM      // 2nmx.pdf (M29) Kd=0.3+/-0.01uM, Ki=0.1+/-0.02uM
2pfy  1.95  2007  Kd=0.3uM      // 2pfy.pdf (PCA)
2qqs  2.82  2007  Kd=0.40uM     // 2qqs.pdf (10-mer) Kd=0.40+/-0.03uM; incomplete ligand
2hkf  2.01  2007  Kd=0.42uM     // 2hkf.pdf (9-mer)
2qpq  1.92  2007  Kd=0.43uM     // 2qpq.pdf (CIT) Kd=0.43+/-0.07uM
2e27  1.70  2007  Kd=0.45nM     // 2e27.pdf (AB0) ligand is ciguatoxin 3C; Ka=2.22x10+9M-1
2nno  1.01  2007  Kd=0.4uM      // 2nmx.pdf (M28) Kd=0.4+/-0.01uM, Ki=0.8+/-0.06uM
2gfd  2.30  2007  Kd=0.52uM     // 2fxs.pdf (RDA) GRP94 in complex with radamined; Kd=0.52+/-0.13uM
2nxl  2.00  2007  Kd=0.54uM     // 2nxd.pdf (10-mer) Kd=0.54+/-0.20uM; incomplete ligand
2jnw   NMR  2007  Kd=0.78uM     // 2jnw.pdf (14-mer) incomplete ligand
2qx0  1.80  2007  Kd=0.78uM     // 2qx0.pdf (PH2)
2e7f  2.20  2007  Kd=0.79uM     // 2e7f.pdf (C2F) wide type; equilibrium dialysis: Kd=10uM (pH=4.85-8.5); Tryptophan fluorescence quenching: Kd=0.6uM, Kd=2.1uM (pH=7.6); Isothermal calorimetry: Kd=0.79uM (pH=7.6), Kd=0.29uM (pH=5.1)
2p8n  1.94  2007  Kd=0.7mM      // 2p8n.pdf (ADE)
2j3q  2.80  2007  Kd=0.7uM      // 2j3q.pdf (TFL) AChE (E) complexes with ThT (L) at P site, Fluorescence Determinations Kd=0.7+/-0.2uM
2pze  1.70  2007  Kd=0.84uM     // 2pze.pdf (ATP)
2fxs  2.00  2007  Kd=0.87uM     // 2fxs.pdf (RDA) HSP82 in complex with radamined; Kd=0.87+/-0.14uM
2nnd  1.60  2007  Kd=0.87uM     // 2nnd.pdf (PRZ) Kd=0.3uM for wt MUP with IBMP
2nns  1.03  2007  Kd=0.9uM      // 2nmx.pdf (M25) Kd=0.9+/-0.02uM, Ki=0.9+/-0.03uM
2r7g  1.67  2007  Kd=0.9uM      // 2r7g.pdf (10-mer) Kd=0.9+/-0.3uM
2hug   NMR  2007  Kd=1.06uM     // 2hug.pdf (14-mer) Kd~1.06uM, Chromo-2 Domain of cpSRP43 complexed with 14-mer cpSRP54 peptide
2z5o  3.20  2007  Kd=1.0uM      // 2z5o.pdf (10-mer) incomplete ligand structure
2joa   NMR  2007  Kd=1.1uM      // 2joa.pdf (7-mer) ligand: ASP-SER-ARG-ILE-TRP-TRP-VAL
2peh  2.11  2007  Kd=1.1uM      // 2peh.pdf (10-mer) Kd=1.1+/-0.01uM
2pv2  1.30  2007  Kd=1.23uM     // 2pv2.pdf (12-mer) Kd=1.23+/-0.15uM
2oqs   NMR  2007  Kd=1.3uM      // 2oqs.pdf (6-mer) peptide ligand is C-terminal HPV-18 E6 peptide (Chain B) [ARG-ARG-GLU-THR-GLN-VAL]
2ph9  2.88  2007  Kd=1.3uM      // 2pgz.pdf (GNT)
2qm7  1.85  2007  Kd=1.3uM      // 2qm7.pdf (GDP) Kd1=1.3+/-0.1uM; Kd2=10+/-3uM
2e5y  1.92  2007  Kd=1.4uM      // 2e5y.pdf (ATP) Kd=1.4uM at 36C; Kd=0.67mM at 65C; protein source: Thermophilic bacterium ps-3; Kd(EF1 epsilon)=22+/-1mM at 25C (protein source: E. coli).
2nn1  1.65  2007  Kd=1.5uM      // 2nmx.pdf (M28) Kd=1.5+/-0.1uM, Ki=2.3+/-0.1uM
2qta  1.85  2007  Kd=1.75uM     // 2qta.pdf (TDP) E401K mutant
2itt  2.73  2007  Kd=1.7nM      // 2itn.pdf (AEE) Kd=1.7+/-0.4nM
2pgz  1.76  2007  Kd=1.8uM      // 2pgz.pdf (COC)
2v25  1.49  2007  Kd=1.9uM      // 2v25.pdf (ASP)
2j6m  3.10  2007  Kd=10.9nM     // 2itn.pdf (AEE) Kd=10.9+/-3.3nM
2ja3  3.05  2007  Kd=100uM      // 2j9l.pdf (ADP) Kd about 100uM
2j9l  2.30  2007  Kd=100uM      // 2j9l.pdf (ATP) Kd about 100uM
2q8y  2.00  2007  Kd=102uM      // 2q8y.pdf (9-mer)
2odd   NMR  2007  Kd=109.4uM    // 2odd.pdf (17-mer) Kd=109.4+/-0.4uM; incomplete ligand
2r58  2.00  2007  Kd=10mM       // 2r58.pdf (MLY)
2oiq  2.07  2007  Kd=10uM       // 2oiq.pdf (STI)
2itp  2.74  2007  Kd=11.3nM     // 2itn.pdf (AEE) Kd=11.3+/-1.5nM
2g78  1.70  2007  Kd=120nM      // 2g78.pdf (REA) Kd=120+/-5nM, binding data for retinal; ligand in structure is retinoic acid
2g79  1.69  2007  Kd=120nM      // 2g78.pdf (RET) Kd=120+/-5nM; ligand in structure is retinal
2ito  3.25  2007  Kd=123.6nM    // 2itn.pdf (IRE) Kd=123.6+/-5.9nM
2oei  1.35  2007  Kd=124uM      // 2oei.pdf (9-mer)
2vhj  1.80  2007  Kd=125uM      // 2vhj.pdf (ADP) NTPase P4 PROTEIN S252A MUTANT, Kd=koff/kon=125uM
2pk6  1.45  2007  Kd=13pM       // 2pk5.pdf (O33)
2vhq  2.15  2007  Kd=140uM      // 2vhq.pdf (ATP) Kd=140+/-30uM, NTPase S252A MUTANT IN COMPLEX WITH ATP AND MG2+
2j4k  2.20  2007  Kd=14uM       // 2j4k.pdf (U5P) Kd=14+/-3uM, Ki=17+/-5uM, Kd=70uM in presence of 100uM UTP
2o9a  1.80  2007  Kd=156.2uM    // 2o9a.pdf (PYR) covalent binding
2jup   NMR  2007  Kd=156uM      // 2jup.pdf (9-mer) incorrect data [ligand in crystal is GLY-PRO-PRO-LEU-ILE-PRO-PRO-PRO-PRO; Kd=156uM is for PPLIPPPP peptide]
2jg0  1.50  2007  Kd=15nM       // 2jf4.pdf (TTZ) compound 4; Kd=15nM, Ki=9nM
2hr6  1.84  2007  Kd=15uM       // 2hr6.pdf (DUD)
2nsj  2.31  2007  Kd=16.3uM     // 2nsh.pdf (C2R) H45Q mutant; Kd=16.3+/-2.6uM
2clk  1.50  2007  Kd=164uM      // 2cle.pdf (G3H)
2jsd   NMR  2007  Kd=17nM       // 2jsd.pdf (NGH)
2qm9  2.31  2007  Kd=17nM       // 2q9s.pdf (TDZ) Kd value derived from EC50
2dwx  2.55  2007  Kd=180uM      // 2dwx.pdf (13-mer) incomplete ligand
2ov4  2.50  2007  Kd=18uM       // 2ov4.pdf (AQP) Kd1=18uM; Kd2=40uM
2uxu  2.30  2007  Kd=18uM       // 2uxh.pdf (NAR) Kd=18+/-0.3uM
2ig0  1.70  2007  Kd=19.7uM     // 2ig0.pdf (10-mer) Kd=19.7+/-0.7uM; incomplete ligand
2i4z  2.25  2007  Kd=1978nM     // 2i4j.pdf (DRH) Kd=1978+/-523.5nM
2i4p  2.10  2007  Kd=1978nM     // 2i4j.pdf (DRH) Kd=1978+/-523.5nM, from apo-form soaked for 30 days
2q8h  2.00  2007  Kd=1mM        // 2q8g.pdf (TF4)
2r0y  1.75  2007  Kd=1mM        // 2r0y.pdf (13-mer) Kd=1~2mM; incomplete ligand
2v3u  1.74  2007  Kd=1mM        // 2v3u.pdf (DSN)
2gh9  1.95  2007  Kd=1uM        // 2gh9.pdf (MLR)
2uyq  1.80  2007  Kd=2.1uM      // 2uyq.pdf (SAM)
2z5s  2.30  2007  Kd=2.20uM     // 2z5s.pdf (15-mer) Kd=2.20+/-0.30uM; incomplete ligand
2nxd  2.00  2007  Kd=2.2uM      // 2nxd.pdf (10-mer) Kd=2.2+/-0.3uM; incomplete ligand
2z5t  2.30  2007  Kd=2.40uM     // 2z5s.pdf (15-mer) Kd=2.40+/-0.40uM; incomplete ligand
2r5a  2.30  2007  Kd=2.5mM      // 2r58.pdf (MLZ)
2r5b  2.00  2007  Kd=2.5nM      // 2r3c.pdf (17-mer) IC50=1.9nM; incomplete ligand
2itz  2.72  2007  Kd=2.6nM      // 2itn.pdf (IRE) Kd=2.6+/-0.2nM
2jdn  1.30  2007  Kd=2.78uM     // 2jdn.pdf (MMA) S22A/Me-alpha-Man; Kd=2.78+/-0.14uM
2nmx  1.55  2007  Kd=2.7uM      // 2nmx.pdf (M25) Kd=2.7+/-0.1uM, Ki=2.0+/-0.1uM
2nsl  2.00  2007  Kd=20.9uM     // 2nsh.pdf (C2R) H45N mutant; Kd=20.9+/-1.9uM
2pk5  1.90  2007  Kd=20pM       // 2pk5.pdf (075)
2j9n  1.50  2007  Kd=20uM       // 2j9n.pdf (BEN)
2v5x  2.25  2007  Kd=220nM      // 2v5w.pdf (V5X)
2pem  2.95  2007  Kd=230uM      // 2pem.pdf (7-mer)
2v87  1.80  2007  Kd=25.1uM     // 2v85.pdf (13-mer) Kd=25.1+/-3.5uM; incomplete ligand
2vba  1.36  2007  Kd=25uM       // 2vb8.pdf (P4T)
2vb8  1.52  2007  Kd=25uM       // 2vb8.pdf (TLM)
2nn8  1.35  2007  Kd=260uM      // 2nn8.pdf (LAT)
2hzl  1.40  2007  Kd=270nM      // 2hzl.pdf (PYR) Kd=270+/-20nM
2rly   NMR  2007  Kd=270uM      // 2jup.pdf (8-mer) peptide ligand is PTPPPLPP peptide [PRO-THR-PRO-PRO-PRO-LEU-PRO-PRO]
2hrm  1.70  2007  Kd=278.5uM    // 2hr6.pdf (UC5) measured in the presence of Mg2+
2cle  1.50  2007  Kd=280uM      // 2cle.pdf (F6F)
2clm  1.51  2007  Kd=280uM      // 2cle.pdf (F6F) X-ray(tryptophan synthase in external aldimine state); Kd(internal aldimine state)
2clf  1.70  2007  Kd=280uM      // 2cle.pdf (F6F) redundant to 2cle but in lower resulution
2o9v  1.63  2007  Kd=288uM      // 2o9v.pdf (10-mer) Kd=288+/-21uM
3b50  1.40  2007  Kd=28nM       // 3b50.pdf (SLB) Kd=28+/-1nM
2uyn  1.60  2007  Kd=2mM        // 2uyn.pdf (2KT)
2nwl  2.96  2007  Kd=2nM        // 2nwl.pdf (ASP) Kd=0.002+/-0.002uM, mutations:D37H, K40H, K125H, K132H, K223H, K264H, E368H
2oi9  2.35  2007  Kd=2uM        // 2e7l.pdf (9-mer)
2o3z  2.25  2007  Kd=2uM        // 2o3z.pdf (AI7)
2r3y  2.50  2007  Kd=3.2uM      // 2r3y.pdf (10-mer) incomplete ligand
2r0z  2.10  2007  Kd=3.4uM      // 2ipu.pdf (6-mer)
2isc  2.70  2007  Kd=3.8nM      // 2i4t.pdf (223) compound 3, Ki=3.8+/-0.3pM
2jdm  1.70  2007  Kd=3.96uM     // 2jdm.pdf (MFU) S22A/Me-alpha-Fuc; Kd=3.96+/-0.91uM
2ntf  3.18  2007  Kd=300nM      // 2ntf.pdf (OHM)
2opy  2.80  2007  Kd=30uM       // 2opy.pdf (CO9)
2puy  1.43  2007  Kd=30uM       // 2puy.pdf (10-mer)
2ra6  1.50  2007  Kd=30uM       // 2ra6.pdf (ETY) Kd=14uM for 2-naphthol; Kd=30uM for 4-ethylphenol
2ogy  2.30  2007  Kd=33.2uM     // 2e7f.pdf (C2F) N199A mutant; equilibrium dialysis: Kd=26.5uM (pH=6.1); Tryptophan fluorescence quenching: Kd=21.3uM (pH=7.6); isothermal calorimetry: Kd=33.2uM (pH=5.1)
2jq9   NMR  2007  Kd=33.4uM     // 2jq9.pdf (17-mer) Kd1=33.4+/-0.2uM(20mM Tris-HCl pH 8.0, 100mM NaCl; circles; Kd2=4.61+/-0.02uM (20mM phosphate pH5.5(NMR conditions)); incomplete ligand
2v83  2.40  2007  Kd=33.8uM     // 2v83.pdf (9-mer)
2v86  2.05  2007  Kd=34.6uM     // 2v83.pdf (9-mer)
2v85  2.00  2007  Kd=34.6uM     // 2v85.pdf (12-mer) Kd=34.6+/-5.0uM
2j4q  2.60  2007  Kd=35uM       // 2j4h.pdf (TTP) Kd=35+/-3uM, mutation:E138A
2hj4  1.80  2007  Kd=4.29uM     // 2hj4.pdf (PNZ) Kd=4.29+/-0.2uM
2qhd  1.95  2007  Kd=4.2uM      // 2qhd.pdf (DAO)
2nng  1.20  2007  Kd=4.4uM      // 2nmx.pdf (ZYX) Kd=4.4+/-0.2uM, Ki=8.2+/-0.3uM
2uwd  1.90  2007  Kd=4.5nM      // 2uwd.pdf (2GG) Kd=4.5+/-2.2nM; IC50=21+/-4nM; GI50=78+/-15nM
2gj5  2.40  2007  Kd=4.74nM     // 2gj5.pdf (VD3) Kd=4.74+/-0.37nM (milk beta-lactoglobulin with VD3); Kd=45.67+/-3.12nM (heated beta-lactoglobulin with VD3 )
2hjb  1.85  2007  Kd=40.3uM     // 2hj4.pdf (PZM) Kd=40.3+/-1.7uM
2jqk   NMR  2007  Kd=402uM      // 2jq9.pdf (19-mer) Kd1=402+/-2uM(20mM Tris-HCl pH 8.0, 100mM NaCl; circles; Kd2=273+/-0.2uM(20mM phosphate pH5.5(NMR conditions)); incomplete ligand
2jdy  1.70  2007  Kd=42.9uM     // 2jdy.pdf (MMA) G24N/Me-alpha-Man; Kd=42.9+/-3.12uM
2p09  1.65  2007  Kd=450nM      // 2p05.pdf (ATP)
2iv9  1.90  2007  Kd=46uM       // 2iv9.pdf (12-mer) Kd=46+/-5uM; incomplete ligand
2p0x   NMR  2007  Kd=494nM      // 2p0x.pdf (ATP) C58A
2igw  1.78  2007  Kd=49mM       // 2igv.pdf (2-mer) ligand is GLY-PRO, Kd=49+/-12mM
2v95  1.93  2007  Kd=5.0nM      // 2v95.pdf (HCY)
2pv3  3.39  2007  Kd=5.57uM     // 2pv2.pdf (12-mer) Kd=5.57+/-0.64uM; incomplete ligand
2e2r  1.60  2007  Kd=5.5nM      // 2e2r.pdf (2OH)
2h5e  2.80  2007  Kd=5.6nM      // 2h5e.pdf (GDP)
2igv  1.67  2007  Kd=5.9mM      // 2igv.pdf (2-mer)
2oi2  2.50  2007  Kd=500nM      // 2oi2.pdf (DP6)
2p15  1.94  2007  Kd=50pM       // 2p15.pdf (EZT)
2cli  1.70  2007  Kd=50uM       // 2cle.pdf (F9F)
2cll  1.60  2007  Kd=50uM       // 2cle.pdf (F9F) X-ray(tryptophan synthase in external aldimine state); Kd(internal aldimine state)
2jo9   NMR  2007  Kd=52.1uM     // 2jo9.pdf (9-mer) Kd=52.1+/-2.14uM
2ity  3.42  2007  Kd=53.5nM     // 2itn.pdf (IRE) Kd=53.5+/-1.8nM
2pql  2.20  2007  Kd=53nM       // 2pql.pdf (TSS)
2imd  1.60  2007  Kd=5nM        // 2imd.pdf (GSH) Selenomethione crystal. Ki(TOH,GSH)=130+/-100uM, GSH is substrate. Kd1(GSH)=5nM; Kd2=2-11uM for second GSH; ternary complex
2pll  1.90  2007  Kd=5nM        // 2pll.pdf (ABH)
2q7q  1.60  2007  Kd=5uM        // 2hj4.pdf (C2B)
2o1v  2.45  2007  Kd=5uM        // 2o1u.pdf (ADP)
2nxm  2.25  2007  Kd=6.4uM      // 2nxd.pdf (10-mer) Kd=6.4+/-1.3uM; incomplete ligand
2i4j  2.10  2007  Kd=684.8nM    // 2i4j.pdf (DRJ) Kd=684.8+/-106.8nM
2i6b  2.30  2007  Kd=68nM       // 2i6a.pdf (89I)
2qbx  2.30  2007  Kd=6uM        // 2qbx.pdf (12-mer) Ephrin type-B receptor 2 complex with antagonistic peptide, IC50~15uM; incomplete ligand
2hqu  2.20  2007  Kd=7.2uM      // 2hqu.pdf (DUP) measured by ITC
2ovq  2.60  2007  Kd=70nM       // 2ovp.pdf (12-mer) CycEdegC doubly phosphorylated at Thr380 and Ser384, Kd=70nM
2pv1  1.30  2007  Kd=73nM       // 2pv1.pdf (7-mer)
2jf4  2.20  2007  Kd=7nM        // 2jf4.pdf (VDM) compound 2; Kd=7nM, Ki=10nM
2r05  2.55  2007  Kd=7uM        // 2r02.pdf (11-mer) Kd=7+/-1uM
2r03  2.59  2007  Kd=7uM        // 2r02.pdf (8-mer) Kd=7+/-7uM
2ipo  2.60  2007  Kd=8.8uM      // 2ipo.pdf (1IP)
2v88  2.00  2007  Kd=82.1uM     // 2v83.pdf (8-mer)
2clh  1.70  2007  Kd=87.6uM     // 2cle.pdf (F19)
2clo  1.50  2007  Kd=87.6uM     // 2cle.pdf (F19) X-ray(tryptophan synthase in external aldimine state); Kd(internal aldimine state)
2r02  2.60  2007  Kd=8uM        // 2r02.pdf (11-mer) Kd=8+/-2uM
2jmj   NMR  2007  Kd=9.1uM      // 2jmj.pdf (10-mer) Kd=9.1+/-1.6uM, ligand: ALA-ARG-THR-M3L-GLN-THR-ALA-ARG-LYS-N-trimethyllysine
2ohl  2.65  2007  Kd=900uM      // 2ohl.pdf (2AQ) ligand is compound 1
2rm0   NMR  2007  Kd=94uM       // 2jup.pdf (9-mer) peptide ligand is PPPLIPPPP peptide [PRO-PRO-PRO-LEU-ILE-PRO-PRO-PRO-PRO]
2e94  2.18  2007  Ki=0.01uM     // 2e8t.pdf (364) IC50=0.03uM
2i2c  1.85  2007  Ki=0.02mM     // 2i2b.pdf (DTA)
2ftd  2.55  2007  Ki=0.041nM    // 2ftd.pdf (ILI) IC50=22nM
2o4j  1.74  2007  Ki=0.08nM     // 2o4j.pdf (VD4)
2p16  2.30  2007  Ki=0.08nM     // 2p16.pdf (GG2)
2e95  2.20  2007  Ki=0.08uM     // 2e8t.pdf (B75) IC50=0.20uM
2uvm  1.94  2007  Ki=0.08uM     // 2uvm.pdf (GVF) Bz(1, 2, 3, 4)P4 binds to the PKB-alpha PH domain, PIC50=6.35, Ki=0.08uM
3bgp  2.80  2007  Ki=0.091uM    // 3bgp.pdf (VX1) compound 2
2e93  2.12  2007  Ki=0.11uM     // 2e8t.pdf (B29) IC50=0.28uM
2e92  2.31  2007  Ki=0.13uM     // 2e8t.pdf (M0N) IC50=0.34uM
2iu0  2.53  2007  Ki=0.13uM     // 2iu0.pdf (203)
2oxd  2.30  2007  Ki=0.15uM     // 2oxd.pdf (K32)
2ot1  2.05  2007  Ki=0.1mM      // 2ot1.pdf (N3P)
2oxx  2.30  2007  Ki=0.20uM     // 2oxd.pdf (K22)
2j4g  2.25  2007  Ki=0.25uM     // 2j4g.pdf (NB1)
2e91  2.14  2007  Ki=0.26uM     // 2e8t.pdf (ZOL) IC50=0.66uM
2jj3  2.28  2007  Ki=0.28nM     // 2jj3.pdf (JJ3)
2pog  1.84  2007  Ki=0.29nM     // 2pog.pdf (WST)
2nt7  2.10  2007  Ki=0.30uM     // 2nt7.pdf (902) compound 49g
2oxy  1.81  2007  Ki=0.30uM     // 2oxd.pdf (K17)
2oz5  2.00  2007  Ki=0.33uM     // 2oz5.pdf (7XY) Kd(OMTS1)=73nM, Kd(OMTS2)=1200nM; Ki=0.33+/-0.04uM; IC50=440+/-50nM.
2j27  1.15  2007  Ki=0.3mM      // 2j27.pdf (PGA) Ki=0.3+/-0.1mM
2v3e  2.00  2007  Ki=0.3uM      // 2v3d.pdf (NND)
2p95  2.20  2007  Ki=0.43nM     // 2p93.pdf (ME5)
2z4b  2.34  2007  Ki=0.44nM     // 2q70.pdf (DC8)
2op3  1.60  2007  Ki=0.49uM     // 2op3.pdf (TF5) covalent binding
2o4r  1.98  2007  Ki=0.4nM      // 2o4j.pdf (VD5)
2g9q  2.50  2007  Ki=0.4uM      // 2g9q.pdf (1AB) ligand is different in reference. IC50=1uM in liver cell glycogenolysis. IC50(rabbit muscle)=0.39+/-0.10uM
2o2u  2.45  2007  Ki=0.4uM      // 2o0u.pdf (738)
2qtu  2.53  2007  Ki=0.53nM     // 2qtu.pdf (3AS)
2ok1  2.40  2007  Ki=0.55uM     // 2ojg.pdf (33A)
3bgz  2.40  2007  Ki=0.55uM     // 3bgp.pdf (VX3) ligand is compound 3
2yxj  2.20  2007  Ki=0.5nM      // 2yxj.pdf (N3C) Bcl-xl in complex with ABT-737
2oyl  1.80  2007  Ki=0.5uM      // 2oyk.pdf (IDC)
2v0n  2.71  2007  Ki=0.5uM      // 2v0n.pdf (C2E) IC50=7+/-2uM.
2p94  1.80  2007  Ki=0.67nM     // 2p93.pdf (ME4)
2o7e  1.75  2007  Ki=0.6uM      // 2o78.pdf (PMI) Ki=0.6uM when substrate is L-Phe
2p2a  2.26  2007  Ki=0.75uM     // 2p2a.pdf (MP9)
2z9g  1.86  2007  Ki=0.7uM      // 2z94.pdf (BNZ) incomplete ligand structure, Hg-containing
2flr  2.35  2007  Ki=0.8uM      // 2flr.pdf (7NH) Ki(fXa)=125uM, Ki(fIIa)=71.5uM, Ki(Trypsin)=46.5uM
2ql9  2.14  2007  Ki=0.94nM     // 2ql5.pdf (5-mer) covalent inhibition; ligand is peptide analogue, AC-DQMD-CHO (chain E) [ACE-ASP-GLN-MET-ASA]
2q54  1.85  2007  Ki=0.98nM     // 2q54.pdf (MU1)
2hw2  1.45  2007  Ki=1.07mM     // 2hw2.pdf (RFP) Ki=1.07+/-0.35mM
2on3  3.00  2007  Ki=1.0nM      // 2on3.pdf (XAP)
2p4j  2.50  2007  Ki=1.1nM      // 2p4j.pdf (23I)
2onz  2.80  2007  Ki=1.3nM      // 2g70.pdf (TMJ) K57A
2eg7  2.00  2007  Ki=1.3uM      // 2eg7.pdf (OTD) Ki=1.3+/-0.2uM for HDDP
2qlb  2.25  2007  Ki=1.3uM      // 2ql5.pdf (5-mer) covalent inhibition; ligand is peptide analogue, AC-ESMD-CHO (chain E) [ACE-GLU-SER-MET-ASA]
2obf  2.30  2007  Ki=1.4nM      // 2g70.pdf (F83)
2qlf  2.80  2007  Ki=1.4nM      // 2ql5.pdf (5-mer) covalent inhibition; ligand is peptide analogue, AC-DNLD-CHO (chain E) [ACE-ASP-ASN-LEU-ASA]
2oc7  2.70  2007  Ki=1.4uM      // 2obo.pdf (HU4) covalent inhibition; Ki is Ki*
2pu1  1.80  2007  Ki=1.4uM      // 2pty.pdf (FSG) R28K mutant
2z94  1.78  2007  Ki=1.4uM      // 2z94.pdf (TLD)
2hvc  2.10  2007  Ki=1.5nM      // 2hvc.pdf (LGD) ligand is compound 4m (LGD2226), Ki for hAR whole-cell binding
2p93  1.90  2007  Ki=1.5nM      // 2p93.pdf (ME1)
3b7i  1.75  2007  Ki=1.5uM      // 3b3c.pdf (PLU) Ki=1.5+/-0.2uM
2uz6  2.40  2007  Ki=1.7nM      // 2uz6.pdf (17-mer) SOLUBLE ACETYLCHOLINE RECEPTOR complex with ALPHA-CONOTOXIN TXIA(A10L)
2psx  2.30  2007  Ki=1.7uM      // 2psx.pdf (4-mer) peptide ligand is LEUPEPTIN (chain B) [ACE-LEU-LEU-ARG]
2opb  2.80  2007  Ki=1.8nM      // 2g70.pdf (F21) K57A
2uz9  2.30  2007  Ki=1.96uM     // 2uz9.pdf (XAN) ligand is Xanthinec
2i4x  1.55  2007  Ki=1.9pM      // 2i4d.pdf (KGQ) Ki=1.9+/-0.8pM, EC50(MT-2)=0.4+/-0.1nM
2hob  1.95  2007  Ki=1.9uM      // 2hob.pdf (6-mer) Ki=1.9+/-0.1uM, SARS-CoV main protease
2qrl  1.60  2007  Ki=100uM      // 2qrk.pdf (OGA)
3b3c  1.46  2007  Ki=105uM      // 3b3c.pdf (PLU) Ki=105+/-11uM
2hah  1.70  2007  Ki=10nM       // 2hah.pdf (3TL) mutations(I37V, N55M, M56I, I57G, V59I, G62F, K63I, L97T, I98P, Q99V, P100N, L101I); Ki(wt FIV)=41nM
3b92  2.00  2007  Ki=10nM       // 3b92.pdf (440)
2oym  1.86  2007  Ki=10uM       // 2oyk.pdf (MNI)
2qe4  2.40  2007  Ki=11.0nM     // 2jj3.pdf (JJ3)
2v3d  1.96  2007  Ki=116uM      // 2v3d.pdf (NBV)
2oc9  2.59  2007  Ki=11nM       // 2oc4.pdf (IMH)
2p3a  1.75  2007  Ki=11nM       // 2p3a.pdf (3TL)
2q15  2.40  2007  Ki=11nM       // 2q11.pdf (3MR)
3bgq  2.00  2007  Ki=11nM       // 3bgp.pdf (VX2) ligand is compound 1
2o9j  2.65  2007  Ki=120nM      // 2o9j.pdf (CZA)
2oa0  3.40  2007  Ki=120nM      // 2o9j.pdf (CZA)
2cem  1.80  2007  Ki=12nM       // 2cej.pdf (2AH) EC50=0.70uM
2ovv  2.00  2007  Ki=12nM       // 2o8h.pdf (PFH)
2jnp   NMR  2007  Ki=130nM      // 2jnp.pdf (NGH)
2ovz  2.00  2007  Ki=13nM       // 2ovx.pdf (5MR) X-ray(E402Q) while Ki(wild type)
2fle  1.90  2007  Ki=14nM       // 2fle.pdf (AI) ligand is compound PC(9); Ki=14+/-3nM
2oz7  1.80  2007  Ki=14nM       // 2oz7.pdf (CA4) ligand is compound 1, affinity for hAR in Transiently-Transfected COS-1 Cells
2p8o  1.50  2007  Ki=14uM       // 2p8o.pdf (BVA) Ki=16uM?; covalent binding
2uwp  1.75  2007  Ki=154nM      // 2uwp.pdf (894)
2f9v  2.60  2007  Ki=15nM       // 2f9v.pdf (BN6) Ki=0.015uM, ligand difference: C=O -> C-OH
2oc0  2.30  2007  Ki=15nM       // 2obo.pdf (HU1) covalent inhibition; Ki is Ki*
2ptz  1.65  2007  Ki=15nM       // 2pty.pdf (PAH) R28K mutant
2pu0  1.90  2007  Ki=15nM       // 2pty.pdf (PAH) R28K mutant; redundant to 2ptz
2jal  1.90  2007  Ki=15uM       // 2jal.pdf (YLL) open ring product
2pwg  2.20  2007  Ki=15uM       // 2pwd.pdf (CTS)
2nta  2.10  2007  Ki=16uM       // 2nt7.pdf (521) compound 26c
2on6  2.50  2007  Ki=172nM      // 2oc4.pdf (IMH)
2iyf  1.70  2007  Ki=177.3uM    // 2iya.pdf (ERY) fixed UDP-Glc=1mM, oleandomycin inhibition Ki=177.3uM
2g70  2.40  2007  Ki=17nM       // 2g70.pdf (HNT)
2jh6  2.21  2007  Ki=17nM       // 2jh6.pdf (894)
1vso  1.85  2007  Ki=18.98uM    // 1vso.pdf (AT1) Ki=18.98+/-1.31uM for R/S racemic; ligand binding to iGluR5 core
2p3d  2.80  2007  Ki=180nM      // 2p3a.pdf (3TL)
2e2p  2.00  2007  Ki=18uM       // 2e2p.pdf (ADP)
2o1c  1.80  2007  Ki=19uM       // 2o1c.pdf (PPV)
2i4t  2.74  2007  Ki=1nM        // 2i4t.pdf (UA2) compound 2, Ki=1000pM
2rcx  2.00  2007  Ki=1nM        // 2rcx.pdf (SM4) covalent inhibition
2q55  1.90  2007  Ki=2.04nM     // 2q54.pdf (MU0)
2i4d  1.50  2007  Ki=2.1pM      // 2i4d.pdf (QFI) Ki=2.1+/-0.2pM
2oax  2.29  2007  Ki=2.232nM    // 2oax.pdf (SNL) ligand is spironolactone
2op9  1.80  2007  Ki=2.2uM      // 2op9.pdf (WR1)
2ojg  2.00  2007  Ki=2.3uM      // 2ojg.pdf (19A)
2cej  2.50  2007  Ki=2.4nM      // 2cej.pdf (1AH) EC50=1.1uM
2i4w  1.55  2007  Ki=2.6pM      // 2i4d.pdf (KGQ) Ki=2.6+/-1.5pM, EC50(PBMC)=2.8+/-0.5nM, EC50(MT-2)=3.5+/-1.5nM, EC50(PM-1)=2.2+/-1.4nM
2r5q  2.30  2007  Ki=2.7nM      // 2r5p.pdf (1UN) Ki=2.7+/-0.3nM
2i4u  1.50  2007  Ki=2.7pM      // 2i4d.pdf (DJR) Ki=2.7+/-1.6pM, EC50(PBMC)=1.1+/-0.5nM, EC50(MT-2)=0.6+/-0.4nM, EC50(PM-1)=3.5+/-1.1nM
2np9  2.45  2007  Ki=2.7uM      // 2np9.pdf (YE1) Crotonase superfamily
2onb  2.70  2007  Ki=2.7uM      // 2onb.pdf (7PA) Ki=2.7uM (noncompetitive inhibition at higher PDPA concentrations); Ki=0.26uM (uncompetitive inhibition at low concentrations of PDPA)
2itk  1.45  2007  Ki=20.4nM     // 2itk.pdf (6-mer) Ki=20.4+/-4.3nM
2jew  1.40  2007  Ki=206nM      // 2jew.pdf (720) compound 21
2psj  1.80  2007  Ki=20nM       // 2psj.pdf (CEI)
2fu8  1.80  2007  Ki=20uM       // 2fu7.pdf (MCO) Ki measured at neutral pH
2ony  2.60  2007  Ki=210nM      // 2g70.pdf (TMJ)
2za3  2.65  2007  Ki=210uM      // 2za3.pdf (U5P) ligand is compound 1, UMP
2h15  1.90  2007  Ki=2135nM     // 2h15.pdf (B19) hCA II in complex with compound 8
2o9r  2.30  2007  Ki=21mM       // 2jie.pdf (TCB)
2uy4  1.75  2007  Ki=21uM       // 2uy3.pdf (AZM) ligand is acetazolamide; Ki=21+/-2uM
2hl4  1.55  2007  Ki=23nM       // 2hl4.pdf (BO1) ligand is compound 1
2z3h  1.50  2007  Ki=23uM       // 1wn6.pdf (BLO) deaminohydroxy blasticidin S
2it4  2.00  2007  Ki=24.1mM     // 2it4.pdf (PPF) Isoform hCA I
2vfz  2.40  2007  Ki=245uM      // 2vfz.pdf (UPF) X-ray(R365K) while Ki(wild type)
2p3c  2.10  2007  Ki=24nM       // 2p3a.pdf (3TL)
2psu  1.93  2007  Ki=24nM       // 2psu.pdf (MUU)
2ihj  2.00  2007  Ki=25.7uM     // 2ihj.pdf (CSF)
3b3x  2.50  2007  Ki=250uM      // 3b3x.pdf (A33) ligand is compound 4
2gvf  2.50  2007  Ki=25nM       // 2gvf.pdf (NHN) compound 38
2o8h  1.80  2007  Ki=25nM       // 2o8h.pdf (227)
2q80  2.70  2007  Ki=25uM       // 2q80.pdf (GRG)
2jiw  1.95  2007  Ki=26uM       // 2jiw.pdf (BEU)
2r9b  2.80  2007  Ki=271nM      // 2r9b.pdf (8-mer) ligand is peptide-based inhibitor(compound 1); Ki=271+/-26nM
3b3s  1.18  2007  Ki=2800uM     // 3b3s.pdf (LEU)
2oi0  2.00  2007  Ki=28nM       // 2oi0.pdf (283)
2v96  2.40  2007  Ki=29uM       // 2v96.pdf (CFQ)
2jh0  1.70  2007  Ki=2nM        // 2jh0.pdf (701)
2nnq  1.80  2007  Ki=2nM        // 2nnq.pdf (T4B)
2oaz  1.90  2007  Ki=2nM        // 2oaz.pdf (I96) compound 102, Co2+ hMetAP2b, Ki=2nM, Mn2+ hMetAP2b, Ki=1500nM
2ojj  2.40  2007  Ki=2nM        // 2ojg.pdf (82A)
2uwo  1.75  2007  Ki=2nM        // 2uwo.pdf (701)
2oqi  2.80  2007  Ki=3.2nM      // 2oqi.pdf (GGO)
2o0u  2.10  2007  Ki=3.2uM      // 2o0u.pdf (C0M)
2uy5  1.60  2007  Ki=3.2uM      // 2uy3.pdf (H35) ligand is kinetin; Ki=3.2+/-0.3uM
2p3b  2.10  2007  Ki=3.3nM      // 2p3a.pdf (3TL)
2r5p  2.30  2007  Ki=3.3nM      // 2r5p.pdf (MK1) Ki=3.3+/-0.3nM
2oag  2.30  2007  Ki=3.4nM      // 2oae.pdf (DLI)
2i2b  2.10  2007  Ki=3.6mM      // 2i2b.pdf (CC5) incomplete ligand
2ima  1.94  2007  Ki=300nM      // 2ilp.pdf (GB4) Ki=300+/-12nM
2o4h  2.70  2007  Ki=300nM      // 2o4h.pdf (AS9) Ki  300nM
2eg8  2.20  2007  Ki=31.8uM     // 2eg7.pdf (FOT) Ki=31.8+/-1.6uM for FOA
2g72  2.00  2007  Ki=315nM      // 2g70.pdf (F21)
2cfd  1.60  2007  Ki=32nM       // 2cfd.pdf (R4A) Ki=32+/-1nM
2hhn  1.55  2007  Ki=32nM       // 2hhn.pdf (GNQ) ligand is sulfone analog 37
2r2w  2.01  2007  Ki=34uM       // 2r2w.pdf (4PG)
2g71  2.20  2007  Ki=35nM       // 2g70.pdf (FTS)
2p53  2.10  2007  Ki=35nM       // 2p53.pdf (NNG)
2jh5  2.50  2007  Ki=367nM      // 2jh5.pdf (895)
2cfg  1.55  2007  Ki=36nM       // 2cfg.pdf (R4A) AGAO IN COMPLEX WITH WC4D3, Ki=36+/-2nM
2oxn  1.70  2007  Ki=36nM       // 2oxn.pdf (OAN)
2i72  2.20  2007  Ki=37nM       // 2i72.pdf (VA1) compound 8, MIC.app=92uM
2pou  1.60  2007  Ki=38nM       // 2pou.pdf (I7A)
2oc2  2.25  2007  Ki=3nM        // 2oc2.pdf (RX3)
2qu6  2.10  2007  Ki=3nM        // 2qu5.pdf (857)
2nnk  1.25  2007  Ki=4.3nM      // 2nmw.pdf (ROC) Ki=4.3+/-0.4nM, mutations(Q506K, L532I, L562I, C566A, I583V, C594A), P21212, redundant to 2nnp
2nnp  1.20  2007  Ki=4.3nM      // 2nmw.pdf (ROC) Ki=4.3+/-0.4nM, mutations(Q506K,L532I,L562I,C566A,I583V,C594A); redundant to 2nmz
2nmy  1.10  2007  Ki=4.3nM      // 2nmw.pdf (ROC) Ki=4.3+/-0.7nM, mutations(Q506K, L532I, L562I, C566A, V581A, C594A), P21212, redundant to 2nmz
2nmz  0.97  2007  Ki=4.3nM      // 2nmw.pdf (ROC) Ki=4.3+/-0.7nM, mutations(Q506K,L532I,L562I,C566A,V581A,C594A), P212121
2glm  2.60  2007  Ki=4.3uM      // 2gll.pdf (SCB) compound 2, IC50=47.6+/-0.29uM
2oc1  2.70  2007  Ki=4.3uM      // 2obo.pdf (HU2) covalent inhibition; Ki is Ki*
2qlj  2.60  2007  Ki=4.4uM      // 2ql5.pdf (5-mer) covalent inhibition; ligand is peptide analogue, AC-WEHD-CHO (chain E) [ACE-TRP-GLU-HIS-ASA]
2gkl  1.86  2007  Ki=4.5uM      // 2gkl.pdf (PD2) wild type protein; Ki=4.5+/-0.5uM for 4-PDCA(inhibitor 2)
2j62  2.26  2007  Ki=4.6pM      // 2j62.pdf (GSZ)
2pwd  1.80  2007  Ki=40uM       // 2pwd.pdf (NOJ)
2j95  2.01  2007  Ki=4nM        // 2j94.pdf (GSX) compound 1b
2ovy  1.80  2007  Ki=4nM        // 2o8h.pdf (PFJ)
2oqv  2.80  2007  Ki=4nM        // 2oqi.pdf (MA9)
2uwl  1.90  2007  Ki=4nM        // 2uwl.pdf (895) ligand is compound 1
2pbw  2.50  2007  Ki=5.56nM     // 1vso.pdf (DOQ) Ki=5.56+/-0.88nM; ligand binding to iGluR5 core
2qft  1.55  2007  Ki=5.5uM      // 2qfq.pdf (GPJ) P101S mutant
2jfz  1.86  2007  Ki=5.8uM      // 2jfn.pdf (003) Ki=5.8+/-0.03uM
2nwn  2.15  2007  Ki=500nM      // 2nwn.pdf (12-mer)
2uxx  2.74  2007  Ki=500uM      // 2uxx.pdf (FAJ) incorrect data [ligand in crystal is FAD-PCNA adduct; Ki(inact)=500uM is for PCNA]
2j94  2.10  2007  Ki=534nM      // 2j94.pdf (G15) compound 1x
2ql7  2.40  2007  Ki=550nM      // 2ql5.pdf (5-mer) covalent inhibition; ligand is peptide analogue, AC-IEPD-CHO (chain E) [ACE-ILE-GLU-PRO-ASA]
2qzr  1.95  2007  Ki=55nM       // 2qzr.pdf (S79)
2qrk  1.75  2007  Ki=55uM       // 2qrk.pdf (AMP)
2o4z  2.10  2007  Ki=566nM      // 2o4z.pdf (HSW) ligand is compound 2
2obo  2.60  2007  Ki=57nM       // 2obo.pdf (HUD) covalent inhibition; Ki is Ki*
2psv  1.75  2007  Ki=58nM       // 2psu.pdf (MUV)
2q38  1.95  2007  Ki=5950nM     // 2q38.pdf (LSA) ligand is saccharin
2cen  1.70  2007  Ki=5nM        // 2cej.pdf (4AH) EC50=0.18uM
2q5k  1.95  2007  Ki=5pM        // 2q54.pdf (AB1)
2oyk  1.50  2007  Ki=5uM        // 2oyk.pdf (9MR)
2jds  2.00  2007  Ki=6.3nM      // 2jds.pdf (L20) Ki=160pM for PKB-alpha-L20 complex
2jdv  2.08  2007  Ki=6.3nM      // 2jdv.pdf (L20) PKA-PKB-2, Ki=160pM for PKB-alpha-L20 complex
2i4v  1.50  2007  Ki=6.3pM      // 2i4d.pdf (DJR) Ki=6.3+/-1.3pM, EC50(MT-2)=12.3+/-3.5nM
2qdt  2.00  2007  Ki=6.5uM      // 2qds.pdf (I38) Ki=6.5+/-2uM for compound 5a
2uy3  1.90  2007  Ki=600uM      // 2uy3.pdf (H33) ligand is 8-chlorotheophylline; Ki=600+/-64uM
2h6t  1.90  2007  Ki=60nM       // 2h6t.pdf (6-mer) Ki for pepA binding to SP3
2q3z  2.00  2007  Ki=60nM       // 2q3z.pdf (7-mer)
2pow  1.75  2007  Ki=63nM       // 2pou.pdf (I7C)
3b3w  1.75  2007  Ki=65uM       // 3b3s.pdf (LEU)
2qfu  1.60  2007  Ki=66uM       // 2qfq.pdf (GPJ) P101L mutant
2o22   NMR  2007  Ki=67nM       // 2o1y.pdf (LIU)
2v2q  2.30  2007  Ki=71.2uM     // 2v2q.pdf (NVG) ligand is compound 3, Ki=71.2+/-6.2uM, IC50=1.67mM
2pov  1.60  2007  Ki=75nM       // 2pou.pdf (I7B)
2q1q  1.90  2007  Ki=7nM        // 2q1q.pdf (OSP)
2q70  1.95  2007  Ki=8.3nM      // 2q70.pdf (DC8)
2qu5  2.95  2007  Ki=8.7nM      // 2qu5.pdf (276)
2z1w  1.63  2007  Ki=83uM       // 2z1w.pdf (BDI) ligand is compound 6
2v2v  2.40  2007  Ki=85.8uM     // 2v2q.pdf (V12) ligand is compound 1, Ki=85.8+/-9.4uM, IC50=1.99mM
2oc4  2.59  2007  Ki=86nM       // 2oc4.pdf (IMH)
2oji  2.60  2007  Ki=86nM       // 2ojg.pdf (33A)
2jfh  1.97  2007  Ki=870uM      // 2jfh.pdf (LK1) compound 2; Ki=870uM; IC50=710uM; ligand is L-Glu
2ql5  2.34  2007  Ki=8nM        // 2ql5.pdf (5-mer) covalent inhibition; ligand is peptide analogue, AC-DMQD-CHO (chain E) [ACE-ASP-MET-GLN-ASA]
2glp  2.42  2007  Ki=9.7uM      // 2gll.pdf (BDE) ligand is compound 1; IC50=39.8+/-0.35uM
2q11  2.40  2007  Ki=900nM      // 2q11.pdf (XX4)
2q8m  2.05  2007  Ki=94uM       // 2q8m.pdf (AMP) Ki=94uM (with Mg2+); Ki=13uM (without Mg2+)
2jld  2.35  2008  IC50<0.04nM   // 2jld.pdf (AG1) Ru containing; IC50<=0.04nM;
3bea  2.02  2008  IC50=0.007uM  // 3bea.pdf (IXH) compound 20, Auto-Pi IC50=0.007uM; BMDM IC50=0.003uM
2ow7  1.77  2008  IC50=0.014mM  // 2ow6.pdf (NK2)
3bel  2.30  2008  IC50=0.014uM  // 3bel.pdf (POX) compound 37
2vv9  1.90  2008  IC50=0.017uM  // 2vv9.pdf (IM9) compound 2e
2vcx  2.10  2008  IC50=0.021uM  // 2vcq.pdf (D26) compound 13
3ctj  2.50  2008  IC50=0.035uM  // 3cth.pdf (320)
3cst  3.20  2008  IC50=0.039uM  // 3csf.pdf (E52)
3d4q  2.80  2008  IC50=0.03nM   // 3d4q.pdf (SM5) compound 18
2r64  2.30  2008  IC50=0.03uM   // 2r64.pdf (740)
2rgp  2.00  2008  IC50=0.03uM   // 2rgp.pdf (HYZ) compound 17
2w3l  2.10  2008  IC50=0.03uM   // 2w3l.pdf (DRO) ligand is compound 31
3bmy  1.60  2008  IC50=0.03uM   // 3bm9.pdf (CXZ) compound 13
3c1x  2.17  2008  IC50=0.045uM  // 3c1x.pdf (CKK) compound 10j
3cp9  2.50  2008  IC50=0.048uM  // 3cp9.pdf (C19) compound 1
2rc9  1.96  2008  IC50=0.04uM   // 2rc9.pdf (1AC) ligand is compound 1, ACC
2vwx  1.65  2008  IC50=0.04uM   // 2vwx.pdf (7X4) compound 1, IC50=0.04+/-0.02uM
3dog  2.70  2008  IC50=0.04uM   // 3dog.pdf (NNN)
3br9  2.30  2008  IC50=0.062uM  // 3br9.pdf (DEY) compound 8e
3d7h  1.55  2008  IC50=0.06nM   // 3d7d.pdf (YC2) compound 4
2r7b  2.70  2008  IC50=0.06uM   // 2r7b.pdf (253) compound 1
3ddp  2.70  2008  IC50=0.072uM  // 3ddp.pdf (RC8) phosphorylated Thr160 CDK2, pCDK2
2vwy  1.65  2008  IC50=0.09uM   // 2vwx.pdf (7X5) compound 2, IC50=0.09+/-0.05uM
2z7i  2.10  2008  IC50=0.10uM   // 2z4v.pdf (742) compound 9
3dct  2.50  2008  IC50=0.112uM  // 3dct.pdf (064) ligand is compound GW4064
3bjc  2.00  2008  IC50=0.11uM   // 3bjc.pdf (WAN) compound 12
3cth  2.30  2008  IC50=0.11uM   // 3cth.pdf (319)
3bi1  1.50  2008  IC50=0.12nM   // 3bhx.pdf (3BI) IC50=0.12+/-0.03nM
3cwe  1.60  2008  IC50=0.12uM   // 3cwe.pdf (825)
3ej1  3.22  2008  IC50=0.12uM   // 3eid.pdf (5BP) compound 1
2vd1  2.25  2008  IC50=0.138uM  // 2vcq.pdf (D28) compound 12
3f5p  2.90  2008  IC50=0.140uM  // 3f5p.pdf (741) IC50=0.140+/-0.088uM
2vgp  1.70  2008  IC50=0.14uM   // 2vgp.pdf (AD6)
3e7b  1.70  2008  IC50=0.16nM   // 3e7a.pdf (E7B) IC50=0.16-22nM, see supplement data
2q8s  2.30  2008  IC50=0.185uM  // 2q8s.pdf (L92) compound 53A, alpha IC50(R)=0.912uM, gama IC50(S)=0.185uM
3bm9  1.60  2008  IC50=0.19uM   // 3bm9.pdf (BXZ) compound 6
3e7a  1.63  2008  IC50=0.1nM    // 3e7a.pdf (5-mer) IC50=0.1-3nM, see supplement data
2qc6  1.85  2008  IC50=0.1uM    // 2qc6.pdf (G12)
3di6  2.65  2008  IC50=0.1uM    // 3di6.pdf (PDZ) compound 4c, EC 2.7.7.49/ 2.7.7.7/ 3.1.26.4
3c45  2.05  2008  IC50=0.21nM   // 3c43.pdf (317)
3ddq  1.80  2008  IC50=0.21uM   // 3ddp.pdf (RRC) phosphorylated Thr160 CDK2, pCDK2
2vx1  1.65  2008  IC50=0.220uM  // 2vwx.pdf (7X8) compound 5, IC50=0.220+/-0.014uM
3eoc  3.20  2008  IC50=0.23uM   // 3eoc.pdf (T2A) compound 12i
2vww  1.90  2008  IC50=0.24uM   // 2vwu.pdf (7X2) IC50=0.24+/-0.16uM
3drp  2.60  2008  IC50=0.2nM    // 3drp.pdf (R8E) IC50=0.2+/-0.1nM, EC 2.7.7.49/ 2.7.7.7/ 3.1.26.4
2vwu  2.00  2008  IC50=0.35uM   // 2vwu.pdf (7X1) IC50=0.35+/-0.13uM
2jdl  2.20  2008  IC50=0.37nM   // 2jdl.pdf (11-mer) incomplete ligand
2q94  1.63  2008  IC50=0.37uM   // 2q92.pdf (A04) compound 6
2z7r  2.00  2008  IC50=0.3nM    // 2z7q.pdf (STU) IC50=0.3-1nM
2rc8  1.45  2008  IC50=0.3uM    // 2rc8.pdf (DSN) ligand is D-serine
3c10  2.00  2008  IC50=0.3uM    // 3c0z.pdf (TSN) IC50=0.3+/-0.1uM
3bv2  2.40  2008  IC50=0.44nM   // 3bv2.pdf (P38) compound 30, TNFa IC50=43nM
3eid  3.15  2008  IC50=0.45uM   // 3eid.pdf (PO5) compound 41
3bv3  2.59  2008  IC50=0.46nM   // 3bv2.pdf (P39) compound 28, TNFa IC50=29nM
3el7  2.80  2008  IC50=0.48uM   // 3el7.pdf (PD3) IC50=0.480+/-0.117uM
3e2m  2.00  2008  IC50=0.4nM    // 3bqn.pdf (E2M) compound 21a, IC50=0.4nM
3drr  2.89  2008  IC50=0.4nM    // 3drp.pdf (R8E) IC50=0.4+/-0.2nM, EC 2.7.7.49/ 2.7.7.7/ 3.1.26.4
2q93  1.60  2008  IC50=0.56uM   // 2q92.pdf (B21) compound 5
2qyn  1.57  2008  IC50=0.57uM   // 2qyk.pdf (NPV) IC50=0.57+/-0.04uM
2vx0  2.10  2008  IC50=0.58uM   // 2vx0.pdf (7X7) Fragment: KINASE DOMAIN, RESIDUES 598-899 Kd=0.58+/-0.12uM;
2qu3  2.00  2008  IC50=0.59uM   // 2qu2.pdf (462)
3b8q  2.75  2008  IC50=0.5nM    // 3b8q.pdf (900)
3bys  2.20  2008  IC50=0.5nM    // 3bys.pdf (AM5)
3d7f  1.54  2008  IC50=0.5nM    // 3d7d.pdf (YBY) compound 2
3drs  3.15  2008  IC50=0.5nM    // 3drp.pdf (R8D) IC50=0.5+/-0.2nM, EC 2.7.7.49/ 2.7.7.7/ 3.1.26.4
2w4i  1.87  2008  IC50=0.5uM    // 2w4i.pdf (VGA) Glutamate racemase (MurI) COMPLEX WITH D-GLUTAMATE AND AN INHIBITOR 7
2qyl  1.95  2008  IC50=0.65uM   // 2qyk.pdf (NPV) IC50=0.65+/-0.01uM
3dwb  2.38  2008  IC50=0.65uM   // 3dwb.pdf (RDF)
3b8r  2.70  2008  IC50=0.6nM    // 3b8r.pdf (887)
2ze1  2.20  2008  IC50=0.6uM    // 2zdz.pdf (411)
2z4y  2.10  2008  IC50=0.71uM   // 2z4v.pdf (252) compound 4; Space Group:  P 21 21 21
3db6  2.85  2008  IC50=0.73uM   // 3db6.pdf (FRS)
2z78  2.10  2008  IC50=0.76uM   // 2z4v.pdf (H86) compound 13
2vwz  1.65  2008  IC50=0.794uM  // 2vwx.pdf (7X6) compound 3, IC50=0.794+/-0.226uM
3bhx  1.60  2008  IC50=0.7nM    // 3bhx.pdf (BHX) IC50=0.7+/-0.26nM
2zdz  2.00  2008  IC50=0.7uM    // 2zdz.pdf (310)
3byu  2.30  2008  IC50=0.8nM    // 3bys.pdf (AM6)
3ds6  2.90  2008  IC50=0.8nM    // 3ds6.pdf (A17) IC50=0.8+/-0.6nM
2vcq  1.95  2008  IC50=0.92uM   // 2vcq.pdf (D25) compound 14
2z4w  2.45  2008  IC50=0.98uM   // 2z4v.pdf (749) compound 5
2qa8  1.85  2008  IC50=0.99uM   // 2qa8.pdf (GEN) ligand is compound 5, Genistein
3f66  1.40  2008  IC50=0.9uM    // 3f66.pdf (IHX) compound 28
2q92  1.90  2008  IC50=1.1uM    // 2q92.pdf (B23) compound 4
2q96  1.60  2008  IC50=1.2uM    // 2q92.pdf (A18) compound 8
3c6u  2.70  2008  IC50=1.35nM   // 3c6t.pdf (M22) compound 22
2viq  2.00  2008  IC50=1.3uM    // 2vin.pdf (D55)
3bg8  1.60  2008  IC50=1.3uM    // 3bg8.pdf (INH) Clavatadine A IC50=1.3uM, Clavatadine B IC50=27uM
2rib  1.80  2008  IC50=1.5mM    // 2ria.pdf (GMH) IC50=1.5+/-0.13mM
2r4f  1.70  2008  IC50=1.5nM    // 2r4f.pdf (RIE) compound 50, IC50=1.5+/-0.2nM
3bz3  2.20  2008  IC50=1.5nM    // 3bz3.pdf (YAM)
2vtr  1.90  2008  IC50=1.5uM    // 2vta.pdf (LZB) compound 11
3bet  1.85  2008  IC50=1.5uM    // 3bet.pdf (CTF) compound 15
3dpd  2.85  2008  IC50=1.66uM   // 3dpd.pdf (41A)
2vcg  1.90  2008  IC50=1.69uM   // 2vcg.pdf (S17) IC50=1.69+/-0.91uM
2q95  1.70  2008  IC50=1.6uM    // 2q92.pdf (A05) compound 7
3e63  1.90  2008  IC50=1.6uM    // 3e62.pdf (5B2)
3cs8  2.30  2008  IC50=1.7uM    // 3cs8.pdf (12-mer) IC50=1.7+/-0.2uM for PGC-1a ID1, IC50=87+/-20uM for PGC-1a ID2
2z4z  2.09  2008  IC50=1.86uM   // 2z4v.pdf (SC0) compound 12
3ce3  2.40  2008  IC50=1.8nM    // 3ce3.pdf (1FN) IC50=1.8+/-0.7nM
2viy  1.82  2008  IC50=1.8uM    // 2viy.pdf (VG3) compound 14
2pjc  1.74  2008  IC50=1.9nM    // 2piy.pdf (343)
2vtj  2.20  2008  IC50=1.9uM    // 2vta.pdf (LZ4) compound 10
3c4f  2.07  2008  IC50=1.9uM    // 3c4c.pdf (C4F)
2r3k  1.70  2008  IC50=100nM    // 2r3f.pdf (SCQ) compound 7
2r3l  1.65  2008  IC50=100nM    // 2r3f.pdf (SCW) compound 8
3c4e  1.98  2008  IC50=100uM    // 3c4c.pdf (C4E) IC50  100uM
2uup  1.88  2008  IC50=105uM    // 2uuo.pdf (LK4) compound 17l
2r3j  1.65  2008  IC50=10nM     // 2r3f.pdf (SCJ) compound 5
2r3m  1.70  2008  IC50=10nM     // 2r3f.pdf (SCX) compound 9
3dej  2.60  2008  IC50=10nM     // 3deh.pdf (RXC) IC50=10+/-1nM
3fc1  2.40  2008  IC50=10nM     // 3fc1.pdf (52P) ligand is compound VX745
2z50  2.01  2008  IC50=11.22uM  // 2z4v.pdf (028) compound 10
3bh8  1.65  2008  IC50=11.2nM   // 3bgm.pdf (10-mer)
3bpr  2.80  2008  IC50=11.3uM   // 2p0c.pdf (OLP) compound 52, IC50=11.3+/-2.1uM
2rjr  2.10  2008  IC50=11.6mM   // 2qve.pdf (295)
2vd0  2.20  2008  IC50=11.6uM   // 2vcq.pdf (D27)
3c0z  2.10  2008  IC50=113uM    // 3c0z.pdf (SHH) IC50=113+/-16uM
3bh9  1.70  2008  IC50=116.9nM  // 3bgm.pdf (10-mer)
2zva  2.60  2008  IC50=11nM     // 2zv8.pdf (1N1)
2pks  2.50  2008  IC50=11uM     // 2pks.pdf (G44) compound 20c
3ccn  1.90  2008  IC50=120nM    // 3ccn.pdf (LKG) compound 3a, IC50=120+/-18nM
3e7o  2.14  2008  IC50=120nM    // 3e7o.pdf (35F)
2vth  1.90  2008  IC50=120uM    // 2vta.pdf (LZ2) compound 7
2vte  2.20  2008  IC50=122uM    // 2vtd.pdf (IK4) compound 17o
3dy6  2.90  2008  IC50=126nM    // 3dy6.pdf (DY6) ligand is compound GW9371, pIC50=6.9
2pj9  1.56  2008  IC50=12nM     // 2piy.pdf (281)
2pj2  1.95  2008  IC50=12nM     // 2piy.pdf (864)
3chd  2.00  2008  IC50=12uM     // 3ch9.pdf (WRG) IC50=12+/-1uM
2zas  2.00  2008  IC50=13.9nM   // 2zas.pdf (1OH) IC50=13.9+/-1.98nM
3dda  1.50  2008  IC50=133uM    // 3dda.pdf (7-mer)
2onc  2.55  2008  IC50=13nM     // 2onc.pdf (SY1) IC50=13+/-6nM
2pj4  2.00  2008  IC50=13nM     // 2piy.pdf (414)
2vj6  1.80  2008  IC50=13nM     // 2vie.pdf (VG5) compound 2, IC50=13+/-2nM
2vto  2.19  2008  IC50=140nM    // 2vta.pdf (LZ8) compound 22
2vtq  1.90  2008  IC50=140nM    // 2vta.pdf (LZA) compound 28
3deh  2.50  2008  IC50=149nM    // 3deh.pdf (RXA) IC50=149+/-15nM
3bi0  1.67  2008  IC50=14nM     // 3bhx.pdf (BIX) IC50=14+/-4.2nM
3cib  1.72  2008  IC50=14nM     // 3cib.pdf (314)
3d7d  1.69  2008  IC50=14nM     // 3d7d.pdf (FBD) compound 3
3ehw  1.80  2008  IC50=15.2uM   // 3ehw.pdf (DUP) ligand is compound 2
3cqu  2.20  2008  IC50=151nM    // 3cqu.pdf (CQU) compound 5d, IC50=151+/-32nM
3eqb  2.62  2008  IC50=15mM     // 3eqb.pdf (LUG)
2pj5  1.65  2008  IC50=15nM     // 2piy.pdf (11B)
3c4c  2.57  2008  IC50=160nM    // 3c4c.pdf (324)
2vo7  1.98  2008  IC50=168nM    // 2vnw.pdf (M05) IC50=168+/-36nM
2ea2  2.50  2008  IC50=16nM     // 2ea2.pdf (F77) compound 9c, enzyme IC50=0.016uM, enzyme IC50=0.016uM w/HSA
2vwv  1.90  2008  IC50=16uM     // 2vwu.pdf (7X3)
2jkm  2.31  2008  IC50=17.76nM  // 2jkk.pdf (BII) IC50=17.76+/-1.21nM
2piz  1.60  2008  IC50=170nM    // 2piy.pdf (606)
2uuo  2.50  2008  IC50=170uM    // 2uuo.pdf (LK3) compound 17d
2pj7  1.77  2008  IC50=17nM     // 2piy.pdf (235)
3chs  2.55  2008  IC50=17nM     // 3cho.pdf (4BU)
3d7g  1.75  2008  IC50=17nM     // 3d7d.pdf (MUD) compound 1
2qn1  2.40  2008  IC50=17uM     // 2qn1.pdf (0AS) X-ray structure(GPb); IC50(GPa)
2ph8  1.70  2008  IC50=1800nM   // 2ph8.pdf (35A)
2vj9  1.60  2008  IC50=180nM    // 2vie.pdf (VG7) compound 6
2vta  2.00  2008  IC50=185uM    // 2vta.pdf (LZ1) compound 6
2pj8  1.70  2008  IC50=18nM     // 2piy.pdf (17A)
2vd4  1.90  2008  IC50=18uM     // 2vd4.pdf (P21) inhibitor 1
2pjb  1.70  2008  IC50=19nM     // 2piy.pdf (983)
2zjf  2.40  2008  IC50=19nM     // 2zjf.pdf (BSU)
3c43  2.30  2008  IC50=19nM     // 3c43.pdf (315)
2vin  1.90  2008  IC50=1mM      // 2vin.pdf (505) IC50  1mM
2vtm  2.25  2008  IC50=1mM      // 2vta.pdf (LZM) compound 8, 54% inhibition IC54=1mM
2r2l  2.23  2008  IC50=1nM      // 2r2l.pdf (PB9)
2w05  1.90  2008  IC50=1nM      // 2w05.pdf (FRT) compound 5b, IC50=0.001uM
2qh6  2.70  2008  IC50=1uM      // 2b23.pdf (ODE)
2r3i  1.28  2008  IC50=1uM      // 2r3f.pdf (SCF) compound 4, IC50=1000nM
3f69  2.80  2008  IC50=1uM      // 3f61.pdf (XDR) IC50<1uM
2k31   NMR  2008  IC50=2.0nM    // 2k31.pdf (35G) IC50=2.0-3.8nM
3c6t  2.70  2008  IC50=2.11nM   // 3c6t.pdf (M14) compound 14
2pja  1.70  2008  IC50=2.2nM    // 2piy.pdf (33Z)
2rg6  1.72  2008  IC50=2.2nM    // 2rg5.pdf (287)
3cjo  2.28  2008  IC50=2.2nM    // 3cjo.pdf (K30) IC50=2.2+/-1.2nM
3dt1  2.80  2008  IC50=2.4nM    // 3ds6.pdf (P40) IC50=2.4+/-1.3nM
2qnx  2.70  2008  IC50=2.4uM    // 2qnx.pdf (UDT) inhibitor 2, IC50=2.4+/-0.8uM
3bqn  1.80  2008  IC50=2.5nM    // 3bqn.pdf (BQN)
3cbp  1.42  2008  IC50=2.5uM    // 3cbp.pdf (SFG) ligand is compound 4, Sinefungin
2z52  2.13  2008  IC50=2.69uM   // 2z4v.pdf (H23) compound 11
2zlg  2.52  2008  IC50=2.6uM    // 2zlf.pdf (MRT) IC50=2.6+/-0.1uM
2ria  1.80  2008  IC50=2.7mM    // 2ria.pdf (289)
2qo1  2.60  2008  IC50=2.7uM    // 2qnx.pdf (VZZ) inhibitor 3, IC50=2.7+/-0.2uM
3daj  2.00  2008  IC50=2.9uM    // 3daj.pdf (FXG) compound 6
3f07  3.30  2008  IC50=2.9uM    // 3ew8.pdf (AGE) IC50=2.9+/-0.6uM, data not shown
3bwf  2.35  2008  IC50=200pM    // 3bwf.pdf (DWC)
2e9o  2.10  2008  IC50=20nM     // 2e9n.pdf (A58)
2piy  1.43  2008  IC50=20nM     // 2piy.pdf (528)
3chq  2.09  2008  IC50=20nM     // 3cho.pdf (4BQ)
2r3h  1.50  2008  IC50=20uM     // 2r3f.pdf (SCE) compound 3, IC50=20000nM
3c7q  2.10  2008  IC50=21nM     // 3c7q.pdf (XIN) IC50=21+/-13nM, VEGFR-2 (mouse) IC50=13+/-4nM
3c72  2.30  2008  IC50=22.7uM   // 3c72.pdf (CX1) compound 2, IC50=22.7+/-1.8uM
2zm1  2.10  2008  IC50=220nM    // 2zm1.pdf (KSF) compound 3
3eio  2.00  2008  IC50=223nM    // 3eio.pdf (AJH)
2pre  2.70  2008  IC50=225nM    // 2pre.pdf (E64)
3d14  1.90  2008  IC50=22nM     // 3d14.pdf (AK1)
2qlq  2.33  2008  IC50=236nM    // 2qlq.pdf (SR2) compound 2, IC50=236nM
3eyl  3.00  2008  IC50=250nM    // 3eyl.pdf (SMK) ligand is compound 32a
2zp0  2.70  2008  IC50=25nM     // 2zp0.pdf (PI0) ligand compound 3 is PI0, benzylsulfonamide-D-ile-gln-P-aminobenzamidine
3el8  2.30  2008  IC50=25nM     // 3el8.pdf (PD5) IC50=25+/-2nM
3cpb  2.70  2008  IC50=25uM     // 3cp9.pdf (C92) compound 2, IC50>25uM
2v13  2.80  2008  IC50=26nM     // 2v13.pdf (C40) inhibitor 7, Purified human renin IC50=0.022uM, Plasma human renin IC50=0.026uM
3cgf  3.00  2008  IC50=270nM    // 3cgf.pdf (JNF) RCSB is JNF, like analogue 8
3cm7  3.10  2008  IC50=270nM    // 3cm7.pdf (X22) ligand is compound 3a
2qzk  1.80  2008  IC50=27nM     // 2ph8.pdf (I21)
3dek  2.40  2008  IC50=27nM     // 3deh.pdf (RXD) IC50=27+/-2nM
3cho  1.80  2008  IC50=280nM    // 3cho.pdf (4BG)
2qn2  2.70  2008  IC50=28uM     // 2qn1.pdf (0MA) X-ray structure(GPb); IC50(GPa)
2ow6  1.19  2008  IC50=2mM      // 2ow6.pdf (NK1)
2vnn  1.87  2008  IC50=2nM      // 2vnm.pdf (CM7) compound 8a
2w17  2.15  2008  IC50=2nM      // 2w17.pdf (I19) (S)-8b, IC50=0.002uM
3be2  1.75  2008  IC50=2nM      // 3b8q.pdf (RAJ)
3cn0  1.52  2008  IC50=3.08uM   // 3cn0.pdf (LJ1) ligand is compound 9
2rg5  2.40  2008  IC50=3.1nM    // 2rg5.pdf (279)
2qyk  2.10  2008  IC50=3.3uM    // 2qyk.pdf (NPV) IC50=3.3+/-0.2uM
3bhb  2.20  2008  IC50=3.4nM    // 3bgm.pdf (10-mer)
3bx5  2.40  2008  IC50=3.5nM    // 3bx5.pdf (304)
2rf2  2.40  2008  IC50=3.6nM    // 2rf2.pdf (MRX) compound 7e
2qu2  2.60  2008  IC50=3.7uM    // 2qu2.pdf (251) ED50=8.9uM
2qnz  2.30  2008  IC50=3.8uM    // 2qnx.pdf (DFD) inhibitor 1, IC50=3.8+/-0.5uM
2vts  1.90  2008  IC50=30nM     // 2vta.pdf (LZC) compound 12
2zmj  2.35  2008  IC50=30nM     // 2zmh.pdf (MI4) IC50=3 x 10-8M
3e01  2.95  2008  IC50=30nM     // 3dya.pdf (PZ2) compound 10, EC 2.7.7.49/ 2.7.7.7/ 3.1.26.4
2vl8  2.31  2008  IC50=30uM     // 2vl8.pdf (UDP) CTS+UDP IC50~30uM, CTS IC50~100uM, UDP IC50~400uM
3ccb  2.49  2008  IC50=30uM     // 3ccb.pdf (B2Y) compound 1
2zlf  2.59  2008  IC50=31uM     // 2zlf.pdf (7-mer) IC50=31+/-1uM
3d4l  2.00  2008  IC50=32nM     // 3d4l.pdf (605)
2vie  1.90  2008  IC50=33nM     // 2vie.pdf (VG0) compound 12
3bsc  2.65  2008  IC50=33uM     // 3br9.pdf (2PD) compound 3
2pt9  2.20  2008  IC50=35uM     // 2i7c.pdf (S4M) X-ray(pfSPDS); IC501=35uM(pfSPDS); IC502=1.7uM(rat SPDS).
2vqj  2.10  2008  IC50=367nM    // 2vqj.pdf (TFG) IC50=367+/-8nM
3dm6  2.60  2008  IC50=37nM     // 3dm6.pdf (757)
3bgm  1.60  2008  IC50=38.5nM   // 3bgm.pdf (9-mer)
2ow3  2.80  2008  IC50=3nM      // 2ow3.pdf (BIM) PDB 2ow3 is for ligand compound 3, not compound 10a, IC50=0.003uM
2qmf  1.75  2008  IC50=3nM      // 2qk5.pdf (CS9) inhibitor 2f
2vaq  3.01  2008  IC50=3nM      // 2vaq.pdf (VAW) IC50=3+/-0.5nM
2vnm  1.79  2008  IC50=3nM      // 2vnm.pdf (CM8) compound 1
2vtp  2.15  2008  IC50=3nM      // 2vta.pdf (LZ9) compound 23
3cic  1.75  2008  IC50=3nM      // 3cib.pdf (316)
3dcv  2.70  2008  IC50=3nM      // 3dcv.pdf (55E)
3dya  2.30  2008  IC50=3nM      // 3dya.pdf (PZL) compound 6, EC 2.7.7.49/ 2.7.7.7/ 3.1.26.4
3cgo  3.00  2008  IC50=3uM      // 3cgf.pdf (JNO) RCSB is JNO, like analogue 2
2v22  2.60  2008  IC50=4.1uM    // 2v22.pdf (C35) IC50=4.1+/-1.4uM, C35 is ligand NCP09
3chf  1.95  2008  IC50=4.3uM    // 3ch9.pdf (5-mer) IC50=4.3+/-0.2uM
2qaf  1.95  2008  IC50=4.4uM    // 2q8z.pdf (U5P) IC50=4.4+/-1.3uM
3bgl  2.23  2008  IC50=4.5nM    // 3bgl.pdf (RID) compound 16a in vitro, Rat microsomal HMGCoA reductase inhibition.
2qve  2.00  2008  IC50=4.8mM    // 2qve.pdf (247)
3eql  2.70  2008  IC50=4.99uM   // 3eql.pdf (MXP) IC50=4.99+/-0.45uM, dMyx complexed with a Thermus thermophilus RNAP holoenzyme
3e62  1.92  2008  IC50=40.9uM   // 3e62.pdf (5B1)
2vj7  1.60  2008  IC50=40nM     // 2vie.pdf (VG6) compound 16
3ctq  1.95  2008  IC50=40nM     // 3ctq.pdf (337) IC50=40+/-35nM
3ddu  1.56  2008  IC50=40nM     // 3ddu.pdf (552) IC50=40+/-0.6nM
3dei  2.80  2008  IC50=40nM     // 3deh.pdf (RXB) IC50=40+/-3nM
2vio  1.80  2008  IC50=40uM     // 2vin.pdf (L1O)
2ei6  2.30  2008  IC50=41nM     // 2ei6.pdf (D92) D92(cis) IC50=41nM, (+)D92(cis) IC50=753nM, (-)D92(cis) IC50=16nM, D92(Trans) IC50=13nM
3cqw  2.00  2008  IC50=42nM     // 3cqu.pdf (CQW) compound 8b, IC50=42+/-30nM
3dbd  3.05  2008  IC50=42nM     // 3dbc.pdf (3FR)
2vtt  1.68  2008  IC50=44nM     // 2vta.pdf (LZD) compound 29
2vrx  1.86  2008  IC50=45nM     // 2vrx.pdf (447) ligand is compound ZM447439
2ea4  2.35  2008  IC50=46nM     // 2ea2.pdf (F79) compound 17a, enzyme IC50=0.046uM, enzyme IC50=0.12uM w/HSA
2vu3  1.85  2008  IC50=47nM     // 2vta.pdf (LZE) compound 33
2pj6  1.60  2008  IC50=49nM     // 2piy.pdf (059)
2rl5  2.65  2008  IC50=4nM      // 2rl5.pdf (2RL)
3bl7  2.31  2008  IC50=4nM      // 3bl7.pdf (DD1) IC50~4nM; human DcpS
3efw  2.29  2008  IC50=4nM      // 3efw.pdf (AK8)
3ekn  2.20  2008  IC50=4nM      // 3ekn.pdf (GS3) compound 2 with IGF-1R enzyme IC50 value, data not sure, IC50=4nM
2rku  1.95  2008  IC50=5.0nM    // 2rku.pdf (R78) compound 1b, IC50=5+/-2.4nM
3che  2.05  2008  IC50=5.1uM    // 3ch9.pdf (4-mer) IC50=5.1+/-0.2uM
2vip  1.72  2008  IC50=5.2uM    // 2vin.pdf (L1R)
2rjs  2.40  2008  IC50=5.3mM    // 2qve.pdf (296)
2qq7  2.38  2008  IC50=5.71uM   // 2qlq.pdf (SR2) compound 2, IC50=5710nM
2vvt  1.65  2008  IC50=5.8uM    // 2vvt.pdf (I24) compound 13
2r3f  1.50  2008  IC50=500nM    // 2r3f.pdf (SC8) compound 1
2vgo  1.70  2008  IC50=500nM    // 2vgo.pdf (AD5) IC50=15nM(Upstate assay conditions); IC50=400nM(Invitrogen assay conditions)
3ch9  2.20  2008  IC50=500uM    // 3ch9.pdf (XRG) IC50=500+/-20uM
2viv  1.72  2008  IC50=520nM    // 2vin.pdf (VG2)
3chp  2.10  2008  IC50=5400nM   // 3cho.pdf (4BO)
3d27  2.20  2008  IC50=55.7uM   // 3d27.pdf (W29) compound 22
3cj3  1.87  2008  IC50=57uM     // 3ciz.pdf (SX4) compound 7c, IC50=17uM
2qmd  1.65  2008  IC50=5nM      // 2qk5.pdf (CS7) inhibitor 2e
3bc5  2.27  2008  IC50=5nM      // 3bc5.pdf (ZAA)
3cid  1.80  2008  IC50=5nM      // 3cib.pdf (318)
2vj1  2.25  2008  IC50=5uM      // 2v6n.pdf (XP1) IC50<5uM
3b9s  1.80  2008  IC50=5uM      // 3b9s.pdf (RW1) covalent&nbsp; complex; IC50~5uM, 10~20 fold weak than 475nM, 200nM
3cpc  2.40  2008  IC50=5uM      // 3cp9.pdf (C52) compound 16, IC50>5uM
3elj  1.80  2008  IC50=5uM      // 3ekn.pdf (GS7) compound 40 with JNK1, IC50=5010nM
2jkk  2.00  2008  IC50=6.24nM   // 2jkk.pdf (BI9) IC50=6.24+/-0.51nM
2jjr  2.30  2008  IC50=6.28nM   // 2jdl.pdf (TAM) IC50=6.28nM
2e9n  2.50  2008  IC50=6.2nM    // 2e9n.pdf (76A)
2vvo  1.85  2008  IC50=6.3mM    // 2vvo.pdf (A6P) IC50=6.3+/-0.5mM
3cjf  2.15  2008  IC50=6.3nM    // 3cjf.pdf (SAV) indazolylpyrimidine 5a
3dcr  1.40  2008  IC50=6.3nM    // 3dck.pdf (KVS)
2pmn  2.80  2008  IC50=6.3uM    // 2pmn.pdf (K51) inhibitor K510
3c5u  2.80  2008  IC50=6.4nM    // 3c5u.pdf (P41) compound 6a
2pj3  1.64  2008  IC50=6.6nM    // 2piy.pdf (86A)
3eht  3.40  2008  IC50=6.8uM    // 3ehs.pdf (16-mer) Corticotropin-releasing factor, CRF(27-41); incomplete ligand
2r3o  1.80  2008  IC50=600nM    // 2r3f.pdf (2SC) compound 11
2viz  1.60  2008  IC50=605nM    // 2viy.pdf (VG4) compound 21
3cy2  2.01  2008  IC50=60nM     // 3cxw.pdf (MB9) multiple ligands; close to a 14-mer peptide
3chr  2.20  2008  IC50=61nM     // 3cho.pdf (4BS)
2zdx  2.54  2008  IC50=648uM    // 2zdx.pdf (P4A) Fragment: Residues 20-411; Mutation: prescission protease site 18, 19;
2rip  2.90  2008  IC50=65nM     // 2rip.pdf (34Q)
3ee2  1.91  2008  IC50=65uM     // 3ee2.pdf (NZO) IC50~65uM
2vti  2.00  2008  IC50=660nM    // 2vta.pdf (LZ3) compound 14
2r4b  2.40  2008  IC50=66nM     // 2r4b.pdf (GW7) compound6, different from GW7, a triple bond to a single bond
3bl9  1.80  2008  IC50=66nM     // 3bl7.pdf (DD2) IC50~66nM
3ecn  2.10  2008  IC50=698uM    // 3ecn.pdf (IBM) IC50=698+/-29uM
2qzx  2.50  2008  IC50=6nM      // 2qzx.pdf (6-mer) Sap5 complexed with pepstatin A, a 6-mer peptide
2v16  2.80  2008  IC50=6nM      // 2v13.pdf (C47) inhibitor 3, Purified human renin IC50=0.006uM, Plasma human renin IC50=0.0008uM
3bym  2.00  2008  IC50=6nM      // 3bym.pdf (AM0)
3bki  1.87  2008  IC50=7.6uM    // 3bki.pdf (FQX)
2jko  1.65  2008  IC50=7.7nM    // 2jkk.pdf (BIJ) IC50=7.7+/-1.36nM
2jkq  2.60  2008  IC50=7.7nM    // 2jkk.pdf (VG8) can not be reliably determined, but expected to mirror the potency of TAF089
2r3n  1.63  2008  IC50=70nM     // 2r3f.pdf (SCZ) compound 10
2viw  2.05  2008  IC50=72nM     // 2vin.pdf (D56)
3dbs  2.80  2008  IC50=75nM     // 3dbs.pdf (GD9) IC50=0.075uM
2zof  2.30  2008  IC50=7nM      // 2zof.pdf (BES) X \ray (mouse CN2); Mn2+ containing; IC50(human CN2)
3byo  2.00  2008  IC50=7nM      // 3bym.pdf (AM9)
2pj0  1.65  2008  IC50=8.1nM    // 2piy.pdf (922)
3ens  2.30  2008  IC50=8.9nM    // 3ens.pdf (ENS) compound 18
2r3g  1.55  2008  IC50=800nM    // 2r3f.pdf (SC9) compound 2
2vle  2.40  2008  IC50=80nM     // 2vle.pdf (DZN)
2qiq  1.90  2008  IC50=80uM     // 2qiq.pdf (CYV) compound 3
3chc  1.90  2008  IC50=81uM     // 3ch9.pdf (ZRG) IC50=81+/-4uM
2w06  2.04  2008  IC50=83nM     // 2w05.pdf (FRV) compound 5e, IC50=0.083uM
2vtn  2.20  2008  IC50=850nM    // 2vta.pdf (LZ7) compound 18
2vtd  1.94  2008  IC50=85uM     // 2vtd.pdf (LKM) compound 17n
2pjt  2.80  2008  IC50=860nM    // 2pjt.pdf (347) IC50=860+/-20nM
2vcw  1.95  2008  IC50=890uM    // 2vcq.pdf (ZZA) compound 1
2qk5  2.20  2008  IC50=8nM      // 2qk5.pdf (CS5) lead inhibitor 1
2qp8  1.50  2008  IC50=8nM      // 2qk5.pdf (SC7) inhibitor 2q
2qzl  1.80  2008  IC50=8nM      // 2qzl.pdf (IXS)
3ccc  2.71  2008  IC50=8nM      // 3ccb.pdf (7AC) compound 30, IC50=0.008uM
2zdt  2.00  2008  IC50=9.6nM    // 2zdt.pdf (46C) X-ray structure(JNK3/46C); IC50=9.6nM(JNK1/46C).
2pj1  1.64  2008  IC50=9.7nM    // 2piy.pdf (578)
2r3p  1.66  2008  IC50=900nM    // 2r3f.pdf (3SC) compound 12
3ddb  1.60  2008  IC50=95uM     // 3dda.pdf (7-mer)
2vqm  1.80  2008  IC50=978nM    // 2vqj.pdf (HA3) IC50=978+/-62nM
2vtl  2.00  2008  IC50=97uM     // 2vta.pdf (LZ5) compound 15
2qhn  1.70  2008  IC50=980nM    // 2qhm.pdf (582)
3db8  3.15  2008  IC50=99nM     // 3db8.pdf (1FR)
2jjk  2.00  2008  IC50=9nM      // 2jjk.pdf (R15) FBbase complex with compound 7a, IC50=0.009uM
2zv9  2.76  2008  IC50=9nM      // 2zv8.pdf (PP2)
3cd8  2.00  2008  IC50=9nM      // 3ccn.pdf (L5G) compound 4, IC50=9+/-2nM
2z8e  1.99  2008  Kd=0.01uM     // 2z8e.pdf (MES)
2q2a  1.79  2008  Kd=0.039uM    // 2pvu.pdf (ARG)
2rkn  1.60  2008  Kd=0.06uM     // 2rkn.pdf (LP3) Kd=0.06+/-0.02uM
3e64  1.80  2008  Kd=0.078uM    // 3e62.pdf (5B3)
2vt3  2.00  2008  Kd=0.07mM     // 2vt3.pdf (ATP)
3c49  2.80  2008  Kd=0.07uM     // 3c49.pdf (KU8) Kd=0.07+/-0.008uM
2zmd  2.88  2008  Kd=0.098uM    // 2zmd.pdf (537) ligand is compound SP600125
3exe  1.98  2008  Kd=0.11uM     // 3exe.pdf (TPP) cofactor ThDP binding to wt E1p in presence of Mn2+; Kd=0.11+/-0.01uM is for Mg2+
3cow  1.80  2008  Kd=0.125uM    // 3cow.pdf (52H) Kd=0.125+/-0.008uM; Ki=0.22+/-0.03uM
3bu8  2.15  2008  Kd=0.12uM     // 3bu8.pdf (19-mer) Kd=0.12+/-0.03uM; incomplete ligand
2vpn  1.55  2008  Kd=0.19uM     // 2vpn.pdf (4CS) Kd=0.19+/-0.02uM
3bxz  3.00  2008  Kd=0.19uM     // 3bxz.pdf (ADP)
3diw  2.10  2008  Kd=0.19uM     // 3diw.pdf (10-mer) Kd=0.19+/-0.05uM; incomplete ligand
2uyw  1.70  2008  Kd=0.1pM      // 2uyw.pdf (BTN)
3dab  1.90  2008  Kd=0.21uM     // 3dab.pdf (15-mer) Kd=0.21+/-0.05uM; incomplete ligand
2qky  3.10  2008  Kd=0.247nM    // 2qky.pdf (13Z) IC50=0.022uM
2jgs  1.90  2008  Kd=0.24uM     // 2jgs.pdf (BTN) Kd=0.24+/-0.04uM
2vwc  2.40  2008  Kd=0.24uM     // 2vwc.pdf (BC2) Kd=0.24uM, IC50=2uM
2qpu  1.70  2008  Kd=0.25mM     // 2qpu.pdf (QPU) Kd=0.25+/-0.03mM
3bb1  2.80  2008  Kd=0.25mM     // 3bb1.pdf (GNP) Kd=0.25+/-0.05mM
2p7z  2.50  2008  Kd=0.262uM    // 2p7a.pdf (OHT)
2p7g  2.10  2008  Kd=0.297uM    // 2p7a.pdf (2OH)
3d0b  1.74  2008  Kd=0.29uM     // 3d0b.pdf (SNX) ligand is compound 16, Kd=0.29uM, IC50=8.9uM
3exf  3.00  2008  Kd=0.29uM     // 3exe.pdf (TPP) Binding of Cofactor ThDP to S-E1p in the Presence of Mg2+ Ions, Kd=0.29+/-0.02uM
3c7n  3.12  2008  Kd=0.2uM      // 3c7n.pdf (ADP)
3bva  1.05  2008  Kd=0.30uM     // 3bva.pdf (2NC) Ka=(3.30+/-0.56)e+6M-1
2jkt  3.40  2008  Kd=0.31uM     // 2jkr.pdf (11-mer) incomplete ligand
3cj4  2.07  2008  Kd=0.31uM     // 3ciz.pdf (SX5) ligand is compound 8e, IC50=1.0uM
2phb  2.30  2008  Kd=0.32nM     // 2phb.pdf (230)
3bum  2.00  2008  Kd=0.32uM     // 3bum.pdf (13-mer) incomplete ligand
2p3i  1.75  2008  Kd=0.33mM     // 2p3i.pdf (MNA) ligand is Neu5Ac-alpha-2Me; Kd measured at 22C
2q2n  1.80  2008  Kd=0.33uM     // 2q2n.pdf (H01) mouse ferrochelatase
3cph  2.90  2008  Kd=0.33uM     // 3cph.pdf (GDP) Kd=0.33+/-0.02uM
3d2e  2.35  2008  Kd=0.38uM     // 3d2e.pdf (ATP) Kd=0.38+/-0.097uM(ATP and Sse1p-Hsp70); Kd=0.1uM(full-length proteins)
2jql   NMR  2008  Kd=0.3uM      // 2jqi.pdf (10-mer)
2w0p  1.90  2008  Kd=0.3uM      // 2w0p.pdf (15-mer) Kd=0.3+/-0.05uM, FILAMIN A REPEAT 21 COMPLEXED WITH THE MIGFILIN PEPTIDE; incomplete ligand
2q2c  2.35  2008  Kd=0.42uM     // 2pvu.pdf (HIS) protein mutant C1G ;  Kd=0.42+/-0.08uM;
3c2o  2.30  2008  Kd=0.45mM     // 3c2f.pdf (NTM) Kd(stQAPRTase)=21uM; Kd=0.45+/-0.03mM
3cj5  1.92  2008  Kd=0.46uM     // 3ciz.pdf (SX6) ligand is compound 8i, IC50=0.25uM
2zb1  2.50  2008  Kd=0.48uM     // 2zaz.pdf (GK4) IC50=3uM
2pvu  1.79  2008  Kd=0.49uM     // 2pvu.pdf (LYS)
2w0s  2.92  2008  Kd=0.5mM      // 2v54.pdf (BVP) BVdU Kd=0.5+/-0.1mM
2jg8  2.05  2008  Kd=0.5uM      // 2jg8.pdf (SEP) Kd=5 x 10-7M
2or9  2.70  2008  Kd=0.5uM      // 2or9.pdf (11-mer) synthetic epitope peptide of 9E10, Kd1=0.50uM 0.70uM 0.28uM in phosphate, TRISMOPS, buffer
2q89  2.30  2008  Kd=0.5uM      // 2q88.pdf (6CS) Kd=0.5+/-0.1uM
2vrj  1.90  2008  Kd=0.5uM      // 2vrj.pdf (NCW) ligand is compound 9, Ki=0.28uM
3ebl  1.90  2008  Kd=0.5uM      // 3ebl.pdf (GA4)
2zm3  2.50  2008  Kd=0.614uM    // 2zm3.pdf (575) IC50=2.42uM
3bun  2.00  2008  Kd=0.61uM     // 3bum.pdf (13-mer) incomplete ligand
2qbu  2.10  2008  Kd=0.645uM    // 2qbu.pdf (SAH) Kd=0.645+/-0.025uM
3dxj  3.00  2008  Kd=0.6uM      // 3dxj.pdf (NE6) IC50=20uM, Kd=0.6+/-0.3uM; ligand is antibiotic myxopyronin (Myx), correspond to code NE6
3bti  2.85  2008  Kd=0.72uM     // 3bt9.pdf (BER) Kd=0.72+/-0.08uM
2p7a  2.30  2008  Kd=0.788uM    // 2p7a.pdf (43M)
3c2r  2.40  2008  Kd=0.78mM     // 3c2f.pdf (PHT) Kd=0.78+/-0.08mM
3ce0  2.80  2008  Kd=0.7uM      // 3c49.pdf (P34) Kd=0.7+/-0.15uM
3dst  1.90  2008  Kd=0.83nM     // 3dss.pdf (GRG) RabGGTase-GGPP complex, co-titration Kd=0.83+/-0.22nM, displacement titration Kd=1.8+/-0.71nM
2jkr  2.98  2008  Kd=0.85uM     // 2jkr.pdf (11-mer) incomplete ligand
3buo  2.60  2008  Kd=0.88uM     // 3bum.pdf (13-mer) incomplete ligand
2z92  2.30  2008  Kd=0.8nM      // 2z91.pdf (ENE)
3cii  4.41  2008  Kd=0.8uM      // 3cii.pdf (9-mer) Kd=0.8+/-0.055uM
2vmd  1.90  2008  Kd=0.95mM     // 2vmc.pdf (MBG)
3coy  2.03  2008  Kd=0.96uM     // 3cow.pdf (53H) Kd=0.96+/-0.03uM; Ki=4+/-0.6uM
3cfv  2.60  2008  Kd=0.9uM      // 3cfs.pdf (18-mer) Kd1=0.9uM(intrinsic tryptophan fluorescence); Kd2=1uM(surface plasmon resonance, SPR)
3ckb  2.30  2008  Kd=1.04mM     // 3ck7.pdf (MLR) Kd=1.04+/-0.017mM
3btl  2.90  2008  Kd=1.09uM     // 3bt9.pdf (MGR) Kd=1.09+/-0.07uM, redundant to 3btk in reference
2rcn  2.25  2008  Kd=1.0uM      // 2rcn.pdf (GDP) Kd=1.0+/-0.3uM
2z97  1.80  2008  Kd=1.0uM      // 2z97.pdf (7HE) one-legged heme-reconstituted P450cam; Kd=1.0+/-0.15uM(putidaredoxin, Pdx)
2vmc  1.90  2008  Kd=1.15mM     // 2vmc.pdf (NGA) Kd for GalNAc, N-acetyl-D-galactosamine
3cfs  2.40  2008  Kd=1.1uM      // 3cfs.pdf (15-mer) Kd1=1.1uM(intrinsic tryptophan fluorescence); Kd2=1uM(surface plasmon resonance, SPR)
2pmk  1.60  2008  Kd=1.2uM      // 2pmk.pdf (128) Kd=1.2+/-0.1uM
3bim  2.60  2008  Kd=1.32uM     // 3bim.pdf (19-mer) BCL6 BTB domain dimer in complex with the BCOR BBD corepressor peptide, Kd=1.32+/-0.02uM; incomplete ligand
2k2r   NMR  2008  Kd=1.3mM      // 2k2r.pdf (10-mer)
3bu6  1.95  2008  Kd=1.3uM      // 3bu3.pdf (15-mer) incomplete ligand
3eeb  2.10  2008  Kd=1.3uM      // 3eeb.pdf (IHP) Kd=1.3+/-0.2uM
3buw  1.45  2008  Kd=1.49uM     // 3bum.pdf (13-mer) incomplete ligand
3e5u  1.83  2008  Kd=1.4uM      // 3e5u.pdf (3C4)
2zju  2.58  2008  Kd=1.557uM    // 2zju.pdf (IM4) Kd=1.57+/-0.21uM, n=3
3e1r  2.00  2008  Kd=1.5uM      // 3e1r.pdf (13-mer) Kd=1.5+/-0.2uM
2q88  1.90  2008  Kd=1.6uM      // 2q88.pdf (4CS) Kd=1.6+/-0.3uM
3btc  2.90  2008  Kd=1.77uM     // 3bt9.pdf (MGR) Kd=1.77+/-0.17uM
3d1e  1.90  2008  Kd=1.7uM      // 3d1e.pdf (10-mer) incomplete ligand
3eg6  1.72  2008  Kd=1.7uM      // 3eg6.pdf (13-mer) Kd=1.7+/-0.1uM, WDR5 bound to MLL1 peptide; incomplete ligand
2vyt  1.90  2008  Kd=1.84mM     // 2vyt.pdf (MLZ) Kd=1.84+/-0.19mM
3eml  2.60  2008  Kd=1.8nM      // 3eml.pdf (ZMA) in presence of 1 M NaCl  Kd=1+/-0.1nM, in absence of 1 M NaCl  Kd=1.8+/-0.2nM
3bzi  2.10  2008  Kd=1.8uM      // 2ojs.pdf (9-mer) incomplete ligand
2pqc  1.60  2008  Kd=1.8uM      // 2pq9.pdf (RC1) Kd=1800+/-600nM
3d1f  2.00  2008  Kd=1.8uM      // 3d1e.pdf (9-mer) DNA polymerase III subunit beta bounds to Nonapeptide from polymerase III C-terminal
2oz2  1.95  2008  Kd=1.93uM     // 2oz2.pdf (D1R) ligand is K11777, Ka=517, 000M-1, Kd=1.93uM
3bt9  2.75  2008  Kd=1.95uM     // 3bt9.pdf (DEQ) Kd=1.95+/-0.18uM
3c2f  2.35  2008  Kd=10.1mM     // 3c2f.pdf (PRP) Kd=10.1+/-3.3mM
3bxg  1.80  2008  Kd=10.98uM    // 2okg.pdf (BG6) protein from Bacillus subtilis; Kd=10.98+/-1.2uM
3bbb  1.30  2008  Kd=100nM      // 3bbb.pdf (2-mer) ligand is dinucleotide d(AG), Kd=100+/-20nM, Ki=280+/-30nM; binding data found in another reference
2rin  1.80  2008  Kd=100uM      // 2reg.pdf (ACH) Kd=100+/-12uM
3chg  2.80  2008  Kd=102uM      // 3chg.pdf (313) Kd=102+/-11uM
2rnw   NMR  2008  Kd=1051uM     // 2rnw.pdf (15-mer) Kd=1051+/-90uM
3c39  1.85  2008  Kd=109uM      // 3c39.pdf (3PG) ligand is 3-phosphoglycerate
2r6f  3.20  2008  Kd=10nM       // 2r6f.pdf (ADP) Kd  10nM
3c9e  1.80  2008  Kd=10nM       // 3c9e.pdf (E64)
3dba  2.57  2008  Kd=10nM       // 3dba.pdf (35G) Kd~10nM
2jqi   NMR  2008  Kd=10uM       // 2jqi.pdf (10-mer) Kd=10-20uM
2vpe  1.70  2008  Kd=11.4uM     // 2vp7.pdf (9-mer) hPHD-HD1 and 9-MER H3K4ME2, Kd=11.4+/-1.1uM
2vo4  1.75  2008  Kd=11.6uM     // 2vo4.pdf (4NM) binding of p-nitrophenol to GmGSTU4-4 and Nb-GSH complex; Kd=11.6+/-0.1uM
2eh8  2.60  2008  Kd=11nM       // 2eh7.pdf (11-mer) HzKR127 Fab with preS1 peptide, Kd=11+/-1.66nM; incomplete ligand
2jb6  2.85  2008  Kd=11pM       // 2jb5.pdf (T5C) MOR03268:TSC 2:1 complex, Kd2~11pM, Kd1=3.1nM
3cd5  2.39  2008  Kd=12.7nM     // 3cct.pdf (7HI) IC50=5.1nM
2vuk  1.50  2008  Kd=125uM      // 2vuk.pdf (P83) Kd=125+/-10uM (ITC); Kd=167+/-12uM (NMR)
3exh  2.44  2008  Kd=13.1uM     // 3exe.pdf (TPP) cofactor ThDP binding to phospho-S1-E1p in presence of Mn2+; Kd=13.1+/-1.1uM is for Mg2+
2z6w  0.96  2008  Kd=13.4nM     // 2z6w.pdf (11-mer)
3ccw  2.10  2008  Kd=13.5nM     // 3cct.pdf (4HI) IC50=7.9nM
3c94  2.70  2008  Kd=136nM      // 3c94.pdf (10-mer) Kd=136+/-11nM; incomplete ligand
3cd7  2.05  2008  Kd=14.3nM     // 3cct.pdf (882) IC50=1.8nM
3ds0  1.60  2008  Kd=14.9uM     // 3ds0.pdf (12-mer) Kd=14.9+/-0.9uM, ligand is Peptide inhibitor of capsid assembly(CAI)
2vmf  2.10  2008  Kd=1400nM     // 2vjx.pdf (MVL) ligand is compound 1a
3emh  1.37  2008  Kd=140nM      // 3emh.pdf (13-mer) WDR5 complex with Mixed-lineage leukemia protein 1, see supplement data; incomplete ligand
2k4i   NMR  2008  Kd=143uM      // 2k4h.pdf (PBU) Kd=143+/-16uM
3ck8  2.10  2008  Kd=146uM      // 3ck7.pdf (BCD) Kd=146+/-5uM
3e6v  1.72  2008  Kd=147nM      // 3e6k.pdf (ABH)
3c84  1.94  2008  Kd=14nM       // 3c79.pdf (TH4) dissociation kinetics Kd=14nM
3cj2  1.75  2008  Kd=14uM       // 3ciz.pdf (SX3) ligand is compound 7e, IC50=17uM
2jk9  1.79  2008  Kd=150nM      // 2jk9.pdf (15-mer) ligand is hPar-4, human prostate apoptosis(sequence is NELNNNLPGGAPAAP), Kd=150+/-12nM; incomplete ligand
2pym  1.90  2008  Kd=150nM      // 2pym.pdf (1UN) Kd=150+/-20nM; Ki=18+/-1nM.
3dnj  1.15  2008  Kd=150nM      // 3dnj.pdf (10-mer) Kd=150-500nM; incomplete ligand
3bl2  2.30  2008  Kd=1580nM     // 3bl2.pdf (19-mer) Kd=1580+/-98.3nM
3cyy  2.40  2008  Kd=16.8uM     // 3cyy.pdf (9-mer) Kd=16.8+/-1.1uM
2rcb  1.62  2008  Kd=163nM      // 2rc8.pdf (DSN) Kd=163+/-45nM
2r1x  1.60  2008  Kd=16uM       // 2r1w.pdf (2-mer) ligand is KDD-KDA; solution affinity
2zpk  1.80  2008  Kd=17.5nM     // 2zpk.pdf (8-mer)
3cpj  2.35  2008  Kd=18.9uM     // 3cph.pdf (GDP) Kd=18.9+/-2uM; Kd=5.8+/-0.5uM for Ypt31 delta2a
2w68  2.50  2008  Kd=18uM       // 2w68.pdf (3-mer) CBM40 from V. cholerae sialidase with different linkage sialosides, Kd=18uM for 3-SL
2r23  1.65  2008  Kd=190uM      // 2r1w.pdf (2-mer) ligand is KO1-KDA
2vfk  1.50  2008  Kd=194uM      // 2vfk.pdf (AMP) Kd=194+/-30uM
3d9k  2.20  2008  Kd=19uM       // 3d9k.pdf (14-mer) Kd=19+/-2uM, SCAF8 bound to RNA polymerase II CTD phosphorylated at Ser2, Ser5; incomplete ligand
3f9w  1.60  2008  Kd=19uM       // 3f9w.pdf (10-mer) Kd=19+/-2uM, SETD8(Y334F) with Histone H4(H4K20)
3d9o  2.00  2008  Kd=1mM        // 3d9k.pdf (14-mer) Kd>1mM, SCAF8(N15M/Y17M) bound to RNA polymerase II CTD unphosphorylated; incomplete ligand
3bze  2.50  2008  Kd=1uM        // 3bze.pdf (9-mer)
3ds1  1.60  2008  Kd=2.0uM      // 3ds0.pdf (12-mer) Kd=2.0+/-0.1uM, ligand is Peptide inhibitor of capsid assembly(CAI); incomplete ligand
2k0x   NMR  2008  Kd=2.1uM      // 2k0x.pdf (PNS) Kd=2.1+/-0.1uM, 2k0x is not a complex, only act holo-ACP
3b5j  2.00  2008  Kd=2.1uM      // 2pmk.pdf (12D) Kd=2.1+/-0.6uM
2vpg  1.60  2008  Kd=2.1uM      // 2vp7.pdf (18-mer) Kd=2.1+/-0.1uM; incomplete ligand
3f17  1.10  2008  Kd=2.36nM     // 3f15.pdf (HS4)
3bux  1.35  2008  Kd=2.36uM     // 3bum.pdf (13-mer) incomplete ligand
2qry  2.25  2008  Kd=2.3nM      // 2qry.pdf (TPS) Kd=2.3+/-0.6nM
2reg  1.90  2008  Kd=2.3uM      // 2reg.pdf (CHT) Kd=2.3+/-1.0uM
3bho  1.80  2008  Kd=2.44uM     // 3bho.pdf (B4P) Kd=2.44+/-0.49uM
3btj  2.98  2008  Kd=2.4uM      // 3bt9.pdf (DEQ) Kd=2.4+/-0.2uM
3c6w  1.75  2008  Kd=2.4uM      // 3c6w.pdf (12-mer) Kd=2.4+/-1.0uM; incomplete ligand
2jst   NMR  2008  Kd=2.6mM      // 2jst.pdf (HLT) Kd=2.6+/-1.7mM
3bex  1.51  2008  Kd=2.7uM      // 3bex.pdf (PAU) TmPanK-III dimer, Kd1=2.7+/-0.16uM; Kd2=6.4+/-0.24uM
3coz  2.00  2008  Kd=2.7uM      // 3cow.pdf (54H) Kd=2.7+/-0.1uM; Ki=18+/-3uM
3bxf  1.70  2008  Kd=2.87uM     // 2okg.pdf (FBP) protein from Bacillus subtilis; Kd=2.87+/-0.06uM
2rio  2.40  2008  Kd=20.4uM     // 2rio.pdf (ADP)
3bra  2.30  2008  Kd=2000uM     // 3bra.pdf (AEF)
2emt  2.80  2008  Kd=201nM      // 2emt.pdf (18-mer) incomplete ligand
3clp  2.00  2008  Kd=205.1uM    // 3cl1.pdf (CMP) R307A mutant Kd=205.1+/-10.4uM, R307E was even more severely reduced
3f3e  1.80  2008  Kd=20nM       // 3f3d.pdf (LEU)
2k62   NMR  2008  Kd=20uM       // 2k62.pdf (ITL) low Kd to 20uM
2qfo  1.68  2008  Kd=20uM       // 2qf6.pdf (A13) Kd(A13)=20+/-10uM, Ki(A13)=18+/-1uM; Kd(A51)=150+/-20uM
3ew2  2.30  2008  Kd=215nM      // 3ew2.pdf (BTN) X-ray(Rhizavidin-Biotin) while Kd(2-iminobiotin)
2rny   NMR  2008  Kd=218uM      // 2rnw.pdf (15-mer) Kd=213+/-13uM
2qv7  2.30  2008  Kd=219uM      // 2qv7.pdf (ADP) Kd=219+/-34uM
3f8c  2.20  2008  Kd=21nM       // 3f8c.pdf (HT1) Kd=21+/-8nM
3fat  1.90  2008  Kd=22.8nM     // 3fat.pdf (AMQ) Kd=22.8+/-1.5nM
3ery  1.95  2008  Kd=2200nM     // 3ery.pdf (9-mer) Kd=2200+/-260nM(ITC); Kd=1600+/-200nM(SPR equilibrium analysis); Kd=3400+/-500nM (SPR kinetic analysis)
3buh  2.30  2008  Kd=220uM      // 3bra.pdf (AED)
3cf1  4.40  2008  Kd=230nM      // 3cf1.pdf (ADP) Kd=230-630nM
3f8f  2.20  2008  Kd=236nM      // 3f8c.pdf (DM1) Kd=236+/-53nM
2z4r  3.05  2008  Kd=24nM       // 2z4r.pdf (ADP)
2k00   NMR  2008  Kd=24uM       // 2k00.pdf (15-mer) Kd1=15uM(pH=6.1; stopped-flow fluorescence); Kd2=24uM(pH=6.5; stopped-flow fluorescence); Kd3=23uM(ITC).
3cwk  1.60  2008  Kd=250nM      // 3cwk.pdf (REA) Kd=250+/-19nM
2pyy  2.10  2008  Kd=25uM       // 2pyy.pdf (GLU)
2r1w  1.70  2008  Kd=25uM       // 2r1w.pdf (KDB) solution affinity
3d7k  2.49  2008  Kd=25uM       // 3d7k.pdf (D7K)
3cda  2.07  2008  Kd=26.3nM     // 3cct.pdf (8HI) IC50=3.0nM
2k46   NMR  2008  Kd=26.3uM     // 2k46.pdf (NGR) Kd=26.3+/-0.7uM
3cd0  2.40  2008  Kd=26.9nM     // 3cct.pdf (6HI) IC50=2.9nM
2v7d  2.50  2008  Kd=260nM      // 2v7d.pdf (10-mer) incomplete ligand
3cct  2.12  2008  Kd=27.4nM     // 3cct.pdf (3HI)
2jiu  3.05  2008  Kd=27.6nM     // 2jiu.pdf (AEE) Kd=27.6+/-0.7nM
2pyn  1.85  2008  Kd=27nM       // 2pym.pdf (1UN) Kd=27+/-5nM; Ki=7.0+/-0.4nM.
3b2q  2.10  2008  Kd=28uM       // 3b2q.pdf (ATP) Kd=28+/-2uM
3d9p  2.10  2008  Kd=29uM       // 3d9k.pdf (14-mer) Kd=29+/-3uM, SCAF8(R112T) bound to RNA polymerase II CTD phosphorylated at Ser2, Ser5; incomplete ligand
3brn  2.00  2008  Kd=2nM        // 3brn.pdf (SRO) monotonin in complex with (5-HT)serotonin, Kd<=2nM
2zbk  3.56  2008  Kd=2uM        // 2zbk.pdf (RDC) Kd=2-2.3uM
3c4h  2.10  2008  Kd=2uM        // 3c49.pdf (DRL) Kd=2+/-0.2uM
3eks  1.80  2008  Kd=2uM        // 3eks.pdf (CY9) Kd=2~20uM
2q64  2.50  2008  Kd=3.0nM      // 2pym.pdf (1UN) Kd=3.0+/-0.5nM; Ki=1.4+/-0.2nM.
3c1n  2.72  2008  Kd=3.13uM     // 3c1n.pdf (THR) The Allosteric Binding Sites; for the primary binding site, Kd=3.13+/-0.16 uM;  for the secondary binding site, Kd=30.5+/-0.03uM
2qtr  1.70  2008  Kd=3.2uM      // 2qtn.pdf (NXX) Kd=3.2+/-0.8uM, nicotinate adenine dinucleotide (NaAD)
3bvb  1.30  2008  Kd=3.2uM      // 3bva.pdf (017) Ka=(3.17+/-0.29)e+5M-1
3bxe  1.80  2008  Kd=3.34uM     // 2okg.pdf (13P) protein from Bacillus subtilis; Kd=3.34+/-0.15uM
2qic  2.10  2008  Kd=3.3uM      // 2qic.pdf (12-mer) Kd=3.3+/-1.6uM; incomplete ligand
2zkj  2.00  2008  Kd=3.3uM      // 2zkj.pdf (ADP) Kd=3.3+/-0.7uM(without AZD7545); Kd=5.9+/-0.9uM(with AZD7545)
3d2r  2.03  2008  Kd=3.3uM      // 2zkj.pdf (ADP) Kd=3.3+/-0.7uM(without AZD7545); Kd=5.9+/-0.9uM(with AZD7545); redundant to 2zkj
2vc9  2.36  2008  Kd=3.6nM      // 2vc9.pdf (NOK) Kd=3.6+/-0.3nM; Ki=21nM
2vpo  1.80  2008  Kd=3.8uM      // 2vpn.pdf (6CS) Kd=3.80+/-0.07uM
3bzf  2.50  2008  Kd=30uM       // 3bze.pdf (9-mer)
2r0h  1.90  2008  Kd=310uM      // 2r0h.pdf (CTO) Kd=310+/-4uM
2r1y  1.60  2008  Kd=31uM       // 2r1w.pdf (2-mer) ligand is KDO-KDR
3f9y  1.50  2008  Kd=32uM       // 3f9w.pdf (10-mer) Kd=32+/-1uM, SETD8(Y334F) with Histone H4(H4K20me1); incomplete ligand
3d9m  1.75  2008  Kd=330uM      // 3d9k.pdf (14-mer) Kd=330+/-50uM, SCAF8 bound to RNA polymerase II CTD phosphorylated at Ser5; incomplete ligand
3d32  1.30  2008  Kd=354nM      // 3d32.pdf (12-mer)
2zit  3.00  2008  Kd=35uM       // 2zit.pdf (NAD) eEF2-ExoA-NAD+ complex, Kd=35+/-3uM
3b82  2.35  2008  Kd=37uM       // 2zit.pdf (NAD) eEF2-ExoA(E546H mutant)-NAD+ complex, relative kd=1.03 fold of 35+/-3uM
2qtn  2.40  2008  Kd=382uM      // 2qtn.pdf (NCN) Kd=382+/-38uM for nicotinate mononucleotide (NaMN)
2zdm  1.93  2008  Kd=386nM      // 2zdk.pdf (46U) ligand is compound 2b(closed form); Kd=386+/-49nM; Ki=208+/-92nM
3f18  1.13  2008  Kd=39.5nM     // 3f15.pdf (HS5)
3bf1  2.30  2008  Kd=3mM        // 3bex.pdf (ADP) TmPanK-III-Pan-ADP ternary complex; Kd=3+/-0.5mM
2vw5  1.90  2008  Kd=3nM        // 2vw5.pdf (BC6) ligand is compound 5
2vnf  1.76  2008  Kd=3uM        // 2vnf.pdf (10-mer) Kd=3+/-0.6uM, Calorimetric titrations H310K4me3 Kd=6.4+/-0.8uM; incomplete ligand
3b4p  1.70  2008  Kd=4.0uM      // 3b4p.pdf (3B4) Kd=4.0+/-0.6uM
3f6e  1.34  2008  Kd=4.14mM     // 3f6b.pdf (8PA)
2zdl  1.80  2008  Kd=402nM      // 2zdk.pdf (45U) ligand is compound 2a(closed form); Kd=402+/-78nM; Ki=285+/-74nM
2rnx   NMR  2008  Kd=402uM      // 2rnw.pdf (13-mer) Kd=402+/-93uM
2qhr  2.00  2008  Kd=41nM       // 2qhr.pdf (11-mer) IC50    .5uM
3c3r  2.02  2008  Kd=41uM       // 3c3o.pdf (13-mer) Kd=41+/-10uM
2pr9  2.51  2008  Kd=42.2nM     // 2pr9.pdf (10-mer)
2zdk  1.67  2008  Kd=428nM      // 2zdk.pdf (50U) ligand is compound 3b(closed form); Kd=428+/-38nM; Ki=226+/-119nM
3dp4  2.11  2008  Kd=43nM       // 3dp4.pdf (AMQ) Kd=43+/-5nM
2zif  2.40  2008  Kd=43uM       // 2zif.pdf (SAM)
3c3o  2.15  2008  Kd=44uM       // 3c3o.pdf (13-mer) Kd=44+/-6uM
3feg  1.30  2008  Kd=45uM       // 3feg.pdf (HC7) ligand is HC-3; Kd=45+/-5uM; Ki=116+/-15uM
3c3q  2.10  2008  Kd=48uM       // 3c3o.pdf (18-mer) Kd=48+/-6uM
3bbf  1.70  2008  Kd=5.2uM      // 3bbb.pdf (GDP) Kd=5.2+/-0.8uM
3coj  3.21  2008  Kd=5.2uM      // 3coj.pdf (13-mer) incomplete ligand
2oz6  2.80  2008  Kd=5.5uM      // 2oz6.pdf (CMP)
2vcb  2.20  2008  Kd=5.5uM      // 2vc9.pdf (OAN) Ki=6.2+/-0.1uM, Kd=5.5+/-0.3uM
2k3w   NMR  2008  Kd=5.8uM      // 2k3w.pdf (16-mer) Kd=5.8+/-0.8uM; incomplete ligand
3f16  1.16  2008  Kd=5.91nM     // 3f15.pdf (HS3) Kd=5.91nM(D); Kd=41.5nM(L)
2vvn  1.85  2008  Kd=50nM       // 2vvn.pdf (NHT)
2q7y  1.95  2008  Kd=50uM       // 2q7y.pdf (IGC)
3ccz  1.70  2008  Kd=51.7nM     // 3cct.pdf (5HI) IC50=1.1nM
3f48  1.90  2008  Kd=512nM      // 3f3d.pdf (ALA)
3cr4  2.15  2008  Kd=53uM       // 3cr4.pdf (PNT) ITC Pnt Kd=53+/-10uM, fluorescence Pnt Kd=39+/-3uM
2zdn  1.98  2008  Kd=562nM      // 2zdk.pdf (49U) ligand is compound 3a(closed form); Kd1=562+/-66nM; Kd2=584+/-107nM(Tricine); Kd3=506+/-34M(Hepes); Kd4=416+/-42nM(PPi); Ki=290+/-65nM
2qbw  1.80  2008  Kd=56nM       // 2qbw.pdf (8-mer) Kd=56+/-5nM; IC50=40nM
3bjm  2.35  2008  Kd=5nM        // 3bjm.pdf (BJM) ITC Kd<=5nM, while Ki=500pM
3btr  2.60  2008  Kd=5uM        // 3btr.pdf (15-mer) Kd=5+/-0.1uM
3ds3  2.70  2008  Kd=6.0uM      // 3ds0.pdf (12-mer) Kd=6.0+/-0.4uM, ligand is Peptide inhibitor of capsid assembly(CAI)
3b2t  1.80  2008  Kd=6.21uM     // 3b2t.pdf (M33) Kd=6.21+/-2.1uM
2pqj  2.80  2008  Kd=6.33nM     // 2pqj.pdf (ADE) Kd=6.33+/-0.73nM; IC50=0.37uM
3blr  2.80  2008  Kd=6.4nM      // 3blr.pdf (CPB) ligand is Flavopiridol
3ctr  2.10  2008  Kd=6.94uM     // 3ctr.pdf (MGP) Kd=6.94+/-2.08uM
2jb5  2.80  2008  Kd=600pM      // 2jb5.pdf (T5C) MOR03268:TSC 1:1 complex, Kd=600+/-300pM
3cyu  1.70  2008  Kd=60nM       // 3cyu.pdf (0CR) Kd=60+/-20nM
3f80  1.60  2008  Kd=60uM       // 3f80.pdf (6HN)
3f1a  1.25  2008  Kd=61.1nM     // 3f15.pdf (HS7)
3b8h  2.50  2008  Kd=63.7uM     // 2zit.pdf (NAD) eEF2-ExoA(E546A mutant)-NAD+ complex, relative kd=1.77 fold of 35+/-3uM
2pqb  1.80  2008  Kd=63nM       // 2pq9.pdf (GG9) Kd=63+/-15nM
3c79  2.48  2008  Kd=63nM       // 3c79.pdf (IM4) dissociation kinetics Kd=63nM; association kinetics Kd=68+/-23nM
3eov  2.60  2008  Kd=63nM       // 3eov.pdf (11-mer) Kd=63nM (Fluorescence), 15.15nM(ITC)
2r2b  1.60  2008  Kd=63uM       // 2r1w.pdf (3-mer) ligand is KDA-KDO-KDO
3ds4  1.12  2008  Kd=64.5uM     // 3ds0.pdf (12-mer) Kd=64.5+/-21.8uM, ligand is Peptide inhibitor of capsid assembly(CAI)
2pmc  2.69  2008  Kd=64.7uM     // 2pl9.pdf (15-mer) X-ray structure:CheY-CheZC15; Kd1=64.7+/-3.1uM(CheY-CheZC15); Kd2=13.2+/-2.1uM(P-CheY-CheZC15); incomplete ligand
3cr5  1.85  2008  Kd=64uM       // 3cr5.pdf (PNT) Kd=64+/-15uM(low salt; ITC); Kd=35+/-12uM(high salt; ITC);
3f19  1.13  2008  Kd=65.1nM     // 3f15.pdf (HS6)
2qhm  2.00  2008  Kd=660nM      // 2qhm.pdf (7CS)
3bug  2.50  2008  Kd=660uM      // 3bra.pdf (AEH)
2q63  2.20  2008  Kd=66nM       // 2pym.pdf (1UN) Kd=66+/-8nM; Ki=9.9+/-0.7nM.
2pl9  2.60  2008  Kd=67.4uM     // 2pl9.pdf (19-mer) X-ray structure:CheY-CheZC19; Kd1=67.4+/-4.5uM(CheY-CheZC19); Kd2=2.2+/-0.2uM(P-CheY-CheZC19).
2vxj  1.90  2008  Kd=68uM       // 2vxj.pdf (3-mer) Kd by ITC
3d9l  2.20  2008  Kd=68uM       // 3d9k.pdf (14-mer) Kd=68+/-8uM, SCAF8 bound to RNA polymerase II CTD phosphorylated at Ser2; incomplete ligand
3f3d  2.30  2008  Kd=69nM       // 3f3d.pdf (MET)
2rfy  1.70  2008  Kd=6uM        // 2rfy.pdf (CBI)
3bu1  1.40  2008  Kd=7.1nM      // 3brn.pdf (HSM) Kd=7.1+/-1.0nM
2zjv  2.70  2008  Kd=7.26uM     // 2zju.pdf (CT4) Kd=7.26+/-1.13uM, n=3
2k2g   NMR  2008  Kd=7.5nM      // 2k2g.pdf (DSV)
3f15  1.70  2008  Kd=7.88nM     // 3f15.pdf (HS1)
2pnx  1.80  2008  Kd=7.9uM      // 2pnx.pdf (12-mer) PHD finger of ING4 complex with an H3K4Me3 histone peptide, Kd=7.9+/-2uM; incomplete ligand
2r75  1.40  2008  Kd=714nM      // 2r75.pdf (01G) Kd=714+/-51nM; IC50(Polymerization)=139uM; IC50(GTPase); =179+/-15uM.
3cgy  2.60  2008  Kd=715uM      // 3cgy.pdf (RDC) Kd=715+/-78uM
3d2t  1.85  2008  Kd=75nM       // 3d2t.pdf (1FL)
3b95  2.99  2008  Kd=7uM        // 3b95.pdf (15-mer) Kd=7+/-1uM; incomplete ligand
3e6k  2.10  2008  Kd=7uM        // 3e6k.pdf (ABH)
2zg1  2.70  2008  Kd=8.0mM      // 2zg1.pdf (SIA)
2zg3  3.00  2008  Kd=8.7mM      // 2zg1.pdf (SIA)
3d62  2.70  2008  Kd=800nM      // 3d62.pdf (959) Ki=400+/-71nM; incomplete ligand structure
3buf  2.30  2008  Kd=800uM      // 3bra.pdf (AEG)
3b78  2.50  2008  Kd=80uM       // 2zit.pdf (NAD) eEF2-ExoA(R551H mutant)-NAD+ complex, relative kd=2.29 fold of 35+/-3uM
3ck7  2.10  2008  Kd=89uM       // 3ck7.pdf (ACX) Kd=89+/-4uM
2qt5  2.30  2008  Kd=9.4uM      // 2qt5.pdf (9-mer) Kd=9.4+/-0.3uM; incomplete ligand
3d9n  1.60  2008  Kd=90uM       // 3d9k.pdf (14-mer) Kd=90+/-4uM, SCAF8 bound to RNA polymerase II CTD phosphorylated at Ser7; incomplete ligand
3bxh  1.85  2008  Kd=94.34uM    // 2okg.pdf (F6P) protein from Bacillus subtilis; Kd=94.34+/-3.1uM
3dsu  1.90  2008  Kd=94nM       // 3dss.pdf (FPP) RabGGTase-FPP complex, co-titration Kd=94+/-14nM, displacement titration Kd=75+/-10nM
3eyf  2.30  2008  Kd=94nM       // 3eyf.pdf (11-mer) Kd1=94nM(T=297K; ITC); Kd2=43nM(T=287K; ITC); Kd3=240nM(T=307K; ITC); Kd4=34nM(T=285K; Biacore analysis); Kd5=120nM(T=297K; Biacore analysis); incomplete ligand
3cdb  2.30  2008  Kd=95.7nM     // 3cct.pdf (9HI) IC50=5.82nM
2qbp  2.50  2008  Ki=0.004uM    // 2qbp.pdf (527)
3e0p  1.70  2008  Ki=0.012uM    // 3e0p.pdf (B3C) compound 23
3c56  2.30  2008  Ki=0.013uM    // 3c52.pdf (PH4) ligand is compound 2
2qi5  1.85  2008  Ki=0.014nM    // 2qhy.pdf (MZ7) ligand is inhibitor 32c
2qi6  1.85  2008  Ki=0.027nM    // 2qhy.pdf (MZ8) ligand is inhibitor 28a
2qi4  1.80  2008  Ki=0.036nM    // 2qhy.pdf (MZ6) ligand is inhibitor 30a
2qbq  2.10  2008  Ki=0.036uM    // 2qbp.pdf (4B3)
2r38  1.81  2008  Ki=0.036uM    // 2r38.pdf (G4G) compound 9 in complex with HIV-1 protease I84V
3ekr  2.00  2008  Ki=0.03uM     // 3eko.pdf (PY9) ligand is compound 14; Ki=0.03uM, IC50=0.06uM, cell IC50=4uM
2p59  2.90  2008  Ki=0.05uM     // 2p59.pdf (GG4) Replicon IC50=0.37um
3c52  2.30  2008  Ki=0.05uM     // 3c52.pdf (PGH)
2qi7  1.85  2008  Ki=0.062nM    // 2qhy.pdf (MZ9) ligand is inhibitor 29b
2qi3  1.95  2008  Ki=0.063nM    // 2qhy.pdf (MZ5) ligand is inhibitor 30d
2qnn  1.48  2008  Ki=0.07uM     // 2pqz.pdf (QN1) ligand is inhibitor 6fg
2r3w  1.92  2008  Ki=0.128uM    // 2r38.pdf (G3G) compound 8 in complex with HIV-1 protease I84V
2vnp  2.19  2008  Ki=0.12nM     // 2vnp.pdf (DED)
3bc3  2.20  2008  Ki=0.155uM    // 3bc3.pdf (OPT) compound 2
2rfh  1.70  2008  Ki=0.15uM     // 2rfh.pdf (23N)
2zq0  1.60  2008  Ki=0.15uM     // 2zq0.pdf (ACR) Ki=0.15+/-0.03uM
2v2h  1.18  2008  Ki=0.17mM     // 2v2c.pdf (PGA) Ki=0.17+/-0.06mM
3e8r  1.90  2008  Ki=0.18nM     // 3e8r.pdf (615)
2qbs  2.10  2008  Ki=0.21uM     // 2qbp.pdf (024)
2za0  1.70  2008  Ki=0.23uM     // 2za0.pdf (MGI) Ki=0.23+/-0.1uM
2zb0  2.10  2008  Ki=0.24uM     // 2zaz.pdf (GK3) IC50=1.5uM
2pwr  1.50  2008  Ki=0.26uM     // 2pqz.pdf (G4G) ligand is inhibitor 6fd
2pvh  2.20  2008  Ki=0.26uM     // 2pvh.pdf (P19)
2z4o  1.60  2008  Ki=0.27nM     // 2qci.pdf (065) Ki=0.27+/-0.06nM
2pwc  1.78  2008  Ki=0.27uM     // 2pqz.pdf (G3G) ligand is inhibitor 6gd
3bm8  2.70  2008  Ki=0.29mM     // 3blu.pdf (PSY) Ki=0.29+/-0.06mM for YopH/PVSN, not D365A mutant
2vh6  1.95  2008  Ki=0.2nM      // 2vh6.pdf (GSV) ligand is compound 21
3eko  1.55  2008  Ki=0.2uM      // 3eko.pdf (PYU) ligand is compound 1; Ki=0.2uM, IC50=0.4uM, cell IC50 >20uM
2p4s  2.20  2008  Ki=0.31nM     // 2p4s.pdf (DIH)
2r6y  2.00  2008  Ki=0.32nM     // 2r6w.pdf (LLC) compound LY117018
2qf6  3.10  2008  Ki=0.32uM     // 2qf6.pdf (A56) ki=0.32+/-0.04uM
3blu  2.00  2008  Ki=0.35mM     // 3blu.pdf (PVS) Ki=0.35+/-0.06mM
2pvn  2.00  2008  Ki=0.35nM     // 2pvh.pdf (P63) Ki=0.00035uM
3c1k  1.84  2008  Ki=0.36nM     // 3c1k.pdf (T15) compound 15
2pvm  2.00  2008  Ki=0.36uM     // 2pvh.pdf (P29)
2v2c  1.89  2008  Ki=0.39mM     // 2v2c.pdf (PGA) Ki=0.39+/-0.14mM
2qnp  1.41  2008  Ki=0.39uM     // 2pqz.pdf (QN2) ligand is inhibitor 6af
2vw1  2.39  2008  Ki=0.3mM      // 2vw1.pdf (DAN)
3ckp  2.30  2008  Ki=0.449uM    // 3ckp.pdf (012)
2r6w  2.00  2008  Ki=0.44nM     // 2r6w.pdf (LLB) compound LY156681
2qbr  2.30  2008  Ki=0.47uM     // 2qbp.pdf (910)
2w26  2.08  2008  Ki=0.4nM      // 2w26.pdf (RIV) morpholinone derivative 5, Ki=0.4nM, IC50=0.7nM
2zaz  1.80  2008  Ki=0.4uM      // 2zaz.pdf (GK1) IC50=2.5uM
3b65  1.80  2008  Ki=0.54nM     // 3b5r.pdf (3B6) ligand is compound s-24; Ki=0.54+/-0.03nM
2vw2  1.70  2008  Ki=0.5mM      // 2vw1.pdf (NHE)
2osm  1.60  2008  Ki=0.631uM    // 2osf.pdf (HTS) compound 4, Ki=0.631+/-0.034uM
2qrp  1.86  2008  Ki=0.63uM     // 2qrg.pdf (S06) ligand is compound 4e, Ki=0.63+/-0.02uM
3bkl  2.18  2008  Ki=0.679uM    // 3bkk.pdf (KAW)
2ri9  1.95  2008  Ki=0.6mM      // 2ri9.pdf (LDY)
2qnq  2.30  2008  Ki=0.77uM     // 2pqz.pdf (QN3) ligand is inhibitor 6cd
2qmg  1.89  2008  Ki=0.7nM      // 2qmg.pdf (SC6) ligand is inhibitor 11; cell line IC50=21nM
3d91  2.20  2008  Ki=0.7nM      // 3d91.pdf (REM) ligand is compound 12 (remikiren)
3bh3  2.10  2008  Ki=0.7uM      // 3bh3.pdf (PNH)
2qd7  1.11  2008  Ki=0.80nM     // 2qci.pdf (065) Ki=0.80+/-0.06nM
2rkf  1.80  2008  Ki=0.83nM     // 2rkf.pdf (AB1) Ki=0.83+/-0.11nM
3bkk  2.17  2008  Ki=0.83uM     // 3bkk.pdf (KAF)
2qd8  1.35  2008  Ki=0.85nM     // 2qci.pdf (065) Ki=0.85+/-0.15nM
3cke  2.40  2008  Ki=0.8uM      // 3bnx.pdf (FDF)
3bgb  1.90  2008  Ki=0.9uM      // 3bgb.pdf (LJG) ligand is compound 9b
3d04  2.40  2008  Ki=0.9uM      // 3cf8.pdf (SAK) IC50=2+/-0.1uM, Ki=0.9+/-0.1uM
2vqt  2.10  2008  Ki=1.0uM      // 2vjx.pdf (15A) ligand is compound 2a
2z7g  2.52  2008  Ki=1.13nM     // 2z7g.pdf (EH9) ligand is compound 2, (+)-EHNA
2qhc  2.80  2008  Ki=1.1nM      // 2qhc.pdf (AB1) Ki=1.1+/-0.3nM
3c2u  1.30  2008  Ki=1.25mM     // 3c2u.pdf (B3P) Ki=1.25+/-0.03mM(pH=8.0)
2v6n  1.98  2008  Ki=1.38uM     // 2v6n.pdf (XP1) IC50=0.1uM, Wu et al. (2006) reported a Ki value of 17.4 nM
3b67  1.90  2008  Ki=1.4nM      // 3b5r.pdf (B67) ligand is compound c-23; Ki=1.4+/-0.3nM
3e93  2.00  2008  Ki=1.4nM      // 3e92.pdf (19B) ligand is compound 19, Ki=1.4nM
2r3t  1.80  2008  Ki=1.4uM      // 2r38.pdf (G4G) compound 9 in complex with HIV-1 protease I50V
2zcq  2.38  2008  Ki=1.5nM      // 2zcp.pdf (B65) IC50=100~300nM
3d1z  1.30  2008  Ki=1.6nM      // 3cyw.pdf (017) Ki=1.6+/-0.1nM
3b5r  1.80  2008  Ki=1.7nM      // 3b5r.pdf (B5R) ligand is compound c-31; Ki=1.7+/-0.2nM
3bqc  1.50  2008  Ki=1.85uM     // 3bqc.pdf (EMO) crystal structure in high pH
2vkm  2.05  2008  Ki=1.8nM      // 2vkm.pdf (BSD) inhibitor 24; IC50=1nM in Chinese hamster cells
2rkd  1.90  2008  Ki=1.9mM      // 2rk7.pdf (3PP) ligand is analogue 12, Ki=1.9+/-0.4mM
3ckz  1.90  2008  Ki=1.9nM      // 3ckz.pdf (ZMR) relative Ki=1.9*0.1nM
2qg0  1.85  2008  Ki=1.9uM      // 2qf6.pdf (A94) Ki=1.9+/-0.2uM
2w54  3.30  2008  Ki=103.6nM    // 2w3r.pdf (HHR) Wild-type R.capsulatus XDH complex with pterin-6-aldehyde; Ki=103.57+/-18.96nM
3cyx  1.20  2008  Ki=10nM       // 3cyw.pdf (ROC) Ki=10+/-1nM
3e92  2.00  2008  Ki=10nM       // 3e92.pdf (G6A) ligand is compound 6, Ki=10nM
3d1g  1.64  2008  Ki=10uM       // 3d1e.pdf (322) RU7 compound binds to DNA polymerase III subunit beta
2vi5  2.30  2008  Ki=110uM      // 2vi5.pdf (Y19) compound 33, Ki =110+/-14uM
2z7h  2.08  2008  Ki=115nM      // 2p1c.pdf (GG3) Ki=115nM, IC50=4.17uM
2vjx  1.85  2008  Ki=11uM       // 2vjx.pdf (IFL) ligand is compound 6
3d67  3.40  2008  Ki=11uM       // 3d67.pdf (GEM)
2e9v  2.00  2008  Ki=12.59nM    // 2e9v.pdf (85A) SMILES line in SI file is: pKi_Experiment=7.9, pKi_MMPBSA=44
3cf8  2.40  2008  Ki=12.7uM     // 3cf8.pdf (QUE) IC50=39.3+/-2.7uM, Ki=12.7+/-0.6uM
2uy0  1.76  2008  Ki=120nM      // 2uxz.pdf (HV1) ligand is compound 15
3bl0  1.90  2008  Ki=121nM      // 3bl0.pdf (BL0) ligand is compound 5
2qw1  1.70  2008  Ki=125uM      // 2qw1.pdf (3MG) Ki=125+/-15uM
2q7o  2.90  2008  Ki=12nM       // 2q7o.pdf (IMH) compound 2, Ki*=12000pM
3d7z  2.10  2008  Ki=12nM       // 3d7z.pdf (GK5) ligand is compound 3, IC50=75nM
3f0r  2.54  2008  Ki=130nM      // 3f0r.pdf (TSN) ligand is compound trichostatin A
2zcr  1.92  2008  Ki=135nM      // 2zcp.pdf (B69)
2zn7  2.10  2008  Ki=13nM       // 2zmm.pdf (410)
2vo5  2.30  2008  Ki=13uM       // 2vjx.pdf (VBZ) ligand is compound 4a
3d4z  1.39  2008  Ki=13uM       // 3d4y.pdf (GIM)
3cf9  2.60  2008  Ki=14.9uM     // 3cf8.pdf (AGI) IC50=11+/-2.5uM, Ki=14.9+/-0.3uM
3ewj  1.80  2008  Ki=143nM      // 3ewj.pdf (642) ligand is compound 21
2osf  1.60  2008  Ki=148uM      // 2osf.pdf (TH0) compound 3, Ki(TH0)=148+/-39uM, Ki(S24)=314+/-69uM, IC50(S24)=1.77uM
1w12  2.40  2008  Ki=14nM       // 1w0z.pdf (SL1)
3dd8  1.90  2008  Ki=14nM       // 3dd8.pdf (2C7)
3efk  2.20  2008  Ki=14nM       // 3efj.pdf (MT4) compound 50, Ki=14+/-1nM
2r9x  1.90  2008  Ki=14uM       // 2pu2.pdf (WH6)
2ra0  2.30  2008  Ki=15.9nM     // 2ra0.pdf (JNJ) ligand is compound 51a
3c88  1.60  2008  Ki=157nM      // 3c88.pdf (5-mer)
3d94  2.30  2008  Ki=157nM      // 3d94.pdf (D94) Ki=157nM, IC50=118nm
3czv  2.00  2008  Ki=16nM       // 3czv.pdf (AZM) Ki=16+/-0.7nM
3fas  1.40  2008  Ki=171nM      // 3fas.pdf (GLU)
2pyi  1.88  2008  Ki=179uM      // 2pyi.pdf (DL8) Ki=179+/-11uM
3cyw  1.40  2008  Ki=17nM       // 3cyw.pdf (017) Ki=17+/-2nM
3d50  1.79  2008  Ki=17uM       // 3d4y.pdf (OEV)
2zc9  1.58  2008  Ki=180nM      // 2zc9.pdf (22U) ligand is compound 2, Ki=180+/-140nM
2zgx  1.80  2008  Ki=180nM      // 2zc9.pdf (29U) ligand is compound 4, Ki=180+/-30nM
2jt5   NMR  2008  Ki=18nM       // 2jt5.pdf (JT5)
3b7u  1.90  2008  Ki=18nM       // 3b7u.pdf (KEL) ligand is KELatorphan
2qrh  1.83  2008  Ki=19.6uM     // 2qrg.pdf (M08) ligand is compound 4c, Ki=19.6+/-0.2uM
3b9g  1.40  2008  Ki=19uM       // 3b9g.pdf (IMH) Ki=6.2nM for wt TvNH
2rka  1.95  2008  Ki=1mM        // 2rk7.pdf (PGA) ligand is analogue 13, Ki=1.0+/-0.04mM
2p4y  2.25  2008  Ki=1nM        // 2p4y.pdf (C03)
2r43  1.58  2008  Ki=1uM        // 2r38.pdf (G3G) compound 8 in complex with HIV-1 protease I50V
3ddg  1.74  2008  Ki=1uM        // 3ddf.pdf (GB7) ligand is compound 12, measured at 20C
3bar  1.90  2008  Ki=2.0uM      // 2q8z.pdf (U5P) Mt Ki=0.19+/-0.01uM, Pf Ki=2.0+/-0.1uM
2pqz  1.55  2008  Ki=2.15uM     // 2pqz.pdf (G0G) ligand is inhibitor 6ad
2qd6  1.28  2008  Ki=2.1nM      // 2qci.pdf (065) Ki=2.1+/-0.4nM
2q8z  1.80  2008  Ki=2.1uM      // 2q8z.pdf (NUP) Ki=2.1uM (source pf); Ki=0.84+/-0.025uM (source mt)
2vr4  1.80  2008  Ki=2.1uM      // 2vjx.pdf (17B) compound 2c
3d1x  1.05  2008  Ki=2.2nM      // 3cyw.pdf (ROC) Ki=2.2+/-0.3nM
2qlm  2.10  2008  Ki=2.3uM      // 2qlm.pdf (F68) ligand is compound 25
3bl1  2.10  2008  Ki=2.52uM     // 3bl1.pdf (BL1) ligand is compound 10
3b66  1.65  2008  Ki=2.5nM      // 3b5r.pdf (B66) ligand is compound s-21; Ki=2.5+/-0.2nM
2qp6  1.45  2008  Ki=208nM      // 2qp6.pdf (MB1) inhibitor 1, Human, recombinant isozymes.
3b7r  1.81  2008  Ki=20nM       // 2r59.pdf (BIR) Ki=20+/-4nM for inhibitor RB3040
2ves  1.90  2008  Ki=20nM       // 2ves.pdf (GVR)
1w0z  1.90  2008  Ki=21nM       // 1w0z.pdf (SI1)
2p1c  2.45  2008  Ki=21nM       // 2p1c.pdf (GG3) Ki=21nM, IC50=250nM
3cs7  2.20  2008  Ki=21pM       // 3cs7.pdf (LG0) ligand is compound 2r
2yz3  2.30  2008  Ki=220nM      // 2yz3.pdf (M5P)
3ddf  1.20  2008  Ki=22uM       // 3ddf.pdf (GB6) ligand is compound 11, measured at 20C
3egk  2.20  2008  Ki=22uM       // 3egk.pdf (M18) compound 5
2rk8  2.00  2008  Ki=230uM      // 2rk7.pdf (PPF) ligand is analogue 10, Ki=230+/-14uM
3dln  1.91  2008  Ki=249nM      // 3dln.pdf (GLU) ligand is glutamate
2pvl  1.90  2008  Ki=24nM       // 2pvh.pdf (P55)
3be9  2.00  2008  Ki=24nM       // 3be9.pdf (P04) ligand is compound 10; IC50=0.29uM (HCT116), IC50=0.88uM (PC3)
3cl2  2.54  2008  Ki=25.9nM     // 3ckz.pdf (G39) relative Ki=81*0.32nM
2jt6   NMR  2008  Ki=25nM       // 2jt5.pdf (JT6)
2zmm  2.10  2008  Ki=25nM       // 2zmm.pdf (35B) ligand is compound 8
2v54  2.40  2008  Ki=25uM       // 2v54.pdf (TYD) Ki=25+/-5uM
3djk  1.00  2008  Ki=26pM       // 3djk.pdf (G55) ligand is compound 3d, Ki=26pM, IC50=5nM
1w10  2.00  2008  Ki=28nM       // 1w0z.pdf (SJ1)
1w13  2.00  2008  Ki=2nM        // 1w0z.pdf (SM1)
2vj8  1.80  2008  Ki=2nM        // 2vj8.pdf (HA2) peptidase activity Ki=0.002uM, Epoxide hydrolase activity IC50=0.15uM
3bla  2.60  2008  Ki=2nM        // 3bl7.pdf (DD3) IC50~2nM
3eqr  2.00  2008  Ki=2nM        // 3eqp.pdf (T74) ligand is compound 2; Ki=0.002uM; IC50=0.01uM in cell lines
3d4y  1.52  2008  Ki=2uM        // 3d4y.pdf (MVL)
2vh0  1.70  2008  Ki=3.1nM      // 2vh0.pdf (GSI) ligand is compound 15
3bmq  1.70  2008  Ki=3.2uM      // 3bmc.pdf (AX5) Pteridine Reductase 1 complex NADP+ and AX5 compound 17, Ki=3.2uM
2uxz  1.75  2008  Ki=3.3nM      // 2uxz.pdf (HI1) ligand is compound 12d
2qo8  1.40  2008  Ki=3.4nM      // 2qo8.pdf (3CC) ligand is compound 2
2q6f  2.00  2008  Ki=3.6uM      // 2q6f.pdf (6-mer) Ki=3.6+/-0.4uM (IBV Mpro/N3); Ki=2.6+/-0.3uM(IBV Mpro/N27); Ki=2.8+/-0.2uM(IBV Mpro/H16)
2za5  2.30  2008  Ki=3.7nM      // 2za5.pdf (2FF) Ki=3.7+/-0.5nM; IC50=3.6+/-0.3nM
2qln  2.15  2008  Ki=3.7uM      // 2qln.pdf (F59) ligand is compound 26
3bft  2.27  2008  Ki=323nM      // 3bft.pdf (S2P) Ki=323+/-84nM
2qhy  1.85  2008  Ki=33nM       // 2qhy.pdf (MZ1) ligand is inhibitor 12h
3cm2  2.50  2008  Ki=340nM      // 3clx.pdf (X23) Fluorescence IC50=970+/-120nM, Cheng-Prusoff, Kenakin, Huang get Ki=870, 420, 340nM
3bmn  1.98  2008  Ki=35uM       // 3bmc.pdf (AX3) Pteridine Reductase 1 complex NADP+ and AX3 compound 15, lack a N atom, Ki>35uM
2q9y  2.85  2008  Ki=36uM       // 2q9y.pdf (BTM) Ki for BTAC in the presence of PPi and Mg2+ is 36uM
3e81  1.63  2008  Ki=37mM       // 3e81.pdf (SLB) competitive inhibitors (versus pNPP) for BT1713
2pu2  1.86  2008  Ki=37uM       // 2pu2.pdf (DK2) IC50(R)=70uM, Ki(S)=158uM, Ki(R)=140uM
3bgs  2.10  2008  Ki=380pM      // 2q7o.pdf (DIH) ligand is compound 4
2vr0  2.80  2008  Ki=38uM       // 2vr0.pdf (HQO)
3efj  2.60  2008  Ki=39nM       // 3efj.pdf (MT3) compound 7, Ki=39+/-6nM
1w14  2.20  2008  Ki=3nM        // 1w0z.pdf (SH1)
2qg2  1.80  2008  Ki=4.0uM      // 2qf6.pdf (A91) Ki=4.0+/-1.0uM
3d83  1.90  2008  Ki=4.4nM      // 3d83.pdf (GK6) ligand is compound 8
2qn3  1.96  2008  Ki=4.4uM      // 2qn3.pdf (F55) ligand is compound 27
3bv9  1.80  2008  Ki=4.4uM      // 3bv9.pdf (6-mer) Ki=4.4+/-2.4uM; IC50=6.9+/-1.2uM
3bc4  1.82  2008  Ki=4.5uM      // 3bc4.pdf (LLG) incomplete ligand structure
3e9b  2.15  2008  Ki=4.5uM      // 3e6k.pdf (S2C)
2qci  1.20  2008  Ki=4.6nM      // 2qci.pdf (065) Ki=4.6+/-0.7nM
2qnb  1.80  2008  Ki=4.6uM      // 2qnb.pdf (BZD) ligand is compound 15
3ds9  1.76  2008  Ki=41nM       // 3ds9.pdf (8-mer) incomplete ligand
2qi0  2.10  2008  Ki=42nM       // 2qhy.pdf (MZ3) ligand is inhibitor 11b
2vc7  2.05  2008  Ki=432.7uM    // 2vc7.pdf (HT5) Ki=432.7+/-53.2uM
2vl1  2.15  2008  Ki=45mM       // 2vl1.pdf (2-mer) Fragment: RESIDUES 2-455
2pnc  2.40  2008  Ki=466uM      // 2pnc.pdf (CLU) Ki=466+/-163uM; Kd~1.2mM
2vvs  2.24  2008  Ki=46nM       // 2vvs.pdf (OAN)
2r2m  2.10  2008  Ki=47.1nM     // 2r2m.pdf (I50) ligand is compound 1
2z3z  1.95  2008  Ki=48.8uM     // 2eep.pdf (AIO) covalent complex
2qtt  1.93  2008  Ki=48uM       // 2qtg.pdf (FMC) Ki=48+/-5uM; ligand in reference is referred to as Formycin A (FMA)
2vsl  2.10  2008  Ki=4nM        // 2vsl.pdf (4-mer) Ki=4+/-2nM; IC50=406+/-37nM
2zda  1.73  2008  Ki=4nM        // 2zc9.pdf (32U) ligand is compound 5, Ki=4+/-1.2nM
3b68  1.90  2008  Ki=4nM        // 3b5r.pdf (B68) ligand is compound s-4; Ki=4+/-0.7nM
3d0e  2.00  2008  Ki=4nM        // 3d0e.pdf (G93) IC50=13nM
3ckr  2.70  2008  Ki=5.001uM    // 3ckp.pdf (009)
3dyo  1.80  2008  Ki=5.0mM      // 3dyo.pdf (IPT) measured with 0.01mM Mg2+
3bmo  1.60  2008  Ki=5.4uM      // 3bmc.pdf (AX4) Pteridine Reductase 1 complex NADP+ and AX4 compound 16, Ki=5.4uM
3cen  1.60  2008  Ki=5.5nM      // 3cen.pdf (FXA) compound 14
3e16  1.60  2008  Ki=5.78uM     // 3e0p.pdf (B4C) compound 12
3e5a  2.30  2008  Ki=5.9nM      // 3e5a.pdf (VX6)
2qi1  2.00  2008  Ki=50nM       // 2qhy.pdf (MZ4) ligand is inhibitor 11c
3d52  1.60  2008  Ki=520uM      // 3d4y.pdf (GHR)
2qoa  1.60  2008  Ki=52nM       // 2qo8.pdf (MAJ) ligand is compound 1, not compound 3
3bfu  1.95  2008  Ki=531nM      // 3bft.pdf (R2P) Ki=531+/-98nM
2qhz  1.85  2008  Ki=53nM       // 2qhy.pdf (MZ2) ligand is inhibitor 12j
2ole  2.40  2008  Ki=56.2nM     // 2ole.pdf (KR2) compound 10f; Ki=56.2nM; IC50=70nM
2jkp  1.99  2008  Ki=59uM       // 2jke.pdf (CTS) ligand is castanospermine 2
2jke  1.70  2008  Ki=59uM       // 2jke.pdf (NOJ) ligand is deoxynojirimycin 1
2pvk  1.90  2008  Ki=5nM        // 2pvh.pdf (P45)
2rd6  2.30  2008  Ki=5nM        // 2rd6.pdf (78P) ligand is compound 4a
3d20  1.05  2008  Ki=5nM        // 3cyw.pdf (017) Ki=5+/-1nM; redundant to 2hs1
2vk6  1.50  2008  Ki=5uM        // 2vk6.pdf (DAN) Ki=5uM(pH=7); Ki=40uM(pH=5)
3bcs  2.00  2008  Ki=6.1uM      // 3bcs.pdf (CJB) ligand is 1(-D-glucopyranosyl) uracil
2r59  1.89  2008  Ki=6.5nM      // 2r59.pdf (PH0) Ki=6.5+/-1nM for inhibitor RB3041
2qrg  1.85  2008  Ki=6.6uM      // 2qrg.pdf (M07) ligand is compound 4a, Ki=6.6+/-0.3uM
2zfp  2.25  2008  Ki=6.8uM      // 2zc9.pdf (19U) ligand is compound 1, Ki=6.8+/-1.5uM
3b7j  2.40  2008  Ki=6.8uM      // 3b7j.pdf (JUG) Ki=6.8uM; IC50=30+/-4uM
2epn  1.61  2008  Ki=60nM       // 2epn.pdf (NGT) Ki=60+/-17nM
2qmj  1.90  2008  Ki=62uM       // 2qmj.pdf (ACR) Ki=62+/-13uM
3f3a  2.00  2008  Ki=64.8uM     // 3f3a.pdf (TRP) Ki=64.8+/-4.67uM
3c8a  1.52  2008  Ki=660nM      // 3c88.pdf (5-mer)
2jk7  2.82  2008  Ki=67nM       // 2jk7.pdf (BI6) Ki=67+/-18nM
3d3x  2.25  2008  Ki=69uM       // 3d3x.pdf (4-mer) IC50=340uM, Type E botulinum toxin complex with SNAP-25 substrate peptide; incomplete ligand
1w11  2.00  2008  Ki=6nM        // 1w0z.pdf (SK1)
2zcs  2.03  2008  Ki=6nM        // 2zcp.pdf (B70)
3d1y  1.05  2008  Ki=6nM        // 3cyw.pdf (ROC) Ki=6+/-1nM
3d9v  3.30  2008  Ki=6nM        // 3d9v.pdf (H52)
3b4f  1.89  2008  Ki=7.2nM      // 3b4f.pdf (TUO) ligand is compound 5
2pq9  1.60  2008  Ki=7.8nM      // 2pq9.pdf (GG9) Ki=7.8+/-0.5nM
2e9u  2.00  2008  Ki=7.94nM     // 2e9u.pdf (A25) -logKi=8.1 in in supporting information
2qrq  1.80  2008  Ki=7.9uM      // 2qrg.pdf (S13) ligand is compound 4b, Ki=7.9+/-0.1uM
3bbt  2.80  2008  Ki=700nM      // 3bbt.pdf (FMM) IC50=1.4+/-0.1uM
3d51  1.43  2008  Ki=70uM       // 3d4y.pdf (GOX)
2vot  1.95  2008  Ki=72nM       // 2vjx.pdf (NHV) ligand is compound 1c
3c8b  1.47  2008  Ki=786nM      // 3c88.pdf (5-mer)
2rkg  1.80  2008  Ki=8.2nM      // 2rkf.pdf (AB1) Ki=8.2+/-0.7nM
2qtg  1.84  2008  Ki=8.3uM      // 2qtg.pdf (MTH) Ki=8.3+/-1.2uM
2v77  1.60  2008  Ki=8.7uM      // 2v77.pdf (PAY)
2rke  1.80  2008  Ki=82.5uM     // 2rk7.pdf (SAT) ligand is analogue 23, Ki =82.5+/-5uM
3cl0  2.20  2008  Ki=84.8nM     // 3ckz.pdf (G39) relative Ki=265*0.32nM
3c89  1.58  2008  Ki=845nM      // 3c88.pdf (5-mer)
2eep  2.20  2008  Ki=88.1nM     // 2eep.pdf (AIO) covalent complex
2rk7  1.90  2008  Ki=89uM       // 2rk7.pdf (OXL) ligand is analogue 1, Ki=89+/-4uM
2pvj  1.70  2008  Ki=8nM        // 2pvh.pdf (P44)
2rcw  2.80  2008  Ki=8nM        // 2rcw.pdf (AAI) ligand is compound 3, A620223
3caj  1.80  2008  Ki=8nM        // 3caj.pdf (EZL) compound 3; redundant to 3dd0
2r9w  1.80  2008  Ki=8uM        // 2pu2.pdf (23C)
3bxs  1.60  2008  Ki=8uM        // 3bxr.pdf (DRS) products 2, Ki=8uM
3bgc  1.80  2008  Ki=9.6uM      // 3bgb.pdf (LJH) ligand is compound 6d
2vnt  2.20  2008  Ki=9.9nM      // 2vnt.pdf (QGG) compound 33 or 34, preference for the R-isomer, QGG(R) Ki=9.9nM, (S)Ki=111nM
2qrm  1.90  2008  Ki=92.5uM     // 2qrg.pdf (M09) ligand is compound 4d, Ki=92.5+/-4.2uM
3f3c  2.10  2008  Ki=950nM      // 3f3a.pdf (PFF) Ki=950+/-100nM
3dc2  2.70  2008  Ki=950uM      // 3dc2.pdf (TLA) Ki=950+/-120uM, IC50=36+/-6uM
2vl4  1.90  2008  Ki=975nM      // 2vjx.pdf (MNM) ligand is compound 5
3emg  2.60  2008  Ki=9nM        // 3emg.pdf (685) IC50=0.07uM
3kf4  1.90  2009  IC50<0.5nM    // 3kf4.pdf (B90) Tyrosine-protein kinase transforming protein Abl complex AP24283
3fz1  1.90  2009  IC50=0.012uM  // 3fyj.pdf (B98) benzthiophene inhibitor bound to human (CDK-2), compound 2 lacks a NH2
3h59  2.10  2009  IC50=0.013uM  // 3h59.pdf (H59) compound 20 bound to C Delta 21 NS5B polymerase, cell activity
3g9e  2.30  2009  IC50=0.019uM  // 3g8i.pdf (RO7) PPAR gamma and compound (S)-2Aa
2w1c  3.24  2009  IC50=0.01uM   // 2w1c.pdf (L0C) compound 9
2wev  2.30  2009  IC50=0.01uM   // 2wev.pdf (CK7)
3cvk  2.31  2009  IC50=0.01uM   // 3cvk.pdf (N34) IC50<0.01uM, compound 4c
3d5m  2.20  2009  IC50=0.01uM   // 3d28.pdf (4MS) IC50<0.01uM, compound 34
3gur  2.50  2009  IC50=0.01uM   // 3gur.pdf (BYG) covalent complex; IC50<0.01uM, ligand is N11+GTT
2wez  1.70  2009  IC50=0.023uM  // 2wez.pdf (ZYE) compound 17, the -OCH3 group on ligand is wrong as CF3 in reference
3ii5  2.79  2009  IC50=0.024uM  // 3ii5.pdf (831) B-Raf wild-type enzyme with compound 10n
3hmm  1.70  2009  IC50=0.025uM  // 3gxl.pdf (855) ALK-5 with GW855857(compound 3d), ALK-5 IC50=0.025uM, TGF beta=0.095uM
3gxl  1.80  2009  IC50=0.025uM  // 3gxl.pdf (QIG) ALK-5 with GW857175(compound 8d), ALK-5 IC50=0.025uM, TGF beta=0.09uM
3igv  2.60  2009  IC50=0.025uM  // 3gyn.pdf (B80) HCV NS5B polymerase complex compound 29, IC50<0.025uM
3ig6  1.83  2009  IC50=0.025uM  // 3ig6.pdf (438) compound 11 bound to uPA
3hf6  1.80  2009  IC50=0.026uM  // 3hf6.pdf (LX0) inhibitor 7b co-crystallized with TPH1
3fei  2.40  2009  IC50=0.02uM   // 3fei.pdf (CTM)
3g8i  2.20  2009  IC50=0.038uM  // 3g8i.pdf (RO7) PPAR alpha and compound (S)-2Aa, IC50=0.038uM
3fyk  3.50  2009  IC50=0.04uM   // 3fyj.pdf (B98) benzthiophene lead bound to MAPKAP Kinase-2 (MK-2), compound 2 lacks a NH2
3gyn  2.15  2009  IC50=0.061uM  // 3gyn.pdf (B42) HCV NS5B polymerase complex compound 49
3ff6  3.19  2009  IC50=0.07uM   // 3ff6.pdf (RCP) ligand is compound 2
3hp5  2.30  2009  IC50=0.07uM   // 3hp2.pdf (52P) p38a in complex with compound 2
3gol  2.85  2009  IC50=0.081uM  // 3gol.pdf (XND) HCV NS5b polymerase in complex with 1, 5 benzodiazepine inhibitor (R)-11d
2w3k  2.05  2009  IC50=0.08nM   // 2w3i.pdf (L1D) compound 17
3fxv  2.26  2009  IC50=0.094uM  // 3fxv.pdf (643) FXR binding to compound 7a
2w6n  1.87  2009  IC50=0.125uM  // 2w6m.pdf (OA2) compound 2c
3jpv  2.35  2009  IC50=0.12uM   // 3jpv.pdf (1DR) human proto-oncogene serine threonine kinase (PIM1) with compound 9
3du8  2.20  2009  IC50=0.146uM  // 3du8.pdf (553) IC50=0.146+/-0.045uM, compound 89S
3kvx  2.40  2009  IC50=0.148uM  // 3kvx.pdf (FMY) compound 9l bind in the ATP pocket of JNK3
3g42  2.10  2009  IC50=0.14uM   // 3g42.pdf (792) compound 11c bound to TACE
3fui  2.20  2009  IC50=0.157uM  // 3fts.pdf (812) compound 14, IC50=0.157+/-0.03uM
3kb3  1.95  2009  IC50=0.15uM   // 3kb3.pdf (A8S) ternary complex of PYL2-ABA-HAB1, (+)-ABA IC50=0.15uM, (-)-ABA IC50=1.7uM
3fv8  2.28  2009  IC50=0.16uM   // 3fv8.pdf (JK3) JNK3 complexed with compound 4g
3fun  1.58  2009  IC50=0.189uM  // 3fts.pdf (798) compound 18, IC50=0.189+/-0.02uM
3hng  2.70  2009  IC50=0.18uM   // 3hng.pdf (8ST) ligand is compound 3
2w3i  1.90  2009  IC50=0.1nM    // 2w3i.pdf (L1C) compound 26
3c7p  1.70  2009  IC50=0.1nM    // 3c7p.pdf (POF) compound 4
3hd3  1.75  2009  IC50=0.1uM    // 3hd3.pdf (25B) structure of 8a bound to cruzain
2wf0  1.60  2009  IC50=0.21uM   // 2wez.pdf (ZY0) compound 22
2wtd  2.75  2009  IC50=0.21uM   // 2wtc.pdf (ZZK) compound 51
3iej  2.18  2009  IC50=0.22uM   // 3iej.pdf (599) compound 32 bound to Cys25Ser CatS
2wbd  2.40  2009  IC50=0.23uM   // 2wbb.pdf (RO5) compound 4, IC50=0.23uM
2wi6  2.18  2009  IC50=0.23uM   // 2wi1.pdf (ZZ6) compound 21e
3kah  2.30  2009  IC50=0.26uM   // 3kab.pdf (4DH) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 20
3ej5  2.50  2009  IC50=0.27mM   // 3ej5.pdf (EJ5) compound 1
3il6  2.50  2009  IC50=0.27uM   // 3il5.pdf (B83) E. faecalis FabH in complex with compound 23i
3g6z  2.00  2009  IC50=0.2nM    // 3g6z.pdf (A7T) compound (+)-26g, in buffer IC50=0.2nM, in plasma IC50=19nM
3i06  1.10  2009  IC50=0.2nM    // 3i06.pdf (QL2) cruzain covalently bound to a purine nitrile, compound 32
3k3b  2.40  2009  IC50=0.2uM    // 3k3b.pdf (L31) compound 3 bound to human kinesin Eg5
2wtc  3.00  2009  IC50=0.31uM   // 2wtc.pdf (VGM) compound 48
2w6p  1.85  2009  IC50=0.333uM  // 2w6m.pdf (OA4) compound 3c
2w71  1.99  2009  IC50=0.334uM  // 2w6m.pdf (L23) compound 6b
3hr1  1.53  2009  IC50=0.37nM   // 3hqw.pdf (PF9) cAMP and cAMP-inhibited cGMP 3, 5-cyclic phosphodiesterase 10A with compound 9
2waj  2.40  2009  IC50=0.398uM  // 2waj.pdf (SNB) compound 16, pIC50=6.4
2wmw  2.43  2009  IC50=0.39uM   // 2wmq.pdf (ZYW) Fragment: KINASE DOMAIN, RESIDUES 1-289
3hqz  1.70  2009  IC50=0.42nM   // 3hqw.pdf (PF8) cAMP and cAMP-inhibited cGMP 3, 5-cyclic phosphodiesterase 10A with compound 3
3fr5  2.20  2009  IC50=0.45uM   // 3fr2.pdf (I4A) compound 30
3gw5  2.00  2009  IC50=0.47nM   // 3gw5.pdf (72X) compound 21l bound to human renin
3g70  2.00  2009  IC50=0.4nM    // 3g6z.pdf (A5T) compound (+)-26h, in buffer IC50=0.4nM, in plasma IC50=36nM
3g3n  2.40  2009  IC50=0.51uM   // 3g3n.pdf (TC8) PDE7A catalytic domain in complex with compound 15, IC50=0.51+/-0.02uM
2wo8  2.00  2009  IC50=0.52uM   // 2wo8.pdf (077) compound 1
2wqb  2.95  2009  IC50=0.54uM   // 2wqb.pdf (QQ1) bound to the TIE2 kinase domain
3fqh  2.26  2009  IC50=0.57uM   // 3fqe.pdf (057) compound 4
3dv1  2.10  2009  IC50=0.59uM   // 3dv1.pdf (AR9) compound 2a
3fr2  2.20  2009  IC50=0.59uM   // 3fr2.pdf (8CA) compound 2a
2zv2  2.40  2009  IC50=0.5uM    // 2zv2.pdf (609) ligand is STO-609
3g1m  1.70  2009  IC50=0.5uM    // 3g1m.pdf (RF3) ligand is compound 2, BDM31381
3fr4  2.16  2009  IC50=0.65uM   // 3fr2.pdf (F8A) compound 26, in reference table 2, n should be 1, not 2
3hp2  2.15  2009  IC50=0.68uM   // 3hp2.pdf (P36) p38a in complex with compound 1
3fnu  3.00  2009  IC50=0.69uM   // 3fnt.pdf (006)
3gc7  1.80  2009  IC50=0.6nM    // 3gc7.pdf (B45) ligand is compound 1
3fej  2.01  2009  IC50=0.74uM   // 3fei.pdf (CTM)
2vpp  2.20  2009  IC50=0.76uM   // 2vpp.pdf (GEO) IC501=0.76+/-0.066uM(ovarian cancer cell line AG6000); IC502=29.89+/-4.27nM(glioblastoma cell line U-87M-G)
2wtj  2.10  2009  IC50=0.7uM    // 2wtc.pdf (WTJ) compound 63
3fpd  2.40  2009  IC50=0.7uM    // 3fpd.pdf (Q4A)
3eq7  2.89  2009  IC50=0.81nM   // 3eq7.pdf (X99) compound 6
3kaf  2.30  2009  IC50=0.83uM   // 3kab.pdf (4D9) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 18d
2wmx  2.45  2009  IC50=0.86uM   // 2wmq.pdf (ZY6) Fragment: KINASE DOMAIN, RESIDUES 1-289
3hw1  2.48  2009  IC50=0.87mM   // 3hvg.pdf (EV2) BACE1-Compound 1 complex, IC50=0.87+/-0.26mM
3fc2  2.45  2009  IC50=0.87nM   // 3fc2.pdf (IBI) compound  BI 6727
3eq8  2.73  2009  IC50=0.88nM   // 3eq7.pdf (X98) compound 8
3g72  1.90  2009  IC50=0.8nM    // 3g6z.pdf (A6T) compound (-)-26h, in buffer IC50=0.8nM, in plasma IC50=88nM
3djf  2.30  2009  IC50=0.8uM    // 3djf.pdf (BC3) BCX-34, compound 4; IC50=0.8+/-0.05uM
2wi5  2.10  2009  IC50=0.90uM   // 2wi1.pdf (ZZ5) compound 13
2w1d  2.97  2009  IC50=0.91uM   // 2w1c.pdf (L0D) compound 5
2wbb  2.22  2009  IC50=0.92uM   // 2wbb.pdf (RO3) compound 1, IC50=0.92uM
3jzb  2.01  2009  IC50=0.97nM   // 3jzb.pdf (4HY) TR alpha complex with Triac, IC50=0.97+/-0.09nM
2zoq  2.39  2009  IC50=0.9uM    // 2zoq.pdf (5ID)
3ezv  1.99  2009  IC50=1.04uM   // 3ezr.pdf (EZV) inhibitor 9
3fy0  2.35  2009  IC50=1.09uM   // 3fxz.pdf (DW1) PAK1 kinase domain with ruthenium complex rac-DW12, IC50=1090+/-80nM
2woa  2.26  2009  IC50=1.15uM   // 2wo8.pdf (576) compound 7a
3ft4  1.90  2009  IC50=1.17uM   // 3ft2.pdf (9-mer) HA-1 peptide
3jzk  2.10  2009  IC50=1.23uM   // 3jzk.pdf (YIN) structure of compound 1a with human MDM2, IC50=1.23+/-0.82uM
2w1i  2.60  2009  IC50=1.2nM    // 2w1c.pdf (L0I) compound 12
3hyf  1.70  2009  IC50=1.2uM    // 3hyf.pdf (ON1) p15-Ec in complex with compound 9
3a4o  3.00  2009  IC50=1.3nM    // 3a4o.pdf (STU)
3e0q  1.90  2009  IC50=1.3uM    // 3e0q.pdf (JFD) compound Sm_VS1; IC50=1.30+/-0.07uM
3f9n  1.90  2009  IC50=1.3uM    // 3f9n.pdf (38M) compound 38
3fci  1.27  2009  IC50=1.3uM    // 3fcf.pdf (3FI) compound 6
3dp0  2.50  2009  IC50=1.42uM   // 3doy.pdf (2BC) compound 3m, IC50=1.42+/-0.28uM
3k3g  2.40  2009  IC50=1.4mM    // 3k3g.pdf (MMU) Urea Transporter Bound to 1, 3-dimethylurea, IC50=1.4+/-0.2mM
3d28  2.30  2009  IC50=1.4uM    // 3d28.pdf (B34) compound 3
3duy  1.97  2009  IC50=1.4uM    // 3duy.pdf (AFJ) compound 1
3dp2  2.40  2009  IC50=1.50uM   // 3doy.pdf (4BE) compound 3j, IC50=1.50+/-0.25uM
3doy  2.40  2009  IC50=1.52uM   // 3doy.pdf (2BE) compound 3i, IC50=1.52+/-0.19uM
3dp3  2.30  2009  IC50=1.52uM   // 3doy.pdf (4BB) compound 3q, IC50=1.52+/-0.11uM
2wi4  2.40  2009  IC50=1.56uM   // 2wi1.pdf (ZZ4) compound 12
3fzs  1.75  2009  IC50=1.5uM    // 3fzp.pdf (B96) compound  BIRB796
3ftw  1.85  2009  IC50=1.67mM   // 3ftw.pdf (11X) ligand is compound 4
3eyg  1.90  2009  IC50=1.6nM    // 3eyg.pdf (MI1) JAK1-CP-690, 550 complex
3idp  2.70  2009  IC50=1.6nM    // 3idp.pdf (L1E) B-Raf V600E kinase domain in complex with compound 1
3il5  2.60  2009  IC50=1.6uM    // 3il5.pdf (B82) E. faecalis FabH in complex with compound 13a
2zvj  2.30  2009  IC50=1.8uM    // 2zvj.pdf (KOM)
3hj0  1.34  2009  IC50=1.96uM   // 3hj0.pdf (A93) compound 4 is a covalent small molecule kinetic stabilizer
3doz  2.50  2009  IC50=1.98uM   // 3doy.pdf (3BE) compound 3k, IC50=1.98+/-0.21uM
3k3i  1.70  2009  IC50=1.9uM    // 3k3i.pdf (JZJ) p38 alpha bound to novel DGF-out compound PF-00215955
3fmr  2.89  2009  IC50=10.6nM   // 3fmq.pdf (TN4)
3fck  1.64  2009  IC50=100uM    // 3fcf.pdf (FCK) compound 22
3hy7  1.69  2009  IC50=106nM    // 3hy7.pdf (097) compound Marimastat
3fu6  2.05  2009  IC50=106uM    // 3fts.pdf (80G) compound 9, IC50=106+/-20uM
3h2a  2.40  2009  IC50=108.9uM  // 3h21.pdf (B57) Dihydropteroate Synthase with compound 7
3co9  2.10  2009  IC50=10nM     // 3co9.pdf (3MS) IC50<10nM, compound 3c
3cwj  2.40  2009  IC50=10nM     // 3cwj.pdf (321) IC50<10nM, compound 3a
3ezr  1.90  2009  IC50=10uM     // 3ezr.pdf (EZR) inhibitor 17
3fmq  2.50  2009  IC50=11.1nM   // 3fmq.pdf (FUG)
3hqy  2.00  2009  IC50=11.5nM   // 3hqw.pdf (PF6) cAMP and cAMP-inhibited cGMP 3, 5-cyclic phosphodiesterase 10A with compound 2
3hhm  2.80  2009  IC50=11.9nM   // 3hhm.pdf (KWT) three quite different data in references
3jzq  1.80  2009  IC50=110nM    // 3jzo.pdf (12-mer) ligand is 12-mer peptide inhibitor pDIQ
3ftv  1.70  2009  IC50=1167uM   // 3fts.pdf (11X) compound 4, IC50=1167+/-168uM
3e3b  3.20  2009  IC50=11nM     // 3e3b.pdf (CCK) compound CC04820 complex with hCK2-alpha2
3fzr  2.70  2009  IC50=11nM     // 3fzp.pdf (3JZ) compound PF-431396
3hxf  1.90  2009  IC50=11uM     // 3hxb.pdf (BD9) Engineered RabGGTase complex with compound 32, IC50=11+/-1.2uM
2w70  1.77  2009  IC50=12.0uM   // 2w6m.pdf (L22) compound 6a
3dgq  1.60  2009  IC50=12.0uM   // 3dd3.pdf (EAA) ligand is ethacrynic acid
3hha  1.27  2009  IC50=12.6nM   // 3hha.pdf (NOW) cathepsin L in complex with AZ12878478 compound 26, pIC50=7.9, 1.26x10-8M
2w1e  2.93  2009  IC50=12nM     // 2w1c.pdf (L0E) compound 10
3fi3  2.20  2009  IC50=12nM     // 3fi2.pdf (JK2) compound SR3737
3fxz  1.64  2009  IC50=130nM    // 3fxz.pdf (FLL) PAK1 kinase domain with ruthenium complex lambda-FL172, IC50=130+/-10nM
3h03  1.90  2009  IC50=135uM    // 3h03.pdf (UBP) GluR2 AMPA receptor with UBP277, IC50=135+/-12uM
2wf4  1.80  2009  IC50=13nM     // 2wf4.pdf (ZY4) different ligand structure
3a29  2.60  2009  IC50=13nM     // 3a29.pdf (2T0) compound 8L
3e3u  1.56  2009  IC50=13nM     // 3e3u.pdf (NVC)
3f8s  2.43  2009  IC50=13nM     // 3f8s.pdf (PF2) compound 5, IC50=12.9+/-4.6uM
3i81  2.08  2009  IC50=13nM     // 3i81.pdf (EBI) compound 9d cocrystallized with IGF-1R
3h3c  2.00  2009  IC50=140nM    // 3h3c.pdf (P1E) PYK2 in complex with compound 2a, cell IC50=88nM
3fu3  2.00  2009  IC50=1443uM   // 3fts.pdf (92G) compound 7, IC50=1443+/-63uM
3e51  1.90  2009  IC50=14nM     // 3e51.pdf (N35) compound 2e
3eta  2.60  2009  IC50=14nM     // 3eta.pdf (351) compound 19
2w6z  1.90  2009  IC50=1500uM   // 2w6m.pdf (L21) compound 5
2v5a  2.31  2009  IC50=150nM    // 2v58.pdf (LZL) inhibitor 3
3fue  2.38  2009  IC50=1510uM   // 3fts.pdf (11S) compound 12, IC50=1510+/-139uM
3dz6  1.83  2009  IC50=15nM     // 3dz2.pdf (M8E) compound 14e
3ft5  1.90  2009  IC50=15uM     // 3ft5.pdf (MO8) fragment 1 complex with hsp90
3h0v  2.24  2009  IC50=15uM     // 3h0v.pdf (M2T) Human AdoMetDC and MMTA
3fal  2.36  2009  IC50=165nM    // 3fal.pdf (LO2) compound 19
3kba  2.00  2009  IC50=16nM     // 3kba.pdf (WOW) Progesterone receptor bound to Compound 20
3kce  1.90  2009  IC50=16uM     // 3kab.pdf (4BY) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 4
3fum  2.15  2009  IC50=170uM    // 3fts.pdf (80A) compound 17, IC50=170+/-5uM
3et7  2.70  2009  IC50=17nM     // 3et7.pdf (349) PYK2 complexed with compound PF-2318841
3hy9  2.02  2009  IC50=17nM     // 3hy7.pdf (098) compound 11
3h23  2.20  2009  IC50=19.3uM   // 3h21.pdf (B54) Dihydropteroate Synthase with compound 4
3gwu  2.14  2009  IC50=19.7uM   // 3gwu.pdf (SRE) Leucine transporter LeuT in complex with sertraline, IC50=19.7+/-9.2uM
3h21  2.32  2009  IC50=19.8uM   // 3h21.pdf (B52) Dihydropteroate Synthase with compound 2
2wf3  2.08  2009  IC50=19nM     // 2wf1.pdf (ZY3) compound 11, in reference, CF3 group is different from O-CH3 in PDB
3e8n  2.50  2009  IC50=19nM     // 3e8n.pdf (VRA) compound RDEA119
3eka  3.10  2009  IC50=1mM      // 3eka.pdf (ASC)
3i0s  2.70  2009  IC50=1nM      // 3i0r.pdf (RT7) HIV reverse transcriptase in complex with inhibitor 7
2w0d  2.00  2009  IC50=2.0nM    // 2w0d.pdf (CGS)
3ik3  1.90  2009  IC50=2.0nM    // 3ik3.pdf (0LI)
3iw4  2.80  2009  IC50=2.1nM    // 3iw4.pdf (LW4) PKC alpha in complex with NVP-AEB071, compound 1, IC50=2.1+/-0.2nM
3jsi  2.72  2009  IC50=2.1nM    // 3jsi.pdf (WTC) Human phosphodiesterase 9 in complex with inhibitor 2, see support info
3ha6  2.36  2009  IC50=2.1uM    // 3ha6.pdf (2JZ) compound 10; covalent complex
3f88  2.60  2009  IC50=2.3nM    // 3f7z.pdf (3HT) compound 20x, combine 3 letter code ligand 2HT and 3HT
3gwv  2.35  2009  IC50=2.54mM   // 3gwu.pdf (RFX) Leucine transporter LeuT in complex with R-fluoxetine, IC50=2.54+/-0.41mM
2wgs  2.55  2009  IC50=2.5uM    // 2wgs.pdf (1AZ) IC50=2.5+/-0.4uM
2zis  2.60  2009  IC50=2.8nM    // 2zir.pdf (NH8) compound 8k
3g6g  2.31  2009  IC50=2.8nM    // 3g6g.pdf (G6G) Proto-oncogene tyrosine-protein kinase Src and DSA8, IC50=2.8+/-0.3nM
3kfc  2.40  2009  IC50=2.8nM    // 3kfc.pdf (61X) Compound 7e was cocrystallized with LXRbeta
3fkt  1.90  2009  IC50=2.8uM    // 3e3w.pdf (SII) inhibitor compound 16, IC50=2.8+/-0.12uM
3jzc  2.50  2009  IC50=2.94nM   // 3jzb.pdf (4HY) TR beta complex with Triac, IC50=2.94+/-0.52nM
3hc8  1.79  2009  IC50=2.9nM    // 3hc8.pdf (PD4) compound 1 Aminopyridiopyrazinones as PDE5 Inhibitors
3fuf  2.60  2009  IC50=2000uM   // 3fts.pdf (14O) compound 13, IC50>=2000uM
3fuh  1.80  2009  IC50=2000uM   // 3fts.pdf (5H1) compound 11 with bestatin, IC50>=2000uM
3fud  2.20  2009  IC50=2000uM   // 3fts.pdf (692) compound 10, IC50>=2000uM
3ex2  1.55  2009  IC50=200uM    // 3ewu.pdf (6CN)
2who  2.00  2009  IC50=20nM     // 2who.pdf (VGI) compound1 with  Delta C55-1b NS5B polymerase; IC50=20nM
2zyb  2.55  2009  IC50=20nM     // 2zm1.pdf (KSL) compound 4
3eyh  2.00  2009  IC50=20nM     // 3eyg.pdf (IZA) JAK1-CMP6 complex
3dg8  2.58  2009  IC50=20uM     // 3dg8.pdf (RJ6) RJF 00670 with bifunctional quadruple mutant TS-DHFR, IC50=20+/-2uM
2w6m  2.00  2009  IC50=21.5uM   // 2w6m.pdf (OA1) compound 2
3fup  2.40  2009  IC50=21.7nM   // 3eyg.pdf (MI1) JAK2-CP-690, 550 complex
3fhr  1.90  2009  IC50=210nM    // 3fhr.pdf (P4O)
3h2n  2.40  2009  IC50=212.6uM  // 3h21.pdf (B62) Dihydropteroate Synthase with compound 18
3fts  2.33  2009  IC50=212uM    // 3fts.pdf (STL) compound 2, IC50=212+/-40uM
3h2m  2.31  2009  IC50=215uM    // 3h21.pdf (B61) Dihydropteroate Synthase with compound 17
3hrb  2.20  2009  IC50=21nM     // 3hrb.pdf (I39) unphosphorylated p38 alpha complexed with compound 45, IC50=21+/-1.8nM
2w12  1.46  2009  IC50=22.2uM   // 2w12.pdf (WR2) X-ray(PH=6.5), where get the PH value
3cde  2.10  2009  IC50=22nM     // 3cde.pdf (N3H)
3d25  1.30  2009  IC50=22nM     // 3d25.pdf (9-mer) VLH/R peptides bound to HLA-A2, IC50=22nM. Kd=35uM is for KP7 TCR/HLA-A2-VLH interaction
3dv5  2.10  2009  IC50=22nM     // 3dv1.pdf (BAV) compound 3
3g76  3.00  2009  IC50=230.8nM  // 3g76.pdf (CZ3) XIAP-BIR3 in complex with a bivalent compound, IC50=230.8+/-32.8nM
3hv6  1.95  2009  IC50=2300nM   // 3hv3.pdf (R39) compound 12; IC501=2300+/-260nM(EFC, enzyme fragment complementation); IC502=5500+/-2800nM(HTRF, homogeneoustime-resolved  fluorescence)
3fuj  1.90  2009  IC50=234uM    // 3fts.pdf (00G) compound 15, wrong N cycle is aromatic in PDB, IC50=234+/-21uM
2w0j  2.05  2009  IC50=240nM    // 2w0j.pdf (ZAT)
3f7u  2.00  2009  IC50=246nM    // 3f7b.pdf (AG4) compound 6d
3ftu  1.90  2009  IC50=247uM    // 3fts.pdf (RE2) compound 3, IC50=247+/-26uM
2w7x  2.07  2009  IC50=24nM     // 2w7x.pdf (D1A)
3ewu  1.60  2009  IC50=24uM     // 3ewu.pdf (UEP) 6-acetyl-UMP, covalent adduct; IC50=24+/-13uM
3exo  2.10  2009  IC50=24uM     // 3exo.pdf (5MS)
2w6q  2.05  2009  IC50=25.4uM   // 2w6m.pdf (OA5) compound 4, the author miss a carbon atom in reference
3h2o  2.70  2009  IC50=25.9uM   // 3h21.pdf (B63) Dihydropteroate Synthase with compound 19
3ejs  1.35  2009  IC50=250nM    // 3ejp.pdf (HN5) compound 7
3eju  1.32  2009  IC50=250nM    // 3ejp.pdf (HN7) compound 5
3jzp  1.74  2009  IC50=250nM    // 3jzo.pdf (12-mer) ligand is 12-mer peptide inhibitor pDI6W
2wcx  2.00  2009  IC50=25nM     // 2wcx.pdf (VGC) compound 9a
3fi2  2.28  2009  IC50=25nM     // 3fi2.pdf (JK1) compound SR3451
3kfa  1.22  2009  IC50=25nM     // 3kf4.pdf (B91) Tyrosine-protein kinase transforming protein Abl complex AP24163, IC50=25nM
2wf2  1.80  2009  IC50=26nM     // 2wf1.pdf (ZY2) compound 10, in reference, CF3 group is different from O-CH3 in PDB
3dtc  2.60  2009  IC50=26nM     // 3dtc.pdf (VIN) IC50=26+/-12nM, compound 16
2wu6  1.92  2009  IC50=29.2nM   // 2wu6.pdf (DKI) Fragment: RESIDUES 127-484  ; IC50=29.2+/-8nM;
3dga  2.70  2009  IC50=29.9uM   // 3dg8.pdf (RJ1) PfDHFR-TS complexed with RJF01302, IC50=29.9+/-0.5uM
3h06  2.80  2009  IC50=292uM    // 3h03.pdf (VBP) GluR2 AMPA receptor with UBP277, IC50=292+/-26uM
3hvg  2.26  2009  IC50=2mM      // 3hvg.pdf (EV0) BACE1-Compound 8 complex, IC50=2+/-0.6mM
2wf1  1.60  2009  IC50=2nM      // 2wf1.pdf (ZY1) compound 9, in reference, CF3 group is different from O-CH3 in PDB
3da6  2.00  2009  IC50=2nM      // 3da6.pdf (BZ9) IC501=2+/-0.7nM(Tie-2/BZ9)
3hwn  2.33  2009  IC50=2nM      // 3hwn.pdf (BD3) CATHEPSIN L with AZ13010160, pIC50=8.7, 2nM
3d3p  1.75  2009  IC50=3.16nM   // 3d3p.pdf (20A) compound 20a, pIC50=8.5, IC50=3.16nM, not 2.76nM
3gfe  2.10  2009  IC50=3.2nM    // 3gfe.pdf (P37) p38a Mitogen-Activated Protein Kinase with a Pyrazolopyridinone Inhibitor
3h0b  2.70  2009  IC50=3.2uM    // 3h0b.pdf (B35) aminoheterocycles as a novel beta-secretase inhibitor, IC50 pH 6.4=3.2uM
2wei  1.65  2009  IC50=3.4nM    // 2wei.pdf (VGG) IC50=3.4+/-0.1nM; Fragment: RESIDUES 70-338;
3kl6  1.45  2009  IC50=3.5nM    // 3kl6.pdf (443) TAK-442
3gs7  1.80  2009  IC50=3.6uM    // 3glz.pdf (8BD) Human transthyretin (TTR) complexed inhibitor 13, inhibition rate 51% at 3.6uM
2w6c  2.69  2009  IC50=3.9nM    // 2w6c.pdf (BM4) IC50=3.9+/-1.3nM
3kai  1.90  2009  IC50=3.9uM    // 3kab.pdf (4FI) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 23b
3ft8  2.00  2009  IC50=30nM     // 3ft5.pdf (MOJ) compound 19
2vur  2.20  2009  IC50=30uM     // 2vur.pdf (YX1) IC50=30uM, but no dose-response curves shows IC50>10mM for cpOGA
3g4f  2.65  2009  IC50=30uM     // 3g4f.pdf (FPF) incubated with the enzyme and 10uM FPP, 2F-FPP exhibits an IC50 value
3ksl  2.05  2009  IC50=30uM     // 3ksl.pdf (SZH) RnPFTase:4 complexes
3hv4  2.60  2009  IC50=310nM    // 3hv3.pdf (L51) compound 21; IC501=310+/-50nM(EFC, enzyme fragment complementation); IC502=290+/-80nM(HTRF, homogeneoustime-resolved  fluorescence)
3fcl  1.70  2009  IC50=315uM    // 3fcf.pdf (3FL) compound 27
3h26  2.50  2009  IC50=32.4uM   // 3h21.pdf (B56) Dihydropteroate Synthase with compound 6
3fqa  2.35  2009  IC50=320mM    // 3fq7.pdf (GAB&PMP) IC50=320+/-0.015mM, GSAMM248I-Gabaculine
3fdn  1.90  2009  IC50=33nM     // 3fdn.pdf (MMH) compound 12w
3f3w  2.60  2009  IC50=34nM     // 3f3v.pdf (1BU) IC50=34+/-12nM
2wi2  2.09  2009  IC50=350uM    // 2wi1.pdf (ZZ3) compound 10, X-ray structure(cocrystal)
2wi3  1.90  2009  IC50=350uM    // 2wi1.pdf (ZZ3) compound 10, X-ray structure(soak)
3gww  2.46  2009  IC50=355mM    // 3gwu.pdf (SFX) Leucine transporter LeuT in complex with S-fluoxetine, IC50=355+/-46mM
3hqw  1.70  2009  IC50=35nM     // 3hqw.pdf (PF4) cAMP and cAMP-inhibited cGMP 3, 5-cyclic phosphodiesterase 10A with compound 1
3jzr  2.10  2009  IC50=36nM     // 3jzo.pdf (12-mer) ligand is 12-mer peptide inhibitor pDI6W
3ex3  1.45  2009  IC50=36uM     // 3ewu.pdf (U5P) 6-azido-UMP, covalent adduct, IC50=36+/-17uM
3hfj  2.02  2009  IC50=36uM     // 3hfj.pdf (DZ9) Bacillus anthracis nadD in complex with compound 3_02
2jle  2.90  2009  IC50=384nM    // 2jle.pdf (I15) compound 6, K103N mutant IC50=384+/-30nM, wt IC50=50+/-8.5nM
2wfg  2.20  2009  IC50=38uM     // 2wfg.pdf (ZZB) include special element B
3igb  2.24  2009  IC50=38uM     // 3igb.pdf (454) Beta-secretase 1 complex compound 3
2zzu  2.50  2009  IC50=39nM     // 2zzu.pdf (359) Fragment: UNP RESIDUES 61-212 ;  UNP RESIDUES 213-466 ; UNP RESIDUES 33-250 ;
3fq7  2.15  2009  IC50=3mM      // 3fq7.pdf (PXG) IC50=3+/-0.008mM, GSAMWT-mCPP
2w1g  2.71  2009  IC50=3nM      // 2w1c.pdf (L0G) compound 16
3h5u  1.95  2009  IC50=3nM      // 3h5s.pdf (H5U) structure 5 bound to C Delta 21 NS5B polymerase, IC50=0.003uM
3i0r  2.98  2009  IC50=3nM      // 3i0r.pdf (RT3) HIV reverse transcriptase in complex with inhibitor 3
3ia6  2.31  2009  IC50=3nM      // 3ia6.pdf (UNT) nuclear hormone receptor PPAR-gamma with compound 17j, IC50=0.003uM
3e37  1.80  2009  IC50=4.05uM   // 3e30.pdf (ED5) compound 5, IC501=4050nM(Human FTase); IC502=3.0nM(P. falciparum FTase)
3dpk  1.95  2009  IC50=4.1nM    // 3dpk.pdf (8C5)
3fc8  1.85  2009  IC50=4.1uM    // 3fc8.pdf (IFA) compound 23b
3hxb  2.25  2009  IC50=4.1uM    // 3hxb.pdf (BD5) Engineered RabGGTase complex with compound 6, IC50=4.1+/-0.2uM
3hab  2.10  2009  IC50=4.2nM    // 3hab.pdf (677) DPP4 in complex with piperidine fused benzimidazole 25, IC50=0.0042uM
3h0z  2.92  2009  IC50=4.3nM    // 3h0y.pdf (45B) Aurora A in complex with a bisanilinopyrimidine, compound 9
3hxe  1.95  2009  IC50=4.7uM    // 3hxb.pdf (BD8) Engineered RabGGTase complex with compound 37, IC50=4.7+/-0.1uM; dissociation constant(KI)=5.4uM
3fcb  1.80  2009  IC50=4.9uM    // 3fc8.pdf (IFB) compound 22b
3dz4  1.84  2009  IC50=400nM    // 3dz2.pdf (C8M) compound 17d
3hdm  2.60  2009  IC50=40nM     // 3hdm.pdf (MMG) serum and glucocorticoid-regulated kinase 1 complex with compound 1
3kf7  2.00  2009  IC50=40nM     // 3kf7.pdf (L9G) structure of p38a in complex with compound 61
3fcf  1.84  2009  IC50=40uM     // 3fcf.pdf (FCF) compound 14
3itu  1.58  2009  IC50=40uM     // 3itu.pdf (IBM) hPDE2A catalytic domain complexed with IBMX
3ess  1.19  2009  IC50=411nM    // 3ess.pdf (18N) IC50=411+/-38nM
3eq9  2.47  2009  IC50=41nM     // 3eq7.pdf (X97) compound 11
3fqs  2.10  2009  IC50=41nM     // 3fqe.pdf (585)
3hhu  1.59  2009  IC50=41nM     // 3hhu.pdf (819) BX-2819 binds to Hsp90, IC50=41nM for inhibition of GM-Bodipy binding
2wmu  2.60  2009  IC50=42uM     // 2wmq.pdf (ZYU) Fragment: KINASE DOMAIN, RESIDUES 1-289
3i7g  1.95  2009  IC50=430nM    // 3i7g.pdf (732) MMP-13 in complex with a non zinc-chelating inhibitor
3fw3  1.72  2009  IC50=43nM     // 3f7b.pdf (ETS) compound dorzolamide
2wot  1.85  2009  IC50=44nM     // 2wot.pdf (ZZG)
3ejt  1.35  2009  IC50=44nM     // 3ejp.pdf (HN6) compound 6
3ft2  1.80  2009  IC50=44nM     // 3ft2.pdf (9-mer) citrulline variant HA-1 peptide, Dissociation rates on cell surface between HA-1 alleles
3ft3  1.95  2009  IC50=44nM     // 3ft2.pdf (9-mer) histidine variant HA-1 peptide, In vitro TAP translocation of peptide
2wih  2.50  2009  IC50=45nM     // 2wih.pdf (P48) compound 28
3hv3  2.00  2009  IC50=470nM    // 3hv3.pdf (R49) compound 19; IC501=470+/-70nM(EFC, enzyme fragment complementation); IC502=900+/-420nM(HTRF, homogeneoustime-resolved  fluorescence)
3coh  2.70  2009  IC50=4nM      // 3coh.pdf (83H) compound 32
3gz9  2.00  2009  IC50=4nM      // 3gz9.pdf (D32) PPARd Complex with compound 10
3k9x  1.90  2009  IC50=4nM      // 3k9x.pdf (MBM) compound 22 bound to FXa
3hxc  1.95  2009  IC50=5.2uM    // 3hxb.pdf (BD6) Engineered RabGGTase complex with compound 8, IC50=5.2+/-0.6uM
3dcq  1.80  2009  IC50=5.94uM   // 3dcq.pdf (2G0) IC50=5.94+/-1.24uM
2w1f  2.85  2009  IC50=5.9nM    // 2w1c.pdf (L0F) compound 7
3h2c  2.60  2009  IC50=500uM    // 3h21.pdf (B58) Dihydropteroate Synthase with compound 10, IC50>500uM
3hdz  1.80  2009  IC50=51nM     // 3hdz.pdf (PD6) compound 1 as PDE5 Inhibitors, structure lack a CH2
2w1h  2.15  2009  IC50=52nM     // 2w1c.pdf (L0F) compound 7
2wmr  2.43  2009  IC50=52uM     // 2wmq.pdf (ZYR) Fragment: KINASE DOMAIN, RESIDUES 1-289
3fu0  1.80  2009  IC50=5308uM   // 3fts.pdf (22F) compound 6
2wu7  2.25  2009  IC50=530nM    // 2wu6.pdf (V25) Fragment: RESIDUES 127-484; IC50=530+/-140nM;
3fl8  2.29  2009  IC50=54nM     // 3fl8.pdf (RAR)
3dpe  1.60  2009  IC50=57nM     // 3dng.pdf (AXB) monoclinic form
3dpf  2.10  2009  IC50=57nM     // 3dng.pdf (AXB) orthorhombic form
3f2a  1.90  2009  IC50=57nM     // 3f2a.pdf (985) Original dose-response IC50=340nM, resynthesized solid IC50=57+/-1.8nM
2wi7  2.50  2009  IC50=58nM     // 2wi1.pdf (2KL) compound 34d
3fyj  3.80  2009  IC50=5nM      // 3fyj.pdf (B97) benzothiophene inhibitor bound to MAPKAP Kinase-2 (MK-2)
3g86  2.20  2009  IC50=5nM      // 3g86.pdf (T18) structure 18 bound to CD21 NS5B polymerase
3h5s  2.00  2009  IC50=5nM      // 3h5s.pdf (H5S) structure 16 bound to C Delta 21 NS5B polymerase, IC50=0.005uM
3h98  1.90  2009  IC50=5nM      // 3h98.pdf (B5P) HCV NS5b 1b complex with compound 4a, IC50=0.005uM
3jzf  2.13  2009  IC50=5uM      // 3jzf.pdf (JZK) compound 1 bound to AccC ATP-site
3jzi  2.31  2009  IC50=5uM      // 3jzi.pdf (JZL) compound 70 bound to biotin carboxylase from E. Coli
3k23  3.00  2009  IC50=6.3nM    // 3k23.pdf (JZN) Glucocorticoid Receptor with Bound D-prolinamide 11, pIC50=8.2+/-0.1
2zir  2.40  2009  IC50=6.4nM    // 2zir.pdf (NH7) compound 8w
3g6h  2.35  2009  IC50=6.4nM    // 3g6g.pdf (G6H) Proto-oncogene tyrosine-protein kinase Src T338I mutant and DSA1, IC50=6.4+/-1.2nM
3kag  1.90  2009  IC50=6.6uM    // 3kab.pdf (4D7) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 19a
3hac  2.00  2009  IC50=6.7nM    // 3hab.pdf (361) DPP4 complex with compound 34, 34a IC50=0.0067uM, 34b IC50=0.0083uM
2w6o  2.50  2009  IC50=60.8uM   // 2w6m.pdf (OA3) compound 3
3h0w  1.81  2009  IC50=600nM    // 3h0v.pdf (N8M) Human AdoMetDC and DMAMA
3hvc  2.10  2009  IC50=600nM    // 3hvc.pdf (GG5) human p38 alpha MAP kinase with 4-FPP
3fty  2.15  2009  IC50=619uM    // 3fts.pdf (3IP) compound 5, IC50=619+/-131uM
3i7i  2.21  2009  IC50=620nM    // 3i7g.pdf (518) MMP-13 in complex with a non zinc-chelating inhibitor
2w0x  2.12  2009  IC50=625uM    // 2w0x.pdf (PD2) compound 4
2wo9  1.70  2009  IC50=62nM     // 2wo8.pdf (068) compound 6c
3kab  2.19  2009  IC50=630uM    // 3kab.pdf (4BL) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 5
3fzt  1.95  2009  IC50=637nM    // 3fzp.pdf (4JZ) compound  PF-4618433
3hdn  3.10  2009  IC50=63nM     // 3hdm.pdf (GMG) serum and glucocorticoid-regulated kinase 1 complex with compound 2
3ig7  1.80  2009  IC50=63nM     // 3ig7.pdf (EFP) inhibitor EFP with CDK-2, compound 19, 9nM x 7=63nM
3f7b  2.05  2009  IC50=64nM     // 3f7b.pdf (AG5) compound 6f
3f7z  2.40  2009  IC50=65nM     // 3f7z.pdf (34O) compound 1
3igg  1.80  2009  IC50=66.5nM   // 3ig7.pdf (EFQ) inhibitor EFQ with CDK-2, compound 15, 95nM x 0.7=66.5nM
3jsw  2.30  2009  IC50=66nM     // 3jsi.pdf (JAR) PDE9A inhibitor 7 bound in PDE9A
2wuu  1.42  2009  IC50=68.7nM   // 2wuu.pdf (NHW) IC50=68.7+/-4.2nM
3ewh  1.60  2009  IC50=69nM     // 3da6.pdf (K11) IC501=69+/-10nM(KDR/K11); IC502=240+/-170nM(Tie-2/K11).
3h0y  2.50  2009  IC50=6nM      // 3h0y.pdf (48B) Aurora A in complex with a bisanilinopyrimidine, compound 5
3hhk  1.70  2009  IC50=6nM      // 3hhk.pdf (77Z) compound 11d bound to NS5B (genotype 1b, BK strain, Delta 21 construct)
3i28  1.95  2009  IC50=6nM      // 3i1y.pdf (34N) soluble epoxide hydrolase and inhibitors 24, human IC50=6nM, rats=9nM
3dng  2.00  2009  IC50=7.4nM    // 3dng.pdf (AXA) compound 2(S)
3kad  1.95  2009  IC50=7.5uM    // 3kab.pdf (4C0) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 18c
3h9o  2.30  2009  IC50=70nM     // 3h9o.pdf (9BD) Phosphoinositide-dependent protein kinase 1 (PDK-1) in complex with compound 9
3dz2  1.86  2009  IC50=70uM     // 3dz2.pdf (A8M) compound 21c
2wou  2.30  2009  IC50=72nM     // 2wot.pdf (ZZF)
3kac  2.00  2009  IC50=740uM    // 3kab.pdf (4BX) Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 with compound 10
3f81  1.90  2009  IC50=74nM     // 3f81.pdf (STT) incomplete&nbsp; ligand&nbsp; structure with SA3 in reference
3fu5  2.30  2009  IC50=75.2uM   // 3fts.pdf (492) compound 8, IC50=75.2+/-7.3uM
2wey  2.80  2009  IC50=76nM     // 2wey.pdf (EV1) ligand is compound 1, papaverine
3fl9  2.40  2009  IC50=77.2mM   // 3fl8.pdf (TOP)
3ewz  1.40  2009  IC50=79uM     // 3ewu.pdf (CNU) 5-cyano-UMP, IC50=79+/-36uM
3dz5  2.43  2009  IC50=7nM      // 3dz2.pdf (M8M) compound 12a
3frz  1.86  2009  IC50=7nM      // 3frz.pdf (AG0) compound 24
3h0e  2.00  2009  IC50=7nM      // 3h0e.pdf (H0E) caspase-3 complex with compound 3
3i1y  2.47  2009  IC50=7nM      // 3i1y.pdf (33N) soluble epoxide hydrolase and inhibitors 1, human IC50=7nM, rats=4.8nM
3fpm  3.30  2009  IC50=8.9uM    // 3fpm.pdf (793) compound 17
3fqk  2.20  2009  IC50=81nM     // 3fqk.pdf (79Z) compound HCV-796; Kd=71+/-28nM; IC50=81+/-19nM
3f8w  2.30  2009  IC50=82.3uM   // 3e9r.pdf (ADN) compound adenosine; IC50=82.3+/-0.7uM
2wd1  2.00  2009  IC50=82nM     // 2wd1.pdf (ZZY)
3h2f  2.20  2009  IC50=86.7uM   // 3h21.pdf (B60) Dihydropteroate Synthase with compound 16
3jzs  1.78  2009  IC50=8nM      // 3jzo.pdf (12-mer) ligand is 12-mer peptide inhibitor pDIQ
3h22  2.40  2009  IC50=8uM      // 3h21.pdf (B53) Dihydropteroate Synthase with compound 3
2wmv  2.01  2009  IC50=9.2uM    // 2wmq.pdf (ZYV) Fragment: KINASE DOMAIN, RESIDUES 1-289
3dp1  2.30  2009  IC50=9.92uM   // 3doy.pdf (2RB) compound 3n, IC50=9.92+/-0.59uM
2wti  2.50  2009  IC50=92nM     // 2wtc.pdf (WTI) compound 53
3gnv  2.75  2009  IC50=93nM     // 3gnv.pdf (XNZ) NS5B-(R)-1b complex, Kd nd, IC50=0.093uM
3hyg  1.40  2009  IC50=93nM     // 3hy7.pdf (099) compound 8
3hv5  2.25  2009  IC50=95nM     // 3hv3.pdf (R24) compound 22; IC501=95+/-25nM(EFC, enzyme fragment complementation); IC502=150+/-40nM(HTRF, homogeneoustime-resolved  fluorescence)
3fuk  1.95  2009  IC50=966uM    // 3fts.pdf (58Z) compound 16, IC50=966+/-322uM
3hxd  1.95  2009  IC50=9uM      // 3hxb.pdf (BD7) Engineered RabGGTase complex with compound 9, IC50=9+/-1uM; dissociation constant(KI)=14.5uM
3k3j  2.00  2009  IC50>12.5uM   // 3k3i.pdf (F4C) p38 alpha bound to novel DGF-out compound PF-00416121, IC50>12.5uM
2wi1  2.30  2009  IC50>4000uM   // 2wi1.pdf (ZZ2) compound 11, IC50>4000uM
3k48  2.80  2009  IC50~0.49uM   // 3k48.pdf (16-mer) peptide 4.2, residues 104-241; not found for peptide 4.2, the IC50 may be 0.49~27 uM
3dvp  2.50  2009  Kd=0.01mM     // 3dvp.pdf (10-mer) Kd=0.01~0.1mM; incomplete ligand
3ikc  2.60  2009  Kd=0.035uM    // 3ijh.pdf (2-mer) Fab fragment of S67-27 complex Kdo(2-8)-7-O-Me-Kdo, KME-KDO, Kd=0.35x10-7M
3csl  2.70  2009  Kd=0.06uM     // 3csl.pdf (HEM) Heme bound with HasA-HasR, Kd=0.06uM
3c8e  1.50  2009  Kd=0.07mM     // 3c8e.pdf (GSH)
3gws  2.20  2009  Kd=0.081nM    // 3gws.pdf (T3)
2wjg  2.20  2009  Kd=0.08uM     // 2wjg.pdf (GDP)
3g15  1.70  2009  Kd=0.10uM     // 3feg.pdf (HC6) ligand is HC-3; Kd=0.10+/-0.003uM; Ki=0.21+/-0.01uM
3fsj  1.37  2009  Kd=0.113mM    // 3fsj.pdf (D7K) Ki=0.38+/-0.04mM
3bwk  2.42  2009  Kd=0.114mM    // 2oz2.pdf (C1P) ligand is K11017, Ka=8800M-1, Kd=0.114mM
2vk2  1.20  2009  Kd=0.13uM     // 2vk2.pdf (GZL) inferred affinity of YtfQ for galactofuranose is Kd=0.13uM
3fzy  1.95  2009  Kd=0.18uM     // 3fzy.pdf (IHP) Kd=0.18+/-0.02uM
3heg  2.20  2009  Kd=0.18uM     // 3hec.pdf (BAX) compound sorafenib; IC50=0.057uM
2w3o  1.85  2009  Kd=0.19uM     // 2w3o.pdf (8-mer) Kd=0.19+/-0.02uM, HUMAN PNKP FHA DOMAIN with AN XRCC1-DERIVED tri-PHOSPHOPEPTIDE
3g7l  2.20  2009  Kd=0.19uM     // 3g7l.pdf (16-mer) Chromodomain of Chp1 in complex with Histone H3K9me3 peptide, Kd=0.19+/-0.02uM; incomplete ligand
3a1c  1.85  2009  Kd=0.1mM      // 3a1c.pdf (ACP)
2w16  2.71  2009  Kd=0.1nM      // 2w16.pdf (8-mer) 8-mer peptide DSN-ARG-DSN-FHO-LYS-FHO-THR-THR
3drf  1.30  2009  Kd=0.1uM      // 3drf.pdf (8-mer)
3drg  2.50  2009  Kd=0.1uM      // 3drf.pdf (9-mer)
3g2t  2.00  2009  Kd=0.1uM      // 3g2t.pdf (13-mer) human GGA1-VHS complexed with SorLA C-terminal Phosphopeptide, Kd=0.1+/-0.03uM; incomplete ligand
3ie3  1.80  2009  Kd=0.21uM     // 3gur.pdf (N11) Kd=0.21+/-0.06uM
3el1  1.70  2009  Kd=0.23nM     // 3ekp.pdf (DR7) ligand is atazanavir; Kd=0.23+/-0.12nM
3eky  1.80  2009  Kd=0.23nM     // 3ekp.pdf (DR7) ligand is atazanavir; Kd=0.23+/-0.12nM; redundant to 3el1
3jvs  1.90  2009  Kd=0.29uM     // 3jvr.pdf (AGY) ligand is compound 3, Kd=0.29+/-0.07uM
3imy  2.55  2009  Kd=0.2nM      // 3imy.pdf (B72) ligand is compound 7
3bwj  2.30  2009  Kd=0.319uM    // 3bwj.pdf (ARX) ligand is compound 1; Kd=0.319+/-0.057uM; IC50=2.6+/-0.3uM
3gds  2.85  2009  Kd=0.31uM     // 3gco.pdf (10-mer) DegS H198P/D320A mutant modified by DFP complex DNRDGNVYYF peptide
3d1v  2.70  2009  Kd=0.324mM    // 3d1v.pdf (D1V) 2-mercapto(3H)quinazolinone; pKd=3.49, Kd=0.324mM(quinazolinone)
3g3r  2.00  2009  Kd=0.33uM     // 3g3r.pdf (ANP) Vtc4p*-AppNHp-Mn2+, Kd=0.33+/-0.04uM
3dla  2.35  2009  Kd=0.35mM     // 3dla.pdf (NXX) incomplete ligand structure
3d7m  2.90  2009  Kd=0.36uM     // 3d7m.pdf (GDP) I56C/Q333C Galpha i1 in complex with GDP-AlF4-, Kd=0.36+/-0.01uM
3ffu  2.80  2009  Kd=0.36uM     // 3ef5.pdf (GTP) Kd=0.36uM(for Mg2+) without GTP
3e8u  2.10  2009  Kd=0.38nM     // 3e8u.pdf (11-mer) Fab 106.3 complex with BNP peptide epitope, Kd=0.38+/-0.07nM
3ekx  1.97  2009  Kd=0.39nM     // 3ekp.pdf (1UN) ligand is NFV; Kd=0.39+/-0.07nM
3ekv  1.75  2009  Kd=0.39nM     // 3ekp.pdf (478) ligand is amprenavir; Kd=0.39+/-0.20nM
2w73  1.45  2009  Kd=0.3uM      // 2w73.pdf (17-mer) A PEPTIDE FROM CALCINEURIN A, Kd1=0.7uM(Temper 35); Kd2=0.3uM(Temper 30)
3g2v  2.10  2009  Kd=0.3uM      // 3g2v.pdf (13-mer) VHS:SoP complex, Kd=0.3+/-0.02uM; incomplete ligand
3hjo  1.95  2009  Kd=0.3uM      // 3hjo.pdf (EAA) Glutathione Transferase Pi Y108V Mutant Complex with EASG, Kd=0.3+/-0.1uM; multiple ligands
3hik  1.77  2009  Kd=0.445uM    // 3hik.pdf (6-mer) Pentamer phosphopeptide-PLHSpT ; Kd=0.445+/-0.180uM
3fvh  1.58  2009  Kd=0.447uM    // 3c5l.pdf (7-mer) Kd=0.447+/-0.110uM
3ed0  2.30  2009  Kd=0.45uM     // 3ed0.pdf (EMO) Kd=0.45uM(ITC); Kd=4.59uM(SPR); Ki=1.9+/-0.3uM; IC50=9.7+/-1.0uM
2zx5  2.65  2009  Kd=0.469pM    // 2zwz.pdf (ZX5) compound 2; Kd=0.469+/-0.14pM; Ki=0.469pM
3f33  1.70  2009  Kd=0.46mM     // 3f33.pdf (PFL) ligand is compound 1; binding data in suppl info
3hxi  1.80  2009  Kd=0.47uM     // 3hxg.pdf (GTG) Kd=0.27uM(fluorescence titration); Kd=0.47+/-0.01uM(ITC)
2w77  2.90  2009  Kd=0.65nM     // 2w16.pdf (10-mer) 10-mer peptide SER-LYS-GLY-FHO-SER-SER-GLY-LYS-FH7-SER, Kd=0.65+/-0.07nM
3eu7  2.20  2009  Kd=0.66uM     // 3eu7.pdf (19-mer) 19 meric peptide from Breast cancer type 2 susceptibility protein; incomplete ligand
3f35  1.92  2009  Kd=0.69mM     // 3f33.pdf (DIE) compound 5(1); binding data in supplementary info; redundant to 3f34
3f34  1.68  2009  Kd=0.69mM     // 3f33.pdf (DIE) ligand is compound 5(2); binding data in suppl info
3g2s  1.70  2009  Kd=0.6uM      // 3g2s.pdf (13-mer) VHS Domain of human GGA1 complexed with SorLA C-terminal Peptide, Kd=0.6+/-0.02uM; incomplete ligand
2zym  1.80  2009  Kd=0.73uM     // 2zym.pdf (ACX) Kd=0.73+/-0.02uM
2kgi   NMR  2009  Kd=0.75uM     // 2kgi.pdf (9-mer) H3(1-9)K4me3 peptide
3gnw  2.39  2009  Kd=0.79nM     // 3gnv.pdf (XNC) NS5B in complex with (S)-4c; Kd=0.79nM, IC50=0.026uM
3e73  2.80  2009  Kd=0.7mM      // 3e73.pdf (GSH)
3a3y  2.80  2009  Kd=0.7nM      // 3a3y.pdf (OBN) X-ray(Na+, K+-ATPase ); Kd=0.7nM(ATPase in E2P-like states).
2k7l   NMR  2009  Kd=0.7uM      // 2k7l.pdf (19-mer) C-terminal domain of human RAP74 with centFCP1-T584PO4 peptide, Kd=0.7+/-0.1uM
2v58  2.10  2009  Kd=0.82nM     // 2v58.pdf (LZJ) ligand is inhibitor 1, Kd=0.82+/-0.22nM(SPR); Kd<5.0nM(ITC).
3iw5  2.50  2009  Kd=0.839uM    // 3iw5.pdf (DF3) ligand is compound 14, Kd=0.839+/-0.145uM
2w7y  2.35  2009  Kd=0.83uM     // 2w7y.pdf (3-mer) Ka=(1.2+/-0.3)x10-6M(UV); Ka=(1.01+/-0.16)x10-6M(ITC)
3ijy  2.85  2009  Kd=0.91uM     // 3ijh.pdf (2-mer) Fab fragment of S67-27 complex Kdo(2-8)Kdo, KDA-KDO, Kd=9.1x10-7M
3esj  2.70  2009  Kd=0.925mM    // 3elc.pdf (CC7) compound 7, Kd=0.925+/-0.71mM, temperature is 10 degree
3e12  1.70  2009  Kd=1.02uM     // 3e0i.pdf (KD0) Kd=1.02+/-0.01uM(pH=7.5); Kd=1.94+/-0.01uM(pH=5.0)
3dxm  2.85  2009  Kd=1.0uM      // 3dxk.pdf (N24) Kd=1.0+/-0.2uM; IC50=11uM
2kdh   NMR  2009  Kd=1.1mM      // 2kdh.pdf (KDH) Kd=1.1mM
2w8j  1.50  2009  Kd=1.1mM      // 2w8j.pdf (PLS) Kd=1.1+/-0.1mM
3img  1.80  2009  Kd=1.1mM      // 3img.pdf (BZ3) ligand is compound 33
3i9g  1.90  2009  Kd=1.1nM      // 3i9g.pdf (S1P) S1P:LT1009 Fab complex, Kd=1.1+/-0.1nM(50uM Ca2+), Kd=130+/-30nM (without Ca2+)
2weq  2.20  2009  Kd=1.27uM     // 2wep.pdf (GDM) Kd=1.27+/-0.09uM
2kfg   NMR  2009  Kd=1.2mM      // 2kff.pdf (12-mer) Rab11-FIP2 DPF peptide FNYESTDPFTAK, Ki=1.2+/-0.1mM
2zyn  1.70  2009  Kd=1.2uM      // 2zym.pdf (BCD) Kd=1.2+/-0.1uM
3f36  1.70  2009  Kd=1.3mM      // 3f33.pdf (IP0) compound 7; binding data in supplementary info
3ekp  2.15  2009  Kd=1.3nM      // 3ekp.pdf (478) ligand is amprenavir; Kd=1.3+/-0.01nM
3ghe  2.40  2009  Kd=1.3uM      // 3ghb.pdf (15-mer) anti-HIV-1 Fab 537-10D complex V3 peptide MN, SUPPLEMENTAL DATA
3h1x  1.40  2009  Kd=1.3uM      // 3h1x.pdf (IMN) ligand is indomethacin; Kd=1.3+/-0.2uM
3fxb  2.90  2009  Kd=1.4uM      // 3fxb.pdf (4CS) the UehA-ectoine complex, Kd=1.4+/-0.1uM
3h6z  2.80  2009  Kd=1.5uM      // 3h6z.pdf (6-mer) dSfmbt-4MBT and histone H4K20me1 peptide complex, Kd=1.5+/-0.03uM
3iue  1.73  2009  Kd=1.5uM      // 3imc.pdf (FG3) ligand is compound 4
3k8d  1.90  2009  Kd=1.7uM      // 3k8d.pdf (KDO) Kd=1.7+/-0.53uM, incomplete ligand structrue
3gpe  2.00  2009  Kd=1.8uM      // 3gpe.pdf (PT5) PKC (alpha)-C2 domain complexed with Ca2+ and PtdIns(4, 5)P2
3ivx  1.73  2009  Kd=1.8uM      // 3imc.pdf (FG6) ligand is compound 8
3hrf  1.90  2009  Kd=10.3uM     // 3hrc.pdf (P47) Human PDK1 kinase domain complex with ATP and PS48
2vr3  1.95  2009  Kd=10.5uM     // 2vr3.pdf (13-mer) Clumping factor A bound to FIBRINOGEN GAMMA-CHAIN; incomplete ligand
2w47  1.40  2009  Kd=10.5uM     // 2vzq.pdf (UNF) Ka=9.5x10+4M-1
3ekw  1.60  2009  Kd=10.9nM     // 3ekp.pdf (DR7) ligand is atazanavir; Kd=10.9+/-1.60nM
2w76  2.80  2009  Kd=10000nM    // 2w16.pdf (6-mer) 6-mer peptide SDB-FHO-GLN-GLN-FHO-GLY, Kd>10000nM
2w6u  3.00  2009  Kd=10000nM    // 2w16.pdf (7-mer) 7-mer peptide SER-ALA-AHO-ORN-ASP-AHO-SER, Kd>10000nM
2wnl  2.70  2009  Kd=1000nM     // 2wn9.pdf (AN5) Kd>1000nM
3ime  2.39  2009  Kd=1000uM     // 3imc.pdf (BZ2) ligand is compound 5
2wzf  2.10  2009  Kd=100nM      // 2wzf.pdf (UDP-BGC)
2kfx   NMR  2009  Kd=100uM      // 2kfx.pdf (WW7) P+L-P.L-P.L.L4, two equilirium, Kd1=100uM; Kd2=0.43pM
2whp  2.20  2009  Kd=100uM      // 2whp.pdf (HI6) Ki=31+/-2uM
3ijh  2.10  2009  Kd=100uM      // 3ijh.pdf (KO2) Fab fragment of S67-27 complex Ko, Kd=1000x10-7M
3hv8  1.45  2009  Kd=104.2nM    // 3hv8.pdf (C2E) ligand is c-di-GMP
2k0g   NMR  2009  Kd=107nM      // 2k0g.pdf (CMP)
3gkz  1.90  2009  Kd=10nM       // 3gkz.pdf (B40) scFv6H4 in complex with METH
3gvu  2.05  2009  Kd=10nM       // 3gvu.pdf (STI) ligand is imatinib
3hx3  1.69  2009  Kd=10nM       // 3hx3.pdf (RET) CRALBP mutant R234W complex 11-cis-retinal
2kbs   NMR  2009  Kd=10uM       // 2kbr.pdf (8-mer) octameric peptide from Cadherin-23(Cad23-PBM peptide), Kd=10+/-0.2uM
2vxn  0.82  2009  Kd=10uM       // 2vxn.pdf (PGH)
3cfn  1.87  2009  Kd=10uM       // 3cfn.pdf (2AN)
3dow  2.30  2009  Kd=11.5uM     // 3dow.pdf (12-mer) Kd=11.5+/-1.1uM, Gamma-aminobutyric acid receptor-associated protein bound to CRT peptide; incomplete ligand
3imc  1.60  2009  Kd=1100uM     // 3imc.pdf (BZ3) ligand is compound 1
2weh  2.10  2009  Kd=1125nM     // 2weg.pdf (FB1) ligand is compound 5
2weo  1.40  2009  Kd=118nM      // 2weg.pdf (FBW) ligand is compound 3
3jvk  1.80  2009  Kd=118uM      // 3jvk.pdf (8-mer) histone H3.3 peptide(GGK(ac)APRKQ); Kd=118+/-28uM
3g5d  2.20  2009  Kd=11nM       // 3f3v.pdf (1N1) Kd=11+/-3nM; IC50=0.4+/-0.2nM
3juq  1.75  2009  Kd=12.4uM     // 3jum.pdf (AJD&AKD) ligand is compound racemic-1, Kd=12.4+/-0.82uM
3cx9  2.80  2009  Kd=12.9uM     // 3cx9.pdf (LPX) Kd=5.6uM(in the absence of myristate); Kd=12.9uM(in the presence of myristate)
3fgc  2.30  2009  Kd=120uM      // 3fgc.pdf (FMN) luciferase/FMN complex, Kd is for reduced FMNH2, not FMN
3gk4  1.90  2009  Kd=120uM      // 3gk1.pdf (53A) compound SBi523 bound to Ca2+ S100B, Kd=0.12+/-0.03mM
3evd  1.50  2009  Kd=124nM      // 3eva.pdf (GTP) Kd=124+/-6nM; Ki=40+/-10nM
3evc  1.60  2009  Kd=124nM      // 3eva.pdf (GTP) Na+ citrate; Kd=124+/-6nM; Ki=40+/-10nM; redundant to 3evd
2wor  1.70  2009  Kd=125uM      // 2wor.pdf (2AN) S100A7 with 1,8 ANS, Kd=125+/-11uM
2wos  1.70  2009  Kd=125uM      // 2wor.pdf (6AN) S100A7 with 2,6 ANS, Kd=125+/-11uM
3ehn  2.80  2009  Kd=12mM       // 3ehn.pdf (NLC)
3h9f  2.60  2009  Kd=12nM       // 3cek.pdf (92M) supplementary information; compound Mps1-IN-2; IC50=145nM
3hv7  2.40  2009  Kd=12nM       // 3hv3.pdf (1AU) compound 4; Kd=12+/-2nM
3ij0  2.45  2009  Kd=13.2uM     // 3iiw.pdf (11-mer) Eed in complex with a trimethylated histone H3K9 peptide, Kd=13.2+/-1.6uM; incomplete ligand
3iw8  2.00  2009  Kd=13.4uM     // 3iw5.pdf (HIZ) compound 25, Kd=13.4+/-2.3uM
3hwx  2.60  2009  Kd=13.9nM     // 3hww.pdf (TPP) EcMenD ThDP complex, Kd=1.39x10-8M, PH=7.5
3gxz  2.50  2009  Kd=13nM       // 3gxz.pdf (11-mer) ligand is Man-9
3a1t  1.80  2009  Kd=14.8uM     // 3a1s.pdf (GDP) crystal form II; Kd=14.8+/-0.4uM
3a1s  1.50  2009  Kd=14.8uM     // 3a1s.pdf (GDP) in crystal form I; Kd=14.8+/-0.4uM
2w4x  2.42  2009  Kd=14uM       // 2w4x.pdf (STZ) Kd=14+/-0.4uM
3f70  2.10  2009  Kd=14uM       // 3f70.pdf (MLZ) L3MBTL2-H4K20me1 complex, Kd=14+/-0.2uM
3h52  2.80  2009  Kd=14uM       // 3h52.pdf (19-mer) binding of NCoR for GR-LBD in the presence of mifepristone; incomplete ligand
3k41  1.90  2009  Kd=150mM      // 3k41.pdf (M6D) EQKM mutant, wildtype Kd=1mM
3gcp  2.25  2009  Kd=15nM       // 3gcp.pdf (SB2) ligand is SB203580
3fbr  3.50  2009  Kd=15uM       // 3dnt.pdf (9-mer) HipA bound the EF-Tu peptide IREGGRTVGA, Kd=15+/-5uM
2zwz  2.36  2009  Kd=16.3nM     // 2zwz.pdf (ZWZ) ligand is compound 1; Kd=16.3+/-2.5nM; Ki=16.3nM
3f39  1.85  2009  Kd=16.5mM     // 3f33.pdf (IPH) compound 9; supplementary information
3gcu  2.10  2009  Kd=165nM      // 3gcp.pdf (R48) ligand is compound 11d; Kd=165+/-58nM
3bpc  1.85  2009  Kd=16uM       // 3bpc.pdf (2-mer) ligand is KDA-KDB
3iiy  2.65  2009  Kd=16uM       // 3iiw.pdf (11-mer) Eed in complex with a trimethylated histone H1K26 peptide, Kd=16+/-1uM; incomplete ligand
3dsz  2.00  2009  Kd=17.1nM     // 3dsz.pdf (LIZ) Kd=17.1+/-2nM for Tb7.N9 structure, Kd=13.2+/-1.5nM for Tb7.N9.N34
2w10  1.90  2009  Kd=170nM      // 2vwf.pdf (12-mer) 12-mer TYROSINE-PROTEIN PHOSPHATASE NON-RECEPTOR TYPE 23, Kd=0.17+/-0.06uM
3ekq  2.20  2009  Kd=176.0nM    // 3ekp.pdf (ROC) ligand is SQV; Kd=176.0+/-4.2nM
3gm0  2.40  2009  Kd=17nM       // 3gkz.pdf (B41) scFv6H4 in complex with MDMA
3ern  2.10  2009  Kd=18.91mM    // 3elc.pdf (CAR) AraCMP, Kd=18.91+/-5.8mM, temperature is 10 degree
3el5  1.60  2009  Kd=18.9nM     // 3ekp.pdf (1UN) ligand is NFV; Kd=18.9+/-0.25nM
3dgo  2.50  2009  Kd=180nM      // 3dgl.pdf (ATP) Kd=180+/-30nM
3h91  1.50  2009  Kd=185uM      // 2l11.pdf (15-mer) Protein 1 Fragment: UNP residues 9-62 ; Kd=185+/-20uM;
3fjg  2.20  2009  Kd=187uM      // 3fir.pdf (3PG)
2v59  2.40  2009  Kd=18nM       // 2v58.pdf (LZK) ligand is inhibitor 2, Kd=6.53+/-0.64nM(SPR); Kd=18+/-9nM(ITC).
3dnt  1.66  2009  Kd=18uM       // 3dnt.pdf (ATP) Kd=18+/-2uM
3f3u  2.50  2009  Kd=18uM       // 3f3t.pdf (1AW) ligand is compound 1b, Kd=18+/-0.9uM
3hg1  3.00  2009  Kd=18uM       // 3hg1.pdf (10-mer) ligand is human leukocyte antigen (HLA)-A*0201-ELA peptide (ELAGIGILTV); Kd=18+/-1uM at temperature 25 degree
3fuc  1.45  2009  Kd=190pM      // 3fuc.pdf (9D9&9DG) PNP in complex with DFPP-DG, Kd=190+/-90pM
3fj7  1.70  2009  Kd=195uM      // 3fir.pdf (PEQ) PEP and PEQ are the same ligands
3d4f  1.55  2009  Kd=19nM       // 3d4f.pdf (LN1) Kd1=19+/-3nM(progress curves); Kd2=27+/-2nM(direct competition reaction.); Ki=0.11+/-0.01uM
2wf5  1.30  2009  Kd=1uM        // 2wf5.pdf (BG6)
3elc  2.50  2009  Kd=2.02mM     // 3elc.pdf (F01) Kd=2.02+/-0.42mM measured at 10C
3dkj  2.00  2009  Kd=2.0uM      // 3dgr.pdf (PRP) human NAMPT complexed benzamide and phosphoribosyl pyrophosphate, Kd=2.0+/-0.2uM(for PRP)
3iuc  2.40  2009  Kd=2.17uM     // 3iuc.pdf (ADP) ITC Kd=3.8uM
3d45  3.00  2009  Kd=2.1uM      // 3d45.pdf (7MG) Kd=2.1+/-0.07uM
3a1e  1.95  2009  Kd=2.2mM      // 3a1c.pdf (ACP)
3g2w  2.40  2009  Kd=2.2uM      // 3g2w.pdf (14-mer) VHS Domain of human GGA1 complexed with a DXXLL hinge peptide, Kd=2.2+/-0.4uM; incomplete ligand
3fwv  2.20  2009  Kd=2.3uM      // 3fwv.pdf (6-mer) TPR Protein, T-MOD(VMY) in complex with MEEVF peptide
3iw7  2.40  2009  Kd=2.3uM      // 3iw5.pdf (IPK) compound 15, Kd=2.3+/-0.57uM; incomplete ligand structure
2kfh   NMR  2009  Kd=2.4mM      // 2kff.pdf (12-mer) Rab11-FIP2 GPF peptide FNYESTGPFTAK, Ki=2.4+/-0.1mM
3f38  1.75  2009  Kd=2.4mM      // 3f33.pdf (2MY) compound 8(1); binding data in supplementary info; redundant to 3f37
3f37  1.54  2009  Kd=2.4mM      // 3f33.pdf (2MY) ligand is compound 8(2); binding data in suppl info
3e3c  2.50  2009  Kd=2.4uM      // 3e3c.pdf (HHG)
2vxa  2.60  2009  Kd=2.5uM      // 2vx9.pdf (RBF) HhDod for RF, Kd=2.5uM
3e6y  2.50  2009  Kd=2.5uM      // 3e6y.pdf (CW1) ligand is cotylenin A
3jup  1.90  2009  Kd=2.63uM     // 3jum.pdf (AKD) ligand is compound S-1, Kd=2.63+/-1.1uM
3gxy  2.40  2009  Kd=2.6uM      // 3gxy.pdf (3-mer)
2w6t  2.90  2009  Kd=2.7nM      // 2w16.pdf (10-mer) 10-mer peptide SER-LYS-GLY-FHO-SER-SER-GLY-ORN-FHO-SER, Kd=2.7+/-0.2nM
2w78  3.00  2009  Kd=2.7nM      // 2w16.pdf (7-mer) 7-mer peptide SER-LYS-GLY-FHO-LYS-FH7-SER, Kd=2.7+/-0.7nM; incomplete ligand structure
3kjd  1.95  2009  Kd=2.9nM      // 3kcz.pdf (78P) ligand is inhibitor ABT-888
3ggw  1.70  2009  Kd=2.9uM      // 3ggw.pdf (12-mer) FAB F22-4 complex a peptide, ITC Kd=2.9+/-0.3uM, SPR Kd=3.3+/-0.2uM; incomplete ligand
3gl6  1.90  2009  Kd=20.7uM     // 2kgi.pdf (9-mer) unmodified Histone H3 N-terminal residues 1-9
3dp9  2.30  2009  Kd=208pM      // 3dp9.pdf (BIG) Kd=208+/-46pM; IC50=6+/-1nM
3gf2  1.80  2009  Kd=20mM       // 3gf2.pdf (SAL) hypothetical regulator ST1710 complexed with sodium salicylate, Kd=20+/-4.9mM
3g0e  1.60  2009  Kd=20nM       // 3g0e.pdf (B49) KIT kinase domain in complex with sunitinib, Kd=20+/-13nM
3hy5  3.04  2009  Kd=20nM       // 3hx3.pdf (RET) wild type CRALBP complex 11-cis-retinal, two fold weak than R234W mutant
3ij1  2.10  2009  Kd=20uM       // 3iiw.pdf (11-mer) Eed in complex with a trimethylated histone H4K20 peptide, Kd=20+/-0.9uM; incomplete ligand
3k5i  2.00  2009  Kd=20uM       // 3k5h.pdf (AIR) Kd=20+/-8uM
3isj  2.20  2009  Kd=210uM      // 3imc.pdf (A8D) ligand is compound 2
3ioc  2.50  2009  Kd=210uM      // 3iob.pdf (A5D) ligand is compound PS-14a, Kd=210+/-20uM
3g19  1.85  2009  Kd=214nM      // 3g19.pdf (3-mer) ligand is LLL tripeptide
2w87  1.60  2009  Kd=22.2uM     // 2vzq.pdf (GCU) Ka=4.5x10+4M-1
3g0f  2.60  2009  Kd=22nM       // 3g0e.pdf (B49) D816H mutant KIT kinase domain in complex with sunitinib, Kd=22+/-15nM
3h1z  1.83  2009  Kd=22uM       // 3h1z.pdf (15-mer) ligand is 15-mer PIPKI gamma-p90 peptide
3jpx  2.05  2009  Kd=235uM      // 3jpx.pdf (15-mer) ligand is 15-mer histone peptide H4K20me3; Kd=235+/-66uM; incomplete ligand
2zq1  1.68  2009  Kd=239nM      // 2zdk.pdf (11U) compound 1b(closed form); Kd=239+/-26nM; Ki=49+/-15nM
3d78  1.60  2009  Kd=23nM       // 3cyz.pdf (NBB) Kd=23+/-4nM
3k5k  1.70  2009  Kd=23nM       // 3k5k.pdf (DXQ) compound 8; Kd=23+/-8nM; IC50=15+/-10nM
3ifp  2.95  2009  Kd=24.5nM     // 3ifl.pdf (7-mer) Amyloid beta A4 protein
3iqg  1.90  2009  Kd=24.9uM     // 3iqg.pdf (5-mer) Kd=24.9+/-3.6uM; incomplete ligand
2kff   NMR  2009  Kd=245uM      // 2kff.pdf (12-mer) Rab11-FIP2 NPF peptide FNYESTNPFTAK, Kd=245+/-35uM
3eyu  2.71  2009  Kd=24nM       // 3eys.pdf (8-mer) Ror2(518-525)
2rol   NMR  2009  Kd=24uM       // 2rol.pdf (12-mer) Eps8L1 SH3 domain complex 12-mer peptide from T-cell surface glycoprotein CD3 epsilon chain
3iux  1.65  2009  Kd=25.1nM     // 3iux.pdf (18-mer) human MDM2 complex with 18-residues inhibitor stingin-1, Kd=25.1+/-5.1nM
2kbr   NMR  2009  Kd=25.4uM     // 2kbr.pdf (18-mer) harmonin N-terminal complex 18-mer peptide of cadherin23, Kd=25.4+/-0.8uM
3iqh  1.90  2009  Kd=25.8uM     // 3iqg.pdf (5-mer) Kd=25.8+/-1.7uM; incomplete ligand
3dgl  1.80  2009  Kd=250nM      // 3dgl.pdf (ATP) Kd=250+/-9nM; redundant to 2p09
2wp1  2.10  2009  Kd=251uM      // 2wp1.pdf (10-mer) Kd=251+/-62uM, BD2 bound to Histone H3 peptide; incomplete ligand
3ekt  1.97  2009  Kd=26pM       // 3ekp.pdf (017) ligand is DRV; Kd=26+/-10pM; same as 6dh0
3f3t  2.50  2009  Kd=26uM       // 3f3t.pdf (1AU) ligand is compound 1c, Kd=26+/-1.3uM; IC50=64.1+/-15.3uM
2khh   NMR  2009  Kd=276nM      // 2khh.pdf (9-mer) ligand is nucleoporin FxFG repeats; Kd=276+/-80nM
2zq2  1.40  2009  Kd=276nM      // 2zdk.pdf (13U) ligand is compound 1d(open form); Kd=276+/-76nM; Ki=102+/-18nM
3gfw  2.74  2009  Kd=27nM       // 3cek.pdf (S22) supplementary information; compound Mps1-IN-1; IC50=367nM
2uzj  1.55  2009  Kd=27uM       // 2uzj.pdf (E64) CYSTEINE PROTEASE INHIBITOR E64 LINKED TO CYSTEINE 47, Kd=27+/-7uM
2zhd  1.94  2009  Kd=287nM      // 2zdk.pdf (12U) compound 1c(open form); Kd=287+/-48nM; Ki=81+/-39nM; redundant to 2zfs
2zfs  1.51  2009  Kd=287nM      // 2zdk.pdf (12U) ligand is compound 1c(closed form); Kd=287+/-48nM; Ki=81+/-39nM
2w92  1.65  2009  Kd=28uM       // 2w92.pdf (NGT) Kd=28+/-4uM
3iub  1.50  2009  Kd=29uM       // 3imc.pdf (FG2) ligand is compound 3
3gk2  1.98  2009  Kd=2mM        // 3gk1.pdf (27A) compound SBi279 bound to Ca2+ S100B, Kd=2+/-1mM
3fhb  2.30  2009  Kd=2uM        // 3c49.pdf (GAB)
2wn9  1.75  2009  Kd=3.0nM      // 2wn9.pdf (ZY5) Kd=3.0+/-0.096nM
3da9  1.80  2009  Kd=3.1uM      // 3da9.pdf (44U) IC50=18uM
3iw6  2.10  2009  Kd=3.29uM     // 3iw5.pdf (PP0) ligand is compound 10, Kd=3.29+/-0.64uM
3ga5  1.87  2009  Kd=3.2uM      // 3ga5.pdf (RGG) Salmonella GBP in complex with GGal; binding data found in another reference
3eqs  1.65  2009  Kd=3.3nM      // 3eqs.pdf (12-mer) human MDM2 in complex with a 12-mer peptide, Kd1=3.3nM(ITC); Kd2=3.4uM(SPR); incomplete ligand
3ivv  1.25  2009  Kd=3.7uM      // 3hqi.pdf (10-mer) SPOPMATH-PucSBC1_pep1 complex, Kd=3.7+/-0.03uM; incomplete ligand structure
2wa8  2.15  2009  Kd=3.8uM      // 2w9r.pdf (10-mer) N-END RULE PEPTIDE Fpep: GRSKGEELFT
3gqo  2.60  2009  Kd=3.9uM      // 3gpo.pdf (APR) macro domain of VEEV virus in complex with ADP-ribose, Kd=3.9+/-0.65uM
2zft  1.76  2009  Kd=300nM      // 2zdk.pdf (10U) ligand is compound 1a(closed form); Kd1=300+/-34nM(Tris); Kd2=316+/-60nM(Tricine); Kd3=301+/-43M(Hepes); Kd4=245+/-38nM(PPi); Ki=117+/-25nM
3fdt  2.00  2009  Kd=30uM       // 2l11.pdf (15-mer) Kd=30+/-5uM;
2wl5  1.80  2009  Kd=30uM       // 2wkt.pdf (COA) ACETYL-COA ACETYLTRANSFERASE H348N MUTANT WITH COENZYME A, Kd=30+/-2uM
2weg  1.10  2009  Kd=314nM      // 2weg.pdf (FBV) ligand is compound 2
3eu5  2.80  2009  Kd=32nM       // 3eu5.pdf (GBO)
2wnj  1.80  2009  Kd=330nM      // 2wn9.pdf (ZY7) Kd=330+/-58nM
3gx0  2.30  2009  Kd=330uM      // 3gx0.pdf (GDS) GST-like protein yfcG in complex with GSH, Kd=330+/-10uM
3hec  2.50  2009  Kd=34.0uM     // 3hec.pdf (STI) compound imatinib; IC50=70.0uM
3el0  2.00  2009  Kd=34.1nM     // 3ekp.pdf (1UN) ligand is NFV; Kd=34.1+/-1.3nM
3gcq  2.00  2009  Kd=342nM      // 3gcp.pdf (1BU) compound 10b, Kd=342+/-39nM
2w2u  2.20  2009  Kd=35uM       // 2w2u.pdf (14-mer) Kd=35.0+/-9.4uM, ligand is a 14-mer peptide of Saci1373 (ESCRT-III); incomplete ligand
3iiw  1.80  2009  Kd=36.4uM     // 3iiw.pdf (11-mer) Eed in complex with a trimethylated histone H3K27 peptide, Kd=36.4+/-2.4uM; incomplete ligand
2vx9  1.65  2009  Kd=36nM       // 2vx9.pdf (RBF) X-ray(dodecin E45A with RF) while Kd(wild type dodecin with RF)
3fea  1.33  2009  Kd=36nM       // 3fe7.pdf (10-mer) Kd=36+/-2nM, p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3c-Leu-NH2
3gp0  1.90  2009  Kd=36nM       // 3gp0.pdf (NIL) ligand is Nilotinib
3k27  1.76  2009  Kd=36uM       // 3jpx.pdf (9-mer) H3K9me3; Kd1=24+/-3uM(fluorescence polarization assay); Kd2=36+/-3uM(ITC)
3dri  1.80  2009  Kd=37.7uM     // 3drf.pdf (6-mer)
2wig  2.15  2009  Kd=370uM      // 2wid.pdf (TC3) nonaged hBChE; compound TA4; Kd=370+/-40uM; Ki=4+/-0.5uM
2we3  2.00  2009  Kd=37uM       // 2we0.pdf (DUT)
3iqi  1.70  2009  Kd=38.7uM     // 3iqg.pdf (5-mer) Kd=38.7+/-2.8uM; incomplete ligand
2w08  1.70  2009  Kd=380uM      // 2w08.pdf (TPO)
3iob  1.80  2009  Kd=380uM      // 3iob.pdf (A4D) ligand is compound PS-6, Kd=380+/-30uM
3jzo  1.80  2009  Kd=3nM        // 3jzo.pdf (12-mer) pDI peptide; Kd=3nM(FP); IC50=550nM
3eys  1.95  2009  Kd=3uM        // 3eys.pdf (6-mer) incomplete ligand
3hqr  2.00  2009  Kd=3uM        // 3hqr.pdf (OGA) ligand is compound NOG
3el9  1.60  2009  Kd=4.00nM     // 3ekp.pdf (DR7) ligand is atazanavir; Kd=4.00+/-0.21nM
3e85  1.95  2009  Kd=4.2uM      // 3e85.pdf (BSU) Kd=4.2+/-1.6uM
3g8e  3.00  2009  Kd=4.5uM      // 3g8e.pdf (IS1) Visfatin with IS001, Kd=4.5+/-0.28uM
3efs  2.30  2009  Kd=4.6uM      // 3efr.pdf (ATP) Kd=4.6+/-0.5uM
3ftq  2.90  2009  Kd=4.7uM      // 3ftq.pdf (GNP) see supplement data
2w9r  1.70  2009  Kd=4.8uM      // 2w9r.pdf (11-mer) DNA Protection During Starvation Protein(Lpep: LVKSKATNLLY)
3k26  1.58  2009  Kd=400uM      // 3jpx.pdf (12-mer) ligand is 12-mer trimethylated H3K4 peptide; Kd>400uM; incomplete ligand
3jzh  2.05  2009  Kd=400uM      // 3jpx.pdf (5-mer)
3eor  2.90  2009  Kd=40mM       // 3elc.pdf (CFV) CDV, Kd~40mM, temperature is 10 degree
3fn0  1.80  2009  Kd=40uM       // 3fn0.pdf (9-mer) Envelope polyprotein gp160
3jzg  2.10  2009  Kd=40uM       // 3jpx.pdf (4-mer) H3K27me3; Kd=108+/-17uM(FP); Kd=40+/-6uM(ITC)
2w9h  1.48  2009  Kd=430nM      // 2w9h.pdf (TOP) Kd=430nM(without NADPH); Kd=0.97nM(with 200uM NADPH)
3dpc  2.30  2009  Kd=44uM       // 3dpc.pdf (10-mer) Phosphorylated Peptide P1-P
2rok   NMR  2009  Kd=45uM       // 2rok.pdf (2-mer) ligand is 7MG-GDP
3gjd  2.00  2009  Kd=46.8nM     // 3gjc.pdf (LEU) redundant to 3f3e
3kv2  1.55  2009  Kd=47.51nM    // 3kv2.pdf (NNH) nor-NOHA (Nx-hydroxy-nor-Larginine), Kd=517nM(SPR), Kd=47.51nM(ITC)
3dxk  2.70  2009  Kd=470nM      // 3dxk.pdf (N23) Kd=470+/-50nM; IC50=32uM
2wnc  2.20  2009  Kd=479nM      // 2wn9.pdf (TKT) Kd=479+/-57nM
2wkt  2.00  2009  Kd=49uM       // 2wkt.pdf (COA) ACETYL-COA ACETYLTRANSFERASE N316A MUTANT WITH COENZYME A, Kd=49+/-3uM
2wc4  1.70  2009  Kd=5.1uM      // 2wbg.pdf (AMF) ligand is compound 9
3g2u  2.30  2009  Kd=5.4uM      // 3g2u.pdf (13-mer) VHS Domain of human GGA1 complexed with Sotilin C-terminal Peptide, Kd=5.4+/-0.4uM; incomplete ligand
3dpo  2.10  2009  Kd=5.5nM      // 3dpo.pdf (11-mer) E. coli DnaK in complex with a short pyrrhocoricin-derived inhibitor peptide; incomplete ligand
3ivg  1.95  2009  Kd=50uM       // 3imc.pdf (FG5) ligand is compound 7
2wuf  1.90  2009  Kd=51uM       // 2wue.pdf (KEM) ligand is compound DSHA; Kd=51+/-2uM
2vzr  1.95  2009  Kd=52.6uM     // 2vzq.pdf (GCU) Ka=1.9x10+4M-1
3a6t  1.96  2009  Kd=52nM       // 3a6s.pdf (8OG) MutT in complex with 8-OXO-DGMP
3jrs  2.05  2009  Kd=52uM       // 3jrq.pdf (A8S) (+)-ABA-bound PYL1, Kd=52uM(ITC), Kd=340uM(SPR)
3ifo  2.15  2009  Kd=54.5nM     // 3ifl.pdf (7-mer) incomplete ligand
3ioe  1.95  2009  Kd=540uM      // 3iob.pdf (A7D) ligand is compound PS-14b, Kd=540+/-20uM
3cz1  1.50  2009  Kd=55.0nM     // 3cyz.pdf (NBB) Kd=55.0+/-8.0nM
3gcs  2.10  2009  Kd=56nM       // 3gcp.pdf (BAX) ligand is sorafenib; Kd=56+/-5nM
3h78  1.70  2009  Kd=57uM       // 3h77.pdf (BE2) PqsD C112A mutant in complex with 2-AMINOBENZOIC ACID
2ke1   NMR  2009  Kd=5uM        // 2ke1.pdf (10-mer) H3K4me0 peptide, Kd1=5.3+/-1.2uM(Fluorescence spectroscopy); Kd2=6.5+/-0.2uM(ITC).
3ebb  1.90  2009  Kd=5uM        // 3ebb.pdf (10-mer) incomplete ligand
3gpo  1.90  2009  Kd=5uM        // 3gpo.pdf (APR) macro domain of Chikungunya virus in complex with ADP-ribose, Kd=5+/-0.4uM
3g08  1.60  2009  Kd=6.843nM    // 3g08.pdf (FEE) Kd=6.843+/-3.001nM
3cyz  1.80  2009  Kd=60.0nM     // 3cyz.pdf (9OD) Kd=60.0+/-15.0nM
3dzt  1.80  2009  Kd=60.2nM     // 3dye.pdf (EAH) Kd=60.2+/-10.5nM
3dgn  2.70  2009  Kd=620nM      // 3dgl.pdf (ADP) Kd=620+/-81nM
3hqh  2.30  2009  Kd=63.6uM     // 3hqh.pdf (15-mer) SPOP-MATHx complex with MacroH2A SBC peptide 1, Kd=63.6+/-0.4uM; incomplete ligand
2wij  2.10  2009  Kd=630uM      // 2wid.pdf (TN7) nonaged hBChE; compound TA5; Kd=630+/-60uM; Ki=8+/-0.6uM
2wl4  1.80  2009  Kd=64uM       // 2wkt.pdf (COA) ACETYL-COA ACETYLTRANSFERASE H348A MUTANT WITH COENZYME A, Kd=64+/-4uM
3cft  1.87  2009  Kd=64uM       // 3cfn.pdf (5NS) Kd=64+/-18uM
2wik  2.10  2009  Kd=660uM      // 2wid.pdf (TC5) nonaged hBChE; compound TA6; Kd=660+/-50uM; Ki=17+/-0.3uM
3el4  2.00  2009  Kd=67.4nM     // 3ekp.pdf (ROC) ligand is SQV; Kd=67.4+/-0.3nM
3h85  2.60  2009  Kd=6uM        // 3h1z.pdf (8-mer) PIPKIgamma-p90 peptide
2w8w  2.14  2009  Kd=7.5mM      // 2w8j.pdf (PLS) Kd=7.5+/-0.5mM
2wfj  0.75  2009  Kd=70nM       // 2wfj.pdf (11-mer) Peptidyl-prolyl cis-trans isomerase G complex with CYCLOSPORIN A peptide
3fql  1.80  2009  Kd=71nM       // 3fqk.pdf (79Z) ligand is compound HCV-796; Kd=71+/-28nM; IC50=81+/-19nM
3f3v  2.60  2009  Kd=73nM       // 3f3v.pdf (1BU) Kd=73+/-16nM; IC50=21+/-5nM
3gcv  2.30  2009  Kd=74nM       // 3gcp.pdf (SS6) compound 10h, Kd=74+/-2nM
3fe7  1.35  2009  Kd=75nM       // 3fe7.pdf (10-mer) Kd=75+/-3nM, p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-Trp-Glu-Ac3c-Leu-NH2
3hww  1.95  2009  Kd=75nM       // 3hww.pdf (AKG) EcMenD oxoglutarate complex, Kd=7.5x10-8M (pH=7.5)
3a1d  1.85  2009  Kd=75uM       // 3a1c.pdf (ADP)
3ivc  2.13  2009  Kd=75uM       // 3imc.pdf (FG4) ligand is compound 6
3ivq  2.10  2009  Kd=76.1uM     // 3hqi.pdf (12-mer) SPOPMATH-CiSBC2 complex, Kd=76.1+/-0.9uM; incomplete ligand
2v57  1.90  2009  Kd=79nM       // 2v57.pdf (PRL) one proflavine to homodimer Kd1=79nM, two proflavine to monomer Kd2=4.3uM
2knh   NMR  2009  Kd=7uM        // 2knh.pdf (18-mer) ligand is HEB peptide, Kd=7+/-2uM
3efr  2.55  2009  Kd=8.3uM      // 3efr.pdf (BTN) Kd=8.3+/-2.1uM
3ifl  1.50  2009  Kd=8.4nM      // 3ifl.pdf (7-mer)
3juo  2.20  2009  Kd=8.55uM     // 3jum.pdf (AJD) ligand is compound R-1, Kd=8.55+/-2.6uM
2vwf  1.58  2009  Kd=8.7uM      // 2vwf.pdf (15-mer) 15-mer GRB2-ASSOCIATED-BINDING PROTEIN 2, Kd=8.7+/-0.3uM; incomplete ligand
3eqy  1.63  2009  Kd=8.9nM      // 3eqs.pdf (12-mer) human MDMX in complex with a 12-mer peptide, Kd1=8.9nM(ITC); Kd2=4.2uM(SPR)
3f78  1.60  2009  Kd=800uM      // 3f78.pdf (ICF)
3gk1  2.10  2009  Kd=80uM       // 3gk1.pdf (32A) ligand is compound SBi132+Ca2+ S100B, Kd=0.08+/-0.02mM
3iod  1.75  2009  Kd=80uM       // 3iob.pdf (A6D) ligand is compound PS-14b, Kd=80+/-10uM
2kmx   NMR  2009  Kd=83.3uM     // 2kmx.pdf (ATP) Ka=1.2x10^4M-1, Kd=8.33x10-5M
2wej  1.45  2009  Kd=839nM      // 2weg.pdf (FB2) ligand is compound 1
2wgi  2.85  2009  Kd=85uM       // 2wgi.pdf (PNM) X-ray structure(W154A-PenG); Kd1=85+/-5uM(carbon dioxide for W154A  OXA-10).
2zsc  1.30  2009  Kd=87nM       // 2zsc.pdf (BTN) X-ray(tamavidin-2 with biotin) while Kd=87+/-20nM(tamavidin 2 with 2-iminobiotin)
3kr8  2.10  2009  Kd=8nM        // 3kr8.pdf (XAV) ligand is inhibitor XAV939, Kd=8+/-3nM
2w85   NMR  2009  Kd=9.17uM     // 2w85.pdf (12-mer) Peroxisomal Membrane Anchor Protein Pex14 complex Peroxin-19, Kd=9.17+/-0.03uM
2wji  1.90  2009  Kd=9.6uM      // 2wjg.pdf (GNP)
3gus  1.53  2009  Kd=900nM      // 3gur.pdf (N11) Kd=0.90uM; IC50=0.8uM
2wer  1.60  2009  Kd=90nM       // 2wep.pdf (RDC) Kd=90+/-0.007nM
2w0z  1.70  2009  Kd=93.8uM     // 2vwf.pdf (9-mer) Gab2a truncated, Kd=93.8+/-3.8uM
3fzn  1.62  2009  Kd=97uM       // 3fzn.pdf (D7K) BFDC in complex with MBP, Kd=97+/-9uM
3i90  2.00  2009  Kd>500uM      // 2l11.pdf (11-mer) Protein 1 Fragment: Chromo domain: UNP residues 9-64  ;
3gv6  1.76  2009  Kd>500uM      // 2l11.pdf (15-mer) protein 1 Fragment: UNP residues 8-65  ; protein 2 Fragment: UNP residues 2-16 ;
3i91  1.55  2009  Kd>500uM      // 2l11.pdf (8-mer) protein 1 Fragment: Chromo domain: UNP residues 8-61 ;
3dkg  1.91  2009  Ki<10uM       // 3dkc.pdf (SX8) compound SGX532; Ki<10uM; IC50>10uM
2wgj  2.00  2009  Ki=0.002uM    // 2wgj.pdf (VGH)
3k84  2.25  2009  Ki=0.003uM    // 3k84.pdf (K84) ligand is compound 4b
3iok  2.10  2009  Ki=0.011uM    // 3io7.pdf (1P6) tyrosine-protein kinase JAK2 complex compound 42
3ggv  3.09  2009  Ki=0.014nM    // 3gga.pdf (GGV) HIV Protease inhibitors with compound 10c
3io7  2.60  2009  Ki=0.017uM    // 3io7.pdf (1P5) Tyrosine-protein kinase JAK2 complex Compound 12
3h8c  2.50  2009  Ki=0.019uM    // 3h89.pdf (NSZ) inhibitors 14
3g35  1.41  2009  Ki=0.021mM    // 3g2y.pdf (F13) ligand is compound 12(F13); Ki=0.021mM
3k83  2.25  2009  Ki=0.022uM    // 3k83.pdf (F27) ligand is compound 17
3h89  2.50  2009  Ki=0.023uM    // 3h89.pdf (NSX) ligand is inhibitor 4
3f5k  1.80  2009  Ki=0.024mM    // 3aht.pdf (CE5) ligand is compound cellopentaose; Ki=0.024+/-0.02mM
3fkv  1.85  2009  Ki=0.027uM    // 3fkv.pdf (BZB) ligand is compound 36, special B atom in ligand
2zjw  2.40  2009  Ki=0.02uM     // 2zjw.pdf (REF) IC50=0.04uM
3k7f  1.95  2009  Ki=0.02uM     // 3k7f.pdf (F2C) ligand is compound 40
3kcf  2.80  2009  Ki=0.035uM    // 3kcf.pdf (JZO) TGFbRI kinase activity of compound 24
2zy1  1.78  2009  Ki=0.04uM     // 2zy1.pdf (830) IC50=8nM
3f5j  1.95  2009  Ki=0.052mM    // 3aht.pdf (CTT) ligand is compound cellotetraose; Ki=0.052+/-0.06mM
3ikg  1.86  2009  Ki=0.057uM    // 3ikd.pdf (J8Z) ligand is compound 22b and Pin1 K77 82Q construct
3h5b  1.29  2009  Ki=0.099nM    // 3h5b.pdf (031) ligand is compound 19b; Ki=0.099nM; IC50=0.026nM
3jya  2.10  2009  Ki=0.1301uM   // 3jya.pdf (LWG) ligand is compound 3b
3fx6  1.85  2009  Ki=0.16uM     // 3fx6.pdf (BPX) CPA-R-5 complex; compound R-5 is incorrect in reference
3ikd  2.00  2009  Ki=0.179uM    // 3ikd.pdf (J9Z) ligand is compound 18b and Pin1 K77 82Q construct
3dk1  1.07  2009  Ki=0.18nM     // 3dk1.pdf (G05) ligand is compound 3; IC50=170nM
3f5l  1.37  2009  Ki=0.191mM    // 3aht.pdf (LB2) ligand is compound laminaribiose; Ki=0.191+/-0.02mM
3g32  1.31  2009  Ki=0.194mM    // 3g2y.pdf (3G3) ligand is compound 6(3G3); Ki=0.194mM
3elm  1.90  2009  Ki=0.19nM     // 3elm.pdf (24F)
2zz6  1.66  2009  Ki=0.19uM     // 2zz1.pdf (6AZ) native enzyme and 6-N3-UMP complex
2zo3  1.70  2009  Ki=0.1nM      // 2zc9.pdf (33U) compound 6, Ki=0.1+/-0.2nM
2wap  2.80  2009  Ki=0.23uM     // 2wap.pdf (PIX) covalent&nbsp; complex; ki=0.23+/-0.03uM, ligand is a little different from PF-3845
3gs6  2.30  2009  Ki=0.26uM     // 2wca.pdf (NP6)
3blt  2.20  2009  Ki=0.29mM     // 3blt.pdf (PSY) equilibrium binding constant Ki=0.29+/-0.06mM, covalently bind to Cys of active site
3eyd  2.30  2009  Ki=0.2nM      // 3eyd.pdf (BE8) compound 17
3gsm  2.40  2009  Ki=0.33uM     // 2wca.pdf (VPU)
3fv3  1.85  2009  Ki=0.3nM      // 3fv3.pdf (6-mer) Sapp1p in complex with pepstatin A
3g0w  1.95  2009  Ki=0.3nM      // 3g0w.pdf (LGB) ligand is compound 6c, Ki=0.3+/-0.1nM
3g5k  1.70  2009  Ki=0.3nM      // 3g5k.pdf (BB2) ligand is compound 1(actinonin)
2wcg  2.30  2009  Ki=0.42uM     // 2wcg.pdf (MT5)
3g90  2.40  2009  Ki=0.44uM     // 3g90.pdf (J72) Mitogen-activated protein kinase, JNK3 with compound 25
3ctt  2.10  2009  Ki=0.45uM     // 2jjb.pdf (3CU)
2wk6  2.50  2009  Ki=0.48mM     // 2wk6.pdf (IUR)
2zga  1.65  2009  Ki=0.48uM     // 2zga.pdf (YDP) incomplete ligand structure
3ckt  1.65  2009  Ki=0.48uM     // 2zga.pdf (YDP) redundant to 2zga
3jq9  2.30  2009  Ki=0.4uM      // 3bmc.pdf (AX1) Pteridine Reductase 1 complex NADP+ and AX1 compound 13, Ki=0.4uM
3h8b  1.80  2009  Ki=0.511uM    // 3h89.pdf (NSY) ligand is inhibitor 9
2znt  1.60  2009  Ki=0.5nM      // 2zns.pdf (DYH) redundant to 3fv1
2w8f  2.70  2009  Ki=0.5uM      // 2w8e.pdf (BS1) APLYSIA CALIFORNICA ACHBP BOUND TO IN SILICO COMPOUND 31, pKi=6.3+/-0.2
3dxh  1.40  2009  Ki=0.65mM     // 3dxh.pdf (UDP) Ki=0.65+/-0.06mM
3hk1  1.70  2009  Ki=0.67uM     // 3hk1.pdf (B64) AFABP/aP2 complexed with 1, Ki=0.67+/-0.18uM
2k1q   NMR  2009  Ki=0.6uM      // 2k1q.pdf (5-mer) hepatitis c virus ns3 serine protease complex with 5-mer phenethylamide inhibitor
3e9i  2.20  2009  Ki=0.6uM      // 3e9h.pdf (XAH) BsLysRS-LXT-AMP complex; ligand is LXT-AMP; Ki=0.6uM for BsLysRS; Ki=86+/-7uM for EsLysRS
2wb5  2.31  2009  Ki=0.74nM     // 2wb5.pdf (VGB) ligand is GlcNAcstatins D; Ki=0.74+/-0.09nM
3g9l  2.20  2009  Ki=0.74uM     // 3g90.pdf (J67) Mitogen-activated protein kinase, JNK3 with compound 47
3ibu  1.41  2009  Ki=0.7nM      // 3ibi.pdf (O48) adducts of sulfamates 2 with hCA II
2w8y  1.80  2009  Ki=0.82nM     // 2w8y.pdf (486) Ki=0.82+/-0.01nM; binding data measured with rabbit protein; LBD of rabbit and human proteins are identical
2wc3  2.00  2009  Ki=0.83uM     // 2wbg.pdf (AM3) ligand is compound 8
3gba  1.35  2009  Ki=0.848nM    // 3gba.pdf (DYH) ligand is compound DH; Ki=0.848+/-0.150nM.
3ffg  1.54  2009  Ki=0.84nM     // 3ffg.pdf (FFG) ligand is compound 5d
3kck  2.20  2009  Ki=0.8nM      // 3kck.pdf (3KC) compound 15a
2zu3  1.75  2009  Ki=0.8uM      // 2zu3.pdf (ZU3)
3jqb  2.40  2009  Ki=0.96uM     // 3bmc.pdf (DX6) Pteridine Reductase 1 complex NADP+ and DX6 compound 7, Ki=0.96uM
3hb4  2.21  2009  Ki=0.9nM      // 3hb4.pdf (E2B) Ki=0.9+/-0.15nM; IC50=42nM
3iss  2.50  2009  Ki=0.9uM      // 3iss.pdf (EPU) MurA3 UDP-MurNAc3 phosphite structure
3g34  1.31  2009  Ki=1.1mM      // 3g2y.pdf (1CE) ligand is compound 11(1CE); Ki=1.1mM
3dcc  1.60  2009  Ki=1.1nM      // 3d8w.pdf (D9Z) ligand is inhibitor CHL, Ki=1.1+/-0.2nM
3g3m  1.40  2009  Ki=1.1uM      // 3g3d.pdf (5FU) Human ODCases with compound 40, 5-fluoro-6-iodo-UMP, but PDB still is 5FU
3ebp  2.00  2009  Ki=1.24uM     // 3ebo.pdf (CPB) ligand is Flavopiridol
3egt  2.00  2009  Ki=1.26nM     // 3dyf.pdf (722)
3jq7  1.80  2009  Ki=1.2uM      // 3bmc.pdf (DX2) Pteridine Reductase 1 complex NADP+ and DX2 compound 2, Ki=1.2uM
2woq  1.75  2009  Ki=1.33mM     // 2woq.pdf (AYC) covalent complex; IC50=2.1mM
3g31  1.70  2009  Ki=1.3mM      // 3g2y.pdf (GF1) ligand is compound 4(GF1); Ki=1.3mM
3ehy  1.90  2009  Ki=1.4uM      // 3ehx.pdf (TBL) ligand is compound 2; Ki=1.4+/-0.2uM
2zxg  1.55  2009  Ki=1.5nM      // 2zxg.pdf (S23) crystal structure(E. coli APN); Ki=1.5+/-0.2nM(E. coli APN); Ki=2.2+/-0.5nM(Hog kidney APN)
3fcq  1.75  2009  Ki=1.7mM      // 3f28.pdf (M3S) ligand is compound 9
2wkz  1.70  2009  Ki=1.7nM      // 2wkz.pdf (5AH)
3e4a  2.60  2009  Ki=1.7nM      // 3e4a.pdf (QIX) incomplete ligand structure in RCSB PDB
3cso  2.71  2009  Ki=1.7uM      // 3cso.pdf (XNI) Ki=1.7+/-1.2uM; IC50=1.8+/-1.1uM
3jvr  1.76  2009  Ki=1.89uM     // 3jvr.pdf (AGX) ligand is compound 2, Ki=1.89+/-0.32uM
3g9n  2.80  2009  Ki=1.8uM      // 3g90.pdf (J88) Mitogen-activated protein kinase, JNK3 with compound 41
2wj1  1.84  2009  Ki=1.9nM      // 2wj1.pdf (S99) compound 2
3gjs  1.90  2009  Ki=10.2uM     // 3gjq.pdf (5-mer) Caspase-3 Binds Ac-YVAD-Cho peptide, Ki=10.2+/-0.41uM
2wd7  1.90  2009  Ki=10.6uM     // 2wd7.pdf (VGD) PTERIDINE REDUCTASE 1 (PTR1) FROM TRYPANOSOMA BRUCEI complex compound 4
2kaw   NMR  2009  Ki=10.7uM     // 2kaw.pdf (SUZ) Ki=10.7+/-1.2uM.
3dux  1.60  2009  Ki=100nM      // 2zc9.pdf (64U) compound 7, Ki=100+/-39nM
3djq  1.53  2009  Ki=1046.4uM   // 3djo.pdf (UDP) Ki=1046.4+/-50.2uM
3g2y  1.31  2009  Ki=10mM       // 3g2y.pdf (GF4)
2vwn  1.61  2009  Ki=10nM       // 2vvc.pdf (H25) ligand is compound 14
3fur  2.30  2009  Ki=10nM       // 3fur.pdf (Z12) PPARg with INT131, displace [3H]-rosiglitazone with a Ki of 10 nM
3hs4  1.10  2009  Ki=10nM       // 3hs4.pdf (AZM)
3gbe  1.70  2009  Ki=10uM       // 3gbd.pdf (NOJ) SmuA in complex with the inhibitor deoxynojirimycin
3dcs  1.80  2009  Ki=11.4nM     // 3d8w.pdf (MZM) ligand is inhibitor MZM, Ki=11.4+/-2nM; redundant to 3daz
3daz  1.60  2009  Ki=11.8nM     // 3d8w.pdf (MZM) ligand is inhibitor MZM, Ki=11.8+/-1.8nM
3iww  2.30  2009  Ki=11nM       // 3iww.pdf (YZE) GCPII in complex with compound 32d
2w67  2.25  2009  Ki=11uM       // 2w66.pdf (F34) ligand is compound 5, Ki=11+/-1uM
3ibc  2.75  2009  Ki=12.4uM     // 3ibc.pdf (5-mer) caspase-7/Ac-YVAD-Cho complex, Ki=12.4+/-0.5uM
3gbb  2.10  2009  Ki=126nM      // 3gba.pdf (MS8) ligand is compound MSV-19; Ki=126+/-45nM.
2jjb  1.90  2009  Ki=12nM       // 2jjb.pdf (3CU+GLC) compound 2; casuarine 6-O-a-glucopyranoside
3eft  1.85  2009  Ki=12nM       // 3eft.pdf (3BS)
3eax  1.90  2009  Ki=12uM       // 3eax.pdf (LZP) ligand is compound LZP6, Ki=12+/-0.6uM; IC50=16+/-2uM
3hfv  2.60  2009  Ki=13.6uM     // 3hfv.pdf (MTY) human mitochondrial phenylalanyl-tRNA synthetase complexed with m-tyrosine
3khv  2.35  2009  Ki=13.99mM    // 3khv.pdf (4AL) AMPM inhibitor
2wks  2.95  2009  Ki=130nM      // 2wks.pdf (CB6) compound 9d, Ki=130+/-13nM
3hig  2.09  2009  Ki=13nM       // 3hig.pdf (BRN) human diamine oxidase in complex with Berenil, Ki=13+/-1nM
3hfz  2.90  2009  Ki=13uM       // 3hfv.pdf (MTY) Thermus thermophilus Phenylalanyl-tRNA synthetase comlexed with m-tyrosine
3ibl  1.55  2009  Ki=14.6nM     // 3ibi.pdf (O59) adducts of sulfamates 3 with hCA II
2wzs  2.25  2009  Ki=140uM      // 2wvz.pdf (MVL) ligand is mannoimidazole
3i7e  1.70  2009  Ki=14pM       // 3i6o.pdf (DJR) ligand is compound 2, Ki=14pM, IC50=1.2nM
2ww2  1.90  2009  Ki=14uM       // 2wvz.pdf (SWA) ligand is swainsonine
3dx2  1.40  2009  Ki=150nM      // 3dx0.pdf (MZB) ligand is compound 2
3djx  1.69  2009  Ki=1557.9uM   // 3djo.pdf (C5P) Ki=1557.9+/-84.3uM
3eb1  2.40  2009  Ki=16.3uM     // 3eax.pdf (LZQ) ligand is compound LZP25, Ki=16.3+/-1.1uM; IC50=20+/-5uM
2zgm  1.90  2009  Ki=16.4mM     // 2zgm.pdf (LAT)
2wl0  1.90  2009  Ki=16nM       // 2wkz.pdf (5AH)
3dnd  2.26  2009  Ki=16uM       // 3dnd.pdf (LL2) ligand B
3evf  1.45  2009  Ki=170nM      // 3eva.pdf (GTA) MPD; Ki=170+/-20nM is for DEN MTase, not yellow fever
3gjt  2.20  2009  Ki=170nM      // 3gjq.pdf (5-mer) Caspase-3 Binds Ac-IEPD-Cho peptide, Ki=170+/-7nM
3ggu  1.80  2009  Ki=170pM      // 3ggt.pdf (017) PRDRV5 in complex with darunavir, Ki=170+/-20pM
3hav  2.45  2009  Ki=170uM      // 3ham.pdf (SRY) streptomycin-ATP-APH(2)-IIa ternary complex, competitive inhibitor
3d6q  1.60  2009  Ki=172uM      // 3d6o.pdf (U3S) Ki=172+/-4uM
3gep  2.60  2009  Ki=176.8uM    // 3gep.pdf (24H) PH8.5, human HGPRT complex (S)-HPMPG, Ki=176.8+/-10uM
3d6p  1.60  2009  Ki=179uM      // 3d6o.pdf (U2S) Ki=179+/-3uM
3g3d  1.70  2009  Ki=18.2uM     // 3g3d.pdf (5FU) Human ODCases with compound 41, 5-fluoro-6-azido-UMP
3jqg  1.90  2009  Ki=18uM       // 3bmc.pdf (AX6) Pteridine Reductase 1 complex NADP+ and AX6 compound 18, Ki=18uM
3gxt  2.70  2009  Ki=18uM       // 3gxt.pdf (NOJ) data from ref. 25, for alpha-galactosidase from Aspergillus niger
3ebo  1.90  2009  Ki=19.01uM    // 3ebo.pdf (57D) ligand is Chrysin
3fnm  1.70  2009  Ki=19.7uM     // 3fnm.pdf (AVN) Ki=19.7+/-7.2uM
3f6g  2.00  2009  Ki=19uM       // 3f6g.pdf (ILE)
3f6h  2.70  2009  Ki=19uM       // 3f6g.pdf (ILE) Fragment: Regulatory domain, UNP residues 390-516 ; IC50=86 +/-20uM; Ki=19 +/-5uM;
3grj  2.49  2009  Ki=1mM        // 3gqz.pdf (G14) AmpC beta-lactamase with compound 12
3dd0  1.48  2009  Ki=1nM        // 3d8w.pdf (EZL)
3dcw  1.50  2009  Ki=1nM        // 3d8w.pdf (EZL) redundant to 3dd0
3jxw  2.80  2009  Ki=1nM        // 3jxw.pdf (LXG) ligand is compound 12b
3jy9  2.10  2009  Ki=1nM        // 3jy9.pdf (JZH) compound 9 in complex with JAK2, Ki=0.001uM
2w8g  2.60  2009  Ki=1uM        // 2w8e.pdf (BS2) APLYSIA CALIFORNICA ACHBP BOUND TO IN SILICO COMPOUND 35, pKi=6.0+/-0.2
3ggj  2.60  2009  Ki=1uM        // 3gep.pdf (25H) PH7.4, human HGPRT complex PEEHx, Ki=1+/-0.5uM
3d9z  1.65  2009  Ki=2.0nM      // 3d8w.pdf (D9Z) ligand is inhibitor CHL, Ki=2.0+/-0.4nM
2wky  2.20  2009  Ki=2.57nM     // 2wky.pdf (IBC)
2wca  2.30  2009  Ki=2.5uM      // 2wca.pdf (NP6)
3fa3  2.60  2009  Ki=2.5uM      // 3fa3.pdf (OAF) Ki=2.5+/-0.2uM.
3kgp  2.35  2009  Ki=2.68mM     // 3kgp.pdf (4AZ) ligand is inhibitor AMBA
3gvb  1.80  2009  Ki=2.6mM      // 3gqz.pdf (3GV) ligand is compound 8
3ibi  1.93  2009  Ki=2.6nM      // 3ibi.pdf (BOW) adducts of sulfamates 1 with hCA II
3dkf  1.80  2009  Ki=2.7nM      // 3dkc.pdf (SX8) compound SGX532; Ki1=2.7nM(unphosphorylated form of MET); Ki2=23nM(phosphorylated form of MET); IC50=4nM
3ejq  1.45  2009  Ki=2.7nM      // 3ejp.pdf (HN3) ligand is compound 3; IC50=29nM
3ejr  1.27  2009  Ki=2.7nM      // 3ejp.pdf (HN4) ligand is compound 4; IC50=29nM
3ejp  1.32  2009  Ki=2.8nM      // 3ejp.pdf (HN2) ligand is compound 2; IC50=30nM
3d7b  1.60  2009  Ki=203uM      // 3d6o.pdf (U4S) Ki=203+/-1uM
3ewc  2.11  2009  Ki=20nM       // 3ewc.pdf (MCF) Ki=20+/-5nM
3eig  1.70  2009  Ki=21nM       // 3eig.pdf (MTX) Ki=21+/-11nM; IC50=3100+/-1600nM; compound methotrexate
3ex6  1.30  2009  Ki=220uM      // 3ex6.pdf (U5P) ligand is compound 1
3fee  1.56  2009  Ki=230nM      // 3fec.pdf (QUS) Ki=230+/-24nM
2zx8  2.33  2009  Ki=231.4pM    // 2zwz.pdf (ZX8)
3hl7  1.88  2009  Ki=23nM       // 3hl7.pdf (I47) ligand is SD-0006, Ki=0.023uM
3ibn  2.20  2009  Ki=24.5nM     // 3ibi.pdf (O60) adducts of sulfamates 4 with hCA II
3fk1  1.70  2009  Ki=2420uM     // 3fjx.pdf (GPF) ligand is glyphosate; Ki=2420+/-87uM; IC50=6600+/-190uM
3iph  2.10  2009  Ki=25.1nM     // 3iph.pdf (G11) p38 in complex with inhibitor 11, Ki=25.1nM
2zx6  2.42  2009  Ki=25.1pM     // 2zwz.pdf (ZX6)
3g0i  2.10  2009  Ki=250uM      // 3g0i.pdf (VPR) Aspergillus niger epoxide hydrolase in complex with valpromide
3ehx  1.90  2009  Ki=25nM       // 3ehx.pdf (BDL) ligand is compound 1; Ki=25+/-2nM
3gc4  1.80  2009  Ki=25nM       // 3eos.pdf (AAQ) ligand is compound 11; Ki=25+/-2nM
3jwq  2.87  2009  Ki=25nM       // 3jwq.pdf (VIA) chimeric PDE5/PDE6 catalytic domain complex sildenafil, Ki=25+/-2nM
3dx1  1.21  2009  Ki=265uM      // 3dx0.pdf (YHO) ligand is compound 3
3bm6  2.10  2009  Ki=26nM       // 3bm6.pdf (C9P) compound 11
3djv  1.60  2009  Ki=27.9uM     // 3djo.pdf (C3P) Ki=27.9+/-1.3uM
3ff3  1.37  2009  Ki=270uM      // 3ff3.pdf (GLU)
3e9h  2.10  2009  Ki=28nM       // 3e9h.pdf (KAA) BsLysRS-LysSA complex; ligand is LysSA; Ki=28+/-3nM for EsLysRS
3h30  1.56  2009  Ki=29.2uM     // 2rkp.pdf (RFZ) Ki=29.2uM(competitive); Ki=39.7uM(noncompetitive)
2zns  2.00  2009  Ki=290nM      // 2zns.pdf (GLU) redundant to 3fuz
3hii  2.15  2009  Ki=290nM      // 3hig.pdf (PNT) human diamine oxidase in complex with Pentamidine, Ki=290+/-19nM
2w5i  2.40  2009  Ki=29uM       // 2w5g.pdf (ATP) ligand is Ap3A; Ki=4.7uM (for p-A3-p); redundant to 2w5g
2zz1  1.57  2009  Ki=29uM       // 2zz1.pdf (6CN) wild type enzyme in complex with 6-CN-UMP
2zz2  1.53  2009  Ki=29uM       // 2zz2.pdf (6CN) ligand is compound 34
3gsg  2.10  2009  Ki=2mM        // 3gqz.pdf (GF1) compound 1
3ge7  1.50  2009  Ki=2nM        // 3eos.pdf (AFQ) ligand is compound 13; Ki=2+/-1nM
3fdm  2.26  2009  Ki=2nM        // 3fdl.pdf (17-mer) alpha/beta foldamer in complex with Bcl-xL; incomplete ligand
3hvj  1.79  2009  Ki=2nM        // 3hvj.pdf (705) compound 5 is a bisubstrate inhibitor, Ki=2nM, IC50=9nM
3g30  1.80  2009  Ki=3.1mM      // 3g2y.pdf (G30) ligand is compound 3(G30); Ki=3.1mM
2wqp  1.75  2009  Ki=3.1uM      // 2wqp.pdf (WQP) ligand is compound 1, Ki=3.1+/-0.1uM
2wr8  1.77  2009  Ki=3.6uM      // 2wr8.pdf (SAH)
3ggc  2.78  2009  Ki=3.6uM      // 3gep.pdf (H26) PH7.4, human HGPRT complex PEEHx, Ki=3.6+/-0.2uM
3dx3  1.42  2009  Ki=300nM      // 3dx0.pdf (YTB) ligand is compound 4a
3hio  2.00  2009  Ki=300nM      // 3hio.pdf (C2X) Ricin A-chain complex Cyclic G(9-DA)GA 2-OMe, Ki=300nM at PH4.0
3c14  2.68  2009  Ki=300uM      // 3c14.pdf (POP) AC activity inhibition by PPi-Ca2+, low affinity range 30-300uM
2vwo  1.60  2009  Ki=31nM       // 2vvc.pdf (LZG) ligand is compound 22
2zx7  2.48  2009  Ki=32.2pM     // 2zwz.pdf (ZX7)
3g1d  1.50  2009  Ki=330uM      // 3g1d.pdf (U) ligand is compound 1
3h0a  2.10  2009  Ki=33nM       // 3gz9.pdf (D30) PPARgamma, Retinoic Acid Receptor Alpha (RXRa) Complex with compound 21 and peptide
3fed  1.29  2009  Ki=34.6nM     // 3fec.pdf (BIX) Ki=34.6+/-5.7nM
3hl5  1.80  2009  Ki=34uM       // 3hl5.pdf (9JZ)
2wbg  1.85  2009  Ki=35.2uM     // 2wbg.pdf (LGS) ligand is compound 7
3jqf  1.60  2009  Ki=35uM       // 3bmc.pdf (AX2) Pteridine Reductase 1 complex NADP+ and AX2 compound 14, lack a N atom, Ki>35uM
3jq8  1.95  2009  Ki=35uM       // 3bmc.pdf (DX3) Pteridine Reductase 1 complex NADP+ and DX3 compound 3, Ki>35uM
3jqa  1.90  2009  Ki=35uM       // 3bmc.pdf (DX4) Pteridine Reductase 1 complex NADP+ and DX4 compound 5, lack a N atom, Ki>35uM
3dx0  1.70  2009  Ki=36nM       // 3dx0.pdf (MSN) redundant to 2f7o
2zu4  1.93  2009  Ki=38nM       // 2zu3.pdf (ZU3)
3d8y  1.72  2009  Ki=396uM      // 3d6o.pdf (T3S) Ki=396+/-2uM
3gr2  1.80  2009  Ki=3mM        // 3gqz.pdf (GF4) ligand is compound 3
2vvc  1.95  2009  Ki=3nM        // 2vvc.pdf (LZF) ligand is compound 15
3hvh  1.30  2009  Ki=3nM        // 3hvh.pdf (542) ligand is inhibitor 3; Ki=3nM, IC50=12nM
3hvk  1.30  2009  Ki=3nM        // 3hvk.pdf (719) ligand is inhibitor 7, Ki=3nM, IC50=15nM
3dxg  1.39  2009  Ki=4.0mM      // 3dxg.pdf (U5P) Ki=4.00+/-0.41mM
3hkt  2.36  2009  Ki=4.1uM      // 3hkt.pdf (2SD)
2zxa  2.57  2009  Ki=4.47nM     // 2zwz.pdf (ZXA) compound 7
3g2z  1.50  2009  Ki=4.4mM      // 3g2y.pdf (GZ2) ligand is compound 2(GZ2); Ki=4.4mM
3hkn  1.80  2009  Ki=4.51uM     // 3hkn.pdf (MFS) ligand is compound 4
3hkq  1.70  2009  Ki=4.55uM     // 3hkq.pdf (1SD) ligand is 1-S-D-Galactopyranosylsulfonamide
3gtc  1.90  2009  Ki=4.5mM      // 3gqz.pdf (GTC) ligand is compound 20
3f82  2.50  2009  Ki=4.6nM      // 3f82.pdf (353) Ki=4.6+/-0.3nM; IC50=3.9+/-0.5uM
2wj2  2.55  2009  Ki=4.7nM      // 2wj1.pdf (OL1) compound 1
3gjq  2.60  2009  Ki=4.7uM      // 3gjq.pdf (5-mer) Caspase-3 Binds Ac-WEHD-Cho peptide, Ki=4.7+/-0.19uM
3dc3  1.70  2009  Ki=4.9nM      // 3d8w.pdf (AZM) ligand is inhibitor AZM, Ki=4.9+/-1nM
3djo  1.60  2009  Ki=40.8uM     // 3djo.pdf (U2P) Ki=40.8+/-3.4uM
3kmc  1.80  2009  Ki=400nM      // 3kmc.pdf (403) catalytic domain of TACE in complex with inhibitor 2
3e90  2.45  2009  Ki=41nM       // 3e90.pdf (NKK)
3d8z  1.98  2009  Ki=423uM      // 3d6o.pdf (TXS) Ki=423+/-6uM
3f7g  2.30  2009  Ki=43nM       // 3f7g.pdf (389) ligand is compound 1
3i6o  1.17  2009  Ki=45pM       // 3i6o.pdf (GR6) ligand is compound 14c, Ki=45pM, IC50=2nM
3f7i  1.90  2009  Ki=46nM       // 3f7g.pdf (G13) ligand is compound 14b
3ebh  1.65  2009  Ki=478.2nM    // 3ebh.pdf (BES) IC50=8~14uM
3dhk  1.73  2009  Ki=47nM       // 2zc9.pdf (23U) compound 3, Ki=47+/-27nM
3eos  1.78  2009  Ki=4nM        // 3eos.pdf (PK2) compound 12, Ki=4+/-2nM
2zxb  2.61  2009  Ki=5.0uM      // 2zwz.pdf (ZXB) compound 8
3ip8  1.50  2009  Ki=5.2mM      // 3ip8.pdf (B85) AMDase in complex with benzylphosphonate, competitive inhibitor Ki=5.2mM
3hek  1.95  2009  Ki=5.4nM      // 3hek.pdf (BD0) HSP90 N-terminal domain in complex with compound 15, Ki=5.4nM, IC50=112nM
3hll  1.95  2009  Ki=5.8nM      // 3hl7.pdf (I45) ligand is PH-797804, Ki=5.8+/-0.3nM
3fl5  2.30  2009  Ki=52nM       // 3fl5.pdf (TXQ) IC50=0.11uM
3i4a  1.90  2009  Ki=52uM       // 3i4a.pdf (LN5) DDAH-1 complex with L-IPO compound 13, Ki=52+/-4uM
2zx9  2.62  2009  Ki=54.2pM     // 2zwz.pdf (ZX9) compound 5, show time-dependent Ki from 1.005nM to 54.2pM
3gc5  1.40  2009  Ki=55nM       // 3eos.pdf (2MQ) ligand is compound 8; Ki=55+/-3nM
3f8e  2.00  2009  Ki=59nM       // 3f8e.pdf (TE1) ligand is compound 4z
3fqe  2.50  2009  Ki=5nM        // 3fqe.pdf (P5C) ligand is compound 3, Ki=5-20nM
3hku  1.80  2009  Ki=5nM        // 3hku.pdf (TOR) ligand is topiramate, Ki=0.005uM
3hvi  1.20  2009  Ki=5nM        // 3hvi.pdf (619) compound 4 is a bisubstrate inhibitor, Ki=5nM, IC50=21nM
3jy0  2.40  2009  Ki=5nM        // 3jy0.pdf (LYG) ligand is compound 6e
2ww0  2.80  2009  Ki=5uM        // 2wvz.pdf (SWA) ligand is swainsonine
2zxd  2.15  2009  Ki=6.0uM      // 2zwz.pdf (ZXD) ligand is compound 9
3hit  2.29  2009  Ki=6.4nM      // 3hio.pdf (DYN) Saporin-L1 complex s3(9-DA)Gs 2-OMe, Ki=6.4+/-1.7nM, in ref.15
3hpt  2.19  2009  Ki=6.5nM      // 3hpt.pdf (YET) human FxA in complex with compound 4
2ko7   NMR  2009  Ki=6.5uM      // 2ko7.pdf (JZF) Ki=6.5 +/-1.0uM
3gqz  1.80  2009  Ki=6.7mM      // 3gqz.pdf (GF7) ligand is compound 5
3djp  1.60  2009  Ki=63.2uM     // 3djo.pdf (UA3) Ki=63.2+/-4.5uM
3k2f  1.98  2009  Ki=63nM       // 3k2f.pdf (NKX) ligand is compound 8
3g1v  1.30  2009  Ki=645uM      // 3g1v.pdf (5FU) ligand is compound 39
3gdt  1.60  2009  Ki=64nM       // 3gdt.pdf (UP6)
3kid  2.71  2009  Ki=656uM      // 3kid.pdf (2BS)
2vvv  1.73  2009  Ki=6nM        // 2vvc.pdf (H21) ligand is compound 10, Ki=0.006uM
3dne  2.00  2009  Ki=6uM        // 3dnd.pdf (LL1) ligand A
3d8w  1.70  2009  Ki=7.0nM      // 3d8w.pdf (D8W) ligand is inhibitor BZM, Ki=7.0+/-0.9nM
3faa  3.35  2009  Ki=7.1nM      // 3faa.pdf (55F) compound 2
3gv9  1.80  2009  Ki=7.5mM      // 3gqz.pdf (GV9) ligand is compound 21
3hiv  2.14  2009  Ki=7.5nM      // 3hio.pdf (TXN) Saporin-L1 complex G(9-DA)Gs3 2-OMe, Ki=7.5+/-1.6nM, in ref15
2znu  1.80  2009  Ki=7.7nM      // 2zns.pdf (NDZ) redundant to 3fv2
3gpj  2.70  2009  Ki=7.8uM      // 3gpj.pdf (SY2) yeast 20S proteasome with syringolin B, chymotrypsin-like Ki=7.8uM, trypsin-like Ki=108uM
3a9i  1.80  2009  Ki=70.7uM     // 2ztj.pdf (LYS)
3ffp  1.81  2009  Ki=72.5nM     // 3ffp.pdf (LC1) ligand is compound 2
3kme  1.85  2009  Ki=725nM      // 3kmc.pdf (Z59) catalytic domain of TACE with inhibitor 8, lack a NH2 group
3dx4  1.38  2009  Ki=76nM       // 3dx0.pdf (GOO) ligand is compound 5
3d6o  1.58  2009  Ki=77uM       // 3d6o.pdf (U1S) Ki=77+/-1uM
3ebi  2.00  2009  Ki=79nM       // 3ebh.pdf (BEY) IC50=24~62uM
3fmz  2.90  2009  Ki=8.3nM      // 3fmz.pdf (2T1) IC501=90nM(human RBP4); IC502=66nM(mouse RBP4).
3jwr  2.99  2009  Ki=8.5nM      // 3jwq.pdf (IBM) chimeric PDE5/PDE6 catalytic domain complex IBMX and peptide, Ki=8.5+/-0.6nM
3hiw  1.80  2009  Ki=8.7nM      // 3hio.pdf (C2X) Saporin-L1 complex cyclic G(9-DA)GA 2-OMe, Ki=8.7+/-2.3nM, in ref15
3f68  1.75  2009  Ki=8.7uM      // 2zc9.pdf (91U) ligand is compound 8, Ki=8.7+/-1.0uM
3dbu  1.70  2009  Ki=8.8nM      // 3d8w.pdf (D8W) ligand is inhibitor BZM, Ki=8.8+/-1.2nM
3f7h  1.80  2009  Ki=82nM       // 3f7g.pdf (419) ligand is compound 14a
2w5g  1.70  2009  Ki=860nM      // 2w5g.pdf (ATP) ligand is 5-ATP(pppA)
2w66  2.27  2009  Ki=89uM       // 2w66.pdf (HQ6)
2vvu  2.30  2009  Ki=8nM        // 2vvc.pdf (H22) ligand is compound 12
3fjz  1.70  2009  Ki=90uM       // 3fjx.pdf (GPF) ligand is glyphosate; Ki=90+/-6uM; IC50=330+/-10uM
2w2i  2.10  2009  Ki=914nM      // 2w2i.pdf (PD2) affinity of compound 38 towards JMJD2E, Formaldehyde DeHydrogenase (FDH) coupled assay
2vwm  1.96  2009  Ki=93nM       // 2vvc.pdf (LZI) ligand is compound 26
2vwl  1.80  2009  Ki=95nM       // 2vvc.pdf (LZH) ligand is compound 23
2wvz  2.40  2009  Ki=96uM       // 2wvz.pdf (KIF) ligand is kifunensine
3eou  1.93  2009  Ki=97nM       // 3eos.pdf (PK3) compound 9, Ki=97+/-5nM
2zu5  1.65  2009  Ki=99nM       // 2zu3.pdf (ZU5)
2jkh  1.25  2009  Ki=9nM        // 2jkh.pdf (BI7) ligand is compound 3
2xp2  1.90  2010  IC50<1.0nM    // 2wgj.pdf (VGH) Fragment: TYROSINE KINASE DOMAIN, RESIDUES 105-423;
3oz1  3.00  2010  IC50<2nM      // 3oz1.pdf (BMB) ligand is compound 2a
3m2w  2.41  2010  IC50<3nM      // 3m2w.pdf (L8I) compound 16A, IC50<3nM
3o1g  1.65  2010  IC50<=1nM     // 3o1g.pdf (O75) compound 7; covalent complex
3m9f  1.80  2010  IC50=0.007nM  // 3m9f.pdf (595) compound 10b, IC50=0.007+/-0.003 nM
3i7c  1.98  2010  IC50=0.018uM  // 3i7b.pdf (BK2) compound NA-PP2
3mbl  2.60  2010  IC50=0.018uM  // 3mbl.pdf (LSG) compound 19
3inh  1.80  2010  IC50=0.02uM   // 3ind.pdf (569) compound (R)-61, not compound 58; IC50=0.02+/-0.004uM
3lhg  2.10  2010  IC50=0.02uM   // 3lhg.pdf (Z81)
3le6  2.00  2010  IC50=0.035uM  // 3le6.pdf (2BZ) compound 3a
3in4  2.30  2010  IC50=0.03uM   // 3in3.pdf (BX2) compoundS- 38; IC50=0.03+/-0.003uM
3inf  1.85  2010  IC50=0.04uM   // 3ind.pdf (X45) compound 37; IC50=0.04+/-0.01uM
3i6z  2.19  2010  IC50=0.05uM   // 3i6m.pdf (G6X) compound 3, affinity is measured on recombinant human brain AChe
2xng  2.60  2010  IC50=0.060uM  // 2xne.pdf (A0H) compound 17
3i7b  1.99  2010  IC50=0.066uM  // 3i7b.pdf (BK1) compound NM-PP1
3in3  2.00  2010  IC50=0.06uM   // 3in3.pdf (472) compound 30; IC50=0.06+/-0.01uM
3lp0  2.79  2010  IC50=0.11uM   // 3lp0.pdf (LP7) compound MK1, IC50=0.11 uM (In vitro); IC50=2.8 uM (Antiviral)
2xcn  3.02  2010  IC50=0.12uM   // 2xcf.pdf (C8D) compound 8d
3kl8  3.37  2010  IC50=0.12uM   // 3kl8.pdf (18-mer) ligand is 18-mer CaMKII inhibitor; Ca-containing; IC50=0.12uM; incomplete ligand
3lp1  2.23  2010  IC50=0.12uM   // 3lp0.pdf (LP8) compound MK2, IC50=0.12 uM (In vitro); IC50=3.0uM (Antiviral)
3kvw  2.28  2010  IC50=0.13uM   // 3kvw.pdf (IRB) ligand is compound 6i
3ah8  2.90  2010  IC50=0.15nM   // 3ah8.pdf (9-mer) peptide YM-254890 ; IC50=0.15+/-0.04nM
3ipe  1.40  2010  IC50=0.15uM   // 3ipb.pdf (JZE) compound  mds84; IC501=0.15+/-0.025uM(Isolated TTR); IC502=12+/-1.4uM(TTR in serum)
3kc3  2.90  2010  IC50=0.16uM   // 3kc3.pdf (MK2) ligand is compound 11d, not compound 5d, IC50=0.16uM, not 1.3uM
2x2m  2.50  2010  IC50=0.17uM   // 2x2k.pdf (X2M) compound SU5416; IC50=0.17+/-0.03uM
3ine  2.00  2010  IC50=0.17uM   // 3ind.pdf (X17) compound (S)-34; IC50=0.17+/-0.04uM
2x9e  3.10  2010  IC50=0.182uM  // 2x9e.pdf (SVE) ligand is compound 15
2xne  2.80  2010  IC50=0.190uM  // 2xne.pdf (ASH) compound 15; IC50=0.190+/-0.138uM
2x8i  1.92  2010  IC50=0.19uM   // 2x8d.pdf (X8I) compound 4a
3kyr  2.60  2010  IC50=0.19uM   // 3kyr.pdf (038) ligand is compound (R)-12
3kry  1.90  2010  IC50=0.1nM    // 3kry.pdf (3KR) compound 19v, IC50<0.1 nM
3l38  2.10  2010  IC50=0.1uM    // 3l38.pdf (879) compound 44, IC50=0.1+/-0.02uM
3lp2  2.80  2010  IC50=0.22uM   // 3lp0.pdf (LP9) compound MK3, IC50=0.22 uM (In vitro); IC50=9.0 uM (Antiviral),  ligand end is -CH3 or -CH2CH3
3oad  2.17  2010  IC50=0.24nM   // 3oad.pdf (LPO) IC50=0.24nM(buffer); 5.6(human plasma)
3iu9  1.75  2010  IC50=0.24uM   // 3iu7.pdf (T07) compound 8; NI2+ containing
3ipb  1.90  2010  IC50=0.2uM    // 3ipb.pdf (JZD) compound  4ajm15; IC501=0.2+/-0.04uM(Isolated TTR); IC502=27+/-4.9uM(TTR in serum)
2x2k  2.60  2010  IC50=0.30uM   // 2x2k.pdf (X2K) compound 33; IC50=0.30+/-0.04uM
3oag  2.30  2010  IC50=0.31nM   // 3oad.pdf (LPQ) IC50=0.31nM(buffer); 7.5(human plasma)
3ixj  2.20  2010  IC50=0.32nM   // 3ixj.pdf (586) compound 1d
3ara  1.70  2010  IC50=0.32uM   // 3ara.pdf (MKH) ligand is compound 16a; IC50=0.32+/-0.018uM
3mj5  2.63  2010  IC50=0.32uM   // 3mj5.pdf (GRM) compound 15g, EC50=9.1 uM
3anr  2.60  2010  IC50=0.35uM   // 3anq.pdf (HRM) compound  harmine
3i6m  2.26  2010  IC50=0.35uM   // 3i6m.pdf (G3X) compound 2, affinity is measured on recombinant human brain AChe
3ksq  2.10  2010  IC50=0.38nM   // 3ksq.pdf (Z96) compound 10a
3is9  2.55  2010  IC50=0.38uM   // 3irx.pdf (AC7) compound 3; Inhibitory activity versus HIV-1 RT with poly(rC)-oligo(dG) as the template primer.
3m8q  2.70  2010  IC50=0.3nM    // 3m8p.pdf (DJZ) compound 5h, not 5d; Antiviral IC50=0.3nM, Enzyme IC50=34 nM
3l3a  2.36  2010  IC50=0.42uM   // 3l38.pdf (625) compound 32
3krr  1.80  2010  IC50=0.48nM   // 3krr.pdf (DQX) Fragment: kinase domain; IC50=0.48 +/-0.02nM, compound NVP-BSK805
3lq8  2.02  2010  IC50=0.4nM    // 3lq8.pdf (88Z)
3lw0  1.79  2010  IC50=0.4uM    // 3lw0.pdf (CCX) compound 10, IC50=0.4+/-0.07um
3g58  2.05  2010  IC50=0.52nM   // 3g45.pdf (988) supplementary information; compound PMNPQ, also for PDE4D7 IC50=5nM
3iu8  1.85  2010  IC50=0.58uM   // 3iu7.pdf (T03) compound 7; NI2+ containing
2wxk  2.90  2010  IC50=0.5nM    // 2wxf.pdf (RW4) Supplementary information; compound INK666
3kwj  2.80  2010  IC50=0.5nM    // 3kwj.pdf (23Q) compound 2g
3mvh  2.01  2010  IC50=0.5nM    // 3mv5.pdf (WFE) compound 42; with GSK3-beta peptide
3lmp  1.90  2010  IC50=0.62uM   // 3lmp.pdf (CEK)
2xd6  2.20  2010  IC50=0.65uM   // 2xd6.pdf (XD6) compound 20; IC501=0.65uM(FP); IC502=0.90uM(TR-Fret);
3l3x  1.55  2010  IC50=0.71uM   // 3l3x.pdf (12-mer) ligand is 12-mer first motif of steroid receptor coactivator 3; IC50=0.71+/-0.1uM, SRC3-1
3gen  1.60  2010  IC50=0.72nM   // 3gen.pdf (B43)
2wxg  2.00  2010  IC50=0.7nM    // 2wxf.pdf (ZZN) Supplementary information; compound SW13
3lkz  2.00  2010  IC50=0.7uM    // 3lkz.pdf (SFG) X-ray(WNV MTase); Bind assay(DENV-2 MTase):IC50=0.7uM(inhibition N7-methylation), 19uM(inhibition 2'-O-methylation); Fragment: West Nile virus methyltransferase (UNP residues 2529-2828)
2xkf  2.35  2010  IC50=0.87uM   // 2xk3.pdf (BX1) compound 2; IC50=0.87+/-0.34uM
3krl  2.40  2010  IC50=0.8nM    // 3krj.pdf (KRL) Fragment: UNP residues 538-678, 753-922; Mutation: C584S;
2x8d  1.90  2010  IC50=0.8uM    // 2x8d.pdf (X8D) compound 3
3lkh  2.05  2010  IC50=0.8uM    // 3lkh.pdf (LT6) compound 44, IC50=0.8uM
3max  2.05  2010  IC50=0.90uM   // 3max.pdf (LLX) IC50=0.90uM (1h), IC50=0.027uM (24h)
3g4g  2.30  2010  IC50=0.91nM   // 3g45.pdf (D71) supplementary information; compound RS25344; Space Group: P 21
3g4i  1.90  2010  IC50=0.91nM   // 3g45.pdf (D71) supplementary information; compound RS25344; Space Group: P 21 21 21
3lj3  2.43  2010  IC50=0.94nM   // 3lj3.pdf (WYE) mTOR is similar with PI3K gamma, IC50 value is for mTOR
2x3t  2.75  2010  IC50=0.9uM    // 2uwg.pdf (9-mer) compound 2, a 9-mer SYNTHETIC GLYCOPEPTIDE, IC50=0.9+/-0.16uM
3irx  2.80  2010  IC50=1.0nM    // 3irx.pdf (UDR) compound 4; Inhibitory activity versus HIV-1 RT with poly(rC)-oligo(dG) as the template primer.
3m1s  3.13  2010  IC50=1.0nM    // 3m1s.pdf (DW1) (R)-DW12
2wzx  1.40  2010  IC50=1.0uM    // 2wzx.pdf (ZX0) compound 2; covalent complex
3nef  2.40  2010  IC50=1.14uM   // 3nef.pdf (PYV) IC50=1.14 +/-0.07uM; Fragment: UNP residues 20-221;
3neg  2.80  2010  IC50=1.14uM   // 3nef.pdf (PYV) IC50=1.14 +/-0.07uM; Fragment: UNP residues 20-221; redundant to 3nef
3krj  2.10  2010  IC50=1.1nM    // 3krj.pdf (KRJ) Fragment: UNP residues 538-678, 753-922; Mutation: C584S;
3lpu  1.95  2010  IC50=1.37uM   // 3lpu.pdf (976) IC50=1.37+/-0.36uM, compound 6
3km4  1.90  2010  IC50=1.3nM    // 3km4.pdf (22X)
3itz  2.25  2010  IC50=1.4nM    // 3itz.pdf (P66) compound 2m
3nzu  2.60  2010  IC50=1.4nM    // 3nzs.pdf (NZU) compound 6; IC50(p110 alpha); X-ray(PI3K gamma)
3ind  2.25  2010  IC50=1.53uM   // 3ind.pdf (593) compound 29; IC50=1.53+/-0.06uM
2xez  2.25  2010  IC50=1.5uM    // 2xey.pdf (XEZ) compound 24
2xk7  1.99  2010  IC50=1.5uM    // 2xk3.pdf (30E) compound 23
3owk  1.80  2010  IC50=1.5uM    // 3owj.pdf (18E) Fragment: UNP RESIDUES 1-331;
2xk6  2.20  2010  IC50=1.6uM    // 2xk3.pdf (EQH) compound 36; IC50=1.6+/-0.7uM
3pa8  2.00  2010  IC50=1.78uM   // 3pa8.pdf (621) IC50=1.78+/-0.16uM; covalent complex
3njy  2.60  2010  IC50=1.7uM    // 3njy.pdf (8XQ) Ni2+ containing; compound 85736331
3mks  2.60  2010  IC50=1.9uM    // 3mks.pdf (C1C) SCF-I2; IC50=6.2+/-1 uM for Cdc4 substrate inhibition, IC50=1.9+/-1uM is for WT Skp1-Cdc4
3kx1  1.51  2010  IC50=100nM    // 3kw9.pdf (KX1)
3mb6  1.75  2010  IC50=100nM    // 3ma3.pdf (01I) UNP residues 1-331;
3l6f  2.10  2010  IC50=102nM    // 3l6f.pdf (15-mer) ligand is 15-mer phosphopeptide MART-1
3gzn  3.00  2010  IC50=10nM     // 3gzn.pdf (B39) covalent complex of NEDD8-MLN492, inhibitor to NAE enzyme
3l0e  2.30  2010  IC50=10nM     // 3l0e.pdf (G58) ligand is compound 18, pIC50=8.0
3fxw  2.00  2010  IC50=1100nM   // 3fxw.pdf (F10) ligand is compound 23
2xvn  2.35  2010  IC50=112uM    // 2xuc.pdf (KLS) Fragment: RESIDUES 29-307 ; IC50=112+/-1uM;
3ho2  2.00  2010  IC50=113nM    // 3hnz.pdf (N32) compound 2
3lnk  1.80  2010  IC50=1150nM   // 3lnk.pdf (74A)
3ndm  3.30  2010  IC50=11nM     // 3ndm.pdf (3ND) compound 31, X-ray(ROCK1); IC50(ROCK2)
3nnx  2.28  2010  IC50=11nM     // 3nnu.pdf (EDD) compound 16(PP-p38); IC50=11nM(Fluoroprobe binding assay); 9nM(biochemical analyses)
3lpt  2.00  2010  IC50=12.2uM   // 3lpt.pdf (723) IC50=12.2+/-3.4uM, compound 3
3k22  2.10  2010  IC50=12.59nM  // 3k22.pdf (JZS) compound 13; pIC50=7.9+/-0.1
3oui  1.70  2010  IC50=12.6uM   // 3oui.pdf (42Z) Fe2+ containing   pIC50=4.9
3ipx  2.00  2010  IC50=120nM    // 3ipx.pdf (B86) compound 1
3lpj  1.79  2010  IC50=120nM    // 3lnk.pdf (Z75)
3lok  2.48  2010  IC50=120nM    // 3lok.pdf (DJK) compound 2c, IC50=120+/-50 nM
3kbz  2.45  2010  IC50=124nM    // 3kbz.pdf (2T4) compound 6
3ljt  1.60  2010  IC50=129nM    // 3ljt.pdf (LA3) Zn2+ binding; Fragment: Catalytic Domain; Mutation: L282K   IC50=129+/-11nM
2x6d  2.80  2010  IC50=12nM     // 2x6d.pdf (X6D) compound 40c
3ivi  2.20  2010  IC50=12nM     // 3ivh.pdf (2LI) compound 56
3kc0  2.80  2010  IC50=12nM     // 3kbz.pdf (2T5) compound 10b
3l3z  2.00  2010  IC50=13.6uM   // 3l3x.pdf (12-mer) ligand is 12-mer third motif of steroid receptor coactivator 3; IC50=13.6+/-2.2uM
2x38  2.20  2010  IC50=130nM    // 2wxf.pdf (IC8) Supplementary information; compound IC87114
2xfj  1.80  2010  IC50=13nM     // 2xfi.pdf (VG5) compound 40
3mvl  2.80  2010  IC50=13nM     // 3mvl.pdf (38P) compound 7k
3lco  3.40  2010  IC50=143nM    // 3lcd.pdf (LC0)
2x8e  2.50  2010  IC50=14nM     // 2x8d.pdf (X8E) compound 28
2xcs  2.10  2010  IC50=14nM     // 2xcr.pdf (RXV) S. AUREUS GYRASE COMPLEX WITH GSK299423 AND DNA, IC50=14+/-5nM, not Protein-Nucleic Acid complex
3i5n  2.00  2010  IC50=14nM     // 3i5n.pdf (B2D) compound 13; IC501=14nM(Cellular); IC502=17nM(Biochemical)
3ika  2.90  2010  IC50=14nM     // 3ika.pdf (0UN) compound WZ4002; covalent complex; PC9-GR cell line,  EGFR Del E746_A750/T790M
3kqa  2.25  2010  IC50=14uM     // 3kqa.pdf (TR9) IC50= 14+/-0.6uM
3ncg  2.49  2010  IC50=150nM    // 3mwu.pdf (BK1) IC50= 150 +/- 20nM; Fragment: CpCDPK1, residues 70-538
3lce  2.00  2010  IC50=156uM    // 3lce.pdf (LCE) IC50=156+/-6uM; covalent complex
2x6e  3.35  2010  IC50=15nM     // 2x6d.pdf (YM4) compound 51; IC50=15+/-3nM
2xfi  1.73  2010  IC50=15nM     // 2xfi.pdf (XFI) compound 4
3koo  2.79  2010  IC50=15nM     // 3koo.pdf (24D)
3l13  3.00  2010  IC50=15nM     // 3l13.pdf (JZW) IC50=1.8(PI3K alpha)  IC50=14/1.4/15(PI3K beta/gamma/sigma), compound 14
3mj2  1.90  2010  IC50=15nM     // 3miy.pdf (MJG) BMS-509744, No equilibrium Kd was reached
3n51  2.10  2010  IC50=15nM     // 3mwu.pdf (BK3) IC50= 15 +/- 5 nM; Fragment: TgCDPK1, residues 30-507
3ncz  3.00  2010  IC50=15nM     // 3ncz.pdf (3NC) compound 22, X-ray(ROCK1); IC50(ROCK2)
2xk4  2.10  2010  IC50=16.9uM   // 2xk3.pdf (OL2) compound 17
3ihz  1.67  2010  IC50=160nM    // 3ihz.pdf (FK5) ligand FK506
3l0n  1.74  2010  IC50=1680uM   // 3ex5.pdf (S5P) IC50=1680+/-540uM
3g8o  1.90  2010  IC50=16nM     // 3g8n.pdf (30X) compound 22, Pyrrolidine 1
3hq5  2.10  2010  IC50=16nM     // 3g8n.pdf (GKK) compound 22, Alkylpyrrolidine ligand
3phe  2.20  2010  IC50=16nM     // 3phe.pdf (C9A) compound 16
3iu7  1.40  2010  IC50=16uM     // 3iu7.pdf (FCD) compound 4; Mn2+ containing
3mlb  1.80  2010  IC50=16uM     // 3mlb.pdf (LJZ) inhibitor 1_02_1, IC50=16+/-4 uM
3iop  2.20  2010  IC50=17nM     // 3ion.pdf (8I1) compound 9i
3k5c  2.12  2010  IC50=17nM     // 3k5c.pdf (0BI) compound 3(NB-216)
3kwb  2.02  2010  IC50=17nM     // 3kwb.pdf (ORH)
2x4r  2.30  2010  IC50=17uM     // 2x4n.pdf (9-mer) CYTOMEGALOVIRUS (CMV, NLVPMVATV); IC50=17+/-2.1uM
2x4o  2.30  2010  IC50=17uM     // 2x4n.pdf (9-mer) HIV-1 ENVELOPE PEPTIDE (KLTPLCVTL); IC50=17+/-1.0uM
2wxf  1.90  2010  IC50=180nM    // 2wxf.pdf (039) Supplementary information; compound PIK-39
3fh8  1.67  2010  IC50=180nM    // 3fh5.pdf (27P) compound 5
3mv5  2.47  2010  IC50=180nM    // 3mv5.pdf (XFE) compound 5; with GSK3-beta peptide
2wa4  2.50  2010  IC50=18uM     // 2w0x.pdf (069) compound 3
3kfn  1.77  2010  IC50=18uM     // 3kfn.pdf (3TL) IC50=18+/-3uM, inhibitor TL-3 and fragment hit 4D9 by soaking
3ful  2.39  2010  IC50=199uM    // 3fh5.pdf (52D) compound 9, 199nM is wrong data in BindingDB
3hnz  2.75  2010  IC50=19nM     // 3hnz.pdf (PMN) compound1
2wa3  2.50  2010  IC50=1mM      // 2w0x.pdf (A29) compound 2
2wxj  2.60  2010  IC50=1nM      // 2wxf.pdf (RW3) Supplementary information; compound INK654
3iad  2.65  2010  IC50=1nM      // 3g45.pdf (15X) supplementary information; compound D159153; IC50<1nM; X-ray(human PDE4D); IC50(MICE PDE4D)
3kc1  2.25  2010  IC50=1nM      // 3kbz.pdf (2T6) compound 19a
3kw9  1.80  2010  IC50=1nM      // 3kw9.pdf (ORG)
3pa3  1.40  2010  IC50=1nM      // 3pa3.pdf (C70) compound 70
3m8p  2.67  2010  IC50=2.1nM    // 3m8p.pdf (65B) NNRTI TMC-125 Etravirine, Antiviral IC50=2.1 nM (WT, 10%FBS); Antiviral IC50=25.9 nM (WT, 40%HuS)
2xk3  2.20  2010  IC50=2.1uM    // 2xk3.pdf (XK3) compound  35; IC50=2.1+/-1.0uM
2x39  1.93  2010  IC50=2.2nM    // 2x39.pdf (X39) compound 21; IC50=2.2+/-1.2nM
3p1d  1.86  2010  IC50=2.3mM    // 3p1d.pdf (MB3) ligand is compound N-Methyl-2-pyrrolidone (NMP)
2xkd  1.96  2010  IC50=2.3uM    // 2xk3.pdf (T3M) compound 12; IC50=2.3+/-0.5uM
2xk8  2.00  2010  IC50=2.4uM    // 2xk3.pdf (5R1) compound 15; IC50=2.4+/-0.5uM
3fhe  2.16  2010  IC50=2.5nM    // 3fh5.pdf (28P) Leukotriene A4 Hydrolase with inhibitor 2, Bioorg Med Chem Lett. 12: 3383-6 (2002)
3k5g  2.00  2010  IC50=2.5nM    // 3k5d.pdf (BJC) compound 25
3m6f  1.85  2010  IC50=2.5nM    // 3m6f.pdf (BJZ) IC50=2.5+/-0.4nM
2xkc  2.50  2010  IC50=2.6uM    // 2xk3.pdf (4VQ) compound 14; IC50=2.6+/-0.5uM
2x7d  2.30  2010  IC50=200nM    // 2x7c.pdf (EGB) ligand is  S-dimethylenastron
3mb7  1.65  2010  IC50=200nM    // 3ma3.pdf (14I) UNP residues 1-331;
3oyl  2.54  2010  IC50=200nM    // 3oyb.pdf (ZZX) PFV S217H mutant intasome bound to magnesium and the INSTI MK2048
2wxn  2.60  2010  IC50=21nM     // 2wxf.pdf (DLN) Supplementary information; compound DL07
3k3e  2.70  2010  IC50=22nM     // 3k3e.pdf (PDB) compound 1r; IC50=22+/-3nM
3ow4  2.60  2010  IC50=22nM     // 3ow3.pdf (SMY) compound 26; IC50=22+/-3nM; with GSK 3 beta peptide
2xg5  2.00  2010  IC50=22uM     // 2xg4.pdf (EC2) compound 5d
2x6k  3.50  2010  IC50=2300nM   // 2x6f.pdf (X6K) Supplementary information; compound PI-103
3kig  1.39  2010  IC50=245nM    // 3kig.pdf (DA4) Zn2+ binding
3l0k  1.34  2010  IC50=24uM     // 3ex0.pdf (6AU) IC50=24+/-13uM
2x6f  3.30  2010  IC50=25.713uM  // 2x6f.pdf (3MA) supplementary information; compound 3-MA, IC50=25713nM
3lfs  2.40  2010  IC50=2500nM   // 3lau.pdf (A07) inhibitor SAR37
3kn0  1.90  2010  IC50=250uM    // 3kmx.pdf (3TO)
3mpt  1.89  2010  IC50=251nM    // 3mpt.pdf (1GK) compound 1; pIC50=6.6
3oyn  2.68  2010  IC50=25nM     // 3oyb.pdf (ZZX) PFV N224H mutant intasome bound to magnesium and the INSTI MK2048
3kdt  2.70  2010  IC50=260nM    // 3kdt.pdf (7HA) compound 2
3msk  2.00  2010  IC50=26uM     // 3msj.pdf (EV4) compound 12b
2xh5  2.72  2010  IC50=27nM     // 2x39.pdf (X37) compound 10; IC50=27+/-18nM
3l5e  1.53  2010  IC50=27nM     // 3l58.pdf (BDW) compound 39
3nnv  2.10  2010  IC50=27nM     // 3nnu.pdf (437) compound 12
3pjc  2.20  2010  IC50=27nM     // 3pjc.pdf (PJC) compound 12; IC50=27+/-7nM
3g4k  1.95  2010  IC50=288nM    // 3g45.pdf (ROL) supplementary information; compound R-rolipram; X-ray(human PDE4D); IC50(MICE PDE4D)
3a4p  2.54  2010  IC50=28nM     // 3a4p.pdf (DFQ) compound 4
3khj  2.80  2010  IC50=28nM     // 3khj.pdf (C64) IC50=28+/-9nM
2wxv  2.60  2010  IC50=2nM      // 2wxv.pdf (WXV) compound 59
3lvp  3.00  2010  IC50=2nM      // 3lvp.pdf (PDR)
3oot  2.55  2010  IC50=2nM      // 3oot.pdf (SSR) compound 5k
3oyp  2.76  2010  IC50=2nM      // 3oyp.pdf (5-mer) compound 3; covalent complex
3pa5  1.70  2010  IC50=2nM      // 3pa3.pdf (C73) compound 1
2x7c  1.90  2010  IC50=2uM      // 2x7c.pdf (KZ9) ligand is S-enastron
3g0c  2.69  2010  IC50=2uM      // 3g0b.pdf (RUF) compound 1
3n5h  2.20  2010  IC50=2uM      // 3n1v.pdf (GO0) compound 9
2wxd  1.60  2010  IC50=3.3uM    // 2wxd.pdf (E18)
3my1  2.80  2010  IC50=3.58uM   // 3my1.pdf (RFZ) with cyclinT1; X-ray(CDK9 2-330); Bind assay(CDK9 1-330)
3ked  2.30  2010  IC50=3.6mM    // 3ked.pdf (DAB) Zn2+ binding
3k5f  2.25  2010  IC50=3.7uM    // 3k5d.pdf (AYH) compound 10
3frg  1.70  2010  IC50=3.98nM   // 3frg.pdf (SK4) compound 4; pIC50=8.4
3mvm  2.00  2010  IC50=3.9nM    // 3mvl.pdf (39P) compound 7v
3arn  1.80  2010  IC50=3.9uM    // 3arn.pdf (MSJ) ligand is compound 9; IC50=3.9+/-0.63uM
3k5u  2.35  2010  IC50=309nM    // 3k5u.pdf (PFQ) compound 8, find a wrong data IC50=0.309nM in BindingDB
3mpm  1.95  2010  IC50=30nM     // 3mpm.pdf (5LK) compound 1a
2xf0  2.40  2010  IC50=30uM     // 2xey.pdf (4UB) compound 13
3lau  2.10  2010  IC50=30uM     // 3lau.pdf (OFI) IC50=0.044uM is for GSK3beta inhibitor, compound 4 for Aurora2 is IC50>30uM
3lfn  2.28  2010  IC50=3160nM   // 3lau.pdf (A27) SAR57, an aminoindazole type inhibitor
2xru  2.90  2010  IC50=31nM     // 2xru.pdf (400) compound  29, PHA-828300
3og7  2.45  2010  IC50=31nM     // 3og7.pdf (032) compound PLX4032
3ovx  1.49  2010  IC50=31nM     // 3ovx.pdf (O64) compound 5; covalent complex
2xct  3.35  2010  IC50=31uM     // 2xcr.pdf (CPF) S. AUREUS GYRASE COMPLEX WITH CIPROFLOXACIN AND DNA, IC50=31+/-10uM, not Protein-Nucleic Acid complex
3mvj  2.49  2010  IC50=3200nM   // 3mv5.pdf (XFE) compound 5
3h0j  2.80  2010  IC50=325nM    // 3h0j.pdf (B36) compound 2
3nc9  2.40  2010  IC50=330nM    // 3nbv.pdf (TR3) compound 6
3l16  2.90  2010  IC50=33nM     // 3l13.pdf (JZX) IC50=5.5(PI3K alpha)  IC50=60/6.6/33(PI3K beta/gamma/sigma), compound 16
2wwj  2.60  2010  IC50=33uM     // 2wwj.pdf (Y28) compound 10a; for JMJD2A, IC502=33uM(MALDI-TOF)
3kdu  2.07  2010  IC50=347nM    // 3kdt.pdf (NKS) compound 12
2wxq  2.70  2010  IC50=34nM     // 2wxf.pdf (ZZQ) Supplementary information; compound AS15
2x7o  3.70  2010  IC50=34nM     // 2x7o.pdf (ZOP) compound 5; IC50=34+/-30nM
3gb2  2.40  2010  IC50=34nM     // 3gb2.pdf (G3B) compound (S)-9b
3oy3  1.95  2010  IC50=35.8nM   // 3oxz.pdf (XY3) compound AP24589;
3kxz  2.37  2010  IC50=35nM     // 3kxz.pdf (925)
2x6j  3.50  2010  IC50=36nM     // 2x6f.pdf (093) supplementary information; compound PIK-93
2xch  2.00  2010  IC50=374nM    // 2xch.pdf (CKG) compound 2
3l5r  1.94  2010  IC50=38nM     // 3l5p.pdf (47X)
2wxp  2.30  2010  IC50=3nM      // 2wxf.pdf (GD9) Supplementary information; compound GDC-0941
2xa4  2.04  2010  IC50=3nM      // 2xa4.pdf (AZ5) compound 9e; IC50<0.003uM; IC50=58nM(high ATP)
2xfk  1.80  2010  IC50=3nM      // 2xfi.pdf (AA9) compound 41
3ns9  1.78  2010  IC50=3nM      // 3ns9.pdf (NS9) compound 4k
3ocg  2.21  2010  IC50=3nM      // 3ocg.pdf (OCG) compound 2f; X-ray(unphosphorylated p38 alpha)
3pa4  1.59  2010  IC50=3nM      // 3pa3.pdf (C72) compound 2a
3i97  2.90  2010  IC50=3uM      // 3i97.pdf (8DR) compound 2
2wzz  1.57  2010  IC50=4.0uM    // 2wzx.pdf (ZX1) compound 3; covalent complex
2xke  2.20  2010  IC50=4.2uM    // 2xk3.pdf (WI2) compound 5
3g45  2.63  2010  IC50=4.4nM    // 3g45.pdf (988) compound PMNPQ
2wxl  1.99  2010  IC50=4.6nM    // 2wxf.pdf (ZS4) compound ZSTK474
3lj7  2.30  2010  IC50=4.6nM    // 3lj6.pdf (OHO) Carbamate inhibitor URB597, incomplete ligand structure
2wxm  2.80  2010  IC50=40nM     // 2wxf.pdf (ZZM) Supplementary information; compound DL06
3lcd  2.50  2010  IC50=40nM     // 3lcd.pdf (BDY)
3otq  3.00  2010  IC50=41nM     // 3otq.pdf (MZL) compound 1
3oqk  2.90  2010  IC50=420nM    // 3oot.pdf (S52) compound 2a
3krx  3.10  2010  IC50=42nM     // 3krw.pdf (BA1) hGRK2-G beta gamma 3 balanol (cocrystal)
3krw  2.90  2010  IC50=42nM     // 3krw.pdf (BA1) ligand is balanol
3lpb  2.00  2010  IC50=42nM     // 3lpb.pdf (NVB)
3nsh  2.20  2010  IC50=470nM    // 3nsh.pdf (957) compound 53
3ivh  1.80  2010  IC50=47nM     // 3ivh.pdf (1LI) compound 1
3nnu  2.40  2010  IC50=48nM     // 3nnu.pdf (EDB) compound 19, IC50=48nM(U-p38, Fluoroprobe binding assay); 66nM(PP-p38, Fluoroprobe binding assay); 8nM(PP-p38, biochemical analyses)
2x4u  2.10  2010  IC50=48uM     // 2x4n.pdf (9-mer) supplementary information; HIV-1 peptide rt468-476 (ILKEPVHGV); IC50=48+/-1.2uM
3kwz  1.49  2010  IC50=4nM      // 3kw9.pdf (KWZ)
3nrm  3.05  2010  IC50=4nM      // 3nrm.pdf (NRM) IC50<=4nM; compound 1j
3ken  2.50  2010  IC50=4uM      // 3ken.pdf (ZZD) Fragment: motor domain of human kinesin Eg5 (residues 1-369)
3l17  3.00  2010  IC50=5.2nM    // 3l13.pdf (JZY) IC50=1.1(PI3K alpha)  IC50=6.2/0.7/5.2(PI3K beta/gamma/sigma), compound 20
3nw7  2.11  2010  IC50=5.3nM    // 3nw5.pdf (LGV) compound 34
2x2l  2.00  2010  IC50=5.3uM    // 2x2k.pdf (X2L) compound 34; IC50=5.3+/-1.3uM
3okh  2.50  2010  IC50=5.72uM   // 3okh.pdf (OKH) compound 1r; with incomplete 14-mer coactivator
3g4l  2.50  2010  IC50=5.8nM    // 3g45.pdf (ROF) supplementary information; compound roflumilast; X-ray(human PDE4D); IC50(MICE PDE4D)
3hmv  2.23  2010  IC50=50.12nM  // 3hmv.pdf (HBT) compound 6; pIC50=7.3
3ls4  2.00  2010  IC50=500nM    // 3ls4.pdf (TCI)
2xml  2.55  2010  IC50=500uM    // 2xml.pdf (OGA) ligand is compound 19
3n1v  2.18  2010  IC50=500uM    // 3n1v.pdf (3N1)
3n46  2.35  2010  IC50=50uM     // 3n1v.pdf (3N5) compound 8
3ipy  2.54  2010  IC50=510nM    // 3ipx.pdf (B87) compound 9
3oc0  2.70  2010  IC50=520nM    // 3kwf.pdf (B2Q) compound 1, supersedes code 3kwh
3k5d  2.90  2010  IC50=53nM     // 3k5d.pdf (XLI) compound 3
3mww  2.80  2010  IC50=57nM     // 3mww.pdf (BIW) compound 8; IC50=57+/-3nM
2x52  1.70  2010  IC50=57uM     // 2uwg.pdf (GYT) compound 23, A SYNTHETIC DIVALENT CARBOHYDRATE LIGAND, IC50=57+/-13uM
3o8h  1.90  2010  IC50=580nM    // 3o8g.pdf (O8H) compound BDM14950
3kec  2.05  2010  IC50=58nM     // 3kec.pdf (3KE) compound 10b; X-ray(catalytic domain); IC501=58nM(MMP-13/CD); IC502=130nM(MMP-13/FL)
3o96  2.70  2010  IC50=58nM     // 3o96.pdf (IQO) inhibitor viii
3n4l  2.70  2010  IC50=59nM     // 3n4l.pdf (842) compound 19; compound 1 with BACE-1 as PDB  3ivh:IC50=47nM
2x81  2.91  2010  IC50=5nM      // 2x81.pdf (ZZL) compound MLN8054
3g0g  2.45  2010  IC50=5nM      // 3g0b.pdf (RUM) compound  13c; IC50=5+/-1nM
3g0d  2.39  2010  IC50=5nM      // 3g0b.pdf (XIH) compound  2
3lxl  1.74  2010  IC50=5nM      // 3lxl.pdf (IZA) ligand is compound 1
3ly2  2.60  2010  IC50=5nM      // 3ly2.pdf (Z72) IC50=0.005uM
3ocb  2.70  2010  IC50=5nM      // 3ocb.pdf (XM1) compound 50; with GSK 3 beta peptide; IC50=5+/-2nM
3oct  1.95  2010  IC50=5nM      // 3oct.pdf (1N1) ligand is compound 1, dasatinib
3ot3  1.44  2010  IC50=5nM      // 3ot3.pdf (22K) compound 22k
2xey  2.70  2010  IC50=6.5uM    // 2xey.pdf (YVQ) compound 31g
3ixk  2.50  2010  IC50=6.6nM    // 3ixk.pdf (929) compound 28; IC50=6.6nM for BACE-1 and Ki=210nM for cathepsin D enzyme
3kwf  2.40  2010  IC50=6.8nM    // 3kwf.pdf (B1Q) compound 8p
3l5f  1.70  2010  IC50=605nM    // 3l58.pdf (BDX) compound 40
3ma3  2.30  2010  IC50=60nM     // 3ma3.pdf (01I) UNP residues 92-403;
2x9f  1.75  2010  IC50=61nM     // 2x9f.pdf (X9F) enzyme IC50=0.061uM
3kga  2.55  2010  IC50=61nM     // 3kga.pdf (LX9) IC50=0.061+/-0.006uM
3h0s  2.43  2010  IC50=634nM    // 3h0j.pdf (B38) compound 7
2x4s  2.55  2010  IC50=63uM     // 2x4n.pdf (9-mer) H5N1 (AVIAN FLU) nucleoprotein (AMDSNTLEL); IC50=63+/-0.1uM
3nok  1.65  2010  IC50=64uM     // 3nok.pdf (DDQ) Mutation: L55F; for detergent additive DDQ, IC50= 64+/-60uM; for another buffer ligand MES, IC50=81+/-5mM;
3my5  2.10  2010  IC50=65uM     // 3my1.pdf (RFZ) with cyclinA
3owl  2.10  2010  IC50=670nM    // 3owj.pdf (19E) Fragment: UNP RESIDUES 1-331;
3pup  2.99  2010  IC50=6nM      // 2yak.pdf (OS1) Ru containing
2xow  2.09  2010  IC50=6uM      // 2xov.pdf (ISM) covalent complex, IC50~6uM
2xwy  2.53  2010  IC50=6uM      // 2xwy.pdf (IB8) compound 33; IC50=6+/-3uM
3n5j  2.35  2010  IC50=6uM      // 3n1v.pdf (GO1) compound 10
3o6t  2.40  2010  IC50=6uM      // 3o6t.pdf (PX5) covalent complex; IC50(MtbTrxC)X-ray(MtbTrxCC40S); IC50<6uM
3lxg  2.30  2010  IC50=7.28nM   // 3lxg.pdf (Z73) ligand WEB-3
2x4t  2.30  2010  IC50=7.33uM   // 2x4p.pdf (9-mer) NLVPMVATV peptide
3o8g  1.90  2010  IC50=7.4uM    // 3o8g.pdf (O8G) compound BDM14801
3hnb  1.15  2010  IC50=7.8uM    // 3hnb.pdf (768) compound 005B10
3gwt  1.75  2010  IC50=7.94pM   // 3gwt.pdf (066) compound 4, pIC50=11.1
3l5c  1.80  2010  IC50=7000nM   // 3l58.pdf (BDQ) compound 31
3oki  2.00  2010  IC50=70nM     // 3okh.pdf (OKI) compound 1a; with incomplete 14-mer coactivator
2xck  2.30  2010  IC50=713nM    // 2xch.pdf (MH4) compound 4
3odk  2.30  2010  IC50=720uM    // 3odk.pdf (ODK) compound 3; IC50(Pin1); X-ray(Pin1R14A)
3ow3  1.90  2010  IC50=742nM    // 3ow3.pdf (SMY) compound 26; IC50=742+/-69nM
3nzs  2.75  2010  IC50=75nM     // 3nzs.pdf (NZS) compound1d; IC50(PI3K alpha); X-ray(PI3K gamma)
3msj  1.80  2010  IC50=770uM    // 3msj.pdf (EV3) compound 3
3l5d  1.75  2010  IC50=78000nM  // 3l58.pdf (BDV) compound 32
3ho9  1.90  2010  IC50=789nM    // 3hnz.pdf (N3A) compound 3a, Platencin A1
3ouh  2.51  2010  IC50=79nM     // 3ouh.pdf (014) Fe2+ containing   pIC50=7.1
2xuc  2.30  2010  IC50=79uM     // 2xuc.pdf (XRG) Fragment: RESIDUES 29-337 ; IC50=79+/-8uM;
2wxi  2.80  2010  IC50=7nM      // 2wxf.pdf (S30) Supplementary information; compound SW30
3g0b  2.25  2010  IC50=7nM      // 3g0b.pdf (T22) compound  27b; IC50=7+/-2nM
3kb7  2.50  2010  IC50=7nM      // 3kb7.pdf (071) compound 49
3l54  2.30  2010  IC50=7nM      // 3l54.pdf (LXX) compound 6; IC50=7nM for PI3K alpha, X-ray: PI3K gamma
3nw6  2.20  2010  IC50=7nM      // 3nw5.pdf (LGW) compound 11a
3nww  2.09  2010  IC50=7nM      // 3nww.pdf (3NW) compound 41, X-ray(unphosphorylated p38 alpha)
3msl  2.40  2010  IC50=7uM      // 3msj.pdf (EV5) compound 14i
3n49  2.50  2010  IC50=7uM      // 3n1v.pdf (3N4) compound 7
3oxz  2.20  2010  IC50=8.6nM    // 3oxz.pdf (0LI) compound Ponatinib;
3ovz  2.02  2010  IC50=8.7nM    // 3ovx.pdf (O96) compound 26; covalent complex
2x6i  3.40  2010  IC50=830nM    // 2x6f.pdf (090) supplementary information; compound PIK-90
3nw5  2.14  2010  IC50=8400nM   // 3nw5.pdf (LGX) compound 11b
3h0q  2.50  2010  IC50=842nM    // 3h0j.pdf (B37) compound 3
2x5o  1.46  2010  IC50=85uM     // 2x5o.pdf (VSV) compound (R)-32; IC501=85+/-3uM; IC502=35+/-1uM(Radioactivity assay.)
2wd3  1.80  2010  IC50=86nM     // 2wd3.pdf (MS4) compound 23; IC50=86+/-8nM
3fh5  1.63  2010  IC50=87nM     // 3fh5.pdf (24P) compound 14; IC501=87nM(enzyme); IC502=449nM(HWB)
3k3h  2.50  2010  IC50=88nM     // 3k3e.pdf (BYE) compound 1s; IC50=88+/-17nM
2wpa  2.51  2010  IC50=8nM      // 2wpa.pdf (889) compound 31
3ion  2.40  2010  IC50=8nM      // 3ion.pdf (8H1) compound 9h
3l58  1.80  2010  IC50=8nM      // 3l58.pdf (CS5) BACE Bound to SCH589432, compound 1
3l8v  2.40  2010  IC50=8nM      // 3l8v.pdf (L8V) IC50=0.008uM
3l9h  2.00  2010  IC50=8nM      // 3l9h.pdf (EMQ)
3lxs  1.50  2010  IC50=8nM      // 3lxs.pdf (4MC) WRR-483, compound 2, IC50=70+/-30 nM (at PH 5.5), IC50=8+/-2 nM (at PH 8.0)
3nif  2.40  2010  IC50=8uM      // 3nid.pdf (NIF) IC50=6-12uM
3iit  1.80  2010  IC50=9.5nM    // 3iit.pdf (D14) compound 45c; incomplete ligand structure
2wxo  2.49  2010  IC50=90nM     // 2wxf.pdf (ZZP) Supplementary information; compound AS5
3oqf  2.78  2010  IC50=91nM     // 3oot.pdf (S51) compound 2m
3nzc  2.00  2010  IC50=96nM     // 3nzc.pdf (D2O) compound 5; X-ray, IC50(pcDHFR); IC50=170nM(rat DHFR)
2wxh  1.90  2010  IC50=9nM      // 2wxf.pdf (ZZO) Supplementary information; compound SW14
3mwu  1.98  2010  IC50=9nM      // 3mwu.pdf (BK3) IC50= 9 +/- 0.5 nM; Fragment: CpCDPK1; Mutation: N-terminal 69 residues replaced with His tag and linker;
3nnw  1.89  2010  IC50=9nM      // 3nnu.pdf (EDD) compound 16(U-p38)
3ot8  1.65  2010  IC50=9nM      // 3ot8.pdf (MI5) compound 17r
3ftz  2.00  2010  IC50>2mM      // 3fh5.pdf (848) compound 8; IC50>2mM
3n1w  2.56  2010  IC50>500uM    // 3n1v.pdf (3N2) IC50>500um; compound 1
3n45  1.88  2010  IC50>500uM    // 3n1v.pdf (3N3) IC50>500um; compound 4
3n3l  2.74  2010  IC50>500uM    // 3n1v.pdf (MS0) IC50>500um; compound 3
3k98  2.40  2010  Kd<1nM        // 3k97.pdf (1RC) compound 15; Kd<1nM; IC50=0.3uM
3lzs  1.95  2010  Kd=0.0109nM   // 3lzs.pdf (017) ligand is Darunavir, Kd=0.0109+/-0.0003nM
3lzv  2.15  2010  Kd=0.026nM    // 3lzs.pdf (017) ligand is Darunavir, Kd=0.026+/-0.005nM; redundant to 3ekt
3myg  2.40  2010  Kd=0.02nM     // 3myg.pdf (EML)
3i02  2.60  2010  Kd=0.03uM     // 3hzk.pdf (KDA&KDO) Kdo(2.4)Kdo(2.4)Kdo, Kd1 = 0.03+/-0.001uM(immobilized glycoconjugates); Kd2 =0.05+/-0.003uM( solution affinity to free oligosaccharides)
3m5e  1.70  2010  Kd=0.043uM    // 3m5e.pdf (JDR) ligand is compound 7b, affinity at 37C
3mhl  1.90  2010  Kd=0.056uM    // 3mhl.pdf (J71) ligand is compound 10b, affinity at 37C
3hu2  2.85  2010  Kd=0.06uM     // 3hu1.pdf (AGS) Kd=0.06+/-0.03uM
3lzu  1.76  2010  Kd=0.087nM    // 3lzs.pdf (017) ligand is Darunavir, Kd=0.087+/-0.062nM
3hu3  2.20  2010  Kd=0.13uM     // 3hu1.pdf (AGS) Kd=0.13+/-0.01uM
3hu1  2.81  2010  Kd=0.13uM     // 3hu1.pdf (AGS) Kd=0.13+/-0.02uM
3psl  1.70  2010  Kd=0.13uM     // 3psl.pdf (6-mer) N-alpha acetylated form of histone H3, N-alpha-H3, Kd=0.13+/-0.02uM
3kdb  1.66  2010  Kd=0.14nM     // 3kdb.pdf (006) ligand is KNI-10006; Kd=0.14+/-0.04nM
3iet  2.20  2010  Kd=0.14uM     // 3iet.pdf (9-mer) glycopeptide, truly tumor-specific glycopeptide containing the Tn antigen
3m3x  1.68  2010  Kd=0.15uM     // 3m3x.pdf (JS7) ligand is compound 10c, affinity at 37C
3lxk  2.00  2010  Kd=0.16nM     // 3lxk.pdf (MI1) ligand is compound CP-690550
3m40  1.60  2010  Kd=0.17uM     // 3m40.pdf (J45) ligand is compound 5a, affinity at 37C
3m67  1.80  2010  Kd=0.18uM     // 3m67.pdf (E36) Kd=0.02uM(thermal shift assay), Kd=0.18uM (ITC)
3fsm  1.60  2010  Kd=0.1uM      // 3fsm.pdf (2NC)
3hzy  2.10  2010  Kd=0.1uM      // 3hzk.pdf (KDA&KDO) Kdo(2.4)Kdo(2.4)Kdo, Kd =0.1+/-0.005uM( solution affinity to free oligosaccharides)
3kdm  1.50  2010  Kd=0.1uM      // 3kdm.pdf (TES) IC50=900nM
3mhm  1.50  2010  Kd=0.1uM      // 3mhm.pdf (J75) ligand is compound 8b, affinity at 37C
2kpl   NMR  2010  Kd=0.23uM     // 2kpl.pdf (11-mer) ligand is 11-mer C-terminus of HPV16 E6; MAGI-1 PDZ1 / E6CT, Kd=0.23+/-0.02uM
2xhx  2.80  2010  Kd=0.25uM     // 2xdk.pdf (T5M) compound 24
3ip6  1.40  2010  Kd=0.25uM     // 3ip5.pdf (PRO)
3kmm  2.80  2010  Kd=0.2nM      // 3kmm.pdf (LHL) ligand is compound 1
2kup   NMR  2010  Kd=0.2uM      // 2kup.pdf (19-mer) ligand is 19-residue peptide from ALK tyrosine kinase receptor, calculated using the AMBER9 software
3hzk  2.15  2010  Kd=0.2uM      // 3hzk.pdf (KDA&KDO) Kdo(2.4)Kdo, Kd=0.2+/-0.02uM(immobilized glycoconjugates); Kd=0.3+/-0.01uM(solution affinity to free oligosaccharides)
3mhi  1.70  2010  Kd=0.2uM      // 3mhi.pdf (J90) ligand is compound 11b, affinity at 37C
3lhj  3.31  2010  Kd=0.31nM     // 3lhj.pdf (LHJ) Ki=2.3nM
2xjj  1.90  2010  Kd=0.31uM     // 2xab.pdf (L81) ligand is compound 4; IC50=25uM
3mho  1.15  2010  Kd=0.32uM     // 3mho.pdf (J43) ligand is compound 7a, affinity at 37C
3nw3  2.50  2010  Kd=0.32uM     // 3ng4.pdf (MU2) ligand is MDP
3ogx  2.80  2010  Kd=0.33uM     // 3ogx.pdf (H1S)
2xdx  2.42  2010  Kd=0.35uM     // 2xdk.pdf (WOE) ligand is compound 6
3hzv  1.90  2010  Kd=0.3uM      // 3hzk.pdf (KDA&KDO) Kdo(2.8)Kdo(2.4)Kdo, Kd=0.3+/-0.03uM(immobilized glycoconjugates); Kd=0.2+/-0.003uM( solution affinity to free oligosaccharides)
2xup  2.70  2010  Kd=0.41pM     // 2xup.pdf (TZ5) ligand is compound 101
3m3r  2.20  2010  Kd=0.48uM     // 3m3r.pdf (BCD) BETA-CYCLODEXTRIN, Kd=0.48+/-0.05uM
3lnz  1.95  2010  Kd=0.49nM     // 3lnz.pdf (12-mer) ligand is 12-mer peptide inhibitor PMI (N8A mutant); incomplete ligand
3fw4  2.30  2010  Kd=0.4nM      // 3fw4.pdf (CAQ) catechol CFe(III), Fe3+ containing Kd=0.4+/-0.2nM; catechol alone Kd=0.20+/-0.06uM
3k1j  2.00  2010  Kd=0.4uM      // 3k1j.pdf (ADP)
3kdc  2.20  2010  Kd=0.52nM     // 3kdb.pdf (JZP) ligand is KNI-10074; Kd=0.52+/-0.24nM
2xgs  2.39  2010  Kd=0.530mM    // 2xgm.pdf (44P) C-UDP; Kd=0.530+/-0.006mM; human OGT IC50=9.0+/-1.0uM
2xab  1.90  2010  Kd=0.54nM     // 2xab.pdf (VHD) ligand is compound 1; Ic50=31nM
3oap  2.05  2010  Kd=0.55uM     // 3oap.pdf (11-mer) ligand:Nuclear receptor coactivator 2(GRIP-1); with REA(9cRA); Kd(ITC)=0.55+/-0.02uM(25oC); Kd(CD spectrum)=0.9+/-0.1uM(25oC)
3hcm  2.00  2010  Kd=0.5mM      // 3hcm.pdf (S45) ligand is compound SEN205A; Kd=0.5-1.0mM
3k5v  1.74  2010  Kd=0.5uM      // 3k5v.pdf (STJ) GNF-2 binding to the imatinib/Abl complex, Kd=0.5+/-0.1uM; IC50=0.26uM
3me9  1.37  2010  Kd=0.5uM      // 3me9.pdf (11-mer) Histone H3, Kd=0.5+/-0.2uM(ITC), Kd=2+/-0.3uM(FP); SGF29: Fragment: UNP Residues 115-293; H3: Fragment: UNP Residues 2-9
3mea  1.26  2010  Kd=0.5uM      // 3me9.pdf (11-mer) Histone H3, Kd=0.5+/-0.2uM(ITC), Kd=2+/-0.3uM(FP); SGF29: Fragment: UNP Residues 129-291; H3: Fragment: UNP Residues 2-4
3meu  1.28  2010  Kd=0.5uM      // 3me9.pdf (14-mer) Histone H3, Kd=0.5+/-0.1uM(ITC); SGF29: Fragment: UNP Residues 115-293; H3: Fragment: UNP Residues 2-14
3m55  1.55  2010  Kd=0.62uM     // 3m53.pdf (11-mer) ligand is TAF10-K189me1 peptide; Kd=0.62+/-0.065uM
3ad8  2.20  2010  Kd=0.69mM     // 3ad7.pdf (PYC) SO-U96 complex with pyrrole 2-carboxylate, inhibit the enzyme competitively with respect to sarcosine, Kd=0.69+/-0.23mM
3m89  2.00  2010  Kd=0.69uM     // 3m89.pdf (GSP) ligand is GTP-gamma-S
3acl  2.35  2010  Kd=0.6uM      // 3acl.pdf (3F1) ligand is compound A
3ip5  1.35  2010  Kd=0.6uM      // 3ip5.pdf (ALA)
3ipa  1.55  2010  Kd=0.6uM      // 3ip5.pdf (ALA) redundant to 3ip5
3p2e  1.68  2010  Kd=0.6uM      // 3p2e.pdf (SAH) ligand is compound AdoHcy
3pb3  1.90  2010  Kd=0.6uM      // 3p2e.pdf (SAH) ligand is compound AdoHcy; redundant to 3p2e
2xjx  1.66  2010  Kd=0.71nM     // 2xab.pdf (XJX) ligand is compound 35; IC50=48nM
3ig1  2.80  2010  Kd=0.73uM     // 3ig1.pdf (JTH) Kd1=0.73+/-0.09uM(fluor); Kd2=6+/-1uM(SPR); Ki=0.14uM; IC50=0.21uM
3ktr  1.70  2010  Kd=0.7uM      // 3ktr.pdf (17-mer) ataxin-2
3otf  2.40  2010  Kd=0.83uM     // 3otf.pdf (CMP)
3mo8  1.69  2010  Kd=0.8mM      // 3mo8.pdf (12-mer) Histone H3.2 TRIMETHYLATED H3K36 PEPTIDE, Kd=0.8+/-0.1mM; BRPF1: PWWP domain; Fragment: UNP residues 1079-1207
3lgl  1.60  2010  Kd=0.9uM      // 3lgf.pdf (11-mer) 11-mer DIMETHYLATED p53 LYSINE 382 PEPTIDE, Kd=0.9+/-0.4uM; incomplete ligand
2xui  2.60  2010  Kd=1.0fM      // 2xud.pdf (TZ5) compound syn1; 1-wk
3k54  1.94  2010  Kd=1.0nM      // 3gen.pdf (1N1) X-ray(BTK Y551E) while Kd(wild type)
3nex  1.70  2010  Kd=1.0uM      // 3nee.pdf (G24) ligand is compound GC-24; Kd=1.0+/-0.2uM
2xht  2.27  2010  Kd=1.1uM      // 2xdk.pdf (C0Y) ligand is compound 21; IC50=22uM in cell lines
3kgu  1.85  2010  Kd=1.2uM      // 3kgt.pdf (GEN) ligand is genistein, Kd=1.2+/-0.4uM
3n5u  3.20  2010  Kd=1.2uM      // 3n5u.pdf (13-mer) ligand:Rb C-terminal peptide 870-882; Kd=1.2+/-0.4uM; imcomplete ligand structure
3neo  2.00  2010  Kd=1.2uM      // 3nee.pdf (G24) ligand is compound GC-24; Kd=1.2+/-0.1uM
2y3p  2.62  2010  Kd=1.3uM      // 2wl2.pdf (SM8) IC50=0.6uM
3m54  1.60  2010  Kd=1.3uM      // 3m53.pdf (11-mer) ligand is TAF10-K189 peptide; Kd=1.3+/-0.10uM
3lka  1.80  2010  Kd=1.5mM      // 3lka.pdf (M4S) ligand is compound PMS
3k00  1.55  2010  Kd=1.7uM      // 3jyr.pdf (MTT) ligand is maltotetraose; Kd=1.7+/-0.2uM
3gy2  1.57  2010  Kd=1.80uM     // 3gy2.pdf (BRN) ligand is diminazene; Kd=1.80+/-0.05uM
3kr1  2.30  2010  Kd=1.8uM      // 3kpj.pdf (VGD) compound 15; binding data measured with AdoHcy; Kd=1.8+/-0.3 uM
3o0e  3.01  2010  Kd=1.8uM      // 3o0e.pdf (17-mer) ligand:colicin peptide OBS1; Kd=1.8+/-0.1uM; incomplete ligand
3lf0  2.40  2010  Kd=1.93uM     // 3lf0.pdf (ATP)
3k02  1.55  2010  Kd=10.0uM     // 3jyr.pdf (TXT) ligand is compound 5c; Kd=10.0+/-0.6uM
3lle  1.85  2010  Kd=10.7uM     // 3lk0.pdf (SGE) compound SC0844, Kd=10.7+/-4.9 uM; IC50=35.9+/-16.4 uM
2kp8   NMR  2010  Kd=100uM      // 2kp8.pdf (XIG) compound 1
3huc  1.80  2010  Kd=1030nM     // 3hub.pdf (G97) ligand is compound 6; Kd=1030+/-180nM
2kvm   NMR  2010  Kd=108.4uM    // 2kvm.pdf (16-mer) ligand is H3K27me2 peptide; Kd=108.4+/-7.4uM, for H3K27me3 peptide Kd=59+/-4.7uM
3l8x  2.40  2010  Kd=10nM       // 3cg2.pdf (N4D) compound 2e
3nga  2.71  2010  Kd=10nM       // 3nga.pdf (3NG) compound CX-4945; Kd<10nM; IC50=13nM
3new  2.51  2010  Kd=10uM       // 3new.pdf (3NE) compound 10; IC50=1.2uM
3omc  1.77  2010  Kd=10uM       // 3omc.pdf (8-mer) incomplete ligand
3iqj  1.15  2010  Kd=11.7uM     // 3iqj.pdf (10-mer) Kd=11.7+/-2.5uM; incomplete ligand
2wib  2.56  2010  Kd=11.8uM     // 2wib.pdf (GDP) Kd=11.8+/-1.48uM
2w97  2.29  2010  Kd=110mM      // 2w97.pdf (GOL) Kd1 = 110mM(in the presence of 30% NH4SO4); Kd2 =167mM(in the absence of NH4SO4).
2l1b   NMR  2010  Kd=110uM      // 2l11.pdf (15-mer) protein 1 Fragment: UNP Residues 7-62 ; protein 2 Fragment: UNP Residues 20-34  ; Kd=110+/-17uM;
3kze  1.80  2010  Kd=112uM      // 3kze.pdf (8-mer) Ac-SSRKEYYA Peptide, Kd=112+/-15uM
3luo  2.55  2010  Kd=113nM      // 3luo.pdf (6-mer) Suc-Ala-Leu-Pro-Phe-pNA, Kd=51+/-21nM(FP), Kd=113+/-20nM(ITC)
3a5y  1.90  2010  Kd=11nM       // 3a5y.pdf (KAA) ligand is compound LysAMS
3m5a  1.75  2010  Kd=11uM       // 3m53.pdf (11-mer) ligand is TAF10-K189me3 peptide; Kd=11+/-0.28uM
3mmr  2.14  2010  Kd=11uM       // 3mmr.pdf (ABH) Kd=11+/-2 uM(pH=8.0); Ki=11+/-2 uM (pH=7.4); Ki=12+/-2 uM (pH=8.0); Ki=10+/-1 uM (pH=8.5)
3nin  2.10  2010  Kd=12.4uM     // 3nih.pdf (5-mer) incomplete ligand structure
3juk  2.30  2010  Kd=12.9uM     // 3juk.pdf (UPG)
3m8u  1.85  2010  Kd=12.9uM     // 3m8u.pdf (GDS) glutathione disulfide(GSSG), Kd=12.9+/-0.3uM measured at T=37C
3nij  2.10  2010  Kd=12.9uM     // 3nih.pdf (4-mer) ligand:Peptide HIAA, incomplete ligand structure; Zn-containing; Kd=12.9+/-0.856uM(lower pH ITC2, pH6.5)
3ies  2.00  2010  Kd=120pM      // 3ies.pdf (M24) ligand is PTC124-AMP; Kd=120+/-30pM
3l5b  1.80  2010  Kd=123uM      // 3l58.pdf (BDO) compound 23
3lp4  1.90  2010  Kd=13.1uM     // 3lp4.pdf (LYS)
3obx  1.60  2010  Kd=130uM      // 3obq.pdf (9-mer) Gag PTAP P7A mutant peptide; Kd=130+/-4uM
3mo5  2.14  2010  Kd=136nM      // 3mo0.pdf (E72) Kd=136+/-22nM; IC50=100+/-3nM; structure:with AdoHcy
3lbz  2.30  2010  Kd=138uM      // 3lbz.pdf (Z89) ligand is inhibitor 79-6, binding data in supporting info, Kd=138+/-31uM, Ki=147uM, IC50=212uM
3kqo  2.40  2010  Kd=140uM      // 3kpj.pdf (ES4) compound 10; binding data measured with AdoHcy; Kd=140+/-27 uM
3lzz  2.50  2010  Kd=146uM      // 3lzz.pdf (GDP) Kd=159+/-51uM (physiological concentration of GDP); Kd=146+/-11uM(radient concentration of GDP)
3kpw  2.40  2010  Kd=14uM       // 3kpj.pdf (1SQ) compound 3; measured with AdoHcy; Kd=14+/-2 uM
3mo0  2.78  2010  Kd=154nM      // 3mo0.pdf (E11) Kd=154+/-9nM; IC50=778+/-25nM; X-ray:with AdoHcy
2xjg  2.25  2010  Kd=15nM       // 2xab.pdf (XJG) ligand is compound 2; IC50=2.5uM
3mj1  1.72  2010  Kd=15nM       // 3miy.pdf (614) inhibitor RO5191614
2l0i   NMR  2010  Kd=15uM       // 2l0i.pdf (14-mer) ligand is Ser2 diheptad phosphorylated CTD peptide, NMR; Kd=15+/-10uM; incomplete ligand
2l11   NMR  2010  Kd=15uM       // 2l11.pdf (15-mer) protein 1 Fragment: UNP Residues 29-81  ; protein 2 Fragment: UNP Residues 2-16  ;  Kd=15+/-8uM;
3kmx  1.70  2010  Kd=15uM       // 3kmx.pdf (G00) Kd=15+/-7uM
3kqy  2.20  2010  Kd=15uM       // 3kpj.pdf (ES0) compound 13; with AdoHcy; Kd=15+/-1 uM
3lxo  1.55  2010  Kd=15uM       // 3lxo.pdf (T3P) Kd=15+/-0.9uM
2rr4   NMR  2010  Kd=16.7uM     // 2rr4.pdf (10-mer) zf-CW domain and the H3K4me3 peptide, Histone H3 H3K4me3 peptide
3kyf  2.10  2010  Kd=165.0nM    // 3kyf.pdf (5GP) PP4397, Kd=165.0+/-76.9nM
3nq3  1.90  2010  Kd=167uM      // 3nq3.pdf (DKA) ligand is capric acid; Ka=6.0+/-0.5*10^3M-1
3g5v  2.00  2010  Kd=16nM       // 3g5v.pdf (16-mer) Epidermal Growth Factor Receptor peptide; Kd1=16+/-8nM(Pms-serine coupling); Kd2=84+/-3nM(Thiol coupling); Kd3=85+/-0.3nM(Amine coupling)
3iqu  1.05  2010  Kd=17.0uM     // 3iqj.pdf (6-mer) Kd=17.0+/-1.6uM
3hdk  1.80  2010  Kd=17.5uM     // 3fsm.pdf (2NC)
3nim  2.00  2010  Kd=17.7uM     // 3nih.pdf (4-mer) Zn-containing; Kd=17.7+/-0.325uM (ITC, pH=8)
3kqm  2.40  2010  Kd=170uM      // 3kpj.pdf (ES3) compound 5; with AdoHcy; Kd=170+/-16 uM
2xg3  1.20  2010  Kd=18.2uM     // 2xg3.pdf (3-mer) ligand L2; Kd=18.2+/-0.2uM, 3 separated ligand structures
3n6k  2.25  2010  Kd=180nM      // 3n1v.pdf (BFH) Kd=184+/-25nm(from SI); IC50=0.2+/-0.06um; compound 11
2wq5  1.65  2010  Kd=180uM      // 2wq5.pdf (MIY)
3kpv  2.40  2010  Kd=180uM      // 3kpj.pdf (ADE) compound 2; with AdoHcy; Kd=180+/-90 uM
3lcv  2.00  2010  Kd=18uM       // 3lcu.pdf (SAM) ligand is adoMet (S-adenosylmethionine)
3llm  2.80  2010  Kd=18uM       // 3llm.pdf (ADP) ligand is mADP
3ny3  1.60  2010  Kd=19.3uM     // 3ny3.pdf (4-mer) ligand is RIFS; Kd=19.3+/-2.6uM
3lk8  1.80  2010  Kd=19.7nM     // 3lk8.pdf (Z79) ligand is compound 3
2x2c  2.41  2010  Kd=19nM       // 2x2c.pdf (11-mer) ligand is cyclosporine; Kd=19+/-2nM; Ki=27+/-5.6nM.
2wzy  2.51  2010  Kd=19pM       // 2wzy.pdf (SQX) ligand is  SPX (13-desmethyl spirolide C), Kd=0.019nM
3okp  2.00  2010  Kd=19uM       // 3oka.pdf (GDD) orthorhombic crystal form; Kd=19+/-4.6uM
3oka  2.20  2010  Kd=19uM       // 3oka.pdf (GDD) triclinic crystal form; Kd=19+/-4.6uM; redundant to 3okp
3omg  1.85  2010  Kd=19uM       // 3omc.pdf (8-mer) incomplete ligand
2xgm  2.55  2010  Kd=1mM        // 2xgm.pdf (LXN) compound alloxan, Kd>1mM; human OGT IC50=18+/-1uM
2xgo  2.60  2010  Kd=1mM        // 2xgm.pdf (ZKD) UDP-S-GLCNAC; Kd>1mM; human OGT IC50=93+/-15uM
3jrx  2.50  2010  Kd=1nM        // 3jrx.pdf (S1A) ligand is compound soraphen A
2l6e   NMR  2010  Kd=1uM        // 2k1c.pdf (14-mer)
3met  2.00  2010  Kd=1uM        // 3me9.pdf (11-mer) Histone H3, Kd=1+/-0.1uM(ITC), Kd=4+/-1uM(FP); SGF29: Fragment: UNP Residues 115-293; H3: Fragment: UNP Residues 2-12
3nyn  2.72  2010  Kd=1uM        // 3nyn.pdf (SGV)
3al3  2.15  2010  Kd=2.1uM      // 3al3.pdf (10-mer) protein 1 Fragment: BRCT7 and BRCT8, UNP residues 1264-1493  ; peptide Fragment: UNP residues 1129-1138 ; Kd=2.1+/-0.1uM;
3p4f  2.35  2010  Kd=2.2uM      // 3p4f.pdf (11-mer) Retinoblastoma-binding protein 5, RbBP5 (371-381, Y381D), Kd=2.2+/-0.2 uM, WDR5 Fragment: 1-308; X-ray: RbBP5 (371-381, Y381D), Assay: RbBP5 (371-380)
3l1n  1.30  2010  Kd=2.34uM     // 3l1n.pdf (PLM) ligand is palmitoleic acid, Kd=2.34uM for LBD2
3gy3  1.70  2010  Kd=2.36uM     // 3gy2.pdf (PNT) ligand is pentamidine; Kd=2.36+/-0.19uM
3lpl  2.10  2010  Kd=2.39uM     // 3lpl.pdf (TDP)
3hkw  1.55  2010  Kd=2.3nM      // 3hkw.pdf (IX6) ligand is compound 4; 1b_J4 polymerase; Kd=2.3+/1.7nM, PDB is 1a, but reference indicates 1b
3ip9  1.80  2010  Kd=2.4uM      // 3ip5.pdf (ABU)
3nes  1.75  2010  Kd=2.4uM      // 3nee.pdf (B72) ligand is compound GC-1; Kd=2.4+/-1.2uM
2x4z  2.10  2010  Kd=2.7nM      // 2x4z.pdf (X4Z) ligand is compound PF-3758309; Kd=2.7+/-0.3nM; Ki=18.7+/-6.6nM;
3iqq  2.01  2010  Kd=2.9uM      // 3iqq.pdf (12-mer) ligand is 12-mer TRTK12 peptide, CapZ protein; Ca2+ containing; Kd=2.9+/-0.5uM; incomplete ligand
3jyr  1.75  2010  Kd=2.9uM      // 3jyr.pdf (ACR) ligand is acarbose; Kd=2.9+/-0.3uM
2krd   NMR  2010  Kd=2000uM     // 2krd.pdf (17-mer) ligan is Switch Region of cardiac Troponin I (147-163); Kd=154+/-30uM, but in the presence of W7, Kd=2000+/-50uM
3kd7  2.85  2010  Kd=200uM      // 3kd7.pdf (6-mer) Hsp90 MEEVD peptide
3l59  2.00  2010  Kd=200uM      // 3l58.pdf (BDJ) ligand is compound 10
3n7s  2.10  2010  Kd=20nM       // 3n7p.pdf (3N6)
3n7r  2.90  2010  Kd=20nM       // 3n7p.pdf (N7R) CLR/RAMP1 complex with compound 2 telcagepant, Kd<20nM below the limit of detection
2wva  2.20  2010  Kd=20pM       // 2wva.pdf (TPU)
3kr0  2.60  2010  Kd=20uM       // 3kpj.pdf (172) compound 14; measured with AdoHcy; Kd=20+/-2.5 uM
3lm1  2.10  2010  Kd=20uM       // 3lly.pdf (LEC)
3nkk  1.12  2010  Kd=20uM       // 3nk8.pdf (JLZ)
3p2k  2.70  2010  Kd=20uM       // 3p2e.pdf (SAM) compound AdoMet
3lnj  2.40  2010  Kd=219nM      // 3lnj.pdf (12-mer) ligand is 12-mer D-peptide inhibitor (DPMI-alpha); Kd=219+/-11 nM; incomplete ligand
3miy  1.67  2010  Kd=21nM       // 3miy.pdf (B49) ligand is sunitinib
3oy8  2.19  2010  Kd=220uM      // 3oy8.pdf (2-mer) GAL-GCO(LBA); Kd=220+/-75uM; IC50=14.18mM
3mss  1.95  2010  Kd=22uM       // 3ms9.pdf (MS7) ligand is imatinib; compound 2
2rqu   NMR  2010  Kd=23.6uM     // 2rqu.pdf (19-mer) ligand is 19-mer from Adenomatous polyposis coli protein, Kd=23.6+/-2uM
3ljo  1.50  2010  Kd=239nM      // 2zdk.pdf (11U) ligand is compound 1b(open form); Kd=239+/-26nM; Ki=49+/-15nM
2xs8  2.50  2010  Kd=24.5uM     // 2xs8.pdf (18-mer) SIV agmTan-1 p6 peptide, Kd=24.5+/-0.5uM; incomplete ligand
3lgs  2.20  2010  Kd=24.8uM     // 3lgs.pdf (SAH) Kd=24.8+/-2.6 uM
3mo2  2.49  2010  Kd=244nM      // 3mo0.pdf (E67) Kd=244+/-29nM; IC50=273+/-10nM; structure:with AdoHcy
3jzj  1.40  2010  Kd=248uM      // 3jyr.pdf (ACR) ligand is acarbose; Kd=248+/-9uM
3o4k  2.11  2010  Kd=24nM       // 3o4k.pdf (LTC) ligand is LTA
3ob2  2.10  2010  Kd=25.8uM     // 3ob1.pdf (12-mer) ligand:ppEGFR; incomplete ligand structure
3m3o  2.10  2010  Kd=250.63uM   // 3afk.pdf (3-mer)
2xdk  1.97  2010  Kd=250uM      // 2xdk.pdf (XDK) ligand is compound 1
3afk  1.95  2010  Kd=251.89uM   // 3afk.pdf (3-mer)
3fh7  2.05  2010  Kd=25nM       // 3fh5.pdf (25P) ligand is compound 20; IC50=47nM(enzyme); IC50=37nM(HWB)
2wq4  1.42  2010  Kd=2700uM     // 2wq4.pdf (SFU) Kd=2700+/-7uM
2l1r   NMR  2010  Kd=270uM      // 2l1r.pdf (SXK) dfbp-o for the regulatory domain of cTnC in presence of cTnI, Kd=270+/-30uM
3adt  2.70  2010  Kd=28.0uM     // 3ads.pdf (HID) compound 5-hydroxy-indole acetate(HIA)
3oq5  2.50  2010  Kd=28uM       // 3oq5.pdf (10-mer) Cellular tumor antigen p53, C-terminal residues 377-386; (p53K382me1), Fragment: MBT Repeats residues 191-530; Kd=28+/-5uM
3p8p  2.50  2010  Kd=28uM       // 3p8e.pdf (LN6) ligand is compound 4; Kd=28+/-2uM
3l81  1.60  2010  Kd=29.6uM     // 3l81.pdf (7-mer) 7-mer Amyloid beta A4 protein from ENPTYKFFEQ, Kd=29.6+/-2.4uM, TYKFFEQ peptide
3obq  1.40  2010  Kd=290uM      // 3obq.pdf (9-mer) human HRS PSAP peptide; Kd=290+/-42uM
2x7x  2.64  2010  Kd=2uM        // 2x7x.pdf (FRU)
3ad7  2.20  2010  Kd=3.01mM     // 3ad7.pdf (MTG) SO-U96 complex with methylthio acetate, inhibit the enzyme competitively with respect to sarcosine, Kd=3.01+/-0.54mM
3kgt  1.95  2010  Kd=3.1uM      // 3kgt.pdf (GEN) ligand is genistein, Kd=3.1+/-0.5uM
3i73  2.40  2010  Kd=3.23uM     // 3i4l.pdf (ADP)
3hmp  2.30  2010  Kd=3.24uM     // 3hmn.pdf (CX4) ligand is compound 4; Kd=3.24+/-0.28uM; IC50=38.41+/-4.6uM
3m58  1.40  2010  Kd=3.3uM      // 3m53.pdf (11-mer) ligand is TAF10-K189me1 peptide; Kd=3.3+/-0.10uM
2xde  1.40  2010  Kd=3.42uM     // 2xde.pdf (1B0) ligand is compound PF-3450074
3kdd  1.80  2010  Kd=3.45nM     // 3kdb.pdf (JZQ) ligand is KNI-10265; Kd=3.45+/-0.69nM
3pd2  1.86  2010  Kd=3.4uM      // 3pd2.pdf (A3S) Kd=3.4+/-0.3uM; compound Ser3AA
3nam  3.10  2010  Kd=3.5nM      // 3nal.pdf (OTK) compound dOTG, Kd= 3.5+/-1.5 nM, The Kd seen like as IC50
3pty  2.00  2010  Kd=3.65uM     // 3pty.pdf (AFO)
3lp7  2.04  2010  Kd=3.6uM      // 3kv2.pdf (HAR) NOHA (Nx-hydroxy-L-arginine)
2xbv  1.66  2010  Kd=3.7nM      // 2xbv.pdf (XBV) ligand is compound 27; Ki=7nM
3nhi  1.43  2010  Kd=3.7nM      // 3nhi.pdf (EAH) ligand is compound LTC4; Kd=3.7+/-0.6nM
3ng4  1.73  2010  Kd=3.7uM      // 3ng4.pdf (2-mer) ligand is GlcNAc-maltose; Affinity for GlcNAc and Beta-maltose separately are in the range of 10^-4M and 10^-5M, while for mixture (MAL-NAG) is 3.7uM
3ob1  2.20  2010  Kd=3.83uM     // 3ob1.pdf (12-mer) ligand:ppSpry2; incomplete ligand structure
2wsx  3.50  2010  Kd=3.9mM      // 2wsx.pdf (NM2) Supplementary information; Kd=3.9+/-0.7mM(detergent solution); Kd=5.3+/-0.8mM(proteoliposomes)
3hmo  2.40  2010  Kd=30.5nM     // 3hmn.pdf (STU) IC50=0.102+/-0.015uM, Kd=0.0305+/-0.001uM; ligand is inhibitor staurosporine
3ljj  1.55  2010  Kd=300nM      // 2zdk.pdf (10U) compound  1a(open form); Kd1=300+/-34nM(Tris); Kd2=316+/-60nM(Tricine); Kd3=301+/-43M(Hepes); Kd4=245+/-38nM(PPi); Ki=117+/-25nM
3lcu  2.10  2010  Kd=300uM      // 3lcu.pdf (SAH) ligand is adoHcy (S-adenosylhomocysteine)
3gy7  1.55  2010  Kd=30uM       // 3gy2.pdf (BEN) bovine beta-trypsin in complexed with bis-benzamidine
3o6l  2.10  2010  Kd=31nM       // 3o6k.pdf (15-mer) ligand is 15-mer Tat peptide; Kd=3.1+/-1.9x10-8M
3l2y  2.70  2010  Kd=32.07uM    // 3kqr.pdf (OPE) Ca2+ binding; Kd=32.07+/-13.4uM
3kmy  1.90  2010  Kd=32uM       // 3kmx.pdf (D8Y)
3pd4  2.40  2010  Kd=33.2uM     // 3pd2.pdf (A3G) Kd=33.3+/-2uM; compound Gly3AA
3o6m  2.40  2010  Kd=33nM       // 3o6k.pdf (9-mer) Kd=3.3+/-0.3x10-8M
3kyg  2.10  2010  Kd=34.3nM     // 3kyf.pdf (5GP) Kd=34.3+/-14.6nM for c-di-GMP
3nil  1.75  2010  Kd=343.2uM    // 3nih.pdf (4-mer) incomplete ligand structure
3o8p  2.10  2010  Kd=350nM      // 3o8p.pdf (BMU) ligand is compound M1, wild type protein binding data from ref. 31
3nik  1.85  2010  Kd=358.8uM    // 3nih.pdf (4-mer) Zn-containing; Kd=358.8+/-20.2uM (ITC, pH=8)
3g5y  1.59  2010  Kd=35nM       // 3g5v.pdf (16-mer) Epidermal Growth Factor Receptor peptide; Kd1=35+/-6nM(Pms-serine coupling); Kd2=143+/-2nM(Thiol coupling); Kd3=154+/-0.1nM(Amine coupling)
3pd3  1.86  2010  Kd=36.2uM     // 3pd2.pdf (A3T) Kd=36.2+/-10uM; compound Thr3AA
3okc  2.40  2010  Kd=36.5uM     // 3oka.pdf (GDP) orthorhombic crystal form; Kd=36.5+/-6.9uM
3kqr  1.50  2010  Kd=36.8uM     // 3kqr.pdf (OPE)
3m3e  2.10  2010  Kd=37.45uM    // 3afk.pdf (3-mer)
2wyf  2.40  2010  Kd=37uM       // 2wyf.pdf (GLA-MBG)
3kqp  2.40  2010  Kd=380uM      // 3kpj.pdf (ES5) compound 11; measured with AdoHcy; Kd=380+/-44 uM
3muk  1.75  2010  Kd=380uM      // 3muk.pdf (8-mer) peptide of Histone H3.3, Fragment: bromodomain, 42-168; X-ray(histone H3 peptide, 22-29), Kd=380+/-105uM
3hzm  1.80  2010  Kd=3uM        // 3hzk.pdf (KDO) Kd=3+/-0.06uM (solution affinity to free oligosaccharides)
3m57  1.70  2010  Kd=4.0uM      // 3m53.pdf (11-mer) ligand is TAF10-K189 peptide; Kd=4.0+/-0.25uM
2xuf  2.55  2010  Kd=4.1fM      // 2xud.pdf (TZ4) compound anti1; 1-mth
2wic  2.05  2010  Kd=4.1uM      // 2wib.pdf (GNP) Kd=4.1+/-0.73uM (with Mg2+)
3mf5  2.00  2010  Kd=4.32uM     // 3mf5.pdf (HJZ) Kd=4.32+/-0.555 uM; IC50=0.042uM
3lqj  1.90  2010  Kd=4.3uM      // 3lqi.pdf (9-mer) H3(1-9)K4me3 peptide; incomplete ligand
3ncq  1.24  2010  Kd=4.4uM      // 3ncq.pdf (ATP) structure(MgATP); Kd1=4.4uM, Kd2=40.8uM, Kd3=3.8(MgATP); Kd1=3.2uM, Kd2=31.2uM, Kd3=8.8(ATP); diverse binding data at multiple binding sites
3npc  2.35  2010  Kd=4.6nM      // 3npc.pdf (B96) ligand is BIRB796
3kqt  2.40  2010  Kd=4.6uM      // 3kpj.pdf (ES7) compound 7; measured with AdoHcy; Kd=4.6+/-0.69 uM
3nee  1.55  2010  Kd=4.6uM      // 3nee.pdf (B72) ligand is compound GC-1; Kd=4.6+/-2.1uM
3nrz  1.80  2010  Kd=4.6uM      // 3nrz.pdf (HPA) Bovine Xanthine Oxidase in Complex with Hypoxanthine, steady-state and reductive half-reactions, PH=8.5
2x00  2.40  2010  Kd=4.7pM      // 2wzy.pdf (GYN) ligand is gymnodimine A, Kd=0.0047nM
3ml4  2.60  2010  Kd=4.7uM      // 3ml4.pdf (13-mer) ligand is Muscle, skeletal receptor tyrosine-protein kinase (Residues 544-556); incomplete ligand
2xhr  2.20  2010  Kd=4.8nM      // 2xdk.pdf (C0P) compound 14
3m53  1.85  2010  Kd=4.9uM      // 3m53.pdf (11-mer) ligand is TAF10-K189 peptide; Kd=4.9+/-0.20uM
2xtn  1.90  2010  Kd=40nM       // 2xtm.pdf (GTP) Kd=40+/-7nM for GIMAP2(1-260), not GIMAP2(1-234)
3m17  2.60  2010  Kd=40nM       // 3m17.pdf (15-mer) monomeric peptide inhibitor, UNP residues 24-290; deg-shFcRn with peptide1
3i5r  1.70  2010  Kd=40uM       // 3i5r.pdf (12-mer) ligand is 12-mer peptide ligand PD1R; incomplete ligand
3l6x  2.40  2010  Kd=40uM       // 3l6x.pdf (18-mer) ligand is 18-mer E-cadherin; lower affinity
3a73  2.19  2010  Kd=420uM      // 3a73.pdf (PJ2) covalent complex
3guz  1.67  2010  Kd=42uM       // 3guz.pdf (PAF)
3nm6  1.60  2010  Kd=45mM       // 3nm5.pdf (TRS) X-ray(with product ADE); Kd(Tris alone)
3ogm  3.34  2010  Kd=48nM       // 3ogk.pdf (OGK) compound coronatine; ; with JAZ1 degron; Kd=48+/-13nM;
3nth  2.80  2010  Kd=48uM       // 3nth.pdf (6-mer) Kd=48uM(ITC), 37uM(SPR); ligand:Aubergine [R13(me2s)]
3hs9  2.15  2010  Kd=490nM      // 3hs8.pdf (12-mer) ligand is 12-mer Intersectin 1-peptide; incomplete ligand
3mxf  1.60  2010  Kd=49nM       // 3mxf.pdf (JQ1) Kd=49+/-2.4nM; IC50=77nM
2xyn  2.81  2010  Kd=4nM        // 2xyn.pdf (VX6)
3l6h  2.30  2010  Kd=4uM        // 3l6g.pdf (BET) ligand is glycine betaine, Kd=4~5uM; redundant to 1r9l
2xzw  1.95  2010  Kd=5.1uM      // 2xul.pdf (AKG) measured at low 2-OG concentrations; Kd1=5.1+/-4.0uM; Kd2=11.1+/-1.8uM; Kd3=106.7+/-14.8uM; diverse binding data at multiple binding site
3k8q  2.50  2010  Kd=5.2pM      // 3k8q.pdf (22A) ligand is SerMe-Imm-H; Ki=5pM
3n9s  1.85  2010  Kd=5.5uM      // 3n9r.pdf (TD4) ligand is compound 1; IC50=131nM; Zn-containing
2xl3  2.70  2010  Kd=5.6uM      // 2xl2.pdf (14-mer) 14-mer peptide Fragment: RESIDUES 369-381 ; 9-mer peptide containing; ternary complex;
2xl2  2.40  2010  Kd=5.6uM      // 2xl2.pdf (14-mer) peptide Fragment: RESIDUES 369-381
3m59  1.70  2010  Kd=5.8uM      // 3m53.pdf (11-mer) ligand is TAF10-K189me2 peptide; Kd=5.8+/-0.22uM
3mle  2.80  2010  Kd=5.8uM      // 3mle.pdf (ADP) second crystal form; Mg-containing
3lq2  1.96  2010  Kd=5.97uM     // 3lpl.pdf (TDP) measured with 0.5mM TDP
3lq4  1.98  2010  Kd=5.97uM     // 3lpl.pdf (TDP) redundant to 3lq2, measured with 5mM TDP
3obu  1.60  2010  Kd=50uM       // 3obq.pdf (9-mer) Gag PTAP peptide; Kd=50+/-0.7uM
3l3q  2.30  2010  Kd=53.2nM     // 3l3q.pdf (15-mer) Fragment:NLS binding domain(71-497); Kd=53.2 +/- 14.9 nM
3iwy  1.93  2010  Kd=53nM       // 3iwy.pdf (12-mer) D-PMI-gamma peptide inhibitor, Kd=4.9uM is for MDMX, Kd=53+/-6nM is for MDM2
3ijg  1.70  2010  Kd=54.0uM     // 3ijg.pdf (AVR) compound (R)-AV1013; Kd=54.0+/-3.1uM; Ki=74.9+/-8.5uM
2xib  2.20  2010  Kd=55.1nM     // 2xib.pdf (DFU) ligand is compound 3; Kd1=55.1+/-10.1nM(pH=7.0); Kd4=372+/-11.0nM(pH=8.5)
3p5o  1.60  2010  Kd=55.2nM     // 3p5o.pdf (EAM) ligand is compound I-BET; Kd=50.5~61.3nM; IC50=32.5-42.5nM
3lk1  1.79  2010  Kd=55.2uM     // 3lk0.pdf (JKE&EMC) compound SC0322, Kd=55.2+/-5.1uM; IC50=177.7+/-16.5uM; binding data for substrate; complex structure for product
2l12   NMR  2010  Kd=55uM       // 2l11.pdf (15-mer) protein 1 Fragment: UNP Residues 7-62 ; protein 2 Fragment: UNP Residues 2-16  ; Kd=55+/-5uM;
2ksp   NMR  2010  Kd=57uM       // 2ksp.pdf (15-mer) ligand is MICAL-L1 like peptide(NPFEEEEED), Kd=57+/-6uM
3nii  2.10  2010  Kd=58.5uM     // 3nih.pdf (4-mer) ligand:Peptide KIAA, incomplete ligand structure; Zn-containing; Kd=58.5+/-3.03uM(ITC1, pH8); Kd=18.0+/-1.90uM(lower pH ITC2, pH6.5)
3o84  2.10  2010  Kd=58nM       // 3o82.pdf (HTJ) ligand is compound 8; structure and Kd=58+/-11nM for strain AB900; Kd=78+/-7nM(FP), 99+/-13nM(ITC) and Ki=58+/-11nM for strain ATCC
3hs8  1.90  2010  Kd=5uM        // 3hs8.pdf (12-mer) ligand is Intersectin 1-peptide
3p8h  2.55  2010  Kd=5uM        // 3p8h.pdf (P8H) Kd=5+/-1 uM; Fragment: UNP residues 200-522;
3ilq  2.05  2010  Kd=6.2uM      // 3ilp.pdf (1O2) compound BbGL-2c; Kd=6.2+/-0.2uM, glycolipid BbGL-2c
3nsq  2.60  2010  Kd=6.2uM      // 3nsq.pdf (CHZ) ligand is danthron
3kqs  2.00  2010  Kd=6.3uM      // 3kpj.pdf (AX7) compound 6; with AdoHcy; Kd=6.3+/-0.02 uM
2wtw  3.30  2010  Kd=6.5nM      // 2wtw.pdf (ZZL) ligand is compound MLN-8054
3iqv  1.20  2010  Kd=6.6uM      // 3iqj.pdf (6-mer) human 14-3-3 sigma with Raf1 peptide and stabilisator Fusicoccin; Kd=6.6+/-0.8uM; redundant to 3iqu
3lqi  1.92  2010  Kd=6.9uM      // 3lqi.pdf (9-mer) H3(1-9)K4me2 peptide; incomplete ligand
2kzu   NMR  2010  Kd=60uM       // 2kzu.pdf (18-mer) ligand is N-terminal residues of the tumor suppressor Rassf1C (23-38)
3kyq  2.44  2010  Kd=60uM       // 3kyq.pdf (DPV)
3if7  1.60  2010  Kd=61nM       // 3if7.pdf (SPU) with Ca2+, Kd= 61+/-10 nM in first process, 2.1 +/-0.2 uM in second process
2won  2.80  2010  Kd=624nM      // 2wom.pdf (ZZE) Kd=624+/-42.5nM; Fragment: P66, RESIDUES 588-1147; Fragment:P51, RESIDUES 588-1027  ;
2xii  1.80  2010  Kd=63.3nM     // 2xib.pdf (TA9) ligand is compound 4; Kd1=63.3+/-12.6nM(pH=7.0); Kd4=157+/-14.3nM(pH=8.5)
2xto  2.80  2010  Kd=630nM      // 2xtm.pdf (GDP) Kd=630+/-40nM is for GIMAP2 (1-260), not GIMAP2 (21-260)
3kpu  2.40  2010  Kd=690uM      // 3kpj.pdf (ES1) compound 1; with AdoHcy; Kd=690+/-220 uM
3lk0  2.04  2010  Kd=696.9uM    // 3lk0.pdf (Z80) compound SC0067, Kd=696.9+/-427.9 uM; IC50=2222.0+/-1364.3 uM
3nan  3.10  2010  Kd=6nM        // 3nal.pdf (HZ1) compound Boc-Tg, Kd= 6+/-1 nM, The Kd seen like as IC50
2koh   NMR  2010  Kd=6uM        // 2koh.pdf (16-mer) ligand is VE-Cadherin-5 C-terminus
3ms9  1.80  2010  Kd=6uM        // 3ms9.pdf (MS9) IC50>100uM, with imatinib; compound 1
3n1c  2.00  2010  Kd=6uM        // 3n1c.pdf (F6P)
3nti  2.80  2010  Kd=6uM        // 3nth.pdf (13-mer) Kd=6uM(ITC), 14uM(SPR); incomplete ligand structure; ligand:Aubergine [R15(me2s)]
2xi7  2.20  2010  Kd=7.20uM     // 2xi7.pdf (XI7) two independent sites:Kd1=7.20+/-1.73uM; Kd2=159+/-42.9uM; IC50=25-50uM
3kr2  2.30  2010  Kd=7.2uM      // 3kpj.pdf (ET2) compound 16; with AdoHcy; Kd=7.2+/-0.9 uM
2kwn   NMR  2010  Kd=7.4uM      // 2kwn.pdf (15-mer) ligand is Histone H4-Nac peptide
3hb8  2.74  2010  Kd=7.5uM      // 3hb8.pdf (UMP) covalent complex
3nkx  2.40  2010  Kd=7.5uM      // 3iqj.pdf (10-mer) Kd=7.5+/-1.2uM; incomplete ligand
3nx7  1.80  2010  Kd=7.88nM     // 3lk8.pdf (NHK) ligand is compound 6
3adu  2.77  2010  Kd=72.8uM     // 3ads.pdf (MYI ) compound 5-methoxy-indole  acetate(MIA)
2wvt  1.80  2010  Kd=755nM      // 2wvs.pdf (FHN) ligand is compound 5; Kd=755+/-55nM(pH=6.0) for BtFuc2970; Kd=230+/-7uM for fucose
3ncr  1.44  2010  Kd=77.5uM     // 3ncq.pdf (ADP) structure(MgADP); Kd1=77.5uM, Kd2=18.4uM, Kd3=20.9(MgADP); Kd1=2.4uM, Kd2=9.1uM, Kd3=22.5(ADP); diverse binding data at multiple binding sites
3oyw  2.50  2010  Kd=78uM       // 3oy8.pdf (TDG) Kd=78+/-20uM; IC50=1.156mM
2xdl  1.98  2010  Kd=790uM      // 2xdk.pdf (2DL) ligand is compound 3
3p8e  2.49  2010  Kd=7uM        // 3p8e.pdf (LN7) compound 4; covalent complex; Kd=7+/-1uM; Ki=7.5+/-0.4uM
3hub  2.25  2010  Kd=8.2nM      // 3hub.pdf (469) ligand is compound 7; Kd=8.2+/-2.9nM; IC50=9nM
3hbo  1.71  2010  Kd=8.2uM      // 3fsm.pdf (2NC)
3k8o  2.40  2010  Kd=8.6pM      // 3k8o.pdf (229) ligand is DATMe-Imm-H; Ki=9pM
2y34  2.01  2010  Kd=80nM       // 2y34.pdf (UN9) ligand is compound BIQ
3hky  1.90  2010  Kd=80nM       // 3hkw.pdf (IX6) ligand is compound 4; 1a_18 polymerase; Kd=80+/-15nM, PDB is 1b, but reference indicates 1a
3m3c  2.00  2010  Kd=86.21uM    // 3afk.pdf (3-mer)
3le8  1.70  2010  Kd=860nM      // 3le8.pdf (2B5) compound 6, Ki=5.4uM
3nal  2.65  2010  Kd=8nM        // 3nal.pdf (DBK) compound DTB, Kd= 8+/-1 nM, The Kd seen like as IC50
3gy4  1.55  2010  Kd=8uM        // 3gy2.pdf (PBZ) ligand is p-aminobenzamidine
2xbp  1.20  2010  Kd=9.6uM      // 2xbp.pdf (ATP) Kd=9.6+/-1.3uM
3ads  2.25  2010  Kd=9.73uM     // 3ads.pdf (IMN) compound indomethacin(IDM); Kd1=9.73uM(SPR); Kd2=17.24uM(ITC); Kd3=934.5uM(ITC)
3ouj  2.30  2010  Kd=900nM      // 3ouj.pdf (AKG) ligand is compound 2-Oxoglutarate(2OG)
3isw  2.80  2010  Kd=90uM       // 3isw.pdf (18-mer) Cystic fibrosis transmembrane conductance regulator, R21A Fragment:residues 2236-2329; Kd=90 +/-9 uM
3n8k  2.25  2010  Kd=90uM       // 3n59.pdf (D1X)
3nq9  1.90  2010  Kd=92.6uM     // 3nq3.pdf (OCA) ligand is caprylic acid; Ka=10.8+/-1.7*10^3M-1
3adv  2.27  2010  Kd=933uM      // 3ads.pdf (SRO) ligand is compound Serotonin(5-HT)
3kqw  2.49  2010  Kd=97uM       // 3kpj.pdf (ES9) compound 9; with AdoHcy; Kd=97+/-5.9 uM
3nht  1.45  2010  Kd=98nM       // 3nhi.pdf (U46) ligand is compound U46619; Kd=98+/-6.8nM
3l8s  2.35  2010  Kd=99.0nM     // 3hub.pdf (BFF) compound 8; Kd=99.0+/-13.7nM, contain a Cl or Br atom
2xcg  1.90  2010  Kd=9nM        // 2xcg.pdf (XCG) Kd=9+/-2nM; Ki=8.3+/-0.6 uM
3nk8  1.15  2010  Kd>1mM        // 3nk8.pdf (JKZ) compound 2; Kd>1mM
3m56  1.65  2010  Kd>70uM       // 3m53.pdf (11-mer) ligand is TAF10-K189me2 peptide
3li2  2.20  2010  Kd~1nM        // 3lhs.pdf (SF8) Fragment: UNP residues 38-327; Fe 3+ containing; close conformation; the Kd is not accuracy
3lhs  1.30  2010  Kd~1nM        // 3lhs.pdf (SF8) Fragment: UNP residues 38-327; Fe 3+ containing; open conformation; the Kd is not accuracy
2xeg  1.59  2010  Ki=0.020nM    // 2xef.pdf (CI9) ligand is compound ARM-P4(4); Ki=0.020+/-0.008nM; IC50=0.46+/-0.18nM
2xei  1.69  2010  Ki=0.024nM    // 2xef.pdf (ARK) ligand is compound ARM-P2(3); Ki=0.024+/-0.008nM; IC50=0.54+/-0.18nM
3liw  2.22  2010  Ki=0.025uM    // 3liw.pdf (RUP)
3i51  1.80  2010  Ki=0.02uM     // 3hgi.pdf (45C) ligand is 4, 5-Dichlorocatechol
3hfb  1.92  2010  Ki=0.03uM     // 3hfb.pdf (ML4) ligand is LP-534193; Ki=0.03+/-0.001uM (Trp as the varied substrate); Ki=0.17+/-0.01uM(Trp as the fixed substrate)
3l4u  1.90  2010  Ki=0.03uM     // 3l4t.pdf (DSK) Ki=0.03+/-0.01uM, compound de-O-sulfonated kotalanol
3mxe  1.85  2010  Ki=0.097nM    // 3mxd.pdf (K54) ligand is compound 18d
3i4y  1.85  2010  Ki=0.09uM     // 3hgi.pdf (35C) ligand is 3, 5-Dichlorocatechol
3l4y  1.80  2010  Ki=0.10uM     // 3l4t.pdf (NR4) Ki=0.10+/-0.02uM, compound NR4-8II
3gt9  1.70  2010  Ki=0.11mM     // 3gt9.pdf (516) ligand is compound 11c
2xmy  1.90  2010  Ki=0.11nM     // 2xmy.pdf (CDK) ligand is compound 11; Ki=0.11+/-0.05nM; IC50=221+/-75nM(A2780); IC50=98+/-10nM(MES-SA)
3a2c  2.90  2010  Ki=0.126uM    // 3a2c.pdf (PDY) pKi=6.9
3iae  2.30  2010  Ki=0.13mM     // 3iae.pdf (D7K) ligand is compound MBP, ligand structure is not consist with the one in reference
3l4x  1.90  2010  Ki=0.13uM     // 3l4t.pdf (NR3) Ki=0.13+/-0.02uM, compound NR4-8
2xef  1.59  2010  Ki=0.145nM    // 2xef.pdf (AR8) ligand is compound ARM-P8(6); Ki=0.145+/-0.050nM; IC50=3.29+/-1.14nM
3m36  2.15  2010  Ki=0.15nM     // 3m35.pdf (M35) ligand is DPC423
3nu3  1.02  2010  Ki=0.15nM     // 3nu3.pdf (478) Ki=0.15+/-0.04nM
2wk2  2.05  2010  Ki=0.15uM     // 2wk2.pdf (3-mer) ligang is chitotriose thiazoline dithioamide 10; multiple ligand
3nuo  1.35  2010  Ki=0.16nM     // 3nu3.pdf (478) Ki=0.16+/-0.01nM
2xhm  1.96  2010  Ki=0.16uM     // 2xhm.pdf (K26)
2xb9  2.75  2010  Ki=0.17uM     // 2xb8.pdf (XNW) compound 4a
3anq  2.60  2010  Ki=0.18uM     // 3anq.pdf (EHB) compound  INDY; IC50=0.24uM
3l4v  2.10  2010  Ki=0.19uM     // 3l4t.pdf (KTL) Ki=0.19+/-0.03uM, compound kotalanol
3l4z  2.00  2010  Ki=0.19uM     // 3l4t.pdf (SSD) Ki=0.19+/-0.02uM, compound Salacinol
3m2u  1.40  2010  Ki=0.1uM      // 3m1v.pdf (TXZ) ligand is N-6-mercaptohexanoylthreonine phosphate (CoB6SH) in reference
3aav  1.70  2010  Ki=0.24uM     // 3aas.pdf (A2C) compound 4; Cu2+ metal containing complex
2wly  2.40  2010  Ki=0.25uM     // 2wk2.pdf (2-mer) ligand is chitotriose thiazoline 4
3lc5  2.62  2010  Ki=0.27uM     // 3lc5.pdf (IZX) compound 16
3nmq  2.20  2010  Ki=0.2nM      // 3nmq.pdf (7PP) structure(Hsp90beta); Ki(Hsp90alpha)
3hf8  1.85  2010  Ki=0.31uM     // 3hf8.pdf (ML0) ligand is LP-533401; Ki=0.31+/-0.01uM (Trp as the varied substrate); Ki=0.81+/-0.03uM(Trp as the fixed substrate)
2xd9  1.95  2010  Ki=0.35uM     // 2xd9.pdf (XD9)
3p4q  3.35  2010  Ki=0.3uM      // 3p4p.pdf (OAA) Escherichia coli menaquinol:fumarate reductase (QFR) in complex with oxaloacetate, Ki=0.0003mM
3kqd  2.75  2010  Ki=0.40nM     // 3ffg.pdf (LGL) compound 5e
3nuj  1.50  2010  Ki=0.41nM     // 3nu3.pdf (478) Ki=0.41+/-0.05nM
3iut  1.20  2010  Ki=0.46uM     // 3iut.pdf (KB2) tetrafluorophenoxymethyl ketone inhibitor 2; RCSB ligand structure no F atom, Ki=0.46+/-0.4uM; IC50=5.1uM
3ioi  1.45  2010  Ki=0.53uM     // 3ioi.pdf (1GW) compound 2; Ki=0.53uM(UDP-Gal as donor); Ki=0.52uM(UDP-GalNAc as donor)
3aaq  2.00  2010  Ki=0.5mM      // 3aaq.pdf (ARU) ligand is compound ARL 67156, poor Ki=0.5mM, data not shown
3l7g  2.70  2010  Ki=0.5mM      // 3l7g.pdf (M44) ligand name M44 is DDP, binding of DDFP as an inhibitor or DDP as a product
3fv1  1.50  2010  Ki=0.5nM      // 2zns.pdf (DYH)
3kqb  2.25  2010  Ki=0.5nM      // 3ffg.pdf (LGJ) compound 4b
3nu6  1.16  2010  Ki=0.5nM      // 3nu3.pdf (478) Ki=0.50+/-0.06nM
3lpp  2.15  2010  Ki=0.60uM     // 3lpp.pdf (KTL)
2xb7  2.50  2010  Ki=0.65nM     // 2xb7.pdf (GUI) ligand is compound NVP-TAE684; Ki=0.65+/-0.07nM; IC50=17nM
3mn8  2.70  2010  Ki=0.67uM     // 3mn8.pdf (GEM) ligand GEMSA, Ki=0.67+/-0.08 uM
3of8  2.20  2010  Ki=0.6nM      // 3of8.pdf (I0Y) compound 1; covalent complex
2xda  1.85  2010  Ki=0.6uM      // 2xd9.pdf (JPS)
3agm  2.00  2010  Ki=0.82nM     // 3agm.pdf (8-mer) compound ARC-670; IC50=42nM
3p8z  1.70  2010  Ki=0.82uM     // 3p8z.pdf (36A)
3a2o  0.88  2010  Ki=0.83nM     // 3a2o.pdf (KNJ) ligand is compound 13k
3fvl  1.85  2010  Ki=0.86uM     // 3fvl.pdf (BHK) ligand is compound L-1
3owj  1.85  2010  Ki=0.86uM     // 3owj.pdf (1EL)
3lea  2.00  2010  Ki=0.8nM      // 3le9.pdf (Z93) ligand is compound 27
3lpk  1.93  2010  Ki=0.8nM      // 3lnk.pdf (Z76) IC50=7.0nM in cell lines
3mdz  2.32  2010  Ki=0.8nM      // 3mdz.pdf (EZL) ligand is compound 3
3m37  1.90  2010  Ki=0.91nM     // 3m35.pdf (M37) ligand is DPC602, compound 40c
3nu9  1.85  2010  Ki=0.9nM      // 3nu3.pdf (478) Ki=0.9+/-0.2nM
3l4w  2.00  2010  Ki=1.0uM      // 3l4t.pdf (MIG) Ki=1.0+/-0.1uM, compound miglitol
3lmk  2.44  2010  Ki=1.16uM     // 3lmk.pdf (GLU)
2xaq  3.20  2010  Ki=1.1uM      // 2xaf.pdf (M84) ligand is 13b; incomplete ligand structure
3iaf  2.80  2010  Ki=1.2mM      // 3iae.pdf (TPP) compound BP, ligand structure is not consist with reference
3k8c  2.10  2010  Ki=1.2mM      // 3k7s.pdf (RES)
3k37  2.00  2010  Ki=1.2nM      // 3k37.pdf (BCZ) ligand is Peramivir; Ki=1.2nM(no preincubation); Ki=0.6nM(preincubation); IC501=27.8nM(no preincubation); IC502=2.8nM(preincubation)
3kjq  1.80  2010  Ki=1.32uM     // 3kjf.pdf (B94) covalent inhibitor, incomplete ligand structure compound 4, Ki=1.32+/-0.12 uM
2xej  1.78  2010  Ki=1.34nM     // 2xef.pdf (OKD) ligand is compound MeO-P4 (10); Ki=1.34+/-0.64nM; IC50=30.2+/-14.4nM
2wpb  2.05  2010  Ki=1.3mM      // 2wnz.pdf (ZZI) compound THB
2wtx  2.20  2010  Ki=1.3mM      // 2wtx.pdf (VDO) compound 4; Ki=1.3+/-0.2mM; IC50=5.3+/-1.4mM, IC50=41uM at 0.15 mM UDP
2xas  3.20  2010  Ki=1.3uM      // 2xaf.pdf (M80) ligand is 14e; incomplete ligand structure
3mxd  1.95  2010  Ki=1.47nM     // 3mxd.pdf (K53) ligand is compound 17c
3fvk  1.50  2010  Ki=1.5nM      // 2zns.pdf (8DX)
3nu4  1.20  2010  Ki=1.5nM      // 3nu3.pdf (478) Ki=1.5+/-0.2nM
3fyz  2.10  2010  Ki=1.6uM      // 3fv7.pdf (MXC) compound 3; incomplete ligand structure; IC50 in supplementary information; Ki=1.6+/-0.3uM; IC50=22+/-1nM(NCF); IC50=187+/-17nM(CENTA)
3k16  3.00  2010  Ki=1.6uM      // 3k05.pdf (4-mer) pSPTF-COO-; Ki=1.6+/-0.3uM
2wtv  2.40  2010  Ki=1.8nM      // 2wtv.pdf (ZZL) ligand is compound MLN8054; Ki=1.8+/-0.2nM
3jyj  1.87  2010  Ki=1.8uM      // 3i6c.pdf (JZI) compound 23a
3lik  1.80  2010  Ki=1.92nM     // 3lik.pdf (EEG) redundant to 3ts4
3p4r  3.05  2010  Ki=1.9mM      // 3p4p.pdf (GUA) Escherichia coli menaquinol:fumarate reductase (QFR) in complex with glutarate, Ki=0.0003mM
3i3d  2.20  2010  Ki=10.3mM     // 3i3b.pdf (IPT) Fragment: Residues 10-1024; Mutation: M543A;
3ldw  2.47  2010  Ki=10.7nM     // 3ldw.pdf (ZOL) with IPP; binding with Mg2+; Ki=10.7+/- 1.2 nM
2xbw  1.72  2010  Ki=10nM       // 2xbv.pdf (455) ligand is compound 10
3k97  1.95  2010  Ki=10nM       // 3k97.pdf (4CD) ligand is compound 2a; IC50=1uM
2x95  1.96  2010  Ki=11.3uM     // 2x8y.pdf (X95) ligand is lisW-S; Ki=7uM(for C-domain of sACE)
3mxr  1.30  2010  Ki=11.3uM     // 3mke.pdf (CZ8) compound 1, Ki=11.3+/-0.6 uM
3pp7  2.35  2010  Ki=115.6uM    // 3pp7.pdf (SVR) ligand is suramin; Ki=115.6+/-2.6uM, incomplete ligand structure
3lir  1.90  2010  Ki=119nM      // 3lik.pdf (EEC)
2x8z  1.98  2010  Ki=11nM       // 2x8y.pdf (X8Z) ligand is L-captopril; Ki1=14nM for C-domains of sACE; Ki2=8.9nM for N-domains of sACE
3mhc  1.70  2010  Ki=11nM       // 3mhc.pdf (ARZ)
3lbj  1.50  2010  Ki=11uM       // 3lbj.pdf (WW8) IC50=19.7+/-3.8uM, compound WK298
3fvg  1.50  2010  Ki=128nM      // 2zns.pdf (MS8)
3i6c  1.30  2010  Ki=12uM       // 3i6c.pdf (GIA) compound 3f
3k15  2.80  2010  Ki=12uM       // 3k05.pdf (5-mer) pSPTF-CONH2; Ki=12+/-2uM
3kjf  2.00  2010  Ki=13.4uM     // 3kjf.pdf (B92) covalent inhibitor, incomplete ligand structure compound 1, Ki=13.4+/-3.7 uM
3g2i  2.00  2010  Ki=13.7uM     // 3g2i.pdf (RUG) ligand is compound 3d; Ki=13.7+/-1uM
3g2l  2.30  2010  Ki=135.9uM    // 3g2l.pdf (LEW) ligand is compound 3b; Ki=135.9+/-9.5uM
3kr5  2.56  2010  Ki=13nM       // 3kr4.pdf (BEY)
3n2u  1.81  2010  Ki=14.3nM     // 3n2u.pdf (D3X) ligand is compound 4; Ki=14.3+/-7.0nM; Zn-containing
3mz3  3.20  2010  Ki=14.8nM     // 3mz3.pdf (B3N) compound M344; with Co2+; Ki=14.8+/-0.8nM
3moh  2.10  2010  Ki=1460uM     // 3moe.pdf (PGA) measured with Mn2+, GDP; Ki=1460+/-48uM(A467G); Ki=2530+/-13uM(WT)
2xnb  1.85  2010  Ki=149nM      // 2xnb.pdf (Y8L) ligand is ompound 14; Ki=149+/-40nM; IC50=131+/-9nM(A2780); IC50=150+/-16nM(MES-SA)
3h9k  2.65  2010  Ki=14nM       // 3h9k.pdf (UFP) ligand is FdUMP, the active metabolite of 5-FU
3ik1  2.25  2010  Ki=14uM       // 3ik1.pdf (20C) ligand is compound 20A
3k05  1.33  2010  Ki=14uM       // 3k05.pdf (5-mer) 5-mer phospho peptide pSQEY-CONH2; Ki=14+/-2uM
3g2h  2.03  2010  Ki=151.3uM    // 3g2h.pdf (KOT) ligand is compound 3a; Ki=151.3+/-2.3uM
2xbx  1.85  2010  Ki=15nM       // 2xbv.pdf (RR8) ligand is compound 2
3g2k  2.00  2010  Ki=16.1uM     // 3g2k.pdf (SKY) ligand is compound 3c; Ki=16.1+/-1.3uM
2x7s  1.64  2010  Ki=1660nM     // 2x7s.pdf (WZC) compound 5; Ki=1660+/-177nM; IC50=549nM(end point); IC50=770+/-51nM(initial rate)
2xaj  3.30  2010  Ki=168uM      // 2xaf.pdf (TCA) ligand is (-)-tPCPA  HCl ; incomplete ligand structure
3fvn  1.50  2010  Ki=169nM      // 2zns.pdf (9DX)
3agl  2.10  2010  Ki=16nM       // 3agl.pdf (A03) ligand is compound ARC-1039; IC50=97nM
3gi4  1.85  2010  Ki=16pM       // 3gi4.pdf (K60) ligand is SAR-KB60, Ki=0.016nM
3acw  1.63  2010  Ki=17.5uM     // 3acw.pdf (651) ligand is compound BPH-651
3g2j  2.14  2010  Ki=17.9uM     // 3g2j.pdf (9GP) ligand is compound 5d; Ki=17.9+/-0.4uM
2x09  2.40  2010  Ki=175uM      // 2x09.pdf (X09) ligand is compound 4; Ki=175+/-8uM
3mi2  1.20  2010  Ki=17nM       // 3mi2.pdf (PFU) ligand is compound 8, Ki=1.7x10-5mM
3abt  3.20  2010  Ki=17uM       // 3abt.pdf (2PF) too big incomplete ligand structure; compound 2-PFPA; Ki=17+/-4.9uM; IC50=8.9uM
3mkf  1.33  2010  Ki=17uM       // 3mke.pdf (CZ7) cefoperazone BATSI, Ki=17+/-2 uM
3ljg  1.31  2010  Ki=18.6nM     // 3lik.pdf (EEF)
2x91  1.98  2010  Ki=180nM      // 2x8y.pdf (LPR) ligand is lisinopril; Ki1=2.4nM for C-domains of sACE; Ki2=44nM for N-domains of sACE
2wyi  2.60  2010  Ki=18uM       // 2wyi.pdf (SWA)
3g6m  1.65  2010  Ki=19.7mM     // 3g6m.pdf (CFF) Fragment: residues 21-426; Ki=19.7+/-0.3 mM
2xc0  2.05  2010  Ki=192nM      // 2xbv.pdf (8NC) ligand is compound 35
2wyj  2.38  2010  Ki=1nM        // 2wyg.pdf (898) ligand is compound 22
3lvw  2.50  2010  Ki=2.12mM     // 3lvv.pdf (GSH)
3kqc  2.20  2010  Ki=2.2nM      // 3ffg.pdf (LGK) compound 5a
3nox  2.34  2010  Ki=2.2nM      // 3nox.pdf (6A5) ligand is compound 24c
3mke  1.75  2010  Ki=2.2uM      // 3mke.pdf (CB4) ceftazidime BATSI, Ki=2.2+/-0.2 uM
3fv7  2.00  2010  Ki=2.3uM      // 3fv7.pdf (MXS) compound 2; incomplete ligand structure; IC50 in supplementary information; Ki=2.3+/-0.3uM; IC50=27+/-1nM(NCF)
3abu  3.10  2010  Ki=2.4uM      // 3abt.pdf (12F) incomplete ligand structure; compound S1201; Ki=2.4+/-0.63uM; IC50=8.1uM
3oe0  2.90  2010  Ki=2.5nM      // 3odu.pdf (16-mer) cyclic peptide ligand CVX15; Ki=2.5+/-1.0nM(SPA), 55.3+/-7.0nM(Filter plate); ; IC50=0.6nM(CXCR4)
2wyn  2.10  2010  Ki=2.8uM      // 2wyn.pdf (2-mer) compound 6
3lpf  2.26  2010  Ki=208nM      // 3k4d.pdf (Z77) inhibitor 2; Ki=208+/-25.4nM; IC50=369+/-31.1nM
2x97  1.85  2010  Ki=2200nM     // 2x8y.pdf (RX4) ligand is RXP407; Ki=12nM for N-domain of sACE
2xj7  2.00  2010  Ki=220nM      // 2xj7.pdf (GC2) ligand is compound 6-Ac-Cas
2xba  1.95  2010  Ki=23.68nM    // 2xb7.pdf (571) compound PHA-E429; Ki=23.68+/-2.35nM; IC50=91nM
2x7t  1.89  2010  Ki=232nM      // 2x7s.pdf (WZB) ligand is compound 4; Ki=232+/-57nM; IC50=290nM(end point); IC50=169+/-31nM(initial rate)
3l0v  1.75  2010  Ki=23nM       // 3l0t.pdf (724) ligand is compound 3
2xaf  3.25  2010  Ki=23uM       // 2xaf.pdf (TCF) ligand is  (+)-Br-cPCPA  HCl; incomplete ligand structure
3lxe  1.90  2010  Ki=250nM      // 3lxe.pdf (TOR) ligand is topiramate
3itc  1.70  2010  Ki=25mM       // 3itc.pdf (CIT) compound citrate; Ki=25+/-15mM, competitive inhibitors of Sco3058
3kr4  2.00  2010  Ki=25nM       // 3kr4.pdf (BES)
3o87  1.78  2010  Ki=25nM       // 3o86.pdf (BSG) compound 9; IC50=130nM; covalent complex; B-containing
2wlz  1.82  2010  Ki=25uM       // 2wk2.pdf (2-mer) ligang is chitotriose thiazoline 3
2x0y  2.25  2010  Ki=25uM       // 2x0y.pdf (X0T) Ki=25+/-2uM; IC50=60+/-10uM
3k0h  2.70  2010  Ki=25uM       // 3k05.pdf (5-mer) pSPTF-CONH2; Ki=25+/-5uM
2xb8  2.40  2010  Ki=26nM       // 2xb8.pdf (XNW) ligand is compound 4a
3hp9  1.60  2010  Ki=26uM       // 3hl8.pdf (CF1) ligand is compound CFAM; Ki=26+/-4uM; IC50=8+/-1nM
3ipq  2.00  2010  Ki=27nM       // 3ipq.pdf (965) ligand is compound GW3965; Ki=27+/-4nM
3ixg  2.14  2010  Ki=27nM       // 3ixb.pdf (BZB)
2xah  3.10  2010  Ki=284uM      // 2xaf.pdf (3PL) ligand is (+)-tPCPA  HCl ; incomplete ligand structure
2xag  3.10  2010  Ki=28uM       // 2xaf.pdf (TCF) ligand is (-)-Br-tPCPA  HCl; incomplete ligand structure
3fuz  1.65  2010  Ki=290nM      // 2zns.pdf (GLU)
3mwe  2.20  2010  Ki=29mM       // 3mwd.pdf (TLA) Truncated Human ATP-Citrate Lyase (UNP residues 1-425) and Truncated Human ATP-Citrate Lyase (UNP residues 487-821)
2wyg  1.88  2010  Ki=2nM        // 2wyg.pdf (461) ligand is compound 21
3i60  2.50  2010  Ki=2nM        // 3i4b.pdf (E86)
3i5z  2.20  2010  Ki=2nM        // 3i4b.pdf (Z48)
3l1s  2.90  2010  Ki=2nM        // 3l1s.pdf (Z92) compound 46, Ki<2nM
3lgp  1.90  2010  Ki=2nM        // 3lgp.pdf (50X) compound 3i, Ki=2nM
3acx  1.31  2010  Ki=2uM        // 3acx.pdf (673) ligand is compound BPH-673
3kku  1.28  2010  Ki=2uM        // 3kku.pdf (B95) ligand is compound 27
3i25  2.10  2010  Ki=3.1nM      // 3i25.pdf (MV7) ligand is compound 2c
3l79  1.86  2010  Ki=3.46mM     // 3l79.pdf (DKX) ligand is compound DK1
3mi3  2.38  2010  Ki=3.56uM     // 3mi3.pdf (LYS)
3l7c  1.93  2010  Ki=3.67mM     // 3l79.pdf (DK4)
3mjl  1.90  2010  Ki=3.6mM      // 3mjl.pdf (2AI) 2-Aminoimidazole is a weak noncompetitive inhibitor
3k0k  2.70  2010  Ki=3.7uM      // 3k05.pdf (4-mer) phospho peptide pSPTF-COOH; Ki=3.7+/-0.3uM
3l4t  1.90  2010  Ki=3.8uM      // 3l4t.pdf (BJ1) KI=3.8+/-0.8uM, compound BJ2661
3oxc  1.16  2010  Ki=3.9nM      // 2nmw.pdf (ROC) Ki=3.9+/-0.8nM, mutations(Q506K, L532I, L562I, C566A, C594A), P212121
3mfv  1.90  2010  Ki=3000uM     // 3mfv.pdf (Z70) ligand is compound AHH, Ki=3000+/-10uM
3mfw  1.47  2010  Ki=300uM      // 3mfv.pdf (B3U) ligand is compound 2AH, Ki=300+/-9uM
2wm0  1.90  2010  Ki=30uM       // 2wk2.pdf (3-mer) ligand is chitobiose thiazoline thioamide 9
3n2v  1.55  2010  Ki=31nM       // 3n2u.pdf (JT5) ligand is compound 30; Ki=31+/-4.8nM; Zn-containing
3aas  1.75  2010  Ki=31uM       // 3aas.pdf (GUS) ligand is compound 1; Cu-containing complex
2xdm  2.40  2010  Ki=32nM       // 2xdm.pdf (BO8) compound 3; Ki=32+/-6nM
3nyx  2.50  2010  Ki=32nM       // 3nyx.pdf (TZ1) ligand is compound 1
3hl8  1.55  2010  Ki=32uM       // 3hl8.pdf (BBP) ligand is compound BCBP; Ki=32+/-4uM; IC50=23+/-3nM
3ieo  2.00  2010  Ki=331nM      // 3ieo.pdf (AMJ) compound 7
3l3l  2.50  2010  Ki=33nM       // 3l3l.pdf (L3L) ligand is compound 4e
3pd8  2.48  2010  Ki=348nM      // 3pd8.pdf (HA7) ligand is compound 5(S); Ki for GluA2(R); structure for GluA2-S1S2
3own  2.00  2010  Ki=34nM       // 3own.pdf (3OX)
3lbl  1.60  2010  Ki=36nM       // 3lbl.pdf (MI6) IC50=0.18+/-0.015uM, compound MI-63
3nba  2.68  2010  Ki=388uM      // 3nba.pdf (APC) compound AMPcPP; Ki=388+/-49uM; Mg containing
3k5x  1.40  2010  Ki=390nM      // 3itc.pdf (P8D) ligand is compound 1; Ki=390+/-21nM
3lpi  2.05  2010  Ki=3nM        // 3lnk.pdf (Z74) IC50=5nM
3iog  1.41  2010  Ki=3uM        // 2wrs.pdf (SDF) ligand is compound 18
3l7b  2.00  2010  Ki=4.01mM     // 3l79.pdf (DKZ) ligand is compound DK3
3fzc  2.00  2010  Ki=4.1uM      // 3fv7.pdf (MXF) compound 5; incomplete ligand structure; IC50 in supplementary information; Ki=4.1+/-0.6uM; IC50=55+/-5nM(NCF); IC50=237+/-7nM(CENTA)
3m1k  1.35  2010  Ki=4.1uM      // 3m1k.pdf (BEW) ligand is compound 4
2xdw  1.35  2010  Ki=4.3nM      // 2xdw.pdf (3-mer) covalent complex
3kek  1.97  2010  Ki=4.4nM      // 3kec.pdf (3EK) ligand is compound 29b; structure(catalytic domain); Ki=4.4+/-0.15nM(MMP-13/FL)
3nu5  1.29  2010  Ki=4.5nM      // 3nu3.pdf (478) Ki=4.5+/-0.6nM
3k4q  2.20  2010  Ki=4.6uM      // 3k4q.pdf (IHS)
3o88  1.64  2010  Ki=430nM      // 3o86.pdf (BSH) compound 17; covalent complex; B-containing
3l7a  1.90  2010  Ki=46.42uM    // 3l79.pdf (DKY) ligand is compound DK2, IC50=250uM
3ipu  2.40  2010  Ki=48nM       // 3ipq.pdf (O40) ligand is compound benzisoxazole urea; Ki=48+/-4nM
3mnu  1.80  2010  Ki=48nM       // 3mnu.pdf (BON)
3mhw  1.45  2010  Ki=5.03mM     // 3mhw.pdf (ABV)
3o5x  2.00  2010  Ki=5.2uM      // 3o5x.pdf (JZG) ligand is compound 9; Ki=5.2+/-0.3uM; IC50=5.5+/-0.4uM
3i3b  2.20  2010  Ki=5.9mM      // 3i3b.pdf (149)
3ok9  1.27  2010  Ki=5.9pM      // 3ok9.pdf (G52) ligand is compound 4; Ki=5.9pM; IC50=1.8nM
3lc3  1.90  2010  Ki=5.9uM      // 3lc3.pdf (IYX)
3moe  1.25  2010  Ki=50uM       // 3moe.pdf (SPV) measured with Mn2+, GTP; Ki=50+/-3uM(A467G); Ki=26+/-1uM(WT)
2x7u  2.12  2010  Ki=5340nM     // 2x7s.pdf (WZA) ligand is compound 3; Ki=5340+/-833nM; IC50=376nM(end point); IC50=2113+/-256nM(initial rate)
3gta  1.70  2010  Ki=53uM       // 3gt9.pdf (851) ligand is compound 26d
3n3g  1.60  2010  Ki=58nM       // 3n3g.pdf (93N) ligand is compound 18
3kgq  1.70  2010  Ki=5mM        // 3kgq.pdf (CIT)
3gjw  2.30  2010  Ki=5nM        // 3gjw.pdf (GJW) ligand is compound 9c
3gn7  2.50  2010  Ki=5nM        // 3gn7.pdf (3GN) ligand is compound 3a; redundant to 2rd6
2wzm  1.64  2010  Ki=6.0uM      // 2wzm.pdf (NA7) Ki=6.0+/-1.2uM, INH-NADPH adducts inhibit activity of AKR5H1
3kjn  1.80  2010  Ki=6.44uM     // 3kjf.pdf (B93) covalent inhibitor, incomplete ligand structure compound 9, Ki=6.44+/-0.29 uM
3l7d  2.00  2010  Ki=6.55mM     // 3l79.pdf (DK5)
3l3n  2.30  2010  Ki=6.6nM      // 3l3n.pdf (LSW)
3oe9  3.10  2010  Ki=6.6nM      // 3odu.pdf (ITD) X-ray:in P1 spacegroup with 2 molecules per asymmetric unit; Ki=6.6+/-1.4nM(SPA), 19.8+/-5.0nM(Filter plate); IC50=8nM(CXCR4)
3krd  2.50  2010  Ki=6.8nM      // 3krd.pdf (FEB) Fellutamide B, Ki=6.8+/-0.2 nM
3pd9  2.10  2010  Ki=600nM      // 3pd8.pdf (HA5) ligand is compound 4(R); Ki for GluA2(R); structure for GluA2-S1S2
3k99  2.10  2010  Ki=60nM       // 3k97.pdf (PFT) ligand is compound 2b; IC50=7uM
3m35  2.20  2010  Ki=60nM       // 3m35.pdf (M35) ligand is DPC423
3l08  2.70  2010  Ki=60pM       // 3l08.pdf (ZIG) compound 1; Pi3K gamma
3nf3  2.40  2010  Ki=638.1nM    // 3nf3.pdf (8-mer) inhibitor JTH-NB72-39; Ki=638.1+/-92.0nM; Zn2+, Ni2+ containing
3mz6  2.00  2010  Ki=63nM       // 3mz3.pdf (B3N) ligand is compound M344; with Fe2+; Ki=63+/-2nM(HDAC8); structure(D101L HDAC8); Kd(metal)=1.1+/-0.3uM(Fe2+ with HDAC8)
3ips  2.26  2010  Ki=64nM       // 3ipq.pdf (O90) compound f3methylAA; Ki=64+/-6nM
3nsn  2.10  2010  Ki=65nM       // 3nsn.pdf (TMX-CTO)
3lpg  2.42  2010  Ki=684nM      // 3k4d.pdf (Z78) inhibitor 3; Ki=684+/-81.6nM; IC50=586+/-31.1nM
2xe4  1.65  2010  Ki=69nM       // 2xe4.pdf (4-mer) 4-mer;
3l3m  2.50  2010  Ki=6nM        // 3l3m.pdf (A92) ligand is compound 25b
3le9  1.85  2010  Ki=6nM        // 3le9.pdf (727) ligand is compound 1
3gi6  1.84  2010  Ki=6pM        // 3gi4.pdf (D78) ligand is SAR-AD78, Ki=0.006nM
3gi5  1.80  2010  Ki=6pM        // 3gi4.pdf (K62) ligand is SAR-KB62, Ki=0.006nM
3iof  1.44  2010  Ki=6uM        // 2wrs.pdf (IFS) ligand is compound 10a
3ijz  2.21  2010  Ki=6uM        // 3ijz.pdf (15C) ligand is compound 23A
3odu  2.50  2010  Ki=7.3nM      // 3odu.pdf (ITD) Ki=7.3+/-1.4nM(SPA), 25.6+/-4.8nM(Filter plate); IC50=8nM(CXCR4)
3oe8  3.10  2010  Ki=7.3nM      // 3odu.pdf (ITD) X-ray:in P1 spacegroup with 3 molecules per asymmetric unit; Ki=7.3+/-1.4nM(SPA), 25.6+/-4.8nM(Filter plate); IC50=8nM(CXCR4)
3n2c  2.81  2010  Ki=7.5uM      // 3n2c.pdf (LWY) Ki=7.5+/-1.0uM; modified colorimetric  Cd-ninhydrin  assay; Zn-containing
3fv2  1.50  2010  Ki=7.7nM      // 2zns.pdf (NDZ)
3n9r  1.80  2010  Ki=70nM       // 3n9r.pdf (TD3) ligand is compound 2; Zn-containing
3o86  1.60  2010  Ki=70nM       // 3o86.pdf (BSF) compound 4; IC50=380nM; covalent complex; B-containing
2xg9  1.80  2010  Ki=70uM       // 2xg9.pdf (GLC-NOJ) ligand is G1M
3n7o  1.80  2010  Ki=72nM       // 3n7o.pdf (N7O) ligand is compound JNJ-18054478
3kej  2.30  2010  Ki=75.9nM     // 3kec.pdf (3EJ) compound 17a; structure(catalytic domain); Ki=75.9+/-21.1nM(MMP-13/FL)
2ksb   NMR  2010  Ki=754uM      // 2ks9.pdf (11-mer) Substance P in isotropic q=0.25 DMPC/CHAPS/GM1 bicelles as a ligand
3mkn  2.00  2010  Ki=76uM       // 3mkn.pdf (DNB) competitive inhibitor DAPIR, Ki=76+/-8uM
3k4d  2.39  2010  Ki=7750nM     // 3k4d.pdf (EVA) ligand is Glucaro-d-lactam; Ki=7750+/-475nM; IC50=26400+/-483nM
3i4b  2.30  2010  Ki=7nM        // 3i4b.pdf (Z48) ligand is compound 2
3nxq  1.99  2010  Ki=7nM        // 3nxq.pdf (RX4) ligand is analogue 21 (RXP407)
3oaw  2.75  2010  Ki=7nM        // 3oaw.pdf (OAW) Ki=7nM(PI3K alpha); X-ray(PI3K gamma)
3kqe  2.35  2010  Ki=8.1nM      // 3ffg.pdf (LGM) compound 5f
3oe6  3.20  2010  Ki=8.2nM      // 3odu.pdf (ITD) X-ray:in I222 spacegroup; Ki=8.2+/-1.0nM(SPA), 14+/-1.7nM(Filter plate); IC50=8nM(CXCR4)
3k39  2.54  2010  Ki=8.3nM      // 3k37.pdf (BCZ) compound 3 Peramivir; Ki1=8.3nM(no preincubation); Ki2=8.2nM(preincubation); IC501=75.2nM(no preincubation); IC502=41.5nM(preincubation)
3lil  1.80  2010  Ki=8.3nM      // 3lik.pdf (EEA)
3g2n  2.10  2010  Ki=81uM       // 3g2n.pdf (OAK) ligand is compound 5a
3k3a  2.59  2010  Ki=84.0nM     // 3k37.pdf (G39) compound 2 Oseltamivir; Ki1=84.0nM(no preincubation); Ki2=82.0nM(preincubation); IC501=659.7nM(no preincubation); IC502=708.0nM(preincubation)
3kwa  2.00  2010  Ki=84uM       // 3kwa.pdf (SPM) Ki=84+/-2uM
3mof  1.75  2010  Ki=860uM      // 3moe.pdf (OXL) measured with Mn2+, GDP; Ki=860+/-33uM(A467G); Ki=106+/-6uM(WT)
2ksa   NMR  2010  Ki=871uM      // 2ks9.pdf (11-mer) Substance P in DMPC/CHAPS isotropic q=0.25 bicelles as a ligand
3aho  1.88  2010  Ki=88.9nM     // 3ahn.pdf (3A2) Zn-containing
3ith  2.80  2010  Ki=8nM        // 3isn.pdf (EDM) compound DAVP-1; Space Group:  P 21
2ks9   NMR  2010  Ki=9.02mM     // 2ks9.pdf (11-mer) 11-mer Substance P, Ki=9020uM
3aau  1.80  2010  Ki=9.0uM      // 3aas.pdf (GZC) ligand is compound 2; Cu-containing complex
3mxs  1.24  2010  Ki=9.8uM      // 3mke.pdf (CZ9) compound 2, Ki=9.8+/-0.5 uM
3ahn  1.80  2010  Ki=90.1nM     // 3ahn.pdf (3A1) Zn-containing
3lbk  2.30  2010  Ki=916nM      // 3lbk.pdf (K23) IC50=1.71+/-1.1027uM, compound WK23
3mtw  1.70  2010  Ki=92nM       // 3mtw.pdf (M3R) ligand is compound 8; Zn2+ containing; Ki=92+/-10nM(L-Ala-L-Arg as substrate)
3igp  1.65  2010  Ki=94.5nM     // 3igp.pdf (DT7) ligand is compound 2
2x96  1.85  2010  Ki=94uM       // 2x8y.pdf (RX3) ligand is RXPA380; Ki=3nM for C-domain of sACE
2xz5  2.80  2010  Ki=98.3uM     // 2xz5.pdf (ACH) Fragment: RESIDUES 20-236  ; mutant Y53C-MMTS; Ki=98.3+/-0.8uM;
2xc4  1.67  2010  Ki=9nM        // 2xbv.pdf (IVK) ligand is compound 11
3ag9  2.00  2010  Ki=9nM        // 3ag9.pdf (A02) ligand is compound ARC-1012; IC50=54nM
3ppj  3.70  2011  IC50<2nM      // 3ppj.pdf (FOI) Fragment: Kinase domain, UNP residues 432-726;
2xvd  1.70  2011  IC50=0.002uM  // 2xvd.pdf (AS6) Fragment: KINASE DOMAIN, RESIDUES 598-899; Mutation: YES;
2yac  2.20  2011  IC50=0.002uM  // 2yac.pdf (937) IC50=0.002+/-0.001uM; Fragment: KINASE DOMAIN RESIDUES 36-345;
2xbj  2.30  2011  IC50=0.003uM  // 2xbj.pdf (XBJ) Fragment: KINASE DOMAIN, RESIDUES 210-531
2yj8  1.30  2011  IC50=0.0065uM  // 2yj2.pdf (YJ8) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333;
2xm9  2.50  2011  IC50=0.009uM  // 2xbj.pdf (LWH) Fragment: KINASE DOMAIN, RESIDUES 210-531
2yj2  1.15  2011  IC50=0.012uM  // 2yj2.pdf (YJ2) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333;
3p7b  1.90  2011  IC50=0.018uM  // 3p5k.pdf (P7B)
3twd  1.90  2011  IC50=0.018uM  // 3twd.pdf (GOB) compound 3
3s7m  2.20  2011  IC50=0.01uM   // 3s7l.pdf (532) ligand is compound (S)-63; IC50=0.01+/-0.01uM
2xu1  1.45  2011  IC50=0.022uM  // 2xu1.pdf (424) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333 ;
2yjc  1.14  2011  IC50=0.022uM  // 2yj2.pdf (424) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333;
3p7c  2.30  2011  IC50=0.022uM  // 3p5k.pdf (P7C)
2y1x  2.40  2011  IC50=0.027uM  // 2y1w.pdf (845) Fragment: CATALYTIC DOMAIN, RESIDUES 135-482; IC50=0.027+/-0.009uM, use full length protein
2yc5  1.60  2011  IC50=0.035uM  // 2yc3.pdf (6BC) IC50=0.035+/-0.007uM; Fragment: RESIDUES 76-302;
3apc  2.54  2011  IC50=0.036uM  // 3apc.pdf (MMD) Fragment: residues 144-1102;
2ycf  1.77  2011  IC50=0.03nM   // 2xk9.pdf (YCF) IC50=0.03+/-0.03nM; Fragment: CATALYTIC DOMAIN, RESIDUES 210-530;
3pj8  1.96  2011  IC50=0.04uM   // 3pj8.pdf (404) ligand is compound 7
2xx2  1.85  2011  IC50=0.05uM   // 2xx2.pdf (13C) Fragment: N-TERMINAL DOMAIN, RESIDUES 1-214;
3p5k  2.09  2011  IC50=0.076uM  // 3p5k.pdf (P5K)
2xk9  2.35  2011  IC50=0.07nM   // 2xk9.pdf (XK9) Fragment: CATALYTIC KINASE DOMAIN, RESIDUES 210-531; IC50=0.07+/-0.03nM;
3tge  1.96  2011  IC50=0.07nM   // 3tge.pdf (TGE) ligand is compound 1
2xx4  2.20  2011  IC50=0.08uM   // 2xx2.pdf (13I) Fragment: N-TERMINAL DOMAIN, RESIDUES 1-214;
3s7l  2.16  2011  IC50=0.08uM   // 3s7l.pdf (591) ligand is compound 28; IC50=0.08+/-0.02uM
3uo9  2.30  2011  IC50=0.08uM   // 3unw.pdf (04A) ligand is BPTES; IC50=0.08+/-0.02uM
2yj9  1.35  2011  IC50=0.095uM  // 2yj2.pdf (YJ9) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333;
2yjb  1.40  2011  IC50=0.095uM  // 2yj2.pdf (YJ9) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333;
3r7q  2.50  2011  IC50=0.108uM  // 3r7q.pdf (FAV) ligand is compound 1f
3qaq  2.90  2011  IC50=0.10uM   // 3qaq.pdf (QAQ) ligand is compound 1
3qj9  2.30  2011  IC50=0.10uM   // 3qj9.pdf (QJ9) ligand is compound 2
3zya  1.90  2011  IC50=0.10uM   // 3zya.pdf (2A8) ligand is compound 3
3lq5  3.00  2011  IC50=0.11uM   // 3lq5.pdf (SLQ) with CyclinT
3p78  2.30  2011  IC50=0.11uM   // 3p5k.pdf (P78)
3qtf  1.57  2011  IC50=0.11uM   // 3qtf.pdf (05S) ligand is compound 19
3r04  1.70  2011  IC50=0.12uM   // 3r00.pdf (UNQ) ligand is compound 21
3r0i  2.10  2011  IC50=0.12uM   // 3r0i.pdf (C0K) ligand is compound 20b; IC50=0.12+/-0.07uM
2xu5  1.60  2011  IC50=0.13uM   // 2xu1.pdf (XU5) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333
3zrk  2.37  2011  IC50=0.13uM   // 3zrk.pdf (ZRK) compound 11, pIC50=6.9
3zrm  2.49  2011  IC50=0.13uM   // 3zrk.pdf (ZRM) compound 13, pIC50=6.9
2ycq  2.05  2011  IC50=0.14nM   // 2xk9.pdf (UPX) IC50=0.14+/-0.02nM; Fragment: CATALYTIC DOMAIN, RESIDUES 210-531;
2yc3  1.40  2011  IC50=0.14uM   // 2yc3.pdf (MW5) IC50=0.14+/-0.01uM; Fragment: RESIDUES 76-302;
3qcq  2.50  2011  IC50=0.158uM  // 3qcq.pdf (3Q0) ligand is compound 12f; PIC50=6.8
2y1d  2.05  2011  IC50=0.15uM   // 2y1d.pdf (34F) IC50=0.15+/-0.02uM; Fragment: RESIDUES 24-412; Mn binding
2xm8  3.40  2011  IC50=0.16uM   // 2xbj.pdf (B4W) Fragment: KINASE DOMAIN, RESIDUES 210-531 ;
2xnm  1.85  2011  IC50=0.16uM   // 2xnm.pdf (WGZ) Fragment: KINASE DOMAIN, RESIDUES 1-271; IC50=0.16+/-0.02uM
2xu3  0.90  2011  IC50=0.16uM   // 2xu1.pdf (XU3) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333 ;
3zrl  2.48  2011  IC50=0.16uM   // 3zrk.pdf (ZRL) compound 12, pIC50=6.8
2yir  2.10  2011  IC50=0.17nM   // 2yiq.pdf (YIR) Fragment: CATALYTIC KINASE DOMAIN, RESIDUES 210-531; IC50=0.17+/-0.01nM
3r21  2.90  2011  IC50=0.18uM   // 3r21.pdf (D36) ligand is compound 10e
3pix  1.85  2011  IC50=0.1uM    // 3pix.pdf (027) Fragment: unp residues 387-659;
2xx5  2.00  2011  IC50=0.20uM   // 2xx2.pdf (13N) Fragment: N-TERMINAL DOMAIN, RESIDUES 1-214;
3o9l  2.40  2011  IC50=0.22nM   // 3o9l.pdf (LPN) IC50=0.22nM(Buffer), 12.3(Plasma); Fragment: unp residues 67-232;
2y5k  2.10  2011  IC50=0.22uM   // 2y5k.pdf (YCU)
3ow6  1.80  2011  IC50=0.22uM   // 3ow6.pdf (MEX)
3opm  2.72  2011  IC50=0.24uM   // 3opm.pdf (LUI) Fragment: DPP4; Mutation: N-terminal His tag;
2yit  2.20  2011  IC50=0.29nM   // 2yiq.pdf (YIT) IC50=0.29+/-0.14nM; Fragment: CHK2 CATALYTIC DOMAIN, RESIDUES 210-531;
3piy  2.55  2011  IC50=0.29uM   // 3pix.pdf (585) Fragment: unp residues 387-659;
3sl8  2.60  2011  IC50=0.29uM   // 3sl4.pdf (JN7) ligand is compound 10o
3n5k  2.20  2011  IC50=0.2nM    // 3n5k.pdf (TG1) ligand is compound 1a, thapsigargin
3zs0  2.30  2011  IC50=0.2uM    // 3zs0.pdf (ZS0)
3qcs  2.49  2011  IC50=0.316uM  // 3qcq.pdf (3Q1) ligand is compound 12k; PIC50=6.5
3u6a  2.20  2011  IC50=0.324uM  // 3u6a.pdf (18P) R-18a, isomer compound
3p3u  1.50  2011  IC50=0.3291uM  // 3p3r.pdf (3M4) ligand is compound 9
3qar  2.65  2011  IC50=0.32uM   // 3qaq.pdf (QAR) ligand is compound 32
2x24  2.40  2011  IC50=0.33uM   // 2x24.pdf (X24)
2y5l  2.20  2011  IC50=0.33uM   // 2y5k.pdf (RO8)
2xu4  1.12  2011  IC50=0.34uM   // 2xu1.pdf (DJT) Fragment: CATALYTIC DOMAIN, RESIDUES 114-333
2xnp  1.98  2011  IC50=0.36uM   // 2xnm.pdf (WCX) IC50=0.36+/-0.06uM; Fragment: KINASE DOMAIN, RESIDUES 1-271;
3qkk  2.30  2011  IC50=0.3uM    // 3qkk.pdf (SMH) ligand is compound 21
3qup  1.90  2011  IC50=0.476uM  // 3qup.pdf (LUN) ligand is compound 11
3q4b  2.19  2011  IC50=0.47nM   // 3q4b.pdf (RX5) compound 9, fragment: UNP residues 70-406; IC50=0.47 nM(0.3nM renin), 0.30 nM(36 pM renin) and 1.1 nM (plasma)
3sfi  2.31  2011  IC50=0.4uM    // 3sdg.pdf (3SF) ligand is compound 42
3zs1  2.60  2011  IC50=0.4uM    // 3zs0.pdf (PVW)
3p7a  2.31  2011  IC50=0.52uM   // 3p5k.pdf (P7A)
3ti6  1.69  2011  IC50=0.54nM   // 3ti3.pdf (G39) ligand is oseltamivir
3q5h  2.16  2011  IC50=0.56uM   // 3q5h.pdf (RX6) compound 3, fragment: UNP residues 67-406; IC50=0.56 nM(0.3nM renin), 0.42 nM(36 pM renin) and 0.48 nM (plasma)
3ro4  2.60  2011  IC50=0.59uM   // 3ro4.pdf (LJ9) ligand is compound 20f
3o23  2.10  2011  IC50=0.5uM    // 3o23.pdf (MQY) Fragment: Kinase domain; Mutation: Y987F;
3qcj  2.26  2011  IC50=0.5uM    // 3qce.pdf (NX4) ligand is compound 15
2ykj  1.46  2011  IC50=0.61uM   // 2yjw.pdf (YKJ) Fragment: N-DOMAIN, RESIDUES 18-233;
2yb9  2.40  2011  IC50=0.6nM    // 2yb9.pdf (HA0) Zn-containing; Fragment: RESIDUES 55-750;
2ye9  2.20  2011  IC50=0.6uM    // 2ye9.pdf (2D4) ligand is compound 13, FP enzyme IC50=0.6uM
3s1y  1.40  2011  IC50=0.6uM    // 3s1y.pdf (S1Y) ligand is compound 6, structure is a little diffrent from PDB
3qg6  2.50  2011  IC50=0.73nM   // 3qg6.pdf (8-mer) 8-mer autoinducing peptides (AIPs) group 4
2xyr  2.50  2011  IC50=0.74uM   // 2xyq.pdf (SFG) Fragment: RESIDUES 6776-7067; ternary complex
3r2a  3.00  2011  IC50=0.75uM   // 3r29.pdf (RHN) ligand is Rhein
2ykc  1.67  2011  IC50=0.78uM   // 2yjw.pdf (YKC) Fragment: N-DOMAIN, RESIDUES 18-233;
3rsv  2.50  2011  IC50=0.7nM    // 3rsv.pdf (3RS) ligand is compound 57
3sn7  1.82  2011  IC50=0.7nM    // 3sn7.pdf (540) ligand is compound 96; IC50=0.7+/-0.03nM
3snl  2.40  2011  IC50=0.7nM    // 3sn7.pdf (548) ligand is compound 115; IC50=0.7+/-0.03nM
2y1g  1.95  2011  IC50=0.7uM    // 2y1d.pdf (FM5) IC50=0.7+/-0.1uM; Fragment: RESIDUES 24-412; Mn binding
3osw  2.55  2011  IC50=0.7uM    // 3osi.pdf (XDI) Fragment: ligand binding domain;
3rm8  1.80  2011  IC50=0.7uM    // 3rm4.pdf (RM8) ligand is compound 2
3mw1  2.80  2011  IC50=0.82nM   // 3mw1.pdf (MIH) IC50=0.82+/-1.98nM
3rhx  2.01  2011  IC50=0.84uM   // 3rhx.pdf (3RH) ligand is ARQ 069; IC50=0.84+/-0.15uM
2yiw  2.00  2011  IC50=0.8nM    // 2yis.pdf (YIW)
3qri  2.10  2011  IC50=0.8nM    // 3qri.pdf (919) ligand is DCC-2036
3rcj  1.70  2011  IC50=0.8uM    // 3rcj.pdf (3RC) ligand is compound 8f
3ti8  1.60  2011  IC50=0.90nM   // 3ti3.pdf (LNV) ligand is laninamivir
3r0t  1.75  2011  IC50=0.91nM   // 3pe1.pdf (FU9) CK2:Fragment: unp residues 1-337;
2yg2  1.70  2011  IC50=0.9uM    // 2yg2.pdf (FLC)
3skh  2.50  2011  IC50=0.9uM    // 3ska.pdf (058) ligand is compound 1
3tjd  2.90  2011  IC50=1.0nM    // 3tjc.pdf (6TP) ligand is compound 19
3ti5  1.90  2011  IC50=1.11nM   // 3ti3.pdf (ZMR) ligand is zanamivir
2xno  1.98  2011  IC50=1.18uM   // 2xnm.pdf (ED8) Fragment: RESIDUES 1-271; IC50=1.18+/-0.16uM
3s7a  1.80  2011  IC50=1.1nM    // 3s7a.pdf (684) ligand is PT684, Human dihydrofolate reductase binary complex with PT684
2ykb  1.93  2011  IC50=1.1uM    // 2yjw.pdf (YKB) Fragment: N-DOMAIN, RESIDUES 18-233;
2yke  1.43  2011  IC50=1.1uM    // 2yjw.pdf (YKE) Fragment: N-DOMAIN, RESIDUES 18-233;
3mg8  2.59  2011  IC50=1.2nM    // 3mg0.pdf (L3T) multi component!!compound 16; IC50=1.2+/-0.35nM for S20 beta5c(substrate Ac-WLA-AMC); Ki below 0.25nM(substrate Suc-LLVY-AMC)
3qo9  2.60  2011  IC50=1.2uM    // 3qo9.pdf (QO9) ligand is compound 7(TSAO-T); IC50=1.2+/-0.14uM
2ycs  2.35  2011  IC50=1.36nM   // 2xk9.pdf (NXP) IC50=1.36+/-0.71nM; Fragment: CATALYTIC DOMAIN, RESIDUES 210-531;
3tic  1.89  2011  IC50=1.36nM   // 3ti3.pdf (ZMR) ligand is zanamivir
4a23  2.40  2011  IC50=1.3uM    // 4a23.pdf (C56) ligand is c5685, mixed isomer ligand code is C56 or C57; IC50=1.3+/-0.1uM
3rxa  1.70  2011  IC50=1.4mM    // 3rxa.pdf (SZ1) Kinetic study using fluorescence-based substrate
3ppk  3.00  2011  IC50=1.4nM    // 3ppj.pdf (FNI) Fragment: Kinase domain, UNP residues 432-726;
3prf  2.90  2011  IC50=1.4nM    // 3ppj.pdf (FP3) Fragment: Kinase domain, UNP residues 432-726;
3r2f  2.53  2011  IC50=1.4nM    // 3r2f.pdf (PB0) ligand is compound 28a; IC50=1.4nM(HPLC)
3nzw  2.50  2011  IC50=1.5uM    // 3nzj.pdf (5-mer) TMC-95A mimic ligand 2b, IC50=1.5+/-0.1uM
3sjo  1.70  2011  IC50=1.65uM   // 3sj9.pdf (AG7)
3qfv  2.65  2011  IC50=1.69uM   // 3qfv.pdf (NM7) IC50=1.69+/-0.13uM
3skc  3.20  2011  IC50=1.6nM    // 3skc.pdf (BR2) ligand is compound 64
3s3q  1.80  2011  IC50=1.71nM   // 3qsd.pdf (C1P) ligand is K11017; IC50=1.71+/-0.13nM; covalent complex
3rz3  2.30  2011  IC50=1.72uM   // 3rz3.pdf (U94) IC50=1.72+/-0.36uM
2yis  2.00  2011  IC50=1.7nM    // 2yis.pdf (YIS)
3ti3  1.80  2011  IC50=1.83nM   // 3ti3.pdf (LNV) ligand is laninamivir
3q32  2.50  2011  IC50=1.8nM    // 3q32.pdf (J2I) Fragment: protein kinase 2 domain (UNP residues 839-1132);
3r7r  2.90  2011  IC50=1.8nM    // 3r7q.pdf (FAZ) ligand is compound 6
2xk1  2.80  2011  IC50=1.8uM    // 2xk1.pdf (EWB) covalent complex, B containing, IC50 = 1.8+/-0.1 uM ; assay method in SI
3tku  2.15  2011  IC50=1.92uM   // 3tku.pdf (M77) IC50=1.92+/-0.36uM
3t9t  1.65  2011  IC50=1.93nM   // 3t9t.pdf (IAQ) ligand is compound 36
3b1u  2.10  2011  IC50=1.9uM    // 3b1t.pdf (YFF) IC50=1.9+/-0.21uM;
3rv3  1.91  2011  IC50=10mM     // 3rup.pdf (ADP) Mg2+ containing
3qd3  2.00  2011  IC50=10nM     // 3qcq.pdf (3Q5) ligand is compound (3R, 6S)-37c; PIC50=8.0
2y6c  1.70  2011  IC50=10uM     // 2y6c.pdf (TQI) Zn-containing; Fragment: RESIDUES 95-258; pIC50=5.0
3r5j  1.77  2011  IC50=110nM    // 3r5j.pdf (6-mer) ligand is peptide (ACE)ADVAD-CHO
3tv4  3.40  2011  IC50=110nM    // 3tv4.pdf (TV4) compound 5, crystal is wildtype, affinity assay is for B-Raf V600E mutant
3svv  2.20  2011  IC50=114nM    // 3svv.pdf (VSP) ligand is compound 9
3qi4  2.50  2011  IC50=117.2uM  // 3qi3.pdf (IBM) IC50=117.2+/-1.2uM
3nwb  1.30  2011  IC50=11nM     // 3nwb.pdf (659) compound 5, with Mg2+; radiochemical assay
3pp0  2.25  2011  IC50=11nM     // 3poz.pdf (03Q) ligand is SYR127063
3rvi  2.65  2011  IC50=11nM     // 3rsv.pdf (RVI) ligand is compound 50
3sni  1.90  2011  IC50=11nM     // 3sn7.pdf (546) ligand is compound 74; IC50=11+/-1.1nM
2xsb  2.11  2011  IC50=11uM     // 2xsb.pdf (GDL)
2yiq  1.89  2011  IC50=12.67nM  // 2yiq.pdf (YIQ) Fragment: CATALYTIC KINASE DOMAIN, RESIDUES 210-531; IC50=12.67+/-11.90nM;
2xel  2.50  2011  IC50=126.6uM  // 2xel.pdf (IA2) IC50=126.6+/-21 uM; Fragment: MOTOR DOMAIN, RESUDES 2-761;
3tib  2.20  2011  IC50=129nM    // 3ti3.pdf (LVO) ligand is laninamivir octanoate(CS-8958)
2y0j  2.43  2011  IC50=12nM     // 2y0j.pdf (AXC) Fragment: CATALYTIC DOMAIN, RESIDUES 432-764;
3o0u  1.80  2011  IC50=12nM     // 3o0u.pdf (O47) Covalent complex; Fragment: UNP Residues 115-329;
3qpp  1.80  2011  IC50=12nM     // 3qpn.pdf (PFW) ligand is compound 16
3szb  1.51  2011  IC50=12uM     // 3sz9.pdf (I1E) ligand is Aldi-1; IC50=12+/-1.0uM; covalent complex; ligand undergoes a beta-elimination progress
2ylo  2.50  2011  IC50=13.1uM   // 2ylo.pdf (YLO) Fragment: LIGAND-BINDING DOMAIN, RESIDUES 664-919; IC50=13.1+/-1.2uM;
3sie  1.93  2011  IC50=13.3nM   // 3shy.pdf (5BO) ligand is compound 4; IC50=13.3+/-4.5nM
2yiu  2.70  2011  IC50=130nM    // 2yiu.pdf (SMA) Paracoccus denitrificans dimeric CYTOCHROME BC1 complex with stigmatellin A
3py0  1.75  2011  IC50=130nM    // 3pxf.pdf (SU9)
3py1  2.05  2011  IC50=130nM    // 3pxf.pdf (SU9)
2xiz  2.21  2011  IC50=130uM    // 2xix.pdf (XIZ) Fragment: KINASE DOMAIN, RESIDUES 14-313;
3src  2.00  2011  IC50=130uM    // 3sra.pdf (28N) ligand is NS2028
3npa  1.97  2011  IC50=136.4uM  // 3np7.pdf (Z57) IC50=136.4+/-4.9uM
3mg7  2.78  2011  IC50=13nM     // 3mg0.pdf (L2T) multi component!!compound 8; IC50=13nM for 20S beta5c site(substrate Ac-WLA-AMC)
3atk  1.74  2011  IC50=1400uM   // 3atk.pdf (SZ1)
3pz3  2.00  2011  IC50=141nM    // 3pz1.pdf (PZ3) Zn2+ binding; IC50=141+/-26 nM; PDB error;
3ooz  1.80  2011  IC50=14nM     // 3ooz.pdf (ZOO)
3qti  2.00  2011  IC50=14nM     // 3qti.pdf (3QT)
3tl5  2.79  2011  IC50=14nM     // 3tl5.pdf (980) ligand is compound 2
2yem  2.30  2011  IC50=15.5nM   // 2ydw.pdf (WSH) Fragment: C-TERMINAL BROMODOMAIN, RESIDUES 333-460; IC50=15.5+/-1.9nM
3rxh  1.70  2011  IC50=15.7mM   // 3rxh.pdf (HSM)
2xj0  3.10  2011  IC50=1500uM   // 2xix.pdf (XJ0) Fragment: KINASE DOMAIN, RESIDUES 14-313;
2yc0  2.15  2011  IC50=1500uM   // 2ybk.pdf (2HG)  Fe-containing; IC50=1500+/-400uM
3qbh  2.24  2011  IC50=150nM    // 3pi5.pdf (QBH)
3tpp  1.60  2011  IC50=15nM     // 3tpp.pdf (5HA)
2xp8  2.10  2011  IC50=15uM     // 2xp3.pdf (4FY)
3as3  2.40  2011  IC50=160uM    // 3arp.pdf (I5I) P21-A; ligand is 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran, IMI;IC50=160+/-78uM(pNP assay)
3qi3  2.30  2011  IC50=164.2uM  // 3qi3.pdf (PDB) ligand is (S)-BAY73-6691; IC50=164.2+/-1.2uM
2xtk  2.00  2011  IC50=164uM    // 2xtk.pdf (AZM) ligand is acetazolamide; IC50=164+/-75uM
3l9l  2.00  2011  IC50=167nM    // 3l9l.pdf (L9L) compound 36; IC50=167+/-50nM
3s0j  2.00  2011  IC50=169.9uM  // 3np7.pdf (Z15) IC50=169.9+/-10uM
3nuu  1.98  2011  IC50=169uM    // 3nuu.pdf (JOZ) compound 11
3oy1  1.70  2011  IC50=16nM     // 3oy1.pdf (589)
3t07  3.30  2011  IC50=16nM     // 3t07.pdf (09C) IC50=16+/-9nM
2y2j  2.06  2011  IC50=16uM     // 2y2g.pdf (ZA4) Fragment: TRANSPEPTIDASE DOMAIN, RESIDUES 101-125, 323-791; Mutation: YES; IC50=16+/-1uM; B containing, covalent complex
3q3b  2.70  2011  IC50=17.2nM   // 3q3b.pdf (55E)
3atl  1.74  2011  IC50=17.2uM   // 3atl.pdf (BEN)
3rxe  1.70  2011  IC50=17.2uM   // 3rxe.pdf (BEN) Kinetic study using fluorescence-based substrate
3qpn  2.00  2011  IC50=17nM     // 3qpn.pdf (PFK) ligand is compound 24
3r22  2.90  2011  IC50=17nM     // 3r21.pdf (D37) ligand is compound 2
3rcd  3.21  2011  IC50=17nM     // 3rcd.pdf (03P) ligand is 34e
3rq7  1.55  2011  IC50=17nM     // 3rq7.pdf (7-mer) ligand is C6H5(CH2)8-derivatized peptide inhibitor(4j)
3ske  1.97  2011  IC50=17nM     // 3ska.pdf (054) ligand is compound 7r
3pdq  1.99  2011  IC50=180nM    // 3pdq.pdf (KC6) Ni binding; Fragment: Catalytic domain, residues 1-359;
3s0n  1.95  2011  IC50=180nM    // 3s0n.pdf (0BB) ligand is compound 2
2xp4  1.80  2011  IC50=180uM    // 2xp3.pdf (G14)
3mrv  1.94  2011  IC50=180uM    // 3mqf.pdf (16F) IC50=180+/-7.8 uM
3ati  1.71  2011  IC50=188uM    // 3ati.pdf (SZ4)
3rxd  1.70  2011  IC50=188uM    // 3rxd.pdf (SZ4) Kinetic study using fluorescence-based substrate, ligand structure in reference is a little different from PDB
2yde  2.28  2011  IC50=189uM    // 2ybk.pdf (S2G) Fe-containing; IC50=189+/-34uM
3o9v  2.75  2011  IC50=18nM     // 3o95.pdf (10T) IC50=17-19 nM
3ohh  2.01  2011  IC50=18nM     // 3ohf.pdf (3HH)
3qk5  2.20  2011  IC50=18nM     // 3qk5.pdf (QK5) ligand is compound 45
2xzg  1.70  2011  IC50=18uM     // 2xzg.pdf (VH1) Fragment: N-TERMINAL DOMAIN, RESIDUES 1-364;
3tpr  2.55  2011  IC50=19.9nM   // 3tpr.pdf (5HA) ligand is compound IV
3ms2  2.10  2011  IC50=192.4uM  // 3mqf.pdf (18S) IC50=192.4+/-5.8 uM
3zst  2.30  2011  IC50=19mM     // 3zst.pdf (ACX) alpha CD, not a common ligand
3owb  2.05  2011  IC50=19nM     // 3ow6.pdf (BSM) IC50=19+/-2 nM
3r02  1.95  2011  IC50=1nM      // 3r00.pdf (UNM) ligand is compound 38
3sji  1.80  2011  IC50=2.06uM   // 3sj9.pdf (AG7) ligand is rupintrivir
3s3r  2.64  2011  IC50=2.09nM   // 3qsd.pdf (0IW) ligand is K11777; IC50=2.09+/-0.08nM; covalent complex
2xpb  2.00  2011  IC50=2.0uM    // 2xp3.pdf (4GE)
3rxk  1.60  2011  IC50=2.1mM    // 3rxk.pdf (SZ8) Kinetic study using fluorescence-based substrate
3p76  1.93  2011  IC50=2.1nM    // 3p76.pdf (P76) Zn binding; Fragment: UNP residues 1-271; X-ray:AaLpxc, Assay:eeLpxc
3rxb  1.70  2011  IC50=2.2mM    // 3rxb.pdf (ALG) Kinetic study using fluorescence-based substrate
3b1t  2.50  2011  IC50=2.2uM    // 3b1t.pdf (YCL) IC50=2.2+/-0.31uM;
3oxi  2.20  2011  IC50=2.2uM    // 3oxi.pdf (SYY) Fragment: UNP residues 40 to 401; with JIP1 peptide
3p79  2.10  2011  IC50=2.3uM    // 3p5k.pdf (P79)
3qzq  1.70  2011  IC50=2.3uM    // 3qzq.pdf (AG7) not a good affinity data
3rxl  1.70  2011  IC50=2.4mM    // 3rxl.pdf (SZ9) Kinetic study using fluorescence-based substrate
3qqu  2.90  2011  IC50=2.4nM    // 3qqu.pdf (01P) ligand is  pyrimidine 8
3rxf  1.70  2011  IC50=2.5mM    // 3rxf.pdf (4AP) Kinetic study using fluorescence-based substrate
3nzi  2.75  2011  IC50=2.6uM    // 3nzi.pdf (7-mer) covalent complex; Peptide: B containing; HTRA1: Fragment: unp residues 158-480;
3so9  2.87  2011  IC50=2.76nM   // 3so9.pdf (017) IC50=2.76+/-0.16nM
3sdg  1.87  2011  IC50=2.8uM    // 3sdg.pdf (3SE) ligand is compound 5
3q96  3.10  2011  IC50=2.9nM    // 3q96.pdf (0NF) ligand is compound 24; Flash Plate Assay
3sff  2.00  2011  IC50=200nM    // 3sff.pdf (0DI) ligand is compound 3
3mrt  1.98  2011  IC50=200uM    // 3mqf.pdf (12E) IC50=200+/-17 uM
3asx  2.00  2011  IC50=20nM     // 3asx.pdf (D99) Fragment: UNP residues 31-370;
3olf  1.90  2011  IC50=20nM     // 3olf.pdf (OLF) compound 7i, SPA method, mutation E281A, E354A
3q0z  2.29  2011  IC50=20nM     // 3q0z.pdf (23E)
3qcy  2.20  2011  IC50=20nM     // 3qcq.pdf (3Q3) ligand is compound (S)-21a; PIC50=7.7
2xp6  1.90  2011  IC50=20uM     // 2xp3.pdf (4G2)
2y2p  1.62  2011  IC50=20uM     // 2y2g.pdf (Z10) IC50=20+/-2uM; Fragment: TRANSPEPTIDASE DOMAIN, RESIDUES 101-125, 323-791; Mutation: YES; B containing, covalent complex
2ybt  2.22  2011  IC50=20uM     // 2ybt.pdf (DW0) IC50=20+/-1uM; Fragment: CATALYTIC DOMAIN, RESIDUES 21-398;
3sl5  2.65  2011  IC50=22nM     // 3sl4.pdf (J25) ligand is compound 10d
3rme  1.80  2011  IC50=22uM     // 3rm4.pdf (RME) ligand is compound 5
3mtb  1.95  2011  IC50=23.2uM   // 3mqf.pdf (23V) IC50=23.2+/-0.5 uM
3px8  1.29  2011  IC50=230uM    // 3px8.pdf (JP2) Fragment: UNP residues 18-275;
3rxm  1.70  2011  IC50=232uM    // 3rxm.pdf (SW1) Kinetic study using fluorescence-based substrate
3os3  2.80  2011  IC50=235nM    // 3orn.pdf (3OS) Fragment: UNP RESIDUES 62-270, 303-393;
3poz  1.50  2011  IC50=23nM     // 3poz.pdf (03P) ligand is compound TAK-285
3rjm  2.55  2011  IC50=246nM    // 3rjm.pdf (6-mer) ligand is compound 33c, ligand is 6-mer peptide, 3PX is just a modified residue
3qpo  1.80  2011  IC50=247nM    // 3qpn.pdf (PFR) ligand is compound 13
2ybp  2.02  2011  IC50=24uM     // 2ybk.pdf (2HG) Fragment: CATALYTIC DOMAIN, RESIDUES 1-359; Ni-containing; IC50=24+/-2uM; 12-mer peptide substrate containing; IC50=17+/-4uM when 10 fold Fe2+ concentration
2ybk  2.40  2011  IC50=24uM     // 2ybk.pdf (2HG) Fragment: CATALYTIC DOMAIN, RESIDUES 1-359; Ni-containing; IC50=24+/-2uM; IC50=17+/-4uM when 10 fold Fe2+ concentration;
3p50  3.30  2011  IC50=24uM     // 3p50.pdf (PFL) IC50=24+/-6.3uM; electrophysiological assay
3mt9  2.05  2011  IC50=25.7uM   // 3mqf.pdf (18O) IC50=25.7+/-0.9 uM
2y68  1.49  2011  IC50=253uM    // 2y68.pdf (T04) IC50=253+/-27uM
2y6o  1.54  2011  IC50=25nM     // 2y6o.pdf (1N1) Fragment: KINASE DOMAIN, RESIDUES 606-896;
3nwe  1.50  2011  IC50=25nM     // 3nwe.pdf (662) mutation: M91I, Y95C; compound 6, with Mg2+; radiochemical assay
3ptg  2.43  2011  IC50=25nM     // 3ptg.pdf (932)
3r6g  2.07  2011  IC50=25nM     // 3r5j.pdf (6-mer) ligand is Peptide Inhibitor (ACE)VDVAD-CHO
3lkj  2.50  2011  IC50=25uM     // 3lkj.pdf (LKJ) Fragment: UNP residues 121-261;
3nc4  2.07  2011  IC50=26.6uM   // 3mqf.pdf (26O) IC50=26.6+/-3.3 uM
2y2i  1.78  2011  IC50=26uM     // 2y2g.pdf (ZA3) IC50=26+/-3uM; Fragment: TRANSPEPTIDASE DOMAIN, RESIDUES 101-125, 323-791; Mutation: YES; B containing, covalent complex
2ybs  2.32  2011  IC50=26uM     // 2ybk.pdf (S2G) protein Fragment: CATALYTIC DOMAIN, RESIDUES 1-359; 12-mer peptide substrate containing; Ni-containing; IC50=26+/-3uM; IC50=33+/-5uM when 10 fold Fe2+ concentration
2ycm  1.80  2011  IC50=274uM    // 2yc3.pdf (30A) IC50=274+/-15uM; Fragment: CYTIDYLTRANSFERASE DOMAIN, RESIDUES 76-302;
3s3o  2.55  2011  IC50=27nM     // 3s3m.pdf (DLU) in vitro strand transfer assay, ligand is Dolutegravir (S/GSK1349572)
3sl4  1.90  2011  IC50=27nM     // 3sl4.pdf (JN4) ligand is compound 12d
2y2n  2.07  2011  IC50=27uM     // 2y2g.pdf (E07) IC50=27+/-2uM; Fragment: TRANSPEPTIDASE DOMAIN, RESIDUES 101-125, 323-791; Mutation: YES; B containing, covalent complex
2y2h  1.96  2011  IC50=27uM     // 2y2g.pdf (ZA2) IC50=27+/-1uM; Fragment: TRANSPEPTIDASE DOMAIN, RESIDUES 101-125, 323-791; Mutation: YES; B containing, covalent complex
3p4w  3.20  2011  IC50=27uM     // 3p4w.pdf (DSF) IC50=27+/-13uM; electrophysiological assay
3soq  1.90  2011  IC50=27uM     // 3sob.pdf (9-mer) ligand is DKK1 peptide;IC501=27+/-5uM(for E1)
3mt8  2.00  2011  IC50=28.3uM   // 3mqf.pdf (17T) IC50=28.3+/-1.7 uM
3otx  1.55  2011  IC50=29.4uM   // 2xtb.pdf (AP5) IC50=29.4+/-0.2uM; Mutation: S2A;
3pvu  2.48  2011  IC50=290nM    // 3psc.pdf (QRW) ligand is CMPD101; IC50=290+/-98nM
3nf9  1.95  2011  IC50=290uM    // 3nf6.pdf (CD9) ligand is compound 8
2y67  1.85  2011  IC50=292uM    // 2y66.pdf (N21) IC50=292+/-6uM;
3nf6  1.90  2011  IC50=295uM    // 3nf6.pdf (IMV) ligand is compound 3
2yak  2.20  2011  IC50=2nM      // 2yak.pdf (OSV) Fragment: AA, RESIDUES 1-285;
3qc4  1.80  2011  IC50=2nM      // 3pwy.pdf (MP7) IC50=2nM for Phosphorylated PDK-AKT; IC50<13nM for Unphosphorylated PDK-AKT; Fragment: kinase domain (UNP residues 51-359); Mutation: E303A, K304A;
3thb  2.50  2011  IC50=2nM      // 3thb.pdf (3TA) ligand is compound 12b; Zn2+containing; IC50=2+/-0.8nM
3b0w  2.20  2011  IC50=2uM      // 3b0w.pdf (DGX) ligand is digoxin
3spk  1.24  2011  IC50=3.02nM   // 3so9.pdf (TPV) IC50=3.02+/-0.10nM
3zxh  1.30  2011  IC50=3.0nM    // 3zxh.pdf (E41) ligand is compound 12
3tia  1.80  2011  IC50=3.12nM   // 3ti3.pdf (LNV) ligand is laninamivir
3qd0  1.99  2011  IC50=3.16nM   // 3qcq.pdf (3Q4) ligand is compound (3S, 6R)-28a; PIC50=8.5
3pp1  2.70  2011  IC50=3.2nM    // 3pp1.pdf (IZG) Fragment: kinase domain;
4a22  1.90  2011  IC50=3.2nM    // 4a22.pdf (TD4) inhibitor 1
3qch  2.40  2011  IC50=3.3uM    // 3qce.pdf (NX2) ligand is compound 12
3q2g  2.30  2011  IC50=3.5nM    // 3q2g.pdf (QGF) Zn binding; X-ray:ADAM-TS1, Assay: ADAM-TS4; Fragment: residues in UNP 256-548;
3piz  2.21  2011  IC50=3.5uM    // 3pix.pdf (03C) Fragment: unp residues 387-659;
3s22  1.65  2011  IC50=3.5uM    // 3s22.pdf (3S2)
3qci  2.27  2011  IC50=3.8uM    // 3qce.pdf (NX3) ligand is compound 14
3ogq  1.80  2011  IC50=30nM     // 3ogq.pdf (AB1) mutation:I37V, N55M, V59I, I98S, Q99V, P100N; binding data from other paper
3owd  1.63  2011  IC50=30nM     // 3ow6.pdf (MEY)
3q7j  2.91  2011  IC50=30uM     // 3q7j.pdf (FBO) ligand is D24
3peq  2.40  2011  IC50=31.6nM   // 3peq.pdf (3EQ) pIC50=7.5; Fragment: unp residues 171-441;
3srv  1.95  2011  IC50=31.6nM   // 3srv.pdf (S19) ligand is compound 20, pIC50=7.5
3ro0  1.50  2011  IC50=31.89uM  // 3ro0.pdf (TPT) ligand is compound 5; IC50=31.89+/-0.64 uM
3nus  2.75  2011  IC50=311uM    // 3nus.pdf (JNZ) compound 8
3oeu  2.60  2011  IC50=31nM     // 3oeu.pdf (OEU)
3p9j  2.80  2011  IC50=31nM     // 3p9j.pdf (P9J) Fragment: unp residues 124-391; Mutation: K124A, T287A, T288A;
3tjc  2.40  2011  IC50=31nM     // 3tjc.pdf (0TP) ligand is compound 8
3pdc  2.60  2011  IC50=32nM     // 3pdc.pdf (ZYI) Fragment: Hydrolase domain (UNP residues 226 to 548);
3ska  1.73  2011  IC50=32nM     // 3ska.pdf (053) ligand is compound 7q
2xln  2.40  2011  IC50=33uM     // 2xln.pdf (EWA) covalent complex, B containing, assay method in SI
3mtd  2.10  2011  IC50=340.5uM  // 3mqf.pdf (25E) IC50=340.5+/-21.7 uM
3nf7  1.80  2011  IC50=340uM    // 3nf6.pdf (CIW) ligand is compound 4
3nuy  2.10  2011  IC50=345uM    // 3nuy.pdf (JPZ) compound 17
3zw3  2.80  2011  IC50=34nM     // 3zvv.pdf (ZW3) ligand is compound 12, HTRF based assay
3shz  2.45  2011  IC50=35.9nM   // 3shy.pdf (5CO) ligand is compound 3; IC50=35.9+/-11.5nM
3nlb  1.90  2011  IC50=35nM     // 3nlb.pdf (5BE)
2ydm  2.44  2011  IC50=36.4nM   // 2ydm.pdf (SLC) IC50=36.4+/-1.5nM; Fragment: EXTRACELLULAR DOMAIN, RESIDUES 68-656; Se containing; Zn binding
2xiy  2.20  2011  IC50=3600uM   // 2xix.pdf (XIY) Fragment: KINASE DOMAIN, RESIDUES 14-313;
2xp5  1.90  2011  IC50=360uM    // 2xp3.pdf (4FF)
3as2  1.80  2011  IC50=360uM    // 3arp.pdf (POY) ligand is Propentofylline, PRO;IC50=360+/-42uM(pNP assay)
3ogp  1.70  2011  IC50=36nM     // 3ogp.pdf (017) mutation:I37V, N55M, V59I, I98S, Q99V, P100N; binding data from other paper
3qkv  3.10  2011  IC50=36nM     // 3qj9.pdf (QKV)
3q4c  3.20  2011  IC50=370nM    // 3q4c.pdf (RSW) Ru containing
3ms7  1.95  2011  IC50=370uM    // 3mqf.pdf (22S) IC50=370+/-9.7 uM
3omm  2.10  2011  IC50=37nM     // 3omm.pdf (OMM) compound 7g, SPA method, mutation E281A, E354A
3q3t  2.60  2011  IC50=37nM     // 3q3t.pdf (RX0) Fragment: UNP residues 67-406;
3zqt  2.29  2011  IC50=38.8uM   // 2ylo.pdf (30Z) IC50=38.8+/-1.3uM; Fragment: LIGAND BINDING DOMAIN, RESIDUES 664-919;
3rl4  1.29  2011  IC50=3800nM   // 3rl3.pdf (5GP) IC50=3800+/-800nM
3px9  1.89  2011  IC50=380uM    // 3px8.pdf (JP3) Fragment: UNP residues 18-275;
3qkm  2.20  2011  IC50=38nM     // 3qkm.pdf (SM9) ligand is compound 5
3p23  2.70  2011  IC50=38uM     // 3p23.pdf (ADP) IC50=38+/-17uM; Mg2+ binding; Fragment: UNP residues 547-977;
4a7b  2.20  2011  IC50=39.8nM   // 4a7b.pdf (3W5) ligand is diastereoisomers 21/22, ligand code is 3W4 or 3W5; IC501=39.8nM(21); IC502=10nM(22)
3np9  2.00  2011  IC50=39.8uM   // 3np7.pdf (Z2T) IC50=39.8+/-0.3uM
3u4r  2.00  2011  IC50=39nM     // 3u4o.pdf (08F) ligand is compound 7q, IC50=0.039uM
3psb  3.40  2011  IC50=3nM      // 3psb.pdf (SM6) Fragment: UNP residues 432-726;
3psd  3.60  2011  IC50=3nM      // 3psd.pdf (SM7) Fragment: UNP residues 432-726;
3sfc  2.10  2011  IC50=3nM      // 3sfc.pdf (S53) ligand is compound 7d
3qcl  2.40  2011  IC50=4.0uM    // 3qce.pdf (NXV) ligand is compound 20
2xpa  1.90  2011  IC50=4.1uM    // 2xp3.pdf (4G5)
2xyu  2.12  2011  IC50=4.5uM    // 2xyu.pdf (Q9G) IC50=4.5+/-0.5uM; Fragment: KINASE DOMAIN, RESIDUES 1548-1832;
3tv6  3.30  2011  IC50=4.8nM    // 3tv6.pdf (B0R) compound 17, crystal is wildtype, affinity assay is for B-Raf V600E mutant
3mrx  1.95  2011  IC50=406.5uM  // 3mqf.pdf (17S) IC50=406.5+/-40.6 uM
3s3m  2.49  2011  IC50=40nM     // 3s3m.pdf (DLU) in vitro strand transfer assay, ligand is Dolutegravir (S/GSK1349572)
3sc1  2.70  2011  IC50=41.4uM   // 3sc1.pdf (3S1) ligand is compound 16
2xni  3.30  2011  IC50=43nM     // 2xni.pdf (TR8) ligand is compound 9a; covalent complex
3m11  2.75  2011  IC50=43nM     // 3m11.pdf (AKI) Fragment: catalytic domain; Mutation: T288D; compound 3
2xo8  2.40  2011  IC50=47.2uM   // 2xo8.pdf (H70) Fragment: MOTOR DOMAIN, RESIDUES 3-761; IC50=47.2+/-3.2uM;
3msc  1.95  2011  IC50=484.2uM  // 3mqf.pdf (24S) IC50=484.2+/-23.3 uM
3pj1  2.00  2011  IC50=48nM     // 3pix.pdf (LHL) Fragment: unp residues 387-659;
3vhu  2.11  2011  IC50=49nM     // 3vhu.pdf (SNL) ligand is spironolactone
3ook  2.29  2011  IC50=4nM      // 3ook.pdf (OOK) compound 7l, SPA method, mutation E281A, E354A
3qrj  1.82  2011  IC50=4nM      // 3qri.pdf (919) ligand is DCC-2036
3r2b  2.90  2011  IC50=4nM      // 3r1n.pdf (05B) ligand is compound 5b; EC50=4nM
3ttz  1.63  2011  IC50=4nM      // 3ttz.pdf (07N) ligand is compound 26, IC50=0.004uM
3o95  2.85  2011  IC50=5.3nM    // 3o95.pdf (01T) IC50=5.1-5.4 nM
3tdc  2.41  2011  IC50=5.4nM    // 3tdc.pdf (0EU) ligand is compound 26h
3sz9  2.10  2011  IC50=5.4uM    // 3sz9.pdf (I3E) ligand is Aldi-3; IC50=5.4+/-1.3uM; covalent complex; ligand undergoes a beta-elimination progress
3pj3  1.85  2011  IC50=5.6uM    // 3pix.pdf (04L) Fragment: unp residues 387-659;
3aw0  2.30  2011  IC50=5.7uM    // 3atw.pdf (6-mer) ligand 6-mer peptide; Mutation: R188I;
3mqf  1.95  2011  IC50=5.7uM    // 3mqf.pdf (20X) IC50=5.7+/-0.4 uM
3qck  2.05  2011  IC50=5.8uM    // 3qce.pdf (NX5) ligand is compound 17
3r01  2.60  2011  IC50=5.8uM    // 3r00.pdf (UNE) ligand is compound 11
3pxy  1.80  2011  IC50=5.9uM    // 3pxf.pdf (JWS)
3pxz  1.70  2011  IC50=5.9uM    // 3pxf.pdf (JWS)
3mta  2.23  2011  IC50=50.4uM   // 3mqf.pdf (22O) IC50=50.4+/-1.9 uM
3l9m  1.90  2011  IC50=50nM     // 3l9l.pdf (L9M) mutation V123A, L173M, Q181K; X-ray(PKAB3 mutation), binding assay(PKA WT); compound 18; IC50= 50+/- 8.7nM
3oof  2.29  2011  IC50=50nM     // 3oof.pdf (OOF) compound 7d, SPA method, mutation E281A, E354A
3vhv  1.35  2011  IC50=510nM    // 3vhu.pdf (LD1) ligand is compound 1d, LD1 or LD2 isomer
3ms4  2.07  2011  IC50=524.3uM  // 3mqf.pdf (21N) IC50=524.3+/-11.4 uM
3u4o  1.77  2011  IC50=53nM     // 3u4o.pdf (08E) ligand is compound 1
3pka  1.25  2011  IC50=540nM    // 3pka.pdf (Y02) Mn binding
3rhk  1.94  2011  IC50=548nM    // 3rhk.pdf (M97) ligand is ARQ 197; IC50=548+/-120nM(the first 20 min)
3pvw  2.49  2011  IC50=54nM     // 3psc.pdf (QRX) ligand is CMPD103A; IC50=54+/-14nM
3ans  1.98  2011  IC50=565nM    // 3ans.pdf (S38) Fragment: hydrolase domain, UNP residues 230-555  ;
3qrk  2.30  2011  IC50=57nM     // 3qri.pdf (9DP) ligand is compound 1
3skf  3.00  2011  IC50=5nM      // 3skf.pdf (PB7) ligand is compound 5
3vhe  1.55  2011  IC50=6.2nM    // 3vhe.pdf (42Q) ligand is compound 20d; enzyme Cinhibitor  dilution  assay
3qd4  2.30  2011  IC50=6.31nM   // 3qcq.pdf (3Q6) ligand is compound 43a; PIC50=8.2
3nzx  2.70  2011  IC50=6.8uM    // 3nzj.pdf (5-mer) TMC-95A mimic ligand 2c, IC50=6.8+/-0.1uM
2y2k  2.09  2011  IC50=6.9uM    // 2y2g.pdf (ZA5) Fragment: TRANSPEPTIDASE DOMAIN, RESIDUES 101-125, 323-791; Mutation: YES; IC50=6.9+/-0.1uM; B containing, covalent complex
3sov  1.27  2011  IC50=61uM     // 3sob.pdf (9-mer) ligand is SOST peptide;IC501=61+/-10uM(for E1)
3pkb  1.25  2011  IC50=620nM    // 3pka.pdf (Y16) Mn binding
3qsd  1.30  2011  IC50=63.9nM   // 3qsd.pdf (074) ligand is CA074; IC50=63.9+/-2.8nM; covalent complex
3lzb  2.70  2011  IC50=63nM     // 3lzb.pdf (ITI) Fragment:696-1022; Mutation: V924R; compound 21
3qcx  2.30  2011  IC50=63nM     // 3qcq.pdf (3Q2) ligand is compound (R)-18a; PIC50=7.2
3avz  2.46  2011  IC50=65nM     // 3atw.pdf (6-mer) ligand 6-mer peptide; Mutation: R188I;
3srb  1.80  2011  IC50=65uM     // 3sra.pdf (28S) ligand is SMER28
3rl3  1.42  2011  IC50=67nM     // 3rl3.pdf (5GP) IC50=67+/-1.6nM
3s2p  2.30  2011  IC50=68nM     // 3s2p.pdf (PMU)
2ycr  2.20  2011  IC50=69.60nM  // 2xk9.pdf (HCW) IC50=69.60+/-40.22nM; Fragment: CATALYTIC DOMAIN, RESIDUES 210-531;
3q2h  2.33  2011  IC50=690pM    // 3q2g.pdf (QHF) Zn binding; X-ray:ADAM-TS1, Assay: ADAM-TS4; Fragment: residues in UNP 256-548;
3pz4  2.10  2011  IC50=6nM      // 3pz1.pdf (3PZ) Zn2+ binding; IC50=6+/-3 nM; X-ray:BMS3:FTase:FPP
3q77  2.00  2011  IC50=6nM      // 3q77.pdf (2HY)
3osi  2.70  2011  IC50=6uM      // 3osi.pdf (XDH) Fragment: ligand binding domain;
3rxg  1.70  2011  IC50=7.1mM    // 3rxg.pdf (SZ3) Kinetic study using fluorescence-based substrate
3pj2  1.75  2011  IC50=7.2uM    // 3pix.pdf (04K) Fragment: unp residues 387-659;
3oev  2.85  2011  IC50=7.4nM    // 3oeu.pdf (3OE)
3q3k  2.00  2011  IC50=7.4nM    // 3q3k.pdf (D90) Fragment: UNP RESIDUES 125-178
3tu9  2.09  2011  IC50=7.5uM    // 3tu9.pdf (5MM) IC50=7.5+/-0.5uM
2yjw  1.61  2011  IC50=7.6uM    // 2yjw.pdf (YJW) Fragment: N-DOMAIN, RESIDUES 18-233;
2yjx  1.83  2011  IC50=7.6uM    // 2yjw.pdf (YJX) Fragment: N-DOMAIN, RESIDUES 18-233;
3r7b  1.80  2011  IC50=710nM    // 3r5j.pdf (5-mer) ligand is Peptide Inhibitor (ACE)DVAD-CHO
3r7n  2.33  2011  IC50=710nM    // 3r5j.pdf (5-mer) ligand is two copies of Peptide Inhibitor (ACE)DVAD-CHO
3pz1  1.95  2011  IC50=724nM    // 3pz1.pdf (3PZ) Zn2+ binding; IC50=724+/-321 nM; PDB error
3pz2  2.35  2011  IC50=724nM    // 3pz1.pdf (3PZ) Zn2+ binding; IC50=724+/-321 nM; PDB error; X-ray: BMS3:RabGGTase:GGPP
3rtn  2.70  2011  IC50=74nM     // 3rsv.pdf (RTN) ligand is compound 42
3pkd  1.47  2011  IC50=760nM    // 3pka.pdf (Y10) Mn binding
2yig  1.70  2011  IC50=79.4nM   // 2yig.pdf (5EL) Fragment: CATALYTIC DOMAIN, RESIDUES 104-274; pIC50=7.1
3o57  2.00  2011  IC50=79.4pM   // 3o56.pdf (ZG2) pIC50=10.1, Fragment: Catalytic domain, 324-675; Mutation: S482A, S487A, S489A;
2y6d  1.60  2011  IC50=79nM     // 2y6c.pdf (TQJ) Zn-containing; pIC50=7.1
3at4  2.20  2011  IC50=8.0nM    // 3at3.pdf (CCK) Fragment: residues 1-335;
3s2a  2.55  2011  IC50=8.1nM    // 3s2a.pdf (2NQ) ligand is compound 16d; IC50=8.1+/-3nM
2yk9  1.32  2011  IC50=8.1uM    // 2yjw.pdf (YK9) Fragment: N-DOMAIN, RESIDUES 18-223;
2y1o  1.49  2011  IC50=8.2uM    // 2y1o.pdf (T26) ligand is compound 9; IC50=8.2+/-0.6uM
3rxp  1.60  2011  IC50=8.3mM    // 3rxp.pdf (SW3) Kinetic study using fluorescence-based substrate
3qsb  1.90  2011  IC50=8.3uM    // 3qsb.pdf (743) ligand is compound 4
3ant  2.40  2011  IC50=8.5nM    // 3ans.pdf (S82) Fragment: hydrolase domain, UNP residues 230-555
3r2y  3.00  2011  IC50=8.5nM    // 3r2y.pdf (P4O) ligand is compound 16
3r00  2.10  2011  IC50=8.5uM    // 3r00.pdf (UNJ) ligand is compound 10
3l9n  2.00  2011  IC50=8.6nM    // 3l9l.pdf (L9N) mutation V123A, L173M, Q181K; X-ray(PKAB3 mutation), binding assay(PKA WT); compound 27; IC50= 8.6+/-0.8nM
3s2o  2.60  2011  IC50=8.9uM    // 3msj.pdf (EV6) compound 14m
3ty0  2.00  2011  IC50=83.1nM   // 3ty0.pdf (082) ligand is compound 51
3rxo  1.60  2011  IC50=83.3uM   // 3rxo.pdf (SW2) Kinetic study using fluorescence-based substrate
3rkz  1.57  2011  IC50=83nM     // 3rkz.pdf (06T) ligand is compound 21
3atm  1.72  2011  IC50=873uM    // 3atm.pdf (TSS)
3rxi  1.60  2011  IC50=873uM    // 3rxi.pdf (TSS) Kinetic study using fluorescence-based substrate
3rxj  1.70  2011  IC50=873uM    // 3rxj.pdf (GBS) Kinetic study using fluorescence-based substrate
3s3n  2.49  2011  IC50=88nM     // 3s3m.pdf (DLU) in vitro strand transfer assay, ligand is Dolutegravir (S/GSK1349572)
3skg  2.88  2011  IC50=8nM      // 3skf.pdf (PB8) ligand is compound 14c
3at3  2.60  2011  IC50=9.2nM    // 3at3.pdf (ATK) Fragment: residues 1-335;
3rdh  2.39  2011  IC50=9.3uM    // 3rdh.pdf (3RD) ligand is FOBISIN101
3n4c  1.90  2011  IC50=9.5nM    // 3n4c.pdf (EF3) Fragment: UNP residues 115 to 331; compound 46
3shy  2.65  2011  IC50=90.9nM   // 3shy.pdf (5FO) ligand is compound 2; IC50=90.9+/-22.4nM
3sfh  2.70  2011  IC50=90nM     // 3sff.pdf (1DI) ligand is compound 4
3thd  1.79  2011  IC50=90uM     // 3thd.pdf (DGJ) ligand is 1-deoxygalactonojirimycin (D-galacto-DNJ)
3zvv  2.50  2011  IC50=915uM    // 3zvv.pdf (XAZ) ligand is compound 1
3r91  1.58  2011  IC50=92nM     // 3r91.pdf (06H) ligand is compound 40
3mt7  2.00  2011  IC50=93.2uM   // 3mqf.pdf (16O) IC50=93.2+/-5.1 uM
3ti4  1.60  2011  IC50=947nM    // 3ti3.pdf (LVO) ligand is laninamivir octanoate(CS-8958)
3ohf  2.10  2011  IC50=94nM     // 3ohf.pdf (3HF) Fragment: UNP residues 14-454;
3pi5  2.40  2011  IC50=950nM    // 3pi5.pdf (3P5) Fragment: UNP residues 48-447
3as1  2.00  2011  IC50=95uM     // 3arp.pdf (CTI) ligand is Chelerythrine, CHE; IC50=95+/-34uM(pNP assay)
3np7  2.05  2011  IC50=95uM     // 3np7.pdf (Z15) complex with compound 3 and 4; IC50=95uM for compound4, IC50=169.9+/-10uM for compound 3, IC50=140+/-10uM for compound 3-4 mixture
3pkc  1.47  2011  IC50=960nM    // 3pka.pdf (Y08) Mn binding
3r92  1.58  2011  IC50=96nM     // 3r92.pdf (06J) ligand is compound 10
3atw  2.36  2011  IC50=98nM     // 3atw.pdf (5-mer) ligand 5-mer peptide; Mutation: R188I;
3qkl  1.90  2011  IC50=9nM      // 3qkk.pdf (SMR) ligand is compound 38
3txo  2.05  2011  IC50=9nM      // 3txo.pdf (07U) ligand is compound 12
2xp3  2.00  2011  IC50>1000uM   // 2xp3.pdf (B21)
3nf8  1.90  2011  IC50>1000uM   // 3nf6.pdf (CDQ) ligand is compound 5
3pke  1.60  2011  IC50>250uM    // 3pka.pdf (Y10) Ni binding
2xix  2.40  2011  IC50>5000uM   // 2xix.pdf (XIX) Fragment: KINASE DOMAIN, RESIDUES 14-313;
2xnn  2.50  2011  IC50>50uM     // 2xnm.pdf (430) Fragment: KINASE DOMAIN, RESIDUES 1-271;
3ob0  2.85  2011  IC50~1mM      // 3oay.pdf (2M6) IC50 estimated from figS5
3oay  1.95  2011  IC50~20mM     // 3oay.pdf (BDF) not accuraacy, IC50~20mM (substrate tetrasaccharide), ~0.1M (substrate monosaccharide)
2ylp  2.30  2011  IC50~50uM     // 2ylo.pdf (056) IC50=50-100 uM; Fragment: LIGAND-BINDING DOMAIN, RESIDUES 664-919;
2ylq  2.40  2011  IC50~50uM     // 2ylo.pdf (YLQ) IC50=50-100 uM; Fragment: LIGAND-BINDING DOMAIN, RESIDUES 664-919;
2xn7  1.43  2011  Kd<0.1nM      // 2xn3.pdf (T44-F6Z) 2-mer ligand, Fragment: RESIDUES 32-380; Mutation:RESIDUES 346-355 OF TBG WERE REPLACED BY GAMFLEAIPRS
2ych  2.20  2011  Kd<1mM        // 2ych.pdf (ATP) Mg-containing
2l65   NMR  2011  Kd<60uM       // 2gkc.pdf (6-mer) ligand is Calicheamicin-Gamma, consists of 6 fragments, MTC-DAG-MRP-EMP-HIB-DSR
3b28  1.35  2011  Kd=0.0034uM   // 3b24.pdf (B2X)
2yln  1.12  2011  Kd=0.021uM    // 2yjp.pdf (CYS)
3uvm  1.57  2011  Kd=0.03uM     // 3uvk.pdf (10-mer) ligand is 10-mer WDR5-interacting motif of MLL4, Kd=0.03+/-0.004uM
3b24  1.70  2011  Kd=0.042mM    // 3b24.pdf (B2J)
2xuz  1.90  2011  Kd=0.04uM     // 2xuz.pdf (EB4)
3q8d  2.30  2011  Kd=0.06uM     // 3q8d.pdf (10-mer) ligand is 10-mer Single-stranded DNA-binding protein; Kd=0.06+/-0.01uM(50mM NaCl),  Kd=0.34+/-0.02uM(200mM NaCl)
2x6w  1.35  2011  Kd=0.079uM    // 2x6w.pdf (4-mer) ligand is hexasaccharide,Kd=0.079+/-0.016uM
3arp  1.55  2011  Kd=0.07uM     // 3arp.pdf (DEQ) ligand is Dequalinlium, DEQ; IC50=0.4+/-0.1uM(pNP assay)
3qx9  2.00  2011  Kd=0.09mM     // 3qx8.pdf (ATP)
3u0d  2.51  2011  Kd=0.101nM    // 3tf6.pdf (DBH) ligand is 2,3-DHBA;containing Fe3+;Kd=0.101+/-0.002nM
3t2v  2.51  2011  Kd=0.103uM    // 3t2v.pdf (KKJ) ligand is mycolic acid;Kd=0.13+/-0.05uM
3uvo  2.20  2011  Kd=0.10uM     // 3uvk.pdf (11-mer) ligand is 11-mer WDR5-interacting motif of SET1B, Kd=0.10+/-0.01uM
3ap4  2.33  2011  Kd=0.12mM     // 3ap4.pdf (LBT) ligand is LACTOSE
3r1v  2.19  2011  Kd=0.12uM     // 3r1o.pdf (AZB)
3uex  2.10  2011  Kd=0.12uM     // 3ueu.pdf (STE) complex between LGB and STE; Kd=0.12uM(fluorescence); Kd=0.63uM(ESI-MS); Kd=2.59uM(EPA)
2y57  3.30  2011  Kd=0.13uM     // 2y54.pdf (V37) Fragment: RESIDUES 20-236; pKd=6.9+/-0.1 by SPR; pKd=7.3+/-0.2 by ITC; pKi=7.5+/-0.1
3rdo  1.40  2011  Kd=0.14nM     // 3rdo.pdf (BTN)
3s8o  1.85  2011  Kd=0.14uM     // 3ov1.pdf (5-mer)
3qo2  2.49  2011  Kd=0.14uM     // 3qo2.pdf (15-mer) ligand is H3(1-15)K9me3; Kd=0.14+/-0.01uM
3t5i  2.10  2011  Kd=0.15uM     // 3t5g.pdf (9-mer) ligand is C-terminal Farnesylated Rheb peptide CSQQGKSS(CMT), Fluorescence polarization measurements
3tdz  2.00  2011  Kd=0.15uM     // 3tdu.pdf (13-mer) ligand is stapled acetylated Ubc12N, 5:9S refers to helical staple
3uvk  1.40  2011  Kd=0.16uM     // 3uvk.pdf (11-mer) ligand is 11-mer WDR5-interacting motif of MLL2, Kd=0.16+/-0.01uM
3ao2  1.80  2011  Kd=0.17mM     // 3ao1.pdf (AVX)
3q6s  1.93  2011  Kd=0.18uM     // 3q6s.pdf (19-mer) ligand is a peptide from Shugoshin-like 1
3aqt  2.50  2011  Kd=0.19uM     // 3aqt.pdf (RCO)
3poa  2.01  2011  Kd=0.1uM      // 3poa.pdf (12-mer) synthetic phosphopeptide (pThr), Fragment: FHA domain; TPO mutation in phosphopeptide ; incomplete ligand
3rse  2.65  2011  Kd=0.1uM      // 3rse.pdf (3-mer) ligand is 3-mer CA fragment of Bos taurus N-WASP peptide; Kd1=0.1+/-0.04uM(site 1); Kd2=10.1+/-1.1uM(site 2);
3zyu  1.50  2011  Kd=0.1uM      // 3zyu.pdf (1GH)
3shv  2.10  2011  Kd=0.22uM     // 3shv.pdf (10-mer) ligand is 10-mer Histone H2A.x peptide, Kd=0.22+/-0.02uM
3uat  2.70  2011  Kd=0.22uM     // 3uat.pdf (18-mer) ligand is 18-mer phosphor-LGN peptide, Kd=0.22+/-0.01uM
3b26  2.10  2011  Kd=0.23uM     // 3b24.pdf (B2L)
3zy5  1.96  2011  Kd=0.23uM     // 3zy2.pdf (GFB)
3orn  2.80  2011  Kd=0.24nM     // 3orn.pdf (3OR) with MgAMP-PNP, Assay: with ATP; Fragment: UNP RESIDUES 62-270, 303-393;
3ka2  1.40  2011  Kd=0.24uM     // 3fsm.pdf (2NC)
3m93  2.90  2011  Kd=0.24uM     // 3m93.pdf (M7G) Kd=0.24+/-0.04uM(ITC), Kd=0.161+/-0.005uM(Fluorescent titration)
2xzq  2.40  2011  Kd=0.26uM     // 2xzq.pdf (12-mer) peptide Fragment: PEPTIDE, RESIDUES 1-12
3tl0  2.05  2011  Kd=0.26uM     // 3tkz.pdf (10-mer) ligand is RLNpYAQLWHR peptide ; Kd=0.26+/-0.02uM
3uvn  1.79  2011  Kd=0.26uM     // 3uvk.pdf (11-mer) ligand is 11-mer WDR5-interacting motif of SET1A, Kd=0.26+/-0.02uM
2lbm   NMR  2011  Kd=0.27uM     // 2lbm.pdf (15-mer) protein Fragment: UNP residues 159-296;
3ove  1.82  2011  Kd=0.27uM     // 3ov1.pdf (5-mer)
3s0e  1.60  2011  Kd=0.28uM     // 3s0b.pdf (EOL)
3pgu  1.70  2011  Kd=0.2uM      // 3pgu.pdf (OLA)
2y56  3.59  2011  Kd=0.31uM     // 2y54.pdf (V11) Fragment: RESIDUES 20-236; pKd=6.5+/-0.1 by SPR; pKd=7.4+/-0.1 by ITC; pKi=7+/-0.1
3r93  2.06  2011  Kd=0.31uM     // 3r93.pdf (15-mer)
2ygu  2.60  2011  Kd=0.322uM    // 2ygu.pdf (HP6) 1/Kd=3.1uM-1
3muf  2.30  2011  Kd=0.32uM     // 3muf.pdf (S3P) ligand is shikimate-3-phosphate  (S3P); Kd=0.32+/-0.07uM
3s0b  1.22  2011  Kd=0.32uM     // 3s0b.pdf (FNA)
2y4m  2.70  2011  Kd=0.345uM    // 2y4j.pdf (GDX) Mg2+ containing
2yki  1.67  2011  Kd=0.35nM     // 2yjw.pdf (YKI)
3zy2  1.54  2011  Kd=0.35uM     // 3zy2.pdf (GDP)
2y36  2.70  2011  Kd=0.38uM     // 2xzq.pdf (12-mer)
2xxn  1.60  2011  Kd=0.39uM     // 2xxn.pdf (15-mer) protein Fragment: TRAF DOMAIN, RESIDUES 63-205 ;
3o9p  2.07  2011  Kd=0.3uM      // 3o9p.pdf (MHI)
3tf6  2.35  2011  Kd=0.40uM     // 3tf6.pdf (DBH) ligand is 2,3-DHBA; Kd=0.40+/-0.01uM
3hau  1.30  2011  Kd=0.42uM     // 3fsm.pdf (2NC)
3qlm  2.50  2011  Kd=0.431uM    // 3qlm.pdf (PLM)
2y1w  2.10  2011  Kd=0.465uM    // 2y1w.pdf (849) Fragment: CATALYTIC DOMAIN, RESIDUES 135-482; cofactor SFG-containing; IC50 assay use full length protein, IC50=0.03+/-0.015uM
4a4e   NMR  2011  Kd=0.476mM    // 4a4e.pdf (2MR) ligand is sDMA
3rdq  1.60  2011  Kd=0.49nM     // 3rdo.pdf (DTB)
3uew  2.00  2011  Kd=0.49uM     // 3ueu.pdf (PLM) complex between LGB and PLM; Kd=0.49uM(ITC); Kd=0.10uM(fluorescence); Kd=2.63uM(ESI-MS); Kd=2.56uM(EPA)
3arq  1.50  2011  Kd=0.4uM      // 3arp.pdf (DM5) ligand is Idarubicin, IDA; Kd=0.4+/-0.02uM
3ll8  2.00  2011  Kd=0.4uM      // 3ll8.pdf (11-mer) ligand is AKAP79 peptide
3rsb  2.80  2011  Kd=0.4uM      // 3rsb.pdf (GTP) Kd=0.4+/-0.04uM
3szm  2.63  2011  Kd=0.4uM      // 3szm.pdf (10-mer) Kd=0.4+/-0.2uM
3rux  1.70  2011  Kd=0.53nM     // 3rux.pdf (BS5)
3rbq  2.00  2011  Kd=0.54uM     // 3rbq.pdf (11-mer) ligand is a 11-mer Guanine nucleotide-binding protein G(t) subunit alpha-1 peptide; Kd=0.54+/-0.28uM
3t1l  1.60  2011  Kd=0.55mM     // 3t1l.pdf (MQT)
2l6j   NMR  2011  Kd=0.55uM     // 2l6j.pdf (5-mer) ligand is C-terminus Hsp90 chaperone peptide MEEVD; Kd=0.55+/-0.06uM
2y4l  2.80  2011  Kd=0.5uM      // 2y4j.pdf (GDP) Mn2+ containing
3ql9  0.93  2011  Kd=0.5uM      // 3ql9.pdf (15-mer) monoclinic form, histone H3K9me3 peptide
3s7b  2.42  2011  Kd=0.5uM      // 3s7b.pdf (NH5) ligand is AZ505
3hlo  1.60  2011  Kd=0.61uM     // 3fsm.pdf (2NC)
3s8n  1.71  2011  Kd=0.62uM     // 3ov1.pdf (5-mer)
3p9t  2.02  2011  Kd=0.63uM     // 3p9t.pdf (TCL)
3u5l  1.39  2011  Kd=0.64uM     // 3u5l.pdf (08K)
2y07  2.40  2011  Kd=0.6uM      // 2xzq.pdf (12-mer)
3qmk  2.21  2011  Kd=0.787uM    // 3qmk.pdf (4-mer) Kd=0.787+/-0.124uM, ligand is heparin hexasaccharide
2y4s  2.10  2011  Kd=0.7uM      // 2y4s.pdf (BCD) protein Fragment: RESIDUES 22-904 ;
3arw  1.50  2011  Kd=0.7uM      // 3arp.pdf (CTI) ligand is Chelerythrine, CHE; Kd=0.7+/-0.03uM(Fluorescence)
3qxd  2.30  2011  Kd=0.7uM      // 3qxa.pdf (15-mer) ligand is 15-mer CLIP peptide
2y06  2.50  2011  Kd=0.80uM     // 2xzq.pdf (12-mer)
3b25  1.75  2011  Kd=0.86uM     // 3b24.pdf (B2K)
3sjt  1.60  2011  Kd=0.88uM     // 3gmz.pdf (5AB) Kd=0.88+/-0.02uM; Mn binding;
3qc9  2.70  2011  Kd=0.88uM     // 3qc9.pdf (ADP) Kd=0.88+/-0.30uM
3pwm  1.46  2011  Kd=0.8nM      // 3pwm.pdf (017)
2yay  1.86  2011  Kd=0.8uM      // 2yay.pdf (DUP) ligand is DUPNPP; Ca-containing
3mp1  2.60  2011  Kd=0.8uM      // 3mp1.pdf (5-mer) H3K4me3 peptide, Kd=0.8+/-0.2 uM(SPR), Kd=4+/-1 uM(FP), Kd=2.3+/-0.3 uM(ITC); X-ray:5-mer, binding assay:11-mer
3t1n  2.60  2011  Kd=0.8uM      // 3t1n.pdf (4-mer) ligand is Cdc27 peptide; Kd=0.8+/-0.1uM
3t1m  1.55  2011  Kd=0.91mM     // 3t1l.pdf (DQT)
3shb  1.80  2011  Kd=0.93uM     // 3shb.pdf (12-mer) ligand is 12-mer Histone H3 peptide
3ap7  1.53  2011  Kd=0.99mM     // 3ap4.pdf (3-mer) ligand is 3'-SL
2xhs  2.80  2011  Kd=0.99uM     // 2xhs.pdf (9-mer)
2l75   NMR  2011  Kd=0.9uM      // 2l75.pdf (14-mer) ligand is H3K9me3; Kd=0.9+/-0.4 uM
3haw  1.30  2011  Kd=1.01uM     // 3fsm.pdf (2NC)
4a4g   NMR  2011  Kd=1.025mM    // 4a4e.pdf (DA2) ligand is aDMA
2xv1  2.15  2011  Kd=1.03uM     // 2xv1.pdf (ECA)
3rl8  2.20  2011  Kd=1.05uM     // 3rl7.pdf (11-mer) ligand is 11-mer peptide from Adenomatous polyposis coli protein; Kd=1.05+/-0.22uM
3arz  1.82  2011  Kd=1.0uM      // 3arp.pdf (I5I) P21-A; ligand is 2-(imidazolin-2-yl)-5-isothiocyanatobenzofuran, IMI; Kd=1.0+/-0.1uM(Fluorescence)
3ary  1.35  2011  Kd=1.0uM      // 3arp.pdf (I5I) space group P21; ligand is IMI; Kd=1.0+/-0.1uM(Fluorescence)
3qnj  2.28  2011  Kd=1.0uM      // 3qnj.pdf (19-mer) ligand is antimicrobial peptide oncocin
4a0j  2.80  2011  Kd=1.0uM      // 4a0i.pdf (6-mer) ligand is HISTONE H3 PEPTIDE C2 form; Kd=1.0+/-0.1uM
3pm1  2.80  2011  Kd=1.18uM     // 3pm1.pdf (ET) Kd=1.18+/-0.04 uM, Mutation: K67S, C72A, E90Q, C141S;
3alt  2.50  2011  Kd=1.19mM     // 3alt.pdf (MLB) ligand is Melibiose; Ca-containing
3rz7  1.80  2011  Kd=1.1nM      // 3ryj.pdf (RZ7)
3mp6  1.48  2011  Kd=1.1uM      // 3mp6.pdf (4-mer) X-ray(H3K4me2) while Kd(H3(1-11)K4me2); whether ligand is 4-mer or 11-mer not clear
3rw9  2.00  2011  Kd=1.1uM      // 3rw9.pdf (DSH)
3uev  1.90  2011  Kd=1.29uM     // 3ueu.pdf (MYR) complex between LGB and MYR; Kd=1.29uM(ITC); Kd=0.33uM(fluorescence); Kd=5.26uM(ESI-MS)
3r0h  2.60  2011  Kd=1.2uM      // 3r0h.pdf (9-mer) The measured binding affinities of the NG2 peptides to PDZ5 and PDZ45 are essentially the same.
3tkz  1.80  2011  Kd=1.2uM      // 3tkz.pdf (10-mer) ligand is RVIpYFVPLNR peptide; Kd=1.2+/-0.3uM
4a4f   NMR  2011  Kd=1.317mM    // 4a4e.pdf (2MR) ligand is sDMA
3tcg  2.00  2011  Kd=1.36uM     // 3tcf.pdf (3-mer)
3qx8  2.30  2011  Kd=1.37mM     // 3qx8.pdf (GTG)
2y8i  3.13  2011  Kd=1.3uM      // 2y8i.pdf (ADP) Fragment: MOTOR DOMAIN, RESIDUES 2-759; Mutation: G680A; Mg binding
3ax5  2.20  2011  Kd=1.4uM      // 3awr.pdf (11-mer) protein Fragment: CYTOSOLIC DOMAIN, UNP RESIDUES 59-126; peptide Fragment: C-TERMINAL HALF, UNP RESIDUES 12-20 ; peptide Mutation: P13C, S16C; Kd=1.4+/-0.5uM
3iaw  1.61  2011  Kd=1.57uM     // 3fsm.pdf (2NC)
3ppr  2.10  2011  Kd=1.5mM      // 3ppo.pdf (4CS)
2y8l  2.50  2011  Kd=1.5uM      // 2y8l.pdf (ADP)
2y8q  2.80  2011  Kd=1.5uM      // 2y8l.pdf (ADP)
3qqa  2.20  2011  Kd=1.5uM      // 3qps.pdf (TCH)
3plu  1.40  2011  Kd=1.69uM     // 3plu.pdf (19-mer) 66 kDa U4/U6.U5 small nuclear ribonucleoprotein component HINDI domain, Kd=1.69+/-0.27uM; Hub-1: Mutation: A20G
3rm4  1.90  2011  Kd=1.69uM     // 3rm4.pdf (3RM)
2xn6  1.29  2011  Kd=1.6nM      // 2xn3.pdf (F6Y-T44) Kd=1.6+/-0.1nM; dimer ligand; Fragment: RESIDUES 32-380; Mutation: RESIDUES 346-355 OF TBG WERE REPLACED BY GAMFLEAIPRS;
3rt4  1.70  2011  Kd=1.6nM      // 3o4k.pdf (LP5) ligand is LPS
4a4h   NMR  2011  Kd=1.706mM    // 4a4e.pdf (DA2) ligand is aDMA
2xp7  2.00  2011  Kd=1.7uM      // 2xp3.pdf (4F8)
3qxc  1.34  2011  Kd=1.7uM      // 3mle.pdf (ATP) Mg-containing
3rz1  1.51  2011  Kd=1.8nM      // 3ryj.pdf (RZ1)
3o1d  2.40  2011  Kd=1.8uM      // 3o1d.pdf (13-mer) with Gemini-0072; Kd=1.8+/-0.07uM. note that the ligand G72 only EC50 data=0.15+/-0.1nM, it increase the Kd of NR2 to receptor
3o1e  2.50  2011  Kd=1.8uM      // 3o1e.pdf (13-mer) with Gemini-0097; Kd=1.8+/-0.08uM. note that the ligand H97 only EC50 data=0.25+/-0.1nM, it increase the Kd of NR2 to receptor
3pwh  3.30  2011  Kd=1.9nM      // 3pwh.pdf (ZMA) ligand is ZM241385
2y7w  2.89  2011  Kd=10.38uM    // 2y7k.pdf (SAL) Kd=10.38+/-0.17uM; Fragment: INDUCER BINDING DOMAIN, RESIDUES 80-301; Mutation: YES;
2l7u   NMR  2011  Kd=104uM      // 2l7u.pdf (7-mer) 7-mer peptide; Kd = 104+/-5 uM; protein Fragment: Ig-like V-type domain residues 23-125; peptide Fragment: Sequence database residues 148-154
3rey  3.31  2011  Kd=10nM       // 3pwh.pdf (XAC)
3p9m  2.00  2011  Kd=10uM       // 3p9l.pdf (8-mer)
2y7k  1.95  2011  Kd=11.80uM    // 2y7k.pdf (SAL)
2xn3  2.09  2011  Kd=1198nM     // 2xn3.pdf (ID8)
3n2e  2.53  2011  Kd=11uM       // 3muf.pdf (OSA) ligand is NSC162535; Kd=11+/-4uM
3rdv  1.75  2011  Kd=12.3uM     // 3rdv.pdf (8-mer)
3te5  2.50  2011  Kd=12.3uM     // 3t4n.pdf (NAI)
3n75  2.00  2011  Kd=12.8nM     // 3n75.pdf (G4P) Kd1=12.8+/-6.6 nM; Kd2=684.9+/-314.3nM
3qs6  2.80  2011  Kd=12.8uM     // 3qs4.pdf (TRP) Kd=12.8+/-1.3uM
2xxy  3.00  2011  Kd=12.9nM     // 2xxy.pdf (KAI) Kd = 12.9+/-1.7 nM; protein mutant D776K; Fragment: LIGAND BINDING DOMAIN, RESIDUES 429-544, 667-806
3rz9  2.29  2011  Kd=120nM      // 3rz9.pdf (13-mer) Kd=120+/-9nM; Solid-phase binding assays
3rlb  2.00  2011  Kd=120pM      // 3rlb.pdf (VIB)
3qip  2.09  2011  Kd=129nM      // 3qin.pdf (P4Y) ligand is compound 2; Kd=129+/-43nM
2x85  1.50  2011  Kd=129uM      // 2x6w.pdf (4-mer) ligand is hexasaccharide;Kd=129+/-11uM
3od0  2.90  2011  Kd=12nM       // 3ocp.pdf (PCG) Kd=12+/-1.6nM; Fragment: Cyclic nucleotie binding domain;
3pju  2.50  2011  Kd=13.1uM     // 3pjt.pdf (C2E)
3pjt  2.52  2011  Kd=13.1uM     // 3pjt.pdf (C2E) Kd=13.1+/-0.9 uM; Fragment: UNP Residues 400-648;
3qin  1.70  2011  Kd=136nM      // 3qin.pdf (P1Y)
3pyy  1.85  2011  Kd=137nM      // 3pyy.pdf (3YY)
3rtx  2.81  2011  Kd=139uM      // 3rtx.pdf (18-mer) ligand is a 18-mer RNA Polymerase II C-terminal domain peptide
2ylc  1.30  2011  Kd=13nM       // 2ylc.pdf (U)
3rz5  1.65  2011  Kd=13nM       // 3ryj.pdf (RZ5)
3njq  2.00  2011  Kd=13uM       // 3njq.pdf (NJQ)
3zyf  1.94  2011  Kd=14.1uM     // 3zyb.pdf (147) ligand is NPG; Kd=14.1+/-0.2uM
3ru1  2.30  2011  Kd=14.2uM     // 3rsv.pdf (3RU)
2yb0  2.28  2011  Kd=140uM      // 2yay.pdf (DUR)
3qio  1.40  2011  Kd=144nM      // 3qin.pdf (QID) ligand is compound 3; Kd=144+/-11nM
3qnd  2.40  2011  Kd=14uM       // 3qnd.pdf (SIA)
2xqq  1.31  2011  Kd=15.2uM     // 2xqq.pdf (7-mer)
3s75  1.50  2011  Kd=150nM      // 3s71.pdf (EVG)
3n5e  2.26  2011  Kd=151nM      // 3n5e.pdf (8-mer) ligand is LR; Kd1=151nM(first binding site)
3q72  1.66  2011  Kd=1574nM     // 3q72.pdf (GNP)
3q7p  2.50  2011  Kd=1574nM     // 3q72.pdf (GNP) redundant to 3q7q
3odi  2.20  2011  Kd=15nM       // 3odi.pdf (11-mer) Voclosporin, E-ISA247, Kd=15+/-4nM
3nfk  1.43  2011  Kd=160uM      // 3nfk.pdf (13-mer) Glycoprotein G, Cyto13-att, PTPN4 PDZ: Fragment: PDZ domain (UNP residues 499-604); ligand: Fragment: UNP residues 512-524
3ryj  1.39  2011  Kd=16nM       // 3ryj.pdf (RYJ)
3o2m  2.70  2011  Kd=16uM       // 3o2m.pdf (46A) Fragment: unp residues 1-364; Mutation: T183E, Y185E; The unactuvated protein
3stj  2.60  2011  Kd=16uM       // 3stj.pdf (7-mer) ligand is PDZ1 peptide
3twv  2.30  2011  Kd=17.2uM     // 3twr.pdf (16-mer) ligand is 16-mer human NUMA1 peptide, chimeric, Kd=17.2+/-3.2uM
2y9g  1.67  2011  Kd=170uM      // 2y9g.pdf (LAT) ([LSL150:(lactose)beta, gamma] binary lactose complex, either LAT or LBT
3ard  3.01  2011  Kd=175nM      // 3arb.pdf (3GH) ternary complexes; another protein CD1d containing
3rm9  2.10  2011  Kd=17uM       // 3rm4.pdf (613)
3rqe  2.80  2011  Kd=17uM       // 3rqe.pdf (14-mer) ligand is Paxillin LD1 peptide; Kd=17+/-3uM
3rl7  2.30  2011  Kd=18.2uM     // 3rl7.pdf (11-mer) ligand is 11-mer peptide from Adenomatous polyposis coli protein; Kd=18.2+/-7.6uM
3pdh  1.80  2011  Kd=183nM      // 3pdh.pdf (18-mer) Cellular tumor antigen p53 18-residue peptide, propionylated p53 18-residue peptide, Temperature at 25 degree, Kd=183+/-17 nM
3puk  3.05  2011  Kd=18uM       // 3puj.pdf (10-mer) Syntaxin-4 N-terminal peptide, Fragment: UNP residues 1-10; Kd=18+/-7 uM
3qs5  2.60  2011  Kd=19.6uM     // 3qs4.pdf (TRP) Kd=19.6+/-2.0uM
3p7i  1.71  2011  Kd=19.9nM     // 3p7i.pdf (P7I)
3q6z  2.23  2011  Kd=192uM      // 3q6z.pdf (APR) Kd=192+/-7uM
2l84   NMR  2011  Kd=19nM       // 2l84.pdf (J28) Fragment: Bromo domain residues 1081-1197;
3uvl  2.20  2011  Kd=2.03uM     // 3uvk.pdf (11-mer) ligand is 11-mer WDR5-interacting motif of MLL3, Kd=2.03+/-0.11uM
2lko   NMR  2011  Kd=2.12uM     // 2lko.pdf (4IP) Kd=2.12+/-0.19uM
3tdu  1.50  2011  Kd=2.15uM     // 3tdu.pdf (16-mer) ligand is NEDD8-conjugating enzyme Ubc12
3sou  1.80  2011  Kd=2.1uM      // 3sou.pdf (9-mer) ligand is H3(1-9) peptide
3t6r  1.95  2011  Kd=2.20uM     // 3t6r.pdf (7-mer) unmodified Histone H3.1 tail N-terminal peptide
3td4  1.79  2011  Kd=2.2uM      // 3td4.pdf (API)
3s71  1.25  2011  Kd=2.3nM      // 3s71.pdf (EVD)
2xzc  1.36  2011  Kd=2.3uM      // 2xza.pdf (XOP) Kd3=6.2+/-0.4uM
3arv  1.50  2011  Kd=2.3uM      // 3arp.pdf (SAU) ligand is Sanguinarine(SAN); IC50=2.3+/-0.3uM(pNP assay)
3s8l  1.71  2011  Kd=2.3uM      // 3ov1.pdf (5-mer)
3ldp  2.20  2011  Kd=2.41uM     // 3ldl.pdf (3P1)
3u5j  1.60  2011  Kd=2.46uM     // 3u5j.pdf (08H)
3ryz  1.37  2011  Kd=2.4nM      // 3ryj.pdf (RYZ)
3twu  1.80  2011  Kd=2.4uM      // 3twr.pdf (16-mer) ligand is 16-mer human MCL1 peptide, Kd=2.4+/-0.2uM;
3qps  2.35  2011  Kd=2.5uM      // 3qps.pdf (CHD)
3t8s  3.77  2011  Kd=2.82nM     // 3t8s.pdf (I3P) ligand is compound 1 (IP3), full-length Kd=12.5nM. similar to code 3uj0
3ovn  1.95  2011  Kd=2.8mM      // 3ao1.pdf (MPV)
2y7i  1.90  2011  Kd=2.9uM      // 2y7i.pdf (ARG)
3ujd  1.50  2011  Kd=20.2uM     // 3uj6.pdf (PC) complex between PfPMT-Y19F and pCho; Kd=20.2+/-6.8uM
2xn5  1.70  2011  Kd=205nM      // 2xn3.pdf (FUN)
3o75  2.30  2011  Kd=209nM      // 3o75.pdf (F1X) Kd=209+/-20nM
2y54  3.65  2011  Kd=20uM       // 2y54.pdf (V63) pKd=4.7+/-0.1; Fragment: RESIDUES 20-236; pKd=5.9+/-0.2 by ITC; pKi=5.3+/-0.1
3pab  2.20  2011  Kd=20uM       // 3p9l.pdf (8-mer) Ovalbumin epitope, EIINFEKL, (S1E), Kd=20-22uM; Fragment: Extracellular domain
3tg5  2.30  2011  Kd=20uM       // 3tg4.pdf (11-mer) ligand is peptide from p53(365-375); incomplete liagnd
3qs4  2.63  2011  Kd=21.0uM     // 3qs4.pdf (TRP) Kd=21.0+/-2.7uM
3tiw  1.80  2011  Kd=21.3nM     // 3tiw.pdf (19-mer) Kd=21.3+/-0.3 nM
3oob  1.89  2011  Kd=21.6uM     // 3oob.pdf (KDH) Mutation: R14A;
2x6x  1.48  2011  Kd=210uM      // 2x6w.pdf (6-mer) ligand is hexasaccharide; Kd=210+/-7uM
3iny  2.75  2011  Kd=217uM      // 3iny.pdf (7DG) Kd=217 +/-14 uM; IC50=251+/-2 uM(data in other paper)
3q7q  2.30  2011  Kd=2256nM     // 3q72.pdf (GNP)
2ydf  2.75  2011  Kd=22nM       // 2ydf.pdf (IO3) binding assay method by biosensor
2l3r   NMR  2011  Kd=22uM       // 2l3r.pdf (11-mer) ligand is H3K4me0/H3K9me3 peptide; Kd=22+/-6uM
3pkn  1.80  2011  Kd=22uM       // 3pkn.pdf (14-mer) La-related protein 4 LARP4: PABP-binding region (UNP residues 13-26); PABP MLLE domain (UNP residues 544-626) with PAM2 motif of LARP4(13-26)
3uj9  1.24  2011  Kd=23.4uM     // 3uj6.pdf (PC) complex between PfPMT and pCho; Kd=23.4+/-1.6uM
3arb  2.70  2011  Kd=234nM      // 3arb.pdf (FEE) ternary complexes; another protein CD1d containing
3rqg  2.50  2011  Kd=23uM       // 3rqe.pdf (13-mer) ligand is Paxillin LD4 peptide; Kd=23+/-6uM
2yga  2.37  2011  Kd=24.5uM     // 2yga.pdf (GDM)
2l98   NMR  2011  Kd=243uM      // 2l98.pdf (STL) Fragment: EF-hand domains 3 and 4, residues 91-161  ; binding assay method by NMR
3sk2  1.01  2011  Kd=244uM      // 3sk2.pdf (GRI)
3ubx  3.10  2011  Kd=25.2nM     // 3ubx.pdf (09N) ligand is C20:2;Kd=25.2+/-0.9nM
3t2c  1.30  2011  Kd=25uM       // 3t2c.pdf (13P) calorimetric titration; Mg2+ containing; the enzyme can bind its first substrate, DHAP
3sl1  1.90  2011  Kd=260uM      // 3gmz.pdf (FB6) Ki=260+/-20uM; Mn binding; Fragment: UNP residues 22-411;
3p3s  1.60  2011  Kd=26nM       // 3p3r.pdf (3M2) ligand is compound 14
2x6y  1.35  2011  Kd=26uM       // 2x6w.pdf (4-mer) ligand is hexasaccharide,kd=26+/-3uM
3ujc  1.19  2011  Kd=26uM       // 3uj6.pdf (PC) ligand is H132A-pCho; Kd=26.0+/-11.3uM
3ocp  2.49  2011  Kd=27nM       // 3ocp.pdf (CMP)
3q6w  1.75  2011  Kd=27nM       // 3q6w.pdf (Q6W) lignad is compound 1; Kd=27+/-7nM
3rjw  2.56  2011  Kd=27nM       // 3rjw.pdf (CIQ) ligand is UNC0638(3)
3mxc  2.00  2011  Kd=286.1nM    // 3mxc.pdf (9-mer) acid peptide, Kd=286.1+/-11.9nM
2xj1  2.13  2011  Kd=28nM       // 2xix.pdf (XJ1)
3rz0  1.80  2011  Kd=28nM       // 3ryj.pdf (RZ0)
3aqa  2.30  2011  Kd=28uM       // 3aqa.pdf (BYH) compound BIC1
3as0  2.00  2011  Kd=28uM       // 3arp.pdf (SAU) ligand is Sanguinarine, SAN
3ppq  1.91  2011  Kd=28uM       // 3ppo.pdf (CHT)
3s73  1.75  2011  Kd=2nM        // 3s71.pdf (EVF)
3pxe  2.85  2011  Kd=2uM        // 3pxe.pdf (10-mer) Kd=2+/-0.1uM; BRCA1:Fragment: BRCT domain, UNP residues 1646-1859; Mutation: E1836K;
3tws  1.70  2011  Kd=3.0uM      // 3twr.pdf (16-mer) ligand is 16-mer human TERF1 peptide, Kd=3.0+/-0.5uM
2y58  3.25  2011  Kd=3.16uM     // 2y54.pdf (V38) Fragment: RESIDUES 20-236; pKd=5.5+/-0.1 by SPR; pKd=6.0+/-0.4 by ITC; pKi=6+/-0.1
2yix  2.30  2011  Kd=3.3nM      // 2yis.pdf (YIX)
2y7p  1.85  2011  Kd=3.4uM      // 2y7k.pdf (SAL) DNTR inducer binding domain in complex with salicylate
2y4k  2.45  2011  Kd=3.5uM      // 2y4j.pdf (GDP) Mg2+ containing
3p2h  2.00  2011  Kd=3.6uM      // 3p2h.pdf (NOO) Kd=3.6-4.1 uM; Mutation: F42M, I149M, L152M, deletion H91, deletion P92;
3u10  2.30  2011  Kd=3.6uM      // 3u0z.pdf (CMP) complex between cAMP and MBP-HCN2; Kd by ITC
3qlb  3.26  2011  Kd=3.7nM      // 3qlb.pdf (2-mer) ligand is CIT-EFE; Kd=3.7+/-2.1nM
3qlc  2.50  2011  Kd=3.7uM      // 3qlc.pdf (15-mer)
3s7f  2.85  2011  Kd=3.7uM      // 3s7b.pdf (13-mer) ligand is p53 substrate peptide
3tjh  2.12  2011  Kd=3.9uM      // 3tf7.pdf (9-mer) ligand is in 9-mer p3A1-H2-Ld peptide format
3r6u  1.61  2011  Kd=30.5uM     // 3r6u.pdf (CHT)
3myq  1.35  2011  Kd=30nM       // 3m96.pdf (E27)
3n7h  1.60  2011  Kd=31.3uM     // 3n7h.pdf (DE3)
3puj  3.31  2011  Kd=31uM       // 3puj.pdf (10-mer) Syntaxin-4 N-terminal peptide, Fragment: UNP residues 1-10; Kd=31+/-8 uM
3qel  2.60  2011  Kd=320nM      // 3qel.pdf (QEL) ligand is ifenprodil
3m6r  2.40  2011  Kd=32nM       // 3m6r.pdf (BB2)
3ta0  2.30  2011  Kd=338uM      // 3ta0.pdf (ATP) Kd measured with Mg2+
3s78  1.98  2011  Kd=340nM      // 3s71.pdf (EVJ)
3skk  1.70  2011  Kd=34uM       // 3gmz.pdf (4U7) Kd=34+/-2uM; Mn binding;
3atp  2.50  2011  Kd=35.6uM     // 3atp.pdf (SER)
3pqz  2.41  2011  Kd=35uM       // 3pqz.pdf (11-mer) cyclic peptide, G7-18NATE, Grb7: Fragment: SH2 domain
3tsz  2.50  2011  Kd=35uM       // 3tsz.pdf (12-mer) ligans is JAM-A_12 peptide
3tvw  2.80  2011  Kd=37.0uM     // 3tv5.pdf (07H) ligand is compound 4; Kd=37.0+/-6.0 uM
3axz  2.25  2011  Kd=372uM      // 3axz.pdf (ADN)
3art  2.23  2011  Kd=37uM       // 3arp.pdf (DEQ) ligand is Dequalinlium, DEQ
3pxf  1.80  2011  Kd=37uM       // 3pxf.pdf (2AN)
3pxq  1.90  2011  Kd=37uM       // 3pxf.pdf (2AN) redundant to 3pxf
3rtm  2.76  2011  Kd=38.4uM     // 3rsv.pdf (RTM) ligand is compound 40
3rsx  2.48  2011  Kd=38.8uM     // 3rsv.pdf (RSV)
3mxy  2.30  2011  Kd=384.8nM    // 3mxc.pdf (9-mer) aicd peptide E683V variant, Kd=384.8+/-37.7nM
3ryy  1.16  2011  Kd=38nM       // 3ryj.pdf (RYY)
3rqf  2.70  2011  Kd=39uM       // 3rqe.pdf (13-mer) ligand is Paxillin LD2 peptide; Kd=39+/-2uM
3n23  4.60  2011  Kd=3nM        // 3n23.pdf (OBN) Kd=3nM(no KCl, also in crystral); 130 nM(10mM KCl), 420nM(50 mM KCl)
2l8j   NMR  2011  Kd=3uM        // 2l8j.pdf (18-mer)
3arr  1.65  2011  Kd=4.0uM      // 3arp.pdf (PNX) ligand is pentoxifyllin(PEN); IC50=3.5+/-0.5uM(pNP assay)
3qkd  2.02  2011  Kd=4.2nM      // 3qkd.pdf (HI0)
3sw9  3.05  2011  Kd=4.2uM      // 3svm.pdf (12-mer) ligand is 12-mer peptide mDnmt3aK44me0-Sinefungin, Kd=4.2+/-0.3uM
3tww  2.00  2011  Kd=4.2uM      // 3twr.pdf (16-mer) ligand is 16-mer human LNPEP peptide, chimeric, Kd=4.2+/-0.3uM
3zyb  2.29  2011  Kd=4.2uM      // 3zyb.pdf (4-mer) ligand GalBG0 (GalB-KPL-NH2); Kd=51.5+/-6.7uM
3q6k  2.52  2011  Kd=4.3nM      // 3q6k.pdf (SRO) Kd=4.3+/-1.1nM
3oj8  1.90  2011  Kd=4.4nM      // 3oj8.pdf (OJ8) Fragment: UNP residues 30-579; Mutation: L192F, F194Y, A377T, S435N, I491V, V495M;
3ay9  1.75  2011  Kd=4.55nM     // 3atu.pdf (ADP) binding data measured with Mg2+
3m6p  2.00  2011  Kd=4.5nM      // 3m6p.pdf (BB2)
3arx  1.16  2011  Kd=4.7uM      // 3arp.pdf (POY) ligand is propentofylline(PRO); Kd=4.7+/-0.5uM(Fluorescence)
3tv5  2.80  2011  Kd=4.8uM      // 3tv5.pdf (RCP) ligand is compound 1; Kd=4.8+/-2.0uM
3s72  1.60  2011  Kd=400nM      // 3s71.pdf (EVE)
3nfl  1.91  2011  Kd=42uM       // 3nfk.pdf (16-mer) Glutamate [NMDA] receptor subunit epsilon-1, GluN2A16 PTPN4 PDZ: Fragment: PDZ domain (UNP residues 499-604); ligand: Fragment: UNP residues 1449-1464;
3n35  2.00  2011  Kd=431uM      // 3n35.pdf (A2G)
3zxe  1.67  2011  Kd=450uM      // 3zxe.pdf (PGZ) ligand is compound 6
3lrh  2.60  2011  Kd=45nM       // 3lrh.pdf (14-mer) huntingtin, alpha-Htt-VL: Fragment: anti-huntingtin VL domain; Mutation: G112A; Htt:Fragment: huntingtin peptide;
2ydw  1.90  2011  Kd=46.0nM     // 2ydw.pdf (WSH)
3ry8  1.40  2011  Kd=460uM      // 3ry8.pdf (FLC) Kd=460+/-80uM
3atv  1.58  2011  Kd=4610nM     // 3atu.pdf (ADP) binding data measured without Mg2+
3aya  2.00  2011  Kd=47uM       // 3aya.pdf (3-mer) THR-A2G-GAL; Fragment: C-TERMINAL DOMAIN, UNP residues 117-250;
3q5u  2.50  2011  Kd=48.7uM     // 3q5u.pdf (13-mer) ligand is Phospholipid scramblase 4 peptide; Kd=48.7+/-6.5uM; incomplete ligand
3m6q  2.40  2011  Kd=48nM       // 3m6q.pdf (BB2)
3tpu  3.10  2011  Kd=48uM       // 3tf7.pdf (9-mer) ligand is in 9-mer p5E8-H2-Ld peptide format
3qt7  2.20  2011  Kd=49nM       // 3qt6.pdf (FM0) ligand is FMVAPP; Ki=49+/-5nM
3qxv  2.50  2011  Kd=4nM        // 3qxt.pdf (MTX)
3s74  1.40  2011  Kd=4nM        // 3s71.pdf (03T)
3pma  2.20  2011  Kd=4uM        // 3pma.pdf (SCR) Kd=4+/-0.4uM;
3atu  1.65  2011  Kd=5.00nM     // 3atu.pdf (ADP) binding data measured with ADP, Mg2+, Na+
3pcu  2.00  2011  Kd=5.08uM     // 3pcu.pdf (LX8) Kd(Rut binding to RXR-alpha-LBD), X-ray(RXR-alpha-LBD complexed with Rut and SRC1 peptide)
3r24  2.00  2011  Kd=5.59uM     // 3r24.pdf (SAM)
3ao1  1.90  2011  Kd=5.5mM      // 3ao1.pdf (BZX)
3twx  1.80  2011  Kd=5.5uM      // 3twr.pdf (16-mer) ligand is 16-mer human FNBP1 peptide, Kd=5.5+/-1.3uM; chimeric peptide
3tdj  1.95  2011  Kd=5.6uM      // 3tdj.pdf (3TJ) ligand is BPAM-97; Kd=5.6+/-0.9uM
3ueu  2.10  2011  Kd=5.81uM     // 3ueu.pdf (DAO) complex between LGB and DAO; Kd=5.81uM(ITC); Kd=0.71uM(fluorescence); Kd=24.4uM(ESI-MS); Kd=24.4uM(EPA)
3qxh  1.36  2011  Kd=5.8uM      // 3mle.pdf (ADP) Mg-containing
3ao5  1.80  2011  Kd=5.9mM      // 3ao1.pdf (BBY)
3zyh  1.50  2011  Kd=51.5uM     // 3zyh.pdf (G0S) ligand is GALBG0; Kd=51.5+/-6.7uM
2yel  1.65  2011  Kd=52.5nM     // 2yel.pdf (WSH) Kd for BRD4-BD1,2
3arg  3.00  2011  Kd=55nM       // 3arb.pdf (DB6) ternary complexes; another protein CD1d containing
3q4l  1.95  2011  Kd=55nM       // 3q4j.pdf (6-mer) ligand is pentapeptide P14;Kd=55nM(N=0.90)
3tdh  2.30  2011  Kd=55uM       // 3t4n.pdf (AMP)
3p3r  1.25  2011  Kd=56.05nM    // 3p3r.pdf (3M1) ligand is Ro41-0960; Kd=56.05+/-4.14nM; IC50=0.755uM(in supp info)
3ta1  1.90  2011  Kd=568uM      // 3ta1.pdf (ADP) Kd measured with Mg2+
3p3t  1.45  2011  Kd=57.91nM    // 3p3r.pdf (3M3) ligand is compound 7; Kd=57.91+/-13.2nM; IC50=0.296uM(in supp info)
3ayc  1.80  2011  Kd=57uM       // 3aya.pdf (5-mer) Fragment: C-TERMINAL DOMAIN, UNP residues 117-250;
3zqe  2.19  2011  Kd=59.0uM     // 3zqe.pdf (DXC)
3p9l  2.00  2011  Kd=5uM        // 3p9l.pdf (8-mer)
3ppo  2.70  2011  Kd=5uM        // 3ppo.pdf (DCK)
3ri1  2.10  2011  Kd=5uM        // 3rhx.pdf (3RH) ligand is ARQ 069; Kd=5+/-1.4uM
3q71  2.20  2011  Kd=6.0uM      // 3q6z.pdf (AR6) Kd=6.0+/-0.1uM
3rth  2.70  2011  Kd=6.1uM      // 3rsv.pdf (RTH) ligand is compound 39
3ov1  1.60  2011  Kd=6.25uM     // 3ov1.pdf (5-mer)
3t7g  2.08  2011  Kd=6.32uM     // 3t7g.pdf (17-mer) ligand is Autophagy-related protein 3
3twr  1.55  2011  Kd=6.4uM      // 3twr.pdf (16-mer) ligand is 16-mer peptide from human SH3 domain-binding protein 2, Kd=6.4+/-0.6uM
3rz8  1.70  2011  Kd=6.7nM      // 3ryj.pdf (RZ8)
3tc5  1.40  2011  Kd=6.8uM      // 3tc5.pdf (3T5)
3b27  1.50  2011  Kd=6.9uM      // 3b24.pdf (B2T)
3aru  1.90  2011  Kd=600uM      // 3arp.pdf (PNX) ligand is pentoxifyllin(PEN)
3i8t  2.10  2011  Kd=600uM      // 3i8t.pdf (LBT) Kd1=600+/-70uM, Kd2=28+/-10mM; Fragment: Galectin 1 domain
3m96  1.40  2011  Kd=60nM       // 3m96.pdf (E38)
3qem  3.00  2011  Kd=60nM       // 3qel.pdf (QEM) ligand is Ro
2yek  1.98  2011  Kd=61.3nM     // 2yek.pdf (EAM) ligand is compound I-BET
3q4j  2.30  2011  Kd=613nM      // 3q4j.pdf (6-mer) ligand is pentapeptide P6;Kd=613nM(N=1.14)
3are  2.80  2011  Kd=617nM      // 3arb.pdf (4GH) ternary complexes; another protein CD1d containing
3odl  2.31  2011  Kd=61nM       // 3odi.pdf (11-mer) Kd=61+/-9nM,
3s77  1.86  2011  Kd=61nM       // 3s71.pdf (EVI)
3arf  2.90  2011  Kd=64nM       // 3arb.pdf (DB3) ternary complexes; another protein CD1d containing
3zqi  1.50  2011  Kd=64nM       // 3zqf.pdf (16-mer) ligand is inducer peptide-TIP2, Kd=64+/-3nM
2lh8   NMR  2011  Kd=65.36uM    // 2lh8.pdf (VIB) Fragment: UNP residues 125-228;
3ayd  1.90  2011  Kd=65uM       // 3aya.pdf (3-mer) Fragment: C-TERMINAL DOMAIN, UNP residues 117-250;
2xj2  2.20  2011  Kd=66nM       // 2xix.pdf (985)
3qfd  1.68  2011  Kd=68uM       // 3qfd.pdf (9-mer) ligand is Mart-1 peptide(27-35); Kd=68+/-4uM
3qzv  2.00  2011  Kd=69uM       // 3qzs.pdf (11-mer) ligand is histone H4K12ac; Kd69+/-1uM
3ppp  2.40  2011  Kd=6uM        // 3ppo.pdf (BET)
3qxt  1.70  2011  Kd=6uM        // 3qxt.pdf (MTX)
2xrw  1.33  2011  Kd=7.1uM      // 2xrw.pdf (14-mer) ligand is pepNFAT4
2xs0  2.60  2011  Kd=7.1uM      // 2xrw.pdf (14-mer) ligand is pepNFAT4
2lct   NMR  2011  Kd=7.27uM     // 2lct.pdf (13-mer) ligand is Syk-derived doubly phosphorylated peptide(pYpY); Kd=7.27+/-0.04uM
3tao  1.45  2011  Kd=7.28uM     // 3tao.pdf (PGH)
3ryx  1.60  2011  Kd=7.3nM      // 3ryj.pdf (RYX)
2yaz  2.40  2011  Kd=7.3uM      // 2yay.pdf (UMP) ligand is DUMP; Mg-containing
3sow  1.95  2011  Kd=7.3uM      // 3sou.pdf (9-mer) ligand is H3(1-9)K4me3  peptide
2yk1  1.85  2011  Kd=7.4nM      // 2yk1.pdf (NCT)
3ozj  2.10  2011  Kd=7.7uM      // 3ozj.pdf (BGV)
3ujb  1.52  2011  Kd=7.9uM      // 3uj6.pdf (SAH) complex between PfPMT and AdoCys; Kd=7.9+/-0.8uM
3zvy  1.95  2011  Kd=7.9uM      // 3zvy.pdf (8-mer) ligand is 8-mer H3 peptide, Kd=7.9+/-0.3uM
3q8h  1.75  2011  Kd=70uM       // 3q8h.pdf (AO9) ligand is compound 5
3t4n  2.30  2011  Kd=72uM       // 3t4n.pdf (ADP)
3mam  1.80  2011  Kd=76uM       // 3mam.pdf (BET)
3o56  2.42  2011  Kd=794pM      // 3o56.pdf (ZG1)
2ygf  2.00  2011  Kd=8.06uM     // 2yga.pdf (GDM)
3o4l  2.54  2011  Kd=8.1uM      // 3o4l.pdf (9-mer) BSLF2/BMLF1 protein (Fragment: residues 286-294)
3qyy  1.90  2011  Kd=8.26uM     // 3qyy.pdf (C2E)
3m94  2.05  2011  Kd=8.4uM      // 3m93.pdf (M7M)
3ao4  1.95  2011  Kd=8.5mM      // 3ao1.pdf (833)
2xm1  2.00  2011  Kd=8.5uM      // 2xm1.pdf (LTM)
2yge  1.96  2011  Kd=8.62uM     // 2yga.pdf (GDM)
3sxu  1.85  2011  Kd=8.9uM      // 3sxu.pdf (5-mer) 5-mer SSB peptide; Kd=8.9+/-0.7uM
2lk1   NMR  2011  Kd=82uM       // 2lk1.pdf (AQN) Fragment: RanBP2-type zinc finger residues 181-210; Kd=82+/-5uM
3rlp  1.70  2011  Kd=84nM       // 3rlp.pdf (3RP)
3p0g  3.50  2011  Kd=84pM       // 3p0g.pdf (P0G)
3r42  1.87  2011  Kd=84uM       // 3r42.pdf (9-mer) ligand is a 9-mer vps27 PSDP1 peptide; Kd=84+/-5uM
3ryv  1.20  2011  Kd=86nM       // 3ryj.pdf (RYV)
3q4k  2.60  2011  Kd=89nM       // 3q4j.pdf (6-mer) ligand is pentapeptide P12;Kd=89nM(N=1.02)
2xxt  1.90  2011  Kd=9.0nM      // 2xxt.pdf (KAI)
3aje  1.80  2011  Kd=9.3uM      // 3aje.pdf (THR)  Kd=9.3+/-0.3 uM;
3smq  2.00  2011  Kd=9.5uM      // 3smq.pdf (TDU) ligand is compound 1;Kd=9.5+/-0.5uM
3tfk  2.75  2011  Kd=9.7uM      // 3tf7.pdf (9-mer) ligand is in 9-mer p4B10-H2-Ld peptide format
3s76  1.60  2011  Kd=9000nM     // 3s71.pdf (EVH)
3s0d  1.24  2011  Kd=90nM       // 3s0b.pdf (CTV)
3ay0  3.05  2011  Kd=910uM      // 3axz.pdf (ADN) Kd=910+/-58uM
3po1  1.65  2011  Kd=95uM       // 3po1.pdf (MKY) ligand is compound 2; Kd=95+/-4uM (by spectrophotometric assay)
3s3k  3.20  2011  Kd=97.69uM    // 3s3e.pdf (CSN) ligand is PNC; Kd=97.69+/-5.58uM
3qzt  1.50  2011  Kd=99uM       // 3qzs.pdf (10-mer) ligand is histone H4K16ac; Kd=99+/-7uM; Form 2
3t2t  1.90  2011  Kd>4mM        // 3t1l.pdf (MQT) ligand is compound 1; Kd=0.55+/-0.15mM
2las   NMR  2011  Kd~1.8uM      // 2las.pdf (13-mer) ligand is M-IR2_peptide
3tf7  2.75  2011  Kd~300uM      // 3tf7.pdf (9-mer) ligand is in 9-mer QL9-H2-Ld peptide format
2xae  2.60  2011  Ki<50.0nM     // 2x2r.pdf (2XA) IC50=53.3+/-1.5 nM; Fragment: MOTOR DOMAIN, RESIDUES 1-368;
3zxz  1.80  2011  Ki=0.004uM    // 3zxz.pdf (KRW) ligand is compound 2
2xpk  2.40  2011  Ki=0.005nM    // 2xpk.pdf (Z0M)
3rti  2.80  2011  Ki=0.043uM    // 1fmp.pdf (FMP)
3u8n  2.35  2011  Ki=0.067nM    // 3u8j.pdf (09S) lignad is compound 5; Ki=0.067+/-0.026nM
3pbb  1.95  2011  Ki=0.095uM    // 3pb7.pdf (PBD) ligand is PBD150; Ki=0.095+/-0.003uM; Zn-containing
2xwd  2.66  2011  Ki=0.11uM     // 2xwd.pdf (LGS) Ki1=0.11+/-0.02uM at pH7.3; Ki2=8.7+/-0.3uM at pH5.5
3r4n  2.00  2011  Ki=0.13uM     // 3r4m.pdf (FU5)
3mv0  2.20  2011  Ki=0.14mM     // 3mv0.pdf (149)
3n76  1.90  2011  Ki=0.14uM     // 3n59.pdf (CA2)
3pe2  1.90  2011  Ki=0.175nM    // 3pe1.pdf (E1B)
3pe1  1.60  2011  Ki=0.223nM    // 3pe1.pdf (3NG)
3pwd  2.20  2011  Ki=0.22uM     // 3pwd.pdf (CZ0)
3ozp  2.00  2011  Ki=0.24uM     // 3ozp.pdf (OAN)
3tu1  1.60  2011  Ki=0.25uM     // 3tu1.pdf (07G)
3pb9  1.12  2011  Ki=0.262uM    // 3pb7.pdf (1BN) ligand is 1-benzylimidazole; Ki=0.262+/-0.062uM; Zn-containing
3opr  1.65  2011  Ki=0.26uM     // 3oph.pdf (SA2) Ki=0.26+/-0.01 uM; Mutation: R164H
3qox  2.30  2011  Ki=0.27uM     // 3qow.pdf (SAH)
3ama  1.75  2011  Ki=0.297uM    // 3ama.pdf (SKE)
3ppm  1.78  2011  Ki=0.29nM     // 3ppm.pdf (JG1)
3pr0  2.20  2011  Ki=0.29nM     // 3ppm.pdf (JG2) Covalently bound mode; Fragment: deltaTM-FAAH, UNP residues 30-579; Mutation: L192F, F194Y, A377T, S435N, I491V, V495M
3sr4  2.50  2011  Ki=0.29uM     // 3sr4.pdf (TT8)
3sm2  1.75  2011  Ki=0.2nM      // 3slz.pdf (478)
3o9f  1.70  2011  Ki=0.2pM      // 3o99.pdf (K2D) ligand is compound 11b;Ki=0.2+/-2pM
3muz  1.90  2011  Ki=0.35mM     // 3muz.pdf (IPT)
2y59  2.50  2011  Ki=0.36uM     // 2y4a.pdf (ZA3) Ki=0.36+/-0.06uM; covalent complex, B-containing
2xog  1.72  2011  Ki=0.37mM     // 2xog.pdf (SFB)
2ybu  2.25  2011  Ki=0.42uM     // 2ybt.pdf (CX9)
2xoi  1.72  2011  Ki=0.46mM     // 2xog.pdf (SFB) redundant to 2xog
3o64  1.88  2011  Ki=0.4nM      // 3o64.pdf (786)
3mg4  3.11  2011  Ki=0.50nM     // 3mg0.pdf (LXT) multi component of protein; Ki=0.50+/-0.12nM for 20S beta5 site(substrate Suc-LLVY-AMC)
3p8n  1.90  2011  Ki=0.53nM     // 3p8n.pdf (L4T) ligand is BI201335; Ki=0.53+/-0.05nM
3opp  1.80  2011  Ki=0.53uM     // 3oph.pdf (SA2) Ki=0.53+/-0.02uM; Mutation: R164S
3nzk  1.80  2011  Ki=0.54nM     // 3nzk.pdf (C90)
3mg0  2.68  2011  Ki=0.56nM     // 3mg0.pdf (BO2) B containing; covalent complex; multi component of protein; Ki=0.56+/-0.072nM; substrate Suc-LLVY-AMC, 20S beta5 site
3rf4  1.80  2011  Ki=0.56uM     // 3rf4.pdf (FUN)
3o9g  1.65  2011  Ki=0.5pM      // 3o99.pdf (F53) ligand is compound 11c;Ki=0.5+/-17pM
3o9b  1.50  2011  Ki=0.5pM      // 3o99.pdf (K2A) ligand is compound 10c;Ki=0.5+/-9pM
2xy9  1.97  2011  Ki=0.65nM     // 2xy9.pdf (3ES)
3ozg  1.99  2011  Ki=0.65nM     // 3ozf.pdf (SSI) ligand is compound 3; Ki=0.65+/-0.04nM by spectrophotometric assay
3amb  2.25  2011  Ki=0.66uM     // 3ama.pdf (VX6)
3rwp  1.92  2011  Ki=0.6nM      // 3rwp.pdf (ABQ)
3o0g  1.95  2011  Ki=0.6uM      // 3o0g.pdf (3O0)
2ya7  1.89  2011  Ki=0.72mM     // 2ya5.pdf (ZMR)
3qfy  2.30  2011  Ki=0.75uM     // 3qfy.pdf (IFM-SO4)
3aox  1.75  2011  Ki=0.83nM     // 3aox.pdf (EMH)
3o9h  1.70  2011  Ki=0.8pM      // 3o99.pdf (K2E) ligand is compound 11d;Ki=0.8+/-2pM
2xwe  2.31  2011  Ki=0.95uM     // 2xwd.pdf (AMF)
3zq9  1.86  2011  Ki=0.95uM     // 2yjq.pdf (NOY-BGC) ligand is Glc-noeuromycin
3o9c  1.85  2011  Ki=0.9pM      // 3o99.pdf (K20) ligand is compound 10d;Ki=0.9+/-4pM
3r4m  1.70  2011  Ki=1.2uM      // 3r4m.pdf (WOE)
2y7x  1.90  2011  Ki=1.3nM      // 2y7x.pdf (MZA)
3u8m  2.70  2011  Ki=1.3nM      // 3u8j.pdf (09R) lignad is compound 4; Ki=1.3+/-0.9nM
3zze  1.87  2011  Ki=1.3nM      // 3zxz.pdf (6XP) ligand is compound 10
3qgw  2.10  2011  Ki=1.3uM      // 3qgw.pdf (L7A)
3o9i  1.45  2011  Ki=1.5pM      // 3o99.pdf (A61) ligand is compound 11e; Ki=1.5+/-1pM
3oaf  1.70  2011  Ki=1.6nM      // 3oaf.pdf (OAG) ligand is OAAG324; Ki=1.6+/-0.06nM
3mbz  2.60  2011  Ki=1.6uM      // 3mbz.pdf (MXC) Fragment: UNP residues 32-275; Ki=1.6 +/- 0.3uM(compound 3); ligand not complete in X-ray(hydrolysis product)
2ya8  1.75  2011  Ki=1.77uM     // 2ya5.pdf (G39)
3pb7  1.40  2011  Ki=1.817uM    // 3pb7.pdf (PBD) ligand is PBD150; Ki=1.817+/-0.154uM; Zn-containing
3m3z  2.10  2011  Ki=1.85uM     // 3ldl.pdf (3F5)
3p8o  2.30  2011  Ki=1.89nM     // 3p8n.pdf (L5T) ligand is analog 1; Ki=1.89+/-0.06nM
3oy0  1.60  2011  Ki=10.1nM     // 3oy0.pdf (OY0)
3oyq  1.47  2011  Ki=10.3nM     // 3oy0.pdf (OYQ)
3t82  2.00  2011  Ki=101nM      // 3t82.pdf (SG4)
3slz  1.40  2011  Ki=102nM      // 3slz.pdf (3TL)
3t83  1.80  2011  Ki=105nM      // 3t82.pdf (MG5&SG5)
3t84  2.00  2011  Ki=106nM      // 3t82.pdf (SG6)
3sio  2.32  2011  Ki=10nM       // 3sio.pdf (MLK)
3qs1  3.10  2011  Ki=11.0nM     // 3qs1.pdf (006)
3t85  2.40  2011  Ki=11.3nM     // 3t82.pdf (SG7)
3pn1  2.00  2011  Ki=110nM      // 3pn1.pdf (IVH)
3svj  1.55  2011  Ki=117nM      // 3str.pdf (4LI)
2l8r   NMR  2011  Ki=119.3uM    // 2l8r.pdf (APR) Ki=119.3+/4.5uM
3r4p  1.70  2011  Ki=11nM       // 3r4m.pdf (FU7)
3n87  2.40  2011  Ki=11uM       // 3n59.pdf (N87)
3old  2.00  2011  Ki=1254.9nM   // 3old.pdf (6-mer)
2xpc  1.49  2011  Ki=125uM      // 2xpc.pdf (051)
3p3j  1.60  2011  Ki=12nM       // 3p3h.pdf (498) Ru containing, Zn binding
2ydv  2.60  2011  Ki=13.8nM     // 2ydo.pdf (NEC) pKi=7.86+/-0.06; Fragment: RESIDUES 1-317; Mutation: YES;
3oe5  1.52  2011  Ki=132nM      // 3nw9.pdf (611)
2y55  2.60  2011  Ki=134uM      // 2y4a.pdf (FP5) Ki=134+/-16uM; covalent complex, B-containing
3mg6  2.60  2011  Ki=13nM       // 3mg0.pdf (LZT) multi component!!compound 6; Ki=13+/-1.4nM for 20S beta5 site(substrate Suc-LLVY-AMC)
3olg  2.30  2011  Ki=14.3nM     // 3old.pdf (7-mer) HSD-G6D-GLC-HSD-G6D-GLC-BGC; Ki=14.3+/-0.2 nM
3ole  1.55  2011  Ki=14.7nM     // 3old.pdf (7-mer) ACI-G6D-GLC-ACI-G6D-GLC-GLC; Ki=14.7+/-1.2 nM
3pn4  1.90  2011  Ki=140nM      // 3pn3.pdf (BB2) AtPDF1B in complex with actinonin
3sm1  1.50  2011  Ki=1442nM     // 3slz.pdf (6-mer) ligand is pepstatin A;  HPLC-based assay with oligopeptide substrate
2y5g  1.29  2011  Ki=146nM      // 2y5f.pdf (FJD)
3ohi  2.30  2011  Ki=14uM       // 3ohi.pdf (HDX)
2xyd  2.15  2011  Ki=150nM      // 2xy9.pdf (3ES)
3ai8  2.11  2011  Ki=154.4uM    // 3ai8.pdf (HNQ)
3s2v  2.50  2011  Ki=157nM      // 3s2v.pdf (3HU)
3q2m  2.90  2011  Ki=159uM      // 3q2m.pdf (CKI) Ki=159+/-11 uM
3prs  1.38  2011  Ki=15nM       // 3ms3.pdf (RIT)
3n2p  1.65  2011  Ki=15nM       // 3mzc.pdf (AYX)
3o99  1.95  2011  Ki=15pM       // 3o99.pdf (K13) ligand is compound 10a; Ki=15+/-8pM
2y5h  1.33  2011  Ki=1620nM     // 2y5f.pdf (Y5H)
3qgy  2.10  2011  Ki=16nM       // 3qgw.pdf (L7O)
3o5n  1.83  2011  Ki=17.2uM     // 3o5n.pdf (BR0)
3oim  1.45  2011  Ki=180nM      // 3oim.pdf (VZ5) ligand is compound 16; Ki=180+/-10nM by membrane-inlet mass spectrometry; Zn-containing
3p3g  1.65  2011  Ki=180pM      // 3p3c.pdf (3P3)
3nb5  1.80  2011  Ki=18nM       // 3nb5.pdf (R21)
3ps6  2.60  2011  Ki=18nM       // 3pre.pdf (3PS) x-ray:PI3Kgamma; assay:PI3Kalpha
3o9d  1.85  2011  Ki=19pM       // 3o99.pdf (K19) ligand is compound 10e; Ki=19+/-23pM
3nw9  1.65  2011  Ki=1nM        // 3nw9.pdf (637)
3ui7  2.28  2011  Ki=1nM        // 3ui7.pdf (C1L)
3ucj  1.85  2011  Ki=1uM        // 3ucj.pdf (AZM) ligand is Co-CA-AZM
3qk0  2.85  2011  Ki=2.0nM      // 3qjz.pdf (QK0) ligand is compound 82; ATP-based cell viability assay
3sn8  1.99  2011  Ki=2.24uM     // 3sn8.pdf (S89) ligand is Cm-FF-H; Ki=2.24+/-0.58uM
3t19  2.60  2011  Ki=2.2nM      // 3t19.pdf (5MA) ligand is compound 5; a standard SPA assay
3u8k  2.47  2011  Ki=2.2nM      // 3u8j.pdf (09P) lignad is compound 2; Ki=2.2+/-0.1nM
3rf5  2.10  2011  Ki=2.37uM     // 3rf4.pdf (FUZ)
3n86  1.90  2011  Ki=2.3uM      // 3n59.pdf (RJP)
3qce  2.10  2011  Ki=2.5uM      // 3qce.pdf (NXY)
3qcf  2.50  2011  Ki=2.5uM      // 3qcf.pdf (NXY) ligand is compound 1
3qaa  1.40  2011  Ki=2.9pM      // 3qaa.pdf (G04)
3n7a  2.00  2011  Ki=200uM      // 3n59.pdf (FA1)
3th9  1.34  2011  Ki=20nM       // 3th9.pdf (9Y9)
3o9a  1.90  2011  Ki=20pM       // 3o99.pdf (K14) ligand is compound 10b; Ki=20+/-15pM
3oil  1.50  2011  Ki=2100nM     // 3oil.pdf (VZ5) ligand is compound 16; Ki=2100+/-220nM by membrane-inlet mass spectrometry; Zn-containing
3tsd  2.65  2011  Ki=218uM      // 3tsd.pdf (XMP) Ki=218+/-6uM
3mzc  1.50  2011  Ki=226nM      // 3mzc.pdf (S6I)
2yhd  2.20  2011  Ki=23.0uM     // 2yhd.pdf (AV6)
3sjf  1.65  2011  Ki=23nM       // 3sje.pdf (JRG)
2xm2  1.95  2011  Ki=24uM       // 2xm1.pdf (LOG)
3p58  1.49  2011  Ki=25.4nM     // 3p58.pdf (P58)
2y77  1.50  2011  Ki=250nM      // 2y71.pdf (CB8)
3t8v  1.80  2011  Ki=260nM      // 3t8v.pdf (BTJ)
3prz  2.60  2011  Ki=26nM       // 3pre.pdf (3RZ) x-ray:PI3Kgamma; assay:PI3Kalpha
3rup  1.99  2011  Ki=27.0mM     // 3rup.pdf (ADP) Ca2+ containing; Ki=27.0+/-2.0mM
3n8n  2.50  2011  Ki=27uM       // 3n59.pdf (N88)
2xxr  1.60  2011  Ki=280nM      // 2xxr.pdf (GLU) GluR6 wt LBD dimer in complex with glutamate
3pjg  2.70  2011  Ki=283uM      // 3pjg.pdf (UGA)
3qvu  2.50  2011  Ki=283uM      // 3qvu.pdf (NPO) ligand is pNP; Ki=283+/-100uM; Human SULT1A1 variant b9+PAP+pNP
3ni5  2.10  2011  Ki=28nM       // 3ni5.pdf (C1H)
3t8w  2.00  2011  Ki=29nM       // 3t8v.pdf (DGZ) ligand is PNAP
3sl0  2.00  2011  Ki=2mM        // 3gmz.pdf (FB5) Ki=2000+/-200uM; Mn binding; Fragment: UNP residues 22-411;
2x2i  2.60  2011  Ki=2nM        // 2x2i.pdf (QPS) ligand is acarbose
2y5f  1.29  2011  Ki=2nM        // 2y5f.pdf (XWG)
2y81  1.70  2011  Ki=2nM        // 2y7z.pdf (931)
2y7z  1.84  2011  Ki=2nM        // 2y7z.pdf (C0Z)
2ya6  2.00  2011  Ki=2uM        // 2ya5.pdf (DAN)
3ml5  2.05  2011  Ki=3.0nM      // 3ml5.pdf (AZM) ligand is acetazolamide
2ydt  1.60  2011  Ki=3.0uM      // 2ydp.pdf (EDG-AHR)
3tza  1.90  2011  Ki=3.15uM     // 3tza.pdf (TZG)
3u8j  2.35  2011  Ki=3.1nM      // 3u8j.pdf (09O) lignad is compound 1; Ki=3.1+/-0.9nM
3b1m  1.60  2011  Ki=3.3nM      // 3b1m.pdf (KRC)
3n3j  1.50  2011  Ki=3.3nM      // 3mzc.pdf (WWV)
2xyf  1.80  2011  Ki=3.6nM      // 2xyf.pdf (G40) ligand is compound 9d
3tam  2.51  2011  Ki=3.7nM      // 3tam.pdf (M06) ligand is compound 6
3str  1.75  2011  Ki=3.96nM     // 3str.pdf (3LI)
2ydo  3.00  2011  Ki=30.9nM     // 2ydo.pdf (ADN) Fragment: RESIDUES 1-317; Mutation: YES; pKi=7.51+/-0.08
3rlr  1.70  2011  Ki=30nM       // 3rlp.pdf (3RR)
3sw8  1.70  2011  Ki=31.72uM    // 3str.pdf (5LI)
3p17  1.43  2011  Ki=33.4uM     // 3p17.pdf (99P) ligand is compound 2; Ki=33.4+/-19.0uM
3nyd  1.23  2011  Ki=330uM      // 3nyd.pdf (3NY) ligand is TSA 5-NBT
3qxm  1.65  2011  Ki=33nM       // 2zns.pdf (NDZ)
3t01  1.60  2011  Ki=33uM       // 3t01.pdf (PPF)
3oe4  1.49  2011  Ki=34nM       // 3nw9.pdf (610)
3shj  2.80  2011  Ki=34nM       // 3shj.pdf (H10) ligand is compound 10; Ki=0.034+/-0.004uM
3ocz  1.35  2011  Ki=35nM       // 3ocz.pdf (SRA)
3rwq  2.55  2011  Ki=35nM       // 3rwp.pdf (3RW) ligand is compound 15
3zuk  2.60  2011  Ki=35nM       // 3zuk.pdf (RDF) Ki=35+/-5nM; PH=8; T=37C
3pfp  2.35  2011  Ki=360nM      // 3pfp.pdf (035-036) ligands are compound (R)-4 and (S)-4; Ki1=360+/-50nM((R)-4); Ki2=620+/-110nM((S)-4); Mn-containing
3p3h  1.50  2011  Ki=36nM       // 3p3h.pdf (84A) Fe containing, Zn binding
3mmf  1.50  2011  Ki=37nM       // 3mmf.pdf (D9H)
2xys  1.91  2011  Ki=38nM       // 2xys.pdf (SY9)
3qvv  2.35  2011  Ki=38uM       // 3qvu.pdf (3QV) ligand is 3CYC; Ki=38+/-12uM; Human SULT1A1 variant b9+PAP+3CyC
2xxw  2.30  2011  Ki=390nM      // 2xxw.pdf (GLU)
2xxx  2.10  2011  Ki=390nM      // 2xxx.pdf (GLU) GluR6 D776K LBD dimer in complex with glutamate (P21 21 21)
3r17  1.70  2011  Ki=390nM      // 3r16.pdf (5UM)
3sx4  2.60  2011  Ki=3nM        // 3sww.pdf (KXA) ligand is compound (+)-3f
3ldq  1.90  2011  Ki=4.32uM     // 3ldl.pdf (3P1)
3t1a  2.40  2011  Ki=4.3nM      // 3t19.pdf (5MA)
3qt6  2.05  2011  Ki=4.3uM      // 3qt6.pdf (2P0) ligand is DOGP; Ki=4.3+/-1.0uM; X-ray(S-DPGP), Ki(RS-DPGP)
3ns7  2.60  2011  Ki=4.68nM     // 3ns7.pdf (3NS) covalent complex; compound 9s; Fragment: UNP residues 136-297;
2xye  2.00  2011  Ki=4.6nM      // 2xye.pdf (CXG) ligand is compound 9a
3qiy  2.30  2011  Ki=4.6uM      // 3qiy.pdf (QI1)
3sw2  2.42  2011  Ki=4.71nM     // 3sw2.pdf (FI1)
3qak  2.71  2011  Ki=4.75nM     // 3qak.pdf (UKA) Ki=4.75+/-0.73nM (in the absence of NaCl)
3q1x  1.59  2011  Ki=4.7uM      // 3p47.pdf (SER)
3p5l  1.50  2011  Ki=40.8nM     // 3p58.pdf (IT5)
3snc  2.58  2011  Ki=40.98uM    // 3sn8.pdf (6-mer) ligand is Peptide aldehyde inhibitor Ac-NSTSQ-H; Ki=40.98+/-2.63uM
3o3j  3.00  2011  Ki=400nM      // 3o3j.pdf (BB4) mutation R118K; compound 6b, Ki=400+/-35nM; X-ray: AtPDF(R118K), Binding assay: AtPDF(WT)
3pn3  1.30  2011  Ki=400nM      // 3pn3.pdf (PN3)
3rlq  1.90  2011  Ki=40nM       // 3rlp.pdf (3RQ)
3snb  2.40  2011  Ki=41.24uM    // 3sn8.pdf (6-mer) ligand is Peptide aldehyde inhibitor Ac-DSFDQ-H; Ki=41.24+/-2.25uM
3oli  1.50  2011  Ki=41.6nM     // 3old.pdf (7-mer)HSD-G6D-GLC-HSD-G6D-GLC-GLC; Ki=41.6+/-9.8 nM
3u9q  1.52  2011  Ki=41.7uM     // 3u9q.pdf (DKA) complex between PPAR gamma and decanoic acid and PGC-1a peptide
3mna  1.50  2011  Ki=41nM       // 3mna.pdf (DWH) ligand is compound 7
3sh1  2.90  2011  Ki=41nM       // 3sh1.pdf (MLK) Ki=41+/-14nM
2y71  1.50  2011  Ki=42.5nM     // 2y71.pdf (CB6)
2y4a  2.70  2011  Ki=42uM       // 2y4a.pdf (BH6) Fragment: RESIDUES 50-515 ; Ki=42+/-7uM; covalent complex, B-containing
3q43  1.80  2011  Ki=43nM       // 3q43.pdf (D66)
2y76  2.50  2011  Ki=440nM      // 2y71.pdf (CB7)
3oku  1.45  2011  Ki=440nM      // 3oku.pdf (VZ4) ligand is compound 15; Ki=440+/-50nM by membrane-inlet mass spectrometry; Zn-containing
3rt8  2.43  2011  Ki=451nM      // 3rt8.pdf (CWD) ligand is compound (S)-2c
3rtf  1.70  2011  Ki=45nM       // 3rtf.pdf (CWD) ligand is compound (S)-2c
3ozs  1.44  2011  Ki=4645nM     // 3nw9.pdf (OZS)
3pww  1.22  2011  Ki=48nM       // 3ms3.pdf (ROC)
3q44  1.80  2011  Ki=490nM      // 3q43.pdf (D50)
2y82  2.20  2011  Ki=4nM        // 2y7z.pdf (930)
3sww  2.00  2011  Ki=4nM        // 3sww.pdf (KXB)
2yjq  2.25  2011  Ki=5.2uM      // 2yjq.pdf (3-mer) ligand is Glc-Glc-oxazine
3u1i  2.30  2011  Ki=5.6uM      // 3u1i.pdf (5-mer) Dengue virus protease covalently bound to a peptide inhibitor, benzoyl-norleucine-Lys-Arg-Argaldehyde (Bz-nKRR-H)
3pb8  1.13  2011  Ki=5.748uM    // 3pb7.pdf (AHN) ligand is N-w-Acetylhistamine; Ki=5.748+/-0.366uM; Zn-containing
2xyt  2.05  2011  Ki=509.2nM    // 2xys.pdf (TC9)
3n0n  1.50  2011  Ki=50nM       // 3mzc.pdf (P9B)
3r16  1.60  2011  Ki=50nM       // 3r16.pdf (5UN)
4a1w  2.50  2011  Ki=50nM       // 4a1u.pdf (19-mer) ligand is ALPHA-BETA-FOLDAMER 4C
3tfu  1.94  2011  Ki=520uM      // 3tfu.pdf (PL8)
3o7u  1.71  2011  Ki=52nM       // 3o7u.pdf (O7U)
3rx5  1.99  2011  Ki=540nM      // 3rx5.pdf (G2I) ligand is compound 2; Ki=540+/-11nM
3qfz  2.39  2011  Ki=570uM      // 3qfz.pdf (NOJ-SO4)
3okv  1.45  2011  Ki=590nM      // 3okv.pdf (VZ4) ligand is compound 15; Ki=590+/-30nM by membrane-inlet mass spectrometry; Zn-containing
3s3v  1.53  2011  Ki=593nM      // 3n0h.pdf (TOP)
3rv4  1.98  2011  Ki=5mM        // 3rup.pdf (ADP) Ca2+ and Mg2+ containing; Ki=5~20mM
3o9e  1.50  2011  Ki=5pM        // 3o99.pdf (A60) ligand is compound 11a; Ki=5+/-6pM
3st5  1.45  2011  Ki=5pM        // 3st5.pdf (G89)
3pgl  2.35  2011  Ki=5uM        // 3pgl.pdf (RZX)
3qiz  2.00  2011  Ki=6.1uM      // 3qiy.pdf (QI2)
3tjm  1.48  2011  Ki=6.36uM     // 3tjm.pdf (7FA)
3qj0  2.30  2011  Ki=6.3uM      // 3qiy.pdf (QI3)
3roc  1.70  2011  Ki=6.4nM      // 3roc.pdf (29A)
3rx8  2.56  2011  Ki=610nM      // 3rx5.pdf (9MR) ligand is compound 1; Ki=610+/-14nM
3n0h  1.92  2011  Ki=617nM      // 3n0h.pdf (TOP) redundant to 3s3v
3o0j  1.95  2011  Ki=65nM       // 3o0j.pdf (3OJ) ligand is AN2898; Ki=65+/-9.8nM; Mg-containing; Zn-containing
3q2j  2.15  2011  Ki=66.1uM     // 3q2j.pdf (CKI)
3ps1  1.85  2011  Ki=67pM       // 3ps1.pdf (ZH2)
3oik  1.50  2011  Ki=680nM      // 3oik.pdf (WZB) ligand is compound 14; Ki=680+/-40nM; membrane-inlet mass spectrometry; Zn-containing; incomplete ligand structure
3ljz  2.00  2011  Ki=7.3nM      // 3ljt.pdf (LA3)
3s9e  1.60  2011  Ki=7.43uM     // 3s9e.pdf (GLU)
3ozr  1.73  2011  Ki=7022nM     // 3nw9.pdf (OZR)
3rt6  2.84  2011  Ki=70nM       // 3rt6.pdf (FWD)
3sna  3.05  2011  Ki=72.73uM    // 3sn8.pdf (6-mer) ligand is Peptide aldehyde inhibitor Ac-NSFSQ-H; Ki=72.73+/-3.60uM
3ozt  1.48  2011  Ki=74.9uM     // 3nw9.pdf (OZZ)
2x2r  2.20  2011  Ki=76.2nM     // 2x2r.pdf (X2O)
3r4o  2.65  2011  Ki=7nM        // 3r4m.pdf (FU3) compound 16; Enzymatic Ki was calculated from enzymatic IC50 using the Cheng-Prusoff equation
3tu7  2.49  2011  Ki=8.17nM     // 3tu7.pdf (0BM)
3snd  1.89  2011  Ki=8.27uM     // 3sn8.pdf (6-mer) ligand is Peptide aldehyde inhibitor Ac-ESTLQ-H; Ki=8.27+/-1.52uM; Cocrystallization
2yfx  1.70  2011  Ki=8.2nM      // 2yfx.pdf (VGH) ligand is crizotinid
3p9h  1.80  2011  Ki=8.7uM      // 3p9g.pdf (11-mer) Gag polyprotein, Ki=8.7+/-3.5uM; Fragment: N-terminal UEV domain (UNP residues 2 to 145); Mutation: Mutation of 43VFNDGS48 to GG
3u8l  2.32  2011  Ki=8.9nM      // 3u8j.pdf (09Q) lignad is compound 3; Ki=8.9+/-0.9nM
3p55  2.00  2011  Ki=80nM       // 3p3h.pdf (670) Fe containing, Zn binding
3loo  2.00  2011  Ki=860nM      // 3loo.pdf (B4P)
3po6  1.47  2011  Ki=87.3nM     // 3po6.pdf (DT9)
3lox  2.65  2011  Ki=8nM        // 3lox.pdf (MCX)
3p4v  2.00  2011  Ki=8uM        // 3nb5.pdf (PMX)
3p44  2.20  2011  Ki=9.7nM      // 3p3h.pdf (067) Ru containing, Zn binding
3rx7  2.02  2011  Ki=940nM      // 3rx5.pdf (G3I) ligand is compound 3; Ki=940+/-12nM
3n4b  1.60  2011  Ki=96nM       // 3mzc.pdf (WWZ)
2y80  1.90  2011  Ki=9nM        // 2y7z.pdf (439)
3ml2  1.80  2011  Ki=9nM        // 3ml2.pdf (SU0)
3oys  1.54  2011  Ki=9nM        // 3oy0.pdf (OYS)
2xlc  2.70  2011  Ki~5mM        // 2xlc.pdf (DEP) covalent complex
3q2a  1.99  2011  Ki~5uM        // 3q14.pdf (PAB)
4dmy  1.63  2012  IC50<0.001uM  // 4dmx.pdf (0LC) incomplete ligand structure
4dtk  1.86  2012  IC50<0.003uM  // 4dtk.pdf (7LI) IC50<0.003 uM ([ATP at Km])
3u4w  1.90  2012  IC50<0.004uM  // 3u4w.pdf (5-mer) compound 4b
4axa  1.90  2012  IC50<10nM     // 4axa.pdf (RKD) ligand is AT13148
3u1y  2.00  2012  IC50<2.13nM   // 3u1y.pdf (03I) compound 1t; IC50<2.13+/-1.72nM
3u4u  2.20  2012  IC50<3nM      // 3u4u.pdf (LNH) compound 5f
4e1z  2.50  2012  IC50<3nM      // 4e1z.pdf (0MX) X-ray(Mouse), IC50(human)
3vap  2.66  2012  IC50<4nM      // 3vap.pdf (0FY) compound 56
4gtq  2.60  2012  IC50<5nM      // 4gtm.pdf (7TQ) Zn-containing
4gtr  2.20  2012  IC50<5nM      // 4gtm.pdf (7TR) Zn-containing
4d89  1.65  2012  IC50=0.002uM  // 3veu.pdf (BXD) compound 60n; soak
4at3  1.77  2012  IC50=0.004uM  // 4at3.pdf (LTI) complex TrkB and Cpd5n
4az3  2.04  2012  IC50=0.005uM  // 4az0.pdf (S35) compound 15a
4emv  1.70  2012  IC50=0.005uM  // 4em7.pdf (0R9)
4a7c  2.30  2012  IC50=0.006uM  // 4a7c.pdf (E46) compound 6b
3tyv  1.65  2012  IC50=0.008uM  // 3tyv.pdf (HI3) compound 56
4a4o  2.70  2012  IC50=0.009uM  // 4a4l.pdf (664) compound 25
3uh4  2.00  2012  IC50=0.011uM  // 3uh2.pdf (XAV) compound TNKS1-XAV939
3vw9  1.47  2012  IC50=0.011uM  // 3vw9.pdf (HPJ) compound 3d
4at4  2.36  2012  IC50=0.012uM  // 4at3.pdf (T6E) complex TrkB and EX429
4a4l  2.35  2012  IC50=0.015uM  // 4a4l.pdf (939) compound 13
4fny  2.45  2012  IC50=0.016uM  // 4fny.pdf (I3K)
4fnz  2.60  2012  IC50=0.016uM  // 4fny.pdf (NZF)
3vqs  1.90  2012  IC50=0.0178uM  // 3vqs.pdf (JT1) complex HCVBK and JTK-853; IC50=0.0178+/-0.0008uM
4hcu  1.43  2012  IC50=0.01uM   // 4hct.pdf (13L) covalent complex
4gh6  2.70  2012  IC50=0.021uM  // 4gh6.pdf (LUO) IC50=0.021+/-0.005uM
3vrv  1.90  2012  IC50=0.029nM  // 3vrt.pdf (YSD) compound 5a
2yer  1.83  2012  IC50=0.02uM   // 2yer.pdf (TQ1) ligand is compound 16e
3qu0  1.95  2012  IC50=0.02uM   // 3qqk.pdf (X40) ligand is compound 42
3qxp  1.75  2012  IC50=0.02uM   // 3qqk.pdf (X64) ligand is compound 51
4gcj  1.42  2012  IC50=0.02uM   // 3qqk.pdf (X64) ligand is compound 51
3zxr  2.15  2012  IC50=0.02uM   // 3zxr.pdf (IQ1) compound 3
4dfn  2.48  2012  IC50=0.02uM   // 4dfl.pdf (0K1)
4dk7  2.45  2012  IC50=0.02uM   // 4dk7.pdf (0KS) Ca-containing, the crystal contains Nuclear receptor coactivator 1
4b1d  1.95  2012  IC50=0.032uM  // 4b1c.pdf (6TG) compound 1m; IC50(FRET assay); IC50=0.049uM(SH-SY5Y assay)
3rde  1.89  2012  IC50=0.035uM  // 3rde.pdf (OYP) ligand is compound 3d
3uvp  2.40  2012  IC50=0.035uM  // 3uvp.pdf (048) compound 45; IC50=0.035+/-0.002uM
4at5  1.71  2012  IC50=0.038uM  // 4at3.pdf (MUJ) complex TrkB and GW2580
4az0  2.17  2012  IC50=0.038uM  // 4az0.pdf (S61) compound 8a
3u2k  1.64  2012  IC50=0.03uM   // 3u2k.pdf (087) ligand is compound 10
4dij  1.90  2012  IC50=0.03uM   // 4dij.pdf (BLF)
4d88  1.70  2012  IC50=0.049uM  // 3veu.pdf (BXQ) compound 48
3zxv  2.26  2012  IC50=0.049uM  // 3zxr.pdf (MXI) compound 11a; IC50=0.049+/-0.006uM
3v5q  2.20  2012  IC50=0.04uM   // 3v5q.pdf (0F4) compound 20; IC50=0.004uM for cellular Ba/F3 assay; IC50=0.04uM(biochemical assay)
4hgt  1.80  2012  IC50=0.04uM   // 4hgt.pdf (15G)
3vg1  1.77  2012  IC50=0.055uM  // 3veu.pdf (0GT) compound 32a; Racemate; soak
4d83  2.40  2012  IC50=0.055uM  // 4d83.pdf (0GT) ligand is compound 32a
4a4x  2.40  2012  IC50=0.059uM  // 4a4x.pdf (JUP) compound rac-17j
3tki  1.60  2012  IC50=0.05nM   // 3tkh.pdf (S25) ligand is compound 25
3qtz  2.00  2012  IC50=0.05uM   // 3qqk.pdf (X42) ligand is compound 52
4avg  2.20  2012  IC50=0.06uM   // 4avg.pdf (SL6) compound R05-2; IC50=0.06+/-0.02uM
4afe  2.60  2012  IC50=0.073uM  // 4a4x.pdf (GGY) compound rac-21
4hct  1.48  2012  IC50=0.073uM  // 4hct.pdf (18R) X-ray(R-52), IC50(RS-52)
4b1c  1.95  2012  IC50=0.079uM  // 4b1c.pdf (1B1) compound 1t; IC50(FRET assay); IC50=0.19uM(SH-SY5Y assay)
3rpv  1.80  2012  IC50=0.07uM   // 3qqk.pdf (26Z) ligand is compound 55
3qtx  1.95  2012  IC50=0.07uM   // 3qqk.pdf (X43) ligand is compound 54
3qtu  1.82  2012  IC50=0.07uM   // 3qqk.pdf (X44) ligand is compound 53
3tv8  2.64  2012  IC50=0.07uM   // 3tv8.pdf (DGJ) ligand is 1-deoxygalactonojirimycin (D-galacto-DNJ), IC50=45uM for L-galacto-DNJ
4eny  2.80  2012  IC50=0.089uM  // 3umx.pdf (J19) compound 2
4aof  3.30  2012  IC50=0.08uM   // 4aof.pdf (7L0) compound 45
4heu  2.00  2012  IC50=0.097nM  // 4heu.pdf (15J)
3vru  2.00  2012  IC50=0.10nM   // 3vrt.pdf (YS3) compound 4a
2ym7  1.81  2012  IC50=0.13uM   // 2ym3.pdf (YM7) ligand is compound 20; IC50=0.13+/-0.051uM
3rak  1.75  2012  IC50=0.13uM   // 3qqk.pdf (03Z) ligand is compound 57
4awk  1.90  2012  IC50=0.13uM   // 4avg.pdf (CI1) compound R05-1; IC50=0.13+/-0.04uM
4d85  2.65  2012  IC50=0.14uM   // 3veu.pdf (0GU) compound 39a
3voz  2.40  2012  IC50=0.14uM   // 3voz.pdf (04A) complex KGA and BPTES; IC50=0.14+/-0.03uM
4hki  2.15  2012  IC50=0.14uM   // 4hki.pdf (FLN)
3uix  2.20  2012  IC50=0.151uM  // 3uix.pdf (Q17) compound 1; IC50=0.151+/-0.001uM
2ydi  1.60  2012  IC50=0.15uM   // 2ydi.pdf (YDI) ligand is compound 1
3ufl  1.90  2012  IC50=0.15uM   // 3ufl.pdf (508) compound 9
4g2f  1.70  2012  IC50=0.16uM   // 4g2f.pdf (C07)
4dce  2.03  2012  IC50=0.174uM  // 4dce.pdf (0JF) IC50=0.174+/-0.012uM
4b4g  2.50  2012  IC50=0.175uM  // 4arw.pdf (KKT) compound 8j; IC50=0.175+/-0.067uM
4hlm  1.95  2012  IC50=0.17uM   // 4hki.pdf (16S)
4dvi  1.90  2012  IC50=0.192uM  // 4dvi.pdf (2IW) ligand is compound 2, IWR2
2yex  1.30  2012  IC50=0.1nM    // 2yer.pdf (YEX) ligand is compound 5a
3ral  1.75  2012  IC50=0.1uM    // 3qqk.pdf (04Z) ligand is compound 56
4b4m  2.35  2012  IC50=0.205uM  // 4arw.pdf (JWT) compound 8k; IC50=0.205+/-0.009uM
3ttj  2.10  2012  IC50=0.21uM   // 3ttj.pdf (JBI) ligand is compound 1; IC50=0.21+/-0.06uM
4h39  1.99  2012  IC50=0.21uM   // 4h36.pdf (10-mer) ligand is pepJIP1; IC50=0.21+/-0.02uM(Protein Substrate: His-SAB (1 C390)), IC50=0.30+/-0.07uM(Protein Substrate: FLAG-ATF2 (2 C115))
4e96  1.92  2012  IC50=0.22uM   // 4e96.pdf (0NS) IC50 (AlphaScreen assay)
4e8z  3.05  2012  IC50=0.23uM   // 4e8z.pdf (IHC) K-containing, IC50(myelin basic protein)
3umx  2.55  2012  IC50=0.24uM   // 3umx.pdf (Q18) compound 1
4efu  2.00  2012  IC50=0.25uM   // 4eeh.pdf (EFU)
4ea3  3.01  2012  IC50=0.27nM   // 4ea3.pdf (0NN)
4ge5  2.00  2012  IC50=0.27uM   // 4ge2.pdf (A89) IC50=0.27+/-0.07uM
4eox  1.78  2012  IC50=0.28nM   // 4eox.pdf (0S5) Na-containing
4fcd  2.02  2012  IC50=0.28nM   // 4fcb.pdf (0T6)
4frj  1.95  2012  IC50=0.28uM   // 4fri.pdf (DWB) IC50=0.28+/-0.10uM
3rk7  1.80  2012  IC50=0.2uM    // 3qqk.pdf (08Z) ligand is compound 43
4hlg  2.00  2012  IC50=0.31uM   // 4hki.pdf (20B)
3u8h  2.30  2012  IC50=0.32uM   // 3u8d.pdf (BHP) ligand is KH064;IC50=0.32+/-0.09uM
3tnh  3.20  2012  IC50=0.35uM   // 3tnh.pdf (F18) ligand is CAN508
4dgn  1.75  2012  IC50=0.35uM   // 4dgm.pdf (LU2) IC50=0.35+/-0.04uM
3vjk  2.49  2012  IC50=0.37nM   // 3vjk.pdf (M51) compound 8g; IC50(Human); IC50=0.29nM(Rat)
3vjm  2.10  2012  IC50=0.37nM   // 3vjm.pdf (W61) compound 8g; IC50(human); IC50=0.59nM(rat)
4b5b  2.06  2012  IC50=0.387uM  // 4arw.pdf (BBE) compound 8p; IC50=0.387+/-0.065uM
3rkb  2.00  2012  IC50=0.38uM   // 3qqk.pdf (12Z) ligand is compound 45
3v8t  2.00  2012  IC50=0.3nM    // 3v5j.pdf (477) compound 7
4hcv  1.48  2012  IC50=0.40uM   // 4hct.pdf (13J) covalent complex
3vrw  2.40  2012  IC50=0.41nM   // 3vrt.pdf (YS5) compound 5c
4a16  2.65  2012  IC50=0.43nM   // 4a16.pdf (H34) ligand is huprine 4;IC50=0.43+/-0.04nM
2ym5  2.03  2012  IC50=0.43uM   // 2ym3.pdf (YM5) ligand is compound 6
4e5h  2.16  2012  IC50=0.43uM   // 4e5f.pdf (0N8) Mn-containing, IC50(in vitro transcription assay)
3zzh  2.10  2012  IC50=0.44mM   // 3zzf.pdf (ARG) complex between AAK domain and Arg; IC50=0.44+/-0.05mM
3uwo  1.70  2012  IC50=0.44uM   // 3uwk.pdf (0DJ) compound 17; IC50=0.44+/-0.13uM
4hl5  2.20  2012  IC50=0.45uM   // 4hki.pdf (15W)
3u8d  1.80  2012  IC50=0.47uM   // 3u8d.pdf (U8D) ligand is LY311727;IC50=0.47+/-0.2uM
3ur9  1.65  2012  IC50=0.49uM   // 3ur9.pdf (K36) covalent bound;ligand is GC376;IC50=0.49+/-0.05uM
4g31  2.28  2012  IC50=0.4nM    // 4g31.pdf (0WH) IC50=0.4+/-0.32nM
4e26  2.55  2012  IC50=0.4uM    // 4e26.pdf (734)
4alg  1.60  2012  IC50=0.50uM   // 4akn.pdf (1GH) compound 14; IC50=0.20-1.23uM; pIC50=6.3
4h3a  1.98  2012  IC50=0.51uM   // 3sgt.pdf (0YY) ligand is compound 15; a continuous spectrophotometric assay
3rk9  1.85  2012  IC50=0.52uM   // 3qqk.pdf (09Z) ligand is compound 44
4abu  1.86  2012  IC50=0.52uM   // 4abq.pdf (FT1) compound C2
4enx  2.80  2012  IC50=0.550uM  // 3umx.pdf (Z20) compound 3
3v9b  2.10  2012  IC50=0.5nM    // 3v9b.pdf (IHM) ligand is compound 1s
4hld  2.00  2012  IC50=0.5nM    // 4hlc.pdf (16T)
3t4v  1.73  2012  IC50=0.5uM    // 3t3y.pdf (MD3) ligand is compound 18; Fe-containing
4a9m  2.06  2012  IC50=0.5uM    // 4a9m.pdf (P9M) compound 6a
4aaw  2.20  2012  IC50=0.5uM    // 4aa7.pdf (R84) compound 37; IC50=0.25uM(Ecoil); IC50=0.5uM(H.in); IC50=0.5uM(S.pn); IC50>200uM(S.au)
4f63  2.55  2012  IC50=0.5uM    // 4f63.pdf (0S7) pIC50=6.3
4b14  1.50  2012  IC50=0.60uM   // 4b10.pdf (4XB) complex PvNMT-NHM-26; IC50(fluorescent-activity cell sorting (FACS) assay)
4hmh  2.30  2012  IC50=0.62uM   // 4hki.pdf (F94)
3vjs  1.93  2012  IC50=0.64uM   // 3vjs.pdf (10S) compound S10
3qtw  1.85  2012  IC50=0.65uM   // 3qqk.pdf (X3A) ligand is compound 30
3v8s  2.29  2012  IC50=0.65uM   // 3v8s.pdf (0HD) compound 18; IC50=0.65+/-0.03uM(ROCK1); IC50=0.67+/-0.12uM(ROCK2)
4dfl  1.98  2012  IC50=0.67uM   // 4dfl.pdf (0K0)
4an3  2.10  2012  IC50=0.6nM    // 4an3.pdf (5Y0) compound 2
4f4p  2.37  2012  IC50=0.6nM    // 4f4p.pdf (0SB)
3s9z  1.79  2012  IC50=0.6uM    // 3s9i.pdf (I92) ligand is compound 4; Mg-containing
4e5d  2.20  2012  IC50=0.6uM    // 4e5d.pdf (0NJ) ligand is compound e
3tn8  2.95  2012  IC50=0.74uM   // 3tn8.pdf (F18) ligand is CAN508
3v6s  2.97  2012  IC50=0.75nM   // 3v6r.pdf (0F0) compound JNK-IN7; covalent complex; IC50=1.54nM(JNK1); IC50=1.99nM(JNK2)
4akn  1.82  2012  IC50=0.79uM   // 4akn.pdf (S5B) compound 1; IC50=0.41-1.51uM; pIC50=6.1
3u18  1.90  2012  IC50=0.81uM   // 3u18.pdf (Y0X) ligand is p425
4e8w  2.87  2012  IC50=0.81uM   // 4e8w.pdf (IHA) K-containing, IC50(myelin basic protein)
4f49  2.25  2012  IC50=0.82uM   // 3ur9.pdf (K36) covalent bound;ligand is GC376;IC50=0.82+/-0.;Porcine transmissible gastroenteritis coronavirus strain Purdue
4abv  1.80  2012  IC50=0.85uM   // 4abq.pdf (FT2) compound C3
4hlf  2.15  2012  IC50=0.87uM   // 4hki.pdf (15Z)
2ym6  2.01  2012  IC50=0.88uM   // 2ym3.pdf (YM6) ligand is compound 8; IC50=0.88+/-0.21uM
4gw8  2.00  2012  IC50=0.88uM   // 4aze.pdf (3RA)
3uok  2.95  2012  IC50=0.8nM    // 3unj.pdf (0C6) compound 10
3saz  2.04  2012  IC50=0.8uM    // 3s9i.pdf (043) ligand is compound 7; Mg-containing
4ge2  1.80  2012  IC50=0.90uM   // 4ge2.pdf (75A) IC50=0.90+/-0.02uM
4h38  1.95  2012  IC50=0.92uM   // 3sgt.pdf (0YX) ligand is compound 13; a continuous spectrophotometric assay
4gg5  2.42  2012  IC50=0.93nM   // 4gg5.pdf (0J3) IC50=0.93+/-0.18nM
3qtr  1.85  2012  IC50=0.93uM   // 3qqk.pdf (X36) ligand is compound 16
3ugc  1.34  2012  IC50=0.947uM  // 3ugc.pdf (046)
3tt0  2.80  2012  IC50=0.9nM    // 3tt0.pdf (07J) ligand is compound 1h
4an2  2.50  2012  IC50=0.9nM    // 4an2.pdf (EUI) compound 1
4aqc  1.90  2012  IC50=0.9nM    // 4aqc.pdf (88A) complex JAK2 and cmp 28; IC50=0.9+/-0.1nM; IC50=61+/-16nM(cell assay)
3u8w  2.15  2012  IC50=1.0nM    // 3u8w.pdf (09J) compound 3j; IC50=1.0+/-0.3nM
2ym3  2.01  2012  IC50=1.0uM    // 2ym3.pdf (YM3) ligand is compound 2
3udq  2.73  2012  IC50=1.0uM    // 3udh.pdf (09E) compound 13
3uh2  2.00  2012  IC50=1.0uM    // 3uh2.pdf (P34) compound TNKS1-PJ34
3ue4  2.42  2012  IC50=1.1nM    // 3ue4.pdf (DB8) ligand is compound 1
3sad  1.82  2012  IC50=1.1uM    // 3s9i.pdf (040) ligand is compound 1; Mg-containing
4awg  2.60  2012  IC50=1.1uM    // 4avg.pdf (CI3) compound R05-3; IC50=1.1+/-0.5uM
4hlh  1.75  2012  IC50=1.1uM    // 4hki.pdf (20D)
4hlk  2.00  2012  IC50=1.1uM    // 4hki.pdf (431)
4hkn  2.05  2012  IC50=1.1uM    // 4hki.pdf (LU2)
4fod  2.00  2012  IC50=1.2nM    // 4fob.pdf (0UV) IC50=0.0012+/-0.0002uM
4hdc  2.05  2012  IC50=1.2nM    // 4gsy.pdf (13Y)
3vqh  1.95  2012  IC50=1.2uM    // 3vqh.pdf (IQB) ligand is H-89, luminescence based assay
4dgm  1.65  2012  IC50=1.2uM    // 4dgm.pdf (AGI) IC50=1.2+/-0.15uM
3r6t  1.20  2012  IC50=1.368uM  // 3r6t.pdf (LU1) ligand is compound 4; Mg-containing
3vf3  1.48  2012  IC50=1.37uM   // 3veu.pdf (0GS) compound 14d
3rin  2.20  2012  IC50=1.3nM    // 3rin.pdf (I2O) ligand is compound 16; IC50=1.3+/-0.05nM
3v66  1.80  2012  IC50=1.3nM    // 3v66.pdf (D3A) compound (4R, 6S)-15a; cell-based assay
4b71  2.50  2012  IC50=1.3uM    // 4b6e.pdf (DJL) IC50=1.3+/-0.1uM
3vsx  2.80  2012  IC50=1.4nM    // 3vsw.pdf (R32) compound 17; IC50(human); IC50=7.0nM(monkey plasma)
3r9n  1.75  2012  IC50=1.4uM    // 3qqk.pdf (Z68) ligand is compound 26
4ehm  2.20  2012  IC50=1.4uM    // 4ehm.pdf (PJA) covalent complex, IC50=1.4+/-0.1uM
2ym4  2.35  2012  IC50=1.5uM    // 2ym3.pdf (4YM) ligand is compound 4
4a9n  1.85  2012  IC50=1.5uM    // 4a9m.pdf (A9N) compound 5
3vyf  2.80  2012  IC50=1.6nM    // 3vyd.pdf (VYF) compound 9; IC50(human); IC50=10nM(monkey plasma)
4f6v  2.30  2012  IC50=1.6uM    // 3th8.pdf (ZYM) ligand is compound 7; Mg-containing
4acf  2.00  2012  IC50=1.6uM    // 4acf.pdf (46B) compound 5b; IC50=1.6+/-0.3uM
4dcd  1.69  2012  IC50=1.77uM   // 3ur9.pdf (K36) covalent bound;ligand is GC376;IC50=1.77+/-0.31uM
3qw7  1.50  2012  IC50=1.8uM    // 3qw5.pdf (5-mer) ligand is peptide RRFC; IC50=1.8+/-0.1uM; Zn-containing
4d8n  1.68  2012  IC50=1.8uM    // 3vfe.pdf (0HM) compound 9, 9a and 9b are two possible structures for the same compound registration 9
4dk8  2.75  2012  IC50=1.8uM    // 4dk7.pdf (0KT) Ca-containing, the crystal contains Nuclear receptor coactivator 1
4gz3  1.90  2012  IC50=1.8uM    // 4gz3.pdf (UDP)
3vf9  2.30  2012  IC50=1.9nM    // 3v5j.pdf (477) compound 3
4h3c  1.93  2012  IC50=1.9uM    // 3sgt.pdf (0YZ) ligand is compound 14; a continuous spectrophotometric assay
4a6w  1.46  2012  IC50=1.9uM    // 4a6v.pdf (5C1) Mn2+ containing;ligand is HA7
4a6v  1.46  2012  IC50=1.9uM    // 4a6v.pdf (IKY) Mn2+ containing;ligand is HA5
4awm  2.60  2012  IC50=1.9uM    // 4avg.pdf (KDH) compound EGCG; IC50=1.9+/-0.4uM
4hbx  1.62  2012  IC50=1.9uM    // 4e96.pdf (14X) IC50 measured in AlphaScreen assay
4b12  1.79  2012  IC50=10.2uM   // 4b10.pdf (C23) complex PvNMT-NHM-22; IC50(fluorescent-activity cell sorting (FACS) assay)
4gto  2.15  2012  IC50=10.5nM   // 4gtm.pdf (7TO) IC50=10.5+/-3.9nM, Zn-containing
3v5j  2.59  2012  IC50=10.9nM   // 3v5j.pdf (0F2) compound 5
4fhi  2.40  2012  IC50=100nM    // 4fhh.pdf (0S4)
3vbv  2.08  2012  IC50=10uM     // 3vbq.pdf (0FK) compound 2b
3vp3  2.70  2012  IC50=11.1uM   // 3voz.pdf (BP8) inhibitor 3, IC50=11.1+/-1.96uM
4gtp  2.75  2012  IC50=11.4nM   // 4gtm.pdf (7TP) IC50=11.4+/-10nM, Zn-containing
4g34  2.70  2012  IC50=11.7nM   // 4g31.pdf (924)
4ac3  2.10  2012  IC50=110uM    // 4aa7.pdf (R83) compound 33; IC50>200uM(Ecoil); IC50=120uM(H.in); IC50=110uM(S.pn); IC50>200uM(S.au)
4hv3  1.54  2012  IC50=115uM    // 4huo.pdf (19L)
3rwi  2.01  2012  IC50=116nM    // 3rwc.pdf (10-mer) ligand is Vif GW10 peptide from Virion infectivity factor
3t0m  1.62  2012  IC50=116uM    // 3t0l.pdf (2CT) ligand is compound A2
4e93  1.84  2012  IC50=118nM    // 4e93.pdf (GUI) IC50(Z'-Lyte Assays)
3udr  1.95  2012  IC50=11uM     // 3udh.pdf (09F) compound 14
3unj  1.90  2012  IC50=11uM     // 3unj.pdf (0BX) complex CDK2 with compound 1
4a9i  2.25  2012  IC50=12.6uM   // 4a9e.pdf (P9I) compound 4; IC50(fluorescence anisotropy assay); IC50=2.0uM(TR-FRET)
4gts  2.45  2012  IC50=12.8nM   // 4gtm.pdf (7TP) Zn-containing, IC50=12.8+/-8.8nM
4h1j  2.00  2012  IC50=1200nM   // 4h1j.pdf (0YH) IC50=1200+/-55nM
4gsy  1.71  2012  IC50=120nM    // 4gsy.pdf (0Y5)
4hn2  1.90  2012  IC50=129nM    // 4hn2.pdf (0EJ) IC50=129+/-7nM
3u4i  2.12  2012  IC50=129uM    // 3u4h.pdf (CVR) ligand is cADPcR ;IC50=129+/-12uM
3q92  2.80  2012  IC50=12nM     // 3q92.pdf (XNB) ligand is compound 8; IC50=12+/-6nM
3rah  1.75  2012  IC50=12nM     // 3qqk.pdf (O1Z) ligand is compound 28
4ael  2.20  2012  IC50=12nM     // 4ael.pdf (4HN) compound 5
4g55  1.69  2012  IC50=12uM     // 2xzg.pdf (VH2) Fragment: N TERMINAL DOMAIN, RESIDUES 1-364
3azb  2.60  2012  IC50=12uM     // 3az8.pdf (KM1) ligand is NAS91-11
3ntp  1.76  2012  IC50=12uM     // 3ntp.pdf (RZD) ligand is inhibitor 2; IC50=12+/-2uM
3s00  1.80  2012  IC50=12uM     // 3qqk.pdf (Z60) ligand is compound 5
3vsw  3.00  2012  IC50=130nM    // 3vsw.pdf (R31) compound rac-7; IC50(human); IC50=2800nM(Monkey plasma)
3ti1  1.99  2012  IC50=130uM    // 3ti1.pdf (B49) ligand is compound 1; IC50=130+/-17uM
4fgz  1.99  2012  IC50=1350uM   // 4fgz.pdf (CQA) IC50=1350+/-43uM
4ajw  2.80  2012  IC50=1395nM   // 4ajw.pdf (VWN) complex PI3K delta and cmp 8
2ym8  2.07  2012  IC50=13nM     // 2ym3.pdf (YM8) ligand is compound (R)-3; IC50=13+/-1.3nM
3uzp  1.94  2012  IC50=13nM     // 3uzp.pdf (0CK) ligand is compound PF670462
3v04  2.70  2012  IC50=13nM     // 3v01.pdf (V04) compound 1
4eg4  3.15  2012  IC50=13nM     // 4eg1.pdf (0OT)
4ehr  2.09  2012  IC50=13nM     // 4ehr.pdf (0Q5)
3twj  2.90  2012  IC50=14.5nM   // 3twj.pdf (07R) ligand is RKI-1447
4d9p  2.26  2012  IC50=145uM    // 4d8a.pdf (Z17) X-ray((R)-compound 17), IC50((RS)-compound 17)
3ril  2.40  2012  IC50=146uM    // 3rik.pdf (3RK) ligand is compound 1; IC50=146+/-7uM
4edy  1.72  2012  IC50=1480nM   // 4ec0.pdf (9PQ)
3ua8  1.90  2012  IC50=14nM     // 3ua8.pdf (08W) compound 21; IC50=14+/-2nM. [3H]-CNQX binding affinitya for ligands, AMPA. Maybe wrong data
3vw6  2.40  2012  IC50=14nM     // 3vw6.pdf (IM6) compound 10
4avu  2.40  2012  IC50=14nM     // 4avu.pdf (LDR) ligand is compound 16
4dfw  1.55  2012  IC50=14nM     // 4dfw.pdf (7-mer) Cl-containing, IC50=0.014+/-0.001uM
4fs3  1.80  2012  IC50=14nM     // 4fs3.pdf (0WE) different ligand structure(double bond)
4e5f  2.39  2012  IC50=15.0uM   // 4e5f.pdf (0N7) Mn-containing, IC50(in vitro transcription assay)
3vf8  2.08  2012  IC50=150nM    // 3v5j.pdf (0JE) compound 2
3sgt  1.85  2012  IC50=150uM    // 3sgt.pdf (P09) ligand is compound 8; a continuous spectrophotometric assay
4egi  1.79  2012  IC50=150uM    // 4egh.pdf (B2J) IC50 = 150 +/- 37 uM; incomplete ligand structure
4eh4  2.50  2012  IC50=1534uM   // 4eh2.pdf (0OL) IC50=1534+/-128uM; another ligand is IRG
3vv6  2.05  2012  IC50=157uM    // 3vv6.pdf (B00) compound 6
3uph  2.00  2012  IC50=15nM     // 3uph.pdf (0C1) compound 26
3qqk  1.86  2012  IC50=15uM     // 3qqk.pdf (X02) ligand is compound 1
3unk  2.10  2012  IC50=15uM     // 3unj.pdf (0BY) complex CDK2 with compound 7
4hup  1.70  2012  IC50=15uM     // 4huo.pdf (19M)
4dh6  2.50  2012  IC50=16.8nM   // 4dh6.pdf (0KN) iodide-containing
3sdk  2.70  2012  IC50=160nM    // 3sdk.pdf (P3N) ligand is compound34; there is an error in PDB's ligand structrue
3rwj  2.70  2012  IC50=16nM     // 3rwc.pdf (8-mer) ligand is Vif HW8 peptide from Virion infectivity factor
3s3i  1.80  2012  IC50=16nM     // 3s3i.pdf (CQ0) ligand is compound 1;IC50=16+/-7.2nM
4a9r  2.85  2012  IC50=16nM     // 4a9r.pdf (RU5) compound 30; IC50=16+/-6.9nM
4aa5  2.38  2012  IC50=16nM     // 4a9y.pdf (NQB) compound 33
3vv8  2.50  2012  IC50=17.1uM   // 3vv6.pdf (B02) compound 36
3vi2  2.10  2012  IC50=170uM    // 3vi2.pdf (HMZ) ligand is HMOA
4hlc  1.55  2012  IC50=174nM    // 4hlc.pdf (T05)
3s1h  1.75  2012  IC50=17uM     // 3qqk.pdf (56Z) ligand is compound 66
3tiy  1.84  2012  IC50=17uM     // 3ti1.pdf (TIY) ligand is compound 2; IC50=17+/-13.uM
3vbx  2.03  2012  IC50=17uM     // 3vbq.pdf (0FO) compound 2c
3ztx  1.95  2012  IC50=18.4nM   // 3ztx.pdf (ZTX) complex Aurora B/INCENP and cmp 1, IC50 is not 5.6nM
3vp4  2.45  2012  IC50=18.6uM   // 3voz.pdf (BP9) inhibitor 4, IC50=18.6+/-2.30uM
4anx  2.73  2012  IC50=18nM     // 4anu.pdf (534) compound 4; Bradford assay
4anw  2.31  2012  IC50=18nM     // 4anu.pdf (O92) compound 31; Bradford assay
4azy  1.79  2012  IC50=198nM    // 4azy.pdf (7F3) compound 10
4fzg  3.00  2012  IC50=19nM     // 4fzc.pdf (4-mer) covalent complex, ligand is Glidobactin
3tkm  1.95  2012  IC50=1nM      // 3tkm.pdf (GW0) ligand is compound GW0742
4dei  2.05  2012  IC50=1nM      // 4deg.pdf (0JL)
3s9i  1.90  2012  IC50=2.0uM    // 3s9i.pdf (XI7) ligand is PDKA; Mg-containing
3udy  2.00  2012  IC50=2.0uM    // 3udh.pdf (09G) compound 11
4b13  1.58  2012  IC50=2.0uM    // 4b10.pdf (X25) complex PvNMT-NHM-25; IC50(fluorescent-activity cell sorting (FACS) assay)
3vi5  2.00  2012  IC50=2.1uM    // 3vi5.pdf (M4M) compound APAS; IC50=2.1+/-0.31uM(without CA); IC50=3.2+/-0.27uM(with CA)
3s68  1.85  2012  IC50=2.2nM    // 3s68.pdf (TCW) ligand is compound 1, Tolcapone. Inhibition of Rat Brain COMT
3vnt  1.64  2012  IC50=2.2nM    // 3vnt.pdf (0JA) compound 6d; IC50=2.0-2.4nM
4bbf  2.00  2012  IC50=2.2nM    // 4bbe.pdf (O19)
3sh0  1.84  2012  IC50=2.2uM    // 3sgt.pdf (SAX) ligand is compound 11; a continuous spectrophotometric assay
4ee0  1.75  2012  IC50=2.34nM   // 4ec0.pdf (0O4)
3upy  1.80  2012  IC50=2.39uM   // 3upy.pdf (FOM) ligand is FSM;IC50=2.39+/-0.62uM
4g9c  3.50  2012  IC50=2.3nM    // 4g9c.pdf (0WP) IC50(B-RafV(600E)), X-ray(B-Raf)
4b11  1.59  2012  IC50=2.3uM    // 4b10.pdf (7I1) complex PvNMT-NHM-13; IC50(fluorescent-activity cell sorting (FACS) assay)
4dmn  2.45  2012  IC50=2.3uM    // 4dmn.pdf (0L9) IC50 = 2.3+/- 0.1 uM
4b00  1.83  2012  IC50=2.44nM   // 4azy.pdf (I6X) compound R-41
4f65  2.26  2012  IC50=2.5nM    // 4f63.pdf (0S9) pIC50=8.6
3vrt  2.40  2012  IC50=2.7nM    // 3vrt.pdf (YS2) compound 3a
4awf  2.30  2012  IC50=2.7uM    // 4avg.pdf (XI7) compound DPBA; Ic50=2.7+/-0.3uM
4fri  2.30  2012  IC50=2.85uM   // 4fri.pdf (DWA) IC50=2.85+/-0.17uM
3rwg  2.10  2012  IC50=2.8nM    // 3rwc.pdf (9-mer) ligand is Nef MW9 peptide from Protein Nef
4fcb  2.10  2012  IC50=2.9nM    // 4fcb.pdf (0T7)
3r8v  1.90  2012  IC50=2.9uM    // 3qqk.pdf (Z62) ligand is compound 2
4hkk  1.95  2012  IC50=2.9uM    // 4hki.pdf (AGI)
3upf  2.60  2012  IC50=200nM    // 3upf.pdf (0BU) complex MNV RdRp and NF023; IC50=200+/-2nM
4d8i  1.38  2012  IC50=205nM    // 4d8e.pdf (5-mer) covalent complex
3uxm  1.95  2012  IC50=20uM     // 3uwk.pdf (0DN) compound dFTM; IC50=20+/-4uM
4huo  1.52  2012  IC50=20uM     // 4huo.pdf (RS8)
4e5g  2.65  2012  IC50=21.3uM   // 4e5f.pdf (XI7) Mn-containing, IC50(in vitro transcription assay)
3sz1  2.30  2012  IC50=21.8uM   // 3sz1.pdf (LU2) ligand is luteolin
3qa2  2.52  2012  IC50=210nM    // 3qa2.pdf (XNA) ligand is compound 3; IC50=210+/-88nM
3v1r  2.80  2012  IC50=21nM     // 3v1r.pdf (JTH) full-length RNase H; IC50=21-67nM
4anu  2.81  2012  IC50=21nM     // 4anu.pdf (EM7) compound 2; Bradford assay
3qi1  2.30  2012  IC50=22nM     // 3qi1.pdf (C6A) ligand is compound 50
4hbv  1.63  2012  IC50=23uM     // 4e96.pdf (15E) IC50 measured in AlphaScreen assay
4a9c  2.10  2012  IC50=24.8uM   // 4a9c.pdf (B5F) IC50=24.8+/-3.0uM, BiPh(2, 3', 4, 5', 6)P5 is not a SHIP2 substrate but inhibits Ins(1, 3, 4, 5)P4 hydrolysis
4hej  2.00  2012  IC50=24000nM  // 4gsy.pdf (14D) IC50(racemic-16), X-ray((S)-16)
3udj  1.80  2012  IC50=242uM    // 3udh.pdf (092) compound 5
3vc4  2.23  2012  IC50=24nM     // 3vbq.pdf (0FS) compound 3
4avw  2.15  2012  IC50=24nM     // 4avw.pdf (G18) ligand is compound 18
4awo  1.70  2012  IC50=24nM     // 4awo.pdf (99B) compound 12i
4ec4  3.30  2012  IC50=25.4nM   // 4eb9.pdf (0O6) IC50=25.4+/-0.1nM
4dea  2.45  2012  IC50=256nM    // 3up7.pdf (NHI) compound 3i; IC50=256+/-38nM
3v01  2.71  2012  IC50=25nM     // 3v01.pdf (3V0) compound 3
4g19  2.00  2012  IC50=261.5uM  // 4g19.pdf (GSH) IC50 = 261.5 +/- 39.8 uM
3sd5  3.20  2012  IC50=262nM    // 3sd5.pdf (SD5) Filter binding assay; IC50=262+/-94 nM
4hkp  1.75  2012  IC50=28.3uM   // 4hib.pdf (16B) IC50=28.3+/-1.5uM
4anm  1.70  2012  IC50=28nM     // 4anm.pdf (WUL) compound 3
4dem  1.85  2012  IC50=28nM     // 4dem.pdf (YS4) Mg-containing, IC50(without preincubation)=1390nM, IC50(with 10 min of preincubation)=28nM
4dhf  2.80  2012  IC50=28nM     // 4dhf.pdf (0K6) Mg-containing
4h5d  2.02  2012  IC50=28nM     // 4h5c.pdf (YS4) ligand is compound 13k
4h5c  2.02  2012  IC50=28nM     // 4h5c.pdf (YS4) ligand is compound 13k, YS0470. Time-Dependent Inhibition IC50 initial 1390 nM to final 28 nM
3vby  2.27  2012  IC50=28uM     // 3vbq.pdf (0FR) compound 2d
4eh3  2.40  2012  IC50=292uM    // 4eh2.pdf (NAR) IC50=292+/-54uM; another ligand is IRG
3avf  1.70  2012  IC50=295.0uM  // 3av9.pdf (8-mer) ligand is peptide 10; IC50=295.0+/-95.9uM
4d8c  2.07  2012  IC50=2nM      // 4d8c.pdf (BXD) ligand is compound 60n
4aa7  2.00  2012  IC50=2uM      // 4aa7.pdf (R82) compound 1; IC50=2uM(Ecoli); IC50=8uM(H.in.); IC50>200uM(S.pn.); IC50>200uM(S.au.)
4h4m  2.85  2012  IC50=3.0nM    // 4h4m.pdf (494)
4h2o  2.14  2012  IC50=3.0uM    // 3sgt.pdf (0YW) ligand is compound 12; a continuous spectrophotometric assay
3uol  2.40  2012  IC50=3.1nM    // 3unj.pdf (0C7) compound 11
3qtq  1.80  2012  IC50=3.1uM    // 3qqk.pdf (X35) ligand is compound 3
3qts  1.90  2012  IC50=3.1uM    // 3qqk.pdf (X46) ligand is compound 34
3sgx  2.45  2012  IC50=3.2uM    // 3sgt.pdf (0FW) ligand is compound 10; a continuous spectrophotometric assay
3vp1  2.30  2012  IC50=3.3uM    // 3vp1.pdf (04A) ligand is compound 3
3rik  2.48  2012  IC50=3.4mM    // 3rik.pdf (3RI) ligand is compound 2; IC50=3.4+/-0.2mM
3t3y  2.00  2012  IC50=3.4uM    // 3t3y.pdf (MD6) ligand is compound 22; Fe-containing
4fli  1.55  2012  IC50=3.59uM   // 4fli.pdf (Y16) Mn-containing
3uhm  1.26  2012  IC50=3.6nM    // 3uhm.pdf (RFN) compound 2a; IC50=3.6+/-0.8nM
4bbe  1.90  2012  IC50=3.6nM    // 4bbe.pdf (3O4)
4drp  1.80  2012  IC50=3.9uM    // 4drk.pdf (0MD) IC50=3.9+/-0.6uM,
4dro  1.10  2012  IC50=3.9uM    // 4drk.pdf (0MD) IC50=3.9+/-0.6uM, incomplete ligand structure
3r0w  1.70  2012  IC50=30.0uM   // 3r0w.pdf (RSY) ligand is compound 2; IC50=30.3+/-1.97uM
3qw6  1.60  2012  IC50=300uM    // 3qw5.pdf (5-mer) ligand is peptide RYGC; IC50=300.0+/-3.5uM; Zn-containing
4hv7  1.87  2012  IC50=300uM    // 4huo.pdf (19J)
3rwf  2.60  2012  IC50=305nM    // 3rwc.pdf (9-mer) ligand is Nef QW9 peptide from Protein Nef
3tv7  2.75  2012  IC50=30nM     // 3tv7.pdf (07Q) ligand is compound (R)-14f; IC50=30+/-22nM
3t0l  1.60  2012  IC50=30uM     // 3t0l.pdf (1CT) ligand is compound A1
4af3  2.75  2012  IC50=31nM     // 4af3.pdf (VX6) complex Aurora B and inhibitor 1; IC50(Human); IC50=19nM(X.laevis)
4hni  2.74  2012  IC50=32nM     // 4hnf.pdf (16W)
3udk  2.51  2012  IC50=32uM     // 3udh.pdf (095) compound 6
3vbg  2.80  2012  IC50=33nM     // 3u15.pdf (03M) complex MDM2 and RO-2443
3s0o  2.00  2012  IC50=33uM     // 3qqk.pdf (50Z) ligand is compound 6
3udm  1.94  2012  IC50=33uM     // 3udh.pdf (09A) compound 8
4eh6  2.10  2012  IC50=3471uM   // 4eh2.pdf (0ON) IC50=3471+/-796uM; another ligand is IRG
4h71  1.93  2012  IC50=35.57uM  // 4h71.pdf (PXE) IC50 (Incubation  time is 4 min) come from the supporting information
4aa0  1.80  2012  IC50=35nM     // 4a9y.pdf (AA0) compound 2
4fhh  2.33  2012  IC50=35nM     // 4fhh.pdf (0U3)
3sgv  1.61  2012  IC50=35uM     // 3sgt.pdf (2BJ) ligand is comound 9; a continuous spectrophotometric assay
4deb  3.05  2012  IC50=371nM    // 3up7.pdf (NHJ) compound 13
4d8a  2.18  2012  IC50=376uM    // 4d8a.pdf (0HY) X-ray((R)-compound 21), IC50((RS)-compound 21)
3vqu  2.40  2012  IC50=37nM     // 3vqu.pdf (O22) compound 9
4aq3  2.40  2012  IC50=37nM     // 4aq3.pdf (398) complex Bcl-2 and cmp 18; IC50=47nM(complex Bcl-xl and cmp 18)
3vbt  2.23  2012  IC50=37uM     // 3vbq.pdf (0F9) compound 2e
4ded  3.05  2012  IC50=38.2nM   // 3up7.pdf (NHU) compound 3g; IC50=38.2+/-8.8nM
4fpf  2.23  2012  IC50=38.9uM   // 4foq.pdf (JKK) IC50=38.9+/-0.8uM
4gtv  1.95  2012  IC50=38nM     // 4gtm.pdf (7TR) IC50=38+/-7nM (fluorometric assay), IC50=123+/-22nM (radiometric assay), Zn-containing
3ava  1.70  2012  IC50=39.7uM   // 3av9.pdf (8-mer) ligand is peptide 4; IC50=39.7+/-7.1uM
4afj  1.98  2012  IC50=398nM    // 4afj.pdf (SJJ) compound 11, pIC50=6.4
3vb6  2.50  2012  IC50=39uM     // 3vb4.pdf (7-mer) covalent bond; IC50=39+/-1uM
4e3f  1.50  2012  IC50=3mM      // 4e3d.pdf (GRE) IC50=3+/-1mM (a standard esterase activity assay)
3umw  2.08  2012  IC50=3nM      // 3umw.pdf (596) compound 14
4foc  1.70  2012  IC50=3nM      // 4fob.pdf (0UU) IC50=0.003+/-0.001uM
3rk5  2.00  2012  IC50=4.0uM    // 3qqk.pdf (07Z) ligand is compound 48
3vjt  2.00  2012  IC50=4.1uM    // 3vjs.pdf (10R) compound R10
4ere  1.80  2012  IC50=4.2nM    // 4ere.pdf (0R2) IC50=4.2+/-0.9nM(human serum free)
4ebv  1.67  2012  IC50=4.2uM    // 4ebv.pdf (0O7) IC50=3.8-4.6 uM
4el9  1.55  2012  IC50=4.37uM   // 3ubd.pdf (AFE) ligand is afzelin
4hby  1.59  2012  IC50=4.4uM    // 4e96.pdf (13F) IC50 measured in AlphaScreen assay
3v3v  2.70  2012  IC50=4.6uM    // 3v3v.pdf (MYU)
3vb5  1.95  2012  IC50=4.6uM    // 3vb4.pdf (5-mer) covalent bond; IC50=4.6+/-0.2uM
3vv7  2.10  2012  IC50=4.6uM    // 3vv6.pdf (0B1) compound 33
3sdi  2.65  2012  IC50=4.7nM    // 3sdi.pdf (3SD) ligand is compound20; X-ray(Saccharomyces cerevisiae S288c), IC50(human)
4b3u  1.80  2012  IC50=4.7uM    // 4arw.pdf (NWL) compound 12b; IC50=4.7+/-4.0uM
3rpy  1.90  2012  IC50=4.8uM    // 3qqk.pdf (27Z) ligand is compound 61
3sqq  1.85  2012  IC50=4.8uM    // 3qqk.pdf (99Z) ligand is compound 62
4h2j  1.81  2012  IC50=4.8uM    // 3sgt.pdf (0YU) ligand is compound 16; a continuous spectrophotometric assay
4hbw  1.69  2012  IC50=4.8uM    // 4e96.pdf (14Z) IC50 measured in AlphaScreen assay
4ddl  2.07  2012  IC50=4.9nM    // 4ddl.pdf (0JQ) Zn-containing
3vi7  2.00  2012  IC50=40.4nM   // 3vi5.pdf (CBD) compound Cibacron Blue; IC50=40.4+/-2.6nM(without CA); IC50=150+/-11nM(with CA)
4acu  1.75  2012  IC50=40.7nM   // 4acu.pdf (QN7) compound 14, pIC50=7.39
4dpf  1.80  2012  IC50=400nM    // 4dpf.pdf (0LG)
3vyd  2.81  2012  IC50=406nM    // 3vyd.pdf (VYD) compound 6; IC50(human); IC50>1000nM(monkey plasma)
3rwh  2.60  2012  IC50=40nM     // 3rwc.pdf (8-mer) ligand is Pol MF8 peptide from Pol protein
3v4v  3.10  2012  IC50=42nM     // 3v4v.pdf (0DU) ligand is compound 28, a4b7 RPMI cells/MadCAM IC50 nM
3av9  1.70  2012  IC50=435uM    // 3av9.pdf (8-mer) ligand is peptide 12; IC50=435+/-91.9uM
3rwe  2.40  2012  IC50=43nM     // 3rwc.pdf (9-mer) ligand is Pol FW9 peptide from Pol protei
4eg6  2.90  2012  IC50=43nM     // 4eg1.pdf (0P5)
4anv  2.13  2012  IC50=441nM    // 4anu.pdf (751) compound 1; Bradford assay
4an9  2.80  2012  IC50=44nM     // 4an9.pdf (2P7) compound 7
4ewo  1.80  2012  IC50=44nM     // 4ewo.pdf (996) IC50(Protein binding in mouse serum, free unbound = 10%), IC50((S):(R)=79:21 at the C4 of the bicyclic ring), X-ray((S)-configuration at the C4 of the bicyclic ring)
4ez3  2.00  2012  IC50=45uM     // 3ti1.pdf (0S0) ligand is compound 4; IC50=45+/-8.3uM
4eeh  1.60  2012  IC50=45uM     // 4eeh.pdf (HH6)
4eg7  2.75  2012  IC50=46nM     // 4eg1.pdf (0P4)
4hco  2.75  2012  IC50=47.38uM  // 4h71.pdf (IMW) IC50 (Incubation  time is 6 min) come from the supporting information
3vbq  1.85  2012  IC50=470pM    // 3vbq.pdf (0F5) compound 6
4awq  1.60  2012  IC50=479nM    // 4awo.pdf (592) compound 1
3tkh  1.79  2012  IC50=47nM     // 3tkh.pdf (07S) ligand is compound 1
3uqp  1.77  2012  IC50=48.8nM   // 3uqp.pdf (8-mer) compound 11
3r8z  1.85  2012  IC50=49uM     // 3qqk.pdf (Z63) ligand is compound 10
3vb4  2.20  2012  IC50=49uM     // 3vb4.pdf (5-mer) covalent bond; IC50=49+/-2uM
3vb7  1.95  2012  IC50=49uM     // 3vb4.pdf (5-mer) covalent bond; IC50=49+/-2uM
3s4q  2.27  2012  IC50=4nM      // 3s4q.pdf (NK0) ligand is compound 24
4fzc  2.80  2012  IC50=4nM      // 4fzc.pdf (4-mer) covalent complex; ligand is Cepafungin I
4dus  2.50  2012  IC50=5.0nM    // 4dus.pdf (0MP) IC50=5.0+/-3.0nM, Compound 16 is mixture of diastereomers (1:1, 2S, 3R and 2R, 3S)
4fll  1.50  2012  IC50=5.14uM   // 4fli.pdf (YZ6) Mn-containing
3t4h  1.65  2012  IC50=5.2uM    // 3t3y.pdf (MD5) ligand is compound 15; Fe-containing
4eb9  2.60  2012  IC50=5.4nM    // 4eb9.pdf (0O6) IC50=5.4+/-0.1nM
4flk  1.47  2012  IC50=5.58uM   // 4fli.pdf (Y10) Mn-containing
4di2  2.00  2012  IC50=5.5nM    // 4di2.pdf (0K9)
3sb0  2.20  2012  IC50=5.5uM    // 3s9i.pdf (I93) ligand is compound 11; Mg-containing
3vjl  2.39  2012  IC50=5.6nM    // 3vjk.pdf (W94) compound 9b; IC50(Human); IC50=2.5nM(Rat)
3rjc  1.85  2012  IC50=5.7uM    // 3qqk.pdf (06Z) ligand is compound 19
4drm  1.48  2012  IC50=5.8uM    // 4drk.pdf (0MC) IC50=5.8+/-0.6uM
4drn  1.07  2012  IC50=5.8uM    // 4drk.pdf (0MC) IC50=5.8+/-0.6uM
3qbn  3.50  2012  IC50=5.9nM    // 3qbn.pdf (E9Z) ligand is compound 1; IC50=5.9+/-1.4nM; X-ray(Homo sapiens), IC50(U. maydis)
4ehv  1.60  2012  IC50=5103uM   // 4eh2.pdf (0SJ) IC50=5103+/-544uM; another ligand is IRG
4eh7  2.10  2012  IC50=520uM    // 4eh2.pdf (0OO) IC50=520+/-192uM; another ligand is IRG
4b95  2.80  2012  IC50=52uM     // 4b95.pdf (UCK) IC50=52+/-2uM
4h36  3.00  2012  IC50=53.4uM   // 4h36.pdf (8-mer) ligand is pepATF2; IC50=53.4+/-5uM(Protein Substrate: His-SAB (1 C390)), IC50=136.9+/-41uM (Protein Substrate: FLAG-ATF2 (2 C115))
4gb9  2.44  2012  IC50=540nM    // 4gb9.pdf (0WR) ligand is compound 14
4eh9  2.10  2012  IC50=5453uM   // 4eh2.pdf (0OQ) IC50=5453+/-513uM; another ligand is IRG
4egh  1.60  2012  IC50=550uM    // 4egh.pdf (0OY) IC50 = 550+/-200 uM; Mg-containing
3veu  1.52  2012  IC50=55nM     // 3veu.pdf (0GO) compound 3
4e1m  1.90  2012  IC50=55nM     // 4e1m.pdf (TQ2) IC50 = 55+/-3 nM (Strand transfer);
3th8  2.11  2012  IC50=560nM    // 3th8.pdf (TH9) ligand is compound 9
3ua9  2.15  2012  IC50=56nM     // 3u9y.pdf (IWR) compound 2, IC50 is 56nM, not 56uM
3u4h  1.88  2012  IC50=56uM     // 3u4h.pdf (C8R) ligand is  8-amino cIDPR;IC50=56+/-9uM
3uqr  3.06  2012  IC50=57.2nM   // 3uqp.pdf (7-mer) compound 13
4fpk  2.40  2012  IC50=57.4uM   // 4foq.pdf (IJ1) IC50=57.4+/-6.0uM
3uwk  1.91  2012  IC50=58uM     // 3uwk.pdf (0DF) compound 1; IC50=58+/-11uM
4f8h  2.99  2012  IC50=58uM     // 4f8h.pdf (RKE)
4dt6  2.60  2012  IC50=59nM     // 4dt6.pdf (6LI) IC50=0.059+/-0.02uM
4e3d  1.60  2012  IC50=5mM      // 4e3d.pdf (GTQ) IC50=5+/-2mM (a standard esterase activity assay)
2ydj  1.85  2012  IC50=5nM      // 2ydi.pdf (YDJ) ligand is compound 4
3rvg  2.50  2012  IC50=5nM      // 3rvg.pdf (17P) ligand is compound 38
3tyq  1.60  2012  IC50=5nM      // 3tyq.pdf (HI4) compound 47; covalent complex
4ejn  2.19  2012  IC50=5nM      // 4ejn.pdf (0R4) IC50 measured in Thermal Shift Assay (TSA)
4fob  1.90  2012  IC50=5nM      // 4fob.pdf (0US) IC50=0.005+/-0.002uM
4hgs  2.40  2012  IC50=5nM      // 4hgs.pdf (15G)
3r8u  2.00  2012  IC50=5uM      // 3qqk.pdf (Z31) ligand is compound 4
3udp  1.95  2012  IC50=6.0uM    // 3udh.pdf (09D) compound 12
3up7  3.05  2012  IC50=6.1nM    // 3up7.pdf (0C9) compound 1; IC50=6.1+/-1.0nM(in vitro); IC50>100uM(in vivo)
4h2m  1.78  2012  IC50=6.1uM    // 3sgt.pdf (0YV) ligand is compound 18; a continuous spectrophotometric assay
3u6j  2.15  2012  IC50=6.2nM    // 3u6h.pdf (03X) complex VEGFR-2 and cmp 26
4anb  2.20  2012  IC50=6.6nM    // 4anb.pdf (YQY) compound 8
4h3b  2.08  2012  IC50=6.76uM   // 4h36.pdf (10-mer) ligand is pepSAB; IC50=6.76+/-0.94uM(Protein Substrate: His-SAB (1 C390)), IC50=7.56+/-1.74uM(Protein Substrate: FLAG-ATF2 (2 C115))
4aac  2.50  2012  IC50=6.7nM    // 4a9y.pdf (AAV) compound 29
3rni  1.95  2012  IC50=6.7uM    // 3qqk.pdf (21Z) ligand is compound 82
4ask  1.86  2012  IC50=60nM     // 2xue.pdf (K0I) ligand is GSK-J1; Co2+ containing
4a9u  2.48  2012  IC50=60nM     // 4a9r.pdf (A9U) compound 47; IC50=60+/-8nM
4deh  2.00  2012  IC50=612nM    // 4deg.pdf (0JK)
4a9s  2.66  2012  IC50=61nM     // 4a9r.pdf (RU9) compound 19; IC50=61+/-31nM
3vid  2.30  2012  IC50=620nM    // 3vid.pdf (4TT) compound A; phosphorylated VEGFR2; IC50=860nM(phosphorylated VEGFR2)
4eyj  2.10  2012  IC50=620nM    // 4eyj.pdf (N61)
4eh8  2.20  2012  IC50=6247uM   // 4eh2.pdf (0OP) IC50=6247+/-358uM; another ligand is IRG
4f64  2.05  2012  IC50=63.1nM   // 4f63.pdf (0S8) pIC50=7.2
3avl  1.88  2012  IC50=65.8uM   // 3av9.pdf (8-mer) ligand is peptide 6; IC50=65.8+/-31.7uM
4ega  2.70  2012  IC50=65nM     // 4eg1.pdf (0P8)
4e1n  2.00  2012  IC50=67nM     // 4e1m.pdf (TQX) IC50 = 67+/-4 nM (Strand transfer);
4azt  2.34  2012  IC50=68uM     // 4azs.pdf (LY2) compound LY294002
4eh2  2.00  2012  IC50=692uM    // 4eh2.pdf (0OK) IC50=692+/-252uM; another ligand is IRG
3tti  2.20  2012  IC50=6nM      // 3tti.pdf (KBI) ligand is compound 1; IC50=6+/-2 nM
3upi  2.00  2012  IC50=6nM      // 3uph.pdf (0C2) compound 27
4deg  2.00  2012  IC50=6nM      // 4deg.pdf (0JJ)
4e20  2.60  2012  IC50=6nM      // 4e1z.pdf (0MY) IC50=6+/-1nM, X-ray(Mouse), IC50(human)
4gtt  2.05  2012  IC50=6nM      // 4gtm.pdf (7TQ) IC50=6+/-4nM (radiometric assay), IC50=72+/-2nM(fluorometric assay), Zn-containing
3vbw  2.48  2012  IC50=6uM      // 3vbq.pdf (0FN) compound 2a
3v5l  1.86  2012  IC50=7.0nM    // 3v5j.pdf (0G1) compound 6
4dbn  3.15  2012  IC50=7.0nM    // 3vnt.pdf (0JA) compound 6d; IC50=6.0-8.3nM
3udn  2.19  2012  IC50=7.0uM    // 3udh.pdf (09B) compound 9
4flj  1.74  2012  IC50=7.45uM   // 4fli.pdf (Y08) Mn-containing
3aza  2.70  2012  IC50=7.4uM    // 3az8.pdf (KM0) ligand is NAS91-10
3rwc  2.50  2012  IC50=7.6nM    // 3rwc.pdf (9-mer) ligand is Nef IW9 peptide from Protein Nef
3vye  2.70  2012  IC50=7.7nM    // 3vyd.pdf (VYE) compound 7; IC50(human); IC50=54nM(monkey plasma)
4em7  1.90  2012  IC50=7.7uM    // 4em7.pdf (0RA)
4hai  2.55  2012  IC50=7.9nM    // 4hai.pdf (I23)
3v6r  2.60  2012  IC50=709nM    // 3v6r.pdf (CQQ) compound JNK-IN2; covalent complex; IC50=809nM(JNK1); IC50=1140nM(JNK2)
3ur0  2.45  2012  IC50=70nM     // 3upf.pdf (SVR) complex MNV RdRp and Suramin; IC50=70+/-3nM
4a9t  2.70  2012  IC50=70nM     // 4a9r.pdf (A9T) author says compound 44; IC50=70+/-3nM; true structure is compound 43; IC50=14+/-8nM, add a Cl atom
4esi  1.87  2012  IC50=70uM     // 4esi.pdf (0RB)
4hnf  2.07  2012  IC50=711nM    // 4hnf.pdf (16W)
3r9d  1.95  2012  IC50=71uM     // 3qqk.pdf (X6B) ligand is compound 87
4aw5  2.33  2012  IC50=765nM    // 4aw5.pdf (30K) complex EphB4 and 7i
4acx  2.00  2012  IC50=77.6nM   // 4acu.pdf (S8Z) compound 23, pIC50=7.11
4dpi  1.90  2012  IC50=78nM     // 4dpf.pdf (0N1)
4h1m  1.99  2012  IC50=78nM     // 4h1j.pdf (0YJ)
2ydk  1.90  2012  IC50=7nM      // 2ydi.pdf (YDK) ligand is compound 3b
4erw  2.00  2012  IC50=7nM      // 3ti1.pdf (STU) ligand is Staurosporine
4e4x  3.60  2012  IC50=7nM      // 4e4x.pdf (T1Q) X-ray(B-Raf(WT)), IC50=7 nM (B-Raf(V600E))
3vp2  2.70  2012  IC50=8.02uM   // 3voz.pdf (BP0) inhibitor 2, IC50=8.02+/-1.47uM
3qai  2.70  2012  IC50=8.0nM    // 3qai.pdf (XNN) ligand is compound 47; IC50=8.0+/-7.1nM
3qw8  1.60  2012  IC50=8.0uM    // 3qw5.pdf (5-mer) ligand is peptide CRGC; IC50=8.0+/-1.2uM; Zn-containing
4edz  2.00  2012  IC50=8.26nM   // 4ec0.pdf (0O5)
4f6x  1.98  2012  IC50=8.2uM    // 3th8.pdf (ZYL) ligand is compound 41; Mg-containing
4drk  1.50  2012  IC50=8.36uM   // 4drk.pdf (I63) IC50=8.36+/-0.98uM
4exg  1.80  2012  IC50=8.5nM    // 4ewo.pdf (916) IC50(Ratios of (S):(R)-configurations (diastereomeric mixture) at the C4 of the bicyclic ring(75:25)), X-ray((S)-configuration at the C4 of the bicyclic ring)
3v8w  2.27  2012  IC50=8.6nM    // 3v5j.pdf (0G2) compound 8
4ebw  2.65  2012  IC50=8.7uM    // 4ebv.pdf (0PF) IC50=7.4-10.3 uM
4dgg  2.65  2012  IC50=800nM    // 4dgg.pdf (I76) IC50=800+/-160nM
4eh5  2.00  2012  IC50=818uM    // 4eh2.pdf (0OM) IC50=818+/-80uM; another ligand is IRG
4awp  1.82  2012  IC50=81nM     // 4awo.pdf (99A) compound 7e
3rmf  1.75  2012  IC50=82uM     // 3qqk.pdf (20Z) ligand is compound 69
4daw  2.00  2012  IC50=83nM     // 4daw.pdf (0H2) X-ray(the racemic complex 1), IC50((R)-1), IC50=0.083+/-0.02uM
4ec0  1.85  2012  IC50=845nM    // 4ec0.pdf (7PQ)
4gdy  2.89  2012  IC50=84nM     // 4gdy.pdf (0X1) compound 4 inhibits KAT II irreversibly via formation of an imine adduct with the aldehyde group of the enzyme co-factor pyridoxal phosphate (PLP), followed by tautomerization to an enamine.
3avb  1.85  2012  IC50=85.2uM   // 3av9.pdf (8-mer) ligand is peptide 2; IC50=85.2+/-24.5uM
4eft  2.12  2012  IC50=85uM     // 4eeh.pdf (EFT)
4aml  1.60  2012  IC50=8mM      // 2uwg.pdf (GYU) compound 20, monovalent IC50=8000+/-1000uM
4eg5  3.10  2012  IC50=8nM      // 4eg1.pdf (0OU)
4frk  2.10  2012  IC50=8nM      // 4fri.pdf (DWD) IC50=0.008+/-0.0003uM
4hgl  2.40  2012  IC50=8nM      // 4hgl.pdf (0YO) SO4-containing
4ejf  2.65  2012  IC50=8uM      // 4ejf.pdf (18-mer) ligand is phage-derived peptide 419
4aa4  2.30  2012  IC50=9.0nM    // 4a9y.pdf (QC0) compound 22
3v4j  2.04  2012  IC50=9.1uM    // 3v4j.pdf (PQR) compound MN30
4dgr  1.55  2012  IC50=9.1uM    // 4dgr.pdf (3LV) IC50=9.1+/-2.2uM, Ca-containing, K-containing
4gtm  2.20  2012  IC50=9.2nM    // 4gtm.pdf (7TM) IC50=9.2+/-4.2nM, Zn-containing
3v49  1.70  2012  IC50=9.6nM    // 3v49.pdf (PK0) compound +/-11b
3rwd  2.60  2012  IC50=9.9nM    // 3rwc.pdf (11-mer) ligand is Nef IW11 peptide from Protein Nef
3t0t  3.10  2012  IC50=91nM     // 3t0t.pdf (I30)
4dum  2.95  2012  IC50=95nM     // 4dt6.pdf (HLI) IC50=0.095+/-0.004uM
4eym  2.35  2012  IC50=98747nM  // 4eyj.pdf (0RX)
4d8e  1.50  2012  IC50=98nM     // 4d8e.pdf (E64) covalent complex
4e4a  1.45  2012  IC50=9mM      // 4e3d.pdf (JKE) IC50=9+/-5mM (a standard esterase activity assay)
4g11  3.40  2012  IC50>10000nM  // 4g11.pdf (0W7)
3rzb  1.90  2012  IC50>100uM    // 3qqk.pdf (02Z) ligand is compound 41
3rpr  1.75  2012  IC50>100uM    // 3qqk.pdf (25Z) ligand is compound 37
3r9h  2.10  2012  IC50>100uM    // 3qqk.pdf (Z67) ligand is compound 90
3r9o  1.90  2012  IC50>100uM    // 3qqk.pdf (Z71) ligand is compound 88
4ai8  2.40  2012  IC50>100uM    // 4ai8.pdf (DZA) complex FIH and Daminozide; IC50(MALDI assay)
4gxs  1.96  2012  IC50>100uM    // 4gxs.pdf (0YS) Zn-containing
3tiz  2.02  2012  IC50>150uM    // 3ti1.pdf (3TI) ligand is compound 3
3avm  1.88  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 13
3avn  2.10  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 14
3avi  1.70  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 23
3avk  1.75  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 24
3avj  1.70  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 27
3avh  1.88  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 7
3avg  1.70  2012  IC50>500uM    // 3av9.pdf (8-mer) ligand is peptide 8
4b6e  2.46  2012  IC50>5mM      // 4b6e.pdf (10L)
4asy  2.30  2012  IC50>60uM     // 4arw.pdf (N5Y) compound 8f
3uyt  2.00  2012  IC50~14nM     // 3uyt.pdf (0CK) IC50=8-14nM(CK1 delta), IC50=7.7+/-2.2nM(CKI epsilon)
4b6f  2.89  2012  IC50~500uM    // 4b6e.pdf (20L) IC50(55    3% I at 500), Where it was not possible to measure a full IC50 curve, the percent inhibition (% I) at the given concentration is indicated.
3tvl  2.30  2012  Kd<0.1mM      // 3tvl.pdf (3PO)
2ll6   NMR  2012  Kd<0.1nM      // 2ll6.pdf (17-mer) ligand is iNOS peptide
3u9n  1.85  2012  Kd<100nM      // 3u9n.pdf (09H) compound 1
4ap0  2.59  2012  Kd<10nM       // 4ap0.pdf (G7X) complex Eg5-ADP-ispinesib
4b74  2.18  2012  Kd=0.022uM    // 4b6e.pdf (1LH)
4asj  2.25  2012  Kd=0.028uM    // 4arw.pdf (N6A) ligand is compound 8a; Kd=0.028+/-0.003uM; IC50=0.073+/-0.01uM
3uug  1.75  2012  Kd=0.031mM    // 3uug.pdf (BDP)
4dy6  2.20  2012  Kd=0.04mM     // 2i2b.pdf (A22)
3s8x  1.30  2012  Kd=0.05uM     // 3m2n.pdf (E59) ligand is compound 2a; Zn-containing; Kd by ITC (37C,pH=7.0)
4b73  2.50  2012  Kd=0.062uM    // 4b6e.pdf (4VA)
4ajn  2.10  2012  Kd=0.069uM    // 4aj1.pdf (88V) compound 29
4arw  2.20  2012  Kd=0.074uM    // 4arw.pdf (HNR) ligand is compound 1; Kd=0.074+/-0.006uM; IC50=0.21+/-0.03uM
4daf  2.50  2012  Kd=0.076uM    // 4d8a.pdf (0J4) X-ray((R)-compound 19), Kd((RS)-compound 19)
3u15  1.80  2012  Kd=0.078uM    // 3u15.pdf (03M) complex between MDMX and RO-2443
4ajo  1.96  2012  Kd=0.093uM    // 4aj1.pdf (88N) compound 33
4fcq  2.15  2012  Kd=0.101uM    // 4fcp.pdf (2N6)
4eki  2.85  2012  Kd=0.10nM     // 4ek9.pdf (0QK) Kd=0.10+/-0.02nM
4dew  1.90  2012  Kd=0.10uM     // 4der.pdf (LU2) Kd=0.10+/-0.01uM (Model:Independent)
4i47  2.65  2012  Kd=0.12uM     // 4emf.pdf (MY6)
4al4  1.78  2012  Kd=0.13uM     // 4aj1.pdf (W7E) compound 26
3rul  2.50  2012  Kd=0.14uM     // 3rul.pdf (7-mer) ligand is Dalbavancin; Kd=0.14+/-0.02uM; covalent complex
3s9t  1.30  2012  Kd=0.15uM     // 3m2n.pdf (E49) ligand is compound 1f; Zn-containing; Kd by ITC (37C,pH=7.0)
4gy5  2.96  2012  Kd=0.15uM     // 4gy5.pdf (17-mer) ligand is H3K9me3 prptide; Zn-containing, Kd=0.15uM(TTD-PHD of UHRF1 robustly bound to H3K9me3 peptide), Kd=0.97uM(TTD domain of UHRF1 binds to H3K9me3)
3uib  2.65  2012  Kd=0.16uM     // 3uib.pdf (SB2) compound LmaMPK10deltaC; Kd=0.16+/-0.015uM
4a7j  1.90  2012  Kd=0.1uM      // 4a7j.pdf (16-mer) compound WDR5-H3R2me2s; Kd=0.1+/-0.01uM; incomplete ligand
4b2d  2.30  2012  Kd=0.20mM     // 4b2d.pdf (SER) X-ray(human PKM2 with L-serine and FBP bound), Kd was measured in the presence of FBP
4gui  1.78  2012  Kd=0.23mM     // 4gui.pdf (QIC) Kd=0.23+/-0.04 mM (K170M DHQD), X-ray (WT DHQD)
3uzc  3.34  2012  Kd=0.248nM    // 3uza.pdf (T4E) compound 4e
3v3q  2.22  2012  Kd=0.25uM     // 3v3q.pdf (TMY)
4dkq  1.89  2012  Kd=0.25uM     // 4dko.pdf (0LK)
4h75  2.10  2012  Kd=0.25uM     // 4h75.pdf (8-mer) Kd=0.25+/-0.03uM; ligand is peptide H3K4(me3)
4db7  2.50  2012  Kd=0.273uM    // 4d8a.pdf (Z25)
3sax  1.10  2012  Kd=0.27uM     // 3m2n.pdf (E50) ligand is compound 1g; Zn-containing; Kd by ITC (37C,pH=7.0)
4a4v  2.00  2012  Kd=0.287uM    // 4a4v.pdf (YFD) ligand is amorfrutin 2
4aqh  2.40  2012  Kd=0.29uM     // 4aqh.pdf (TB7) ligand is AZ3976; Kd1=0.29+/-0.05uM(latent PAI-1,ITC),Kd2=0.38+/-0.05uM(Active PAI-1,ITC),Kd3=0.24+/-0.03uM(Active PAI-1,SPR),Kd4=0.19+/-0.01uM(latent PAI-1,SPR);IC501=26uM(enzymatic chromogenic assay),IC502=16uM(plasma clot lysis assay)
2lcs   NMR  2012  Kd=0.2uM      // 2lcs.pdf (16-mer) ligand is a peptide from Serine/threonine-protein kinase STE20
2lkk   NMR  2012  Kd=0.2uM      // 2lkk.pdf (OLA) ligand is compound oleate
4ewn  1.90  2012  Kd=0.2uM      // 4ewn.pdf (0VR)
4dkr  1.80  2012  Kd=0.30uM     // 4dko.pdf (0LJ)
4fut  2.00  2012  Kd=0.31uM     // 4fut.pdf (ATP) Mg-containing, Kd=0.31+/-0.09uM
4b5s  1.68  2012  Kd=0.32mM     // 4b5s.pdf (PYR) ligand is pyruvate; Kd=0.32+/-0.02mM
4gby  2.81  2012  Kd=0.35mM     // 4gby.pdf (XYP) Kd=0.35+/-0.03mM
4glr  1.90  2012  Kd=0.35nM     // 4glr.pdf (18-mer) incomplete ligand structure
3ask  2.90  2012  Kd=0.37uM     // 3ask.pdf (13-mer) ligand is H3K9me3; Kd=0.37+/-0.01uM
3v3l  1.65  2012  Kd=0.37uM     // 3v3l.pdf (V3L) Kd=0.37+/-0.02uM
3u0t  2.50  2012  Kd=0.3nM      // 3u0t.pdf (11-mer) ligand in assay is Amyloid beta 17-40 fragments; ligand in crystal is Amyloid beta A4 C-terminal residues 30-40
4dve  2.09  2012  Kd=0.3nM      // 4dve.pdf (BTN)
4dko  1.98  2012  Kd=0.3uM      // 4dko.pdf (0LM)
3v7d  2.31  2012  Kd=0.41uM     // 3v7d.pdf (19-mer) complex Cdc4 and Sic1; Kd=0.41+/-0.007uM.  ScSkp1-ScCdc4-pSic1 peptide complex; incomplete ligand
3tay  1.85  2012  Kd=0.42mM     // 3tay.pdf (MN0) Kd=0.42+/-0.095mM
4f3h  2.50  2012  Kd=0.42uM     // 4f3h.pdf (C2E) covalent complex
3ui2  3.18  2012  Kd=0.43uM     // 3ui2.pdf (13-mer) Kd=0.39uM is for full-length cpSRP43, correct Kd=0.43uM for cpSRP43 Delta CD3
3t6b  2.40  2012  Kd=0.44uM     // 3t6b.pdf (5-mer) ligand is peptide tynorphin; Kd=0.44+/-0.02uM (at 25C); Kd=0.22+/-0.03uM (at 35C)
3t6j  2.98  2012  Kd=0.44uM     // 3t6j.pdf (5-mer) ligand is opioid peptide tynorphin; Kd=0.44+/-0.02uM (at 25C); Kd=0.22+/-0.03uM (at 35C)
3tpx  1.80  2012  Kd=0.45nM     // 3tpx.pdf (12-mer) ligand is D-peptide inhibitor DPMI-delta; Kd=0.45+/-0.41nM
4b0b  1.90  2012  Kd=0.47mM     // 4b0b.pdf (54F) fragment 2; Ka=2140+/-31.8M(ITC)
4b5t  1.92  2012  Kd=0.47mM     // 4b5s.pdf (2KT) ligand is ketobutyrate; Kd=0.47+/-0.02mM
4b5w  1.79  2012  Kd=0.47mM     // 4b5s.pdf (PYR) ligand is pyruvate; Kd=0.47+/-0.001mM (with 0.5mM Co2+)
4der  1.90  2012  Kd=0.49uM     // 4der.pdf (AGI) Kd=0.49+/-0.13uM (Model:Independent)
4erf  2.00  2012  Kd=0.4nM      // 4ere.pdf (0R3) IC50=1.1+/-0.5nM(0% human serum), IC50=4.2+/-1.8nM(15% human serum)
4fcr  1.70  2012  Kd=0.4nM      // 4fcp.pdf (0TM)
4eu0  1.70  2012  Kd=0.4uM      // 4etz.pdf (C2E) one molecule (c-di-GMP) in the asymmetric unit
4f20  2.50  2012  Kd=0.5083mM   // 4f1z.pdf (13-mer) ligand is peptide from Dermokine; incomplete ligand
4d8z  2.20  2012  Kd=0.51uM     // 4d8a.pdf (0J2) X-ray((R)-compound 24), Kd((RS)-compound 24)
3vhd  1.52  2012  Kd=0.52nM     // 3vha.pdf (VHE) ligand is compound 16
4ay5  3.15  2012  Kd=0.54uM     // 4ay5.pdf (UDP) complex hOGT and UDP; Kd=0.54+/-0.01uM
4dj7  2.81  2012  Kd=0.5uM      // 4dj6.pdf (3-mer) ligand is SIA-NAG-GAL
4euv  2.00  2012  Kd=0.5uM      // 4etz.pdf (C2E) 1 molecule (c-di-GMP) in the asymmetric unit
4etz  2.05  2012  Kd=0.5uM      // 4etz.pdf (C2E) two molecules (c-di-GMP) in the asymmetric unit
4dma  2.30  2012  Kd=0.65uM     // 4dm6.pdf (15-mer) ligand is peptide from Nuclear receptor coactivator 1; The SRC-2 RID binds to liganded ER-alpha LBD dimers with a stoichiometry of 1 coactivator per homodimer and a Kd of 0.65 uM.Kd=0.65+/-0.005uM
4aq4  1.80  2012  Kd=0.68uM     // 4aq4.pdf (G3P) complex between UgpB and G3P; Kd=0.68+/-0.02uM
4gbz  2.89  2012  Kd=0.77mM     // 4gby.pdf (BGC) Kd=0.77+/-0.01mM
2y9q  1.55  2012  Kd=0.7uM      // 2xrw.pdf (18-mer) ligand is pepMNK1
4e8y  2.60  2012  Kd=0.81uM     // 4e8y.pdf (IHA) K-containing, IC50(myelin basic protein), the complex include ligand M7B
3sfg  2.21  2012  Kd=0.865uM    // 3sfg.pdf (2TU) Kd=0.865+/-0.4uM
4h5e  2.04  2012  Kd=0.86uM     // 4h5c.pdf (IPR) Kd=0.86+/-0.06uM; another ligand is YS4
4euc  2.64  2012  Kd=0.8uM      // 4eu3.pdf (0RQ)
4gah  2.30  2012  Kd=0.8uM      // 4gah.pdf (0ET) Kd=0.8+/-0.1uM
4glw  2.00  2012  Kd=0.8uM      // 4glw.pdf (0XT)
4e34  1.40  2012  Kd=0.97uM     // 4e34.pdf (10-mer) Kd (F*-iCAL36 (F*-ANSRWPTSII) for CALP)
4g0p  1.80  2012  Kd=0.98mM     // 4g0p.pdf (U5P) Kd=0.98+/-0.01mM
4guj  1.50  2012  Kd=0.9mM      // 4gui.pdf (SKM) Kd=0.9+/-0.2 mM (K170M DHQD), X-ray (WT DHQD)
4ara  2.50  2012  Kd=0.9uM      // 4ara.pdf (C56) complex between Mus musculus AChE and R-6
4g69  2.00  2012  Kd=1.05uM     // 4g69.pdf (11-mer) Kd=1.05+/-0.22uM; ligand is from Adenomatous polyposis coli protein
4fm8  1.90  2012  Kd=1.06uM     // 4fm7.pdf (0UQ) ligand is compound 12a; binding free energy = -8.15 kcal/mol (ITC); IC50=2.4uM
3uil  2.20  2012  Kd=1.0uM      // 3t2v.pdf (DAO) ligand is lauric acid; Kd=1.0+/-0.63uM
3uza  3.27  2012  Kd=1.16nM     // 3uza.pdf (T4G) compound 4g
4dst  2.30  2012  Kd=1.1mM      // 4dsn.pdf (9LI) Kd=1.1+/-0.5mM; Mg-containing
4ai5  2.22  2012  Kd=1.2mM      // 4ai5.pdf (ADK) complex between Y16F-mutant and 3-MeA
3vhc  1.41  2012  Kd=1.3nM      // 3vha.pdf (VHC) ligand is compound 11
4arb  2.25  2012  Kd=1.3uM      // 4ara.pdf (C57) complex between Mus musculus AChE and S-6
2lnw   NMR  2012  Kd=1.40uM     // 2lnw.pdf (9-mer) ligand is pY1408; Kd=1.40+/-0.05uM
4des  1.75  2012  Kd=1.40uM     // 4der.pdf (57D) Kd=1.40+/-0.06uM (Model:Independent); IC50=12.16+/-1.08uM
3udh  1.70  2012  Kd=1.4mM      // 3udh.pdf (091) ligand is compound 1
2liq   NMR  2012  Kd=1.4uM      // 2liq.pdf (3-mer)
3ual  1.80  2012  Kd=1.55uM     // 3ual.pdf (14-mer) Kd=1.55+/-0.06uM(WT); Kd=4.99+/-0.59uM(F33A); Kd=1.53+/-0.05uM(E35A); Kd=1.55+/-0.29uM(F37A); incomplete ligand
4dsu  1.70  2012  Kd=1.5mM      // 4dsn.pdf (BZI) Kd=1.5+/-0.3mM; Mg-containing
3que  2.70  2012  Kd=1.5nM      // 3que.pdf (3FF)
2llo   NMR  2012  Kd=1.5uM      // 2llo.pdf (19-mer) ligand is ER alpha peptide; Kd=1.5+/-0.2uM(CaM:ER=1:2)
2llq   NMR  2012  Kd=1.5uM      // 2llq.pdf (19-mer) ligand is ER alpha peptide; Kd=1.5+/-0.2uM(CaM:ER=1:1)
3r5n  2.00  2012  Kd=1.67uM     // 3r5m.pdf (MLO)
2ll7   NMR  2012  Kd=1.6nM      // 2ll6.pdf (17-mer) ligand is eNOS peptide
3v31  1.57  2012  Kd=1.6uM      // 3uxg.pdf (18-mer) complex ANKRA2 and HDAC4; Kd=1.6+/-0.2uM
3asl  1.41  2012  Kd=1.73uM     // 3ask.pdf (11-mer) Kd=1.73+/-0.09uM
4b4q  2.00  2012  Kd=1.76uM     // 4b4q.pdf (6-mer) Kd=1.76+/-0.78uM (back scattering interferometry (BSI))
4ekg  2.80  2012  Kd=1.7nM      // 4ek9.pdf (0QJ) Kd=1.7+/-0.2nM
3rum  1.85  2012  Kd=1.7uM      // 3rul.pdf (7-mer) ligand is Ristocetin; Kd=1.7+/-0.3uM; covalent complex
4fxq  1.96  2012  Kd=1.7uM      // 4fk7.pdf (G9L) Kd=1.7+/-0.2uM, Ki=1.8+/-0.4uM, IC50=6.1+/-1.2uM;
3ut5  2.73  2012  Kd=1.8uM      // 3ut5.pdf (4-mer) complex sT2R-ustiloxin; Kd=1.8+/-0.6uM
4gao  3.28  2012  Kd=1.8uM      // 4gao.pdf (12-mer) ligand is UBC12(NAc1-21)
4abk  1.60  2012  Kd=1.9uM      // 3q6z.pdf (AR6) Kd=1.9+/-0.1uM
4dkp  1.80  2012  Kd=1.9uM      // 4dko.pdf (0LL)
4dn0  2.30  2012  Kd=1.9uM      // 4dn0.pdf (C2E) Na-containing; Kd = 1.9 +/- 0.1 uM
3uii  2.60  2012  Kd=10.0uM     // 3uig.pdf (10-mer) Kd=10.0+/-1.4uM; incomplete ligand
3uik  2.70  2012  Kd=10.6uM     // 3uig.pdf (10-mer) complex K62Y/H80W mutated Survivin and H3; Kd=10.6+/-0.7uM; incomplete ligand
3qbc  1.65  2012  Kd=10.8uM     // 3qbc.pdf (B55) Kd=10.8+/-0.4uM(SPR)
3zsq  1.70  2012  Kd=10.9uM     // 3zcm.pdf (O4N) ligand is compound 10; Kd=10.9+/-2.7uM(Core3H); Kd=74+/-16uM(Core4H)
4aza  2.16  2012  Kd=103.0nM    // 4aza.pdf (14-mer) ligand is EIF4G1_D5S PEPTIDE;Kd=103.0+/-2.3nM
2y6s  2.80  2012  Kd=103nM      // 2y6s.pdf (17-mer) ligand is peptide from ENVELOPE GLYCOPROTEIN; Kd=103+/-47nM
4es0  1.82  2012  Kd=103nM      // 4erq.pdf (14-mer) ligand is Histone-lysine N-methyltransferase SETD1B
4av0  2.10  2012  Kd=104.6nM    // 4auy.pdf (HNV) ligand is compound 6; Kd=104.6+/-21.9nM
4agm  1.52  2012  Kd=105uM      // 4agl.pdf (P86) ligand is compound 4; Kd=105uM(ITC); Kd=104+/-23uM(NMR)
4agn  1.60  2012  Kd=107uM      // 4agl.pdf (NXG) ligand is compound 9; Kd=107uM(ITC); Kd=114+/-8uM(NMR)
3uxg  1.85  2012  Kd=109uM      // 3uxg.pdf (17-mer) complex RFXANK and HDAC4; Kd=109+/-23uM; incomplete ligand
3t0x  1.96  2012  Kd=10nM       // 3t0v.pdf (DIW)
4g8l  2.80  2012  Kd=10nM       // 4g8l.pdf (25A)
4f1q  2.80  2012  Kd=11.2uM     // 4f0e.pdf (0RZ)
4dmw  2.50  2012  Kd=11.4uM     // 4dmw.pdf (UDP) Kd=11.4+/-0.9uM; Mn-containing; Kd by nonradioactive glycotransferase assay, Kd(UDP-glucose-Mn-Tcd); X-ray(UDP-Mn-TcdA)
4e9c  1.70  2012  Kd=1100nM     // 4e9c.pdf (11-mer) incomplete ligand structure, ligand is LDPPLHSpTA phosphopeptide
4dai  2.50  2012  Kd=110nM      // 4d8a.pdf (0J5) Kd = 110 +/- 1 nM
2lo6   NMR  2012  Kd=113uM      // 2lo6.pdf (14-mer) ligand is pSer5 CTD; Kd=113+/-5uM
4hbm  1.90  2012  Kd=12.0nM     // 2lzg.pdf (0Y7) Kd=12.0+/-0.1nM
4g8m  2.05  2012  Kd=12.8nM     // 4g8m.pdf (G8M)
4f14  1.20  2012  Kd=12.93uM    // 4f14.pdf (13-mer) Kd = 12.93 +/- 0.84 uM; incomplete ligand
3u6w  2.21  2012  Kd=120nM      // 3u6w.pdf (KIV) compound KIV-MtuLeuA425; Kd=120+/-15nM
2yim  1.41  2012  Kd=120uM      // 2yim.pdf (MC4)
3uih  2.40  2012  Kd=121uM      // 3uig.pdf (15-mer) Kd=121+/-15uM; incomplete ligand
3uyr  1.70  2012  Kd=127nM      // 3uo1.pdf (8-mer) ligand is pC35-55Ld; Kd=127+/-1.4nM
3au6  3.30  2012  Kd=12nM       // 3au6.pdf (DG3) complex of ttPolX and Mg-dGTP. Kd=12+/-1.6nM
3sbi  1.40  2012  Kd=12nM       // 3m2n.pdf (E90) ligand is compound 2j; Zn-containing; Kd by ITC (37C,pH=7.0)
4g68  1.80  2012  Kd=12nM       // 4g68.pdf (3-mer) Kd=12+/-1nM
4aj4  1.90  2012  Kd=130uM      // 4aj1.pdf (VAB) ligand is compound 18
4dgb  1.70  2012  Kd=130uM      // 4dgb.pdf (6-mer) ligand is peptide from capsid protein; Kd measured with DTT; no binding to HIV-2 without DTT
3u3u  2.50  2012  Kd=133.3nM    // 3u3l.pdf (EAH) ligand is compound LTE4; Kd=133.3+/-23.3nM
4ab8  1.60  2012  Kd=136uM      // 4ab8.pdf (VXU) ligand is CC 00413
3zt3  1.95  2012  Kd=1375uM     // 3zcm.pdf (ZT4) ligand is compound 2; Kd=1375+/-149uM(Core3H); Kd=763+/-372uM(Core4H)
3uoh  2.80  2012  Kd=13nM       // 3unj.pdf (0C4) compound 8; Kd=13+/-2.2nM; IC50=2.1+/-0.4nM
4djs  3.03  2012  Kd=13nM       // 4djs.pdf (17-mer) incomplete ligand structure; Kd=13+/-2nM
2lsk   NMR  2012  Kd=13uM       // 2lsk.pdf (16-mer)
3ttn  2.00  2012  Kd=14.3nM     // 3ttm.pdf (SPD)
3r0y  1.65  2012  Kd=14.53uM    // 3r0w.pdf (RSZ) ligand is compound 1; IC50=14.53+/-1.65uM
3zt2  1.70  2012  Kd=1435uM     // 3zcm.pdf (ZT2) ligand is compound 3; Kd=1435+/-304uM(Core3H); Kd=724+/-347uM(Core4H)
4ago  1.45  2012  Kd=15.5uM     // 4agl.pdf (P74) ligand is compound 11; Kd by ITC
4gkc  1.30  2012  Kd=150nM      // 4ede.pdf (RET) Kd=150+/-12nM, covalent complex
4fl3  1.90  2012  Kd=150uM      // 4fl1.pdf (ANP) Kd=150+/-30uM, Mg-containing
4aba  1.25  2012  Kd=153uM      // 4ab8.pdf (SW1) ligand is CC 11513
4eqf  3.00  2012  Kd=155nM      // 4eqf.pdf (7-mer) Kd=155+/-31nM; ligand is peptide from Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2
3zt4  2.20  2012  Kd=1570uM     // 3zcm.pdf (ZT2) compound 1; Kd=1570+/-337uM(Core3H); Kd=750+/-311uM(Core4H); redundant to 3zt2
3qn7  1.90  2012  Kd=157nM      // 3qn7.pdf (17-mer) ligand is Bicyclic peptide inhibitor;Kd157+/-39nM
4ahv  1.80  2012  Kd=15mM       // 3vq4.pdf (Z5P) ligand is compound 64
3uo6  2.80  2012  Kd=15nM       // 3unj.pdf (0BY) compound 7; Kd=15+/-1.5nM; IC50=2.5+/-0.3nM
4e6c  2.39  2012  Kd=15uM       // 4e6a.pdf (0O8) Kd=15+/-5uM, incomplete ligand structure
4fys  2.01  2012  Kd=15uM       // 4fyr.pdf (6-mer) Kd=15+/-4.0 uM
2lzg   NMR  2012  Kd=16.9nM     // 2lzg.pdf (13Q) Kd=16.9+/-0.2nM; NMR Structure
4ajl  1.77  2012  Kd=160uM      // 4aj1.pdf (88W) ligand is compound 24
3unz  2.80  2012  Kd=16nM       // 3unj.pdf (0BZ) compound 6; Kd=16+/-1.6nM; IC50=3.7+/-0.7nM
4glx  1.90  2012  Kd=16nM       // 4glw.pdf (0XS) compound 20a, but has 26-mer DNA in crystal on RCSB PDB website, Kd(S. pneumoniae LigA), X-ray(E. coli LigA), IC50(E. coli LigA)
4de7  3.00  2012  Kd=16uM       // 4de7.pdf (UDP) Kd = 16 +/- 1 uM; incomplete ligand structure
4ds1  1.85  2012  Kd=17.9uM     // 4ds1.pdf (11-mer) Kd = 17.9+/-3.8 uM; incomplete ligand
4fn5  2.90  2012  Kd=173nM      // 4fn5.pdf (8-mer) ligand is peptide from Argyrin B
3uvq  2.20  2012  Kd=17nM       // 3uvq.pdf (FS8) compound 16e
2y1n  2.00  2012  Kd=17uM       // 2y1n.pdf (12-mer) ligand is ZAP-70 peptide; Kd=17+/-0.4uM
3ud7  2.80  2012  Kd=18.1uM     // 3ud7.pdf (GNS-IDY) compound 89
4auy  2.10  2012  Kd=18.3nM     // 4auy.pdf (HNW) compound 4; Kd=18.3+/-5.9nM
3vjc  1.89  2012  Kd=18.9nM     // 3vjc.pdf (ZGA) ligand is ZA-A; Kd=18.9+/-0.4nM
3v30  1.57  2012  Kd=184uM      // 3uxg.pdf (17-mer) complex RFXANK and RFX5; Kd=184+/-44uM; incomplete ligand
3uij  2.71  2012  Kd=19.8uM     // 3uig.pdf (15-mer) complex K62Y/H80W mutated Survivin and SmacN; Kd=19.8+/-2.3uM; incomplete ligand
4flp  2.23  2012  Kd=190.1nM    // 4flp.pdf (JQ1) Kd=190.1+/-7.6nM; K-containing
4a4w  2.00  2012  Kd=19nM       // 4a4v.pdf (YFB) ligand is amorfrutin B
4egk  1.69  2012  Kd=19nM       // 4egh.pdf (RDC) Kd value from ref.28
4fvq  1.75  2012  Kd=1uM        // 4fvq.pdf (ATP) Mg-containing
4fvr  2.00  2012  Kd=1uM        // 4fvq.pdf (ATP) Mg-containing
4det  2.05  2012  Kd=2.10uM     // 4der.pdf (KMP) Kd=2.10+/-0.63uM (Model:Independent); IC50=8.26+/-1.06uM
3u0p  2.80  2012  Kd=2.1uM      // 3tyf.pdf (LSC) lipid, not good drugs; Kd=2.1+/-1.1uM
4deu  1.60  2012  Kd=2.29uM     // 4der.pdf (NAR) Kd=2.29+/-0.18uM (Model:Independent); IC50=12.39+/-1.16uM
4ft2  3.20  2012  Kd=2.3uM      // 4fsx.pdf (15-mer) Intermolecular interaction between the chromodomain of ZMET2 and H3(1 C15)K9me2 peptide
4dru  2.10  2012  Kd=2.4nM      // 4dru.pdf (0LN)
4f9g  2.95  2012  Kd=2.4uM      // 4f9g.pdf (C2E) Kd=2.4+/-0.5uM
4htp  2.25  2012  Kd=2.4uM      // 4htp.pdf (11-mer) ligand is cArt-Pep
4eqj  1.80  2012  Kd=2.52uM     // 4ep2.pdf (8-mer) Kd = 2.52 +/- 0.4 uM; X-ray(Pr-3), Kd(the D25N (inactive) variants of Pr-3); incomplete ligand structure
3udv  1.88  2012  Kd=2.55uM     // 3ud5.pdf (J1C) compound HPPK-19; Kd=2.55+/-0.15uM; IC50=3.16+/-0.34uM
2yhw  1.64  2012  Kd=2.5uM      // 2yhw.pdf (BM3) ligand is N-acetylmannosamine
2yhy  1.82  2012  Kd=2.5uM      // 2yhw.pdf (BM3) ligand is N-acetylmannosamine;ADP containing; redundant to 2yhw
3r5t  1.45  2012  Kd=2.65nM     // 3r5t.pdf (VBN) Fe-containing; Kd=2.65+/-0.63nM
2lgf   NMR  2012  Kd=2.7uM      // 2lgf.pdf (15-mer) ligand is L-selectin;Ca2+ containing, Kd=2.7+/-1.2 uM
3ubd  1.53  2012  Kd=2.9uM      // 3ubd.pdf (SL0) ligand is compound SL0101
3v78  2.30  2012  Kd=2.9uM      // 3v78.pdf (ET) complex between Rv3066 and ethidium; Kd=2.9+/-0.2uM
4agp  1.50  2012  Kd=20.6uM     // 4agl.pdf (P51) ligand is compound 12; Kd by ITC
4gwi  1.60  2012  Kd=202uM      // 4gwi.pdf (BDZ) Kd=202+/-31uM, Mg-containing, Ca-containing
4e9d  2.75  2012  Kd=20nM       // 4e9c.pdf (10-mer) incomplete ligand structure, ligand is 3-(1-benzothiophen-2-yl)propanoyl-derivatized DPPLHSpTA peptide
3uef  2.45  2012  Kd=21.0uM     // 3uec.pdf (12-mer) hs wt H3T3(1-12); Kd=21.0+/-1.8uM; incomplete ligand
3ud9  2.34  2012  Kd=21.2uM     // 3ud7.pdf (SGN-IDY) compound 91
4aje  2.35  2012  Kd=210uM      // 4aj1.pdf (2B4) ligand is compound 20
4aia  1.80  2012  Kd=220uM      // 4ai5.pdf (ADK) Kd=220uM(pH=7.8,ITC); Kd=470uM(pH=5.8,ITC); Kd=78uM(pH=7.8,fluorescence); Kd=165uM(pH=5.8,fluorescence)
4fl2  2.19  2012  Kd=220uM      // 4fl1.pdf (ANP) Kd=220+/-30uM; Mg-containing
4agl  1.70  2012  Kd=225uM      // 4agl.pdf (P84) ligand is compound 3; Kd=225uM(ITC); Kd=184+/-23uM(NMR)
2yme  2.40  2012  Kd=22nM       // 2ymd.pdf (CWB)
4fbx  2.33  2012  Kd=22nM       // 4fbx.pdf (7-mer) Kd measured in FA displacement assay; ligand is bisubstrate inhibitor; incomplete ligand
4gq4  1.27  2012  Kd=22nM       // 4gq3.pdf (0RT)
3v43  1.47  2012  Kd=23.3uM     // 3v43.pdf (18-mer) peptide H3(1-18)K14ac; incomplete ligand
4avi  2.40  2012  Kd=23.6nM     // 4auy.pdf (XNS) ligand is compound 2; Kd=23.6+/-3.6nM
3umq  2.20  2012  Kd=24.1uM     // 3t2v.pdf (BUA) ligand is butyric acid; Kd=24.1+/-2.0uM
4a4c  2.70  2012  Kd=244uM      // 2y1n.pdf (12-mer) Kd=244+/-7uM
4dbm  2.30  2012  Kd=24nM       // 4dbm.pdf (0J0) Kd=24+/-6.8nM
3tcy  1.55  2012  Kd=24uM       // 3tcy.pdf (PHE) Phe-soaked cPAH; Kd=24+/-1.1uM; redundant to 3tk2
3tk2  1.35  2012  Kd=24uM       // 3tcy.pdf (PHE) cPAH co-crystallized with Phe; Kd=24+/-1.1uM
3u90  1.90  2012  Kd=24uM       // 3u90.pdf (SDS) complex between apoferritin and SDS; Kd=24+/-9uM(at 293K)
4abf  1.30  2012  Kd=24uM       // 4ab8.pdf (513) ligand is CC 33513
4ad3  2.00  2012  Kd=24uM       // 4acz.pdf (GLC-DMJ)
4g0a  2.10  2012  Kd=25.3nM     // 4g0a.pdf (3-mer) incomplete ligand
4dcv  2.60  2012  Kd=25.7uM     // 4dcs.pdf (GCP) Kd=25.7+/-2.8uM (no salt), nucleotide binding content (GD1/GD2):empty/GMPPCP
2lbv   NMR  2012  Kd=26nM       // 2lbv.pdf (ACD)
3sap  1.75  2012  Kd=26nM       // 3m2n.pdf (E2I) ligand is compound 2i; Zn-containing; Kd by ITC (37C,pH=7.0)
4fnn  2.24  2012  Kd=27.2nM     // 3t2v.pdf (STE) ligand is stearic acid; Kd=27.2+/-7.4nM
3uw9  2.30  2012  Kd=27.4uM     // 3mb3.pdf (11-mer) ligand is H4K8K12; Kd=27.4+/-0.9uM
3ztc  2.65  2012  Kd=27.7uM     // 3ztc.pdf (TR0) compound 2; Kd=27.7+/-0.2uM
4abg  1.52  2012  Kd=271uM      // 4ab8.pdf (91B) ligand is CC 35913
4esg  1.70  2012  Kd=2762nM     // 4erq.pdf (17-mer) peptide in crystal is Ac-EPPLPNPHGSARAEVHLRK-NH2, peptide in assay is Ac-LNPHGSARAEVHLR-NH2
4aji  1.93  2012  Kd=280uM      // 4aj1.pdf (88R) ligand is compound 21
3ued  2.70  2012  Kd=29.6uM     // 3uec.pdf (12-mer) hs wt H3T3ph(1-12); Kd=29.6+/-5.4uM; incomplete ligand
3uo4  2.45  2012  Kd=299nM      // 3unj.pdf (0C0) ligand is compound 3; Kd=299+/-27nM; IC50=149+/-23nM
4exz  1.61  2012  Kd=29nM       // 4ede.pdf (RET) Kd=29+/-5nM, covalent complex
4b76  2.14  2012  Kd=29uM       // 4b6e.pdf (PW1)
4bd3   NMR  2012  Kd=29uM       // 4bd3.pdf (11-mer) ligand is H3K36me3 peptide; Kd=29+/-5uM
3rqw  2.91  2012  Kd=2mM        // 3rqw.pdf (ACH)
4eo6  1.79  2012  Kd=2nM        // 4eo6.pdf (0S2) Kd(HCV NS5B GT-1b delta21); IC50(RNA dependent HCV GT-1b NS5B polymerase)
4g0q  1.80  2012  Kd=3.00mM     // 4g0p.pdf (C5P) Kd=3.00+/-0.48mM
3ttm  2.00  2012  Kd=3.0nM      // 3ttm.pdf (PUT)
3u51  2.24  2012  Kd=3.1uM      // 3u4w.pdf (6-mer) compound 1; IC50=25+/-3.0uM
3tz4  2.25  2012  Kd=3.2uM      // 3tz4.pdf (03H) with ADP; ligand is compound 4; Kd=3.2+/-0.6uM
4ah9  1.70  2012  Kd=3.5mM      // 3vq4.pdf (0MB) ligand is compound 68
3run  1.40  2012  Kd=3.6uM      // 3rul.pdf (7-mer) ligand is VANCOMYCIN; Kd=3.6+/-0.7uM; covalent complex
4f5y  2.40  2012  Kd=3.70uM     // 4f5y.pdf (C2E) a dimeric receptor-ligand complex with 2:1 stoichiometry, Ca-containing
2lyw   NMR  2012  Kd=30.0uM     // 2lyw.pdf (13-mer) Kd=30+/-10uM
4gzw  2.45  2012  Kd=30.0uM     // 4gzp.pdf (3-mer) ligand is SIA-NAG-GAL; Kd=30.0+/-5.5uM
4dcy  2.00  2012  Kd=30.2uM     // 4dcx.pdf (L2M) Kd=30.2+/-1.6uM
2lp8   NMR  2012  Kd=30.5nM     // 2lp8.pdf (18-mer) ligand is BakI81F; Kd=30.5+/-5.7nM
4dcx  2.00  2012  Kd=31.4uM     // 4dcx.pdf (L2D) Kd=31.4+/-2.7uM
4abb  1.25  2012  Kd=31uM       // 4ab8.pdf (K9S) ligand is CC 12313
4emr  1.75  2012  Kd=32.1nM     // 4emf.pdf (MGP)
4e67  2.10  2012  Kd=330nM      // 4e67.pdf (8-mer) ligand is PLHSpTA peptide
4epy  1.80  2012  Kd=340uM      // 4epr.pdf (0QY)
4aft  3.20  2012  Kd=342nM      // 4afo.pdf (QMR) complex AcAChBP and Varenicline
3t2w  1.50  2012  Kd=35nM       // 3szj.pdf (BTN)
4f3i  1.40  2012  Kd=36.1nM     // 2lsp.pdf (0S6) ligand is MS417;Kd=36.1+/-7.8nM
4avj  2.10  2012  Kd=36.5nM     // 4auy.pdf (J73) ligand is compound 5; Kd=36.5+/-6.4nM
4fmu  2.10  2012  Kd=360nM      // 4fmu.pdf (0UM) Kd=360+/-15nM
4b4n  1.81  2012  Kd=362uM      // 4b4n.pdf (15-mer) ligand is CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR SUBUNIT 6
4ffs  1.90  2012  Kd=36pM       // 4ffs.pdf (BIG)
4hcz  1.85  2012  Kd=36uM       // 4hcz.pdf (10-mer) ligand is H3K36me3 peptide, Kd=36+/-4uM
4axd  2.05  2012  Kd=37uM       // 4axd.pdf (ANP) ligand is AMPPNP, Kd=37+/-9 uM
2yi5  2.50  2012  Kd=39nM       // 2yi0.pdf (YI5) ligand is ICPD 34
3uo5  2.70  2012  Kd=39nM       // 3unj.pdf (0BX) compound 1; Kd=39+/-5.9nM; IC50=10+/-1.6nM
3tct  1.30  2012  Kd=3nM        // 3tct.pdf (3MI) Kd4=154nM for the second binding site
3ud8  2.37  2012  Kd=4.13uM     // 3ud7.pdf (GNX-IDY) compound 90
4f7v  1.73  2012  Kd=4.16uM     // 4f7v.pdf (J1D) Kd=4.16+/-0.25uM
2ltx   NMR  2012  Kd=4.1uM      // 2ltv.pdf (15-mer) Kd=4.1+/-0.1uM
3so6  1.37  2012  Kd=4.1uM      // 3so6.pdf (14-mer) ligand is LDLR tail peptide; Kd=4.1+/-134uM
3tgs  2.70  2012  Kd=4.1uM      // 3tgs.pdf (03G) ligand is NBD-556
2lty   NMR  2012  Kd=4.2uM      // 2ltv.pdf (15-mer) Kd=4.2+/-0.1uM
3tif  1.80  2012  Kd=4.2uM      // 3tif.pdf (ADP) Kd=4.2+/-0.6uM
4g0k  2.56  2012  Kd=4.3uM      // 4g0k.pdf (0VS)
4ef4  2.15  2012  Kd=4.42uM     // 4ef4.pdf (C2E) Ca-containing; Kd = 4.42 +/- 0.02 uM
4ep2  1.90  2012  Kd=4.43uM     // 4ep2.pdf (8-mer) Kd = 4.43 +/- 0.9 uM; X-ray(WT protease), Kd(the D25N (inactive) variants of WT protease); incomplete ligand structure
3r7o  2.30  2012  Kd=4.4nM      // 3q6w.pdf (M61) lignad is compound 1 (MK-2461)
3u3z  1.50  2012  Kd=4.4uM      // 3szm.pdf (4-mer) Kd=4.4+/-0.3uM
2ltz   NMR  2012  Kd=4.5uM      // 2ltv.pdf (15-mer) Kd=4.5+/-0.2uM
3r8i  2.30  2012  Kd=4.5uM      // 3r8i.pdf (XCX) ligand is compound 2
3v2x  1.85  2012  Kd=4.5uM      // 3uxg.pdf (11-mer) complex Megalin and ANKRA2; Kd=4.5+/-0.5uM
3zyr  1.65  2012  Kd=4.6uM      // 3zyr.pdf (8-mer) ligand is compound H
3rzi  1.95  2012  Kd=4.7uM      // 3rzi.pdf (TRP) Kd=21+/-1uM (Phe only); Kd=4.7+/-0.1uM (Trp only); Kd=5.0+/-0.1uM (Phe to Trp-bound protein); Kd=1.08+/-0.03uM (Trp to Phe-bound protein)
2yi7  1.40  2012  Kd=4.8nM      // 2yi0.pdf (BZ8) ligand is ICPD 47
3uig  2.40  2012  Kd=4.8uM      // 3uig.pdf (15-mer) complex Survivin and H3T3ph; Kd=4.80+/-1.13uM; incomplete ligand
4g0y  1.65  2012  Kd=4.99mM     // 4g0p.pdf (AMP) Kd=4.99+/-0.67mM
3v2o  1.89  2012  Kd=4.9uM      // 3uxg.pdf (19-mer) complex Megalin and ANKRA2; Kd=4.9+/-0.6uM; incomplete ligand
4abe  1.30  2012  Kd=400uM      // 4ab8.pdf (913) ligand is CC 32913
3re4  2.00  2012  Kd=40nM       // 3re4.pdf (TO1)
3up2  2.30  2012  Kd=40nM       // 3unj.pdf (0C8) ligand is compound 5; Kd=40+/-5.6nM; IC50=28+/-4.8nM
3vha  1.39  2012  Kd=40nM       // 3vha.pdf (VHA) ligand is compound 8
3unn  1.70  2012  Kd=40uM       // 3unn.pdf (8-mer) Kd=40+/-3uM, ligand is phospho-T4 peptide from Mediator of DNA damage checkpoint protein 1
3va4  1.54  2012  Kd=40uM       // 3va4.pdf (11-mer) incomplete ligand
4abd  1.25  2012  Kd=40uM       // 4ab8.pdf (SW2) ligand is CC 21913
4aj2  1.75  2012  Kd=4200uM     // 4aj1.pdf (52C) compound 14
3uvu  2.38  2012  Kd=42nM       // 3uvu.pdf (19-mer) Kd=42+/-6.5nM
4ede  1.40  2012  Kd=42nM       // 4ede.pdf (RET) Kd=42+/-6nM, covalent complex, incomplete ligand
3rsr  2.30  2012  Kd=44uM       // 3rsr.pdf (N5P) Kd1=44uM(S-site), Kd2=5mM(A-site)
4fi9  3.05  2012  Kd=45.6nM     // 4fi9.pdf (14-mer)
3r5m  2.80  2012  Kd=45.7uM     // 3r5m.pdf (MLO)
4azf  2.55  2012  Kd=450nM      // 4aze.pdf (3RA)
2yq6  1.80  2012  Kd=45nM       // 2yq6.pdf (19-mer) ligand is BimSAHB
4a2a  1.80  2012  Kd=45uM       // 4a2a.pdf (16-mer) complex FtsA and Ftsz; Kd=45-58uM; incomplte ligand
3uvx  1.91  2012  Kd=46.1uM     // 3mb3.pdf (11-mer) ligand is H4K12K16; Kd=46.1+/-0.9uM; incomplete ligand
4gwk  1.53  2012  Kd=460uM      // 4gwk.pdf (3PG) Kd=460+/-40uM
4ab9  1.20  2012  Kd=466uM      // 4ab8.pdf (VXQ) ligand is CC 00813
3uod  2.50  2012  Kd=49nM       // 3unj.pdf (0C3) ligand is compound 4; Kd=49+/-5.2nM; IC50=35+/-4.1nM
4ahu  1.90  2012  Kd=5.4mM      // 3vq4.pdf (ICO) ligand is compound 67
3tkw  1.55  2012  Kd=5.4uM      // 3tkg.pdf (017) ligand is DRV; Kd=5.4+/-1.4uM
3zrc  2.90  2012  Kd=5.4uM      // 3zrc.pdf (L8B) compound 15; Kd=5.4+/-0.uM;
3ug2  2.50  2012  Kd=5.6nM      // 3ug2.pdf (IRE) Kd=5.6nM(G719S/T790M); Kd=31.9nM(G719S); Kd=14.2nM(WT)
2lsr   NMR  2012  Kd=5.7uM      // 2lsr.pdf (16-mer) ligand is 16-mer peptide from Cadherin-23; Kd=5.7+/-0.6uM
3tz2  2.85  2012  Kd=5.7uM      // 3tz2.pdf (CLT) ligand is compound 4;Kd=5.7+/-0.7uM
4e81  1.90  2012  Kd=5.8uM      // 4e81.pdf (10-mer) Kd=5.8+/-1.7uM; ligand is apidaecin peptide fragment; incomplete ligand
4fk7  1.78  2012  Kd=5.8uM      // 4fk7.pdf (P34) Kd = 5.8 +/- 2.6 uM, Ki = 9.6 +/- 0.3 uM, IC50 = 32.3 +/- 1.1 uM; incomplete ligand structure; X-ray(the catalytic domain of Certhrax ), Kd,Ki,IC50 (full length Certhrax)
4b1j  2.08  2012  Kd=50.0nM     // 4a0d.pdf (A1R) complex between hPARG26 and ADP-HPD; Kd=50.0+/-6.4nM; IC50=1.10+/-0.22uM
3t0w  1.50  2012  Kd=50nM       // 3t0v.pdf (DIW)
3upk  2.00  2012  Kd=50uM       // 3su9.pdf (UD1) ligand is UNAG
4i3z  2.05  2012  Kd=51.3uM     // 4i3z.pdf (ADP) Kd=51.3+/-1.1uM([Mg2+]=10mM,[ADP]=5mM), Mg-containing
3zsx  1.95  2012  Kd=519uM      // 3zcm.pdf (N44) ligand is compound 9; Kd=519+/-49uM(Core3H); Kd=880+/-99uM(Core4H)
3uoj  2.90  2012  Kd=51nM       // 3unj.pdf (0C5) compound 9; Kd=51+/-5.5nM; IC50=43+/-8.0nM
4fl1  1.79  2012  Kd=520uM      // 4fl1.pdf (ANP) Kd=520+/-60uM; Mg-containing
3sbh  1.65  2012  Kd=52nM       // 3m2n.pdf (E65) ligand is compound 2f; Zn-containing; Kd by ITC (37C,pH=7.0)
3tzd  1.81  2012  Kd=52uM       // 3tzd.pdf (19-mer) complex Cbx3-H1K26me2; incomplete ligand
4fak  1.70  2012  Kd=52uM       // 4fak.pdf (SAM) Kd1=52+/-0.4 uM, Kd2=606+/-2 uM; each monomer of OrfX bound AdoMet but with different binding affinities
4aoc  2.70  2012  Kd=53.8uM     // 4aoc.pdf (A1Q)
4gq6  1.55  2012  Kd=53nM       // 4gq3.pdf (12-mer)
4ewr  1.50  2012  Kd=541nM      // 4erq.pdf (14-mer) ligand is Histone-lysine N-methyltransferase SETD1A
4ery  1.30  2012  Kd=54nM       // 4erq.pdf (14-mer) ligand is Histone-lysine N-methyltransferase MLL3, Win motif peptide
3v3b  2.00  2012  Kd=55nM       // 3v3b.pdf (16-mer) peptide SAH-p53-8; incomplete ligand
4efg  1.58  2012  Kd=55nM       // 4ede.pdf (RET) Kd=55+/-5nM, covalent complex
4fm7  1.56  2012  Kd=57nM       // 4fm7.pdf (0UP) ligand is compound 14g; binding free energy = -9.88 kcal/mol (ITC); IC50=0.10uM
4avh  2.10  2012  Kd=59.5nM     // 4auy.pdf (FK9) ligand is compound 1; Kd=59.5+/-4.7nM
2ltw   NMR  2012  Kd=59.8uM     // 2ltv.pdf (14-mer) Kd=59.8+/-3.4uM
3zsy  2.20  2012  Kd=595uM      // 3zcm.pdf (OM3) ligand is compound 7; Kd=595+/-16uM(Core3H); Kd=1180+/-198uM(Core4H)
3upv  1.60  2012  Kd=5uM        // 3upv.pdf (7-mer) ligand is PTVEEVD; Kd=5+/-0.4uM
4g0z  1.75  2012  Kd=6.13mM     // 4g0p.pdf (5GP) Kd=6.13+/-1.03mM
4a6s  2.15  2012  Kd=6.3uM      // 4a6s.pdf (GS9) ligand is compound 11; Kd=6.3+/-0.4uM
3t4p  1.77  2012  Kd=6.43uM     // 3t4p.pdf (4-mer) Kd=6.43+/-0.9uM
4ahs  1.75  2012  Kd=6.4mM      // 3vq4.pdf (AKH) ligand is compound 66
2lha   NMR  2012  Kd=6.4uM      // 2lha.pdf (IHP)
4ahr  1.90  2012  Kd=6.5mM      // 3vq4.pdf (I2E) ligand is compound 63
4g0l  2.62  2012  Kd=6.5uM      // 4g0k.pdf (GSH)
4duh  1.50  2012  Kd=6.6uM      // 4duh.pdf (RLI) Kd=6.6+/-2.0uM
2ynn  1.78  2012  Kd=6.8uM      // 2ynn.pdf (8-mer) Kd=6.8+/-2.6uM
3uvw  1.37  2012  Kd=6.8uM      // 3mb3.pdf (12-mer) ligand is H4K5K8; Kd=6.8+/-0.1uM
2ltv   NMR  2012  Kd=6.9uM      // 2ltv.pdf (12-mer) Kd=6.9+/-0.3uM
4fqo  1.65  2012  Kd=6.9uM      // 4fqo.pdf (AZ3) Kd=6.9+/-0.9uM
4av5  1.40  2012  Kd=61.0nM     // 4auy.pdf (FYZ) ligand is compound 8; Kd=61.0+/-9.6nM
3uec  2.18  2012  Kd=61.7uM     // 3uec.pdf (4-mer) ligand is N-TERMINAL FRAGMENT OF HISTONE H3, Kd=61.7+/-8.5uM
4ad2  2.10  2012  Kd=625nM      // 4acz.pdf (GLC-IFM)
4g8n  2.30  2012  Kd=63nM       // 4g8m.pdf (G8M)
3rg2  3.10  2012  Kd=63uM       // 3rg2.pdf (2-mer) ligand is SVS-PNS (compound 1); Kd=63+/-4.8uM; covalent complex
4gzx  2.45  2012  Kd=645uM      // 4gzp.pdf (2-mer) ligand is SIA-GAL; Kd=645+/-55uM
3tsk  2.00  2012  Kd=67nM       // 3ts4.pdf (QEG) ligand is compound 8
4b9w  2.10  2012  Kd=68.0uM     // 4b9w.pdf (13-mer) Kd=68+/-6uM; ligand is peptide from PIWI-LIKE PROTEIN 2; incomplete ligand
2ymd  1.96  2012  Kd=693uM      // 2ymd.pdf (SRO) Kd=693+/-29uM
4aci  1.65  2012  Kd=6mM        // 4aci.pdf (CIT) Mg-containing; Crystal Form II
3u2q  2.70  2012  Kd=6nM        // 3u2q.pdf (12-mer) compound LFF571(4)
4b0j  2.50  2012  Kd=7.1mM      // 4b0b.pdf (3MQ) fragment 1, ITC K=141+/-3.68
2yi0  1.60  2012  Kd=7.5nM      // 2yi0.pdf (YI0) ligand is ICPD 26
2y8o  1.95  2012  Kd=7.5uM      // 2xrw.pdf (14-mer) ligand is pepMKK6
4ay6  3.30  2012  Kd=7.5uM      // 4ay5.pdf (12V) complex hOGT and UDP-55-GlcNac; Kd=7.5+/-0.1uM
3zso  1.75  2012  Kd=7.6uM      // 3zcm.pdf (O2N) ligand is compound 11; Kd=7.6+/-1.2uM(Core3H); Kd=76+/-11uM(Core4H)
4f1l  1.90  2012  Kd=7.6uM      // 4f0e.pdf (0RY)
4aze  3.15  2012  Kd=7.8nM      // 4aze.pdf (3RA)
4eej  1.50  2012  Kd=70nM       // 4ede.pdf (RET) Kd=70+/-6nM, covalent complex
4abh  1.25  2012  Kd=71uM       // 4ab8.pdf (7Z3) ligand is CC 38513
3th0  1.75  2012  Kd=75.8uM     // 3th0.pdf (5-mer) ITC assay, T=22.5C, ligand is P22 TSP
3ttp  2.23  2012  Kd=750pM      // 3ttp.pdf (017) ligand is darunavir
4erq  1.91  2012  Kd=75nM       // 4erq.pdf (14-mer) ligand is Histone-lysine N-methyltransferase MLL2, Win motif peptide
4ajk  2.03  2012  Kd=770uM      // 4aj1.pdf (88S) compound 22
4aj1  1.87  2012  Kd=770uM      // 4aj1.pdf (AJ1) compound 12, SPR Kd=770uM, NMR Kd=1000uM
3v4t  2.50  2012  Kd=77uM       // 3su9.pdf (UD1) ligand is UNAG
3udd  1.95  2012  Kd=79nM       // 3udd.pdf (34M) ligand is compound 24
4eo8  1.80  2012  Kd=7nM        // 4eo6.pdf (0S3) Kd(HCV NS5B GT-1b delta21); IC50(RNA dependent HCV GT-1b NS5B polymerase)
4dcs  2.25  2012  Kd=8.0uM      // 4dcs.pdf (GDP) Kd=8.0+/-1.0uM (no salt)
3tb6  2.21  2012  Kd=8.4uM      // 3tb6.pdf (ARB) Kd=8.4+/-0.4uM
4b0c  2.70  2012  Kd=8.5mM      // 4b0b.pdf (C9H) fragment 3, ITC K=118+/-2.98
2yfa  1.80  2012  Kd=8.5uM      // 2yfa.pdf (LMR)
4f8j  1.60  2012  Kd=8.6uM      // 3tx6.pdf (HC4) ligand is COU
4fxp  1.95  2012  Kd=80.4uM     // 4fxp.pdf (ADX) Kd1=80.4+/-5.2uM(first site); Kd2=460+/-99uM(second site)
4emf  1.77  2012  Kd=83.9nM     // 4emf.pdf (M7G)
4aom  1.94  2012  Kd=85nM       // 4aom.pdf (18-mer) ligand is MYOSIN-A;Kd=85+/-6nM
2loz   NMR  2012  Kd=86.5uM     // 2loz.pdf (14-mer) ligand is Rho GTPase-activating protein 7.
4fem  2.50  2012  Kd=86.96uM    // 4fe9.pdf (ACX) Kd = 86.96 +/- 19.7 uM;
4dxg  2.50  2012  Kd=87.0nM     // 4dxg.pdf (4-mer) Kd=87.0+/-4.5nM
4erz  1.75  2012  Kd=88nM       // 4erq.pdf (14-mer) ligand is Histone-lysine N-methyltransferase MLL4, Win motif peptide
3u3f  3.10  2012  Kd=8uM        // 3u3f.pdf (17-mer) ligand is paxillin LD4 motifs peptide
3tz0  2.50  2012  Kd=9.2uM      // 3tz0.pdf (03H) ligand is compound 2; Kd=9.2+/-1.4uM
3usx  2.28  2012  Kd=9.53uM     // 3t2v.pdf (MYR) ligand is Myristic Acid; Kd=9.53+/-0.10uM
4dow  1.95  2012  Kd=9.6uM      // 4dow.pdf (12-mer) ligandis H4K20me2 peptide
3uda  2.51  2012  Kd=9.71uM     // 3ud7.pdf (SUS-IDY) compound 92
3vje  2.12  2012  Kd=9.7nM      // 3vjc.pdf (ZGA) ligand is ZA-A; Kd=9.7+/-0.4nM
4agq  1.42  2012  Kd=9.7uM      // 4agl.pdf (P96) ligand is compound 13; Kd by ITC
4av4  1.90  2012  Kd=94.3nM     // 4auy.pdf (FVQ) ligand is compound 7; Kd=94.3+/-18.1nM
4fxz  2.60  2012  Kd=94.3nM     // 4fxz.pdf (LEU) Kd=99.4+/-51.nM(detergents: C12M)
3ztd  2.79  2012  Kd=96.2uM     // 3ztc.pdf (ZTD) compound 1; Kd=86.1+/-1.6uM(FP); Kd=96.2+/-4.6uM(ITC)
4fe9  2.00  2012  Kd=990.1uM    // 4fe9.pdf (MTT) Kd = 990.1 +/- 107.8 uM; Na-cnotaining
4b8y  1.90  2012  Kd=9nM        // 4b8y.pdf (6-mer) Fe-containing; Kd=9+/-0.5nM; ligand is peptide from VIRULENCE FACTOR
4fmq  2.10  2012  Kd=9uM        // 2xrw.pdf (17-mer) ligand is pepSynth-revD
3uzd  1.86  2012  Kd=9uM        // 3uxg.pdf (17-mer) complex 14-3-3 gamma and pHDAC4; Kd=9+/-2uM; incomplete ligand
4euo  1.28  2012  Kd=9uM        // 4euo.pdf (ABU) Kd=9+/-2uM
3ud5  2.00  2012  Kd>150uM      // 3ud5.pdf (J1A) compound HPPK-17
3zt1  1.75  2012  Kd>2000uM     // 3zcm.pdf (OM1) compound 4; Kd(Core3H); Kd>2000uM(Core4H)
3zsz  2.00  2012  Kd>2000uM     // 3zcm.pdf (OM2) compound 6; Kd(Core3H); Kd>2000uM(Core4H)
3zsw  1.80  2012  Kd>2000uM     // 3zcm.pdf (ZSW) compound 8; Kd(Core3H); Kd>2000uM(Core4H)
4awj  2.50  2012  Kd~10000uM    // 3ztc.pdf (V6F) compound 13
4edu  2.58  2012  Kd~102uM      // 4edu.pdf (16-mer) ligand is H2AK36mel peptide
3qo3  2.15  2012  Kd~125nM      // 3qo3.pdf (ATP)
3az9  2.75  2012  Kd~1uM        // 3az8.pdf (K91) ligand is NAS91
3az8  3.10  2012  Kd~1uM        // 3az8.pdf (S21) ligand is NAS21
4emt  1.50  2012  Kd~5uM        // 4emt.pdf (C2E)
4hxj  2.00  2012  Kd~74.3uM     // 4hxj.pdf (3-mer)
4bb2  2.48  2012  Kd~85nM       // 4bb2.pdf (STR)
4fe6  2.00  2012  Ki<0.10nM     // 4fe6.pdf (0TQ)
4a7i  2.40  2012  Ki=0.002uM    // 4a7i.pdf (A7I) ligand is compound 1a
4djr  1.55  2012  Ki=0.003nM    // 4djo.pdf (0KJ)
4aoi  1.90  2012  Ki=0.004uM    // 3zxz.pdf (4K0) ligand is compound 24
4ap7  1.80  2012  Ki=0.011uM    // 3zxz.pdf (F47) ligand is compound 12
3vdc  2.55  2012  Ki=0.012mM    // 3vd4.pdf (IPT) complex N460T and IPTG; Ki=0.012+/-0.001mM
3utu  1.55  2012  Ki=0.012nM    // 3utu.pdf (1TS) ligand is compound 65
3uw5  1.71  2012  Ki=0.014uM    // 3uw4.pdf (4-mer)
3vd4  2.00  2012  Ki=0.015mM    // 3vd4.pdf (IPT) complex between N460D and IPTG; Ki=0.015+/-0.001mM
4amy  2.00  2012  Ki=0.015nM    // 4amy.pdf (2P2) covalent complex; compound IC-1; Ki=0.015+/-0.005nM; IC50=0.26+/-0.09nM
4gid  2.00  2012  Ki=0.017nM    // 4gid.pdf (0GH)
3uw4  1.79  2012  Ki=0.017uM    // 3uw4.pdf (4-mer)
4ase  1.83  2012  Ki=0.01nM     // 4ag8.pdf (AV9) complex between tivozanib and plus-JM
4agc  2.00  2012  Ki=0.020nM    // 4ag8.pdf (AXI) complex between axitinib and plus-JM
3t5u  1.75  2012  Ki=0.026uM    // 3t5u.pdf (A09) ligand is compound 53
4djp  1.40  2012  Ki=0.028nM    // 4djo.pdf (M73)
4an0  2.20  2012  Ki=0.02nM     // 4amy.pdf (2P6) covalent complex; compound IC-3; Ki=0.02+/-0.005nM; IC50=0.2+/-0.04nM
4e7r  2.25  2012  Ki=0.02uM     // 4e7r.pdf (0NW)
3vd7  2.87  2012  Ki=0.033mM    // 3vd4.pdf (GTZ) complex N460S and GTZ; Ki=0.033+/-0.005mM
4dq2  2.50  2012  Ki=0.03uM     // 3v7c.pdf (BTX) ligand is compound 2; Ki=0.03+/-0.01uM
4az2  2.60  2012  Ki=0.047uM    // 4ax9.pdf (9MU) ligand is compound 3b or 3c, but RS chiral bond not identical
4djq  1.40  2012  Ki=0.048nM    // 4djo.pdf (M86)
4an1  1.90  2012  Ki=0.055nM    // 4amy.pdf (2P8) covalent complex; compound IC-4; IC50=0.83+/-0.09nM
3t0b  2.40  2012  Ki=0.05mM     // 3t08.pdf (IPT) ligand is IPTG; Na-containing
4e3n  1.49  2012  Ki=0.05nM     // 4e3i.pdf (0NE) covalent complex
4app  2.20  2012  Ki=0.064uM    // 4app.pdf (N53) ligand is compound 3; Ki(SDS-PAGE and autoradiography, ref 13)
3uz5  1.90  2012  Ki=0.06uM     // 3uxd.pdf (0CU) complex between R13-3/11H and 5,7-Cl; Ki=0.06+/-0.02uM
3tfv  3.00  2012  Ki=0.08uM     // 3tfn.pdf (2CN) ligand is compound 16
4bbh  1.63  2012  Ki=0.08uM     // 4bbh.pdf (YBN)
3v7s  3.10  2012  Ki=0.09uM     // 3v7c.pdf (36F) ligand is compound 14;Ki=0.09+/-0.01uM
3vd9  2.05  2012  Ki=0.10mM     // 3vd4.pdf (IPT) complex between N460S and IPTG; Ki=0.10+/-0.01mM
3sud  1.96  2012  Ki=0.14nM     // 3su0.pdf (SUE) ligand is MK-5172; Ki=0.14+/-0.02nM
4amz  2.00  2012  Ki=0.15nM     // 4amy.pdf (2P4) covalent complex; compound IC-2; Ki=0.15+/-0.08nM; IC50=0.3+/-0.15nM
3t09  1.75  2012  Ki=0.16mM     // 3t08.pdf (149) ligand is D-galactonolactone; Na-containing
4b7q  2.73  2012  Ki=0.18nM     // 4b7j.pdf (ZMR) Ki=0.18+/-0.03nM
4djv  1.73  2012  Ki=0.19uM     // 4dju.pdf (0KM) ligand is R-4b in crystal structure
4ayw  3.30  2012  Ki=0.1mM      // 4ayt.pdf (ANP) plate form
3t2q  2.40  2012  Ki=0.22mM     // 3t08.pdf (149) ligand is D-galactonolactone; Na-containing
4acg  2.60  2012  Ki=0.22nM     // 4acc.pdf (6LQ) compound 25
2yfe  2.00  2012  Ki=0.236uM    // 2yfe.pdf (YFE) ligand is Amorfrutin 1
3s54  1.42  2012  Ki=0.23nM     // 3s43.pdf (017) ligand is DRV; in space group P21212
3s53  1.50  2012  Ki=0.23nM     // 3s43.pdf (017) ligand is DRV; in space group P212121; redundant to 3s54
4b7r  1.90  2012  Ki=0.23nM     // 4b7j.pdf (G39) Ki=0.23+/-0.12nM
3s56  1.88  2012  Ki=0.24nM     // 3s43.pdf (ROC) ligand is SQV
3t2p  2.60  2012  Ki=0.25mM     // 3t08.pdf (IPT) the ligand is IPTG; Na-containing
4ax9  1.90  2012  Ki=0.27nM     // 4ax9.pdf (N5N) ligand is compound 19f
3tfn  2.07  2012  Ki=0.27uM     // 3tfn.pdf (2CJ) ligand is compound 6
4afh  1.88  2012  Ki=0.29nM     // 4afg.pdf (L0B) complex between Ct-AChBP and lobeline; Ki=0.29+/-0.06nM
4ayt  2.85  2012  Ki=0.2mM      // 4ayt.pdf (ACP) rod form A
4ayx  2.90  2012  Ki=0.2mM      // 4ayt.pdf (ACP) rod form B
4e3m  1.44  2012  Ki=0.2nM      // 4e3i.pdf (0ND) covalent complex
4fk6  2.20  2012  Ki=0.2nM      // 4fk6.pdf (0UJ)
3t64  1.65  2012  Ki=0.2uM      // 3t60.pdf (DU3) ligand is compound 15a
3t60  2.40  2012  Ki=0.2uM      // 3t60.pdf (DUA) lignad is compound 24
4fns  2.60  2012  Ki=0.2uM      // 4fns.pdf (DGJ) Ki = 0.2 +/- 0.03 uM
4djh  2.90  2012  Ki=0.32nM     // 4djh.pdf (JDC)
4gfd  1.80  2012  Ki=0.33nM     // 4gfd.pdf (0YB)
3tfp  2.00  2012  Ki=0.34uM     // 3tfn.pdf (03L) ligand is compound 8 (the Cl atom is missing in the reference)
4fea  3.79  2012  Ki=0.34uM     // 4fea.pdf (0TE) Ki (the specific velocity plot)
3s9y  1.70  2012  Ki=0.36uM     // 3s9y.pdf (FNU) ligand is compound 41; Ki=0.36+/-0.03uM(Mt ODCases), X-ray(Hs ODCases)
4ea1  2.46  2012  Ki=0.36uM     // 4e9u.pdf (3RX) ligand is compound E-3; redundant to 4ea2
4ea2  2.05  2012  Ki=0.36uM     // 4e9u.pdf (RWZ) ligand is compound Z-3
4ewh  2.50  2012  Ki=0.3nM      // 4ewh.pdf (T77)
3pwk  1.50  2012  Ki=0.45mM     // 3pwk.pdf (L14)
3vf5  1.25  2012  Ki=0.46nM     // 3vf5.pdf (031) Ki=0.46+/-0.04nM
4a4q  1.80  2012  Ki=0.4nM      // 4a4q.pdf (UX9) ligand is compound 13i
2y8c  2.10  2012  Ki=0.4uM      // 2y8c.pdf (DUQ) ligand is compound 4c
4asd  2.03  2012  Ki=0.52nM     // 4ag8.pdf (BAX) complex between sorafenib and plus-JM
4djw  1.90  2012  Ki=0.53uM     // 4dju.pdf (0KP) ligand is R-4j in crystal structure
4dv8  1.63  2012  Ki=0.58nM     // 4dv8.pdf (0LX) Zn-containing
3vh9  1.29  2012  Ki=0.58uM     // 3vh9.pdf (HQY) ligand is compound 9
4fkk  2.60  2012  Ki=0.5nM      // 4fkk.pdf (BES) ligand is bestatin
3t70  1.80  2012  Ki=0.5uM      // 3t60.pdf (DU4) ligand is compound 15g
3vfa  1.43  2012  Ki=0.65nM     // 3vfa.pdf (031) Ki=0.65+/-0.05nM
4b9k  2.00  2012  Ki=0.67uM     // 4b95.pdf (TG0)
4ayv  2.80  2012  Ki=0.68nM     // 4ax9.pdf (9MQ) compound 19g
3su3  1.30  2012  Ki=0.74nM     // 3su0.pdf (SU3) ligand is Vaniprevir; Ki=0.74+/-0.07nM
3vf7  1.30  2012  Ki=0.80nM     // 3vf7.pdf (031) Ki=0.80+/-0.08nM
3sue  2.20  2012  Ki=0.84nM     // 3su0.pdf (SUE) ligand is MK-5172; Ki=0.84+/-0.05nM
4e3k  1.43  2012  Ki=0.8nM      // 4e3i.pdf (0NA) covalent complex
3t08  2.00  2012  Ki=0.91mM     // 3t08.pdf (IPT) ligand is IPTG; Na-containing
3vfb  1.55  2012  Ki=0.92nM     // 3vfb.pdf (031) Ki=0.92+/-0.10nM
4e4n  1.90  2012  Ki=0.9nM      // 4e4l.pdf (0NL)
4e3b  1.50  2012  Ki=0.9uM      // 4e34.pdf (10-mer) Ki = 0.9 +/- 0.4 uM; incomplete ligand
3t3e  2.15  2012  Ki=1.02uM     // 3t3d.pdf (GPQ) ligand is  GlcClU;Ki=1.02+/-0.15uM
3u6h  2.00  2012  Ki=1.0nM      // 3u6h.pdf (03X) Ki=1.0+/-0.3nM; IC50=20+/-7.5nM(PC3), compound 26
3v5p  2.10  2012  Ki=1.1nM      // 3sx9.pdf (C88) ligand is compound 12; Ki by nonradioactive luciferase assay
4ag8  1.95  2012  Ki=1.1nM      // 4ag8.pdf (AXI) complex between axitinib and minus-JM
4de1  1.26  2012  Ki=1.1uM      // 4dds.pdf (0J6)
4e3j  1.80  2012  Ki=1.2nM      // 4e3i.pdf (0N4) covalent complex
4e6d  2.22  2012  Ki=1.2nM      // 4e4l.pdf (0NU)
3zvt  3.10  2012  Ki=1.2uM      // 2y4a.pdf (B07) Ki=1.2+/-0.2uM; Ki2=1.5+/-0.2uM; covalent complex; B-containing
3zv7  2.26  2012  Ki=1.2uM      // 3zv7.pdf (NHG) ligand is compound 2a; Ki=1.2+/-0.24uM
4gqq  1.35  2012  Ki=1.3mM      // 4gqq.pdf (0XR) Ki=1.3+/-0.1mM (uncompetitive)
3sx9  2.65  2012  Ki=1.3nM      // 3sx9.pdf (BK7) ligand is compound 3b; nonradioactive Kinaseglo luciferase assay
4e3i  1.60  2012  Ki=1.3nM      // 4e3i.pdf (0N3) covalent complex
3u9c  3.20  2012  Ki=1.3uM      // 3u87.pdf (04G) complex CK2 alpha and resorufin
4de0  1.12  2012  Ki=1.3uM      // 4dds.pdf (0JB)
4e28  2.30  2012  Ki=1.3uM      // 4e28.pdf (0MZ)
4do5  1.51  2012  Ki=1.48uM     // 4do4.pdf (DGJ) Ki=1.48+/-0.15uM
3qqs  1.97  2012  Ki=1.5uM      // 3qqs.pdf (17C) ligand is ACS172; Ki=1.5+/-0.1uM
4dld  2.00  2012  Ki=1.5uM      // 4dld.pdf (TZG) Ki=1.5+/-0.2uM
4e9u  2.10  2012  Ki=1.5uM      // 4e9u.pdf (RWY) Mg-containing
4b7n  2.84  2012  Ki=1.65nM     // 4b7j.pdf (ZMR) Ki=1.65+/-0.40nM, Influenza A virus (A/Netherlands/2631_1202/2010(H1N1))
2yiv  1.28  2012  Ki=1.66mM     // 2yiv.pdf (NBN) ligand is n-BIC
4ge9  2.43  2012  Ki=1.6nM      // 4ge9.pdf (0L0) compound 4 inhibits KAT II irreversibly via formation of an imine adduct with the aldehyde group of the enzyme co-factor pyridoxal phosphate (PLP), followed by tautomerization to an enamine.
4g8v  1.70  2012  Ki=1.6uM      // 4g8v.pdf (0EY) Ki=1.6+/-0.2uM
4a95  1.55  2012  Ki=1.73uM     // 4a95.pdf (9MT) ligand is compound 1; Ki=1.73+/-0.16uM(PvNMT); Ki=1.69+/-0.22uM(HsNMT1); Ki=11.39+/-2.11(HsNMT2)
3qdd  1.79  2012  Ki=1.7nM      // 3qdd.pdf (94M) ligand is compound 14
4e4l  2.00  2012  Ki=1.7nM      // 4e4l.pdf (0NH)
4frs  1.70  2012  Ki=1.7nM      // 4frs.pdf (0V6)
3v7c  2.70  2012  Ki=1.83uM     // 3v7c.pdf (C77) ligand is compound 7;Ki=1.83+/-0.33uM
4ei4  2.22  2012  Ki=1.8nM      // 4ehz.pdf (0Q2)
4dfg  1.23  2012  Ki=1.8pM      // 4dfg.pdf (0JV)
3t3h  2.60  2012  Ki=1.94uM     // 3t3d.pdf (GPV) ligand is GlcIU; Ki=1.94+/-0.09uM
3ts4  1.59  2012  Ki=1.9nM      // 3ts4.pdf (EEG) ligand is compound 3
3shc  1.90  2012  Ki=1.9uM      // 3p17.pdf (B01) ligand is compound 8; Ki=1.9+/-0.8uM
3tne  2.40  2012  Ki=1.9uM      // 3tne.pdf (RIT) data from ref 11
4e3g  1.55  2012  Ki=10.6uM     // 4e3d.pdf (PHB) Ki measured in CO2 hydration assay
4b6o  2.00  2012  Ki=100nM      // 4b6o.pdf (3DQ)
4fai  1.65  2012  Ki=101.3nM    // 4f9u.pdf (PBD) Ki=101.3+/-0.2nM(pH=7); Zn-containing
4fbe  1.88  2012  Ki=101.3nM    // 4f9u.pdf (PBD) Ki=101.3+/-0.2nM(pH=7); Zn-containing; redundant to 4fai
3ump  1.85  2012  Ki=1026uM     // 3umo.pdf (ATP) Ki=1026+/-100uM
4aa2  1.99  2012  Ki=107uM      // 4aa1.pdf (11-mer) complex AnCE and BPPb; incomplete ligand
4a6l  2.05  2012  Ki=10nM       // 4a6l.pdf (P43) ligand is compound 2
4ehz  2.17  2012  Ki=10nM       // 4ehz.pdf (JAK)
4b7j  2.42  2012  Ki=11.1nM     // 4b7j.pdf (G39) Ki=11.1+/-1.10nM
3u7n  2.30  2012  Ki=11.2nM     // 3u7n.pdf (UHF) ligand is PMT1067; Ki=11.2+/-1.6nM (T=303K;pH=7;50mM HEPES buffer)
3uxk  2.20  2012  Ki=11.7uM     // 3uxk.pdf (BHO) ligand is compound BzH; Ki=11.7+/-1.2uM
4hge  2.30  2012  Ki=11.9nM     // 4hge.pdf (15V)
4gqr  1.20  2012  Ki=110uM      // 4gqq.pdf (MYC) Ki=110+/-15uM (competitive binding)
3twp  1.83  2012  Ki=119uM      // 3qqs.pdf (SAL) ligand is ACS10; Ki=119+/-20uM
3uuo  2.11  2012  Ki=11nM       // 3uuo.pdf (0CV) ligand is compound 1
3veh  2.00  2012  Ki=11uM       // 3rv6.pdf (0GA) ligand is methyl-AMT; Ki=11+/-1uM; Ki(Z/E=9:1) while X-ray(Z-form)
3sv8  2.50  2012  Ki=12.2nM     // 3su0.pdf (SV6) ligand is Telaprevir; Ki=12.2+/-0.9nM; covalent complex
4a50  2.75  2012  Ki=12.2nM     // 4a50.pdf (DQ6/DQ7) compound 29; Ki=12.2+/-3.8nM(rac-29); Ki=11.1+/-3.9nM(S-29); Ki=6.4+/-3.9nM(R-29)
3t3d  2.50  2012  Ki=12.39uM    // 3t3d.pdf (CJB) ligand is GlcU; Ki=12.39+/-0.94uM
4gk7  2.80  2012  Ki=12.5nM     // 4gk7.pdf (4-mer) Ki=12.5+/-1.5nM (GlbA inhibited the CT-L activity)
4b5d  2.20  2012  Ki=12.8nM     // 4b5d.pdf (SW4) Ki=12.8+/-0.4nM
3zvw  2.00  2012  Ki=125uM      // 2y4a.pdf (FP5) Ki=125+/-8uM; covalent complex, B-containing
3umo  1.70  2012  Ki=129uM      // 3umo.pdf (ATP) Ki=129+/-55uM; measured with 50mM KCl
4a6c  1.50  2012  Ki=12nM       // 4a6b.pdf (QG9) ligand is compound 19b
4g0c  2.00  2012  Ki=12nM       // 4g0c.pdf (AZM) Zn-containing
3rv8  2.29  2012  Ki=12uM       // 3rv6.pdf (RVC/VCE) ligand is (Z/E)-cyclopropyl-AMT; Ki=12+/-1uM;
3rv9  2.14  2012  Ki=12uM       // 3rv6.pdf (RVD) ligand is ethyl-AMT; Ki=12+/-2uM; Ki(Z/E=10:3), X-ray(Z)
3si4  1.27  2012  Ki=132.2uM    // 3p17.pdf (B04) ligand is compound 5; Ki=132.2+/-35.3uM
3spf  1.70  2012  Ki=138uM      // 3spf.pdf (B50) ligand is compound 4; Ki=138+/-7.6uM
4gzp  2.30  2012  Ki=14.3nM     // 4gzp.pdf (G39) Ki=14.3+/-2.3nM; Ca-containing
4b6r  2.00  2012  Ki=1420nM     // 4b6o.pdf (3DQ)
3sut  1.90  2012  Ki=14nM       // 3sur.pdf (OAN) ligand is PUGNAc; Ki=14+/-2nM
3rv7  2.50  2012  Ki=14uM       // 3rv6.pdf (RVB) ligand is (Z)-isopropyl-AMT; Ki=14+/-2uM; Ki(Z/E=4:1), X-ray(Z)
4eu3  1.58  2012  Ki=150mM      // 4eu3.pdf (CIT) Ki=150+/-20mM (LCR assays)
3r88  1.73  2012  Ki=15uM       // 3qqs.pdf (14F) ligand is ACS145; Ki=15+/-4uM
3t03  2.10  2012  Ki=160nM      // 3t03.pdf (3T0) ligand is GQ-16; another ligand is nuclear receptor coactivator 1(18-mer)
3su0  1.16  2012  Ki=162nM      // 3su0.pdf (TSV) ligand is Danoprevir; Ki=162+/-16nM
4dkt  2.98  2012  Ki=16uM       // 4dkt.pdf (5-mer) ligand is peptide from TDFA; Ki=16+/-10uM
3t3i  2.65  2012  Ki=17.00uM    // 3t3d.pdf (GPW) ligand is GlcCF3U;Ki=17.00+/-1.28uM
4gzt  2.19  2012  Ki=17.0nM     // 4gzp.pdf (G39) Ki=17.0+/-1.5nM; Ca-containing
3tzm  1.70  2012  Ki=17nM       // 3tzm.pdf (085) ligand is compound SB-431542
4e5j  2.35  2012  Ki=18.7uM     // 4e5f.pdf (581) Mn-containing
4a51  2.75  2012  Ki=185.8nM    // 4a50.pdf (DQ8) compound 25; Ki=185.8+/-30.4nM
3tvc  2.43  2012  Ki=18nM       // 3ts4.pdf (E3P) ligand is compound 18
3qs8  2.00  2012  Ki=18uM       // 3qqs.pdf (17D) ligand is ACS174; Ki=18+/-2uM
4f39  1.83  2012  Ki=1980nM     // 4f39.pdf (KAI)
3r6c  1.83  2012  Ki=19uM       // 3qqs.pdf (17N) ligand is ACS179; Ki=19+/-5uM
3u6i  2.10  2012  Ki=1nM        // 3u6i.pdf (044) ligand is compound (R)-58a
3uri  2.10  2012  Ki=1nM        // 3uri.pdf (8-mer) complex between endothiapepsin and DB5 peptide
4flh  2.60  2012  Ki=1nM        // 4flh.pdf (14K) Ki(a modified in vitro AlphaScreen assay)
4h3f  1.70  2012  Ki=1nM        // 4h1e.pdf (10O)
4h4b  2.90  2012  Ki=2.0mM      // 4h4b.pdf (11H) Ki=2.0+/-0.2mM
4f1s  3.00  2012  Ki=2.0nM      // 4f1s.pdf (F1S) Ki=2.0+/-0.7nM nM(PI3K-alpha), X-ray(PI3K-gamma)
4fcf  1.09  2012  Ki=2.4nM      // 4fcf.pdf (MA4) Ki=2.4+/-0.2nM
4hf4  2.00  2012  Ki=2.4nM      // 4heu.pdf (15H)
4ddy  1.36  2012  Ki=2.4uM      // 4dds.pdf (DN6)
3s43  1.26  2012  Ki=2.53nM     // 3s43.pdf (478) ligand is amprenavir
3sxf  2.04  2012  Ki=2.5nM      // 3sx9.pdf (BK5) ligand is compound 3a; Ki by nonradioactive luciferase assay
3t3u  2.10  2012  Ki=2.5nM      // 3sx9.pdf (BK6) ligand is compound 2b; Ki by nonradioactive luciferase assay
4efs  1.63  2012  Ki=2.5nM      // 3ts4.pdf (E37) ligand is compound 16
3u78  2.69  2012  Ki=2.5uM      // 3u78.pdf (E67) compound E67-KIAA1718; IC50=3.7+/-0.3uM
3sha  1.52  2012  Ki=2.6uM      // 3p17.pdf (P97) ligand is compound 10; Ki=2.6+/-1.1uM
3v7x  1.03  2012  Ki=2.7nM      // 3v7x.pdf (D7A) complex between compound I and hCAII; Ki=2.7+/-0.1nM
3uxl  2.20  2012  Ki=2.7uM      // 3uxk.pdf (CFI) ligand is compound CfN
3uzj  1.69  2012  Ki=2.82uM     // 3uxd.pdf (0CT) complex between R13-3/11H and benzotriazole; Ki=2.82+/-0.19uM
3v51  1.95  2012  Ki=2.8nM      // 3sx9.pdf (I76) ligand is compound 11; Ki by nonradioactive luciferase assay
4f09  2.40  2012  Ki=200nM      // 4ehz.pdf (JAK)
3su1  1.40  2012  Ki=208nM      // 3su0.pdf (TSV) ligand is Danoprevir; Ki=208+/-66nM
3uwl  2.07  2012  Ki=208uM      // 3uwl.pdf (FOZ) complex EfTS and 5-FTHF; Ki=208+/-15uM
4acc  2.21  2012  Ki=20nM       // 4acc.pdf (7YG) ligand is compound 23
4fsl  2.50  2012  Ki=20nM       // 4fsl.pdf (0VB) I-containig
3suw  1.90  2012  Ki=20uM       // 3sur.pdf (GC2) ligand is NHAc-CAS; Ki=20+/-3uM
4gkh  1.86  2012  Ki=21.5uM     // 4ej7.pdf (0J9) Ki=21.5+/-1.7uM
4acm  1.63  2012  Ki=210nM      // 4acc.pdf (7YG) compound 23 with CDK2
3rv6  2.04  2012  Ki=21uM       // 3rv6.pdf (RVA/VAE) ligand is (Z/E)-phenyl-AMT; Ki=21+/-1uM; RVA(Z)/VAE(E)
3qtv  1.63  2012  Ki=22.5uM     // 3p17.pdf (06P) ligand is compound 7; Ki=22.5+/-13.2uM
4ach  2.60  2012  Ki=22nM       // 4acc.pdf (KDI) compound 51
4e5w  1.86  2012  Ki=22nM       // 4e4l.pdf (0NT)
3st6  1.75  2012  Ki=240uM      // 3rv6.pdf (RVE) ligand is AMT; Ki=240+/-40uM
4e35  1.40  2012  Ki=24uM       // 4e34.pdf (10-mer) Ki = 24 +/- 2 uM; incomplete ligand
4dfu  1.98  2012  Ki=25.1uM     // 4dfu.pdf (QUE)
3rj7  1.20  2012  Ki=25.3nM     // 3rj7.pdf (RCS) ligand is compound 4
4g8y  1.80  2012  Ki=25.8uM     // 4g8v.pdf (0FT) Ki=25.8+/-2.4uM
4f08  2.82  2012  Ki=250nM      // 4ehz.pdf (1RS)
4dfb  1.95  2012  Ki=25uM       // 3r81.pdf (KAN) Ki for Kanamycin A is referred to Kinase inhibitor Quercetin
3vhk  2.49  2012  Ki=25uM       // 3vhk.pdf (BPK) ligand is compound E
4bc5  1.98  2012  Ki=25uM       // 4bc2.pdf (5FX) Ki=25+/-2uM
4b05  1.80  2012  Ki=26.1nM     // 4b05.pdf (32D) ligand is AZD3839
3su5  1.55  2012  Ki=2635nM     // 3su0.pdf (SU3) ligand is Vaniprevir; Ki=2635+/-702nM
3sym  2.40  2012  Ki=27.1uM     // 3sym.pdf (GP0) ligang is compound 5; Ki=27.1+/-1.4uM
3suf  2.19  2012  Ki=27.8nM     // 3su0.pdf (SUE) ligand is MK-5172; Ki=27.8+/-12.1nM
3rbm  2.61  2012  Ki=270nM      // 3rbm.pdf (B73) ligand is BPH-703; Mg-containing
4fs4  1.74  2012  Ki=270nM      // 4fs4.pdf (H24) ligand is compound 4, ligand structure is diffrent: -NH2 and =NH
2lsp   NMR  2012  Ki=274uM      // 2lsp.pdf (13-mer) ligand is NF-kB-K310ac peptide
3rr4  1.68  2012  Ki=28.05uM    // 3gev.pdf (HRD) ligand is compound 11a; Ki=28.05+/-11.97uM
4b6q  1.54  2012  Ki=28nM       // 4b6o.pdf (BZ5)
3suv  1.60  2012  Ki=28uM       // 3sur.pdf (NOK) ligand is NHAc-DNJ; Ki=28+/-4uM
3vdb  2.05  2012  Ki=3.03mM     // 3vd4.pdf (149) complex between N460T and galactonolactone; Ki=3.03+/-0.20mM
4e3l  1.43  2012  Ki=3.0nM      // 4e3i.pdf (0NB) covalent complex
3t6y  2.60  2012  Ki=3.0uM      // 3t60.pdf (DU2) ligand is compound 15f
4de3  1.44  2012  Ki=3.0uM      // 4dds.pdf (DN8)
3s45  1.51  2012  Ki=3.24nM     // 3s43.pdf (478) ligand is amprenavir
3t3g  2.40  2012  Ki=3.27uM     // 3t3d.pdf (GPU) ligna is  GlcBrU; Ki=3.27+/-0.44uM
4dju  1.80  2012  Ki=3.6uM      // 4dju.pdf (0KK)
3u7s  2.05  2012  Ki=3.7nM      // 3ggt.pdf (017) complex between PRDRV1 and darunavir; Ki=3700+/-300pM
4g3g  2.50  2012  Ki=3.7nM      // 4g3e.pdf (0WA) X-ray(mNIK V408(m)L) while Ki(hNIK)
4fev  1.89  2012  Ki=3.8uM      // 4ej7.pdf (PP1) Ki=3.8+/-0.4uM
4agd  2.81  2012  Ki=3.9nM      // 4ag8.pdf (B49) complex Sunitinib/plus-JM
4g90  1.90  2012  Ki=30.8uM     // 4g8v.pdf (0G0) Ki=30.8+/-4.4uM
4eky  2.45  2012  Ki=303.0uM    // 4ej2.pdf (D1J) Ki=303.0+/-6.7uM
4e3o  1.60  2012  Ki=310nM      // 4e3i.pdf (0NG) covalent complex
4el0  2.40  2012  Ki=32.4uM     // 4ej2.pdf (D1K) Ki=32.4+/-0.5uM
3u92  1.90  2012  Ki=32.8nM     // 3u92.pdf (KAI) ligand is kainate
4ej2  2.65  2012  Ki=3204uM     // 4ej2.pdf (D1F) Ki=3204+/-144uM
4eke  2.60  2012  Ki=33.4uM     // 4ej2.pdf (D1I) Ki=33.4+/-4.0uM
4e0w  2.35  2012  Ki=33nM       // 4e0w.pdf (KAI) redundant to 3u92
4dhl  2.30  2012  Ki=33uM       // 4dhl.pdf (0K7) Ki=33+/-10uM; Zn-containing
3sv6  1.40  2012  Ki=34.4nM     // 3su0.pdf (SV6) ligand is Telaprevir; Ki=34.4+/-3.0nM; covalent complex
4gki  1.88  2012  Ki=34.4uM     // 4ej7.pdf (0JN) Ki=34.4+/-1.9uM
4abj  1.45  2012  Ki=34nM       // 4abi.pdf (13-mer) compound 3; Ki=34+/-5nM; incomplete ligand
4ge6  1.40  2012  Ki=34nM       // 4ge2.pdf (B26) Ki=32-36 nM
3u7m  2.15  2012  Ki=35.1nM     // 3u7m.pdf (FHF) ligand is PMT1039(15e); Ki=35.1+/-3.1nM(T=303K;pH=7;50mM HEPES buffer)
3qw5  1.60  2012  Ki=358nM      // 3qw5.pdf (5-mer) ligand is peptide RRGF; Zn-containing
4dff  2.11  2012  Ki=35nM       // 4dff.pdf (0JP) Zn-containing; Mg-containing
4i8n  2.50  2012  Ki=35uM       // 4i8n.pdf (1CG)
3u81  1.13  2012  Ki=36uM       // 3r6t.pdf (SAH)
3rbu  1.60  2012  Ki=370pM      // 3rbu.pdf (G88) Ki=370+/-80pM(HPLC assay); Zn-containing
4dsy  2.30  2012  Ki=37uM       // 4dhl.pdf (0LO) Ki=37+/-16uM; Zn-containing; Fe-containing
4ek9  2.50  2012  Ki=38000nM    // 4ek9.pdf (EP4)
4exs  2.40  2012  Ki=39.0uM     // 4exs.pdf (X8Z) Zn-containing
3s5y  2.10  2012  Ki=39.1nM     // 3s5y.pdf (DGJ) Ki=39.1+/-1.9 nM
3uxd  1.80  2012  Ki=39.3uM     // 3uxd.pdf (0CU) complex between R1-7/10H and 5,7-Cl; Ki=39.3+/-0.2uM
3suu  1.60  2012  Ki=3nM        // 3sur.pdf (OGN) ligand is Gal-PUGNAc; Ki=3+/-2nM
3t3v  2.04  2012  Ki=3nM        // 3sx9.pdf (BK4) ligand is compound 2a; nonradioactive Kinaseglo luciferase assay
4h1e  1.90  2012  Ki=3nM        // 4h1e.pdf (10J)
4h3i  1.96  2012  Ki=3nM        // 4h1e.pdf (10V)
4djo  1.78  2012  Ki=3pM        // 4djo.pdf (MK5)
4en4  2.15  2012  Ki=3uM        // 4en4.pdf (GT0)
4aph  1.99  2012  Ki=4.0uM      // 4aph.pdf (8-mer) complex between C-domain of ACE and Ang II peptide; incomplete ligand
4a6b  1.80  2012  Ki=4.2nM      // 4a6b.pdf (QG8) ligand is compound 19d
4g3e  2.50  2012  Ki=4.2nM      // 4g3e.pdf (0WC) X-ray(mNIK) while Ki(hNIK)
3t0d  1.93  2012  Ki=4.3mM      // 3t08.pdf (149) ligand is D-galactonolactone; Na-containing
3tcp  2.69  2012  Ki=4.3nM      // 3tcp.pdf (CKJ) ligand is compound 43
4du8  2.10  2012  Ki=4.3uM      // 4dpt.pdf (2P0) Ki(protein=S.epidermidis MDD,ligand=DPGP) while X-ray(protein=D283A MDD, ligand=DPGP)
4dpy  2.14  2012  Ki=4.3uM      // 4dpt.pdf (2P0) Ki(protein=S.epidermidis MDD,ligand=DPGP) while X-ray(protein=S192A MDD, ligand=DPGP)
4el5  2.00  2012  Ki=4.3uM      // 4ej2.pdf (D1M) Ki=4.3~5.1uM
4e6q  1.95  2012  Ki=4.4nM      // 4e4l.pdf (0NV)
4g3f  1.64  2012  Ki=4.4nM      // 4g3e.pdf (0WB) X-ray(mNIK) while Ki(hNIK)
4acd  2.60  2012  Ki=4.9nM      // 4acc.pdf (GR9) compound 18
3tll  1.37  2012  Ki=40.83uM    // 3gev.pdf (62D) ligand is compound 11b; Ki=40.83+/-4.27uM
3zzf  2.20  2012  Ki=400mM      // 3zzf.pdf (NLG) complex between AAK domain and NAG; Ki=400+/-55mM
4fse  2.65  2012  Ki=40nM       // 4fse.pdf (0VA) I-containig
4dt2  2.70  2012  Ki=43uM       // 4dhl.pdf (0LV) Ki=43+/-14uM, the equilibrium dissociation constant for competitive inhibitor binding
3su2  1.50  2012  Ki=44.8nM     // 3su0.pdf (TSV) ligand is Danoprevir; Ki=44.8+/-3.6nM
4eo4  2.87  2012  Ki=450nM      // 4eo4.pdf (SSA) apparent Ki = 450 +/- 145 nM; Zn-containing
3s6t  2.30  2012  Ki=45nM       // 3s6t.pdf (OAN)
3u93  1.88  2012  Ki=494nM      // 3u93.pdf (GLU) ligand is glutamate
4dk5  2.95  2012  Ki=4nM        // 4dk5.pdf (0KO)
4e5i  2.94  2012  Ki=5.01uM     // 4e5f.pdf (0N9) Mn-containing
3tt4  1.88  2012  Ki=5.3nM      // 3ts4.pdf (E1S) ligand is compound 17
4djy  1.86  2012  Ki=5.4nM      // 4dju.pdf (0KR) ligand is R-24 in crystal structure
4fjz  3.00  2012  Ki=509nM      // 4fjy.pdf (4FJ) incomplete ligand structure
4dpt  2.19  2012  Ki=50nM       // 4dpt.pdf (FM0) Ki (Protein: S. epidermidis MDD, Ligand: FMVAPP), X-ray(Protein: MDD, Ligand: FMVAPP, ATP-gamma-S)
4dpu  1.90  2012  Ki=50nM       // 4dpt.pdf (FM0) Ki (Protein: S. epidermidis MDD, Ligand: FMVAPP), X-ray(Protein: S192A MDD, Ligand: FMVAPP, ATP-gamma-S)
4eoh  2.10  2012  Ki=50uM       // 4en4.pdf (TEP)
4do4  1.40  2012  Ki=51nM       // 4do4.pdf (DJN) Ki=51+/-6nM
3u7l  2.01  2012  Ki=52.4nM     // 3u7l.pdf (UDB) ligand is PMT497; Ki=52.4+/-6.5nM(T=303K;pH=7;50mM HEPES buffer)
4alx  2.30  2012  Ki=52nM       // 4alx.pdf (IZN) complex between DHbetaE and Ls-AChBP; Ki=52+/-5nM
3qwc  1.75  2012  Ki=55.4uM     // 3p17.pdf (98P) ligand is compound 11; Ki=55.4+/-21.4uM
3su4  2.25  2012  Ki=554nM      // 3su0.pdf (SU3) ligand is Vaniprevir; Ki=554+/-64nM
3ryw  2.90  2012  Ki=570nM      // 3rbm.pdf (K9H) ligand is BPH-811; Mg-containing
4ha5  1.83  2012  Ki=58nM       // 4h1e.pdf (13W)
4djx  1.50  2012  Ki=59nM       // 4dju.pdf (0KQ) liagnd is R-17h in crystal structure
3t3c  2.10  2012  Ki=59pM       // 3t3c.pdf (017) ligand is DRV; Ki=59+/-7pM
4afg  2.00  2012  Ki=5nM        // 4afg.pdf (QMR) complex between Ct-AChBP and varenicline; Ki=5+/-1nM
4few  1.98  2012  Ki=6.2uM      // 4ej7.pdf (PP2) Ki=6.2+/-0.5uM
4abi  1.55  2012  Ki=6.3nM      // 4abi.pdf (13-mer) compound 6; /ki=6.3+/-1.8nM; incomplete ligand
4gg7  2.27  2012  Ki=6.3nM      // 4gg5.pdf (0J8)
3uu1  1.82  2012  Ki=6.3uM      // 3qqs.pdf (14B) ligand is ACS142; Ki=6.3+/-0.8uM
3s1g  1.82  2012  Ki=6.5uM      // 3gev.pdf (ITE) ligand is compound 8a; Ki=6.5+/-2.9uM
4ayy  2.60  2012  Ki=6.7nM      // 4ax9.pdf (9MX) compound 19d
3sug  1.80  2012  Ki=620nM      // 3su0.pdf (SUE) ligand is MK-5172; Ki=620+/-71nM
3v7t  2.09  2012  Ki=62nM       // 3v7t.pdf (0GX) ligand is compound 2
3qx5  1.35  2012  Ki=63.5uM     // 3p17.pdf (02P) ligand is compound 9; Ki=63.5+/-13.6uM
3sv2  1.30  2012  Ki=64.0uM     // 3p17.pdf (P05) ligand is compound 6; Ki=64.0+/-20.0uM
3si3  1.55  2012  Ki=69.3uM     // 3p17.pdf (B03) ligand is compound 4; Ki=69.3+/-0.1uM
3v5t  2.13  2012  Ki=6nM        // 3sx9.pdf (UW9) ligand is compound 13; Ki by nonradioactive luciferase assay
4h3g  1.85  2012  Ki=6nM        // 4h1e.pdf (10Q)
4ge7  2.10  2012  Ki=7.1nM      // 4ge7.pdf (0K5) compound 3 inhibits KAT II irreversibly via formation of an imine adduct with the aldehyde group of the enzyme co-factor pyridoxal phosphate (PLP), followed by tautomerization to an enamine.
3upx  2.27  2012  Ki=7.5nM      // 3sx9.pdf (B6A) ligand is compound 10; nonradioactive Kinaseglo luciferase assay
3uf9  2.68  2012  Ki=7.78mM     // 3uf9.pdf (FST) Ki=7.78+/-1.23mM
4ge4  2.41  2012  Ki=7.7nM      // 4ge4.pdf (0KE) compound 2 inhibits KAT II irreversibly via formation of an imine adduct with the aldehyde group of the enzyme co-factor pyridoxal phosphate (PLP), followed by tautomerization to an enamine.
4e49  1.45  2012  Ki=7.7uM      // 4e3d.pdf (RCO) Ki measured in CO2 hydration assay
3syr  2.40  2012  Ki=7.9uM      // 3sym.pdf (GPK) ligand is GLcFU; Ki=7.9+/-0.3uM
3v4x  1.95  2012  Ki=700nM      // 3v4x.pdf (F24) Ki=700+/-18.5nM(nonlinear fit method); Ki=606nM(graphical method); Ki=53.7nM(human HMGCS)
3axk  1.90  2012  Ki=70uM       // 3axk.pdf (NDP)
3sur  1.90  2012  Ki=70uM       // 3sur.pdf (NGT) ligand is NAG-thiazoline; Ki=70+/-4uM
4exh  2.00  2012  Ki=712nM      // 4exh.pdf (6-mer) Ki=712+/-39nM, covalent complex
3sus  1.80  2012  Ki=71uM       // 3sur.pdf (GNL) ligand is Gal-NAG-thiazoline; Ki=71+/-5uM
3tvx  2.84  2012  Ki=72uM       // 3tvx.pdf (PNX) ligand is pentoxifylline
3qto  1.52  2012  Ki=74.8uM     // 3p17.pdf (10P) ligand is compound 3; Ki=74.8+/-20.5uM
3sm0  1.57  2012  Ki=740nM      // 3gev.pdf (AEK) ligand is compound 10a; Ki=740+/-170nM
3v5g  1.50  2012  Ki=74nM       // 3v5g.pdf (0F3) compound 1; IC50(stopped-flow assay); IC50=123nM(Spectrophotometric Esterase Assay)
4b6p  2.30  2012  Ki=74nM       // 4b6o.pdf (2HN)
4de2  1.40  2012  Ki=76.0uM     // 4dds.pdf (DN3)
4e0x  2.00  2012  Ki=76nM       // 4e0w.pdf (KAI)
4aa1  1.99  2012  Ki=76uM       // 4aa1.pdf (8-mer) ligand is Ang II peptide; incomplete ligand
3v2w  3.35  2012  Ki=77nM       // 3v2w.pdf (ML5) ligand is compound 2a
3axm  1.65  2012  Ki=8.5uM      // 3axk.pdf (6PG) Mg-containing
3vbd  1.05  2012  Ki=8.6nM      // 3v7x.pdf (0FZ) ligand is compound 2a; Ki=8.6+/-0.6nM
4b9z  2.00  2012  Ki=81.4uM     // 4b9z.pdf (ACR) ligand is Acarbose
3sv7  1.55  2012  Ki=823nM      // 3su0.pdf (SV6) ligand is Telaprevir; Ki=823+/-60nM; covalent complex
3u7k  1.90  2012  Ki=84.9nM     // 3u7k.pdf (MDB) ligand is PMT387(7a); Ki=84.9+/-12.8nM (T=303K;pH=7.0;50mM HEPES buffer)
3vw7  2.20  2012  Ki=8nM        // 3vw7.pdf (VPX) ligand is compound 4
4dds  1.36  2012  Ki=9.7uM      // 4dds.pdf (0J7)
4e3h  1.50  2012  Ki=90nM       // 4e3d.pdf (HQE) Ki measured in CO2 hydration assay
4h3j  1.60  2012  Ki=90nM       // 4h1e.pdf (10W)
4f9u  1.80  2012  Ki=944nM      // 4f9u.pdf (PBD) Ki=944+/-93nM(pH=7); Zn-containing
4f9v  2.10  2012  Ki=944nM      // 4f9u.pdf (PBD) Ki=944+/-93nM(pH=7); Zn-containing; redundant to 4f9u
3su6  1.10  2012  Ki=958nM      // 3su0.pdf (SU3) ligand is Vaniprevir; Ki=958+/-162nM
4b6s  1.90  2012  Ki=970nM      // 4b6o.pdf (2HN)
3sv9  1.60  2012  Ki>10000nM    // 3su0.pdf (SV6) ligand is Telaprevir
3uqg  2.20  2012  Ki>10uM       // 3sx9.pdf (B5A) ligand is compound 7b
3upz  2.20  2012  Ki>2.5uM      // 3sx9.pdf (B5A) ligand is compound 7b; nonradioactive Kinaseglo luciferase assay
3uqf  2.27  2012  Ki>20uM       // 3sx9.pdf (BK5) ligand is compound 3a
3srg  2.19  2012  Ki~2uM        // 3srg.pdf (OCH) Ca-containing
4fck  1.90  2012  Ki~55mM       // 4fci.pdf (GPA) Co-containing
4fci  1.82  2012  Ki~55mM       // 4fci.pdf (GPA) Mn-containing
4lp0  1.95  2013  IC50<0.01uM   // 4lp0.pdf (1YM) ligand is compound 31
4lpb  1.75  2013  IC50<0.01uM   // 4lp0.pdf (1YP) ligand is compound 35
4jg8  3.10  2013  IC50<2.5nM    // 4jg6.pdf (1LE) Covalent complex, Different ligand structure(double bond)
4gjd  2.65  2013  IC50=0.003uM  // 4gj8.pdf (0N0) IC50 = 0.003 +/- 0.002 uM
4jsr  1.70  2013  IC50=0.004uM  // 4jsr.pdf (1NQ) mass spectrometry assay
4c4g  2.65  2013  IC50=0.006uM  // 4c4e.pdf (7RO) IC50 = 0.006 +/- 0.003 uM, different ligand structure
4i7c  2.80  2013  IC50=0.006uM  // 4i7b.pdf (14-mer) covalent complex; DELFIA TRF assay
4jt9  2.24  2013  IC50=0.0072uM  // 4jsr.pdf (1NS) mass spectrometry assay
4jr5  1.91  2013  IC50=0.007uM  // 4jr5.pdf (1LS) A mass spectrometry-based assay
4i1c  2.00  2013  IC50=0.008uM  // 4i0d.pdf (1BE) AlphaScreen assay
4i9i  2.40  2013  IC50=0.008uM  // 4i9i.pdf (1DY) Enzymatic TNKS1 autoparsylation assay
4bky  1.83  2013  IC50=0.012uM  // 4bky.pdf (82B)
4mq1  2.35  2013  IC50=0.012uM  // 4mq1.pdf (2C3) The ligand in crystal is not equal to the ligand in literature(4mq1 4mq2 swap).
4bzo  2.10  2013  IC50=0.013uM  // 4bzn.pdf (676)
4mz4  1.63  2013  IC50=0.013uM  // 4mz4.pdf (2F3) ligand is compound 2e
4hvs  1.90  2013  IC50=0.016uM  // 4hvs.pdf (647)
4ijp  2.25  2013  IC50=0.016uM  // 4ifc.pdf (1EH) MS-based biochemical assay
4gmc  2.70  2013  IC50=0.018uM  // 4gmc.pdf (1BI) X-ray(HCV NS5B), IC50(HCV NS5B_delta21)
4jik  1.90  2013  IC50=0.018uM  // 4jik.pdf (1KO)
4hhz  2.72  2013  IC50=0.019uM  // 4hhy.pdf (15S)
4bty  3.10  2013  IC50=0.020uM  // 4btw.pdf (JWF) IC50 = 0.020 +/- 0.002 uM
4c4i  2.65  2013  IC50=0.022uM  // 4c4e.pdf (X20) IC50 = 0.022 +/- 0.001 uM
4jje  1.48  2013  IC50=0.023uM  // 4jj7.pdf (6-mer)
4c4e  2.60  2013  IC50=0.025uM  // 4c4e.pdf (4T9) IC50 = 0.025 +/- 0.012 uM
4hyf  2.80  2013  IC50=0.025uM  // 4hyf.pdf (1AK) IC50 = 0.025 +/- 0.006 uM
4c4f  2.36  2013  IC50=0.026uM  // 4c4e.pdf (7CE) IC50 = 0.026 +/- 0.010 uM
4bkz  2.20  2013  IC50=0.027uM  // 4bky.pdf (1WS)
4g17  2.10  2013  IC50=0.029uM  // 4g16.pdf (0VN) X-ray(CK1-gamma-3), IC50(CK1-gamma)
4bnu  2.00  2013  IC50=0.02uM   // 4bnt.pdf (9KQ) IC50 = 0.02 uM (AcAcCoA as substrate), IC50 = 0.5 uM (3-OH decanoyl-NAC as substrate)
4bnx  2.30  2013  IC50=0.02uM   // 4bnt.pdf (O74) IC50 = 0.02 uM (AcAcCoA as substrate), IC50 = 0.6 uM (3-OH decanoyl-NAC as substrate)
4cby  2.72  2013  IC50=0.02uM   // 4cbt.pdf (KEE) Zn-containing; IC50(HDAC4 WT), X-ray(HDAC4 L728A)
4l02  2.75  2013  IC50=0.02uM   // 4l02.pdf (1V2) ligand is compound 23
4bqw  1.79  2013  IC50=0.033uM  // 4bqw.pdf (QNM) Mn-containing
4jt8  2.26  2013  IC50=0.033uM  // 4jsr.pdf (1NR) mass spectrometry assay
4i6q  1.85  2013  IC50=0.03uM   // 3zep.pdf (1DT) ligand is compound 1h;IC50=0.03+/-0.004uM
4bnv  2.50  2013  IC50=0.03uM   // 4bnt.pdf (Q7U) IC50 = 0.03 uM (AcAcCoA as substrate), IC50 = 1.0 uM (3-OH decanoyl-NAC as substrate)
4ivs  2.64  2013  IC50=0.044uM  // 4ivs.pdf (VSI) IC50=0.044+/-0.005uM
4idv  2.90  2013  IC50=0.04uM   // 4idt.pdf (13V) NIK biochemical chemiluminescent assay
4k69  1.50  2013  IC50=0.04uM   // 4k2y.pdf (1P9) ligand is compound 15; IC50 = 0.04 +/- 0.01 uM
4hys  2.42  2013  IC50=0.055uM  // 4hys.pdf (1BJ)
4bo2  1.90  2013  IC50=0.05uM   // 4bnt.pdf (36K) IC50 = 0.05 uM (AcAcCoA as substrate), IC50 = 2.1 uM (3-OH decanoyl-NAC as substrate)
4bo1  2.20  2013  IC50=0.05uM   // 4bnt.pdf (NKH) IC50 = 0.05 uM (AcAcCoA as substrate), IC50 = 2.0 uM (3-OH decanoyl-NAC as substrate)
4cbt  3.03  2013  IC50=0.05uM   // 4cbt.pdf (9F4) Zn-containing
4nb6  2.85  2013  IC50=0.060uM  // 4nb6.pdf (444) ligand is compound 1
4hw7  2.90  2013  IC50=0.062uM  // 4hvs.pdf (64M)
3zov  2.10  2013  IC50=0.06uM   // 3zkg.pdf (WZV) ligand is RO5464694
4lyn  2.00  2013  IC50=0.06uM   // 4lyn.pdf (1YG) ligand is compound 33
4btw  2.80  2013  IC50=0.071uM  // 4btw.pdf (JW7) IC50 = 0.071 +/- 0.007 uM
4ju3  2.00  2013  IC50=0.085uM  // 4ju3.pdf (1O1) IC50=0.085+/-0.02uM, RdRp assay, Scintillation Proximity Assay
4jve  2.30  2013  IC50=0.086uM  // 4jv7.pdf (1MQ) IC50=0.086+/-0.009uM, Different ligand structure(double bond)
4j3e  1.91  2013  IC50=0.088uM  // 4j3e.pdf (NUT)
4lxm  2.30  2013  IC50=0.088uM  // 4lxa.pdf (1YU) ligand is compound 12a
3w55  3.00  2013  IC50=0.08uM   // 2e14.pdf (1FM)
4bo5  2.60  2013  IC50=0.08uM   // 4bnt.pdf (WI4) IC50 = 0.08 uM (AcAcCoA as substrate), IC50 = 2.9 uM (3-OH decanoyl-NAC as substrate)
4mq2  2.80  2013  IC50=0.097uM  // 4mq1.pdf (2C4) IC50 = 0.097 +/- 0.06 uM,the ligand in crystal is not equal to the ligand in literature(4mq1 4mq2 swap).
4gjc  2.40  2013  IC50=0.09uM   // 4gj8.pdf (0MJ) IC50 = 0.09 +/-0.05 uM; X-ray((3S,5R)-9), IC50(rac-9)
4li6  2.05  2013  IC50=0.106uM  // 4li6.pdf (1XO) ligand is compound 19;The protein in crystal(Tankyrase-1) and in binding data(Tankyrase-2) is not identical.
4bo7  2.60  2013  IC50=0.10uM   // 4bnt.pdf (J2T) IC50 = 0.10 uM (AcAcCoA as substrate), IC50 = 1.9 uM (3-OH decanoyl-NAC as substrate)
4bfy  2.30  2013  IC50=0.12uM   // 4bfs.pdf (ZVY) IC50 = 0.12 uM (IC50 at Km for ATP), IC50 = 0.12 uM (IC50 at 50xKm for ATP)
4bo8  2.70  2013  IC50=0.12uM   // 4bnt.pdf (34X) IC50 = 0.12 uM (AcAcCoA as substrate), IC50 = 3.9 uM (3-OH decanoyl-NAC as substrate)
4jg7  3.00  2013  IC50=0.12uM   // 4jg6.pdf (1LC) IC50=0.12+/-0.02uM, covalent complex, Different ligand structure(double bond)
4bo4  2.70  2013  IC50=0.13uM   // 4bnt.pdf (36G) IC50 = 0.13 uM (AcAcCoA as substrate), IC50 = 3.1 uM (3-OH decanoyl-NAC as substrate)
4g16  2.30  2013  IC50=0.14uM   // 4g16.pdf (0VM) X-ray(CK1-gamma-3), IC50(CK1-gamma)
4h4d  1.35  2013  IC50=0.15uM   // 4h4c.pdf (10E) covalent complex
4n3r  1.90  2013  IC50=0.15uM   // 4n3r.pdf (2GU) ligand is compound 2
4j0a  2.40  2013  IC50=0.16uM   // 4iz0.pdf (1JL)
4l7f  1.95  2013  IC50=0.16uM   // 4l7f.pdf (1V5)
4jzf  1.84  2013  IC50=0.175uM  // 4jzd.pdf (1NL) ligand is compound 21a
4gj7  2.80  2013  IC50=0.17uM   // 4gj5.pdf (0LT)
4i10  2.07  2013  IC50=0.17uM   // 4hzt.pdf (1BS)
4j0t  2.05  2013  IC50=0.184uM  // 3zlq.pdf (6T9) ligand is compound 14i
3zm5  2.94  2013  IC50=0.18uM   // 3zm5.pdf (IGM) ligand is compound 22n; Malachite green assay
4bo6  2.80  2013  IC50=0.18uM   // 4bnt.pdf (36P) IC50 = 0.18 uM (AcAcCoA as substrate), IC50 = 1.6 uM (3-OH decanoyl-NAC as substrate)
4h58  3.10  2013  IC50=0.192uM  // 4bb4.pdf (10Z) ligand is compound 48
4msg  1.80  2013  IC50=0.1nM    // 4msg.pdf (2C6) ligand is compound 22
4mt9  2.00  2013  IC50=0.1nM    // 4msg.pdf (2D6) ligand is compound 49
4gs8  2.99  2013  IC50=0.1uM    // 2ypu.pdf (MGJ) ligand is bdm43079, compound 5
4i7d  2.40  2013  IC50=0.1uM    // 4i7b.pdf (14-mer) covalent complex; DELFIA TRF assay
4idt  2.40  2013  IC50=0.1uM    // 4idt.pdf (T28) NIK biochemical chemiluminescent assay
4bo0  2.40  2013  IC50=0.20uM   // 4bnt.pdf (FXE) IC50 = 0.20 uM (AcAcCoA as substrate), IC50 = 5.4 uM (3-OH decanoyl-NAC as substrate)
4k4f  2.90  2013  IC50=0.20uM   // 4k4e.pdf (K4F) ligand is compound 18
4lh5  2.19  2013  IC50=0.20uM   // 4lh5.pdf (LF0) ligand is Mut101
4h4e  1.70  2013  IC50=0.21uM   // 4h4c.pdf (10G) covalent complex
4j08  2.10  2013  IC50=0.22uM   // 4iz0.pdf (1JH)
4j51  2.30  2013  IC50=0.259uM  // 4j51.pdf (N75) IC50=0.259+/-0.007uM
4bie  2.36  2013  IC50=0.25uM   // 4bf2.pdf (IE6) ligand is compound 4;PIC501=6.6+/-1.1(ASk1 Full length N-terminal GST tag),PIC502=6.8+/-0.4(ASk1 Full length N-terminal 6HisAvi tag)
4bib  2.43  2013  IC50=0.25uM   // 4bf2.pdf (IEO) ligand is compound 1;PIC501=6.6+/-0.4(ASk1 Full length N-terminal GST tag),PIC502=6.2+/-0.1(ASk1 Full length N-terminal 6HisAvi tag)
4bnz  2.50  2013  IC50=0.26uM   // 4bnt.pdf (8M5) IC50 = 0.26 uM (AcAcCoA as substrate), IC50 = 3.7 uM (3-OH decanoyl-NAC as substrate)
4byj  2.75  2013  IC50=0.27uM   // 4byi.pdf (FH5) IC50 = 0.27 +/- 0.008 uM
4krs  2.29  2013  IC50=0.299uM  // 4krs.pdf (1SX) ligand is compound 4
3w54  2.30  2013  IC50=0.2nM    // 3vva.pdf (RNB) ligand is CCB
4bti  2.29  2013  IC50=0.2nM    // 4bti.pdf (7R9)
4jjs  2.20  2013  IC50=0.2uM    // 4jjs.pdf (1M9)
3zm6  1.84  2013  IC50=0.30uM   // 3zm5.pdf (2GN) ligand is compound 22m; Malachite green assay
4bo3  2.50  2013  IC50=0.30uM   // 4bnt.pdf (U98) IC50 = 0.30 uM (AcAcCoA as substrate), IC50 = 4.1 uM (3-OH decanoyl-NAC as substrate)
4bo9  2.90  2013  IC50=0.31uM   // 4bnt.pdf (3X3) IC50 = 0.31 uM (AcAcCoA as substrate), IC50 = 7.8 uM (3-OH decanoyl-NAC as substrate)
4brx  2.05  2013  IC50=0.32uM   // 4brx.pdf (KGW) IC50 = 0.32 +/- 0.09 uM
4d8s  2.40  2013  IC50=0.32uM   // 4d8s.pdf (0HX) Ca-containing; the method of getting IC50 from supporting information S9
4ju4  2.40  2013  IC50=0.34uM   // 4ju3.pdf (1O3) IC50=0.34+/-0.18uM, RdRp assay, Scintillation Proximity Assay
4jg6  2.60  2013  IC50=0.36uM   // 4jg6.pdf (1LB) IC50=0.36+/-0.01uM, Covalent complex, Different ligand structure(double bond)
4i5p  1.74  2013  IC50=0.377uM  // 4i5m.pdf (1D1)
4j0s  1.84  2013  IC50=0.382uM  // 4j0r.pdf (1H3) IC50=0.382(0.346-0.420)uM, AlphaScreen Peptide Displacement Assay (ALPHA Assay)
4j0r  1.72  2013  IC50=0.386uM  // 4j0r.pdf (1H2) IC50=0.386(0.345-0.420)uM, AlphaScreen Peptide Displacement Assay (ALPHA Assay)
4m5o  2.00  2013  IC50=0.38uM   // 4ln7.pdf (X48) ligand is compound 4
4bqx  1.79  2013  IC50=0.3uM    // 4bqw.pdf (UN9) Mn-containing
4ez5  2.70  2013  IC50=0.3uM    // 4ez5.pdf (0RS) IC50=0.3+/-0.1uM; IC50(TR-FRET method come from Supporting Information)
4i12  1.78  2013  IC50=0.406uM  // 4i0d.pdf (1BC) AlphaScreen assay
4mwv  2.00  2013  IC50=0.40nM   // 4mwq.pdf (BCZ) ligand is Peramivir;IC50 = 0.40(0.25-0.67) nM
4ff8  2.40  2013  IC50=0.40uM   // 4feq.pdf (14S)
4mwr  1.80  2013  IC50=0.41nM   // 4mwq.pdf (ZMR) ligand is Zanamivir;IC50 = 0.41(0.10-1.72) nM
4j0y  1.77  2013  IC50=0.435uM  // 3zlq.pdf (1H6) ligand is compound 67
3vs3  2.17  2013  IC50=0.43nM   // 3vry.pdf (VSE) ligand is RK-20449
4i0f  1.80  2013  IC50=0.45uM   // 4i0d.pdf (1BF) AlphaScreen assay
4mk5  1.90  2013  IC50=0.45uM   // 4ln7.pdf (28A) ligand is compound 5
4lkm  2.00  2013  IC50=0.46uM   // 4lkl.pdf (8-mer) ligand is PL-74
4i0z  1.80  2013  IC50=0.47uM   // 4hzt.pdf (1BB)
3vva  2.59  2013  IC50=0.48nM   // 3vva.pdf (CHW) ligand is AF2779OH
4i31  1.93  2013  IC50=0.48nM   // 4i31.pdf (17-mer) IC50=0.48+/-0.27nM; incomplete ligand
4jj7  1.18  2013  IC50=0.4uM    // 4jj7.pdf (6-mer)
4kio  2.18  2013  IC50=0.501uM  // 4kio.pdf (G5K) pIC50 = 6.3
4bw3  1.50  2013  IC50=0.50uM   // 4bw1.pdf (9BM)
4jda  2.65  2013  IC50=0.51uM   // 3oqu.pdf (A9S) ligand is (-)-ABA
4cfw  2.45  2013  IC50=0.51uM   // 4cfn.pdf (SQ9) IC50 = 0.51 +/- 0.05 uM
4jju  1.91  2013  IC50=0.51uM   // 4jjs.pdf (1MB)
3wix  1.90  2013  IC50=0.54uM   // 3wix.pdf (LC3) ligand is compound 4
3zjv  2.31  2013  IC50=0.54uM   // 3zjt.pdf (AN3213) The crystal structure is a ternary complex of leucyl-tRNA synthetase, RNA and AN3213.
4l6q  2.79  2013  IC50=0.54uM   // 4l6q.pdf (1WU) ligand is compound 4
4inu  3.10  2013  IC50=0.55nM   // 4inr.pdf (1G6) Different ligand structure(double bond)
4bfz  2.10  2013  IC50=0.55uM   // 4bfs.pdf (ZVZ)
4li5  2.64  2013  IC50=0.55uM   // 4li5.pdf (1WY) covalent complex
4c35  2.19  2013  IC50=0.56uM   // 4c33.pdf (NU3) IC50 = 0.56 +/- 0.05 uM (AlphaScreen kinase assay)
4mcc  1.95  2013  IC50=0.56uM   // 4mcb.pdf (21X) ligand is compound 27
3wd2  2.20  2013  IC50=0.58uM   // 3wd0.pdf (A1L) ligand is Azide 2
4iqu  2.40  2013  IC50=0.58uM   // 4iqt.pdf (1FQ) compound 4b, IC50 value
4ikr  1.78  2013  IC50=0.59uM   // 4ikr.pdf (PVP) IC50=0.59+/-0.04uM, Co-contained
3vtb  2.00  2013  IC50=0.5nM    // 3vtb.pdf (TKA) ligand is compound 4b, ADTK1
4btu  2.37  2013  IC50=0.5nM    // 4bti.pdf (6XS)
4hzx  2.20  2013  IC50=0.5nM    // 4hzw.pdf (G39)
4i4e  1.55  2013  IC50=0.5uM    // 4i4e.pdf (1BQ)
4kil  1.75  2013  IC50=0.5uM    // 4kil.pdf (1R5) ligand is compound 9
3wiy  2.15  2013  IC50=0.61uM   // 3wix.pdf (LC6) ligand is compound 10
4i0d  1.91  2013  IC50=0.61uM   // 4i0d.pdf (1B7) AlphaScreen assay
4ir5  1.70  2013  IC50=0.61uM   // 4ir3.pdf (IR5) compound 17
4jwr  2.35  2013  IC50=0.61uM   // 4jv7.pdf (1MY)
4b72  1.60  2013  IC50=0.63uM   // 4b70.pdf (2FB) ligand is compound 41
4bw4  1.67  2013  IC50=0.63uM   // 4bw1.pdf (9B6)
4gw6  2.65  2013  IC50=0.63uM   // 4gvm.pdf (LF2) IC50 = 0.63 +/- 0.3 uM
4i4f  1.75  2013  IC50=0.64uM   // 4i4e.pdf (1BR)
4ikt  1.60  2013  IC50=0.67uM   // 4ikr.pdf (TFV) IC50=0.67+/-0.03uM, Co-contained
4ju6  2.20  2013  IC50=0.67uM   // 4ju3.pdf (1O6) IC50=0.67+/-0.26uM, RdRp assay, Scintillation Proximity Assay
4ju7  2.20  2013  IC50=0.67uM   // 4ju3.pdf (1O6) IC50=0.67+/-0.26uM, RdRp assay, Scintillation Proximity Assay
4b6c  2.20  2013  IC50=0.69uM   // 4b6c.pdf (B5U) ligand is compound 6
3zc6  2.42  2013  IC50=0.6nM    // 3zc6.pdf (VFC) ligand is compound 6d;IC50=0.6+/-0.3nM
4dwk  3.00  2013  IC50=0.6uM    // 2ypu.pdf (MGK) ligand is bdm41671, compound 3
4jj8  2.94  2013  IC50=0.73uM   // 4jj7.pdf (6-mer)
4mk2  1.85  2013  IC50=0.73uM   // 4ln7.pdf (28B) ligand is compound 3
3zeb  2.20  2013  IC50=0.74uM   // 3zeb.pdf (SV1) IC50=0.74+/-0.13uM, the ring is open
4hzt  1.80  2013  IC50=0.75uM   // 4hzt.pdf (0ZA)
4li7  2.20  2013  IC50=0.770uM  // 4li6.pdf (1XP) ligand is compound 33;The protein in crystal(Tankyrase-1) and in binding data(Tankyrase-2) is not identical.
4j1h  2.20  2013  IC50=0.776uM  // 3zlq.pdf (1HJ) ligand is compound 109
4gvm  2.16  2013  IC50=0.78uM   // 4gvm.pdf (LF2) IC50 = 0.78 +/- 0.06 uM
4iqt  2.60  2013  IC50=0.78uM   // 4iqt.pdf (1FO) ligand is compound 4c
4mwq  2.00  2013  IC50=0.79nM   // 4mwq.pdf (G39) ligand is Oseltamivir Carboxylate; IC50 = 0.79(0.51-1.23) nM
4hxm  1.50  2013  IC50=0.79uM   // 4hxk.pdf (1A8) IC50 = 0.79 +/- 0.8 uM
4bsq  1.96  2013  IC50=0.7nM    // 4bs5.pdf (QQV) covalent complex
4kp6  1.50  2013  IC50=0.81nM   // 4kp6.pdf (1S1) ligand is compounf 44
4lkl  1.58  2013  IC50=0.82uM   // 4lkl.pdf (8-mer) ligand is PL-55
4ir6  1.80  2013  IC50=0.84uM   // 4ir3.pdf (IR6) compound 20
4inb  1.80  2013  IC50=0.89uM   // 4inb.pdf (1F6) HIV-1 capsid assembly assay (CAA)
3zlq  2.10  2013  IC50=0.904uM  // 3zlq.pdf (6T9) ligand is compound 14i
4ii9  1.66  2013  IC50=0.93uM   // 4ii9.pdf (8-mer) IC50=0.93+/-0.07uM
3vuc  2.60  2013  IC50=0.9nM    // 3vuc.pdf (HHE) ligand is compound 5
4ivt  1.60  2013  IC50=1.01uM   // 4ivs.pdf (VTI) IC50=1.01+/-0.091uM
4jv7  2.20  2013  IC50=1.0uM    // 4jv7.pdf (1MN) IC50=1.0+/-0.1uM
3zmi  2.20  2013  IC50=1.117uM  // 3zmh.pdf (L6C) L29 data set 1;IC50=1.117+/-0.05uM, covalent complex
3zot  2.40  2013  IC50=1.117uM  // 3zmh.pdf (L6C) L29 data set 2;IC50=1.117+/-0.05uM; covalent complex
4i6b  1.80  2013  IC50=1.17uM   // 4i5m.pdf (11G)
4k3l  1.50  2013  IC50=1.1mM    // 4k3k.pdf (2-mer) ligand is AcLF
4bdt  3.10  2013  IC50=1.1nM    // 4bds.pdf (HUW) ligand is huprine W
3zm4  2.37  2013  IC50=1.1uM    // 3zls.pdf (22T) ligand is fragment 1
4bqy  1.53  2013  IC50=1.1uM    // 4bqw.pdf (FNT) Fe-containing
4feq  2.20  2013  IC50=1.1uM    // 4feq.pdf (0T8)
4azp  2.10  2013  IC50=1.26uM   // 4azm.pdf (A9M) ligand is AEA; binding affinity=1.26+/-0.18uM
4bw1  1.40  2013  IC50=1.26uM   // 4bw1.pdf (S5B)
4mti  2.15  2013  IC50=1.2nM    // 4mti.pdf (2DX) ligand is compound 63;IC50 = 1.2(1.1-1.3) nM
4mxa  3.00  2013  IC50=1.2nM    // 4mx9.pdf (BK7) ligand is inhibitor RM-1-132, compound 15n
3zki  2.40  2013  IC50=1.2uM    // 3zkg.pdf (WZV) ligand is RO5464694
4gja  2.60  2013  IC50=1.2uM    // 4gj8.pdf (0M3) X-ray((3S,5R)-5), IC50 = 1.2 +/- 0.5 uM ((rac)-5)
4l3p  2.68  2013  IC50=1.2uM    // 4l3p.pdf (1UH) ligand is compound 1b; Binding assay method is ALPHAScreen.
4hzw  1.70  2013  IC50=1.31nM   // 4hzw.pdf (LNV)
3zlk  1.95  2013  IC50=1.32uM   // 4arw.pdf (Y46) compound 15a; IC50=1.32+/-3.7uM
4hy5  1.75  2013  IC50=1.3nM    // 4hy0.pdf (1AQ) Zn-containing; IC50 = 1.2~1.5 nM
4mcv  2.73  2013  IC50=1.3nM    // 4mcv.pdf (29K) IC50 = 1.3 +/- 0.2 nM
4btt  2.59  2013  IC50=1.43nM   // 4bti.pdf (VYR) different ligand structure
4bzn  1.90  2013  IC50=1.441uM  // 4bzn.pdf (UGX)
3vo3  1.52  2013  IC50=1.4nM    // 3vo3.pdf (0KF) ligand is compound 19
4hvd  1.85  2013  IC50=1.4nM    // 4hvd.pdf (933) IC50 = 1.4 +/- 0.3 nM (a kinasefiltration assay)
4j6i  2.90  2013  IC50=1.4nM    // 4j6i.pdf (1JV)
4mu7  1.79  2013  IC50=1.4nM    // 4mti.pdf (2DY) ligand is compound 48;IC50 = 1.4(1.3-1.6) nM
4gsc  2.81  2013  IC50=1.4uM    // 2ypu.pdf (MGW) ligand is bdm41559, compound 2
3zlo  2.60  2013  IC50=1.5nM    // 3zk6.pdf (X8U) ligand is compound 6;IC50=1.5+/-0.4nM
4mcb  1.94  2013  IC50=1.5uM    // 4mcb.pdf (21W) ligand is compound 38
4ght  1.96  2013  IC50=1.67uM   // 4ght.pdf (AG7) covalent complex
4g2w  2.28  2013  IC50=1.6nM    // 4g2w.pdf (NI0) Zn-containing, Mg-containing
4gk2  2.19  2013  IC50=1.6nM    // 4gk2.pdf (L66)
4int  2.90  2013  IC50=1.6uM    // 4inr.pdf (1G5) Different ligand structure(double bond)
4mzj  1.47  2013  IC50=1.6uM    // 4mzj.pdf (19-mer) ligand is pGly[801,805], a stapled myoA tail peptide
4iku  1.30  2013  IC50=1.79uM   // 4ikr.pdf (SHX) IC50=1.79+/-0.08uM, Co-contained
4ibm  1.80  2013  IC50=1.8uM    // 4ibm.pdf (IR1)
4jv9  2.50  2013  IC50=1.8uM    // 4jv7.pdf (1MO) IC50=1.8+/-0.1uM
4hhy  2.36  2013  IC50=1.92nM   // 4hhy.pdf (15R)
4jht  1.18  2013  IC50=10.2uM   // 4jht.pdf (8XQ) a formaldehyde dehydrogenase based assay; Mn-containing
4m5r  1.40  2013  IC50=1000uM   // 4ln7.pdf (MSR) ligand is compound 1
4i7f  2.50  2013  IC50=100nM    // 4i7f.pdf (NVE)
4iz0  2.22  2013  IC50=100uM    // 4iz0.pdf (2BI)
4dr9  1.90  2013  IC50=10nM     // 3uwb.pdf (BB2) ligand is actinonin
4kfp  1.84  2013  IC50=10nM     // 4kfp.pdf (1R7) ligand is compound 29
4mb9  1.85  2013  IC50=10nM     // 4mb9.pdf (28F) ligand is compound 20
4b78  1.50  2013  IC50=10uM     // 4b70.pdf (KGG) ligand is compound 91
3zmj  2.30  2013  IC50=11.71uM  // 3zmh.pdf (L61) IC50=11.71+/-0.75uM, covalent complex
4bdc  3.00  2013  IC50=11.7uM   // 4bda.pdf (ODH) ligand is compound 13  IC50=11.7+/-2.0uM;Mobility Shift Assay
4lc7  1.70  2013  IC50=11.8uM   // 4lc7.pdf (1WP) ligand is compound 40
4l34  1.80  2013  IC50=114nM    // 4bs4.pdf (1VG) Zn-contained
4dho  1.70  2013  IC50=118uM    // 3t0l.pdf (Y09) ligand is compound B9
3w5e  2.30  2013  IC50=11nM     // 3w5e.pdf (NVW) ligand is compound 31e
4g2j  2.40  2013  IC50=11nM     // 4e90.pdf (0WF) Zn-containing, Mg-containing;
4jbs  2.79  2013  IC50=11nM     // 4jbs.pdf (P52) IC50=11+/-2nM, Zn-contained
4m4q  2.50  2013  IC50=11nM     // 4ln7.pdf (21A) ligand is compound 7
4m5u  2.20  2013  IC50=11nM     // 4m5u.pdf (20F) ligand is compound 16;IC50 = 0.011    0.0005 uM
4j04  2.00  2013  IC50=11uM     // 4iz0.pdf (1JF)
4kb8  1.95  2013  IC50=12.9nM   // 4kb8.pdf (1QN) ligand is compound 4
3wfg  1.40  2013  IC50=120nM    // 3wfg.pdf (WFG) ligand is compound 2e
4kc1  1.50  2013  IC50=1220uM   // 4kc1.pdf (WS1) ligand is 8-GLC
4jx7  2.40  2013  IC50=123nM    // 4jx7.pdf (1N6) IC50 = 123 +/- 14 nM
4j4o  1.73  2013  IC50=125nM    // 4j4n.pdf (D44) IC50=125+/-2.9nM
4men  1.81  2013  IC50=125uM    // 4men.pdf (25K) ligand is compound 3; 33% inhibition
4kqq  2.10  2013  IC50=126uM    // 4kqo.pdf (VPP) ligand is (5S)-penicilloic acid;IC50 = 126 +/- 18 uM;co-crystallization
4kqr  2.01  2013  IC50=126uM    // 4kqo.pdf (VPP) ligand is (5S)-penicilloic acid;IC50 = 126 +/- 18 uM;co-crystallization; soaking
4fz6  1.85  2013  IC50=127nM    // 4fyn.pdf (0VG)
4dvf  1.80  2013  IC50=128nM    // 4dv9.pdf (7-mer)
4dhn  1.80  2013  IC50=128uM    // 3t0l.pdf (0KC) ligand is compound B10
4lqy  1.54  2013  IC50=129uM    // 4lqy.pdf (AMP) IC50 = 129 +/- 73 uM
3vtd  2.70  2013  IC50=12nM     // 3vtb.pdf (TKD) ligand is compound 5b, ADTK4
4j1f  2.25  2013  IC50=12nM     // 3zlq.pdf (1HL) ligand is compound 89
4kmu  3.85  2013  IC50=12nM     // 4kmu.pdf (RFP) ligand is RMP
3ukr  2.48  2013  IC50=12uM     // 3ukr.pdf (CKH) ligand is compound 1;IC50=12+/-1uM
4b81  2.80  2013  IC50=12uM     // 4b7z.pdf (ZN4) ligand is compound 5;Ellman assay
4j4n  2.75  2013  IC50=132nM    // 4j4n.pdf (D44) IC50=132+/-1.09nM
4bnt  2.30  2013  IC50=137.69uM  // 4bnt.pdf (36E)
3vtc  1.50  2013  IC50=13nM     // 3vtb.pdf (TK3) ligand is compound 5a, ADTK3
3wax  1.90  2013  IC50=13nM     // 3wav.pdf (DWX) ligand is 3BoA;IC50=13+/-2.4nM
4j1k  2.18  2013  IC50=13nM     // 3zlq.pdf (1HG) ligand is compound 111
4dzw  3.05  2013  IC50=13nM     // 4dwb.pdf (0MQ) Mg-containing
4kbc  1.98  2013  IC50=14.2nM   // 4kb8.pdf (1QJ) ligand is compound 3
4gye  2.27  2013  IC50=142nM    // 4gye.pdf (6-mer)
4l0s  1.90  2013  IC50=145nM    // 4bs4.pdf (1UZ) Zn-contained
4l32  1.85  2013  IC50=146nM    // 4bs4.pdf (1VF) Zn-contained
3zo4  1.65  2013  IC50=149nM    // 3zo1.pdf (QWI) ligand is compound 41
4bjc  2.20  2013  IC50=14nM     // 4bjc.pdf (RPB) Zn-containing; IC50(Fluorescence method come from ref. 7.)
4gk4  2.10  2013  IC50=14nM     // 4gk2.pdf (L90)
4i0r  2.10  2013  IC50=14nM     // 4i0r.pdf (1B4)
4jzr  2.10  2013  IC50=15.8nM   // 4jzr.pdf (4JR) ligand is compound 4b; pIC50 = 7.8
4bde  2.55  2013  IC50=15.9uM   // 4bda.pdf (CWS) ligand is compound 15  IC50=15.9+/-9.0uM;Mobility Shift Assay
3zlx  2.20  2013  IC50=157uM    // 3zls.pdf (5EZ) ligand is fragment 18
4b0g  2.50  2013  IC50=15nM     // 4b0g.pdf (VEK) ligand is compound 21a
4bfp  2.40  2013  IC50=15nM     // 4bfp.pdf (SWY)
4bgg  2.56  2013  IC50=15nM     // 4bgg.pdf (844) ligand is compound 26, LDN-213844, assay for ACVRLK2
4dht  1.80  2013  IC50=15uM     // 3t0l.pdf (0KG) ligand is compound B2
4ie5  1.95  2013  IC50=15uM     // 4idz.pdf (MD6) IC50=15+/-1.1uM, Zn-contained
4l31  2.00  2013  IC50=162nM    // 4bs4.pdf (F08) Zn-contained
4dhm  1.70  2013  IC50=165uM    // 3t0l.pdf (0KB) ligand is compound B11
4kqo  2.31  2013  IC50=166nM    // 4kqo.pdf (JPP) IC50 = 166 +/- 62 nM, the ligand in the crystal is not complete.
2ly0   NMR  2013  IC50=16uM     // 2ly0.pdf (A2Y) ligand is M2WJ332
4dhs  1.74  2013  IC50=16uM     // 3t0l.pdf (Y03) ligand is compound B3
4mk1  1.85  2013  IC50=16uM     // 4ln7.pdf (27Y) ligand is comound 2
4hvg  2.75  2013  IC50=17.0nM   // 4hvd.pdf (19Q) IC50 = 17.0 +/- 3.4 nM (a kinasefiltration assay)
4c38  1.58  2013  IC50=17.4nM   // 4c33.pdf (VUP) IC50 = 17.4 +/- 6.0 nM (AlphaScreen kinase assay)
4alu  2.60  2013  IC50=17nM     // 4alu.pdf (79O) ligand is compound 3
4g1f  2.90  2013  IC50=17nM     // 4g1f.pdf (0WG)
4ke0  2.30  2013  IC50=17nM     // 4k8s.pdf (1R8) ligand is compound 13
4m3q  2.72  2013  IC50=17nM     // 4m3q.pdf (24K) ligand is compound 3
3wav  1.80  2013  IC50=180nM    // 3wav.pdf (DWV) ligand is compound 10
4mx0  2.10  2013  IC50=184.7nM  // 4mwq.pdf (BCZ) ligand is Peramivir;IC50 = 184.7(129-264) nM
4dwb  2.10  2013  IC50=1840nM   // 4dwb.pdf (0M7) Mg-containing
4dv9  2.08  2013  IC50=189nM    // 4dv9.pdf (8-mer)
4ipf  1.70  2013  IC50=18nM     // 4ipf.pdf (1F0) IC50=18+/-11nM
4jhq  1.99  2013  IC50=18nM     // 4jhq.pdf (B6F) IC50=18+/-2.0nM, Fe-containing
4kjv  1.70  2013  IC50=18nM     // 4kju.pdf (1RK) ligand is compound 36
4hvh  2.30  2013  IC50=19.0nM   // 4hvd.pdf (19R) IC50 = 19.0 +/- 6.2 nM (a kinasefiltration assay)
4c37  1.70  2013  IC50=19.7nM   // 4c33.pdf (Z21) IC50 = 19.7 +/- 2.6 nM (AlphaScreen kinase assay)
4c36  1.98  2013  IC50=19.8nM   // 4c33.pdf (ZO9) IC50 (AlphaScreen kinase assay)
4bb4  1.65  2013  IC50=190nM    // 4bb4.pdf (32W) Mg2+ containing;ligand is compound 3
4jrg  1.90  2013  IC50=196nM    // 4jrg.pdf (I09)
3zlw  2.12  2013  IC50=198uM    // 3zls.pdf (MT8) ligand is fragment 3
3w2r  2.05  2013  IC50=19nM     // 3w2r.pdf (W2R) ligand is compound 4
4j1e  1.78  2013  IC50=19nM     // 3zlq.pdf (1HM) ligand is compound 88
4im0  2.40  2013  IC50=19nM     // 4im0.pdf (1FV) Immunoprecipitation kinase assay
4hyh  1.70  2013  IC50=1nM      // 4hyh.pdf (1AM)
4iwd  1.99  2013  IC50=1nM      // 4iwd.pdf (1JC)
4ktc  2.30  2013  IC50=1nM      // 4ktc.pdf (1X3) ligand is compound 6; IC50=1nM, EC50=6nM
4l8m  2.10  2013  IC50=1nM      // 4l8m.pdf (F46) ligand is compound 32a; IC50 = 0.001 +/- 0.0002 uM
4mk8  2.09  2013  IC50=1nM      // 4mk7.pdf (28Q) ligand is compound 4
4mka  2.05  2013  IC50=1nM      // 4mk7.pdf (2AY) ligand is compound 13
3zo1  2.00  2013  IC50=1uM      // 3zo1.pdf (SIJ) ligand is compound 12
4awi  1.91  2013  IC50=1uM      // 4awi.pdf (AQ2) ligand is compound 4, PIC50=6.0
4jql  1.72  2013  IC50=1uM      // 4jql.pdf (VJ6)
3wc5  1.70  2013  IC50=2.0nM    // 3wab.pdf (DDK) ligand is compound 1a
4jlg  1.90  2013  IC50=2.0nM    // 4jlg.pdf (1L8) ligand is (R)-PFI-2
4lgu  2.00  2013  IC50=2.1nM    // 4lge.pdf (1YH) ligand is compound A
3zju  2.40  2013  IC50=2.1uM    // 3zjt.pdf (AN3016) The crystal structure is a ternary complex of leucyl-tRNA synthetase, RNA and AN3016.
4hxl  1.52  2013  IC50=2.2uM    // 4hxk.pdf (1A9) IC50 = 2.2 +/- 0.1 uM
3zjt  2.20  2013  IC50=2.3uM    // 3zjt.pdf (AN3017) The crystal structure is a ternary complex of leucyl-tRNA synthetase, RNA and AN3017.
4lnf  2.95  2013  IC50=2.4mM    // 4lnf.pdf (GLN)
4mzl  2.01  2013  IC50=2.4uM    // 4mzj.pdf (18-mer) ligand is hydrogen bond surrogate (HBS) myoA helix mimetic peptide
4ke1  1.91  2013  IC50=2.5nM    // 4k8s.pdf (1R6) ligand is compound 19
4btl  2.50  2013  IC50=2.5uM    // 4b7z.pdf (5GZ) ligand is compound 24; Ellman assay
4ezl  2.94  2013  IC50=2.6nM    // 4ezj.pdf (0SE)
4mx9  3.10  2013  IC50=2.6nM    // 4mx9.pdf (2E8) inhibitor UW1294
4inr  2.70  2013  IC50=2.6uM    // 4inr.pdf (1G1) Different ligand structure(double bond); covalent complex
4hy4  1.25  2013  IC50=2.7nM    // 4hy0.pdf (1BG) IC50 = 2.5~2.9 nM; Zn-containing
4bda  2.60  2013  IC50=2.7uM    // 4bda.pdf (VFB) ligand is compound 11  IC50=2.7+/-0.2uM;Mobility Shift Assay
4ie6  2.50  2013  IC50=2.8uM    // 4idz.pdf (UN9) IC50=2.8+/-0.9uM, Zn-contained
4mbl  2.60  2013  IC50=2.9nM    // 4mbi.pdf (26L) ligand is compound 9g
4dtt  3.22  2013  IC50=2.9uM    // 2ypu.pdf (I41) IDE-CF-(1), ligand is compund 41367, hits 1
4hy0  2.84  2013  IC50=200nM    // 4hy0.pdf (1AQ) Zn-containing; IC50 = 140~280 nM
4nie  2.01  2013  IC50=20nM     // 4nie.pdf (NBH) ligand is compound 2;IC50 = 20 nM(dual FRET)
4fic  2.50  2013  IC50=20uM     // 4fic.pdf (0UL)
4l2g  2.05  2013  IC50=210nM    // 4bs4.pdf (1V4) Zn-contained
4mww  1.90  2013  IC50=214770nM  // 4mwq.pdf (G39) ligand is Oseltamivir Carboxylate; IC50 = 214770(126699-364063) nM
4jr3  2.70  2013  IC50=218nM    // 4jq7.pdf (KJR)
4bjb  2.30  2013  IC50=219nM    // 4bjb.pdf (P34) Zn-containing; IC50(Fluorescence method come from ref. 7.)
4j3m  1.90  2013  IC50=21nM     // 3w51.pdf (AJ8) ligand is compound 15
4hww  1.30  2013  IC50=223nM    // 4hww.pdf (X7A) Mn-containing
4bdi  2.32  2013  IC50=227.7uM  // 4bda.pdf (HAU) ligand is compound 19  IC50=227.7+/-22.2uM;Mobility Shift Assay
3way  1.75  2013  IC50=22nM     // 3wav.pdf (DWY) ligand is 4BoA;IC50=22+/-5.4nM
3wd1  2.30  2013  IC50=22nM     // 3wd0.pdf (ST7) ligand is Syn-triazole 4
3zep  2.35  2013  IC50=22nM     // 3zep.pdf (1NX) ligand is compound 12a;IC50=22+/-9nM
4bjx  1.59  2013  IC50=22nM     // 4bjx.pdf (73B) ligand is I-BET726
4b84  2.60  2013  IC50=22uM     // 4b7z.pdf (Z5K) ligand is compound 12;Ellman assay
4l0v  1.70  2013  IC50=233nM    // 4bs4.pdf (1V1) Zn-contained
4eyr  1.80  2013  IC50=237nM    // 4eyr.pdf (RIT) IC50 = 237 +/- 5.6 nM
3zmg  1.74  2013  IC50=23nM     // 3zlq.pdf (6Z0) ligand is compound 14d
4ixu  1.90  2013  IC50=23nM     // 4ixu.pdf (38I) measuring urea levels in a colorimetric assay, B-contained; Mn-containing
4kiq  2.50  2013  IC50=23nM     // 4kin.pdf (1RA) ligand is compound 9d
3wbl  2.00  2013  IC50=23uM     // 3wbl.pdf (PDY) ligand is  TEI-I01800
4ixv  2.30  2013  IC50=240nM    // 4ixu.pdf (XA1) measuring urea levels in a colorimetric assay, B-contained; Mn-containing
4fxj  2.90  2013  IC50=240uM    // 4fxf.pdf (PHE) IC50 = 240 +/- 0.1 uM (the standard lactate dehydrogenase coupled assay)
4nrc  1.86  2013  IC50=241uM    // 4nr9.pdf (2LY) ligand is compound 3; IC50= 241+/-28uM; AlphaLISA binding assay
4jbo  2.49  2013  IC50=24nM     // 4jbo.pdf (WPH)
4jp9  1.80  2013  IC50=24nM     // 4joo.pdf (1M5)
4k4e  2.30  2013  IC50=24nM     // 4k4e.pdf (K4E) ligand is compound 52,but the structure of the ligand is not correct
4kn7  3.69  2013  IC50=24nM     // 4kmu.pdf (1RM) ligand is bxRIF2c
4meq  1.77  2013  IC50=250uM    // 4men.pdf (25O) lgand is compound 4; 32% inhibition
4meo  1.72  2013  IC50=250uM    // 4men.pdf (25V) ligand is compound 5; 31% inhibition
4la7  1.98  2013  IC50=267nM    // 4la7.pdf (A1O) ligand is Quinabactin
4i0t  1.70  2013  IC50=26nM     // 4i0r.pdf (1B6)
4i11  1.89  2013  IC50=27.2uM   // 4hzt.pdf (1CH)
4l0i  2.30  2013  IC50=272nM    // 4bs4.pdf (1UW) Zn-contained
4alw  1.92  2013  IC50=27nM     // 4alu.pdf (HY7) ligand is compound 6d
4dhr  1.40  2013  IC50=27uM     // 3t0l.pdf (Y04) ligand is compound B4
4j0v  1.94  2013  IC50=28nM     // 3zlq.pdf (1H7) ligand is compound 66
4l53  2.55  2013  IC50=28nM     // 4l53.pdf (1UO) ligand is compound 13a
3w2t  2.36  2013  IC50=29.2nM   // 3w2t.pdf (LF7)
4joa  2.70  2013  IC50=29nM     // 4joa.pdf (3DK)
4jrv  2.80  2013  IC50=29nM     // 4jq7.pdf (KJV)
4lww  1.64  2013  IC50=29nM     // 4lts.pdf (LWW) ligand is compound 4
4j53  2.50  2013  IC50=2nM      // 4j52.pdf (1J4)
4lgh  2.84  2013  IC50=2nM      // 4lgg.pdf (0JN) ligand is 1NM-PP1
4lxa  1.95  2013  IC50=2nM      // 4lxa.pdf (1YS) ligand is compound 11a
4n4v  2.00  2013  IC50=2nM      // 4n4v.pdf (2GY) ligand is compound 4
4i7b  3.00  2013  IC50=2uM      // 4i7b.pdf (14-mer) covalent complex; DELFIA TRF assay; incomplete ligand
4bcb  1.70  2013  IC50=3.0nM    // 4bcb.pdf (4I4) ligand is  compound 13;IC50=3.0+/-0.3nM
4mwu  1.80  2013  IC50=3.24nM   // 4mwq.pdf (LNV) ligand is  Laninamivir;IC50 = 3.24(2.48-4.23) nM
4ehe  3.30  2013  IC50=3.2nM    // 4ehe.pdf (RI8) X-ray (B-Raf), IC50 (B-Raf_V600E); IC50 (method radioactivity come from supporting information)
4ie4  2.50  2013  IC50=3.3uM    // 4idz.pdf (8XQ) IC50=3.3+/-1.1uM, Zn-contained
4jmu  2.00  2013  IC50=3.4uM    // 4jmu.pdf (1ML)
4lge  1.55  2013  IC50=3.5nM    // 4lge.pdf (1Y0) ligand is compound 2
3w1f  2.70  2013  IC50=3.67nM   // 3w1f.pdf (1O5) ligand is compound 23d
4bdk  3.30  2013  IC50=3.6uM    // 4bda.pdf (RQQ) ligand is compound 22  IC50=3.6+/-1.2uM;Mobility Shift Assay
4ezj  2.67  2013  IC50=3.8nM    // 4ezj.pdf (0SC)
4hbp  2.91  2013  IC50=3.8nM    // 4hbp.pdf (17J) covalent complex
3zly  2.11  2013  IC50=300uM    // 3zls.pdf (YSO) ligand is fragment 8
3zlv  2.50  2013  IC50=300uM    // 3zlt.pdf (HI6) IC50=300+/-48uM
3zbf  2.20  2013  IC50=30nM     // 3zbf.pdf (VGH) ligand is crizotinib
4gvu  1.55  2013  IC50=30nM     // 4gvu.pdf (8-mer) IC50 = 30 +/- 6.8 nM
3w5t  2.29  2013  IC50=30uM     // 3w5p.pdf (LHP) ligand is LCA propionate
4ith  2.25  2013  IC50=316.9nM  // 4ith.pdf (RCM)
4g2l  3.00  2013  IC50=32nM     // 4e90.pdf (0WL) Zn-containing, Mg-containing
4kbi  2.06  2013  IC50=32nM     // 4kai.pdf (1C0) ligand is compound 4
4kb7  1.85  2013  IC50=32nM     // 4kai.pdf (690) ligand is compound 32
4dhq  1.75  2013  IC50=32uM     // 3t0l.pdf (Y06) ligand is compound B6
4bcd  1.50  2013  IC50=33nM     // 4bcb.pdf (TDV) ligand is  compound 9i;IC50=33+/-4nM
3wab  2.15  2013  IC50=34nM     // 3wab.pdf (DDW) ligand is compound 2
4lh7  1.90  2013  IC50=34uM     // 4lh6.pdf (1X8) ligand is compound 5c
4joo  1.80  2013  IC50=36.83uM  // 4joo.pdf (1M4)
4bdd  2.67  2013  IC50=36.9uM   // 4bda.pdf (Z0O) ligand is compound 14  IC50=36.9+/-9.0uM;Mobility Shift Assay
4l2k  2.10  2013  IC50=360nM    // 4bs4.pdf (1V8) Zn-contained
3w33  1.70  2013  IC50=36nM     // 3w32.pdf (W19) ligand is compound 19b
4i0s  1.98  2013  IC50=36nM     // 4i0r.pdf (1B5)
4k8s  2.39  2013  IC50=36nM     // 4k8s.pdf (1QT) ligand is compound 14
4dhp  1.75  2013  IC50=36uM     // 3t0l.pdf (Y07) ligand is compound B7
4kw6  3.00  2013  IC50=374uM    // 4kw6.pdf (QDO) covalent complex.
4itj  1.80  2013  IC50=377.2nM  // 4ith.pdf (1HX)
4dxj  2.35  2013  IC50=38.0nM   // 4dwb.pdf (0M9) Mg-containing
4nrb  2.08  2013  IC50=38uM     // 4nr9.pdf (2LX) ligand is compound 1; IC50= 38+/-4uM; AlphaLISA binding assay
3zls  2.50  2013  IC50=39.4uM   // 3zls.pdf (92P) ligand is fragment 6
4jq7  2.73  2013  IC50=393nM    // 4jq7.pdf (KJQ)
4bae  2.35  2013  IC50=3nM      // 4bae.pdf (RWX) ligand is compound 4
4c4j  2.50  2013  IC50=3nM      // 4c4e.pdf (X21) IC50 = 3 +/- 2 nM
4gv1  1.49  2013  IC50=3nM      // 4gv1.pdf (0XZ)
4hyi  1.40  2013  IC50=3nM      // 4hyh.pdf (1AO)
4izy  2.30  2013  IC50=3nM      // 4izy.pdf (1J2) X-ray( JNK1-beta); IC50( JNK1)
4j52  2.30  2013  IC50=3nM      // 4j52.pdf (1J3)
4jnc  1.96  2013  IC50=3nM      // 4jnc.pdf (1LF)
4jnm  2.20  2013  IC50=3nM      // 4jnm.pdf (1LJ) A mass spectrometry-based assay
4l6s  2.20  2013  IC50=3nM      // 4l6s.pdf (1WQ) ligand is compound 3j
4lgg  2.41  2013  IC50=3nM      // 4lgg.pdf (VGG) ligand is 3MB-PP1
4jlh  2.09  2013  IC50=4.0uM    // 4gvm.pdf (0L9) IC50 = 4.0 +/- 0.6 uM
4hxs  1.43  2013  IC50=4.1uM    // 4hxk.pdf (1A3) IC50 = 4.1 +/- 0.4 uM
4hxr  1.53  2013  IC50=4.1uM    // 4hxk.pdf (1A4) IC50 = 4.1 +/- 0.5 uM
4hlw  2.50  2013  IC50=4.2uM    // 4hlw.pdf (17W)
4kz0  2.87  2013  IC50=4.2uM    // 4kz0.pdf (1UJ) ligand is compound 2
4k3k  1.85  2013  IC50=4.44mM   // 4k3k.pdf (SFK) ligand is 4MF
3wiz  2.45  2013  IC50=4.4nM    // 3wix.pdf (LC6) ligand is compound 10
4gzf  2.05  2013  IC50=4.4nM    // 4gye.pdf (6-mer) IC50 = 4.4 +/- 0.2 nM
4lts  1.69  2013  IC50=4.4nM    // 4lts.pdf (LTS) ligand is compound 15
4mvh  2.50  2013  IC50=4.5nM    // 4muw.pdf (2F5) ligadn is compound 26; IC50 = 4.5 +/- 0.44 nM
4ie2  2.21  2013  IC50=4.5uM    // 4ie1.pdf (1EC) measuring urea levels in a colorimetric assay; Mn-containing
4j06  2.00  2013  IC50=4.6uM    // 4iz0.pdf (1JG)
4eev  1.80  2013  IC50=4.7nM    // 4eev.pdf (L1X)
4htx  1.90  2013  IC50=4.7nM    // 4htx.pdf (19F)
4i33  1.90  2013  IC50=4.7nM    // 4i31.pdf (17-mer) IC50=4.7+/-1.6nM; incomplete ligand
3wi6  2.99  2013  IC50=4.7uM    // 3wi6.pdf (YRZ) ligand is TEI-L03090
4mcd  1.55  2013  IC50=4.7uM    // 4mcb.pdf (22L) ligand is compound 1
4mep  1.85  2013  IC50=4.7uM    // 4men.pdf (24Y) ligand is compound 1
4kin  1.97  2013  IC50=4.8nM    // 4kin.pdf (1M8) ligand is compound 5c
3v3m  1.96  2013  IC50=4.8uM    // 3v3m.pdf (0EN) ligand is compound 16;IC50=4.8+/-0.9uM
4mzk  1.82  2013  IC50=4.9uM    // 4mzj.pdf (19-mer) ligand is pGly[807,811], a stapled myoA tail peptide
4mbc  1.75  2013  IC50=400nM    // 4mb9.pdf (28G) ligand is compound 11
4j1i  2.05  2013  IC50=40nM     // 3zlq.pdf (1HH) ligand is compound 110
4b80  2.50  2013  IC50=40uM     // 4b7z.pdf (A36) ligand is compound 4; Ellman assay
4bek  2.39  2013  IC50=41.2uM   // 4bek.pdf (XK0) ligand is compound 1
4jbp  2.45  2013  IC50=41nM     // 4jbo.pdf (YPH)
4ln7  1.73  2013  IC50=41nM     // 4ln7.pdf (1ZQ) ligand is compound 6
4b82  2.10  2013  IC50=41uM     // 4b7z.pdf (B3Z) ligand is compound 10;Ellman assay
4mk7  2.80  2013  IC50=435nM    // 4mk7.pdf (28O) ligand is compound 2
4iti  2.86  2013  IC50=439.5nM  // 4ith.pdf (1HW)
4idz  2.46  2013  IC50=44uM     // 4idz.pdf (OGA) IC50=44+/-1.1uM, Ni-containing
4bj9  2.05  2013  IC50=45nM     // 4bj9.pdf (UHB) Zn-containing; IC50(Fluorescence method come from ref. 7.)
4jib  1.72  2013  IC50=45nM     // 4jib.pdf (1L6)
4k2y  2.30  2013  IC50=470uM    // 4k2y.pdf (ES2) ligand is compound 2;IC50 = 470 +/- 180 uM
4fyo  1.40  2013  IC50=47nM     // 4fyn.pdf (0VF)
4jpe  1.80  2013  IC50=48nM     // 4joo.pdf (1M7)
4e1e  2.65  2013  IC50=490nM    // 4dwb.pdf (0MW) Mg-containing
4kc2  1.70  2013  IC50=493uM    // 4kc1.pdf (WS2) ligand is 8-Gal
4j1c  2.01  2013  IC50=49nM     // 3zlq.pdf (1HO) ligand is compound 70
4ksq  3.30  2013  IC50=49nM     // 4ksp.pdf (1SW) ligand is compound 5B
4m84  2.00  2013  IC50=49nM     // 4m84.pdf (21E) ligand is compound 35
4n4t  2.31  2013  IC50=49nM     // 4n4t.pdf (2GV) ligand is compound 3
4b7z  2.30  2013  IC50=49uM     // 4b7z.pdf (Q4Q) ligand is compound 3; Ellman assay
4bgh  1.95  2013  IC50=4nM      // 4bgh.pdf (3I6)
4jai  3.20  2013  IC50=4nM      // 4jai.pdf (XU2)
4l52  2.54  2013  IC50=4nM      // 4l3p.pdf (1UL) ligand is compound 12az; Binding assay method is ALPHAScreen.
4lxk  2.05  2013  IC50=4nM      // 4lxa.pdf (1YT) ligand is compound 11d
3zmh  2.30  2013  IC50=5.267uM  // 3zmh.pdf (L62) IC50=5.267+/-0.08uM; covalent complex
4j3d  2.00  2013  IC50=5.3nM    // 4j3d.pdf (1JS) Zn-containing
4jaj  2.70  2013  IC50=5.54uM   // 4jai.pdf (XU1)
3wc7  1.90  2013  IC50=5.5nM    // 3wab.pdf (EF1) ligand is EF6265
4j70  2.80  2013  IC50=5.7uM    // 4j70.pdf (1KR) IC50=5.7+/-1.2uM; covalent complex
4bic  2.62  2013  IC50=50.12nM  // 4bf2.pdf (IE4) ligand is compound 2;PIC501=7.3+/-0.4(ASk1 Full length N-terminal GST tag),PIC502=7.1+/-0.03(ASk1 Full length N-terminal 6HisAvi tag)
4fgy  2.84  2013  IC50=500nM    // 4fgy.pdf (11-mer)
4hze  1.60  2013  IC50=509nM    // 4hww.pdf (X7A) Mn-containing
4kai  2.30  2013  IC50=50nM     // 4kai.pdf (1PV) ligand is compound 3
4mot  1.75  2013  IC50=50nM     // 4mot.pdf (2B7) ligand is compound 21
4j0p  1.97  2013  IC50=51nM     // 3zlq.pdf (1H8) ligand is compound 1b
4bhz  2.85  2013  IC50=53.5uM   // 4bhz.pdf (Z0B) binding data from a mobility shift microfluidics assay
4j17  1.81  2013  IC50=54nM     // 3zlq.pdf (1HQ) ligand is compound 69
4l0l  2.10  2013  IC50=54nM     // 4l0l.pdf (PFV) ligand is compound 17; IC50 = 54 +/- 44 nM
4m6p  1.75  2013  IC50=54nM     // 4lv9.pdf (20R) ligand is compound 14
4au8  1.90  2013  IC50=551nM    // 4au8.pdf (Z3R) ligand is compound 4a
4gk3  1.90  2013  IC50=56nM     // 4gk2.pdf (L87)
4k60  1.50  2013  IC50=570uM    // 4k2y.pdf (1P8) ligand is compound 3; IC50 = 570 +/- 330 uM
4kn4  3.96  2013  IC50=57nM     // 4kmu.pdf (1RL) ligand is bxRIF2b
4dwg  2.01  2013  IC50=58.0nM   // 4dwb.pdf (0M8) Mg-containing
4bi0  2.84  2013  IC50=58.6uM   // 4bhz.pdf (Z0W) binding data from a mobility shift microfluidics assay
3waw  1.95  2013  IC50=580nM    // 3wav.pdf (DWW) ligand is 2BoA;IC50=580+/-120nM
4kc4  1.60  2013  IC50=584uM    // 4kc1.pdf (WS3) compound 17
3w69  1.90  2013  IC50=58nM     // 3w69.pdf (LTZ) ligand is compound 35
4i32  2.30  2013  IC50=58nM     // 4i31.pdf (17-mer) IC50=58+/-15nM; incomplete ligand
4l2f  2.05  2013  IC50=595nM    // 4bs4.pdf (1V3) Zn-contained
2yoj  1.76  2013  IC50=5nM      // 2yoj.pdf (8Y6) ligand is compound 11
4i6f  2.90  2013  IC50=5nM      // 4i5m.pdf (1C7)
4i6h  1.91  2013  IC50=5nM      // 4i5m.pdf (1C8)
4jzd  2.20  2013  IC50=5nM      // 4jzd.pdf (1NJ) ligand is compound 1
4dhu  1.67  2013  IC50=5uM      // 3t0l.pdf (0KH) ligand is compound B1
4jvi  2.90  2013  IC50=5uM      // 4jvd.pdf (QZN) IC50=5.0+/-1.6uM
4kba  1.98  2013  IC50=6.0nM    // 4kb8.pdf (1QM) ligand is compound 5
4ixh  2.10  2013  IC50=6.1nM    // 4ixh.pdf (Q21) IC50=6.1+/-0.5nM
4m6q  2.41  2013  IC50=6.1nM    // 4lv9.pdf (20T) ligand is compound 26; The ligand in crystal is not equal to the ligand in binding assay
4ifh  3.29  2013  IC50=6.1uM    // 4ifh.pdf (1EF) compound 10; BDM44619;
4hyu  2.15  2013  IC50=6.2nM    // 4hys.pdf (1BK)
4mds  1.60  2013  IC50=6.2uM    // 4mds.pdf (23H)
4bhn  2.30  2013  IC50=6.31nM   // 4bf2.pdf (BH9) ligand is compound 5;PIC501=8.2+/-0.1(ASk1 Full length N-terminal GST tag),PIC502=8.3+/-0.1(ASk1 Full length N-terminal 6HisAvi tag)
4bw2  1.92  2013  IC50=6.31uM   // 4bw1.pdf (UTH)
4ezk  2.80  2013  IC50=6.3nM    // 4ezj.pdf (0SD)
4b70  1.60  2013  IC50=6.3uM    // 4b70.pdf (WM9) ligand is compound 19b
4fxf  2.55  2013  IC50=6.5uM    // 4fxf.pdf (FBP) IC50 = 6.5 +/- 0.3 uM (the standard lactate dehydrogenase coupled assay)
4kbk  2.10  2013  IC50=6.6nM    // 4kb8.pdf (1QG) ligand is compound 6
3zim  2.85  2013  IC50=6.8nM    // 3zim.pdf (KKR) ligand is compound 3
3w2s  1.90  2013  IC50=6.9nM    // 3w2s.pdf (W2R) ligand is compound 4
4anq  1.76  2013  IC50=605nM    // 2yfx.pdf (VGH) ligand is crizotinid
4hxq  1.45  2013  IC50=60nM     // 4hww.pdf (X8A) Mn-containing
4mbj  3.60  2013  IC50=61nM     // 4mbj.pdf (DFS) ligand is compound 4
4is6  2.50  2013  IC50=627nM    // 4is6.pdf (16-mer) ligand is GP100 peptide
4ark  2.60  2013  IC50=63nM     // 4ark.pdf (M3K) ligand is compound 1
4msk  2.30  2013  IC50=63nM     // 4msg.pdf (2C8) ligand is compound 34
4ehg  3.50  2013  IC50=64nM     // 4ehe.pdf (RI9) IC50 (method radioactivity come from supporting information)
3wff  2.05  2013  IC50=660nM    // 3wff.pdf (WFF) ligand is compound 2b
3w2q  2.20  2013  IC50=66nM     // 3w2q.pdf (HKI) ligand is neratinib(3)
4l0t  2.10  2013  IC50=66nM     // 4bs4.pdf (1V0) Zn-contained
4l0b  1.80  2013  IC50=67nM     // 4bs4.pdf (1UT) Zn-contained
4i06  1.80  2013  IC50=67nM     // 4hww.pdf (X8A) Mn-containing
4klb  2.62  2013  IC50=68.5uM   // 4klb.pdf (1RV) IC50 = 68.5 +/- 3.0uM
4hvi  2.40  2013  IC50=68.9nM   // 4hvd.pdf (19S) IC50 = 68.9 +/- 23.3 nM (a kinasefiltration assay)
4bi1  2.70  2013  IC50=69.1uM   // 4bhz.pdf (ZO6) binding data from a mobility shift microfluidics assay
4bs4  1.89  2013  IC50=6nM      // 4bs4.pdf (A64) Zn-contained
4bs5  1.25  2013  IC50=6nM      // 4bs5.pdf (MG2) covalent complex
4c4h  2.80  2013  IC50=6nM      // 4c4e.pdf (7RO) IC50 = 6 +/- 3 nM
4kju  1.60  2013  IC50=6nM      // 4kju.pdf (1RH) ligand is compound 21j;IC50 = 0.006 +/- 0.002 uM
4iks  1.70  2013  IC50=7.23uM   // 4ikr.pdf (TFD) IC50=7.23+/-0.02uM, Co=contained, Different ligand structures (methyl)
4aua  2.31  2013  IC50=7.2uM    // 4aua.pdf (4AU) ligand is fragment A
4bdj  3.01  2013  IC50=7.2uM    // 4bda.pdf (Z2M) ligand is compound 20  IC50=7.2+/-2.9uM;Mobility Shift Assay
4li8  2.52  2013  IC50=7.5nM    // 4li6.pdf (1XQ) ligand is compound 35; The protein in crystal(Tankyrase-1) and in binding data(Tankyrase-2) is not identical.
4bio  2.45  2013  IC50=7.6uM    // 4bio.pdf (8XQ) Fe-containing; IC50 (MS-based assay)
4gj6  2.58  2013  IC50=7.6uM    // 4gj5.pdf (0LS)
3vry  2.48  2013  IC50=7.7nM    // 3vry.pdf (B43) ligand is RK-24466
4bid  2.80  2013  IC50=7.94nM   // 4bf2.pdf (IE8) ligand is compound 3;PIC501=8.1+/-0.1(ASk1 Full length N-terminal GST tag),PIC502=8.2+/-0.1(ASk1 Full length N-terminal 6HisAvi tag)
4b77  1.80  2013  IC50=7.9uM    // 4b70.pdf (54M) ligand is compound 83
4kzl  2.00  2013  IC50=700nM    // 4bs4.pdf (20D) Zn-contained
3uli  2.00  2013  IC50=70nM     // 3uli.pdf (1N3) ligand is compound 4g
4l10  1.70  2013  IC50=71nM     // 4bs4.pdf (A63) Zn-contained
4fgx  1.59  2013  IC50=73nM     // 4dv9.pdf (7-mer)
4jsc  2.50  2013  IC50=74nM     // 4jrg.pdf (1OY)
4mwx  1.80  2013  IC50=75.7nM   // 4mwq.pdf (ZMR) ligand is Zanamivir; IC50 = 75.7(57.4-99.7) nM
3w32  1.80  2013  IC50=75nM     // 3w32.pdf (W32) ligand is compound 20a
4mgv  1.72  2013  IC50=75nM     // 4mgv.pdf (D5I) ligand is compound 4a;IC50 = 75    6.32 nM
4bdg  2.84  2013  IC50=76.2uM   // 4bda.pdf (P3J) ligand is compound 17  IC50=76.2+/-3.3uM;Mobility Shift Assay
4bdh  2.70  2013  IC50=76.8uM   // 4bda.pdf (WVI) ligand is compound 18  IC50=76.8+/-1.4uM;Mobility Shift Assay
4k9h  2.29  2013  IC50=76nM     // 4k8s.pdf (1QU) ligand is compound 7
4j0z  2.13  2013  IC50=77nM     // 3zlq.pdf (1H5) ligand is compound 68
4lh6  1.65  2013  IC50=77uM     // 4lh6.pdf (1X7) ligand is compound 1
4c66  1.87  2013  IC50=79.4uM   // 4c66.pdf (H4C)
4do3  2.25  2013  IC50=79uM     // 4do3.pdf (0LA) IC50 = 79 +/- 20 uM (PH=7.4), IC50 = 15.5 +/- 0.1 uM (PH=6.0)
3rtp  2.40  2013  IC50=7nM      // 3rtp.pdf (34I) ligand is compound 2
4alv  2.59  2013  IC50=7nM      // 4alu.pdf (R9P) ligand is compound 5m
4l33  2.10  2013  IC50=7nM      // 4bs4.pdf (F70) Zn-contained
4jze  1.52  2013  IC50=7nM      // 4jzd.pdf (1NK) ligand is compound 1
4kip  2.27  2013  IC50=7nM      // 4kin.pdf (1R9) ligand is compound 8
4mbi  2.30  2013  IC50=7nM      // 4mbi.pdf (26K) ligand is compound 11o
4b83  2.40  2013  IC50=7uM      // 4b7z.pdf (B3V) ligand is compound 11;Ellman assay
4kzc  3.25  2013  IC50=8.2nM    // 4kz0.pdf (1UK) ligand is compound 17
4hzz  1.60  2013  IC50=8.31nM   // 4hzw.pdf (G39)
3wd9  2.50  2013  IC50=8.3nM    // 3wd9.pdf (QPC) ligand is compound 10f
4ie0  2.53  2013  IC50=8.3uM    // 4idz.pdf (PD2) IC50=8.3+/-1.1uM, Zn-contained
4i5m  1.80  2013  IC50=8.8nM    // 4i5m.pdf (R78)
4jkt  2.77  2013  IC50=80.4nM   // 4jkt.pdf (04A) IC50=80.4+/-7.2nM
3zo2  1.98  2013  IC50=80nM     // 3zo1.pdf (15I) ligand is compound 14
4bdf  2.70  2013  IC50=81.1uM   // 4bda.pdf (H3R) ligand is compound 16  IC50=81.1+/-24.5uM;Mobility Shift Assay
3w2p  2.05  2013  IC50=8100nM   // 3w2p.pdf (W2P) ligand is compound 2, convalent bond
3w2o  2.35  2013  IC50=8400nM   // 3w2o.pdf (03P) ligand is TAK-285(1)
4bdb  2.50  2013  IC50=85.6uM   // 4bda.pdf (ODO) ligand is compound 12  IC50=85.6+/-7.9uM;Mobility Shift Assay
4l09  2.05  2013  IC50=850nM    // 4bs4.pdf (1UR) Zn-contained
4b85  2.10  2013  IC50=88uM     // 4b7z.pdf (B3W) ligand is compound 17;Ellman assay
4mwy  1.80  2013  IC50=89.6nM   // 4mwq.pdf (LNV) ligand is Laninamivir;IC50 = 89.6(71.1-113) nM
4e90  2.50  2013  IC50=8nM      // 4e90.pdf (7RG) Zn-containing, Mg-containing;
4eqc  2.01  2013  IC50=8nM      // 4eqc.pdf (XR1)
4jq8  2.83  2013  IC50=8nM      // 4jq7.pdf (KJ8)
4ie7  2.60  2013  IC50=9.0uM    // 4idz.pdf (RHN) IC50=9.0+/-1.1uM, Zn-contained, Different ligand structure(carboxyl)
3vzv  2.80  2013  IC50=9.2nM    // 3vzv.pdf (VZV) ligand is compound 14b
4muw  2.64  2013  IC50=9.7nM    // 4muw.pdf (2F4) ligand is compound 1; IC50 = 9.7 +/- 0.86 nM
4hg7  1.60  2013  IC50=90nM     // 4hfz.pdf (NUT)
3wi2  2.26  2013  IC50=92nM     // 3wi2.pdf (P98) ligand is compound 7g
4bi2  3.11  2013  IC50=94.1uM   // 4bhz.pdf (ZO8) binding data from a mobility shift microfluidics assay
4jpc  1.80  2013  IC50=94nM     // 4joo.pdf (1M6)
4bfd  2.30  2013  IC50=96nM     // 4bek.pdf (8T3) ligand is compound 18
4ie3  2.35  2013  IC50=980nM    // 4ie1.pdf (1EE) measuring urea levels in a colorimetric assay; Mn-containing
4l7g  1.38  2013  IC50=99.3uM   // 4l7g.pdf (1W0) ligand is compound 34
4bcc  1.65  2013  IC50=9nM      // 4bcb.pdf (JKT) ligand is  compound 14;IC50=9.0+/-0.1nM
4byi  2.60  2013  IC50=9nM      // 4byi.pdf (FH3) IC50 = 9 +/- 3 nM
4mk9  2.05  2013  IC50=9nM      // 4mk7.pdf (28R) ligand is compound 12
4g2y  2.40  2013  IC50>1000nM   // 4g2w.pdf (NI5) Zn-containing, Mg-containing
4k5z  1.80  2013  IC50>1000uM   // 4k2y.pdf (1P7) ligand is compound 11
4gjb  2.75  2013  IC50>100uM    // 4gj8.pdf (0ME) X-ray(S-6), IC50(rac-6)
4l7h  1.85  2013  IC50>200uM    // 4l7h.pdf (1W1) ligand is Compound S1
4l7j  1.65  2013  IC50>200uM    // 4l7j.pdf (1W2) ligand is Compound S2
3vzd  2.30  2013  IC50~0.5uM    // 3vzb.pdf (UUL) ligand is SKI-II;with Mg and ADP
4ga3  2.39  2013  IC50~30nM     // 4ga3.pdf (4GA) IC50 (a  continuous  spectrophotometric assay); Mg-containing
4bxn  2.79  2013  Kd<10nM       // 4a1z.pdf (6LX) ligand is compound 1
4mdt  2.59  2013  Kd<10uM       // 4mdt.pdf (24G)
4j9a  3.20  2013  Kd<6nM        // 4j8t.pdf (DOG)
4lop  2.05  2013  Kd=0.007uM    // 4loo.pdf (SB4)
4loq  2.32  2013  Kd=0.007uM    // 4loo.pdf (SB4)
4avt  3.20  2013  Kd=0.0088uM   // 4avt.pdf (GHE) ligand is CPHPC, assay with calcium ions
4f7l  2.90  2013  Kd=0.01uM     // 4f6s.pdf (0SO) compound 2
2yns  2.10  2013  Kd=0.025uM    // 2ynr.pdf (12-mer) ligand is B54NLS; Kd=0.025+/-0.004uM; incomplete ligand
4kln  2.62  2013  Kd=0.02uM     // 4kln.pdf (AGS) Kd = 0.02 +/- 0.001 uM
4fil  2.40  2013  Kd=0.034uM    // 4fil.pdf (0UE) Kd=0.034+/-0.009 uM
4f6w  2.39  2013  Kd=0.03uM     // 4f6s.pdf (0SS) compound 1
4gpk  3.20  2013  Kd=0.03uM     // 4gpk.pdf (8-mer) Kd = 0.03 +/- 0.01 uM
3zi0  1.90  2013  Kd=0.04uM     // 3zhx.pdf (FM8) Mn-containing; ligand is compound 14i
4ly1  1.57  2013  Kd=0.0552uM   // 4lxz.pdf (20Y) ligand is compound 1
4ggz  1.75  2013  Kd=0.066nM    // 4ggz.pdf (BTN) Kd=0.066+/-0.015nM
4i9h  2.17  2013  Kd=0.068uM    // 4i8x.pdf (1E4) IC50=0.440uM
4bg6  2.30  2013  Kd=0.069uM    // 4bg6.pdf (10-mer) Kd = 0.069 +/- 0.025 uM; incomplete ligand
4cfe  3.02  2013  Kd=0.06uM     // 4cfe.pdf (992) Kd = 0.06 +/- 0.013 uM (biolayer interferometry), Kd = 0.085 +/- 0.03 uM (circular dichroism)
4fr3  1.90  2013  Kd=0.07uM     // 3ux0.pdf (6-mer) ligand is TASK3 PHOSPHOPEPTIDE;bond with 16-O-Me-FC-H
4ko8  1.98  2013  Kd=0.07uM     // 4kln.pdf (AGS) Kd=0.07+/-0.01 uM
4hy9  1.55  2013  Kd=0.08uM     // 4ezo.pdf (12-mer) Kd = 0.08 +/- 0.03 uM; incomplete ligand
4f7n  2.65  2013  Kd=0.08uM     // 4f6s.pdf (0SV) compound 11
3zhz  2.25  2013  Kd=0.09uM     // 3zhx.pdf (FM7) ligand is compound 14f
4kom  2.60  2013  Kd=0.10uM     // 4kol.pdf (4-mer)
4k9y  2.00  2013  Kd=0.111uM    // 4k8a.pdf (K9Y) ligand is compound 13
4i54  2.50  2013  Kd=0.11uM     // 4i53.pdf (1C1) Kd=0.11+/-0.03uM
4jyb  2.10  2013  Kd=0.11uM     // 4jyb.pdf (GNP) ligand is GMPPNP; Kd=0.11+/-0.01 uM
4loh  2.25  2013  Kd=0.11uM     // 4loh.pdf (1SY) ligand is c[G(2',5')pA(3',5')p]
4hpy  1.50  2013  Kd=0.12nM     // 4hpo.pdf (19-mer) incomplete ligand
3wdz  2.60  2013  Kd=0.12uM     // 3wdz.pdf (14-mer) ligand is Peptide from Sequestosome-1;Ka=8.5+/-2.4  106M-1; incomplete ligand
4g4p  1.50  2013  Kd=0.13uM     // 4g4p.pdf (GLN) Kd=0.13+/-0.01uM
4bcq  2.40  2013  Kd=0.147uM    // 4bcf.pdf (TJF) ligand is comound 6
4b8p  2.30  2013  Kd=0.14uM     // 2ynr.pdf (12-mer) ligand is A89NLS; Kd=0.14+/-0.023uM; incomplete ligand
3zke  2.20  2013  Kd=0.16uM     // 3zke.pdf (11-mer) ligand is NEK9 peptide
4lkg  2.99  2013  Kd=0.16uM     // 4kol.pdf (3-mer)
4loi  1.89  2013  Kd=0.17uM     // 4loh.pdf (1YC) ligand is c[G(2',5')pA(2',5')p]
4lxz  1.85  2013  Kd=0.182uM    // 4lxz.pdf (SHH) ligand is SAHA
4lg6  1.80  2013  Kd=0.18uM     // 4lg6.pdf (17-mer) ligand is CCDC8 peptide
4lrh  2.80  2013  Kd=0.19nM     // 4lrh.pdf (FOL)
2rt5   NMR  2013  Kd=0.19uM     // 2rt5.pdf (8-mer) ligand is peptide from Silencing mediator of retinoic acid and thyroid hormone receptor;Kd=0.19+/-0.18uM,ITC
4lwc  1.61  2013  Kd=0.19uM     // 4luo.pdf (1XU) ligand is compound 8; incomplete ligand
4lhv  1.95  2013  Kd=0.1nM      // 4lhv.pdf (GDP)
4jyc  2.20  2013  Kd=0.20uM     // 4jyb.pdf (GDP) Kd=0.20+/-0.01 uM
4lkj  2.80  2013  Kd=0.20uM     // 4kol.pdf (3-mer)
3zhx  2.00  2013  Kd=0.21uM     // 3zhx.pdf (FM6) Mn-containing; ligand is compound 14a
4iaw  2.40  2013  Kd=0.234nM    // 4iaw.pdf (LIZ) Different ligand structure; Y-containing
4iuo  1.80  2013  Kd=0.23mM     // 4gui.pdf (QIC) Kd=0.23+/-0.04mM
4btk  2.00  2013  Kd=0.24uM     // 4btj.pdf (DTQ) Kd=0.46 uM(Phosphorylated TTBK1), Kd=0.24 uM(Nonphosphorylated TTBK1)
4gqp  2.00  2013  Kd=0.25nM     // 4gqp.pdf (B40) Kd=0.25+/-0.014nM
4li0  3.30  2013  Kd=0.26uM     // 4lhv.pdf (GDP)
4iax  1.90  2013  Kd=0.273nM    // 4iaw.pdf (LIZ) Different ligand structure; Y-containing
2m3z   NMR  2013  Kd=0.27uM     // 2m3z.pdf (1HF) ligand is compound 3;Kd=0.27+/-0.07uM
4jgv  3.01  2013  Kd=0.27uM     // 4jgv.pdf (T94) Kd=0.27+/-0.03uM
4iue  2.38  2013  Kd=0.28uM     // 3w51.pdf (AJ4) ligand is compound 11
4io2  1.37  2013  Kd=0.2uM      // 4io2.pdf (GLU) Kd=0.2+/-0.02uM
4nj3  1.85  2013  Kd=0.30uM     // 4nj3.pdf (2KD)
4gv8  2.10  2013  Kd=0.32uM     // 4gv8.pdf (DUP) Mg-containing
4kon  2.60  2013  Kd=0.33uM     // 4kol.pdf (SIA-GAL)
3zh8  2.74  2013  Kd=0.341uM    // 3zh8.pdf (C58) ligand is CRT0066854
4b7p  1.70  2013  Kd=0.346nM    // 4b7p.pdf (9UN) ligand is NMS-E973
4hyb  1.70  2013  Kd=0.35uM     // 4ezo.pdf (11-mer) Kd = 0.35 +/- 0.01 uM; incomplete ligand
4n07  1.87  2013  Kd=0.35uM     // 4n07.pdf (2J9) ligand is compound 3; Kd=0.35+/-0.02 uM
4jfk  1.15  2013  Kd=0.36uM     // 4jfi.pdf (JFK) Kd=0.36+/-0.1uM
3zll  2.00  2013  Kd=0.395uM    // 4arw.pdf (4WF) ligand is compound 2; Kd=0.395+/-0.02uM; IC50=1.14+/-0.19uM
4ezo  1.90  2013  Kd=0.3uM      // 4ezo.pdf (15-mer) Kd = 0.3 +/- 0.1 uM; incomplete ligand
4loj  1.77  2013  Kd=0.3uM      // 4loh.pdf (1SY) ligand is c[G(2',5')pA(3',5')p]
4cff  3.92  2013  Kd=0.40uM     // 4cfe.pdf (C1V) Kd = 0.40 +/- 0.15 uM
3w07  1.03  2013  Kd=0.42mM     // 3w07.pdf (U5P) Kd=0.42+/-0.02mM
4b33  1.50  2013  Kd=0.43mM     // 4b2i.pdf (1NP) ligand is compound 9
3v2p  1.87  2013  Kd=0.44uM     // 3v2n.pdf (STE) Kd=0.44+/-0.06uM
4j4v  2.30  2013  Kd=0.44uM     // 4j4v.pdf (SVR) Kd=0.44+/-0.095uM; incomplete ligand structure
4i67  2.33  2013  Kd=0.45uM     // 4i67.pdf (4-mer) Kd=0.45+/-0.036uM
4b32  1.50  2013  Kd=0.46mM     // 4b2i.pdf (03V) ligand is compound 10
3zk6  2.48  2013  Kd=0.46uM     // 3zk6.pdf (H1I) ligand is compound 2; Kd=230+/-20nM
3w9k  1.80  2013  Kd=0.48uM     // 3w9k.pdf (MYR) Kd=0.48+/-0.05uM
3v2q  2.20  2013  Kd=0.51uM     // 3v2n.pdf (PLM) Kd=0.51+/-0.07uM
4n6h  1.80  2013  Kd=0.52nM     // 4n6h.pdf (EJ4)
4jbl  2.00  2013  Kd=0.54mM     // 4il5.pdf (MET) Kd=0.54+/-0.03mM
4f0c  1.90  2013  Kd=0.54uM     // 4f0c.pdf (GDS) ligand is GSSG
3zlr  2.03  2013  Kd=0.55nM     // 3zk6.pdf (X0B) ligand is WEHI-539
3ux0  1.75  2013  Kd=0.55uM     // 3ux0.pdf (6-mer) ligand is TASK3 PHOSPHOPEPTIDE;bond with FC-H
4b2l  1.50  2013  Kd=0.57mM     // 4b2i.pdf (TR7) ligand is compound 8
4hwb  2.61  2013  Kd=0.57nM     // 4hwb.pdf (NHE) Kd = 0.57 +/- 0.01 nM
4kii  1.85  2013  Kd=0.59uM     // 4kii.pdf (RHL) Rh-containing
4ddh  2.07  2013  Kd=0.5mM      // 4ddh.pdf (MS0) Kd=0.5+/-0.01 mM
4e1k  2.00  2013  Kd=0.5uM      // 4e1k.pdf (0N5)
4bqg  1.90  2013  Kd=0.60uM     // 4bqg.pdf (50Q)
4mjo  2.40  2013  Kd=0.60uM     // 4mjo.pdf (2C1) ligand is compound 3; Kd=0.60+/-0.03uM
4k6i  2.10  2013  Kd=0.629uM    // 4k4j.pdf (9RA) ligand is Targretin; Ka=1.59+/-0.04 uM^(-1)(25 C)
3zcw  1.69  2013  Kd=0.65uM     // 3zcw.pdf (4A2) ligand is BI8;ADP containing;Kd1=0.65+/-0.01uM(BJ8, 1st site)
4nmx  1.85  2013  Kd=0.66uM     // 4nmx.pdf (15-mer) ligand is peptide 2-8;Kd = 0.66 +/- 0.11 uM
4fht  2.15  2013  Kd=0.67uM     // 4fht.pdf (DHB) Kd=0.67+/-0.01uM
4jff  2.43  2013  Kd=0.6nM      // 4jfd.pdf (10-mer)
4f6u  2.10  2013  Kd=0.70uM     // 4f6s.pdf (0SR) compound 5
4b34  1.55  2013  Kd=0.73mM     // 4b2i.pdf (ABV) ligand is compound 6
4k4j  2.00  2013  Kd=0.752uM    // 4k4j.pdf (1O8) ligand is 9cUAB30; Ka=1.33+/-0.04 uM^(-1)(25 C)
4m7c  2.05  2013  Kd=0.75uM     // 4m7c.pdf (13-mer) ligand is Peptide from Structure-specific endonuclease subunit SLX4;Kd = 0.75 +/- 0.12 uM
4hp0  1.19  2013  Kd=0.76uM     // 4hp0.pdf (4-mer)
4irx  1.45  2013  Kd=0.76uM     // 4irx.pdf (INS) Kd=0.76+/-0.08uM
4kao  2.39  2013  Kd=0.77uM     // 4k8a.pdf (KAO) ligand is compound 27
4hmk  3.00  2013  Kd=0.79uM     // 4hmk.pdf (LEU) Na-containing, Br-containing; Kd = 0.79 +/- 0.05 uM
4hod  3.30  2013  Kd=0.79uM     // 4hod.pdf (LEU) Na-containing, Cl-containing; Kd = 0.79 +/- 0.05 uM
4mz5  2.10  2013  Kd=0.79uM     // 4mz5.pdf (13-mer) ligand is peptide from dUTPase;Kd = 0.79 +/- 0.26 uM; incomplete ligand
4de5  2.25  2013  Kd=0.7mM      // 4ddh.pdf (0JD) Kd=0.7+/-0.02 mM
4fzj  1.63  2013  Kd=0.7mM      // 4ddh.pdf (0W1) Kd=0.7+/-0.02 mM
4fmn  2.69  2013  Kd=0.80uM     // 4e4w.pdf (9-mer) Kd = 0.80 +/- 0.02 uM; incomplete ligand
4jnj  1.90  2013  Kd=0.85nM     // 4jnj.pdf (BTN) Kd=0.85+/-0.02nM
4io3  1.66  2013  Kd=0.87uM     // 4io2.pdf (ASP) Kd=0.87+/-0.08uM
4l50  2.10  2013  Kd=0.88uM     // 4l4z.pdf (D8X) ligand is D8P; Kd=0.88+/-0.14uM
3v2n  1.80  2013  Kd=0.8uM      // 3v2n.pdf (MYR) Kd=0.8+/-0.1uM
4c4n  2.36  2013  Kd=0.8uM      // 4c4m.pdf (6-mer)
4hbn  2.60  2013  Kd=0.8uM      // 4hbn.pdf (CMP) Kd = 0.8 +/- 0.05 uM
4km0  1.30  2013  Kd=0.91uM     // 4klx.pdf (CP6) ligand is PYR
3zkf  2.60  2013  Kd=0.96uM     // 3zke.pdf (11-mer) ligand is P-NEK9 peptide; incomplete ligand
4g5f  2.33  2013  Kd=0.9mM      // 4ddh.pdf (0JD) Kd=0.9+/-0.04 mM
4kqp  0.95  2013  Kd=0.9uM      // 4g4p.pdf (GLN) Kd=0.9+/-0.2uM
4az5  1.73  2013  Kd=1.02uM     // 4az5.pdf (NGW) ligand is NGT; Kd=1.02+/-0.14uM
4ch2  1.60  2013  Kd=1.03uM     // 4ch2.pdf (14-mer) Kd = 1.03 +/- 0.05 uM; incomplete ligand
4ch8  1.75  2013  Kd=1.03uM     // 4ch2.pdf (14-mer) Kd = 1.03 +/- 0.05 uM; incomplete ligand
4nkt  1.90  2013  Kd=1.08uM     // 4nkt.pdf (2KH) Kd=1.08+/-0.02 uM
4b2i  1.30  2013  Kd=1.0mM      // 4b2i.pdf (LZ1) ligand is compound 5
4ezw  1.80  2013  Kd=1.0uM      // 4ezo.pdf (7-mer) Kd = 1.0 +/- 0.3 uM; incomplete ligand
4bgy  2.68  2013  Kd=1.1mM      // 4bgw.pdf (3-mer) Kd = 1.1 +/- 0.2 mM (MST)
4dlj  2.60  2013  Kd=1.20uM     // 4dli.pdf (6RG) Kd = 1.20 +/- 0.30 uM
4lkk  2.49  2013  Kd=1.20uM     // 4kol.pdf (2-mer)
4kne  2.00  2013  Kd=1.26uM     // 4klx.pdf (1CY) ligand is CYC
4ef6  1.94  2013  Kd=1.2mM      // 4ddh.pdf (I2E) Kd=1.2+/-0.01 mM
4azc  2.09  2013  Kd=1.38uM     // 4az5.pdf (NGW) ligand is NGT; Kd=1.38+/-0.04uM
4jn4  2.30  2013  Kd=1.38uM     // 4jn4.pdf (ATP) Kd=1.38+/-0.06uM; Mg-containing
4jne  1.96  2013  Kd=1.38uM     // 4jn4.pdf (ATP) Kd=1.38+/-0.06uM; Mg-containing
4b35  1.40  2013  Kd=1.3mM      // 4b2i.pdf (4ME) ligand is compound 4
3zos  1.92  2013  Kd=1.3nM      // 3zos.pdf (0LI) ligand is ponatinib
4hva  2.07  2013  Kd=1.3uM      // 4hva.pdf (4HV)
4jv8  1.45  2013  Kd=1.42uM     // 4jv6.pdf (1M1) Kd=1.42+/-0.48uM
4km2  1.40  2013  Kd=1.43uM     // 4klx.pdf (TOP) ligand is TMP
4l4v  1.90  2013  Kd=1.65uM     // 4l4t.pdf (1VY) ligand is rRL-6-CH2OH; Kd =1.65+/-0.16 uM
4ksp  2.93  2013  Kd=1.6nM      // 4ksp.pdf (1SU) ligand is compound 8B
4ezx  1.70  2013  Kd=1.6uM      // 4ezo.pdf (7-mer) Kd=1.6+/-0.5 uM
4k3p  2.15  2013  Kd=1.6uM      // 4k3k.pdf (6-mer) ligand is AcQLALF
2ynr  2.30  2013  Kd=1.70uM     // 2ynr.pdf (12-mer) ligand is B54NLS; Kd=1.70+/-0.23uM
4g5y  1.80  2013  Kd=1.7mM      // 4ddh.pdf (0OC) Kd = 1.7 +/- 0.08 mM
4f70  3.00  2013  Kd=1.82uM     // 4f6s.pdf (0ST) compound 4
4i60  2.50  2013  Kd=1.87uM     // 4i60.pdf (B1R) Ru-contained
4lps  2.00  2013  Kd=1.8uM      // 4lps.pdf (GDP) Ni2+ containing; Kd=1.8+/-0.6 uM
4bkj  1.70  2013  Kd=1.9nM      // 3zos.pdf (STI) ligand is lmatinib
4br3  2.20  2013  Kd=1.9uM      // 4br3.pdf (U85)
4i9o  2.00  2013  Kd=1.9uM      // 4i9o.pdf (KI1) covalent complex
4iut  2.70  2013  Kd=1.9uM      // 4iup.pdf (15-mer) Kd=1.9+/-0.06uM; incomplete ligand
4iuv  2.80  2013  Kd=1.9uM      // 4iup.pdf (15-mer) Kd=1.9+/-0.16uM; incomplete ligand
4knm  1.90  2013  Kd=10.0nM     // 4kni.pdf (E1E) ligand is compound 2f
4jfl  1.20  2013  Kd=10.5uM     // 4jfi.pdf (1KY) Kd=10.5+/-2.3uM
4bxu   NMR  2013  Kd=100nM      // 4bxu.pdf (15-mer)
4bcs  1.80  2013  Kd=103nM      // 4bcs.pdf (BTN) Kd at PH=7 by ITC
4i7l  1.52  2013  Kd=103uM      // 4i7j.pdf (IPH)
4att  1.25  2013  Kd=104.6nM    // 4att.pdf (HNV) ligand is 1OMe; Kd=53+/-2.3nM(SPR); Kd=104.6+/-21.9nM(ITC)
2m0v   NMR  2013  Kd=1079nM     // 2m0u.pdf (5-mer) lgand is C-terminal CFTR peptide;Kd=1079+/-79nM
4ceb  1.75  2013  Kd=1080uM     // 4ce9.pdf (ZSV) Kd=1080+/-123 uM
4ht0  1.60  2013  Kd=10nM       // 4ht0.pdf (V50) Zn-containing
4knj  2.00  2013  Kd=11.1nM     // 4kni.pdf (E1F) ligand is compound 2j
4bup  2.17  2013  Kd=11.2uM     // 4au7.pdf (SAM) Kd=11.2+/-1uM
4lbp  1.87  2013  Kd=11.4uM     // 4lbp.pdf (1WG)
4ido  2.09  2013  Kd=11.63uM    // 4idn.pdf (GDP) Kd=11.63+/-1.18uM; Mg-containing
4i9r  2.60  2013  Kd=112nM      // 4i9r.pdf (RET) Kd=112+/-17nM, Covalent binding
4bi6  1.45  2013  Kd=113.3uM    // 4bi6.pdf (PGA) Ki=560+/-59uM, Kd=113.3+/-41.7uM
4mr4  1.66  2013  Kd=1142nM     // 4mr3.pdf (1K0) ligand is RVX-208; Kd = 1142 +/- 46 nM
4mr3  1.68  2013  Kd=1142nM     // 4mr3.pdf (1K0) ligand is RVX-208; Kd=1142+/-46 nM
4k3q  1.85  2013  Kd=115.1uM    // 4k3k.pdf (6-mer) ligand is AcQLDAF
4fcm  2.69  2013  Kd=115uM      // 4fcm.pdf (9-mer) Kd = 115 +/- 3 uM; incomplete ligand
4j2t  3.20  2013  Kd=11nM       // 4j2t.pdf (1HT) Kd=11+/-1nM
4c73  1.80  2013  Kd=12.1uM     // 4c6u.pdf (TLH) Ki = 12.1 +/- 0.6 uM
4c0r  1.55  2013  Kd=12.2uM     // 4c0r.pdf (GDS) Kd = 12.2 +/- 0.6 uM; Cd-containing
4apo  1.90  2013  Kd=12.3uM     // 4aif.pdf (6-mer) ligand is TOMM20;Kd=12.3+/-0.5uM
4lil  2.60  2013  Kd=12.5uM     // 4lik.pdf (UTP) Kd = 12.5 +/- 0.72 uM
4igt  1.24  2013  Kd=12.8nM     // 4igr.pdf (3ZA)
4i2w  3.60  2013  Kd=120.8uM    // 4i2w.pdf (10-mer)
3zhf  1.70  2013  Kd=120uM      // 2ymt.pdf (9-mer) ligand is preS1 Site 1 peptide;Kd=120+/-10uM; incomplete ligand
3wde  1.44  2013  Kd=124nM      // 3wdc.pdf (7-mer) ligand is Cyclomarin A;Kd=124+/-12nM
4bh3  2.00  2013  Kd=12mM       // 4bgw.pdf (3-mer) Kd = 12 +/- 2.5 mM (MST)
3wdc  1.18  2013  Kd=12nM       // 3wdc.pdf (7-mer) ligand is Cyclomarin A;Kd=12+/-3nM
4hs8  2.60  2013  Kd=12nM       // 4hs6.pdf (16-mer) incomplete ligand
4i2z  2.90  2013  Kd=13.5uM     // 4i2w.pdf (10-mer) incomplete ligand
4ipj  2.15  2013  Kd=13.5uM     // 4ipi.pdf (LMR) Kd=13.5+/-0.4uM, Mn-containing
3w5n  1.80  2013  Kd=135uM      // 3w5n.pdf (RAM)
4ijl  1.70  2013  Kd=135uM      // 4ijh.pdf (1EK)
4i9u  2.50  2013  Kd=137uM      // 4i8x.pdf (1E7) IC50=770uM
4hpi  1.19  2013  Kd=14.2uM     // 4hp0.pdf (3-mer)
4aif  2.01  2013  Kd=14.4uM     // 4aif.pdf (7-mer) ligand is peptide from HSP90-beta;Kd=14.4+/-1.0uM(N=1.1),Kd2=18.6+/-2.0uM(N=1.2)
3vvy  1.63  2013  Kd=14.6uM     // 3vvy.pdf (ET) ligand is Ethidium bromide; Kd=14.6+/-0.10uM
4luv  1.40  2013  Kd=1400uM     // 4luo.pdf (1XS) ligand is compound 2; 1XS in Site-2, 1DZ in Site-1
4k3h  2.45  2013  Kd=140nM      // 4k3h.pdf (1OM)
4bt9  1.90  2013  Kd=143.5uM    // 4bt9.pdf (9-mer) Kd = 143.5 +/- 10.5 uM
4kn1  2.30  2013  Kd=144nM      // 4kmz.pdf (04J) ligand is Aminopterin; Kd=144+/-5 nM(pH 7.4),crystal(pH 8.0)
4cgj  2.15  2013  Kd=1460uM     // 4ce9.pdf (NZL) Kd=1460+/-89 uM
4ieh  2.10  2013  Kd=14nM       // 4ieh.pdf (1E9) Bcl-2/BAK complex, IC50=17nM
4ikn  1.85  2013  Kd=14uM       // 4ikn.pdf (6-mer) Kd=14.0+/-2.8uM; incomplete ligand
4j7e  1.63  2013  Kd=14uM       // 4j7e.pdf (I29)
4io6  1.60  2013  Kd=15.1uM     // 4io2.pdf (MET) Kd=15.1+/-2.5uM
4c1m  2.00  2013  Kd=15.8nM     // 4c1m.pdf (NIH) ligand is compound HX1, Kd=0.0158uM
4aq6  1.98  2013  Kd=15.8uM     // 3zds.pdf (OMD) Fe-containing; Kd=15.8+/-1.4uM
4bks  2.20  2013  Kd=150uM      // 4bks.pdf (X6C) Kd=150+/-9uM
4ear  1.70  2013  Kd=151pM      // 4ear.pdf (IM5) Ki = 151 +/- 16 pM
3vx3  2.10  2013  Kd=15nM       // 3vx3.pdf (ADP) Kd=15+/-1.8nM
3zp9  1.31  2013  Kd=15nM       // 3zp9.pdf (9TH) ligand is compound 9; Kd=15+/-2nM
4j8b  1.88  2013  Kd=16.1uM     // 4j73.pdf (6-mer) Kd=16.1+/-0.6uM
4as9  2.71  2013  Kd=16.3uM     // 4as9.pdf (4QS)
4kni  1.80  2013  Kd=16.7nM     // 4kni.pdf (E1E) ligand is compound 2f
4knn  1.40  2013  Kd=16.7nM     // 4kni.pdf (E1F) ligand is compound 2j
4ad6  1.85  2013  Kd=16.7uM     // 4ad6.pdf (GSY) ligand is compound 21a; Kd=16.7+/-3.5uM
4kox  1.80  2013  Kd=16.9uM     // 4klv.pdf (CLS) ligand is Cephalothin; Kd = 16.9 +/- 1.2 uM
4i9s  2.58  2013  Kd=162nM      // 4i9r.pdf (RET) Kd=162+/-30nM, Covalent binding
4bqt  2.88  2013  Kd=1640nM     // 4afo.pdf (C5E) complex AcAChBP and Cytisine
4klv  1.30  2013  Kd=165.3uM    // 4klv.pdf (KLV) ligand is 4-Methylumbelliferyl phosphate; Kd = 165.3 +/- 9.5 uM
4j8t  2.05  2013  Kd=168nM      // 4j8t.pdf (DOG) Kd=168+/-59nM
4j3l  2.09  2013  Kd=16nM       // 3w51.pdf (AJ5) ligand is compound 17
4au7  2.07  2013  Kd=17.2uM     // 4au7.pdf (SAH) Kd=17.2+/-7uM
3vw2  2.34  2013  Kd=17.9uM     // 3vvy.pdf (BER) ligand is berberine; Kd=17.9+/-0.03uM
4j86  1.48  2013  Kd=170.9uM    // 4j73.pdf (6-mer) Kd=170.9+/-10.2uM
4jg0  1.81  2013  Kd=172nM      // 4jfx.pdf (12-mer) incomplete ligand
4kov  1.60  2013  Kd=176.7uM    // 4klv.pdf (KOV) ligand is Cefuroxime; Kd = 176.7 +/- 6.2 uM
4bgx  2.48  2013  Kd=17mM       // 4bgw.pdf (SIA-GAL) Kd = 17 +/- 3 mM (MST)
4kax  1.85  2013  Kd=17uM       // 4kax.pdf (GTP)
4auj  1.53  2013  Kd=18.3nM     // 4auj.pdf (HNW) ligand is 2OH; Kd=18.3+/-5.9nM(ITC); Kd=36.9+/-3.0nM(SPR)
4ayu  1.50  2013  Kd=18.6uM     // 4avt.pdf (N8P) ligand is N-Acetyl-D-Proline
4fz3  2.10  2013  Kd=184.3uM    // 4fz3.pdf (6-mer) Kd=184.3+/-9.8 uM
4f9y  1.85  2013  Kd=184nM      // 4f9w.pdf (LM3)
4kby  2.36  2013  Kd=186nM      // 4kby.pdf (C2E) Ka/Kd = 5.39*10^6/1.86*10^(-7)
4j22  2.12  2013  Kd=18nM       // 3w51.pdf (AJ7) ligand is compound 16
4mm5  3.20  2013  Kd=18nM       // 4mm4.pdf (SRE) ligand is sertraline; Kd = 18 +/- 2 nM
4ih6  2.20  2013  Kd=18uM       // 4ih5.pdf (1EP)
4gvc  1.54  2013  Kd=19.3uM     // 4gvc.pdf (8-mer) ligand is phosphorylated Syndecan1 Peptide
4ljh  1.45  2013  Kd=19.4uM     // 4ljh.pdf (GAL-MHD) ligand is compound 15; Kd=19.4+/-1.5 uM
4hfz  2.69  2013  Kd=1900nM     // 4hfz.pdf (15-mer) Kd = 1900 +/- 200 nM; incomplete ligand
3vzg  2.70  2013  Kd=19mM       // 3vy7.pdf (2-mer) ligand is O-(alpha-D-mannosyl)-L-threonine
4k0o  2.15  2013  Kd=1mM        // 4k0o.pdf (NAG-MBG)
4bb9  1.47  2013  Kd=1uM        // 4bb9.pdf (F1P)
4b3c  1.90  2013  Kd=2.1mM      // 4b2i.pdf (5H1) ligand is compound 1
4b3d  1.59  2013  Kd=2.1mM      // 4b2i.pdf (5MI) ligand is compound 2
4jn2  1.71  2013  Kd=2.1pM      // 4jn1.pdf (4CC) ligand is dabigatran
4l4z  2.30  2013  Kd=2.1uM      // 4l4z.pdf (D5X) ligand is D5P; Kd=2.1+/-0.3 uM
4iuu  2.70  2013  Kd=2.22uM     // 4iup.pdf (15-mer) Kd=2.22+/-0.2uM; incomplete ligand
4ezy  1.85  2013  Kd=2.26uM     // 4ezo.pdf (7-mer) Kd = 2.26 +/- 0.01 uM; incomplete ligand
4jin  2.10  2013  Kd=2.28uM     // 4jin.pdf (1L7) Kd=2.28+/-0.03uM, other binding data: Kd=6.1+/-0.4uM, ATP 10uM; Kd=10.1+/-0.9uM, ATP 30uM
3zi8  1.50  2013  Kd=2.2uM      // 3zi8.pdf (FU4) ligand is alpha-MeFuc-fucose
4gs9  1.72  2013  Kd=2.2uM      // 4gs9.pdf (0XB)
4i8x  2.23  2013  Kd=2.3mM      // 4i8x.pdf (6P3) IC50>2mM
4dli  1.91  2013  Kd=2.40uM     // 4dli.pdf (IRG) Kd=2.40+/-1.90uM
4lno  2.90  2013  Kd=2.4mM      // 4lnf.pdf (GLN)
4jx9  1.40  2013  Kd=2.4nM      // 4jwk.pdf (URI) ligand is Uridine; Kd=3.11*10^(-9) M(fluorescence), 2.4*10^(-9) M(SPR)
4dzy  2.10  2013  Kd=2.4uM      // 4dzy.pdf (WJ1) Kd=2.4+/-0.4uM; IC50=6.3 uM; Mg-containing; K-containing
4jiz  2.10  2013  Kd=2.4uM      // 4jiz.pdf (8-mer)
4bqh  1.75  2013  Kd=2.58uM     // 4bqh.pdf (9VU) Kd=2.58+/-0.07uM
4iur  2.50  2013  Kd=2.63uM     // 4iup.pdf (15-mer) Kd=2.63+/-0.2uM; incomplete ligand
4kmz  2.30  2013  Kd=2.7nM      // 4kmz.pdf (FOL) ligand is Folic acid; Kd=2.7+/-1.5 nM(pH 7.4), 23+/-5 nM(pH 6.5),crystal(pH 8.0)
4fmo  3.04  2013  Kd=2.94uM     // 4e4w.pdf (8-mer) Kd = 2.94 +/- 0.03 uM; incomplete ligand
4hj2  2.10  2013  Kd=2.95mM     // 4hj2.pdf (LZ6) Kd=2.95+/-0.5mM, Kd=6.05+/-0.8mM (for fast and slow reactions, respectively)
4ba3  2.10  2013  Kd=2.9uM      // 2ynr.pdf (12-mer) ligand is A89NLS; Kd=2.9+/-0.36uM; incomplete ligand
4nxu  2.30  2013  Kd=2.9uM      // 4nxu.pdf (ADP) Kd=2.9+/-0.8uM
4j84  1.47  2013  Kd=20.4uM     // 4j73.pdf (5-mer) Kd=20.4+/-0.7uM
4lar  2.38  2013  Kd=20.7uM     // 4lar.pdf (1WE)
4j8r  2.30  2013  Kd=20nM       // 4j8r.pdf (16-mer) incomplete ligand
4j7d  1.25  2013  Kd=20uM       // 4j7d.pdf (I31)
4j93  1.74  2013  Kd=20uM       // 4j93.pdf (1JR)
4luz  1.90  2013  Kd=20uM       // 4luo.pdf (1XT) ligand is compound 7
4del  1.58  2013  Kd=21.1nM     // 4del.pdf (PGH) Zn-containing; Kd=21.1+/-0.2 nM
3vw1  2.21  2013  Kd=21.2uM     // 3vvy.pdf (CVI) ligand is violet; Kd=21.2+/-0.52uM
3vw0  2.60  2013  Kd=21.2uM     // 3vvy.pdf (DEQ) ligand is dequalinium; Kd=21.2+/-0.42uM
4nku  1.94  2013  Kd=21.3uM     // 4nkt.pdf (2-mer) Kd=21.3+/-3.2 uM; ligand is A-U
4io7  1.92  2013  Kd=211uM      // 4io2.pdf (PHE) Kd=211+/-45uM
4jv6  1.87  2013  Kd=217nM      // 4jv6.pdf (18F)
2ypo  2.00  2013  Kd=21uM       // 2ypo.pdf (PHE) Kd=21+/-1uM
4l58  1.48  2013  Kd=21uM       // 4l58.pdf (12-mer) ligand is H3K4me3; Kd = 21 +/- 9 uM; incomplete ligand
4j78  1.48  2013  Kd=22.5uM     // 4j73.pdf (5-mer) Kd=22.5+/-1.3uM
4i1r  2.70  2013  Kd=22.6uM     // 4i1r.pdf (LZU) Kd=22.6+/-0.5uM
4izm  4.50  2013  Kd=220nM      // 4izm.pdf (ASP)
3vws  2.10  2013  Kd=225uM      // 3vws.pdf (VWS) ligand is NITD107
4io8  2.58  2013  Kd=228nM      // 4io8.pdf (3FD) Kd=228+/-16nM
4aw8  2.00  2013  Kd=22nM       // 4aw8.pdf (ZN) Zn2+ containing; Kd=22+/-2nM
4g8o  2.71  2013  Kd=22nM       // 4g8o.pdf (96P) Kd = 22 +/- 6 nM
4g8r  2.19  2013  Kd=22nM       // 4g8o.pdf (96P) Kd = 22 +/- 6 nM
4hso  2.10  2013  Kd=22uM       // 4hsn.pdf (TYR) Kd = 22 +/- 2 uM
4jg1  1.55  2013  Kd=232nM      // 4jfx.pdf (12-mer) incomplete ligand
4m1d  1.80  2013  Kd=23nM       // 4m1d.pdf (14-mer) Kd = 0.023 +/- 0.001 uM
4io4  1.94  2013  Kd=24.5uM     // 4io2.pdf (SER) Kd=24.5+/-1.9uM
4bkt  2.35  2013  Kd=240uM      // 4bks.pdf (QD0) Kd=240+/-17uM
4c6v  2.70  2013  Kd=25.6uM     // 4c6u.pdf (TLG) Kd = 25.6 +/- 0.5 uM
4c6u  2.40  2013  Kd=25.6uM     // 4c6u.pdf (TLG) Kd=25.6+/-0.5uM
4b3b  1.19  2013  Kd=250uM      // 4b2i.pdf (6-mer) ligand is FHTA peptide; Kd=250+/-50uM
4mr5  1.63  2013  Kd=251nM      // 4mr3.pdf (1K0) ligand in PDB is RVX-208, Kd=251+/-17 nM(Ligand in PDB is wrong)
4mr6  1.67  2013  Kd=251nM      // 4mr3.pdf (1K0) ligand is RVX-208; Kd=251+/-17 nM
4k3r  1.86  2013  Kd=259.1uM    // 4k3k.pdf (6-mer) ligand is AcQLDLA
4jal  2.00  2013  Kd=25uM       // 4jal.pdf (SAH)
3vvz  2.51  2013  Kd=26.4uM     // 3vvy.pdf (RHQ) ligand is rhodamine 6G;Kd=26.4+/-0.08uM
4bi7  1.60  2013  Kd=26.4uM     // 4bi6.pdf (PGA) Kd=26.4+/-2.6uM, Ki=87+/-15uM
3wb5  2.50  2013  Kd=26.8uM     // 3wb4.pdf (0B4) ligand is compound 6
4gvd  1.85  2013  Kd=26.9uM     // 4gvc.pdf (8-mer) ligand is Syndecan1 Peptide
4j74  1.20  2013  Kd=26uM       // 4j74.pdf (I18)
4j73  1.44  2013  Kd=27.7uM     // 4j73.pdf (7-mer) Kd=27.7+/-2.5uM; incomplete ligand
4jjm  2.09  2013  Kd=27nM       // 4jjm.pdf (11-mer) ligand is cyclosporin A peptide
4igk  1.75  2013  Kd=28.2uM     // 4ifi.pdf (7-mer) Kd=28.2+/-2uM
4k3m  1.85  2013  Kd=281.2uM    // 4k3k.pdf (5-mer) ligand is AcALDLF; incomplete ligand
4ht2  1.45  2013  Kd=290nM      // 4ht0.pdf (V50) Zn-containing
4gng  1.73  2013  Kd=290uM      // 4gne.pdf (15-mer) Kd = 290 +/- 8 uM; Zn-containing; incomplete ligand structure
4mmf  2.70  2013  Kd=295nM      // 4mm4.pdf (29Q) ligand is mazindol; Kd = 295 +/- 7 nM
4hu1  1.95  2013  Kd=29nM       // 4ht0.pdf (V13) Zn-containing
4hnn  2.40  2013  Kd=2uM        // 4hnn.pdf (LYS) Kd=2+/-0.3 uM (the first lysine), Kd=0.38+/-0.14 mM (the second lysine)
4k55  1.91  2013  Kd=3.06uM     // 4jkw.pdf (H6P)
4nk9  2.57  2013  Kd=3.1nM      // 4nk9.pdf (2K5) ligand is compound 1
4i9c  3.10  2013  Kd=3.1uM      // 4i9c.pdf (5-mer) SDS-PAGE
4f6s  2.60  2013  Kd=3.24uM     // 4f6s.pdf (0SQ) compound 7
4efk  1.70  2013  Kd=3.2mM      // 4ddh.pdf (0OC) Kd=3.2+/-0.2 mM
4ifi  2.20  2013  Kd=3.34uM     // 4ifi.pdf (6-mer) Kd=3.34+/-0.2uM
3zdv  1.41  2013  Kd=3.3uM      // 3zdv.pdf (F1A-MMA) ligand is compound 5e
4jfm  1.02  2013  Kd=3.3uM      // 4jfi.pdf (1KZ) Kd=3.3+/-0.5uM
4gne  1.47  2013  Kd=3.4mM      // 4gne.pdf (7-mer) Zn-containing; Kd = 3.4 +/- 0.12 mM; incomplete ligand structure
3zln  2.29  2013  Kd=3.4nM      // 3zk6.pdf (H0Y) ligand is compound 3
4j77  1.76  2013  Kd=3.4uM      // 4j73.pdf (6-mer) Kd=3.4+/-0.3uM; incomplete ligand
4n7j  1.67  2013  Kd=3.4uM      // 4n5d.pdf (2GQ) The ligand structure in PDB is wrong.
4n7m  2.12  2013  Kd=3.4uM      // 4n5d.pdf (2GQ) ligand is compound 5
4ddm  1.83  2013  Kd=3.5mM      // 4ddh.pdf (0HO) Kd=3.5+/-0.04 mM
4gw5  2.20  2013  Kd=3.5uM      // 4gw1.pdf (12-mer) Kd = 3.5 +/- 0.1 uM
4kot  1.55  2013  Kd=3.5uM      // 4klv.pdf (CE3) ligand is Cefotaxime; Kd = 3.5 +/- 0.2 uM
4ksy  1.88  2013  Kd=3.79nM     // 4ksy.pdf (1SY)
4b60  1.83  2013  Kd=3.7uM      // 4b60.pdf (17-mer) ligand is FIBRINOGEN GAMMA CHAIN;Kd=3.7+/-0.1uM; incomplete ligand
4kmd  1.70  2013  Kd=3.86uM     // 4kmd.pdf (17-mer) Kd = 3.86 +/- 0.62 uM; incomplete ligand
4nxv  2.30  2013  Kd=3.8uM      // 4nxu.pdf (GDP) Kd=3.8+/-0.9uM
4fgt  2.00  2013  Kd=3.92uM     // 4fgt.pdf (4-mer) ligand is 4-mer CG peptide, ITC Ka=2.55 x 10 E5 M-1
4igq  2.35  2013  Kd=30.1uM     // 4igo.pdf (3-mer)
4g93  4.20  2013  Kd=300uM      // 4g93.pdf (0YP)
4hs6  1.53  2013  Kd=30nM       // 4hs6.pdf (16-mer) incomplete ligand
4j81  1.75  2013  Kd=31.9uM     // 4j73.pdf (5-mer) Kd=31.9+/-2.6uM
4nka  2.19  2013  Kd=311.4nM    // 4nka.pdf (2K7) ligand is compound 2
4i7p  1.60  2013  Kd=317uM      // 4i7j.pdf (ES3)
4mme  2.50  2013  Kd=318nM      // 4mm4.pdf (29Q) ligand is mazindol; Kd=318+/-10nM
4jfe  2.70  2013  Kd=31uM       // 4jfd.pdf (10-mer)
4avs  1.40  2013  Kd=322uM      // 4avs.pdf (N7P) ligand is N-acetyl-L-proline
4eoy  2.22  2013  Kd=326nM      // 4eoy.pdf (8-mer) Mg-containing
4bh4  1.90  2013  Kd=32mM       // 4bgw.pdf (3-mer) Kd = 32 +/- 8 mM (MST)
4l6t  1.86  2013  Kd=32nM       // 4l6t.pdf (5-mer) ligand is GM1;Kd=32+/-2 nM
4kp8  1.80  2013  Kd=3330nM     // 4kni.pdf (E1G) ligand is compound 3j
4azi  1.98  2013  Kd=35.56nM    // 4az5.pdf (OAN) ligand is PUGNAc; Kd=35.56+/-2.27nM
2lyb   NMR  2013  Kd=35uM       // 2lya.pdf (8SP) ligand is di-C8-PS;Kd=35+/-1uM
3wb4  2.25  2013  Kd=36.6uM     // 3wb4.pdf (0B3) ligand is (R)-3
4k3o  2.00  2013  Kd=36.7uM     // 4k3k.pdf (6-mer) ligand is AcQADLF
4jfx  1.95  2013  Kd=360nM      // 4jfx.pdf (12-mer) incomplete ligand
2m0u   NMR  2013  Kd=365nM      // 2m0u.pdf (5-mer) ligand is C-terminal CFTR peptide;Kd=365+/-35nM
4jfd  2.46  2013  Kd=36uM       // 4jfd.pdf (10-mer)
4ge1  2.15  2013  Kd=370nM      // 4ge1.pdf (TSS)
4k67  2.70  2013  Kd=372uM      // 4k62.pdf (3-mer) incomplete ligand structure
4jpy  2.13  2013  Kd=37uM       // 3tcy.pdf (PHE) Fe3+ and Phe-bound cPAH; Kd=37+/-0.3uM
4kcx  2.00  2013  Kd=37uM       // 4kcx.pdf (1QK)
4mnq  2.74  2013  Kd=37uM       // 4mnq.pdf (9-mer) Kd = 37 +/-5 uM
3zm9  1.90  2013  Kd=38nM       // 3zm9.pdf (QMQ) ligand is compound 1; Kd1=38nM for the first monomer; Kd2=190nM for the second monomer
4j21  1.93  2013  Kd=39nM       // 3w51.pdf (AJ6) ligand is compound 14
4jvb  1.75  2013  Kd=39nM       // 4jv6.pdf (1M0) Kd=39+/-11nM
2ypp  2.30  2013  Kd=39uM       // 2ypo.pdf (TYR) Kd=39+/-1uM
4b8o  2.08  2013  Kd=4.0nM      // 2ynr.pdf (11-mer) ligand is SV40TAGNLS;Kd=4.0+/-0.2nM
4btm  2.54  2013  Kd=4.1uM      // 4btj.pdf (F8E) Kd = 30 uM(Phosphorylated TTBK1), Kd = 4.1 uM(Nonphosphorylated TTBK1)
4ej8  2.35  2013  Kd=4.1uM      // 4ej8.pdf (1F1) Kd=4.1+/-1.4uM
2m0o   NMR  2013  Kd=4.2uM      // 2m0o.pdf (11-mer) ligand is H3K36me3 peptide;Kd=4.2+/-0.3uM
4kod  2.96  2013  Kd=4.37uM     // 4kln.pdf (ADP) Kd = 4.37 +/- 0.96 uM
4jck  1.15  2013  Kd=4.3mM      // 4jc1.pdf (1LL)
4lkf  1.64  2013  Kd=4.3uM      // 4lkd.pdf (4-mer) ligand is peptide WKYL; Kd = 4.3 +/- 1.1 uM
4lke  1.65  2013  Kd=4.3uM      // 4lkd.pdf (4-mer) ligand is peptide WRIA; Kd = 4.3 +/- 0.2 uM; incomplete ligand
4blb  2.80  2013  Kd=4.47uM     // 4blb.pdf (17-mer) Kd = 4.47 +/- 0.417 uM; incomplete ligand
4k19  2.74  2013  Kd=4.4nM      // 4k19.pdf (1OD) ligand is &#64258;uvibactin; Fe3+ containing; Fe-Kd = 4.4(8) nM
4b9h  2.10  2013  Kd=4.5uM      // 4b9h.pdf (4-mer) ligand is chitin tetramer (GlcNAc)4;Kd for Ecp6 binds chitin with 1:1 stoichiometry
4lkd  2.31  2013  Kd=4.5uM      // 4lkd.pdf (4-mer) ligand is peptide QRSA; Kd = 4.5 +/- 0.5 uM; incomplete ligand
4jwk  1.87  2013  Kd=4.79nM     // 4jwk.pdf (CTN) ligand is Cytidine; Kd= 4.79*10^(-9) M(fluorescence), 5.3*10^(-9) M(SPR)
4ipi  1.75  2013  Kd=4.8uM      // 4ipi.pdf (LMR) Kd=4.8+/-0.1uM, Mn-containing
4ipn  2.41  2013  Kd=408.7uM    // 4ipn.pdf (1FT) Kd=408.7+/-9.3uM
4kn0  2.10  2013  Kd=40nM       // 4kmz.pdf (MTX) ligand is Methotrexate; Kd=40+/-7 nM(pH 7.4), 332+/-64 nM(pH 6.5),crystal(pH 8.0)
4hfp  2.40  2013  Kd=42nM       // 4hfp.pdf (15U) Kd=42+/-2nM
4gw1  2.24  2013  Kd=430nM      // 4gw1.pdf (12-mer) Kd = 430 +/- 30 nM
4mm4  2.89  2013  Kd=431nM      // 4mm4.pdf (8PR) ligand is paroxetine;Kd = 431 +/- 24 nM
4gu9  2.40  2013  Kd=43uM       // 4gu6.pdf (4GU)
4j82  1.46  2013  Kd=44.2uM     // 4j73.pdf (5-mer) Kd=44.2+/-1.6uM
4gu6  1.95  2013  Kd=44nM       // 4gu6.pdf (10N)
4nbn  1.75  2013  Kd=44uM       // 4n5d.pdf (2J7) ligand is compound 14
4gnf  1.55  2013  Kd=450uM      // 4gne.pdf (15-mer) Kd = 450 +/- 20 uM; Zn-containing; incomplete ligand structure
4cc2  1.55  2013  Kd=46.5uM     // 4cc2.pdf (12-mer)
4cc7  1.97  2013  Kd=46.5uM     // 4cc2.pdf (12-mer); incomplete ligand
4ayq  1.10  2013  Kd=47nM       // 4ayp.pdf (MVL) ligand is compound 2
4ijh  1.50  2013  Kd=47uM       // 4ijh.pdf (1EJ)
4i7j  1.67  2013  Kd=480uM      // 4i7j.pdf (BNZ)
4kow  1.45  2013  Kd=49.3uM     // 4klv.pdf (CFX) ligand is Cefoxitin; Kd=49.3+/-2.9 uM
4bea  2.57  2013  Kd=5.0nM      // 4bea.pdf (13-mer) ligand is STAPLED EIF4E INTERACTING PEPTIDE;Kd=5.+/-0.7nM
4dx9  2.99  2013  Kd=5.0uM      // 4dx8.pdf (15-mer) Kd = 5.0 +/- 0.15 uM; incomplete ligand
4bj8  2.40  2013  Kd=5.13nM     // 4bj8.pdf (BTN) Kd=5.13+/-2.36nM
4ddk  1.75  2013  Kd=5.1mM      // 4ddh.pdf (0HN) Kd=5.1+/-0.2 mM
4e70  1.61  2013  Kd=5.26uM     // 4e70.pdf (N7I)
4gxl  2.02  2013  Kd=5.2uM      // 4gxl.pdf (14-mer) Kd(NDP52 371-381), X-ray(NDP52 368-381); incomplete ligand
4lp6  2.15  2013  Kd=5.36nM     // 4lp6.pdf (Q4I) ligand is compound 5
2lsv   NMR  2013  Kd=5.41uM     // 2lsv.pdf (9-mer) ligand is ATP-dependent molecular chaperone HSP82;Kd=5.41+/-0.33uM
4l1u  2.42  2013  Kd=5.45uM     // 4l1u.pdf (13-mer) ligand is peptide from Transcription elongation factor SPT5; Kd = 5.45 +/- 0.38 uM; incomplete ligand
4j2c  1.80  2013  Kd=5.6uM      // 4j2c.pdf (17-mer) Kd=5.6+/-0.7uM; incomplete ligand
4idn  2.25  2013  Kd=5.77uM     // 4idn.pdf (GNP) Kd=5.77+/-0.479uM; Mg-containing
4f7j  2.60  2013  Kd=5.82uM     // 4f6s.pdf (0SU) compound 3
4kfq  2.20  2013  Kd=5.86nM     // 4kfq.pdf (KFQ) ligand is TK40
4hmq  2.10  2013  Kd=5.8nM      // 4hmo.pdf (FCE) Kd = 5.8 +/- 1.4 nM
4gue  1.80  2013  Kd=5.8uM      // 4gue.pdf (QCT)
4ih7  2.30  2013  Kd=5.8uM      // 4ih5.pdf (1ER)
4jc1  1.50  2013  Kd=50uM       // 4jc1.pdf (TDG)
4kn2  2.60  2013  Kd=54nM       // 4kmz.pdf (LYA) ligand is Pemetrexed; Kd = 54 +/- 17 nM(pH 7.4), 323 nM(pH 6.5),crystal(pH 8.2)
4k66  3.00  2013  Kd=554uM      // 4k62.pdf (4-mer) incomplete ligand structure
4ib5  2.20  2013  Kd=559.67nM   // 4ib5.pdf (13-mer) Kd=559.67+/-256.70nM
4k0u  2.15  2013  Kd=55nM       // 3uym.pdf (15-mer) Kd=55+/-20nM
4azb  2.10  2013  Kd=57.69nM    // 4az5.pdf (OAN) ligand is PUGNAc; Kd=57.69+/-10.84nM
4luo  1.54  2013  Kd=580uM      // 4luo.pdf (1DZ) ligand is compound 4;Kd of Same ligand in two site: 580 uM(Site-1),>2000 uM(Site-2)
4hiq  1.18  2013  Kd=6.2nM      // 4hiq.pdf (16V) Kd1=6.2+/-2.0 nM, Kd2=139+/-80 nM (for the first and the second binding sites of V122I-TTR)
4jr0  1.80  2013  Kd=6.3nM      // 4jr0.pdf (6-mer) Kd=6.3+/-0.6nM; incomplete ligand
4ezr  1.90  2013  Kd=6.3uM      // 4ezo.pdf (8-mer) Kd=6.3+/-0.3 uM
4ezq  2.00  2013  Kd=6.3uM      // 4ezo.pdf (9-mer) Kd = 6.3 +/- 0.3 uM; incomplete ligand
4lk6  2.86  2013  Kd=6.3uM      // 4ljh.pdf (GAL-LRD) ligand is compound 17; Kd = 6.3 +/- 0.2 uM
4jdf  1.69  2013  Kd=6.4mM      // 4jdf.pdf (SPD) Kd=6.4+/-1.2mM
3vfq  2.80  2013  Kd=6.4uM      // 3q6z.pdf (AR6) First,Kd1=6.4+/-0.2uM;Second, Kd2=261+/-30uM
4ezz  2.05  2013  Kd=6.4uM      // 4ezo.pdf (7-mer) Kd=6.4+/-0.6 uM
4k5y  2.98  2013  Kd=6.7nM      // 4k5y.pdf (1Q5) Kd = 6.7(2.5) nM
4n5d  2.06  2013  Kd=607uM      // 4n5d.pdf (2FQ) ligand is compound 1
4gny  1.64  2013  Kd=60uM       // 4gny.pdf (SDS) Kd=52uM(ITC, 15C, pH=7.0), Kd=60uM(ITC, 25C, pH=7.0)
4k63  3.10  2013  Kd=60uM       // 4k62.pdf (4-mer) incomplete ligand structure
4jmx  2.55  2013  Kd=62.1nM     // 4jmx.pdf (IM2) Kd=62.1+/-11.2nM, Different ligand structures (ring); covalent complex
4ht6  1.90  2013  Kd=620nM      // 4ht6.pdf (11-mer) Kd = 620 +/- 270 nM
4igr  2.65  2013  Kd=63nM       // 4igr.pdf (3ZA)
4j8g  1.90  2013  Kd=64.5uM     // 4j73.pdf (11-mer) Kd=64.5+/-5.4uM
2lya   NMR  2013  Kd=65uM       // 2lya.pdf (PC8) ligand is di-C8-PC;Kd=65+/-2uM
4nra  1.85  2013  Kd=65uM       // 4nr9.pdf (2LW) ligand is compound 6
4nks  2.50  2013  Kd=67.9nM     // 4nks.pdf (2M2) ligand is compound 3
4jkw  2.01  2013  Kd=69.9uM     // 4jkw.pdf (IPE)
4jpx  1.55  2013  Kd=7.0uM      // 3tcy.pdf (PHE) Kd=7.0+/-0.3uM
4h85  2.10  2013  Kd=7.0uM      // 4h85.pdf (HRI) Kd=7.0+/-1.5uM; K-containing, Mg-containing
4ejl  2.44  2013  Kd=7.2uM      // 4ej8.pdf (IOP) Kd=7.2+/-1.7uM
4ezt  2.00  2013  Kd=7.4uM      // 4ezo.pdf (9-mer) Kd = 7.4 +/- 0.4 uM; incomplete ligand
4h81  2.05  2013  Kd=7.5uM      // 4h81.pdf (WJ2) Kd=7.5 +/-2.2uM; K-containing, Mg-containing
4b6u   NMR  2013  Kd=7.7uM      // 4b6u.pdf (M7G) ligand is m7GDP;Kd=7.7+/-0.3uM
4cdr  3.15  2013  Kd=7.9uM      // 4cdr.pdf (9-mer) covalent complex
4c1t  2.39  2013  Kd=70.8nM     // 4c1t.pdf (4-mer)
4lw1  1.63  2013  Kd=710uM      // 4luo.pdf (1XS) ligand is compound 2; Kd=710uM(site 1), Kd>1400uM(site 2)
4jfz  1.75  2013  Kd=71nM       // 4jfx.pdf (12-mer) incomplete ligand
2mc1   NMR  2013  Kd=71uM       // 2mc1.pdf (13-mer) ligand is Tyrosine-protein kinase SYK
4cc3  1.97  2013  Kd=72.5uM     // 4cc2.pdf (12-mer)
4i7m  1.48  2013  Kd=72uM       // 4i7j.pdf (2LP)
4cgi  2.07  2013  Kd=752uM      // 4ce9.pdf (NZL) Kd=752+/-158 uM
4ayp  0.85  2013  Kd=755nM      // 4ayp.pdf (SMD) ligand is compound 1
2lto   NMR  2013  Kd=770uM      // 2lto.pdf (13-mer) ligand is DNA-directed RNA polymerase II subunit RPB1;Kd1=770+/-30uM(NMR);Kd2=900+/-200uM(fluoresence)
3wdd  1.18  2013  Kd=780nM      // 3wdc.pdf (7-mer) ligand is Cyclomarin A;Kd=780+/-80nM
4kzq  2.25  2013  Kd=788nM      // 4bs4.pdf (DFL) Zn-containing
4ih5  1.90  2013  Kd=78uM       // 4ih5.pdf (12R)
4azg  2.40  2013  Kd=79.05nM    // 4az5.pdf (OAN) ligand is PUGNAc; Kd=79.05+/-0.44nM
4loo  1.95  2013  Kd=7nM        // 4loo.pdf (SB4) in monoclinic crystal form
4ly9  2.35  2013  Kd=7nM        // 4ly9.pdf (1YY)
4his  1.20  2013  Kd=8.1nM      // 4hiq.pdf (3MI) Kd1=8.1+/-0.8 nM, Kd2~1 uM (for the first and the second binding sites of V122I-TTR)
4h7q  2.10  2013  Kd=8.8uM      // 4h7q.pdf (COI) Kd=8.8+/-0.5uM; K-containing, Mg-containing
4c94  3.00  2013  Kd=8.9uM      // 4c94.pdf (KXN) Kd1 = 8.9 +/- 1.8 uM, Kd2 = 399.1 +/- 10.6 uM ( two distinct ligand binding sites )
4c1u  2.00  2013  Kd=81nM       // 4c1t.pdf (3-mer)
4ghi  1.50  2013  Kd=81nM       // 4ghi.pdf (0X3)
4kp5  1.45  2013  Kd=833nM      // 4kni.pdf (E1F) ligand is compound 2j
2m41   NMR  2013  Kd=8uM        // 2m41.pdf (15-mer) ligand is peptide from Capicua
4h3q  2.20  2013  Kd=8uM        // 4h3p.pdf (13-mer) incomplete ligand
4iho  2.80  2013  Kd=8uM        // 4iho.pdf (9-mer)
4jym  1.35  2013  Kd=9.05uM     // 4jym.pdf (KKN) Kd=9.05+/-2.03 uM
4lk7  1.76  2013  Kd=9.1uM      // 4ljh.pdf (2-mer) ligand is 04G-GAL (compound 16); Kd=9.1+/-0.6 uM
4io5  1.72  2013  Kd=9.27uM     // 4io2.pdf (ALA) Kd=9.27+/-1.24uM
4jjq  1.95  2013  Kd=9.4uM      // 4jjq.pdf (10-mer) Kd=9.4+/-2.1uM; incomplete ligand
4np9  1.92  2013  Kd=9.4uM      // 4np9.pdf (I3P) Kd=9.4+/-1.4 uM
4mz6  1.88  2013  Kd=9.62uM     // 4mz6.pdf (13-mer) Kd = 9.62 +/- 1.54 uM; incomplete ligand
2m3m   NMR  2013  Kd=9.63uM     // 2m3m.pdf (11-mer) ligand is Protein E6;(E6CT11);Kd=9.63+/-0.02uM
4btb  1.90  2013  Kd=9.8uM      // 4bt9.pdf (9-mer) Kd = 9.8 +/- 0.2 uM
4i7k  1.72  2013  Kd=905uM      // 4i7j.pdf (MBN)
3vfj  2.05  2013  Kd=91nM       // 3vfj.pdf (7-mer) ligand is MonodeChloro- Teicoplanin A2-2;Kd=91+/-7nM
4kab  2.71  2013  Kd=93uM       // 4k8a.pdf (4KA) ligand si compound 6
3ueo  2.60  2013  Kd=94uM       // 3ueo.pdf (12-mer) Kd=94+/-15uM; incomplete ligand
3w0l  2.92  2013  Kd=95nM       // 3w0l.pdf (F6R) Kd=95+/-25nM
4k8a  2.91  2013  Kd=95uM       // 4k8a.pdf (K8A) ligand is compound 3
4l51  1.90  2013  Kd=995uM      // 4l4z.pdf (HSX) ligand is R5P; Kd=995+/-50 uM
4ayr  1.10  2013  Kd=99nM       // 4ayp.pdf (IFL)
3zjc  3.15  2013  Kd=9uM        // 3zjc.pdf (GNP) Kd=9+/-1uM
4lkh  3.10  2013  Kd>1.0mM      // 4kol.pdf (SIA-NAG)
4bv2  3.30  2013  Kd>180uM      // 4bv2.pdf (13-mer) Kd(microscale thermophoresis); incomplete ligand
4k64  2.60  2013  Kd>1mM        // 4k62.pdf (3-mer) incomplete ligand structure
4gj8  2.50  2013  Kd>500uM      // 4gj8.pdf (0LU/0LW)
4gj9  2.60  2013  Kd>500uM      // 4gj8.pdf (0M2) X-ray(R-4), Kd,IC50(rac-4)
4j79  1.56  2013  Kd>800uM      // 4j73.pdf (6-mer)
2ymt  1.80  2013  Kd~10nM       // 2ymt.pdf (9-mer) ligand is a phage peptide; incomplete ligand
4aro  1.59  2013  Kd~160nM      // 4aro.pdf (IHS) ligand is MIHS
4l5j  2.60  2013  Kd~1mM        // 4l4z.pdf (HSX) ligand is R5P
3zha  2.55  2013  Kd~1uM        // 3zha.pdf (19-mer) ligand is COLLAGEN MODEL PEPTIDE 18-T8R11
4j8s  1.55  2013  Kd~2uM        // 4j8s.pdf (15-mer) incomplete ligand
2m3o   NMR  2013  Kd~5uM        // 2m3o.pdf (11-mer) ligand is alpha-hENaC peptide
4j24  2.10  2013  Ki<0.05uM     // 4j24.pdf (19-mer) incomplete ligand
4gee  1.70  2013  Ki<1nM        // 4gee.pdf (0WT) Ki (the coupled spectrophotometric Enzchek assay)
4ggl  1.69  2013  Ki<1nM        // 4gee.pdf (CJC) Ki (the coupled spectrophotometric Enzchek assay)
4gm8  2.60  2013  Ki<1nM        // 4gm3.pdf (5-mer) IC50 = 2.4 +/- 1.7 nM
4gm3  3.39  2013  Ki<1nM        // 4gm3.pdf (5-mer) IC50 = 2.9 +/- 1.4 nM
4i5h  1.90  2013  Ki<2nM        // 4i5h.pdf (G17)
4k1b  2.08  2013  Ki=0.003nM    // 4k0y.pdf (1OC) ligand is compound 17
4gbd  1.98  2013  Ki=0.0048nM   // 4gbd.pdf (MCF) Zn-containing; Ki=0.0048+/-0.0005nM
4gih  2.00  2013  Ki=0.0048uM   // 4gfm.pdf (0X5)
4kb9  1.29  2013  Ki=0.01nM     // 4kb9.pdf (G79) ligand is compound 16a
4fp1  1.68  2013  Ki=0.027mM    // 4fp1.pdf (BFM) Ki=0.027+/-0.004mM
4gmy  2.40  2013  Ki=0.028uM    // 4gfm.pdf (0X5)
4jk5  1.55  2013  Ki=0.028uM    // 4jk5.pdf (18-mer) Ki=0.028+/-0.004uM
4fxy  2.80  2013  Ki=0.029uM    // 4fxy.pdf (0W2) ligand is compound R2, inhibition respect to fluororgenic substrate: dynorphin
4ijq  2.00  2013  Ki=0.03uM     // 4ijq.pdf (SV2) Ki=0.03+/-0.002uM; Mg-containing
4gd6  1.53  2013  Ki=0.042uM    // 4gd6.pdf (17K) Ki = 0.042 +/- 0.004 uM; covalent complex
4hw2  2.80  2013  Ki=0.055uM    // 4hw2.pdf (19H) Ki = 0.055 +/- 0.018 uM
4lmn  2.80  2013  Ki=0.05nM     // 4lmn.pdf (EUI) Ki = 262.5 nM(-ATP), 0.05 nM(+ATP)
4jk6  2.20  2013  Ki=0.064uM    // 4jk5.pdf (18-mer) Ki=0.064+/-0.005uM
4gfm  2.30  2013  Ki=0.06uM     // 4gfm.pdf (0X2)
4gs6  2.20  2013  Ki=0.071uM    // 4gs6.pdf (1FM) Ki = 0.071 +/- 0.032 uM; covalent complex
4hra  3.15  2013  Ki=0.08nM     // 4hra.pdf (EP6) Ki =0.08 +/- 0.03nM
4bny  1.80  2013  Ki=0.08uM     // 4bnt.pdf (36I) IC50= 0.08 uM (AcAcCoA as substrate), IC50=2.7uM (3-OH decanoyl-NAC as substrate)
4hvb  2.35  2013  Ki=0.111nM    // 4hvb.pdf (19P) Ki (displacement fluorescence polarization (FP) assay come from ref 5)
4bcm  2.45  2013  Ki=0.123uM    // 4bcf.pdf (T7Z) ligand is compound 4
4imz  1.70  2013  Ki=0.12uM     // 4imq.pdf (4-mer) covalent complex
4bco  2.05  2013  Ki=0.131uM    // 4bcf.pdf (T6Q) ligand is compound 12t
2yol  3.20  2013  Ki=0.13uM     // 2yol.pdf (EBN) ligand is compound 40
3zcz  2.60  2013  Ki=0.17uM     // 3zcz.pdf (TFR) ligand is compound 12;K-=0.17+/-0.02uM
4ew3  1.70  2013  Ki=0.18uM     // 4ew2.pdf (DXZ)
4hgc  1.29  2013  Ki=0.1nM      // 4hgc.pdf (14-mer) incomplete ligand
4ivc  2.35  2013  Ki=0.1nM      // 4iva.pdf (1J6)
4m1j  1.80  2013  Ki=0.20nM     // 4m1j.pdf (B0S) Ki = 0.20 +/- 0.04 nM, B-containing
4isu  2.30  2013  Ki=0.21mM     // 4isu.pdf (IKM) Ki=0.21+/-0.02mM by radioactive binding assay
4ew2  1.60  2013  Ki=0.21uM     // 4ew2.pdf (DXY)
4gfo  2.30  2013  Ki=0.24uM     // 4gfm.pdf (0X2)
4gql  1.15  2013  Ki=0.26nM     // 4gql.pdf (R47) Zn-containing
4gr0  1.50  2013  Ki=0.28nM     // 4gql.pdf (R4B) Zn-containing
4btx  2.78  2013  Ki=0.29uM     // 4btw.pdf (WF8) IC50 = 0.29 +/- 0.06 uM
4hw3  2.40  2013  Ki=0.32uM     // 4hw2.pdf (19G) Ki=0.32+/-0.01uM
4da5  2.40  2013  Ki=0.36uM     // 4da5.pdf (0H7) Ki=0.36+/-0.01 uM, IC50=0.47+/-0.08 uM (coupled spectrophotometric assay)
4ivd  1.93  2013  Ki=0.3nM      // 4iva.pdf (15T)
4ca5  1.85  2013  Ki=0.41nM     // 4ca5.pdf (3EF) Ki=0.41+/-0.03nM; Zn-containing
4bt4  1.60  2013  Ki=0.46mM     // 4bt3.pdf (QFH) Ki=0.46+/-0.18 mM; Zn-containing
4ks2  2.60  2013  Ki=0.46nM     // 4ks1.pdf (1SJ) ligand is compound 5
4hev  2.50  2013  Ki=0.46uM     // 4hev.pdf (AXM) Zn-containing
4jfw  2.10  2013  Ki=0.46uM     // 4jfs.pdf (H58) Different ligand structures (double bond)
4mss  1.80  2013  Ki=0.4uM      // 4mss.pdf (2CZ)
4jfv  1.88  2013  Ki=0.52uM     // 4jfs.pdf (H57) Different ligand structures (double bond)
3v0p  1.90  2013  Ki=0.53uM     // 3v0l.pdf (4GW) ligand is compound 1; bound with HAA
4inh  1.70  2013  Ki=0.56uM     // 4imq.pdf (4-mer) covalent complex
4hnc  1.89  2013  Ki=0.67mM     // 4fp1.pdf (0UT) Ki=0.67+/-0.12 mM(WT MR), X-ray(tmMR); Mg-containing
4jia  1.85  2013  Ki=0.6nM      // 4ji9.pdf (1K3)
4m0e  2.00  2013  Ki=0.6uM      // 4m0e.pdf (1YL) Ki=0.6+/-0.8uM
4mdn  1.91  2013  Ki=0.6uM      // 4mdn.pdf (Y30)
3zmm  2.51  2013  Ki=0.72nM     // 3zmm.pdf (F9J) ligand is compond 6; Ki=0.72+/-0.005nM
4bt3  1.10  2013  Ki=0.76mM     // 4bt3.pdf (WTZ) Ki=0.76+/-0.40 mM; Zn-containing
4mf1  2.11  2013  Ki=0.7nM      // 4mf0.pdf (29Y) ligand is compound (S,S)-13b
4eos  2.57  2013  Ki=0.89uM     // 4eoi.pdf (1RO) Ki = 0.89 +/- 0.26 uM
4eol  2.40  2013  Ki=0.89uM     // 4eoi.pdf (1RO) Ki=0.89+/-0.26 uM; X-ray(Cyclin-dependent kinase 2 (H84S, Q85M, K89D mutation)), Ki(Cyclin-dependent kinase 2)
4eon  2.40  2013  Ki=0.89uM     // 4eoi.pdf (1RO) Ki=0.89+/-0.26 uM; X-ray(Cyclin-dependent kinase 2 (H84S, Q85M, Q131E mutation)), Ki(Cyclin-dependent kinase 2); Mg-containing
4eoi  2.00  2013  Ki=0.89uM     // 4eoi.pdf (1RO) Ki=0.89+/-0.26 uM; X-ray(Cyclin-dependent kinase 2 (K89D, Q131E mutation)), Ki(Cyclin-dependent kinase 2)
4eop  1.99  2013  Ki=0.89uM     // 4eoi.pdf (1RO) Ki=0.89+/-0.26 uM; X-ray(Cyclin-dependent kinase 2 (Q131E mutation)), Ki(Cyclin-dependent kinase 2); Mg-containing
4az6  1.36  2013  Ki=0.8nM      // 4az5.pdf (OAN) ligand is PUGNAc; Ki=0.8+/-0.1nM
4hws  1.70  2013  Ki=0.8nM      // 4hwo.pdf (1B3) Zn-containing; Ki by a coupled spectrophotometric assay
4jh0  2.35  2013  Ki=0.94nM     // 4jh0.pdf (1MD) Ki=0.94+/-0.18nM
4baq  1.89  2013  Ki=0.98nM     // 4bah.pdf (M4Z) ligand is compound 4; Ki=0.98+/-0.02nM
4i72  2.05  2013  Ki=0.9nM      // 4i71.pdf (UA2) Ca-containing
4hxz  2.70  2013  Ki=0.9uM      // 4gee.pdf (19Y) Ki (the coupled spectrophotometric Enzchek assay)
4bps  1.08  2013  Ki=1.02mM     // 4bps.pdf (3EB) Ki=1.02+/-0.22 mM(by spectrophotometric assay )
4bam  1.88  2013  Ki=1.14nM     // 4bah.pdf (MM9) ligand is compound 3; Ki=1.14+/-0.02nM
4k18  2.05  2013  Ki=1.1nM      // 4k0y.pdf (1OB) ligand is compound 2
4heg  1.46  2013  Ki=1.20nM     // 4hdb.pdf (G52) Ki=1.20+/-0.08nM
4bak  1.94  2013  Ki=1.22nM     // 4bah.pdf (M67) ligand is compound 5; Ki=1.22+/-0.08nM
4hz5  2.70  2013  Ki=1.2uM      // 4gee.pdf (19Y) Ki (the coupled spectrophotometric Enzchek assay)
4kyh  2.50  2013  Ki=1.2uM      // 4kyh.pdf (ZST) ligand is zopolrestat
4mdq  2.12  2013  Ki=1.2uM      // 4mdn.pdf (28W)
4gpl  3.00  2013  Ki=1.3uM      // 4gpl.pdf (7-mer) Ki = 1.3 +/- 0.6 uM
4iu0  1.77  2013  Ki=1.3uM      // 4iu0.pdf (ABH) Measure the urea colorimetrically, B-contained; Mn-containing
4gj3  2.50  2013  Ki=1.4nM      // 4gii.pdf (0XP)
4i5c  2.10  2013  Ki=1.5nM      // 4i5c.pdf (C5I)
4ks1  2.20  2013  Ki=1.5nM      // 4ks1.pdf (2H8) ligand is compound 4
4f3c  1.93  2013  Ki=1.5pM      // 4f1w.pdf (BIG) Ki=1.5+/-0.4 pM
4imq  1.50  2013  Ki=1.5uM      // 4imq.pdf (4-mer) covalent complex
4bt5  1.10  2013  Ki=1.72mM     // 4bt3.pdf (23B) Ki=1.72+/-0.98 mM; Zn-containing
4m0f  2.30  2013  Ki=1.7nM      // 4m0f.pdf (1YK)
4j45  1.48  2013  Ki=1.7uM      // 4j44.pdf (4-mer)
4j44  1.30  2013  Ki=1.87uM     // 4j44.pdf (4-mer)
4gii  2.31  2013  Ki=1.8nM      // 4gii.pdf (0X6)
4ish  1.82  2013  Ki=1.9nM      // 4ish.pdf (1GE)
4ivb  1.90  2013  Ki=1.9nM      // 4iva.pdf (1J5)
3zcl  1.40  2013  Ki=10.1nM     // 3zbx.pdf (5TF) ligand is compound 28f
4mo8  1.85  2013  Ki=10.1nM     // 4mo8.pdf (2VQ) ligand is compound 7
3zn0  2.80  2013  Ki=10.7uM     // 3zms.pdf (6-mer) ligand is peptide PRSFAA
4in9  1.55  2013  Ki=10.7uM     // 4in9.pdf (4-mer)
4k5o  1.90  2013  Ki=104uM      // 4k3n.pdf (1OT) ligand is compound 6
4jjf  2.20  2013  Ki=10nM       // 4jjf.pdf (2-mer) ligand is FE9-N2I; Fe-contained; covalent complex
4jyu  1.80  2013  Ki=10nM       // 4jyu.pdf (1OK) ligand is compound (R)-2
3ufa  1.80  2013  Ki=10uM       // 3ufa.pdf (VPF) ligand is compound 41
4bxk  2.20  2013  Ki=11.21nM    // 4bxk.pdf (1IU) Ki=11.21+/-0.74 nM; Zn-containing; different ligand structure
4f9w  2.00  2013  Ki=114nM      // 4f9w.pdf (LM4)
4bcj  3.16  2013  Ki=11nM       // 4bcf.pdf (T9N) lignad is compound 3
4k3n  2.00  2013  Ki=11nM       // 4k3n.pdf (1OT) ligand is compound 6
2yoh  1.60  2013  Ki=11uM       // 2yof.pdf (WMJ) ligand is compound 30
4jsa  1.50  2013  Ki=11uM       // 4js6.pdf (FB2) Ki=11+/-2uM; Hg-containing
4k5l  1.91  2013  Ki=11uM       // 4k3n.pdf (19N) ligand is compound 1
4j47  1.35  2013  Ki=12.02uM    // 4j44.pdf (4-mer)
4i8w  1.96  2013  Ki=12.7pM     // 4hla.pdf (G07)
4k5n  1.91  2013  Ki=127uM      // 4k3n.pdf (1OU) ligand is compound 5
4bcn  2.10  2013  Ki=12nM       // 4bcf.pdf (T9N) ligand is compound 3
4j5p  2.30  2013  Ki=12nM       // 4j5p.pdf (BR1) covalent complex; Ki=77nM (3h preincubation of inhibitor); Ki=12nM (6h preincubation of inhibitor)
4ele  2.35  2013  Ki=13.2nM     // 4elb.pdf (31I) Ki = 13.2 +/- 0.5 nM; Ca-containing
4ks5  2.70  2013  Ki=130nM      // 4ks1.pdf (1SO) ligand is compound 8
4mjp  1.85  2013  Ki=131uM      // 4mjp.pdf (27O) ligand is (R)-Vedaprofen
3wjw  1.59  2013  Ki=134uM      // 3wjw.pdf (U6M) ligand is 6-methyl-UMP; Ki=134+/-5uM
4axm  2.80  2013  Ki=13nM       // 4axm.pdf (V65) ligand is compound 19, ligand is wrong(-CN-->-CONH2)
4gr8  1.30  2013  Ki=14.7nM     // 4gql.pdf (R4C) Zn-containing
4ivk  1.80  2013  Ki=140uM      // 4ivk.pdf (CEP) covalent complex
4iic  1.90  2013  Ki=14uM       // 4iic.pdf (IFM) Ki=14+/-2uM
4gr3  1.49  2013  Ki=15.5nM     // 4gql.pdf (R45) Zn-containing
4eb8  2.30  2013  Ki=151pM      // 4ear.pdf (IM5) Ki=151+/-16 pM
4m48  2.96  2013  Ki=156nM      // 4m48.pdf (21B)
4k0y  1.95  2013  Ki=15nM       // 4k0y.pdf (1OA) ligand is compound 1
4n6z  2.20  2013  Ki=16nM       // 4n6z.pdf (2HW) ligand is compound 3f
4hla  1.95  2013  Ki=16pM       // 4hla.pdf (017)
4hwp  1.81  2013  Ki=17.2nM     // 4hwo.pdf (X16) Zn-containing; Ki by a coupled spectrophotometric assay
4c6x  1.95  2013  Ki=175.4uM    // 4c6u.pdf (TLM) Ki = 175.4 +/- 3.0 uM
4jyv  2.19  2013  Ki=17nM       // 4jyu.pdf (1OJ) ligand is compound (R)-26
4jfi  1.05  2013  Ki=18.1uM     // 4jfi.pdf (1KT) Ki=18.1+/-1.2uM
4ca6  1.91  2013  Ki=180nM      // 4ca5.pdf (3EF) Ki=180+/-25nM; Zn-containing
4hwr  1.90  2013  Ki=182nM      // 4hwo.pdf (1B2) Zn-containing; Ki(a coupled spectrophotometric assay)
4i71  1.28  2013  Ki=18nM       // 4i71.pdf (AGV) Ca-containing
3zmz  3.00  2013  Ki=18uM       // 3zms.pdf (6-mer) ligand is peptide PRSFAV
4kyk  2.00  2013  Ki=18uM       // 4kyh.pdf (IMN) ligand is indomethacin
4i73  2.18  2013  Ki=190nM      // 4i71.pdf (MBY) Ca-containing
4i74  1.68  2013  Ki=190nM      // 4i71.pdf (MBY) Ca-containing
4k5m  1.75  2013  Ki=193uM      // 4k3n.pdf (1OV) ligand is compound 2
4mjq  1.73  2013  Ki=193uM      // 4mjp.pdf (27R) ligand is Bromfenac
4n70  2.10  2013  Ki=1pM        // 4n70.pdf (2HX) ligand is compound 5c
4bah  1.94  2013  Ki=2.01nM     // 4bah.pdf (MEL) ligand is Melagatran; Ki=2.01+/-0.09nM
4j28  1.73  2013  Ki=2.0uM      // 4j28.pdf (EAT) Ki=2.0+/-0.1uM
4jfj  1.08  2013  Ki=2.1uM      // 4jfi.pdf (1KU) Ki=2.1+/-0.2uM
4kp0  2.80  2013  Ki=2.24nM     // 4kp0.pdf (KPK)
4j48  2.10  2013  Ki=2.41uM     // 4j44.pdf (4-mer)
4ban  1.87  2013  Ki=2.43nM     // 4bah.pdf (M6S) ligand is compound 2; Ki=2.43+/-0.07nM
4iid  2.30  2013  Ki=2.4uM      // 4iic.pdf (NOJ) Ki=2.4+/-0.3uM
4gj2  2.40  2013  Ki=2.5nM      // 4gii.pdf (0XH)
3vtr  2.50  2013  Ki=2.714uM    // 3vtr.pdf (TCG)
4kww  2.55  2013  Ki=2.8uM      // 4kww.pdf (PHT) Ki = 2.8 +/- 0.4 uM
4hwo  1.91  2013  Ki=2.9nM      // 4hwo.pdf (409) Zn-containing; Ki by a coupled spectrophotometric assay
4mm6  3.10  2013  Ki=205nM      // 4mm4.pdf (29E) ligand is duloxetine;Ki = 205 +/- 15 nM
4mm9  2.90  2013  Ki=2070nM     // 4mm4.pdf (FVX) ligand is fluvoxamine;Ki = 2070 +/- 272 nM
4ca8  1.99  2013  Ki=210nM      // 4ca5.pdf (3ES) Zn-containing; Ki=210nM, 95% confidence interval 180-246 nM
4n99  2.30  2013  Ki=216uM      // 4n94.pdf (2J1) ligand is compound 7
3zpr  2.70  2013  Ki=224nM      // 3zpq.pdf (3WC) ligand is compound 20; pKi=6.65
4bch  2.96  2013  Ki=22nM       // 4bcf.pdf (T7Z) ligand is compound 4
4hzm  1.45  2013  Ki=23.2uM     // 4hzm.pdf (1BW)
4i80  3.10  2013  Ki=23.8nM     // 4i80.pdf (9-mer)
4mm7  2.85  2013  Ki=235.5uM    // 4mm4.pdf (29J) ligand is desvenlafaxine;Ki = 235500 +/- 82352 nM
4k77  2.40  2013  Ki=235nM      // 4k6z.pdf (1Q4) ligand is compound 6
4lch  1.60  2013  Ki=24pM       // 4lcf.pdf (1WN) ligand is compound 24c; Ki=0.024+/-0.004 nM (EcLpxC)
4bds  2.10  2013  Ki=25nM       // 4bds.pdf (THA) ligand is tacrine
2yof  1.82  2013  Ki=25uM       // 2yof.pdf (74W) ligand is compound 53
4j03  2.92  2013  Ki=26nM       // 4j03.pdf (FVS) Ki=26+/-3nM
4amw  1.90  2013  Ki=28.3mM     // 2x2i.pdf (5DI) Ki=28.3+/-2.1mM
3zmt  3.10  2013  Ki=28.4uM     // 3zms.pdf (6-mer) ligand is peptide PRSFLV
4n98  1.70  2013  Ki=280uM      // 4n94.pdf (4FC) ligand is compound 5
4mjr  1.62  2013  Ki=283uM      // 4mjp.pdf (0LA) (S)-Carprofen
3zn1  3.10  2013  Ki=29.1uM     // 3zms.pdf (6-mer) ligand is peptide PRLYLV
4hy1  1.90  2013  Ki=2nM        // 4gee.pdf (19X) Ki by coupled spectrophotometric Enzchek assay
4hxw  1.69  2013  Ki=2nM        // 4gee.pdf (1A0) Ki (the coupled spectrophotometric Enzchek assay)
4jjg  2.50  2013  Ki=2nM        // 4jjf.pdf (2-mer) ligand is FE9-IC9; Fe-contained, Different ligand structures (number of carbon); covalent complex
4k6z  2.73  2013  Ki=2nM        // 4k6z.pdf (1Q3) ligand is compound 37
4bs0  1.09  2013  Ki=2uM        // 4bs0.pdf (6NT)
3v0l  1.75  2013  Ki=3.0uM      // 3v0l.pdf (2GW) ligand is compound 2
3zpt  1.54  2013  Ki=3.1nM      // 3zps.pdf (M8Y) ligand is (R)-19a
4hdf  1.29  2013  Ki=3.2nM      // 4hdb.pdf (G52) Ki=3.2+/-0.2nM
4m2r  1.99  2013  Ki=3.2nM      // 4m2r.pdf (BZ1) ligand is BRZ
4he9  1.06  2013  Ki=3.5nM      // 4hdb.pdf (G52) Na-containing; Ki = 3.5 +/- 0.2 nM; covalent complex
4jft  2.10  2013  Ki=3.5uM      // 4jfs.pdf (1KN)
4j26  2.30  2013  Ki=3.64uM     // 4j24.pdf (12-mer) Ki=3.64+/-0.21uM
4hdp  1.22  2013  Ki=30.9nM     // 4hdb.pdf (G52) Na-containing; Ki=30.9+/-0.6nM
4c70  1.75  2013  Ki=305uM      // 4c6u.pdf (TLJ) Ki = 305.0 +/- 8.0 uM
4lh3  1.81  2013  Ki=30mM       // 4lh2.pdf (GUA) ligand is Glutarate; Ki = 30 +/- 3 mM
4lpf  2.30  2013  Ki=310uM      // 4lpf.pdf (3TR) ki=310+/-30uM
4kzu  2.10  2013  Ki=313nM      // 4bs4.pdf (A73) Zn-containing
2yog  1.50  2013  Ki=31uM       // 2yof.pdf (74X) ligand is compound 28
4ccd  1.97  2013  Ki=32uM       // 4ccc.pdf (2DG) Ki = 32 +/- 1.8 uM; covalent complex
4bvb  2.00  2013  Ki=33.4uM     // 4bv2.pdf (OCZ) Ki = 33.4 +/- 4.4 uM
4h42  2.01  2013  Ki=341uM      // 4h42.pdf (11E)
4k5p  1.85  2013  Ki=345uM      // 4k3n.pdf (1OS) ligand is compound 7
4c6z  1.80  2013  Ki=357.0uM    // 4c6u.pdf (TLE) Ki = 357.0 +/- 35.0 uM
3znr  2.40  2013  Ki=36nM       // 3znr.pdf (NU9) ligand is TMP269,1
4m2v  1.72  2013  Ki=36nM       // 4m2r.pdf (BZ1) ligand is BRZ
4c71  1.80  2013  Ki=384.0uM    // 4c6u.pdf (7RD) Ki = 384.0 +/- 12.0 uM
3zns  2.45  2013  Ki=39nM       // 3znr.pdf (NU7) ligand is TMP942,3
4bao  1.87  2013  Ki=4.29nM     // 4bah.pdf (MVF) ligand is compound 1; Ki=4.29+/-0.10nM
3zpu  1.80  2013  Ki=4.2nM      // 3zps.pdf (M8B) ligand is (R)-19b
4iie  2.00  2013  Ki=4.6mM      // 4iic.pdf (CGB) Ki=4.6+/-1.0mM
4giu  1.67  2013  Ki=4.7uM      // 4giu.pdf (636) ligand is compound 34, Uncompetitive Ki value
4bbg  2.75  2013  Ki=4.8nM      // 4bbg.pdf (V02) ligand is compound 46;Ki=4.8+/-1.2nM
4ks3  2.60  2013  Ki=430nM      // 4ks1.pdf (1SL) ligand is compound 6
4ca7  1.82  2013  Ki=44nM       // 4ca5.pdf (3EF) Zn-containing
4lvt  2.05  2013  Ki=44pM       // 4lvt.pdf (1XJ) ligand is Navitoclax(1); Ki=0.044nM(TR-FRET)
3zdh  2.20  2013  Ki=45nM       // 3zdg.pdf (XRS) ligand is compound 7
3zmu  3.20  2013  Ki=49.6uM     // 3zms.pdf (6-mer) ligand is peptide PKSFLV
4bck  2.05  2013  Ki=4nM        // 4bcf.pdf (T3E) ligand is compound 12c
4ij1  1.79  2013  Ki=4uM        // 4giu.pdf (17C) ligand is compound ACS172, Competitive Ki value
3zps  1.55  2013  Ki=5.0nM      // 3zps.pdf (EQM) ligand is (R)-17b, ring of ligand is opening in the crystal.
4elb  2.60  2013  Ki=5.0nM      // 4elb.pdf (34R/34S) Ki = 5.0 +/- 0.6 nM; Ca-containing
4f2w  2.00  2013  Ki=5.0pM      // 4f1w.pdf (TDI) Ki=5.0+/-0.4 pM
4j46  1.42  2013  Ki=5.24uM     // 4j44.pdf (4-mer)
4mfe  2.61  2013  Ki=5.4mM      // 4mfe.pdf (3PY) ligand is 3-Hydroxypyruvate
4jfs  2.00  2013  Ki=5.4uM      // 4jfs.pdf (16Z)
4jsz  1.90  2013  Ki=5000uM     // 4js6.pdf (FB2) Ki=5000+/-1100uM; Zn-containing
4eor  2.20  2013  Ki=500nM      // 4eoi.pdf (4SP) Ki=500+/-30nM
4jss  1.50  2013  Ki=500uM      // 4js6.pdf (BEW) Ki=500+/-60uM; Zn-containing
4iwz  1.60  2013  Ki=51nM       // 4iwz.pdf (1GO) Ki=51+/-3.1nM by stopped-flow CO2 hydrase assay; Zn-containing
4m2w  1.66  2013  Ki=52nM       // 4m2r.pdf (ETS) ligand is DRZ
3zmv  3.00  2013  Ki=55uM       // 3zms.pdf (6-mer) ligand is peptide PLSFLV
4bcp  2.26  2013  Ki=568nM      // 4bcg.pdf (T3C) ligand is compound 12u
4lh2  1.67  2013  Ki=58mM       // 4lh2.pdf (SIN) ligand is Succinate; Ki = 58 +/- 4 mM
4iq6  3.12  2013  Ki=58nM       // 4iq6.pdf (IQ6)
4lxd  1.90  2013  Ki=59nM       // 4lvt.pdf (1XV) ligand is compound 2
4gfn  1.90  2013  Ki=5nM        // 4gee.pdf (SUY) Ki (the coupled spectrophotometric Enzchek assay)
4lko  2.43  2013  Ki=6.0nM      // 4jh0.pdf (1WH)
4amx  2.10  2013  Ki=6.5mM      // 2x2i.pdf (5GF) ligand is 5FGlcF
3w37  1.70  2013  Ki=6.68uM     // 3w37.pdf (ACR)
4iif  2.45  2013  Ki=6.6uM      // 4iic.pdf (CTS) Ki=6.6+/-0.6uM
4gkm  1.67  2013  Ki=6.8uM      // 4giu.pdf (683) ligand is compound 14
4elg  2.10  2013  Ki=6.9nM      // 4elb.pdf (52I/52J) Ki=6.9+/-0.5 nM; Ca-containing
4bqs  2.15  2013  Ki=62uM       // 4bqs.pdf (K2Q) Ki=62+/-1uM
4n9a  1.90  2013  Ki=64uM       // 4n94.pdf (2J2) ligand is compound 8
3zpq  2.80  2013  Ki=67.6nM     // 3zpq.pdf (XF5) ligand is compound 19; pKi=7.17
4iva  1.50  2013  Ki=68.4nM     // 4iva.pdf (1J5) Ki=1.9nM(when protein is JAK1); Ki(JAK2)/Ki(JAK1)=36
4f3k  1.85  2013  Ki=69.0pM     // 4f1w.pdf (HCE) Ki=69.0+/-12.1 pM
3zbx  2.20  2013  Ki=6nM        // 3zbx.pdf (6XE) ligand is compound 7
4bci  3.10  2013  Ki=6nM        // 4bcf.pdf (T3E) ligand is compound 12c
4hym  1.90  2013  Ki=6nM        // 4gee.pdf (CJC) Ki by coupled spectrophotometric Enzchek assay
4lrr  2.41  2013  Ki=6uM        // 4lrr.pdf (CF9) ligand is compound 3; Ki=6+/-0.2 uM
4isi  1.94  2013  Ki=7.3nM      // 4isi.pdf (1GG)
4gly  1.52  2013  Ki=7.7uM      // 4gly.pdf (14-mer)
4ks4  2.50  2013  Ki=72nM       // 4ks1.pdf (1SN) ligand is compound 7
3zc5  2.20  2013  Ki=74nM       // 3zbx.pdf (W9Z) ligand is compound 8
4kx8  2.40  2013  Ki=74nM       // 4kx8.pdf (4-mer) ligand is peptide from amastatin (L20-VAL-VAL-SAP)
4kxb  2.40  2013  Ki=75uM       // 4kx8.pdf (BES) ligand is bestatin
2lwi   NMR  2013  Ki=773uM      // 2lwi.pdf (KOB) ligand is  Kobe2601;Ki=77+/-49uM
4mm8  3.31  2013  Ki=778nM      // 4mm4.pdf (RFX) ligand is fluoxetine;Ki = 778 +/- 76 nM
3zdg  2.48  2013  Ki=79nM       // 3zdg.pdf (XRX) ligand is compound 4
4bcf  3.01  2013  Ki=7nM        // 4bcf.pdf (T6Q) ligand is compound 12t
4bcg  3.08  2013  Ki=7nM        // 4bcg.pdf (T3C) ligand is compound 12u
4n5t  1.70  2013  Ki=7nM        // 4n5t.pdf (15-mer)
4elh  2.10  2013  Ki=8.2nM      // 4elb.pdf (53I/53J) Ki=8.2+/-0.5 nM; Ca-containing
4c72  1.50  2013  Ki=8.2uM      // 4c6u.pdf (TLG) Ki = 8.2 +/- 0.8 uM
4mf0  2.67  2013  Ki=8.4nM      // 4mf0.pdf (29Z) ligand is compound 13a
4hdb  1.49  2013  Ki=8.9nM      // 4hdb.pdf (G52) Na-containing; Kd=8.9+/-0.4nM
4i8z  1.75  2013  Ki=8.9pM      // 4hla.pdf (G08)
4kvm  2.60  2013  Ki=8.9uM      // 4kvm.pdf (5-mer) Ki = 8.9 +/- 0.1 uM
4eok  2.57  2013  Ki=8600nM     // 4eoi.pdf (4SP) Ki = 8600 +/- 3200 nM
4m2u  2.00  2013  Ki=9.1nM      // 4m2r.pdf (ETS) ligand is DRZ
4elf  2.30  2013  Ki=9.4nM      // 4elb.pdf (35I) Ca-containing; Ki=9.4+/-0.5 nM
4mma  3.30  2013  Ki=920nM      // 4mm4.pdf (CXX) ligand is clomipramine;Ki = 920 +/- 76 nM
4n6y  2.60  2013  Ki=92nM       // 4n6y.pdf (2HV) ligand is compound 1a
4jhz  2.83  2013  Ki=957nM      // 4jhz.pdf (1KV) ligand is inhibitor 8
4bcw  1.50  2013  Ki>100uM      // 4bcw.pdf (TU0) ligand is compound 9,the ring is open.
4hwt  2.30  2013  Ki>50000nM    // 4hwo.pdf (1B2) Zn-containing; Ki(a coupled spectrophotometric assay)
4iu4  1.80  2013  Ki~10uM       // 4iu0.pdf (S2C) Measure the urea colorimetrically, B-contained; Mn-containing
4fyh  2.44  2013  Ki~14uM       // 4fyh.pdf (TR5)
4iu1  1.95  2013  Ki~50uM       // 4iu0.pdf (NNH) Measure the urea colorimetrically; Mn-containing
4whz  1.79  2014  IC50<1nM      // 4whz.pdf (3NL) ligand is compound 26k
4uro  2.59  2014  IC50<4nM      // 4url.pdf (NOV) ligand is Novobiocin
4kql  2.31  2014  IC50=0.0017uM  // 4knr.pdf (1SG) ligand is compound 24a, WG578
4o12  2.50  2014  IC50=0.002uM  // 4l4l.pdf (2QG) ligand is compound GMX1778
4c61  2.45  2014  IC50=0.004uM  // 4c61.pdf (LMM) ligand is compound 23b
4mqu  2.22  2014  IC50=0.004uM  // 4mqu.pdf (MG9) ligand is compound 27
4mha  2.59  2014  IC50=0.0052uM  // 4mh7.pdf (4MH) ligand is compound 22
4jps  2.20  2014  IC50=0.005uM  // 4jps.pdf (1LT) ligand is compound 8
4l4l  2.12  2014  IC50=0.005uM  // 4l4l.pdf (1XC) ligand is compound PRib-GNE-617, PRPP adduct of GNE-617. affinity is for GNE-617
4lwu  1.14  2014  IC50=0.005uM  // 4lwt.pdf (20U) ligand is RO5499252, compound 20, HTRF binding assay
4d0x  1.82  2014  IC50=0.008uM  // 4d0w.pdf (953) ligand is compound 28
4ncg  2.58  2014  IC50=0.011uM  // 4ncg.pdf (2KW) ligand is compound 36
4mzs  1.85  2014  IC50=0.012uM  // 4mzo.pdf (2EV) covalent ligand, compound 57, IC50 is for human Cathepsin S
4n9e  1.72  2014  IC50=0.015uM  // 4n9b.pdf (2HL) ligand is compound 63
3wcb  3.00  2014  IC50=0.018uM  // 3wc9.pdf (8PH) BPH-1237/TcSQS
4n9d  1.70  2014  IC50=0.019uM  // 4n9b.pdf (2HJ) ligand is compound 51
4l4m  2.44  2014  IC50=0.01uM   // 4l4l.pdf (1XD) ligand is GNE-643
4u45  2.58  2014  IC50=0.01uM   // 4u43.pdf (3DC) ligand is compound 25
4n8e  2.30  2014  IC50=0.020uM  // 4n8d.pdf (2KV) ligand is compound 12a
4d1s  1.66  2014  IC50=0.022uM  // 4d0w.pdf (BJG) ligand is compound 24
4lwi  1.70  2014  IC50=0.023uM  // 4lwe.pdf (FJ6) compound 60
4lwh  1.70  2014  IC50=0.027uM  // 4lwe.pdf (FJ5) compound 93
4d0w  1.77  2014  IC50=0.02uM   // 4d0w.pdf (VVQ) ligand is compound 6
4k2g  2.30  2014  IC50=0.02uM   // 4k2f.pdf (1OQ) ligand is compound 4, BRD-A33442372
4nld  2.75  2014  IC50=0.02uM   // 4nld.pdf (2N7) ligand is compound 2
4nw5  1.94  2014  IC50=0.02uM   // 4nw5.pdf (2NR) ligand is compound 8
4tw9  2.40  2014  IC50=0.02uM   // 4tw9.pdf (386) ligand is compound 1; IC50=0.02+/-0.02uM
4tyt  1.80  2014  IC50=0.02uM   // 4tyt.pdf (S3C) ligand is ML302F; IC50=0.02+/-0.07uM
4oon  3.20  2014  IC50=0.030uM  // 4ool.pdf (2U4) ligand is compound 17
4j3j  3.20  2014  IC50=0.031uM  // 4j3j.pdf (D3C) ligand is compound 21r, but two N atoms are different
4kwp  1.25  2014  IC50=0.032uM  // 4kwp.pdf (EXX) ligand is compound K164
4d2v  2.45  2014  IC50=0.037uM  // 4d2p.pdf (45R) ligand is compound 7
4wwo  2.30  2014  IC50=0.0380uM  // 4wwn.pdf (3VD) ligand is compound 16
4twc  1.70  2014  IC50=0.040uM  // 4twc.pdf (37J) ligand is compound 5;
4nxs  2.55  2014  IC50=0.043uM  // 4nxs.pdf (2OZ) DGJ-pFPhT; IC50=0.043+/-0.0062uM (PH=7)
4knb  2.40  2014  IC50=0.047uM  // 4knb.pdf (1RU) ligand is compound R-(5a)
4k2f  1.99  2014  IC50=0.04uM   // 4k2f.pdf (A08) ligand is compound 3, BRD-A08522488
4oty  2.35  2014  IC50=0.04uM   // 4oty.pdf (LUR) ligand is compound 1(lumiracoxib);  IC50= 0.04+/-0.01uM (substrate 2-AG);
4whh  1.90  2014  IC50=0.04uM   // 4rcp.pdf (5-mer) ligand is peptide 22
3wcf  2.22  2014  IC50=0.053uM  // 3wc9.pdf (BH8) ligand is BPH1218
4o0z  2.05  2014  IC50=0.057uM  // 4l4l.pdf (2RM) ligand is compound GNE-200
4cl9  1.40  2014  IC50=0.05uM   // 4cl9.pdf (IES) ligand is DUAL946 (1), IC50=0.05uM
4kpx  2.21  2014  IC50=0.05uM   // 4knr.pdf (1SE) ligand is compound 14b, WG766
4pis  2.10  2014  IC50=0.06uM   // 4pid.pdf (3FU) ligand is inhibitor 14
4c1e  1.40  2014  IC50=0.072uM  // 4c1c.pdf (MCO) ligand is D-captopril
4o10  1.55  2014  IC50=0.078uM  // 4l4l.pdf (2QF) ligand is compound GNE-201
4lwe  1.50  2014  IC50=0.07uM   // 4lwe.pdf (FJ2) compound 24
4mro  2.20  2014  IC50=0.087uM  // 4mqu.pdf (MG0) ligand is compound 23
3wch  2.50  2014  IC50=0.089uM  // 3wc9.pdf (8PH) ligand is BPH1237
4piq  2.07  2014  IC50=0.08uM   // 4pid.pdf (3FS) ligand is inhibitor 9
4j1p  1.08  2014  IC50=0.09uM   // 4j1p.pdf (1K0) target is BRD2(BD2)
4oas  1.70  2014  IC50=0.10nM   // 4oas.pdf (2SW) ligand is compound 25; IC50=0.10+/-0.04nM (biochemical potency HTRF IC50)
4pkb  2.09  2014  IC50=0.116uM  // 4pkb.pdf (MAY) ligand is MAFP; IC50=0.116+/-0.0046uM
4pzw  1.80  2014  IC50=0.11uM   // 4pzw.pdf (2X4) ligand is compound 13
4op1  2.39  2014  IC50=0.129uM  // 4op1.pdf (2UW) ligand is compound 59; IC50=0.129+/-0.030uM
4tn2  2.70  2014  IC50=0.12uM   // 4tlr.pdf (33J) ligand is compound 5g
4wwp  2.40  2014  IC50=0.12uM   // 4wwn.pdf (3VE) ligand is compound 27
4uvc  3.10  2014  IC50=0.131uM  // 4uv8.pdf (D52) ligand is compound 21d
4o76  1.70  2014  IC50=0.13uM   // 4o70.pdf (1M3) ligand is TG101209
4tkg  1.95  2014  IC50=0.140uM  // 4pml.pdf (09L) ligand is AZD2281
3wcg  2.80  2014  IC50=0.14uM   // 3wc9.pdf (BH3) ligand is BPH-1344
4nzm  2.00  2014  IC50=0.14uM   // 4nzm.pdf (0EJ) ligand is 5-PA-InsP5
4ool  2.30  2014  IC50=0.14uM   // 4ool.pdf (2U2) ligand is compound 14
4cku  1.85  2014  IC50=0.15uM   // 4cku.pdf (P2F) ligand is compound 1SR
4ow0  2.10  2014  IC50=0.15uM   // 4ovz.pdf (S88) ligand is compound 3k; IC50=0.15+/- 0.01uM; modified residues ipeptidelinking
4w9s  1.80  2014  IC50=0.15uM   // 4w9s.pdf (3K1) ligand is compound 11
4wlb  1.70  2014  IC50=0.18uM   // 4wlb.pdf (3QQ) ligand is compound 48
4usj  2.85  2014  IC50=0.1mM    // 4usi.pdf (ARG) ligand is arginine; Kd=0.1~1mM
4ode  1.80  2014  IC50=0.1nM    // 4occ.pdf (2U0) ligand is compound 4; HTRF IC50=0.1+/-0.01nM; biochemical assay using serum free buffer
4odf  2.20  2014  IC50=0.1nM    // 4occ.pdf (2U1) ligand is compound 47; HTRF IC50=0.1+/-0.01nM; biochemical assay using serum free buffer
4ogn  1.38  2014  IC50=0.1nM    // 4occ.pdf (2U5) ligand is compound 3; HTRF IC50=0.1+/-0.01nM; biochemical assay using serum free buffer
4ogt  1.54  2014  IC50=0.1nM    // 4occ.pdf (2U6) ligand is compound 46; HTRF IC50=0.1+/-0.05nM; biochemical assay using serum free buffer
4phw  2.50  2014  IC50=0.1nM    // 4phw.pdf (2W1) ligand is compound 4
4o1l  2.50  2014  IC50=0.20uM   // 4o1g.pdf (HO4) ligand is compound 1a; IC50=0.20+/-0.02uM
4q6r  2.40  2014  IC50=0.21uM   // 4q6r.pdf (30J) ligand is compound 31; IC50=0.21+/-0.04uM
4cc6  2.01  2014  IC50=0.23uM   // 4cc5.pdf (L5Y) ligand is compound 12
4pnk  2.56  2014  IC50=0.25uM   // 4pni.pdf (KZQ) GRK2-G-belta-gamma ; GSK180736A; log IC50 = -6.6
3wcl  2.24  2014  IC50=0.26uM   // 3wc9.pdf (BH3) ligand is BPH1344
4mzo  1.47  2014  IC50=0.271uM  // 4mzo.pdf (2EW) covalent ligand, compound 56, IC50 is for human Cathepsin S
3wci  2.30  2014  IC50=0.27uM   // 3wc9.pdf (BH5) ligand is BPH1325
4tkf  2.60  2014  IC50=0.285uM  // 4pml.pdf (33C) ligand is IWR-1
4clb  1.60  2014  IC50=0.28uM   // 4clb.pdf (83T) ligand is I-BET295
4o9s  2.30  2014  IC50=0.28uM   // 4o9s.pdf (2RY) ligand is compound 15; IC50=0.28+/-0.07uM; hRBP4 SPA
3wt5  1.90  2014  IC50=0.29nM   // 3wt5.pdf (YA1) ligand is compound 8a, crystal form 1
4ps5  1.40  2014  IC50=0.29uM   // 4o70.pdf (2TA) ligand is TG101348; was PDB entry 4O73(superseded)
4pl3  2.90  2014  IC50=0.29uM   // 4pl3.pdf (31J) MKC9989 inhibitor; Mouse IRE1-alpha IC50=0.29+/-0.04uM
4mib  2.30  2014  IC50=0.2nM    // 4mia.pdf (28M) ligand is compound 48
4q1n  2.09  2014  IC50=0.2nM    // 4pyv.pdf (2Y9) ligand is compound 31
4m7b  1.95  2014  IC50=0.2uM    // 4m7b.pdf (28C) ligand is compound 12
4mex  3.90  2014  IC50=0.2uM    // 4mex.pdf (9-mer) ligand is 9-mer Salinamide A peptide
4u5t  3.30  2014  IC50=0.2uM    // 4u5t.pdf (3CG) NSC13778; Sb-containing
3wym  2.00  2014  IC50=0.30nM   // 3wym.pdf (3K9) ligand is compound 27h
4uv8  2.80  2014  IC50=0.335uM  // 4uv8.pdf (D69) LSD1(KDM1A)-CoREST; ligand is compound 20e
4tjy  1.90  2014  IC50=0.367uM  // 4pml.pdf (3GN) ligand is ABT-888
3zmq  3.30  2014  IC50=0.36uM   // 3zmp.pdf (10-mer) ligand is 10-mer Src-derived peptide inhibitor: AC-4
4oya  2.03  2014  IC50=0.36uM   // 4oya.pdf (1VE) ligand is compound 8
4cik  1.78  2014  IC50=0.37uM   // 4cik.pdf (XO3) ligand is compound 17, clotlysis IC50 value
4m8t  3.00  2014  IC50=0.37uM   // 4lv0.pdf (RMM) ligand is compound 24
4o1b  1.65  2014  IC50=0.385uM  // 4o13.pdf (DGB) ligand is compound 11(APO866); biochemical IC50 =0.385+/-0.224 uM
4pvt  2.00  2014  IC50=0.3uM    // 4pvt.pdf (S3C) ligand is ML302F; IC50=0.3+/-0.09uM
4m3b  2.00  2014  IC50=0.40uM   // 4m3b.pdf (2B2) ligand is compound 19
4whl  2.71  2014  IC50=0.40uM   // 4rcp.pdf (5-mer) ligand is peptide 8
4u79  2.23  2014  IC50=0.40uM   // 4u6r.pdf (3EL) ligand is comppound 19
4tki  2.15  2014  IC50=0.416uM  // 4pml.pdf (33E) ligand is BSI-201
4cqg  2.57  2014  IC50=0.41nM   // 4cqg.pdf (OT5) ligand is OTSSP167, MPK38 also known as maternal embryonic leucine zipper kinase (MELK)
4nzn  1.75  2014  IC50=0.42uM   // 4nzm.pdf (2OU) ligand is 2-O-Bn-5-PA-InsP4
4psq  2.40  2014  IC50=0.44uM   // 4o9s.pdf (2WL) ligand is compound 1; IC50=0.44+/-0.18uM; hRBP4 SPA
4pnr  1.71  2014  IC50=0.456uM  // 4pml.pdf (G18) ligand is TIQ-A
4lq3  2.60  2014  IC50=0.45uM   // 4lq3.pdf (20V) ligand is PPNDS
4okg  2.06  2014  IC50=0.48nM   // 4okg.pdf (2SZ) compound B
4bg1  1.89  2014  IC50=0.49uM   // 4bg1.pdf (IVL) ligand is compound 26
4ovz  2.50  2014  IC50=0.49uM   // 4ovz.pdf (P85) ligand is compound 3j; IC50=0.49+/- 0.01uM; modified residues ipeptidelinking
4pvo  1.48  2014  IC50=0.49uM   // 4pvo.pdf (SVB) IC50=0.49+/-0.18uM; ML302 undergoes hydrolysis to give ML302M, revealing binding of ML302M (ML302 + ML302F) Chain A and ML302F Chain B
4oba  1.60  2014  IC50=0.4nM    // 4oba.pdf (2TW) ligand is compound 4; HTRF IC50=0.4+/-0.1nM (serum free)
4c7t  2.05  2014  IC50=0.4uM    // 4c7t.pdf (5RI) ligand is compound PHM16
4uyh  1.73  2014  IC50=0.50uM   // 4uyf.pdf (9S3) ligand is compound 28; BRD2 N-terminal bromodomain
4qt0  3.20  2014  IC50=0.51uM   // 4qt0.pdf (38Q) ligand is compound 1; IC50=0.51 +/-0.14uM
4wj5  1.65  2014  IC50=0.51uM   // 4wj5.pdf (10-mer) ligand is [am-phg][NVA]AGIGILT[PRG]; IC50=0.51+/-0.01uM
3wnt  2.07  2014  IC50=0.53uM   // 3wnr.pdf (9BE) [Covalent complex] compound 2; rhMIF covalently modified with 2 binding in the downwards orientation
3wnr  2.01  2014  IC50=0.53uM   // 3wnr.pdf (9BE) [Covalent complex] compound 2; rhMIF covalently modified with 2 binding in the upwards orientation
4m3g  2.30  2014  IC50=0.55uM   // 4m3b.pdf (2G1) ligand is compound 17
4m3e  2.11  2014  IC50=0.56uM   // 4m3b.pdf (2B3) ligand is compound 20
4pjt  2.35  2014  IC50=0.57nM   // 4pjt.pdf (2YQ) ligand is BMN 673
4oq5  2.86  2014  IC50=0.5uM    // 4oq5.pdf (2UU) ligand is compound 17
4bgm  2.40  2014  IC50=0.61uM   // 4bg1.pdf (DLT) ligand is compound 24
4lp9  1.35  2014  IC50=0.62uM   // 4lp9.pdf (7-mer)
4jvq  2.40  2014  IC50=0.63uM   // 4jvq.pdf (1ML) ligand is compound 9
4olc  2.60  2014  IC50=0.64uM   // 4olc.pdf (DCD) ligand is Disulfiram; on page 10506, Fig2
4umu  2.02  2014  IC50=0.65uM   // 4umt.pdf (0V0) ligand is compound 4; Astex
4c68  1.38  2014  IC50=0.68uM   // 4c68.pdf (EN5) ternay complex of PvNMT-NHM-compound 10
4uzd  3.20  2014  IC50=0.6nM    // 4uyn.pdf (QMN) ligand is compound 47
4j5b  2.01  2014  IC50=0.6uM    // 4j58.pdf (6B4) compound 27
4umt  1.98  2014  IC50=0.72uM   // 4umt.pdf (47W) ligand is compound 5; Astex
4l7d  2.25  2014  IC50=0.75uM   // 4l7b.pdf (1VX) ligand is compound 59
4cxw  3.10  2014  IC50=0.81uM   // 4cxw.pdf (6MK) ligand is compound 12
4pni  1.85  2014  IC50=0.81uM   // 4pni.pdf (KQQ) GSK2163632A; log IC50 = -6.09
4qn7  2.30  2014  IC50=0.84nM   // 4qn5.pdf (G39)
4pv0  2.00  2014  IC50=0.85nM   // 4puz.pdf (CG4) ligand is compound 9
4wwn  2.70  2014  IC50=0.85uM   // 4wwn.pdf (3VC) ligand is compound 1
4nau  2.33  2014  IC50=0.87nM   // 4nah.pdf (2W3) ligand is compound D
4o4r  2.40  2014  IC50=0.88uM   // 4o4r.pdf (20V) compound PPNDS; IC50=0.88+/-0.03uM
4n1t  1.60  2014  IC50=0.8nM    // 4n1t.pdf (2GD) ligand is TH287, ligand 2
4tjw  1.70  2014  IC50=0.963uM  // 4pml.pdf (P34) ligand is PJ-34
4uv9  3.00  2014  IC50=0.975uM  // 4uv8.pdf (D70) ligand is compound 20b
4m3m  2.10  2014  IC50=0.9nM    // 4m3m.pdf (22N) ligand is compound 2, IC50=0.9nM for H3N2, IC50=0.7nM for H1N1, Crystal is H3N8
4w7t  1.80  2014  IC50=0.9uM    // 4u93.pdf (3JC) ligand is compound 1
4urk  2.90  2014  IC50=1.09uM   // 4urk.pdf (A82) ligand is compound 2 (AZD6482)
4d2t  2.70  2014  IC50=1.0uM    // 4d2p.pdf (3I7) ligand is compound 4
4o72  1.40  2014  IC50=1.0uM    // 4o70.pdf (2R4) ligand is NU7441
4pzx  1.80  2014  IC50=1.0uM    // 4pzw.pdf (2X5) ligand is compound 18
4op2  2.24  2014  IC50=1.176uM  // 4op2.pdf (2UX) ligand is compound 4; IC50=1.176+/-0.073uM
3wns  1.66  2014  IC50=1.1uM    // 3wnr.pdf (9AI) [Covalent complex] compound 3
4j5d  1.32  2014  IC50=1.1uM    // 4j58.pdf (728) compound 26
4n1b  2.55  2014  IC50=1.1uM    // 4l7b.pdf (2FS) ligand is compound 43
4p0w  2.41  2014  IC50=1.1uM    // 4p0v.pdf (1XH) liand is compound 13
4hrc  2.80  2014  IC50=1.2nM    // 4hnp.pdf (OV2) ligand is compound 3
4p0v  2.40  2014  IC50=1.2uM    // 4p0v.pdf (1WO) ligand is compound 11
4p0x  2.50  2014  IC50=1.2uM    // 4p0v.pdf (1WO) ligand is compound 11
4qye  2.05  2014  IC50=1.2uM    // 4qye.pdf (3DL) ligand is compound 1
4ux6  3.00  2014  IC50=1.2uM    // 4ux6.pdf (YWO) ligand is compound 2
3wke  2.75  2014  IC50=1.3nM    // 3wk4.pdf (AUB) ligand is compound t-AUCB
4cli  2.05  2014  IC50=1.3nM    // 4cli.pdf (5P8) ligand is compound 8K
4lqg  1.77  2014  IC50=1.3nM    // 4lqg.pdf (CTW) compound 4
4qyh  1.90  2014  IC50=1.3nM    // 4qye.pdf (3DX) ligand is compound 16
3wgw  2.80  2014  IC50=1.3uM    // 3wgw.pdf (T2B) compound T2AA, PCNA/PIP-box interaction inhibition is IC50=1.3uM
4msu  2.50  2014  IC50=1.42uM   // 4msu.pdf (2EU) ligand is compound 1
3wyl  2.68  2014  IC50=1.4nM    // 3wyl.pdf (3KB) ligand is compound 20a
4bis  2.49  2014  IC50=1.4uM    // 4bis.pdf (8HQ) in table IC50=1.4uM, in text of pp. 3112, IC50=4uM
4j59  1.92  2014  IC50=1.4uM    // 4j58.pdf (671) compound 28
4nak  1.80  2014  IC50=1.4uM    // 4nak.pdf (PBQ) ligand is compound 4a, assay with 40uM Cd2+
4pnm  2.19  2014  IC50=1.4uM    // 4pml.pdf (NU1) ligand is Nu1025
4hrd  2.80  2014  IC50=1.5nM    // 4hnp.pdf (OV1) ligand is compound 1
4k9g  1.55  2014  IC50=1.5uM    // 4k9g.pdf (1Q1) ligand is ISO-66, named 1Q1
4pnt  1.60  2014  IC50=1.5uM    // 4pml.pdf (IQD) ligand is 1,5-IQD
4u03  2.04  2014  IC50=1.69uM   // 4u03.pdf (TLL) ligand is 5MTHFGLU2
4u0m  2.30  2014  IC50=1.69uM   // 4u03.pdf (TLL) ligand is 5MTHFGLU2
4u0n  2.10  2014  IC50=1.69uM   // 4u03.pdf (TLL) ligand is 5MTHFGLU2
4oyb  1.70  2014  IC50=1.6uM    // 4oya.pdf (1VJ) ligand is compound 7
4uva  2.90  2014  IC50=1.78uM   // 4uv8.pdf (D73) ligand is compound 20a
3wt7  2.40  2014  IC50=1.79nM   // 3wt5.pdf (YA2) ligand is compound 9a
4d09  2.50  2014  IC50=1.7nM    // 4d08.pdf (788) ligand is compound 3
4j3i  1.24  2014  IC50=1.8uM    // 4j1p.pdf (1K0) target is BRD4(BD1)
4knr  2.10  2014  IC50=1.8uM    // 4knr.pdf (1S8) ligand is compound 5c, WG188
4nhx  2.10  2014  IC50=1.9uM    // 4nhk.pdf (OGA) ligand is N-oxalylglycine (NOG)
4obz  2.90  2014  IC50=1.9uM    // 4obz.pdf (2S4) ligand is compound 7
4c1c  1.18  2014  IC50=10.7uM   // 4c1c.pdf (MCO) ligand is D-captopril
4bpj  1.60  2014  IC50=1000nM   // 4bpi.pdf (19-mer) ligand is alpha beta Puma BH3 peptide 3
4nrt  2.02  2014  IC50=1000nM   // 4nrt.pdf (2NG) ligand is compound 6; IC50=1000+/-90nM
4rfy  1.70  2014  IC50=100nM    // 4rfy.pdf (3OU) ligand is compound 1b; Human Whole Blood IC50
4ckr  2.20  2014  IC50=105nM    // 4ckr.pdf (DI1) ligand is compound DDR1-IN-1
4qtd  1.50  2014  IC50=1080nM   // 4qta.pdf (38Z) SCH772984
4d08  1.90  2014  IC50=10nM     // 4d08.pdf (Q2T) ligand is compound 12
4o2e  1.98  2014  IC50=10nM     // 4o2c.pdf (9-mer) ligand is SL9
4qg7  1.67  2014  IC50=10nM     // 4qg7.pdf (32K) ligand is compound 18
4lv4  2.08  2014  IC50=10uM     // 4lv4.pdf (8HC) ligand is HCA
4o7c  1.55  2014  IC50=10uM     // 4o70.pdf (2RK) ligand is SB614067-R
4p74  2.70  2014  IC50=10uM     // 4p71.pdf (2U9) ligand is compound 3a
4pnq  1.85  2014  IC50=10uM     // 4pml.pdf (32X) ligand is 5-AIQ
4j5e   .99  2014  IC50=11.4uM   // 4j58.pdf (7B7) compound 24
4cxy  2.65  2014  IC50=11.8uM   // 4cxy.pdf (DGR) ligand is compound 21
4n8d  1.65  2014  IC50=11.9uM   // 4n8d.pdf (2KS) ligand is compound syn-7aa
4og7  2.08  2014  IC50=114nM    // 4og3.pdf (2SE) ligand is compound 20 (MIV-7); IC50= 114+/-2nM
4nru  2.30  2014  IC50=115nM    // 4nrt.pdf (2NG) ligand compound 6; IC50=115+/-15nM
4pp7  3.40  2014  IC50=11nM     // 4pp7.pdf (2VX) ligand is compound 18; crystal is compound 18 in complex with wt B-Raf; IC50 is V600E mutant B-Raf
4oym  1.70  2014  IC50=11uM     // 4oya.pdf (1ZC) ligand is compound 6
4pl5  3.40  2014  IC50=11uM     // 4pl3.pdf (31L) OICR573 inhibitor; Mouse IRE1-alpha IC50=11+/-9.9uM
4ot6  2.05  2014  IC50=1200nM   // 4ot5.pdf (2V1) ligand is compound 15
4na4  2.50  2014  IC50=120nM    // 4n9y.pdf (A1R) ligand is ADD-HPD
4mwe  2.45  2014  IC50=1231nM   // 4mvw.pdf (2EN) ligand is chem1475
3wk7  2.20  2014  IC50=127uM    // 3wk4.pdf (S0D) ligand is compound 4
4p6e  1.80  2014  IC50=1290nM   // 4p6e.pdf (2FC) ligand is compound 7; IC50=1290+/-453nM
3wv2  2.30  2014  IC50=12nM     // 3wv2.pdf (WGG) ligand is compound 44
4qga  1.94  2014  IC50=12nM     // 4qg7.pdf (31Z) ligand is compound 19
4l7o  2.00  2014  IC50=13.2uM   // 4l6z.pdf (1VD) ligand is compound 18i
4mwc  2.65  2014  IC50=1360nM   // 4mvw.pdf (2EM) ligand is chem1540
4u93  1.55  2014  IC50=13nM     // 4u93.pdf (990) ligand is compound 9
4o0j  2.05  2014  IC50=13uM     // 4o0j.pdf (LF8) ligand is KF115; I N-LEDGF/75 binding IC50=13+/-1.5uM
4o7f  1.80  2014  IC50=13uM     // 4o70.pdf (2RQ) ligand is SB251527
4njd  2.50  2014  IC50=14.47uM  // 4njd.pdf (NJD) KY-04031; LNCap cells Viability IC50=14.47+/-1.26uM; LNCap cells AR luciferase IC50=2.50+/-0.28uM
4l7n  1.80  2014  IC50=14.4uM   // 4l6z.pdf (1VB) ligand is compound 18h
4pkt  2.40  2014  IC50=14.9uM   // 4pkr.pdf (30O) ligand is compound 13; IC50=14.9+/-2.4uM
4w9q  1.08  2014  IC50=140nM    // 4w9o.pdf (3JP) ligand is compound 10
4o91  2.39  2014  IC50=149nM    // 4o91.pdf (NG2) ligand is compound 1
4u6r  2.50  2014  IC50=14nM     // 4u6r.pdf (3E4) ligand is compound 16
4lq9  2.04  2014  IC50=14uM     // 4lq3.pdf (21D) ligand is NAF2
4ok6  2.40  2014  IC50=14uM     // 4ojq.pdf (2T7) ligand is compound 13
4pkr  2.20  2014  IC50=15.2uM   // 4pkr.pdf (2ZL) ligand is compound 10; IC50=15.2+/-0.5uM
4pks  2.30  2014  IC50=15.2uM   // 4pkr.pdf (30H) ligand is compound 11; IC50=15.2+/-0.9uM
4m7x  1.42  2014  IC50=15.7uM   // 4m7x.pdf (27Q) ligand is compound N7-Pan (7)
4lm5  2.25  2014  IC50=150nM    // 4lm5.pdf (Q17) ligand is compound 1
4c8r  2.82  2014  IC50=153nM    // 4c8r.pdf (6YT)
4q9s  2.07  2014  IC50=156uM    // 4q9s.pdf (30G) ligand is compound 1; TR-FRET
3we4  2.00  2014  IC50=15nM     // 3we4.pdf (5FI) ligand is compound PF4078671
4no9  2.90  2014  IC50=15nM     // 4nnn.pdf (2L0) ligand is compound 3
4o13  1.75  2014  IC50=15nM     // 4o13.pdf (2P1) ligand is compound 1(GNE-618); biochemical IC50 =0.015+/-0.004 uMol; NAMPT WT
3wk5  2.77  2014  IC50=15uM     // 3wk4.pdf (S0C) ligand is compound 2
4jln  2.15  2014  IC50=16.7nM   // 4jlj.pdf (18V) ligand is compound F4
4umr  3.00  2014  IC50=160uM    // 4d2p.pdf (QBB) ligand is compound 1
4hnp  2.80  2014  IC50=164.5nM  // 4hnp.pdf (ONK) ligand is compound 4
4mw6  2.56  2014  IC50=1678nM   // 4mvw.pdf (2EE) ligand is chem1476
4p7e  2.40  2014  IC50=17.5uM   // 4p7e.pdf (2HB) ligand is compound 65(GLPG0634); Human Whole Blood Potency
4l23  2.50  2014  IC50=17.9nM   // 4l23.pdf (X6K) ligand is PI103
3wkd  2.48  2014  IC50=171uM    // 3wk4.pdf (S0K) ligand is compound 10
4md6  2.00  2014  IC50=17nM     // 4md6.pdf (24E) ligand is compound 57
4obp  2.27  2014  IC50=17nM     // 4obo.pdf (2QU) ligand is compound 29
4oho  2.58  2014  IC50=17nM     // 4ohk.pdf (2TG) ligand is compound 24
4i9z  2.08  2014  IC50=18.2nM   // 4i9z.pdf (5BA) ligand is compound 10a
4cfm  2.85  2014  IC50=18.2uM   // 4cfm.pdf (4QE) ligand is compound 29
4ph4  2.80  2014  IC50=18nM     // 4ph4.pdf (2UG) ligand is PIK-III
4o71  1.36  2014  IC50=18uM     // 4o70.pdf (CPB) ligand is Flavopiridol
4kpz  2.09  2014  IC50=1950uM   // 4knr.pdf (1SF) ligand is compound 39
3wkc  2.20  2014  IC50=195uM    // 3wk4.pdf (S0J) ligand is compound 9
4og6  1.49  2014  IC50=197nM    // 4og3.pdf (2S9) ligand is compound 13 (MIV-4); IC50= 197+/-24nM
4mw2  2.30  2014  IC50=198nM    // 4mvw.pdf (2E9) ligand is chem1472
4mw1  2.49  2014  IC50=19nM     // 4mvw.pdf (44F) ligand is chem1444
4nan  1.80  2014  IC50=19uM     // 4nak.pdf (2JM) ligand is compound 4e, assay with 40uM Cd2+
4o70  1.55  2014  IC50=19uM     // 4o70.pdf (1QK) ligand is Dinaciclib
4o7a  1.34  2014  IC50=19uM     // 4o70.pdf (2RF) ligand is SB409514
4oyi  1.70  2014  IC50=19uM     // 4oya.pdf (1VK) ligand is compound 4
4wh9  1.50  2014  IC50=1mM      // 4wh7.pdf (3M8) ligand is compound 7
4o6e  1.95  2014  IC50=1nM      // 4o6e.pdf (2SH) ligand is compound 28
4qgg  1.62  2014  IC50=1nM      // 4qg7.pdf (32C) ligand is compound 46
4qgh  1.78  2014  IC50=1nM      // 4qg7.pdf (32E) ligand is compound 47
4rio  2.69  2014  IC50=1nM      // 4rio.pdf (3QX) ligand is compound 5g
4uwk  2.83  2014  IC50=1nM      // 4uwf.pdf (UJB) ligand is compound 15
4l7l  2.10  2014  IC50=1uM      // 4l6z.pdf (1VA) ligand is compound 6j
4occ  1.80  2014  IC50=2.0nM    // 4occ.pdf (2TZ) ligand is compound 48; HTRF IC50 biochemical assay, buffer containing 15% human serum
4cxx  2.76  2014  IC50=2.11uM   // 4cxx.pdf (640) ligand is compound 16
3zmp  2.62  2014  IC50=2.13uM   // 3zmp.pdf (10-mer) ligand is 10-mer Src-derived peptide inhibitor: AC-1
4d2p  2.55  2014  IC50=2.1uM    // 4d2p.pdf (6Z7) ligand is compound 2
4p0n  2.08  2014  IC50=2.2nM    // 4p0n.pdf (1IR/1IS) ligand is compound 24 racemic; IC50=2,2+/-0.1nM
4l70  2.00  2014  IC50=2.2uM    // 4l6z.pdf (1V9) ligand is compoiund 6a
4l7u  2.80  2014  IC50=2.2uM    // 4l6z.pdf (1VC) ligand is compound 19e
4nal  1.80  2014  IC50=2.2uM    // 4nak.pdf (H70) ligand is compound 4b, assay with 40uM Cd2+
4l7b  2.41  2014  IC50=2.3uM    // 4l7b.pdf (1VV) ligand is compound (S,R,S)-1a
4nhy  2.60  2014  IC50=2.3uM    // 4nhk.pdf (PD2) ligand is 2,4-PDCA
4tpm  2.77  2014  IC50=2.4nM    // 4tpm.pdf (35E) ligand is compound 8; IC50=2.4+/-0.7nM
4txe  1.80  2014  IC50=2.4uM    // 4tx6.pdf (38F) ligand is compound 5
4qlt  2.80  2014  IC50=2.5nM    // 4qlq.pdf (39V) ligand is compound 2; belta-5i
4o77  2.00  2014  IC50=2.5uM    // 4o70.pdf (2RE) ligand is SB202190
4tpp  2.65  2014  IC50=2.6nM    // 4tpm.pdf (35D) ligand is compound 47; IC50=2.6+/-0.6nM
4tx6  1.90  2014  IC50=2.6uM    // 4tx6.pdf (38B) ligand is compound 1
4tk0  1.65  2014  IC50=2.8uM    // 4pml.pdf (32Z) ligand is DPQ
4u5j  2.26  2014  IC50=2.93uM   // 4u5j.pdf (RXT) C-src
4x7i  1.77  2014  IC50=20.3nM   // 4x7i.pdf (3YS) ligand is LY2886721
4pyv  2.65  2014  IC50=200nM    // 4pyv.pdf (2XF) ligand is compound 4
4o4k  2.10  2014  IC50=200uM    // 4o24.pdf (2PK) ligand is Mirin; IC50 is estimated to be 200-300 uM chromatin bound RPA;
3wf7  1.85  2014  IC50=206nM    // 3we4.pdf (FS9) ligand is compound F179
4mx1  1.59  2014  IC50=209uM    // 4mx1.pdf (1MX) ligand is compound 13
4o7b  1.50  2014  IC50=20uM     // 4o70.pdf (2RJ) ligand is SB284847-BT
4uy1  2.20  2014  IC50=20uM     // 4uy1.pdf (TJM) ligand is compound 7
3ws8  2.60  2014  IC50=210nM    // 3ws8.pdf (X4C) ligand is compound 14c
4rrs  1.80  2014  IC50=210nM    // 4r5n.pdf (3UY) ligand is compound 51
4r17  2.10  2014  IC50=21nM     // 4r17.pdf (3K4) compound 1; IC50=21+/-2nM; incubated 2h
4r18  2.40  2014  IC50=21nM     // 4r17.pdf (ABA) ligand is compound 1; incubated 6h at PH 6.8; IC50=21+/-2nM
4o75  1.55  2014  IC50=21uM     // 4o70.pdf (2RC) ligand is Fostamatinib
4pkw  1.75  2014  IC50=22.5uM   // 4pkr.pdf (GM6) ligand is compound 17; IC50=22.5+/-1.6uM
4jlm  2.18  2014  IC50=22.7nM   // 4jlj.pdf (1NN) ligand is compound F3
4jvj  2.80  2014  IC50=22nM     // 4jvj.pdf (1MV) ligand is compound 6f, optimized M2 assay
4p73  3.03  2014  IC50=22nM     // 4p71.pdf (GAX) ligand is compound 1a
4c1f  2.01  2014  IC50=23.3uM   // 4c1c.pdf (X8Z) ligand is L-captopril
4k6v  1.50  2014  IC50=23.4uM   // 4k6t.pdf (1P4-18D) compound 12b; consist of 1P4 and three 18D; cell binding assay
4cfv  2.00  2014  IC50=23.6uM   // 4cfm.pdf (75X) ligand is compound 36
3wf8  1.98  2014  IC50=232nM    // 3we4.pdf (F76) ligand is compound F176
4nw7  2.15  2014  IC50=237nM    // 4nw7.pdf (2O5) ligand is compound 8
3wyk  2.50  2014  IC50=23nM     // 3wyk.pdf (3KG) ligand is compound 1
4bfr  2.80  2014  IC50=23nM     // 4bfr.pdf (J82) ligand is compound 28
4lng  1.91  2014  IC50=2400nM   // 4l9p.pdf (JAN) FPP-tipifarnib
4nnw  2.60  2014  IC50=244nM    // 4nnn.pdf (2MK) ligand is compound 2
3w8o  1.85  2014  IC50=24nM     // 3w8m.pdf (WPC) ligand is Iron Phthalocyanine, FE-Pc, include metal atom
3wv3  1.60  2014  IC50=24nM     // 3wv2.pdf (WLL) ligand is compound 7a
4o1d  1.71  2014  IC50=24nM     // 4o13.pdf (DGB) ligand is compound 11(APO866); biochemical IC50 =0.024+/-0.021 uM
4pid  1.59  2014  IC50=24uM     // 4pid.pdf (2UQ) ligand is inhibitor 2
4nrp  1.80  2014  IC50=25.85uM  // 4nrp.pdf (OGA) Mn2+ containing;ligand is N-oxalylglycine
4muk  1.90  2014  IC50=253nM    // 4mq6.pdf (2DV) compound 20
4bzr  1.84  2014  IC50=25nM     // 4bzr.pdf (K26) ligand is compound 1, K-26. data is for aRabbit lung sACE
4o74  1.45  2014  IC50=25nM     // 4o70.pdf (R78) ligand is BI2536
4otg  2.60  2014  IC50=26nM     // 4otg.pdf (2V9) ligand is Lestaurtinib; IC50=26+/-0.7nM; PRK1 wild-type
4rro  1.80  2014  IC50=26nM     // 4r5n.pdf (3UX) ligand is compound 48
4nnn  2.50  2014  IC50=270nM    // 4nnn.pdf (ALD) ligand is compound 1
4lnb  1.75  2014  IC50=275nM    // 4l9p.pdf (ED5) FPP-ED5
4no1  2.50  2014  IC50=27nM     // 4nnn.pdf (CIX) ligand is compound 4
4mvw  2.90  2014  IC50=28nM     // 4mvw.pdf (43E) ligand is chem1433
4ohm  2.40  2014  IC50=28nM     // 4ohk.pdf (2TF) ligand is compound 51
4mx5  1.52  2014  IC50=28uM     // 4mx1.pdf (5MX) ligand is compound 15
4oz3  1.70  2014  IC50=28uM     // 4oya.pdf (1Z8) ligand is compound 5; IC50=28+/-3.8uM
4mvy  2.31  2014  IC50=29nM     // 4mvw.pdf (387) ligand is chem1387
4o28  2.00  2014  IC50=29nM     // 4o13.pdf (1QS) ligand is compound 8(GNE-617); biochemical IC50 =0.029+/-0.010 uM
3wka  2.01  2014  IC50=29uM     // 3wk4.pdf (S0G) ligand is compound 7
4nwk  1.62  2014  IC50=2nM      // 4nwk.pdf (2R8) ligand is compound 35(BMS-605339); GT-1a screen IC50
4o15  1.80  2014  IC50=2nM      // 4o13.pdf (2P1) ligand is compound 1(GNE-618); biochemical IC50 =2+/-0.2nM; NAMPT mutant
4rce  2.40  2014  IC50=2nM      // 4rce.pdf (3LN) ligand is compound 2; IC50=2+/-1nM
4j5c  1.03  2014  IC50=3.0uM    // 4j58.pdf (7I6) compound 30
4pnl  1.50  2014  IC50=3.0uM    // 4pml.pdf (DRL) ligand is DR-2313
4ctj  1.47  2014  IC50=3.12mM   // 4ctj.pdf (3A9) fragment 217 (3A9)
4uvb  2.80  2014  IC50=3.26uM   // 4uv8.pdf (D51) ligand is compound 21a
4knx  1.90  2014  IC50=3.2uM    // 4knr.pdf (1S9) ligand is compound 7b, WG176
4jpa  2.00  2014  IC50=3.3nM    // 4jp4.pdf (AZ6) ligand is compound 5b
4nvq  2.03  2014  IC50=3.3nM    // 4nvq.pdf (2OD) ligand is compound 12(A-366)
4c5w  1.70  2014  IC50=3.3uM    // 4bg1.pdf (NM3) ligand is compound 14
4oq6  1.81  2014  IC50=3.3uM    // 4oq5.pdf (2UV) ligand is compound 36
4osf  1.62  2014  IC50=3.6uM    // 3wnr.pdf (4MT) [Covalent complex] compound 8
4tju  1.57  2014  IC50=3.6uM    // 4pml.pdf (CNQ) ligand is 3,4-CPQ-5-C
4cqe  2.30  2014  IC50=3.7nM    // 4cqe.pdf (CQE) ligand is compound 20
4p2t  2.15  2014  IC50=3.7uM    // 4p2t.pdf (24Q) ligand is compound 3; IC50=3.7+/-0.7uM
4pnc  1.54  2014  IC50=3.7uM    // 4pnc.pdf (7NP) ligand is compound 1; IC50=3.7+/-0.3uM
4lwt  1.60  2014  IC50=3.9uM    // 4lwt.pdf (20Q) ligand is RO5027344, compound 5
4m3d  1.90  2014  IC50=3.9uM    // 4m3b.pdf (2H2) ligand is compound 21
4pku  2.40  2014  IC50=30.0uM   // 4pkr.pdf (30P) ligand is compound 15; IC50=30.0+/-1.0uM
4og5  1.63  2014  IC50=302nM    // 4og3.pdf (2S7) ligand is compound 16 (MIV-5); IC50= 302+/-49nM
4ngh  2.68  2014  IC50=30nM     // 4ngh.pdf (17-mer) ligand is 17-mer SAH-MPER(671-683KKK)(q)pSer peptide
4mw4  2.50  2014  IC50=316nM    // 4mvw.pdf (2EB) ligand is chem1473
4d2w  1.92  2014  IC50=31uM     // 4d2p.pdf (NF5) ligand is compound 5
4ok5  2.15  2014  IC50=31uM     // 4ojq.pdf (2T2) ligand is compound 9
4mwb  2.31  2014  IC50=324nM    // 4mvw.pdf (2EK) ligand is chem1509
4myq  1.90  2014  IC50=32nM     // 4myq.pdf (19T) ligand is A-33
4tk5  2.02  2014  IC50=32nM     // 4pml.pdf (UHB) ligand is EB47
4w7p  2.80  2014  IC50=32nM     // 4w7p.pdf (3J7) ligand is compound 6
4mra  2.34  2014  IC50=33.5uM   // 4mra.pdf (QUE) ligand is QUERCETIN, IC50=20.9, 33.5 or 34.8 uM for GPb from refs
4n7e  2.70  2014  IC50=330nM    // 4n7e.pdf (2JQ) ligand is AF38469
4nat  1.72  2014  IC50=330nM    // 4nah.pdf (2W5) ligand is compound A
3wf6  2.03  2014  IC50=33nM     // 3we4.pdf (FZ9) ligand is compound F109
4d2d  2.52  2014  IC50=340uM    // 4d2b.pdf (3-mer) ligand is tri-Alanine peptide
4bhf  2.05  2014  IC50=343uM    // 4bg1.pdf (MZT) ligand is compound 64
4nrq  2.50  2014  IC50=347.2uM  // 4nrq.pdf (PD2) Mn2+ containing;ligand is pyridine-2,4-dicarboxylate
4r6v  2.35  2014  IC50=35.3nM   // 4qqc.pdf (FI3) ligand is FIIN-3
4npv  2.40  2014  IC50=35nM     // 4npv.pdf (0NK) ligand is compound 7a
4ohp  2.40  2014  IC50=35nM     // 4ohk.pdf (2TJ) ligand is compound 15
4urn  2.30  2014  IC50=35uM     // 4url.pdf (NOV) ligand is Novobiocin
4ov5  2.20  2014  IC50=36.9nM   // 4ov5.pdf (14-mer) ligand is A1L9 peptide; IC50=36.9+/-2.9nM
4qls  2.80  2014  IC50=36nM     // 4qlq.pdf (37Y) ligand is compound 11; belta-5i
4wsk  1.92  2014  IC50=371.6nM  // 4wsk.pdf (3U2) [Covalent complex] [Incomplete ligand] [Nonstandard assay: Temp 37, pH=4.5, McIlvaine buffer=150mM, 0.1% (w/v) BSA] [Different protein in assay: human] compound 4; Structure differs;
4o2f  1.90  2014  IC50=387nM    // 4o2c.pdf (8-mer) ligand is HL8
4oar  2.41  2014  IC50=38pM     // 4oar.pdf (2S0) ligand is UPA-SMRT; IC50=0.038+/-0.011nM
4pl0  2.70  2014  IC50=39.5uM   // 4pl0.pdf (ANP) ligand is AMP-PNP; IC50=39.5+/-0.6uM
4qtc  1.40  2014  IC50=398nM    // 4qta.pdf (38Z) SCH772984
4l2x  2.55  2014  IC50=39nM     // 4jvj.pdf (YL2) ligand is compound 6m, optimized M2 assay
4mw0  2.20  2014  IC50=39nM     // 4mvw.pdf (392) ligand is chem1392
4qsm  3.00  2014  IC50=39nM     // 4qsm.pdf (38K) ligand is compound 2; IC50=0.039+/-0.007uM
4r02  2.50  2014  IC50=39nM     // 4r02.pdf (3E5) ligand is compound 6a; BSc4999 (alpha-Keto Phenylamide); intracellular inhibition
4tlr  1.86  2014  IC50=3nM      // 4tlr.pdf (33H) ligand is compound 22a
4uwh  1.93  2014  IC50=3nM      // 4uwf.pdf (JXM) ligand is compound 4
4wcu  2.35  2014  IC50=3nM      // 4w1o.pdf (3KQ) ligand is compound 15
4p1r  2.24  2014  IC50=4.1nM    // 4p0n.pdf (2KR) ligand is compound 7; IC50=4.1+/-1.5nM
4qyg  1.75  2014  IC50=4.1nM    // 4qye.pdf (3DW) ligand is compound 14
4umq  2.60  2014  IC50=4.2uM    // 4d2p.pdf (B5S) ligand is compound 3
4oow  2.57  2014  IC50=4.3uM    // 4oow.pdf (CAQ) quercetagetin; strain J4 (genotype 1b); IC50=4.3+/-0.7uM
4rcp  1.60  2014  IC50=4.42uM   // 4rcp.pdf (5-mer) ligand is peptide 2(PL-2)
4c1d  1.20  2014  IC50=4.4uM    // 4c1c.pdf (X8Z) ligand is L-captopril
4pyq  1.39  2014  IC50=4.4uM    // 4p7k.pdf (2X1) ligand is ureido-benzamidine
4k6w  1.50  2014  IC50=4.5uM    // 4k6t.pdf (1P0-18D) trivalent sialic acid inhibitor ME0408, compound 12a; consist of 1P0 and three 18D; cell-binding assay
4wgi  1.85  2014  IC50=4.5uM    // 4wgi.pdf (3M6) ligand is compound 7
4o78  1.34  2014  IC50=4.6uM    // 4o70.pdf (SAV) ligand is GW612286X
4m7y  1.80  2014  IC50=4.8uM    // 4m7x.pdf (2GH) ligand is compound N5-Pan (6)
4qag  1.71  2014  IC50=4.8uM    // 4qag.pdf (F95) ligand is F3284-8495; IC50 measured at pH=7.4 with 1 mM Mg2+
4csj  2.30  2014  IC50=4.9nM    // 4csj.pdf (NN7) ligand is compound 30
4m3f  2.00  2014  IC50=4.9uM    // 4m3b.pdf (2D1) ligand is compound 8
4rfz  1.17  2014  IC50=40nM     // 4rfy.pdf (3OV) ligand is compound 4b; Human Whole Blood IC50
4u6x  1.68  2014  IC50=414nM    // 4u6x.pdf (15-mer) ALQDA peptide, ALQDAGDSSRKEYFI; incomplete ligand structure
4oti  1.93  2014  IC50=43nM     // 4otg.pdf (MI1) ligand is Tofacitinib;  IC50=43+/-4nM; PRK1 wild-type
4clz  1.90  2014  IC50=43uM     // 4clk.pdf (4DS) ligand is compound DIDS
4qqc  2.40  2014  IC50=45.3nM   // 4qqc.pdf (37O) ligand is FIIN-2
4qrc  1.90  2014  IC50=452nM    // 4qq5.pdf (0LI) ligand is Ponatinib; BaF3 Cell Viability Assay
4mw5  2.35  2014  IC50=45nM     // 4mvw.pdf (415) ligand is chem1415
4pm0  2.10  2014  IC50=45nM     // 4pm0.pdf (32V) ligand is compound 24
4wsj  1.64  2014  IC50=46.8nM   // 4wsj.pdf (3U3) [Covalent complex] [Incomplete ligand] [Nonstandard assay: Temp 37, pH=4.5, McIlvaine buffer=150mM, 0.1% (w/v) BSA] [Different protein in assay: human] compound 5; Structure differs;
4nk3  1.90  2014  IC50=465nM    // 4nk3.pdf (MK7) ligand is compound 3 (MK-7655)
4nhc  2.91  2014  IC50=46nM     // 4ngh.pdf (17-mer) ligand is 17-mer SAH-MPER(671-683KKK)(q)) peptide
4mao  2.60  2014  IC50=47nM     // 4mao.pdf (28D) ligand is compound 20, RMM58
4qq5  2.20  2014  IC50=482nM    // 4qq5.pdf (37O) ligand is FIN-2; BaF3 Cell Viability Assay
4j8m  1.85  2014  IC50=48nM     // 4j8m.pdf (CJ5) ligand is compound CD532
4rrn  1.80  2014  IC50=48nM     // 4r5n.pdf (3UW) ligand is compound 45
4nah  2.38  2014  IC50=490nM    // 4nah.pdf (2VJ) ligand is compound B; multiple ligands
3wk8  2.20  2014  IC50=49uM     // 3wk4.pdf (S0E) ligand is compound 5
4nw6  1.74  2014  IC50=4nM      // 4nw5.pdf (2NS) ligand is compound 27
4px6  1.60  2014  IC50=4nM      // 4px6.pdf (2X6) ligand is compound 3b
4ra5  2.61  2014  IC50=4nM      // 4ra4.pdf (3L0) ligand is compound11a
4rcf  1.78  2014  IC50=4nM      // 4rce.pdf (3LO) ligand is compound 40; IC50=4+/-1nM; human embryonic kidney cells
4uyn  1.90  2014  IC50=4nM      // 4uyn.pdf (Y3M) ligand is compound 16
4o5b  2.37  2014  IC50=5.03nM   // 4o0j.pdf (LF9) ligand is KF116; I N-LEDGF/75 binding IC50=5.03+/-0.36uM
4o55  2.24  2014  IC50=5.03uM   // 4o0j.pdf (LF9) ligand is KF116; I N-LEDGF/75 binding IC50=5.03+/-0.36uM
4n1u  1.60  2014  IC50=5.0nM    // 4n1t.pdf (2GE) ligand is TH588, compound 3
4wn1  3.13  2014  IC50=5.1nM    // 4wn1.pdf (3SJ) ligand is compound 42b
4u0g  3.20  2014  IC50=5.1uM    // 4u0g.pdf (7-mer) ligand is ADEP-2B5Me; IC50=5.1+/-0.5uM
4l1a  1.90  2014  IC50=5.39nM   // 4l1a.pdf (AB1) ligand is Lopinavir
4pl4  3.00  2014  IC50=5.4uM    // 4pl3.pdf (31K) OICR464 inhibitor; Mouse IRE1-alpha IC50=5.4+/-5.2uM
4pkv  2.50  2014  IC50=5.6uM    // 4pkr.pdf (30R) ligand is compound 16; IC50=5.6+/-3.0uM
4o7e  1.85  2014  IC50=5.7uM    // 4o70.pdf (2RN) ligand is SB610251-B
4mh7  2.51  2014  IC50=5.9uM    // 4mh7.pdf (MH7) ligand is compound 7
4url  2.29  2014  IC50=500nM    // 4url.pdf (XAM) ligand is Kibdelomycin;
4ojq  2.25  2014  IC50=500uM    // 4ojq.pdf (2SX) ligand is compound 1
4rg0  2.50  2014  IC50=50nM     // 4rfy.pdf (3P0) ligand is compound 5b; Human Whole Blood IC50
4cqf  2.30  2014  IC50=50uM     // 4cqf.pdf (9Z8) ligand is compound 1a
4o5g  2.30  2014  IC50=50uM     // 4o24.pdf (2PV) ligand is PFM39; IC50 is estimated to be 50-75 uM chromatin bound RPA;
4o43  2.40  2014  IC50=50uM     // 4o24.pdf (2PW) ligand is PFM03; IC50 is estimated to be 50-75 uM chromatin bound RPA;
4o24  2.30  2014  IC50=50uM     // 4o24.pdf (2Q0) ligand is PFM01; IC50 is estimated to be 50-75 uM chromatin bound RPA;
4pf3  1.10  2014  IC50=51nM     // 4pf3.pdf (HFN) ligand is compound 37a
4bgk  2.18  2014  IC50=520nM    // 4bg1.pdf (RTK) ligand is compound 78
4w9n  1.84  2014  IC50=54.7uM   // 4w9n.pdf (TCL) IC50=54.7+/-1.2uM
4lmu  2.38  2014  IC50=55nM     // 4lmu.pdf (QUE) ligand is quercetin
4q9z  2.60  2014  IC50=55nM     // 4q9s.pdf (PZW) ligand is compound 35
4to8  2.10  2014  IC50=56.9mM   // 4to8.pdf (FLC) CITRATE ANION; IC50=56.9+/-3.5mM
3wf9  2.04  2014  IC50=567nM    // 3we4.pdf (FS7) ligand is compound F177
4og8  1.53  2014  IC50=56nM     // 4og3.pdf (2SF) ligand is compound 19b (MIV-6R); IC50= 56+/-3nM
4mvx  2.55  2014  IC50=57nM     // 4mvw.pdf (C13) ligand is chem1356
4od9  1.90  2014  IC50=58nM     // 4obz.pdf (2RZ) ligand is compound 24
4kcg  2.09  2014  IC50=5nM      // 4kcg.pdf (1QC) IC50 for the DI-39 inhibitor
4nus  2.39  2014  IC50=5nM      // 4nus.pdf (2NK) ligand is LJH685
4ohk  2.80  2014  IC50=5nM      // 4ohk.pdf (2TE) ligand is compound 65
4olh  2.40  2014  IC50=5nM      // 4olh.pdf (2TO) ligand is compound 51
4qo4  1.70  2014  IC50=5nM      // 4qo4.pdf (35S) ligand is compound 16; HTRF IC50 human serum
4wki  1.60  2014  IC50=5nM      // 4wk7.pdf (3PW) ligand is compound 11
4nuf  2.80  2014  IC50=5uM      // 4nuf.pdf (16-mer) EID1 bound to SHP: IC50 ~5-10 uM
2mlm   NMR  2014  IC50=6.11uM   // 2mlm.pdf (2W7) ligand is compound 1a, structure in PDB is an open ring
3wk6  2.10  2014  IC50=6.3uM    // 3wk4.pdf (S0B) ligand is compound 3
4mk0  2.40  2014  IC50=6.3uM    // 4l9i.pdf (29X) ligand is benzolactam derivative CCG-206584, plogIC50=5.2
4qlq  2.40  2014  IC50=6.6nM    // 4qlq.pdf (38N) ligand is compound 8; belta-5i
4mxc  1.63  2014  IC50=6.7nM    // 4mxc.pdf (DWF) compound 3h
4lte  2.71  2014  IC50=60nM     // 4lte.pdf (5-mer) ligand is 5-mer macrocyclic Inhibitor
3wkb  2.20  2014  IC50=61uM     // 3wk4.pdf (S0I) ligand is compound 8
4nrm  2.17  2014  IC50=627.9uM  // 4nrm.pdf (FLC) Mn2+ containing;ligand is acetate
4wz8  2.23  2014  IC50=62nM     // 4wz8.pdf (3W7) ligand is compound 6
4wbo  2.81  2014  IC50=63.10uM  // 4wbo.pdf (ANW) ligand is Amlexanox; pIC50=4.2
4p90  2.49  2014  IC50=64nM     // 4p90.pdf (2K0) ligand is compound 15
4py1  2.16  2014  IC50=64nM     // 4py1.pdf (2YK) ligand is compound 15; IC50 of LRRK2.;tyrosine kinase 2 (Tyk2) ATP-binding site residues are 74% similar to those in LRRK2
4obq  2.19  2014  IC50=65nM     // 4obo.pdf (2QT) ligand is compound 31
4q1s  2.60  2014  IC50=67.9uM   // 4q1s.pdf (2YD) ligand is KM; for y-belta 5 activity
4bpi  1.98  2014  IC50=670nM    // 4bpi.pdf (19-mer) ligand is alpha beta Puma BH3 peptide 2
4fc0  2.95  2014  IC50=69nM     // 4fc0.pdf (0T2) ligand is compound 5
4qgf  1.83  2014  IC50=69nM     // 4qg7.pdf (32B) ligand is compound 38
3whw  2.70  2014  IC50=6nM      // 3whw.pdf (RUX) Ruthenium-based inhibitor, compound 4
4lwv  2.32  2014  IC50=6nM      // 4lwv.pdf (20W) ligand is compound 16, RO5545353
4u0i  2.00  2014  IC50=6nM      // 4u0i.pdf (0LI) ligand is ponatinib; IC50 in vitro
4pce  1.29  2014  IC50=7.0uM    // 4pce.pdf (2N0) ligand is compound 2
4c1g  1.71  2014  IC50=7.2uM    // 4c1c.pdf (MCO) ligand is D-captopril
3wk4  2.11  2014  IC50=7.4uM    // 3wk4.pdf (S0A) ligand is compound 1
4l7c  2.40  2014  IC50=7.4uM    // 4l7b.pdf (1VW) ligand is compound 22
4pci  1.25  2014  IC50=7.5uM    // 4pce.pdf (2NJ) ligand is compound 3
4p6g  1.58  2014  IC50=7.70nM   // 4p6e.pdf (2FZ) ligand is compound 5; IC50=7.70+/-5.85
4puz  2.08  2014  IC50=7.7nM    // 4puz.pdf (CG9) ligand is compound 68(GS-9973)
4no8  2.70  2014  IC50=70nM     // 4nnn.pdf (2LV) ligand is compound 6
3wk9  2.20  2014  IC50=70uM     // 3wk4.pdf (S0F) ligand is compound 6
4ok3  2.30  2014  IC50=71uM     // 4ojq.pdf (2SY) ligand is compound 7
4jlj  2.00  2014  IC50=745.7nM  // 4jlj.pdf (1NM) ligand is compound F1
4wk7  1.24  2014  IC50=74nM     // 4wk7.pdf (3PQ) ligand is compound 1
4r5n  1.80  2014  IC50=76nM     // 4r5n.pdf (3J9) ligand is compound 50
4rj6  2.70  2014  IC50=76nM     // 4rj3.pdf (3R0) ligand is compound 4
4ia0  2.17  2014  IC50=77nM     // 4i9z.pdf (5BB) ligand is compound 2e
4obo  2.10  2014  IC50=77nM     // 4obo.pdf (2QV) ligand is compound 22
4no6  3.00  2014  IC50=780nM    // 4nnn.pdf (2M1) ligand is compound 5
4uyd  1.37  2014  IC50=79.43uM  // 4uyd.pdf (V1T) ligand is compound 1; pIC50=4.1
4lxb  1.61  2014  IC50=7nM      // 4loy.pdf (7R9) ligand is compound 58
4ona  2.40  2014  IC50=7nM      // 4ona.pdf (UW1) ligand is compound 26
4op3  2.82  2014  IC50=7nM      // 4op3.pdf (2UY) ligand is compound 39; IC50=0.007+/-0.002uM
4uwf  2.99  2014  IC50=7nM      // 4uwf.pdf (EUT) ligand is compound 2
4uwg  2.70  2014  IC50=7nM      // 4uwf.pdf (RBQ) ligand is compound 3
4qlu  2.80  2014  IC50=8.3nM    // 4qlq.pdf (38X) ligand is compound 9; belta-5i
4twd  3.20  2014  IC50=8.3uM    // 4twd.pdf (377) ligand is Memantine
4cfx  3.50  2014  IC50=8.7uM    // 4cfm.pdf (G6T) ligand is compound 44
4c1h  1.10  2014  IC50=80.4uM   // 4c1c.pdf (X8Z) ligand is L-captopril
4p75  2.96  2014  IC50=80uM     // 4p71.pdf (2NM) ligand is compound 4a
3wf5  2.10  2014  IC50=81nM     // 3we4.pdf (FZ8) ligand is compound F108
4p72  2.62  2014  IC50=82uM     // 4p71.pdf (2NL) ligand is compound 2a
4u6y  1.47  2014  IC50=83nM     // 4u6x.pdf (15-mer) FLNKD peptide, FLNKDLEVDGHFVTM
4v25  2.60  2014  IC50=84nM     // 4v25.pdf (SZ6) ligand is VER-246608
4oc6  2.64  2014  IC50=85nM     // 4obz.pdf (2S1) ligand is compound 2
4nwm  2.03  2014  IC50=8nM      // 4nwm.pdf (2P5) ligand is compound 20
4oq3  2.30  2014  IC50=8nM      // 4oq3.pdf (2V8) ligand is compound 7; TR-FRET IC50
4p10  2.00  2014  IC50=8nM      // 4p10.pdf (2B8) ligand is compound 5; wild type TAFIa for biological experiments
4u44  2.43  2014  IC50=8nM      // 4u43.pdf (3D9) ligand is compound 16
4ogv  2.20  2014  IC50=9.0nM    // 4occ.pdf (2U7) ligand is compound 49; HTRF IC50, buffer containing 15% human serum
4n00  1.80  2014  IC50=9.5nM    // 4n00.pdf (2EX) ligand is compound 62
4rlk  1.24  2014  IC50=9.5uM    // 4rlk.pdf (E91)
4rll  1.85  2014  IC50=9.5uM    // 4rlk.pdf (E91)
4l7r  2.20  2014  IC50=9.6uM    // 4l6z.pdf (M00) ligand is compound 19c
4bhi  2.15  2014  IC50=90nM     // 4bg1.pdf (RUJ) ligand is compound 98
3ws9  2.99  2014  IC50=92nM     // 3ws8.pdf (X4D) ligand is compound 14d
4tpt  2.60  2014  IC50=92nM     // 4tpt.pdf (35H) ligand is compound 22
4rj3  1.63  2014  IC50=93nM     // 4rj3.pdf (3QS) ligand is compound 8
4mw9  2.65  2014  IC50=96nM     // 4mvw.pdf (2EJ) ligand is chem1478
4uzh  2.00  2014  IC50=9800nM   // 4uyn.pdf (JVE) ligand is compound 1
4pmt  2.10  2014  IC50=997nM    // 4pmm.pdf (31Y) ligand is compound 1
4oth  1.80  2014  IC50=9nM      // 4otg.pdf (DRN) ligand is Ro-31-8220; IC50=9+/-3nM; PRK1 wild-type
4urm  2.94  2014  IC50=9nM      // 4url.pdf (XAM) ligand is Kibdelomycin;
4mw7  2.75  2014  IC50>10000nM  // 4mvw.pdf (2EF) ligand is chem1469
4oz2  2.10  2014  IC50>1000uM   // 4oya.pdf (1Z6) ligand is compound 1
4oyp  2.28  2014  IC50>1000uM   // 4oya.pdf (BZ2) ligand is compound 2
4cfu  2.20  2014  IC50>100uM    // 4cfm.pdf (2WC) ligand is compound 37
4tuh  1.80  2014  IC50>100uM    // 4tuh.pdf (38H) ligand is compound 10
4ctk  1.53  2014  IC50>10mM     // 4ctj.pdf (SVN) fragment 97 (2A4)
4oyo  1.75  2014  IC50>300uM    // 4oya.pdf (1WC) ligand is compound 3
4pns  1.65  2014  IC50>30uM     // 4pml.pdf (32Y) ligand is INH2BP
4pml  1.87  2014  IC50>30uM     // 4pml.pdf (3AB) ligand is 3-AB
4pnn  1.65  2014  IC50>30uM     // 4pml.pdf (JPZ) ligand is 4-HQN
4j58  1.28  2014  IC50>500uM    // 4j58.pdf (53Z) compound 23
4wh7  1.62  2014  IC50>5mM      // 4wh7.pdf (8H8) ligand is compound 1
4waf  2.39  2014  IC50>=10uM    // 4waf.pdf (3K6) ligand is compound 4; IC50>=10uM
4n8r  2.03  2014  IC50~10uM     // 4n5g.pdf (K08) ligand is K8008, IC50 is estimated value
4n5g  2.11  2014  IC50~10uM     // 4n5g.pdf (K09) ligand is K8012, IC50 is estimated value
4o7d  2.30  2014  IC50~1mM      // 4o7d.pdf (ONL) ligand is DON
4pyn  1.20  2014  IC50~30uM     // 4p7k.pdf (SAH)
4pyo  2.10  2014  IC50~30uM     // 4p7k.pdf (SAH)
4ojr  1.82  2014  IC50~38nM     // 4ojr.pdf (2SQ) ligand is GSK1264; IN F815K mutant
4p1u  2.52  2014  Kd<0.003uM    // 4nce.pdf (21G) ligand is compound 2, VX787
4lj3  1.70  2014  Kd<1nM        // 4lj3.pdf (C2E) substrate c-di-GMP and Ca++, MST assay, Kd <=1nM
4nb3  1.35  2014  Kd=0.022uM    // 4nb3.pdf (15-mer) ligand is 3,4 dichlorophenylalanine ATRIP derived peptide 33
4qyy  1.65  2014  Kd=0.05uM     // 4qyy.pdf (3G7) compound 4; unphosphorylated ERK2 (apo ERK2); TdF
4mo4  1.67  2014  Kd=0.06mM     // 4mo4.pdf (ACP)
4w97  1.60  2014  Kd=0.08uM     // 4w97.pdf (UCA) ligand is HIP-CoA; Kd=0.08+/-0.01uM
4ncm  2.82  2014  Kd=0.10uM     // 4nce.pdf (704) ligand is compound 3
4cg8  1.75  2014  Kd=0.11uM     // 4cg8.pdf (G8S) compound14
4po0  2.73  2014  Kd=0.12uM     // 4or0.pdf (NPS) Kd=0.12-0.20uM; fluorometric assay
4u0e  2.04  2014  Kd=0.12uM     // 4u0a.pdf (1B0) PF74; -DTT
4wm9  2.40  2014  Kd=0.12uM     // 4wm9.pdf (NXL) ligand is avibactam
4u0s  2.49  2014  Kd=0.158uM    // 4u04.pdf (ADP) Kd=0.158+/-0.021uM
4nzo  1.90  2014  Kd=0.17uM     // 4nzm.pdf (2OV) ligand is 2,5-di-O-Bn-InsP4
4w9h  2.10  2014  Kd=0.185uM    // 4w9c.pdf (3JF) ligand is 7; Kd=0.185+/-0.006uM
4oyk  2.00  2014  Kd=0.18uM     // 4oyk.pdf (19-mer) ligand is a Ubiquitin thioesterase peptide(49-67); binding to HOIP wt; Kd=0.18+/-0.084uM
4o0a  1.20  2014  Kd=0.19uM     // 4o0a.pdf (2P9) ligand is compound 8
4txc  1.95  2014  Kd=0.24uM     // 4txc.pdf (38G) ligand is compound 6; Kd=0.24+/-0.09uM
4q3s  2.11  2014  Kd=0.26uM     // 4q3q.pdf (X7A) SmARG-ABHPE; Kd=0.26+/-0.02uM; PH=8.5
4qnb  2.00  2014  Kd=0.26uM     // 4qnb.pdf (1B0) ligand is PF74; Kd=0.26+/-0.09uM
4w9k  2.10  2014  Kd=0.291uM    // 4w9c.pdf (3JO) ligand is 14; Kd=0.291+/-0.02uM
4p0b  2.70  2014  Kd=0.29uM     // 4p0a.pdf (10-mer) Injectant:HOIP PUB 550uM ; Cell:OTULIN 50 uM;
4uu8  2.90  2014  Kd=0.29uM     // 4utn.pdf (9-mer) ligand is 3,3-dimethyl- succinylated CPS1-peptide 5c; Kd=0.29+/-0.04uM
4qab  2.98  2014  Kd=0.2nM      // 4qaa.pdf (KK2) ligand is compound 32; Kd=0.0002+/-0.0001uM
4v05  2.57  2014  Kd=0.2nM      // 4uxq.pdf (66T) ligand is AZD4547; Kd=0.2+/-0.01nM
4m13  1.85  2014  Kd=0.2uM      // 4m0y.pdf (1E0) ligand is compound 8, Kd1: allosteric pocket, Kd2: ATP pocket
4m14  1.55  2014  Kd=0.2uM      // 4m0y.pdf (QWS) ligand is compound 9, Kd1: allosteric pocket, Kd2: ATP pocket
4tzm  2.30  2014  Kd=0.2uM      // 4tzm.pdf (16-mer) ligand is HTP-3 closure motif1
4mg8  1.85  2014  Kd=0.33uM     // 4mg5.pdf (27J) ligand is compound alpha-zearalanol
4pvv  2.50  2014  Kd=0.33uM     // 4o1g.pdf (HO4) ligand is compound 1a; IC50=0.33+/-0.02uM
4q0a  1.90  2014  Kd=0.33uM     // 4q0a.pdf (4OA) ligand is LCA; Kd=0.33+/-0.26uM; direct titration: Kd 0.3 and 9.5 uM for the first and the second binding events
4q3t  2.14  2014  Kd=0.33uM     // 4q3q.pdf (HAR) SmARG-NOAH; Kd=0.33+/-0.09uM; PH=8.5;the first binding site
4psx  2.51  2014  Kd=0.34uM     // 4psw.pdf (15-mer)
4m0y  1.70  2014  Kd=0.35uM     // 4m0y.pdf (M0Y) ligand is compound 1, Kd1: allosteric pocket, Kd2: ATP pocket
4q3u  2.50  2014  Kd=0.36uM     // 4q3q.pdf (NNH) SmARG-nor NOAH; Kd=0.36+/-0.08uM; PH=8.5
4qaa  2.70  2014  Kd=0.36uM     // 4qaa.pdf (KK1) ligand is compound 15; Kd=0.36+/-0.03uM
4d3h  2.00  2014  Kd=0.37uM     // 4d3h.pdf (2BA) ligand is compound c-di-AMP
4c1w  1.84  2014  Kd=0.39nM     // 4c1w.pdf (SLT)
4tzn  3.12  2014  Kd=0.3uM      // 4tzm.pdf (16-mer) ligand is HTP-3 motif-6
4tzq  2.30  2014  Kd=0.3uM      // 4tzm.pdf (17-mer) ligand is HTP-3 motif-1
4qnu  2.60  2014  Kd=0.40uM     // 4qnu.pdf (GEK) ligand is Cx-SaM; crystal space P21212
4mg7  2.15  2014  Kd=0.44uM     // 4mg5.pdf (27H) ligand is compound ferutinine
4nbl  1.76  2014  Kd=0.47uM     // 4n6g.pdf (2J6) ligand is compound 12
3wha  1.30  2014  Kd=0.48nM     // 3wha.pdf (WHA) ligand is compound 16l
4mgc  2.15  2014  Kd=0.48uM     // 4mg5.pdf (27M) ligand is compound benzophenone-2, BP-2
4qac  2.10  2014  Kd=0.4nM      // 4qaa.pdf (KK3) ligand is compound 33; Kd=0.0004+/-0.0002uM
4cga  1.74  2014  Kd=0.4uM      // 4cg8.pdf (QLW) ligand is compound 5
4o3u  3.04  2014  Kd=0.4uM      // 4o3t.pdf (15-mer) ZAP2.3; Kd=0.4+/-0.3uM
4p00  3.20  2014  Kd=0.4uM      // 4p00.pdf (C2E) UDP-bound complex; c-di-GMP binds to WT BcsA-B; Kd=0.4+/-0.04uM
4p02  2.65  2014  Kd=0.4uM      // 4p00.pdf (C2E) UDP-free complex; c-di-GMP binds to WT BcsA-B; Kd=0.4+/-0.04uM
4lj5  2.40  2014  Kd=0.51uM     // 4lj5.pdf (ADP)
4n84  2.50  2014  Kd=0.51uM     // 4n7g.pdf (10-mer) ligand is a 12-carbon-linker cyclic peptide derived from ExoS, Beta-SS-12
4n7u  1.46  2014  Kd=0.51uM     // 4n7u.pdf (2JA) ligand is compound cHDMAPP
2mkr   NMR  2014  Kd=0.54uM     // 2mkr.pdf (13-mer) ligand is 13-mer Acidic Transactivation Domain of Epstein-Barr nuclear antigen 2 (EBNA2)
4q3r  2.17  2014  Kd=0.54uM     // 4q3q.pdf (XA2) SmARG-ABHDP; Kd=0.54+/-0.08uM; PH=8.5
4r4i  1.40  2014  Kd=0.54uM     // 4r4i.pdf (3HV) ligand is compound 7j; Kd= 0.54+/- 0.2uM
4n7y  2.16  2014  Kd=0.55uM     // 4n7g.pdf (11-mer) ligand is a 8-carbon-linker cyclic peptide derived from ExoS, Beta-RS-8
4r4t  1.28  2014  Kd=0.55uM     // 4r4t.pdf (3J0) ligand is compound 7f; Kd= 0.55+/- 0.1uM
4w9j  2.20  2014  Kd=0.588uM    // 4w9c.pdf (3JH) ligand is 13; Kd=0.588+/-0.04uM
4np3  1.61  2014  Kd=0.5mM      // 4mrd.pdf (2L2) ligand is compound 5a
4oag  2.00  2014  Kd=0.5uM      // 4oag.pdf (ADP) Kd=0.5+/-0.008uM
4pow  1.55  2014  Kd=0.5uM      // 4pow.pdf (OP1) ligand is pyronopaline; Kd=0.5+/-0.07uM
4cg9  1.83  2014  Kd=0.62uM     // 4cg8.pdf (GQG) ligand is compound 12
4q6e  1.12  2014  Kd=0.667uM    // 4q6d.pdf (KR5) ligand is compound 18
3w9r  1.90  2014  Kd=0.66uM     // 3w9r.pdf (A8S) ligand is (+)-ABA
4pfu  2.05  2014  Kd=0.67uM     // 4pft.pdf (MAB) ligand is Mannobiose
4ktu  1.35  2014  Kd=0.685uM    // 4kts.pdf (14-mer) ligand is microviridin J peptide, at PH 6.5
4pn1  2.80  2014  Kd=0.68uM     // 4pn1.pdf (18-mer) ligand is from Spt5 CTD; Kd=0.68+/-0.10uM
4kxl  1.69  2014  Kd=0.6uM      // 4kxl.pdf (6C6) ligand is compound 7
4msl  2.70  2014  Kd=0.70uM     // 4msl.pdf (2ET) ligand is compound AF40431
4utr  2.90  2014  Kd=0.70uM     // 4utn.pdf (9-mer) ligand is glutarylated CPS1-peptide 6a;  Kd=0.70+/-0.11uM
4utn  3.00  2014  Kd=0.71uM     // 4utn.pdf (9-mer) ligand is succinylated CPS1-peptide 5a; Kd=0.71+/-0.05uM
4m7j  1.95  2014  Kd=0.781uM    // 4m7j.pdf (3-mer) ligand is  Kdo(2.8)Kdo(2.4)Kdo trisaccharide
2mg5   NMR  2014  Kd=0.7uM      // 2mg5.pdf (16-mer) ligand is eNOSpThr495 Peptide, assay with 0.225 uM free Ca2+
4uu7  3.00  2014  Kd=0.83uM     // 4utn.pdf (9-mer) ligand is 3-methyl- succinylated CPS1-peptide 5b; Kd=0.83+/-0.17uM
4oo9  2.60  2014  Kd=0.86nM     // 4oo9.pdf (2U8) Kd=0.86+/-0.04nM
4pxf  2.75  2014  Kd=0.8mM      // 4pxf.pdf (11-mer) ligand is ArrFL-1; light-activated Rhodopsin meta II
4kxn  1.90  2014  Kd=0.8uM      // 4kxl.pdf (6K6) ligand is compound 5
4ocp  1.94  2014  Kd=0.8uM      // 4ock.pdf (ADP) ligand is ADP; Kd=0.8+/-0.1uM
4pd8  2.75  2014  Kd=0.94uM     // 4pb1.pdf (P0C) ligand is pyrrolo-cytidine; Kd=0.94+/-0.17uM
4qxr  2.37  2014  Kd=0.99uM     // 4qxo.pdf (1YE) ligand is DMXAA; hSTING(S162A/G230I/Q266I)
2mwp   NMR  2014  Kd=0.9uM      // 2mwo.pdf (12-mer) ligand is a 12-mer p53K382me2 peptide
4m12  2.15  2014  Kd=0.9uM      // 4m0y.pdf (1YZ) ligand is compound 7, Kd1: allosteric pocket, Kd2: ATP pocket
4qfs  3.55  2014  Kd=0.9uM      // 4qfg.pdf (32H) ligand is Br2-A769662 core; Kd=900+/-200nM
2mow   NMR  2014  Kd=1.09uM     // 2mow.pdf (12-mer) ligand is 12-mer Trf4p NIM peptide
4l3o  2.52  2014  Kd=1.0uM      // 4l3o.pdf (16-mer) ligand is 16-mer cyclic peptide S2iL5, assay temp=10C
4p3h  1.45  2014  Kd=1.0uM      // 4p2t.pdf (25G) ligand is compound 2; IC50=1.0+/-0.1uM
4w9i  2.40  2014  Kd=1.10uM     // 4w9c.pdf (3JS) ligand is 10; Kd=1.10+/-0.07uM
4qh7  1.83  2014  Kd=1.14uM     // 4qh7.pdf (12-mer) Ana2 peptide 1; Kd=1.14+/-0.07uM
4pz8  3.10  2014  Kd=1.19uM     // 4pz6.pdf (18-mer) ligand is Spt5-CDT; Kd=1.19+/-0.37uM
4mrg  1.69  2014  Kd=1.1mM      // 4mrd.pdf (24W) ligand is compound 3
4cki  2.12  2014  Kd=1.1uM      // 4cki.pdf (ADN) ligand is ADENOSINE
4csd  1.35  2014  Kd=1.23uM     // 4csd.pdf (MFU) ligand is alpha-MeFuc
4onf  2.00  2014  Kd=1.2nM      // 4onf.pdf (7-mer) ligand is Amyloid belta1-10 peptide
4rdn  2.10  2014  Kd=1.2uM      // 4rdn.pdf (6MD) Kd=1.2+/-0.1uM
4u0f  2.22  2014  Kd=1.2uM      // 4u0a.pdf (3A8) BI-2; -DTT
4cfl  1.32  2014  Kd=1.33uM     // 4cfk.pdf (8DQ) ligand is compound LY303511
4mga  1.80  2014  Kd=1.37uM     // 4mg5.pdf (27L) ligand is compound 4-tert-octylphenol, 4-OP
4ouj  1.46  2014  Kd=1.39mM     // 4ouj.pdf (LBT) ligand is B-lactose; Kd=1.39+/-0.17mM, PH=8.0
4psh  2.60  2014  Kd=1.3nM      // 4psh.pdf (ARG) Kd= 1.3+/-0.9nM
2mpm   NMR  2014  Kd=1.3uM      // 2mpm.pdf (16-mer) ligand is 16-mer peptide of 8-23 of CCR3, Su1617
4q3q  2.00  2014  Kd=1.3uM      // 4q3q.pdf (ABH) SmARG-ABH; Kd=1.3+/-0.2uM; PH=8.5
4tkn  3.00  2014  Kd=1.3uM      // 4tkn.pdf (19-mer) KRIT1- NPXF2;ligand is 19-mer peptide from Krev interaction trapped protein 1; Kd=1.3+/-0.3uM
4wk1  1.98  2014  Kd=1.3uM      // 4wk1.pdf (2BA) ligand is c-di-AMP; Kd=1.3+/-0.07uM
4qdk  1.70  2014  Kd=1.4uM      // 4qdk.pdf (SAH) ligand is SAH;Kd=1.4+/-0.1uM(wild-type); Kd=8.1+/-0.2uM(H139N mutant);Kd=31.0+/-1.7uM(H139Q mutant)
4rww  1.60  2014  Kd=1.4uM      // 4rww.pdf (2BA) ligand is Cyclic-di-AMP (c-di-AMP)
4oys  2.90  2014  Kd=1.52nM     // 4oys.pdf (1TT) ligand is compound SAR405; Kd=1.52+/-0.77nM
4u0u  2.98  2014  Kd=1.52uM     // 4u04.pdf (ADP) protein is wild type; Kd=1.52+/-0.14uM
4jmg  1.40  2014  Kd=1.5nM      // 4jmg.pdf (13-mer) ligand is  Ptpn11_pY580 peptide
4lj8  2.10  2014  Kd=1.5uM      // 4lj5.pdf (ADP)
4r4o  1.33  2014  Kd=1.5uM      // 4r4o.pdf (3HW) ligand is compound 7e; Kd= 1.5+/- 0.3uM
4rqk  1.55  2014  Kd=1.5uM      // 4rqk.pdf (R1S) ligand is RS1
4oee  1.50  2014  Kd=1.73uM     // 4oee.pdf (GNX-IDY) ligand is S3I2; Kd=1.73+/-0.31uM
4mn3  1.54  2014  Kd=1.77uM     // 4mn3.pdf (7-mer) ligand is compound 11
4lbo  1.65  2014  Kd=1.7uM      // 4lbl.pdf (3-mer) ligand is GM3: SIA-2-3-Gal-beta-1-4-Glc
4q9o  2.20  2014  Kd=1.7uM      // 4q9m.pdf (2ZW) ligand is UK-106051; Kd=1.7+/-0.3 uM
4ndu  1.30  2014  Kd=1.8mM      // 4ndu.pdf (AMG) ligand is alpha-methylgalactoside, data from Goldstein et al. 2007
4d1d  3.70  2014  Kd=1.8uM      // 4d1a.pdf (5ND/5NL) ligand is D-NMH, R-S mixture in crystal structure 5ND and 5NL
4o2a  2.50  2014  Kd=1.8uM      // 4o2a.pdf (2RR) ligand is BAL27862; Kd=1.8+/-0.5uM
4qq4  1.75  2014  Kd=1.8uM      // 4o62.pdf (16-mer) ligand is peptide H3K4me3
4qxq  2.42  2014  Kd=1.99uM     // 4qxo.pdf (1YE) ligand is DMXAA; hSTING(S162A/Q266I)
4tv3  2.85  2014  Kd=1.9nM      // 4tv3.pdf (ML9) PIK3-alpha isolated delta-ABD-LBS subunit; PF-04691502; Kd=1.9+/-0.1nM; Temp 10
3wp0  2.04  2014  Kd=10.2uM     // 3wp0.pdf (15-mer) ligand is a phosphor-Lgl2a peptide
4w9d  2.20  2014  Kd=10.2uM     // 4w9c.pdf (3JK) ligand is 3; Kd=10.2+/-0.50uM
4qc1  1.99  2014  Kd=10.35uM    // 4q6f.pdf (11-mer) ligand is H3K14ac peptide
4tsx  1.94  2014  Kd=10.3uM     // 4tsx.pdf (LF0) BI-D; Kd=10.3+/-2.3uM
4c3k  3.10  2014  Kd=10.6uM     // 4c3k.pdf (ADP) ITC Kd for binding site 1
4ozl  1.49  2014  Kd=10.6uM     // 4ozj.pdf (AMP)
4ibc  1.75  2014  Kd=1049uM     // 4ibb.pdf (12G) ligand is compound GA246, estimate Kd value
4ibg  1.41  2014  Kd=108.0uM    // 4ibb.pdf (1D6) ligand is compound VPL48
4nj9  1.95  2014  Kd=108nM      // 4nj9.pdf (2M9) ligand is MPTS
4qsu  1.90  2014  Kd=10mM       // 4qsu.pdf (TDR) ligand is Thymine
4qsv  1.90  2014  Kd=10mM       // 4qsv.pdf (THM) ligand is Thymidine
4o2c  1.80  2014  Kd=10nM       // 4o2c.pdf (10-mer) ligand is NAc-SL9
4poh  2.30  2014  Kd=10nM       // 4poh.pdf (2VR) ligand is compound 4; Kd=10+/-1nM
4oi6  2.04  2014  Kd=10uM       // 4oi6.pdf (CIT)
4c16  1.93  2014  Kd=11.04uM    // 4c16.pdf (4-mer) ligand is GAL-FUC-Q6Z-4WC, glycomimetic compound 1
4nmv  1.40  2014  Kd=11.1uM     // 4nmo.pdf (10-mer) ligand is peptide iCAL36(BRB-K-1); Kd=11.1+/-3.9uM
4mrf  1.55  2014  Kd=11.2mM     // 4mrd.pdf (2CK) ligand is compound 2
4nms  1.70  2014  Kd=11.4uM     // 4nmo.pdf (10-mer) ligand is peptide iCAL36(FLB-K-1); Kd=11.4+/-3.7uM
4p4s  3.30  2014  Kd=11.5uM     // 4p4s.pdf (GCP) ligand is GMPPCP
4qht  2.56  2014  Kd=11.5uM     // 4qht.pdf (ANP) ligand is AMP-PNP
4rpn  2.27  2014  Kd=110nM      // 4rpn.pdf (PCI) ligand is PCP; Kd1=110nM
4ce3  2.31  2014  Kd=110uM      // 4ce1.pdf (L4V) ligand is compound 27d
4q4s  1.25  2014  Kd=111.6nM    // 4q4o.pdf (S98) ligand is compound 4a; Kd=111.6+/-11.8nM
4wk2  2.50  2014  Kd=115nM      // 4wjk.pdf (6-mer) binding data measured in 5 mM Mg2+ and absence of Ca2+, ligand is GRGDSP linear peptide
4kva  2.14  2014  Kd=115uM      // 4kv9.pdf (GTP) 1,15 or 1.15 x 10-4M, author's problem
4k10  2.30  2014  Kd=119.5nM    // 4jzb.pdf (NI9) ligand is 46I, complex is LmFPPS-46I-Mg2+
4r7m  2.85  2014  Kd=11nM       // 4r5t.pdf (3MW) ligand is compound 13m
4lbl  1.58  2014  Kd=11uM       // 4lbl.pdf (3-mer) ligand is GM3: SIA-2-3-Gal-beta-1-4-Glc
4phu  2.33  2014  Kd=12.04nM    // 4phu.pdf (2YB) TAK-875; hGPR40 mutant L42A,F88A,G103A,Y202F with GS linker Kd=12.04+/-0.9nM
4mrh  1.12  2014  Kd=12.6mM     // 4mrd.pdf (2CQ) ligand is compound 4
4qh8  1.90  2014  Kd=12.8uM     // 4qh7.pdf (13-mer) Ana2 peptide 2; Kd=12.8+/-1.5uM
4u4s  1.90  2014  Kd=1200uM     // 4u4s.pdf (3C1) ligand is compound 6; Kd=1200+/-40uM
4pd7  2.91  2014  Kd=120uM      // 4pb1.pdf (ZE8) ligand is zebularine; Kd=120+/-5uM
4pz5  1.96  2014  Kd=121nM      // 4pz5.pdf (16-mer) Fibronectin-binding protein BBK32; Kd=121+/-26.3nM
4n9c  1.75  2014  Kd=126uM      // 4n9b.pdf (2ZM) ligand is compound 24
4q0k  1.34  2014  Kd=13.4uM     // 4psb.pdf (GA3) Kd=13.4+/-0.5uM (pH=5.5)
4nl1  2.30  2014  Kd=130uM      // 4nhv.pdf (Z13) ligand is compound 11; Kd= 130+/-1uM
4prb  1.75  2014  Kd=131.5uM    // 4pr5.pdf (11-mer) HPVG-A4; Kd=131.5+/-0.5uM
4wvl  2.41  2014  Kd=131nM      // 4wvl.pdf (3US) ligand is compound 1
4k43  2.90  2014  Kd=132nM      // 4k41.pdf (1PO) ligand is compound GC-04
4rvr  1.98  2014  Kd=136nM      // 4ir3.pdf (3WQ) compound 19, GSK2801, ITC data is available
4nbk  1.94  2014  Kd=136uM      // 4n6g.pdf (2J5) ligand is compound 6
4pd5  2.91  2014  Kd=1370uM     // 4pb1.pdf (GEO) ligand is gemcitabine; Kd=1370+/-430uM
4m8e  2.40  2014  Kd=13nM       // 4m8e.pdf (29V) ligand is (S)-1
4l9i  2.32  2014  Kd=13uM       // 4l9i.pdf (8PR) ligand is paroxetine, biolayer interferometry
4pnu  1.90  2014  Kd=13uM       // 4ovf.pdf (2VD) compound 5l; ITC data is available
4pgh  2.80  2014  Kd=13uM       // 4pgh.pdf (SAM) Kd=13+/-2uM (pH=6.5)
4wj7  2.75  2014  Kd=13uM       // 4wj7.pdf (13-mer) ligand is KRIT1 NPxY/F3; Kd=13+/-2.5uM
3wp1  2.80  2014  Kd=14.1uM     // 3wp0.pdf (17-mer) ligand is a phosphor-Lgl2c peptide
4nmt  1.40  2014  Kd=14.1uM     // 4nmo.pdf (10-mer) ligand is peptide iCAL36(TFA-K-1); Kd=14.1+/-2.0uM
4ckj  1.65  2014  Kd=14.3uM     // 4cki.pdf (ADN) ligand is ADENOSINE
4m5j  1.70  2014  Kd=14.5uM     // 4m5g.pdf (YH5) ligand is compound 7
4kif  2.50  2014  Kd=14.6uM     // 4kib.pdf (PPY) ligand is phenylpyruvic acid
4uof  2.10  2014  Kd=14.6uM     // 4uof.pdf (DAT) ligand is dADP
4nmo  1.40  2014  Kd=14.9uM     // 4nmo.pdf (10-mer) ligand is iCAL36(Ac-K-1) peptide; Kd=14.9+/-5.8uM
4w50  2.42  2014  Kd=1400nM     // 4w4z.pdf (12-mer) ligand is APY peptide
4qtn  2.80  2014  Kd=142nM      // 4qtn.pdf (NNR) Kd=142+/-96nM
4ce2  2.38  2014  Kd=144uM      // 4ce1.pdf (BO5) ligand is compound 27b
4pul  1.65  2014  Kd=146.1nM    // 4puj.pdf (2WU) ligand is compound 2; Kd=146.1+/-25.6nM; TGT mutant Asp102Asn
4kv9  1.93  2014  Kd=146uM      // 4kv9.pdf (GDP) 1,46 or 1.46 x 10-4M, author's problem
4u91  2.00  2014  Kd=149nM      // 4u90.pdf (11-mer) ligand is 3d; Kd=149+/-23nM
4pg3  2.70  2014  Kd=14nM       // 4pg3.pdf (KRS) ligand is cladosporin; Kd=14+/-1.4nM
4qlv  2.90  2014  Kd=14nM       // 4qlq.pdf (39Q) ligand is compound 17; belta-5i
4ovh  2.25  2014  Kd=14uM       // 4ovf.pdf (2VE) compound 5b; ITC data is available
4o4y  1.85  2014  Kd=15.5nM     // 4ma3.pdf (14-mer) ligand is IDES hinge peptide (TCPPCPAPELLG)
4k7i  2.25  2014  Kd=1500uM     // 4k7i.pdf (CAQ) ligand is compound 1, CATECHOL, 15N-HSQC experiments
4mmm  1.47  2014  Kd=150uM      // 4k7i.pdf (BP7) ligand is compound 4
4pb1  2.80  2014  Kd=1530uM     // 4pb1.pdf (RBV) ligand is ribavirin; Kd=1530+/-350uM
4ci3  3.50  2014  Kd=156.6nM    // 4ci1.pdf (Y70) ligand is compound pomalidomide
4pp3  2.00  2014  Kd=15nM       // 4poh.pdf (2VZ) ligand is compound 2 ; Kd=15+/-2nM
4uxq  1.85  2014  Kd=16.0nM     // 4uxq.pdf (0LI) ligand is Ponatinib; Kd=16.0+/-0.04nM
4q4q  1.41  2014  Kd=1638.9nM   // 4q4o.pdf (SAQ) ligand is compound 4b; Kd=1638.9+/-204.7nM
4ogj  1.65  2014  Kd=164nM      // 4ogi.pdf (2TA) ligand is TG-101348; Kd=164+/-10nM
4qem  1.20  2014  Kd=16nM       // 4qem.pdf (HC4) ligand is (i) p-Coumaric acid
4lzs  2.20  2014  Kd=16uM       // 4lys.pdf (L46) ligand is compound XD46
4pb2  2.30  2014  Kd=16uM       // 4pb1.pdf (5UD) ligand is 5-fluorouridine; Kd=16+/-1uM
4lov  1.50  2014  Kd=17.1nM     // 4lov.pdf (KGM) ligand is Heptylmannoside
4oef  1.80  2014  Kd=17.5uM     // 4oee.pdf (SGN-IDY) ligand is S6I2; Kd=17.5+/-1.8uM
4k8o  2.65  2014  Kd=170uM      // 4k8o.pdf (ATP)
4muv  1.25  2014  Kd=1731nM     // 4muv.pdf (PCG) ligand is cyclic-GMP
4tu4  1.73  2014  Kd=175uM      // 4tt2.pdf (37N) ligand is compound 2; Kd=175+/-3uM
4ci2  2.95  2014  Kd=177.8nM    // 4ci1.pdf (LVY) ligand is compound lenalidomide
4j09  1.90  2014  Kd=17uM       // 4j09.pdf (6-mer) ligand is RJPXD33 peptide (TNLYMLPKWDIP-NH2)
4uoh  2.01  2014  Kd=17uM       // 4uog.pdf (ADP) ligand is ADP
4m5l  1.09  2014  Kd=18.9uM     // 4m5g.pdf (YH4) ligand is compound 9
4pre  1.65  2014  Kd=180.5uM    // 4pr5.pdf (11-mer) HPVG-Q5; Kd=180.5+/-5.5uM
4cy1  1.50  2014  Kd=181nM      // 4cy1.pdf (15-mer) ligand is KAT8 REGULATORY NSL COMPLEX SUBUNIT 1, KANSL1 peptide
4mp7  1.80  2014  Kd=1827nM     // 4mp2.pdf (PFT) ligand is PA7
4pum  1.93  2014  Kd=188.1nM    // 4puj.pdf (2WU) ligand is compound 2; Kd=188.1+/-59.1nM; TGT mutant Asp156Asn
4qsx  1.93  2014  Kd=18mM       // 4qsx.pdf (38S) ligand is 3'-deoxy thymidine
4pp5  2.00  2014  Kd=18nM       // 4poh.pdf (2W0) ligand is compound 1 ; Kd=18+/-3nM
4m5m  1.12  2014  Kd=18uM       // 4m5g.pdf (DX4) ligand is compound 18
4cu1  1.89  2014  Kd=19.4uM     // 4cu1.pdf (71S) ligand is compound 8S
4mmp  1.57  2014  Kd=19.7nM     // 4mmp.pdf (SLB) ligand is compound Neu5Ac
4tk1  2.70  2014  Kd=190uM      // 4tk1.pdf (11-mer) GABAA receptor alpha3(alpha-11 WT) ; Kd=190+/-30uM; space group P21212
4tk2  4.10  2014  Kd=190uM      // 4tk1.pdf (11-mer) GABAA receptor alpha3(alpha-11 WT) ; Kd=190+/-30uM; space group P61
4d1a  3.40  2014  Kd=19uM       // 4d1a.pdf (I5H) ligand is compound L-IMH, Kd assay by stopped-flow spectrophotofluorimetry
4usw  2.05  2014  Kd=2.03mM     // 4usu.pdf (ATP) Kd=2.03+/-0.42mM
4pzv  1.70  2014  Kd=2.0uM      // 4pzv.pdf (J1D) HP-26; Kd=2.0+/-0.3uM
4mg9  2.00  2014  Kd=2.11uM     // 4mg5.pdf (27K) ligand is compound butylparaben
4ncn  1.87  2014  Kd=2.12uM     // 4n3g.pdf (GTP)
4u7t  2.90  2014  Kd=2.14uM     // 4u7p.pdf (12-mer) peptide from Histone H3; Kd=2.14+/-0.13uM  without dsDNA
4jmh  2.41  2014  Kd=2.1nM      // 4jmg.pdf (13-mer) ligand is Shc-PY239/240 peptide
4c52  2.05  2014  Kd=2.1uM      // 4c52.pdf (X0D) ligand is compound 39b
4n7g  2.25  2014  Kd=2.2uM      // 4n7g.pdf (11-mer) ligand is a peptide derived from ExoS, 420-QGLLDALDLAS-430, ESp
4prn  1.65  2014  Kd=2.2uM      // 4pr5.pdf (11-mer) HPVG-A4; TK3 TCR
4pr5  1.80  2014  Kd=2.2uM      // 4pr5.pdf (11-mer) HPVG-D5; TK3 TCR
4pra  1.85  2014  Kd=2.2uM      // 4pr5.pdf (11-mer) HPVG-Q5; TK3 TCR
4prp  2.50  2014  Kd=2.2uM      // 4pr5.pdf (11-mer) HPVG-Q5; TK3 TCR-HLA-B 35:01
3wig  2.70  2014  Kd=2.30nM     // 3wig.pdf (CHU) ligand is compound CH5126766
3zev  3.00  2014  Kd=2.3nM      // 3zev.pdf (8-mer) ligand is NEUROTENSIN peptide
4pft  1.75  2014  Kd=2.3nM      // 4pft.pdf (MAB) ligand is Mannobiose
4mg6  2.10  2014  Kd=2.42uM     // 4mg5.pdf (27G) ligand is compound benzylbutylphtalate, BBP
4nrl  2.72  2014  Kd=2.4nM      // 4nrj.pdf (SIA) ligand is Neu5Ac-alpha-(2,3)Gal receptor analogues, 6 SLN-LN; Kd=2.4+/-0.4nM
4my6  1.70  2014  Kd=2.4uM      // 4my6.pdf (3VH) compound 4a
4q6f  1.91  2014  Kd=2.50uM     // 4q6f.pdf (5-mer) ligand is unmodified H3K4 histone peptide
4up5  1.65  2014  Kd=2.5mM      // 4up0.pdf (94W) ligand is CF4
4qf7  1.48  2014  Kd=2.5nM      // 4qem.pdf (C0R) ligand is (iv) Corticosterone
4kxm  2.24  2014  Kd=2.6uM      // 4kxl.pdf (6IA) ligand is compound 1, a C=C bond is different
4o3f  2.11  2014  Kd=2.78uM     // 4o33.pdf (TZN) Kd=2.78+/-0.90uM
4uwl  2.80  2014  Kd=2.7nM      // 4uwf.pdf (7A5) ligand is compound 31; Kd=2.7+/-0.9nM
4ll3  1.95  2014  Kd=2.7pM      // 3ttp.pdf (017) ligand is darunavir
4qij  2.20  2014  Kd=2.9uM      // 4qii.pdf (1HA) 1-hydroxy-2-naphthoyl-CoA(HNA-CoA); Kd=2.9+/-0.3uM
4r4c  1.40  2014  Kd=2.9uM      // 4r4c.pdf (3HS) ligand is compound 7i; Kd=2.9+/- 0.8uM
4mgd  1.90  2014  Kd=20.19uM    // 4mg5.pdf (27N) ligand is compound HPTE
4tpw  1.50  2014  Kd=20.5uM     // 4tpw.pdf (33R) ligand is 4EGI1-1E; m7GTP-eIF4E; Kd=20.5+/-2.2uM
4mue  2.06  2014  Kd=200nM      // 4mq6.pdf (2DH) compound 11
4tte  1.80  2014  Kd=202uM      // 4tt2.pdf (36Z) ligand is compound 1; Kd=202+/-5uM
2mwo   NMR  2014  Kd=20uM       // 2mwo.pdf (15-mer) ligand is a 15-mer p53K370me2 peptide
4lzr  1.85  2014  Kd=20uM       // 4lys.pdf (LOC) ligand is compound XD25
4oru  1.55  2014  Kd=210uM      // 4oru.pdf (PEU) ligand is polyethylene glycol; Kd by fluorometric titration (30% PEG 4000 solution)
4ibd  1.84  2014  Kd=214.6uM    // 4ibb.pdf (1DL) ligand is compound VPL27
4cig  1.70  2014  Kd=214uM      // 4cie.pdf (X0P) ligand is compound 101121
4lnp  1.41  2014  Kd=214uM      // 4ln2.pdf (10-mer) ligand is 10-mer proline rich peptide from Vinculin, prr2
4v27  1.90  2014  Kd=217nM      // 4v27.pdf (2-mer) ManIFG(24); mannose-alpha-1,3-isofagomine; wild type protein
4qsw  1.80  2014  Kd=21mM       // 4qsw.pdf (38T) ligand is 5-methyl uridine
4w9c  2.20  2014  Kd=22.2uM     // 4w9c.pdf (3JG) ligand is 2; 2-pVHL-Elo B-EloC; Kd=22.2+/-1.46uM
4rpo  1.95  2014  Kd=22.8nM     // 4rpn.pdf (T6C) ligand is TCP;  2,4,6-trichlorophenol
4oeu  2.20  2014  Kd=22nM       // 4oes.pdf (HIS) YpYntA binds to Ni(L-His)2; Kd=22+/-6nM
4ofl  2.70  2014  Kd=22nM       // 4oes.pdf (HIS) YpYntA binds to Ni(L-His)2; Kd=22+/-6nM
4qev  1.80  2014  Kd=22nM       // 4qev.pdf (31O) ligand is ME
4o42  1.87  2014  Kd=22uM       // 4nw2.pdf (15-mer) NS1K229me2; Kd=22+/-1.1uM
4tt2  2.50  2014  Kd=22uM       // 4tt2.pdf (6-mer) ligand is H4(1-20)K5Ac peptide
4lyw  1.95  2014  Kd=237nM      // 4lys.pdf (21Q) ligand is compound XD14
4mpn  1.75  2014  Kd=239nM      // 4mp2.pdf (PV0) ligand is PS10
4myh  3.38  2014  Kd=23uM       // 4myh.pdf (GSH)
4psb  1.42  2014  Kd=23uM       // 4psb.pdf (GA3) Kd=23+/-1uM (pH=7.4)
4ocq  1.88  2014  Kd=24.7uM     // 4ock.pdf (A2G) ligand is GalNAc; Kd=24.7+/-1.5uM
4oz1  1.74  2014  Kd=2400nM     // 4oz1.pdf (10-mer) UHM/SF3b155 ULM5; Kd=2400+/-1nM
4ln2  1.00  2014  Kd=248uM      // 4ln2.pdf (11-mer) ligand is 11-mer proline rich peptide from Vinculin, prr1
4ci1  2.98  2014  Kd=249.2nM    // 4ci1.pdf (EF2) ligand is compound thalidomide
4nrk  2.63  2014  Kd=24nM       // 4nrj.pdf (SIA) ligand is Neu5Ac-alpha-(2,6)Gal receptor analogues, 3 SLN-LN;Kd=24+/-17nM
4prd  1.75  2014  Kd=25.4uM     // 4pr5.pdf (11-mer) HPVG-D5; Kd=25.4+/-8.1uM
4prh  2.50  2014  Kd=25.4uM     // 4pr5.pdf (11-mer) HPVG-D5; Kd=25.4+/-8.1uM; TK3 TCR-HLA-B 35:08
4qk4  2.81  2014  Kd=250nM      // 4qjr.pdf (PIK) ligand is PI(4.5)P2; Kd=250+/-25nM
4c1y  2.23  2014  Kd=251uM      // 4ah4.pdf (MFB) ligand is b-methylfucoside, Beta MeFuc
4cjq  1.70  2014  Kd=256uM      // 4cie.pdf (VXO) ligand is compound 40812
4m8h  2.20  2014  Kd=25nM       // 4m8e.pdf (R4M) ligand is (R)-1
4uyf  1.60  2014  Kd=25nM       // 4uyf.pdf (73B) ligand is compound 47; Kd=25+/-8nM
4uyg  2.50  2014  Kd=25nM       // 4uyf.pdf (73B) ligand is compound 47; Kd=25+/-8nM; redundant to 4uyf
4qbm  1.65  2014  Kd=26.08uM    // 4q6f.pdf (9-mer) ligand is H4K16acK20ac
4ck3  1.79  2014  Kd=268uM      // 4cie.pdf (K1T) ligand is compound 17650
4cu7  2.20  2014  Kd=26nM       // 4cu7.pdf (GIF) ligand is compound GIF
4ibb  1.75  2014  Kd=270.7uM    // 4ibb.pdf (1DK) ligand is compound GA-017
4lbu  1.17  2014  Kd=276nM      // 4kwo.pdf (1WJ) ligand is compound 6b
4nym  3.55  2014  Kd=279uM      // 4nyi.pdf (RND) ligand is compound 2; to K-RasG12D
4nvp  2.50  2014  Kd=27nM       // 4nvp.pdf (7CH) ligand is 7-CH-cAMP; Kd=27+/-7nM
4pmm  2.00  2014  Kd=27nM       // 4pmm.pdf (31V) ligand is compound 2
4k42  2.90  2014  Kd=285nM      // 4k41.pdf (NWM) ligand is compound SF-01
4og3  2.01  2014  Kd=285nM      // 4og3.pdf (2S6) ligand is compound 11 (MIV-3)R isome
4leq  1.41  2014  Kd=288nM      // 4kwo.pdf (1WK) ligand is compound 6a
4u90  2.00  2014  Kd=288nM      // 4u90.pdf (10-mer) ligand is 3v; Kd=288+/-86nM
4uac  1.60  2014  Kd=288nM      // 4ua8.pdf (ACR) ligand is acarbose; Kd=288+/-5.9nM
4myd  1.37  2014  Kd=28uM       // 4myd.pdf (164) ligand is compound SHCHC
4orx  1.60  2014  Kd=297uM      // 4oru.pdf (PEU) ligand is polyethylene glycol
4ory  1.80  2014  Kd=297uM      // 4oru.pdf (PEU) ligand is polyethylene glycol
4nmr  1.55  2014  Kd=298uM      // 4nmo.pdf (10-mer) ligand is peptide iCAL36(Ac-K-5) ; Kd=298+/-5uM
4qer  1.20  2014  Kd=29nM       // 4qem.pdf (STL) ligand is (ii) Resveratrol
4ruu  1.40  2014  Kd=29nM       // 4ruu.pdf (RET) Kd=29+/-5nM
4m5h  1.11  2014  Kd=29uM       // 4m5g.pdf (YH2) ligand is compound 2
4nw2  1.90  2014  Kd=29uM       // 4nw2.pdf (15-mer) NS1K229me3; Kd=29+/-1.2uM; incomplete ligand structure
4d1c  3.70  2014  Kd=2uM        // 4d1a.pdf (B5H) ligand is compound BVH
4pio  1.51  2014  Kd=2uM        // 4pin.pdf (AVI) ligand is N-alpha-dimethylhistidine; Kd=2+/-1uM; EgtD solution contained 7 mM SAH
4qqi  2.03  2014  Kd=3.0uM      // 4lg6.pdf (17-mer) ligand is DNA-binding protein RFX7
4qxo  1.88  2014  Kd=3.12uM     // 4qxo.pdf (1YE) ligand is DMXAA; hSTING(group2)
4nni  2.64  2014  Kd=3.13uM     // 4nni.pdf (VGL) ligand is POA, the active form of PZA
4w9f  2.10  2014  Kd=3.27uM     // 4w9c.pdf (3JU) ligand is 5; Kd=3.27+/-0.22uM
4tq3  2.41  2014  Kd=3.2uM      // 4tq3.pdf (GPP) Kd=3.2+/-0.1uM; with Mg2+
4n7h  1.70  2014  Kd=3.3uM      // 4n7h.pdf (13-mer) ligand is 1st PPXY Motif of ARRDC3
4pf5  2.04  2014  Kd=3.3uM      // 4pf5.pdf (M3N) Ps.Man9(5); a synthetic derivative of high-mannose chain
4qfg  3.46  2014  Kd=3.3uM      // 4qfg.pdf (AMP) Kd=3300+/-1000nM
4n6g  2.14  2014  Kd=3.4uM      // 4n6g.pdf (2GQ) ligand is compound 5
4mgb  1.85  2014  Kd=3.67uM     // 4mg5.pdf (XDH) ligand is compound TCBPA
4pox  2.29  2014  Kd=3.7uM      // 4pow.pdf (2W2) ligand is nopaline;Kd=3.7+/-0.6uM
4tmp  2.30  2014  Kd=3.7uM      // 4tmp.pdf (11-mer) ligand is H3K9ac peptide
4tun  1.93  2014  Kd=3.87uM     // 4tun.pdf (MVH)
4p0a  2.30  2014  Kd=30.3uM     // 4p0a.pdf (10-mer) Injectant:P97 peptide 2mM; Cell:HOIP PUB 150 uM
4w4z  2.41  2014  Kd=30nM       // 4w4z.pdf (13-mer) ligand is APY-bAla8.am peptide
4trc  2.40  2014  Kd=30uM       // 4trc.pdf (ADE) ligand is adenine
4qf8  1.65  2014  Kd=31nM       // 4qem.pdf (SPD) ligand is (iii) Spermidine
4nmq  1.40  2014  Kd=32.3uM     // 4nmo.pdf (10-mer) ligand is peptide iCAL36(Ac-K-4)
4nyj  2.85  2014  Kd=322uM      // 4nyi.pdf (2PZ) ligand is compound 1; to K-RasG12D
4w9w  1.72  2014  Kd=33.1nM     // 4w9w.pdf (YDJ) ligand is AZD7762
4k7n  2.30  2014  Kd=330uM      // 4k7i.pdf (MCT) ligand is compound 2, 4-METHYLCATECHOL, 15N-HSQC experiments
4oks  2.25  2014  Kd=33uM       // 4ojq.pdf (2T9) ligand is compound 19; IC50=3uM
4q4o  1.35  2014  Kd=34.3nM     // 4q4o.pdf (2YM) ligand is compound 3a; Kd=34.3+/-6.5nM
4mq6  1.70  2014  Kd=340nM      // 4mq6.pdf (29W) compound 10
4jzb  1.90  2014  Kd=342.5nM    // 4jzb.pdf (P2H) ligand is 300B, complex is LmFPPS-300B-IPP-Ca2+
4puj  1.42  2014  Kd=35.0nM     // 4puj.pdf (CKR) ligand is compound 1; Kd=35+/-6.9nM
4g2r  2.28  2014  Kd=35.8uM     // 4g2r.pdf (H1L) ligand is compound haloxyfop-R
4tz2  1.70  2014  Kd=350uM      // 4tyl.pdf (39R) ligand is compound 5
4mp2  1.75  2014  Kd=3570nM     // 4mp2.pdf (PV1) ligand is PA1
4or0  2.58  2014  Kd=35nM       // 4or0.pdf (NPS) ligand is NPS;using microcalorimetry
4ibf  2.29  2014  Kd=36.8uM     // 4ibb.pdf (1D5) ligand is compound VPL42
4q4r  1.45  2014  Kd=369.2nM    // 4q4o.pdf (SQO) ligand is compound 2b; Kd=369.2+/-25.3nM
4d1b  3.80  2014  Kd=36uM       // 4d1a.pdf (5FH) ligand is compound L-BH
4pd6  2.08  2014  Kd=36uM       // 4pb1.pdf (URI) ligand is uridine; Kd=36+/-3uM
4ogi  1.73  2014  Kd=37nM       // 4ogi.pdf (R78) ligand is BI-2536; Kd=37+/-3nM
4qgd  1.80  2014  Kd=37nM       // 4qem.pdf (PZZ) ligand is (v) Gramine derivative
4usi  1.45  2014  Kd=38.9uM     // 4usi.pdf (AKG) ligand is 2-oxoglutarate
4wt2  1.42  2014  Kd=38pM       // 4wt2.pdf (3UD) ligand is compound 25(AM-7209)
4cc5  1.88  2014  Kd=38uM       // 4cc5.pdf (L5V) ligand is compound 3
4p5z  2.00  2014  Kd=39.3nM     // 4p4c.pdf (Q7M) ligand is compound 7m
4w9x  2.14  2014  Kd=39.8nM     // 4w9w.pdf (3JW) ligand is Baricitinib
3wgg  2.10  2014  Kd=39.9uM     // 3wgg.pdf (8NA) ligand is compound alpha-NAD+
4pp0  1.57  2014  Kd=39.9uM     // 4pow.pdf (OP1) ligand is pyronopaline; Kd=39.9+/-7uM
4je7  2.10  2014  Kd=395nM      // 4je7.pdf (BB2) ligand is actinonin
4qpl  1.90  2014  Kd=39nM       // 4qpl.pdf (V3L) iso-ADPr; Kd=39+/-7nM
4o6w  1.45  2014  Kd=3nM        // 4o6w.pdf (7-mer) ligand is compound 3m
4c5d  2.30  2014  Kd=4.0uM      // 4c52.pdf (X0R) ligand is compound 41
4nyt  2.25  2014  Kd=4.1mM      // 4nyt.pdf (PC) ligand is Phosphocholine
4mg5  2.05  2014  Kd=4.53uM     // 4mg5.pdf (27E) ligand is compound chlordecone
4us3  2.10  2014  Kd=4.8uM      // 4us3.pdf (TRP) ligand is HiLiDe; L-Trp Kd=4.8+/-0.6uM
4us4  2.60  2014  Kd=4.8uM      // 4us3.pdf (TRP) ligand is MhsT LCP;  L-Trp Kd=4.8+/-0.6uM
4mdr  1.85  2014  Kd=40.6uM     // 4mdr.pdf (10-mer) ligand is a sorting peptide from the amyloid precursor protein (APP)
4q4p  1.54  2014  Kd=407.4nM    // 4q4o.pdf (2YO) ligand is compound 3b; Kd=407.4+/-46.0nM
2mov   NMR  2014  Kd=40nM       // 2mov.pdf (IOR) ligand is compound MG-H1
4rrv  1.41  2014  Kd=40nM       // 4rqk.pdf (15-mer) ligand is PIFtide
4p4t  2.30  2014  Kd=41.0uM     // 4p4s.pdf (GDP) ligand is GDP
4ce1  2.01  2014  Kd=41.8uM     // 4ce1.pdf (7FK) ligand is compound 27c
4mpe  1.95  2014  Kd=426nM      // 4mp2.pdf (PV8) ligand is PS8
4mrd  2.55  2014  Kd=428uM      // 4mrd.pdf (NAG-BDP) ligand is HA oligosaccharide 4
4q6d  1.12  2014  Kd=43.5nM     // 4q6d.pdf (WW3) ligand is compound 31
4r91  1.58  2014  Kd=430nM      // 4r8y.pdf (3KT) ligand is compound 41
4cj4  1.80  2014  Kd=432uM      // 4cie.pdf (S3G) ligand is compound GL5243104
4o36  1.22  2014  Kd=436nM      // 4o36.pdf (15-mer) Ribonuclease pancreatic, S-peptide 2;Kd=436+/-32nM
4o3t  2.99  2014  Kd=43uM       // 4o3t.pdf (11-mer) ZAP14; Kd=43+/-28uM
4mnp  2.50  2014  Kd=45.5nM     // 4mmp.pdf (SLB) ligand is compound Neu5Ac
4mzf  2.10  2014  Kd=45nM       // 4mzf.pdf (9-mer) ligand is histone H3(K4me3-R8me2a) peptide
4muf  2.50  2014  Kd=460nM      // 4mq6.pdf (2DJ) compound 12
4lys  1.83  2014  Kd=46uM       // 4lys.pdf (2SJ) ligand is compound XD1
4ibj  1.54  2014  Kd=47.0uM     // 4ibb.pdf (1D9) ligand is compound VPL58
4pd9  3.10  2014  Kd=470uM      // 4pb1.pdf (ADN) ligand is adenosine; Kd=470+/-100uM
4cjp  2.00  2014  Kd=481uM      // 4cie.pdf (4D2) ligand is compound 40811
4d1j  1.80  2014  Kd=485nM      // 4d1j.pdf (DGJ) Kd=485+/-42 nM
4c9x  1.20  2014  Kd=48nM       // 4c9w.pdf (VHS) ligand is S-crizotinib
4u43  2.18  2014  Kd=48uM       // 4u43.pdf (3D8) ligand is compound 6
4ny3  1.80  2014  Kd=49.5uM     // 4ny3.pdf (6-mer) PPP2CA C-terminal peptide(TPDYFL peptides); Kd=49.5+/-1.8uM
4nyf  1.90  2014  Kd=49nM       // 4nyf.pdf (4BI) ligand is compound 16
4u0c  1.77  2014  Kd=49uM       // 4u0a.pdf (17-mer) ligand in crystal is (1407-TNNSPSGVFTFGANSST-1423) peptide
4u0d  3.00  2014  Kd=49uM       // 4u0a.pdf (17-mer) ligand in crystal is (1407-TNNSPSGVFTFGANSST-1423) peptide
4m3p  1.90  2014  Kd=4uM        // 4m3p.pdf (HCS) ligand is Homocysteine, Kd in presence of potassium ion
4ozj  1.45  2014  Kd=4uM        // 4ozj.pdf (ADP)
4ozn  2.60  2014  Kd=4uM        // 4ozj.pdf (ATP)
4pin  1.90  2014  Kd=4uM        // 4pin.pdf (AVI) ligand is N-alpha-dimethylhistidine; Kd=4+/-2uM
4pov  2.20  2014  Kd=5.21nM     // 4pop.pdf (2VY) [Incomplete ligand] compound 7; RCSB wrongly save functional group -C-OH as -C=O, same as compound 9, 2VY in PDB code 4pop
4n9b  2.86  2014  Kd=5.2uM      // 4n9b.pdf (2HH) ligand is compound 7
4r6w  1.59  2014  Kd=5.4uM      // 4r6w.pdf (SAH) AdoHcy with pCho; AdoHcy Kd=5.4+/-0.1uM for SAH
4r6x  2.55  2014  Kd=5.4uM      // 4r6w.pdf (SAH) AdoHcy with pEA; Kd=5.4+/-0.1uM for SAH
4w9g  2.70  2014  Kd=5.53uM     // 4w9c.pdf (3JV) ligand is 6; Kd=6.53+/-0.59uM
4np2  1.75  2014  Kd=5.5mM      // 4mrd.pdf (2L1) ligand is compound 5
4non  2.50  2014  Kd=5.71uM     // 4non.pdf (GDP) Kd=5.71+/-0.59uM
4utx  3.10  2014  Kd=5.78uM     // 4utn.pdf (9-mer) ligand is 3-nitro- propionylated CPS1-peptide 5i; Kd=5.78+/-2.36uM
4uua  2.80  2014  Kd=5.78uM     // 4utn.pdf (9-mer) ligand is 3S-Z-amino- succinylated CPS1-peptide 5i; Kd=5.78+/-2.36uM
3wqw  2.00  2014  Kd=5.9uM      // 3wqv.pdf (6-mer) ligand is (GlcN)x6
4m5k  1.30  2014  Kd=5.9uM      // 4m5g.pdf (YH3) ligand is compound 8
4ibk  1.85  2014  Kd=50.4uM     // 4ibb.pdf (1DE) ligand is compound VPL60
4tz8  2.15  2014  Kd=500uM      // 4tyl.pdf (39U) ligand is compound 12
4k7o  1.98  2014  Kd=50uM       // 4k7i.pdf (EKZ) ligand is compound 3, 4-tert-butylbenzene-1,2-diol, 15N-HSQC experiments
4o61  1.90  2014  Kd=50uM       // 4o61.pdf (CIT) ligand is citrate
4u0b  2.80  2014  Kd=50uM       // 4u0a.pdf (15-mer) CPSF6 peptide, P212121 crystal form; -DTT
4u0a  2.05  2014  Kd=50uM       // 4u0a.pdf (15-mer) CPSF6 peptide, P6 crystal form; -DTT
4puk  1.49  2014  Kd=52.4nM     // 4puj.pdf (2WU) ligand is compound 2; Kd=52.4+/-6.9nM
4r1e  1.98  2014  Kd=52nM       // 4r1e.pdf (15-mer) peptide-fragment chimera 3; Kd=52+/-8nM
4clp  1.90  2014  Kd=54.2mM     // 4clk.pdf (CMP) Kd=54.2+/-13.4 mM
4lpg  2.35  2014  Kd=55.6uM     // 4lpg.pdf (1MV) ligand is compound 6a, CL01131
4ua8  1.54  2014  Kd=550nM      // 4ua8.pdf (MLR) ligand is maltotriose; Kd=550+/-14nM
4wiv  1.56  2014  Kd=550nM      // 4wiv.pdf (3P2) ligand is compound 32
4nnr  1.98  2014  Kd=55nM       // 4nnr.pdf (FK5)
2mji   NMR  2014  Kd=56.7uM     // 2mji.pdf (KTR) ligand is Ketorolac, ITC data
3wqm  2.10  2014  Kd=560nM      // 3wqm.pdf (B29) inhibitor BPH-629
4w5j  1.65  2014  Kd=57nM       // 4w5j.pdf (AP5) Kd1=57+/-2nM; Kd2=177+/-53nM
4u0x  2.03  2014  Kd=590nM      // 4u0x.pdf (ZXM) ligand is compound S02030
4r5g  3.45  2014  Kd=6.0uM      // 4r5g.pdf (3JE) ligand PET-16 binding to wt Dna-ADP; Kd=6.0+/-1.8uM
3wqv  2.04  2014  Kd=6.2uM      // 3wqv.pdf (5-mer) ligand is (GlcN)x5
4mre  1.58  2014  Kd=6.4mM      // 4mrd.pdf (2C9) ligand is compound 1
2mnz   NMR  2014  Kd=6.4uM      // 2mnz.pdf (10-mer) ligand is H3K4me0(1-10aa) peptide
4m0z  2.00  2014  Kd=6.4uM      // 4m0y.pdf (M0Z) ligand is compound 5, Kd1: allosteric pocket, Kd2: ATP pocket
4qok  3.00  2014  Kd=6.4uM      // 4qok.pdf (10-mer) HLA-A*0201 restricted Melan-A/MART-1 26-35 (EAAGIGILTV) antigen (A2-EAA); Kd=6.4+/-0.2uM
4ono  2.71  2014  Kd=6.5uM      // 4ono.pdf (PMK) Kd1=24.7+/-3.4uM(1.6TCRs),Kd2=7.3+/-2.0uM(1.22TCRs),Kd3= 6.5+/-2.0uM(2.4TCRs),Kd4=16.0+/-2.4uM(22.2TCRs)
4m5i  1.08  2014  Kd=6.7uM      // 4m5g.pdf (YH6) ligand is compound 3
4kp4  3.00  2014  Kd=6.8uM      // 4kp4.pdf (ANP) ligand is non-hydrolysable ATP analogue AMPPNP
4nja  2.20  2014  Kd=600nM      // 4nj9.pdf (2M9) ligand is MPTS
4tyl  1.85  2014  Kd=600uM      // 4tyl.pdf (39O) ligand is compound 1
4je8  2.40  2014  Kd=6100nM     // 4je7.pdf (3-mer) ligand is Met-Ala-Ser
4mul  1.75  2014  Kd=610nM      // 4mq6.pdf (2DW) compound 13
4pda  2.61  2014  Kd=61uM       // 4pb1.pdf (CTN) ligand is cytidine; Kd=61+/-5uM
4umn  1.99  2014  Kd=63.13nM    // 4umn.pdf (13-mer) ligand is M06; Kd=63.13+/-17.81nM
4ca4  2.84  2014  Kd=65.5nM     // 4ca4.pdf (KGM)
4mzh  2.20  2014  Kd=66nM       // 4mzf.pdf (9-mer) ligand is histone H3(K4me3-R8me2s) peptide
4q9m  2.06  2014  Kd=66nM       // 4q9m.pdf (2ZW) ligand is UK-106051 with FPP; Kd=66+/-7 nM
4o9w  1.69  2014  Kd=69.91nM    // 4o9w.pdf (6-mer) Kd=69.91+/-15.95nM
4o37  1.40  2014  Kd=694nM      // 4o37.pdf (15-mer) Ribonuclease pancreatic, S-peptide 3; Kd=694+/-57nM
4w9e  2.60  2014  Kd=7.09uM     // 4w9c.pdf (3JT) ligand is 4; Kd=7.09+/-0.59uM
4buq  2.20  2014  Kd=7.3nM      // 4buq.pdf (KGM) ligand is compound HM
4pop  2.20  2014  Kd=7.44nM     // 4pop.pdf (2VY) compound 9;
4qfr  3.34  2014  Kd=7.4nM      // 4qfg.pdf (32J) ligand is Cl-A769662; Kd=7.4+/-0.1nM
4m5n  2.00  2014  Kd=7.5uM      // 4m5g.pdf (YH7) ligand is compound 21
4v04  2.12  2014  Kd=7.7nM      // 4uxq.pdf (0LI) ligand is Ponatinib; Kd=7.7+/-0.03nM
4v01  2.33  2014  Kd=7.7nM      // 4v01.pdf (0LI) ligand is ponatinib; Kd=7.7+/-0.03nM
4pms  2.80  2014  Kd=7.9nM      // 4pmm.pdf (31X) ligand is compound 4
4wht  2.22  2014  Kd=7.9nM      // 4wht.pdf (12-mer) E2 antigenic region 412-423 Epitope peptide; Glasgow; P1 crystal form; Kd=7.9+/-0.7nM
4why  2.62  2014  Kd=7.9nM      // 4wht.pdf (12-mer) Epitope peptide; ntigenic region 412-423 Epitope peptide; Glasgow; P21 crystal form; Kd=7.9+/-0.7nM
4ibe  1.95  2014  Kd=70.6uM     // 4ibb.pdf (11Y) ligand is compound VPL-029
4o45  1.87  2014  Kd=70uM       // 4nw2.pdf (15-mer) NS1; Kd=70+/-5uM
4mpc  1.70  2014  Kd=711nM      // 4mp2.pdf (PV2) ligand is PS2
4k6u  1.90  2014  Kd=72.8uM     // 4k6t.pdf (1P4-SIA) compound 11b; consist of 1P4 and three SIA; SPR data is available
4ibi  1.47  2014  Kd=73.0uM     // 4ibb.pdf (1D8) ligand is compound VPL57
4d1y  2.60  2014  Kd=74nM       // 4d1y.pdf (RBF) ligand is RIBOFLAVIN
4whs  1.35  2014  Kd=75uM       // 4who.pdf (3N8) ligand is 4CF, PH=8.5; ITC PH=7,5
4whq  1.78  2014  Kd=75uM       // 4who.pdf (3N8) ligand is 4CF, with O2, PH=6.5; ITC PH=7.5; redundant to 4whs
4whr  1.58  2014  Kd=75uM       // 4who.pdf (3N8) ligand is 4CF, with O2, PH=8.5; ITC PH=7.5; redundant to 4whs
4k6t  2.00  2014  Kd=78.6uM     // 4k6t.pdf (1P0-SIA) compound 11a; consist of 1P0 and three SIA; SPR data is available
4c9w  1.65  2014  Kd=781nM      // 4c9w.pdf (VGH) ligand is R-crizotinib
4cjr  1.80  2014  Kd=793uM      // 4cie.pdf (FYM) ligand is compound 101119
4wf2  2.31  2014  Kd=8.03nM     // 4wf2.pdf (BTX) ligand is biotinol-5'-AMP
4utv  2.40  2014  Kd=8.20uM     // 4utn.pdf (9-mer) ligand is 3-phenyl- succinylated CPS1-peptide 5h; Kd=8.20+/-0.55uM
4r4q  1.35  2014  Kd=8.2uM      // 4r4q.pdf (3HZ) ligand is compound 7b; Kd= 8.2+/- 2.6uM
4ock  1.72  2014  Kd=8.3uM      // 4ock.pdf (ANP) ligand is AMPPNP; Kd=8.3+/-0.5uM
4ocv  1.47  2014  Kd=8.3uM      // 4ock.pdf (ANP) ligand is AMPPNP; Kd=8.3+/-0.5uM
4od7  1.60  2014  Kd=8.3uM      // 4od7.pdf (9-mer) PWATCDS; Kd=8.3+/-0.4uM
4um9  2.50  2014  Kd=8.5nM      // 4um8.pdf (13-mer) transforming growth factor beta 3 peptide; Kd calculated from IC50 value
4j7i  2.56  2014  Kd=8.8uM      // 4j7i.pdf (11-mer) ligand is Transcription initiation factor TFIID subunit 10 peptide
4qkd  1.35  2014  Kd=80.9uM     // 4qkd.pdf (AKG) Kd=80.9+/-8.12nM; modification of ALKBH7 Leu-110;Mn2+ containing
4qjr  2.40  2014  Kd=80nM       // 4qjr.pdf (PIZ) ligand is PIP3; Kd=80+/-12nM
4mji  2.99  2014  Kd=81.8uM     // 4mji.pdf (8-mer)
4po7  2.66  2014  Kd=85nM       // 4po7.pdf (13-mer) incomplete ligand structure
4nyi  2.96  2014  Kd=868uM      // 4nyi.pdf (2PX) ligand is compound 3; to K-RasG12D
4qew  1.70  2014  Kd=86nM       // 4qev.pdf (31P) ligand is ET
4csy  2.41  2014  Kd=878uM      // 4c16.pdf (SIA-MAG-GAL-FUC) ligand is Sialyl Lewis X, consist of SIA-MAG-GAL-FUC
4qzs  1.45  2014  Kd=89nM       // 4qzs.pdf (JQ1) ligand is (+)-JQ1; Kd=89=/-5nM
4cs9  2.01  2014  Kd=8mM        // 4cs8.pdf (AMP) fluorescence-based thermal shift assays (TSA)
4poj  2.00  2014  Kd=8nM        // 4poh.pdf (2VP) ligand is compound 3 ; Kd=8+/-2nM
4wke  1.62  2014  Kd=8nM        // 4wk7.pdf (3PU) ligand is compound 10
4rn6  3.00  2014  Kd=8uM        // 4h6s.pdf (15U) active site inhibitor S-argatroban, ITC Kd=8+/-0.1uM
4qsk  2.70  2014  Kd=8uM        // 4qsh.pdf (2BA) ligand is c-di-AMP; Kd=8+/-0.2uM; space group C2
4qsh  2.51  2014  Kd=8uM        // 4qsh.pdf (2BA) ligand is c-di-AMP; Kd=8+/-0.2uM; space group P21
4tk3  2.70  2014  Kd=8uM        // 4tk1.pdf (11-mer) GABAA receptor alpha3(alpha-11 SL) ; Kd=8+/-1uM; space group P21212
4tk4  3.60  2014  Kd=8uM        // 4tk1.pdf (11-mer) GABAA receptor alpha3(alpha-11 SL) ; Kd=8+/-1uM; space group P61
4oeg  1.60  2014  Kd=9.01uM     // 4oee.pdf (SUS-IDY) ligand is S9I2; Kd=9.01+/-0.23uM
4jaz  2.85  2014  Kd=9.17uM     // 4jaz.pdf (STL) ITC Ka=1.09x10E5M-1, Kd=9.17uM
4lph  2.30  2014  Kd=9.2uM      // 4lpg.pdf (YL3) ligand is compound 7, CL03093
4w9l  2.20  2014  Kd=9.52uM     // 4w9c.pdf (3JJ) ligand is 15; Kd=9.52+/-1.02uM
4uye  1.65  2014  Kd=9.54nM     // 4uyd.pdf (9F9) ligand is compound 3; IC50=79.43nM; for cellular protein interaction assay, IC50=0.98uM
4m5g  1.31  2014  Kd=9.7uM      // 4m5g.pdf (YH1) ligand is compound 1
4u4x  1.56  2014  Kd=9.8uM      // 4u4s.pdf (3C2) ligand is compound 5; Kd=9.8+/-0.7uM
4o62  1.78  2014  Kd=9.9uM      // 4o62.pdf (11-mer) ligand is peptide H3K4me3
4lnw  1.90  2014  Kd=90.9nM     // 4lnw.pdf (T3) ligand is T3
4nmp  1.30  2014  Kd=91.9uM     // 4nmo.pdf (10-mer) peptide iCAL36(Ac-K-3)
4pri  2.40  2014  Kd=93.2uM     // 4pr5.pdf (11-mer) HPVG; Kd=93.2+/-3.8uM; TK3 TCR-HLA-B 35:08
4ql1  1.50  2014  Kd=93nM       // 4ql1.pdf (35Q) ligand is compound OICR-9429
4og4  1.45  2014  Kd=952nM      // 4og3.pdf (2VK) ligand is compound 11 (MIV-3)S isomer
4wym  2.60  2014  Kd=99.8uM     // 4qnb.pdf (17-mer) Kd by AUC, analytical ultracentrifugation; Kd=83.3uM by FP
4tsz  2.00  2014  Kd=99nM       // 4tsz.pdf (6-mer) ligand is peptide P14(AcQChaDLdiClF); PaSC; Kd=99+/-18nM
4wmc  2.30  2014  Kd=9nM        // 4wm9.pdf (NXL) ligand is avibactam
4oct  2.28  2014  Kd=9uM        // 4o61.pdf (AKG) ligand is 2OG; ALKBH5 wild-type
4pnw  2.00  2014  Kd=9uM        // 4ovf.pdf (2VM) compound 5m
4rqv  1.50  2014  Kd=9uM        // 4rqk.pdf (R2S)
4pji  2.50  2014  Kd>200uM      // 4pj5.pdf (30W)
4oaz  2.25  2014  Kd~1.7uM      // 4oay.pdf (C2E) ligand is cyclic dinucleotide c-di-GMP
4qta  1.45  2014  Kd~200nM      // 4qta.pdf (38Z) SCH772984
4qtb  1.40  2014  Kd~200nM      // 4qta.pdf (38Z) SCH772984
4ocx  2.39  2014  Kd~3.6pM      // 4ocx.pdf (MT1)
4pmp  1.80  2014  Kd~400nM      // 4pmm.pdf (31W) compound 3
4ciz  3.40  2014  Kd~51nM       // 4ciz.pdf (RET) ligand is 9-cis-retinal
4led  2.37  2014  Kd~5mM        // 4led.pdf (XXR) ligand is D-rhamnose, estimated ITC Kd=5~10mM
4nro  2.30  2014  Kd~9.6uM      // 4nro.pdf (AKG) Mn2+ containing;ligand is alpha-ketoglutarate
4man  2.07  2014  Ki<0.01nM     // 4man.pdf (1Y1) ligand is ABT-199
4nud  1.20  2014  Ki<0.0845uM   // 4nuc.pdf (NUD) ligand is compound 27(MS436)
4cmt  1.73  2014  Ki<0.2nM      // 4cli.pdf (GWH) ligand is compound 6i
4cmu  1.80  2014  Ki<0.2nM      // 4cli.pdf (IV7) ligand is compound 8a
4kz5  1.35  2014  Ki<10mM       // 4kz3.pdf (1U3) ligand is fragment compound 5
4okp  1.37  2014  Ki<2mM        // 4okp.pdf (2V0) ligand is compound 46
4l2l  1.65  2014  Ki=0.002mM    // 4l2l.pdf (1V6) ligand is compound 4 (ARM1)
4cwr  2.00  2014  Ki=0.005uM    // 4cwf.pdf (HAJ) ligand is compound 7o
4cws  2.30  2014  Ki=0.012uM    // 4cwf.pdf (G3R) ligand is compound 12b
4lv2  1.65  2014  Ki=0.01uM     // 4lv0.pdf (N95) ligand is compound 7
4qbb  1.60  2014  Ki=0.03uM     // 4qbb.pdf (E69) ligand is E64-R-P-NH2; Ki=0.03+/-0.002uM
4r6t  2.60  2014  Ki=0.03uM     // 4r5t.pdf (R5T) ligand is compound 7
4ngm  1.84  2014  Ki=0.0449nM   // 4ngm.pdf (JB7) ligand is compound 22a
4jyt  2.00  2014  Ki=0.04uM     // 4jyt.pdf (N4A) ligand is compound 10, Ki=0.04uM
4jzi  2.00  2014  Ki=0.04uM     // 4jzi.pdf (N4C) ligand is compound 24
4len  1.50  2014  Ki=0.04uM     // 4len.pdf (2GK) ligand is compound 5
4lv1  1.74  2014  Ki=0.04uM     // 4lv0.pdf (NL9) ligand is compound 3
4m8x  2.05  2014  Ki=0.063nM    // 4m8x.pdf (KGQ) ligand is GS-8374, with PR2
4kz4  1.42  2014  Ki=0.07mM     // 4kz3.pdf (4A1) ligand is fragment compound 60
4cwq  2.00  2014  Ki=0.088uM    // 4cwf.pdf (W2D) ligand is compound 7n
4tyo  1.75  2014  Ki=0.08uM     // 4tyo.pdf (39X) ligand is compound 7
4m8y  2.22  2014  Ki=0.11nM     // 4m8x.pdf (KGQ) ligand is GS-8374, with PR1
4mhz  1.95  2014  Ki=0.134uM    // 4mhz.pdf (PBD) Apo-ls-QC-PBD150, without Zn2+
4nue  1.30  2014  Ki=0.15uM     // 4nuc.pdf (NUE) ligand is compound 28(MS267)
4qy3  1.50  2014  Ki=0.15uM     // 4qy3.pdf (3G1) ligand is compound 3
4wkv  2.14  2014  Ki=0.161uM    // 4wks.pdf (3QK) ligand is C8-B(OH)2; B-containing; Ki=1.61+/-0.03x10-7M
4cwp  1.95  2014  Ki=0.170uM    // 4cwf.pdf (TV2) ligand is compound 7l
4cwt  1.90  2014  Ki=0.179uM    // 4cwf.pdf (IK9) ligand is compound 18a
4ppb  2.82  2014  Ki=0.1nM      // 4pp9.pdf (2VV) ligand is compound 28
4na7  2.80  2014  Ki=0.20nM     // 4na7.pdf (1T5) ligand is compound 1
4os2  1.79  2014  Ki=0.20uM     // 4os1.pdf (14-mer) bicyclic peptide UK602 (bicyclic 1); Ki=0.20+/-0.01uM
3zj6  2.40  2014  Ki=0.22uM     // 3zj6.pdf (VM2) ligand is compound 1
4jit  2.80  2014  Ki=0.23uM     // 4jit.pdf (3ZF) ligand is compound 2
4lsj  2.35  2014  Ki=0.268nM    // 4lsj.pdf (LSJ) ligand is compound 10
4cd6  1.64  2014  Ki=0.26mM     // 4cd4.pdf (2-mer) ligand is compound 3, ManIFG
4mc6  1.31  2014  Ki=0.26nM     // 4mc6.pdf (23K) ligand is compound 48
4kza  1.60  2014  Ki=0.2mM      // 4kz3.pdf (NZ9) ligand is fragment compound 48
4cd0  2.23  2014  Ki=0.2nM      // 4ccb.pdf (AWJ)
4jz1  1.90  2014  Ki=0.2uM      // 4jz1.pdf (F4D) ligand is compound 8
3wmc  2.10  2014  Ki=0.31uM     // 3wmb.pdf (NF6) ligand is naphthalimide derivative Q2
4mhy  1.38  2014  Ki=0.342uM    // 4mhy.pdf (PBD) Zn-ls-QC-PBD150, with Zn2+
4mc9  1.19  2014  Ki=0.36nM     // 4mc9.pdf (23L) ligand is compound 47
4os6  1.75  2014  Ki=0.36uM     // 4os1.pdf (14-mer) bicyclic peptide UK604 (bicyclic 2); Ki=0.36+/-0.03uM
4ty7  2.09  2014  Ki=0.3nM      // 4ty6.pdf (39F) ligand is compound 16b
4lhm  1.52  2014  Ki=0.41mM     // 4lhm.pdf (AZZ) Ki measured at 0.8mM AZT concentration
4j3u  1.70  2014  Ki=0.46uM     // 4j3u.pdf (9-mer) ligand is G2S beta CD, combined with SGD and GLC
4wkt  1.78  2014  Ki=0.55mM     // 4wks.pdf (BUB) ligand is C4-B(OH)2; B-containing; Ki=5.5+/-0.9x10-4M
4qge  2.00  2014  Ki=0.5nM      // 4qge.pdf (35O) ligand is compound 3r
4ob2  1.52  2014  Ki=0.5uM      // 4ob0.pdf (BUB) PtNHase-BuBA soaking; Ki=0.5+/-0.1uM
4ob1  1.63  2014  Ki=0.5uM      // 4ob0.pdf (BUB) ligand is BuBA; Ki=0.5+/-0.1uM
4r8y  1.90  2014  Ki=0.64uM     // 4r8y.pdf (3KO) ligand is compound 38
4mlx  1.65  2014  Ki=0.65mM     // 4mlt.pdf (TM7) ligand is compound ATM
4ocz  2.94  2014  Ki=0.66nM     // 4ocz.pdf (2RU) ligand is inhibitor 4; Ki=0.66+/-0.10nM
4mse  2.81  2014  Ki=0.69uM     // 4lkq.pdf (2ZU) ligand is compound ZT1597
4o04  1.82  2014  Ki=0.69uM     // 4o04.pdf (2Q8) ligand is compound 8; Ki=0.58+/-0.13uM
4clj  1.66  2014  Ki=0.70nM     // 4cli.pdf (5P8) ligand is compound 8k
4n1z  2.35  2014  Ki=0.72nM     // 4n1z.pdf (N1Z) ligand is BPH-1222
4p6w  1.95  2014  Ki=0.7nM      // 4p6w.pdf (MOF) ligand is MOF
4pqn  1.71  2014  Ki=0.7nM      // 4pqn.pdf (2W6) ligand is compound 28(GNE-9822)
4r5v  2.10  2014  Ki=0.7uM      // 4r5t.pdf (R5V) ligand is compound 13d
4o3b  1.91  2014  Ki=0.82uM     // 4o3a.pdf (GLU) 7.5 mM L-Asp; L-Glu being present in one subunit, and neither L-Asp nor L-Glu being present in the other subunit
4cmo  1.83  2014  Ki=0.85nM     // 4cli.pdf (YPW) ligand is compound 6h
4kz6  1.68  2014  Ki=0.8mM      // 4kz3.pdf (ZB6) ligand is fragment compound 13
4ppa  2.67  2014  Ki=0.8nM      // 4pp9.pdf (2VU) ligand is compound 11
4l19  1.66  2014  Ki=0.8uM      // 4l19.pdf (1UA) ligand is compound 2 (Q1)
4r5t  1.98  2014  Ki=0.8uM      // 4r5t.pdf (R5T) ligand is compound 7
4od0  2.92  2014  Ki=0.91nM     // 4ocz.pdf (2RV) ligand is inhibitor 18; Ki=0.91+/-0.13nM
4nuc  1.40  2014  Ki=0.91uM     // 4nuc.pdf (435) ligand is compound 4(MS435)
4ppc  2.95  2014  Ki=0.93nM     // 4pp9.pdf (2VW) ligand is compound 27
4r3w  1.91  2014  Ki=1.0mM      // 4r3w.pdf (A2P) 2,5-ADP; Ki=1.0+/-0.08mM
4kwg  2.10  2014  Ki=1.0uM      // 4kwf.pdf (2AK) ligand is compound 1, competitive Inhibition Data versus Varied Aldehyde
4msc  2.47  2014  Ki=1.1uM      // 4lkq.pdf (2ZT) ligand is compound ZT1595
4lkt  2.57  2014  Ki=1.26uM     // 4lkt.pdf (EIC)
4cd8  1.47  2014  Ki=1.3mM      // 4cd4.pdf (2-mer) ligand is compound 4
4kzb  1.37  2014  Ki=1.3mM      // 4kz3.pdf (NZ2) ligand is fragment compound 50, R-S mixture, ligand name could be NZ2 or NZ3
4mlt  2.00  2014  Ki=1.4mM      // 4mlt.pdf (TM4) ligand is compound TM
4na8  2.30  2014  Ki=1.50nM     // 4na7.pdf (1T6) ligand is compound 16
4oyt  2.40  2014  Ki=1.55mM     // 4oyt.pdf (FON) (6R)-5FTHF
4ngq  2.08  2014  Ki=1.570nM    // 4ngq.pdf (J37) ligand is compound 22b;Kd=1.570=+/-0.071nM
4p5d  2.11  2014  Ki=1.5uM      // 4p5d.pdf (N6P) ligand is compound 1a; Ki=1.5+/-0.1uM
4kz8  2.28  2014  Ki=1.6mM      // 4kz3.pdf (1U6) ligand is fragment compound 20
4mnw  1.49  2014  Ki=1.72uM     // 4mnv.pdf (14-mer) ligand is bicyclic peptide TBMB(UK749)
4nwc  2.01  2014  Ki=1.74uM     // 4nwc.pdf (2QE) ligand is compound 1; Ki=1.74+/-0.29uM
4kz3  1.67  2014  Ki=1.7mM      // 4kz3.pdf (1U1) ligand is fragment compound 44
4mbf  1.54  2014  Ki=1.7uM      // 4mbf.pdf (2AW) ligand is compound PSR-4-157, miss a ring bond in PDB website
4m6u  1.80  2014  Ki=1.8mM      // 4m6u.pdf (TTN) tartronate was a competitive inhibitor of MR
4o2b  2.30  2014  Ki=1.8uM      // 4o2a.pdf (LOC) ligand is colchicine;Ki=1.8+/-0.15uM
4mny  1.70  2014  Ki=1.96uM     // 4mnv.pdf (14-mer) ligand is bicyclic peptide TBAB(UK903)
4mqp  1.83  2014  Ki=10.4uM     // 4mqp.pdf (2B1) ligand is compound 2, competitive reversible inhibitor of BioA with respect to SAM. But structure is different from that in PDB
4ngp  1.63  2014  Ki=10.97nM    // 4ngp.pdf (J31) ligand is compound 20(H)b;Kd=10.97+/-0.57nM
4oc4  1.66  2014  Ki=105nM      // 4oc0.pdf (2QN) ligand is compound 4
4owm  1.99  2014  Ki=1090uM     // 4n5v.pdf (3F0) substrate is compound 3FA
4o9v  1.90  2014  Ki=10nM       // 4o97.pdf (NT4) ligand is compound 15
4cft  1.79  2014  Ki=11.16uM    // 4cft.pdf (M48) ligand is compound 7
4civ  2.90  2014  Ki=11.2uM     // 4civ.pdf (48P) ligand is compound 5
4mnv  1.80  2014  Ki=11.56uM    // 4mnv.pdf (14-mer) ligand is bicyclic peptide TBMB(UK729), 10+4=14 mer; incomplete ligand structure
4joj  1.20  2014  Ki=110uM      // 4joe.pdf (10-mer) ligand is peptide F-iCAL36 (ANSRFPTSII)
4qir  1.70  2014  Ki=112nM      // 4qhp.pdf (379) ligand is compound 11; Ki=112+/-16nM
4r59  1.65  2014  Ki=11nM       // 4r59.pdf (3J3) ligand is compound 5d
4cd1  2.00  2014  Ki=12.8uM     // 4cd1.pdf (8E9) ligand is compound PSB-071, data from ref (Baqi et al., 2009)
4lm3  1.49  2014  Ki=1200uM     // 4lkq.pdf (9ZE) ligand is compound ZT0464 (4)
4qgi  1.90  2014  Ki=125uM      // 4qgi.pdf (ROC) Saquinavir(SQV); Ki=125+/-15uM
3zj8  3.01  2014  Ki=127uM      // 3zj6.pdf (LR1) ligand is compound 3
4quo  1.65  2014  Ki=12nM       // 4qhp.pdf (3DZ) ligand is compound 35; Ki=12+/-7nM
4os4  2.00  2014  Ki=13.6uM     // 4os1.pdf (15-mer) bicyclic peptide UK603 (bicyclic 1); Ki=13.6+/-0.5uM
4llx  1.75  2014  Ki=1300uM     // 4lkq.pdf (5ZE) ligand is compound ZT0434 (18)
4n4s  2.20  2014  Ki=133nM      // 4n4s.pdf (2H1) ligand is compound 3
4k6y  1.48  2014  Ki=14.8uM     // 4joe.pdf (10-mer) ligand is peptide iCAL36-Q (ANSRWQTSII)
3wq5  1.80  2014  Ki=140uM      // 3wq5.pdf (VPA) [Nonstandard assay: Temp 40,PH=4.0,Tris Hcl=10mM] ligand is PhPA
4kiu  2.40  2014  Ki=140uM      // 4ki7.pdf (KIU) ligand is compound 49d
4ozo  2.60  2014  Ki=147uM      // 4oue.pdf (OTN) ligand is oNPTG; Ki=147+/-59 uM
4mc1  1.39  2014  Ki=14nM       // 4mc1.pdf (526) ligand is compound 52
4o44  2.89  2014  Ki=14nM       // 4o44.pdf (2RS) ligand is compound 2; Ki=14+/-4nM
4pcs  1.77  2014  Ki=14nM       // 4pcs.pdf (2M7) ligand is compound 5
4r76  2.50  2014  Ki=14nM       // 4r5t.pdf (R5X) ligand is compound 13l
4r95  1.99  2014  Ki=14nM       // 4r8y.pdf (3KW) ligand is compound 54
4rak  2.04  2014  Ki=14nM       // 4rak.pdf (652) ligand is compound 18
4ciw  2.20  2014  Ki=15.0uM     // 4civ.pdf (XH2) ligand is compound 6
4ih3  2.49  2014  Ki=15.2uM     // 4ih3.pdf (PDC)
4keq  2.28  2014  Ki=150uM      // 4keq.pdf (5PN)
4kwf  2.31  2014  Ki=15uM       // 4kwf.pdf (3AK) ligand is compound 3, competitive Inhibition Data versus Varied Aldehyde
4k78  1.80  2014  Ki=16.2uM     // 4joe.pdf (10-mer) ligand is peptide iCAL36-QDTRL (ANSRWQDTRL)
4omc  2.30  2014  Ki=16.7pM     // 4omc.pdf (5-mer) ligand is inhibitor I1: meta-guanidinomethyl- Phac-RVR-Amba; Ki=16.7+/-0.6pM
4r93  1.71  2014  Ki=16nM       // 4r8y.pdf (779) ligand is compound 46
4rj4  2.78  2014  Ki=16nM       // 4rj3.pdf (3QW) ligand is compound 6
4w9p  1.50  2014  Ki=16nM       // 4w9o.pdf (3JR) ligand is (S)-19
4llp  1.75  2014  Ki=16uM       // 4lkq.pdf (4ZE) ligand is compound ZT0401(NA)
4uub  2.90  2014  Ki=17.2uM     // 4utn.pdf (9-mer) ligand is 2R-butyl- succinylated CPS1-peptide 5j; Ki=17.2+/-1.31uM
4mnx  1.85  2014  Ki=17.73uM    // 4mnv.pdf (14-mer) ligand is bicyclic peptide TATA(UK811)
4obv  2.84  2014  Ki=178mM      // 4obv.pdf (2SU) ligand is alpha-FMT; Ki=178+/-73mM
4cpx  1.85  2014  Ki=17nM       // 4coe.pdf (V78) ligand is compound 10e
4nga  2.15  2014  Ki=17nM       // 4nga.pdf (2KF) ligand is compound 7j
4rj8  2.50  2014  Ki=17nM       // 4rj3.pdf (3QS) ligand is compound 8
4w9o  1.27  2014  Ki=17nM       // 4w9o.pdf (3JQ) ligand is (R)-19
4r5b  1.50  2014  Ki=185nM      // 4r59.pdf (3J4) ligand is compound 5e
4cae  1.46  2014  Ki=18nM       // 4cae.pdf (3F3) ligand is compound 20b
4cpq  2.35  2014  Ki=18nM       // 4coe.pdf (9MW) ligand is compound 9b
4jxs  1.90  2014  Ki=18uM       // 4jxs.pdf (18U) ligand is compound 4
4jog  1.47  2014  Ki=190uM      // 4joe.pdf (10-mer) ligand is peptide V-iCAL36 (ANSRVPTSII)
4cd5  1.10  2014  Ki=194nM      // 4cd4.pdf (2-mer) ligand is compound 4
4jxw  2.30  2014  Ki=19uM       // 4jxs.pdf (1MW) ligand is compound 6
4c2v  1.49  2014  Ki=1nM        // 4c2v.pdf (YJA)
4ps8  2.99  2014  Ki=1nM        // 4ps3.pdf (2WK) ligand is compound 10
4q1c  2.00  2014  Ki=2.0nM      // 4q18.pdf (2XM) ligand is compound 8; Ki=2.0+/-0.6nM
4wku  2.00  2014  Ki=2.1uM      // 4wks.pdf (3QJ) ligand is C6-B(OH)2; B-containing; Ki=2.1+/-0.4x10-6M
4jls  2.20  2014  Ki=2.2uM      // 4jit.pdf (3ZE) ligand is compound 8
4bf1  1.35  2014  Ki=2.4nM      // 4bf1.pdf (9FK) ligand is compound 10
4o3a  1.80  2014  Ki=2.57mM     // 4o3a.pdf (ASP) 250 mM L-Asp; Ki= 2.57+/-0.13mM; redundant to 4o3c
4o3c  1.50  2014  Ki=2.57mM     // 4o3a.pdf (ASP) 50 mM L-Asp; Ki= 2.57+/-0.13mM
4os1  2.20  2014  Ki=2.5uM      // 4os1.pdf (15-mer) bicyclic peptide UK601 (bicyclic 1); Ki=2.5+/-0.1uM
4tw8  3.00  2014  Ki=2.611uM    // 4tw6.pdf (37M) ligand is iFit-FL; Ki=2611+/-340nM
4cwn  1.80  2014  Ki=2.6uM      // 4cwf.pdf (6LV) ligand is compound 7h
4tpk  2.70  2014  Ki=2.71nM     // 4tpk.pdf (3F9) ligand is compound (+)-1
2yne  1.72  2014  Ki=2.7nM      // 2ynd.pdf (YNE) ligand is compound 2a
4p5e  1.35  2014  Ki=2.8uM      // 4p5d.pdf (N6P) ligand is compound 1a; Ki=2.8+/-0.1uM
4pqa  1.78  2014  Ki=2.8uM      // 4pqa.pdf (X8Z) ZnZn(NmDapE)
4o0t  2.60  2014  Ki=2.9uM      // 4o0r.pdf (2OL) ligand is compound 17
4cpz  2.20  2014  Ki=20.85nM    // 4cpm.pdf (ZMR) ligand is Zanamivir
4ovg  1.90  2014  Ki=204uM      // 4ovf.pdf (2VF) compound 2a
4cpt  1.70  2014  Ki=20nM       // 4coe.pdf (1T8) ligand is compound 10b
4o09  1.96  2014  Ki=20nM       // 4o04.pdf (2R6) ligand is compound 30; Ki=0.020+/-0.004uM
4q93  2.10  2014  Ki=22.3uM     // 4q93.pdf (STL) Resveratrol(RSV)
4rj7  2.55  2014  Ki=22nM       // 4rj3.pdf (3R1) ligand is compound 1
4os5  2.26  2014  Ki=23.7uM     // 4os1.pdf (15-mer) bicyclic peptide UK603 (bicyclic 2); Ki=23.7+/-0.6uM
4g95  1.35  2014  Ki=24.4nM     // 4g95.pdf (OAG) ligand is OAAG324
4os7  2.00  2014  Ki=24uM       // 4os1.pdf (15-mer) bicyclic peptide UK607 (bicyclic); Ki=24+/-2uM
4oc1  1.75  2014  Ki=254nM      // 4oc0.pdf (2QS) ligand is compound 5
4p58  2.06  2014  Ki=25uM       // 4p58.pdf (2F6) ligand is compound 6
4cd4  1.20  2014  Ki=263nM      // 4cd4.pdf (2-mer) ligand is compound 3
4tw7  1.25  2014  Ki=26nM       // 4tw6.pdf (37K) ligand is iFit4; Ki=26+/-4nM
3wq6  1.80  2014  Ki=26uM       // 3wq5.pdf (ZPA) [Nonstandard assay: Temp 40 ,PH=4.0,Tris Hcl 10 mM ] ligand is BsPA
4ciy  2.10  2014  Ki=27.0uM     // 4civ.pdf (NDY) ligand is compound 8
4joe  1.14  2014  Ki=275uM      // 4joe.pdf (10-mer) ligand is peptide A-iCAL36 (ANSRAPTSII)
4ngn  1.64  2014  Ki=28.1nM     // 4ngn.pdf (J96) ligand in paper is compound 20a(Br), ligand in RCSB PDB is compound 9b (for code 4NGR in paper)
4ngr  1.90  2014  Ki=28.1nM     // 4ngr.pdf (J21) ligand is compound 9b;Kd=28.1+/-1.5nM
4cpu  1.82  2014  Ki=29.5nM     // 4coe.pdf (V78) ligand is compound 10d
4wks  1.63  2014  Ki=2mM        // 4wks.pdf (3QD) ligand is C2-B(OH)2; B-containing; Ki=2+/-0.4x10-3M
4ps3  2.90  2014  Ki=2nM        // 4ps3.pdf (2WH) ligand is compound 22
4r5a  1.64  2014  Ki=2nM        // 4r59.pdf (3J4) ligand is compound 5e
4kz7  1.43  2014  Ki=3.2mM      // 4kz3.pdf (1U5) ligand is fragment compound 16
4lv3  1.42  2014  Ki=3.2uM      // 4lv0.pdf (25N) ligand is compound 14
4o0v  2.80  2014  Ki=3.3nM      // 4o0r.pdf (2OL) ligand is compound 17; PAK4 Ser residue modified
4k1e  1.30  2014  Ki=3.59nM     // 4k1e.pdf (14-mer) ligand is modified peptide SFTI inhibitor FCQR
4mvn  1.70  2014  Ki=3.5uM      // 4mvn.pdf (I1S) ligand is compound 31, incorrect structure, different from that in PDB
4ngt  2.31  2014  Ki=3.88nM     // 4ngt.pdf (J42) ligand is compound 28b;Kd=3.88+/-0.35nM
4nwd  2.60  2014  Ki=3.96uM     // 4nwc.pdf (2QD) ligand is compound 2; Ki=3.96+/-0.99uM
4uma  1.76  2014  Ki=3.9uM      // 4uma.pdf (GZ3) ligand is vinyl phosphonate 6; Ki=3.9+/-0.4uM
4mrz  1.58  2014  Ki=300uM      // 4lkq.pdf (2ZV) ligand is compound ZT0429 (10)
4qme  1.60  2014  Ki=302nM      // 4qhp.pdf (37B) ligand is compound (R,S)-1
4ty6  1.85  2014  Ki=30nM       // 4ty6.pdf (39D) ligand is compound 11h
4cpw  1.70  2014  Ki=31.5nM     // 4coe.pdf (V78) ligand is compound 11d
4n3w  1.90  2014  Ki=315uM      // 4n3w.pdf (15-mer) ligand is Acetylated Histone 4 Peptide (H4K20ac)
4oc0  1.85  2014  Ki=318nM      // 4oc0.pdf (2R7) ligand is compound 3
4jxv  1.76  2014  Ki=31uM       // 4jxs.pdf (1MU) ligand is compound 5
4cwf  2.00  2014  Ki=32.4uM     // 4cwf.pdf (H05) ligand is compound 3
2ynd  1.89  2014  Ki=32nM       // 2ynd.pdf (646) ligand is compound 1a
4cu8  2.50  2014  Ki=33.9uM     // 4cu7.pdf (DGJ) ligand is compound DGJ
4q2k  2.20  2014  Ki=33nM       // 4q2k.pdf (5BF) ligand is compound 5b
4cix  2.90  2014  Ki=34.0uM     // 4civ.pdf (W4N) ligand is compound 7
4owo  1.99  2014  Ki=34uM       // 4n5v.pdf (6F0) substrate is compound 6FA
4kwo  1.32  2014  Ki=353nM      // 4kwo.pdf (1UD) ligand is compound beta 6c
4cpr  1.80  2014  Ki=35nM       // 4coe.pdf (378) ligand is compound 9e
4umc  2.34  2014  Ki=360uM      // 4uma.pdf (PEQ) ligand is (S)-phospholactate 8; Ki=360+/-30uM
4o0r  2.40  2014  Ki=36nM       // 4o0r.pdf (X4Z) ligand is compound 1
4nh9  2.77  2014  Ki=375nM      // 4nh7.pdf (2LC) ligand is SNX0723
4mi9  1.85  2014  Ki=376.87uM   // 4mho.pdf (26W) ligand is compound S20
4o05  1.79  2014  Ki=37nM       // 4o04.pdf (2Q9) ligand is compound 23; Ki=0.037+/-0.017uM
4ou3  1.95  2014  Ki=38.7uM     // 4ou3.pdf (6-mer) CNGRCG tumor-homing peptide
4llj  1.56  2014  Ki=380uM      // 4lkq.pdf (1XN) ligand is compound ZT0214 (11)
4n8q  2.08  2014  Ki=380uM      // 4n5v.pdf (FA0) substrate is compound 4FA
4p7s  2.87  2014  Ki=38nM       // 4p7m.pdf (2OK) ligand is compound 2; Ki=38+/-9nM
4p7m  3.02  2014  Ki=39nM       // 4p7m.pdf (2OE) ligand is compound 1; Ki=39+/-8nM
4ps7  2.69  2014  Ki=39nM       // 4ps3.pdf (2WJ) ligand is compound 3
4r92  1.71  2014  Ki=39nM       // 4r8y.pdf (3KU) ligand is compound 44
4nh8  1.65  2014  Ki=3nM        // 4nh7.pdf (2LC) ligand is SNX0723
4o97  2.20  2014  Ki=3nM        // 4o97.pdf (NTX) ligand is compound 43
4cnh  1.90  2014  Ki=4.0nM      // 4cli.pdf (3U9) ligand is compound 6b
3wmb  2.70  2014  Ki=4.28uM     // 3wmb.pdf (NF1) ligand is naphthalimide derivative Q1
4v24  1.80  2014  Ki=4.3nM      // 4v24.pdf (GYR) ligand is PF-543 (compound 1)
4bf6  1.82  2014  Ki=4.5nM      // 4bf1.pdf (X0Q) ligand is compound 13
4k76  1.75  2014  Ki=4.5uM      // 4joe.pdf (10-mer) ligand is peptide iCAL36-TRL (ANSRWPTTRL)
4pee  1.95  2014  Ki=4.8nM      // 4pcs.pdf (2OX) ligand is compound 4
4mic  2.45  2014  Ki=4.98uM     // 4mho.pdf (26Y) ligand is compound S6
4ms0  1.79  2014  Ki=410uM      // 4lkq.pdf (2ZX) ligand is compound ZT0443 (5)
4na9  2.24  2014  Ki=41nM       // 4na7.pdf (1T7) ligand is compound 29, Ki for Factor VIIa is 41nM
4o07  1.86  2014  Ki=42nM       // 4o04.pdf (FGH) ligand is compound 28; Ki=0.042+/-0.012uM
4ntj  2.62  2014  Ki=43.9nM     // 4ntj.pdf (AZJ) ligand is ADZ1283; P2Y12R D294 mutant+ BRIL; Ki= 43.9+/-10.0nM
4pp9  2.58  2014  Ki=43nM       // 4pp9.pdf (2VT) ligand is compound 1
4joh  1.47  2014  Ki=450uM      // 4joe.pdf (10-mer) ligand is peptide H-iCAL36 (ANSRHPTSII)
4lkq  1.62  2014  Ki=450uM      // 4lkq.pdf (1XM) ligand is compound ZT0017 (1)
4owv  1.90  2014  Ki=45uM       // 4n5v.pdf (BE2) ligand is anthranilate
4mi6  1.90  2014  Ki=48.68uM    // 4mho.pdf (26V) ligand is compound S2
4cpy  1.80  2014  Ki=491.35nM   // 4cpm.pdf (G39) ligand is Oseltamivir
4nh7  2.00  2014  Ki=4nM        // 4nh7.pdf (E0G) ligand is SNX2112
4ual  1.71  2014  Ki=4nM        // 4uak.pdf (3FV) ligand is BDP5290
4ob0  1.20  2014  Ki=5.0uM      // 4ob0.pdf (PBC) ligand is PBA; Ki=5.0+/-0.9uM
4mhs  2.00  2014  Ki=5.14uM     // 4mho.pdf (26Q) ligand is compound S1
4oc3  1.79  2014  Ki=5.3nM      // 4oc0.pdf (2QP) ligand is compound 1
4oc2  1.65  2014  Ki=5.3nM      // 4oc0.pdf (2QQ) ligand is compound 6
4cps  1.55  2014  Ki=5.4nM      // 4coe.pdf (1T8) ligand is compound 10a
4r5x  1.85  2014  Ki=5.5uM      // 4r5t.pdf (R5X) ligand is compound 13l
4u8w  1.30  2014  Ki=5.8pM      // 4u8w.pdf (G10) ligand is inhibitor 4
4msa  1.62  2014  Ki=500uM      // 4lkq.pdf (2ZM) ligand is compound ZT0449 (6)
4mrw  1.96  2014  Ki=500uM      // 4lkq.pdf (MRW) ligand is compound ZT0120 (b) (3)
4kij  2.80  2014  Ki=50uM       // 4ki7.pdf (KIJ) ligand is compound 35c
4nq6  1.80  2014  Ki=53uM       // 4nq6.pdf (3R9) Ki = 53 +/- 5 uM
4itp  1.70  2014  Ki=54nM       // 4itp.pdf (1GD)
4k75  1.50  2014  Ki=56.2uM     // 4joe.pdf (10-mer) ligand is peptide iCAL36-QDTRL (ANSRWQDTRL)
4lm0  1.66  2014  Ki=560uM      // 4lkq.pdf (5NI) ligand is compound ZT0448 (c)(8)
4oak  2.00  2014  Ki=59.7uM     // 4muq.pdf (2-mer) ligand is D-Alanine-D-Alanine
4lm1  1.60  2014  Ki=590uM      // 4lkq.pdf (7ZE) ligand is compound ZT0450 (19)
4o0b  1.93  2014  Ki=5nM        // 4o04.pdf (2QA) ligand is compound 31; Ki=0.005+/-0.002uM
4cwo  2.31  2014  Ki=6.1uM      // 4cwf.pdf (T62) ligand is compound 8b
4m0r  1.96  2014  Ki=6.2uM      // 4giu.pdf (644) ligand is compound 38
4mc2  1.56  2014  Ki=6.4nM      // 4mc2.pdf (525) ligand is compound 50
4q1e  1.85  2014  Ki=6.8nM      // 4q18.pdf (2Y7/2Y8) ligand is compound 10; Ki=6.8+/-1.6nM; R,S
4o0y  2.20  2014  Ki=60nM       // 4o0r.pdf (2OO) ligand is compound 13; PAK4 Ser residue modified
4own  2.11  2014  Ki=60uM       // 4n5v.pdf (5RG) substrate is compound 5FA
4tw6  1.40  2014  Ki=61uM       // 4tw6.pdf (37L) ligand is iFit
4rj5  3.10  2014  Ki=66nM       // 4rj3.pdf (3QY) ligand is compound 5
4o0x  2.48  2014  Ki=68nM       // 4o0r.pdf (2OQ) ligand is compound 8; PAK4 Ser residue modified
4jof  1.20  2014  Ki=68uM       // 4joe.pdf (10-mer) ligand is peptide L-iCAL36 (ANSRLPTSII)
4oma  1.60  2014  Ki=68uM       // 4oma.pdf (LCS) ligand is L-cycloserine; Ki=0.068+/-0.07mM
4kup  1.31  2014  Ki=6uM        // 4kup.pdf (1TZ) ligand is compound (S)-H4-A4, prepare crystal with 20mM acylhydrazone inhibitor
4kiw  2.57  2014  Ki=7.5uM      // 4ki7.pdf (KIW) ligand is compound 49e
4ngs  1.68  2014  Ki=7.6nM      // 4ngs.pdf (J34) ligand is compound 13b;Kd=7.6+/-1.2nM
4cp7  1.80  2014  Ki=7.8nM      // 4coe.pdf (9MW) ligand is compound 9a
4pct  2.10  2014  Ki=70nM       // 4pcs.pdf (H76) ligand is compound 11
4prj  2.80  2014  Ki=72nM       // 4pqn.pdf (2VU) ligand is compound 2
4q18  2.00  2014  Ki=735nM      // 4q18.pdf (2XJ) ligand is compound 4; Ki=735+/-55nM
4ovf  2.05  2014  Ki=74uM       // 4ovf.pdf (2VG) compound 1e
4mi3  2.15  2014  Ki=75.29uM    // 4mho.pdf (26R) ligand is compound S21
4bzs  2.10  2014  Ki=75nM       // 4bzr.pdf (K26) ligand is compound 1, K-26. data is for N-domain
4caf  1.70  2014  Ki=75nM       // 4cae.pdf (370) ligand is compound 34a
4ng9  2.20  2014  Ki=75nM       // 4ng9.pdf (2KE) ligand is compound 7d
4loy  1.77  2014  Ki=8.1nM      // 4loy.pdf (6XS) ligand is Compound 15 (SAR107375)
4mho  2.00  2014  Ki=8.25uM     // 4mho.pdf (26M) ligand is compound S3
4q19  2.09  2014  Ki=8.9nM      // 4q18.pdf (2XL) ligand is compound 5; Ki=8.9+/-0.9nM
4cq0  1.45  2014  Ki=8106nM     // 4cq0.pdf (SXS) ligand is compound 5b, but structure is different from that in PDB
4jok  1.09  2014  Ki=85.3uM     // 4joe.pdf (10-mer) ligand is peptide Y-iCAL36 (ANSRYPTSII)
4oc5  1.70  2014  Ki=85nM       // 4oc0.pdf (2QM) ligand is compound 2
4qkx  3.30  2014  Ki=85nM       // 4qkx.pdf (35V) ligand is compound 2; Ki=85+/-29nM
4qhp  1.60  2014  Ki=9.0nM      // 4qhp.pdf (32Q/32R) ligand is compound 36; Ki=9.0+/-3nM
4q1f  2.10  2014  Ki=9.2nM      // 4q18.pdf (2XN) ligand is compound 12R; Ki=9.2+/-1.1nM
4lm4  1.48  2014  Ki=910uM      // 4lkq.pdf (JPZ) ligand is compound ZT0902 (25)
4p6x  2.50  2014  Ki=91nM       // 4p6w.pdf (HCY) ligand is cortisol
4lm2  1.55  2014  Ki=940uM      // 4lkq.pdf (8ZE) ligand is compound ZT0462 (14)
4msn  2.30  2014  Ki=94uM       // 4lkq.pdf (2ZQ) ligand is compound ZT0451 (7)
4omd  2.70  2014  Ki=977pM      // 4omc.pdf (5-mer) ligand is iInhbitor I2: Phac-RVR-Amba ; Ki=977+/-196pM
4llk  1.55  2014  Ki=990uM      // 4lkq.pdf (MEW) ligand is compound ZT0217 (60)
4umb  2.17  2014  Ki=99uM       // 4uma.pdf (0V5) ligand is (R)-phospholactate 7; Ki=99+/-16uM
4o4g  2.71  2014  Ki=9nM        // 4o44.pdf (2RT) ligand is compound 1; Ki=9+/-2nM
4k72  1.90  2014  Ki>1000uM     // 4joe.pdf (10-mer) ligand is peptide iCAL36-VQD (ANSRVQDSII)
4old  1.48  2014  Ki>2mM        // 4okp.pdf (2UZ) ligand is compound 45
4oue  2.35  2014  Ki>500uM      // 4oue.pdf (IPT) ligand is IPTG
4uat  1.30  2014  Ki~1.3uM      // 4uat.pdf (XBP) ligand is XuBP; Crystal form I, 25% PEG-550MME, 0.1 M MES-NaOH pH 6.5; RsCbbY mutant D10N Mg2+ containing
4uau  1.45  2014  Ki~1.3uM      // 4uau.pdf (XBP) Crystal form II, 25% PEG- 1000, 0.1 M MES-NaOH pH 6.5; RsCbbY mutant D10N
4tnw  3.20  2014  Ki~167uM      // 4tnv.pdf (POV) ligand is POPS
4nzb  2.68  2014  Ki~67uM       // 4nzb.pdf (NSE)
4wx6  2.15  2015  IC50<0.001uM  // 4wx4.pdf (3VK) [Covalent complex] compound 6
5alh  1.90  2015  IC50<0.086uM  // 5ai0.pdf (4UA) compound 29
5akl  2.00  2015  IC50<0.086uM  // 5ai0.pdf (6N8) compound 20
5alr  2.60  2015  IC50<0.086uM  // 5ai0.pdf (8TM) compound 39
5ali  1.85  2015  IC50<0.086uM  // 5ai0.pdf (Q3B) compound 30
5alp  2.06  2015  IC50<0.086uM  // 5ai0.pdf (QYD) compound 37
5akj  2.03  2015  IC50<1.37uM   // 5ai0.pdf (6N4) compound 18
4yff  3.07  2015  IC50<10nM     // 4yff.pdf (4CV) [Nonstandard assay: 20 mM Tris, 15 mM MgCl2] compound 53;
5dl1  3.00  2015  IC50<10uM     // 5dl1.pdf (5C2) ligand is compound AV145, IC50 value between 2-10uM
4wuy  1.63  2015  IC50<15nM     // 4wuy.pdf (3UJ) [Nonstandard assay: p53(361-380) peptide as a substrate] LLY-507
4r1v  1.20  2015  IC50<1nM      // 4r1v.pdf (3E8) compound 22
4wx4  1.03  2015  IC50=0.0006uM  // 4wx4.pdf (3VF) compound 3a
5ew3  2.50  2015  IC50=0.0012uM  // 5ew3.pdf (5T2) ligand is compound AAL993, cellular assays, CHO cells
5bvw  1.94  2015  IC50=0.0015uM  // 5bvk.pdf (1N1) ligand is compound dasatinib, 0.0015uM at 40% inhibition, not exact IC50 value
5bvn  2.21  2015  IC50=0.0015uM  // 5bvk.pdf (4VD) ligand is compound 4, 0.0015uM at 54% inhibition, not exact IC50 value
4uib  1.94  2015  IC50=0.001uM  // 4uia.pdf (GWX) compound 3p
4ys7  2.50  2015  IC50=0.001uM  // 4yqh.pdf (4GK) [Nonstandard assay: Temp 37, 2.5mM Tris-HCl, 2mM MgCl2] compound 39
5bpa  1.79  2015  IC50=0.001uM  // 5bot.pdf (4UF) ligand is compound 15
4unr  1.98  2015  IC50=0.002uM  // 4unn.pdf (QZE) compound 23
4zg7  1.75  2015  IC50=0.002uM  // 4zg6.pdf (4O0) [Nonstandard assay: Temp 37] compound PAT-347; LPC substrate;
4u01  2.80  2015  IC50=0.0035uM  // 4u01.pdf (39W) [Different protein in assay: full length 1b Con1 HCV NS3/4A protease] compound 16c
3wv1  1.98  2015  IC50=0.0039nM  // 3wv1.pdf (WHH) [Nonstandard assay: Temp=37,50 mM Tris-HCl (pH 7.5), 10 mM CaCl2, 150 mM NaCl] compound 21k
5ak2  2.19  2015  IC50=0.0039uM  // 5ak2.pdf (85Z) ligand is compound 24
4qmn  2.09  2015  IC50=0.003uM  // 4qml.pdf (DB8) ligand is Bosutinib
4yne  2.02  2015  IC50=0.003uM  // 4ymj.pdf (4EK) racemic 14 in assay, compound 14(R) in crystal;
5am1  2.15  2015  IC50=0.003uM  // 5ai0.pdf (I5T) compound 49
5bue  2.40  2015  IC50=0.003uM  // 5bue.pdf (4V8) ligand is compoud 10
4xv1  2.47  2015  IC50=0.0042uM  // 4xv1.pdf (904) PLX7904;
4qmy  1.88  2015  IC50=0.004uM  // 4qml.pdf (STU) ligand is Staurosporine
5a3t  1.90  2015  IC50=0.004uM  // 4uf0.pdf (MMK) ligand is KDM5-C49
5cs2  1.65  2015  IC50=0.004uM  // 5cs2.pdf (7-mer) ligand is the cyclic peptide cyclomarinA (1)
5d9k  2.55  2015  IC50=0.004uM  // 5d9k.pdf (584) ligand is compound 25
4xv2  2.50  2015  IC50=0.0054uM  // 4xv1.pdf (P06) ligand is dabrafenib;
5am3  2.20  2015  IC50=0.005uM  // 5ai0.pdf (AUB) compound 51
5buj  1.85  2015  IC50=0.005uM  // 5bue.pdf (4VB) ligand is compound 19
5bvo  1.98  2015  IC50=0.005uM  // 5bvk.pdf (4VE) ligand is compound 9, 0.005uM at 59% inhibition, not exact IC50 value
4otf  1.95  2015  IC50=0.006uM  // 4otf.pdf (2VL) compound 2, GDC0834
4yl0  1.52  2015  IC50=0.006uM  // 4yk5.pdf (4DZ) ligand is MF63;
4ylj  2.58  2015  IC50=0.006uM  // 4ylj.pdf (4E1) [Nonstandard assay: Temp 30, ATP=15uM] compound 5j
5alz  2.30  2015  IC50=0.006uM  // 5ai0.pdf (XQ9) compound 47
4yl3  1.41  2015  IC50=0.007uM  // 4yk5.pdf (4U9) compound 5;
4ryg  2.65  2015  IC50=0.008uM  // 4ryc.pdf (3ZJ) compound 54a
4zyi  1.67  2015  IC50=0.008uM  // 4zyf.pdf (4TH) compound 2
4yqh  2.31  2015  IC50=0.009uM  // 4yqh.pdf (4F7) [Nonstandard assay: Temp 37, 2.5mM Tris-HCl, 2mM MgCl2] compound 14
5bve  2.00  2015  IC50=0.010nM  // 5bvd.pdf (4VG) ligand is compound 11
4qmt  1.50  2015  IC50=0.010uM  // 4qml.pdf (H1N) ligand is Hesperadin
5ajx  2.58  2015  IC50=0.011uM  // 5ajv.pdf (FD9) ligand is compound 67
4wt6  2.30  2015  IC50=0.012uM  // 4wsy.pdf (3U6) compound 18
4xv3  2.80  2015  IC50=0.012uM  // 4xv1.pdf (P02) ligand is PLX7922;
5d7r  1.55  2015  IC50=0.013uM  // 5d7d.pdf (57Y) ligand is compound 28
4qmp  2.00  2015  IC50=0.014uM  // 4qml.pdf (DKI) ligand is CDK1/2 Inhibitor III
4x9v  1.43  2015  IC50=0.014uM  // 4x9r.pdf (6-mer) phosphopeptide macrocycle 3c
4x9r  1.40  2015  IC50=0.015uM  // 4x9r.pdf (6-mer) phosphopeptide macrocycle 3b
4z1q  1.40  2015  IC50=0.015uM  // 4z1q.pdf (558) [Nonstandard assay: NaCl=40mM] compound 3;
5ake  2.26  2015  IC50=0.015uM  // 5ai0.pdf (6N0) compoud 14
5cte  2.34  2015  IC50=0.016uM  // 5ctb.pdf (57L) [Different protein in assay: rat ACC1 used in assay] ligand is compound 3.5.1, IC50 for rat ACC1
4wsy  2.30  2015  IC50=0.017uM  // 4wsy.pdf (3U5) compound 1
4qmo  1.90  2015  IC50=0.019uM  // 4qml.pdf (34L) ligand is C16
5als  2.57  2015  IC50=0.019uM  // 5ai0.pdf (5DQ) compound 40
4pry  1.70  2015  IC50=0.020uM  // 4pry.pdf (5-mer) [Different ligand in assay: Ac-LETD-AOMK] ligand is unnatural peptide Ac-LETD-CHO
5ak0  2.03  2015  IC50=0.021uM  // 5ajv.pdf (8V1) ligand is compound 43
5alu  1.87  2015  IC50=0.022uM  // 5ai0.pdf (HD2) compound 42
5e1e  2.30  2015  IC50=0.022uM  // 5e1e.pdf (5JG) ligand is compound 30
4qmv  2.40  2015  IC50=0.023uM  // 4qml.pdf (34W) ligand is PF-03814735
4yk5  1.42  2015  IC50=0.023uM  // 4yk5.pdf (4DV) compound 30;
5d9l  2.15  2015  IC50=0.024uM  // 5d9k.pdf (583) ligand is compound 1
4zg9  2.95  2015  IC50=0.026uM  // 4zg6.pdf (4O2) [Nonstandard assay: Temp 37] compound PAT-352; LPC substrate;
5d11  2.30  2015  IC50=0.028uM  // 5d10.pdf (56G) ligand is compound 5b
4zjr  2.70  2015  IC50=0.029uM  // 4zjr.pdf (4P3) [Incomplete ligand] compound 48
4d2s  2.50  2015  IC50=0.02uM   // 4d2r.pdf (DYK) compound 23
4zga  2.60  2015  IC50=0.02uM   // 4zg6.pdf (4O3) [Nonstandard assay: Temp 37] compound PAT-494; LPC substrate;
5aae  3.11  2015  IC50=0.035uM  // 5aad.pdf (7HD) compound 14d
4z2i  2.00  2015  IC50=0.036uM  // 4z2g.pdf (M6B) compound 30
5aaf  2.78  2015  IC50=0.036uM  // 5aad.pdf (NL4) compound 14a
4qpa  2.85  2015  IC50=0.037uM  // 4qp1.pdf (35W) compound 39; SAR IC50 data
5alg  2.40  2015  IC50=0.03uM   // 5ai0.pdf (R4N) compound 28
5d12  3.00  2015  IC50=0.043uM  // 5d10.pdf (G97) ligand is compound 1a
5aag  2.85  2015  IC50=0.046uM  // 5aad.pdf (6F2) compound 14b
4q4i  2.31  2015  IC50=0.047uM  // 4q4e.pdf (4-mer) ligand is Amastatin
4rz1  2.60  2015  IC50=0.04uM   // 4rz1.pdf (3ZN) compound 24
4wx7  2.40  2015  IC50=0.04uM   // 4wx4.pdf (3VJ) [Covalent complex] compound 2c
5apj  2.08  2015  IC50=0.04uM   // 5aph.pdf (76E) ligand is compound 15, IC50 is displacement of tritiated T0901317 from human RORg LBD
4yv2  2.17  2015  IC50=0.051uM  // 4yv0.pdf (4K3) [Covalent complex] [Incomplete ligand] fragment 6; open circle in RCSB; code is 4yu2 in paper
4zpg  2.00  2015  IC50=0.055uM  // 4zpe.pdf (4QF) compound 10;
4ybs  1.83  2015  IC50=0.057uM  // 4yab.pdf (4BK) compound 7g;
4zur  1.13  2015  IC50=0.068uM  // 4zum.pdf (7XA) [Nonstandard assay: pH=8.2, 25 mM Tris, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2] compound 6;
5aep  1.95  2015  IC50=0.068uM  // 5aep.pdf (QUP) compound 15
4y6p  1.90  2015  IC50=0.069uM  // 4y67.pdf (R77) compound 8d;
4nxo  2.73  2015  IC50=0.06uM   // 4ifh.pdf (2H7) compound 1; BDM44768
4qr5  1.41  2015  IC50=0.06uM   // 4qr3.pdf (BNM) compound 40a
5aen  1.86  2015  IC50=0.06uM   // 5aen.pdf (DP8) [Nonstandard assay: 50 mM Tris-HCl, 50 mM NaCl, 0.01% Triton-X 100] compound 23
5aph  1.54  2015  IC50=0.06uM   // 5aph.pdf (VYI) ligand is compound 25, IC50 is displacement of tritiated T0901317 from human RORg LBD
5ct7  3.17  2015  IC50=0.070uM  // 5ct7.pdf (55J) ligand is compound 1, RAF265
4qp9  2.00  2015  IC50=0.071uM  // 4qp1.pdf (35X) compound 34; SAR IC50 data
5d10  2.70  2015  IC50=0.072uM  // 5d10.pdf (563) ligand is compound 5c
4yps  2.10  2015  IC50=0.075uM  // 4ymj.pdf (4F6) racemic 10 in assay, compound 10(R) in crystal;
5djv  2.30  2015  IC50=0.077uM  // 5dgn.pdf (5BL) ligand is biaryl compound 8e
4y6m  2.27  2015  IC50=0.07uM   // 4y6m.pdf (48Q) ligand is PG418
5axq  1.77  2015  IC50=0.080nM  // 5axp.pdf (4LP) ligand is compound 19e
4wag  3.41  2015  IC50=0.083uM  // 4wae.pdf (3K7) compound 49
4qmw  1.60  2015  IC50=0.086uM  // 4qml.pdf (KS1) ligand is pp-121
5ak5  2.22  2015  IC50=0.086uM  // 5ai0.pdf (V2Z) compound 12
5bui  2.12  2015  IC50=0.089uM  // 5bue.pdf (4V9) ligand is compound 2
5ai5  2.28  2015  IC50=0.093uM  // 5ai0.pdf (BSU) compound 3
5ajw  2.50  2015  IC50=0.104uM  // 5ajv.pdf (S6L) ligand is compound 49
4wq3  1.79  2015  IC50=0.10uM   // 4wq3.pdf (3SU-3SU) compound 4, dual compound 3 linked;
4qw4  2.80  2015  IC50=0.113uM  // 4qux.pdf (3BV) carfizomib
5am4  1.87  2015  IC50=0.113uM  // 5ai0.pdf (MVJ) compound 52
4y67  1.60  2015  IC50=0.117uM  // 4y67.pdf (RC5) compound 8c;
4qoc  1.70  2015  IC50=0.12nM   // 4qoc.pdf (35T) compound 16
4yll  1.40  2015  IC50=0.12uM   // 4ylj.pdf (4E3) [Nonstandard assay: Temp 30, ATP=15uM] compound 5t
4zuq  1.22  2015  IC50=0.13uM   // 4zum.pdf (6XA) [Nonstandard assay: pH=8.2, 25 mM Tris, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2] compound 5;
4x9w  1.80  2015  IC50=0.14uM   // 4x9r.pdf (5-mer) phosphopeptide macrocycle 4c
4ybm  1.46  2015  IC50=0.14uM   // 4yab.pdf (4BJ) compound 7b;
5d7c  1.55  2015  IC50=0.14uM   // 5d6p.pdf (57W) ligand is compound 12
5a83  2.09  2015  IC50=0.158uM  // 5a81.pdf (YD3) compound 42
5bvd  1.90  2015  IC50=0.16nM   // 5bvd.pdf (4VF) ligand is compound 3
4qo9  2.20  2015  IC50=0.16uM   // 4qml.pdf (627) ligand is Danusertib (wrong code 4QMR in paper)
4xt9  2.25  2015  IC50=0.16uM   // 4xt9.pdf (43V) compound 2c; pIC50=6.8;
5c83  2.33  2015  IC50=0.16uM   // 5c0k.pdf (4YN) ligand is compound 21
4zup  1.42  2015  IC50=0.17uM   // 4zum.pdf (5XA) [Nonstandard assay: pH=8.2, 25 mM Tris, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2] compound 4;
5c26  1.95  2015  IC50=0.17uM   // 5c26.pdf (50H) ligand is compound 1
5aly  1.90  2015  IC50=0.1845uM  // 5ai0.pdf (B7H) compound 46
4ylk  1.40  2015  IC50=0.18uM   // 4ylj.pdf (4E2) [Nonstandard assay: Temp 30, ATP=15uM] compound 5s
4zpf  1.80  2015  IC50=0.18uM   // 4zpe.pdf (4QD) [Different ligand in assay: ] compound 6; Ligand in binding assay is racemic
5bvf  1.90  2015  IC50=0.19nM   // 5bvd.pdf (4VJ) ligand is compound 19
4q4e  1.90  2015  IC50=0.19uM   // 4q4e.pdf (BB2) ligand is Actinonin
4uia  2.18  2015  IC50=0.19uM   // 4uia.pdf (FH9) compound 3a
4xv9  2.00  2015  IC50=0.19uM   // 4xv1.pdf (1OO) ligand is PLX5568;
4uco  2.50  2015  IC50=0.1uM    // 4uco.pdf (D41) compound 10
4ybt  1.82  2015  IC50=0.1uM    // 4yab.pdf (4BV) compound 7l;
4ymj  2.00  2015  IC50=0.1uM    // 4ymj.pdf (4EJ) compound 1
5alf  2.32  2015  IC50=0.204uM  // 5ai0.pdf (OE1) compound 27
5aad  3.10  2015  IC50=0.212uM  // 5aad.pdf (5GX) compound 7a;
4yl1  1.41  2015  IC50=0.216uM  // 4yk5.pdf (4U8) compound 3;
4z2g  2.60  2015  IC50=0.217uM  // 4z2g.pdf (M6V) compound 26
5awj  2.20  2015  IC50=0.21nM   // 5awj.pdf (YSL) ligand is compound 5
4qmz  1.88  2015  IC50=0.21uM   // 4qml.pdf (B49) ligand is sunitinib
4zjw  2.50  2015  IC50=0.22uM   // 4zjr.pdf (4P1) compound 16
4qw3  2.90  2015  IC50=0.243uM  // 4qux.pdf (BO2) bortezomib
5ai9  1.80  2015  IC50=0.244uM  // 5ai0.pdf (K78) compound 6
4unq  2.30  2015  IC50=0.24uM   // 4unn.pdf (H6D) compound 36
5alk  2.33  2015  IC50=0.252uM  // 5ai0.pdf (WMR) compound 32
5akh  2.10  2015  IC50=0.256uM  // 5ai0.pdf (6NM) compound 16
4qr4  1.28  2015  IC50=0.25uM   // 4qr3.pdf (BNK) compound 18c
4wpf  2.20  2015  IC50=0.25uM   // 4wpf.pdf (3SN) compound 3
5aln  2.00  2015  IC50=0.267uM  // 5ai0.pdf (5ZM) compound 35
4qmq  1.77  2015  IC50=0.26uM   // 4qml.pdf (34U) ligand is CP-673451
4py2  2.15  2015  IC50=0.272uM  // 4py2.pdf (43E) ligand is compound 1433; aminoacylation enzyme inhibition assay
4zum  1.42  2015  IC50=0.27uM   // 4zum.pdf (FKS) compound 1;
4qp8  2.45  2015  IC50=0.28uM   // 4qp1.pdf (362) compound 24; SAR IC50 data
5alm  2.00  2015  IC50=0.294uM  // 5ai0.pdf (7GM) compound 34
4qvl  2.80  2015  IC50=0.298uM  // 4qux.pdf (BO2) bortezomib
4uit  1.30  2015  IC50=0.2uM    // 4uit.pdf (N1D) compound 17; pIC50=6.7
4uns  2.18  2015  IC50=0.2uM    // 4unn.pdf (QZ3) compound 33
4qps  1.80  2015  IC50=0.30uM   // 4qps.pdf (37Q) [Covalent complex] compound 4, covalent
4qws  3.00  2015  IC50=0.316uM  // 4qux.pdf (3BV) carfilzomib
4yoi  1.82  2015  IC50=0.33uM   // 4yo9.pdf (4F4) compound 1A;
4x2i  1.20  2015  IC50=0.35uM   // 4x2i.pdf (3X0) ligand is CPI-13; AlphaLISA assay
3wyj  2.10  2015  IC50=0.36uM   // 3wyj.pdf (H78) compound 19
4wz4  1.05  2015  IC50=0.36uM   // 4wz4.pdf (3VU) [Covalent complex] [Uncommon element] [Nonstandard assay: TEMP 37] compound 37 (rac)
4z2j  2.60  2015  IC50=0.374uM  // 4z2g.pdf (M6G) [Incomplete ligand] compound 31
4wnk  2.42  2015  IC50=0.38uM   // 4wnk.pdf (453) ligand is CCG215022
4zyc  1.95  2015  IC50=0.38uM   // 4zyc.pdf (4SS) compound 5;
4zuo  1.33  2015  IC50=0.39uM   // 4zum.pdf (XS6) compound 3;
4wtu  1.85  2015  IC50=0.3nM    // 4wtu.pdf (3UT) [Nonstandard assay: pH=4.5, 50 mM acetate] compound 15
4y73  2.14  2015  IC50=0.3nM    // 4y73.pdf (XPY) compound 18
4yoj  1.90  2015  IC50=0.41uM   // 4yo9.pdf (RFM) compound 2A;
4unn  2.50  2015  IC50=0.42uM   // 4unn.pdf (QZZ) compound 8
4wzv  1.65  2015  IC50=0.43nM   // 4wzv.pdf (E40) [Nonstandard assay: Temp 37, Tris 50 mM, NaCl 150 mM, CaCl2 10 mM, Brij 35 0.05%, DMSO 1%] compound 3
5fdg  2.10  2015  IC50=0.43uM   // 4zhz.pdf (0N8) compound 3, same structure as L-742001
4qvm  2.80  2015  IC50=0.446uM  // 4qux.pdf (BO2) bortezomib
4qw5  3.00  2015  IC50=0.449uM  // 4qux.pdf (3BV) carfilzomib
4zpe  1.70  2015  IC50=0.45uM   // 4zpe.pdf (4QA) compound 5;
5ctc  2.70  2015  IC50=0.45uM   // 5ctb.pdf (57K) [Different protein in assay: rat ACC1 used in assay] ligand is compound 1.4, IC50 for rat ACC1
4qmm  1.85  2015  IC50=0.46uM   // 4qml.pdf (35R) Ligand is AT9283
4zg6  1.80  2015  IC50=0.472uM  // 4zg6.pdf (4NY) [Nonstandard assay: Temp 37] compound PAT-078; LPC substrate
4qt2  1.44  2015  IC50=0.48uM   // 4qt2.pdf (RAP) ligand is rapamycin; oxidized crystal form; another reduced crystal form deposited as code 4qt3
5ajy  2.37  2015  IC50=0.496uM  // 5ajv.pdf (87T) ligand is compound 69
4ufz  2.33  2015  IC50=0.49uM   // 4ufz.pdf (IA7) compound 22g
5ey8  3.50  2015  IC50=0.49uM   // 5ey8.pdf (5SV) AMPC20
4wrs  2.20  2015  IC50=0.4nM    // 4rpv.pdf (3U1) compound 13o
4xbd  1.45  2015  IC50=0.4uM    // 4xbb.pdf (M40) [Incomplete ligand] [Nonstandard assay: pH=8, Tris buffer] compound 44-o(Orthorhombic P Form)
4yv9  1.95  2015  IC50=0.4uM    // 4yv9.pdf (11-mer) ligand is Cyclosporin A
4y2x  2.50  2015  IC50=0.51uM   // 4y2j.pdf (4A0) fragment 9
4qw7  2.70  2015  IC50=0.521uM  // 4qux.pdf (3BV) carfilzomib
4qwx  2.90  2015  IC50=0.540uM  // 4qux.pdf (04C) ONX0914
4qwk  2.80  2015  IC50=0.543uM  // 4qux.pdf (3BV) carfilzomib
5a0c  2.10  2015  IC50=0.54nM   // 5a09.pdf (JJV) ligand is compound 28
4wvs  2.09  2015  IC50=0.54uM   // 4wvs.pdf (5-mer) ligand is linear 7
4qzx  2.60  2015  IC50=0.553uM  // 4qux.pdf (04C) ONX0914
5ajv  3.01  2015  IC50=0.575uM  // 5ajv.pdf (8R2) ligand is compound 44
4wf6  2.65  2015  IC50=0.5uM    // 4wf6.pdf (407) compound 3r; MK-31; MSA assay data
4wq2  1.64  2015  IC50=0.5uM    // 4wq2.pdf (3SU) compound 3
5c84  2.36  2015  IC50=0.64uM   // 5c0k.pdf (4YL) ligand is compound 20
4qwl  2.60  2015  IC50=0.661uM  // 4qux.pdf (3BV) carfilzomib
4zro  2.06  2015  IC50=0.69uM   // 4zro.pdf (5-mer) [Covalent complex] compound 6
5alo  2.00  2015  IC50=0.738uM  // 5ai0.pdf (A0J) compound 36
5aki  1.81  2015  IC50=0.754uM  // 5ai0.pdf (6NF) compound 17
4qw1  2.90  2015  IC50=0.773uM  // 4qux.pdf (BO2) bortezomib
4z1s  1.06  2015  IC50=0.79uM   // 4z1s.pdf (559) [Nonstandard assay: NaCl=40mM] compound 15
4ql8  2.10  2015  IC50=0.7nM    // 4ql8.pdf (JAD) compound 26, whole cell radioligand competition binding assay
4rcd  1.90  2015  IC50=0.7nM    // 4rcd.pdf (3LL) [Different protein in assay: R-5K, R-4K] compound 42
4udb  2.36  2015  IC50=0.7nM    // 4uda.pdf (CV7) ligand is dibC, desisobutyrylciclesonide
4xg9  2.91  2015  IC50=0.7nM    // 4xg3.pdf (X9G) ligand is O282
4wp7  1.80  2015  IC50=0.80uM   // 4wp7.pdf (3SR) ligand is CM026
4yrs  2.75  2015  IC50=0.85mM   // 4yrs.pdf (4JS) ligand is Chem 1698
4qvp  2.30  2015  IC50=0.891uM  // 4qux.pdf (BO2) bortezomib
4ya8  3.30  2015  IC50=0.8uM    // 4y6m.pdf (49W) ligand is PG394
5axp  1.95  2015  IC50=0.94nM   // 5axp.pdf (4LK) ligand is compound 1
5f5i  2.63  2015  IC50=0.95uM   // 5f2s.pdf (5V1) compound 30b
4xkx  1.80  2015  IC50=0.9nM    // 4xkx.pdf (43K) compound 28
4qwg  2.60  2015  IC50=1.069uM  // 4qux.pdf (3BV) carfilzomib
4wy6  2.10  2015  IC50=1.07uM   // 4wy1.pdf (3VP) [Nonstandard assay: Temp 37, PH=4.5, 100 mM sodium acetate] compound 36
4xub  1.98  2015  IC50=1.07uM   // 4xua.pdf (43D) compound 7
5ald  2.26  2015  IC50=1.08uM   // 5ai0.pdf (FCW) compound 25
4rvm  1.86  2015  IC50=1.0nM    // 4rvk.pdf (3X7) compound 19
5ale  1.95  2015  IC50=1.132uM  // 5ai0.pdf (ONR) compound 26
5bpe  2.70  2015  IC50=1.13uM   // 5bpe.pdf (E22) ligand is compound 9
4qwr  2.90  2015  IC50=1.184uM  // 4qux.pdf (3BV) carfilzomib
4ptc  2.71  2015  IC50=1.1nM    // 4ptc.pdf (2WE) compound 3
5cf8  1.80  2015  IC50=1.1nM    // 5cf8.pdf (50V) ligand is compound 11(BMS-911543)
4qxs  1.90  2015  IC50=1.1uM    // 4qxs.pdf (WC1) compound 9i, WC01088
4uxh  2.40  2015  IC50=1.1uM    // 4uxh.pdf (T5A) ligand is Ap5DT
5d1u  2.85  2015  IC50=1.1uM    // 4wf6.pdf (56P) compound 5c; MSA assay data
4qxj  2.80  2015  IC50=1.265uM  // 4qux.pdf (04C) ONX 0914
5a5r  2.01  2015  IC50=1.26uM   // 5a5n.pdf (NP8) compound 60
5a5s  1.36  2015  IC50=1.26uM   // 5a5n.pdf (NP8) compound 60
4ztl  2.39  2015  IC50=1.2uM    // 4ztl.pdf (4S1) compound 1
5afx  2.39  2015  IC50=1.2uM    // 5ael.pdf (PVZ) compound 37;
5am0  1.88  2015  IC50=1.32uM   // 5ai0.pdf (LWS) compound 48
4qw6  2.90  2015  IC50=1.397uM  // 4qux.pdf (3BV) carfilzomib
3wzu  3.01  2015  IC50=1.3uM    // 3wzu.pdf (1FM) ligand is 5Z7O
4qmu  1.55  2015  IC50=1.3uM    // 4qml.pdf (SKE) ligand is JNJ-7706621
4qr3  1.37  2015  IC50=1.40uM   // 4qr3.pdf (BNJ) compound 12a
4x47  2.00  2015  IC50=1.41mM   // 4x47.pdf (DAN) [Nonstandard assay: Temp 37, PH=6.5] Neu5Ac2en
4z2l  2.30  2015  IC50=1.41uM   // 4z2g.pdf (M6F) compound 33
4xs2  2.73  2015  IC50=1.52uM   // 4xs2.pdf (42P) compound 1
5a3w  2.00  2015  IC50=1.5uM    // 4uf0.pdf (PD2) ligand is 2,4-PDCA
4yax  2.25  2015  IC50=1.5uM    // 4yab.pdf (4AE) compound 5g;
4yrt  2.05  2015  IC50=1.65mM   // 4yrt.pdf (781) ligand is Chem 1781
4z2k  2.30  2015  IC50=1.66uM   // 4z2g.pdf (M6E) compound 32
4qwj  2.90  2015  IC50=1.686uM  // 4qux.pdf (3BV) carfilzomib
4py4  2.76  2015  IC50=1.69uM   // 4py4.pdf (XL2) ligand is compound 8
4z9l  2.10  2015  IC50=1.6nM    // 1pmq.pdf (880)
5auy  2.00  2015  IC50=1.6uM    // 5aut.pdf (MRI) ligand is compound 9, morin
4rss  1.83  2015  IC50=1.7nM    // 4rss.pdf (4MG) compound 16h
5d1t  2.20  2015  IC50=1.7uM    // 4wf6.pdf (56R) compound 5a; MSA assay data
4yuw  1.97  2015  IC50=1.7uM    // 4yuw.pdf (4JU) ligand is 4MCHA
5am5  2.26  2015  IC50=1.82uM   // 5ai0.pdf (6NZ) compound 53
4zsp  1.91  2015  IC50=1.83uM   // 4zsm.pdf (4RZ) compound 6
4rxa  2.20  2015  IC50=1.8uM    // 4rxa.pdf (3F2) compound 7
4yog  2.00  2015  IC50=1.8uM    // 4yo9.pdf (4F5) compound 3B;
4wvu  2.02  2015  IC50=1.97uM   // 4wvs.pdf (5-mer) compound 8;
4xg8  2.40  2015  IC50=1.9nM    // 4xg3.pdf (X8G) ligand is O272
5c4u  2.08  2015  IC50=1.9nM    // 4ypq.pdf (4Y7) MRL-367;
5c42  3.50  2015  IC50=1.9nM    // 5c42.pdf (29T) ligand is compound 3, JLJ555
4u82  1.66  2015  IC50=1.9uM    // 3wyj.pdf (FPS) ligand is FSPP
4rvt  2.40  2015  IC50=1.9uM    // 4rvt.pdf (3XM) compound 11e
5c7e  3.10  2015  IC50=10.0uM   // 5c6v.pdf (11-mer) ligand is 11-mer Arabidopsis IAA10 peptide
5ap5  2.80  2015  IC50=10.8nM   // 5ap0.pdf (7RO) ligand is compound 1, with ATP present at 21uM
5ap1  2.05  2015  IC50=10.8nM   // 5ap0.pdf (O38) ligand is compound ONCOII, with ATP present at 10.7uM
4uxb  3.22  2015  IC50=10.9nM   // 4r5w.pdf (P34) complex is PARP1/PJ34
4rs0  2.81  2015  IC50=1000nM   // 4rrw.pdf (IBP) ligand is S-ibuprofen
4zlz  2.00  2015  IC50=100nM    // 4z3v.pdf (4RV) compound 8;
5a5p  2.03  2015  IC50=100uM    // 5a5n.pdf (JTF) compound 11
4w4x  2.65  2015  IC50=102.8nM  // 4w4v.pdf (3HN) ligand is SR12327
4u2y  2.48  2015  IC50=102uM    // 4u2y.pdf (RZM) ligand is DDGIM
5c7f  2.70  2015  IC50=105.6uM  // 5c6v.pdf (11-mer) ligand is 11-mer Arabidopsis IAA1 peptide
4twy  1.60  2015  IC50=108uM    // 4tww.pdf (3BL) compound 40
4ykn  2.90  2015  IC50=10nM     // 4ykn.pdf (4EL) compound 5e
4zh2  4.20  2015  IC50=10uM     // 4zh2.pdf (4OB) [Nonstandard assay: Temp 37, pH=8, 50 mM Tris-HCl, 100 mM KCl, 10 mM MgCl2] ligand is CBR703; for gram-negative enteric bacterial RNAP
5aux  1.50  2015  IC50=10uM     // 5aut.pdf (KMP) ligand is compound 6, kaempferol
4xuc  1.80  2015  IC50=1100nM   // 4xuc.pdf (43G) compound 18
5c3k  2.02  2015  IC50=110uM    // 5c0k.pdf (4XF) ligand is compound 4
4wyo  2.89  2015  IC50=111nM    // 4wyo.pdf (3W2) compound 1;
4y62  1.60  2015  IC50=1133uM   // 4y62.pdf (48E) compoud 16a
4w4v  2.01  2015  IC50=115nM    // 4w4v.pdf (3H8) ligand is SR-11165
4uvx  1.95  2015  IC50=11nM     // 4uvl.pdf (H2W) compound 14f
4y46  2.04  2015  IC50=11nM     // 4y46.pdf (4F2) compound 22
4y8c  2.70  2015  IC50=11nM     // 4y86.pdf (49D) [Nonstandard assay: pH=8, 50 mM Tris-HCl, 10 mM MgCl2] (S)-C33;
4qmx  1.88  2015  IC50=11uM     // 4qml.pdf (H8H) ligand is Saracatinib
5al3  1.75  2015  IC50=11uM     // 5aku.pdf (TGW) ligand is compound 11
4re9  2.91  2015  IC50=12.1uM   // 4ifh.pdf (3M9) compound 16
4tvj  2.10  2015  IC50=12.3nM   // 4r5w.pdf (09L) complex is PARP1/Olaparib
4uiu  1.64  2015  IC50=12.6nM   // 4uit.pdf (TVU) compound 32; pIC50=7.9
4uvu  1.95  2015  IC50=1200nM   // 4uvl.pdf (U1T) compound 13n
5c0k  2.20  2015  IC50=1200uM   // 5c0k.pdf (4WK) ligand is compound 3
5ci7  1.74  2015  IC50=120nM    // 5ci7.pdf (51W) ligand is compound 3
5ai8  1.85  2015  IC50=125.6uM  // 5ai0.pdf (K2T) compound 5
4yjn  2.60  2015  IC50=12nM     // 4yjn.pdf (UW4) compound 37;
4zlo  2.50  2015  IC50=12uM     // 4zji.pdf (4PV) compound 1
5alt  2.15  2015  IC50=13.1uM   // 5ai0.pdf (9XZ) compound 41
5ap6  2.10  2015  IC50=13.3nM   // 5ap0.pdf (PWU) ligand is compound 2, with ATP present at 125uM
4rvk  1.85  2015  IC50=13.5nM   // 4rvk.pdf (3XK) compound 8
5djr  2.40  2015  IC50=13.9uM   // 5dgn.pdf (5BK) ligand is biaryl compound 6
4ucv  2.60  2015  IC50=1310uM   // 4ucv.pdf (I6G) compound 5
5afk  2.46  2015  IC50=132uM    // 5afh.pdf (5VU) fragment 2;
4rx9  1.75  2015  IC50=13nM     // 4rx7.pdf (3YT) compound 1; enzyme assay
4y85  2.33  2015  IC50=13nM     // 4y83.pdf (499) [Nonstandard assay: Temp 30, 50 mM HEPES, 1 mM DTT, 0.02% (w/v) Tween 20, 0.02% (w/v) BSA] compound 2
4yp8  2.64  2015  IC50=13nM     // 4yo6.pdf (4GF) compound 30
4p4b  1.93  2015  IC50=14nM     // 4p44.pdf (2G2) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor CTT54
4x7q  2.33  2015  IC50=14nM     // 4x7q.pdf (3YR) compound 1s
4yzn  1.55  2015  IC50=15.4uM   // 4yzm.pdf (4K5) [Nonstandard assay: Temp 30, 50 mM Tris-HCl, 0.1 mM EGTA, 25 uM [gamma-32P]ATP (~300 cpm/pmol), 10 mM MgCl2, 2 mM DTT, 150 uM LRRKtide] compound 19;
5cqj  2.15  2015  IC50=15.4uM   // 5cqj.pdf (53Q) ligand is clomiphene
4uiv  1.72  2015  IC50=15.8nM   // 4uit.pdf (XZB) compound 44; pIC50=7.8
4rn2  2.39  2015  IC50=1500nM   // 4rn0.pdf (L7G) compound 3
5aku  1.80  2015  IC50=150nM    // 5aku.pdf (29F) ligand is compound 37
4y2t  2.40  2015  IC50=150uM    // 4y2j.pdf (49Q) fragment 6
4y5h  2.06  2015  IC50=15nM     // 4y46.pdf (519) compound 13
4zsa  2.00  2015  IC50=15nM     // 4zsa.pdf (4UT) [Nonstandard assay: Temp 37, 50 mM HEPES, 50 mM MgCl2, 0.5 mM MnCl2] compound 7n;
5bq0  1.57  2015  IC50=15nM     // 5bpy.pdf (4US) ligand is compound 13, BMS-824171
5c6v  3.10  2015  IC50=16.0uM   // 5c6v.pdf (11-mer) ligand is 11-mer Arabidopsis NINJA peptide
4r6e  2.20  2015  IC50=16.7nM   // 4r5w.pdf (3JD) complex is PARP1/Niraparib
4wno  1.56  2015  IC50=160nM    // 4wno.pdf (3RF) compound 1
5aib  1.95  2015  IC50=160uM    // 5ai0.pdf (KJU) compound 8
5dda  1.83  2015  IC50=1653nM   // 5dd9.pdf (59M) ligand is compound MI-333
4p4f  1.86  2015  IC50=168nM    // 4p44.pdf (2GB) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor NC-2-40
4p44  1.75  2015  IC50=16nM     // 4p44.pdf (2F7) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor JRB-4-81
4p45  1.87  2015  IC50=16nM     // 4p44.pdf (2F9) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor JRB-4-73
5cy3  1.76  2015  IC50=16nM     // 5cxh.pdf (55Y) ligand is compound 12
4xg3  2.30  2015  IC50=17.5nM   // 4xg3.pdf (X3G) ligand is G206
4uuh  2.52  2015  IC50=17nM     // 4uuh.pdf (T40) compound 23
4y83  2.89  2015  IC50=17nM     // 4y83.pdf (49B) [Nonstandard assay: Temp 30, 50 mM HEPES, 1 mM DTT] compound 3
5abw  1.60  2015  IC50=17nM     // 5abw.pdf (WQQ) [Incomplete ligand] ligand is compound 12
5ccl  1.50  2015  IC50=17uM     // 5ccl.pdf (4ZW) ligand is screening hit compound 1, not EPZ031686
5cwa  2.10  2015  IC50=17uM     // 5cwa.pdf (0GA) ligand is methyl-AMT
4p4d  1.65  2015  IC50=1800nM   // 4p44.pdf (2GR) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor MP1C
4p4e  1.67  2015  IC50=180nM    // 4p44.pdf (2G4) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor MP1D
4yux  1.60  2015  IC50=180uM    // 4yux.pdf (4JT) ligand is fragment 1
4x6y  2.10  2015  IC50=19.1nM   // 4x6x.pdf (S94) [Different ligand in assay: Ligand in binding assay is racemic compound] compound 1
4uiz  1.19  2015  IC50=19.95uM  // 4uit.pdf (N1D) compound 17; pIC50=4.7
4uvw  2.10  2015  IC50=19nM     // 4uvl.pdf (NYJ) compound 17
4uw1  3.37  2015  IC50=19nM     // 4uw1.pdf (92R) compound 12
4xe0  2.43  2015  IC50=19nM     // 4xe0.pdf (40L) ligand is Idelalisib
4ztn  2.23  2015  IC50=19nM     // 4ztl.pdf (4S3) compound 19
5a3n  2.00  2015  IC50=19nM     // 5a3n.pdf (LQT) ligand is KDOAM-25
5c7b  2.68  2015  IC50=1mM      // 5c0k.pdf (4YD) ligand is compound 5, 52% inhibition at 1mM
4xyf  1.85  2015  IC50=1nM      // 4xmo.pdf (44X) ligand is (S)-21f
4qwf  3.00  2015  IC50=1uM      // 4qux.pdf (3BV) carfilzomib
4wyy  1.28  2015  IC50=1uM      // 4wyy.pdf (3VT) [Covalent complex] [Uncommon element] [Nonstandard assay: Temp 37] compound 11 (rac)
4x8g  3.29  2015  IC50=1uM      // 4x8c.pdf (3Z0) ligand is GSK199
5ajz  2.35  2015  IC50=2.01uM   // 5ajv.pdf (MJP) ligand is compound 51
4zsq  2.30  2015  IC50=2.25uM   // 4zsm.pdf (4RX) compound 7
4qz7  2.80  2015  IC50=2.262uM  // 4qux.pdf (04C) ONX0914
4yo6  2.32  2015  IC50=2.2uM    // 4yo6.pdf (4GD) compound 1
4x6x  1.80  2015  IC50=2.3nM    // 4x6x.pdf (S74) [Different ligand in assay: Ligand in binding assay is racemic compound] compound 14
4zim  2.65  2015  IC50=2.4nM    // 4zim.pdf (4OK) compound 1
4uiy  1.30  2015  IC50=2.51uM   // 4uit.pdf (5V2) compound 44; pIC50=5.6
5a82  1.86  2015  IC50=2.51uM   // 5a81.pdf (YEJ) compound 30
5cf5  2.45  2015  IC50=2.5nM    // 5cf4.pdf (50W) ligand is compound 18
4xsz  3.68  2015  IC50=2.5uM    // 4xsx.pdf (42U) [Nonstandard assay: Temp 37, PH=8, 20 mM NaCl] CBR 9393
4yad  1.73  2015  IC50=2.5uM    // 4yab.pdf (4A7) compound 3b;
5boy  2.03  2015  IC50=2.5uM    // 5bot.pdf (4UE) ligand is compound 11
5d6p  2.05  2015  IC50=2.5uM    // 5d6p.pdf (57U) ligand is compound 1f
5dj5  2.40  2015  IC50=2.5uM    // 5dj5.pdf (GR2) ligand is synthetic strigolactone GR24
5all  2.20  2015  IC50=2.678uM  // 5ai0.pdf (II6) compound 33
4xh6  2.04  2015  IC50=2.71uM   // 4xh6.pdf (HUL) hispidulin
5alj  2.10  2015  IC50=2.737uM  // 5ai0.pdf (T5J) compound 31
4umj  1.85  2015  IC50=2.7uM    // 3zl6.pdf (BFQ) ligand is ibandronate
5eds  2.80  2015  IC50=2.88uM   // 5eds.pdf (5MT) ligand is compound 5
4ynd  2.79  2015  IC50=2.8nM    // 4ynd.pdf (4GQ) [Nonstandard assay: PH=9, 20 mM Tris, 2.5mM DTT, 0.01% Triton X-100] compound 23a
4qz6  2.90  2015  IC50=2.979uM  // 4qux.pdf (04C) ONX0914
4yay  2.90  2015  IC50=2.9nM    // 4yay.pdf (ZD7) ZD7155
5ar4  2.70  2015  IC50=200nM    // 5ar3.pdf (SB2) ligand is compound 2, SB-203580
5ai0  1.75  2015  IC50=206.4uM  // 5ai0.pdf (JF6) compound 1
4ttv  2.80  2015  IC50=209nM    // 4ttv.pdf (BC9) ligand is BC194
4yz9  2.46  2015  IC50=20nM     // 4yz9.pdf (4K7) GSK2850163
5a0a  1.78  2015  IC50=20nM     // 5a09.pdf (JJS) ligand is compound 20
4xum  2.40  2015  IC50=21.3uM   // 4xta.pdf (IMN) ligand is indomethacin
4xg4  2.30  2015  IC50=21.5nM   // 4xg3.pdf (X4G) ligand is G207
5c4t  1.77  2015  IC50=21.8nM   // 4ypq.pdf (4Y6) MRL-673;
4z90  3.00  2015  IC50=21.9uM   // 4z90.pdf (4LE) ligand is isoflurane;
4wpn  1.95  2015  IC50=210nM    // 4wp7.pdf (3ST) ligand is CM053;
4z7h  2.90  2015  IC50=218nM    // 4z7h.pdf (4L5) [Nonstandard assay: Temp 37, 40 mM Tris, 20 mM MgCl2, 1mM DTT] compound 3(Imidazopyridine);
5auu  1.70  2015  IC50=21uM     // 5aut.pdf (LU2) ligand is compound 1, luteolin
4y2p  2.05  2015  IC50=2200uM   // 4y2j.pdf (3C5) fragment 2
4x69  1.42  2015  IC50=22nM     // 4x68.pdf (OP0) [Nonstandard assay: Temp 30] ligand is OP0595
4rxe  2.50  2015  IC50=230nM    // 4rxa.pdf (3YQ) compound 9
4pv7  3.24  2015  IC50=232.8nM  // 4pv7.pdf (CJP) compound 1
4rsc  1.80  2015  IC50=232nM    // 4rsc.pdf (A3V) ligand is emixustate
5ctb  2.40  2015  IC50=23nM     // 5ctb.pdf (57J) [Different protein in assay: rat ACC1 used in assay] ligand is compound I, IC50 for rat ACC1
4qna  1.85  2015  IC50=23uM     // 4qml.pdf (X11) ligand is TP fragment
5a1f  2.10  2015  IC50=24.5uM   // 4uf0.pdf (OGA) ligand is NOG
4wy3  1.89  2015  IC50=240uM    // 4tww.pdf (3X5) compound 44
4ybi  1.84  2015  IC50=249nM    // 4ybi.pdf (4B2) ligand is LY2811376;
4rn0  1.76  2015  IC50=255nM    // 4rn0.pdf (L6G) compound 1
4ztm  2.66  2015  IC50=25nM     // 4ztl.pdf (4S2) compound 4
4uda  2.03  2015  IC50=26.0nM   // 4uda.pdf (DEX) ligand is Dexa, dexamethasone;
5ddd  2.14  2015  IC50=260nM    // 5dd9.pdf (59X) ligand is compound MI-836
4xm7  2.70  2015  IC50=267uM    // 4xm6.pdf (41S) compound 4;
5ab0  2.50  2015  IC50=26nM     // 5ab0.pdf (10-mer) DG025 peptide
4xua  1.75  2015  IC50=26uM     // 4xua.pdf (43C) compound 1
4zun  1.40  2015  IC50=26uM     // 4zum.pdf (SS9) compound 2;
4x68  1.68  2015  IC50=271nM    // 4x68.pdf (OP0) [Nonstandard assay: Temp 30] ligand is OP0595
5av0  1.85  2015  IC50=280uM    // 5aut.pdf (47X) ligand is compound 15, 7,3',4'-trihydroxyisoflavone
4x49  2.01  2015  IC50=29.6uM   // 4x47.pdf (G39) [Nonstandard assay: Temp 37, PH=6.5] Oseltamivir carboxylate
4uuq  2.36  2015  IC50=29nM     // 4uuq.pdf (64D) ligand is SAR127303
4x7o  2.65  2015  IC50=2nM      // 4x7h.pdf (3Z6) compound 52;
4xmo  1.75  2015  IC50=2nM      // 4xmo.pdf (46G) ligand is (R)-20c
4qz3  2.80  2015  IC50=3.085uM  // 4qux.pdf (04C) ONX 0914
4qwu  3.00  2015  IC50=3.120uM  // 4qux.pdf (BO2) bortezomib
4ura  2.23  2015  IC50=3.16uM   // 4ura.pdf (LEL) ligand is compound 14a
4wz5  1.60  2015  IC50=3.1uM    // 4wz5.pdf (3VU) [Covalent complex] [Uncommon element] [Nonstandard assay: TEMP=37, KHCO3=3mM] compound 37 (rac)
4zs2  2.16  2015  IC50=3.23uM   // 4zs2.pdf (FLU) [Nonstandard assay: in ssRNA, Temp 37, 50 mM HEPES ] ligand is fluorescein; IC50 value against FTO demethylation
5alx  2.23  2015  IC50=3.277uM  // 5ai0.pdf (DUL) compound 45
3wyy  3.05  2015  IC50=3.2nM    // 3wyx.pdf (O17) compound 19c
3wqh  2.85  2015  IC50=3.3nM    // 3wqh.pdf (SKK) ligand is Anagliptin
5ap2  2.80  2015  IC50=3.3nM    // 5ap0.pdf (PWU) ligand is compound 2, with ATP present at 10.7uM
4d2r  2.10  2015  IC50=3.3uM    // 4d2r.pdf (DYK) compound 23
4tmf  2.05  2015  IC50=3.3uM    // 4tmf.pdf (JS2) [Different ligand in assay: compound 7] ligand is compound 7a, hydrolysis at N1 of compound 7
4y6r  1.90  2015  IC50=3.3uM    // 4y67.pdf (RF7) compound 7a;
4qz0  3.00  2015  IC50=3.502uM  // 4qux.pdf (04C) ONX 0914
5a09  1.81  2015  IC50=3.5nM    // 5a09.pdf (JJD) ligand is compound 19
4zly  1.65  2015  IC50=3.5uM    // 4z3v.pdf (4RU) compound 2
4qz1  3.00  2015  IC50=3.658uM  // 4qux.pdf (04C) ONX 0914
4zk5  2.89  2015  IC50=3.7nM    // 4zk5.pdf (4P4) compound 13;
4xta  2.50  2015  IC50=3.7uM    // 4xta.pdf (DIF) ligand is diclofenac
5c4s  2.23  2015  IC50=3.8nM    // 4ypq.pdf (4Y5) MRL-299;
4uxj  3.00  2015  IC50=3.8uM    // 4uxh.pdf (TTP) ligand is dTTP
4rxd  2.00  2015  IC50=300nM    // 4rxa.pdf (RIS) compound 2
5al4  1.90  2015  IC50=300nM    // 5aku.pdf (WLH) ligand is compound 6
4xyc  3.30  2015  IC50=31nM     // 4xyc.pdf (2K9) compound 3
5auv  1.50  2015  IC50=31uM     // 5aut.pdf (AGI) ligand is compound 2, apigenin
4xg7  1.76  2015  IC50=32.6nM   // 4xg3.pdf (X7G) ligand is O259
5ar7  2.71  2015  IC50=320nM    // 5ar3.pdf (SR8) ligand is compound 3, Biaryl Urea
5ak6  2.15  2015  IC50=326.4uM  // 5ai0.pdf (YPN) compound 13
4uvv  1.90  2015  IC50=32nM     // 4uvl.pdf (W8L) compound 13h
5ai4  1.93  2015  IC50=337.1uM  // 5ai0.pdf (4VY) compound 2
4w4w  1.90  2015  IC50=34.7nM   // 4w4v.pdf (3HJ) ligand is SR12326
5akg  2.51  2015  IC50=34.81uM  // 5ai0.pdf (6N6) compound 15
4w4y  2.30  2015  IC50=344.8nM  // 4w4v.pdf (3HQ) ligand is SR12130
5afn  2.22  2015  IC50=34uM     // 5afh.pdf (OJD) fragment 5;
5ap4  2.85  2015  IC50=350nM    // 5ap0.pdf (O38) ligand is compound ONCOII, with ATP present at 21uM
4p4i  1.87  2015  IC50=35nM     // 4p44.pdf (2G5) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor T33
4rx8  1.59  2015  IC50=35nM     // 4rx7.pdf (3YX) compound 11; enzyme assay
4zsr  1.65  2015  IC50=36.1uM   // 4zsm.pdf (4RY) compound 8
5al2  1.90  2015  IC50=360nM    // 5aku.pdf (O53) ligand is compound 34
4x2l  2.55  2015  IC50=36uM     // 4wy1.pdf (3WP) [Nonstandard assay: Temp 37, PH=4.5, 100 mM sodium acetate] compound 6;
4rse  2.39  2015  IC50=396nM    // 4rsc.pdf (A6V) ligand is MB-001
5afl  2.35  2015  IC50=398uM    // 5afh.pdf (FHV) fragment 3;
5bot  1.85  2015  IC50=39uM     // 5bot.pdf (4UM) ligand is compound 1
4rpv  3.05  2015  IC50=3nM      // 4rpv.pdf (3UR) compound 3
4rx5  1.36  2015  IC50=3nM      // 4rx5.pdf (3YO) [Nonstandard assay: Temp 37] compound 23
4yzc  2.49  2015  IC50=3nM      // 4yz9.pdf (STU) Nonstandard assay: ligand is staurosporine, STS; inhibit pIRE1a kinase enzymatic activity
4zom  2.27  2015  IC50=3nM      // 4zom.pdf (4Q3) compound 4j
4yvz  2.50  2015  IC50=3uM      // 4yvz.pdf (3AT) [Incomplete ligand] [Nonstandard assay: pH 9.5, 50 mM glycine/NaOH, 50 mM NaCl, 10 mM MgCl2, 0.3mM ATP] 3'-dATP
4qvw  3.00  2015  IC50=4.138uM  // 4qux.pdf (BO2) bortezomib
3wyx  2.90  2015  IC50=4.3nM    // 3wyx.pdf (O38) compound 33
4qwi  2.60  2015  IC50=4.401uM  // 4qux.pdf (3BV) carfilzomib
4y2b  2.20  2015  IC50=4.4nM    // 4y2b.pdf (EPK) compound 22
5dls  2.15  2015  IC50=4.4nM    // 5dls.pdf (5CV) ligand is compound VER-00158411
4yhf  2.20  2015  IC50=4.6nM    // 4yhf.pdf (4C9) [Covalent complex] [Incomplete ligand] compound 3; reversible covalent inhibitor;
5es1  2.80  2015  IC50=4.6nM    // 5es1.pdf (5RC) ligand is compound 1
4wvt  1.96  2015  IC50=4.87uM   // 4wvs.pdf (6-mer) compound 5;
4x6k  1.94  2015  IC50=4.87uM   // 4x47.pdf (3XR) [Nonstandard assay: Temp 37, PH=6.5] Siastatin B
5a3u  3.30  2015  IC50=4.8nM    // 5a3u.pdf (R8J) compound 1
4xjr  3.00  2015  IC50=4.8uM    // 4xjr.pdf (OEL) [Covalent complex] [Incomplete ligand] [Nonstandard assay: pH 4.6, NaOAc 50 mM, CaCl2 5 mM] compound 5; Miss a F atom in PDB;
5ai6  2.30  2015  IC50=40.19uM  // 5ai0.pdf (4XH) compound 4
4r1y  2.00  2015  IC50=400nM    // 4r1v.pdf (3EH) compound 1
5cf4  2.38  2015  IC50=40nM     // 5cf4.pdf (50Y) ligand is compound 12
4zh3  4.08  2015  IC50=40uM     // 4zh2.pdf (4OD) [Nonstandard assay: Temp 37, pH=8, 50 mM Tris-HCl, 100 mM KCl, 10 mM MgCl2, 1mMDTT, 10 mg/ml BSA, 5% methanol, 5.5% glycero] ligand is CBRH16-Br; for gram-negative enteric bacterial RNAP
4rvl  1.85  2015  IC50=41.7nM   // 4rvk.pdf (3XL) compound 7
5akw  2.07  2015  IC50=410nM    // 5aku.pdf (NKI) ligand is compound 29
4x7j  2.30  2015  IC50=41nM     // 4x7h.pdf (3Z1) compound 7;
4x7h  2.00  2015  IC50=42nM     // 4x7h.pdf (3Z2) compound 10b
5afj  2.22  2015  IC50=42uM     // 5afh.pdf (42R) fragment 1;
5alv  1.80  2015  IC50=43.48uM  // 5ai0.pdf (6TZ) compound 43
4ucu  2.10  2015  IC50=447uM    // 4ucu.pdf (8HC) compound 6
5clm  2.61  2015  IC50=44nM     // 5clm.pdf (52K) ligand is compound 3R-6a
3wpn  2.80  2015  IC50=44uM     // 3wpn.pdf (B4S) ligand is PVZB1194
4yuy  1.58  2015  IC50=460uM    // 4yuy.pdf (1SQ) ligand is fragment 2
4v0i  2.54  2015  IC50=468nM    // 4v0i.pdf (J82) compound 3(S)
4tn4  2.20  2015  IC50=470nM    // 4tmr.pdf (33G) ligand is pyrazolopyran (+)-16
5d1j  1.80  2015  IC50=48nM     // 5d1j.pdf (56H) ligand is compound 21
5aic  1.89  2015  IC50=49.6uM   // 5ai0.pdf (TGX) compound 9
4zla  1.90  2015  IC50=49.9nM   // 4zla.pdf (BES) BESTATIN;
5c7a  2.36  2015  IC50=495uM    // 5c0k.pdf (4YE) ligand is compound 7, 52% inhibition at 495uM
4x7k  1.80  2015  IC50=4nM      // 4x7h.pdf (3Z3) compound 34;
4z3v  1.60  2015  IC50=4nM      // 4z3v.pdf (4L6) compound 11;
5ccm  2.30  2015  IC50=4nM      // 5ccm.pdf (4ZX) ligand is compound EPZ030456, cell IC50=48nm
5a85  1.72  2015  IC50=5.01uM   // 5a81.pdf (78J) compound 13
4wy1  1.98  2015  IC50=5.1uM    // 4wy1.pdf (3VO) [Nonstandard assay: Temp 37, PH=4.5, 100 mM sodium acetate] compound 24b;
4yzm  3.00  2015  IC50=5.38uM   // 4yzm.pdf (4K4) [Nonstandard assay: Temp 30, 50 mM Tris-HCl, 0.1 mM EGTA] ligand is LRRK2-In1
4qz5  2.80  2015  IC50=5.452uM  // 4qux.pdf (04C) ONX 0914
5akz  2.18  2015  IC50=5.49uM   // 5ai0.pdf (6NX) compound 24
4uvy  1.95  2015  IC50=5.5nM    // 4uvl.pdf (SGW) compound 15e
5ap0  2.15  2015  IC50=5.5nM    // 5ap0.pdf (AU5) [Nonstandard assay: with ATP present at its Km concentration 10.7uM] ligand is compound AZ3146, with ATP present at 10.7uM
5c7c  2.32  2015  IC50=5.5uM    // 5c0k.pdf (4YC) ligand is compound 18
5d6q  1.50  2015  IC50=5.8uM    // 5d6p.pdf (57V) ligand is compound 7
4ptg  2.36  2015  IC50=5.9nM    // 4ptc.pdf (2WG) compound 24
5ahj  2.80  2015  IC50=5.9nM    // 5ahj.pdf (7IM) ligand is macyranone A
4qp7  2.25  2015  IC50=5.9uM    // 4qp1.pdf (363) compound 17; SAR IC50 data
4uix  1.58  2015  IC50=50.1nM   // 4uit.pdf (TVU) compound 32; pIC50=7.3
4yfi  2.70  2015  IC50=500nM    // 4yff.pdf (4CW) compound 1;
5ar5  2.66  2015  IC50=500nM    // 5ar3.pdf (IQ7) ligand is compound 5, Benzimidazole
4uiw  1.73  2015  IC50=50nM     // 4uit.pdf (H1B) compound 45; pIC50=7.3
5ap7  2.45  2015  IC50=510nM    // 5ap0.pdf (SVE) ligand is compound NMS-P715, with ATP present at 125uM
4xxs  1.86  2015  IC50=52nM     // 4xxs.pdf (SI5) [Nonstandard assay: Temp 37, PH=4.5, 100 mM sodium acetate] compound 5
4y2s  2.30  2015  IC50=52uM     // 4y2j.pdf (49P) fragment 5
5a6n  1.70  2015  IC50=52uM     // 5a6n.pdf (U7E) compound 2;
4yv0  1.95  2015  IC50=530uM    // 4yv0.pdf (4JW) fragment 4; code is 4yu0 in paper
5al1  1.75  2015  IC50=53uM     // 5aku.pdf (GN5) ligand is compound 36
5cxz  1.70  2015  IC50=552nM    // 5cxh.pdf (55U) ligand is compound 6
4y29  1.98  2015  IC50=566nM    // 4y29.pdf (CTI) ligand is chelerythrine
4s3f  1.70  2015  IC50=580nM    // 4s38.pdf (43W) compound 8
4y2u  2.75  2015  IC50=580uM    // 4y2j.pdf (49R) fragment 7
3wzk  2.30  2015  IC50=58nM     // 3wzj.pdf (O23) compound 11f
4y87  3.10  2015  IC50=58nM     // 4y86.pdf (49E) [Nonstandard assay: pH=8, 50 mM Tris-HCl, 10 mM MgCl2] (R)-C33;
5ak4  1.79  2015  IC50=59.2uM   // 5ai0.pdf (GVG) compound 11
4rx7  1.80  2015  IC50=5nM      // 4rx7.pdf (3YV) compound 10; enzyme assay
4xhk  1.90  2015  IC50=5nM      // 4x7q.pdf (3YR) compound 1s
5a0b  2.23  2015  IC50=5nM      // 5a09.pdf (JJX) ligand is compound 24
5cxh  1.90  2015  IC50=5nM      // 5cxh.pdf (55M) ligand is compound 11
4qz2  2.70  2015  IC50=6.167uM  // 4qux.pdf (04C) ONX 0914
5c4o  2.24  2015  IC50=6.1nM    // 4ypq.pdf (4F1) MRL-871; space group P 61 2 2
5aia  2.26  2015  IC50=6.268uM  // 5ai0.pdf (KWB) compound 7
4qvq  2.60  2015  IC50=6.366uM  // 4qux.pdf (BO2) bortezomib
4zs3  2.45  2015  IC50=6.55uM   // 4zs2.pdf (A4F) [Nonstandard assay: in ssRNA, Temp 37, 50 mM HEPES ] ligand is 5-aminofluorescein; IC50 value against FTO demethylation
3wzj  2.75  2015  IC50=6.6nM    // 3wzj.pdf (O43) compound 27b
4xct  1.30  2015  IC50=6.7nM    // 4wzv.pdf (N73) [Nonstandard assay: Temp 37, Tris 50 mM, NaCl 150 mM, CaCl2 10 mM, Brij 35 0.05%, DMSO 1%] compound 1
5diq  2.10  2015  IC50=6.8uM    // 5dgn.pdf (5B9) ligand is salicylic acid derivative 3a
4tmr  2.70  2015  IC50=60nM     // 4tmr.pdf (99S) ligand is pyrazolopyran (+)-1
4zh4  3.99  2015  IC50=60uM     // 4zh2.pdf (4OE) [Nonstandard assay: Temp 37, pH=8, 50 mM Tris-HCl, 100 mM KCl, 10 mM MgCl2, 1mMDTT, 10 mg/ml BSA, 5% methanol, 5.5% glycero] ligand is CBRH18; for gram-negative enteric bacterial RNAP
4ucs  1.90  2015  IC50=61uM     // 4ucs.pdf (9MJ) compound 4
5fdd  2.51  2015  IC50=63.30uM  // 4zhz.pdf (4P8) compound 1
4tww  2.42  2015  IC50=63uM     // 4tww.pdf (3A7) compound 41
5dde  1.78  2015  IC50=65nM     // 5dd9.pdf (5A0) ligand is compound MI-859
5ddf  1.66  2015  IC50=674nM    // 5dd9.pdf (5A1) ligand is compound MI-273
4x7n  2.35  2015  IC50=6nM      // 4x7h.pdf (3Z5) compound 44;
4qvv  2.80  2015  IC50=7.010uM  // 4qux.pdf (BO2) bortezomib
5alw  2.20  2015  IC50=7.05uM   // 5ai0.pdf (JQN) compound 44
4qzw  3.00  2015  IC50=7.155uM  // 4qux.pdf (04C) ONX0914
4qw0  2.90  2015  IC50=7.192uM  // 4qux.pdf (BO2) bortezomib
5djp  2.40  2015  IC50=7.1uM    // 5dgn.pdf (5BJ) ligand is biaryl compound 5
4rlp  2.79  2015  IC50=7.3nM    // 4rlo.pdf (72B) [Uncommon element] ligand is FL772
4qms  1.88  2015  IC50=7.4uM    // 4qml.pdf (1N1) Ligand is Dasatinib (wrong code 4QO9 in paper)
4z7i  3.31  2015  IC50=7.7nM    // 4z7i.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: Temp 37, 50 mM HEPES, 100 mM NaCl ] ligand is DG025 peptide
5c7d  2.25  2015  IC50=7.7uM    // 5c0k.pdf (4YF) ligand is compound 17
4qvn  2.90  2015  IC50=7.925uM  // 4qux.pdf (BO2) bortezomib
5ar8  2.79  2015  IC50=7.9nM    // 5ar3.pdf (XYW) ligand is compound 4, Biphenylsulfonamide
4p4j  1.66  2015  IC50=700nM    // 4p44.pdf (2H9) [Nonstandard assay: Temp 37, pH=7.4, 50 mM Tris-HCl, 1% Triton X-100 ] inhibitor T33D
5afm  2.85  2015  IC50=70uM     // 5afh.pdf (9Z0) fragment 4;
5al5  2.05  2015  IC50=71nM     // 5aku.pdf (JL9) ligand is compound 5
4xjt  2.60  2015  IC50=7200nM   // 4xjs.pdf (41Z) [Nonstandard assay: pH=4.5] [Different protein in assay: Protein in binding assay is Wild Type] compound 1a;
4trw  2.85  2015  IC50=72uM     // 4trw.pdf (4-mer) inhibitor R-26
4r5w  2.84  2015  IC50=74.1nM   // 4r5w.pdf (XAV) complex is PARP1/XAV939
4pte  2.03  2015  IC50=74nM     // 4ptc.pdf (2WF) compound 14
4uct  2.10  2015  IC50=767uM    // 4uct.pdf (5U1) compound 7
4xjs  2.80  2015  IC50=76nM     // 4xjs.pdf (733) [Nonstandard assay: pH=4.5, 50 mM HEPES, 2 mM EDTA, 1 mM CHAPS, 2.5 mM sodium acetate, 100 uM NAD, 250 uM GW323434X, and 0.4 nM CD38] compound 1bf;
4s3e  1.35  2015  IC50=770nM    // 4s38.pdf (0CG) compound 7
5dd9  1.62  2015  IC50=779nM    // 5dd9.pdf (59K) ligand is compound MI-326
4qt1  2.40  2015  IC50=7nM      // 4qt1.pdf (3C9) compound 12
4qvy  2.51  2015  IC50=8.037uM  // 4qux.pdf (BO2) bortezomib
4x3u  1.63  2015  IC50=8.1uM    // 4x3k.pdf (SVR) ligand is Suramin
5cf6  2.50  2015  IC50=8.2nM    // 5cf4.pdf (50O) ligand is compound 3
4z2h  2.35  2015  IC50=8.3uM    // 4z2g.pdf (M6A) compound 29
5ak3  2.28  2015  IC50=8.49uM   // 5ai0.pdf (XM0) compound 10
4yab  1.90  2015  IC50=8.5uM    // 4yab.pdf (4CN) compound 1;
5auw  1.50  2015  IC50=8.9uM    // 5aut.pdf (QUE) ligand is compound 4, quercetin
4y2j  2.15  2015  IC50=800uM    // 4y2j.pdf (49G) fragment 1
4ryc  2.45  2015  IC50=80nM     // 4ryc.pdf (3ZK) eutomers compound 47a; ligand in assay is 47;
5ddb  1.54  2015  IC50=82nM     // 5dd9.pdf (59Q) ligand is compound MI-319
4yv1  1.85  2015  IC50=830uM    // 4yv0.pdf (4K2) fragment 5; code is 4yu1 in paper
4xdo  1.97  2015  IC50=84uM     // 4xdo.pdf (OGA) [Nonstandard assay: PH=8, 50 mM HEPES, 100 uM sodium ascorbate, 20 mM NaCl] N-oxaylglycine
5a5z  2.60  2015  IC50=84uM     // 5a5z.pdf (WJZ) [Nonstandard assay: HEPES 50 mM, pH 7.5] compound 11
4wnp  1.88  2015  IC50=8nM      // 4wno.pdf (3RJ) compound 6
4xy2  2.03  2015  IC50=8nM      // 4xy2.pdf (490) compound 38b
4yuz  1.97  2015  IC50=9.1uM    // 4yuz.pdf (4JV) ligand is fragment 3
4y6s  2.10  2015  IC50=9.3uM    // 4y67.pdf (48S) compound 7b;
4yat  2.18  2015  IC50=9.3uM    // 4yab.pdf (4A8) compound 5b;
4trz  3.25  2015  IC50=9.4uM    // 4trw.pdf (4-mer) inhibitor R-27
4w4s  2.00  2015  IC50=9.5uM    // 4w4s.pdf (B29) ligand is BPH-629
5am2  1.70  2015  IC50=9.685uM  // 5ai0.pdf (KUF) compound 50
5d1s  2.10  2015  IC50=9.6uM    // 4wf6.pdf (56Q) compound 3a; MSA assay data
4xg6  2.40  2015  IC50=9.7nM    // 4xg3.pdf (X6G) ligand is O194
4yyl  1.91  2015  IC50=9.7uM    // 4yyl.pdf (4KN) [Nonstandard assay: Temp 37, 20 mM Tris-HCl, 100 mM NaCl, 10 mM beta-mercaptoethanol, 1.0 mM MgCl2, 1.0 mM MnCl2] compound 1
4qz4  3.00  2015  IC50=9.830uM  // 4qux.pdf (04C) ONX 0914
4y32  1.70  2015  IC50=90.1uM   // 4y32.pdf (7-mer) analogue compound 1b;
4xm6  2.35  2015  IC50=90uM     // 4xm6.pdf (41R) compound 3;
4y2v  2.40  2015  IC50=91uM     // 4y2j.pdf (4A5) fragment 8
5ap3  2.70  2015  IC50=93nM     // 5ap0.pdf (AU5) ligand is compound AZ3146, with ATP present at 21uM
4xm8  2.70  2015  IC50=950uM    // 4xm6.pdf (41T) compound 5;
4ux4  1.80  2015  IC50=97nM     // 4ux4.pdf (E9L) compound 17a
5auz  1.60  2015  IC50=98uM     // 5aut.pdf (GEN) ligand is compound 13, genistein
5akk  1.90  2015  IC50=99.3uM   // 5ai0.pdf (1P8) compound 19
4x7l  1.90  2015  IC50=9nM      // 4x7h.pdf (3Z4) compound 39;
5ece  2.20  2015  IC50=9nM      // 5ece.pdf (5N2) ligand is Phthalazinone 1, AZ9482 (compound 1)
4y2y  2.30  2015  IC50=9uM      // 4y2j.pdf (49Z) fragment 10
4ylu  2.10  2015  IC50>100uM    // 4rsp.pdf (R30) compound 11
5bvk  2.29  2015  IC50>100uM    // 5bvk.pdf (4VC) ligand is compound 1
4xbb  1.85  2015  IC50>10uM     // 4xbb.pdf (3ZR) [Incomplete ligand] [Nonstandard assay: pH=8, Tris buffer] compound 17
5a5o  2.04  2015  IC50>1mM      // 5a5n.pdf (J5I) fragment 5
4ypf  2.20  2015  IC50>2mM      // 4ypf.pdf (4FS) ligand is Chem 84
4yrc  2.10  2015  IC50>2mM      // 4yrc.pdf (0P6) ligand is Chem 89
4yrg  2.15  2015  IC50>2mM      // 4yrg.pdf (4HU) ligand is Chem 149
4yrr  2.30  2015  IC50>2mM      // 4yrr.pdf (691) ligand is Chem 1691
4xue  2.30  2015  IC50>5000nM   // 4xuc.pdf (43J) compound 27b
4ucr  2.15  2015  IC50>500uM    // 4ucr.pdf (JCF) compound 3
5aes  2.75  2015  IC50~1.3mM    // 5aes.pdf (5B0) compound 3
4rn1  2.18  2015  IC50~10000nM  // 4rn0.pdf (L8G) compound 2
4xsx  3.71  2015  IC50~10uM     // 4xsx.pdf (42S) [Nonstandard assay: Temp 37, PH=8, 20 mM NaCl] CBR 703; range 10~20uM
4v1f  1.70  2015  IC50~20nM     // 4v1f.pdf (BQ1) ligand is BDQ, IC50 is 20-25nM
4rxc  2.31  2015  IC50~33uM     // 4rxa.pdf (HRX) compound 8
4zsm  1.96  2015  IC50~4mM      // 4zsm.pdf (4RW) compound 3
5a00  2.75  2015  Kd<0.03uM     // 4zzx.pdf (D7N) compound 20by
4xhe  1.90  2015  Kd<0.05nM     // 4xhe.pdf (40P) A-AChBP in complex with pinnatoxin A
4pzh  1.06  2015  Kd<10nM       // 4pyx.pdf (V13) [Nonstandard assay: Temp 37 , pH =7.0,] compound 5
4x61  2.85  2015  Kd<1nM        // 4x60.pdf (3XV) EPZ015666
4x60  2.35  2015  Kd<1nM        // 4x60.pdf (3XV) EPZ015666;
4s2i  1.60  2015  Kd=0.001uM    // 4s2i.pdf (NXL) ligand is Avibactam
4wr7  1.50  2015  Kd=0.002nM    // 4wr7.pdf (3TV) [Nonstandard assay: Temp 37,50 mM sodium phosphate] compound 3e
4y8d  2.10  2015  Kd=0.0089uM   // 4y8d.pdf (49J) [Different protein in assay: GAK-specific NbGAK_4 nanobody] compound 12i
5bs4  1.29  2015  Kd=0.0099nM   // 5bry.pdf (4UX) ligand is entry7(compound 25g)
5aix  2.10  2015  Kd=0.012uM    // 5ais.pdf (KRX) compound 2
4xtx  2.30  2015  Kd=0.027nM    // 4xtv.pdf (590) compound 57;
4ww6  1.06  2015  Kd=0.062nM    // 4wr7.pdf (3TV) [Nonstandard assay: Temp 37,50 mM sodium phosphate] compound 3e
4ww8  1.42  2015  Kd=0.067nM    // 4wr7.pdf (VD9) [Nonstandard assay: Temp 37,50 mM sodium phosphate] compound 4e
5ah2  2.13  2015  Kd=0.083nM    // 5agu.pdf (11-mer) ligand is GRISELIMYCIN peptide
4zzz  1.90  2015  Kd=0.087uM    // 4zzx.pdf (FSU) compound 10b
3wtn  2.09  2015  Kd=0.091uM    // 3wth.pdf (N2Y) ligand is DN-IMI
3wtl  2.30  2015  Kd=0.092uM    // 3wth.pdf (N1Y) ligand is CH-IMI
5epl  1.81  2015  Kd=0.094uM    // 5epk.pdf (6-mer) peptide inhibitor UNC3866
3wtm  2.48  2015  Kd=0.100uM    // 3wth.pdf (N1Y) ligand is CH-IMI
3wzn  1.30  2015  Kd=0.10uM     // 3wzn.pdf (BTN) ligand is BTN
4odl  2.92  2015  Kd=0.113uM    // 4odk.pdf (16-mer) [Multiple sites: site1: Kd=0.113+/-0.012uM; site 2: Kd=2.93+/-0.12uM] TtSlyDFL:S2
3wto  2.25  2015  Kd=0.119uM    // 3wth.pdf (N2Y) ligand is DN-IMI
4zzx  1.65  2015  Kd=0.125uM    // 4zzx.pdf (FSU) compound 10b
4x1s  1.90  2015  Kd=0.134uM    // 4x1n.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: NaCl=140mM, sodium phosphate=20mM] ligand is Mupain-1-16 D9A;
4xtz  1.90  2015  Kd=0.153nM    // 4xtv.pdf (594) compound 69
4wup  1.75  2015  Kd=0.15nM     // 4wr7.pdf (3UF) [Nonstandard assay: Temp 37,50 mM sodium phosphate] compound 4c
3wzp  1.20  2015  Kd=0.15uM     // 3wzn.pdf (ZOF) ligand is iminobiotin long tail (IMNtail)
4yoz  2.25  2015  Kd=0.16uM     // 4yoz.pdf (9-mer) [Nonstandard assay: Temp 15, pH=8.0, 25 mM Tris, 200 mM NaCl, and 5 mM BME] ligand is HPV E7 peptide
4odn  1.60  2015  Kd=0.183uM    // 4odk.pdf (17-mer) [Multiple sites: site1: Kd=0.183+/-0.018uM; site 2: Kd=5.68+/-0.27uM] TtSlyDFL:S2-plus2
4wmu  1.55  2015  Kd=0.18uM     // 4wmr.pdf (19H) compound 2
5agu  2.17  2015  Kd=0.1nM      // 5agu.pdf (11-mer) ligand is GRISELIMYCIN peptide
4xrq  1.95  2015  Kd=0.232uM    // 4xrq.pdf (1B0) ligand is PF-3450074
4rd0  1.71  2015  Kd=0.24uM     // 4rcy.pdf (GDP) ligand is GDP
4x8n  2.10  2015  Kd=0.24uM     // 4x8n.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: PH=8, NaCl=150mM, Tris-HCl =25mM, BME=5mM] ligand is phosphorylated RbBP5;
4xii  2.70  2015  Kd=0.25uM     // 4xii.pdf (40V) compound 8g
4zzd  2.35  2015  Kd=0.25uM     // 4zzd.pdf (RBF) [Nonstandard assay: pH=8, 20 mM Tris-HCl, 150 mM NaCl, 1 mMEDTA] RIBOFLAVIN;
5e0a  2.60  2015  Kd=0.26uM     // 4ebs.pdf (NAG)
5c7n  1.75  2015  Kd=0.27uM     // 5c7n.pdf (BMF) compound 20
5cfa  1.45  2015  Kd=0.290uM    // 5cfa.pdf (15-mer) ligand is 15-mer peptide from Fibrinogen alpha chain
3wtk  2.69  2015  Kd=0.294uM    // 3wth.pdf (TH4) ligand is Thiacloprid
3wtj  2.24  2015  Kd=0.297uM    // 3wth.pdf (TH4) ligand is Thiacloprid
5agv  1.93  2015  Kd=0.2nM      // 5agu.pdf (11-mer) ligand is CYCLOHEXYL GRISELIMYCIN  peptide
4xu3  2.24  2015  Kd=0.315nM    // 4xtv.pdf (44R) compound 90;
5cp9  1.90  2015  Kd=0.31mM     // 5cp9.pdf (6O5) ligand is compound MB605; Kd=0.31+/-0.04mM
4xu1  1.70  2015  Kd=0.324nM    // 4xtv.pdf (44O) compound 82;
4yee  2.00  2015  Kd=0.32uM     // 4yee.pdf (4CQ) gBCD;
4z68  1.86  2015  Kd=0.32uM     // 4z68.pdf (12-mer) [Nonstandard assay: TEMP 4, NaCl=110mM, TCEP=1mM] [Different protein in assay: ] ligand is HsArpinCt peptide;
4rd3  1.69  2015  Kd=0.34uM     // 4rcy.pdf (GDP) ligand is GDP
4zhl  2.06  2015  Kd=0.34uM     // 4zhl.pdf (10-mer) [Nonstandard assay: Temp 37, 10 mM Hepes, 140 mM NaCl, 0.1% BSA] ligand is mupain-1-IG peptide
5ai1  2.10  2015  Kd=0.34uM     // 5ai1.pdf (EQU) amino acid ID is Y30F/Y55F/Y115F/D38N in paper;
5c11  2.80  2015  Kd=0.34uM     // 5c11.pdf (10-mer) ligand is 10-mer histone H3C4me3 peptide
4ymh  1.88  2015  Kd=0.35uM     // 4ymg.pdf (SAH) higher affinity in presence of Mg2+;
4x1n  1.80  2015  Kd=0.38uM     // 4x1n.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: NaCl=140mM, sodium phosphate=20mM] ligand is Mupain-1-16;
5cvd  1.30  2015  Kd=0.39uM     // 5cvd.pdf (9-mer) ligand is 9-mer alpha-N-dimethylated human CENP-A peptide
4zeb  1.89  2015  Kd=0.3uM      // 4ra1.pdf (AGR) ligand is agrocinopine A; another lower resolution structure is 4ze9
5a2k  1.70  2015  Kd=0.45uM     // 5a2i.pdf (6-mer) [Incomplete ligand] [Nonstandard assay: 10 mM sodium phosphate buffer containing 150 mM NaCl] ligand is glycopeptide m1*
4zvi  2.20  2015  Kd=0.47uM     // 4zvi.pdf (4S4) compound 18a;
4x1r  2.10  2015  Kd=0.4uM      // 4x1n.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: NaCl=140mM, sodium phosphate=20mM] ligand is Mupain-1-12;
5e0l  1.31  2015  Kd=0.4uM      // 5e0l.pdf (14-mer) ligand is 14-mer Protein Chica peptide, Chica (415-424)
3wth  2.54  2015  Kd=0.514uM    // 3wth.pdf (IM4) ligand is imidacloprid
4rd6  1.94  2015  Kd=0.52uM     // 4rcy.pdf (GDP) ligand is GDP
4zb6  1.80  2015  Kd=0.53uM     // 4f0c.pdf (GDS) ligand is GSSG
4xtv  1.45  2015  Kd=0.54nM     // 4xtv.pdf (44K) compound 36;
5ais  1.85  2015  Kd=0.57uM     // 5ais.pdf (CWC) compound 7
4xu2  1.85  2015  Kd=0.592nM    // 4xtv.pdf (44Q) compound 87;
3wzq  1.70  2015  Kd=0.59uM     // 3wzn.pdf (ZOF) ligand is iminobiotin long tail (IMNtail)
4x13  2.00  2015  Kd=0.5mM      // 4x0z.pdf (5-mer) [Nonstandard assay: Temp 37, SVGA cells] ligand is LSTc pentasaccharide
4xty  1.80  2015  Kd=0.614nM    // 4xtv.pdf (44L) compound 63;
5d9p  1.80  2015  Kd=0.63mM     // 5d9p.pdf (NBG) Kd=0.63+/-0.03mM; ligand is compound 1
5aiv  2.04  2015  Kd=0.65uM     // 5ais.pdf (M1W) compound 9
4pli  1.65  2015  Kd=0.69mM     // 4pl6.pdf (11-mer) ligand is H3K36me3 peptide
4yv5  1.90  2015  Kd=0.6uM      // 4yv5.pdf (SVR) [Multiple sites: site 1: Kd=0.6uM; site 2=6.2uM] ligand is Suramin
4rt1  1.70  2015  Kd=0.73uM     // 4rt0.pdf (C2E) ligand is c-di-GMP
4xu0  1.60  2015  Kd=0.769nM    // 4xtv.pdf (44N) compound 73;
4x34  1.80  2015  Kd=0.76uM     // 4x34.pdf (10-mer) [Incomplete ligand] ligand is p53K381acK382me2 peptide;
4tqn  1.70  2015  Kd=0.77uM     // 4tqn.pdf (UL4) compound 10, UL04
5c13  2.10  2015  Kd=0.79uM     // 5c13.pdf (10-mer) ligand is  histone H3C4me3 peptide
4x0z  1.85  2015  Kd=0.7mM      // 4x0z.pdf (4-mer) [Nonstandard assay: Temp 37, SVGA cells] GM1 oligosaccharide
5agj  2.00  2015  Kd=0.7uM      // 5agi.pdf (ANZ) [Nonstandard assay: pH=8, 50 mM HEPES-KOH, 30 mM KCl, 30 mM MgCl2] ligand is AN2690-AMP;
4cwb  1.56  2015  Kd=0.81uM     // 4crj.pdf (X6L) compound 7
3x00  1.30  2015  Kd=0.83nM     // 3x00.pdf (ZOF) ligand is bis iminobiotin long tail (Bis-IMNtail)
4odm  1.75  2015  Kd=0.855uM    // 4odk.pdf (16-mer) [Multiple sites: site1: Kd=0.855+/-0.332uM; site 2: Kd=18.83+/-6.2uM] TtSlyDFL:S2-W23A
4xk9  2.20  2015  Kd=0.86nM     // 4xhe.pdf (41J) A-AChBP in complex with pinnatoxin G
4xqu  3.25  2015  Kd=0.86uM     // 4xq5.pdf (SIA-NAG-GAL) ligand is 3'-SLN
4pl6  1.68  2015  Kd=0.8mM      // 4pl6.pdf (11-mer) ligand is H3K4me3 peptide
4xkb  1.50  2015  Kd=0.8uM      // 4xkb.pdf (DE9) [Nonstandard assay: Temp 20, pH=7.6,Tris-HCl=100mM, NaCl=100mM] ligand is Deuteroporphyrin IX;
4tkj   .87  2015  Kd=0.913uM    // 3wvm.pdf (PLM) [Nonstandard assay: 20 mM Tris-HCl, pH 8.0, and 100 mM NaCl, or 20 mM potassium phosphate, pH 7.0, and 100 mM NaCl] ligand is palmitic acid
4xtw  2.30  2015  Kd=0.933nM    // 4xtv.pdf (44M) compound 46;
4zb8  2.00  2015  Kd=0.94uM     // 4f0c.pdf (GDS) ligand is GSSG
4wri  1.40  2015  Kd=0.97nM     // 4wri.pdf (OKA) [Different protein in assay: OABP2 is a mixture of homologues, OABP2.1, OABP2.2, and OABP2.3] crystal is OABP2.1
4u5v  1.97  2015  Kd=0.9mM      // 4u54.pdf (RH2) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 17
4ris  2.30  2015  Kd=0.9uM      // 4rir.pdf (18-mer) ligand is gp120 (165-182) L179A/I181A peptide
4txs  2.78  2015  Kd=1.01mM     // 4txs.pdf (3AQ) fragement 114
4tjz   .87  2015  Kd=1.07uM     // 3wvm.pdf (DKA) [Nonstandard assay: 20 mM Tris-HCl, pH 8.0, and 100 mM NaCl, or 20 mM potassium phosphate, pH 7.0, and 100 mM NaCl] ligand is capric acid, DKA
4rr6  1.88  2015  Kd=1.0uM      // 4rr6.pdf (A3S) ligand is L-Ser3AA
4ra1  1.75  2015  Kd=1.16uM     // 4ra1.pdf (ALX-BNX) ligand is D-Glucose-2-phosphate; mixture of alpha ALX and beta BNX
4und  2.20  2015  Kd=1.1nM      // 4r5w.pdf (2YQ) complex is PARP1/Talazoparib
4crj  2.00  2015  Kd=1.1uM      // 4crj.pdf (YH5) compound 3
4d4d  1.40  2015  Kd=1.1uM      // 4d4b.pdf (MAN-IFM) ligand is compound 3; 1,6-ManIFG, two combined units
4rme  2.30  2015  Kd=1.21uM     // 4rfw.pdf (13-mer) ligand is coactivator peptide GRIP-1
4rxh  1.76  2015  Kd=1.23uM     // 4rxh.pdf (8-mer) [Multiple sites: site1: Kd=1.23uM; site2: 1.69uM] ligand is SV40 NLS (125-PPKKKRKV-132) peptide
3wti  2.68  2015  Kd=1.27uM     // 3wth.pdf (CT4) ligand is Clothianidin
4x14  2.30  2015  Kd=1.2mM      // 4x0z.pdf (4-mer) [Nonstandard assay: Temp 37, SVGA cells] ligand is GM1 oligosaccharide
5ct2  2.00  2015  Kd=1.2mM      // 5ct2.pdf (CXS) ligand is compound CAPS
4y5d  1.20  2015  Kd=1.2uM      // 4y59.pdf (MT6) ligand is ALiS-2
5eq0  1.18  2015  Kd=1.2uM      // 5epk.pdf (6-mer) peptide inhibitor UNC3866
5cyi  2.00  2015  Kd=1.31uM     // 5cyi.pdf (55S) [Covalent complex] [Incomplete ligand] CDK2/Cyclin A covalent complex with ligand NU6300, but RCSB used structure of NU6310
4zei  2.30  2015  Kd=1.33uM     // 4ra1.pdf (LAO) ligand is L-arabinose-2-phosphate
4xkc  2.00  2015  Kd=1.36uM     // 4xkb.pdf (MD9) [Nonstandard assay: Temp 20, pH=7.6,Tris-HCl=100mM, NaCl=100mM] ligand is Magnesium Deuteroporphyrin IX;
4u5u  1.96  2015  Kd=1.3mM      // 4u54.pdf (3D2) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 16
4urx  2.49  2015  Kd=1.3mM      // 4uru.pdf (HXY) compound 4a
4cst  1.10  2015  Kd=1.3nM      // 4css.pdf (CWK) compound 10j
4pxm  1.90  2015  Kd=1.3nM      // 4pxm.pdf (EST) radioligand binding assays
4yc9  1.82  2015  Kd=1.3nM      // 4yab.pdf (4C1) compound 8i
4x3s  1.60  2015  Kd=1.3uM      // 4x3k.pdf (10-mer) [Incomplete ligand] [Different ligand in assay: Kd: binding assay SETDB1 peptide] ligand is SETDB1-K1170me3 peptide
4xyn  2.55  2015  Kd=1.3uM      // 4xyn.pdf (15-mer) [Incomplete ligand] ligand is human RAGE-derived W61 peptide;
4oex  2.14  2015  Kd=1.45uM     // 4oew.pdf (5EO) compound 1
4yz5  2.27  2015  Kd=1.48mM     // 4yw1.pdf (SLT) [Incomplete ligand] [Nonstandard assay: PH=8, 20mM Tris, 50 mM NaCl] 3'-SL
5a2j  1.65  2015  Kd=1.4uM      // 5a2i.pdf (6-mer) [Nonstandard assay: 10 mM sodium phosphate buffer containing 150 mM NaCl] ligand is glycopeptide m1
5c0m  1.60  2015  Kd=1.4uM      // 5c0m.pdf (10-mer) SGF29-HC4me3, ligand is a Carba containing peptide
4z46  1.85  2015  Kd=1.51mM     // 4z46.pdf (1PT) [Uncommon element] [Nonstandard assay: 10 mM Hepes, 150 mM NaCl, 3 mM EDTA] ligand is OXALIPLATIN; also contains Cisplatin in crystal
4zec  2.15  2015  Kd=1.5uM      // 4ra1.pdf (C84) ligand is agrocin 84
4ycv  3.41  2015  Kd=1.5uM      // 4ycv.pdf (KRS) [Nonstandard assay: PH=8, 20 mM Tris-HCl, 200 mM NaCl, 5 mM DTT] ligand is cladosporin, Thermal Shift Assay
4urw  2.76  2015  Kd=1.6mM      // 4uru.pdf (DXO) compound 3
4yw2  2.00  2015  Kd=1.6mM      // 4yw1.pdf (2-mer) [Incomplete ligand] [Nonstandard assay: PH=8, 20mM Tris, 50 mM NaCl] ligand is 6'-SL
4wph  2.92  2015  Kd=1.6uM      // 4wph.pdf (11-mer) ligand is ICP0 peptide
4ymq  2.00  2015  Kd=1.6uM      // 4ymq.pdf (ZBD) compound 14
4ysl  1.46  2015  Kd=1.6uM      // 4ysl.pdf (GSH) ligand is glutathione;
4urv  2.58  2015  Kd=1.7mM      // 4uru.pdf (UMK) compound 2
5ea3  2.75  2015  Kd=1.7nM      // 5ea3.pdf (5NK) ligand is compound JNJ-2408068
4zdu  2.30  2015  Kd=1.7uM      // 4zdu.pdf (16-mer) [Different protein in assay: delta-IBB importin-alpha(70-529)] NP ncNLS peptide;
5cbr  2.00  2015  Kd=1.80uM     // 5cbr.pdf (4ZK) ligand is compound (S)-37, functional Kb value
4tkh   .93  2015  Kd=1.84uM     // 3wvm.pdf (MYR) [Nonstandard assay: 20 mM Tris-HCl, pH 8.0, and 100 mM NaCl, or 20 mM potassium phosphate, pH 7.0, and 100 mM NaCl] ligand is myristic acid
5epk  1.80  2015  Kd=1.8uM      // 5epk.pdf (6-mer) peptide inhibitor UNC3866
3wvm   .88  2015  Kd=1.95uM     // 3wvm.pdf (STE) [Nonstandard assay: 20 mM Tris-HCl, pH 8.0, and 100 mM NaCl, or 20 mM potassium phosphate, pH 7.0, and 100 mM NaCl] ligand is stearic acid, STE
4czs  1.73  2015  Kd=10.0uM     // 4czs.pdf (5-mer) ligand is 5-mer Man-WYD
4xqa  1.41  2015  Kd=10.3uM     // 4k6t.pdf (423) compound 17a; SPR data is available
4wv6  1.75  2015  Kd=10.4uM     // 4wv4.pdf (14-mer) [Nonstandard assay: PH=8, NaCl=150mM, Tris-HCl=25mM, belta-mercaptoethanol=1mM] ligand is TAF8-NLS peptide;
4x1f  2.00  2015  Kd=10.8nM     // 4x1f.pdf (3WF) [Nonstandard assay: pH 8.5, Tris-HCl 20 mM, NaCl 200 mM, TCEP 1mM, 0.05% Tween 20, 5% DMSO] ligand is Ethinyl estradiol, EE2;
4rlt  2.05  2015  Kd=10.9uM     // 4rlj.pdf (FSE) ligand is Fisetin, this pdf is protected
5boj  1.75  2015  Kd=100nM      // 5boj.pdf (4TX) ligand is compound GEM, Gemfibrozil
4ucd  2.66  2015  Kd=100uM      // 4uc8.pdf (M81) compound M81
4x0f  3.22  2015  Kd=101nM      // 4x0f.pdf (ROL) [Different ligand in assay: Ligand in binding assay is racemic] ligand is R-rolipram
4w53  1.56  2015  Kd=102uM      // 4w52.pdf (MBN) ligand is Toluene
5aba  1.62  2015  Kd=1040uM     // 5ab9.pdf (UL7) compound 5;
4twt  2.85  2015  Kd=10nM       // 4twt.pdf (12-mer) ligand is peptide macrocycle (M21)
4xxh  2.40  2015  Kd=10uM       // 1byk.pdf (T6P)
5cst  1.78  2015  Kd=110nM      // 5cst.pdf (CDP) ligand is cytidine diphosphate (CDP)
4yyn  1.85  2015  Kd=110uM      // 4yy6.pdf (11-mer) H4(1-11) K5cr/K8cr peptide;
4zmf  2.39  2015  Kd=110uM      // 4zme.pdf (AMP)
4rgd  1.20  2015  Kd=113.9uM    // 4rgd.pdf (CIT) quantitative lipid cosedimentation assays
4pgd  2.70  2015  Kd=119nM      // 4pg9.pdf (9-mer) ligand is peptide FAPGNYPAF
5ea7  2.85  2015  Kd=11nM       // 5ea3.pdf (5NO) ligand is compound BMS-433771
5ajo  1.48  2015  Kd=11uM       // 5ajn.pdf (17-mer) ligand is glycopeptide MUC5AC-3,13
5cyv  1.52  2015  Kd=11uM       // 5cyv.pdf (WCA) ligand is p-coumaroyl-CoA
5fjx  2.45  2015  Kd=11uM       // 5fjw.pdf (8-mer) ligand is Gcs1 WxxF peptide
4y2q  2.40  2015  Kd=1200uM     // 4y2j.pdf (49N) fragment 3
4qtl  1.80  2015  Kd=120nM      // 4qiy.pdf (WWO) compound 10d
4rh5  1.60  2015  Kd=127.3nM    // 4rh5.pdf (9-mer) ligand is Eps15 pTyr849 peptide (846-854)
5aom  1.74  2015  Kd=1270uM     // 5ab9.pdf (FY8) compound 12;
5e1s  2.26  2015  Kd=12nM       // 5e1s.pdf (5JA) Inhibitor BI 885578
4rlw  2.20  2015  Kd=13.4uM     // 4rlj.pdf (BUN) ligand is Butein
4rra  1.70  2015  Kd=13.4uM     // 4rr6.pdf (A3T) ligand is L-Thr3AA
4y3b  1.80  2015  Kd=13.4uM     // 4y32.pdf (7-mer) analogue compound 3b; ITC data for 3b is available
4zl4  2.37  2015  Kd=13.8nM     // 4zl4.pdf (4PK) WEHI-842
4yw7  1.82  2015  Kd=130nM      // 4yw6.pdf (4J0) ligand is 5u3;
4pgc  2.30  2015  Kd=1311nM     // 4pg9.pdf (9-mer) ligand is peptide FAPGN(3,5-diiodotyrosine)PAL
4xya  2.05  2015  Kd=1370nM     // 4xy8.pdf (43S) [Nonstandard assay: NaCl=150mM, HEPES=50mM, pH=7.5(Temp 25)] compound 11;
4wmx  2.00  2015  Kd=14.1uM     // 4wmr.pdf (3R7) compound 6
5efc  1.90  2015  Kd=14.1uM     // 5efa.pdf (GTP) ligand is GTP
5e1b  1.65  2015  Kd=14.3uM     // 5e1b.pdf (6-mer) ligand is SPKRIA peptide, RCC1, ITC  Kd1 and kd2 is quite different
5d1r  2.00  2015  Kd=14.4uM     // 5d1r.pdf (56S) ligand is compound Isopropyl laurate
5efa  1.90  2015  Kd=14.7uM     // 5efa.pdf (MGT) ligand is m7GTP
4ym2  2.10  2015  Kd=1400uM     // 4ym2.pdf (SGA-BGC) ligand is lactose-3'-sulfate
5acw  1.80  2015  Kd=145uM      // 5acw.pdf (RHU) compound 1
4res  3.41  2015  Kd=14nM       // 4res.pdf (BUF) ligand is bufalin
4x5r  1.65  2015  Kd=14nM       // 4x50.pdf (3XO) compound 6; Direct ITC assay
4w57  1.68  2015  Kd=14uM       // 4w52.pdf (N4B) ligand is n-Butylbenzene
4rlu  2.20  2015  Kd=15.2uM     // 4rlj.pdf (HCC) ligand is HCC, 2',4,4'-TRIHYDROXYCHALCONE
5d7e  1.90  2015  Kd=150.6uM    // 5d7e.pdf (8-mer) ligand is H3K9ac peptide
4oew  2.44  2015  Kd=152nM      // 4oew.pdf (5IO) compound 5
4rrg  1.93  2015  Kd=1538.5uM   // 4rr6.pdf (A3T) [Multiple sites: site 1: Kd=1538.5uM; site 2: Kd=3875.9uM] ligand is L-Thr3AA
4odk  1.40  2015  Kd=158uM      // 4odk.pdf (16-mer) [Multiple sites: site 2: Kd=158+/-19uM] TtSlyDFL:T1
4qpd  2.10  2015  Kd=15nM       // 4qpd.pdf (THG) ligand is tetrahydrofolate
2ms4   NMR  2015  Kd=15uM       // 2ms4.pdf (9-mer) ligand is 9-mer CrkII peptide
4xqb  1.60  2015  Kd=163.4uM    // 4k6t.pdf (425) compound 17b; SPR data is available
4wy7  2.10  2015  Kd=167nM      // 4wy7.pdf (16-mer)
5ahu  2.69  2015  Kd=167nM      // 5ael.pdf (G76) compound 51;
4q46  1.80  2015  Kd=169uM      // 4q46.pdf (GDP)
4pg9  2.40  2015  Kd=16nM       // 4pg9.pdf (9-mer) ligand is peptide FAPGNYPAL
4qjw  1.55  2015  Kd=16nM       // 4qiy.pdf (WWO) compound 10d
4qxt  1.58  2015  Kd=16nM       // 4qxt.pdf (19-mer) ligand is FC27-MSP2 (14-30)
4odp  1.75  2015  Kd=17.06uM    // 4odk.pdf (16-mer) [Multiple sites: site 2: Kd=17.06+/-1.13uM] TtSlyD delta IF:S2-W23A
4wop  2.39  2015  Kd=17.2uM     // 4wop.pdf (CTP) ligand is CTP
4z8a  1.76  2015  Kd=17.3uM     // 4z88.pdf (17-mer) [Nonstandard assay: 10 mM Tris-HCl, 100 mM NaCl] Cacophony derived peptide
4cjn  1.95  2015  Kd=17.54uM    // 4cjn.pdf (QNZ) compound 2; Binding to PBP2a allosteric site; 6.9ug/mL and MW=393.39 means Kd=17.54uM
4x50  2.00  2015  Kd=17.7nM     // 4x50.pdf (3X8) compound 2; Direct ITC assay
4w5a  2.60  2015  Kd=170uM      // 4w5a.pdf (11-mer) ligand is H3K9me3S10ph peptide
4x63  3.05  2015  Kd=171nM      // 4x60.pdf (3XV) EPZ015666
4pvx  2.18  2015  Kd=172nM      // 4pvx.pdf (YS1) ligand is YS05035
4w52  1.50  2015  Kd=175uM      // 4w52.pdf (BNZ) ligand is benzene
4pge  2.00  2015  Kd=17nM       // 4pg9.pdf (9-mer) ligand is peptide FAPGNYPAW
5csz  1.80  2015  Kd=17nM       // 5csz.pdf (11-mer) gantenerumab fab bind to synthetic A 40 monomers
5a3o  1.60  2015  Kd=18.5uM     // 5a3o.pdf (DH6-MMA) [Incomplete ligand] compound 3; miss a carbon atom;
4rxz  1.55  2015  Kd=181nM      // 4rxz.pdf (12-mer) ligand is PMI peptide
5am6  1.96  2015  Kd=185nM      // 5am6.pdf (38O) ligand is TKI258, e.g. dovitinib
5e1m  1.75  2015  Kd=189nM      // 5e1b.pdf (6-mer) ligand is PPKRIA peptide, RCC1, ITC  Kd1 and kd2 is quite different
5cin  1.70  2015  Kd=18nM       // 5cil.pdf (15-mer) Loop+4E10ep
4nxq  2.10  2015  Kd=18uM       // 4nxq.pdf (8-mer) Kd=18+/-1uM, QM PDZ/Caspr4;
4w55  1.64  2015  Kd=18uM       // 4w52.pdf (3H0) ligand is n-Propylbenzene
5alb  2.16  2015  Kd=19.6pM     // 5alb.pdf (TIQ) ligand is compound ticagrelor
4tyb  2.93  2015  Kd=19.99mM    // 4txs.pdf (3B1) fragement 328
4crl  2.40  2015  Kd=195pM      // 4crl.pdf (C1I) ligand is cortistatin A
4pvy  2.05  2015  Kd=197nM      // 4pvx.pdf (JD1) ligand is JDS05119
4u0w  2.00  2015  Kd=1mM        // 4u0v.pdf (16G) GlcNAc-6-P (NagR), data from ref 7
4x5q  1.12  2015  Kd=1nM        // 4x50.pdf (3XN) compound 5; Competitive ITC assay
4tky  2.50  2015  Kd=2.0uM      // 4tky.pdf (7-mer) [Different protein in assay: wild type Escherichia coli DsbA] ligand is peptide 3: PFATCDS
4z0u  2.00  2015  Kd=2.0uM      // 4z0u.pdf (10-mer) H1/SSB
4ycw  2.90  2015  Kd=2.1uM      // 4ycw.pdf (KRS) [Nonstandard assay: with LYS; Thermal Shift Assay] ligand is cladosporin
4zek  2.09  2015  Kd=2.2uM      // 4ra1.pdf (LAH) ligand is L-arabinose-2-isopropylphosphate
4xek  1.79  2015  Kd=2.2uM      // 4xek.pdf (19-mer) [Multiple sites: site 1: Kd=2.2 uM; site 2: Kd=33 uM] ligand is Leupaxin-LD4 peptide
4ydn  1.35  2015  Kd=2.3nM      // 4ydm.pdf (2WN) [Multiple sites: Kd1=2.3 nM; Kd2=719 nM] ligand is probe 4, protein is two T4-binding sites TTR;
4zyf  1.80  2015  Kd=2.3nM      // 4zyf.pdf (4T4) compound 1;
5e8f  2.10  2015  Kd=2.3nM      // 5e8f.pdf (5-mer) ligand is 5-mer fully modified geranylgeranylated PDE6C Peptide
4tkb   .86  2015  Kd=2.56uM     // 3wvm.pdf (DAO) [Nonstandard assay: 20 mM Tris-HCl, pH 8.0, and 100 mM NaCl, or 20 mM potassium phosphate, pH 7.0, and 100 mM NaCl] ligand is lauric acid
4qjp  1.62  2015  Kd=2.5nM      // 4qiy.pdf (V1F) [Nonstandard assay: Temp 37, pH 7.0] compound 9d
4wz6  2.05  2015  Kd=2.5uM      // 4wz6.pdf (ATP)
4zzy  2.20  2015  Kd=2.5uM      // 4zzx.pdf (D7N) compound 20by
5afv  2.25  2015  Kd=2.6uM      // 5afv.pdf (JH5) [Nonstandard assay: NaCl=150mM; Tris/HCl=25mM] ligand is hit 10;
5a81  2.03  2015  Kd=2.9uM      // 5a81.pdf (78J) compound 13
5azg  1.81  2015  Kd=2.9uM      // 5azg.pdf (10-mer) ligand is UNC-51 peptide
4z89  2.64  2015  Kd=20.2uM     // 4z88.pdf (17-mer) [Incomplete ligand] Cacophony derived peptide
4q0l  2.00  2015  Kd=20nM       // 4pyx.pdf (V14) [Nonstandard assay: Temp=37, pH =7.0,] compound 3
4ymg  1.90  2015  Kd=21uM       // 4ymg.pdf (SAM) higher affinity in presence of Mg2+;
5a5q  1.97  2015  Kd=21uM       // 5a5n.pdf (6XC) compound 25
5aoj  1.47  2015  Kd=21uM       // 5ab9.pdf (Y0V) compound 9
5dhf  2.29  2015  Kd=2200nM     // 5dh9.pdf (13-mer)
4y4v  2.04  2015  Kd=224uM      // 4y4v.pdf (DAL) [Nonstandard assay: pH=7.9, 20 mM HEPES, 150 mM sodium chloride] ligand is D-Ala
4q06  1.15  2015  Kd=22nM       // 4pyx.pdf (V90) [Nonstandard assay: Temp 37 , pH =7.0,] [Different protein in assay: A65S, N67Q, I91L, F130V, V134L, L203A] compound 1
5a46  2.63  2015  Kd=22nM       // 5a46.pdf (38O) ligand is dovitinib
4x5z  1.86  2015  Kd=23.6nM     // 4x5y.pdf (3XY) ligand is MI-136
5dqe  2.18  2015  Kd=234uM      // 5dqe.pdf (5E4) ligand is bromo-fenamic acid, ITC Kd for TEAD2 or TEAD4 is not clear
4y94  2.40  2015  Kd=238nM      // 4y93.pdf (IHP) [Nonstandard assay: 150 mM NaCl, 25 mM Tris, 5% glycerol] ligand is IP6
4rrf  1.70  2015  Kd=239.2uM    // 4rr6.pdf (A3S) [Multiple sites: site 1: Kd=239.2uM; site 2: Kd=555.6uM] ligand is L-Ser3AA
4r73  1.60  2015  Kd=23nM       // 4r73.pdf (G6P) ligand is endogenous G6P/M6P mixture in crystal
5e4w  2.80  2015  Kd=23uM       // 5e4w.pdf (9-mer) ligand is the A3CT motif IV peptide
5e73  1.71  2015  Kd=23uM       // 5e73.pdf (UO1) ligand is compound 47
4yym  1.50  2015  Kd=240uM      // 4yy6.pdf (11-mer) H4(1-11) K5bu/K8bu peptide;
4qp1  2.70  2015  Kd=247uM      // 4qp1.pdf (EMU) compound 1
4uin  2.50  2015  Kd=24nM       // 4uik.pdf (QI9) ligand is quinine
4xgz  2.50  2015  Kd=24nM       // 4xgz.pdf (19-mer) ligand is human paxillin LD2 motif
4ynl  2.10  2015  Kd=24uM       // 4ynl.pdf (6-mer) ligand is Heterocyst inhibition-signaling peptide, PatS6
4x8o  2.10  2015  Kd=250nM      // 4x8l.pdf (AP5) inhibitor Ap5a
5dqf  2.15  2015  Kd=253uM      // 5dqf.pdf (CZE) ligand is Cetirizine, RS mixture in crystal (CZE/LCR)
3x1k  2.55  2015  Kd=256uM      // 3x1k.pdf (ANP) ligand is AMP-PNP; RCSB confused code 3x1k and 3x1m
4z2p  1.60  2015  Kd=25uM       // 4z28.pdf (12-mer) [Incomplete ligand] ligand is hoef-peptide(L9F)
5cs5  1.90  2015  Kd=26.6mM     // 5cs5.pdf (PIN) ligand is compound PIPES
4or4  2.21  2015  Kd=26.8uM     // 4or4.pdf (M7G) [Nonstandard assay: Temp 20] ligand is m7GDP,
4ret  4.00  2015  Kd=26nM       // 4res.pdf (DGX) [Incomplete ligand] [Different ligand in assay: ligand in assay is digitoxigenin, differs for a carbon and oxygen atom] ligand is digoxin, named DGX
4xbo  2.60  2015  Kd=26uM       // 4xbo.pdf (SAH)
4x3k  1.45  2015  Kd=27.7uM     // 4x3k.pdf (7-mer) ligand is H3K27me3 peptide
5a7b  1.40  2015  Kd=271uM      // 5a7b.pdf (KMN) compound 3
4yrd  2.44  2015  Kd=27uM       // 4yrd.pdf (3IT) 3-isopropenyl-tropolone;
4x3t  2.14  2015  Kd=28.9uM     // 4x3k.pdf (45E) ligand is MS37452
5btx  2.10  2015  Kd=280uM      // 5btx.pdf (CMP) ligand is CYCLIC AMP, CAMP
4x2s  4.21  2015  Kd=285nM      // 4x2s.pdf (ASP) [Nonstandard assay: NaCl=100mM]
4ywa  1.19  2015  Kd=28nM       // 4yw6.pdf (4J9) 3u3;
5dms  1.90  2015  Kd=29.58uM    // 5dms.pdf (9-mer) ligand is 9-mer F-box only protein 43
4z7f  3.19  2015  Kd=29.8nM     // 4z7f.pdf (FOL) [Nonstandard assay: PH=8, 20mM Tris-HCl, 100mM NaCl, 0.018% (w/v) n-Dodecyl-beta-D-Maltopyranoside] FOLIC ACID;
5cqu  2.35  2015  Kd=290nM      // 5cqu.pdf (JRJ) compound 14, final deposition
4rwj  2.49  2015  Kd=2nM        // 4rwj.pdf (66T) ligand is AZD4547
5bnj  2.64  2015  Kd=2nM        // 5bnj.pdf (4TV) ligand is compound 1
5e8r  2.55  2015  Kd=2nM        // 5e8r.pdf (5L6) ligand is compound MS023
4zba  1.50  2015  Kd=3.09uM     // 4f0c.pdf (GDS) ligand is GSSG
4urz  2.24  2015  Kd=3.0mM      // 4uru.pdf (VJP) compound 6
4rt0  1.80  2015  Kd=3.13uM     // 4rt0.pdf (C2E) [Different protein in assay: L69M in crystal, wildtype in assay] ligand is c-di-GMP
4u5n  2.31  2015  Kd=3.3mM      // 4u54.pdf (3D4) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 12;
4uc5  2.19  2015  Kd=3.3uM      // 4uc5.pdf (PHE) [Multiple sites: site 1: Kd=3.3 uM; site 2: Kd=11 uM] ligand is allosteric inhibitor phe, two binding site
4x8p  2.20  2015  Kd=3.3uM      // 4x8n.pdf (12-mer) [Nonstandard assay: PH=8, NaCl=150mM, Tris-HCl =25mM, BME=5mM] ligand is RbBP5;
4ycu  2.10  2015  Kd=3.3uM      // 4ycu.pdf (KRS) [Nonstandard assay: with LYS; Thermal Shift Assay] ligand is cladosporin
4qb3   .94  2015  Kd=3.4uM      // 4qb3.pdf (30M) compound 4b,  Olinone
4rrq  1.79  2015  Kd=3.4uM      // 4rr6.pdf (A3S) [Different protein in assay: Protein in binding assay is wild type] ligand is L-Ser3AA
4x3e  2.30  2015  Kd=3.4uM      // 4x3e.pdf (13-mer) [Incomplete ligand] ligand is trimethylated Jarid2K116me3 peptide;
4xcb  1.60  2015  Kd=3.4uM      // 4xac.pdf (HY0) ligand is hygromycin B;
4css  1.07  2015  Kd=3.5nM      // 4css.pdf (CWX) compound 10e
4d62  2.50  2015  Kd=3.64mM     // 4d62.pdf (SIA) [Nonstandard assay: pH=6.0, 10 mM MES-NaOH] ligand is 3-sialyllactose, also named as SIA in RCSB
4ofb  3.05  2015  Kd=3.7uM      // 4ofb.pdf (14-mer) ligand is nonphosphopeptide inhibitor 8.6 3-14
5e1o  2.00  2015  Kd=3.7uM      // 5e1b.pdf (6-mer) ligand is RPKRIA peptide, RCC1, ITC  Kd1 and kd2 is quite different
5ey9  2.50  2015  Kd=3.87uM     // 5ey8.pdf (5SV) [Incomplete ligand] ligand is AMPC12; But still find AMPC20 in RCSB PDB; MST Kd data
4u5o  2.00  2015  Kd=3.8mM      // 4u54.pdf (3D5) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 15
5cbs  1.80  2015  Kd=3.90uM     // 5cbr.pdf (E42) ligand is compound (R)-38, functional Kb value
4u5s  2.12  2015  Kd=3.9mM      // 4u54.pdf (3D0) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 13
2mps   NMR  2015  Kd=3.9uM      // 2mps.pdf (16-mer) ligand is Tumor protein p73 TAD(10-25)
5ct1  2.00  2015  Kd=30.2mM     // 5ct1.pdf (NHE) ligand is compound CHES
4wey  1.55  2015  Kd=318uM      // 4wet.pdf (EG6) compound 41
4zph  2.80  2015  Kd=31nM       // 4zp4.pdf (PRL) [Nonstandard assay: pH=8, 20mM Tris, 400mM NaCl] ligand is Proflavine
4z2o  1.17  2015  Kd=31uM       // 4z28.pdf (12-mer) Hoef-peptide; high resolution
3wut  2.30  2015  Kd=323nM      // 3wut.pdf (14-mer) ligand is TEX14 (792-804) peptide
4v11  1.95  2015  Kd=324nM      // 4v11.pdf (10-mer) ligand is SV2A peptide phosphorylated at Thr84, SV2A pT84
4ym4  3.12  2015  Kd=33.6uM     // 4ym4.pdf (12-mer) Thr9 phosphorylated N-terminal peptide 1-15;
4pgb  2.80  2015  Kd=33nM       // 4pg9.pdf (9-mer) ligand is peptide FAPGNWPAL
4odq  2.00  2015  Kd=34.25uM    // 4odk.pdf (16-mer) [Multiple sites: site 2: Kd=34.25+/-3.40uM] TtSlyD delta IF:S3
5c3p  2.10  2015  Kd=34.4uM     // 5c3p.pdf (AKG) ligand is compound alpha-KG
4zji  1.99  2015  Kd=340nM      // 4zji.pdf (4OQ) compound 11
4qp6  3.10  2015  Kd=343uM      // 4qp1.pdf (36N) compound 3
5dtj  2.71  2015  Kd=34uM       // 5dtj.pdf (5G8) ligand is reactivator compound SP134
5eay  1.55  2015  Kd=34uM       // 5ean.pdf (13-mer) ligand is 13-mer human Dna2 peptide (residues 1 to 20) containing the alpha 1 helix
5azf  1.60  2015  Kd=36.1uM     // 5azf.pdf (4-mer) ligand is 4-mer WEEL peptide
4rrr  1.86  2015  Kd=36.2uM     // 4rr6.pdf (A3T) [Different protein in assay: Protein in binding assay is wild type] ligand is L-Thr3AA
4x21  1.95  2015  Kd=36nM       // 4x21.pdf (3WH) compound 7d;
4z8m  2.95  2015  Kd=36nM       // 4z8m.pdf (19-mer) MAVS T6BM2 peptide
4y16  2.60  2015  Kd=37.1nM     // 4y16.pdf (48G) NC-alphaGC;
4qn9  2.65  2015  Kd=38.5uM     // 4qn9.pdf (DXC) ligand is detergent sodium deoxycholate (DC)
5ael  2.60  2015  Kd=39.2nM     // 5ael.pdf (QAF) compound 5
5c5h  2.40  2015  Kd=394nM      // 5c5h.pdf (4YB) ligand is OSB-AMS
4xy8  1.70  2015  Kd=397nM      // 4xy8.pdf (43U) [Nonstandard assay: NaCl=150mM, HEPES=50mM, pH=7.5(Temp 25)] compound 7d;
4wn5  1.15  2015  Kd=39nM       // 4wn5.pdf (MVC) ligand is 18:1-1-monoacylglycerol;
5ea6  2.75  2015  Kd=39nM       // 5ea3.pdf (5NP) ligand is compound BTA-9881
5e74  1.78  2015  Kd=39uM       // 5e73.pdf (5KH) ligand is compound 50
4tya  2.94  2015  Kd=4.04mM     // 4txs.pdf (3AE) fragment 204
4cl6  2.41  2015  Kd=4.05uM     // 4cl6.pdf (7SB) [Nonstandard assay: Temp 20, pH=7.5, 100 mM sodium phosphate, 7.5% DMSO] ligand is N42FTA
4u5l  2.53  2015  Kd=4.0mM      // 4u54.pdf (3D6) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 11
4rqz  2.40  2015  Kd=4.0uM      // 4rqz.pdf (10-mer) ligand is 10-mer activating peptide
4z88  2.09  2015  Kd=4.1uM      // 4z88.pdf (17-mer) [Incomplete ligand] Aplip1 peptide
5e1d  1.45  2015  Kd=4.1uM      // 5e1b.pdf (6-mer) ligand is YPKRIA peptide, RCC1, ITC  Kd1 and kd2 is quite different
5d21  1.90  2015  Kd=4.2nM      // 5d21.pdf (56N) ligand is compound GalAxPSG3
4xc2  1.90  2015  Kd=4.3uM      // 4xc2.pdf (11-mer) [Different protein in assay: 15N-labeled GABARAPL1] KBTBD6 AIM peptide;
4yef  1.72  2015  Kd=4.44uM     // 4yee.pdf (4CQ) gBCD;
4wrq  2.41  2015  Kd=4.6uM      // 4wrq.pdf (18-mer) [Incomplete ligand] ligand is Chibby peptide
4r07  2.00  2015  Kd=4.8uM      // 4r07.pdf (UCG) [Nonstandard assay: Temp=298K,pH =5.5, NaCL=100 mM ] ligand is ORN06
4or6  2.29  2015  Kd=4.9uM      // 4or6.pdf (GDP) [Nonstandard assay: Temp 20] ligand is GDP,
4omk  1.75  2015  Kd=40.10uM    // 4omj.pdf (SQL) ligand is squalene
4qjo  1.80  2015  Kd=40nM       // 4qiy.pdf (V1F) [Nonstandard assay: Temp 37, pH 7.0] compound 9d
5aer  2.19  2015  Kd=40uM       // 5aer.pdf (14-mer) D2 Receptor peptide; 1:2 two-site binding model
5cil  1.81  2015  Kd=41nM       // 5cil.pdf (13-mer) WDWD+4E10ep
4zt8  1.98  2015  Kd=41uM       // 4zt8.pdf (CYT) ligand is CYS; SPR Kd=41uM, fluorescence Kd=0.23mM
4xtt  2.71  2015  Kd=43.1nM     // 4xtt.pdf (2BA)
4z93  1.27  2015  Kd=44.6nM     // 4z93.pdf (4LD) compound 18
4wyp  1.50  2015  Kd=440uM      // 4wyp.pdf (AMP) [Nonstandard assay: PH=6.4, 20mM MES] ligand is 5'AMP
3wsy  3.11  2015  Kd=441nM      // 3wsy.pdf (15-mer) ligand is propeptide fragment: pro14-28
4wet  1.63  2015  Kd=444uM      // 4wet.pdf (WEF) compound 40
4xmb  2.43  2015  Kd=44nM       // 4xmb.pdf (41P) compound 12e
4u7o  2.40  2015  Kd=450uM      // 4u7o.pdf (AN2) AMPPNP
4cp5  2.32  2015  Kd=452uM      // 4cp5.pdf (EOI) ligand is compound 6, S-PMPApp
4xy9  1.83  2015  Kd=4651nM     // 4xy8.pdf (43U) [Nonstandard assay: NaCl=150mM, HEPES=50mM, pH=7.5(Temp 25)] compound 7d;
4nxr  1.90  2015  Kd=46uM       // 4nxq.pdf (8-mer) Kd=46+/-2uM, QM PDZ/NRXN1
5agi  1.47  2015  Kd=46uM       // 5agi.pdf (ANZ) [Nonstandard assay: pH=8, 50 mM HEPES-KOH, 30 mM KCl, 30 mM MgCl2] ligand is AN2690-AMP;
5ab9  1.36  2015  Kd=470nM      // 5ab9.pdf (92O) compound 2;
5aol  1.50  2015  Kd=4800uM     // 5ab9.pdf (UFV) compound 11;
4qj0  1.55  2015  Kd=48nM       // 4qiy.pdf (WWX) compound 10p
4ucc  2.05  2015  Kd=48uM       // 4uc8.pdf (ZKW) compound M76
4u68  1.80  2015  Kd=49.3uM     // 4u68.pdf (11-mer) Rhi-CD structure with H3K9me3 peptide
4z6i  1.95  2015  Kd=493nM      // 4z6h.pdf (4L3) [Nonstandard assay: Temp 15, 20 mM HEPES, 150 mM NaCl, 0.5 mM TCEP] compound (2R,3S)-24
5fjw  2.80  2015  Kd=4uM        // 5fjw.pdf (9-mer) ligand is Dsl1 WxWx(MSE) peptide
4x1q  2.28  2015  Kd=5.04uM     // 4x1n.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: NaCl=140mM, sodium phosphate=20mM] ligand is Mupain-1;
5e0m  1.65  2015  Kd=5.2uM      // 5e0l.pdf (13-mer) ligand is 13-mer Protein Chica peptide, Chica (468-476)
4omj  1.60  2015  Kd=5.44uM     // 4omj.pdf (2TX) ligand is 2,3-oxidosqualene
5a4c  2.09  2015  Kd=5.7nM      // 5a46.pdf (XOJ) ligand is PDA
4x6s  2.55  2015  Kd=5.7uM      // 4x6s.pdf (11-mer) peptide 2;
4y59  1.22  2015  Kd=5.8uM      // 4y59.pdf (T21) ligand is ALiS-1
4z7q  2.70  2015  Kd=50.9uM     // 4z7n.pdf (5-mer) AGDV-NH2 peptide;
4q08  1.07  2015  Kd=500nM      // 4pyx.pdf (V90) compound 1
4qiy  1.30  2015  Kd=50nM       // 4qiy.pdf (WWX) [Nonstandard assay: Temp 37, pH=7] compound 10p
5a14  2.00  2015  Kd=50nM       // 5a14.pdf (LQ5) [Nonstandard assay: Temp=10 or 15C, 50 mM HEPES, 300 mM NaCl, 1 mM DTT] compound 1;
4wyz  1.45  2015  Kd=50uM       // 4wyp.pdf (U3P) [Nonstandard assay: PH=6.4, 20mM MES] ligand is 3'UMP;
4xhv  1.23  2015  Kd=50uM       // 4xhv.pdf (10-mer) Nrx-1 C-term peptide
4zme  1.98  2015  Kd=50uM       // 4zme.pdf (ADN) Adenosine;
4qjx  1.95  2015  Kd=52nM       // 4qiy.pdf (WWO) compound 10d
5cfb  3.04  2015  Kd=52nM       // 5cfb.pdf (SY9) ligand is Strychnine
4qfo  2.30  2015  Kd=53.4uM     // 4qfo.pdf (2-mer) ligand is Met-Leu
4ryl  2.10  2015  Kd=53nM       // 4ryl.pdf (3ZG) ligand is SGC707, binds an allosteric site at the interface of the two PRMT3 subunits
4r0a  1.90  2015  Kd=55uM       // 4r07.pdf (URI) ligand is uridine
4r75  1.28  2015  Kd=57nM       // 4r73.pdf (S7P) ligand is S7P
4qfp  1.90  2015  Kd=58.6uM     // 4qfp.pdf (2-mer) ligand is Val-Thr
4uil  2.85  2015  Kd=58nM       // 4uik.pdf (QI9) ligand is quinine
4x3h  2.40  2015  Kd=59.4uM     // 4x3h.pdf (9-mer) [Nonstandard assay: PH=8, 10 mM Tris-Cl, 0.5% NP-40, 100 mM NaCl] TARPgamma2 peptide
5dif  2.09  2015  Kd=590nM      // 5dh9.pdf (15-mer)
4unp  2.30  2015  Kd=590uM      // 4unn.pdf (TXW) compound 28, Kd data available
4pyy  1.75  2015  Kd=59nM       // 4pyx.pdf (V14) [Nonstandard assay: Temp 37 , pH =7.0,] compound 3
5ajp  1.65  2015  Kd=5uM        // 5ajn.pdf (17-mer) ligand is glycopeptide MUC5AC-13, assay with UDP and Mn2+
5dah  2.61  2015  Kd=5uM        // 5dah.pdf (11-mer) [Different ligand in assay: ligand is Histone H3 peptide (15-34)] ligand in paper is Histone H3 peptide (1-36), but only 11-mer in PDB
4uru  2.83  2015  Kd=6.0mM      // 4uru.pdf (6W2) compound 1
4ury  2.47  2015  Kd=6.0mM      // 4uru.pdf (RV1) compound 5
4x5p  1.00  2015  Kd=6.2nM      // 4x50.pdf (3XJ) compound 7; Direct ITC assay
5acy  2.01  2015  Kd=6.4nM      // 5acy.pdf (9S3) I-BET858
4q09  1.20  2015  Kd=6.7nM      // 4pyx.pdf (V14) compound 3
4qjm  1.75  2015  Kd=6.7nM      // 4qiy.pdf (V1F) [Nonstandard assay: Temp 37, pH 7.0] compound 9d
3wuv  2.79  2015  Kd=6.7uM      // 3wut.pdf (14-mer) ligand is ALIXN-TEX14C chimera peptide 2
5aut  1.70  2015  Kd=6.7uM      // 5aut.pdf (2AN) ligand is compound ANS
5ahw  2.15  2015  Kd=6.82uM     // 5ahw.pdf (CMP)
4zud  2.80  2015  Kd=6.9nM      // 4zud.pdf (OLM) ligand is olmesartan;
4yy6  1.45  2015  Kd=60uM       // 4yy6.pdf (11-mer) butyryllysine peptide H4(1-11) K5bu/K8bu
4z6h  1.80  2015  Kd=612nM      // 4z6h.pdf (4L2) [Nonstandard assay: Temp 15, 20 mM HEPES, 150 mM NaCl, 0.5 mM TCEP] compound 6
4x1p  1.60  2015  Kd=62.8uM     // 4x0w.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: PH=5, 10 mM sodium acetate] ligand is mupain-1-17; 4x0w is lower resolution structure;
5am7  1.96  2015  Kd=64.5nM     // 5am6.pdf (38O) ligand is TKI258, e.g. dovitinib
4qy8  1.35  2015  Kd=64nM       // 4qxt.pdf (19-mer) ligand is 3D7-MSP2 (14-30)
4rwk  2.98  2015  Kd=64nM       // 4rwj.pdf (66T) ligand is AZD4547
4yyi  1.50  2015  Kd=64uM       // 4yy6.pdf (11-mer) H4(1-11) K5ac/K8ac peptide;
4uce  2.95  2015  Kd=680uM      // 4uc8.pdf (MZS) compound M72
5bv3  2.25  2015  Kd=68nM       // 5bv3.pdf (M7G) ligand is m7GDP, Kd=68nM for close site
4w54  1.79  2015  Kd=68uM       // 4w52.pdf (PYJ) ligand is Ethylbenzene
5f2k  1.60  2015  Kd=697nM      // 5f2k.pdf (SAH)
4x11  2.30  2015  Kd=6mM        // 4x0z.pdf (SIA) [Nonstandard assay: Temp 37, SVGA cells] ligand is GD1a oligosaccharide
4pdk  2.80  2015  Kd=6nM        // 4p9u.pdf (3VV) [Multiple sites: site 1: Kd=6nM; site 2: Kd=88nM]
4qyo  1.21  2015  Kd=6nM        // 4qxt.pdf (11-mer) ligand is peptide MSP2 (14-22)
4r3s  1.70  2015  Kd=6nM        // 4qxt.pdf (15-mer) ligand is peptide MSP2 (11-23)
4xcu  1.71  2015  Kd=6nM        // 4xcu.pdf (40M) [Covalent complex] BLU9931
4xh2  2.00  2015  Kd=6nM        // 4xgz.pdf (18-mer) ligand is human paxillin LD4 motif
5cgj  3.36  2015  Kd=6uM        // 5cgj.pdf (51M) ligand is RA839
5cs3  2.50  2015  Kd=7.0mM      // 5cs3.pdf (EP1) ligand is compound (H)EPPS
4qiz  1.55  2015  Kd=7.1nM      // 4qiy.pdf (WWX) [Nonstandard assay: Temp 37, pH=7] compound 10p
4q07  1.15  2015  Kd=7.3nM      // 4pyx.pdf (V14) [Nonstandard assay: Temp=37] [Different protein in assay:  A65S, N67Q, I91L, F130V, V134L, L203A] compound 3
3wuu  2.90  2015  Kd=7.3uM      // 3wut.pdf (14-mer) ligand is TEX14N-ALIXC chimera peptide 1
5btr  3.20  2015  Kd=7.3uM      // 5btr.pdf (5-mer) [Nonstandard assay: in the presence of 0.5 mM resveratrol]
5alc  1.70  2015  Kd=7.4nM      // 5alb.pdf (TIQ) ligand is compound ticagrelor
4zed  1.75  2015  Kd=7.5uM      // 4ra1.pdf (AGW) ligand is agrocinopine-3'-O-benzoate
5d1w  3.59  2015  Kd=7.5uM      // 5d1r.pdf (PLM) ligand is compound PALMITIC ACID
4qfl  1.75  2015  Kd=7.7uM      // 4qfl.pdf (2-mer) ligand is peptide Ala-Phe
5ea4  2.30  2015  Kd=7.8nM      // 5ea3.pdf (5NM) ligand is compound JNJ-49153390
4ux9  2.34  2015  Kd=7.9uM      // 4ux9.pdf (12-mer) JNK1 binds to MKK7 residues 37-48
4xt2  1.70  2015  Kd=70nM       // 4xt2.pdf (43L) (S,R)-24
4pyx  1.80  2015  Kd=730nM      // 4pyx.pdf (V90) [Nonstandard assay: Temp 37 , pH =7.0,] compound 1
5dq8  2.31  2015  Kd=73uM       // 5dq8.pdf (FLF) ligand is FA, flufenamic acid
5c5t  1.60  2015  Kd=746uM      // 5c5t.pdf (AKG) Kd under 520 nm absorbance measurements
4zow  2.45  2015  Kd=75uM       // 4zow.pdf (CLM) ligand is chloramphenicol
4qfn  2.30  2015  Kd=76uM       // 4qfn.pdf (2-mer) ligand is Gly-Glu
4d52  1.76  2015  Kd=775uM      // 4ah4.pdf (GIV) ligand is L-Gal; name GIV for beta L-Gal and GXL for alpha L-Gal
4wf4  1.70  2015  Kd=777uM      // 4wet.pdf (WF4) compound 4
4ymx  1.48  2015  Kd=79nM       // 4yms.pdf (ARG) [Nonstandard assay: 20 mM Hepes, 200 mM NaCl] ligand is ARGININE
4ycl  3.25  2015  Kd=7nM        // 2ear.pdf (CZA)
4qip  2.00  2015  Kd=7uM        // 4qip.pdf (SDS) [Multiple sites: inner SDS binding site (Kd=7uM), outer SDS binding site (Kd=100uM] two binding sites
4oiv  1.70  2015  Kd=8.29uM     // 4oiv.pdf (XX9) ligand is NDB
4xx9  1.40  2015  Kd=8.4uM      // 4xx9.pdf (RF4) [Different protein in assay: in binding assay is wild type protein] RF4
4u54  2.41  2015  Kd=8.7mM      // 4u54.pdf (3C5) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 1
5ea5  3.05  2015  Kd=8.7nM      // 5ea3.pdf (TM3) ligand is compound TMC-353121
5a2i  1.88  2015  Kd=8.8uM      // 5a2i.pdf (6-mer) [Nonstandard assay: 10 mM sodium phosphate buffer containing 150 mM NaCl] ligand is glycopeptide m2*
4ty9  2.78  2015  Kd=8.96mM     // 4txs.pdf (3B0) fragement 162
4x8t  2.20  2015  Kd=8.9mM      // 4x8s.pdf (3Z8) compound 7
4wci  1.65  2015  Kd=8.9uM      // 4wci.pdf (16-mer) ligand is proline-rich peptide (aa 378-393) from human RIN3e1
5cc2  2.50  2015  Kd=80uM       // 5cc2.pdf (CKA) ligand is compound 7-CKA
4yw6  1.40  2015  Kd=83nM       // 4yw6.pdf (G0P) ligand is GalAG1;
4wmy  1.60  2015  Kd=85nM       // 4wmy.pdf (3S6) ligand is allyl-beta-galactofuranose
4xmr  1.30  2015  Kd=86uM       // 4xmr.pdf (ILE) isoleucine;
4r74  1.93  2015  Kd=8nM        // 4r73.pdf (F6P) ligand is F6P
4rwl  2.19  2015  Kd=8nM        // 4rwj.pdf (3ZC) ligand is E3810
4z7n  2.60  2015  Kd=9.03uM     // 4z7n.pdf (4-mer) AGDV peptide;
4yp1  2.65  2015  Kd=9.1uM      // 4yp1.pdf (2BA) [Nonstandard assay: pH=8, 20 mM Tris-HCl, 80 mM NaCl] ligand is Cyclic di-AMP (c-di-AMP)
4uu5  1.23  2015  Kd=9.2uM      // 4uu5.pdf (17-mer) ligand is Crb-17-peptide
4ty8  2.78  2015  Kd=9.31mM     // 4txs.pdf (3AV) fragement 117
4x5y  1.59  2015  Kd=9.3nM      // 4x5y.pdf (3XW) ligand is MI-503
4rcg  2.60  2015  Kd=9.3uM      // 4r43.pdf (GDP) ligand is GDP
4y7r  1.90  2015  Kd=9.3uM      // 4y7r.pdf (8-mer) [Nonstandard assay: PH=6, 200 mM phosphate, 300 mM NaCl] MYC MbIIIb peptide;
4zjj  2.20  2015  Kd=9.9nM      // 4zji.pdf (4OR) compound 2
4wmv  2.40  2015  Kd=93uM       // 4wmr.pdf (3R4) compound 4, named 3R4
5cso  1.78  2015  Kd=940nM      // 5cso.pdf (CTN) ligand is cytidine
4qp2  2.23  2015  Kd=940uM      // 4qp1.pdf (36R) compound 2
5aoi  1.78  2015  Kd=940uM      // 5ab9.pdf (RZH) compound 6;
5acx  1.80  2015  Kd=9uM        // 5acw.pdf (WL3) compound 2
4u58  2.56  2015  Kd>10.0mM     // 4u54.pdf (3C6) [Nonstandard assay: Temp=25,PH=6.0;100 mM citrate, 200 mM NaCl, 10% DMSO] compound 14
5aok  1.35  2015  Kd>2000uM     // 5ab9.pdf (GOH) compound 10
4y5s  2.54  2015  Kd~185uM      // 4y5s.pdf (AKG) [Nonstandard assay: Temp 37] alpha-Ketoglutarate;
4d63  2.20  2015  Kd~23mM       // 4d62.pdf (SIA) ligand is 6-sialyllactose, also named as SIA in RCSB
4zyr  3.31  2015  Kd~2uM        // 4zyr.pdf (9PG) alpha-NPG
4ydq  2.30  2015  Kd~300nM      // 4ydq.pdf (HFG) HF; Kd in the presence of AMPPNP is  9nM;
4pde  2.80  2015  Kd~364nM      // 4pde.pdf (GDP) GDP; estimated Kd value
4xpj  2.61  2015  Kd~8.11uM     // 4xpj.pdf (LPY) ligand is lysophosphatidylinositol
5ceo  2.28  2015  Ki<0.0005uM   // 5ceo.pdf (50D) ligand is compound 2
4qvx  2.10  2015  Ki<0.01nM     // 4qvx.pdf (3CQ) compound 17
4uxl  2.40  2015  Ki<0.025nM    // 4uxl.pdf (5P8) ligand is PF-06463922
5bry  1.34  2015  Ki=0.0015nM   // 5bry.pdf (4UY) ligand is entry 6(compoud 25f)
4crc  1.60  2015  Ki=0.0019uM   // 4cr5.pdf (OTM) compound 10
4yth  2.04  2015  Ki=0.002uM    // 4ytc.pdf (467) compound 44
5dgu  1.22  2015  Ki=0.0045nM   // 5dgu.pdf (5B7) ligand is compound 30b
5em6  2.78  2015  Ki=0.004uM    // 5em6.pdf (5Q3) ligand is compound 19
4ytf  1.78  2015  Ki=0.007uM    // 4ytc.pdf (4HZ) compound 22
5dgw  1.62  2015  Ki=0.009nM    // 5dgu.pdf (5B5) ligand is compound 30j
4zhm  1.90  2015  Ki=0.009uM    // 4zhl.pdf (10-mer) [Nonstandard assay: Temp 37, 10 mM Hepes, 140 mM NaCl, 0.1% BSA] ligand is mupain-16-IG peptide
4ytc  2.16  2015  Ki=0.013uM    // 4ytc.pdf (4HW) compound 1
5em7  2.81  2015  Ki=0.019uM    // 5em7.pdf (5Q4) ligand is compound 13
4crb  1.85  2015  Ki=0.027uM    // 4cr5.pdf (7P0) compound 9
4yo8  2.10  2015  Ki=0.030nM    // 4wkn.pdf (4EZ) compound 54
5dia  1.96  2015  Ki=0.035nM    // 5dgz.pdf (5E6) ligand is compound 36
4rac  2.05  2015  Ki=0.03uM     // 4rab.pdf (3L4) compound 7b
5ceq  1.91  2015  Ki=0.042uM    // 5ceo.pdf (50F) ligand is compound 11
4ynb  2.00  2015  Ki=0.043nM    // 4wkn.pdf (4EH) compound 32
4xuz  1.50  2015  Ki=0.044uM    // 4xux.pdf (4D6) [Uncommon element] [Nonstandard assay: 50 mM Na phosphate, 0.1 mg/mL BSA] [Different protein in assay: recombinant E. coli strains] compound 9f
4y8z  2.20  2015  Ki=0.04nM     // 4y8z.pdf (4CE) compoud 13
4rab  2.26  2015  Ki=0.04uM     // 4rab.pdf (3L3) compound 10c
4x0u  1.95  2015  Ki=0.04uM     // 4x0u.pdf (3W9) [Covalent complex] ligand is DEAB; covalent inactivation of ALDH7A1 by DEAB;
5bwc  2.45  2015  Ki=0.061uM    // 5bwb.pdf (HBP) ligand is compound ORTHO-7
4cra  1.80  2015  Ki=0.06uM     // 4cr5.pdf (XJ8) compound 8
4zbf  2.20  2015  Ki=0.074uM    // 4zbf.pdf (4M7) compound 24
4ran  2.55  2015  Ki=0.07uM     // 4rab.pdf (3L6) compound 11a
4crd  2.10  2015  Ki=0.08uM     // 4cr5.pdf (OTJ) compound 11
4rad  2.00  2015  Ki=0.08uM     // 4rab.pdf (3L5) compound 7c
4yik  1.48  2015  Ki=0.128uM    // 4yik.pdf (2O2) [Nonstandard assay: Temp 37,  2-4 nM enzyme in 20 mM Tris.HCl, 20 mM MgCl2, 2 mM EDTA and 2 mM DTT, pH 7.5] compound 3: mdN
5cep  1.99  2015  Ki=0.145uM    // 5ceo.pdf (50E) ligand is compound 3
4zo5  2.50  2015  Ki=0.15nM     // 4zo5.pdf (4Q0) compound 8j
4yur  2.65  2015  Ki=0.16nM     // 4yur.pdf (4J7) [Nonstandard assay: pH=8.0, 20mM MgCl2, 1 mM DTT] ligand is centrinone
4wkn  2.00  2015  Ki=0.19nM     // 4wkn.pdf (TDI) compound 2
4raq  2.53  2015  Ki=0.19uM     // 4rab.pdf (3L8) compound 6b
4oel  1.40  2015  Ki=0.1uM      // 4oel.pdf (2-mer) ligand is Ser-Tyr
4o2p  2.10  2015  Ki=0.20uM     // 4o2p.pdf (11V) ligand is compound 3-R
4zip  1.11  2015  Ki=0.21nM     // 4zip.pdf (G64) compound 5o
4wkc  1.64  2015  Ki=0.21pM     // 4wkb.pdf (BIG) ligand is BuTDIA
5em5  2.65  2015  Ki=0.262uM    // 5em5.pdf (5Q2) ligand is compound 2
5cjf  1.83  2015  Ki=0.26nM     // 5cjf.pdf (520) ligand is compound 20
4wkp  1.58  2015  Ki=0.28nM     // 4wkn.pdf (3QA) compound 36
4pv5  2.30  2015  Ki=0.29uM     // 4pv5.pdf (CBW) ligand is 18-beta-glycyrrhetinic acid (GA)
4qhc  1.90  2015  Ki=0.2uM      // 4qhc.pdf (33V) [Covalent complex] ligand is Penem 2
5dhj  2.46  2015  Ki=0.2uM      // 5dgz.pdf (5E5) ligand is compound 4
4zbi  2.50  2015  Ki=0.31uM     // 4zbf.pdf (4M6) compound 20
4wko  1.90  2015  Ki=0.34nM     // 4wkn.pdf (HCE) compound 22
4xj0  2.58  2015  Ki=0.3nM      // 4xj0.pdf (41B) ligand is (S)-14k
4r0i  1.90  2015  Ki=0.3uM      // 4r0i.pdf (3KM) compound 6
4qll  1.85  2015  Ki=0.42mM     // 4qlj.pdf (CTT) ligand is cellotetraose
4z0k  1.41  2015  Ki=0.462uM    // 4yzu.pdf (4LN) compound 14a
4q99  1.50  2015  Ki=0.52uM     // 4q7p.pdf (HT4) ligand is 4-CH3-2mp
4ty1  2.70  2015  Ki=0.55nM     // 4ty1.pdf (38W) compound 29
4r3b  1.37  2015  Ki=0.56uM     // 4r3b.pdf (3GE) [Incomplete ligand] ligand is PSR-3-283A, named 3GE, ligand is open circle in RCSB
4qlk  1.83  2015  Ki=0.57mM     // 4qlj.pdf (CTT) ligand is cellotetraose
4wr8  2.60  2015  Ki=0.59uM     // 4wr8.pdf (3TX) [Nonstandard assay: PH=6, 500 mM boric acid] compound 3a
4crf  2.30  2015  Ki=0.5nM      // 4cr5.pdf (R9B) compound 13
4q1a  1.90  2015  Ki=0.5nM      // 4q1a.pdf (2XZ) compound 6
5cgc  3.10  2015  Ki=0.5nM      // 5cgc.pdf (51D) PKi=9.3; PIC50=8.6; ligand is compound 14
5cgd  2.60  2015  Ki=0.5nM      // 5cgc.pdf (51E) PKi=9.3; PIC50=9.2; ligand is compound 25
5brn  2.30  2015  Ki=0.5uM      // 5brn.pdf (4X2) ligand is compound 25
4ymb  1.93  2015  Ki=0.62uM     // 4yma.pdf (4E7) compound 2f;
4wrb  1.81  2015  Ki=0.65uM     // 4wr8.pdf (3TW) [Nonstandard assay: PH=6, 500 mM boric acid] compound 3b
5dhh  3.00  2015  Ki=0.66nM     // 5dhg.pdf (DGW) pKi=9.18; ligand is SB-612111
4rhu  2.57  2015  Ki=0.69uM     // 4rht.pdf (45T-3QE) compound 5, RS mixture of 45T and 3QE
4s1g  2.10  2015  Ki=0.6nM      // 4s1g.pdf (43T) compound 12
5bsk  2.61  2015  Ki=0.6uM      // 5brn.pdf (4X7) ligand is compound 26
5dhg  3.00  2015  Ki=0.72nM     // 5dhg.pdf (DGV) pKi=9.14, ligand is compound 35, C-35
4y8y  2.60  2015  Ki=0.7nM      // 4y8y.pdf (4D5) compound 9
5aml  1.36  2015  Ki=0.7nM      // 5amd.pdf (51J) ligand is compound 3e
5dit  2.25  2015  Ki=0.7uM      // 5dit.pdf (5B8) ligand is compound 41
4zls  1.53  2015  Ki=0.82nM     // 4zls.pdf (G61) compound 17a
5avi  2.70  2015  Ki=0.87uM     // 5avi.pdf (4KM)  ligand is compound 4
5em8  2.80  2015  Ki=1.090uM    // 5em8.pdf (5Q4) ligand is compound 13
4rhy  2.32  2015  Ki=1.13uM     // 4rht.pdf (3QG) compound 14
5a69  2.20  2015  Ki=1.1nM      // 5a69.pdf (OGN) [Nonstandard assay: Temp 37] Ki=1.1+/-0.1nM, ligand is Gal-PUGNAc
3wz6  1.40  2015  Ki=1.1uM      // 3wz6.pdf (IXZ) compound 5
4yvc  3.20  2015  Ki=1.1uM      // 4yvc.pdf (4KH) [Nonstandard assay: Temp 30, 100 mM HEPES, 10 mM MgCl2, 25 mM NaCl, 2 mM DTT,1.5% DMSO] compound 4
5cas  2.10  2015  Ki=1.4nM      // 5c8k.pdf (4ZQ) ligand is compound 41a
4x6n  2.10  2015  Ki=1.5nM      // 4x6m.pdf (3Y5) compound 26
3wz8  1.45  2015  Ki=1.5uM      // 3wz6.pdf (IXV) compound 8
5cau  2.25  2015  Ki=1.6nM      // 5c8k.pdf (4ZR) ligand is compound 41b
5e2p  2.11  2015  Ki=1.6nM      // 5e2o.pdf (7P0) ligand is compound 27
4rhx  2.03  2015  Ki=1.6uM      // 4rht.pdf (3QF) compound 9
4ykk  1.38  2015  Ki=1.7mM      // 4ykj.pdf (DSN) D-serine;
4yhq  1.30  2015  Ki=1.7nM      // 4ye3.pdf (G10) [Nonstandard assay: Temp 37, pH=5.6, 100 mM MES, 400 mM sodium chloride] GRL-5010A;
4yt7  2.30  2015  Ki=1.7nM      // 4yt6.pdf (4K1) compound 35
5abh  1.95  2015  Ki=1.7nM      // 5abe.pdf (YWN) [Nonstandard assay: Temp 37, 1X PBS buffer (0.03% BSA)] [Different protein in assay: Protein in binding assay is human OGA] compound 31;
3wz7  1.90  2015  Ki=1.8uM      // 3wz6.pdf (IXY) compound 6
4q1b  2.15  2015  Ki=1.9nM      // 4q1a.pdf (2Y0) compound 7
4x6o  2.10  2015  Ki=1.9nM      // 4x6m.pdf (3Y4) compound 30
4re2  2.00  2015  Ki=10.4uM     // 4re2.pdf (MVL) [Nonstandard assay: Temp 30, PH=5.0 ] ligand is mannoimidazole;
4u2w  1.00  2015  Ki=1000nM     // 4u2w.pdf (16-mer) [Different ligand in assay: ] ligand is HV-BBI(3-18), Ki=1000nM is for HV-BBI(5-15)
4zz3  2.50  2015  Ki=1000nM     // 4zz1.pdf (4DW) [Nonstandard assay: Temp 37, pH=7.5, 0.1 M Hepes] ligand is PMX;
4riv  1.63  2015  Ki=100nM      // 4riu.pdf (LSA) ligand is SAC
4yve  3.40  2015  Ki=100nM      // 4yvc.pdf (4KK) [Nonstandard assay: Temp 30, 100 mM HEPES, 10 mM MgCl2, 25 mM NaCl, 2 mM DTT,1.5% DMSO] compound 10
4twp  2.40  2015  Ki=100pM      // 4twp.pdf (AXI) ligand is axitinib
4p6c  1.86  2015  Ki=100uM      // 4p6c.pdf (RES) ligand is 4PEH
4r3c  2.06  2015  Ki=101nM      // 4r3c.pdf (3GF) ligand is MW150
5fl4  1.82  2015  Ki=101nM      // 5fl4.pdf (9FK) ligand is compound 2
4xar  2.26  2015  Ki=107nM      // 4xaq.pdf (40F) [Nonstandard assay: pH=7.6, K3PO4=10mM, KBr=100mM] compound 1;
4x6i  1.87  2015  Ki=10nM       // 4x6h.pdf (3Y1) [Nonstandard assay: Temp 37, PH=6] compound 6;
5bml  2.95  2015  Ki=10nM       // 4yvc.pdf (4TW) [Nonstandard assay: Temp 30, 100 mM HEPES, 10 mM MgCl2, 25 mM NaCl, 2 mM DTT,1.5% DMSO] compound 37
4zx0  1.60  2015  Ki=10nM       // 4zwx.pdf (5L2) compound 623
5a6k  2.10  2015  Ki=1130nM     // 5a6k.pdf (NSG) ligand is Gal-NGT
4rn4  1.53  2015  Ki=114nM      // 4rn4.pdf (3T7) compound 3
4xir  1.70  2015  Ki=115nM      // 4xip.pdf (40X) [Nonstandard assay: 50 mMKCl, 5 mMMgCl2, 20 mMHEPES, 0.1% CHAPS (Sigma C5070), 0.1% bovine gamma-globulin (Sigma G7516), and 2 mM dithiothreitol (Sigma 646563)] compound 13;
4y79  2.10  2015  Ki=11nM       // 4y76.pdf (4O6) [Nonstandard assay: NaCl=150mM, CaCl2=5mM, HEPESa=50mM] compound 1c;
4yt6  2.07  2015  Ki=11nM       // 4yt6.pdf (4JY) compound 19
4ruy  1.14  2015  Ki=12.8nM     // 4rux.pdf (3W6) compound 2b
5can  2.80  2015  Ki=124nM      // 5c8k.pdf (4ZB) ligand is compound 27
4rux  1.14  2015  Ki=12nM       // 4rux.pdf (3W3) compound 2d
4x8v  2.50  2015  Ki=130nM      // 4x8s.pdf (3Z9) compound 18
4ufk  2.40  2015  Ki=130uM      // 4ufh.pdf (LDU) ligand is DIL
4re4  2.29  2015  Ki=135nM      // 4re4.pdf (IFM) [Nonstandard assay:  Temp 30, PH=5.0 ] ligand is isofagomine
4x8s  2.10  2015  Ki=13mM       // 4x8s.pdf (3Z7) compound 6
4yti  2.52  2015  Ki=13nM       // 4ytc.pdf (VJK) ligand is VX-509;
4zz1  1.35  2015  Ki=13nM       // 4zz1.pdf (3YF) [Nonstandard assay: Temp 37, pH=7.5, 0.1 M Hepes] compound 5;
5cnj  2.65  2015  Ki=144nM      // 5cni.pdf (52Q) ligand is compound 14a
5dgz  2.50  2015  Ki=14nM       // 5dgz.pdf (L20) ligand is compound 1
4q87  1.55  2015  Ki=14uM       // 4q7p.pdf (4FH) ligand is 4-CF3-1,2-HOPTO
5abf  2.10  2015  Ki=14uM       // 5abe.pdf (XRJ) [Nonstandard assay: Temp 37, 1X PBS buffer (0.03% BSA)] [Different protein in assay: Protein in binding assay is human OGA] compound 25;
4z84  1.55  2015  Ki=1500nM     // 4z83.pdf (NVX) ligand is (+)-1c
5cnm  2.84  2015  Ki=156nM      // 5cni.pdf (52Q) ligand is compound 14a
4q1d  2.00  2015  Ki=16.6nM     // 4q1a.pdf (2Y1) compound 9
4xnv  2.20  2015  Ki=161nM      // 4xnv.pdf (BUR) ligand is BPTU;
4x24  1.50  2015  Ki=166pM      // 4wkb.pdf (TDI) ligand is MTDIA
4x6j  1.59  2015  Ki=16nM       // 4x6h.pdf (3Y2) [Covalent complex] [Nonstandard assay: Temp 37, PH=6] compound 5;
5c1m  2.10  2015  Ki=16pM       // 5c1m.pdf (4VO) ligand is BU72, Ki in presence of nanobody 39
4z2b  1.80  2015  Ki=17.5nM     // 4z2b.pdf (4LC) compound 3;
4um1  2.83  2015  Ki=1700nM     // 4um1.pdf (09P) ligand is NS3573
4x48  1.89  2015  Ki=170nM      // 4x48.pdf (XPF) compound 3
5cbm  2.30  2015  Ki=17nM       // 4zqt.pdf (4ZN) compound 12; S isomer
4xnw  2.70  2015  Ki=18.4nM     // 4xnv.pdf (2ID) ligand is MRS-2500;
4u7q  1.70  2015  Ki=180pM      // 4u7q.pdf (3EM) compound 1
4ufm  2.40  2015  Ki=190uM      // 4ufh.pdf (DGJ) ligand is DGJ
4rao  1.87  2015  Ki=1uM        // 4rab.pdf (3L7) compound 6c
5c2e  2.10  2015  Ki=2.0nM      // 5c1w.pdf (4Y1) ligand is compound 15d
5dk4  1.90  2015  Ki=2.0nM      // 5dk4.pdf (5BX) ligand is indolmycin
5e2o  2.08  2015  Ki=2.0nM      // 5e2o.pdf (5JM) ligand is compound 6
4q9y  1.55  2015  Ki=2.1uM      // 4q7p.pdf (M3T) ligand is 3-CH3-TP
5c28  1.56  2015  Ki=2.2uM      // 5c1w.pdf (4XV) ligand is compound 6
4ufl  2.40  2015  Ki=2.3mM      // 4ufh.pdf (DZX) ligand is DGN
4qd6  2.45  2015  Ki=2.3nM      // 4qd6.pdf (30T) compound 4b
4zqt  1.98  2015  Ki=2.3uM      // 4zqt.pdf (4QP) [Incomplete ligand] compound 12; R isomer
5egm  1.84  2015  Ki=2.4nM      // 5egm.pdf (5NY) ligand is compound 82
4re3  2.55  2015  Ki=2.7nM      // 4re3.pdf (GIM) [Nonstandard assay: Temp 30, PH=5.0] ligand is glucoimidazole
5caq  2.50  2015  Ki=2.7nM      // 5c8k.pdf (4ZJ) ligand is compound 33
4wkb  1.37  2015  Ki=2.7pM      // 4wkb.pdf (TDI) ligand is MTDIA
4wbg  1.90  2015  Ki=2.85uM     // 4wbg.pdf (AZR) [Covalent complex] ligand is aztorenam
5amd  1.50  2015  Ki=2.8nM      // 5amd.pdf (45I) ligand is compound 3i
5ek0  3.53  2015  Ki=20.7nM     // 5ek0.pdf (5P2) ligand is compound GX-936
5c8k  3.00  2015  Ki=20nM       // 5c8k.pdf (4YV) ligand is compound 1
4yih  1.82  2015  Ki=21.7uM     // 4yih.pdf (2O2) [Nonstandard assay: Temp 37,  2-4 nM enzyme in 20 mM Tris.HCl, 20 mM MgCl2, 2 mM EDTA and 2 mM DTT, pH 7.5] compound 3: cdN
5cav  2.73  2015  Ki=216nM      // 5c8k.pdf (4ZQ) ligand is compound 41a
4ygf  2.00  2015  Ki=21nM       // 4ygf.pdf (AZM) ligand is acetazolamide (AAZ)
4ps1  1.73  2015  Ki=220nM      // 4pry.pdf (5-mer) ligand is unnatural (BAL)LQ(HYP)(1U8) PEPTIDE, HYP CV8/9-AOMK
4yha  2.20  2015  Ki=225nM      // 4ygf.pdf (MZM) methazolamide (MZA)
4x6h  1.00  2015  Ki=22nM       // 4x6h.pdf (2-mer) ligand is 3XT-I37; covalent complex; Nonstandard assay: Temp 37, PH=6; compound 9
4zy4  2.60  2015  Ki=22nM       // 4zy4.pdf (4T3) compound 4
5cal  2.70  2015  Ki=22nM       // 5c8k.pdf (4Z8) ligand is compound 24
4ruz  1.63  2015  Ki=23.1nM     // 4rux.pdf (3W8) compound 2a
4q7w  1.45  2015  Ki=2300uM     // 4q7p.pdf (6MH) ligand is 6-CH3-1,2-HOPTO
4q8y  1.45  2015  Ki=2300uM     // 4q7p.pdf (HQT) ligand is 2,1-HIQTO
4xip  1.70  2015  Ki=235nM      // 4xip.pdf (40W) compound 5
5c91  2.44  2015  Ki=245.8uM    // 5c91.pdf (4YU) [Covalent complex] ligand is compound 1, Ki=245.8+/-54.8uM for disrupting Nedd4-1:Ub binding
4wef  2.50  2015  Ki=2577uM     // 4wef.pdf (DF4) [Nonstandard assay: IC50 kinetics assay using a pH 4.5 acetate buffer and 0.5 mM MUNANA] ligand is difluorosialic acid; without preincubation
4xas  2.35  2015  Ki=260nM      // 4xaq.pdf (40H) [Nonstandard assay: pH=7.6, K3PO4=10mM, KBr=100mM] compound 5;
4q7v  1.60  2015  Ki=260uM      // 4q7p.pdf (5MH) ligand is 5-CH3-1,2-HOPTO
4y63  1.30  2015  Ki=261uM      // 4y63.pdf (48O) [Incomplete ligand] compound 15; structure differs;
4zy5  2.35  2015  Ki=26nM       // 4zy4.pdf (4T5) compound 17
4q8x  1.55  2015  Ki=270uM      // 4q7p.pdf (7FH) ligand is 5-CF3-1,2-HOPTO
4nct  2.60  2015  Ki=28.4nM     // 4nct.pdf (2K2) ligand is PKC412
5c8n  2.40  2015  Ki=28nM       // 5c8k.pdf (4YX) ligand is compound 23
5a0e  1.25  2015  Ki=298nM      // 5a0e.pdf (11-mer) CsA analogue, JW47
4um3  2.70  2015  Ki=29nM       // 4um1.pdf (09R) ligand is NS3920
4zwy  1.50  2015  Ki=2nM        // 4zwx.pdf (4SN) [Incomplete ligand] compound 625; seems RCSB confused these pdb codes
4zwz  1.62  2015  Ki=2nM        // 4zwx.pdf (510) compound 626
4zwx  1.70  2015  Ki=2nM        // 4zwx.pdf (5KZ) compound 623
5edq  2.80  2015  Ki=2nM        // 5edq.pdf (5N3) ligand is compound 15
4q1w  1.85  2015  Ki=2pM        // 4q1w.pdf (017)
4u7v  1.38  2015  Ki=3.2uM      // 4u7q.pdf (3EN) compound 2
4x8u  2.10  2015  Ki=3.5mM      // 4x8s.pdf (3ZB) compound 15
4zae  1.86  2015  Ki=3.6nM      // 4zae.pdf (4M1) compound 13
4rsp  1.62  2015  Ki=3.6uM      // 4rsp.pdf (5-mer) [Covalent complex] compound 6; Peptidomimetic compound
4y8x  1.90  2015  Ki=3.7nM      // 4y8x.pdf (4GR) compound 3
4u6z  1.80  2015  Ki=3.9uM      // 4u1b.pdf (Q07) compound 19
5byi  1.15  2015  Ki=30.7nM     // 5byi.pdf (4WA) ligand is compound 1d
5edr  2.60  2015  Ki=34.3nM     // 5edq.pdf (5N4) ligand is compound 27
4qf9  2.28  2015  Ki=37.1uM     // 4qf9.pdf (35K) compound 1b
4ykj  1.40  2015  Ki=37uM       // 4ykj.pdf (ALA) ligand is alanine
4wa9  2.20  2015  Ki=3800pM     // 4twp.pdf (AXI) ligand is axitinib
4ufh  2.16  2015  Ki=380nM      // 4ufh.pdf (GIF) ligand is IGF
5cao  2.60  2015  Ki=38nM       // 5c8k.pdf (4ZG) ligand is compound 29
4q7s  1.80  2015  Ki=38uM       // 4q7p.pdf (2YU) ligand is 4-CH3-1,2-HOPTO
4u3f  3.23  2015  Ki=4.1nM      // 4u3f.pdf (Y52) compound 18
4ye3  1.35  2015  Ki=4.3nM      // 4ye3.pdf (G04) [Nonstandard assay: Temp 37, pH=5.6, 100 mM MES, 400 mM sodium chloride] ligand is GRL-4410A;
4yml  1.75  2015  Ki=4.5nM      // 4yml.pdf (4F0) compound 2
4yx9  1.75  2015  Ki=4.5uM      // 4yx9.pdf (4HY) tiratricol, compound 3
4z1k  1.35  2015  Ki=4.7nM      // 4z0q.pdf (4KB) compound 4b
5c2a  2.00  2015  Ki=4.8nM      // 5c1w.pdf (4Y2) ligand is compound 9s
4u1b  1.89  2015  Ki=4.9uM      // 4u1b.pdf (Q08) compound 20
4zxy  2.06  2015  Ki=400nM      // 4zxx.pdf (4T1) compound (R)-4
4z83  1.80  2015  Ki=40nM       // 4z83.pdf (4L7) ligand is (+)-1p
5fl6  1.95  2015  Ki=43.6nM     // 5fl4.pdf (Y0R) ligand is compound 3
4xx4  2.40  2015  Ki=44nM       // 4xx4.pdf (70Y) [Different protein in assay: Rat AUC 2037nM hr at 10 mpk p.o.] compound 4
5bms  2.90  2015  Ki=455nM      // 4zy4.pdf (4T6) compound 29
4q1y  1.50  2015  Ki=45pM       // 4q1w.pdf (017)
4q7p  1.65  2015  Ki=48uM       // 4q7p.pdf (3MH) ligand is 3-CH3-1,2-HOPTO
4y0a  1.91  2015  Ki=4950uM     // 4y0a.pdf (SKM) ligand is shikimate
4oem  1.52  2015  Ki=5.0uM      // 4oel.pdf (2-mer) ligand is Gly-Lys
4ryd  2.15  2015  Ki=5.5pM      // 4ryd.pdf (5-mer) compound 19; para-guanidinomethyl-Phac-R-Tle-R-Amba
4rfc  1.65  2015  Ki=5.7nM      // 4rfc.pdf (3O1) compound 4c
4z1e  2.01  2015  Ki=5.7nM      // 4z0q.pdf (DF5) comopound 5c
4z1n  1.47  2015  Ki=5.89nM     // 4z0q.pdf (4KD) [Incomplete ligand] compound 4a
4x6m  2.40  2015  Ki=5.8nM      // 4x6m.pdf (3Y3) compound 25
4riu  1.65  2015  Ki=50nM       // 4riu.pdf (3QR) compound 1
5cap  2.40  2015  Ki=52nM       // 5c8k.pdf (4ZH) ligand is compound 30
4ufj  2.20  2015  Ki=52uM       // 4ufh.pdf (IF7) ligand is IGL
4wcf  1.93  2015  Ki=53uM       // 4wcf.pdf (3KN) compound III
4u69  1.60  2015  Ki=54.8uM     // 4u1b.pdf (Q07) compound 19
4xit  1.86  2015  Ki=54nM       // 4xip.pdf (40Z) compound 26
4xx3  2.40  2015  Ki=56nM       // 4xx3.pdf (70X) [Different protein in assay: Rat AUC 31nM hr at 10 mpk p.o.] compound 3
5e13  1.34  2015  Ki=57.8uM     // 5e13.pdf (5J9) ligand is compound 11c
4x6p  1.93  2015  Ki=5nM        // 4x6m.pdf (3YU) [Nonstandard assay: Temp 37] compound 33
4zy6  2.15  2015  Ki=5nM        // 4zy4.pdf (4T6) compound 29
5bwb  2.57  2015  Ki=5uM        // 5bwb.pdf (4VV) ligand is compound 2BIM-7, double bond position is different
5amg  1.55  2015  Ki=6.0nM      // 5amd.pdf (IW7) ligand is compound 3d
4u71  1.80  2015  Ki=6.0uM      // 4u1b.pdf (Q03) compound 15
5fl5  2.05  2015  Ki=6.4nM      // 5fl4.pdf (82E) ligand is compound 1
4u73  1.80  2015  Ki=6.6uM      // 4u1b.pdf (Q02) compound 2
4z0q  1.45  2015  Ki=6.8nM      // 4z0q.pdf (4K9) compound 5e
5a6a  2.69  2015  Ki=60.6nM     // 5a69.pdf (NGT) [Nonstandard assay: Temp 37] Ki=60.6+/-3.0nM, ligand is NGT
4u6w  1.83  2015  Ki=61.3uM     // 4u1b.pdf (Q08) compound 20
4ufi  2.40  2015  Ki=630nM      // 4ufh.pdf (AGK) ligand is AGF
5c8m  2.90  2015  Ki=64nM       // 5c8k.pdf (4YW) ligand is compound 17
4q83  1.55  2015  Ki=64uM       // 4q7p.pdf (3FH) ligand is 3-CF3-1,2-HOPTO
4x3i  1.80  2015  Ki=671uM      // 4x3h.pdf (7-mer) [Nonstandard assay: PH=8, 10 mM Tris-Cl, 0.5% NP-40, 100 mM NaCl] CaMKIIalpha peptide;
5dwr  2.00  2015  Ki=6pM        // 5dwr.pdf (5H7) ligand is compound 8
4q90  1.54  2015  Ki=7.0mM      // 4q7p.pdf (4H2) ligand is 4-CH3-2MPyr
4qrh  1.65  2015  Ki=7.0uM      // 4qrh.pdf (0O2) ligand is (p)ppGpp
4z1j  1.27  2015  Ki=7.7nM      // 4z0q.pdf (4KC) compound 4e
5a6b  1.77  2015  Ki=7.9nM      // 5a69.pdf (OAN) [Nonstandard assay: Temp 37] Ki=7.9+/-0.7nM, ligand is PUGNAc
4cr5  2.00  2015  Ki=70uM       // 4cr5.pdf (0TU) compound 5
4xaq  2.21  2015  Ki=71.7nM     // 4xaq.pdf (40F) [Nonstandard assay: pH=7.6, K3PO4=10mM, KBr=100mM] compound 1;
4zx1  1.50  2015  Ki=725nM      // 4zwx.pdf (5L3) compound 625
4wov  1.80  2015  Ki=72nM       // 4wov.pdf (3SM) ligand is BMS066
4yc0  1.50  2015  Ki=74uM       // 4yc0.pdf (5OF) ligand is M6;
4xe1  1.80  2015  Ki=77.3nM     // 4xe1.pdf (IL5) [Nonstandard assay: CO2 hydration reaction, 20 mM Hepes, 20 mM NaClO4] ligand is compound 2
4y64  1.60  2015  Ki=790uM      // 4y64.pdf (48C) [Incomplete ligand] compound 13e; structure differs;
4q1x  1.90  2015  Ki=7pM        // 4q1w.pdf (017)
5c2h  2.09  2015  Ki=8.2pM      // 5c1w.pdf (4XU) ligand is compound 15h
4wxi  2.60  2015  Ki=8.4nM      // 4wxi.pdf (3VM) ligand is (S)-23;
4x3r  1.86  2015  Ki=8.6pM      // 4x3r.pdf (686) [Nonstandard assay: pH=7.4, 25 mM Bis-Tris propane, 150 mM NaCl, 100 uM ZnCl2, 0.001% (w/w) octaethylene glycol monododecyl] compound 7;
5c1w  1.70  2015  Ki=8.7uM      // 5c1w.pdf (4XS) ligand is compound 5
4rfd  1.63  2015  Ki=8.9nM      // 4rfc.pdf (3O5) compound 5c
4cr9  1.70  2015  Ki=80uM       // 4cr5.pdf (OTW) compound 6
5e2r  1.60  2015  Ki=86.2nM     // 5cjf.pdf (520) ligand is compound 20
4xiq  1.84  2015  Ki=86nM       // 4xip.pdf (40Y) compound 6;
5c29  2.05  2015  Ki=880nM      // 5c1w.pdf (4XY) ligand is compound 9h
5abe  2.00  2015  Ki=890uM      // 5abe.pdf (XQO) [Nonstandard assay: Temp 37, 1X PBS buffer (0.03% BSA)] [Different protein in assay: Protein in binding assay is human OGA] compound 21
4zxx  2.60  2015  Ki=8nM        // 4zxx.pdf (4T0) compound 1
4rkx  1.59  2015  Ki=8uM        // 4rkx.pdf (3S9) ligand is compound 2477
4zz2  1.45  2015  Ki=9.1nM      // 4zz1.pdf (3YG) [Nonstandard assay: Temp 37, pH=7.5, 0.1 M Hepes] compound 7;
4u70  1.60  2015  Ki=9.5uM      // 4u1b.pdf (Q04) compound 16
4yes  1.50  2015  Ki=9.6nM      // 4yes.pdf (45S) compound 10
4u6c  1.91  2015  Ki=9.9uM      // 4u1b.pdf (Q06) compound 18
4rfm  2.10  2015  Ki=90pM       // 4rfm.pdf (3P6) compound 28
4ps0  1.63  2015  Ki=92000nM    // 4pry.pdf (5-mer) ligand is (BAL)LQ(HYP)(1U8) PEPTIDE, HYP CV8/9-AOMK
4q81  1.55  2015  Ki=950uM      // 4q7p.pdf (7MH) ligand is 4,6-CH3-1,2-HOPTO
5abg  2.00  2015  Ki=9nM        // 5abe.pdf (V0N) [Nonstandard assay: Temp 37, 1X PBS buffer (0.03% BSA)] [Different protein in assay: Protein in binding assay is human OGA] compound 34;
4yzu  1.41  2015  Ki=9uM        // 4yzu.pdf (4K6) compound 1
5c6o  3.00  2015  Ki>200uM      // 5c6o.pdf (4YH) ligand is verapamil
5c6p  3.00  2015  Ki>200uM      // 5c6o.pdf (4YH) ligand is verapamil
4u6e  1.90  2015  Ki>500uM      // 4u1b.pdf (Q02) compound 15
4xsy  4.01  2015  Ki~5uM        // 4xsx.pdf (42T) [Nonstandard assay: pH=8, 50 mM Tris-Cl, 20 mM NaCl, 10 mM MgCl2, 0.1 mM EDTA, 2.5 ug acetylated BSA/mL] CBR 9379
5bmm  2.50  2016  IC50<0.004uM  // 5bmm.pdf (5-mer) ligand is DNA-templated macrocyclic inhibitor MC25b
4zt7  2.40  2016  IC50<10nM     // 4zt2.pdf (4RC) compound 13
4zt6  2.25  2016  IC50<10nM     // 4zt2.pdf (4RD) compound 11
4zt5  2.35  2016  IC50<10nM     // 4zt2.pdf (4RN) compound 8
4zt4  2.30  2016  IC50<10nM     // 4zt2.pdf (4RO) compound 7
4zt2  2.70  2016  IC50<10nM     // 4zt2.pdf (4RP) compound 5
4zt3  2.80  2016  IC50<10nM     // 4zt2.pdf (4RQ) compound 6
4yec  1.12  2016  IC50<25nM     // 4yec.pdf (5-mer) [Nonstandard assay: Temp 37] PmC11 and Ac-VLTK-AOMK
5bqh  1.60  2016  IC50<3nM      // 5bqg.pdf (4UK) compound 5
5jau  1.95  2016  IC50=0.0014uM  // 5jad.pdf (6HU) ligand is compound 16,Thio-PAF Assay
5j8x  2.53  2016  IC50=0.0016uM  // 5fq9.pdf (OK3) [Uncommon element] compound 2
5k0i  1.30  2016  IC50=0.002uM  // 5k0i.pdf (6PW) ligand is compound 14
5hln  3.10  2016  IC50=0.003nM  // 5hln.pdf (65C) ligand is CHIR99021
5fqc  1.45  2016  IC50=0.003uM  // 5fq9.pdf (OK3) [Uncommon element] compound 2
5jyo  2.10  2016  IC50=0.003uM  // 5jyo.pdf (63J) ligand is CB-839
5e91  2.42  2016  IC50=0.004uM  // 5e91.pdf (5L4) compound 1; HTRF assay
5jog  2.46  2016  IC50=0.0058uM  // 5jog.pdf (6LT) ligand is CNS5i-3
5k0s  2.45  2016  IC50=0.006uM  // 4py2.pdf (0OU) ligand is compound 1312; aminoacylation enzyme inhibition assay
5lgo  1.12  2016  IC50=0.006uM  // 5lgo.pdf (6VZ) [Different protein in assay: protein in assay is human cationic trypsin] ligand is compound 15
5hmh  1.79  2016  IC50=0.007uM  // 5hmh.pdf (62R) compound 21
5tkd  1.92  2016  IC50=0.007uM  // 5tkd.pdf (7GL) ligand is compound 18
5ei8  2.17  2016  IC50=0.008uM  // 5eh0.pdf (5OE) compound 24c
5lck  1.89  2016  IC50=0.008uM  // 5lcj.pdf (6TT) [Covalent complex] ligand is compound 3; covalent inhibitor
5czb  1.96  2016  IC50=0.0099uM  // 5czb.pdf (55W) compound 31
5fxs  1.90  2016  IC50=0.009uM  // 5fxq.pdf (OZN) ligand is compound 24
5iha  1.96  2016  IC50=0.009uM  // 5ih8.pdf (6BE) ligand is compound 8f; IC50=0.009uM at ATP=20uM, IC50=0.41uM at ATP=2mM
5ftq  1.70  2016  IC50=0.010uM  // 5fto.pdf (U4W) compoudn 17
5hex  2.73  2016  IC50=0.010uM  // 5hex.pdf (604) compound 30
5ji6  2.15  2016  IC50=0.011uM  // 5jhu.pdf (6KN) ligand is compound 21
5g3n  1.80  2016  IC50=0.012uM  // 5g3m.pdf (X28) compound 4
5kjk  1.93  2016  IC50=0.012uM  // 5kjk.pdf (6T1) ligand is compound 48 (AZ370)
5fwj  2.10  2016  IC50=0.013uM  // 4uf0.pdf (MMK) ligand is KDM5-C49
5hkm  2.10  2016  IC50=0.013uM  // 5hkm.pdf (61Y) compound 34
5ihc  2.14  2016  IC50=0.013uM  // 5ih8.pdf (6BB) ligand is compound 12b; assay at ATP=20uM
5kit  1.60  2016  IC50=0.013uM  // 5kit.pdf (6TA) ligand is compound 41; RCSB PDB maked with wrong compound 37 in title
5tkb  2.16  2016  IC50=0.013uM  // 5tkb.pdf (7DJ) ligand is compound 30
5e90  2.05  2016  IC50=0.014uM  // 5e90.pdf (5L4) compound 1; HTRF assay
5fxq  2.30  2016  IC50=0.014uM  // 5fxq.pdf (GD5) ligand is compound 12
5hmi  1.74  2016  IC50=0.015uM  // 5hmh.pdf (62T) compound 10
5iu2  2.70  2016  IC50=0.016uM  // 5iu2.pdf (6DA) ligand is compound 28
5jjr  1.99  2016  IC50=0.016uM  // 5jjr.pdf (68E) compound 29
5fp0  2.35  2016  IC50=0.017uM  // 5fp0.pdf (SZC) compound 16
5kjn  2.72  2016  IC50=0.017uM  // 5kjk.pdf (6TL) ligand is compound 47
5eh0  2.18  2016  IC50=0.018uM  // 5eh0.pdf (5NW) compound 34e
5i2r  2.50  2016  IC50=0.019uM  // 5edb.pdf (67A) compound 26
5lh8  1.54  2016  IC50=0.019uM  // 5lgo.pdf (6WH) [Different protein in assay: protein in assay is human cationic trypsin] ligand is compound 8
5b0x  2.30  2016  IC50=0.020uM  // 5b0x.pdf (HCK) compound 1
5t68  2.93  2016  IC50=0.023uM  // 5t68.pdf (77V) ligand is compound 19
5fun  2.30  2016  IC50=0.026uM  // 4uf0.pdf (GZA) ligand is GSK467
4wnm  2.50  2016  IC50=0.026uM  // 4wnm.pdf (3RT) ligand is CC-509
5dri  2.80  2016  IC50=0.02uM   // 5c7v.pdf (5EQ) compound 23
5ktx  1.27  2016  IC50=0.02uM   // 5ktu.pdf (6XH) ligand is compound 59
5i89  1.07  2016  IC50=0.033uM  // 5i83.pdf (69B) ligand is compound 27
5aeh  1.85  2016  IC50=0.037uM  // 5adq.pdf (8IR) compound 6
5fxr  2.40  2016  IC50=0.038uM  // 5fxq.pdf (8LN) ligand is compound 10
5hls  2.18  2016  IC50=0.039uM  // 5hls.pdf (62G) compound 10 (CPI-0610)
5ktw  1.09  2016  IC50=0.03uM   // 5ktu.pdf (6XG) ligand is compound 44
5j1v  2.52  2016  IC50=0.041uM  // 5j1v.pdf (6FD) ligand is compound 13
5byz  1.65  2016  IC50=0.042uM  // 4zsg.pdf (4WE) compound 3
5g3w  1.60  2016  IC50=0.042uM  // 5g1c.pdf (C65) ligand is compound E-1a
5ei2  2.67  2016  IC50=0.046uM  // 5eh0.pdf (5O7) compound 24b
5jjs  1.65  2016  IC50=0.048uM  // 5jjs.pdf (6L2) ligand is compound 27
5hmk  2.17  2016  IC50=0.04uM   // 5hmh.pdf (62Q) compound 3
5li3  2.40  2016  IC50=0.053uM  // 5g1c.pdf (9RB) ligand is compound E-4a; PDB code is 5G14 in paper, but 5LI3 in RCSB
5hlp  2.45  2016  IC50=0.054uM  // 5hln.pdf (65A) ligand is BRD3937
5eth  2.80  2016  IC50=0.056uM  // 5ejv.pdf (5RT) compound 3
5kre  2.00  2016  IC50=0.059uM  // 5kre.pdf (6WG) [Covalent complex] ligand is covalent inhibitor 2
5jo0  1.80  2016  IC50=0.05uM   // 5jaz.pdf (L56) ligand is compound 6b
5k4l  3.18  2016  IC50=0.05uM   // 5k4l.pdf (6QN) ligand is compound 18
5hzn  2.20  2016  IC50=0.061uM  // 5hhw.pdf (66A) compound 1 (NVP-AEW541)
5kjm  2.19  2016  IC50=0.065uM  // 5kjk.pdf (6TM) [Incomplete ligand] ligand is compound 30 (AZ931); 7 N-atoms in RCSB PDB, but 6 N-atoms in paper
5jmp  1.70  2016  IC50=0.067uM  // 5jaz.pdf (LC7) ligand is compound 6f
5k0j  1.94  2016  IC50=0.075uM  // 5k03.pdf (6P2) ligand is compound 24
5dw1  1.55  2016  IC50=0.08uM   // 5dw1.pdf (5GD) ligand is compound RVX-297
5eec  1.87  2016  IC50=0.08uM   // 5ee8.pdf (ZXM) [Uncommon element] ligand is compound S02030
5f3i  2.24  2016  IC50=0.08uM   // 5f2s.pdf (5UJ) compound 54j
5bns  2.20  2016  IC50=0.095uM  // 4z8d.pdf (4VM) compound 36
5byy  2.79  2016  IC50=0.098uM  // 4zsg.pdf (4WG) compound 2
5ei6  2.01  2016  IC50=0.099uM  // 5eh0.pdf (5OQ) compound 15b
5jyp  2.74  2016  IC50=0.10uM   // 5jyp.pdf (ZBS) ligand is trans-CBTBP(1S, 3S-CBTBP); 1S, 3S or 1R, 3R
5i8b  1.52  2016  IC50=0.11uM   // 5i83.pdf (69F) ligand is compound 23
5f3g  2.50  2016  IC50=0.126uM  // 5f2s.pdf (5UL) compound 53a
5f2f  1.67  2016  IC50=0.12uM   // 5f2f.pdf (5U7) compound 7; biofilm assay
5jbi  1.70  2016  IC50=0.12uM   // 5jaz.pdf (6J8) ligand is compound 6c
5lz9  2.06  2016  IC50=0.12uM   // 5lyy.pdf (7BR) ligand is compound (S)-23
5f3e  2.16  2016  IC50=0.138uM  // 5f2s.pdf (5UO) compound 54a
5jic  1.40  2016  IC50=0.13uM   // 4m7x.pdf (N7E) ligand is compound MeO-N5-PanAm (11)
5ee8  1.54  2016  IC50=0.13uM   // 5ee8.pdf (ZXM) [Uncommon element] ligand is compound S02030
5he2  2.79  2016  IC50=0.13uM   // 5he0.pdf (F0S) compound 12n
5hfu  2.92  2016  IC50=0.13uM   // 5hex.pdf (603) compound 27
5g1c  1.81  2016  IC50=0.14uM   // 5g1c.pdf (9RB) ligand is compound E-4a
5eud  2.24  2016  IC50=0.15uM   // 5eud.pdf (5S6) compound 2
5he0  2.56  2016  IC50=0.15uM   // 5he0.pdf (453) compound 12h
5jc1  1.65  2016  IC50=0.15uM   // 5jaz.pdf (6JB) ligand is compound 6d
5kr8  2.12  2016  IC50=0.15uM   // 5kqf.pdf (6WE) ligand is compound 5
5dy5  1.95  2016  IC50=0.163uM  // 5dy5.pdf (5GR) compound 9
5jmw  1.55  2016  IC50=0.175uM  // 5jaz.pdf (L50) ligand is compound 6a
5a8y  1.90  2016  IC50=0.17nM   // 5a8x.pdf (VBM) ligand is compound 13
5ecv  2.09  2016  IC50=0.17uM   // 5c7v.pdf (5M2) compound 25
5eue  2.83  2016  IC50=0.17uM   // 5eud.pdf (5S5) compound 1
5ih8  1.85  2016  IC50=0.18uM   // 5ih8.pdf (6BJ) ligand is compound 1a; IC50=0.18uM at ATP=20uM, IC50=18.8uM at ATP=2mM
5enh  1.95  2016  IC50=0.19mM   // 5enh.pdf (5QB) compound 12
5j1w  2.42  2016  IC50=0.19uM   // 5j1v.pdf (6FB) ligand is compound 14
5hx8  2.20  2016  IC50=0.1nM    // 5hx8.pdf (66P) compound 10
5kzi  2.10  2016  IC50=0.1nM    // 5kzi.pdf (6YN) ligand is compound 8b
5ejv  2.58  2016  IC50=0.204uM  // 5ejv.pdf (444) ligand is compound T090131718
5lc0  2.70  2016  IC50=0.20uM   // 5lc0.pdf (6T8) [Uncommon element] ligand is cn-716; ring closed in RCSB PDB
4yqu  1.94  2016  IC50=0.221uM  // 4yqm.pdf (4GB) [Covalent complex] covalent inhibitor C1-31
5cls  1.75  2016  IC50=0.22uM   // 5cls.pdf (52T) inhibitor (+)-31a
5jat  2.04  2016  IC50=0.23uM   // 5jad.pdf (6HR) ligand is compound 12,Thio-PAF Assay
5jap  2.46  2016  IC50=0.23uM   // 5jad.pdf (6HZ) ligand is compound 8,Thio-PAF Assay
5lcj  1.78  2016  IC50=0.23uM   // 5lcj.pdf (6TS) [Covalent complex] ligand is compound 1; covalent inhibitor
5eob  1.75  2016  IC50=0.24nM   // 5eob.pdf (5QQ) Compound 23
5m55  2.40  2016  IC50=0.24uM   // 5m51.pdf (7GG) ligand is compound 71
5lma  1.43  2016  IC50=0.25uM   // 5lma.pdf (6ZG) ligand is compound 1; pIC50=6.6
5itd  3.02  2016  IC50=0.262uM  // 5is5.pdf (6CY) ligand is compound 11
5enf  1.37  2016  IC50=0.27mM   // 5enf.pdf (5Q7) ligand is compound 4
5fbn  1.80  2016  IC50=0.27nM   // 5fbn.pdf (5WF) compound 1
5jnl  1.60  2016  IC50=0.27uM   // 5jaz.pdf (L54) ligand is compound 6g
5he3  2.74  2016  IC50=0.28uM   // 5he0.pdf (FF1) compound 12i
5he1  3.15  2016  IC50=0.28uM   // 5he0.pdf (ZS2) compound 12k
5jaz  1.40  2016  IC50=0.28uM   // 5jaz.pdf (LC5) ligand is compound 6h
5hk9  1.80  2016  IC50=0.29uM   // 5hk9.pdf (64O) ligand is compound 8h
5lsy  1.62  2016  IC50=0.29uM   // 5lss.pdf (76M) ligand is compound 4
5ke0  1.68  2016  IC50=0.2nM    // 5ke0.pdf (6S9) ligand is compound 11
5f2s  2.08  2016  IC50=0.2uM    // 5f2s.pdf (5TZ) compound 15
5i5x  1.65  2016  IC50=0.2uM    // 5i5x.pdf (68C) ligand is compound 27; pIC50 = 6.7
5fbo  1.89  2016  IC50=0.31nM   // 5fbo.pdf (5WH) compound 3
5kqf  1.98  2016  IC50=0.31uM   // 5kqf.pdf (6WD) ligand is compound 12
5fq9  1.50  2016  IC50=0.33uM   // 5fq9.pdf (C6S) [Uncommon element] compound 1
5toz  1.98  2016  IC50=0.346nM  // 5toz.pdf (7H4) [Covalent complex] ligand is covalent inhibitor PF-06651600
5hka  2.05  2016  IC50=0.35uM   // 5hk9.pdf (64N) ligand is compound 8c
5c20  2.75  2016  IC50=0.3883uM  // 5c1u.pdf (GHZ) compound 2
5k4x  1.37  2016  IC50=0.38uM   // 5k4x.pdf (6Q9) ligand is compound 1
5edi  2.20  2016  IC50=0.3nM    // 5edb.pdf (5M9) compound 24
5eol  2.20  2016  IC50=0.3nM    // 5eol.pdf (5QO) ligand is compound 9c
5fcw  1.98  2016  IC50=0.3uM    // 5fcw.pdf (5YA) compound 6
5fqb  1.90  2016  IC50=0.3uM    // 5fq9.pdf (OK3) [Uncommon element] compound 2
5t4b  1.76  2016  IC50=0.42nM   // 5t4b.pdf (75N) ligand is compound 34a
5b5b  2.00  2016  IC50=0.43nM   // 5b5b.pdf (AKX) compound 3a
5k5e  2.80  2016  IC50=0.443uM  // 5k5e.pdf (6QS) ligand is compound 16
5dp8  2.40  2016  IC50=0.44uM   // 5dp3.pdf (5ED) compound 8
5hm0  1.40  2016  IC50=0.44uM   // 5hls.pdf (62V) compound 3
5b4k  2.90  2016  IC50=0.46nM   // 5b4k.pdf (6DT) compound 2
5f9e  2.00  2016  IC50=0.46nM   // 5f9e.pdf (5VS) ligand is compound 10
5elz  1.80  2016  IC50=0.46uM   // 4m7x.pdf (3V9) ligand is compound N-Pip-PanAm (12)
4ztq  2.80  2016  IC50=0.48uM   // 4zs0.pdf (4RM) compound 77
5lss  1.79  2016  IC50=0.49uM   // 5lss.pdf (76H) ligand is compound 3
5lyh  2.17  2016  IC50=0.49uM   // 5lxp.pdf (7B8) inhibitor H10,IC50=0.49+/-0.07uM
5a4e  2.68  2016  IC50=0.4uM    // 5a3x.pdf (7QQ) compound 5
5dgm  2.86  2016  IC50=0.4uM    // 5dgm.pdf (59Z) compound 7
5bnr  1.89  2016  IC50=0.53uM   // 4z8d.pdf (4VL) compound 23
5i86  1.05  2016  IC50=0.53uM   // 5i83.pdf (69A) ligand is compound 14
5jiy  1.48  2016  IC50=0.54uM   // 5jhn.pdf (11-mer) ligand is Histone H3K9norLeucine mutant peptide, K9Nle
5fpu  2.24  2016  IC50=0.55uM   // 4uf0.pdf (K0I) ligand is GSKJ1
4z22  2.62  2016  IC50=0.57uM   // 4z22.pdf (4KG) [Different protein in assay: M205S protein in crystal, wild-type in assay] inhibitor DR718A
5koq  2.70  2016  IC50=0.58nM   // 5koq.pdf (6VR) ligand is compound 14
5ene  1.49  2016  IC50=0.59mM   // 5ene.pdf (5Q8) ligand is compound 3
5dcz  2.23  2016  IC50=0.5nM    // 5dcz.pdf (59B) ligand is compound 23
5eak  2.80  2016  IC50=0.5nM    // 5eak.pdf (24R) compound 19
5hmy  2.10  2016  IC50=0.5uM    // 5hmw.pdf (LNY) compound 15
5ih5  2.25  2016  IC50=0.5uM    // 5ih4.pdf (AUE) Epiblastin A (compound 15)
5kqd  2.60  2016  IC50=0.5uM    // 5kpr.pdf (PKZ) ligand is Palmitoyl-CoA
5ktu  1.38  2016  IC50=0.62uM   // 5ktu.pdf (6XB) ligand is compound 7
5m53  1.90  2016  IC50=0.62uM   // 5m51.pdf (7GJ) ligand is compound 11
4wn0  2.20  2016  IC50=0.6mM    // 4wn0.pdf (G3P) ligand is D-glycerol-1-phosphate (GroP)
4yht  3.05  2016  IC50=0.6nM    // 4yht.pdf (4EF) [Different protein in assay: Bra-f in bioassay has v600e mutation] compound 11
5b4l  2.40  2016  IC50=0.76nM   // 5b4k.pdf (6DW) compound 16f
5lxp  2.07  2016  IC50=0.76uM   // 5lxp.pdf (7AG) inhibitor H5
5enb  1.73  2016  IC50=0.78mM   // 5enb.pdf (5Q5) ligand is compound thiourea 1
5ism  2.00  2016  IC50=0.7nM    // 5ism.pdf (6DG) ligand is compound 30
5a54  2.63  2016  IC50=0.7uM    // 5a3x.pdf (5PW) compound 15
5fah  1.10  2016  IC50=0.7uM    // 5fah.pdf (5VT) [Nonstandard assay: pH 5.6, 150mM NaCl] compound 1
5ehy  2.26  2016  IC50=0.81uM   // 5eh0.pdf (5O4) compound 39
5dp9  1.90  2016  IC50=0.84uM   // 5dp3.pdf (5EX) compound 9
5k0f  1.81  2016  IC50=0.86uM   // 5k03.pdf (6P1) ligand is compound 22+23; racemate; , IC50=0.86uM for comp 22, IC50=0.47uM for comp 23
5ivt  1.15  2016  IC50=0.8nM    // 5ivq.pdf (6EE) ligand is compound 9t(MK-8718)
5a3x  2.26  2016  IC50=0.8uM    // 5a3x.pdf (QIV) compound 2
5lz8  2.11  2016  IC50=0.98uM   // 5lyy.pdf (7BP) ligand is compound ( +/-)-18
5bqi  1.88  2016  IC50=0.9nM    // 5bqg.pdf (4UL) compound 8
5i5z  2.60  2016  IC50=0.9nM    // 5i5z.pdf (68U) ligand is compound 7
5f3c  2.06  2016  IC50=0.9uM    // 5f2s.pdf (5U8) compound 52d
5j4y  2.59  2016  IC50=0.9uM    // 5j47.pdf (6JG) ligand is compound 12h
5k0b  2.36  2016  IC50=0.9uM    // 5k03.pdf (6PS) ligand is compound 18
5drc  2.18  2016  IC50=1.05uM   // 5c7v.pdf (5ER) compound 9
5k09  2.70  2016  IC50=1.0uM    // 5k03.pdf (6PQ) ligand is compound 15
5ho8  2.70  2016  IC50=1.1uM    // 5hkm.pdf (63E) compound 16
5joh  1.99  2016  IC50=1.1uM    // 5jog.pdf (6M3) ligand is CNS5i-1b
5k0c  1.95  2016  IC50=1.1uM    // 5k03.pdf (6OZ) ligand is compound 20
5t6g  2.45  2016  IC50=1.1uM    // 5t6d.pdf (N40) ligand is compound 7m
5e8z  1.51  2016  IC50=1.243uM  // 5e8z.pdf (5L4) compound 1; HTRF assay
5c1y  1.97  2016  IC50=1.246uM  // 5c1u.pdf (GHY) compound 1
5ax3  2.98  2016  IC50=1.2uM    // 5ax3.pdf (5ID) ternary complex with a peptide PEP in allosteric site and 5-IOD in ATP site, IC50 for PEP is 9.8uM
5cuq  1.70  2016  IC50=1.2uM    // 5cuq.pdf (NSC) ligand is NSC12155
5lsx  2.90  2016  IC50=1.2uM    // 5lss.pdf (76O) ligand is compound 9
5trj  2.57  2016  IC50=1.2uM    // 5trh.pdf (7HO) ligand is compound 9b
5a4t  2.15  2016  IC50=1.3uM    // 5a3x.pdf (AJG) compound 14
5j4v  2.94  2016  IC50=1.4uM    // 5j47.pdf (6JH) ligand is compound 12g
5kos  2.41  2016  IC50=1.5nM    // 5kos.pdf (6VS) ligand is compound 8 (TAK-272)
5lrk  2.30  2016  IC50=1.5nM    // 5lrg.pdf (6-mer) ligand is compound 3
5lrg  2.02  2016  IC50=1.5nM    // 5lrg.pdf (6-mer) ligand is peptide compound 1
5jlz  1.99  2016  IC50=1.5uM    // 5jlz.pdf (15-mer) ligand is modified alpha-enolase peptide 26-40 with citrulline at the position 32 (CIT26)
5k0t  2.60  2016  IC50=1.657uM  // 4py2.pdf (415) ligand is compound 1415; aminoacylation enzyme inhibition assay
5ha9  4.01  2016  IC50=1.65uM   // 5ha9.pdf (TP0) IC50=1.65+/-0.25uM, ligand is 11d, PA-10
5e0g  1.20  2016  IC50=1.6uM    // 5e0g.pdf (5LG) compound 1
5t6f  1.90  2016  IC50=1.6uM    // 5t6d.pdf (N38) ligand is compound 7l; orthorhombic crystal
5c1x  1.86  2016  IC50=1.767uM  // 5c1u.pdf (GHX) compound VIII
5fgk  2.36  2016  IC50=1.7nM    // 5fgk.pdf (5XG) compound 25
5i7u  1.95  2016  IC50=1.7nM    // 5i7u.pdf (6AJ) ligand is compound 17c
5f37  2.22  2016  IC50=1.7uM    // 5f2s.pdf (N5J) compound 58
5jas  2.06  2016  IC50=1.7uM    // 5jad.pdf (6HW) ligand is compound 11,Thio-PAF Assay
4xuh  2.22  2016  IC50=1.87uM   // 4xuh.pdf (SFI) ligand is sulindac sulfide
5duf  1.50  2016  IC50=1.8uM    // 5dtw.pdf (G7A) ligand is GSK729A
5ieg  1.82  2016  IC50=1.8uM    // 5f0e.pdf (6A9) ligand is N-9'-methoxynonyl-1-deoxynojirimycin (MON-DNJ)
4yqv  2.06  2016  IC50=1.95uM   // 4yqm.pdf (4GG) [Covalent complex] covalent inhibitor C4-10
5lrj  2.20  2016  IC50=1.9nM    // 5lrg.pdf (6-mer) ligand is peptide compound 2
5dlv  2.00  2016  IC50=10.4uM   // 5dlt.pdf (5D5) ligand is TUDCA
5lxc  2.15  2016  IC50=10.8nM   // 5lxc.pdf (7AA) comp.1 (EHT 5372)
5kbq  2.58  2016  IC50=100nM    // 5kbq.pdf (IPV) ligand is compound 1
5jim  1.26  2016  IC50=103uM    // 5jid.pdf (P8S) ligand is Perfluoroktansulfonsyra (PFOS)
5f2w  2.60  2016  IC50=104.2uM  // 5f2s.pdf (5UP) compound 16
5jdc  1.78  2016  IC50=104.2uM  // 5jcj.pdf (6JP) ligand is NP-13
5jzn  2.85  2016  IC50=1084nM   // 5jzn.pdf (GUI) ligand is NVP-TAE684
4ufu  2.10  2016  IC50=10nM     // 4ufu.pdf (2ZI) compound 18c (TA-12)
5ceh  3.14  2016  IC50=10nM     // 5ceh.pdf (50P) ligand is CPI-455, inhibition of full-length KDM5A
5dsx  2.41  2016  IC50=10nM     // 5drt.pdf (5EW) compound 10
5hx6  2.23  2016  IC50=10nM     // 5hx6.pdf (65U) [Different protein in assay: wild type protein in assay] compound 14
5lj0  1.82  2016  IC50=10nM     // 5lj0.pdf (6XX) ligand is compound 16; pIC50=8.0
5t4f  1.90  2016  IC50=10nM     // 5t4b.pdf (75M) ligand is compound 34p
5lj2  1.19  2016  IC50=10uM     // 5lj0.pdf (6XW) ligand is compound 4; pIC50=5.0
5iee  1.92  2016  IC50=11.4uM   // 5f0e.pdf (NOJ) ligand is 1-deoxynojirimycin (DNJ)
5f32  2.05  2016  IC50=11.5uM   // 5f2s.pdf (5V7) compound 40
5j5t  2.85  2016  IC50=110nM    // 5j5t.pdf (6G2) ligand is compound 1
5i59  2.25  2016  IC50=112nM    // 5i56.pdf (67Q) ligand is MPX-007; assay at 1uM glycine
5i58  2.52  2016  IC50=119nM    // 5i56.pdf (67R) ligand is MPX-004; assay at 1uM glycine
4q15  2.35  2016  IC50=11nM     // 4q15.pdf (HFG) ligand is Halofuginone
5jgd  3.10  2016  IC50=11nM     // 5jga.pdf (6KD) ligand is compound 12
5k05  2.14  2016  IC50=11uM     // 5k03.pdf (6P5) ligand is compound 8
5sxn  2.10  2016  IC50=11uM     // 5koq.pdf (74U) ligand is compound 4
5sy2  2.25  2016  IC50=11uM     // 5koq.pdf (74V) ligand is compound 7
5ghv  2.80  2016  IC50=12.1nM   // 4xg3.pdf (X5G) ligand is O178
5dxg  1.86  2016  IC50=1200nM   // 5dx3.pdf (13-mer) SRC2-P5
5i12  1.59  2016  IC50=1200nM   // 5i0l.pdf (H27) compound 2
5kkr  3.51  2016  IC50=120nM    // 5kkr.pdf (6U7) ligand is APS-2-79
5axi  2.50  2016  IC50=120uM    // 5axi.pdf (5-mer) ligand is 5-mer peptide Cblin
5hn7  2.15  2016  IC50=120uM    // 5hn7.pdf (04M) ligand is BPH-1158
5b1s  1.58  2016  IC50=124uM    // 5b1s.pdf (BSX) TcSpdSyn in complex with dcSAM and compound 1
5dv2  2.07  2016  IC50=1250uM   // 5dv2.pdf (C5P) ligand is cytidine-5'-monophosphate (CMP)
5db3  1.71  2016  IC50=12nM     // 5db0.pdf (58Q) compound 31 (MI-574)
5ewm  2.76  2016  IC50=12nM     // 5ewj.pdf (5SM) ligand is EVT-101
5ehp  1.85  2016  IC50=12uM     // 5ehp.pdf (5OA) compound 2 (SHP836); Allosteric Inhibitor
5m57  2.30  2016  IC50=12uM     // 5m51.pdf (4SP) ligand is compound 6
5i40  1.04  2016  IC50=13.7uM   // 5i1q.pdf (67N) compound 1
5ewj  2.77  2016  IC50=130nM    // 5ewj.pdf (QEL) ligand is Ifenprodil
5kde  2.65  2016  IC50=130uM    // 5kde.pdf (6RT) ligand is compound 1
4ui3  2.00  2016  IC50=133nM    // 4ufu.pdf (06R) compound 13c (TA-26)
5dtq  2.61  2016  IC50=139uM    // 5dtm.pdf (5F6) compound 3
5emk  2.52  2016  IC50=13nM     // 5emk.pdf (5QH) [Different protein in assay: IC50 for protein PRMT5] compound 9
5jgb  2.80  2016  IC50=13nM     // 5jga.pdf (6JV) ligand is compound 10
5t1a  2.81  2016  IC50=13nM     // 5t1a.pdf (VT5) ligand is CCR2-RA-[R]; the presence of allosteric BMS-681 increased total binding
5tt7  1.77  2016  IC50=13nM     // 5tr6.pdf (7KF) ligand is compound 1
5ku3  1.14  2016  IC50=13uM     // 5ktu.pdf (6XH) ligand is compound 59
5dp6  3.01  2016  IC50=14.71uM  // 5dp3.pdf (5EB) compound 7
5ezz  2.10  2016  IC50=145nM    // 5edb.pdf (5T6) compound 19; cell data
5khx  2.40  2016  IC50=14nM     // 5khx.pdf (6TE) ligand is PF-4950736
5fbe  1.43  2016  IC50=14uM     // 5fah.pdf (5W5) compound 2
5lyy  2.17  2016  IC50=14uM     // 5lyy.pdf (7BJ) ligand is compound 5
5bpp  2.03  2016  IC50=15.86uM  // 5bpp.pdf (A4Z) LTA4H and bufexamac complex
5lmb  1.95  2016  IC50=15.8nM   // 5lma.pdf (6ZF) ligand is compound 6; pIC50=7.8
5dt2  2.30  2016  IC50=150nM    // 5drt.pdf (5EV) compound 11
5j75  2.00  2016  IC50=150nM    // 5j74.pdf (6GQ) [Nonstandard assay: Temp 4 C] ligand is ML342; Kd not given
5tjx  1.41  2016  IC50=153nM    // 5tjx.pdf (GBT) ligand is compound 30; tans-isomer in crystal
5eko  2.00  2016  IC50=15785nM  // 5ekn.pdf (N17) compound 117; Kd not determined
5acb  2.70  2016  IC50=158nM    // 5acb.pdf (5I1) [Covalent complex] ligand is THZ531; covalent inhibitor
5l72  3.06  2016  IC50=158nM    // 5l72.pdf (6PF) ligand is compound 3; pIC50=6.8
5lg3  3.57  2016  IC50=158uM    // 5lg3.pdf (Z80) ligand is chlorpromazine (CPZ)
5bnm  1.70  2016  IC50=15uM     // 4z8d.pdf (4VK) compound 6
5kgw  2.34  2016  IC50=16.1uM   // 5kgw.pdf (7SK) ligand is compound 5c
5fwa  1.80  2016  IC50=16.3uM   // 5fub.pdf (J7C) compound 1 (CP1)
5fqt  2.00  2016  IC50=160nM    // 5fqp.pdf (7QN) compound 16
4ui5  1.65  2016  IC50=167nM    // 4ufu.pdf (BJ4) compound 20b (TA-41)
5jrq  2.29  2016  IC50=169nM    // 5jrq.pdf (6N9) ligand is VEM-6-VEM
5kgx  2.67  2016  IC50=16uM     // 5kgw.pdf (7SK) ligand is compound 5c
5hvy  2.39  2016  IC50=17.4nM   // 5hvy.pdf (66X) compound 20
5bqg  1.44  2016  IC50=17.4uM   // 5bqg.pdf (4UJ) compound 4
5h7h  1.95  2016  IC50=170uM    // 5h7g.pdf (5-mer) ligand is F1324(10-13) peptide
5jid  1.20  2016  IC50=175uM    // 5jid.pdf (8PF) ligand is Perfluorooctanoic acid (PFOA)
5l4h  3.30  2016  IC50=177uM    // 5l47.pdf (6JW) ligand is brominated barbiturate
5lwn  1.60  2016  IC50=17nM     // 5lwm.pdf (79R) ligand is compound 5 (FM409)
5ho7  3.00  2016  IC50=17uM     // 5hkm.pdf (63L) compound 9
5ful  1.89  2016  IC50=18.3uM   // 5fub.pdf (SAH) ligand is SAH; protein is mPRMT (21-445) in paper
5dgj  1.00  2016  IC50=18.5uM   // 5dg6.pdf (V64) compound 21
5dp5  2.03  2016  IC50=18.70uM  // 5dp3.pdf (5E9) compound 4
5a7c  1.90  2016  IC50=180uM    // 5a7c.pdf (5D4) ligand is HMBA; AlphaScreen assay
5emm  2.37  2016  IC50=18nM     // 5emm.pdf (5QL) [Different protein in assay: IC50 for protein PRMT5] compound 15
5i0l  2.45  2016  IC50=18nM     // 5i0l.pdf (H27) compound 2; the PDB code in paper is 5IOL, not 5I0L
5fum  2.50  2016  IC50=18uM     // 5fum.pdf (SOF) compound 2
5kls  3.30  2016  IC50=194nM    // 5klb.pdf (6UC) ligand is UK-59811
5fqp  1.88  2016  IC50=19nM     // 5fqp.pdf (GQD) compound 12
5j3s  3.40  2016  IC50=19nM     // 5j3s.pdf (6FQ) ligand is compound 163
5m51  1.90  2016  IC50=19uM     // 5m51.pdf (NU6) ligand is compound 8
5eyd  1.85  2016  IC50=1nM      // 5eyc.pdf (5T1) compound 23
5adq  2.10  2016  IC50=2.01uM   // 5adq.pdf (A95) compound 1
5k5s  2.60  2016  IC50=2.04mM   // 5k5s.pdf (TRP) ligand is L-Trp; IC50 in presence of 2 mM Ca2+
5ans  1.60  2016  IC50=2.056uM  // 5ans.pdf (RX8) compound 25
5jar  2.11  2016  IC50=2.0uM    // 5jad.pdf (6HV) ligand is compound 10,Thio-PAF Assay
5ads  1.80  2016  IC50=2.15uM   // 5adq.pdf (QNS) compound 4
5f1z  2.65  2016  IC50=2.1nM    // 5f1z.pdf (5U3) compound 20
5adt  2.15  2016  IC50=2.23uM   // 5adq.pdf (1TC) compound 5
5f4n  1.91  2016  IC50=2.2nM    // 5f4n.pdf (5UY) ligand is compound 12
5g3m  1.85  2016  IC50=2.2uM    // 5g3m.pdf (9JH) compound 1
5hbe  2.38  2016  IC50=2.3nM    // 5fgk.pdf (5Y6) compound 42
5hbj  3.00  2016  IC50=2.3nM    // 5fgk.pdf (5Y8) compound 109
5jga  2.00  2016  IC50=2.3nM    // 5jga.pdf (6KC) ligand is compound 11c
5bqs  1.90  2016  IC50=2.3uM    // 4z8d.pdf (4VN) compound 29
4zs0  3.00  2016  IC50=2.3uM    // 4zs0.pdf (4QV) compound 6
4zsj  2.48  2016  IC50=2.3uM    // 4zsg.pdf (4R0) compound 5
5adr  2.10  2016  IC50=2.3uM    // 5adq.pdf (QS5) compound 3
5jin  1.85  2016  IC50=2.3uM    // 5jhn.pdf (11-mer) ligand is Histone H3K9M mutant peptide
5e0h  1.95  2016  IC50=2.4uM    // 5e0g.pdf (5LH) compound 3
5icv  1.53  2016  IC50=2.4uM    // 5icv.pdf (5-mer) ligand is CoA-Ac-MKAVQAD-NH2 (CoA-Ac-MKAV7)
5ih6  2.30  2016  IC50=2.5uM    // 5ih4.pdf (AUG) ligand is compound 18
5idn  2.26  2016  IC50=2.6nM    // 5icp.pdf (6A7) ligand is compound 25
5hkb  1.65  2016  IC50=2.6uM    // 5hk9.pdf (64L) ligand is compound 1a
5eif  1.50  2016  IC50=2.8mM    // 5e9q.pdf (4M0) compound 1;  DENV 2'O-MTase activity
5hzx  1.90  2016  IC50=2.8nM    // 5hzx.pdf (2GE) ligand is TH588
5a4q  2.37  2016  IC50=2.9uM    // 5a3x.pdf (Y3L) compound 11
5jr6  2.30  2016  IC50=20.2uM   // 5jr6.pdf (5-mer) ligand is 5-mer peptide Apstatin
5ho6  1.97  2016  IC50=204nM    // 5hlw.pdf (63K) compound 12 (SAR125844)
5dry  2.41  2016  IC50=20nM     // 5drt.pdf (5EK) compound 3
5lsc  1.50  2016  IC50=20uM     // 5lsc.pdf (752) ligand is compound 1
5fus  1.87  2016  IC50=21.1uM   // 5fus.pdf (DAO) ligand is dodecanoic acid (Lauric acid)
5d7a  2.90  2016  IC50=21nM     // 5ax9.pdf (58C) ligand is NCB-0846
5di1  2.90  2016  IC50=21nM     // 5di1.pdf (5DF) compound 13
5f1l  2.30  2016  IC50=21nM     // 5eu1.pdf (5U2) compound 11
5j5d  2.40  2016  IC50=21uM     // 5j5d.pdf (6GT)
5dpa  2.06  2016  IC50=22.46uM  // 5dp3.pdf (5F2) compound 6
5jq9  2.10  2016  IC50=22.5uM   // 5jq9.pdf (6MB) [Different protein in assay: protein in assay is BaDHPS from Bacillus anthracis] ligand is compound 16
5db1  1.86  2016  IC50=22nM     // 5db0.pdf (58O) compound 18 (MI-336)
5hld  2.31  2016  IC50=22uM     // 5hl9.pdf (63V) ligand is CENTA, not MOENOMYCIN that exists in all crystals
5hl9  2.70  2016  IC50=22uM     // 5hl9.pdf (AIX) ligand is ampicillin, not MOENOMYCIN that exists in all crystals
4xwk  3.50  2016  IC50=23.2uM   // 4xwk.pdf (4C8) ligand is PBDE-100
4r5y  3.50  2016  IC50=23nM     // 4r5y.pdf (3K3) ligand is BGB-283
5eml  2.39  2016  IC50=23nM     // 5eml.pdf (5QK) [Different protein in assay: IC50 for protein PRMT5] compound 10
5hlw  1.97  2016  IC50=23nM     // 5hlw.pdf (62E) compound 14
5l4e  3.50  2016  IC50=24.4uM   // 5l47.pdf (EDP) ligand is Thiopental
5cuh  1.83  2016  IC50=24uM     // 5cuh.pdf (LTQ) compound 3
5kmh  3.20  2016  IC50=24uM     // 5klb.pdf (6U8) ligand is Br-verapamil
5f00  1.95  2016  IC50=250nM    // 5edb.pdf (5T8) compound 21; cell data
4ui8  2.05  2016  IC50=25nM     // 4ufu.pdf (IY5) compound 21c (TA-55)
4zts  2.90  2016  IC50=25nM     // 4zs0.pdf (4RK) compound 88
5db2  1.54  2016  IC50=25nM     // 5db0.pdf (58R) compound 7 (MI-389)
5dyt  2.55  2016  IC50=25nM     // 5dyt.pdf (5HB) IC50=25+/-3.8nM, ligand is compound 8
5e7r  2.11  2016  IC50=25nM     // 5e7r.pdf (5KW) [Covalent complex] TAK1-10
5eym  2.70  2016  IC50=25nM     // 5eyk.pdf (5U5) ligand is compound BI 847325
5ei4  1.05  2016  IC50=26.4uM   // 5egu.pdf (5NV) compound 7; ITC Kd not determined
5gjf  2.89  2016  IC50=260nM    // 5gjd.pdf (6V4) compound 3
5jsm  2.19  2016  IC50=260nM    // 5jrq.pdf (6NB) ligand is VEM-3-VEM
5kbr  2.36  2016  IC50=260nM    // 5kbq.pdf (IPW) ligand is compound 2
5fqr  1.88  2016  IC50=26nM     // 5fqp.pdf (QHG) compound 10a
4yh3  1.60  2016  IC50=26uM     // 4yh3.pdf (Y80) compound 16a with BRD4(1)
4yh4  1.33  2016  IC50=26uM     // 4yh3.pdf (Y81) compound 19d
5dp7  2.08  2016  IC50=27.57uM  // 5dp3.pdf (5EC) compound 5
5l8t  1.85  2016  IC50=279uM    // 5l8t.pdf (6RR) ligand is compound 2
5arg  1.99  2016  IC50=27nM     // 5arf.pdf (H41) ligand is compound S-4
5a8z  2.00  2016  IC50=28nM     // 5a8x.pdf (IUL) ligand is compound 24
5izq  3.60  2016  IC50=3.04nM   // 5izq.pdf (83A) ligand is compound 4
5lxd  2.58  2016  IC50=3.16nM   // 5lxc.pdf (7A7) comp.2 (EHT 1610)
5k4i  1.76  2016  IC50=3.1nM    // 5k4i.pdf (6QB) ligand is compound 22
5to8  1.98  2016  IC50=3.1nM    // 5to8.pdf (7FM) ligand is compound 10a
5h8x  1.30  2016  IC50=3.1uM    // 5h8x.pdf (5XT) ligand is compound 14
5tr6  1.93  2016  IC50=3.2nM    // 5tr6.pdf (7KG) ligand is TAK-659
5lkr  2.52  2016  IC50=3.306uM  // 5lkr.pdf (6YC) ligand is compound 3
5iv4  1.79  2016  IC50=3.3uM    // 5iv3.pdf (LRI) ligand is RU-0204277 (LRE1)
5f94  2.51  2016  IC50=3.4nM    // 5f94.pdf (3UO) compound 15
5icp  2.18  2016  IC50=3.8nM    // 5icp.pdf (69Z) ligand is compound 6
5ab1  1.96  2016  IC50=3.8uM    // 5ab1.pdf (4-mer) compound 18; competitive enzyme-linked lectinosorbent assay (ELLSA)
5anq  2.00  2016  IC50=3.98uM   // 5anq.pdf (5YQ) compound 9a ; in vitro LANCE assay
5a4l  2.73  2016  IC50=3.9uM    // 5a3x.pdf (ZC3) compound 8
5lt6  2.05  2016  IC50=3.9uM    // 5lss.pdf (76J) ligand is compound 8
4y5i  1.40  2016  IC50=301.3uM  // 4y5i.pdf (9-mer) compound 2a
5fdp  2.25  2016  IC50=309nM    // 5fdp.pdf (5WR) compound 6c
5f20  2.91  2016  IC50=30nM     // 5f1z.pdf (5U4) compound 8
5fi6  2.52  2016  IC50=30nM     // 5fi2.pdf (5XY) compound 7e
5i94  2.98  2016  IC50=30nM     // 5fi2.pdf (69V) compound 14d
4yqm  2.38  2016  IC50=31nM     // 4yqm.pdf (4G9) [Covalent complex] covalent inhibitor C1-27
5ety  2.90  2016  IC50=31nM     // 5ety.pdf (K56) ligand is compound K-756
5jt2  2.70  2016  IC50=33.5nM   // 5jrq.pdf (6NC) ligand is VEM-BISAMIDE-2
5dv4  1.80  2016  IC50=3370uM   // 5dv2.pdf (NMY) ligand is neomycin
5emj  2.27  2016  IC50=33nM     // 5emj.pdf (5QJ) [Different protein in assay: IC50 for protein PRMT5] compound 8
5tol  2.51  2016  IC50=33nM     // 5tol.pdf (7H3) ligand is compound 2e
5f0h  1.99  2016  IC50=33uM     // 5eyr.pdf (5TC) compound 28
5lay  2.71  2016  IC50=34nM     // 5lav.pdf (6SS) ligand is compound 6g
5ifu  2.45  2016  IC50=34uM     // 4q15.pdf (GBM) ligand is Glyburide; ATP depletion assay
5ehg  2.02  2016  IC50=369uM    // 5e9q.pdf (5O0) compound 29; DENV 2'O-MTase activity
5f02  1.43  2016  IC50=36nM     // 5edb.pdf (5T9) compound 15
5kx7  2.80  2016  IC50=36nM     // 5kx7.pdf (6YD) ligand is compound 37
5i24  1.85  2016  IC50=37.8nM   // 5i23.pdf (66U) [Incomplete ligand] compound 1(CF021); -NH2-OH- merged into NH in PDB site
5db0  1.50  2016  IC50=37nM     // 5db0.pdf (58P) mixture of 3-(RS), ligand name is 58P or 6E6; IC50 is 46nM for 3-(R), 42nM for 3-(S)
4xhl  3.01  2016  IC50=37uM     // 4xh0.pdf (CKI) [Different protein in assay: IC50 assay for wt HRR25 (1-394)] IC50 assay for wt HRR25 (1-394), not K38R mutant
5dh3  2.47  2016  IC50=38.1nM   // 5dh3.pdf (5BS) ligand is XMU-MP-1
5kx8  2.67  2016  IC50=38nM     // 5kx7.pdf (6YE) ligand is compound 1
5jcj  1.76  2016  IC50=38uM     // 5jcj.pdf (6JM) ligand is compound 7
5sz9  2.85  2016  IC50=38uM     // 5koq.pdf (74Y) ligand is compound 3
5dxe  1.50  2016  IC50=390nM    // 5dx3.pdf (13-mer) ligand is Stapled Peptide SRC2-SP4
5dtr  2.34  2016  IC50=39uM     // 5dtm.pdf (5F7) compound 5
5f6u  1.55  2016  IC50=3mM      // 5f6d.pdf (5VK) ligand is compound 8
5eyc  1.80  2016  IC50=3nM      // 5eyc.pdf (5SZ) compound 5
5eyk  1.93  2016  IC50=3nM      // 5eyk.pdf (5U5) ligand is compound BI 847325
5j79  2.69  2016  IC50=3nM      // 5j79.pdf (6GE) ligand is compound 3
5i83  1.35  2016  IC50=4.1uM    // 5i83.pdf (68Y) ligand is compound 12
5jdi  1.38  2016  IC50=4.3uM    // 5jcj.pdf (6JO) ligand is compound 2
5drt  2.69  2016  IC50=4.4uM    // 5drt.pdf (5EG) compound 2
5amn  2.57  2016  IC50=4.5nM    // 5amn.pdf (DTQ) compound 6
4z16  2.90  2016  IC50=4.8nM    // 4z16.pdf (4LH) [Covalent complex] compound 9
5j47  1.99  2016  IC50=4.9uM    // 5j47.pdf (6JJ) ligand is compound 5d
5f1u  2.35  2016  IC50=400nM    // 5f1u.pdf (3VN) potent allosteric inhibitor bislysine
5iuh  2.10  2016  IC50=402nM    // 5iug.pdf (34Y) ligand is compound 5d
5fi7  2.50  2016  IC50=40nM     // 5fi2.pdf (5XZ) compound 14b
5i3m  2.17  2016  IC50=40nM     // 5i0l.pdf (67F) [Different protein in assay: Protein in binding assay is WT] compound 3
5l44  1.75  2016  IC50=40uM     // 5l44.pdf (K26) ligand is K-26 tripeptide
5e8w  1.86  2016  IC50=41uM     // 5e8w.pdf (STU) [Different protein in assay: wildtype protein in bioassay] ligand is staurosporine; HTRF assay
5cuu  2.96  2016  IC50=42.3uM   // 5cuu.pdf (4GA) ligand is BPH-1260
4zcw  1.99  2016  IC50=42.5nM   // 4za0.pdf (4NG) ligand is SF2312
5f01  1.52  2016  IC50=420nM    // 5edb.pdf (5T7) compound 22; cell data
5t4e  1.77  2016  IC50=4376nM   // 5t4b.pdf (75L) ligand is compound 19a
5d6f  1.55  2016  IC50=43uM     // 5cls.pdf (57R) inhibitor (+)-31b
5sy3  2.30  2016  IC50=43uM     // 5koq.pdf (74Z) ligand is compound 2
4ui7  1.80  2016  IC50=44nM     // 4ufu.pdf (VT3) compound 21b (TA-49)
5ely  1.81  2016  IC50=44nM     // 5d29.pdf (5PU) ligand is compound (R)-1
5fqs  1.94  2016  IC50=44nM     // 5fqp.pdf (J0W) compound 11a
4yxd  3.00  2016  IC50=45.9uM   // 4yxd.pdf (FTN) ligand is flutolanil, has some cofactors in crystal
5jnn  2.30  2016  IC50=4504nM   // 5jnn.pdf (6LM) ligand is Phaseic acid (PA)
5ehi  1.30  2016  IC50=452uM    // 5e9q.pdf (5O3) compound 28; DENV 2'O-MTase activity
4ui4  2.40  2016  IC50=45nM     // 4ufu.pdf (RJN) compound 38 (TA-29)
5idp  2.65  2016  IC50=45nM     // 5icp.pdf (6A6) ligand is compound 17
5k8v  2.25  2016  IC50=460nM    // 5fub.pdf (6RE) compound 1 (CP1); Why add a H atom compared to CP1 in code 5fwa
5fue  2.20  2016  IC50=468.2nM  // 5fue.pdf (UV4) [Nonstandard assay: assay at Temp 30C] compound 13a
5l99  2.00  2016  IC50=481uM    // 5l8t.pdf (6S0) ligand is compound 6
5i56  2.28  2016  IC50=48nM     // 5i56.pdf (67P) ligand is TCN-201; assay at 1uM glycine
5hbh  2.50  2016  IC50=49.2nM   // 5fgk.pdf (5Y7) compound 54
5l98  2.26  2016  IC50=490uM    // 5l8t.pdf (6RY) ligand is compound 4
5jrs  1.97  2016  IC50=4nM      // 5jrs.pdf (6MV) ligand is compound 23
5laz  1.66  2016  IC50=4nM      // 5lav.pdf (6ST) ligand is compound 3
5jiq  1.45  2016  IC50=4uM      // 5jid.pdf (27M) ligand is 2,2',4,4'-tetrahydroxybenzophenone (BP2)
5lax  2.60  2016  IC50=4uM      // 5jlz.pdf (15-mer) ligand is alpha-enolase peptide 26-40 (26)
5ief  2.38  2016  IC50=5.2uM    // 5f0e.pdf (NBV) ligand is N-butyl-1-deoxynojirimycin (NB-DNJ)
5cei  2.24  2016  IC50=5.3nM    // 5cei.pdf (50R) compound 22
5a7i  2.89  2016  IC50=5.5uM    // 5a7i.pdf (B6K) ligand is biphenyl 3,3',4,4',5,5'- hexakisphosphate
5f6v  1.49  2016  IC50=5.8mM    // 5f6d.pdf (5VL) ligand is compound 1; cocktail soak crystal
5kmf  3.20  2016  IC50=508nM    // 5klb.pdf (6U9) ligand is nimodipine
5hn9  2.12  2016  IC50=50uM     // 5hn7.pdf (04W) ligand is BPH-1186
5i23  1.95  2016  IC50=51.7nM   // 5i23.pdf (66V) compound 2(CF022)
5i4o  2.05  2016  IC50=53nM     // 5i0l.pdf (V28) [Different protein in assay: Protein in binding assay is WT] compound 7
4uhg  1.70  2016  IC50=540nM    // 4ufu.pdf (SZ5) compound 13b (TA-21)
5kdf  2.45  2016  IC50=540uM    // 5kde.pdf (6RU) ligand is compound 6
5l6p  2.26  2016  IC50=55nM     // 5l6o.pdf (6P8) [Covalent complex] ligand is compound 6; covalent inhibitor
5hna  2.69  2016  IC50=59uM     // 5hn7.pdf (63D) ligand is BPH-1251
4ynk  2.30  2016  IC50=5nM      // 4ynk.pdf (YW2) compound 5b
5j7b  2.53  2016  IC50=5nM      // 5j79.pdf (6GD) ligand is compound 27
5jfr  1.60  2016  IC50=5nM      // 5jfr.pdf (6KP) ligand is compound 10; pIC50=8.3
5kcv  2.70  2016  IC50=5nM      // 5kcv.pdf (6S1) ligand is compound 21a; allosteric inhibitor; IC50 for phosphorylation AKT1
4wi1  1.65  2016  IC50=5uM      // 4q15.pdf (3O6) ligand is TCMDC-124506
5ivs  1.46  2016  IC50=6.1nM    // 5ivq.pdf (6EF) ligand is compound 9a
5e0j  1.20  2016  IC50=6.1uM    // 5e0g.pdf (5LJ) compound 10
5trk  2.06  2016  IC50=6.2uM    // 5trh.pdf (7HH) ligand is compound 12d
5a7j  2.90  2016  IC50=6.3uM    // 5a7i.pdf (K2Y) ligand is benzene 1,2,4,5- tetrakisphosphate
5hg1  2.76  2016  IC50=6.3uM    // 5hex.pdf (62C) compound 1
5a8x  2.23  2016  IC50=6.5nM    // 5a8x.pdf (IUY) ligand is compound 5
5hm3  2.25  2016  IC50=6.8uM    // 5hm3.pdf (649) ligand is PhU-AMS
5th7  1.95  2016  IC50=6.9uM    // 5t5g.pdf (75P) ligand is compound 3
5fqv  1.74  2016  IC50=610nM    // 5fqp.pdf (VQI) compound 15
5gjg  2.61  2016  IC50=610nM    // 5gjd.pdf (6V5) compound 4
4za0  2.31  2016  IC50=62.3nM   // 4za0.pdf (PAH) ligand is Phosphonoacetohydroxamate (PhAH)
5dp4  2.21  2016  IC50=62.88uM  // 5dp3.pdf (5E8) compound 3
5g11  2.48  2016  IC50=62nM     // 5g11.pdf (7H1) ligand is PFSAHA
5i43  1.95  2016  IC50=63nM     // 5i0l.pdf (67M) [Different protein in assay: Protein in binding assay is WT] compound 8
5hoa  2.14  2016  IC50=64nM     // 5hlw.pdf (63K) compound 12 (SAR125844)
5hor  2.20  2016  IC50=6nM      // 5hlw.pdf (63K) compound 12 (SAR125844)
5j6d  1.90  2016  IC50=6nM      // 5j6d.pdf (6H5) ligand is compound 51
5l6o  1.88  2016  IC50=6nM      // 5l6o.pdf (6P6) [Covalent complex] ligand is compound 3; covalent inhibitor
4z8d  2.00  2016  IC50=6uM      // 4z8d.pdf (4LB) compound 9
5kqg  1.50  2016  IC50=7.1uM    // 5kqg.pdf (6VX) ligand is compound 7
5kup  1.39  2016  IC50=7.2nM    // 5kup.pdf (6XL) ligand is compound 9
5enm  1.98  2016  IC50=70nM     // 5enk.pdf (5QU) Compound 10
5fi2  2.50  2016  IC50=70nM     // 5fi2.pdf (5XX) compound 7d
5i2z  2.30  2016  IC50=72nM     // 5i0l.pdf (V24) [Different protein in assay: Protein in binding assay is WT] compound 6
5k4j  1.60  2016  IC50=77.5nM   // 5k4i.pdf (6QB) ligand is compound 22; IC50 ratio of CDK2/ERK2=25
4ufy  1.70  2016  IC50=7nM      // 4ufu.pdf (M3W) compound 18b (TA-13)
5i13  2.15  2016  IC50=8.26uM   // 4zhz.pdf (4P9) compound 2
5trh  2.70  2016  IC50=8.4uM    // 5trh.pdf (7HL) ligand is compound 5
5dg6  2.35  2016  IC50=8.6uM    // 5dg6.pdf (V66) compound 22
5ega  2.15  2016  IC50=8.7uM    // 5ega.pdf (GK0) ligand is compound 23
5i0b  3.09  2016  IC50=8.7uM    // 5i0b.pdf (67U) ligand is KY-04045; radiometric assay
5tri  2.30  2016  IC50=8.7uM    // 5trh.pdf (7HM) ligand is compound 7
5da3  1.70  2016  IC50=80nM     // 5da3.pdf (58V) ligand is compound IPA
5law  1.64  2016  IC50=80nM     // 5lav.pdf (6SJ) ligand is compound 14; in crystal is eutomer 14, but in assay is rac-14
5lav  1.73  2016  IC50=819nM    // 5lav.pdf (6SK) ligand is compound 6b
5lqq  2.40  2016  IC50=81nM     // 5lqq.pdf (72P) ligand is compound 51
4ui6  1.80  2016  IC50=87nM     // 4ufu.pdf (ECZ) compound 20c (TA-47)
5ezx  1.90  2016  IC50=87nM     // 5edb.pdf (5T5) compound 20; cell data
5ax9  2.40  2016  IC50=8nM      // 5ax9.pdf (4KT) compound 9
5enk  2.11  2016  IC50=8nM      // 5enk.pdf (5QV) Compound 18
5jyy  2.10  2016  IC50=8nM      // 5jyy.pdf (6PY) ligand is compound 1
5f39  2.65  2016  IC50=8uM      // 5f2s.pdf (5UB) compound 37
5loh  3.10  2016  IC50=9.1uM    // 5loh.pdf (STU) ligand is staurosporine (STU)
5k1i  2.61  2016  IC50=9.2nM    // 5k1i.pdf (6PT) ligand is compound 6
5t4h  2.61  2016  IC50=9.31nM   // 5t4b.pdf (75J) ligand is compound 34n
5ekx  1.76  2016  IC50=9.3mM    // 5e9q.pdf (2CQ) compound 2; DENV 2'O-MTase activity
5g10  1.71  2016  IC50=9.7nM    // 5g10.pdf (6DK) ligand is SATFMK
5f95  2.53  2016  IC50=9.8nM    // 5f94.pdf (3UP) compound 18
5fd2  2.89  2016  IC50=90nM     // 5fd2.pdf (5XJ) ligand is compound 6a
5ddc  1.62  2016  IC50=92nM     // 5ddc.pdf (59V) ligand is compound MI-2-3
5hng  3.01  2016  IC50=93uM     // 5hkm.pdf (62O) compound 10
5g2n  2.68  2016  IC50=94nM     // 5g2n.pdf (6E2) compound 39i (Copanlisib)
5d29  1.80  2016  IC50=97nM     // 5d29.pdf (5Q1) ligand is compound (S)-1
5hn8  2.70  2016  IC50=97uM     // 5hn7.pdf (HXK) ligand is BPH-1182
5hlb  2.42  2016  IC50=98.5uM   // 5hl9.pdf (AZR) ligand is aztreonam, not MOENOMYCIN that exists in all crystals
5eiw  1.61  2016  IC50=9mM      // 5e9q.pdf (X0V) compound 3; DENV 2'O-MTase activity
5k5n  2.20  2016  IC50=9nM      // 5k5n.pdf (6QH) ligand is PF-367 (PF-04802367); mobility shift assay
5iui  1.88  2016  IC50>10000nM  // 5iug.pdf (45Q) ligand is compound 4
5fnq  1.91  2016  IC50>1000uM   // 5fnq.pdf (S0W) compound 1; ITC Kd not determined
5l97  2.05  2016  IC50>1000uM   // 5l8t.pdf (6RW) ligand is compound 3
5f04  1.84  2016  IC50>100uM    // 5eyr.pdf (5TB) compound 3
5f0c  1.87  2016  IC50>100uM    // 5eyr.pdf (5TE) compound 4
5f27  1.68  2016  IC50>100uM    // 5eyr.pdf (5TT) compound 2
5kql  1.45  2016  IC50>100uM    // 5kqg.pdf (6VY) ligand is compound 9; IC50>>100uM
4zsg  1.79  2016  IC50>10uM     // 4zsg.pdf (4QX) compound 4
4zsl  2.25  2016  IC50>10uM     // 4zsg.pdf (4QZ) compound 6
5jah  2.06  2016  IC50>1mM      // 5jad.pdf (6HQ) ligand is compound 3
5lj1  1.90  2016  IC50>31.6uM   // 5lj0.pdf (6XX) ligand is compound 16; pIC50<=4.5
5f6d  1.55  2016  IC50>3mM      // 5f6d.pdf (5VJ) ligand is compound 6
5l96  2.15  2016  IC50>500uM    // 5l8t.pdf (6RZ) ligand is compound 1
5d6e  1.49  2016  IC50>50uM     // 5cls.pdf (94A) inhibitor (-)-31b
5enc  1.59  2016  IC50>5mM      // 5enc.pdf (5QD) ligand is compound 2
5eni  1.69  2016  IC50>5mM      // 5eni.pdf (5QA) compound 13
5enj  1.63  2016  IC50>5mM      // 5enj.pdf (5Q9) compound 14
5jao  2.06  2016  IC50~100uM    // 5jad.pdf (6HX) ligand is compound 6,Thio-PAF Assay
5lz2  2.10  2016  IC50~1mM      // 5lyy.pdf (7BX) ligand is compound 4
5a5d  1.74  2016  Kd<10nM       // 5a5d.pdf (5LC) CFe-5-Lic
5anu  1.80  2016  Kd=0.0004uM   // 5ans.pdf (58T) compound 15
5anv  1.16  2016  Kd=0.0005uM   // 5ans.pdf (RGJ) compound 19
5fnu  1.78  2016  Kd=0.0013uM   // 5fnq.pdf (L6I) compound 7
5ih9  1.79  2016  Kd=0.002uM    // 5ih8.pdf (6BF) ligand is compound 8a; has SPR derived KD data
5izj  1.85  2016  Kd=0.003nM    // 5izf.pdf (4-mer) ligand is compound  ARC-1411 (6J9-AZ1-DAR-DAR)
5anw  1.37  2016  Kd=0.003uM    // 5ans.pdf (9CQ) compound 24
5fa7  1.67  2016  Kd=0.004uM    // 5fa7.pdf (5VR) ligand is FPI-1523
5fck  1.86  2016  Kd=0.006uM    // 5fah.pdf (5WC) compound 6; SPR data available
5j5x  2.60  2016  Kd=0.0095nM   // 5izf.pdf (7-mer) ligand is compound  ARC-1416 (6J9-AZ1-DAL-DAR-DAR-DAR-DAR)
4zam  1.42  2016  Kd=0.011uM    // 4zam.pdf (MA4) KRC-2
5fao  3.01  2016  Kd=0.011uM    // 5fa7.pdf (5VW) ligand is FPI-1465
5e89  1.50  2016  Kd=0.014uM    // 5e88.pdf (TD2) compound 4
5g1n  2.10  2016  Kd=0.017uM    // 5g1n.pdf (PAL) [Nonstandard assay: pH 8.3, 150 mM NaCl] [Multiple sites: site 1: Kd=0.017 uM; site 2: Kd=0.027 uM; site 3: Kd=1.4 uM] ligand is PALA; three non-equivalent binding sites
5fap  2.70  2016  Kd=0.01uM     // 5fa7.pdf (602) ligand is FPI-1602
5f4l  2.70  2016  Kd=0.024uM    // 5f4l.pdf (5VE) ligand is compound (R,R)-JP-III-048 (4)
5i22   NMR  2016  Kd=0.024uM    // 5i22.pdf (17-mer) ligand is CHIKV nsP3 peptide
5ive  1.78  2016  Kd=0.027uM    // 5isl.pdf (6E8) ligand is compound  N8
5a2s  2.65  2016  Kd=0.02uM     // 5a2s.pdf (OTF) compound 14
5el2  1.75  2016  Kd=0.034mM    // 5el2.pdf (KBR) [Multiple sites: site 1: Kd1=0.034 mM; site 2: Kd2=0.714 mM] ligand is Icaridin; two binding sites
5e8a  1.50  2016  Kd=0.034uM    // 5e88.pdf (5KS) compound 5
5fas  1.74  2016  Kd=0.034uM    // 5fa7.pdf (5VR) FPI-1523
5i8g  1.41  2016  Kd=0.03uM     // 5i83.pdf (69E) Compound 28 (CPI-637); has Kd for this compound
5ags  1.47  2016  Kd=0.040uM    // 5agr.pdf (38Y) [Uncommon element] compound 11
5l7k  2.10  2016  Kd=0.043nM    // 5l7k.pdf (6-mer) ligand is 6-mer myristoylated NPHP3 peptide (myrGTASSL); stopped flow assay
5ivj  1.57  2016  Kd=0.046uM    // 5isl.pdf (6ED) ligand is compound N11
5f4p  2.60  2016  Kd=0.047uM    // 5f4l.pdf (5VG) ligand is (R,R)-BNM-III-170 (compound 5)
5tbm  1.85  2016  Kd=0.049uM    // 5tbm.pdf (79A) ligand is PT2385
5isl  1.69  2016  Kd=0.052uM    // 5isl.pdf (MMK) ligand is compound  KDM5-C49
5izu  2.49  2016  Kd=0.054uM    // 5izu.pdf (15-mer) ligand is SAPAP3 E-PBM peptide (963-977)
5hvt  1.75  2016  Kd=0.055uM    // 5hvs.pdf (NVS) ligand is compound NVS-2
5e88  1.60  2016  Kd=0.065uM    // 5e88.pdf (5KT) compound 12
5h9p  2.04  2016  Kd=0.068uM    // 4y24.pdf (TD2) ligand is TD-139
5iw0  1.63  2016  Kd=0.06uM     // 5isl.pdf (6EP) ligand is compound  N19
5hvs  1.75  2016  Kd=0.071uM    // 5hvs.pdf (65V) compound 3i
5agt  1.45  2016  Kd=0.075uM    // 5agr.pdf (A2H) [Uncommon element] compound 13
5ijp  2.75  2016  Kd=0.07uM     // 5ijj.pdf (I6P) ligand is inositol hexakisphosphate (InsP6)
5hva  2.10  2016  Kd=0.086uM    // 5hva.pdf (DUP) ligand is dUMPNPP
5f4r  2.80  2016  Kd=0.095uM    // 5f4l.pdf (5VF) ligand is (R,R)-BNM-IV-147 (compound 6)
5f4u  3.10  2016  Kd=0.095uM    // 5f4l.pdf (5VH) ligand is (R,R)-BNM-IV-197 (compound 7)
5lwe  2.80  2016  Kd=0.11nM     // 5lwe.pdf (79K) ligand is vercirnon
5fat  2.09  2016  Kd=0.11uM     // 5fa7.pdf (602) ligand is FPI-1602
5cqt  1.60  2016  Kd=0.124uM    // 5coi.pdf (EB3) compound 28
5dx4  2.30  2016  Kd=0.137uM    // 5coi.pdf (E0C) compound 85
5teg  1.30  2016  Kd=0.14uM     // 5teg.pdf (8-mer) ligand is histone H4K20 norleucine mutant peptide (2)
2mwy   NMR  2016  Kd=0.15uM     // 2mwy.pdf (15-mer) ligand is transactivation domain TAD1 of human p53 (residues 15-29)
5ech  2.14  2016  Kd=0.16mM     // 5ech.pdf (JAA) ligand is JA
5eci  1.56  2016  Kd=0.16mM     // 5ech.pdf (JAA) ligand is JA
5elv  1.92  2016  Kd=0.16uM     // 5elv.pdf (5PX) compound 5 (BPAM-521)
2rvn   NMR  2016  Kd=0.17uM     // 2rvn.pdf (18-mer) ligand is 18-mer H3K9me peptide
5khi  2.10  2016  Kd=0.17uM     // 5khg.pdf (6SX) [Multiple sites: site 1: Kd=0.17 uM; site 2: Kd=2.76 uM] ligand is purine riboside-3', 5'-cyclic monophosphate (cPuMP)
5js3  1.16  2016  Kd=0.185uM    // 5js3.pdf (6MG) ligand is compound 3
5izf  2.10  2016  Kd=0.18nM     // 5izf.pdf (6-mer) ligand is compound  ARC-1408 (6J9-AZ1-DAR-ACA-DAR-NH2)
5izk  3.25  2016  Kd=0.19uM     // 5izk.pdf (GDP) ligand is GDP
5cy9  1.55  2016  Kd=0.218uM    // 5coi.pdf (E0A) compound 58
5ggn  1.21  2016  Kd=0.22mM     // 5ggn.pdf (LEC) ligand is pNP-beta-GlcNAc
4y24  2.32  2016  Kd=0.22uM     // 4y24.pdf (TD2) ligand is TD-139
5jt9  1.26  2016  Kd=0.233uM    // 5js3.pdf (7AF) ligand is compound 2
5i2e  1.60  2016  Kd=0.23uM     // 5i2e.pdf (67D) ligand is compound 7
5l3j  2.83  2016  Kd=0.23uM     // 5l3j.pdf (6G9) ligand is compound 24
4znx  2.10  2016  Kd=0.24uM     // 4znx.pdf (12-mer) ligand is peptide APP12
5ejl  2.30  2016  Kd=0.24uM     // 5ejl.pdf (C2E) ligand is c-di-GMP
5t1l  2.48  2016  Kd=0.24uM     // 5t1l.pdf (12-mer) ligand is CQA(Ph)2DLSTRRLKC peptide
5igq  3.90  2016  Kd=0.25uM     // 5igo.pdf (11-mer) ligand is 11-mer Trib1 peptide
5j19  2.00  2016  Kd=0.25uM     // 5j19.pdf (15-mer) ligand is Phosphorylated peptide from Partner of Numb (pPon)
5l4i  1.45  2016  Kd=0.26uM     // 5jid.pdf (6J3) ligand is Clonixin
5ijj  1.95  2016  Kd=0.28uM     // 5ijj.pdf (I6P) ligand is inositol hexakisphosphate (InsP6)
5ggk  1.30  2016  Kd=0.29mM     // 5ggk.pdf (MBE) ligand is pNP-beta-Man
5e2n  1.53  2016  Kd=0.29nM     // 5dog.pdf (V14) [Nonstandard assay: Temp 37] CA XIII-10h
4rfr  1.50  2016  Kd=0.29uM     // 4rfr.pdf (RHN) ligand is rhein
5etr  1.32  2016  Kd=0.30uM     // 5etk.pdf (5RW) ligand is compound 34
5kau  1.95  2016  Kd=0.30uM     // 5kat.pdf (RHQ) ligand is RHODAMINE 6G (RH6G)
5aqt  1.90  2016  Kd=0.31mM     // 5aqf.pdf (5P7) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] kd=0.31+/-0.01mM, HSC70/BAG1 Compound 23
5j31  2.40  2016  Kd=0.31uM     // 5j31.pdf (10-mer) ligand is alkyne cross-linked cyclic peptide H derived from ExoS
5jvi  1.12  2016  Kd=0.31uM     // 5js3.pdf (6QC) ligand is compound 5
5cu4  1.56  2016  Kd=0.320uM    // 5cu4.pdf (54S) ligand is compound CAM4066 (7)
5i2f  1.25  2016  Kd=0.32uM     // 5i2e.pdf (BS5) ligand is Bio-AMS
5etq  1.96  2016  Kd=0.33uM     // 5etk.pdf (YH2) ligand is compound 40
5jss  1.19  2016  Kd=0.354uM    // 5js3.pdf (6NG) ligand is compound 6
5dbm  1.86  2016  Kd=0.35uM     // 4yk0.pdf (58N) ligand is CPI703
5ivy  1.45  2016  Kd=0.36uM     // 5isl.pdf (6EO) ligand is compound N16
5aqv  1.75  2016  Kd=0.37mM     // 5aqf.pdf (KC7) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=0.37+/-0.03mM, HSC70/BAG1 Compound 28
5jxn  1.38  2016  Kd=0.388uM    // 5js3.pdf (6NN) ligand is compound 4
5eom  2.55  2016  Kd=0.41uM     // 5eog.pdf (CTP)
5khk  2.07  2016  Kd=0.41uM     // 5khg.pdf (6SZ) [Multiple sites: site 1: Kd=0.41 uM; site 2: Kd=3.08 uM] ligand is 2-NH2-cPuMP
2n8t   NMR  2016  Kd=0.43mM     // 2n8t.pdf (14-mer) ligand is Cx43CT 276-289 peptide phosphorylated (Ser(P)279, Ser(P)282)
5d0r  2.24  2016  Kd=0.43uM     // 5d0r.pdf (B1T)
5ant  2.00  2016  Kd=0.440uM    // 5ans.pdf (RJE) compound 27
5in9  2.60  2016  Kd=0.44uM     // 5in9.pdf (6C0) ligand is compound 48
5duc  2.70  2016  Kd=0.45uM     // 5dtw.pdf (G51) ligand is GSK951A
5ivv  1.85  2016  Kd=0.45uM     // 5isl.pdf (6EN) ligand is compound N12
5lz5  2.05  2016  Kd=0.45uM     // 5lyy.pdf (7K4) ligand is compound (s)-15; ITC data available
5ewz  2.34  2016  Kd=0.46uM     // 5ewz.pdf (11-mer) ligand is diphosphorylated Gab2-pS210pT391 peptide
5kbe  2.50  2016  Kd=0.46uM     // 5kbe.pdf (IPH) ligand is phenol
5ekm  1.33  2016  Kd=0.48uM     // 5ekh.pdf (TG5) compound 4
5k8n  3.23  2016  Kd=0.48uM     // 5k8n.pdf (6R6) ligand is 5-nitroanthranilic acid (5NAA)
5gmh  2.20  2016  Kd=0.49uM     // 5gmf.pdf (RX8) [Nonstandard assay: pH 5.5, 150 mM NaCl] ligand is R848
5ix1  2.60  2016  Kd=0.49uM     // 5ix1.pdf (15-mer) ligand is H3(1-15)K4me3 peptide
5i3y  2.15  2016  Kd=0.4nM      // 5i3v.pdf (68K) ligand is compound 9
2n9x   NMR  2016  Kd=0.4uM      // 2n9x.pdf (17-mer) LIR motif of FUNDC1 binds to LC3
5d25  1.70  2016  Kd=0.50uM     // 5d24.pdf (56M) compound 2
5t52  1.70  2016  Kd=0.52nM     // 5t52.pdf (A2G/NGA) [Different ligand in assay: Kd=0.54 nM, beta-GalNAc] alpha-GalNAc + beta-GalNAc, App Kd
4ybj  2.61  2016  Kd=0.53nM     // 4ybj.pdf (4A9) ligand is DAS-DFGO-I; assay by KINOMEscan service
5lz7  2.10  2016  Kd=0.53uM     // 5lyy.pdf (7BK) ligand is compound (R)-15; ITC data available
5t1k  2.48  2016  Kd=0.53uM     // 5t1k.pdf (12-mer) ligand is CQFDA(Ph)2STRRLKC peptide
5k6s  2.79  2016  Kd=0.55uM     // 5k6s.pdf (19-mer) ligand is 19-mer cpS-BubR1 peptide; 663-TLSIKKL(pS)PIIEDDREADH-681
5swf  2.82  2016  Kd=0.55uM     // 5k6s.pdf (9-mer) ligand is 9-mer dpSpS-BubR1 peptide; 668-KL(pS)PIIED(pS)-676
5kbh  2.55  2016  Kd=0.55uM     // 5kbe.pdf (3CH) ligand is  3-chlorophenol
5h7g  1.85  2016  Kd=0.57nM     // 5h7g.pdf (13-mer) ligand is F1324 peptide; SPR data available
5etv  1.72  2016  Kd=0.57uM     // 5etk.pdf (5RZ) ligand is compound 13
5lwd  1.23  2016  Kd=0.57uM     // 5lif.pdf (79E) ligand is compound 6
5ett  1.55  2016  Kd=0.59uM     // 5etk.pdf (5RY) ligand is compound 50
5ggp  1.60  2016  Kd=0.5mM      // 5ggp.pdf (12-mer) ligand includes 2-mer monosaccharide and 10-mer peptide, GlcNAc-beta1,2-Man-peptide
4zfi  2.00  2016  Kd=0.5uM      // 4zfi.pdf (4NJ) compound 1a; MST assay
5hff  1.75  2016  Kd=0.5uM      // 5heb.pdf (9-mer) ligand is a mutant C-terminal peptide derived from CRIPT (T-2F)
5htl  1.37  2016  Kd=0.5uM      // 5htl.pdf (C2E) ligand is c-di-GMP
5h5r  1.20  2016  Kd=0.61uM     // 5h5q.pdf (15-mer) ligand is GXpep-2 peptide
5ee7  2.50  2016  Kd=0.62nM     // 5ee7.pdf (5MV) [Different ligand in assay: ligand in binding assay is Tritium-labelled] ligand is antagonist MK-0893; pKd=9.21
5svx  1.56  2016  Kd=0.64uM     // 5svi.pdf (11-mer) ligand is H3K4me3 peptide
5fnt  1.79  2016  Kd=0.67uM     // 5fnq.pdf (0PL) compound  6
5i3w  2.15  2016  Kd=0.6nM      // 5i3v.pdf (68L) ligand is compound 2
2n0u   NMR  2016  Kd=0.6uM      // 2mwy.pdf (48M) SJ057
5j18   NMR  2016  Kd=0.71nM     // 5j18.pdf (6FS) ligand is Rigosertib; MST assay
5ar0  1.90  2016  Kd=0.72uM     // 5aqz.pdf (GB8) ligand is compoud 17
5f1c  2.90  2016  Kd=0.745uM    // 5f1c.pdf (ATP)
5svy  1.05  2016  Kd=0.74uM     // 5svi.pdf (11-mer) ligand is H3K4me1 peptide
5kax  2.00  2016  Kd=0.78uM     // 5kat.pdf (RHQ) ligand is RHODAMINE 6G (RH6G)
5kbg  2.80  2016  Kd=0.78uM     // 5kbe.pdf (JZ0) ligand is o-cresol
2n0w   NMR  2016  Kd=0.7uM      // 2mwy.pdf (48L) ligand is SJ212
5etp  1.05  2016  Kd=0.7uM      // 5etk.pdf (5RZ) ligand is compound 13
5ftg  1.45  2016  Kd=0.7uM      // 5ftg.pdf (NBR) compound 10a
5k4z  1.64  2016  Kd=0.7uM      // 5k4x.pdf (6Q8) ligand is compound 6; Kd is available for comp 6
5l0c  3.10  2016  Kd=0.7uM      // 5l0c.pdf (PIO) [Multiple sites: site 1: Kd=0.7uM; site 2: Kd=0.59uM] ligand is PIP2
5d26  1.82  2016  Kd=0.81uM     // 5d24.pdf (L28) compound 3
5e7n  1.21  2016  Kd=0.81uM     // 5e7n.pdf (5KR) compound 20c
5eel  2.47  2016  Kd=0.83uM     // 5d0j.pdf (9-mer) ligand is Bicyclic Peptide Inhibitor (G7-B4)
5h9r  1.58  2016  Kd=0.84uM     // 4y24.pdf (TGZ) ligand is TAZTDG
5t54  1.65  2016  Kd=0.87nM     // 5t52.pdf (3-mer) [Different ligand in assay: ] ligand is BG-A, oligosaccharide
5d3l  1.50  2016  Kd=0.88uM     // 5d24.pdf (57F) compound 13
5aqq  2.72  2016  Kd=0.8mM      // 5aqf.pdf (BBW) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=0.8+/-0.5mM, HSC70/BAG1 Compound 13
5ggo  1.50  2016  Kd=0.8mM      // 5ggo.pdf (2-mer) ligand is GalNAc-beta1,3-GlcNAc-beta-pNP (2-mer of LEC+NGA)
5heb  1.65  2016  Kd=0.8uM      // 5heb.pdf (9-mer) ligand is a C-terminal peptide derived from CRIPT
5ekg  2.80  2016  Kd=0.91uM     // 5ekg.pdf (19-mer) [Multiple sites: major site Kd=0.91uM; minor site Kd=140uM] ligand is XPG2 peptide
5egs  2.15  2016  Kd=0.97uM     // 5egs.pdf (5NR) fragment 7
5k7h  2.35  2016  Kd=0.99uM     // 5k7h.pdf (IVC) ligand is isovaleryl coenzyme A; MST assay
5kcb  2.10  2016  Kd=0.99uM     // 5kat.pdf (ET) ligand is ethidium bromide (ET)
5g2g  1.60  2016  Kd=0.9uM      // 5g2g.pdf (EQU) ligand is equilenin
5hip  1.99  2016  Kd=0.9uM      // 5hio.pdf (61O) compound 1
5aqu  1.92  2016  Kd=1.04mM     // 5aqf.pdf (UX0) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=1.04+/-0.55mM, HSC70/BAG1 Compound 26
5k8o  2.89  2016  Kd=1.09uM     // 5k8n.pdf (6R7) ligand is compound 5NSA; Kd for 5NSA with Mn2+ ion is 0.59uM
5ekh  1.34  2016  Kd=1.11uM     // 5ekh.pdf (5RD) compound 1
4xo8  1.70  2016  Kd=1.1nM      // 4xo8.pdf (KGM)
5aei  1.83  2016  Kd=1.1nM      // 5aei.pdf (10-mer) ligand is peptide (KR)5
5drs  1.10  2016  Kd=1.1nM      // 5dog.pdf (5EF) [Nonstandard assay: Temp 37] CAII-10n
4yjl  2.10  2016  Kd=1.1uM      // 4yje.pdf (13-mer) ligand is peptide Amer1-A2 (496-508)
5hja  1.65  2016  Kd=1.1uM      // 5hja.pdf (XA2) [Different ligand in assay: racemic] inhibitor ABHDP; affinity is for ABHDP, racemic (DL)
5hv0  1.63  2016  Kd=1.1uM      // 5hv0.pdf (AKG) ligand is cofactor 2-OXOGLUTARIC ACID
5cp5  1.79  2016  Kd=1.234uM    // 5coi.pdf (EB0) compound 17
5ets  1.95  2016  Kd=1.24uM     // 5etk.pdf (5RX) ligand is compound 35
5lvl  1.40  2016  Kd=1.25uM     // 5lvl.pdf (537) ligand is PS653
5kbf  2.00  2016  Kd=1.2nM      // 5k8s.pdf (CMP) ligand is cAMP
5fb1  2.10  2016  Kd=1.2uM      // 5fb0.pdf (15-mer) ligand is 15-mer histone H3 K9me3 peptide
5fh6  2.30  2016  Kd=1.2uM      // 5fh6.pdf (5XM) ligand is compound 10
5ivc  1.57  2016  Kd=1.2uM      // 5isl.pdf (6E7) ligand is compound N3
5izm  3.40  2016  Kd=1.2uM      // 5izk.pdf (GNP) ligand is GDPNP
5svz  2.00  2016  Kd=1.2uM      // 5svz.pdf (15-mer) [Nonstandard assay: boiled] +/-0.2, Tat
5lwm  1.55  2016  Kd=1.34nM     // 5lwm.pdf (79T) ligand is compound 4 (FM381); commercial displacement assay
5lif  1.31  2016  Kd=1.34uM     // 5lif.pdf (6XO) ligand is compound 5
5eh5  1.21  2016  Kd=1.35uM     // 5eh5.pdf (XCZ) compound 1
5ipj  2.10  2016  Kd=1.3nM      // 5ipj.pdf (6CD) ligand is compound 17; DiscoveRx assay
5d3s  1.75  2016  Kd=1.3uM      // 5d24.pdf (579) compound 12
5fsy  1.70  2016  Kd=1.3uM      // 5fsx.pdf (AR6) ligand is ADP-ribose
5fyq  3.00  2016  Kd=1.3uM      // 5fyq.pdf (13-mer) ligand is 13-mer trifluoroacetylated Ran peptide, Ran(31-43) TfAcK37
5l4f  1.48  2016  Kd=1.3uM      // 5jid.pdf (6J1) ligand is 2,6-Dinitro-p-cresol (DNPC)
5t5g  2.10  2016  Kd=1.3uM      // 5t5g.pdf (75P) Kd = 1.3 +/- 0.3 uM, ligand is compound 2.
5dw2  1.12  2016  Kd=1.44uM     // 5dw1.pdf (5GD) ligand is compound RVX-297
5aqo  2.12  2016  Kd=1.4mM      // 5aqf.pdf (CWS) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=1.4+/-0.1mM, HSC70/BAG1 Compound 8
5ivn  1.00  2016  Kd=1.4nM      // 5ivn.pdf (12-mer) ligand is Cadherin derived peptide (BC2)
5egu  2.21  2016  Kd=1.4uM      // 5egu.pdf (5NQ) compound 1
5eng  1.30  2016  Kd=1.4uM      // 5eic.pdf (5QN) ligand is compound 12
5lso  2.22  2016  Kd=1.4uM      // 5lso.pdf (6-mer) ligand is cyclic peptide inhibitor compound 3
5tb6  1.79  2016  Kd=1.53uM     // 5luu.pdf (77X) Kd=1.53+/-0.01uM; CREBBP(1)/CPD-A
4z5w  2.20  2016  Kd=1.55uM     // 4z5w.pdf (5-mer) complex of PSK and DcPSKR-LRR; MST assay
5ez0  2.35  2016  Kd=1.58uM     // 5eyz.pdf (11-mer) ligand is peptide p38 gamma-KETPL
5iay   NMR  2016  Kd=1.59uM     // 5iay.pdf (16-mer) ligand is 16-mer Spacer peptide
5aip  2.30  2016  Kd=1.5mM      // 5aip.pdf (4HP) ligand is 4-hydroxyphenylacetate (4-HPA)
5eeq  1.60  2016  Kd=1.5uM      // 5d0j.pdf (12-mer) ligand is Bicyclic Peptide Inhibitor (G7-B1)
5etk  1.09  2016  Kd=1.5uM      // 5etk.pdf (5RU) ligand is compound 18
5il1  1.71  2016  Kd=1.5uM      // 5il0.pdf (SAM) ligand is AdoMet (SAM)
5t1m  2.53  2016  Kd=1.5uM      // 5t1m.pdf (12-mer) ligand is CQYDLSTRRLKC
5e2q  2.40  2016  Kd=1.64uM     // 5e2q.pdf (8-mer) ligand is peptide angiotensin-II
5eta  2.80  2016  Kd=1.6uM      // 5eta.pdf (16-mer) ligand is KIM domain of the Toxoplasma protein GRA24 (GRA24 KIM1 peptide)
5ih2  1.80  2016  Kd=1.72uM     // 5ih2.pdf (12-mer) ligand is proline-rich motifs in cAbl peptide (PRM758)
5aqn  2.45  2016  Kd=1.7mM      // 5aqf.pdf (JG8) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=1.7+/-0.6mM, HSC70/BAG1 Compound 7
4z0f  2.30  2016  Kd=1.7uM      // 4z09.pdf (13-mer) ligand is RON2hp [Phe2038(6CW)] peptide, sequence #11
5fsn  1.69  2016  Kd=1.7uM      // 5fsi.pdf (6Q3) ligand is compound 6
5izl  2.72  2016  Kd=1.85uM     // 5izk.pdf (GCP) ligand is GDPCP
5dlz  1.70  2016  Kd=1.8uM      // 5dlx.pdf (5D1) compound 1
5eis  1.60  2016  Kd=1.8uM      // 5egu.pdf (5OU) compound 5
5fos  1.35  2016  Kd=1.8uM      // 5fos.pdf (17-mer) ligand is RadA-OP peptide
5h5q  1.10  2016  Kd=1.8uM      // 5h5q.pdf (15-mer) ligand is GXpep-1 peptide
5hf1  1.75  2016  Kd=1.8uM      // 5heb.pdf (9-mer) ligand is a mutant C-terminal peptide derived from CRIPT (T-2F)
5itf  2.51  2016  Kd=1.8uM      // 5itf.pdf (12-mer) ligand is GQ(2-Br-F)DLSTRRLKG meditope peptide
5fsx  2.00  2016  Kd=1.9mM      // 5fsx.pdf (ADP) ligand is ADP
5ikb  2.05  2016  Kd=1.9nM      // 5ikb.pdf (KAI) ligand is kainate
5j74  2.70  2016  Kd=1.9nM      // 5j74.pdf (6GN) ligand is TO1-2p; Flow cytometry results
5du8  2.23  2016  Kd=1.9uM      // 5dtw.pdf (5FK) ligand is GSK572A
5ekn  2.59  2016  Kd=1.9uM      // 5ekn.pdf (N58) compound 58; assay by differential scanning fluorimetry (DSF)
5hfc  1.85  2016  Kd=1.9uM      // 5heb.pdf (9-mer) ligand is a mutant C-terminal peptide derived from CRIPT (T-2F)
4z07  2.50  2016  Kd=10.3nM     // 4z07.pdf (PCG) PKG1beta; Kd = 10.3 +/- 0.5 nM
5ehw  1.39  2016  Kd=1005uM     // 5eh5.pdf (5OO) compound 10
5fpp  2.40  2016  Kd=100uM      // 5fpp.pdf (HI6)
5g4n  1.35  2016  Kd=101uM      // 5g4m.pdf (O83) compound 3
5j3v  3.05  2016  Kd=104.5nM    // 5j3v.pdf (17-mer) [Different ligand in assay: Histone H3 (1-28) in assay] Histone H3 (11-27) in crystal, Histone H3 (1-28) in assay
5jek  2.40  2016  Kd=104uM      // 5jek.pdf (18-mer) pMAVS/IRF-3 complex, ligand is 18-mer pMAVS peptide
5c85  1.70  2016  Kd=105uM      // 5c7n.pdf (4YO) compound 8
4yx4  1.01  2016  Kd=1073.4nM   // 4yx4.pdf (FB2) compound 1
5flq  1.70  2016  Kd=1080uM     // 5eh5.pdf (IO2) compound 4
5eqy  2.50  2016  Kd=10nM       // 5eqe.pdf (5RA) compound 65
5t6j  1.75  2016  Kd=11.63uM    // 5t51.pdf (13-mer) ligand is protein DSN1 (560-572)
5fng  2.05  2016  Kd=1105uM     // 5eh5.pdf (YIE) compound 40
5icx  2.60  2016  Kd=110nM      // 5icx.pdf (16-mer) ligand is (AcN)-CQFDLSTRRLRCGGSK peptide
5fou  1.50  2016  Kd=113uM      // 5fot.pdf (6-mer) [Nonstandard assay: pH 6.0, 100 mM NaCl] ligand is FHPA TETRAPEPTIDE
5knj  2.88  2016  Kd=116nM      // 5knj.pdf (6UX) ligand is compound 1
4zv2  1.43  2016  Kd=1170uM     // 4zv1.pdf (GLN) L-glutamine
4zki  3.40  2016  Kd=1195uM     // 4u7o.pdf (ADP) ADP
4yhz  2.30  2016  Kd=11nM       // 4yhp.pdf (12-mer) ligand is H3K4me3 peptide
2n06   NMR  2016  Kd=12.0uM     // 2mwy.pdf (44Z) ligand is SJ298
4rqi  2.44  2016  Kd=12.3uM     // 4rqi.pdf (18-mer) ligand is peptide RAP1-YLP 89-106
5hbn  1.60  2016  Kd=12.9uM     // 5hbn.pdf (RPI) ligand is phospho-arginine (pArgAA)
5ii2  2.10  2016  Kd=12.9uM     // 5hrv.pdf (LU2) compound 15, according to structure in RCSB PDB
5t1i  1.60  2016  Kd=121.5uM    // 5t1i.pdf (15-mer) +/-36.2, HP1gamma_110-176/H3(38-52)
5flt  1.67  2016  Kd=1280uM     // 5eh5.pdf (VJJ) compound 3
5gjd  2.79  2016  Kd=12nM       // 5gjd.pdf (6V3) compound 2; SPR Kd available
5i1q  1.50  2016  Kd=12nM       // 5i1q.pdf (67C) compound 5; BROMOscan bromodomain selectivity data
5d3t  1.93  2016  Kd=12uM       // 5d24.pdf (56Y) compound 16
5ezg  1.84  2016  Kd=12uM       // 5eyr.pdf (5T4) compound 22
5f1j  1.63  2016  Kd=12uM       // 5eyr.pdf (5TO) compound 1
5etu  2.53  2016  Kd=130uM      // 5etu.pdf (12-mer) ligand is L5E meditope variant, CQFDESTRRLKC
5eqe  2.40  2016  Kd=132uM      // 5eqe.pdf (5R8) compound 11
5j0d  1.05  2016  Kd=134nM      // 5j0d.pdf (6F9) ligand is compound 102
5iyv  2.56  2016  Kd=135uM      // 5ixq.pdf (12-mer) ligand is peptide hormone IDL1
5fh7  1.47  2016  Kd=137nM      // 5fh6.pdf (5XL) ligand is compound 18
5g4m  1.38  2016  Kd=138uM      // 5g4m.pdf (O82) compound 2
5csd  1.45  2016  Kd=13nM       // 5csd.pdf (ACD) [Multiple sites: site 1:13nM; site 2: 2.3uM] Mp1p-LBD2-1AA
5fb7  1.50  2016  Kd=13nM       // 5csd.pdf (ACD) [Multiple sites: site 1:13nM; site 2: 2.3uM] Mp1p-LBD2-2AA
5l3a  1.98  2016  Kd=13uM       // 5l3a.pdf (6DP) ligand is compound 1
5f1h  1.82  2016  Kd=14.1nM     // 5eu1.pdf (5U6) compound 2 (BI-9564)
4yje  1.90  2016  Kd=14.4uM     // 4yje.pdf (11-mer) ligand is peptide Amer1-A1 (325-335)
2ncz   NMR  2016  Kd=140.5uM    // 2ncz.pdf (12-mer) ligand is NSD3_1 peptide
5ie1  2.30  2016  Kd=140nM      // 5i3v.pdf (6BS) ligand is compound 5
5btv  1.70  2016  Kd=140uM      // 5btv.pdf (4-mer) ligand is a 4-mer Tau-pS324 peptide; MST assays
5tha  1.80  2016  Kd=140uM      // 5tef.pdf (GP3) kd=140+/-30uM, ligand is GpppG.
4yc8  2.90  2016  Kd=14nM       // 4ybj.pdf (4B7) ligand is DAS-CHO-I; assay by KINOMEscan service
5ewk  1.60  2016  Kd=14uM       // 5ewk.pdf (P34) inhibitor PJ34
5f90  1.64  2016  Kd=14uM       // 5f8y.pdf (4-mer) ligand is Gb3 allyl; ligand name is GAL-BGC-GLA-5VQ
5eu1  1.60  2016  Kd=15.4nM     // 5eu1.pdf (5SW) compound 1 (BI-7273)
5iy4  2.95  2016  Kd=15.55uM    // 5iy4.pdf (16-mer) ligand is PIP box of DVC1 peptide
5jeo  1.72  2016  Kd=15.8uM     // 5jek.pdf (19-mer) ligand is 19-mer Phosphorylated Rotavirus NSP1 peptide
5exw  1.90  2016  Kd=150nM      // 5evz.pdf (7DT) ligand is 7-deazaATP
5htc  1.50  2016  Kd=150nM      // 5htb.pdf (66M) inhibitor ARC-3372
5hyq  2.48  2016  Kd=150nM      // 5hyq.pdf (12-mer) ligand is amidated meditope; CQFDLSTRRLKC-(Am)
5etx  2.35  2016  Kd=154.3nM    // 5epn.pdf (5RS) ligand is compound 5172-Linear
4yb7  2.20  2016  Kd=158uM      // 4yb5.pdf (ATP) [Multiple sites: ] Kd = 158 +/- 13 uMligand is His
5fov  1.74  2016  Kd=1590uM     // 5fot.pdf (6-mer) [Nonstandard assay: pH 6.0, 100 mM NaCl] ligand is FHTG TETRAPEPTIDE
2n3k   NMR  2016  Kd=159nM      // 2n3k.pdf (17-mer) ligand is 17-mer peptide of MLV Integrase C-term
4ybk  2.50  2016  Kd=15nM       // 4ybj.pdf (4B7) ligand is DAS-CHO-I; assay by KINOMEscan service
5i29  1.21  2016  Kd=15nM       // 5i1q.pdf (67B) compound 2; BROMOscan bromodomain selectivity data
5d7x  1.35  2016  Kd=15uM       // 5d7x.pdf (XZ8) compound 1b; BROMOscan assays
5ggl  1.27  2016  Kd=16.52mM    // 5ggl.pdf (6ZC) ligand is pNP-alpha-GlcNAc
5a3r  3.05  2016  Kd=16.7nM     // 5a3q.pdf (DL5) Ligand is TNP-AMPPCP
5esq  2.55  2016  Kd=1600nM     // 5esq.pdf (12-mer) ligand is Cyclic beta-alanine-linked meditope, AQFDLSTRRLKA
5fbi  1.47  2016  Kd=1600uM     // 5fah.pdf (5WD) compound 4; NMR Kd available
5etf  2.40  2016  Kd=161.5uM    // 5eta.pdf (15-mer) [Different protein in assay: protein in bindng assay is wild type] ligand is KIM domain of MKK6
5aqf  1.88  2016  Kd=165uM      // 5aqf.pdf (ADN) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=165+/-37uM, HSC70/BAG1 Adenosine
5i3v  1.62  2016  Kd=16nM       // 5i3v.pdf (68M) ligand is compound 1
5jq7  2.69  2016  Kd=16uM       // 5jq3.pdf (T0R) [Nonstandard assay: assay at PH=5.2] ligand is toremifene; Kd by thermal-shift assay
5ckr  2.95  2016  Kd=17.2nM     // 5ckr.pdf (57M) ligand is Muraymycin D2
5lp6  2.90  2016  Kd=17.2uM     // 5lp6.pdf (71P) [Different protein in assay: crystal: tubulin:RB3:TTL, binding assay:tubulin] Kd=17.2+/-2.5uM, T2ReTTL in complex with TH
5lne  2.20  2016  Kd=17.43uM    // 5lne.pdf (2-mer) ligand is Thomsen-Friedenreich (TF) antigen; also named Gal-beta1-3GalNAc (A2G-GAL)
5ggj  1.42  2016  Kd=17.78mM    // 5ggj.pdf (PNA) ligand is pNP-alpha-Man
5fwr  2.13  2016  Kd=17.7nM     // 5fwr.pdf (3X8) same as 4x50
5id0  2.48  2016  Kd=1700nM     // 5id0.pdf (11-mer) ligand is (AHA)QFDLSTRRLK peptide
5fh8  1.55  2016  Kd=170nM      // 5fh6.pdf (5XK) ligand is compound 28
5htb  1.70  2016  Kd=170nM      // 5htb.pdf (6L5) inhibitor ARC-3353
5ewh  1.63  2016  Kd=170uM      // 5c7n.pdf (5SG) compound 7
4yhm  2.16  2016  Kd=173pM      // 4yhi.pdf (4CC) aDabi-Fab2b: Dabigatran complex
5er4  1.81  2016  Kd=1752uM     // 5er4.pdf (5RL) ligand is compound SC0025
5klt  2.60  2016  Kd=175nM      // 5klr.pdf (16-mer) Kd = 175 +/- 35 nM. ligand is peptide P4[M]
5hbs   .89  2016  Kd=18.5nM     // 5h8t.pdf (RTL) ligand is all-trans-retinol
5tca  3.15  2016  Kd=18.85nM    // 5tca.pdf (J55) ligand is JH3; BLI assay
4yk0  1.65  2016  Kd=181uM      // 4yk0.pdf (98) ligand is CPI098
5fv7  2.84  2016  Kd=182nM      // 5fv7.pdf (R3Z) compound 1
5khj  2.01  2016  Kd=183.8uM    // 5khg.pdf (6SY) ligand is uridine-3', 5'-cyclic monophosphate (cUMP)
5i8p  2.37  2016  Kd=185nM      // 5i8p.pdf (VQ7) ligand is compound 1
5ia0  1.95  2016  Kd=187nM      // 5i9v.pdf (A5B) ligand is alisertib (MLN8237)
4yho  1.82  2016  Kd=18pM       // 4yhi.pdf (4CC) ligand is Dabigatran
5k03  1.81  2016  Kd=18uM       // 5k03.pdf (6P4) ligand is compound 2
4yb5  2.24  2016  Kd=19.3uM     // 4yb5.pdf (HIS) [Multiple sites: Kd = 19.3 +/- 0.2 uM, 14.5 +/- 0.2 uM, 36 +/-1 uM, 50 +/- 1 uM, 47 +/- 1 uM. sequential binding model (five events)] ligand is His
2ndg   NMR  2016  Kd=19.4uM     // 2ndf.pdf (13-mer) ligand is histone H3 crotonylation at K18 (H3K18cr)
5his  1.77  2016  Kd=19.6uM     // 5hio.pdf (60P) compound 3
5l9g  1.75  2016  Kd=19.8nM     // 5l9g.pdf (MO0) ligand is mannopine
5ia2  1.62  2016  Kd=19nM       // 5i9v.pdf (L66) ligand is compound 66
5klr  2.20  2016  Kd=19nM       // 5klr.pdf (16-mer) Kd = 19 +/- 4 nM. ligand is peptide P4[R]
5hjq  2.30  2016  Kd=19uM       // 5hjq.pdf (I3P) ligand is inositol(1,4,5)triphosphate; IP3
5aqr  1.91  2016  Kd=1mM        // 5aqf.pdf (N8Y) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=1.0+/-0.09mM, HSC70/BAG1 Compound 16
5ekj  1.13  2016  Kd=1uM        // 5ekh.pdf (TG4) compound 3
5f0f  1.76  2016  Kd=1uM        // 5eyr.pdf (5TD) compound 15
5eyz  2.09  2016  Kd=1uM        // 5eyz.pdf (13-mer) ligand is tailored peptide Cyto8-RETEV
5f1r  2.25  2016  Kd=1uM        // 5f1r.pdf (42O) compound 1
4yk6  1.70  2016  Kd=2.0uM      // 4yje.pdf (11-mer) ligand is peptide Amer1-A4 (365-375)
4ysi  1.02  2016  Kd=2.0uM      // 4ysi.pdf (8-mer) ligand is 8-mer WT vIRF1 peptide
5eld  1.40  2016  Kd=2.19mM     // 5eld.pdf (5-mer) ligand is A-penta-BGA (A2G-NDG-NAG-GAL-FUC)
5aqp  2.08  2016  Kd=2.1mM      // 5aqf.pdf (1LQ) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=2.1+/-0.6mM, HSC70/BAG1 Compound 10
5a3s  3.30  2016  Kd=2.1nM      // 5a3q.pdf (128) ligand is TNP-ATP; another ligand thapsigargin in crystal
5hjb  2.70  2016  Kd=2.1uM      // 5hjb.pdf (8-mer) ligand is H3K9cr peptide
5tcc  3.37  2016  Kd=2.21uM     // 5tca.pdf (J56) ligand is JH4; BLI assay
5ey0  1.60  2016  Kd=2.26mM     // 5ey0.pdf (GTP)
5epn  2.30  2016  Kd=2.2nM      // 5epn.pdf (5R2) ligand is compound 5172-mcP1P3
5hgc  2.43  2016  Kd=2.2nM      // 5hgc.pdf (HCY) ligand is cortisol
5d6y  2.29  2016  Kd=2.2uM      // 5d6w.pdf (10-mer) ligand is peptide histone H3K23me3
5hey  1.50  2016  Kd=2.2uM      // 5heb.pdf (9-mer) ligand is a C-terminal peptide derived from CRIPT
5d0c  1.49  2016  Kd=2.340uM    // 5coi.pdf (E0B) compound 42
2n1g   NMR  2016  Kd=2.3uM      // 2n1g.pdf (16-mer) ligand is PolD3 RIR-motif peptide
5c4l  2.35  2016  Kd=2.3uM      // 5c4k.pdf (SIS) ligand is sisomicin
5l0h  2.90  2016  Kd=2.3uM      // 5l0c.pdf (PIO) ligand is PIP2
5g46  1.76  2016  Kd=2.5mM      // 5g42.pdf (6VD) ligand is CT49
5a3q  3.05  2016  Kd=2.5nM      // 5a3q.pdf (DL5) ligand is TNP-AMPPCP; another ligand thapsigargin in crystal
5eje  1.90  2016  Kd=2.5uM      // 5eje.pdf (AP5) [Multiple sites: site1:Kd=2.5uM; site2:Kd=250uM] Ap5a-bound AdKcc,ox
5khd  1.75  2016  Kd=2.5uM      // 5khd.pdf (C2E) ligans is c-di-GMP
5d1n  2.71  2016  Kd=2.7uM      // 5bw4.pdf (SAH) ligand is SAH
5em9  1.60  2016  Kd=2.7uM      // 5elq.pdf (8-mer) ligand is phosphorylated C-terminal 5HT4(a)R PDZ binding motif; p5-HT4(a)R
5eto  1.07  2016  Kd=2.7uM      // 5etk.pdf (5RY) ligand is compound 50
5i9y  1.23  2016  Kd=2.8nM      // 5i9v.pdf (1N1) ligand is Dasatinib
5svl  2.90  2016  Kd=2.8nM      // 5svk.pdf (ATP) ligand is ATP; scintillation proximity assays (SPA)
5dus  1.43  2016  Kd=2.95uM     // 5dus.pdf (APR) ligand is ADP-ribose
5sxm  2.00  2016  Kd=2.9nM      // 5sxm.pdf (8-mer)
5khg  2.24  2016  Kd=20.23uM    // 5khg.pdf (CC7) ligand is cytidine-3', 5'-cyclic monophosphate (cCMP)
5fe9  2.35  2016  Kd=20.98uM    // 5fdz.pdf (5WS) [Nonstandard assay: ITC at Temp 15C] compound SL1122 (compound 13)
5g43  2.58  2016  Kd=200uM      // 5g42.pdf (5IM) ligand is CT16
5dkn  1.53  2016  Kd=202.6uM    // 5dkn.pdf (B7I) compound 5a (SBi4225); Kd calculated from fluorescent polarization competition assay (FPCA) IC50 data
5a6x  1.55  2016  Kd=202nM      // 5a6x.pdf (MFU) ligand is alpha-methyl-fucoside, compound 2
5fs5  1.42  2016  Kd=206.4nM    // 5fs5.pdf (KGM) ligand is HM
5ixq  1.86  2016  Kd=20uM       // 5ixq.pdf (12-mer) ligand is peptide hormone IDA; Kd=20+/-0.9 uM
5lvn  1.38  2016  Kd=20uM       // 5lvl.pdf (ADN) ligand is Adenosine
5tdw  1.70  2016  Kd=20uM       // 5tdr.pdf (11-mer) ligand is H3K4me3 peptide
5aqj  1.96  2016  Kd=2100uM     // 5aqf.pdf (Q88) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=2100+/-170uM, HSC70/BAG1 Compound 6
5l2w  2.80  2016  Kd=210nM      // 5l2i.pdf (1QK) ligand is compound Dinaciclib
5f3t  2.05  2016  Kd=210uM      // 5f3t.pdf (5UH) [Nonstandard assay: SPR at Temp 4C] ligand is compound JF-31-MG46
5fog  2.30  2016  Kd=213uM      // 5fog.pdf (VRT) ligand is Nva2AA
5er5  1.26  2016  Kd=215.4uM    // 5er5.pdf (ET) ligand is SC1990; should has a Br- iron in ligand
5fol  1.77  2016  Kd=215uM      // 5fog.pdf (SO8) ligand is Ile2AA
4d7b  1.15  2016  Kd=21nM       // 4d7b.pdf (TCW) [Multiple sites: site 1: Kd=21 nM; site 2: Kd=58 nM] ligand is tolcapone; two ligand-binding sites
5eq1  1.55  2016  Kd=21uM       // 5c7n.pdf (BEA) compound 1
5awu  2.70  2016  Kd=22.4uM     // 5awt.pdf (11-mer) ligand is 11-mer peptide Eps15-645-654
5klp  2.00  2016  Kd=22.7uM     // 5klp.pdf (IHP) [Different protein in assay: ten mutations in protein] ligand is IP6; ten mutations to facilitate crystal-packing interactions
5kh7  1.70  2016  Kd=220uM      // 5b8d.pdf (6T7) Kd = 220 +/- 20 uM. ligand is compound 3
5aqk  2.09  2016  Kd=223uM      // 5aqf.pdf (GDP) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] HSC70/BAG1 GDP
5ji8  1.42  2016  Kd=23.4uM     // 5ji8.pdf (6KT) ligand is compound 1, pKd=4.63
5ko1  2.16  2016  Kd=230nM      // 5knj.pdf (6UY) ligand is compound 4
5hog  3.09  2016  Kd=230uM      // 5hog.pdf (17-mer) ligand is CIP-Box Motif of the Dna2 Nuclease (207-223)
5etl  1.82  2016  Kd=23uM       // 5etk.pdf (5RV) ligand is compound 24
5hu9  1.53  2016  Kd=24.2nM     // 5hu9.pdf (66K) ligand is CHMFL-074; MST assay
5syn  1.64  2016  Kd=240nM      // 5sym.pdf (71T) ligand is ML349; FP Kd data available
5ezh  1.70  2016  Kd=24uM       // 5eyr.pdf (841) compound 21
5fsl  1.25  2016  Kd=24uM       // 5fsi.pdf (UAN) Kd=24+/-0.4uM, ligand is compound 3
5i88  1.40  2016  Kd=250nM      // 5i1q.pdf (69G) compound 4; BROMOscan bromodomain selectivity data
5lvr  2.05  2016  Kd=250uM      // 5luu.pdf (78Y) Kd=250+/-10uM; PCAF/CPD-E
5d2a  2.13  2016  Kd=2570nM     // 5d2a.pdf (12-mer) ligand is (Het2G1-Cys)2 dendrimer
5i8c  1.54  2016  Kd=25nM       // 5i8c.pdf (9-mer) ligand is HIV-1 Clade A BG505 Fusion Peptide (residue 512-520)
5ia5  1.78  2016  Kd=25nM       // 5i9v.pdf (GV0) ligand is golvatinib (E7050)
5ixt  1.94  2016  Kd=25uM       // 5ixq.pdf (17-mer) ligand is N-terminal extended IDA peptide hormone PKGV-IDA
4xtm  2.70  2016  Kd=26.97uM    // 4xtm.pdf (A2G) GalNAc; Kd = 26.97 +/- 0.89 uM
5hfb  1.62  2016  Kd=26.9uM     // 5heb.pdf (9-mer) ligand is a C-terminal peptide derived from CRIPT
5c4k  3.05  2016  Kd=27.5uM     // 5c4k.pdf (GET) ligand is G418
5iql  2.10  2016  Kd=27.5uM     // 5iql.pdf (8-mer) [Different ligand in assay: ITC assay use H3(15-39)K27cr peptide] ligand is H3(24-31)K27cr peptide, ITC assay is for H3(15-39)K27cr peptide
5evz  1.85  2016  Kd=270nM      // 5evz.pdf (ADP) ligand is ADP
5csh  1.59  2016  Kd=270uM      // 5csh.pdf (54E) compound 4
2n7b   NMR  2016  Kd=279uM      // 2n7b.pdf (4-mer) ligand is 6'sulfo sialyl Lewisx; Neu5Ac-Gal-GlcNac-Fuc-SO3-
5jr2  1.75  2016  Kd=27nM       // 5jr2.pdf (13-mer) ligand is APYd3 peptide inhibitor (17)
4zs9  1.37  2016  Kd=27uM       // 4zs9.pdf (RAF) Kd=27+/-2uM, complex is BlG16BP/raffinose
5c2o  2.35  2016  Kd=28.2uM     // 5c2o.pdf (TTP) dTTP
2n27   NMR  2016  Kd=280nM      // 2n27.pdf (4DY) [Multiple sites: site 1: Kd=280 nM; site 2: Kd=1205 nM] capsaicin (CAP); two independent binding sites
5cxi  2.00  2016  Kd=280nM      // 5cw8.pdf (5TW) ligand is 4-BNC-CoA
5dts  1.94  2016  Kd=280uM      // 5dtk.pdf (5F8) compound 2
5dva  2.50  2016  Kd=280uM      // 5dtk.pdf (5FL) compound 1
5fpk  1.34  2016  Kd=280uM      // 5fot.pdf (6-mer) [Nonstandard assay: pH 6.0, 100 mM NaCl] ligand is FATA TETRAPEPTIDE
5b56  2.30  2016  Kd=29.1uM     // 5b56.pdf (12-mer) [Multiple sites: site 1: Kd=29.1 uM; site 2: Kd=3.2 mM] ligand is HIV-1 VPR C-Terminal domain (85-96)
5hes  2.14  2016  Kd=29nM       // 5hes.pdf (032) [Nonstandard assay: ITC at Temp 37C] ligand is Vemurafenib
5etb  1.33  2016  Kd=29uM       // 5c7n.pdf (5RO) compound 15
5f3z  2.00  2016  Kd=29uM       // 5f3t.pdf (5V5) [Nonstandard assay: SPR at Temp 4C] ligand is compound PC-79-SH52
5iop  2.50  2016  Kd=29uM       // 5iop.pdf (12-mer) ligand is GQ(4-Br-F)DLSTRRLKG meditope peptide
5tdr  1.42  2016  Kd=29uM       // 5tdr.pdf (11-mer) ligand is H3K4me2 peptide; Kd data from ref.16
4yhp  2.53  2016  Kd=2nM        // 4yhp.pdf (16-mer) ligand is H3K9me3 peptide, use peptide IP assay.
5dlx  1.90  2016  Kd=2uM        // 5dlx.pdf (5D2) compound 2
5elq  1.10  2016  Kd=2uM        // 5elq.pdf (8-mer) ligand is 8-mer C-terminal DGKzeta PDZ binding motif
5lz4  2.07  2016  Kd=2uM        // 5lyy.pdf (7BW) ligand is compound 13; ITC data available
4zgk  2.00  2016  Kd=3.1uM      // 4zfi.pdf (4NX) compound 2a; MST assay
5cks  2.12  2016  Kd=3.1uM      // 5cks.pdf (52L) ligand is DAHP Oxime
5avf  1.95  2016  Kd=3.2uM      // 5ave.pdf (TAU) ligand is taurine
4ze6  1.17  2016  Kd=3.3mM      // 4y38.pdf (011) fragment compound 39
5svk  2.77  2016  Kd=3.3nM      // 5svk.pdf (ATP) ligand is ATP; scintillation proximity assays (SPA)
5aqz  1.65  2016  Kd=3.3uM      // 5aqz.pdf (SGV) ligand is compound sangivamycin 10
5hrw  1.80  2016  Kd=3.3uM      // 5hrv.pdf (64E) compound 11, according to structure in RCSB PDB
5ii1  2.02  2016  Kd=3.3uM      // 5hrv.pdf (6BL) compound 9, according to structure in RCSB PDB
4y4j  1.03  2016  Kd=3.4mM      // 4y38.pdf (LNR) fragment compound 97
5fb0  2.70  2016  Kd=3.4uM      // 5fb0.pdf (15-mer) ligand is 15-mer H31-15T3ph peptide
5gu4  1.55  2016  Kd=3.4uM      // 5gu4.pdf (9-mer) ligand is C9      2 (DDMGFGLFD) peptide
5aqh  2.00  2016  Kd=3.5mM      // 5aqf.pdf (ZVO) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=3.5+/-0.6mM, HSC70/BAG1 Compound 3
5b4w  2.60  2016  Kd=3.5nM      // 5b4w.pdf (18-mer) ligand is (PlxnB1)-binding macrocyclic peptide PB1m6
5dtw  2.44  2016  Kd=3.5uM      // 5dtw.pdf (5F9) ligand is C20-CoA
5ave  1.80  2016  Kd=3.6uM      // 5ave.pdf (SER) ligand is L-serine
5e3a  2.05  2016  Kd=3.6uM      // 5e2q.pdf (5-mer) ligand is opioid peptide leu-enkephalin
5tbn   NMR  2016  Kd=3.6uM      // 5tbn.pdf (12-mer) ligand is histone H3K4me2 peptide
5f2u  1.85  2016  Kd=3.7nM      // 5f2u.pdf (4-mer) ligand is 4-mer fully modified farnesylated INPP5E Peptide
5agr  1.30  2016  Kd=3.7uM      // 5agr.pdf (A52) [Uncommon element] compound 2
5etm  1.46  2016  Kd=3.9uM      // 5etk.pdf (5RW) ligand is compound 34
5awt  2.70  2016  Kd=30.2uM     // 5awt.pdf (11-mer) ligand is 11-mer peptide Eps15-640-649
5eoc  1.98  2016  Kd=30.3nM     // 5eoc.pdf (14-mer) ligand is Cyclic variant of Hepatitis C Virus E2 epitope I
5i9x  1.43  2016  Kd=30nM       // 5i9v.pdf (DB8) ligand is bosutinib (SKI-606); Kinobeads binding assay
5th2  1.84  2016  Kd=30uM       // 5th2.pdf (12-mer) ligand is CQFDQSTRRLKC peptide
5dtt  2.10  2016  Kd=310uM      // 5dtk.pdf (5F5) compound 3
5kew  2.10  2016  Kd=315.4nM    // 5kev.pdf (6SB) ligand is bile salt taurodeoxycholate (TDC)
4yxi   .96  2016  Kd=318.8nM    // 4yx4.pdf (4J8) compound 2
5e2w  1.50  2016  Kd=31nM       // 5e2t.pdf (18-mer) ligand is peptide-12, i.e. triply phosphorylated TAU peptide TPP-2
5ly3  1.60  2016  Kd=31nM       // 5ly3.pdf (16-mer) ligand is 16-mer arcadin-2 C-terminal peptide
5aqg  2.24  2016  Kd=31uM       // 5aqf.pdf (ZJB) [Different protein in assay: crystal: HSC70/BAG1, binding assay:HSC70] Kd=31+/-11uM, HSC70/BAG1 Compound 2
5l8n  2.12  2016  Kd=31uM       // 5l8n.pdf (6RQ) ligand is compound 1
5eok  2.80  2016  Kd=320uM      // 5eod.pdf (9-mer) peptide P39
5fnd  2.00  2016  Kd=320uM      // 5fnd.pdf (IQ5) compound 2
5i25  2.85  2016  Kd=324uM      // 5eod.pdf (8-mer) peptide HKP
5doh  1.05  2016  Kd=32nM       // 5dog.pdf (5DU) [Nonstandard assay: Temp 37] CAII-2m
5gic  2.35  2016  Kd=330.9nM    // 5gic.pdf (DLC) ligand is DLAM-2P
5eh7  1.43  2016  Kd=330uM      // 5eh5.pdf (5O5) compound 37
5fni  1.60  2016  Kd=330uM      // 5eh5.pdf (YIH) compound 37; redundant to 5eh7
5a5v  2.04  2016  Kd=33nM       // 5a5d.pdf (PXJ) CFe-6-Lic
5gr9  2.77  2016  Kd=33nM       // 5gr9.pdf (12-mer) ligand is 12-mer TDIF/CLE41 peptide
5a7y  2.50  2016  Kd=33uM       // 5a7y.pdf (SAH) same as 1qan
5jal  2.06  2016  Kd=3400uM     // 5jad.pdf (6HO) [Incomplete ligand] PDB use ligand structure of fragment 5 in paper, should be fragment 4
5eb3  2.40  2016  Kd=35.2mM     // 5eb1.pdf (UEG) ligand is compound VB6; SPR data
5gow   NMR  2016  Kd=35.3uM     // 5gow.pdf (19-mer) ligand is DP1 acidic string peptide
5fut  1.60  2016  Kd=352nM      // 5fut.pdf (PQ7) ligand is compound BR25
5jox  1.80  2016  Kd=35uM       // 5jov.pdf (EDG) ligand is AraDNJ
5d6j  2.25  2016  Kd=36uM       // 5d6j.pdf (ATP)
5hed  1.70  2016  Kd=36uM       // 5heb.pdf (9-mer) ligand is a mutant C-terminal peptide derived from CRIPT (T-2F)
5f2p  1.80  2016  Kd=37.5uM     // 5eu1.pdf (5TY) compound 3
5i38  2.60  2016  Kd=377uM      // 5i38.pdf (KOJ) ligand is kojic acid (KA); MST assay
5g4o  1.48  2016  Kd=37uM       // 5g4m.pdf (O80) compound 6
5h9q  1.93  2016  Kd=38.0uM     // 4y24.pdf (TD2) ligand is TD-139
5eps  1.47  2016  Kd=38uM       // 5c7n.pdf (5QX) compound 11
5epy  2.30  2016  Kd=39.9nM     // 5epn.pdf (5R2) ligand is compound 5172-mcP1P3
5ihh  1.35  2016  Kd=390nM      // 5en3.pdf (6B5) ligand is 7-MeO-Lut; MST assay
5dx3  2.09  2016  Kd=39nM       // 5dx3.pdf (13-mer) ligand is Stapled Peptide SRC2-SP3
4xoc  1.42  2016  Kd=3nM        // 4xo8.pdf (KGM) FimHL F18 .HM
5f08  1.92  2016  Kd=3uM        // 5eyr.pdf (5TG) compound 14
5ixf   NMR  2016  Kd=3uM        // 5ixf.pdf (14-mer) ligand is AMSH-P2 derived peptide
5tef  1.95  2016  Kd=4.0uM      // 5tef.pdf (GTG) kd=4.0+/-0.5uM; ligand is m7GpppG.
5chk  2.20  2016  Kd=4.12uM     // 5chk.pdf (55R) avidin-HABA, MST assay
5kbi  2.90  2016  Kd=4.12uM     // 5kbe.pdf (CAQ) ligand is catechol
5exx  3.31  2016  Kd=4.1uM      // 5exs.pdf (C2E) [Different protein in assay: full-length PaFleQ used for bioassay] ligand is c-di-GMP
5dpw  2.19  2016  Kd=4.22uM     // 5dpw.pdf (14-mer) complex is PLEKHM1-LIR/LC3A
5eou  2.40  2016  Kd=4.37uM     // 5eou.pdf (ATP) [Nonstandard assay: ITC assay at Temp 10C]
5etn  1.40  2016  Kd=4.3uM      // 5etk.pdf (5RX) ligand is compound 35
5elf  1.55  2016  Kd=4.57mM     // 5eld.pdf (5-mer) ligand is A-penta-HMO (A2G-GAL-BGC-GLC-FUC)
4y3y  1.35  2016  Kd=4.5mM      // 4y38.pdf (DCL) fragment compound 42
5edl  1.95  2016  Kd=4.5nM      // 5edl.pdf (VIB) ligand is thiamine
5l4m  1.58  2016  Kd=4.6uM      // 5jid.pdf (SBK) ligand is 3,5,6-Trichloro-2-pyridinyloxyacetic acid (Triclopyr)
2n14   NMR  2016  Kd=4.7uM      // 2mwy.pdf (49H) SJ295
5cqx  1.63  2016  Kd=4.7uM      // 5cqx.pdf (15-mer) ligand is MazE residues 68-82
5czm  1.30  2016  Kd=4.8nM      // 5cxa.pdf (R47) compound 1; delta G=-11.6 kcal/mol
5ehe  1.50  2016  Kd=4.8nM      // 5dog.pdf (WWO) [Nonstandard assay: Temp 37] CA II-10d
4yb6  1.98  2016  Kd=4.8uM      // 4yb5.pdf (HIS) [Multiple sites: Kd = 4.8 +/- 0.7 uM, 2.3 +/- 0.1 uM. sequential binding model (two events)] ligand is His/AMP
5ayy  3.09  2016  Kd=4.8uM      // 5ayy.pdf (NTM) ligand is Quinolinate, QA
5ks7  2.90  2016  Kd=4.8uM      // 5ks7.pdf (2BA) ligand is cyclic-di-AMP
5h8b  2.55  2016  Kd=4.91pM     // 5h8b.pdf (5Y2) compound 2
5d0j  2.60  2016  Kd=4.93uM     // 5d0j.pdf (9-mer) ligand is G7-TEdFP peptide (G7-B4NS)
5l2i  2.75  2016  Kd=40.1nM     // 5l2i.pdf (LQQ) ligand is Palbociclib
5d3c  1.31  2016  Kd=40pM       // 5cxa.pdf (56O) compound 2; delta G=-14.2 kcal/mol
5igm  1.60  2016  Kd=41.7nM     // 5igk.pdf (BMF) ligand is bromosporine (BSP)
5igk  1.70  2016  Kd=41.8nM     // 5igk.pdf (BMF) ligand is bromosporine (BSP)
5l8o  2.39  2016  Kd=415uM      // 5l8n.pdf (CHD) ligand is cholate
4yyt  1.07  2016  Kd=418.3nM    // 4yx4.pdf (S2O) compound 5
5hfj  3.10  2016  Kd=41uM       // 5hfj.pdf (SAM) ligand is cofactor SAM (AdoMet); MST assay
5igl  2.10  2016  Kd=42.7nM     // 5igk.pdf (BMF) ligand is bromosporine (BSP)
5hyr  2.27  2016  Kd=42nM       // 5dx3.pdf (13-mer) ligand is Stapled Peptide SRC2-SP2
5erg  2.20  2016  Kd=44.33uM    // 5eqj.pdf (SAM) ligand is SAM
5d3x  1.69  2016  Kd=440nM      // 5d3v.pdf (4IP) ITC Kd=391nM in figure S2, but 440nM in page 5
5mf6  1.87  2016  Kd=44uM       // 5mf6.pdf (7M2) ligand is compound 7 (UBCS039); MST assay
5hgq  3.28  2016  Kd=45.2nM     // 5hgq.pdf (KRS) ligand is cladosporin
5hjc  2.60  2016  Kd=45uM       // 5hjb.pdf (9-mer) ligand is histone H3 peptide acetylation at K18 (H3K18ac)
5iug  1.93  2016  Kd=46.4nM     // 5iug.pdf (729) ligand is compound 5a; SPR Kd calculated from Kon Koff
5l3f  3.50  2016  Kd=463nM      // 5l3e.pdf (11-mer) ligand is 11-mer peptide polymyxin B
5ia3  1.79  2016  Kd=46nM       // 5i9v.pdf (P17) ligand is PD173955
5ek9  2.08  2016  Kd=47nM       // 5ek9.pdf (5P4) [Nonstandard assay: Temp 10] 9 bound to BRD2-BD2
4zcs  2.45  2016  Kd=47uM       // 4zcp.pdf (CDC) Kd = 47 +/ -5 uM. ligand is CDPCho
5h8g  2.00  2016  Kd=48.2pM     // 5h8b.pdf (5Y4) compound 7b
5meh  0.95  2016  Kd=481nM      // 5meh.pdf (DMJ) ligand is DMJ
5fe7  2.08  2016  Kd=488uM      // 5fdz.pdf (5WU) fragment ZB2216 (fragment 11)
5khh  1.77  2016  Kd=49.32uM    // 5khg.pdf (6SW) ligand is inosine-3', 5'-cyclic monophosphate (cIMP)
5i9i  2.70  2016  Kd=49.7nM     // 5i8p.pdf (5HV) ligand is Darapladib
4y38  1.10  2016  Kd=4mM        // 4y38.pdf (0A9) ligand is fragment compound 29
5csw  2.66  2016  Kd=4nM        // 5csw.pdf (P06) ligand is dabrafenib
5ep7  1.20  2016  Kd=4uM        // 5eic.pdf (5QR) ligand is compound 3
5eqp  2.35  2016  Kd=4uM        // 5eqe.pdf (5R9) compound 37
5fns  1.79  2016  Kd=4uM        // 5fnq.pdf (XYY) compound 5
5l9o  1.84  2016  Kd=4uM        // 5l9g.pdf (GOP) ligand is glucopine
5hrv  1.70  2016  Kd=5.1uM      // 5hrv.pdf (64C) compound 10, according to structure in RCSB PDB
5hrx  1.73  2016  Kd=5.1uM      // 5hrv.pdf (64F) compound 12, according to structure in RCSB PDB
5ect  1.30  2016  Kd=5.2uM      // 5ect.pdf (DUP) ligand is dUPNPP; assay by near-UV CD titration
5hwu  2.10  2016  Kd=5.35uM     // 5hva.pdf (DUP) ligand is dUMPNPP
5faq  1.96  2016  Kd=5.3uM      // 5fa7.pdf (5VW) FPI-1465
5kxc  1.80  2016  Kd=5.45uM     // 5kxc.pdf (6Y2) ligand is LacdiNAc-pNP
5gs9  2.50  2016  Kd=5.5uM      // 5gs9.pdf (ARG) ligand is arginine
5iq6  3.00  2016  Kd=5.5uM      // 5iq6.pdf (6CJ) ligand is HeE1-2Tyr
5du4  1.70  2016  Kd=5.6uM      // 5dtw.pdf (5FF) ligand is GSK366A
4zv1  1.52  2016  Kd=5.73uM     // 4zv1.pdf (ARG) ligand is L-argnine
5d3j  1.70  2016  Kd=5.7uM      // 5d24.pdf (L33) compound 6
5edd  1.97  2016  Kd=5.7uM      // 5ect.pdf (DUP) ligand is dUPNPP; assay by near-UV CD titration
5hjd  2.81  2016  Kd=5.7uM      // 5hjb.pdf (7-mer) ligand is histone H3  peptide Crotonylation at K18 (H3K18cr)
5d24  1.65  2016  Kd=5.8uM      // 5d24.pdf (L26) compound 14
5ema  1.32  2016  Kd=5.9uM      // 5elq.pdf (8-mer) ligand is phosphorylated C-terminal LRRC3B PDZ binding motif (pLRRC3B)
5icz  2.55  2016  Kd=5000nM     // 5icz.pdf (12-mer) ligand is GQFDLSTRRLKG peptide
5ejw  2.60  2016  Kd=500uM      // 5ejw.pdf (5PZ) ligand is compound MS351
5g45  2.07  2016  Kd=500uM      // 5g42.pdf (A7W) ligand is CT24
5dtk  1.60  2016  Kd=50uM       // 5dtk.pdf (5F3) compound 17
5ewy  1.40  2016  Kd=50uM       // 5ewk.pdf (5TQ) inhibitor P6E
5duw  1.70  2016  Kd=510uM      // 5duw.pdf (5GO) ligand is lactose-3'-sulfate
4r06  2.22  2016  Kd=513nM      // 4r06.pdf (3E7) ligand is SR2067
5fnj  1.67  2016  Kd=5150uM     // 5eh5.pdf (YI6) compound 33
5i7y  1.45  2016  Kd=52nM       // 5i1q.pdf (69G) compound 4; BROMOscan bromodomain selectivity data
5ia4  1.80  2016  Kd=52nM       // 5i9v.pdf (88Z) ligand is foretinib (XL880)
5f2r  2.15  2016  Kd=52uM       // 5evz.pdf (ACP) ligand is AMPPCP
5l4j  1.62  2016  Kd=52uM       // 5jid.pdf (6JD) ligand is 4,4'-Dihydroxydiphenyl sulfone (Bisphenol S, BPS)
5dxb  2.08  2016  Kd=530nM      // 5dx3.pdf (13-mer) ligand is Stapled Peptide SRC2-SP1
5ia1  2.04  2016  Kd=530nM      // 5i9v.pdf (ZZL) ligand is MLN8054
5i7x  1.18  2016  Kd=53nM       // 5i1q.pdf (67B) compound 2; BROMOscan bromodomain selectivity data
5f9b  2.25  2016  Kd=54.82uM    // 5f9b.pdf (5VN) compound 19 (caulophyllogenin)
5arf  1.92  2016  Kd=540nM      // 5arf.pdf (I9H) compound 6
4xtp  1.97  2016  Kd=55.40uM    // 4xtp.pdf (TNR) TN; Kd = 55.40 +/- 2.84 uM
5ei3  1.71  2016  Kd=56.5uM     // 5ehc.pdf (5O8) compound 7a
5id1  2.49  2016  Kd=560nM      // 5id1.pdf (12-mer) ligand is (MPT)QFDLSTRRLKC peptide
4zij  1.78  2016  Kd=565uM      // 4zij.pdf (SFQ) ligand is sulfonamide 1
5a6i  1.86  2016  Kd=56nM       // 4d7b.pdf (TCW) [Multiple sites: site 1: Kd=56 nM; site 2: Kd=1.1 uM] ligand is tolcapone; two ligand-binding sites
5b2d  2.18  2016  Kd=56uM       // 5b2d.pdf (SLT) ligand is 3-sialyllactose
4yxu  1.08  2016  Kd=57.4nM     // 4yx4.pdf (4JE) compound 4
5f8y  1.70  2016  Kd=57uM       // 5f8y.pdf (X6X) ligand is galactosamine; BLI assay
5huw  1.95  2016  Kd=588.2nM    // 5huw.pdf (12-mer) [Multiple sites: site 1: Kd=588.2 nM; site 2: Kd=100 uM] ligand is 12-mer HSV-1 Large Terminase NLS peptide; nano-ITC data
5ad1  1.32  2016  Kd=58nM       // 5a5d.pdf (8LC) ligand is CFe-8-Lic
5ajc  1.70  2016  Kd=58uM       // 5ajc.pdf (4-mer) ligand is sialyl lewis X tetrasaccharide (SLex), include Gal-GlcNac-Fuc-NueAc
5csp  1.50  2016  Kd=58uM       // 5csp.pdf (54G) compound 5
5cu2  1.71  2016  Kd=58uM       // 5ct0.pdf (54G) [Nonstandard assay: PH=8] 19 and 9 (PDB: 5CU2), co-soaked into CK2 alpha
2ndf   NMR  2016  Kd=59.5uM     // 2ndf.pdf (13-mer) ligand is histon H3 acetylation at K18 (H3K18ac)
5l3g  3.10  2016  Kd=594nM      // 5l3e.pdf (11-mer) ligand is 11-mer peptide polymyxin E (colistin)
5e2m  1.41  2016  Kd=59nM       // 5dog.pdf (V14) [Nonstandard assay: Temp 37] CA I-10h
5fnr  1.89  2016  Kd=59uM       // 5fnq.pdf (XMS) compound 4
4ztr  2.85  2016  Kd=5nM        // 4zs0.pdf (4RJ) compound 9
5e80  2.60  2016  Kd=5nM        // 5e80.pdf (5KP) ligand is compound 2a
4z0e  1.90  2016  Kd=5uM        // 4z09.pdf (13-mer) ligand is RON2hp [Phe2038TRN] peptide, sequence #9
4z0d  2.10  2016  Kd=5uM        // 4z09.pdf (13-mer) ligand is RON2hp [Phe2038Trp] peptide, sequence #2
5eyr  1.57  2016  Kd=5uM        // 5eyr.pdf (5T0) compound 5
5dkr  1.74  2016  Kd=6.0uM      // 5dkn.pdf (5CZ) compound 17 (SBi29); Kd calculated from fluorescent polarization competition assay (FPCA) IC50 data
5hhx  3.00  2016  Kd=6.16nM     // 5hhv.pdf (16-mer) ligand is a high affinity IL-17A peptide antagonist (HAP)
5h8e  2.15  2016  Kd=6.33pM     // 5h8b.pdf (5Y3) compound 7h
5emb   .85  2016  Kd=6.3uM      // 5elq.pdf (8-mer) ligand is C-terminal phosphorylated PTHR PDZ binding motif (pPTHR)
5g1p  3.19  2016  Kd=6.3uM      // 5g1n.pdf (CP) [Nonstandard assay: pH 8.3, 150 mM NaCl] ligand is CP (carbamoyl phosphate); equivalent binding sites per huATCase trimer
5eqq  1.65  2016  Kd=6.7nM      // 5epn.pdf (5RS) ligand is compound 5172-Linear
4y3j  1.31  2016  Kd=6.8mM      // 4y38.pdf (HIC) compound 30
5fdz  2.40  2016  Kd=6.8uM      // 5fdz.pdf (5X0) [Nonstandard assay: ITC at Temp 15C] compound 14
5svi  1.61  2016  Kd=6.8uM      // 5svi.pdf (8-mer) ligand is H3K4me0 peptide
5cw8  2.60  2016  Kd=60nM       // 5cw8.pdf (55X) ligand is 3och-CoA
5kh3  1.60  2016  Kd=60uM       // 5b8d.pdf (6U6) Kd = 60 +/- 3 uM. ligand is compound 3
5ttf  1.72  2016  Kd=610nM      // 5ttf.pdf (7KZ) Kd = 610 +/- 68 nM. complex is G9a/compound 18
5dyo  2.36  2016  Kd=61pM       // 5dyo.pdf (FLU) ligand is flourescein
5en3  1.25  2016  Kd=620nM      // 5en3.pdf (7LU) ligand is compound 7-Cl-Lut; MST assay
5i80  1.45  2016  Kd=62nM       // 5i1q.pdf (67B) compound 2; BROMOscan bromodomain selectivity data
5ljj  3.00  2016  Kd=62nM       // 5ljj.pdf (AD5) ligand is Reversine
5cs6  1.88  2016  Kd=630uM      // 5cs6.pdf (K82) compound 3
5flp  1.71  2016  Kd=631uM      // 5eh5.pdf (6J5) compound 5
2nd0   NMR  2016  Kd=635uM      // 2ncz.pdf (19-mer) ligand is LANA peptide
5ha1  1.35  2016  Kd=64.1nM     // 5h8t.pdf (RNE) ligand is retinylamine
5l2t  2.37  2016  Kd=650nM      // 5l2i.pdf (6ZZ) ligand is compound Ribociclib
5l3e  2.80  2016  Kd=660nM      // 5l3e.pdf (E11) [Multiple sites: site 1: Kd=28 uM; site 2: Kd=660 nM] ITC identify two types of binding sites for E11
5fox  1.30  2016  Kd=675uM      // 5fot.pdf (6-mer) [Nonstandard assay: pH 6.0, 100 mM NaCl] ligand is FHAA TETRAPEPTIDE
5f41  2.00  2016  Kd=67uM       // 5f3t.pdf (5V6) [Nonstandard assay: SPR at Temp 4C] ligand is compound FD-83-KI26
5epp  1.88  2016  Kd=68.9uM     // 5epp.pdf (15-mer) ligand is 15-mer VBM Motif in Rhomboid Protease, RHBDL4
5ito  2.35  2016  Kd=68.9uM     // 5ito.pdf (6DB) ligand is octopine
5fot  1.19  2016  Kd=680uM      // 5fot.pdf (6-mer) [Nonstandard assay: pH 6.0, 100 mM NaCl] ligand is FHTU TETRAPEPTIDE
5bw4  2.10  2016  Kd=68uM       // 5bw4.pdf (SAM) ligand is SAM
5fe6  1.77  2016  Kd=6910uM     // 5fdz.pdf (5WZ) fragment ZB1916 (fragment 10)
5jqb  2.68  2016  Kd=6mM        // 5jq3.pdf (IBP) [Nonstandard assay: assay at PH=5.2] ligand is ibuprofen; Kd by thermal-shift assay
5csx  2.51  2016  Kd=6nM        // 5csw.pdf (54J) ligand is BI 882370
5k8s  1.15  2016  Kd=6nM        // 5k8s.pdf (CMP) ligand is cAMP
5brz  2.62  2016  Kd=7.1nM      // 5brz.pdf (9-mer) ligand is 9-mer peptide A1-MAGE-A3
5u4x  1.88  2016  Kd=7.1nM      // 5u4x.pdf (7VM) [Nonstandard assay: binding only occurred in the presence of SAM, SAM = 50 uM] Kd = 7.1 +/- 1.8 nM. ligand is TP-064
5kva  1.83  2016  Kd=7.32uM     // 5kva.pdf (SAM) ITC Kd=8.6uM in Fig. 4a, but 7.32uM in table 2; mad author
4ud7  1.60  2016  Kd=7.4nM      // 4ud7.pdf (16-mer) Kd=7.4+/-1.5nM, ligand is compound YS-2(peptide)
5d3p  1.95  2016  Kd=7.4uM      // 5d24.pdf (57E) compound 10
5hda  2.39  2016  Kd=7.4uM      // 5hda.pdf (9-mer) ligand is Epstein-Barr nuclear antigen 2, EBNA2 PXLXP motif
5f74  2.35  2016  Kd=7.6uM      // 5f74.pdf (AMP)
5lbq  3.30  2016  Kd=7.78uM     // 5l3e.pdf (767) ligand is MC3767
5d3h  1.70  2016  Kd=7.9uM      // 5d24.pdf (57G) compound 4
5e5g  1.95  2016  Kd=700uM      // 5e2l.pdf (DTR) ligand is D-Trp
5fnf  2.10  2016  Kd=700uM      // 5fnf.pdf (TQL) compound 3
5flo  1.66  2016  Kd=709uM      // 5eh5.pdf (J4K) compound 6
5fpi  2.77  2016  Kd=72uM       // 5fpi.pdf (8-mer) ligand is Integrin alpha4 internalisation peptide QYKSILQE
5ehr  1.70  2016  Kd=73nM       // 5ehr.pdf (5OD) Allosteric Inhibitor SHP099
5lvq  2.05  2016  Kd=73uM       // 5luu.pdf (2LX) Kd=73+/-1uM; PCAF/CPD-D
5lom  1.50  2016  Kd=74.1nM     // 5l9g.pdf (SNW) ligand is Deoxyfructosylglutamine (DFG)
5hpm  2.67  2016  Kd=74nM       // 5hpm.pdf (11-mer) ligand is Cyclic amidated, acetylated linked meditope; (AcN)-CQFDLSTRRLKC-(Am)
5ey4  1.86  2016  Kd=750uM      // 5evz.pdf (DTP) ligand is 2'-deoxyATP
5bs0  2.40  2016  Kd=76.7nM     // 5brz.pdf (9-mer) ligand is 9-mer peptide titin
5eb2  2.71  2016  Kd=76.9mM     // 5eb1.pdf (TRP) ligand is L-Trp; SPR data
5e6o  1.80  2016  Kd=76.9uM     // 5e6o.pdf (4-mer) peptide Trp-Glu-Glu-Leu (WEEL)
5gid  2.15  2016  Kd=769.2nM    // 5gic.pdf (VDP) ligand is DLAM-4P; crystal in C2 form
5dnu  1.20  2016  Kd=77.6uM     // 5dnu.pdf (KKN) ligand is karrikin (KAR1)
5fnc  2.20  2016  Kd=77uM       // 5fnc.pdf (IEE) compound 1
5kat  2.10  2016  Kd=78.7uM     // 5kat.pdf (P4P) ligand is tetraphenylphosphonium (TPP)
5f1x  1.90  2016  Kd=780nM      // 5evz.pdf (ATP) ligand is ATP
5l9l  1.80  2016  Kd=79.4nM     // 5l9g.pdf (GOP) ligand is glucopine
5hv1  3.10  2016  Kd=79.4uM     // 5hv1.pdf (RFP) ligand is RIFAMPICIN (RIF)
5eh8  1.38  2016  Kd=791uM      // 5eh5.pdf (5O6) compound 19
5hkh  2.55  2016  Kd=8.1uM      // 5hkh.pdf (9-mer) ligand is 9-mer UBA5 LIR/UFIM peptide
5h5s  1.85  2016  Kd=8.2uM      // 5h5q.pdf (14-mer) ligand is GXpep-3 peptide
5j32  1.93  2016  Kd=8.3uM      // 5j32.pdf (IPM) [Nonstandard assay: ITC assay at Temp 15C] ligand is isopropylmalate
5hwv  1.65  2016  Kd=8.5uM      // 5hwv.pdf (MBN) ligand is toluene;
5luu  1.61  2016  Kd=8.63uM     // 5luu.pdf (77X) Kd=8.63+/-0.05uM, BRD4(1)/CPD-A
5ehv  1.21  2016  Kd=826uM      // 5eh5.pdf (5ON) compound 35
5dd0  2.49  2016  Kd=83.7nM     // 5dd0.pdf (13-mer) ligand is MPER peptide, kd measured by Bio-Layer Interferometry
5e2v  1.64  2016  Kd=831nM      // 5e2t.pdf (18-mer) ligand is peptide-6, i.e. doubly phosphorylated TAU peptide TPP-1
5l2s  2.27  2016  Kd=83nM       // 5l2i.pdf (6ZV) ligand is compound Abemaciclib
5icy  2.50  2016  Kd=8700nM     // 5icy.pdf (12-mer) ligand is SQFDLSTRRLKS peptide
5h9s  1.82  2016  Kd=87uM       // 4y24.pdf (TGZ) ligand is TAZTDG
5i3x  1.85  2016  Kd=8nM        // 5i3v.pdf (68J) ligand is compound 6
4z7o  2.85  2016  Kd=9.03uM     // 4z7o.pdf (4-mer) [Different protein in assay: 10E5 Fab in crystal was not mentioned in bioassay] ligand is AGDV peptide
5kq5  3.41  2016  Kd=9.0nM      // 5kq5.pdf (STU) ligand is compound 7
5t3n  2.40  2016  Kd=9.1nM      // 5k8s.pdf (75G) ligand is Sp-2Cl-cAMPS
5f25  1.68  2016  Kd=9.1uM      // 5eu1.pdf (5TU) compound 4
5d3n  2.15  2016  Kd=9.2uM      // 5d24.pdf (L40) compound 7
5huy  1.98  2016  Kd=9.4uM      // 5huw.pdf (12-mer) [Multiple sites: site 1: Kd=9.4 uM; site 2: Kd=66.9 uM] ligand is 16-mer HCMV pUL56 NLS peptide; nano-ITC data
5ff6  2.50  2016  Kd=9.5uM      // 5ff6.pdf (12-mer) ligand is L10Q meditope variant, CQFDLSTRRQKC
5iok  2.22  2016  Kd=9.5uM      // 5iok.pdf (8-mer) ligand is histone H3K9cr peptide
5du6  2.61  2016  Kd=9.6uM      // 5dtw.pdf (G59) ligand is GSK059A
5fom  2.10  2016  Kd=9.8uM      // 5fog.pdf (A2H) [Uncommon element] ligand is AN6426-AMP
4ue1  1.45  2016  Kd=9.9nM      // 4ud7.pdf (16-mer) Kd=9.9+/-1.5nM, ligand is compound YS-1(peptide)
4xoe  2.40  2016  Kd=9.9uM      // 4xo8.pdf (KGM)
5itp  1.85  2016  Kd=9.9uM      // 5ito.pdf (6DB) ligand is octopine
5fls  1.67  2016  Kd=905uM      // 5eh5.pdf (6ZX) compound 2
4zsh  1.80  2016  Kd=90nM       // 4zsh.pdf (4XW) PxR-LBD with 9CDHRA
5lli  2.40  2016  Kd=90nM       // 5lli.pdf (6Z3) ligand is VH298; SPR Kd=10nM; FP Kd=80nM
4yxo  1.06  2016  Kd=91.4nM     // 4yx4.pdf (4JC) compound 3
5epr  1.65  2016  Kd=91uM       // 5c7n.pdf (5QY) compound 12
5e2l  2.50  2016  Kd=93uM       // 5e2l.pdf (DPN) ligand is D-Phe
5fow  1.80  2016  Kd=93uM       // 5fot.pdf (6-mer) [Nonstandard assay: pH 6.0, 100 mM NaCl] ligand is WHTA TETRAPEPTIDE
5e3d  1.71  2016  Kd=95uM       // 5c7n.pdf (5JL) compound 4
5glu  2.10  2016  Kd=96uM       // 5glu.pdf (3-mer) ligand is SiaLac; 3-mer of SIA-GAL-GLC
5jan  2.12  2016  Kd=980uM      // 5jad.pdf (6HP) [Incomplete ligand] PDB use ligand structure of fragment 2 in paper, should be fragment 5
5l9i  1.90  2016  Kd=99nM       // 5l9g.pdf (SNW) ligand is DFG
5cxa  1.30  2016  Kd=9nM        // 5cxa.pdf (55L) compound 3; delta G=-11.2 kcal/mol
5i9z  1.70  2016  Kd=9nM        // 5i9v.pdf (627) ligand is danusertib (PHA739358)
5ld8  2.13  2016  Kd=9nM        // 5ld8.pdf (6U5) ligand is GSK3011724A; chemoproteomic affinities, also has SPR Kd in the 10-20nM range
2n9e   NMR  2016  Kd=9uM        // 2n9e.pdf (15-mer) ligand is  BRCA1-A complex subunit RAP80 (RAP80 SIM)
5i3a  2.20  2016  Kd=9uM        // 5i38.pdf (HQE) ligand is hydroquinone (HQ) in configuration A
4y4g  1.44  2016  Kd>10.0mM     // 4y38.pdf (GGB) fragment compound 53
5c87  1.55  2016  Kd>200uM      // 5c7n.pdf (4YS) compound 5
5dy7  1.69  2016  Kd>200uM      // 5c7n.pdf (5GT) compound 10
5dya  1.65  2016  Kd>200uM      // 5c7n.pdf (5GV) compound 14
5em3  1.40  2016  Kd>200uM      // 5c7n.pdf (5Q0) compound 6
5eva  1.45  2016  Kd>200uM      // 5c7n.pdf (5S9) compound 19
5ewd  1.58  2016  Kd>200uM      // 5c7n.pdf (5SH) compound 2
5hn0  2.05  2016  Kd>200uM      // 5hmw.pdf (LNN) [Nonstandard assay: ITC assay at Temp 4C] compound 4; IC50=769 uM
5ele  1.60  2016  Kd>30mM       // 5eld.pdf (5-mer) ligand is A-penta-BGA (A2G-NDG-NAG-GAL-FUC)
5fsm  1.67  2016  Kd>40uM       // 5fsi.pdf (N91) ligand is compound 5
5ivf  1.68  2016  Kd>40uM       // 5isl.pdf (6EB) ligand is compound  N10
5ir1  2.48  2016  Kd>5.4uM      // 5ir1.pdf (12-mer) ligand is GQ(3-Br-F)-DLSTRRLKG meditope peptide
5e3g  1.65  2016  Kd>50uM       // 5c7n.pdf (5JQ) compound 3
5euk  2.50  2016  Kd>50uM       // 5euk.pdf (12-mer) ligand is F3H meditope variant, CQHDLSTRRLKC
5f88  2.48  2016  Kd>50uM       // 5f88.pdf (12-mer) ligand is L5Y meditope variant, CQFDYSTRRLKC
5i2i  2.55  2016  Kd>50uM       // 5i2i.pdf (12-mer) ligand is cyclic F3Q variant of the meditope; CQQDLSTRRLKG
5ivz  2.48  2016  Kd>50uM       // 5ivz.pdf (12-mer) ligand is GQFDLST(Cit)RLKG meditope peptide
5g42  1.72  2016  Kd>5mM        // 5g42.pdf (4TU) ligand is CT6
5iv2  2.48  2016  Kd>8.0uM      // 5iv2.pdf (12-mer) ligand is GQFDLSTR(Cit)LKG meditope peptide
5f67  1.76  2016  Kd~0.13uM     // 5f67.pdf (19-mer) ligand is TRP channel tail (TRPCT)
5im3  2.30  2016  Kd~1.5uM      // 5im3.pdf (DTP) bind approximately three dATP per polypeptide
5jer  2.91  2016  Kd~200uM      // 5jek.pdf (19-mer) ligand is 19-mer Rotavirus NSP1 peptide
5dtm  2.20  2016  Kd~50uM       // 5dtm.pdf (5F4) compound 1
5iis  2.10  2016  Ki<0.001uM    // 5iis.pdf (6CB) ligand is compound 3a
5ew9  2.18  2016  Ki<0.01nM     // 5ew9.pdf (5VC) ligand is MK-5108
4zy1  2.50  2016  Ki=0.0072uM   // 4zw3.pdf (4U5) pfa-m17,compound 10r
4zy0  2.20  2016  Ki=0.0091uM   // 4zw3.pdf (4TM) pfa-m17,compound 10q
4zyq  2.60  2016  Ki=0.0097uM   // 4zw3.pdf (4U6) compound 10s
4ydg  3.25  2016  Ki=0.015uM    // 4ydf.pdf (G3G) compound 10
5hz6  1.14  2016  Ki=0.016uM    // 5hz6.pdf (65Y) compound 11
5edc  1.29  2016  Ki=0.022uM    // 5edb.pdf (5M7) compound 13
5hct  1.36  2016  Ki=0.0254uM   // 5hct.pdf (61P) compound 13; +/-0.0002
4zw3  1.80  2016  Ki=0.027uM    // 4zw3.pdf (4S9) PfA-M1, compound 9b
5d48  1.81  2016  Ki=0.03uM     // 5d45.pdf (L96) compound 1
4zx9  2.60  2016  Ki=0.041uM    // 4zw3.pdf (4TK) pfa-m17,compound 10b
5diu  1.30  2016  Ki=0.043uM    // 5diu.pdf (5BG) compound 3
5j7p  1.85  2016  Ki=0.052uM    // 5j7p.pdf (6H1) [Covalent complex] [Incomplete ligand] RDR03785 (compound 3); Miss a ring in PDB
5b25  1.90  2016  Ki=0.058nM    // 5b25.pdf (4QJ) compound 3
4zy2  2.10  2016  Ki=0.060uM    // 4zw3.pdf (4TL) compound 10o
4zx3  2.00  2016  Ki=0.065uM    // 4zw3.pdf (4TK) pfa-m1, compound10b
5l2z  1.79  2016  Ki=0.06nM     // 5l2y.pdf (70C) [Nonstandard assay: assay at temp 37C] ligand is compound 56
4zx4  1.90  2016  Ki=0.078uM    // 4zw3.pdf (4TL) pfa-m1, compound 10o
4zx8  2.70  2016  Ki=0.080uM    // 4zw3.pdf (4TY) pfa-m17, compound9b
5k0h  2.20  2016  Ki=0.081uM    // 5k0h.pdf (6PK) ligand is compound 2
5a9u  1.60  2016  Ki=0.08nM     // 5a9u.pdf (5P8) ligand is lorlatinib
5hz9  2.30  2016  Ki=0.093uM    // 5hz6.pdf (5M8) compound 6
5d47  1.70  2016  Ki=0.10uM     // 5d45.pdf (L19) compound 2; author gives wrong compound 3
5d45  1.65  2016  Ki=0.12uM     // 5d45.pdf (57P) compound 3; author gives wrong compound 2
5l2y  1.82  2016  Ki=0.14nM     // 5l2y.pdf (70D) [Nonstandard assay: assay at temp 37C] ligand is compound 54
5div  1.65  2016  Ki=0.14uM     // 5diu.pdf (5BH) compound 29
5lxb  2.34  2016  Ki=0.17nM     // 5lxb.pdf (7A9) [Different protein in assay: assay use wildtype 5-HTBP protein] ligand is palonosetron
5ayt  1.40  2016  Ki=0.17uM     // 5ayt.pdf (L6Y)
5edb  1.18  2016  Ki=0.1uM      // 5edb.pdf (5M8) compound 10
5fho  2.30  2016  Ki=0.213uM    // 5fhm.pdf (5XN) compound 7
4ufd  1.43  2016  Ki=0.21nM     // 4ufd.pdf (S49) compound 5
5dh5  2.00  2016  Ki=0.23nM     // 5dh4.pdf (5AY) ligand is Pyp-1
5l7e  1.86  2016  Ki=0.25uM     // 5l7e.pdf (6Q0) ligand is compound 1; pKi=6.6, pIC50=5.9
5ew0  1.30  2016  Ki=0.26uM     // 5ev8.pdf (3C7) compound 1a (L-CS319)
5dxt  2.25  2016  Ki=0.2nM      // 5dxh.pdf (5H5) compound 4
5sz4  1.60  2016  Ki=0.2nM      // 5sz0.pdf (72D) ligand is compound 4a
5sz7  1.78  2016  Ki=0.2nM      // 5sz0.pdf (72H) ligand is compound 4p
5kr1  1.60  2016  Ki=0.32nM     // 5kqx.pdf (017) ligand is DRV
5iwg  1.66  2016  Ki=0.346uM    // 5iwg.pdf (IWX) ligand is compound  BRD4884
5cgv  2.17  2016  Ki=0.34uM     // 5cgv.pdf (0N8) ligand is L-742,001
5iub  2.10  2016  Ki=0.35nM     // 5iu4.pdf (6DV) ligand is compound 12x
5fdr  2.60  2016  Ki=0.36nM     // 5fc4.pdf (5X3) compound 60
5aaa  1.73  2016  Ki=0.38nM     // 5a9u.pdf (VGH) ligand is crizotinib
5jfp  1.49  2016  Ki=0.48nM     // 5jfp.pdf (6KK) ligand is compound 15d
5hz8  1.12  2016  Ki=0.4uM      // 5hz6.pdf (65Z) compound 9
5ix0  1.72  2016  Ki=0.519uM    // 5iwg.pdf (6EZ) ligand is compound  BRD7232
5kqy  1.65  2016  Ki=0.51nM     // 5kqx.pdf (017) ligand is DRV
5iu4  1.72  2016  Ki=0.53nM     // 5iu4.pdf (ZMA) ligand is compound ZM241385
4zj8  2.75  2016  Ki=0.55nM     // 4zj8.pdf (SUV) ligand is suvorexant
5dhu  2.33  2016  Ki=0.5uM      // 5dhp.pdf (5A8) compound 11q
4zx5  1.95  2016  Ki=0.64uM     // 4zw3.pdf (4TM) compound 10q
5eei  1.32  2016  Ki=0.6nM      // 5edu.pdf (SHH) ligand is SAHA
5kr0  1.80  2016  Ki=0.71nM     // 5kqx.pdf (478) ligand is APV
5l30  1.73  2016  Ki=0.72nM     // 5l2y.pdf (70A) ligand is compound 59
5cr7  2.90  2016  Ki=0.79mM     // 5cr7.pdf (5WO) compound 2c
5aab  2.20  2016  Ki=0.88nM     // 5a9u.pdf (VGH) ligand is crizotinib
5trf  2.10  2016  Ki=0.88nM     // 5trf.pdf (7HC) ligand is SAR405838 (MI-77301)
5eek  1.59  2016  Ki=0.8nM      // 5edu.pdf (TSN) ligand is trichostatin A(TSA)
5sz0  1.63  2016  Ki=0.8nM      // 5sz0.pdf (72D) ligand is compound 4a
5l7f  1.80  2016  Ki=0.90nM     // 5l79.pdf (2-mer) ligand is compound probe 1; consist of R47-6PJ
5e2s  1.50  2016  Ki=0.98nM     // 5e28.pdf (5CX) compound 4c
4uja  1.93  2016  Ki=0.9nM      // 4uj1.pdf (4L7) compound 1p
4zjc  2.83  2016  Ki=1.1nM      // 4zj8.pdf (4OT) ligand is SB-674042
5een  1.86  2016  Ki=1.1nM      // 5edu.pdf (5OG) ligand is Belinostat
5iu7  1.90  2016  Ki=1.1nM      // 5iu4.pdf (6DY) ligand is compound 12c
4zw8  2.00  2016  Ki=1.1uM      // 4zw3.pdf (4T2) pfa-m1,compound 9r
5fhn  1.60  2016  Ki=1.27uM     // 5fhm.pdf (5XO) compound 8
5hcy  2.46  2016  Ki=1.2nM      // 5hcx.pdf (60D) compound 13
5sz1  1.55  2016  Ki=1.2nM      // 5sz0.pdf (72E) ligand is compound 4b
5aac  1.70  2016  Ki=1.3nM      // 5a9u.pdf (VGH) ligand is crizotinib
5ef8  2.60  2016  Ki=1.4nM      // 5edu.pdf (LBH) ligand is panobinostat
5hj9  1.28  2016  Ki=1.4uM      // 5hj9.pdf (X7A) [Uncommon element] [Different ligand in assay: S-isomer] inhibitor ABHPE; affinity is for ABHPE, S-isomer (L)
5iua  2.20  2016  Ki=1.5nM      // 5iu4.pdf (6DX) ligand is compound 12b
5kby  2.24  2016  Ki=1.5nM      // 5kby.pdf (6RL) ligand is trelagliptin (SYR-472)
5d2r  1.90  2016  Ki=1.5uM      // 5d2r.pdf (56W) ligand is inhibitor 1
5k13  1.85  2016  Ki=1.8nM      // 5k13.pdf (6Q7) ligand is compound 2
5jg1  1.16  2016  Ki=1.9nM      // 5jfp.pdf (6KR) ligand is compound 15i
4zw6  1.90  2016  Ki=1.9uM      // 4zw3.pdf (4SY) compound 9q
4zyu  1.95  2016  Ki=1067nM     // 4zyt.pdf (3YA) [Nonstandard assay: Temp 37] Ki=1067+/-271nM, GARFTase / AGF50
4ujb  1.95  2016  Ki=10nM       // 4uj1.pdf (8BQ) compound 1b
5evb  1.84  2016  Ki=10uM       // 5ev8.pdf (3R9) compound 1b (D-CS319)
5evd  1.80  2016  Ki=10uM       // 5ev8.pdf (VC2) compound 2b (D-VC26)
5f5b  2.30  2016  Ki=113uM      // 5f5b.pdf (5-mer) Ac-VRMA-CHO; +/-4
4uff  1.55  2016  Ki=11nM       // 4ufd.pdf (6V2) compound 3
4yv8  2.00  2016  Ki=11nM       // 4yv8.pdf (5-mer) [Covalent complex] ligand is 5-mer covalent inhibitor lichostatinal
5e28  1.30  2016  Ki=12.3nM     // 5e28.pdf (BC5) compound 4h
5jy3  2.40  2016  Ki=12nM       // 5jy3.pdf (6OX) ligand is compound 15 (BMS-852927)
5drq  1.63  2016  Ki=12pM       // 5dro.pdf (5EM) ligand is LPC-040
5evk  1.63  2016  Ki=12uM       // 5ev8.pdf (3C7) compound 1a (L-CS319)
5j5r  1.60  2016  Ki=130nM      // 5j5r.pdf (6G1) inhibitor VCC234718
5jf2  2.00  2016  Ki=13nM       // 5jez.pdf (SF7) ligand is AT002
5kyj  2.80  2016  Ki=13nM       // 5kya.pdf (6Y8) [Different protein in assay: assay use only LXRbeta] ligand is compound 14
5j7w  2.50  2016  Ki=13uM       // 4o7u.pdf (MTX) ligand is methotrexate
5f1v  2.20  2016  Ki=140nM      // 5f1u.pdf (3VN) potent allosteric inhibitor bislysine
5dhp  2.27  2016  Ki=140uM      // 5dhp.pdf (5AQ) compound 12a
5jf8  1.80  2016  Ki=1428nM     // 5jez.pdf (PN3) ligand is inhibitor RAS358 (21)
5elw  1.40  2016  Ki=14nM       // 5dnl.pdf (5LD) ligand is (R)-C348
5hi7  2.15  2016  Ki=14nM       // 5hi7.pdf (62X) ligand is GSK2807
5k51  2.96  2016  Ki=15.8uM     // 5jsq.pdf (6QD) ligand is compound 6
5hdv  1.71  2016  Ki=15nM       // 5hd0.pdf (60V) compound 11
5ayf  2.01  2016  Ki=15uM       // 5ayf.pdf (C7H) ligand is cyproheptadine
5ewa  2.30  2016  Ki=15uM       // 5ev8.pdf (9BZ) compound 2a (L-VC26)
5j9z  2.50  2016  Ki=16nM       // 5j9y.pdf (6HJ) [Different protein in assay: Protein in binding assay is mutant T790M / L858R] ligand is compound 1a
5l7g  2.01  2016  Ki=16nM       // 5l7e.pdf (6QE) ligand is compound 25d; pKi=7.8, pIC50=6.3
4ycn  3.50  2016  Ki=17nM       // 4ycm.pdf (7BL) BLLB; coupled enzyme assay
4zyt  1.70  2016  Ki=17nM       // 4zyt.pdf (3Y9) [Nonstandard assay: Temp 37] Ki=17+/-3nM, GARFTase / AGF23
5kxi  3.94  2016  Ki=18.2nM     // 5kxi.pdf (NCT) ligand is nicotine.
5fdi  1.85  2016  Ki=18.5nM     // 5fdc.pdf (5WM) compound 4
5iu8  2.00  2016  Ki=18nM       // 5iu4.pdf (6DZ) ligand is compound 12f
5j41  1.19  2016  Ki=199uM      // 5j41.pdf (2-mer) ligand is 3LF-GSH, hydrolyzed Piperlongumine (hPL)
4ycm  3.20  2016  Ki=19nM       // 4ycm.pdf (7BS) BLS; coupled enzyme assay
4zw7  1.95  2016  Ki=19uM       // 4zw3.pdf (4SZ) pfa-m1;compound 9m
5dxh  3.00  2016  Ki=1nM        // 5dxh.pdf (5H2) compound 5
5ef7  1.90  2016  Ki=1nM        // 5edu.pdf (5OJ) ligand is HPOB
5hdu  1.58  2016  Ki=1nM        // 5hd0.pdf (60W) compound 8
5dht  2.59  2016  Ki=1uM        // 5dhp.pdf (5A9) compound 11c
5cj6  2.07  2016  Ki=2.03nM     // 5cj6.pdf (51Y) compound 6
5sz2  1.63  2016  Ki=2.0nM      // 5sz0.pdf (72G) ligand is compound 4e
5edu  2.79  2016  Ki=2.2nM      // 5edu.pdf (TSN) ligand is trichostatin A(TSA)
5hu1  1.50  2016  Ki=2.2nM      // 5htz.pdf (66F) compound 3
5ehn  2.60  2016  Ki=2.3pM      // 5ehn.pdf (5NZ) ligand is syn-TZ2PA5
5foo  2.10  2016  Ki=2.4mM      // 5foo.pdf (JAZ) ligand is 6-phospho-cyclophellitol
5htz  1.95  2016  Ki=2.4nM      // 5htz.pdf (66J) compound 9
5sz3  1.69  2016  Ki=2.5nM      // 5sz0.pdf (72H) ligand is compound 4p
5hk2  3.20  2016  Ki=2.6nM      // 5hk1.pdf (61V) ligand is 4-IBP
5d75  1.83  2016  Ki=200nM      // 5d75.pdf (FK5) ligand is FK506
5he4  1.53  2016  Ki=20nM       // 5hd0.pdf (60T) compound 23
5sz5  1.27  2016  Ki=20nM       // 5sz0.pdf (72E) ligand is compound 4b
5jsq  1.50  2016  Ki=21.3uM     // 5jsq.pdf (6MS) ligand is compound 3
5eg4  1.32  2016  Ki=21nM       // 5eg4.pdf (5N7) compound 31
5dex  2.40  2016  Ki=22.6nM     // 5dex.pdf (5E0) ligand is FRA-19
4zyv  2.05  2016  Ki=22nM       // 4zyt.pdf (G71) [Nonstandard assay: Temp 37] Ki=22+/-3nM, GARFTase / AGF71
5dfp  2.20  2016  Ki=22nM       // 5dey.pdf (59U) compound 1 (FRAX1036)
5kz0  2.30  2016  Ki=22nM       // 5kz0.pdf (6YL) ligand is compound 6f
5fkj  3.13  2016  Ki=22pM       // 5fkj.pdf (G0W) ligand is C-547
5el9  1.10  2016  Ki=23.0nM     // 5dnl.pdf (5DL) ligand is (S)-C348
5eie  2.10  2016  Ki=23nM       // 5ehn.pdf (TZ2) ligand is TZ2
5exn  1.49  2016  Ki=23nM       // 5exl.pdf (5SU) ligand is compound (S)-24
5dhr  2.31  2016  Ki=23uM       // 5dhp.pdf (5AJ) compound 11o
5j7q  2.05  2016  Ki=26.6uM     // 5j7p.pdf (6H2) ligand is compound 14
5dro  2.01  2016  Ki=26pM       // 5dro.pdf (ZH2) [Different protein in assay: C181A] ligand is LPC-011
5sym  1.55  2016  Ki=280nM      // 5sym.pdf (71Q) ligand is ML348
4uj9  1.87  2016  Ki=2nM        // 4uj1.pdf (S3N) compound 1l
5hcv  2.50  2016  Ki=2nM        // 5hcv.pdf (60R) compound 21
5hg5  1.52  2016  Ki=2nM        // 5hg5.pdf (633) [Covalent complex] compound 10; Ki estimated
5dhq  2.29  2016  Ki=2uM        // 5dhp.pdf (5AK) compound 12c
5ij7  2.62  2016  Ki=3.10nM     // 5ij7.pdf (6BN) inhibitor 1
5fl1  1.95  2016  Ki=3.2nM      // 5fl1.pdf (DV1) [Different protein in assay: binding data for hOGA protein] compound 11b
5kr2  1.78  2016  Ki=3.3nM      // 5kqx.pdf (ROC) ligand is SQV
5drr  1.59  2016  Ki=3.5pM      // 5dro.pdf (5EN) ligand is LPC-058
5kqx  2.40  2016  Ki=3.6nM      // 5kqx.pdf (ROC) ligand is SQV
5dey  2.10  2016  Ki=3.7nM      // 5dey.pdf (59T) compound 12 (G-5555)
5exl  2.30  2016  Ki=3.7nM      // 5exl.pdf (5SS) ligand is compound (S)-10
4uj1  1.77  2016  Ki=300nM      // 4uj1.pdf (NVX) compound 1c
5he5  1.55  2016  Ki=336nM      // 5hd0.pdf (60S) compound 17
5ehq  2.50  2016  Ki=33pM       // 5ehn.pdf (5O2) ligand is anti-TZ2PA5
5fdc  1.75  2016  Ki=34.8nM     // 5fdc.pdf (5WN) compound 1
5efj  1.73  2016  Ki=350nM      // 5edu.pdf (4-mer) ligand is HC toxin, a peptide-like inhibitor
5fl0  1.95  2016  Ki=350nM      // 5fl0.pdf (71I) [Different protein in assay: binding data for hOGA protein] compound 15e
5hg9  2.15  2016  Ki=35nM       // 5hg5.pdf (63A) [Covalent complex] compound 14; Ki estimated
5fdo  2.80  2016  Ki=361nM      // 5fc4.pdf (5X2) compound 49
4zw5  1.80  2016  Ki=37uM       // 4zw3.pdf (4SA) pfa-m1; compoud 9f
5jf3  1.60  2016  Ki=38nM       // 5jez.pdf (SF5) ligand is AT018
5hg8  1.42  2016  Ki=3nM        // 5hg5.pdf (634) [Covalent complex] compound 12; Ki estimated
5i4v  2.61  2016  Ki=3nM        // 5i4v.pdf (67S) [Different protein in assay: assay for ligand binding domain of human LXR Beta] ligand is compound 17
5hcx  2.60  2016  Ki=4.1nM      // 5hcx.pdf (60B) compound 7
5efb  2.54  2016  Ki=4.3nM      // 5edu.pdf (5OK) ligand is Oxamflatin
5hk1  2.51  2016  Ki=4.3nM      // 5hk1.pdf (61W) ligand is PD144418
5cdh  2.00  2016  Ki=4.3uM      // 5cdh.pdf (TLA) [Nonstandard assay: Temp 37 C and pH 5.5 with 6.4 pmoles of enzyme] competitive inhibition, L(+)-tartrate as the inhibitor and pNPP as the substrate
5ime  2.22  2016  Ki=4.6nM      // 5ime.pdf (6BZ) ligand is compound 9
5fky  1.80  2016  Ki=4.7nM      // 5fky.pdf (2J4) [Nonstandard assay: Temp 37] ligand is compound 11a
5eef  2.15  2016  Ki=4.8nM      // 5edu.pdf (TSN) ligand is trichostatin A(TSA)
5g53  3.40  2016  Ki=430nM      // 5g53.pdf (NEC) ligand is agonist NECA; assay at 100mM NaCl
5dqc  2.47  2016  Ki=45.6nM     // 5dqc.pdf (5E7) compound 2
5hdz  1.49  2016  Ki=45nM       // 5hd0.pdf (954) compound 16
5eij  1.99  2016  Ki=4860nM     // 5eij.pdf (5OT) ligand is compound 3
5hdx  1.60  2016  Ki=48nM       // 5hd0.pdf (60U) compound 15
5dxu  2.64  2016  Ki=4nM        // 5dxh.pdf (5H5) compound 4
5hd0  1.65  2016  Ki=4nM        // 5hd0.pdf (60Y) compound 6
5hg7  1.85  2016  Ki=4nM        // 5hg5.pdf (630) [Covalent complex] compound 1; Ki estimated
5j8z  1.70  2016  Ki=5.0nM      // 5j8z.pdf (FC4) ligand is racemic compound D; ligand codes are FC4 and 6KE
5kzq  2.80  2016  Ki=5.3nM      // 5kzq.pdf (6YS) ligand is compound 19f
4zx6  2.05  2016  Ki=5.4uM      // 4zw3.pdf (4U6) compound 10s
5l7h  1.84  2016  Ki=50nM       // 5l7e.pdf (6QG) ligand is compound 44; pKi=7.3, pIC50=6.6
5j4n  2.59  2016  Ki=56uM       // 5j4n.pdf (AG2) ligand is agmatine
5kap  2.95  2016  Ki=58.6uM     // 5jsq.pdf (6RH) ligand is compound 5
5dh4  2.20  2016  Ki=58nM       // 5dh4.pdf (5AV) compound 6
5j9y  2.80  2016  Ki=58nM       // 5j9y.pdf (6HL) [Different protein in assay: Protein in binding assay is mutant T790M / L858R] ligand is compound 1b
5hu0  1.83  2016  Ki=595nM      // 5htz.pdf (66H) ligand is compound (R)-13
5j9f  2.10  2016  Ki=59nM       // 5izq.pdf (83A) ligand is compound 4
5he7  1.71  2016  Ki=5nM        // 5hd0.pdf (60X) compound 9
5kdr  2.60  2016  Ki=5nM        // 5kdr.pdf (YT5) ligand is moiramide B
5khm  1.48  2016  Ki=5nM        // 5khm.pdf (XNH) ligand is compound 13; pKi=8.3
5fto  2.22  2016  Ki=6.2nM      // 5fto.pdf (YMX) compound 2, Entrectinib; Ki calculated from IC50
5exm  2.09  2016  Ki=6.3nM      // 5exl.pdf (5ST) ligand is compound (S)-17
5f91  2.00  2016  Ki=6.3uM      // 5f91.pdf (5WJ) compound 7
5aa9  1.93  2016  Ki=6.4nM      // 5a9u.pdf (5P8) ligand is loratinib
5jf6  1.70  2016  Ki=62nM       // 5jez.pdf (BB4) ligand is inhibitor 6b (AB47)
5jf5  1.80  2016  Ki=63nM       // 5jez.pdf (7JT) ligand is AT020
5fcz  2.45  2016  Ki=63uM       // 5fcz.pdf (TNX) ligand is NTA-glucal
5jf1  2.00  2016  Ki=64nM       // 5jez.pdf (BB2) ligand is actinonin
5jf4  2.40  2016  Ki=65nM       // 5jez.pdf (6JT) ligand is AT019
5etj  2.30  2016  Ki=66pM       // 5etj.pdf (IM5) ligand is DADMe-ImmG; inhibition assay, should be Ki data, not Kd data
5m1z  2.00  2016  Ki=66uM       // 5m1z.pdf (2-mer) [Nonstandard assay: Temp 40] +/-4, comp.2
4zyz  1.60  2016  Ki=67nM       // 4zyt.pdf (3YD) [Nonstandard assay: Temp 37] Ki=67+/-10nM, GARFTase / AGF145
4zyw  2.05  2016  Ki=68nM       // 4zyt.pdf (G94) [Nonstandard assay: Temp 37] Ki=68+/-11nM, GARFTase / AGF94
5kya  2.60  2016  Ki=6nM        // 5kya.pdf (6Y4) [Different protein in assay: assay use only LXRbeta] ligand is compound 7
5dhs  2.62  2016  Ki=6uM        // 5dhp.pdf (5AG) compound 11j
5ev8  2.30  2016  Ki=6uM        // 5ev8.pdf (3R9) compound 1b (D-CS319)
4ydf  2.80  2016  Ki=7.9uM      // 4ydf.pdf (4B1) compound 9
5kam  2.48  2016  Ki=77.3uM     // 5jsq.pdf (IMP) ligand is compound IMP
4ufe  1.59  2016  Ki=7nM        // 4ufd.pdf (3ZD) compound 2
4ufg  1.65  2016  Ki=7nM        // 4ufd.pdf (D6J) compound 4
4zyx  1.65  2016  Ki=7nM        // 4zyt.pdf (3YB) [Nonstandard assay: Temp 37] Ki=7+/-1nM, GARFTase / AGF117
5jxq  1.20  2016  Ki=7nM        // 5jxq.pdf (6OK) ligand is compound 6b
5fhm  1.55  2016  Ki=8.15uM     // 5fhm.pdf (5XP) compound 6
5jfu  1.70  2016  Ki=8.5nM      // 5jfp.pdf (6KQ) ligand is compound 15h
5aa8  1.86  2016  Ki=8.6nM      // 5a9u.pdf (5P8) ligand is lorlatinib
5efh  2.16  2016  Ki=800nM      // 5edu.pdf (FKS) ligand is trifluoroketone inhibitor
4uj2  2.02  2016  Ki=80nM       // 4uj1.pdf (NVV) compound 1e
5a6h  1.57  2016  Ki=88.0nM     // 5a6h.pdf (OE2) ligand is Psammaplin C (NP-6)
5e2k  1.40  2016  Ki=9.3nM      // 5e28.pdf (BX4) compound 4g
5jf7  2.10  2016  Ki=909nM      // 5jez.pdf (6JU) ligand is inhibitor SMP289
4zz0  1.65  2016  Ki=99nM       // 4zyt.pdf (3YE) [Nonstandard assay: Temp 37] Ki=99+/-13nM, GARFTase / AGF147
5sz6  1.15  2016  Ki=99nM       // 5sz0.pdf (72G) ligand is compound 4e
4zyy  1.85  2016  Ki=9nM        // 4zyt.pdf (3YC) [Nonstandard assay: Temp 37] Ki=9+/-1nM, GARFTase / AGF118
5d4a  1.70  2016  Ki>1.4uM      // 5d45.pdf (57Q) compound 4
5ls6  3.47  2017  IC50<0.001uM  // 5ls6.pdf (74D) [Nonstandard assay: PH 8.5] Human PRC2 complex with compound 10
5uac  3.80  2017  IC50<0.005uM  // 5uac.pdf (RFP) ligand is Rifampin
5mmn  1.90  2017  IC50<0.2uM    // 5mmn.pdf (O54) [Different protein in assay: Protein in bingding assay is gyrase] ATPase inhibition assay, comp.27
5nhf  2.14  2017  IC50<0.32nM   // 5ngu.pdf (8X5) KM ATP, comp.8
5nhl  2.07  2017  IC50<0.3nM    // 5ngu.pdf (8XB) KM ATP, comp.17
5nho  2.24  2017  IC50<0.3nM    // 5ngu.pdf (8XN) KM ATP, comp.18
5nhh  1.94  2017  IC50<1.13nM   // 5ngu.pdf (8XH) KM ATP, comp.12
5tqu  2.60  2017  IC50<25nM     // 5tqu.pdf (I53) ligand is compound 1
5mw2  2.35  2017  IC50<3nM      // 5mw2.pdf (U52) ligand is BI-3802
5j58  2.80  2017  IC50<50nM     // 5j58.pdf (N56) ligand is compound 16
5j59  2.40  2017  IC50<50nM     // 5j58.pdf (N93) ligand is compound 31
5v49  2.30  2017  IC50<50nM     // 5v49.pdf (8WA) ligand is compound 13
6b8u  2.68  2017  IC50=0.0002uM  // 5mz3.pdf (8EN) ligand is compound 2
5tza  1.70  2017  IC50=0.001uM  // 5tz3.pdf (7OG) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 9.
6bfa  2.80  2017  IC50=0.001uM  // 6bfa.pdf (UW5) compound is 32 not the 33.
5nhv  2.00  2017  IC50=0.0028uM  // 5ngu.pdf (8QB) KM ATP, comp.23
5u00  1.41  2017  IC50=0.002uM  // 5tz3.pdf (7OV) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 34.
5vgo  1.62  2017  IC50=0.002uM  // 5vgo.pdf (9B1) ligand is G-744.
5nhj  2.12  2017  IC50=0.0054uM  // 5ngu.pdf (8XE) KM ATP, comp.14
5k76  2.74  2017  IC50=0.005uM  // 5k72.pdf (6R1) 28
5xs2  2.04  2017  IC50=0.005uM  // 5xqx.pdf (8D6) compound 17
6b4w  2.90  2017  IC50=0.005uM  // 6b4w.pdf (CQ7)  23 bound in the TTK ATP pocket,
6b8j  2.60  2017  IC50=0.005uM  // 6b8j.pdf (65C)  GSK3:compound 1
6bfd  1.62  2017  IC50=0.005uM  // 6bfd.pdf (DJS) 5b;+/-0.0003
5nob  1.85  2017  IC50=0.0063uM  // 5nob.pdf (92T) comp.16
5nb7  1.33  2017  IC50=0.006uM  // 5nar.pdf (8NQ) comp.2
5q0m  2.20  2017  IC50=0.0079uM  // 5q0i.pdf (9L1) comp.34
5q1c  2.30  2017  IC50=0.0084uM  // 5q0i.pdf (9NA) comp.31
5q0n  2.40  2017  IC50=0.0087uM  // 5q0i.pdf (9L4) comp.27
5q15  1.90  2017  IC50=0.0089uM  // 5q0i.pdf (9MP) comp.22
5tzc  2.36  2017  IC50=0.008uM  // 5tz3.pdf (7OJ) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 27.
5w5o  2.89  2017  IC50=0.008uM  // 5w5j.pdf (9XA) 7F
5wg3  2.90  2017  IC50=0.008uM  // 5wg3.pdf (AFM) CCG258748
5q1a  2.00  2017  IC50=0.0096uM  // 5q0i.pdf (9N4) comp.14
5trs  3.08  2017  IC50=0.010uM  // 5tho.pdf (7HZ) IC50=0.010+/-0.002uM, ligand is PKS2144.
5o83  2.90  2017  IC50=0.011uM  // 5o83.pdf (9NQ) comp.3h (CDZ173/leniolisib)
5q16  2.00  2017  IC50=0.0135uM  // 5q0i.pdf (9MS) comp.20
5tzz  1.60  2017  IC50=0.014uM  // 5tz3.pdf (7OJ) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 33.
5trg  2.80  2017  IC50=0.015uM  // 5tho.pdf (7HJ) ligand is DPLG-2.
5try  3.00  2017  IC50=0.016uM  // 5tho.pdf (7J0) IC50=0.016+/-0.001uM, ligand is PKS2206.
5ts0  2.85  2017  IC50=0.016uM  // 5tho.pdf (7J1) IC50=0.016+/-0.002uM, ligand is PKS2208.
5tx5  2.56  2017  IC50=0.016uM  // 5tx5.pdf (7MJ) [Different protein in assay: protein in crystal is C34A, C127A, C233A, and C240A mutant.] ligand is compound 5.
5tys  2.01  2017  IC50=0.019nM  // 5tyr.pdf (7OA) IC50=0.019+/-0.017nM, ligand is GRL-142
5ngb  2.90  2017  IC50=0.019uM  // 5ngb.pdf (8WH) +/-0.004, comp.37
5q0v  1.87  2017  IC50=0.0205uM  // 5q0i.pdf (9LS) comp.24
5q14  1.85  2017  IC50=0.021uM  // 5q0i.pdf (9MM) comp.28
5lgu  3.20  2017  IC50=0.022uM  // 5lgt.pdf (6W1) ligand is compound 34
5nhp  1.99  2017  IC50=0.023uM  // 5ngu.pdf (8XK) KM ATP, comp.22
5tho  3.00  2017  IC50=0.023uM  // 5tho.pdf (7C7) IC50=0.023+/-0.002uM, ligand is PKS2205.
5q0o  1.90  2017  IC50=0.0244uM  // 5q0i.pdf (9L7) comp.13
5uoy  1.82  2017  IC50=0.027uM  // 5uoy.pdf (8HM) ligand is compound 16j.
5v88  1.60  2017  IC50=0.028uM  // 5v83.pdf (8ZD) IC50=0.028+/-0.003uM, ligand is NAcM-COV
5ox6  1.99  2017  IC50=0.029uM  // 5ox6.pdf (A1Z) ligand is vadadustat
5v1b  2.49  2017  IC50=0.034uM  // 5v18.pdf (8UY) ligand is compound 17.
5ngu  2.74  2017  IC50=0.036uM  // 5ngu.pdf (8X2) KM ATP, comp.4
5ohj  1.60  2017  IC50=0.0378nM  // 5ohj.pdf (9VE) [Different protein in assay: PDE4] +-0.022, (S*,S**)-18e, cell-free
5lmk  2.40  2017  IC50=0.037uM  // 5lmk.pdf (6ZK) ligand is compound 1l
5lyx  1.90  2017  IC50=0.038uM  // 5lyw.pdf (7BF) +/-0.001, comp.27
5q0p  1.80  2017  IC50=0.039uM  // 5q0i.pdf (9LA) comp.29
5mmp  2.05  2017  IC50=0.03uM   // 5mmn.pdf (G3Z) [Different protein in assay: Protein in bingding assay is gyrase] Supercoiling inhibition assay., comp.36
5ukm  3.03  2017  IC50=0.03uM   // 5ukk.pdf (T0E) IC50=0.03+/-0.001uM, ligand is 14as.
5pzn  2.25  2017  IC50=0.041uM  // 5pzk.pdf (8XP) comp.18
5trr  3.10  2017  IC50=0.041uM  // 5tho.pdf (7HY) IC50=0.041+/-0.006uM, ligand is PKS2169.
5nev  2.97  2017  IC50=0.044uM  // 5lqf.pdf (72L) complex is CDK2-cyclin A/compound73
5q0x  2.26  2017  IC50=0.045uM  // 5q0i.pdf (643) comp.33
5q1b  2.30  2017  IC50=0.0487uM  // 5q0i.pdf (9N7) comp.36
5q19  1.98  2017  IC50=0.048uM  // 5q0i.pdf (9N1) comp.6
5tzx  1.90  2017  IC50=0.052uM  // 5tz3.pdf (7OY) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 32.
5n4s  1.20  2017  IC50=0.055uM  // 5n4s.pdf (R38) comp.3
5ggz  2.02  2017  IC50=0.056uM  // 5ggz.pdf (6TN) IC50=0.056+/-0.002uM, compound 50 bound to the active site of Hsp90
5j7g  1.85  2017  IC50=0.058uM  // 5j7f.pdf (6GG) [Different protein in assay: assay MDM2 1   ?25, x-ray MDM2 18   ?25] MDM2 18-125
5j7f  2.00  2017  IC50=0.058uM  // 5j7f.pdf (6GG) [Nonstandard assay: PH=8] MDM2 1-125; ligand is 19
5q0w  1.90  2017  IC50=0.058uM  // 5q0i.pdf (9LV) comp.12
5uwf  1.87  2017  IC50=0.059uM  // 5uoy.pdf (8Q7) ligand is compound 16d.
5naw  1.25  2017  IC50=0.05uM   // 5nar.pdf (8RZ) comp.13
5nba  1.87  2017  IC50=0.05uM   // 5nar.pdf (8S5) comp.14
5q0s  2.50  2017  IC50=0.062uM  // 5q0i.pdf (9LJ) comp.25
5wg5  3.10  2017  IC50=0.066uM  // 5wg3.pdf (ZSO) CCG224061
5q18  1.90  2017  IC50=0.0675uM  // 5q0i.pdf (9MY) comp.32
5t1u  1.78  2017  IC50=0.069uM  // 5t1u.pdf (P6U) [Nonstandard assay: Temp 37, pH=4.5] comp.6u
5q1f  2.30  2017  IC50=0.0725uM  // 5q0i.pdf (9NJ) comp.30
5t1w  2.96  2017  IC50=0.077uM  // 5t1u.pdf (74B) [Nonstandard assay: Temp 37, pH=4.5] comp.16
5v86  1.37  2017  IC50=0.079uM  // 5v83.pdf (8ZA) IC50=0.079+/-0.013uM, ligand is NAcM-OPT
5y3n  2.40  2017  IC50=0.079uM  // 5y3n.pdf (8MF) [Different protein in assay: Protein in binding assay is full-length] 12b
6bfx  1.99  2017  IC50=0.079uM  // 6bfd.pdf (DKJ) 29;+/-0.0004
5lgr  2.00  2017  IC50=0.0817uM  // 5lgp.pdf (12-mer) CARM1-Compound 5
5lgs  2.10  2017  IC50=0.0876uM  // 5lgp.pdf (9-mer) CARM1-Compound 6
5lgq  2.11  2017  IC50=0.0901uM  // 5lgp.pdf (11-mer) CARM1-Compound 4
5q13  1.90  2017  IC50=0.091uM  // 5q0i.pdf (9MD) comp.19
5lgp  2.04  2017  IC50=0.092uM  // 5lgp.pdf (13-mer) CARM1-Compound 3
5m5q  2.20  2017  IC50=0.09uM   // 5m5q.pdf (7K1) comp.4
6b3e  3.06  2017  IC50=0.103uM  // 6b3e.pdf (CJM) 5 in yellow bound to CDK12
5wg4  2.31  2017  IC50=0.10uM   // 5wg3.pdf (AFV) CCG257284
5ofx  1.75  2017  IC50=0.11mM   // 5odu.pdf (RAF) +/-0.01, Raffinose (25)
5gso  2.60  2017  IC50=0.11uM   // 5gso.pdf (5GI) [Nonstandard assay: Temp 30] WT EV71 3C-NK-1.8k
5l13  2.40  2017  IC50=0.11uM   // 5l13.pdf (6ZE) ALDH2 in complex with compound 2
5mhq  1.30  2017  IC50=0.11uM   // 5mhq.pdf (8QT) IC50 = 0.11 +/- 0.02; binding assay is CDK2/A; CDK2-CCT068127 complex
5q1e  1.85  2017  IC50=0.12uM   // 5q0i.pdf (9NG) comp.11
5y3o  2.70  2017  IC50=0.138uM  // 5y3n.pdf (8M9) [Different protein in assay: Protein in binding assay is full-length] 21
5l2m  1.70  2017  IC50=0.13uM   // 5l13.pdf (6ZY) ALDH1A1 in complex with 15
5x9p  1.86  2017  IC50=0.13uM   // 5x9o.pdf (80L) 5 bound to BCL6
5tz3  1.72  2017  IC50=0.14uM   // 5tz3.pdf (7OM) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 7.
5qc4  2.00  2017  IC50=0.15uM   // 3kwn.pdf (BC7) compound 36
5q0u  1.90  2017  IC50=0.175uM  // 5q0i.pdf (9LP) comp.35
5ngs  1.85  2017  IC50=0.17uM   // 5ngr.pdf (8WW) comp.1a
5v3y  1.98  2017  IC50=0.19uM   // 5v3w.pdf (5V8) IC50=0.19+/-0.01uM, ligand is TAM16.
5g0q  1.65  2017  IC50=0.1nM    // 5g0q.pdf (IF6) [Covalent complex] [Nonstandard assay: Temp 37] AcGH79(wt)-5 complex
5wo4  1.84  2017  IC50=0.1nM    // 5wo4.pdf (B7V)  28 in JAK1
5m0s  2.10  2017  IC50=0.202uM  // 5m0d.pdf (7CW) COM.5
5v84  2.70  2017  IC50=0.20uM   // 5v84.pdf (96V) ligand is compound 6.
5o11  2.40  2017  IC50=0.216uM  // 5o11.pdf (3NG) CX-4945
5t90  2.80  2017  IC50=0.21uM   // 5t90.pdf (18-mer) IC50=0.21+/-0.04uM, LsIA-LsAChBP complex
5mz3  2.15  2017  IC50=0.22uM   // 5mz3.pdf (8EN) comp.2
6bfw  1.84  2017  IC50=0.22uM   // 6bfd.pdf (DK7) 24;+/-0.011
5q0j  2.00  2017  IC50=0.239uM  // 5q0i.pdf (9KV) comp.7
5t37  1.76  2017  IC50=0.241uM  // 5t36.pdf (758) comp.4
5l6h  2.30  2017  IC50=0.24uM   // 5l6h.pdf (6O2) [Covalent complex] Uba1-Ub-ABPA3
5ugd  1.38  2017  IC50=0.24uM   // 5ugd.pdf (89S) IC50=0.24+/-0.004uM, ligand is YO-2
5v42  1.99  2017  IC50=0.24uM   // 5v3w.pdf (I66) IC50=0.24+/-0.02uM, ligand is TAM3.
5yjp  1.80  2017  IC50=0.24uM   // 5yjm.pdf (8W6) human chymase/O-ethylamidoxime 5b
5lqf  2.06  2017  IC50=0.25uM   // 5lqf.pdf (4SP) [Different protein in assay: crystal:CDK1-cyclinB-CKS2, binding assay:CDK1] complex is CDK1-cyclinB-CKS2/compound3
5tyr  1.80  2017  IC50=0.26nM   // 5tyr.pdf (7O7) IC50=0.26+/-0.05nM, ligand is GRL-121
5v3x  1.94  2017  IC50=0.26uM   // 5v3w.pdf (I28) IC50=0.26+/-0.03uM, ligand is TAM1.
5jz9  2.68  2017  IC50=0.27mM   // 5jz9.pdf (6OR) [Nonstandard assay: Temp 21] HsaD-27
5l15  2.40  2017  IC50=0.27nM   // 5l15.pdf (G39) NA/Ose
5b5p  1.60  2017  IC50=0.2nM    // 5b5o.pdf (WNN) [Nonstandard assay: Temp 37] ligand is compound 23
5uiu  2.02  2017  IC50=0.2nM    // 5uiq.pdf (8CG) ligand is compound 40.
5kcx  2.20  2017  IC50=0.2uM    // 5kcx.pdf (6S3) 24 PIM1
5l6j  2.68  2017  IC50=0.2uM    // 5l6h.pdf (61T) [Covalent complex] Uba1-Ub-MLN7243
5wys  3.00  2017  IC50=0.2uM    // 5wys.pdf (7V6) [Uncommon element] [Different ligand in assay: ligand in binding assay is Br] comp.3i PDB file is wrong, chemical formula is wrong
5uyu  1.90  2017  IC50=0.31nM   // 5uyu.pdf (8QV) ligand is compound 13
5lgt  3.00  2017  IC50=0.31uM   // 5lgt.pdf (6W3) ligand is compound 15
5h19  1.90  2017  IC50=0.32uM   // 5h13.pdf (LQF) [Nonstandard assay: pH 8] EED-EBD-EED162
5nsp  2.30  2017  IC50=0.34uM   // 5nob.pdf (97E) comp.14
5vfd  1.93  2017  IC50=0.36uM   // 5vfd.pdf (9CM) ligand is compound 3.
6eqs  1.32  2017  IC50=0.37uM   // 6enx.pdf (BV8) [Different protein in assay: ] hSIRT5/29;+/- 0.10
6eo0  2.40  2017  IC50=0.37uM   // 6enx.pdf (BVT) [Different protein in assay: protein in binding assay is human specis] zSIRT5/29;+/- 0.10
6ax1  2.26  2017  IC50=0.38nM   // 6ax1.pdf (C0S) 3
5mm9  1.55  2017  IC50=0.38uM   // 5mm9.pdf (8SH) comp.2b
5ugg  1.20  2017  IC50=0.38uM   // 5ugd.pdf (89M) IC50=0.38+/-0.010uM, ligand is PSI-112
5lp1  1.91  2017  IC50=0.398nM  // 5lp1.pdf (71H)
5wbz  2.40  2017  IC50=0.39uM   // 5wbm.pdf (A4J) Compound 12;hKHK-A IC50;
5wre  1.95  2017  IC50=0.39uM   // 5wre.pdf (7TL) [Different protein in assay: protein in binding assay is wild type] HAP_R01;
5jzb  2.10  2017  IC50=0.41mM   // 5jz9.pdf (6OT) [Nonstandard assay: Temp 21] HsaD-2
5vqz  2.23  2017  IC50=0.41uM   // 5vqq.pdf (9HY) [Covalent complex] K103N/Y181C:3;+/-0.07; 24h
5xqx  2.30  2017  IC50=0.41uM   // 5xqx.pdf (8CC) compound 4
5qbv  1.80  2017  IC50=0.43uM   // 3mpe.pdf (N2D) compound 12; Ki(human CatS); X-ray(CatS C25S)
5uqv  2.84  2017  IC50=0.43uM   // 5uqv.pdf (8JM) IC50=0.43+/-0.07uM, ligand is GNE-6640
5tuq  2.71  2017  IC50=0.45uM   // 5tuq.pdf (J63) [Different protein in assay: protein in crystal is C280S mutant.] IC50=0.45+/-0.07uM, pol assay. ligand is compound 4a.
5up0  2.04  2017  IC50=0.46uM   // 5uoy.pdf (8HP) ligand is compound 3.
5vqx  2.40  2017  IC50=0.48uM   // 5vqq.pdf (9HY) [Covalent complex] Y181C-3;+/-0.03; 24h
5ncy  1.90  2017  IC50=0.4nM    // 5ncy.pdf (8TK) [Different protein in assay: Protein in binding assay is recombinant human PI3Kd] comp.13
5tex  2.15  2017  IC50=0.4uM    // 5kcx.pdf (7AU) 23 PIM1
5vqv  2.58  2017  IC50=0.4uM    // 5vqq.pdf (9J1) [Covalent complex] Y181C-5;+/-0.04; 24h
5n3w  2.30  2017  IC50=0.50uM   // 5n3w.pdf (8KW) +/-0.04, comp.9 IC50: epoxide hydrolase
5nar  1.55  2017  IC50=0.50uM   // 5nar.pdf (8RW) comp.7
5nb6  1.75  2017  IC50=0.50uM   // 5nar.pdf (8S2) comp.18
6ayd  3.00  2017  IC50=0.50uM   // 5oy4.pdf (C2J) comp.1
5vp1  1.86  2017  IC50=0.51nM   // 5vp1.pdf (9GA) 20 Bound in the PDE2A
5vqy  2.35  2017  IC50=0.51uM   // 5vqq.pdf (9J1) [Covalent complex] K103N/Y181C:5;+/-0.05; 24h
5odu  1.56  2017  IC50=0.52mM   // 5odu.pdf (AMG) +/-0.07, Me-alpha-Gal (12)
5tyn  1.53  2017  IC50=0.52nM   // 5tyj.pdf (7NS) [Covalent complex] [Uncommon element] compound is 3
5jzs  2.27  2017  IC50=0.54mM   // 5jz9.pdf (FGZ) [Nonstandard assay: Temp 21] HsaD-32
5u9d  1.33  2017  IC50=0.55nM   // 5u9d.pdf (83P) ligand is compound 3
5q1i  1.95  2017  IC50=0.57uM   // 5q0i.pdf (9O1) comp.23
5mat  2.07  2017  IC50=0.58uM   // 5mat.pdf (7KJ) +/-0.02, comp.29c
6aud  2.02  2017  IC50=0.596uM  // 6aud.pdf (BWY) [Different protein in assay: Protein in binding assay is PI3Kgamma, crystal is PI3Kgamma_K802T mutant.] S-isomer 8
5l17  2.40  2017  IC50=0.5nM    // 5l15.pdf (ZMR) NA/Zan
5u7d  1.75  2017  IC50=0.5nM    // 5u7d.pdf (19F) ligand is compound 1.
5vp0  2.20  2017  IC50=0.61nM   // 5vp0.pdf (9GJ)  36 bound in the PDE2A
5ukk  2.60  2017  IC50=0.61uM   // 5ukk.pdf (8DJ) IC50=0.61+/-0.12uM, ligand is 14ak.
5uqx  2.23  2017  IC50=0.61uM   // 5uqv.pdf (8JP) IC50=0.61+/-0.15uM, ligand is GNE-6776
5gub  1.78  2017  IC50=0.635uM  // 5gub.pdf (2-mer) Smon0123/C delta 0S
5t2m  2.80  2017  IC50=0.63nM   // 5t23.pdf (74N) [Different protein in assay: Protein in binding assay is human] comp.7m
5ukl  2.15  2017  IC50=0.63uM   // 5ukk.pdf (SIX) IC50=0.63+/-0.33uM, ligand is 14bd.
5n1v  2.52  2017  IC50=0.64uM   // 5n1v.pdf (8GQ) comp.11
5tzh  1.60  2017  IC50=0.679uM  // 5tz3.pdf (7OP) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 30.
5usf  2.75  2017  IC50=0.69nM   // 5usf.pdf (YSA) ligand is TyrSA.
5ntw  1.64  2017  IC50=0.6nM    // 5nti.pdf (98N) comp.7
5nqe  2.71  2017  IC50=0.70uM   // 5nqe.pdf (94Z) comp.4s
5v41  2.05  2017  IC50=0.71uM   // 5v3w.pdf (J24) IC50=0.71+/-0.05uM, ligand is TAM5.
5t8e  2.71  2017  IC50=0.72nM   // 5t8e.pdf (77U) IC50=0.72+/-0.25nM, ligand is compound B.
5l2o  2.05  2017  IC50=0.76uM   // 5l13.pdf (6ZW) ALDH1A1 in complex with compound 32
5q1d  1.89  2017  IC50=0.76uM   // 5q0i.pdf (9ND) comp.21
5q0q  2.60  2017  IC50=0.785uM  // 5q0i.pdf (9LD) comp.17
5t2d  2.90  2017  IC50=0.794nM  // 5t23.pdf (74L) [Different protein in assay: Protein in binding assay is human] comp.7j
5urk  2.95  2017  IC50=0.79uM   // 5urj.pdf (8LP) [Different protein in assay: crystal:395-2129, binding assay:full-length] ligand is compound 6.
5vom  1.67  2017  IC50=0.79uM   // 5vom.pdf (9GY) 8;
5ntp  1.70  2017  IC50=0.7nM    // 5nti.pdf (98E) comp.5
5lub  2.10  2017  IC50=0.7uM    // 5lu8.pdf (3Y7) apo-AEP +compound 11
5lyw  1.69  2017  IC50=0.7uM    // 5lyw.pdf (7BH) +/-0.2, comp.16
5m0d  2.40  2017  IC50=0.814uM  // 5m0d.pdf (7C8) COM.11
5wuu  1.72  2017  IC50=0.81uM   // 5wuu.pdf (7UU) DCBD-005, +/- 0.03; Alpha screen assay
5yjk  2.40  2017  IC50=0.82uM   // 5y9l.pdf (8VX) compound 34 in the active site of human KLK7
6enx  1.95  2017  IC50=0.83uM   // 6enx.pdf (BJW) [Different protein in assay: protein in binding assay is human specis] zSIRT5/10;+/- 0.10
5vlp  2.90  2017  IC50=0.84uM   // 5vl7.pdf (17-mer) [Different protein in assay: crystal:PCSK9-P-CRD, binding assay:PCSK9-P] IC50=0.84+/-0.08uM, ligand is MESFPGWNLV(hR)IGLLR
5jv1  2.30  2017  IC50=0.86uM   // 5juz.pdf (YL6) ligand is compound 42
5h17  2.30  2017  IC50=0.89uM   // 5h13.pdf (LQE) [Nonstandard assay: pH 8] EED-EBD-EED210
5gmp  2.80  2017  IC50=0.8nM    // 5gmp.pdf (F62) [Different protein in assay: Protein in binding assay has another mutation, L858R] compound 8 binding with EGFRT790M
5ncz  1.94  2017  IC50=0.8nM    // 5ncy.pdf (8TN) [Different protein in assay: Protein in binding assay is recombinant human PI3Kd] comp.15c
5vfc  1.64  2017  IC50=0.90nM   // 5vfc.pdf (9BA) IC50=0.90+/-0.20nM, ligand is compound 18.
5kgn  1.95  2017  IC50=0.933nM  // 5kgn.pdf (13-mer) iPGM/Ce-2d
5tzw  1.59  2017  IC50=0.987uM  // 5tz3.pdf (7P4) [Different protein in assay: Protein in binding assay is full length PDE2a enzymes. Protein in crystal is residues 579 to 918.] ligand is compound 31.
5y1y  1.91  2017  IC50=0.98uM   // 5y1y.pdf (HNQ) BRD4_BD1 in complex with nitroxoline;+/- 0.04
5vo6  2.65  2017  IC50=0.9nM    // 5vo6.pdf (9J4) compund2/JAK3;
5tur  2.95  2017  IC50=0.9uM    // 5kcx.pdf (7LK) 4 PIM1
5ur1  2.20  2017  IC50=1.06nM   // 5ur1.pdf (YY9) [Covalent complex] ligand is compound 2l.
5n4t  1.16  2017  IC50=1.06uM   // 5n4s.pdf (R59) comp.4
5gsw  3.19  2017  IC50=1.15uM   // 5gso.pdf (5GI) [Nonstandard assay: Temp 30] N69S EV71 3C-NK-1.8k
5wr7  2.76  2017  IC50=1.1nM    // 5wr7.pdf (RCH) ligand is CH7057288,IC50=1.1+/-0.12nM
5jv0  2.40  2017  IC50=1.1uM    // 5juz.pdf (YL5) ligand is compound 38
5pzm  2.54  2017  IC50=1.1uM    // 5pzk.pdf (8XS) comp.8
5vqr  2.55  2017  IC50=1.2uM    // 5vqq.pdf (9KG) [Covalent complex] WT-5;+/-0.2; 24h
5v8v  2.60  2017  IC50=1.3nM    // 5v8v.pdf (90D) ligand is compound 3p
5vrp  3.22  2017  IC50=1.3nM    // 5v8v.pdf (9JD) ligand is compound 3n
5wfj  2.48  2017  IC50=1.3nM    // 5wfj.pdf (9Z4)  JAK3 kinase domain bound with compound 13a
5ngt  1.54  2017  IC50=1.3uM    // 5ngr.pdf (8WZ) comp.4b
5oxg  2.13  2017  IC50=1.3uM    // 5oxg.pdf (B4B) LDN-212854
5u5h  1.80  2017  IC50=1.3uM    // 5u5h.pdf (7VV) ligand is compound 19.
5u62  1.90  2017  IC50=1.3uM    // 5u5h.pdf (7WD) ligand is compound 16.
6bfe  1.51  2017  IC50=1.40uM   // 6bfd.pdf (DJV) 11;+/-0.144
5q0z  2.26  2017  IC50=1.42uM   // 5q0i.pdf (9M1) comp.5
5wbq  2.40  2017  IC50=1.47uM   // 5wbm.pdf (A3J) Compound 7
5ku9  2.20  2017  IC50=1.49uM   // 5ku9.pdf (6XJ) compound 1 bound to Mcl-1
5j9k  2.55  2017  IC50=1.4uM    // 5j9k.pdf (15-mer) [Different ligand in assay: assay: 11-mer]
5kv9  2.00  2017  IC50=1.4uM    // 5kv8.pdf (I57) [Nonstandard assay: Temp 37, pH=4.6] hPIV-3 HN in complex with inhibitors 5
5h15  2.27  2017  IC50=1.57uM   // 5h13.pdf (LQD) EED-EBD-EED709
5v40  1.99  2017  IC50=1.57uM   // 5v3w.pdf (JS1) IC50=1.57+/-0.15uM, ligand is TAM6.
5ta6  2.50  2017  IC50=1.5nM    // 5ta6.pdf (79D) ligand is compound 8.
5tob  2.12  2017  IC50=1.5nM    // 5tob.pdf (YAM) ligand is compound PF-562271.
5u3b  2.00  2017  IC50=1.5nM    // 5u39.pdf (7TD) ligand is compound 1(-)
5tbj  2.32  2017  IC50=1.5uM    // 5lv2.pdf (LHD) Table 3, IC50=1.5+/-0.5uM
5tg1  1.40  2017  IC50=1.5uM    // 5tg1.pdf (V56) [Covalent complex] ligand is compound 13.
5w5j  2.85  2017  IC50=1.5uM    // 5w5j.pdf (9WS) 1
5k32  1.99  2017  IC50=1.6nM    // 5k32.pdf (6Q2) ligand is compound 21
5vpm  2.90  2017  IC50=1.6nM    // 5v8v.pdf (9G7) ligand is compound 4e
5gx6  1.81  2017  IC50=1.6uM    // 5gub.pdf (2-mer) Smon0123/C delta 4S
5t23  2.78  2017  IC50=1.6uM    // 5t23.pdf (74F) comp.5d
5y5n  2.30  2017  IC50=1.74uM   // 5y5n.pdf (8NO) compound 6. +/- 0.26
5td7  2.85  2017  IC50=1.7uM    // 5td7.pdf (FKS) [Different protein in assay: crystal:zHDAC10 (Y307F), binding assay:zHDAC10] Ki=0.7+/-0.2uM, ligand is AAT.
5xaf  2.55  2017  IC50=1.7uM    // 5xaf.pdf (84F) [Nonstandard assay: Temp 37] 14c
5q0y  2.20  2017  IC50=1.87uM   // 5q0i.pdf (9LY) comp.26
5ni0  1.67  2017  IC50=1.8uM    // 5mm9.pdf (8XW) comp.10c
5vqt  2.56  2017  IC50=1.8uM    // 5vqq.pdf (9K7) [Covalent complex] WT-3;+/-0.2; 24h
5t2p  1.69  2017  IC50=1.9uM    // 5t2p.pdf (K89) [Different protein in assay: Protein in binding assay is WT] +/-0.22, SBA_R01
5y9l  2.15  2017  IC50=1.9uM    // 5y9l.pdf (8R3) compound 25 in the active site of human KLK7
5twl  2.42  2017  IC50=10.5nM   // 5twl.pdf (H91) complex is MELK(2-333)/HTH-01-091
5le1  1.40  2017  IC50=10.6uM   // 5lca.pdf (6UW) VIM-2 in complex with compound 16
5usq  2.55  2017  IC50=100nM    // 5usq.pdf (8LY) ligand is compound 32.
5gn5  2.85  2017  IC50=104nM    // 5gn5.pdf (6XZ) compound is 17, IC50=104+/-7nM
5vgi  2.07  2017  IC50=104nM    // 5vgi.pdf (9DJ) IC50=104+/-10nM, ligand is compound 6
5ul5  2.20  2017  IC50=106nM    // 5ul5.pdf (8D7) [Nonstandard assay: Temp 37] IC50=106+/-16nM, ligand is (R)-MB-004
5ml5  1.90  2017  IC50=10nM     // 5ml5.pdf (1VI) comp.11b
5w85  2.25  2017  IC50=10nM     // 5w84.pdf (9YS) 10  in IRAK4
5h13  1.90  2017  IC50=11.58uM  // 5h13.pdf (LQA) [Nonstandard assay: pH 8] EED-EED396
5h0g  1.80  2017  IC50=111nM    // 5h09.pdf (OOU) RK- 21252
5izc  1.92  2017  IC50=112uM    // 4wcf.pdf (6F4) compound 4c
5h0b  1.65  2017  IC50=11nM     // 5h09.pdf (OOQ) RK-21060
5wqa  2.30  2017  IC50=11nM     // 5wqa.pdf (J20)  selaginpulvilins K;
5ti7  1.65  2017  IC50=11uM     // 5ti2.pdf (7CQ) IC50=11+/-0.181uM, ligand is 8302.
5up3  2.95  2017  IC50=12.59nM  // 5uor.pdf (8GS) ligand is compound 6.
5gn6  2.50  2017  IC50=120nM    // 5gn5.pdf (6Y0) compound is 17b, IC50=120+/-8nM
5tq6  2.06  2017  IC50=123.6nM  // 5tq3.pdf (7GV) ligand is compound 3.
5mli  1.63  2017  IC50=125.9uM  // 5mkx.pdf (82I) pIC50 = 3.9 +/- 0.55, complex is BRD4 BD1/15
5lzj  1.20  2017  IC50=125uM    // 5lzg.pdf (7BT) comp.1
5ly2  2.43  2017  IC50=12nM     // 5ly1.pdf (14-mer) R6Kme
5gmi  2.71  2017  IC50=12uM     // 5gmi.pdf (19-mer) JAM-C
5mxv  1.63  2017  IC50=12uM     // 5mxv.pdf (K3T) comp.1
5x79  1.90  2017  IC50=12uM     // 5x79.pdf (GF5) [Covalent complex] 1 bound to GSTP1-1
5twz  2.63  2017  IC50=13.5nM   // 5twy.pdf (45R) Z'-LYTE assay
5myd  2.30  2017  IC50=13.9uM   // 5myd.pdf (DUP) dUPPNP
5kj0  1.51  2017  IC50=130nM    // 5kj0.pdf (6TB) ligand is compound 2;DB-1-264
5h09  1.95  2017  IC50=1323nM   // 5h09.pdf (OOO) RK-21058
5ne3  1.35  2017  IC50=14.36nM  // 5ne1.pdf (NXL) [Uncommon element] [Nonstandard assay: Temp 37] avibactam
5kv8  1.95  2017  IC50=14.5uM   // 5kv8.pdf (6Y6) [Nonstandard assay: Temp 37, pH=4.6] hPIV-3 HN in complex with inhibitors 6
6eks  1.87  2017  IC50=144uM    // 6eks.pdf (G39) [Nonstandard assay: Temp 37] oseltamivir carboxylate;+/-1
5uis  2.50  2017  IC50=146nM    // 5uiq.pdf (8C1) ligand is compound 14.
5tpg  1.50  2017  IC50=14nM     // 5l01.pdf (7H5) 17a bound to TPH1
5wej  1.95  2017  IC50=15.3uM   // 5wej.pdf (V45) [Nonstandard assay: TEMP 37;] NVPro/8B
5iaw  2.58  2017  IC50=15.44uM  // 5iaw.pdf (10-mer) FXR LBD bound to tschimgine with SRC2-3
5m6h  2.50  2017  IC50=150nM    // 5m6e.pdf (7J6) comp.9
5tyl  1.75  2017  IC50=15nM     // 5tyj.pdf (7N7) compound is 4
5wbr  2.58  2017  IC50=16.79uM  // 5wbm.pdf (A3Y) Compound 8
5t92  2.22  2017  IC50=16nM     // 5t92.pdf (77W) ligand is compound 9.
5lcf  1.86  2017  IC50=17.8uM   // 5lca.pdf (6TJ) VIM-2 in complex with 30
5t97  3.00  2017  IC50=17nM     // 5t92.pdf (782) ligand is compound 40.
5mw6  1.65  2017  IC50=18648nM  // 5mw2.pdf (RC0) comp.1
5ulg  2.10  2017  IC50=189nM    // 5ul5.pdf (8E4) [Nonstandard assay: Temp 37] IC50=189+/-31nM, ligand is MB-008
5uuu  2.70  2017  IC50=18nM     // 5uuu.pdf (QRW) ligand is compound 115h.
5gty  3.14  2017  IC50=19.01nM  // 5gty.pdf (816) CHMFL-EGFR-26 in complex with EGFR T790M protein
5lx6  1.25  2017  IC50=1900nM   // 4r5w.pdf (78P) complex is PARP10/veliparib
5b5o  1.20  2017  IC50=1900nM   // 5b5o.pdf (WMM) [Nonstandard assay: Temp 37] ligand is compound 2
5mwd  1.85  2017  IC50=1918nM   // 5mw2.pdf (TJ3) comp.2
5u2f  2.53  2017  IC50=193nM    // 5u28.pdf (82Y) ligand is SF2558HA.
5nu1  1.85  2017  IC50=1nM      // 5nti.pdf (8YB) comp.8
5tl9  1.20  2017  IC50=1nM      // 5t36.pdf (7DN) comp.16
5t8j  2.70  2017  IC50=1nM      // 5t8e.pdf (77T) IC50=1+/-0.3nM, ligand is compound 1c.
5inh  1.84  2017  IC50=1uM      // 5inh.pdf (6C1) [Uncommon element] [Nonstandard assay: PH=8] [Different protein in assay: Protein in binding assay is human] mouse ATX. Crystal structure of 16
5t2i  2.30  2017  IC50=2.0nM    // 5t23.pdf (74J) [Different protein in assay: Protein in binding assay is human] comp.7k
5tw3  2.85  2017  IC50=2.0nM    // 5tw3.pdf (7N1) IC50=2.0+/-0.4nM, ligand is compound 2.
5vqs  2.50  2017  IC50=2.0uM    // 5vqq.pdf (9KD) [Covalent complex] WT-4;+/-0.3; 24h
5vqw  2.50  2017  IC50=2.0uM    // 5vqq.pdf (9KD) [Covalent complex] Y181C-4;+/-0.4; 24h
5td2  2.68  2017  IC50=2.2nM    // 5tc0.pdf (7AE) [Different protein in assay: Protein in binding assay is Axl. Protein in crystal is Mer(I650M).] ligand is compound 21.
5tq3  2.69  2017  IC50=2.2nM    // 5tq3.pdf (7GZ) ligand is compound 5.
5ov9  2.40  2017  IC50=2.2uM    // 5ov9.pdf (CVI) crystal violet
5t2y  1.94  2017  IC50=2.2uM    // 5t2y.pdf (753) +/-0.4, comp.17
5nhy  1.72  2017  IC50=2.3nM    // 5nhy.pdf (8XT) +/-0.8, BAY-707
5ubt  2.83  2017  IC50=2.4nM    // 5ubr.pdf (85S) ligand is compound 9.
5toe  2.30  2017  IC50=2.5uM    // 5kcx.pdf (7GK) 3 PIM1
5lhg  3.34  2017  IC50=2.5uM    // 5lgt.pdf (6X3) ligand is compound 17
5ox5  2.25  2017  IC50=2.6uM    // 5ox5.pdf (B2E) CCT6
5gx7  1.99  2017  IC50=2.76uM   // 5gub.pdf (2-mer) Smon0123/C delta 6S
5l2n  1.70  2017  IC50=2.8uM    // 5l13.pdf (6ZU) ALDH1A1 in complex with 34
5lgn  3.20  2017  IC50=2.9uM    // 5lgn.pdf (6W0) ligand is compound 19
5lch  1.94  2017  IC50=20.3uM   // 5lca.pdf (6TU) [Different ligand in assay: Ligand in binding assay is racemic.] VIM-2 in complex with 42
5xmv  2.16  2017  IC50=20.9nM   // 5xmp.pdf (8AU) [Different protein in assay: source of protein in binding assay is  Arabidopsis thaliana ] [Different ligand in assay: lligand in binding assay is racemates] (+)-5
5h6v  2.42  2017  IC50=208nM    // 5h6v.pdf (7HS) ligand is compound 1
5mkx  1.68  2017  IC50=20uM     // 5mkx.pdf (82I) pIC50 = 4.7 +/- 0.1, complex is PCAF/15
5mkz  1.62  2017  IC50=20uM     // 5mkx.pdf (RNK) pIC50 = 4.7 +/-0= 0.27, complex is BDR4 BD1/12
5sxk  3.55  2017  IC50=20uM     // 5sw8.pdf (71K) +/-4, frag.18
5tq7  2.10  2017  IC50=21.2nM   // 5tq3.pdf (7GT) ligand is compound 4.
5h0e  2.10  2017  IC50=210nM    // 5h09.pdf (OOS) RK-21107
5u6v  1.78  2017  IC50=21nM     // 5u6v.pdf (7WY) ligand is compound 20, AlphaScreen Assay
5op6  2.45  2017  IC50=21uM     // 5op6.pdf (A0W) GSK128863
5ti6  1.70  2017  IC50=21uM     // 5ti2.pdf (7CO) IC50=21+/-0.254uM, ligand is 8236.
5tyk  1.65  2017  IC50=22.4nM   // 5tyj.pdf (7N4) [Covalent complex] [Uncommon element] compound is 5
5m6f  2.39  2017  IC50=220nM    // 5m6e.pdf (7HU) comp.7
5mja  2.14  2017  IC50=220nM    // 5mja.pdf (7O3) [Covalent complex] +/-18, EphB1/comp.1
5n9t  1.73  2017  IC50=220nM    // 5n9r.pdf (8QQ) comp.5
5lhu  2.02  2017  IC50=22uM     // 5lht.pdf (HIS) L-His-bound ATP-PRT
5myr  1.83  2017  IC50=22uM     // 5mxv.pdf (UDY) comp.6
5tq8  1.59  2017  IC50=23.1nM   // 5tq3.pdf (7GS) ligand is compound 2
5vex  3.00  2017  IC50=23.44uM  // 5vew.pdf (97V) ligand is NNC0640
5u2c  3.30  2017  IC50=235nM    // 5u28.pdf (82Y) ligand is SF2558HA
5xmr  2.55  2017  IC50=24.5nM   // 5xmp.pdf (8AO) [Different protein in assay: source of protein in binding assay is  Arabidopsis thaliana ] [Different ligand in assay: lligand in binding assay is racemates] (+)-20;
5mw3  2.09  2017  IC50=240nM    // 5mvs.pdf (5JT) ligand is compound 2
5k5c  1.85  2017  IC50=24mM     // 5jij.pdf (TRE) trehalose
5xkm  2.16  2017  IC50=24nM     // 5xkm.pdf (87R) 38a bound in the PDE2A
5m39  1.38  2017  IC50=24uM     // 5m39.pdf (7EA) comp.1
5ngr  2.20  2017  IC50=24uM     // 5ngr.pdf (8WT) comp.2
5ti2  1.65  2017  IC50=24uM     // 5ti2.pdf (7CJ) IC50=24+/-0.322uM, ligand is 8110.
5tc0  2.24  2017  IC50=25nM     // 5tc0.pdf (79Y) [Different protein in assay: Protein in binding assay is Axl. Protein in crystal is Mer(I650M).] ligand is compound 19.
5typ  1.88  2017  IC50=25nM     // 5tyj.pdf (7NJ) [Covalent complex] [Uncommon element] compound is 1
5xmt  2.55  2017  IC50=26.2nM   // 5xmp.pdf (8B0) [Different protein in assay: source of protein in binding assay is  Arabidopsis thaliana ] [Different ligand in assay: lligand in binding assay is racemates]  (+)-7
5q1g  2.00  2017  IC50=263uM    // 5q0i.pdf (9NM) comp.3
5ual  3.89  2017  IC50=263uM    // 5uac.pdf (RFP) ligand is Rifampin
5swh  2.50  2017  IC50=26nM     // 5swh.pdf (71D) [Different protein in assay: crystal: SrcCD V284C, assay: Src3D V284C] IC50(Src3D V284C)=26+/-2nM
5ti4  1.62  2017  IC50=26uM     // 5ti2.pdf (7CM) IC50=26+/-0.202uM, ligand is 8200.
5wpb  1.55  2017  IC50=270uM    // 5wpb.pdf (B8P) IC50(FP,11a)=270+/-80uM
5u2e  1.99  2017  IC50=277nM    // 5u28.pdf (837) ligand is  ligand is SF2535.
5q0r  1.91  2017  IC50=27uM     // 5q0i.pdf (9LG) comp.15
5teh  2.99  2017  IC50=28nM     // 5teh.pdf (S56) [Different protein in assay: crystal: SrcCD V284C, assay: Src3D V284C] IC50(Src3D V284C)=28+/-3nM
5ttv  1.93  2017  IC50=29nM     // 5tts.pdf (7KX) [Covalent complex] ligand is compound 6, ATP=1mM
5opc  2.30  2017  IC50=29uM     // 5opc.pdf (A1Z) Vadadustat
5q0t  2.14  2017  IC50=29uM     // 5q0i.pdf (9LM) comp.16
5w86  2.61  2017  IC50=2nM      // 5w84.pdf (9YV) 7 in IRAK4
5x8i  1.90  2017  IC50=2nM      // 5x8i.pdf (SQZ) compound 25
5k1v  2.90  2017  IC50=2uM      // 5j6s.pdf (6PX) ligand is compound 1
5m3a  1.65  2017  IC50=2uM      // 5m39.pdf (7E7) comp.2
5mky  1.67  2017  IC50=2uM      // 5mkx.pdf (I0D) pIC50 = 5.7 +/- 0.11, complex is BRD9/20
5mjb  2.23  2017  IC50=3.0nM    // 5mja.pdf (7O3) [Covalent complex] +/-1.2, EphB1_G703C/comp.1
6b1o  1.91  2017  IC50=3.1nM    // 6b1o.pdf (C8S) ligand is Saxagliptin M2, IC50=3.1 +/- 0.3 nmol/L
5xzr  2.80  2017  IC50=3.27uM   // 5xzr.pdf (8J6) [Nonstandard assay: PH=5]  SHP2 in complex with compound 10
5t28  2.80  2017  IC50=3.2nM    // 5t23.pdf (74Q) [Different protein in assay: Protein in binding assay is human] comp.5k
5tg2  1.75  2017  IC50=3.2uM    // 5tg1.pdf (V69) ligand is compound 21.
5jh6  2.37  2017  IC50=3.3nM    // 5e7r.pdf (T92) [Covalent complex] TAK1-7
5v8q  1.44  2017  IC50=3.6nM    // 5v8q.pdf (97A) ligand is compound 2f.
5t66  1.95  2017  IC50=3.7nM    // 5t66.pdf (C6S) [Covalent complex] [Uncommon element] [Nonstandard assay: preincubation time = 30 min] +/-0.1, cyclic boronate 1
5ksx  2.65  2017  IC50=3.7uM    // 5juz.pdf (7AM) ligand is compound 29
5mym  2.28  2017  IC50=3.9uM    // 5mxv.pdf (HYV) comp.3
5u5t  1.60  2017  IC50=3.9uM    // 5u5h.pdf (7W7) ligand is compound 14.
5xmu  2.39  2017  IC50=30.9nM   // 5xmp.pdf (8A0) [Different protein in assay: source of protein in binding assay is  Arabidopsis thaliana ] [Different ligand in assay: lligand in binding assay is racemates] (+)-4
5orx  1.88  2017  IC50=308uM    // 5orl.pdf (A6H) comp.10, refers to Aurora-ACA alone
5twx  2.55  2017  IC50=30nM     // 5twx.pdf (7P7) ligand is compound 3.
5myn  1.56  2017  IC50=30uM     // 5mxv.pdf (ZUF) comp.5
5mxx  1.75  2017  IC50=31nM     // 5mxx.pdf (W4A) comp.1
5myv  2.90  2017  IC50=31nM     // 5mxx.pdf (W4A) comp.1
5k6a  1.70  2017  IC50=31uM     // 5k6a.pdf (6QT) ligand is compound 1, in vitro enzyme reporter assay
5lca  1.93  2017  IC50=32.8uM   // 5lca.pdf (B06) VIM-2 in complex with 17
5vnd  2.20  2017  IC50=320nM    // 5vnd.pdf (9ES) [Different protein in assay: Protein in binding assay is WT] ligand is H3B-6527
5ntq  2.26  2017  IC50=33.8nM   // 5nti.pdf (444) comp.6
5l01  1.90  2017  IC50=33nM     // 5l01.pdf (6Z4) 15a bound to TPH1
5swg  3.11  2017  IC50=33uM     // 5sw8.pdf (CAQ) [Multiple sites] ligand in crystal is Frag.5 and Frag.21, binding assay is Frag.21
5j9l  2.75  2017  IC50=34nM     // 5e7r.pdf (6HF) [Covalent complex] TAK1-10
6b1e  1.77  2017  IC50=34nM     // 6b1e.pdf (LF7) [Nonstandard assay: Tem 37] ligand is Vildagliptin,IC50=34+/-7.7nM/L
5uwm  1.62  2017  IC50=356nM    // 5uwk.pdf (8OA) IC50=356+/-95nM, ligand is compound (R)-17a
5m7m  2.70  2017  IC50=357nM    // 5m7m.pdf (7HR) [Nonstandard assay: Temp 37, pH=8.5, NaCl=500mM] +/-53, comp.9, LPC 16:0 as substrate
5tyj  1.75  2017  IC50=35nM     // 5tyj.pdf (7ND) [Covalent complex] [Uncommon element] compound is 3.10
5mrd  1.41  2017  IC50=36.4uM   // 5mrd.pdf (S26) [Different protein in assay: ] +/-0.8, PS267
5w84  2.90  2017  IC50=360nM    // 5w84.pdf (9YY) 4 in IRAK4
5h22  1.50  2017  IC50=36nM     // 5h22.pdf (7FT) IC50=36+/-3.9nM
5u7j  1.90  2017  IC50=389.6nM  // 5u7d.pdf (7XV) ligand is compound 3.
5npd  1.95  2017  IC50=38nM     // 5npb.pdf (94B) [Nonstandard assay: Temp 37] [Different protein in assay: protein in binding assay is WT] +/-3, GAA, comp.4
6alz  2.21  2017  IC50=38pM     // 6alz.pdf (BKM) PP1:TTN
6ez6  2.04  2017  IC50=39.81nM  // 6eyz.pdf (C5Z) [Covalent complex]  8;PIC50=7.4;
5uah  4.10  2017  IC50=398uM    // 5uac.pdf (RFP) ligand is Rifampin
5vlr  2.80  2017  IC50=3nM      // 5vlr.pdf (9EM) IC50=3+/-1nM, ligand is compound 22.
5juz  2.40  2017  IC50=3uM      // 5juz.pdf (YL4) ligand is compound 33
5v5e  2.30  2017  IC50=3uM      // 5v5d.pdf (8N4) IC50=2.8+/-3uM, ligand is compound 4.
5tq4  2.30  2017  IC50=4.2nM    // 5tq3.pdf (7GY) ligand is compound 13.
5q0l  2.50  2017  IC50=4.36uM   // 5q0i.pdf (9KY) comp.8
5m6u  2.85  2017  IC50=4.3nM    // 5m6u.pdf (7KA) comp.11
5k0x  2.23  2017  IC50=4.4nM    // 5k0x.pdf (K0X) 11 in complex with Mer
5llm  3.25  2017  IC50=4.5uM    // 5llm.pdf (6Z6)
5q12  2.00  2017  IC50=4.64uM   // 5q0i.pdf (9MA) comp.2
5uit  1.84  2017  IC50=4.6nM    // 5uiq.pdf (8CD) ligand is compound 20.
5nhz  1.85  2017  IC50=4.7uM    // 5mm9.pdf (8XZ) comp.10b
5dyw  2.50  2017  IC50=4.9nM    // 5dyt.pdf (5HF) IC50=4.9+/-0.3nM, ligand is compound 2
5tnt  1.40  2017  IC50=4.9nM    // 5tno.pdf (7GQ) ligand is compound 16.
5v24  2.50  2017  IC50=400nM    // 5v19.pdf (8V7) ligand is compound 13.
5qby  2.25  2017  IC50=40nM     // 3mpe.pdf (N2A) compound 27; Ki(human CatS); X-ray(CatS C25S)
5mri  2.00  2017  IC50=40uM     // 5mrh.pdf (Q9Y) comp.18
5mar  1.89  2017  IC50=41.2uM   // 5mar.pdf (7KE) +/-11.9, comp.48
5mxk  1.93  2017  IC50=410uM    // 5mwo.pdf (ZHA) against EthR-DNA106, comp.4
5ti5  1.83  2017  IC50=41uM     // 5ti2.pdf (7CN) IC50=41+/-0.811uM, ligand is 8228.
5u7l  2.38  2017  IC50=423nM    // 5u7d.pdf (7Y4) ligand is compound 56.
5gvl  2.50  2017  IC50=42nM     // 5gvk.pdf (GI8) [Different protein in assay: assay uses PfSHMT]
5xmp  2.40  2017  IC50=43.0nM   // 5xmp.pdf (8A3) [Different protein in assay: source of protein in binding assay is  Arabidopsis thaliana ] [Different ligand in assay: lligand in binding assay is racemates] COMPOUND 11
5t36  1.40  2017  IC50=43nM     // 5t36.pdf (755) comp.5
5ue4  1.80  2017  IC50=440nM    // 5ue4.pdf (5XQ) [Nonstandard assay: Temp 37] [Different protein in assay: crystal:proMMP-9desFnII ,bindingassay:proMMP-9] ligand is JNJ0966
5m6m  2.37  2017  IC50=44nM     // 5m6e.pdf (7H8) comp.12
5sys  2.80  2017  IC50=44nM     // 5sys.pdf (72F) [Different protein in assay: crystal: SrcCD V284C, assay: Src3D V284C] IC50(Src3D V284C)=44+/-7nM
5ti3  1.70  2017  IC50=44uM     // 5ti2.pdf (7CG) IC50=44+/-1.363uM, ligand is 8152.
5ujo  1.35  2017  IC50=44uM     // 5ujo.pdf (LSI) [Covalent complex] [Uncommon element] [Different protein in assay: Protein in binding assay is wildtype, protein in crystal is E166A mutant] IC50=44+/-4uM, ligand is compound 3
5v9t  3.05  2017  IC50=45nM     // 5v9p.pdf (90V) ligand is compound 50.
5l6i  2.76  2017  IC50=45uM     // 5l6h.pdf (B39) [Covalent complex] Uba1-Ub-MLN4924
5n49  1.94  2017  IC50=470nM    // 5mg2.pdf (8LW) comp.7/ BRPF2 BD
5ttu  1.72  2017  IC50=47nM     // 5tts.pdf (7KV) [Covalent complex] ligand is compound 7, ATP=1mM
5mkj  2.50  2017  IC50=48.5uM   // 5mj5.pdf (4CU) +/-4.6, comp.9
5t4u  1.50  2017  IC50=4800nM   // 5t4u.pdf (12Q) comp.5b
5uox  2.50  2017  IC50=5.01nM   // 5uor.pdf (8GY) ligand is compound 19.
5t2b  2.30  2017  IC50=5.0nM    // 5t23.pdf (74O) [Different protein in assay: Protein in binding assay is human] comp.7e
5j8i  2.40  2017  IC50=5.1nM    // 5e7r.pdf (6H4) [Covalent complex] TAK1-2
5ne1  2.09  2017  IC50=5.25nM   // 5ne1.pdf (OK3) [Uncommon element] [Nonstandard assay: Temp 37] cyclic boronate 2
5gnk  1.80  2017  IC50=5.3nM    // 5gnk.pdf (80U) EGFR T790M in complex with compound 21
5urj  2.75  2017  IC50=5.3uM    // 5urj.pdf (8LS) [Different protein in assay: crystal:395-2129, binding assay:full-length] ligand is compound 3.
5urm  2.80  2017  IC50=5.3uM    // 5urj.pdf (8LV) [Different protein in assay: crystal:395-2129, binding assay:full-length] ligand is compound 12.
5vqq  2.55  2017  IC50=5.3uM    // 5vqq.pdf (9JP) [Covalent complex] WT-2;+/-1.0; 24h
5v5d  2.10  2017  IC50=5.4uM    // 5v5d.pdf (8OY) IC50=5.4+/-0.6uM, ligand is compound 1.
5vlk  2.20  2017  IC50=5.55uM   // 5vl7.pdf (11-mer) [Different protein in assay: crystal:PCSK9-P-CRD, binding assay:PCSK9-P] IC50=5.55+/-0.36uM, ligand is WNLV(hR)IGLLR
5q17  2.10  2017  IC50=5.64uM   // 5q0i.pdf (9MV) comp.10
5v19  3.10  2017  IC50=500uM    // 5v19.pdf (8V4) ligand is compound 7.
5ml0  1.64  2017  IC50=501nM    // 5mkx.pdf (P2L) [Different protein in assay: Protein in binding assay is Human] pIC50 = 6.3 +/- 0.04. complex is mouse PCAF/(R)-23
5j7s  2.37  2017  IC50=50nM     // 5e7r.pdf (6H3) [Covalent complex] TAK1-5
5mys  1.59  2017  IC50=50uM     // 5mxv.pdf (YP6) comp.7
5one  2.60  2017  IC50=52nM     // 5one.pdf (9YQ) +/-3.0
6eku  1.75  2017  IC50=52uM     // 6eks.pdf (ZMR) [Nonstandard assay: Temp 37] zanamivir;+/-2
5uiq  2.64  2017  IC50=55.056uM  // 5uiq.pdf (8BV) ligand is compound 51.
5q0i  1.70  2017  IC50=56.1uM   // 5q0i.pdf (0X0) comp.1
5dyy  2.65  2017  IC50=56.9nM   // 5dyt.pdf (5HH) IC50=56.9+/-9.8nM, ligand is compound 7
5lvx  2.20  2017  IC50=56nM     // 5lvx.pdf (7E4/79B) [Covalent complex] ligand is JZ-5907
5tts  2.34  2017  IC50=56nM     // 5tts.pdf (7KU) [Covalent complex] ligand is compound 4, ATP=1mM
5tq5  2.30  2017  IC50=58.8nM   // 5tq3.pdf (7GX) ligand is compound 16.
5t1t  2.34  2017  IC50=58nM     // 5t1s.pdf (76P) comp.3
5npf  1.38  2017  IC50=58uM     // 5npb.pdf (945) [Covalent complex] [Nonstandard assay: Temp 37] [Different ligand in assay: ligand in binding assay is unreacted and ligand in crystal is ring-opened] +/-4.5, GBA2, comp.6, reacted
5o0s  1.16  2017  IC50=58uM     // 5npb.pdf (9FQ) [Nonstandard assay: Temp 37] +/-4.5, GBA2, comp.6, unreacted
5tiu  1.49  2017  IC50=5nM      // 5tiu.pdf (7CU) ligand is compound 8.
5x5o  1.87  2017  IC50=5nM      // 5x5o.pdf (7Z0) 3g;+/-0.62
5tyo  1.57  2017  IC50=6.1nM    // 5tyj.pdf (7NM) [Covalent complex] [Uncommon element] compound is 2
5uvc  2.65  2017  IC50=6.1nM    // 5uuu.pdf (8PV) ligand is compound 30i.
5q10  2.20  2017  IC50=6.28uM   // 5q0i.pdf (9M4) comp.18
5uor  2.75  2017  IC50=6.31nM   // 5uor.pdf (8GV) ligand is compound 17.
5t2l  2.55  2017  IC50=6.3nM    // 5t23.pdf (74H) [Different protein in assay: Protein in binding assay is human] comp.7l
5h21  1.59  2017  IC50=6.4uM    // 5h21.pdf (RMR) ligand is compound DC-BD-29
5lhh  3.05  2017  IC50=6.7nM    // 5lgt.pdf (6X0) ligand is compound 49
5ubg  1.90  2017  IC50=6.8uM    // 5ubg.pdf (PRT) IC50=6.8+/-0.7uM, ligand is PR-ATP
5v83  2.00  2017  IC50=6.91uM   // 5v83.pdf (8Z7) IC50=6.91+/-0.442uM, ligand is NAcM-HIT
5t4v  1.65  2017  IC50=60nM     // 5t4u.pdf (N48) comp.22
5v3o  3.20  2017  IC50=60nM     // 5v3o.pdf (8W7) ligand is compound 6.
5v7t  2.30  2017  IC50=610nM    // 5v7t.pdf (91V) ligand is compound 3.
5mwo  1.96  2017  IC50=610uM    // 5mwo.pdf (J6W) against EthR-DNA106, comp.7
5n20  1.38  2017  IC50=61uM     // 5n1v.pdf (8GN) comp.1
5mrh  2.50  2017  IC50=63uM     // 5mrh.pdf (Q9Z) comp.1
5mih  1.80  2017  IC50=64uM     // 5mih.pdf (7NU) +/-42, comp.3
5u7i  2.00  2017  IC50=66.6nM   // 5u7d.pdf (7XS) ligand is compound 4.
5v7i  2.47  2017  IC50=66nM     // 5v7i.pdf (8Z1) ligand is racemic compound 2
5op8  2.30  2017  IC50=66uM     // 5op8.pdf (A1H)  Molidustat
5h0h  1.72  2017  IC50=686nM    // 5h09.pdf (OOV) RK-21253
5hcl  1.50  2017  IC50=6mM      // 5hcl.pdf (5Y9) BRD4-BD1/DMA
5h3q  2.10  2017  IC50=6nM      // 5h3q.pdf (7HF) A1 bound to TrkA with the JM region;without JM region IC50=37163.3nM
5ksv  2.20  2017  IC50=6uM      // 5ksv.pdf (15-mer) ligand is CLIP2
5vew  2.70  2017  IC50=7.08uM   // 5vew.pdf (97Y) ligand is PF-06372222.
5q11  2.20  2017  IC50=7.19uM   // 5q0i.pdf (9M7) comp.4
5u7k  2.06  2017  IC50=7.1nM    // 5u7d.pdf (7Y1) ligand is compound 39.
5jk3  2.37  2017  IC50=7.3nM    // 5e7r.pdf (6L4) [Covalent complex] TAK1-22
5xms  2.45  2017  IC50=7.3nM    // 5xmp.pdf (8B3) [Different protein in assay: source of protein in binding assay is  Arabidopsis thaliana ] [Different ligand in assay: lligand in binding assay is racemates] (+)-3
5lm6  1.17  2017  IC50=7.7uM    // 5lca.pdf (H32) VIM-2 in complex with 35
5ogk  3.60  2017  IC50=7.7uM    // 5oge.pdf (GDD) +/-0.4 GDP-M
5lhi  3.40  2017  IC50=7.8nM    // 5lgt.pdf (6X5) ligand is compound 50
5vqu  2.60  2017  IC50=7.8uM    // 5vqq.pdf (9JP) [Covalent complex] Y181C-2;+/-2.5; 24h
6eyz  2.20  2017  IC50=7.94nM   // 6eyz.pdf (C5W) [Covalent complex]  4;PIC50=8.1;
5q1h  2.20  2017  IC50=7.95uM   // 5q0i.pdf (9NP) comp.9
5t2g  2.55  2017  IC50=7.9nM    // 5t23.pdf (74K) [Different protein in assay: Protein in binding assay is human] comp.7i
5mts  2.60  2017  IC50=70nM     // 5mts.pdf (XKA) comp.2
5uir  2.64  2017  IC50=71.9nM   // 5uiq.pdf (8BY) ligand is compound 12.
5oy3  2.14  2017  IC50=71uM     // 5oy3.pdf (17-mer) enzyme assay
5v9p  3.00  2017  IC50=727nM    // 5v9p.pdf (90S) ligand is compound 35.
5ur5  1.93  2017  IC50=72nM     // 5ur5.pdf (8KP) [Incomplete ligand] IC50=72+/-15nM, ligand is compound 4m
5v7w  2.65  2017  IC50=76nM     // 5v7t.pdf (91J) ligand is compound 4.
5vee  2.50  2017  IC50=779nM    // 5ved.pdf (981) ligand is FRAX486
5t27  2.60  2017  IC50=79nM     // 5t23.pdf (74F) comp.5d
5h2u  2.24  2017  IC50=7nM      // 5h2u.pdf (1N1) PTK6 in complex with Dasatinib
5k00  1.77  2017  IC50=7nM      // 5k00.pdf (6PV) MELK/5
5o4y  2.30  2017  IC50=7nM      // 5o45.pdf (16-mer) peptide 57
5xg4  3.00  2017  IC50=7uM      // 5xg4.pdf (QUE) uPA-quercetin
5jmx  1.44  2017  IC50=8.2uM    // 5jmx.pdf (DZ5) IC50 = 8.2 +/- 0.1 uM, ligand is 6c
5tyh  2.10  2017  IC50=8.4mM    // 5t2y.pdf (7O4) comp.1
5gmj  2.99  2017  IC50=8.4uM    // 5gmi.pdf (19-mer) [Nonstandard assay: Temp 4] JAM-B
5h14  1.90  2017  IC50=8.76uM   // 5h13.pdf (LQB) [Nonstandard assay: pH 8] EED-EBD-EED666
5n2f  1.70  2017  IC50=80nM     // 5n2d.pdf (8HW) comp.2a
5ksu  2.73  2017  IC50=82.5uM   // 5ksu.pdf (15-mer) ligand is CLIP1
5npb  1.90  2017  IC50=82nM     // 5npb.pdf (93Z) [Covalent complex] [Nonstandard assay: Temp 37] +/-1, GAA, comp.5
5t1s  2.30  2017  IC50=84nM     // 5t1s.pdf (76Q) comp.1
5ur6  1.63  2017  IC50=87nM     // 5ur5.pdf (8KM) [Incomplete ligand] IC50=87+/-3nM, ligand is compound 4i
5or9  2.00  2017  IC50=88uM     // 5or8.pdf (JR5) comp.13
5mqv  2.15  2017  IC50=8nM      // 5ml5.pdf (D5Q) +/-1. comp.16b
5w4w  1.99  2017  IC50=8nM      // 5w4w.pdf (9WG) inhibitor 9
6bfn  2.26  2017  IC50=9.3nM    // 6bfn.pdf (DL1)  JH-I-25/IRAK1
5uwl  2.55  2017  IC50=9.4nM    // 5uwk.pdf (8OJ) IC50=9.4+/-1.7nM, ligand is compound (S)-17a
5v5n  2.01  2017  IC50=9.5nM    // 5v5n.pdf (EDH) ligand is Takinib EDHS-206 1
5ick  2.47  2017  IC50=9.786uM  // 5iaw.pdf (11-mer) FXR LBD bound to feroline with SRC2-3
5ntk  1.90  2017  IC50=9.7nM    // 5nti.pdf (99N) comp.2
5myl  1.72  2017  IC50=9.9uM    // 5mxv.pdf (Q2N) comp.2
5gn7  3.20  2017  IC50=900nM    // 5gn5.pdf (6XZ) compound is 17, IC50=900+/-77nM
5gn9  3.20  2017  IC50=90nM     // 5gn5.pdf (6Y0) compound is 17b, IC50=90+/-7nM
5u5k  2.33  2017  IC50=95uM     // 5u5h.pdf (7VY) ligand is compound 2.
5gvk  2.24  2017  IC50=99nM     // 5gvk.pdf (G45) [Different protein in assay: assay uses PfSHMT]
5o45  0.99  2017  IC50=9nM      // 5o45.pdf (15-mer) peptide 71
5xvk  1.88  2017  IC50=9uM      // 5xvk.pdf (8GC) [Nonstandard assay: Temp 37] moNNMT-MNA-SAH Complex
5xvq  2.29  2017  IC50=9uM      // 5xvk.pdf (8GC) [Nonstandard assay: Temp 37] moNNMT-MNA-SAH Complex
5j6s  2.80  2017  IC50>100uM    // 5j6s.pdf (6GA) ligand is compound 2
5npe  1.95  2017  IC50>100uM    // 5npb.pdf (948) [Covalent complex] [Nonstandard assay: Temp 37] +/-1, GAA, comp.2
5npc  1.96  2017  IC50>100uM    // 5npb.pdf (94E) [Nonstandard assay: Temp 37] [Different protein in assay: protein in binding assay is WT] +/-1, GAA, comp.6
5vt1  1.90  2017  IC50>50uM     // 5vt1.pdf (9JS) ligand is compound 2
5orb  2.10  2017  IC50>51uM     // 5or8.pdf (JR6) comp.30
5lzg  1.13  2017  IC50~0.8mM    // 5lzg.pdf (7BN) comp.2
5lzh  1.13  2017  IC50~0.8mM    // 5lzg.pdf (7BN) comp.2
5tx3  2.90  2017  IC50~1.4nM    // 5twl.pdf (7MY) IC50 = 1.4 ~ 3.3 nM. complex is MELK(1-340)/MRT199665
5jv2  2.30  2017  IC50~100uM    // 5juz.pdf (6O3) [Nonstandard assay: Temp 37] ligand is compound 49
5n2d  2.35  2017  IC50~6nM      // 5n2d.pdf (8J8) comp.1a
5ml4  2.40  2017  Kd<2nM        // 5ml2.pdf (RRQ) comp.7
5ufr  2.07  2017  Kd=0.002uM    // 5ufo.pdf (88J) ligand is compound S-12, TF binding assay
5jur  2.93  2017  Kd=0.003uM    // 5jun.pdf (6NS) cap-binding domain of PB2/compound 4
5org  1.99  2017  Kd=0.004uM    // 5org.pdf (6DB) +/-0.0001, octopine
5n1z  1.81  2017  Kd=0.0065uM   // 5n1v.pdf (8GQ) ligand is compound 11
5ul6  1.45  2017  Kd=0.006uM    // 5ul6.pdf (15-mer) Kd=0.006+/-0.002uM, complex is nSH3CrkII      RMNS1.
5llg  1.12  2017  Kd=0.0074nM   // 5llc.pdf (VD9) ligand is compound 1
5uhi  3.20  2017  Kd=0.0092uM   // 5ufo.pdf (8A4) ligand is compound 28, TF binding assay
5lyr  1.14  2017  Kd=0.013uM    // 5lyr.pdf (2-mer) +/-0.002, ligand is compound 9
6euw  1.00  2017  Kd=0.017uM    // 6euv.pdf (BYB) A/H5N1 PB2 cap-binding/ VX-787N;+/- 0.004
5h1e  2.60  2017  Kd=0.029uM    // 5h1e.pdf (13-mer) rat VDR-LBD/1,25D3/SRC2-3(peptide) complex
5ufo  2.80  2017  Kd=0.037uM    // 5ufo.pdf (87J) ligand is compound 20, TF binding assay
5nmf  2.89  2017  Kd=0.038uM    // 5nmd.pdf (9-mer) A2-SLYNTIATL
5n8b  1.03  2017  Kd=0.043uM    // 5n7x.pdf (13-mer) [Nonstandard assay: pH=5.0] AFPDYLAEYHGG
5lle  1.90  2017  Kd=0.060nM    // 5llc.pdf (V51) ligand is compound 2
5kly  1.30  2017  Kd=0.061uM    // 5kly.pdf (6UR)
5llh  1.90  2017  Kd=0.067nM    // 5llc.pdf (V49) ligand is compound 4
5ukj  2.80  2017  Kd=0.069uM    // 5uk8.pdf (3K6) ligand is compound 1.
5x4q  2.00  2017  Kd=0.078uM    // 5x4m.pdf (7Z6) BCL6/7
6axl  2.40  2017  Kd=0.078uM    // 6axk.pdf (14-mer) Fab317-(NPNA)3;+/-0.016
5nme  2.94  2017  Kd=0.082uM    // 5nmd.pdf (9-mer) A2-SLYNTVATL
5m63  2.74  2017  Kd=0.11uM     // 5m63.pdf (7-mer) DP2
5km5  2.10  2017  Kd=0.121uM    // 5kly.pdf (TR5) [Different protein in assay: Protein in binding assay is H112N, and wt in crystal.] Structure is a catalytic product complex with hHint2
5m3b  1.50  2017  Kd=0.12uM     // 5m29.pdf (CBY) [Uncommon element] +/- 0.02 Cbi
5vr8  2.00  2017  Kd=0.135uM    // 5vr8.pdf (UDX) ligand is UDX
5tyi  2.15  2017  Kd=0.13uM     // 5tyi.pdf (9-mer) [Nonstandard assay: PO4(3-), 1mM and 50mM] Kd(1mM, PO4(3-))=0.13+/-0.0004uM, Kd(50mM,PO4(3-))=0.83+/-0.001uM
5m34  1.60  2017  Kd=0.15uM     // 5m29.pdf (CBY) [Uncommon element] +/- 0.03 Cbi
5h1t  1.95  2017  Kd=0.16mM     // 5h1t.pdf (7FF) [Nonstandard assay: PH=8] ligand is compound 1
5vlh  2.86  2017  Kd=0.16uM     // 5vl7.pdf (14-mer) [Different protein in assay: crystal:PCSK9-P-CRD, binding assay:PCSK9-P] kd=0.16+/-0.004uM, ligand is pep1, CRLPWNLQRIGLPC
5wa9  1.15  2017  Kd=0.175uM    // 5kly.pdf (9ZD)
5na0  2.90  2017  Kd=0.17nM     // 5n7v.pdf (8QZ) comp.5
5yu9  1.95  2017  Kd=0.18uM     // 5yu9.pdf (1E8) [Covalent complex] [Different protein in assay: Protein in binding assay is L858R/T790M.] Ibrutinib;
5h1v  2.00  2017  Kd=0.1mM      // 5h1t.pdf (7FU) ligand is compound 6
5mev  2.94  2017  Kd=0.1uM      // 5ku9.pdf (7LW) ligand is compound 21
6ayi  2.09  2017  Kd=0.21uM     // 6ayh.pdf (C3G) EcGusR/PNPG
5u06  2.10  2017  Kd=0.22uM     // 5u06.pdf (9-mer) [Nonstandard assay: PO4(3-), 1mM and 50mM] Kd(1mM, PO4(3-))=0.22+/-0.0004uM, Kd(50mM,PO4(3-))=2.94+/-0.008uM
5wyx  2.40  2017  Kd=0.22uM     // 5wyx.pdf (CU8) [Nonstandard assay: PH=5.5] CU-CPT8m
5iz6  2.15  2017  Kd=0.23uM     // 5b6g.pdf (9-mer)
5nu3  1.75  2017  Kd=0.23uM     // 5lpj.pdf (99E) [Nonstandard assay: Temp 4] CBP bound to XDM-CBP:
5ul1  3.00  2017  Kd=0.23uM     // 5uk8.pdf (8DY) ligand is compound 7.
5unj  1.96  2017  Kd=0.24uM     // 5unj.pdf (14-mer) Kd=0.24+/-0.04uM for RJW100 bound LRH-1 LBD interact with coactivator PGC1, Kd is not 0.24uM for full-length LRH-1
5w10  2.15  2017  Kd=0.24uM     // 5w10.pdf (CMP) Lcd1GAF in complex with cAMP
5k48  1.74  2017  Kd=0.251uM    // 5k48.pdf (S5Z) Kd = 0.251 +/- 0.221 uM, ligand is compound 1
5mb1  1.65  2017  Kd=0.253uM    // 5may.pdf (7KT) [Incomplete ligand] ligand is compound 7a, 7KT-FUL in PDB
5wtt  2.70  2017  Kd=0.25uM     // 5wtt.pdf (8-mer) ligand is CCN1 epitope, steady-state analysis
5mxf  1.90  2017  Kd=0.26mM     // 5mxf.pdf (MFU) +/-0.6, n=4 Me-alpha-L-Fuc
5g1a  1.42  2017  Kd=0.27uM     // 5g17.pdf (7H1) [Nonstandard assay: Temp 30, PH=8] PFSAHA bound to HDAHbo
5nwk  3.30  2017  Kd=0.27uM     // 5nwi.pdf (5-mer) +/-0.02, CPP, +FC
5twh  2.50  2017  Kd=0.28uM     // 5twg.pdf (17-mer) Kd=0.68+/-0.1uM, ligand is pT353 peptide.
5n69  2.45  2017  Kd=0.29uM     // 5n69.pdf (2OW) [Nonstandard assay: Temp 10] +/-0.04, OM, MgADP.VO4
5u98  2.00  2017  Kd=0.2nM      // 5u98.pdf (9-mer) ligand is SPT5a
5g17  1.51  2017  Kd=0.2uM      // 5g17.pdf (6DK) [Nonstandard assay: Temp 30, PH=8] HDAHbo T101A - SATFMK.
6axk  2.10  2017  Kd=0.305uM    // 6axk.pdf (14-mer) Fab311-(NPNA)3;+/-0.06
5h1u  1.90  2017  Kd=0.31mM     // 5h1t.pdf (6KT) ligand is compound 2
5may  1.65  2017  Kd=0.328uM    // 5may.pdf (PK6) [Incomplete ligand] ligand is compound 7b, PK6-FUL in PDB
5nxq  2.41  2017  Kd=0.32uM     // 5nxq.pdf (19-mer) +/-0.02, A2
5xg5  1.54  2017  Kd=0.33mM     // 5xg5.pdf (A2G) N-acetyl-D-galactosamine
5mes  2.24  2017  Kd=0.34uM     // 5ku9.pdf (7LT) ligand is compound 29
5vb5  2.23  2017  Kd=0.35uM     // 5vb5.pdf (92A) Kd=0.35+/-0.22uM, ligand is compound 2
5wbl  3.35  2017  Kd=0.36uM     // 5wbl.pdf (16-mer) [Different protein in assay: Assay:Human, X-ray: Arabidopsis thaliana] PRAS40;
5jop  1.75  2017  Kd=0.39nM     // 5jop.pdf (4-mer) ligand is tetrasaccharide, TS14 glycan; ITC Kd=51nM
5v79  2.25  2017  Kd=0.39uM     // 5u0v.pdf (8Y4) Kd=2.05+/-0.02uM, ligand is compound 62
5llc  1.10  2017  Kd=0.3nM      // 5llc.pdf (V26) ligand is compound 13
5g60  1.99  2017  Kd=0.3uM      // 5g5z.pdf (NYT) complex is FusA/nystose
5lsh  1.06  2017  Kd=0.41mM     // 5lsh.pdf (KTS)
5wyr  2.45  2017  Kd=0.41uM     // 5wyq.pdf (DFG) Ki=0.41+/-0.07uM,SAM for substrate
5klz  1.50  2017  Kd=0.423uM    // 5kly.pdf (AMP) [Different protein in assay: Protein in binding assay is H112N, and wt in crystal.]
5v7a  2.35  2017  Kd=0.42uM     // 5u0v.pdf (8Y7) Kd=0.42+/-0.04uM, ligand is compound 61
5vb6  2.04  2017  Kd=0.43uM     // 5vb5.pdf (927) Kd=0.43+/-0.18uM, ligand is compound 2
5vll  2.37  2017  Kd=0.43uM     // 5vl7.pdf (14-mer) [Different protein in assay: crystal:PCSK9-P-CRD, binding assay:PCSK9-P] kd=0.43+/-0.05uM, ligand is pep3, CFIPWNLQRIGLLC
5u4a  1.90  2017  Kd=0.44uM     // 5u48.pdf (7VG) [Uncommon element] Kd=0.44+/-0.01uM, ligand is compound 4.
5u4e  1.45  2017  Kd=0.45uM     // 5u48.pdf (XLB) [Uncommon element] Kd=0.45+/-0.01uM, ligand is compound 8.
5m04  1.85  2017  Kd=0.46uM     // 5m04.pdf (GDP)
5nu5  1.60  2017  Kd=0.47uM     // 5lpj.pdf (99E) [Nonstandard assay: Temp 4] p300 bound to XDM-CBP:
5n8w  1.10  2017  Kd=0.47uM     // 5n7x.pdf (14-mer) [Nonstandard assay: pH=5.0] GGwhdeatwkpG
5u4f  1.50  2017  Kd=0.47uM     // 5u48.pdf (IWW) [Covalent complex] [Uncommon element] Kd=0.47+/-0.03uM, ligand is compound 10.
5u48  1.50  2017  Kd=0.47uM     // 5u48.pdf (S4B) [Uncommon element] Kd=0.47+/-0.02uM, ligand is compound 2.
5u4d  1.55  2017  Kd=0.47uM     // 5u48.pdf (XLO) Kd=0.47+/-0.01uM, ligand is compound 7
5llo  1.60  2017  Kd=0.4nM      // 5llc.pdf (5EF) ligand is compound 12
5g61  2.40  2017  Kd=0.4uM      // 5g5z.pdf (FNY) complex is FusA/fructofuranosyl-nystose
5uk8  2.50  2017  Kd=0.4uM      // 5uk8.pdf (8DV) ligand is compound 5
5gut  2.10  2017  Kd=0.51uM     // 5gut.pdf (SAH) Kd(AdoHcy, N1248A)=0.51uM
5t2t  1.97  2017  Kd=0.51uM     // 5ltn.pdf (0N8) [Nonstandard assay: with ions] Kd = 0.51 +/- 0.11 uM. ligand is L-742,001
6aol  2.76  2017  Kd=0.54uM     // 6aol.pdf (VC1) 30;+/- 0.05
5oku  2.07  2017  Kd=0.55uM     // 5oei.pdf (0L1) +/-0.49; adipate
5n87  2.29  2017  Kd=0.56nM     // 5n7v.pdf (N66) NTRC 0060-0
5vqi  2.50  2017  Kd=0.56uM     // 5vqi.pdf (13-mer) [Multiple sites: site 1:kd=0.56uM;site 2: kd=9.90uM] NIT-2 NLS
5wa8  1.30  2017  Kd=0.587uM    // 5kly.pdf (9ZA)
5o0a  1.81  2017  Kd=0.58mM     // 5o0a.pdf (9FH) frag.1
5llp  1.48  2017  Kd=0.58nM     // 5llc.pdf (6Z9) ligand is compound 16
5ybe  2.11  2017  Kd=0.58uM     // 5ybe.pdf (19-mer) KANK1/KIF21A;+/-0.05
5gmv  2.25  2017  Kd=0.59uM     // 5gmv.pdf (8-mer) Kd=0.59+/-0.06uM, LC3B-FUNDC1 pS17 peptide complex
5t18  1.50  2017  Kd=0.5nM      // 5t18.pdf (73T) +/-0.2, comp.14f
5bjt  3.20  2017  Kd=0.5uM      // 5bjt.pdf (19-mer) [Nonstandard assay: pH=6]
5wqk  1.70  2017  Kd=0.5uM      // 5wqj.pdf (7NC) [Nonstandard assay: PH=9] compound 3
6awn  3.62  2017  Kd=0.63nM     // 6awn.pdf (8PR) ligand is paroxetine,Kd=0.63+/-0.07nM
6aom  2.87  2017  Kd=0.63uM     // 6aol.pdf (VC5) 6;+/- 0.05
5u0z  2.29  2017  Kd=0.65uM     // 5u0v.pdf (7PM) Kd=0.65+/-0.03uM, ligand is compound 59
5km1  1.65  2017  Kd=0.663uM    // 5kly.pdf (5GP) [Different protein in assay: Protein in binding assay is H112N, and wt in crystal.]
5wl0  2.40  2017  Kd=0.67nM     // 5wl0.pdf (21G) PB2LONG-VX787
5twg  2.30  2017  Kd=0.68uM     // 5twg.pdf (15-mer) Kd=0.28+/-0.1uM, ligand is pT367 peptide.
5nwi  2.35  2017  Kd=0.69uM     // 5nwi.pdf (5-mer) +/-0.05, CPP, -FC
5j20  1.76  2017  Kd=0.72nM     // 5j20.pdf (6FJ) ligand is compound 20
5u49  2.22  2017  Kd=0.73uM     // 5u48.pdf (S2L) Kd=0.73+/-0.02uM, ligand is compound 3
5nkb  1.50  2017  Kd=0.76nM     // 5njz.pdf (8ZT) ligand is compound 4a
5vad  2.36  2017  Kd=0.76nM     // 5vad.pdf (91Y) ligand is compound B, ATP/PPi exchange enzymatic assay
5nfb  1.59  2017  Kd=0.77uM     // 5nf7.pdf (8VT) comp.4
5u4g  1.80  2017  Kd=0.79uM     // 5u48.pdf (7UV) [Uncommon element] Kd=0.79+/-0.03uM, ligand is compound 11.
5wxh  1.30  2017  Kd=0.7uM      // 5wxg.pdf (7-mer)
5fso  1.67  2017  Kd=0.81uM     // 5fsi.pdf (S76) ligand is compound 7
5u0y  1.88  2017  Kd=0.83uM     // 5u0v.pdf (7PJ) Kd=0.83+/-0.01uM, ligand is compound 58
5n2x  1.21  2017  Kd=0.87uM     // 5mnr.pdf (8KN) [Nonstandard assay: buffer is Cacodylate] +/-0.27, comp.6
5nai  1.15  2017  Kd=0.8uM      // 5n4s.pdf (93W) VIM-5(Oxidized):comp.1
5n58  1.96  2017  Kd=0.8uM      // 5n4s.pdf (93W) VIM-5:comp.1
5w7j  2.20  2017  Kd=0.8uM      // 5w7i.pdf (10-mer) [Different ligand in assay: ligand in binding assay is Snap25b] ANK17-E89A/Snap25111-1;+/-0.3
5y5w  3.30  2017  Kd=0.8uM      // 5y5w.pdf (9-mer) Kd(H4K20Me3)=0.8+/-0.04uM
5n0f  1.69  2017  Kd=0.90uM     // 5m77.pdf (7K2) +/-0.03, ManSIFG 2
5tvn  2.90  2017  Kd=0.91nM     // 5tvn.pdf (7LD) ligand id LSD.
5wbk  3.11  2017  Kd=0.94uM     // 5wbk.pdf (14-mer) [Different protein in assay: Assay:Human, X-ray: Arabidopsis thaliana] S6K1;
5mmg  1.23  2017  Kd=0.970uM    // 5eic.pdf (UT0) ligand is compound 10
5myk  1.60  2017  Kd=0.99nM     // 5my4.pdf (16-mer) [Different ligand in assay: Ligand in binding assay is hAbetapE3-18] +/-0.31, mAbetapE3-18 PEGb
5u4c  1.70  2017  Kd=0.99uM     // 5u48.pdf (XBS) [Uncommon element] Kd=0.99+/-0.02uM, ligand is compound 6.
5n55  1.99  2017  Kd=1.03uM     // 5n4s.pdf (8NN) VIM-5(Oxidized):comp.2
5xyf  2.20  2017  Kd=1.05uM     // 5xyf.pdf (18-mer) TIN2TRFH-TPP1TBM/TRF2TBM;+/- 0.17
5tbe  2.44  2017  Kd=1.06nM     // 5tbe.pdf (78L) ligand is compound 3, Kd=(1.06+-4.40)nM
5tpc  2.00  2017  Kd=1.0mM      // 5tpb.pdf (6-mer) Kd=1.0+/-0.1mM, ligand is GD1a. ligand is glycan.
5v4b  2.60  2017  Kd=1.0uM      // 5v4b.pdf (15-mer) Kd=1.0+/-0.2uM, the Skp1-FBXW7 complex bound to DISC1 193   ?07/pT198/pS202
5nad  2.80  2017  Kd=1.1nM      // 5n7v.pdf (8RH) BAY 1217389
5h08  2.53  2017  Kd=1.1uM      // 5h08.pdf (7WL) human PTPRZ1-D1 complexed with NAZ2329
5n21  1.58  2017  Kd=1.1uM      // 5n1v.pdf (8HN) comp.7
5ttw  1.74  2017  Kd=1.1uM      // 5ttw.pdf (5-mer) [Nonstandard assay: PH=8] Kd=1.1+/-0.27uM, ligand is compound 3
5u1q  2.10  2017  Kd=1.1uM      // 5u1q.pdf (9-mer) [Nonstandard assay: PO4(3-), 1mM] Kd(1mM, PO4(3-))=1.1+/-0.01uM
6eqp  2.35  2017  Kd=1.1uM      // 6ep4.pdf (BUW) ethropropazine/hBChE; +/-0.1
5hlm  2.50  2017  Kd=1.27uM     // 5hlm.pdf (B9F) [Uncommon element] Kd=1.27+/-0.06uM, ligand is compound 7
5h63  1.92  2017  Kd=1.2uM      // 5h60.pdf (UD1) [Different protein in assay: Protein in binding assay is WT] ligand is UDP-GlcNAc
5lto  3.46  2017  Kd=1.2uM      // 5lto.pdf (GLN) [Covalent complex] Data is from a reference
5u2j  1.60  2017  Kd=1.2uM      // 5u2j.pdf (16-mer) Kd=1.2+/-0.4uM, ligand is H3K14bu peptide.
6eux  2.05  2017  Kd=1.2uM      // 6euv.pdf (BYB) B/Memphis PB2 cap-midlink/VX-787N; +/-0.2
5lo5  1.44  2017  Kd=1.34uM     // 5lo5.pdf (70M) Kd(69)=1.34+/-0.2uM, kon=1.75E+5, koff=4.29E-1
5tqs  1.88  2017  Kd=1.39uM     // 5tq1.pdf (11-mer) Kd=1.39+/-0.03uM, ligand is ErbB2-pep.
5ngz  2.40  2017  Kd=1.3mM      // 5ngz.pdf (2BG)
5mty  2.31  2017  Kd=1.3nM      // 5mtx.pdf (HB9) comp.6j
5wa4  2.65  2017  Kd=1.3uM      // 5w99.pdf (16-mer) TbtD/N-terminal region of the leader peptide
5kk8  2.11  2017  Kd=1.45uM     // 5kk8.pdf (ADP) [Nonstandard assay: in presence of ATPgammaS]
5tdb  1.10  2017  Kd=1.45uM     // 5tda.pdf (4-mer) ligand is ADMA-RIFS peptide.
5mme  1.35  2017  Kd=1.4uM      // 5eic.pdf (8Q6) ligand is compound 9
5mql  3.25  2017  Kd=1.4uM      // 5mqj.pdf (G65) [Multiple sites: site 1: Kd =1.4 +/- 0.1 uM, site 2: Kd =36 +/- 8 uM] [Different protein in assay: Protein in binding assay is S74E] +/-0.1, masitinib
5y48  1.70  2017  Kd=1.4uM      // 5y48.pdf (URA)
5k0m  1.83  2017  Kd=1.5nM      // 5k0m.pdf (6PU) Kd = 1.5 +/- 0.1 nM. ligand is A395(5)
5gg4  3.11  2017  Kd=1.5uM      // 5gg4.pdf (13-mer) [Nonstandard assay: Temp 20] USP7-RNF169
5oei  1.78  2017  Kd=1.60uM     // 5oei.pdf (OOG) +/-0.67; 2-oxoadipate
5n31  1.37  2017  Kd=1.61uM     // 5mnr.pdf (8LB) [Nonstandard assay: buffer is Cacodylate] +/-0.22, compd 5
5mo8  1.82  2017  Kd=1.64uM     // 5ct0.pdf (C98) [Nonstandard assay: PH=8] ligand is compound 21
5hki  2.40  2017  Kd=1.6mM      // 5hkf.pdf (6ZJ) [Uncommon element] MtOPRT-FDC
5ofw  1.50  2017  Kd=1.6mM      // 5ofw.pdf (9TW) [Different protein in assay: crystal:PHGDH-93, binding assay: sPHGDH] +/-0.2, frag.5
5lrq  1.70  2017  Kd=1.6uM      // 5lrq.pdf (4WG) compound 2
5m9d   NMR  2017  Kd=1.6uM      // 5m9d.pdf (16-mer) +/-0.1, pS2pS7-CTD
5tzf  2.40  2017  Kd=1.6uM      // 5tzd.pdf (C2E) Kd=1.6+/-0.5uM, ligand is c-di-GMP, BldD CTD (D116A)-(c-di-GMP)2 form1
5tzg  2.50  2017  Kd=1.6uM      // 5tzd.pdf (C2E) Kd=1.8+/-0.5uM, ligand is c-di-GMP, BldD CTD (D116A)-(c-di-GMP)2 form2
5nmg  2.75  2017  Kd=1.77uM     // 5nmd.pdf (9-mer) A2-SLFNTIAVL
5n7v  2.52  2017  Kd=1.7nM      // 5n7v.pdf (8PT) MPI-0479605
5vsk  3.33  2017  Kd=1.838uM    // 5vs6.pdf (9HS) USP7/8;+/-  0.895
5n8t  1.61  2017  Kd=1.84uM     // 5n7x.pdf (13-mer) [Nonstandard assay: pH=5.0] Gdlwqheatwkkq; incomplete ligand structure
5ota  2.10  2017  Kd=1.8uM      // 5org.pdf (AQQ) +/-0.3, octopinic acid
5sve  2.60  2017  Kd=1.8uM      // 5sve.pdf (18-mer) +/-0.1, NFATc1 LxVP
5tzd  1.75  2017  Kd=1.8uM      // 5tzd.pdf (C2E) Kd=1.8+/-0.5uM, ligand is c-di-GMP. BldD CTD -(c-di-GMP)2
5u4b  1.45  2017  Kd=1.8uM      // 5u48.pdf (XOS) Kd=1.8+/-0.1uM, ligand is compound 5
5wle  1.95  2017  Kd=1.9uM      // 5wle.pdf (12-mer) H3K4me3;+/- 0.7;pH=7.5
5lpj  1.65  2017  Kd=10.1uM     // 5lpj.pdf (XDM) [Nonstandard assay: Temp 4] CBP bound to XDM1
5gj9  2.10  2017  Kd=10.2uM     // 5gj9.pdf (VGL) Kd=10.2+/-0.5uM, ligand is POA
5j82  2.17  2017  Kd=1000nM     // 5j20.pdf (6GV) Kd = 1000 +/- 40 nM, ligand is compound 8
5mgk  2.30  2017  Kd=100uM      // 5mge.pdf (7MW) ligand is compound 2
5t70  2.10  2017  Kd=102uM      // 5t6w.pdf (10-mer) Kd=102+/-15.8uM, ligand is peptide T3N.
5vs6  2.27  2017  Kd=104nM      // 5vs6.pdf (9QD) USP7/1;+/- 15
5usz  2.10  2017  Kd=106nM      // 5usy.pdf (SKE) ligand is JNJ-7706621.
5vse  1.60  2017  Kd=1070nM     // 5vsc.pdf (9HG) G9a-SAM-17;+/- 80
5mra  3.74  2017  Kd=10nM       // 5mra.pdf (DM2) [Multiple sites: site1:10nM; site2: 1uM] doxorubicin, Kd1, in the presence of Ca2+
5nkk  2.64  2017  Kd=10uM       // 5nkk.pdf (GDP)
5x54  2.30  2017  Kd=10uM       // 5x54.pdf (5-mer) EWWW
6axj  2.38  2017  Kd=10uM       // 6axj.pdf (11-mer)  Yaf9 YEATS/H3K27ac;+/-2
5vc5  1.93  2017  Kd=11.0nM     // 5v5y.pdf (96M) [Nonstandard assay: Temp 15] Kd=11.0+/-1.6nM, ligand is PD166285(compound 3)
5w7i  2.11  2017  Kd=11.2uM     // 5w7i.pdf (10-mer) ANK17/Snap25111-120;+/-2.1
5nn4  1.83  2017  Kd=11.57mM    // 5nn4.pdf (SC2) +/-0.74, NAC
6azl  2.48  2017  Kd=11.8uM     // 6au5.pdf (11-mer) (AHA)QFDLST R(EtCOOH)RLK
5vcw  2.25  2017  Kd=1105nM     // 5v5y.pdf (93J) Kd=1105+/-82.9nM, ligand is Pelitinib
5j71  1.65  2017  Kd=110nM      // 5j6a.pdf (P35) PDK2 + 5
5v35  2.50  2017  Kd=110nM      // 5u9i.pdf (FAR) [Incomplete ligand] Kd=110+/-9nM, ligand is FC, AIPL1-FKBP V71F:FC complex
5m5d  1.07  2017  Kd=111uM      // 5lyr.pdf (2-mer) +/-11, ligand is compound 7
5lws  1.03  2017  Kd=115uM      // 5lwr.pdf (7B2) EP-1-2
5n84  2.30  2017  Kd=11nM       // 5n7v.pdf (8Q5) Mps-BAY2b
5ta2  1.48  2017  Kd=11nM       // 5t9u.pdf (78X) ligand is compound 7
5ioz  2.02  2017  Kd=11uM       // 5ioy.pdf (6C4) amide 4 bound to subpocket II of EthR.
5xw6  3.10  2017  Kd=12.26uM    // 5xw6.pdf (128) [Nonstandard assay: Temp 4;] TNP-ATP-bound ckP2X7; +/- 2.64
5x4m  1.65  2017  Kd=1200uM     // 5x4m.pdf (7ZF) BCL6/1
5w6i  3.10  2017  Kd=125nM      // 5w5s.pdf (12-mer) [Different protein in assay: protein in binding assay is H1N1 A/California/07/ 2009 (H1/Cal)] P3;+/- 20;
6b7b  1.98  2017  Kd=1280uM     // 6b7a.pdf (CWJ) CoaD in complex with compound 2; +/-402
5orv  1.88  2017  Kd=1297uM     // 5orl.pdf (A65) ligand is compound 8
5f63  1.45  2017  Kd=12nM       // 5f5z.pdf (5W2) ligand is compound 5
5lpl  1.65  2017  Kd=12uM       // 5lpj.pdf (71X) [Nonstandard assay: Temp 4] CBP bound to XDM3c:
5v5y  1.90  2017  Kd=13.4nM     // 5v5y.pdf (8X7) [Nonstandard assay: Temp 15] Kd=13.4+/-1.2nM, ligand is MK1775
5vc6  2.00  2017  Kd=13.6nM     // 5v5y.pdf (P48) [Nonstandard assay: Temp 15] Kd=13.6+/-2.0nM, ligand is PHA-848125
5ut0  2.10  2017  Kd=1323nM     // 5usy.pdf (35R) ligand is AT9283.
5tci  2.45  2017  Kd=132nM      // 5tcf.pdf (79V) ligand is BRD4592.
5mk1  2.50  2017  Kd=132uM      // 5mjy.pdf (18-mer) ligand is CHMP4A peptide
5wkf  2.95  2017  Kd=136uM      // 5wjl.pdf (10-mer)  D30 TCR/GTS1;+/-7.0
6b7f  2.56  2017  Kd=136uM      // 6b7a.pdf (CW4)  CoaD in complex with compound 15;+/- 23
5wxg  1.70  2017  Kd=137uM      // 5wxg.pdf (7-mer) H3K4ac
5ldm  2.46  2017  Kd=139uM      // 5ldk.pdf (2AM) LigT/2'-AMP
5j6l  1.75  2017  Kd=13nM       // 5j20.pdf (6GC) ligand is compound 16
5ml2  1.60  2017  Kd=13nM       // 5ml2.pdf (NH6) +/-4, comp.3
5ipc  1.30  2017  Kd=13uM       // 5ipc.pdf (6CE) complex (ES1) of H112N-3
5jsg  2.50  2017  Kd=14.2uM     // 5jsg.pdf (6P9) Spindlin1 bound to compound EML405(2)
5wyq  2.16  2017  Kd=14.4uM     // 5wyq.pdf (SAM) Kd=14.4+/-3.1uM
5vwi  1.75  2017  Kd=14.5uM     // 5vwi.pdf (8-mer) PDZ3/beta-PIX;+/- 2.1
5j64  1.38  2017  Kd=140nM      // 5j20.pdf (6G7) Kd = 140 +/- 17 nM, ligand is compound 1
5wkh  3.20  2017  Kd=142.5uM    // 5wjl.pdf (10-mer) D30 TCR/GTS3/4; +/-2.5
5ku6  1.80  2017  Kd=143nM      // 5jn8.pdf (MZM) fluorescent thermal shift assay
5mi3  2.80  2017  Kd=146nM      // 5mi3.pdf (GDP) [Multiple sites: site 1: Kd =146 +/1 nM; site 2: Kd = 5.7 +/- 0.5 nM; site 3: Kd = 1.64 +/- 0.02 nM] Kd = 146 +/- 1 nM
5uc1  2.35  2017  Kd=14nM       // 5uc1.pdf (486) [Nonstandard assay: in the presence of NCoR] Kd = 14 +/- 2 nM, ligand is RU-486
5wuk  2.03  2017  Kd=14nM       // 5wuk.pdf (73K) EED226; +/-8
5u5l  2.55  2017  Kd=14uM       // 5u5l.pdf (7VA) ligand is rivoglitazone.
5vcv  1.92  2017  Kd=150nM      // 5v5y.pdf (1N1) Kd=150+/-9.1nM, ligand is Dasatinib
5vfm  2.06  2017  Kd=150uM      // 5vfj.pdf (HC4) Kd=150+/-20uM, ligand is CuA. Microscale thermophoresis (MST) assays
5wbf  2.19  2017  Kd=155uM      // 5wbf.pdf (LAC) TlpC LBD/lactate
5nk6  1.27  2017  Kd=158nM      // 5njz.pdf (90W) ligand is compound 2d
6bnh   NMR  2017  Kd=158uM      // 6bnh.pdf (13-mer) BRD4 ET domain/JMJD6 peptide; +/- 14
5kj2  1.95  2017  Kd=15nM       // 5kj2.pdf (6TF) Kd=15+/-0.1nM
5lvf   NMR  2017  Kd=15uM       // 5lvf.pdf (16-mer) [Nonstandard assay: Temp 10] pThr4-CTD, +/-1
5orl  1.69  2017  Kd=15uM       // 5orl.pdf (A4W) comp.1
5jn9  2.10  2017  Kd=16.2nM     // 5jn8.pdf (EZL) fluorescent thermal shift assay
5uwi  2.14  2017  Kd=1600nM     // 5uwh.pdf (18-mer) ligand is HDAC5 NES Peptide
5uwp  2.05  2017  Kd=1600nM     // 5uwh.pdf (19-mer) ligand is mDia2 NES Peptide
5j8m  1.90  2017  Kd=160nM      // 5j20.pdf (6DL) ligand is compound 6
5gvp  2.26  2017  Kd=165nM      // 5gvk.pdf (GCF) [Different protein in assay: assay uses PfSHMT]
5os4  1.88  2017  Kd=1665uM     // 5orl.pdf (A8H) ligand is compound 17
5njz  1.77  2017  Kd=16nM       // 5njz.pdf (8ZH) ligand is compound 1g
5j3l  1.66  2017  Kd=16uM       // 5ioy.pdf (6FR) ligand is compound 5
5jzi  2.50  2017  Kd=16uM       // 5jzi.pdf (10-mer) HCV1406-NS3/A2 complex
5mtx  1.80  2017  Kd=17.7nM     // 5mtx.pdf (FJI) comp.8m
5oug  2.57  2017  Kd=1703.44uM  // 5oug.pdf (9Z0) +/-627.74, fragment.4, crystal is fragment4+lobeline
5mi5  2.15  2017  Kd=170nM      // 5mi4.pdf (OAN) +/-10, PUGNAc
5nvz  2.70  2017  Kd=170nM      // 5nvv.pdf (9BN) +/-30, comp.16
5nvw  2.20  2017  Kd=170nM      // 5nvv.pdf (9BW) +/-30, ligand is compound 6
5ugh  2.06  2017  Kd=170nM      // 5ugh.pdf (8AJ) Kd=170+/-1.1nM, ligand is PF-9366.
5orr  2.09  2017  Kd=170uM      // 5orl.pdf (A5Q) comp.5
5v8o  3.10  2017  Kd=171uM      // 5v8h.pdf (8ZM) ligand is compound 15.
5x9h  3.60  2017  Kd=172uM      // 5x9g.pdf (ATP) full-length MgtE in complex with ATP AND MG2+
6bhh  1.85  2017  Kd=174uM      // 6bhd.pdf (18-mer) 3TD(W358A)- H3K9me2/K14ac;+/-12
5ntt  2.75  2017  Kd=1764nM     // 5mrb.pdf (SVE) +/-204, NMS-P715
5ldo  2.75  2017  Kd=177uM      // 5ldk.pdf (3AM) LigT/3'-AMP
5j6n  1.90  2017  Kd=17nM       // 5j20.pdf (6FF) ligand is compound 14
5j9x  1.80  2017  Kd=17nM       // 5j20.pdf (6GC) Kd = 17 +/- 1.8 nM, ligand is compound 16
5j6a  2.05  2017  Kd=17nM       // 5j6a.pdf (P46) PDK2 + 17
5mg2  1.75  2017  Kd=17nM       // 5mg2.pdf (7M8) compound 5/ TAF1 BD2
5w5s  2.28  2017  Kd=17nM       // 5w5s.pdf (12-mer) [Different protein in assay: protein in binding assay is H1N1 A/California/07/ 2009 (H1/Cal)] P5;+/- 4;
5iyy  1.60  2017  Kd=17uM       // 5ijr.pdf (R40) Kd = 17 +/- 1 uM, ligand is R7
5wqd  3.00  2017  Kd=17uM       // 5wqd.pdf (16-mer) wide type;
5y62  3.00  2017  Kd=18.4mM     // 5y61.pdf (5GP) YfiR-GMP
5gmn  1.80  2017  Kd=18.8uM     // 5gmm.pdf (949) protein is CA II, ligand is Polmacoxib
5lla  1.50  2017  Kd=18.9nM     // 5lla.pdf (6YQ) [Nonstandard assay: Temp 37] complex is CA XIII-2 a
5j27  1.70  2017  Kd=180nM      // 5j20.pdf (6FF) Kd = 180 +/- 61 nM, ligand is compound 14
5u7m  3.03  2017  Kd=180nM      // 5u7m.pdf (83G) ligand is BMS-378806.
5os2  1.92  2017  Kd=1821uM     // 5orl.pdf (A7K) compound 15
5nk2  1.65  2017  Kd=182nM      // 5njz.pdf (8ZZ) compound 2b
5x73  2.50  2017  Kd=184nM      // 5x72.pdf (P59) complex with R-1;
5gvm  2.24  2017  Kd=186nM      // 5gvk.pdf (G57) [Different protein in assay: assay uses PfSHMT]
5j2x  1.22  2017  Kd=18nM       // 5j20.pdf (6DL) Kd = 18 +/- 4.2 nM, ligand is compound 6
5y61  2.99  2017  Kd=19.1mM     // 5y61.pdf (5GP) YfiBL43P-YfiR-GMP
5otc  2.20  2017  Kd=19.3uM     // 5org.pdf (AQK) +/-1.37,noroctipinic acid
5kma  1.55  2017  Kd=19.6uM     // 5kly.pdf (777)
5wip  2.62  2017  Kd=19.6uM     // 5wic.pdf (XXO)  239852;+/-1.2
5o58  1.55  2017  Kd=191nM      // 5o1u.pdf (2-mer) +/-36, 5'-pApG, 2-mer RNA
5nki  1.68  2017  Kd=19nM       // 5njz.pdf (8ZW) ligand is compound 4b
5nkc  1.45  2017  Kd=19nM       // 5njz.pdf (90T) ligand is compound 2h
6asz  1.52  2017  Kd=19uM       // 5kog.pdf (6-mer)
5wlg  2.10  2017  Kd=19uM       // 5wlg.pdf (9-mer) Kd(WT)=19.0+/-0.3uM,
5nk4  1.45  2017  Kd=2.0nM      // 5njz.pdf (90E) ligand is compound 2c
5mro  1.80  2017  Kd=2.0uM      // 5mrm.pdf (Q9P) +/-0.1, compound 1
5ouh  2.50  2017  Kd=2.14uM     // 5oug.pdf (L0B) +/-1.06, alpha-lobeline
5n18  1.45  2017  Kd=2.1uM      // 5n16.pdf (8HZ) +/-0.2, compound 1
5o2d  1.60  2017  Kd=2.1uM      // 5o2d.pdf (9HH) MnK2-13
6esj  2.98  2017  Kd=2.1uM      // 6ep4.pdf (PRM) propidium/hBChE;+/- 0.4
5gv2  2.06  2017  Kd=2.23uM     // 5gv2.pdf (ARG) Kd=2.23+/-0.20uM
5n93  2.10  2017  Kd=2.2nM      // 5n7v.pdf (8QE) TC-Mps1-12
5g5z  2.01  2017  Kd=2.2uM      // 5g5z.pdf (DQR) complex is FusA/kestose
5x74  2.25  2017  Kd=2.3nM      // 5x72.pdf (JAY) complex with 2c; +/-0.8
6azk  2.48  2017  Kd=2.3uM      // 6au5.pdf (11-mer) (AHA)QFDLST R(PrOH)RLK
5lvd  1.25  2017  Kd=2.4mM      // 5lvd.pdf (79F) TLN-5
5n9s  2.30  2017  Kd=2.4nM      // 5n7v.pdf (8QW) BAY 1161909
6euv  2.70  2017  Kd=2.4nM      // 6euv.pdf (21G) A/Victoria(H3N2) PB2 cap-midlink;+/- 1.3
5tpb  2.60  2017  Kd=2.6mM      // 5tpb.pdf (3-mer) Kd=2.6+/-0.5mM, ligand is sialyl-T.  ligand is glycan.
5nbw  2.40  2017  Kd=2.6nM      // 5nbw.pdf (8SK) Benzo[a]pyrene
5mgx  2.18  2017  Kd=2.6uM      // 5mgx.pdf (8-mer) [Different ligand in assay: full length Hsp90beta] +/-0.2, Hsp90 MEEVD
5n9r  2.23  2017  Kd=2.6uM      // 5n9r.pdf (8RN) +/-0.1, compound 2
5lpm  1.50  2017  Kd=2.77uM     // 5lpj.pdf (71Y) [Nonstandard assay: Temp 4] p300 bound to XDM3d:
5j6m  1.64  2017  Kd=2.7nM      // 5j20.pdf (6FJ) ligand is compound 20
6au5  2.48  2017  Kd=2.7uM      // 6au5.pdf (11-mer) (AHA)QFDLST R(nBu)RLK
6ayh  2.05  2017  Kd=2.7uM      // 6ayh.pdf (C3G) SeGusR/PNPG
5n8j  1.05  2017  Kd=2.87uM     // 5n7x.pdf (12-mer) [Nonstandard assay: pH=5.0] GyGlanvdessG,  code in paper is 5N8S
5n53  1.48  2017  Kd=2.8mM      // 5n53.pdf (8NB) [Different protein in assay: crystal:PHGDH-93, binding assay: sPHGDH] +/-1.6, frag.15
5gja  2.10  2017  Kd=2.8uM      // 5gja.pdf (6PC) Kd=2.8+/-0.2uM, ligand is 2-PA
5jy0  2.60  2017  Kd=2.8uM      // 5jwg.pdf (4-mer) PeDPP11:LDVW; incomplete ligand structure
6bw3  2.20  2017  Kd=2.96uM     // 6bw3.pdf (12-mer) Kd(PRDM3)=2.96+/-0.34uM
5szc  1.19  2017  Kd=20.4uM     // 5szb.pdf (18-mer) Kd(H3K4me1)=20.4+/-2.3uM
5uwj  2.22  2017  Kd=2000nM     // 5uwh.pdf (15-mer) ligand is FMRP NES Peptide
5nvv  2.10  2017  Kd=200nM      // 5nvv.pdf (9BT) +/-30, compound 3
5tgc  3.25  2017  Kd=200nM      // 5tgc.pdf (ATP) ligand is ATP
5ml3  1.40  2017  Kd=203pM      // 5ml2.pdf (DL3) +/-31, comp.5
5h85  1.70  2017  Kd=20uM       // 5eic.pdf (5XS) ligand is compound 20
5ipa  1.78  2017  Kd=20uM       // 5ioy.pdf (6C8) ligand is compound 7
5vfj  2.08  2017  Kd=20uM       // 5vfj.pdf (DHC) Kd=20+/-10uM, ligand is CaA. Microscale thermophoresis (MST) assays
5wbm  2.16  2017  Kd=20uM       // 5wbm.pdf (A4G) ligand is compound 3
5vdq  3.25  2017  Kd=215uM      // 5vdo.pdf (9BG) Kd=215+/-81uM, ligand is 2',5'-cGpAp, complex is cGAS161/2',5'-cGpAp
5nkg  1.10  2017  Kd=21nM       // 5njz.pdf (8ZK) ligand is compound 3d
5wyz  2.30  2017  Kd=21nM       // 5wyx.pdf (7VF) [Nonstandard assay: PH=5.5] CU-CPT9b
5yjm  1.90  2017  Kd=21nM       // 5yjm.pdf (8W3) human chymase/O-phenylamidoxime 5f
5kab  1.97  2017  Kd=21uM       // 5k9w.pdf (OTA) PTP1B delta7 P185G:TCS401
5vdt  2.58  2017  Kd=21uM       // 5vdo.pdf (4BW) Kd=21+/-5uM, ligand is 3',3'-cGAMP, complex is cGAS161/3',3'-cGAMP
5w99  1.59  2017  Kd=21uM       // 5w99.pdf (A1V) PbtD-TSP;+/-3
5xvu  3.00  2017  Kd=22.3uM     // 5xvu.pdf (ATP) [Nonstandard assay: in the absence of Mg2+]
5w94  3.19  2017  Kd=22.6uM     // 5w94.pdf (6-mer) Scc2/4 complex bound to the Ctf19 phosphorylated peptide;+/- 3.0
5b6c  1.55  2017  Kd=221uM      // 5b6c.pdf (11-mer) Kd=221+/-36uM, N-terminal domain of p97 and the SHP box of Ufd1
5m17  1.03  2017  Kd=221uM      // 5lyr.pdf (2-mer) +/-11, ligand is compound 5
5nk8  1.76  2017  Kd=229nM      // 5njz.pdf (90Z) ligand is compound 2f
5tcy  1.90  2017  Kd=22nM       // 5a5d.pdf (5LC) ligand is H227L-5-Lic
5j1r  1.92  2017  Kd=22uM       // 5ioy.pdf (6FG) ligand is compound 8
6ezq  2.39  2017  Kd=22uM       // 6ezq.pdf (C7K) ligand is compound 3f; +/- 3
5n34  1.22  2017  Kd=23.27uM    // 5mnr.pdf (8JQ) [Nonstandard assay: buffer is Cacodylate] +/-1.74, compound 3
5v13  1.84  2017  Kd=23.3nM     // 5v13.pdf (JH3) [Different ligand in assay: x-ray:The protein sample contained a 10-fold molar excess of racemic JH III] ligand is 10-R JH III.
5moc  1.80  2017  Kd=23.6uM     // 5mhc.pdf (12-mer) [Different ligand in assay: p53 CTD (15-mer)] +/-2.2
6bhe  1.35  2017  Kd=23.9uM     // 6bhd.pdf (18-mer) 3TDH3K9me3/K14ac;+/-0.9
5jq5  1.94  2017  Kd=2341nM     // 5jq5.pdf (I74) CDK2/ICEC0942
5jhk  1.80  2017  Kd=23uM       // 5ijr.pdf (6K8) Kd = 23 +/- 1 uM, ligand is R8
5wic  2.55  2017  Kd=23uM       // 5wic.pdf (FOA) 1E6;+/-1.9
5ulp  1.55  2017  Kd=24.3uM     // 5ulp.pdf (KB1) ligand is MS2042
5m77  1.46  2017  Kd=24.7nM     // 5m77.pdf (2-mer) +/-7.9, (ManS)2IFG 3
5mwj  2.04  2017  Kd=24.7nM     // 5mwj.pdf (EBU) [Multiple sites: Kd2=522+/-39.6 nM second binding, not multiple sites] +/-24.2, comp.18, Kd1
5km3  1.20  2017  Kd=24.9uM     // 5kly.pdf (U5P) [Different protein in assay: Protein in binding assay is H112N, and wt in crystal.]
5lud  1.25  2017  Kd=248uM      // 5lud.pdf (76X)
5ujv  2.70  2017  Kd=249uM      // 5ujv.pdf (A8S) Kd=249+/-14.1uM, ligand is ABA
5ta4  1.50  2017  Kd=24nM       // 5t9u.pdf (838) ligand is compound 8
5jgq  1.60  2017  Kd=24uM       // 5ijr.pdf (6JY) Kd = 24 +/- 0 uM, ligand is R6
5yco  2.20  2017  Kd=25.7uM     // 5yco.pdf (17-mer) PCNA-UHRF2PIP
5nw1  2.10  2017  Kd=250nM      // 5nvv.pdf (9BH) +/-50, ligand is compound 18
5oq4  2.70  2017  Kd=25nM       // 5oq4.pdf (A3W) comp.1
5t9u  2.30  2017  Kd=25nM       // 5t9u.pdf (7HG) ligand is compound 3
5ofv  1.50  2017  Kd=26.2mM     // 5ofv.pdf (9TZ) [Different protein in assay: crystal:PHGDH-93, binding assay: sPHGDH] +/-31.8, frag.14
5u0g  1.54  2017  Kd=26.2uM     // 5txy.pdf (7QY) ligand is compound 17
5n7g  2.95  2017  Kd=26.3uM     // 5n7g.pdf (7-mer) +/-7.3
5t9w  2.00  2017  Kd=2600nM     // 5t9u.pdf (78E) ligand is compound 5
5nkh  1.29  2017  Kd=26nM       // 5njz.pdf (8ZQ) compound 3e
5nkd  1.41  2017  Kd=26nM       // 5njz.pdf (91K) compound 2i
5ka3  2.14  2017  Kd=26uM       // 5k9w.pdf (OTA) PTP1B YAYA:TCS401; redundant to 5k9w
5k9w  2.01  2017  Kd=26uM       // 5k9w.pdf (OTA) PTP1B:TCS401
5vdk  2.70  2017  Kd=27.0nM     // 5v5y.pdf (8X7) Kd=27.0+/-3.6nM, ligand is MK1775
5ovr  2.15  2017  Kd=27.2uM     // 5ovr.pdf (AXK) +/-0.6, compound 2
5cpr  2.22  2017  Kd=27.5nM     // 5cpr.pdf (539) A-196/UV420H1-SAM complex
5vcy  1.56  2017  Kd=270nM      // 5v5y.pdf (DB8) Kd=270+/-17.2nM, ligand is Bosutinib
5h5o  2.12  2017  Kd=274nM      // 4kg1.pdf (PCG) Ka/Kd = 3.65*10^6/2.74*10(-7)
5os0  1.74  2017  Kd=2792uM     // 5orl.pdf (A6Z) comp.13
5w6r  2.73  2017  Kd=27nM       // 5w5s.pdf (12-mer) [Different protein in assay: protein in binding assay is H1N1 A/California/07/ 2009 (H1/Cal)] P6;+/- 9;
5w6t  2.59  2017  Kd=27nM       // 5w5s.pdf (12-mer) [Different protein in assay: protein in binding assay is H1N1 A/California/07/ 2009 (H1/Cal)] P7;+/- 7;
5ko5  1.36  2017  Kd=27uM       // 5ko5.pdf (CYT) Kd = 27 +/- 3 uM. ligand is cytosine
5u0d  1.59  2017  Kd=28.6uM     // 5txy.pdf (7R7) ligand is compound 14
5hyx  2.60  2017  Kd=280nM      // 5hyx.pdf (13-mer) [Nonstandard assay: Temp 20, pH 6.0, NaCl 100 mM] ligand is RGF1(peptide)
5tpx  2.10  2017  Kd=280nM      // 5tpx.pdf (7H7) ligand is L-45
5vcx  2.70  2017  Kd=2817nM     // 5v5y.pdf (H8H) Kd=2817+/-144.4nM, ligand is Saracatinib
5vd3  1.80  2017  Kd=2817nM     // 5v5y.pdf (H8H) Kd=2817+/-144.4nM, ligand is Saracatinib
5vkm  2.20  2017  Kd=281uM      // 5vkk.pdf (2-mer) [Incomplete ligand] [Different protein in assay: x-ray:(5A: N67A, N112A, N135A, N164A, N231A), assay:wt] Kd=281+/-10uM, ligand is alpha-2-6 sialyllactose
5v2l  2.10  2017  Kd=288uM      // 5v2l.pdf (ATP) Kd=288+/-36uM, ligand is ATP.
6b7e  2.10  2017  Kd=28uM       // 6b7a.pdf (CWA)  CoaD in complex with compound 14;+/- 4
5gmm  2.00  2017  Kd=29.1uM     // 5gmm.pdf (949) protein is CA I, ligand is Polmacoxib
5myo  1.59  2017  Kd=29.3pM     // 5my4.pdf (10-mer) AbetapE3-12 PEGb, octamers
5ly1  2.50  2017  Kd=29.8nM     // 5ly1.pdf (14-mer)
5tzy  3.22  2017  Kd=2nM        // 5tzr.pdf (7OS) Kd=2+/-0.3nM; ternary complex of GPR40/MK-8666/AgoPAM-AP8
5mqt  3.20  2017  Kd=2uM        // 5mqj.pdf (STI) [Multiple sites: site 1: Kd = 2 +/- 0.8 uM, site 2: Kd =36 +/- 6 uM] [Different protein in assay: Protein in binding assay is S74E] +/-0.8, imatinib
5lpk  2.10  2017  Kd=3.06uM     // 5lpj.pdf (XDM) [Nonstandard assay: Temp 4] p300 bound to XDM1:
5mrp  1.90  2017  Kd=3.0uM      // 5mrm.pdf (6BC) +/-0.3, compound 2
5nn6  2.00  2017  Kd=3.0uM      // 5nn4.pdf (MIG) NHE-DNJ
5w1w  3.10  2017  Kd=3.0uM      // 5w1v.pdf (9-mer) GF4 TCR-HLA-E-LVL;+/- 0.2
6bw4  2.00  2017  Kd=3.15uM     // 6bw3.pdf (12-mer) Kd(PRDM16)=3.15+/-0.36uM
5tq1  1.49  2017  Kd=3.21uM     // 5tq1.pdf (11-mer) Kd=3.21+/-0.36uM, ligand is IR-pep.
5vzy  2.32  2017  Kd=3.2nM      // 5vzx.pdf (15-mer) [Different ligand in assay: ligand in binding assay is 18-mer] Abeta11-28;
5mn1  0.79  2017  Kd=3.3mM      // 5mn1.pdf (2AP) +/-1.0
5mnb  0.94  2017  Kd=3.3mM      // 5mn1.pdf (2AP) +/-1.0, Determined by "low c value" ITC, 2-Aminopyridine
5mnx  1.42  2017  Kd=3.3mM      // 5mn1.pdf (2AP) +/-1.0, Determined by "low c value" ITC, 2-Aminopyridine
5mon  0.94  2017  Kd=3.3mM      // 5mn1.pdf (2AP) +/-1.0, Determined by "low c value" ITC, 2-Aminopyridine
5jnc  2.00  2017  Kd=3.3uM      // 5jn8.pdf (6LH) fluorescent thermal shift assay
5mav  2.58  2017  Kd=3.3uM      // 5mav.pdf (19-mer) +/-0.4, PARG peptide
5vwk  2.35  2017  Kd=3.3uM      // 5vwi.pdf (8-mer)  PDZ1/beta-PIX;+/- 0.3
5mnr  1.25  2017  Kd=3.44uM     // 5mnr.pdf (JC2) [Nonstandard assay: buffer is Cacodylate] +/-1.26, compound 7
5u0f  1.21  2017  Kd=3.4uM      // 5txy.pdf (7R1) ligand is compound 25
5nka  1.38  2017  Kd=3.5uM      // 5njz.pdf (91H) ligand is compound 2g
5txy  1.21  2017  Kd=3.5uM      // 5txy.pdf (7Q1) ligand is compound 10
5ty8  1.45  2017  Kd=3.5uM      // 5txy.pdf (7Q1) ligand is compound 10
5u13  1.95  2017  Kd=3.9uM      // 5u0v.pdf (YH5) Kd=3.9+/-0.2uM, ligand is compound 36
5jjm  2.15  2017  Kd=30.6nM     // 5jjm.pdf (8-mer) DHT-bound human AR-LBD with UBA3 59S-72V peptide
5nw0  2.30  2017  Kd=300nM      // 5nvv.pdf (9BK) +/-40, compound 17
5mod  2.08  2017  Kd=300uM      // 5ct0.pdf (86L) [Nonstandard assay: PH=8] ligand is compound 3
5vfn  2.39  2017  Kd=300uM      // 5vfj.pdf (HCI) Kd=300+/-50uM, ligand is CiA. Microscale thermophoresis (MST) assays
5m2q  1.70  2017  Kd=30nM       // 5m29.pdf (CBY) [Uncommon element] +/- 7 Cbi
5jhd  2.46  2017  Kd=30uM       // 5isz.pdf (9-mer) ligand is peptide LS10
5w88   NMR  2017  Kd=30uM       // 5w88.pdf (9XG) 3-mDPA;
5wcl   NMR  2017  Kd=30uM       // 5w88.pdf (9XG) 3-mDPA;
5ovx  2.10  2017  Kd=31.4uM     // 5ovr.pdf (AY5) [Nonstandard assay: Temp 30] +/-0.8, compound 3
5myg  2.30  2017  Kd=31nM       // 5myg.pdf (LS8) [Nonstandard assay: Temp 15] comp.16
5usy  2.00  2017  Kd=31nM       // 5usy.pdf (SKE) ligand is JNJ-7706621.
5tya  1.50  2017  Kd=32.9uM     // 5txy.pdf (7QS) ligand is compound 13
5nw2  2.20  2017  Kd=320nM      // 5nvv.pdf (9B8) +/-20, compound 19
5w6u  2.88  2017  Kd=3230nM     // 5w5s.pdf (12-mer) [Different protein in assay: protein in binding assay is H1N1 A/California/07/ 2009 (H1/Cal)] P2;+/- 311;
5vd0  2.13  2017  Kd=324nM      // 5v5y.pdf (8X7) Kd=324+/-27.3nM, ligand is MK1775
5isz  2.06  2017  Kd=32uM       // 5isz.pdf (9-mer) ligand is peptide LS01
5wii  2.79  2017  Kd=32uM       // 5wic.pdf (AO4) 4H10;+/-1.8
6b7a  1.99  2017  Kd=32uM       // 6b7a.pdf (CWM) CoaD in complex with compound 1; +/-4
5ma7  1.30  2017  Kd=336uM      // 5lvd.pdf (7K0) TLN-6
5w4r  3.00  2017  Kd=33nM       // 5w4r.pdf (9WD) compound 24b
5ka1  1.84  2017  Kd=33uM       // 5k9w.pdf (OTA) PTP1B delta 7:TCS401
5j8u  1.75  2017  Kd=340nM      // 5j20.pdf (6DL) ligand is compound 1
5ndd  2.80  2017  Kd=344nM      // 5ndd.pdf (8TZ) +/-740, AZ8838
5o91  3.20  2017  Kd=349nM      // 5mrb.pdf (C5N) +/-81, comp.5
5ory  1.99  2017  Kd=357uM      // 5orl.pdf (AY4) comp.11
5ml6  1.87  2017  Kd=358pM      // 5ml2.pdf (9GD) +/-36, comp.8
5f61  1.45  2017  Kd=35nM       // 5f5z.pdf (5W0) ligand is compound 3
5b6g  1.99  2017  Kd=36nM       // 5b6g.pdf (9-mer)
5h5f  1.70  2017  Kd=37.2uM     // 5h5d.pdf (SAM) Kd=37.2+/-3.59uM, Sfm1-SAM
5tus  2.66  2017  Kd=37.4uM     // 5tus.pdf (7LL) Kd=37.4+/-4.7uM, ligand is NSAH.
5w1v  3.31  2017  Kd=37.4uM     // 5w1v.pdf (9-mer) GF4 TCR-HLA-E-LIL;+/- 3.9
5os3  1.81  2017  Kd=3753uM     // 5orl.pdf (A7N) comp.16
5x62  2.20  2017  Kd=379nM      // 5x62.pdf (SAH) SAH-bound YNL092W
5kad  1.90  2017  Kd=37uM       // 5k9w.pdf (OTA) PTP1B N193A :TCS401
5tw5  1.85  2017  Kd=38.1nM     // 5tw2.pdf (7LM) ligand is compound 23.
5jm4  2.34  2017  Kd=38nM       // 5jm4.pdf (11-mer) [Different ligand in assay: Ligand in binding assay is FITC-labeled] ligand is peptide 22
5nk3  1.59  2017  Kd=38nM       // 5njz.pdf (92Q) ligand is compound 1l
5mk9  0.92  2017  Kd=38uM       // 5m28.pdf (BCD) +/-0.4, beta-cyclodextrin
5km2  1.25  2017  Kd=39.1uM     // 5kly.pdf (C5P) [Different protein in assay: Protein in binding assay is H112N, and wt in crystal.]
5ne5  1.05  2017  Kd=39nM       // 5ne5.pdf (KIF) Kifunensine (compound 1)
5ka9  2.07  2017  Kd=39uM       // 5k9w.pdf (OTA) PTP1B L192A:TCS401
5n70  1.81  2017  Kd=3nM        // 5n70.pdf (8-mer) ligand is peptide [1-8]
5vi6  1.24  2017  Kd=3nM        // 5vi6.pdf (4-mer) Kd=3+/-1nM, ligand is Trapoxin A
5j1x  2.10  2017  Kd=3uM        // 5ijr.pdf (AR5) Kd = 3 +/- 1 uM, ligand is R5
5wqj  1.20  2017  Kd=3uM        // 5wqj.pdf (7N3) [Nonstandard assay: PH=9] compound 1
5wrs  2.75  2017  Kd=3uM        // 5wrs.pdf (ATP) apparent dissociation constant  values
5mek  1.74  2017  Kd=4.2uM      // 5mek.pdf (A3P) +/-2.6, PAP
5fsc  1.95  2017  Kd=4.4mM      // 5fsb.pdf (G8Z) Kd = 4.4 +/- 1.5 mM, ligand is All4MeMan
5mi9  3.30  2017  Kd=4.5nM      // 5mi8.pdf (GDP) nonphosphorylated protein
5l26  3.40  2017  Kd=4.5uM      // 5l24.pdf (URI)
5u11  1.99  2017  Kd=4.5uM      // 5u0v.pdf (7PS) Kd=4.5+/-0.1uM, ligand is compound 41
5u14  1.95  2017  Kd=4.6uM      // 5u0v.pdf (7PV) Kd=4.6+/-0.1uM, ligand is compound 60
5wp5  1.50  2017  Kd=4.6uM      // 5wp4.pdf (SAH) AtPMT2/SAH
5n8e  1.10  2017  Kd=4.7uM      // 5n7x.pdf (13-mer) [Nonstandard assay: pH=5.0] RDPAPAWAHGGG
5nf9  1.87  2017  Kd=4.7uM      // 5nf7.pdf (8VW) comp.2
5mlo  1.96  2017  Kd=4.8uM      // 5mlo.pdf (15-mer) ZRANB3 PIP box peptide
5n17  1.60  2017  Kd=4.8uM      // 5n16.pdf (8FK) +/-1.0, compound 1
5mz8  2.20  2017  Kd=4.9mM      // 5mz8.pdf (SIN) +/-0.7, succinate, by MST
5km0  1.53  2017  Kd=4.9uM      // 5kly.pdf (IMP) [Different protein in assay: Protein in binding assay is H112N, and wt in crystal.]
5n2z  1.37  2017  Kd=4.9uM      // 5mnr.pdf (8JH) [Nonstandard assay: buffer is Cacodylate] +/-0.32, compound 1
5m29  1.50  2017  Kd=40nM       // 5m29.pdf (CBY) [Uncommon element] +/- 10 Cbi
5tuz  1.95  2017  Kd=40nM       // 5tuy.pdf (7L6) [Nonstandard assay: PH=8] Kd=40+/-5nM, ligand is compound 4.
5os5  1.74  2017  Kd=410uM      // 5orl.pdf (A8K) compound 18
5ufp  1.90  2017  Kd=42.5nM     // 5t0t.pdf (86D) ligand is PT2399
5lny  1.88  2017  Kd=42nM       // 5lny.pdf (70K) Kd = 42 +/- 5.7 nM. ligand is compound 3b
5tcj  2.40  2017  Kd=42nM       // 5tcf.pdf (79V) ligand is BRD4592
5ut4  2.00  2017  Kd=42uM       // 5ut4.pdf (DQX) Kd=42+/-3.5uM, ligand is 2.
5vc4  2.10  2017  Kd=43.7nM     // 5v5y.pdf (XZN) [Nonstandard assay: Temp 15] Kd=43.7+/-10nM, ligand is Bos.isomer
5orz  1.92  2017  Kd=432uM      // 5orl.pdf (A6W) comp.12
5f60  1.35  2017  Kd=43nM       // 5f5z.pdf (5VZ) ligand is compound 2
5t78  2.20  2017  Kd=43nM       // 5t6p.pdf (8-mer) Kd=43+/-3.6nM, ligand id MUC1 Glycopeptide.
5vcz  1.50  2017  Kd=444nM      // 5v5y.pdf (XZN) Kd=444+/-41.0nM, ligand is Bos. isomer
5tuy  2.60  2017  Kd=445nM      // 5tuy.pdf (7L6) [Nonstandard assay: PH=8] Kd=445+/-40nM, ligand is compound 4.
5wbp  2.74  2017  Kd=44uM       // 5wbm.pdf (A2J) Compound 5
5n3v  1.12  2017  Kd=45.24uM    // 5mnr.pdf (8L5) [Nonstandard assay: buffer is Cacodylate] +/-3.41, compound 4
5goe  1.80  2017  Kd=45.7uM     // 5goe.pdf (GDP) GDPbound MFN1IMC(T109A)
5jna  2.00  2017  Kd=45nM       // 5jn8.pdf (TOR) fluorescent thermal shift assay
5tgy   NMR  2017  Kd=45nM       // 5tgy.pdf (7BU) [Uncommon element] [Nonstandard assay: Temp 50] Kd=45+/-4nM, ligand is (CF3)4PZn
5ka7  2.06  2017  Kd=45uM       // 5k9w.pdf (OTA) PTP1B T178A:TCS401
5yc1  2.51  2017  Kd=46.1uM     // 5yc1.pdf (5-mer) GPIbbeta
5w38  1.80  2017  Kd=46.5nM     // 5w38.pdf (7-mer) [Covalent complex] [Different ligand in assay: ligand in crystal is 3-mer] Man5-IgG3 Fc
5x72  1.95  2017  Kd=467nM      // 5x72.pdf (P59/P69) complex with R-1 AND S-1;+/- 65
5nk7  1.89  2017  Kd=468nM      // 5njz.pdf (8ZZ) compound 2a
5ttg  1.66  2017  Kd=46nM       // 5ttf.pdf (7KZ) Kd = 46 +/- 15 nM. complex is GLP/compound 18
5mrb  2.20  2017  Kd=471nM      // 5mrb.pdf (C5N) +/-50, compound 5/Mps1 C604Y
5mnc  0.92  2017  Kd=48.5mM     // 5mn1.pdf (ANL) +/-7.3, Determined by "low c value" ITC, Aniline
5mny  1.43  2017  Kd=48.5mM     // 5mn1.pdf (WOT) +/-7.3, Determined by "low c value" ITC, Aniline
5moo  1.44  2017  Kd=48.5mM     // 5mn1.pdf (WOT) +/-7.3, Determined by "low c value" ITC, Aniline
5ogl  2.70  2017  Kd=48.5uM     // 5ogl.pdf (9UB) (omegaZZZ)-PPC-GlcNAc
5gmu  1.80  2017  Kd=480uM      // 5gmu.pdf (7LH)
5m28  1.08  2017  Kd=48uM       // 5m28.pdf (MLR) +/-1.9, maltotriose
5tw2  1.75  2017  Kd=49.7nM     // 5tw2.pdf (7LP) ligand is compound 5.
5os1  1.90  2017  Kd=494uM      // 5orl.pdf (A7H) comp.14
5u9i  2.30  2017  Kd=49nM       // 5u9i.pdf (FAR) [Incomplete ligand] Kd=49+/-8nM, ligand is FC, AIPL1-FKBP:FC complex
5mka  1.15  2017  Kd=49uM       // 5m28.pdf (RCD) +/-1.3, gamma-cyclodextrin
5ll4  1.12  2017  Kd=4nM        // 5ll4.pdf (6YH) [Nonstandard assay: Temp 37] complex is CA II-1 a
5jsj  2.35  2017  Kd=4uM        // 5jsg.pdf (6PD) Spindlin1 bound to compound EML631(6)
5lsg  2.00  2017  Kd=4uM        // 5lsg.pdf (QZQ) PPAR gamma /BA
5mqe  1.65  2017  Kd=4uM        // 5mpz.pdf (PKU) ligand is compound 1
5v2p  2.00  2017  Kd=5.1nM      // 5v2p.pdf (19-mer) [Nonstandard assay: Temp 15] Kd=5.1+/-1.6nM, ligand is peptide AID-CAP.
5y59  2.40  2017  Kd=5.1uM      // 5y58.pdf (12-mer) [Nonstandard assay: Tem 16 C,PH=8] ligand is Sir4 peptide,Kd=5.1+/-0.9uM
5v2q  1.70  2017  Kd=5.2nM      // 5v2p.pdf (19-mer) [Nonstandard assay: Temp 15] Kd=5.2+/-1.5nM, ligand is peptide AID-CEN.
5g5f  2.30  2017  Kd=5.2uM      // 5g5f.pdf (GSH) GSH-MiGSTU
5ltn  1.88  2017  Kd=5.38uM     // 5ltn.pdf (XI7) [Nonstandard assay: with ions] Kd = 5.38 +/- 2.06 uM. ligand is DPBA
5irr  2.04  2017  Kd=5.4uM      // 5irr.pdf (GSP)
5mxo  1.20  2017  Kd=5.4uM      // 5mhc.pdf (3-mer) [Nonstandard assay: FC-A 1 mM] [Different ligand in assay: p53 CTD (15-mer)] +/-0.84
5twj  2.30  2017  Kd=5.58uM     // 5twj.pdf (SAM) Kd=5.58+/-0.31uM, ligand is SAM
5j86  1.87  2017  Kd=5.5nM      // 5j20.pdf (6GW) Kd = 5.5 +/- 3.2 nM, ligand is compound 18
5b5f  1.20  2017  Kd=5.6uM      // 5b5f.pdf (6F3) ligand is compound ALiS3
5b5g  1.50  2017  Kd=5.6uM      // 5b5f.pdf (6FX) ligand is compound ALiS4
5nfa  1.59  2017  Kd=5.6uM      // 5nf7.pdf (8VQ) comp.2
5xup  2.10  2017  Kd=5.6uM      // 5xup.pdf (12-mer) [Different ligand in assay: ligand in binding assay is 15-mer] TRF1TRFH-TERB1TBM;+/- 0.69
5m9w  1.21  2017  Kd=5.7mM      // 5lvd.pdf (7GR) TLN-1
5n7x  1.12  2017  Kd=5.7uM      // 5n7x.pdf (12-mer) [Nonstandard assay: pH=5.0] +/-0.29;EWVHPQFEQKAK
5nzo  1.29  2017  Kd=5.8mM      // 5nzo.pdf (9EZ) [Different protein in assay: crystal:PHGDH-93, binding assay: sPHGDH] +/-2.0, frag.3
5w1e  2.06  2017  Kd=5.8uM      // 5w1e.pdf (PHB) +/-0.5uM
5tzo  1.67  2017  Kd=5.9uM      // 5tvy.pdf (7V7) ligand is Fentanyl.
5jn8  1.85  2017  Kd=50nM       // 5jn8.pdf (AZM) fluorescent thermal shift assay
5mi6  2.00  2017  Kd=50nM       // 5mi4.pdf (NHT) Kd=50+/-7.6nM; ligand is thiamet-G(2)
5jgi  1.38  2017  Kd=50uM       // 5ijr.pdf (AAG) Kd = 50 +/- 3 uM, ligand is R4
5vsc  1.40  2017  Kd=510nM      // 5vsc.pdf (9HJ)  G9a-SAM-13; +/- 62
5mgj  2.10  2017  Kd=51uM       // 5mge.pdf (7MX) ligand is compound 1
5t8r  2.40  2017  Kd=51uM       // 5t8r.pdf (10-mer) Kd=51+/-2uM, peptide sequence is ARTKQTARKS.
5moe  1.89  2017  Kd=520uM      // 5ct0.pdf (OQC) [Nonstandard assay: PH=8] ligand is compound 6
6b7d  1.80  2017  Kd=52uM       // 6b7a.pdf (CWG)  CoaD in complex with compound 9;+/- 12
5lo6  2.40  2017  Kd=53.9nM     // 5lo5.pdf (70O) Kd(36)=53.9+/-9.3nM, kon=2.53E+4, koff=1.39E-3
5mgf  1.90  2017  Kd=54uM       // 5mge.pdf (7MW) ligand is compound 2
6bhi  1.40  2017  Kd=55.6uM     // 6bhd.pdf (16-mer) 3TD(W358A)- H3K9me3/K14ac;+/-5.5
5km9  1.45  2017  Kd=55.9uM     // 5kly.pdf (ADN) complex with hHint2
2ndo   NMR  2017  Kd=565uM      // 2ndo.pdf (SFQ) Kd=565+/-33uM, EcDsbA/sulfonamide1 co-complex
5uff  2.14  2017  Kd=57.1uM     // 5ufc.pdf (8B7) ligand is 2'-Fucosyllactose
5ut6  1.65  2017  Kd=57.3uM     // 5ut4.pdf (8MY) Kd=57.3+/-2.8uM, ligand is compound 8
5tv1  2.40  2017  Kd=57nM       // 5tv1.pdf (IHP) site1, ligand is IP6,domain, MST-measured fluorescence binding isotherm
5vsd  1.85  2017  Kd=57nM       // 5vsc.pdf (9HJ)  GLP-SAM-13;+/- 8
5u0w  1.97  2017  Kd=58uM       // 5u0v.pdf (9MG) Kd=58+/-8uM, ligand is compound 7
5if6  2.50  2017  Kd=59nM       // 5ier.pdf (3QZ) Kd = 59 +/- 7.5 nM. complex is OHP9_1c/17-OHP
6au2  1.63  2017  Kd=5mM        // 6au2.pdf (CGJ) compound 2
5n16  1.76  2017  Kd=5uM        // 5n16.pdf (8FN) +/-2.5, comp.1
5x9o  1.58  2017  Kd=5uM        // 5x9o.pdf (80R) 1a with BCL6
5fsb  1.65  2017  Kd=6.0mM      // 5fsb.pdf (6YR) Kd = 6.0 +/- 0.3 mM, ligand is 2MeSeFuc
5ty1  1.60  2017  Kd=6.1uM      // 5txy.pdf (7QV) ligand is compound 11
5ty9  1.53  2017  Kd=6.1uM      // 5txy.pdf (7QV) ligand is compound 11
5x13  1.70  2017  Kd=6.2uM      // 5x11.pdf (HC4) [Nonstandard assay: TEMP 4] ligand is p-coumaric acid
5xxk  1.66  2017  Kd=6.337nM    // 5xxk.pdf (12-mer) apled peptide (M011) bound to Mdm2-M62A
5lu2  2.50  2017  Kd=6.3uM      // 5ltw.pdf (13-mer) Correct Kd=6.3uM for pHSPB6(11-23) phosphopeptide; wrong Kd=0.56uM is for full length pHSPB6
5tco  2.10  2017  Kd=6.46nM     // 5tbe.pdf (79Q) ligand is compound 2, Kd=(6.46+3.14)/2nM
5nzp  1.30  2017  Kd=6.5mM      // 5nzp.pdf (9EW) [Different protein in assay: crystal:PHGDH-93, binding assay: sPHGDH] +/-4.7, frag.16
5tbp  2.60  2017  Kd=6.67uM     // 5tbp.pdf (7A4) ligand is K-80003.
5myx  1.49  2017  Kd=6.85nM     // 5my4.pdf (16-mer) +/-1.56, mAbetapE3-18 PEGb
5f62  1.35  2017  Kd=6.8nM      // 5f5z.pdf (5W1) ligand is compound 4
5ufc  1.89  2017  Kd=6.9uM      // 5ufc.pdf (3-mer) ligand is H-trisaccharide
5go2  1.91  2017  Kd=600uM      // 5go2.pdf (CIT)
5n99  1.50  2017  Kd=61.3uM     // 5n7x.pdf (5-mer) [Nonstandard assay: pH=5.0] NQpWQ
5osd  1.99  2017  Kd=619uM      // 5orl.pdf (A9B) comp.20
5jcb  2.30  2017  Kd=62.04uM    // 5jcb.pdf (NV4) tubulin-1S
5t6z  2.00  2017  Kd=62.1uM     // 5t6w.pdf (10-mer) Kd=62.1+/-6.57uM, ligand is peptide TW10.
5ofi  2.00  2017  Kd=62.7uM     // 5odu.pdf (9TQ) +/-3.8, flurescent ligand 1
5wbo  2.25  2017  Kd=62uM       // 5wbm.pdf (A1Y) ligand is compound 4
5ot8  2.35  2017  Kd=63.8uM     // 5org.pdf (6DB) +/-13.8, octopine
5ijr  1.52  2017  Kd=637uM      // 5ijr.pdf (HRG) Kd = 637 +/- 70 uM, ligand is R9
5t9z  1.40  2017  Kd=64nM       // 5t9u.pdf (78R) ligand is compound 6
5w5u  2.46  2017  Kd=64nM       // 5w5s.pdf (12-mer) [Different protein in assay: protein in binding assay is H1N1 A/California/07/ 2009 (H1/Cal)] P4;+/- 19;
5lt9  3.00  2017  Kd=64uM       // 5lt9.pdf (ARG) [Covalent complex] Data is from a reference
5vgy  1.39  2017  Kd=65.5uM     // 5txy.pdf (9AA) ligand is compound 27'
5nge  2.35  2017  Kd=65nM       // 5nge.pdf (8WK) FT671
5t35  2.70  2017  Kd=66nM       // 5t35.pdf (759) [Multiple sites: BRD4BD2-MZ1: Kd=15+/-1 nM; VCB-(MZ1-BRD4BD2): Kd=3.7+/-0.7 nM] +/-6, MZ1, PROTAC
5o0b  1.74  2017  Kd=66uM       // 5o0a.pdf (9FE) frag.2
5xn3  1.34  2017  Kd=671nM      // 5xn3.pdf (8-mer) cR8-SPSB2; +/-109
5gtr  2.80  2017  Kd=67nM       // 5gs4.pdf (10-mer) [Nonstandard assay: PH=8] [Different ligand in assay: FITC labeled] ER alpha LBD in complex with 6
5u28  1.80  2017  Kd=67nM       // 5u28.pdf (82V) Kd=67+/-7nM, ligand is SF2523
5ldk  2.10  2017  Kd=67uM       // 5ldk.pdf (ATP) LigT/ATP
5ldp  1.80  2017  Kd=67uM       // 5ldk.pdf (ATP) LigT/ATP
5ose  1.90  2017  Kd=681uM      // 5orl.pdf (A98) compound 21
5n1x  1.72  2017  Kd=689uM      // 5n1v.pdf (8HH) comp.2
5x4n  1.94  2017  Kd=68uM       // 5x4m.pdf (7ZL) BCL6/4
5fyx  1.80  2017  Kd=69.6uM     // 5aan.pdf (FD6) dNCS-1 bound to penothiazine FD16
6awp  3.80  2017  Kd=69nM       // 6awn.pdf (FVX) ligand is fluvoxamine,Ki=69+/-9nM,ligand in binding assay is possitive,in PDB is neutral
5t8q  2.63  2017  Kd=69uM       // 5t8f.pdf (76Y) ligand is fragment 17.
5ioy  1.77  2017  Kd=6uM        // 5ioy.pdf (6C5) [Nonstandard assay: pH = 8.0] urea 3 bound to EthR
5ja0  1.90  2017  Kd=6uM        // 5ja0.pdf (FPP) ligand is FPP, titrated in presence of Mg2+
5u6k  2.60  2017  Kd=6uM        // 5u6k.pdf (13-mer) Kd=6+/-2uM, ligand is pSer304 BLM peptide
5gp7  1.50  2017  Kd=7.1uM      // 5gp7.pdf (10-mer) [Different ligand in assay: Ligand in binding assay is USP25 (1049-1055), ] TNKS1 ARC5 in complex with the tankyrase-binding motif of USP25
6b7c  1.56  2017  Kd=7.2uM      // 6b7a.pdf (CWP)  CoaD in complex with compound 3;+/- 4.5
5kww  2.50  2017  Kd=7.4nM      // 5kww.pdf (6YA) RSV F in complex with fusion inhibitor JNJ-53718678
5vsb  1.85  2017  Kd=7.614uM    // 5vs6.pdf (9QA) USP7/1;+/- 3.216
6f0y   NMR  2017  Kd=7.78uM     // 6f0y.pdf (15-mer) Rtt109(419-433 )and Asf1;+/-1.23
5u0e  1.27  2017  Kd=7.7uM      // 5txy.pdf (7R4) ligand is compound 24
5kej  2.35  2017  Kd=7.8uM      // 5g5f.pdf (GTX) GSX-MiGSTU
5ngf  2.33  2017  Kd=7.8uM      // 5nge.pdf (8WN) [Covalent complex] FT827
5szb  1.20  2017  Kd=7.8uM      // 5szb.pdf (18-mer) Kd(H3K4me0)=7.8+/-0.5uM
5ow1  2.05  2017  Kd=70.4uM     // 5ovr.pdf (AY8) [Nonstandard assay: Temp 30] +/-4.7, comp.1
5kzp  2.26  2017  Kd=70nM       // 5kzp.pdf (15-mer) cyclic C1 immunogen bound to HCV1
5w4v  2.65  2017  Kd=70nM       // 5w4r.pdf (9WA) compound 19b
5njx  2.49  2017  Kd=70uM       // 5njx.pdf (16-mer) [Different protein in assay: Protein in binding assay is TPR domain of FKBP51] +/-32
5aan  1.60  2017  Kd=71uM       // 5aan.pdf (XOC) dNCS-1 bound to penothiazine FD44
5nk9  1.59  2017  Kd=724nM      // 5njz.pdf (912) compound 2e
5my8  1.70  2017  Kd=72nM       // 5mxx.pdf (RXZ) +/-5, SPHINX31
5u7o  3.03  2017  Kd=73nM       // 5u7m.pdf (83J) ligand is BMS-626529.
5wir  2.10  2017  Kd=75.1nM     // 5wir.pdf (15-mer) hTRF1TRFH      TERB1TBM;+/-9.0
5umz  1.90  2017  Kd=75.62nM    // 5umz.pdf (13-mer) [Nonstandard assay: Temp 4] Kd=75.62+/-21.1nM, ligand is TNRC6A cNLS
5nvy  2.90  2017  Kd=760nM      // 5nvv.pdf (9B5) +/-20, comp.11
5vc3  1.97  2017  Kd=77.5nM     // 5v5y.pdf (DB8) [Nonstandard assay: Temp 15] Kd=77.5+/-6.0nM, ligand is Bosutinib
5mi7  2.10  2017  Kd=77nM       // 5mi4.pdf (OAN) +/-7.7, PUGNAc
5mtv  2.79  2017  Kd=77uM       // 5mtv.pdf (AGS)
5vd2  2.05  2017  Kd=78.7nM     // 5v5y.pdf (34W) [Nonstandard assay: Temp 15] Kd=78.7+/-8.3nM, ligand is PF-03814735
5orw  2.00  2017  Kd=796uM      // 5orl.pdf (A6E) compound 9
5t7s  1.90  2017  Kd=79uM       // 5t7s.pdf (LBT) ligand is lactose
5n2t  1.38  2017  Kd=8.40uM     // 5mnr.pdf (8KK) [Nonstandard assay: buffer is Cacodylate] +/-0.35, compound 2
5u12  1.84  2017  Kd=8.5uM      // 5u0v.pdf (5RU) Kd=8.5+/-2.1uM, ligand is compound 13
6axp  2.48  2017  Kd=8.5uM      // 6au5.pdf (11-mer) (AHA)QFDLST R(nOc)RLK
5j7j   NMR  2017  Kd=8.6uM      // 5j7j.pdf (19-mer) Kd(FP)=8.6+/-0.6uM
5gsa  2.49  2017  Kd=82nM       // 5gsa.pdf (73K) EED226 compound bound EED
5ll9  1.45  2017  Kd=833nM      // 5ll9.pdf (6YQ) [Nonstandard assay: Temp 37] complex is CA XII-2a
5ot9  2.45  2017  Kd=84.4uM     // 5org.pdf (AOZ) +/-6.7, histopine
5gs4  2.40  2017  Kd=85nM       // 5gs4.pdf (10-mer) [Nonstandard assay: PH=8] [Different ligand in assay: FITC-labeled] ER alpha LBD in complex with 2
5mpz  1.40  2017  Kd=85uM       // 5mpz.pdf (4I8) compound 3
5o4z  1.70  2017  Kd=860nM      // 5o1u.pdf (A) +/-94, 5'-pApA
5f5z  1.76  2017  Kd=86nM       // 5f5z.pdf (5VY) ligand is compound 1
5jhb  2.48  2017  Kd=873nM      // 5jha.pdf (6K5) p110 gamma PIKiN3
5uxf  1.50  2017  Kd=87nM       // 5uxf.pdf (2BA) ligand is c-di-AMP
5mge  1.95  2017  Kd=87uM       // 5mge.pdf (7MX) ligand is compound 1
5t6p  1.97  2017  Kd=880nM      // 5t6p.pdf (8-mer) Kd=880+/-123nM, ligand id MUC1 peptide.
5x4o  2.05  2017  Kd=88uM       // 5x4m.pdf (YAM) BCL6/5
5ort  2.56  2017  Kd=894uM      // 5orl.pdf (A5Z) comp.7
5mk3  2.00  2017  Kd=89uM       // 5mjy.pdf (18-mer) ligand is CHMP4C peptide
5vdp  2.30  2017  Kd=89uM       // 5vdo.pdf (1SY) Kd=89+/-6uM, ligand is 2',3'-cGAMP, complex is cGAS161/2',3'-cGAMP
5ml8  2.60  2017  Kd=8nM        // 5ml2.pdf (V98) +/-2, comp.4
5lyn  2.00  2017  Kd=9.04uM     // 5lyn.pdf (7-mer) +/-0.05, PTVEEVD
5mlw  2.45  2017  Kd=9.24uM     // 5mlo.pdf (11-mer) ZRANB3 APIM peptide
6ayn  2.48  2017  Kd=9.2uM      // 6au5.pdf (11-mer) (AHA)QFDLST R(PrNH2)RLK
5n3y  1.34  2017  Kd=9.32uM     // 5mnr.pdf (8L2) [Nonstandard assay: buffer is Cacodylate] +/-0.28, compound 8
5nzq  1.50  2017  Kd=9.3mM      // 5nzq.pdf (5AO) [Different protein in assay: crystal:PHGDH-93, binding assay: sPHGDH] +/-3.8, frag.10
5mrm  1.80  2017  Kd=9.3uM      // 5mrm.pdf (Q9T) +/-0.6, compound 4
5wio  2.52  2017  Kd=9.3uM      // 5wic.pdf (XXE) 105055;+/-0.4
5x4p  2.06  2017  Kd=9.3uM      // 5x4m.pdf (7ZO) BCL6/6
6b27  1.73  2017  Kd=9.3uM      // 6b27.pdf (14-mer)  STAC2/CaV1.1(747-760)
6bhd  1.25  2017  Kd=9.3uM      // 6bhd.pdf (18-mer) 3TD H3K9me2/K14ac;+/-0.2
5nyz  2.50  2017  Kd=9.4uM      // 5nyz.pdf (DUP)
5nz2  2.85  2017  Kd=9.4uM      // 5nyz.pdf (DUP)
5gof  1.60  2017  Kd=90.1uM     // 5goe.pdf (GTP) GTP-bound MFN1IMC(T109A)
5ll5  1.42  2017  Kd=909nM      // 5ll5.pdf (6YH) [Nonstandard assay: Temp 37] complex is CA XII-1a
5gvn  2.30  2017  Kd=90nM       // 5gvk.pdf (G6F) [Different protein in assay: assay uses PfSHMT]
5nvx  2.20  2017  Kd=90nM       // 5nvv.pdf (4YY) +/-10, compound 10
5mob  1.67  2017  Kd=90uM       // 5mmx.pdf (A8S) [Nonstandard assay: Temp 5] +/-10, ABA, absence of phosphatase
6at0  1.29  2017  Kd=91.7uM     // 5kog.pdf (6-mer)
5oui  3.10  2017  Kd=93.57uM    // 5oug.pdf (AVB) +/-35.08, CU2017
5vsf  1.70  2017  Kd=94nM       // 5vsc.pdf (9HG) GLP-SAM-17; +/- 14
5xo2  2.20  2017  Kd=94uM       // 5xo2.pdf (7-mer) [Covalent complex] ligand is Deoxy-GlcNAc-type glycopeptide,Kd =94+/-26 uM
5xof  1.96  2017  Kd=98uM       // 5xo2.pdf (7-mer) [Covalent complex] ligand is GlcNAc-type glycopeptide,Kd =98+/-1.0uM
5vd1  1.70  2017  Kd=990nM      // 5v5y.pdf (P48) Kd=990+/-55.2nM, ligand is PHA-848125
5lb7  1.50  2017  Kd=9uM        // 5lb7.pdf (9-mer) ligand is 9-mer peptide derived from ASPM
6eww  2.68  2017  Kd=9uM        // 6eww.pdf (8-mer) [Different protein in assay: protein in binding assay is 14-3-3 gamma] ligand is peptide pepS100; kd = 1+/-0.5uM
5lm4  3.10  2017  Kd>131uM      // 5llm.pdf (6Z6)
5jq8  1.94  2017  Kd>2000nM     // 5jq5.pdf (I73) CDK2/ICEC0943
5jpt  2.94  2017  Kd>25uM       // 5jpt.pdf (CDP) Prp43/CDP
5mgl  2.65  2017  Kd>500uM      // 5mge.pdf (7MU) [Incomplete ligand] comp.3
5mgg  2.10  2017  Kd>500uM      // 5mge.pdf (7MU) comp.3
5mgm  2.80  2017  Kd>500uM      // 5mge.pdf (7MZ) comp.4
5vdo  3.22  2017  Kd>500uM      // 5vdo.pdf (1YC) ligand is 2',2'-cGAMP, complex is cGAS161/2',2'-cGAMP
5vdr  3.04  2017  Kd>500uM      // 5vdo.pdf (9B7) ligand is 3',3'-cdIMP, complex is cGAS161/3',3'-cdIMP
5vds  2.77  2017  Kd>500uM      // 5vdo.pdf (9BJ) ligand is 3',3'-cdUMP, complex is cGAS161/3',3'-cdUMP
5xxf  3.10  2017  Kd~1.8uM      // 5xxe.pdf (17-mer) Rap1PBM-Poz1-Tpz1PBM
5ieo  1.85  2017  Kd~100nM      // 5ien.pdf (VDY)
5iep  1.89  2017  Kd~100nM      // 5ien.pdf (VDY)
5u51  2.80  2017  Kd~12uM       // 5u51.pdf (G4P) ligand is ppGpp
5whc  2.55  2017  Kd~12uM       // 5whc.pdf (AJJ)  2 in complex with USP7-CD
5ier  2.01  2017  Kd~13uM       // 5ier.pdf (3QZ) complex is OHP9/17-OHP
5u66  1.70  2017  Kd~1mM        // 5u4y.pdf (15-mer) Kd~1+/-0.5mM, ligand is peptide LH1.
5vdu  2.73  2017  Kd~200uM      // 5vdo.pdf (9BS) Kd=100~300uM, ligand is ligand is F2, complex is cGAS161/F2
5vdv  3.00  2017  Kd~200uM      // 5vdo.pdf (9BV) Kd=100~300uM, ligand is F3, complex is cGAS161/F3
5vdw  2.71  2017  Kd~200uM      // 5vdo.pdf (9BY) Kd=100~300uM, ligand is F1, complex is cGAS161/F1
5ien  2.09  2017  Kd~300nM      // 5ien.pdf (VDY)
5mt4  1.65  2017  Kd~500uM      // 5mt0.pdf (M7O) comp.9
5mt0  1.29  2017  Kd~500uM      // 5mt0.pdf (QJS) comp.8
5n1y  1.39  2017  Kd~600uM      // 5c0h.pdf (10-mer) A2-MVW peptide
5f29  1.82  2017  Kd~9uM        // 5f29.pdf (2BA) ligand is c-di-AMP. ligand:protein ratio is 0.5
5wfz  2.35  2017  Ki<0.01uM     // 5w3i.pdf (KU0) E119D mutant)/8e (SRI-30049);
5u6c  2.10  2017  Ki<0.05nM     // 5u6b.pdf (7YS) ligand is compound 1.
5if4  2.39  2017  Ki<1nM        // 5iez.pdf (6AK) ligand is compound 5
5kkt  2.80  2017  Ki<1nM        // 5kkt.pdf (6U2) ligand is compound 37
5tqf  1.85  2017  Ki<5nM        // 5tqe.pdf (7KR) [Different protein in assay: Protein in binding assay is TF/FVIIa.] ligand is compound 7.
5wal  2.45  2017  Ki=0.0017uM   // 5wal.pdf (9ZS) ligand is compound 6-TYK2
5mw4  2.19  2017  Ki=0.002nM    // 5mvs.pdf (5JU) comp.7
5vo1  2.45  2017  Ki=0.007uM    // 5vo1.pdf (9FS) 10 bound to the DLK kinase domain
5w7u  2.20  2017  Ki=0.009uM    // 5w3i.pdf (GY8) 8f (SRI-29928);+/-0.007
5ult  1.53  2017  Ki=0.014nM    // 5ult.pdf (8FM) ligand is compound 25
5wlo  1.27  2017  Ki=0.015nM    // 5wlo.pdf (GR7) ligand is inhibitor 5j
5oq5  1.40  2017  Ki=0.0200uM   // 5oop.pdf (4K4) comp.2
5uv5  3.00  2017  Ki=0.020uM    // 5uv5.pdf (Y55) Ki=0.020+/-0.004uM, ligand is YLC2-155.
5opb  1.55  2017  Ki=0.0241uM   // 5oop.pdf (A1N) comp.7
5uov  1.33  2017  Ki=0.025nM    // 5uov.pdf (8FP) ligand is compound 4b
5oq6  1.95  2017  Ki=0.0277uM   // 5oop.pdf (4K4) comp.2
5oot  2.10  2017  Ki=0.0285uM   // 5oop.pdf (4K4) ligand is compound 2
5nee  1.70  2017  Ki=0.02nM     // 5nea.pdf (8V5) ligand is compound 8
5wb6  2.35  2017  Ki=0.02nM     // 5wb6.pdf (9ZM) [Nonstandard assay: Temp 37] 14
5xp7  2.01  2017  Ki=0.038mM    // 5xp5.pdf (8C6) kinase inhibition assay,
5mim  1.90  2017  Ki=0.046uM    // 5mim.pdf (1N) [Different ligand in assay: Ligand in binding assay is racemate.] comp.1
5opv  1.90  2017  Ki=0.0515uM   // 5oop.pdf (A3H) comp.23
5opu  1.55  2017  Ki=0.0530uM   // 5oop.pdf (A3K) comp.22
5nea  1.30  2017  Ki=0.05nM     // 5nea.pdf (8V8) ligand is compound 7
5we9  1.80  2017  Ki=0.06uM     // 5w3i.pdf (GY7) 7b (SRI-29731); +/-0.01
5mqy  1.13  2017  Ki=0.077uM    // 5mqy.pdf (GH4) [Covalent complex] comp.35
5lpd  1.50  2017  Ki=0.07nM     // 5jfd.pdf (71U) compound 3
5v82  1.89  2017  Ki=0.07nM     // 5v82.pdf (96Y) ligand is compound 19
5hz5  1.40  2017  Ki=0.086uM    // 5hz5.pdf (65X) human FABP5 with compound 12
5iu6  2.51  2017  Ki=0.13mM     // 5iu6.pdf (7HX) Ki = 0.13 +/- 0.04 mM
5q0f  2.12  2017  Ki=0.13nM     // 5q0d.pdf (9FA) [Nonstandard assay: Temp 37] comp.14
5u6b  2.84  2017  Ki=0.13nM     // 5u6b.pdf (7YS) Ki=0.13+/-0.01nM, ligand is compound 1.
5h4j  1.80  2017  Ki=0.13uM     // 5h4j.pdf (FKM) [Nonstandard assay: Temp 37] ligand is TAS-114
5vo2  2.96  2017  Ki=0.154uM    // 5vo1.pdf (9FV) 7;
5jzy  1.27  2017  Ki=0.15nM     // 5jfd.pdf (6OV) compound 1
5w9g  2.10  2017  Ki=0.15uM     // 5w3i.pdf (KU2) 9k (SRI-30023);+/-0.003
5wev  1.85  2017  Ki=0.15uM     // 5wal.pdf (9ZS) compound 6- JAK2;
5tku  2.12  2017  Ki=0.16nM     // 5tks.pdf (7DK) [Nonstandard assay: Temp 37] ligand is compound 16.
5q0g  2.60  2017  Ki=0.18nM     // 5q0d.pdf (9F7) [Nonstandard assay: Temp 37] comp.20
5tdi  1.40  2017  Ki=0.18nM     // 5tdi.pdf (7AS) [Covalent complex] [Nonstandard assay: PH=5.5] Ki=0.18+/-0.06nM, ligand is ODN.
5op4  2.00  2017  Ki=0.194uM    // 5oop.pdf (A0T) ligand is compound 4a
5vb7  2.34  2017  Ki=0.19uM     // 5vb5.pdf (921) ligand is compound 3
5g22  2.32  2017  Ki=0.1uM      // 5g1z.pdf (YN4) 26 (cyan carbons) in complex with PvNMT and non-hydrolizable MyrCoA
5n8v  1.55  2017  Ki=0.207uM    // 5l87.pdf (KZZ) PEX14-5
5op5  1.90  2017  Ki=0.216uM    // 5oop.pdf (3FE) ligand is compound 5
6b97  1.76  2017  Ki=0.237uM    // 6b96.pdf (CZY) ligand is compound 9
5op2  1.90  2017  Ki=0.240uM    // 5oop.pdf (A0Q) comp.3b
5tqg  1.90  2017  Ki=0.24nM     // 5tqe.pdf (7KS) [Different protein in assay: Protein in binding assay is TF/FVIIa.] ligand is compound 26.
5jfd  1.46  2017  Ki=0.29nM     // 5jfd.pdf (2TS) compound 7
5m4q  1.73  2017  Ki=0.31mM     // 5m4j.pdf (PRO) Ki=0.31+/-0.04 mM; same as 5mby
5mby  1.55  2017  Ki=0.31mM     // 5mby.pdf (PRO) Ki=0.31+/-0.04 mM
5t8o  2.41  2017  Ki=0.31uM     // 5t8f.pdf (76Z) Ki=0.31+/-0.11uM, ligand is compound 3
5oq7  2.10  2017  Ki=0.322uM    // 5oop.pdf (A0Q) comp.3b
5unf  2.80  2017  Ki=0.34nM     // 5unf.pdf (8ES)  ligand is compound 1, crystal: monoclinic
5ung  2.80  2017  Ki=0.34nM     // 5unf.pdf (8ES)  ligand is compound 1, crystal: orthorhombic
6b4l  2.25  2017  Ki=0.34uM     // 5vkc.pdf (CJY) ligand is compound 5
5unh  2.90  2017  Ki=0.35nM     // 5unf.pdf (8EM) ligand is compound 2.
5wef  2.00  2017  Ki=0.36uM     // 5w3i.pdf (GY6) mutant/inhibitor 7a (SRI-29770);+/-0.01
5waf  2.03  2017  Ki=0.45nM     // 5wac.pdf (A0Y) [Uncommon element] [Different ligand in assay: ligand in crystal is covalently bound phosphate ion] CR192
5hh6  1.80  2017  Ki=0.4uM      // 5hh4.pdf (60N) inhibition assay, Ki=0.4+/-0.1uM
5ura  1.85  2017  Ki=0.4uM      // 5ur9.pdf (8KS) [Different ligand in assay: crystal:SBFI-26 as S enantiomer] ligand is SBFI- 26.
5hh5  1.80  2017  Ki=0.5uM      // 5hh4.pdf (60M) inhibition assay, Ki=0.5+/-0.1uM
5upz  1.27  2017  Ki=0.63nM     // 5uov.pdf (8HD) ligand is compound 3b
5q0e  2.12  2017  Ki=0.69nM     // 5q0d.pdf (9FD) [Nonstandard assay: Temp 37] comp.8
5kns  2.79  2017  Ki=0.75uM     // 5kns.pdf (3L7) [Nonstandard assay: MgCl2 12mM] Ki=0.75+/-0.04uM, ligand is compound 5
5knx  2.40  2017  Ki=0.8uM      // 5knx.pdf (6WC) [Nonstandard assay: MgCl2 12mM] Ki=0.8+/-0.08uM, ligand is compound 7
5m7s  2.40  2017  Ki=0.9nM      // 5m7s.pdf (NHT) Thiamet-G
5ur9  2.20  2017  Ki=0.9uM      // 5ur9.pdf (8KS) [Different ligand in assay: crystal:SBFI-26 as S enantiomer] ligand is SBFI- 26.
5vp9  1.86  2017  Ki=1.03nM     // 5voj.pdf (9H7) 18f/WT NS3 4A; +/- 0.13
5q0d  2.12  2017  Ki=1.0nM      // 5q0d.pdf (9EY) [Nonstandard assay: Temp 37] comp.1
5uw5  2.94  2017  Ki=1.10uM     // 5uw3.pdf (19-mer) Ki=1.10+/-0.22uM, ligand is presegetalin A1 [14-32].
5wqc  1.96  2017  Ki=1.1nM      // 5wqc.pdf (7MA) OX2R-EMPA (cryocooled crystal structur/Synchrotron)
5ws3  2.30  2017  Ki=1.1nM      // 5ws3.pdf (7MA) [Different protein in assay: Protein in binding assay is human] ligand is EMPA; same as 5wqc
5hh4  2.00  2017  Ki=1.1uM      // 5hh4.pdf (60M) inhibition assay, Ki=1.1+/-0.2uM
5m23  1.97  2017  Ki=1.25nM     // 5m23.pdf (7DC) +/-0.36, peptidomimetic 7 trans
5t8p  2.32  2017  Ki=1.28uM     // 5t8f.pdf (774) Ki=1.28+/-0.3uM, ligand is compound 2
5ljt  1.00  2017  Ki=1.2nM      // 5ljq.pdf (A6N) hCAII/compound13
5n24  1.50  2017  Ki=1.2nM      // 5n24.pdf (8HE) ligand is compound 1
5oq8  2.00  2017  Ki=1.41uM     // 5oop.pdf (A0Q) ligand is compound 3b
5x5g  2.00  2017  Ki=1.49uM     // 5x5g.pdf (OP0) [Covalent complex] Ki=1.49+/-0.05uM, enzyme kinetic assay
5mlj  1.80  2017  Ki=1.4nM      // 5mkx.pdf (9ST) complex is GCN5 / (R,R)-32
5uoo  1.69  2017  Ki=1.4nM      // 5uoo.pdf (8FV) Ki=1.4+/-0.4nM,  ligand is compound 31
5knr  2.86  2017  Ki=1.4uM      // 5knr.pdf (3L5) [Nonstandard assay: MgCl2 12mM] Ki=1.4+/-0.2uM, ligand is compound 6
5ndf  2.30  2017  Ki=1.4uM      // 5ndf.pdf (LU2) +/-0.05 Luteolin
5uex  2.29  2017  Ki=1.5nM      // 5ueu.pdf (89D) Ki=1.5+/-0.2nM, ligand is compound 61a.
5kyk  2.70  2017  Ki=1.6uM      // 5kyk.pdf (6ZD) [Covalent complex] KRAS G12C-Compound 47
5w3i  1.95  2017  Ki=1.6uM      // 5w3i.pdf (GY5) inhibitor 6e (SRI-29685)
5gwa  1.59  2017  Ki=1.71uM     // 5gwa.pdf (NXL) [Covalent complex] Ki = 1.71 +/- 0.10uM; The compound is a covalent inhibitor and reacts with S47 residue
5vkc  2.31  2017  Ki=1.8nM      // 5vkc.pdf (9EA) ligand is compound 33
5n1s  1.30  2017  Ki=10.2nM     // 5n1s.pdf (8GE) lgiand is compound 4
5v8p  2.50  2017  Ki=10.2uM     // 5v8p.pdf (90G) [Nonstandard assay: Temp 37] ligand is ABS-143.
6eo8  1.94  2017  Ki=100nM      // 4n3l.pdf (2FN) ligand is compound 3
5g2b  1.83  2017  Ki=100nM      // 5g2b.pdf (LQY) pKi = 7, ligand is compound NPD-008(8)
5wcm  1.20  2017  Ki=100uM      // 3m8t.pdf (4NZ)
5n1r  1.30  2017  Ki=11.1nM     // 5n1r.pdf (8GH) lgiand is compound 2
5uig  3.50  2017  Ki=11.2nM     // 5uig.pdf (8D1) ligand is cmpd-1, pKi=7.95+/-0.06
5gwy  2.85  2017  Ki=11.3uM     // 5gwy.pdf (PRD) [Covalent complex] Ki=11.3+/-1.0uM
6en5  1.75  2017  Ki=11.45nM    // 6en5.pdf (BJ2) N-domain of ACE bound to 16; Ki=11.45+/-1.37nM
5qcm  2.20  2017  Ki=110nM      // 5qck.pdf (BVJ) [Nonstandard assay: Temp 37] comp.21
5vtb  2.40  2017  Ki=110nM      // 5vtb.pdf (15-mer) Ki=(BCL11A2-16)=110nM, Ki(BCL11A2-12)=268nM
5qcl  2.11  2017  Ki=11nM       // 5qck.pdf (BUY) [Nonstandard assay: Temp 37] comp.6
5u8f  1.34  2017  Ki=11nM       // 5u69.pdf (82G) [Different protein in assay: crystal: EED residues D77 to 441, binding assay: full length] ligand is compound 15.
5l8a  1.57  2017  Ki=12.3uM     // 5l87.pdf (6RB) PEX14-3
5jha  2.51  2017  Ki=1264nM     // 5jha.pdf (6K7) p110 gamma PIKiN2
5q0h  2.50  2017  Ki=12nM       // 5q0d.pdf (9F1) [Nonstandard assay: Temp 37] comp.28
5knv  2.86  2017  Ki=13.4uM     // 5knv.pdf (6W9) [Nonstandard assay: MgCl2 12mM] Ki=13.4+/-1.0uM, ligand is compound 3
5uwn  3.20  2017  Ki=13.5nM     // 5uwk.pdf (8O7) Ki=13.5+/-3.7nM, ligand is compound 10d
5nih  1.30  2017  Ki=134nM      // 5neb.pdf (8VE) +/-43, LM-12b
5thj  1.50  2017  Ki=1350uM     // 5th4.pdf (0TR) Ki=1350+/-40uM, ligand is Tropolone.
5hvu  2.80  2017  Ki=13nM       // 5hvu.pdf (65R) ligand is comound 30
5m4f  1.52  2017  Ki=13nM       // 5m44.pdf (7FC) [Different protein in assay: Protein in binding assay is CK2alpha2beta2] FLC21
5m4i  2.22  2017  Ki=13nM       // 5m44.pdf (7FC) [Different protein in assay: Protein in binding assay is CK2alpha2beta2] FLC21
5m56  2.24  2017  Ki=13nM       // 5m44.pdf (7FC) [Different protein in assay: Protein in binding assay is CK2alpha2beta2] FLC21
5u8a  1.45  2017  Ki=13nM       // 5u69.pdf (82D) [Different protein in assay: crystal: EED residues D77 to 441, binding assay: full length] ligand is compound 10.
5ugc  1.58  2017  Ki=13nM       // 5ug8.pdf (8BS) [Covalent complex] [Different protein in assay: protein in crystal is L858R, T790M, V948R mutant.] ligand is compound 21.
5m4u  2.20  2017  Ki=13uM       // 5m44.pdf (7FC) [Different protein in assay: Protein in binding assay is CK2alpha2beta2] FLC21
5uln  1.35  2017  Ki=14.2nM     // 5uln.pdf (8JS) ligand is compound 22(S)
6b96  1.88  2017  Ki=14.3nM     // 6b96.pdf (CZV) ligand is compound 16
5vjp  1.98  2017  Ki=14.9uM     // 5vjn.pdf (IR9) Ki=14.9+/-2.9uM, ligand is L-DIAB
5th4  1.47  2017  Ki=1420uM     // 5th4.pdf (BEW) Ki=1420+/-30uM, ligand is 1,2-HOPTO.
5mae  1.00  2017  Ki=146nM      // 5mae.pdf (7KN) comp.23
5nf5  2.85  2017  Ki=152nM      // 5neb.pdf (8VN) +/-31, CIP-AS
5mhp  2.43  2017  Ki=15nM       // 5mhp.pdf (7NB) [Nonstandard assay: Temp 37] comp.11
5k1f  1.94  2017  Ki=16.2uM     // 5k1d.pdf (IMP) ligand is IMP
5obj  2.90  2017  Ki=16.5uM     // 5obj.pdf (9QK) comp.2
5n25  1.40  2017  Ki=16.6nM     // 5n25.pdf (8HK) ligand is compound 3
5ueu  2.26  2017  Ki=16.7nM     // 5ueu.pdf (0S6) ligand is compound 2a
6eo9  1.84  2017  Ki=160nM      // 4n3l.pdf (2OJ) ligand is compound 2
5wae  1.80  2017  Ki=160nM      // 5wac.pdf (A1J) [Uncommon element] [Different ligand in assay: ligand in crystal is covalently bound phosphate ion] CR167
5uf0  1.35  2017  Ki=160uM      // 5ueu.pdf (89J) ligand is fragment 1
5uga  1.82  2017  Ki=161nM      // 5ug8.pdf (8BM) [Different protein in assay: protein in crystal is L858R, T790M, V948R mutant.] ligand is compound 18.
5ugb  2.53  2017  Ki=161nM      // 5ug8.pdf (8BM) ligand is compound 18.
5mte  1.40  2017  Ki=167nM      // 5mte.pdf (BB2) [Nonstandard assay: Temp 37] +/-10, arabinose
5neb  2.05  2017  Ki=17nM       // 5neb.pdf (8VE) +/-5, LM-12b
5mkr  1.87  2017  Ki=17uM       // 5mkr.pdf (TI8) ligand is compound 8
5mks  1.99  2017  Ki=17uM       // 5mkr.pdf (TI8) ligand is compound 8
5nfh  2.80  2017  Ki=18nM       // 5nfh.pdf (8W2) [Different protein in assay: Protein in binding assay is LdMetRS] DDD806905
5gwz  2.44  2017  Ki=19.4uM     // 5gwz.pdf (6-mer) [Covalent complex] compound 1 bound to PEDV Mpro
5tqe  1.90  2017  Ki=190nM      // 5tqe.pdf (7KQ) [Different protein in assay: Protein in binding assay is TF/FVIIa.] ligand is compound 4.
5ng9  1.15  2017  Ki=191nM      // 5neb.pdf (8VN) +/-50, CIP-AS
5tt3  2.20  2017  Ki=193nM      // 5tt3.pdf (EZL) ligand is EZA
5ljq  1.05  2017  Ki=1nM        // 5ljq.pdf (ANV) hCAII/compound3
6awo  3.53  2017  Ki=2.0nM      // 6awn.pdf (SRE) ligand is Sertraline,Ki=2.0+/-0.2nM,ligand in binding assay is possitive,in PDB is neutral
5m4k  2.60  2017  Ki=2.17uM     // 5m4e.pdf (7F9) comp.10
5uwk  1.60  2017  Ki=2.3nM      // 5uwk.pdf (8OM) ligand is compound (S)-10a
5iz8  3.06  2017  Ki=2.41uM     // 5b6g.pdf (9-mer) Ki(FP)=2.41+/-0.88uM
5uv1  2.40  2017  Ki=2.4uM      // 5uv1.pdf (0FV) Ki=2.4+/-0.5uM, ligand is FGPP.
5opr  1.95  2017  Ki=2.56uM     // 5oop.pdf (A3E) comp.8
5upf  1.69  2017  Ki=2.5nM      // 5upe.pdf (8HV) ligand is compound 53
5osk  2.11  2017  Ki=2.5uM      // 5osk.pdf (A9Q) +/-0.1, comp.7j
5u6d  1.64  2017  Ki=2.6nM      // 5u69.pdf (7XG) [Different protein in assay: crystal: EED residues D77 to 441, binding assay: full length] ligand is compound 35.
6esy  2.80  2017  Ki=2.6uM      // 6ep4.pdf (TFX) thioflavin T/hBChE;+/- 0.5
5v4q  2.20  2017  Ki=2.7mM      // 5v4q.pdf (8WY) [Covalent complex] [Nonstandard assay: Temp 37] [Different ligand in assay: ] Ki=2.7+/-0.7mM, ligand is DON.
5knu  2.81  2017  Ki=2.8uM      // 5knu.pdf (6WA) [Nonstandard assay: MgCl2 12mM] Ki=2.8+/-0.3uM, ligand is compound 8
5mjn  1.17  2017  Ki=2.9nM      // 5mjn.pdf (7O8) ligand is compound 17
5k1d  1.94  2017  Ki=20.8uM     // 5k1d.pdf (5GP) ligand is GMP
5o4f  2.10  2017  Ki=208nM      // 5neb.pdf (8VE) +/-55, LM-12b
5y7w  2.25  2017  Ki=20nM       // 5y7w.pdf (16-mer) yl-2 and NCOA1 complex;+/- 4
5un9  2.50  2017  Ki=21nM       // 5un8.pdf (NHT) [Nonstandard assay: Temp 37] ligand is thiamet-G.
6b4u  1.95  2017  Ki=21nM       // 5vkc.pdf (CN7) ligand is compound 14; Ki=21+/-7.9nM
6b98  1.97  2017  Ki=22.4uM     // 6b96.pdf (D07) ligand is compound 1
5w13  1.95  2017  Ki=22nM       // 5w12.pdf (SM2) [Uncommon element] SM23;+/- 2
5iez  2.60  2017  Ki=23nM       // 5iez.pdf (6AL) ligand is compound 2
5qck  2.64  2017  Ki=23nM       // 5qck.pdf (BUV) [Nonstandard assay: Temp 37] comp.4
5u6j  2.30  2017  Ki=23nM       // 5u6j.pdf (82J) ligand is compound 14
5vij  2.11  2017  Ki=24.3nM     // 5dex.pdf (5DX) ligand is ST1
5thi  1.50  2017  Ki=245uM      // 5th4.pdf (0TR) Ki=245+/-14uM, ligand is Tropolone.
6b4n  1.30  2017  Ki=27.9pM     // 6b4n.pdf (G53) inhibitor 3g (GRL-5311) with wild-type HIV-1 protease
5tg6  1.78  2017  Ki=28.3uM     // 5tg4.pdf (J4W) [Covalent complex] [Uncommon element] ligand is BA4.
5u8c  1.60  2017  Ki=29.58nM    // 5u8c.pdf (84J) Ki=29.58+/-0.24nM; ligand is NVP-AAM077
5tg7  2.28  2017  Ki=29.8uM     // 5tg4.pdf (JW3) [Covalent complex] [Uncommon element] ligand is BA3.
5kks  3.30  2017  Ki=2nM        // 5kks.pdf (6U1) Ligand is compound 28
5ug8  1.46  2017  Ki=2nM        // 5ug8.pdf (8BP) [Covalent complex] [Different protein in assay: protein in crystal is L858R, T790M, V948R mutant.] ligand is compound 7.
5wei  2.25  2017  Ki=2uM        // 5w3i.pdf (GY6) E119D mutant/inhibitor 7a (SRI-29770); +/-2
5iza  1.50  2017  Ki=3.12uM     // 5b6g.pdf (9-mer) Ki(FP)=3.12+/-0.70uM
5nx2  3.70  2017  Ki=3.2nM      // 5nx2.pdf (10-mer) [Different protein in assay: Protein in binding assay is WT] Peptide 5
5tkt  2.12  2017  Ki=3.2nM      // 5tks.pdf (7DS) [Nonstandard assay: Temp 37] ligand is compound 13.
5ufs  2.12  2017  Ki=3.2nM      // 5ufs.pdf (1TA) ligand is TA
5n0d  1.70  2017  Ki=3.3nM      // 5n0d.pdf (8F2) ligand is compound 30a
5nn5  2.00  2017  Ki=3.4uM      // 5nn4.pdf (NOJ) DNJ
5tp0  1.25  2017  Ki=3.66uM     // 5tp0.pdf (BRN) Ki=3.66+/-0.08uM; ligand is diminazene
5n0e  1.75  2017  Ki=3.6nM      // 5n0d.pdf (8F3) compound 30b
5voj  1.80  2017  Ki=3.6nM      // 5voj.pdf (9H4) 19b/WT NS3 4A; +/- 0.04
5iz9  2.93  2017  Ki=3.80uM     // 5b6g.pdf (9-mer) Ki(FP)=3.80+/-0.72uM
5g57  1.73  2017  Ki=3.98nM     // 5g2b.pdf (6M5) pKi = 8.4, ligand is compound NPD-001(1)
5m7t  2.60  2017  Ki=3.9uM      // 5m7s.pdf (GDV) PugNAc-imidazole
6f3f  2.42  2017  Ki=30uM       // 6f3f.pdf (ADP) [Different protein in assay: Protein in binding assay is SrcdeltaC]  Src in complex with ADP;+/-8
5tt8  2.40  2017  Ki=315nM      // 5tt3.pdf (D8W) ligand is BZA.
5vih  2.40  2017  Ki=32.2nM     // 5dex.pdf (5DZ) ligand is ST6
5tuo  2.50  2017  Ki=323nM      // 5tt3.pdf (1SA) ligand is compound 1
6b16  2.29  2017  Ki=32nM       // 6b16.pdf (C7Y) compound 5;
5t19  2.10  2017  Ki=32uM       // 5t19.pdf (73U) ligand is compound 5b
5o07  1.80  2017  Ki=33.8nM     // 5o07.pdf (1VQ) ligand is compound 3
5mfs  1.57  2017  Ki=330nM      // 5mfr.pdf (7ML) [Incomplete ligand] +/-40, I2
5mft  1.59  2017  Ki=34nM       // 5mfr.pdf (7MF) [Incomplete ligand] +/-7, I3
5maj  1.00  2017  Ki=35nM       // 5mae.pdf (7KH) com.30
5nf6  2.55  2017  Ki=35nM       // 5neb.pdf (8VN) +/-7, CIP-AS
5dpx  1.85  2017  Ki=35uM       // 5dpx.pdf (L3B)
5knt  2.55  2017  Ki=37uM       // 5knt.pdf (6WB) [Nonstandard assay: MgCl2 12mM] Ki=37+/-2uM, ligand is compound 1
5wac  2.06  2017  Ki=38nM       // 5wac.pdf (A1M) [Uncommon element] [Different ligand in assay: ligand in crystal is covalently bound phosphate ion] CR157
5uv2  2.20  2017  Ki=39.5uM     // 5uv1.pdf (LA6) Ki=39.5+/-5.2uM; ligand is FNPP
5ufi  2.58  2017  Ki=4.0nM      // 5ufi.pdf (8B1) ligand is DI-591
5m2v  3.18  2017  Ki=4.0uM      // 5m2v.pdf (7E5) comp.1b
5obr  2.62  2017  Ki=4.4uM      // 5obj.pdf (9QT) comp.5
6ep4  2.30  2017  Ki=4.5uM      // 6ep4.pdf (DME) decamethonium/hBChE; +/-0.2uM
5g1z  1.50  2017  Ki=4.74uM     // 5g1z.pdf (U53) quinoline 1 in a ternary complex with P. vivax NMT and S-(2- oxo)pentadecylCoA (NHM)
5m44  2.71  2017  Ki=40nM       // 5m44.pdf (7EY) [Different protein in assay: Protein in binding assay is CK2alpha2beta2] TTP22
5m4c  1.94  2017  Ki=40nM       // 5m44.pdf (7EY) [Different protein in assay: Protein in binding assay is CK2alpha2beta2] TTP22
6equ  1.65  2017  Ki=419nM      // 6equ.pdf (BVE) hCA II/2
5vt4  3.21  2017  Ki=45uM       // 5vsj.pdf (9KJ) compound 5;+/- 4
5w14  1.88  2017  Ki=46nM       // 5w12.pdf (9TJ) [Uncommon element] 3c;+/- 3
5tg4  1.44  2017  Ki=475uM      // 5tg4.pdf (JW1) [Covalent complex] [Uncommon element] ligand is BA16! not BA3!
5uey  2.41  2017  Ki=5.1nM      // 5ueu.pdf (88M) Ki=5.1+/-0.1nM, ligand is compound 25e.
5mfr  1.40  2017  Ki=50000nM    // 5mfr.pdf (7MK) [Incomplete ligand] +/-3000, I1
5vii  1.95  2017  Ki=51.8nM     // 5dex.pdf (5DY) ST3
5wzr  2.79  2017  Ki=51nM       // 5wzn.pdf (DJN)  Gal-NHAc-DNJ
5w12  1.88  2017  Ki=53nM       // 5w12.pdf (9TG) [Uncommon element] EC04
5v6u  2.80  2017  Ki=5470uM     // 5v6u.pdf (8YM) Ki=5470+/-398uM, ligand is compound 1, Ac-DEVD-AFC cleavage assays
5om9  1.80  2017  Ki=56uM       // 5om9.pdf (O2S) [Covalent complex] [Nonstandard assay: Temp 37, NaCl=500 mM] +/-5, comp.11
5m25  2.43  2017  Ki=6.50nM     // 5m23.pdf (7DU) +/-0.36, peptidomimetic 7 cis
5tfx  1.50  2017  Ki=60.9nM     // 5tfx.pdf (7B1) ligand is compound 13
5u69  1.28  2017  Ki=600nM      // 5u69.pdf (LQD) [Different protein in assay: crystal: EED residues D77 to 441, binding assay: full length] ligand is compound 1.
5wag  1.93  2017  Ki=6110nM     // 5wac.pdf (A0V) [Uncommon element] [Different ligand in assay: ligand in crystal is covalently bound phosphate ion] S06017
5ti0  1.42  2017  Ki=61uM       // 5th4.pdf (7CZ) Ki=61+/-5uM, ligand is Thiotropolone.
5ofu  2.62  2017  Ki=63.8uM     // 5oey.pdf (AMP) [Nonstandard assay: Temp 37]
5u94  2.20  2017  Ki=64nM       // 5u94.pdf (G93) kinase assay, Ki=64+/-23nM
5wex  1.26  2017  Ki=66.3nM     // 5uln.pdf (8JS) ligand is compound 10(Se)
5v0n  2.16  2017  Ki=67.1nM     // 5v0n.pdf (8W4) ligand is compound 5g
5tks  1.55  2017  Ki=68nM       // 5tks.pdf (7DL) [Nonstandard assay: Temp 37] ligand is compound 9.
5m0m  2.10  2017  Ki=6nM        // 5m0d.pdf (7CF) +/-2, comp.17
5qcn  2.30  2017  Ki=6nM        // 5qck.pdf (BVM) [Nonstandard assay: Temp 37] comp.38
5w8v  2.35  2017  Ki=6nM        // 5w8v.pdf (9YP)  human HGPRT in complex with compound 20
5v1y  1.42  2017  Ki=7.1nM      // 5v1y.pdf (16-mer) Ki=7.1+/-0.9nM, ligand is RPN2(940-953)
5wad  2.09  2017  Ki=7.8nM      // 5wac.pdf (QQZ) [Uncommon element] CR161
5xhr  1.80  2017  Ki=7.9uM      // 5xhr.pdf (PXH) [Covalent complex] MPC-1 with P99
5nin  1.70  2017  Ki=75nM       // 5nin.pdf (16-mer) [Different protein in assay: Protein in binding assay is biotinylated CaM] +/-8, AKAP79(77-92)
5ula  1.50  2017  Ki=77nM       // 5ula.pdf (5MJ) ligand is MS402
5kez  1.83  2017  Ki=7nM        // 5kez.pdf (11-mer) HPA/piHA-Dm complex
5two  1.93  2017  Ki=8.06nM     // 5two.pdf (7MV) ligand is VSP-51.
5n6s  2.10  2017  Ki=8.2nM      // 5n6s.pdf (8P5) ligand is compound 5
5tv3  2.90  2017  Ki=8.2nM      // 5tt3.pdf (7L3) ligand is 3.
5l87  0.87  2017  Ki=8.43uM     // 5l87.pdf (6RD) PEX14-2
5ops  2.00  2017  Ki=8.63uM     // 5oop.pdf (A3Q) comp.9
5vjn  1.78  2017  Ki=8.7uM      // 5vjn.pdf (IR8) Ki=8.7+/-1.5uM, ligand is D-DIAB
5j87  1.59  2017  Ki=8.9nM      // 5j87.pdf (N42) [Covalent complex] 9 in complex with BTK
5m7u  2.30  2017  Ki=8nM        // 5m7s.pdf (XHA) ligand is VV347
5ug9  1.33  2017  Ki=8nM        // 5ug8.pdf (8AM) [Covalent complex] ligand is compound 16.
5lce  1.39  2017  Ki=9.2nM      // 5jfd.pdf (6TH) compound 2
5vsj  2.46  2017  Ki=95uM       // 5vsj.pdf (9HV) ligand is compound 6; +/-16
5thn  1.33  2017  Ki=96uM       // 5th4.pdf (7CZ) Ki=96+/-13uM, ligand is Thiotropolone.
5tg5  1.75  2017  Ki=97.3uM     // 5tg4.pdf (JW8) [Covalent complex] [Uncommon element] ligand is BA8.
5uez  1.51  2017  Ki=970nM      // 5ueu.pdf (89G) Ki=970+/-200nM; ligand is compound 11
5upe  1.93  2017  Ki=9nM        // 5upe.pdf (8HY) ligand is compound 5
5za1  2.52  2018  IC50<0.030uM  // 5za1.pdf (9A0) ligand is compound 6
6bsl  1.45  2018  IC50<1nM      // 6bsl.pdf (EVV) ligand is compound 22
5oqw  2.31  2018  IC50<40nM     // 5oqw.pdf (A4E) ligand is ASTX660
5uy8  2.39  2018  IC50<5nM      // 5uy8.pdf (8UM) ligand is compound 32b
6hd4  2.03  2018  IC50=0.0023uM  // 6hd4.pdf (FYW) ligand is compound 7; IC50=0.0023+/-0.0009uM
6f22  1.55  2018  IC50=0.002uM  // 6f1x.pdf (C9B) ligand is compound 29
5qil  1.98  2018  IC50=0.003nM  // 5qik.pdf (J2V) ligand is compound 2b
6ccy  2.18  2018  IC50=0.003uM  // 6ccy.pdf (EX4) ligand is compound 5
6f3d  2.38  2018  IC50=0.004uM  // 6f3d.pdf (CJT) ligand is compound 2
5kpk  2.40  2018  IC50=0.005uM  // 5kpk.pdf (6VK) IC50 = 0.005 +/- 0.003 uM. ligand is BRD0209
6c6o  2.30  2018  IC50=0.005uM  // 6apz.pdf (ENG) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2-Br-4-OH
6c4g  2.39  2018  IC50=0.005uM  // 6c4g.pdf (EQG) ligand is compound 27; IC50 = 0.005+/-0.001uM
6f23  1.84  2018  IC50=0.005uM  // 6f1x.pdf (C8Z) ligand is compound 16
5qim  1.75  2018  IC50=0.006nM  // 5qik.pdf (J2Y) ligand is compound 3e
6ffn  1.75  2018  IC50=0.006uM  // 6ffn.pdf (D8K) [Covalent complex] ligand is compound 6
6ba7  2.50  2018  IC50=0.007uM  // 6apz.pdf (D1Y) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2-Cl-4-OH
5xyz  2.64  2018  IC50=0.008uM  // 5xyx.pdf (GYL) [Covalent complex][Incomplete ligand] ligand is 8,IC50=0.008+/-0.004uM
6do3  2.17  2018  IC50=0.0094uM  // 6do3.pdf (7-mer) [Incomplete ligand] [Different ligand in assay: Ligand in binding assay is SPPPMAGG] ligand is peptide SPPPMAGG. AlphaScreen competition assay, IC50 = 0.0083-0.0110uM (95% CI)
5ni5  2.30  2018  IC50=0.009uM  // 5ni5.pdf (8YB) ligand is compound 1
6esn  1.84  2018  IC50=0.009uM  // 5ni5.pdf (BWE) ligand is compound 32
5o7e  1.87  2018  IC50=0.010uM  // 5o7e.pdf (9NB) IC50 = 0.010 +/- 0.002. ligand is compound 3
6df7  2.00  2018  IC50=0.010uM  // 6df4.pdf (G9V) Ligand is compound 27; bingind assay: TR-FRET
5y6e  1.80  2018  IC50=0.0137uM  // 5y6d.pdf (8PO) ligand is compound 12
6ckx  2.80  2018  IC50=0.013uM  // 6ckx.pdf (8M1) ligand is compound 29; Binding assay is LANCE Ultra assay
6fgq  2.37  2018  IC50=0.014uM  // 5ni5.pdf (D9N) ligand is compound 23
5yg3  2.40  2018  IC50=0.014uM  // 5yfz.pdf (8UC) [Different protein in assay: Protein in binding assay is Plasmodium falciparum] ligand is compound (+)-57,IC50=0.014+/-0.002uM
5kpm  2.69  2018  IC50=0.015uM  // 5kpk.pdf (6VM) IC50 = 0.015 +/- 0.011 uM. ligand is BRD3731
5nib  1.82  2018  IC50=0.019uM  // 5ni5.pdf (8Y5) ligand is compound 25
6do4  2.20  2018  IC50=0.021uM  // 6do3.pdf (6-mer) [Incomplete ligand] [Different ligand in assay: ] ligand is peptide SelS(GPSSGG). AlphaScreen competition assay, IC50 = 0.019-0.024uM (95% CI)
6f3i  2.14  2018  IC50=0.021uM  // 6f3d.pdf (CKN) ligand is compound 33
6df4  1.30  2018  IC50=0.023uM  // 6df4.pdf (G9Y) Ligand is compound 8; bingind assay: TR-FRET
5owc  1.75  2018  IC50=0.026uM  // 5ow8.pdf (AYZ) [Nonstandard assay: Temp 37] ligand is compound 31
6hvj  2.28  2018  IC50=0.028uM  // 6hvh.pdf (GV8) ligand is compound 70
6bbu  2.08  2018  IC50=0.029uM  // 6bbu.pdf (D7D) [Nonstandard assay: 1 mM ATP] ligand is compound 25
6fex  1.29  2018  IC50=0.029uM  // 6fer.pdf (D6Z) ligand is compound 2.45
5ni8  1.94  2018  IC50=0.02uM   // 5ni5.pdf (8Y2) ligand is compound 10
5ni7  2.45  2018  IC50=0.02uM   // 5ni5.pdf (8Y8) ligand is compound 8
6bfp  1.29  2018  IC50=0.02uM   // 6bfp.pdf (DJY) enzymic inhibition assay, IC50(trypsin, BCX4161=0.02uM
6f1x  1.90  2018  IC50=0.02uM   // 6f1x.pdf (C9Q) ligand is compound 7
6gin  2.20  2018  IC50=0.032uM  // 6gi6.pdf (IR2) ligand is compound 16
6cck  1.61  2018  IC50=0.037uM  // 6cck.pdf (EXJ) ligand is compound 53
6ed6  2.86  2018  IC50=0.037uM  // 6e99.pdf (J0P) [Nonstandard assay: ATP = 100 uM] ligand is compound 12
6bir  2.30  2018  IC50=0.03uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] [Different protein in assay: protein in binding assay is HLA_DRB1*04:05] ligand is compound Vim424Cit
6frf  2.10  2018  IC50=0.040uM  // 5eic.pdf (E3T) ligand is compound 18
6gip  2.17  2018  IC50=0.042uM  // 6gi6.pdf (EUN) ligand is compound 21
5osy  2.06  2018  IC50=0.0430uM  // 5osx.pdf (AJQ) IC50 = 0.0430 +/- 0.0080 uM, ligand is compound 15
5yg4  2.30  2018  IC50=0.043uM  // 5yfz.pdf (8UF) [Different protein in assay: Protein in binding assay is Plasmodium falciparum] ligand is (+)-59,IC50=0.043+/-0.002uM
6dzq  2.25  2018  IC50=0.043uM  // 6dcy.pdf (HJP) ligand is compound 1; IC50 = 0.043 +/- 0.009uM
6ft8  1.45  2018  IC50=0.044uM  // 6ft7.pdf (E6T) ligand is compound 8g
6h1i  1.69  2018  IC50=0.044uM  // 6h1h.pdf (FJH) ligand is compound 2
6hvh  2.36  2018  IC50=0.047uM  // 6hvh.pdf (GV2) ligand is compound 37
5qin  1.57  2018  IC50=0.04nM   // 5qik.pdf (J2V) ligand is compound 2b
6ew3  2.14  2018  IC50=0.04uM   // 5jmx.pdf (S3C) IC50 = 0.04 +/- 0.002 uM, ligand is ML302F
5yso  2.50  2018  IC50=0.04uM   // 5yso.pdf (90C) compound is DN200434
6cco  1.82  2018  IC50=0.051uM  // 6cck.pdf (EXV) ligand is compound 28
5y6d  2.10  2018  IC50=0.055uM  // 5y6d.pdf (8PL) ligand is compound 11
6cz3  1.80  2018  IC50=0.056uM  // 6cz3.pdf (FLJ) binding assay: mobility shift assay; ligand is compound 2c;IC50=0.056+/-0.004uM
6mr5  1.85  2018  IC50=0.05uM   // 6mr5.pdf (W45) ligand is MCA
6ffs  1.86  2018  IC50=0.063uM  // 6ffn.pdf (D8E) [Covalent complex] ligand is compound 4
6dcz  2.89  2018  IC50=0.068uM  // 6dcy.pdf (G5Y) ligand is compound 3; IC50 = 0.068 +/- 0.011uM
6do5  2.50  2018  IC50=0.0695uM  // 6do3.pdf (6-mer) [Incomplete ligand] [Different ligand in assay: ] ligand is peptide USP1(IGLLGG). AlphaScreen competition assay, IC50 = 0.0458-0.1053uM (95% CI)
6f3g  2.37  2018  IC50=0.069uM  // 6f3d.pdf (CJN) ligand is compound 17
6bu1  1.58  2018  IC50=0.06uM   // 6apz.pdf (E9S) [Incomplete ligand] ligand is PDKA-substituent 2-Br-3-OH
6cje  3.36  2018  IC50=0.06uM   // 6cj5.pdf (F4A) ligand is compound 1
6f3e  2.67  2018  IC50=0.070uM  // 6f3d.pdf (CJQ) ligand is compound 3
6h7z  2.00  2018  IC50=0.075nM  // 5of0.pdf (FVW) [Nonstandard assay: Temp 37] IC50 = 0.075 +/- 0.005 nM; ligand is compound 13b
6cgp  2.50  2018  IC50=0.076uM  // 6cgp.pdf (F1Y) ligand is compound 4i; IC50 = 0.076+/-0.0036uM
6cz4  1.50  2018  IC50=0.076uM  // 6cz3.pdf (FKY) binding assay: mobility shift assay; ligand is compound PF-6683324;IC50=0.076+/-0.001uM
5wgd  1.80  2018  IC50=0.078uM  // 5wgd.pdf (13-mer) ligand is peptide SRC2-LP1
6ggn  2.00  2018  IC50=0.08nM   // 6ggn.pdf (EYH) ligand is compound 15a
5ux4  2.81  2018  IC50=0.09uM   // 5ux4.pdf (3UT) ligand is compound 4
6f5h  2.16  2018  IC50=0.09uM   // 6f5h.pdf (CQ5) ligand is compound 46
5wzu  2.20  2018  IC50=0.10uM   // 5wzo.pdf (7W3) ligand is compound 24
5t31  2.85  2018  IC50=0.110uM  // 5kpk.pdf (75F) IC50 = 0.110 +/- 0.001 uM. ligand is BRD0705
5lh4  1.37  2018  IC50=0.11uM   // 5lh4.pdf (6W4) [Different protein in assay: Protein in binding assay is human cationic trypsin] ligand is compound 1
5ncq  3.00  2018  IC50=0.11uM   // 5ncq.pdf (8T8) IC50 = 0.11 +/- 0.06 uM. ligand is compound 7
5wdj  2.40  2018  IC50=0.11uM   // 5wdj.pdf (AEY) ligand is compound 6
6ft9  1.87  2018  IC50=0.11uM   // 6ft7.pdf (E6W) ligand is compound 16
6q73  2.21  2018  IC50=0.126uM  // 6q6y.pdf (HKK) ligand is compound 11
6bsk  2.57  2018  IC50=0.12uM   // 6bsk.pdf (MVG) ligand is compound 12b
6cis  1.51  2018  IC50=0.135uM  // 6cd4.pdf (X26) Ligand is compound JWG-047;IC50 = 0.135+/-0.004uM, AlphaScreen Binding Assay
6hkz  2.09  2018  IC50=0.13nM   // 5of0.pdf (GBZ) [Nonstandard assay: Temp 37] IC50 = 0.13 +/- 0.01 nM. ligand is compound 22b
6fqo  1.35  2018  IC50=0.140uM  // 5eic.pdf (E2T) ligand is compound 16
6ep9  2.01  2018  IC50=0.145uM  // 6bik.pdf (BNB) Lanthascreen assay, compound 9
6fr0  1.50  2018  IC50=0.146uM  // 5eic.pdf (E3H) ligand is compound 17
5x02  2.40  2018  IC50=0.14nM   // 5x02.pdf (F6M) [Covalent complex] Mobility shift assay: IC50=0.14nM, kinase inhibition assay: IC50=2.0nM
5w8i  1.95  2018  IC50=0.150uM  // 5w8h.pdf (9YD) [Nonstandard assay: without EDTA] IC50 = 0.150 +/- 0.001 uM. ligand is compound 27
5mwa  1.55  2018  IC50=0.15uM   // 5mwa.pdf (8S9) IC50(22d)=0.15+/-0.04uM
6apz  2.25  2018  IC50=0.15uM   // 6apz.pdf (BQ4) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 3-OH
5y8c  1.42  2018  IC50=0.16uM   // 5y8c.pdf (8P9) ligand is 6m, IC50 = 0.16 +/- 0.04 uM
6c7d  1.79  2018  IC50=0.17nM   // 6c7d.pdf (EOJ) Ligand is compound 23; pIC50 = 9.77; Binding assay is IMAP assay
6gi6  1.98  2018  IC50=0.194uM  // 6gi6.pdf (EZB) ligand is compound 11
6etj  2.51  2018  IC50=0.19uM   // 6etj.pdf (BWW) Ligand is compound KAN0438241; IC50 = 0.19+/-0.04uM; Bingind assay: ADP-GLO
6hdq  1.70  2018  IC50=0.1uM    // 6hdn.pdf (FZE) ligand is compound 26
6ciy  1.68  2018  IC50=0.201uM  // 6cd4.pdf (F3J) Ligand is compound JWG-069;IC50 = 0.201+/-0.007uM, AlphaScreen Binding Assay
5wzv  2.20  2018  IC50=0.21uM   // 5wzo.pdf (7W0) ligand is compound Me-indoxam
5g6u  1.84  2018  IC50=0.22uM   // 5g6u.pdf (YJM) IC50 = 0.22 +/- 0.03 uM, ligand is GlcNS6S
5wzt  2.40  2018  IC50=0.22uM   // 5wzo.pdf (7W6) ligand is compound 14
6biy  2.05  2018  IC50=0.22uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] ligand is compound His2B
6giu  1.39  2018  IC50=0.22uM   // 6giu.pdf (L69) IC50 = 0.22 +/- 0.01 uM
6ft4  1.34  2018  IC50=0.235uM  // 6fsy.pdf (E5W) alpha screen assay
5y8w  1.76  2018  IC50=0.23uM   // 5y8c.pdf (8PU) ligand is 6a, IC50 = 0.23 +/- 0.01 uM
6czv  1.88  2018  IC50=0.23uM   // 6czu.pdf (FOY) [Covalent complex] [Incomplete ligand] AlphaScreen assay; Liand is compound 1
6cmr  2.21  2018  IC50=0.246uM  // 6cmr.pdf (5OD) ligand is compound SHP099; IC50 = 0.246+/-0.009uM
6c7f  1.82  2018  IC50=0.24nM   // 6c7d.pdf (EOS) Ligand is compound 39; pIC50 = 9.61; Binding assay is IMAP assay
6c2y  2.74  2018  IC50=0.25uM   // 6c2y.pdf (EJS) ligand is compound 33; IC50 = 0.25+/-0.07uM
6ccq  1.92  2018  IC50=0.25uM   // 6cck.pdf (EX7) ligand is compound 20
6g4m  2.63  2018  IC50=0.25uM   // 6fld.pdf (DQ5) [Different protein in assay: X-ray(Tetronarce californica), IC50(human)] ligand is compound 1; IC50 = 0.25 +/- 0.02 uM
6hdo  2.61  2018  IC50=0.25uM   // 6hdn.pdf (FZH) ligand is compound 27
6biz  2.10  2018  IC50=0.27uM   // 6bij.pdf (15-mer) [Nonstandard assay: Temp 37, PH=5.4] ligand is compound His2BCit
6cw8  1.90  2018  IC50=0.27uM   // 6cw8.pdf (FGY) IC50=0.27+/-0.01uM
5wzs  2.30  2018  IC50=0.28uM   // 5wzo.pdf (7W9) ligand is compound 8
6e9w  2.96  2018  IC50=0.28uM   // 6e99.pdf (J0P) [Nonstandard assay: ATP = 100 uM] ligand is compound 12
5zh2  2.66  2018  IC50=0.29uM   // 5zh2.pdf (9CU) ligand is compound 16, IC50 = 0.29 +/- 0.04 uM
6g6w  2.72  2018  IC50=0.2nM    // 6g6w.pdf (EO5) ligand is compound 39
6f2n  1.15  2018  IC50=0.2uM    // 5jmx.pdf (CF8) IC50 = 0.2 +/- 0.03 uM, ligand is 6c
5yzd  2.64  2018  IC50=0.2uM    // 5yxw.pdf (4-mer) ligand is FIP
6c8p  1.64  2018  IC50=0.2uM    // 6apz.pdf (EQA) [Incomplete ligand] ligand is PDKA-substituent 2-F
6g5j  1.85  2018  IC50=0.2uM    // 6g5j.pdf (EM8) ligand is compound (R)-12
6biv  2.90  2018  IC50=0.30uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] ligand is compound LL37_Cit91
6bix  2.20  2018  IC50=0.31uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] ligand is compound LL37_Cit91
6dqb  1.79  2018  IC50=0.32uM   // 6dq4.pdf (HZM) [Different protein in assay: protein in binding assay is KDM5A(1-1090)] ligand is compound N71; AlphaLISA, IC50 = 0.32+/-0.02uM
5z9e  1.80  2018  IC50=0.33mM   // 5z4h.pdf (27K) [Nonstandard assay: Temp 30] lligand is compound 37
5wgq  2.30  2018  IC50=0.33uM   // 5wgd.pdf (13-mer) ligand is peptide SRC2-LP1
5yve  3.40  2018  IC50=0.33uM   // 5yve.pdf (AF9) ligand is AF-219,IC50=0.33+/-0.07uM
6bx6  2.90  2018  IC50=0.33uM   // 6bx6.pdf (EDJ) ligand is compound SBI-0206965; IC50 = 0.33+/-0.07uM
6h7y  1.81  2018  IC50=0.35nM   // 5of0.pdf (FVZ) [Nonstandard assay: Temp 37] IC50 = 0.35 +/- 0.01 nM; ligand is compound 11a
6dqa  1.89  2018  IC50=0.36uM   // 6dq4.pdf (H6V) [Different protein in assay: protein in binding assay is KDM5A(1-1090)] ligand is compound N70; AlphaLISA, IC50 = 0.36+/-0.01uM
6ft3  1.28  2018  IC50=0.377uM  // 6fsy.pdf (E5T) alpha screen assay
6mx8  1.96  2018  IC50=0.37nM   // 5j7h.pdf (6GY) ligand is compound 11q (Brigatinib)
6hvi  1.96  2018  IC50=0.380uM  // 6hvh.pdf (GV5) ligand is compound 38
6c7i  1.71  2018  IC50=0.38nM   // 6c7d.pdf (EP7) Ligand is compound 31; pIC50 = 9.42; Binding assay is IMAP assay
6acb  2.80  2018  IC50=0.39nM   // 5zz2.pdf (9T9) ligand is compound 17c,IC50=0.39+/-0.05nM
6i8l  1.58  2018  IC50=0.39uM   // 6i8b.pdf (H7Q)
6eum  1.18  2018  IC50=0.3uM    // 5jmx.pdf (BY5) IC50 = 0.3 +/- 0.01 uM, ligand is 6k
5o7n  1.50  2018  IC50=0.3uM    // 5o7n.pdf (9NK) IC50=0.3+/-0.09uM
6fkp  2.00  2018  IC50=0.3uM    // 6fap.pdf (10-mer) ligand is H3 10-mer peptide(ARTKQTARKS); Binding assay: AlphaLISA competition assay
5ylt  1.69  2018  IC50=0.41uM   // 5ylt.pdf (C7N) [Nonstandard assay: pH 8.8] ligand is 2n,IC50=0.41+/-0.14uM
5y0z  2.00  2018  IC50=0.46uM   // 5y0z.pdf (8K9) ligand is NPD11033,IC50=0.46+/-0.056uM
6bin  2.50  2018  IC50=0.46uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] [Different protein in assay: protein in binding assay is HLA_DRB1*04:01] ligand is compound CII1240
6ffh  2.65  2018  IC50=0.46uM   // 6ffh.pdf (D7W) ligand is compound 4(fenobam)
6czu  1.47  2018  IC50=0.48uM   // 6czu.pdf (FP7) [Covalent complex] [Incomplete ligand] AlphaScreen assay; Liand is compound 1A, and Epoxypropyl in the ligand is opened
5x27  2.95  2018  IC50=0.4nM    // 5x26.pdf (7XR) ligand is SKLB5; IC50=0.4+/-0.3nM
5l9h  2.25  2018  IC50=0.4uM    // 5g2b.pdf (CVL) ligand is compound NPD-340(2)
6gy1  2.10  2018  IC50=0.50uM   // 6gy1.pdf (FGQ) [Different protein in assay: X-ray(Rattus norvegicus), IC50(human)] ligand is compound 21
5kpl  2.60  2018  IC50=0.515uM  // 5kpk.pdf (6VL) IC50 = 0.515 +/- 0.257uM. ligand is BRD0705
6bjo  1.75  2018  IC50=0.51uM   // 6bjo.pdf (DUY) ligand is compound BIO124
5z4o  1.73  2018  IC50=0.53mM   // 5z4h.pdf (HX8) [Nonstandard assay: Temp 30] lligand is compound 36
6d4o  2.90  2018  IC50=0.53uM   // 6d4o.pdf (FUV) [Different ligand in assay: Ligand in binding assay is subtrate] Ligand is compound Amoxapine-GlcA ; IC50 = 0.53+/-0.01uM
6ar4  1.69  2018  IC50=0.573uM  // 6ar4.pdf (BQA) ligand is 1o
6bil  2.40  2018  IC50=0.58uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] [Different protein in assay: protein in binding assay is HLA_DRB1*04:01] ligand is compound Fib74cit
6axb  1.80  2018  IC50=0.5uM    // 6apz.pdf (C0V) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent naphthyl
5y8z  1.84  2018  IC50=0.62uM   // 5y8c.pdf (8Q3) ligand is 5t, IC50 = 0.62 +/- 0.09 uM
5zun  1.35  2018  IC50=0.64nM   // 5zun.pdf (9JX) ligand is compound 31
6f5l  1.63  2018  IC50=0.65nM   // 6ety.pdf (CQB) IC50(7)=0.65+/-0.11nM
5zz4  2.90  2018  IC50=0.67nM   // 5zz4.pdf (9M3) [Nonstandard assay: unactivated form of BTK, BTK[U]] ligand is 2e,IC50=0.67nM,unactivated conformation of BTK (BTK[U])
6h1h  1.54  2018  IC50=0.67uM   // 6h1h.pdf (FJE) ligand is compound 7
6iil  2.20  2018  IC50=0.68uM   // 6iik.pdf (A8F) ligand is compound IU1-47
6aak  2.67  2018  IC50=0.71nM   // 6aah.pdf (9T6) ligand is peficitinib,IC50=0.71(0.38-1.4)nM
6gop  2.90  2018  IC50=0.7nM    // 6gop.pdf (F6K) [Multiple sites:  site 1: IC50=0.7 +/- 0.04 nM(chymotrypsin-like activity); site 2: IC50=144 +/- 12 nM(caspase-like activity); site 3: IC50=118 +/- 28 nM(trypsin-like activity)] ligand is HomoSalA   IC50 = 0  ? +/- 0.04 nM
5wkl  1.85  2018  IC50=0.7uM    // 5wkj.pdf (AVY/B3J) [Covalent complex] ligand is compound 10c, protein source is Middle East respiratory syndrome-related coronavirus
6bbv  1.80  2018  IC50=0.803uM  // 6bbu.pdf (D7D) [Nonstandard assay: 1 mM ATP] ligand is compound 25
5yqo  1.48  2018  IC50=0.815uM  // 5yql.pdf (L5C) ligand is compound 24a
5o7i  2.38  2018  IC50=0.82uM   // 5lrq.pdf (9N8) compound 46, IC50=0.82+/-0.1uM
6iin  2.53  2018  IC50=0.83uM   // 6iik.pdf (A8O) ligand is compound IU1-248
6e4f  1.15  2018  IC50=0.85nM   // 6e4f.pdf (HRA) ligand is compound ARQ 531
6aum  2.95  2018  IC50=0.8nM    // 6aum.pdf (BXV) ligand is t-TUCB
5y86  1.90  2018  IC50=0.8uM    // 5y86.pdf (HRM) ligand is harmine
6f8u  2.10  2018  IC50=0.8uM    // 6f6u.pdf (CZQ) ligand is GEBR-20b; IC50 = 0.8 +/- 0.2 uM
6bij  2.10  2018  IC50=0.90uM   // 6bij.pdf (13-mer) [Nonstandard assay: Temp 37, PH=5.4] [Different protein in assay: protein in binding assay is HLA_DRB1*04:01] ligand is compound FIb72,74Cit
6e9l  2.80  2018  IC50=0.92uM   // 6e99.pdf (J0P) [Nonstandard assay: ATP = 100 uM] ligand is compound 12
5okt  2.13  2018  IC50=0.93uM   // 5okt.pdf (9XK) [Different protein in assay: Protein in binding assay is rat] IC50 = 0.93 +/- 0.15 uM. ligand is IWP-2
5w0e  1.41  2018  IC50=0.94nM   // 5w0e.pdf (9U4) ligand is compound 3
5z4h  2.00  2018  IC50=0.95mM   // 5z4h.pdf (A8K) [Nonstandard assay: Temp 30] lligand is compound 7
5nr7  2.35  2018  IC50=0.95uM   // 5nq5.pdf (YUI) IC50 = 0.95 +/- 0.08 uM. ligand is compound 43
6cyb  1.62  2018  IC50=0.96nM   // 6cyb.pdf (FKV) Ligand is compound 11
6hkj  2.09  2018  IC50=0.99nM   // 5of0.pdf (G8W) [Nonstandard assay: Temp 37] IC50 = 0.99 +/- 0.05nM. ligand is compound 13a
5xgh  2.97  2018  IC50=1.02uM   // 5xgh.pdf (84U) HTRF assay, IC50=1.02+/-0.005uM
6ck6  3.32  2018  IC50=1.0nM    // 6cj5.pdf (N45) ligand is compound 23
6dl9  1.80  2018  IC50=1.0uM    // 6apz.pdf (GXD) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2,6-Cl
6e99  1.88  2018  IC50=1.0uM    // 6e99.pdf (J0G) [Nonstandard assay: ATP = 100 uM] ligand is compound 47
5zwe  2.72  2018  IC50=1.1nM    // 5zwe.pdf (9K0) [Covalent complex] ligand is compound 1,IC50=1.1+/-0.06nM
5zob  2.00  2018  IC50=1.1uM    // 5zmq.pdf (5-mer) [Nonstandard assay: Temp 37] ligand is compound 3,IC50=1.1+/-0.07uM
6au9  2.10  2018  IC50=1.1uM    // 6apz.pdf (BXS) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent dioxine
5wzw  1.95  2018  IC50=1.23uM   // 5wzo.pdf (U8D) ligand is compound LY311727
5zfi  1.80  2018  IC50=1.2uM    // 5zfi.pdf (9C9) ligand is 22g
6c7j  1.85  2018  IC50=1.32nM   // 6c7d.pdf (EPV) Ligand is compound 46; pIC50 = 8.88; Binding assay is IMAP assay
6bkh  1.79  2018  IC50=1.3nM    // 6bik.pdf (DVD) Lanthascreen assay, compound 10
6hmx  2.53  2018  IC50=1.3nM    // 6hmx.pdf (GEZ) ligand is compound 7
6g3y  2.51  2018  IC50=1.3uM    // 6g3y.pdf (ELB) ligand is TH5675
5zz2  2.60  2018  IC50=1.41nM   // 5zz2.pdf (9M0) ligand is compound 11b,IC50=1.41+/-0.30nM
6few  1.44  2018  IC50=1.41uM   // 6fer.pdf (D6W) ligand is compound 2a
6fil  1.73  2018  IC50=1.41uM   // 6fer.pdf (D6W) ligand is compound 2a
6g8n  3.00  2018  IC50=1.430uM  // 6g7f.pdf (EQB) ligand is compound 2; IC50 = 1.430 +/- 0.089 uM
5w0i  1.43  2018  IC50=1.4nM    // 5w0f.pdf (9UA) ligand is compound 8
6bqa  1.03  2018  IC50=1.4uM    // 6bik.pdf (67C) compound 5
5vil  2.64  2018  IC50=1.5nM    // 5vil.pdf (9E1) [Nonstandard assay: ATP = 1mM] [Different protein in assay: Protein in binding assay is full length] IC50 = 1.5 +/- 0.87 nM, ligand is compound 18
5zeq  1.90  2018  IC50=1.5nM    // 5zeq.pdf (9B3) [Uncommon element] ligand is compound 1
5yof  1.51  2018  IC50=1.5uM    // 5yod.pdf (7HS) [Incomplete ligand] [Different protein in assay: Protein in binding assay is WT] ligand is compound 1
6c7b  2.13  2018  IC50=1.5uM    // 6apz.pdf (ENY) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent methoxynaphthyl
6bln  1.30  2018  IC50=1.6nM    // 6bik.pdf (DY4) Lanthascreen assay, compound 12
6dko  1.56  2018  IC50=1.6uM    // 6apz.pdf (GXG) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2,6-F
6bib  1.95  2018  IC50=1.6uM    // 6bib.pdf (DW7) [Covalent complex] inhibitor 1
5mwg  1.50  2018  IC50=1.7uM    // 5mwg.pdf (WGX) ligand is compound 16
6hjj  2.13  2018  IC50=1.7uM    // 6hjj.pdf (G7T) IC50 = 1.7 +/- 0.4 uM; ligand is compound ASDO6
5wg8  1.65  2018  IC50=1.82uM   // 5wg8.pdf (LB1) [Nonstandard assay: substrate: DiFMUP] phosphatase assay
5zwf  2.10  2018  IC50=1.8nM    // 5zwe.pdf (9KR) [Covalent complex] ligand is compound 2,IC50=1.8+/-0.06nM
5yjf  2.49  2018  IC50=1.8uM    // 5yjf.pdf (8WO) [Nonstandard assay: Tem 37 C] ligand is JBSNF-000088,IC50=1.8uM
6cjw  3.38  2018  IC50=1.8uM    // 6cj5.pdf (FYV) ligand is compound 2
6ev0  2.30  2018  IC50=1.8uM    // 6eut.pdf (BYK) [Different ligand in assay: ligand in binding assay is racemic] ligand is compound 11; Both R and S form of 11 appear in complex structure
5zwh  2.38  2018  IC50=1.9nM    // 5zwe.pdf (9N9) [Covalent complex] ligand is compound 3,IC50=1.9+/-0.04nM
6br2  3.18  2018  IC50=1.9nM    // 6br2.pdf (E3S) ligand is compound 2
6br3  3.00  2018  IC50=1.9nM    // 6br2.pdf (E3V) ligand is compound 10; IC50 = 1.9+/-0.3nM
5mxq  2.00  2018  IC50=1.9uM    // 5mxq.pdf (U8K) ligand is ANT-090 (32)
6g7f  2.70  2018  IC50=10.1uM   // 6g7f.pdf (EPW) ligand is Cystargolide B
6h7u  2.80  2018  IC50=10.4mM   // 6gz9.pdf (FVT) ligand is 5-aminolevulinic acid
6hzp  2.50  2018  IC50=10.4mM   // 6gz9.pdf (FVT) ligand is valacyclovir
5xpn  1.96  2018  IC50=102nM    // 5xpl.pdf (8BO) ligand is 4a,IC50=102+/-0.50nM
6c0u  2.65  2018  IC50=1030nM   // 6c0t.pdf (EE4) ligand is compound N46; IC50 = 1030+/-43nM
6c5t  2.75  2018  IC50=108nM    // 6c5q.pdf (EKP) Ligand is compound SR11023
5nwd  1.45  2018  IC50=10nM     // 5nsx.pdf (9C8) ligand is compound 32
5ows  1.80  2018  IC50=10nM     // 5nsx.pdf (KC8) ligand is compound 9, Structure of ligand in PDB is wrong, and the name is compound 8
5w0q  1.70  2018  IC50=10nM     // 5w0f.pdf (9U7) ligand is compound 10
6gn1  2.60  2018  IC50=10nM     // 6gn1.pdf (F4N) ligand is PIK-75
5nq5  2.85  2018  IC50=10uM     // 5nq5.pdf (952) IC50 = 10 +/- 2 uM. ligand is compound 1
5wi1  1.99  2018  IC50=10uM     // 5wi0.pdf (AOY) ligand is compound 5
6f34  3.13  2018  IC50=11.4uM   // 5oqt.pdf (ALA) 
5yfz  2.16  2018  IC50=110nM    // 5yfz.pdf (8UO) [Different protein in assay: Protein in binding assay is Plasmodium falciparum] ligand is compound (+)-65
6bl1  2.02  2018  IC50=110nM    // 6bkx.pdf (DWG) [Covalent complex] ligand is compound 13
6fdq  2.30  2018  IC50=113uM    // 6fdk.pdf (2UQ) ligand is compound 5
5yjy  3.40  2018  IC50=115nM    // 5yjy.pdf (8WF) ligand is compound AC0-12
6hsz  2.37  2018  IC50=116nM    // 6hqy.pdf (GOW) ligand is compound 2; IC50 = 116 +/- 38 nM
5xv7  2.32  2018  IC50=11nM     // 5xv7.pdf (EMH) ligand is Alectinib
6dvl  2.10  2018  IC50=11nM     // 6dvl.pdf (HBG) Ligand is compound 1
6eqm  1.35  2018  IC50=11nM     // 6eqm.pdf (BUH) Ligand is compound CNP520; IC50 = 11+/-0.4nM
6fyv  2.46  2018  IC50=11nM     // 6fyi.pdf (3NG) ligand is CX-4945
6g93  1.67  2018  IC50=11nM     // 6g8x.pdf (EU2) ligand is compound 11
6gl3  2.77  2018  IC50=11nM     // 6gl3.pdf (EMW) ligand is compound 44
6h3k  2.48  2018  IC50=11nM     // 6h3k.pdf (FMW) ligand is BOS172722
6fr2  2.26  2018  IC50=12.0nM   // 6fr2.pdf (E3N) ligand is compound 22; IC50 = 12.0 +/- 1.9 nM
6iik  1.97  2018  IC50=12.25uM  // 6iik.pdf (IU1) ligand is compound IU1
6e2n  2.10  2018  IC50=12.5nM   // 6e2m.pdf (KK8) ligand is compound 2
5wfc  2.28  2018  IC50=12.5uM   // 5wf7.pdf (A97) ligand is GSK343
6fnx  1.19  2018  IC50=12.6uM   // 6fnx.pdf (DYZ) ligand is F1p; Bingding assay: HTRF
6hu0  1.75  2018  IC50=122nM    // 6hqy.pdf (T86) ligand is compound 9; IC50 = 122 +/- 19 nM
5nra  1.27  2018  IC50=123nM    // 5nr8.pdf (95K) IC50 = 123 +/- 47 nM, ligand is 7g
6by8  1.90  2018  IC50=123nM    // 6bxy.pdf (FNV) IC50(FP)=123+/-21nM
6hu2  1.99  2018  IC50=1260nM   // 6hqy.pdf (T34) ligand is compound 11; IC50 = 1260 +/- 170 nM
5nzm  2.35  2018  IC50=127uM    // 5nzm.pdf (9ET) ligand is murrayamine-I
5nut  1.60  2018  IC50=12nM     // 5nsx.pdf (9A8) ligand is compound 34
5wh6  1.60  2018  IC50=12nM     // 5wh5.pdf (AKJ) S_Zl-n-91
6bg3  1.05  2018  IC50=12uM     // 6bg3.pdf (DOJ) ligand is compound 34
6ful  1.65  2018  IC50=12uM     // 6fuk.pdf (E7Z) ligand is compound 8
6fo7  2.59  2018  IC50=13.6nM   // 6fo7.pdf (LX3) [Different protein in assay: X-ray(Danio rerio); IC50(human)] ligand is compound 2c
5w2p  2.00  2018  IC50=130.9nM  // 5w2o.pdf (6U5) EC50(DG-167)=130.9+/-18.2nM, microscale thermophoresis assay
5w2q  1.80  2018  IC50=130.9nM  // 5w2o.pdf (6U5) EC50(DG-167)=130.9+/-18.2nM, microscale thermophoresis assay
5yg2  2.20  2018  IC50=130nM    // 5yfz.pdf (N05) [Different protein in assay: Protein in binding assay is Plasmodium falciparum] [Different ligand in assay: in binding assay is racemic,in PDB is single conformation] ligand is compound (+)-66
5mzg  1.85  2018  IC50=138nM    // 5mze.pdf (2GE) [Nonstandard assay: pH=8] IC50 = 138 +/- 2.8 nM, ligand is TH588
5olb  1.82  2018  IC50=13nM     // 5ohi.pdf (6ZO) IC50 = 13 +/- 3.1 nM, mATX+ PF-8380 (2)
5xyx  2.61  2018  IC50=14.445uM  // 5xyx.pdf (FTZ) ligand is compound 1, IC50=14.445+/-1.211uM
6eox  1.30  2018  IC50=140nM    // 6ekn.pdf (BKW) ligand is compound 2b
6fyp  2.29  2018  IC50=143nM    // 6fyi.pdf (3NG) ligand is CX-4945
6cyc  1.54  2018  IC50=14nM     // 6cyb.pdf (FKJ) Ligand is compound 9
6dvn  2.20  2018  IC50=14nM     // 6dvl.pdf (HB7) Ligand is compound 3
6cq4  3.20  2018  IC50=14uM     // 6cq0.pdf (F8P) Ligand is compound 131; IC50 = 14+/-3.8uM
6dxg  1.91  2018  IC50=14uM     // 6dxg.pdf (HGJ) ligand is compound 1; IC50 = 14+/-2uM
6as6  1.40  2018  IC50=15.2uM   // 6apz.pdf (BSV) [Incomplete ligand] ligand is PDKA-substituent 3-Prop-6-Me
5nvh  1.60  2018  IC50=15nM     // 5nsx.pdf (9B2) ligand is compound 30
5ocj  1.80  2018  IC50=15uM     // 5ocj.pdf (9SW) IC50 = 15 +/- 5 uM, ligand is CyC8beta
6ez9  1.61  2018  IC50=16.9nM   // 6ety.pdf (C68) [Different protein in assay: E424M inactive mutant] IC50(5)=16.9+/-7.2nM
6bsm  2.33  2018  IC50=160nM    // 6bsl.pdf (E7D) ligand is compound 4
5nrf  1.45  2018  IC50=163nM    // 5nr8.pdf (95Q) IC50 = 163 +/- 70 nM, ligand is 7i
6g2a  1.80  2018  IC50=164uM    // 6g1p.pdf (A3R) ligand is compound ADP-HPM
6cho  1.85  2018  IC50=167nM    // 6chl.pdf (F14) ligand is compound 7
5nvf  1.55  2018  IC50=16nM     // 5nsx.pdf (9AW) ligand is compound 29
5nwb  1.60  2018  IC50=16nM     // 5nsx.pdf (9C5) ligand is compound 33
5uz0  1.79  2018  IC50=16nM     // 5uy8.pdf (8US) IC50 = 16 +/- 11 nM. ligand is compound 28a
5w0f  1.60  2018  IC50=16nM     // 5w0f.pdf (9U7) ligand is compound 3
6f6u  1.83  2018  IC50=16uM     // 6f6u.pdf (CV8) ligand is GEBR-7b; IC50 = 16 +/- 2.2 uM
6f8v  1.85  2018  IC50=16uM     // 6f6u.pdf (D0B) ligand is GEBR-18b; IC50 = 16 +/- 5 uM
6c2x  2.60  2018  IC50=17.4uM   // 6apz.pdf (EHV) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2-Br-6-Me
6fo9  2.70  2018  IC50=17.6nM   // 6fo7.pdf (E0E) [Different protein in assay: X-ray(Danio rerio); IC50(human)] ligand is compound 2b
5y5u  2.14  2018  IC50=17.7nM   // 5y5t.pdf (8OU) ligand is SKI-G-618
5yz7  1.90  2018  IC50=17.8uM   // 5yz7.pdf (94X) [Incomplete ligand] [Nonstandard assay: Temp 30] [Different ligand in assay: ligand in binding assay is racemic,in PDB is single form] ligand is 7'carba-4BD,IC50=17.8+/- 5.2uM
5nr8  1.35  2018  IC50=175nM    // 5nr8.pdf (95N) IC50 = 175 +/- 7.1 nM, ligand is 7a
5nt4  1.90  2018  IC50=17nM     // 5nsx.pdf (97Z) ligand is compound 31
6f8x  1.95  2018  IC50=17uM     // 6f6u.pdf (D08) ligand is GEBR-26g; IC50 = 17 +/- 5 uM
6c7g  1.68  2018  IC50=18.20nM  // 6c7d.pdf (EOY) Ligand is compound 43; pIC50 = 7.74; Binding assay is IMAP assay
6fo8  2.30  2018  IC50=18.4nM   // 6fo7.pdf (DZT) [Different protein in assay: X-ray(Danio rerio); IC50(human)] ligand is compound 2d
5zmq  1.99  2018  IC50=18.4uM   // 5zmq.pdf (4-mer) [Nonstandard assay: Temp 37] ligand is compound 1B,IC50=18.4+/-1.9uM
6bmx  2.42  2018  IC50=18.9uM   // 6bmr.pdf (DYV) [Multiple sites: Src Homology 2 domains:IC50=18.9uM; phosphatese domain IC50 > 100uM] ligand is compound 8
6di1  1.10  2018  IC50=180nM    // 6di0.pdf (GJD) Ligand is compound 7; binding assay: microfluidic, off-chip mobility shift kinase assay
6cef  1.80  2018  IC50=180uM    // 6ce6.pdf (EYJ) ligand is compound 2; IC50 = 180+/-52uM
6gxu  1.92  2018  IC50=180uM    // 6gx3.pdf (FG8) ligand is compound 33c, IC50 = 180 +/- 30 uM (schistosoma mansoni)
6htz  1.84  2018  IC50=183nM    // 6hqy.pdf (GRK) ligand is compound 8; IC50 = 183 +/- 39 nM
5w0l  1.55  2018  IC50=18uM     // 5w0f.pdf (9U7) ligand is compound 17
6buv  1.86  2018  IC50=18uM     // 6buv.pdf (E9A) IC50(N2-8)=18+/-2uM, enzyme inhibition assay
6ht8  2.50  2018  IC50=190nM    // 6hqy.pdf (GQE) ligand is compound 3; IC50 = 190 +/- 54 nM
6hu1  2.00  2018  IC50=191nM    // 6hqy.pdf (GT2) ligand is compound 10; IC50 = 191 +/- 17 nM
6ftn  2.00  2018  IC50=199.5nM  // 6ftn.pdf (E78) ligand is compound 9
6chm  2.28  2018  IC50=199uM    // 6chl.pdf (F1V) ligand is compound 5
6bqk  1.97  2018  IC50=1nM      // 6bqj.pdf (Z1E) [Different protein in assay: protein in binding assay is genotype-1a] ligand is compound 18
6bg5  1.10  2018  IC50=1uM      // 6bg3.pdf (DQD) ligand is compound 45
6q6y  2.03  2018  IC50=1uM      // 6q6y.pdf (HKQ) ligand is compound 14
6h9b  2.75  2018  IC50=2.0uM    // 6h9b.pdf (FWH) ligand is compound 4f; IC50=2.0+/-0.5uM
6ge0  1.82  2018  IC50=2.1nM    // 6g8x.pdf (EVQ) ligand is compound 21
6bt0  2.60  2018  IC50=2.1uM    // 5yxh.pdf (E7V) [Nonstandard assay: Temp 30] ligand is compund NR1
6es0  2.38  2018  IC50=2.26uM   // 6es0.pdf (BW8) ligand is compound CSR35; IC50=2.26+/-0.11uM
5y93  1.62  2018  IC50=2.27uM   // 5y8c.pdf (8Q9) ligand is 6f, IC50 = 2.27 +/- 1.24 uM
6ds0  3.19  2018  IC50=2.2nM    // 6drx.pdf (H8M) Ligand is compound LY266097
6fqu  1.43  2018  IC50=2.2uM    // 5eic.pdf (E3B) ligand is compound 15
5of0  1.48  2018  IC50=2.32nM   // 5of0.pdf (9TB) [Nonstandard assay: Temp 37] IC50 = 2.32 +/- 0.55 nM. ligand is compound 7a
5zwi  2.40  2018  IC50=2.3nM    // 5zwe.pdf (9KX) [Covalent complex] ligand is compound 4,IC50=2.3+/-0.05nM
6fdc  1.45  2018  IC50=2.3uM    // 6f6u.pdf (DD5) [Different ligand in assay: ligand is tautomeric mixtures] ligand is GEBR-32a; IC50 = 2.3 +/- 0.7 uM
6g4n  2.90  2018  IC50=2.3uM    // 6fld.pdf (E2W) [Different protein in assay: X-ray(Tetronarce californica), IC50(human)] ligand is compound 2; IC50 = 2.3 +/- 0.2 uM
6g1u  1.79  2018  IC50=2.45uM   // 6g1u.pdf (E1K) [Covalent complex] [Different protein in assay: X-ray(TcAChE); IC50(hAChE)] ligand is compound 5; IC50 = 2.45 +/- 0.28 uM
5vio  2.84  2018  IC50=2.4nM    // 5vil.pdf (9E4) [Nonstandard assay: ATP = 1mM] [Different protein in assay: Protein in binding assay is full length] IC50 = 2.4 +/- 1.3 nM, ligand is compound 19
6bic  2.25  2018  IC50=2.4uM    // 6bib.pdf (5LH) [Covalent complex] inhibitor 2
6c7e  1.43  2018  IC50=2.82nM   // 6c7d.pdf (EOG) Ligand is compound 19; pIC50 = 8.55; Binding assay is IMAP assay
6dlj  2.60  2018  IC50=2.8uM    // 6apz.pdf (GXM) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2-Nitro
6bid  1.15  2018  IC50=2.9uM    // 6bib.pdf (DW4) [Covalent complex] inhibitor 3
6ew7  1.60  2018  IC50=2.9uM    // 6ew6.pdf (C1W) ligand is compound 2
6ezg  2.20  2018  IC50=20.4nM   // 6ezg.pdf (C6K) [Different protein in assay: X-ray(Tetronarce californica); IC50(human)] ligand is compound 6b; IC50 = 20.4 +/- 0.8 nM
5yov  1.45  2018  IC50=20.9nM   // 5yov.pdf (8XR) IC50=20.9+/-1.1nM
6fyi  2.60  2018  IC50=200nM    // 6fyi.pdf (EAE) ligand is TG003; IC50 = 200 nM (published); IC50 = 260 +/- 2 nM (in house)
6fdu  2.30  2018  IC50=204uM    // 6fdk.pdf (D5W) ligand is compound 3
6gmd  1.66  2018  IC50=205uM    // 6gih.pdf (A8Q) ligand is compound 3
5xpl  2.05  2018  IC50=20nM     // 5xpl.pdf (8C9) ligand is 5b,IC50=20+/-0.55nM
5nat  1.17  2018  IC50=20uM     // 5nat.pdf (8RT)
5o48  1.69  2018  IC50=20uM     // 5o48.pdf (9K2) ligand is IMP-72
6f8r  1.83  2018  IC50=20uM     // 6f6u.pdf (CZK) ligand is GEBR-54; IC50 = 20 +/- 3 uM
5zh3  2.86  2018  IC50=21.3uM   // 5zh2.pdf (9CF) ligand is compound 17,IC50=21.3+/-2uM
5y5t  1.80  2018  IC50=211nM    // 5y5t.pdf (8OR) ligand is SKI-O-85
6fzu  1.80  2018  IC50=216uM    // 6fzu.pdf (EE8) ligand is compound 1; IC50 = 216 +/- 15 uM
5wvd  3.00  2018  IC50=21nM     // 5wvd.pdf (7UX) [Different protein in assay: Protein in binding assay is full length and inactive (unphosphorylated)] ligand is DS12881479
6g9a  1.91  2018  IC50=21nM     // 6g8x.pdf (ESQ) ligand is compound 14
6bmv  2.05  2018  IC50=21uM     // 6bmr.pdf (DZS) [Different protein in assay: Src Homology 2 domains:IC50=21uM; phosphatese domain IC50 > 100uM] ligand is compound 9
6e2m  2.25  2018  IC50=2200nM   // 6e2m.pdf (KK7) ligand is compound 1
6c5q  2.40  2018  IC50=220nM    // 6c5q.pdf (EKS) Ligand is compound SR10171
6htt  1.75  2018  IC50=220nM    // 6hqy.pdf (GQZ) ligand is compound 7; IC50 = 220 +/- 4 nM
5o1s  1.90  2018  IC50=225uM    // 5o1s.pdf (9HB) [Covalent complex] IC50app = 225 uM. ligand is DMF
6g28  1.23  2018  IC50=228uM    // 6g1p.pdf (AR6) ligand is ADPr
5qik  1.58  2018  IC50=22nM     // 5qik.pdf (J2M) ligand is compound 1
5w8h  1.80  2018  IC50=23.4uM   // 5w8h.pdf (9Y1) [Nonstandard assay: without EDTA] IC50 = 23.4 +/- 5.7 uM. ligand is compound 15
6fob  2.75  2018  IC50=23.5nM   // 6fo7.pdf (DZW) [Different protein in assay: X-ray(Danio rerio); IC50(human)] ligand is compound 2e
6dxx  2.70  2018  IC50=230nM    // 6dxx.pdf (WTF) Ligand is compound ARN19702, crystalized in presence of Triton X-100
6ccs  2.06  2018  IC50=230uM    // 6cck.pdf (EXD) ligand is compound 5
5xpm  2.20  2018  IC50=23nM     // 5xpl.pdf (8C0) [Different ligand in assay: Ligand in binding assay is racemic.] ligand is 4b,IC50=23+/-0.72nM.
6cjy  3.05  2018  IC50=23nM     // 6cj5.pdf (F4J) ligand is compound 8
6f8w  1.60  2018  IC50=23uM     // 6f6u.pdf (D0E) ligand is GEBR-18a; IC50 = 23 +/- 4 uM
5wjj  1.60  2018  IC50=240nM    // 5wjj.pdf (AQY) ligand is compound 1
5o9h  2.70  2018  IC50=241nM    // 5o9h.pdf (9P2) ligand is NDT9513727
6fgl  2.10  2018  IC50=24uM     // 6fg6.pdf (UO1) ligand is compound 8
5oae  2.70  2018  IC50=25.11uM  // 5oae.pdf (SVF) IC50 = 25.11 + 0.98 uM, ligand is compound 3
6ary  2.26  2018  IC50=25.1nM   // 6arx.pdf (BT7) [Covalent complex] ligand is PRC1214,IC50=25.1+/-1.2nM
5yql  1.60  2018  IC50=25.9uM   // 5yql.pdf (A2I) ligand is compound 1
6gx3  2.10  2018  IC50=250uM    // 6gx3.pdf (FF2) ligand is compound 9b, IC50 = 250 +/- 20 uM (schistosoma mansoni)
6dud  1.66  2018  IC50=256nM    // 6da4.pdf (HB4) [Covalent complex] ligand is compound 12
6hjk  2.40  2018  IC50=25nM     // 6hjj.pdf (G7W) IC50 = 25 +/- 2 nM; ligand is ligand ASDO2
5wfd  2.65  2018  IC50=26.2uM   // 5wf7.pdf (A9G) ligand is GSK126
6ela  1.49  2018  IC50=26nM     // 6ekn.pdf (B9Z) ligand is compound 3a
6bky  2.17  2018  IC50=270nM    // 6bkx.pdf (K32) [Covalent complex] ligand is compound 2
6ccl  1.77  2018  IC50=273uM    // 6cck.pdf (EXG) ligand is compound 4
5xst  2.30  2018  IC50=27nM     // 5xsr.pdf (8E6) [Nonstandard assay: Temp 37, PH=8.0] ligand is compound 15
6g07  1.66  2018  IC50=27uM     // 6fzu.pdf (EEZ) ligand is compound 10; IC50 = 27 +/- 2 uM
5wg6  3.90  2018  IC50=28.6uM   // 5wf7.pdf (A9G) ligand is GSK126
5nt0  1.75  2018  IC50=280nM    // 5nsx.pdf (97H) ligand is compound 13
6fn9  2.27  2018  IC50=284uM    // 6fn9.pdf (DW8) ligand is compound Mov2; IC50 = 284 +/- 60 uM
6mrg  2.77  2018  IC50=28nM     // 6mrg.pdf (JXV) [Different protein in assay: X-ray(Rattus norvegicus); IC50(human)] IC50 = 28 +/- 8 nM
6esm  1.10  2018  IC50=2960nM   // 6ekn.pdf (B9Z) ligand is compound 3a
5nwh  2.60  2018  IC50=29nM     // 5nqr.pdf (9CH) ligand is TH5427
6cyd  1.69  2018  IC50=2nM      // 6cyb.pdf (FKG) Ligand is compound 4
6g9n  1.76  2018  IC50=3.0nM    // 6g8x.pdf (ESN) ligand is compound 27
5yzc  2.33  2018  IC50=3.0uM    // 5yxw.pdf (95C) ligand is AS-48
6exm  1.60  2018  IC50=3.0uM    // 6eut.pdf (QQH) [Different ligand in assay: ligand in binding assay is racemic] ligand is compound 17
6hm6  2.10  2018  IC50=3.16uM   // 6hm6.pdf (GDK) ligand is compound 20
6ewe  1.46  2018  IC50=3.1uM    // 5jmx.pdf (C0W) IC50 = 3.1 +/- 0.3 uM, ligand is 6c
5x33  3.70  2018  IC50=3.2nM    // 5x33.pdf (7Y9) [Different ligand in assay: ] ligand is BIIL260,ligand in PDB is neutral,but in binding assay is positively charged.
6cen  1.61  2018  IC50=3.2uM    // 6cen.pdf (7-mer) ligand is peptide PTD2
6b41  2.61  2018  IC50=3.3nM    // 6b41.pdf (CJV) [Incomplete ligand] ligand is compound 10,IC50=3.3+/-0.4nM
5ohi  1.66  2018  IC50=3.4nM    // 5ohi.pdf (9V8) IC50 = 3.4 +/- 2.1 nM, Autotaxin/BI-2545 (19) complex
5o4s  1.75  2018  IC50=3.4uM    // 5mwg.pdf (9KW) ligand is compound 26
5xag  2.56  2018  IC50=3.5uM    // 5xag.pdf (93X) [Nonstandard assay: Tem 37 C] ligand is 14b,IC50=3.5+/-0.1uM
6dcy  2.08  2018  IC50=3.5uM    // 6dcy.pdf (G5V) ligand is compound 2; IC50 = 3.5 +/- 0.6uM
6b31  3.18  2018  IC50=3.6nM    // 6b31.pdf (CFJ) [Different ligand in assay: Ligand in binding assay is Racemic,in PDB is S form] ligand is 18h
6cjh  3.60  2018  IC50=3.8uM    // 6cj5.pdf (ET8) ligand is compound 3
6aah  1.83  2018  IC50=3.9nM    // 6aah.pdf (9T6) ligand is peficitinib,IC50=3.9(2.1-7.2)nM
6eji  2.30  2018  IC50=303uM    // 6eji.pdf (UD2) ligand is compound UDP-CH2-GalNAc; IC50=303+/-24uM
6ccn  1.87  2018  IC50=30uM     // 6cck.pdf (EXS) ligand is compound 29
6fu5  3.26  2018  IC50=31.6nM   // 6fu5.pdf (E7N) ligand is compound CSLP18; IC50 = 31.6 +/- 8.7 nM
6alc  1.39  2018  IC50=31nM     // 6alc.pdf (BKD) TR-FRET assay
6c0r  2.05  2018  IC50=31nM     // 6c0j.pdf (K5C) K103N/Y181C mutant; ligand is compound 25a; IC50 = 31+/-0.83nM
6g91  1.80  2018  IC50=3200nM   // 6g8x.pdf (EQW) ligand is compound 10
6ehh  2.40  2018  IC50=32nM     // 5mze.pdf (2GE) [Nonstandard assay: pH=8] IC50 = 32 +/- 15 nM, ligand is TH588
6ek3  1.60  2018  IC50=330nM    // 6ek3.pdf (OUL) ligand is compound 1
6gh9  2.09  2018  IC50=33uM     // 6gh9.pdf (MIX) ligand is mitoxantrone; IC50 = 33 +/- 11 uM
6d8e  2.54  2018  IC50=340nM    // 6d8e.pdf (FZP) [Covalent complex] ligand is compound 2b; IC50 = 340+/-42nM
5ye7  2.31  2018  IC50=3431nM   // 5ye7.pdf (8U0) ligand is compound 11
5ye9  1.88  2018  IC50=355nM    // 5ye7.pdf (8U6) ligand is compound 14a
5nve  1.50  2018  IC50=35nM     // 5nsx.pdf (9AQ) ligand is compound 35
6cq0  3.19  2018  IC50=35uM     // 6cq0.pdf (F8M) Ligand is compound 114; IC50 = 35+/-2.2uM
5wi0  2.05  2018  IC50=360uM    // 5wi0.pdf (AQ1)  ligand is compound 2
6ekd  2.10  2018  IC50=363nM    // 6ekd.pdf (B9K) Ligand is compound 44; IC50 = 363+/-34nM
5xpp  2.85  2018  IC50=36nM     // 5xpl.pdf (8BF) [Different ligand in assay: Ligand in binding assay is recemic] ligand is 3a,IC50=36+/-016nM,
6duh  2.00  2018  IC50=38nM     // 6c0j.pdf (K5C) Y181I mutant; ligand is compound 25a; IC50 = 38+/-1.1nM
6ce8  1.55  2018  IC50=390uM    // 6ce6.pdf (EYV) ligand is compound 22; IC50 = 390+/-160uM
6dvm  1.47  2018  IC50=3nM      // 6dvl.pdf (HBJ) Ligand is compound 2
6fyk  2.39  2018  IC50=3nM      // 6fyi.pdf (EAZ) ligand is Indazole1
5yun  2.67  2018  IC50=3uM      // 5yun.pdf (MYC) ligand is Myricetin
6g9h  1.73  2018  IC50=4.0nM    // 6g8x.pdf (ERW) ligand is compound 16
6g8m  2.70  2018  IC50=4.18uM   // 6g7f.pdf (EQE) ligand is compound 1
6g9j  1.98  2018  IC50=4.1nM    // 6g8x.pdf (ERK) ligand is compound 18
6g97  1.90  2018  IC50=4.2nM    // 6g8x.pdf (EQZ) ligand is compound 13
6c0n  2.00  2018  IC50=4.3nM    // 6c0j.pdf (K5C) ligand is compound 25a; IC50 = 4.3+/-0.08nM
6g9d  1.80  2018  IC50=4.3nM    // 6g8x.pdf (ER8) ligand is compound 15
6chq  1.79  2018  IC50=4.4uM    // 6chl.pdf (F0V) ligand is compound 28
6cd4  1.23  2018  IC50=4.59uM   // 6cd4.pdf (EX1) Ligand is compound JWG-046;IC50 = 4.59+/-0.14uM, AlphaScreen Binding Assay
6bke  1.95  2018  IC50=4.5nM    // 6bik.pdf (DVJ) Lanthascreen assay, compound 11
6cqf  2.25  2018  IC50=4.5nM    // 6cqd.pdf (F97) ligand is compound GNE-1858
5zh5  3.08  2018  IC50=4.64uM   // 5zh2.pdf (9CX) ligand is compound 13, IC50 = 4.64 +/- 0.5 uM
6aam  1.98  2018  IC50=4.8nM    // 6aah.pdf (9T6) ligand is peficitinib,IC50=4.8nM
6enm  1.59  2018  IC50=4.8nM    // 6ekn.pdf (LPW) ligand is compound 1b
5nsx  1.80  2018  IC50=400nM    // 5nsx.pdf (97K) ligand is compound 20
6g9k  1.94  2018  IC50=40nM     // 6g8x.pdf (ESK) ligand is compound 23
6bkx  1.65  2018  IC50=410nM    // 6bkx.pdf (DWP) [Covalent complex] ligand is compound 1
6bl2  1.92  2018  IC50=41nM     // 6bkx.pdf (DWS) [Covalent complex] ligand is compound 15
5xig  2.41  2018  IC50=420nM    // 5xig.pdf (87F) [Nonstandard assay: Temp 37] ligand is In-1,IC50=420+/-37.5nM
6dgt  2.60  2018  IC50=42nM     // 6dgt.pdf (GFJ) ligand is compound (P)-28
6c0t  1.98  2018  IC50=43.1nM   // 6c0t.pdf (EE4) ligand is compound N46; IC50 = 43.1+/-1.5nM
6fer  2.87  2018  IC50=44.1uM   // 6fer.pdf (D6Q) ligand is compound 2.38
6gxw  2.07  2018  IC50=440uM    // 6gx3.pdf (FGN) ligand is compound 31c, IC50 = 440 +/- 40 uM (schistosoma mansoni)
6gih  1.96  2018  IC50=44uM     // 6gih.pdf (EZN) ligand is compound 7
6da4  2.90  2018  IC50=456nM    // 6da4.pdf (G4V) [Covalent complex] ligand is compound 10
6ck3  2.90  2018  IC50=45nM     // 6cj5.pdf (F67) ligand is compound 9
6cec  1.55  2018  IC50=45uM     // 6ce6.pdf (EY7) ligand is compound 24; IC50 = 45+/-8uM
6arv  2.00  2018  IC50=46nM     // 6arj.pdf (BW7) ligand is compound 2, IC50 = 46 +/- 9 nM.
6bq0  2.00  2018  IC50=46nM     // 6bq0.pdf (E3A) [Covalent complex] ligand is compound 10
6db4  1.66  2018  IC50=49nM     // 6da4.pdf (G4Y) ligand is compound 34
5x28  2.95  2018  IC50=4nM      // 5x26.pdf (7XU) ligand is SKLB6; IC50=4+/-2nM
6aaj  2.37  2018  IC50=5.0nM    // 6aah.pdf (9T6) ligand is peficitinib,IC50=5.0(3.7-6.9)nM
6cn6  2.45  2018  IC50=5.0nM    // 6cn5.pdf (F7J) Ligand is compound 36
5yji  1.99  2018  IC50=5.0uM    // 5yjf.pdf (8WO) [Nonstandard assay: Tem 37 C] ligand is JBSNF-000088,IC50=5.0uM
6ei4  2.00  2018  IC50=5.25uM   // 5oae.pdf (B5N) IC50 = 5.25 + 1.60 uM, ligand is compound 16.
6g0w  2.34  2018  IC50=5.2uM    // 6g0w.pdf (EGW) ligand is compound 8b
6cj1  1.53  2018  IC50=5.42uM   // 6cd4.pdf (F2S) Ligand is compound JWG-071;IC50 = 5.42+/-0.18uM, AlphaScreen Binding Assay
6anl  2.00  2018  IC50=5.4nM    // 5wjj.pdf (T75) ligand is compound 15a
6dug  2.23  2018  IC50=5.4nM    // 6c0j.pdf (K5C) K101P mutant; ligand is compound 25a; IC50 = 5.4+/-0.16nM
6f6r  1.80  2018  IC50=5.6nM    // 6f6r.pdf (CVE) [Uncommon element] [Incomplete ligand] ligand is compound 10; IC50 (concentration of substrate is Km )
6ccm  1.79  2018  IC50=5.6uM    // 6cck.pdf (EXP) ligand is compound 30
5zms  1.80  2018  IC50=5.9uM    // 5zmq.pdf (4-mer) [Nonstandard assay: Temp 37] ligand is compound 2B,IC50=5.9+/-0.55uM
6hdn  1.90  2018  IC50=50.12uM  // 6hdn.pdf (FZB) ligand is compound 9
6hu3  1.66  2018  IC50=504nM    // 6hqy.pdf (GRZ) ligand is compound 12; IC50 = 504 +/- 46 nM;
5xij  2.50  2018  IC50=50nM     // 5xig.pdf (873) ligand is In-9,IC50=50+/-3.5nM
6ey7  2.90  2018  IC50=50uM     // 6ey7.pdf (C3W) ligand is compound 2
6ekn  1.20  2018  IC50=510nM    // 6ekn.pdf (B9N) ligand is compound 3b
5w6o  2.35  2018  IC50=520nM    // 5w6o.pdf (9X1) [Nonstandard assay: Temp 37] IC50 = 520 +/- 150 nM. ligand is TCD-717
6e06  2.50  2018  IC50=54.4uM   // 6czd.pdf (CTP) crystals grown in citrate precipitant
6e05  2.50  2018  IC50=54.4uM   // 6czd.pdf (CTP) crystals grown in sulfate precipitant
6db3  1.97  2018  IC50=56nM     // 6da4.pdf (G54) ligand is compound 23
6cki  2.95  2018  IC50=57nM     // 6cj5.pdf (FZJ) ligand is compound 12
6cq5  3.35  2018  IC50=57uM     // 6cq0.pdf (F8S) Ligand is compound 150; IC50 = 57+/-4.1uM
6g1v  1.82  2018  IC50=59.2nM   // 6g1u.pdf (E1N) [Covalent complex] [Different protein in assay: X-ray(TcAChE); IC50(hAChE)] ligand is compound 6; IC50 = 59.2 +/- 5.7 nM
5w5k  2.70  2018  IC50=5nM      // 5w5k.pdf (K70) IC50(7i)=5+/-1nM
5x26  2.95  2018  IC50=5nM      // 5x26.pdf (7XO) ligand is SKLB3; IC50=5+/-2nM
5yea  1.81  2018  IC50=5nM      // 5ye7.pdf (8U9) ligand is compound 41
5ztn  2.50  2018  IC50=5nM      // 5ztn.pdf (CUR) ligand is curcumin
6bkw  1.50  2018  IC50=5nM      // 6bik.pdf (DXM) Lanthascreen assay, compound 13
6cmj  2.40  2018  IC50=5nM      // 6cmj.pdf (F6J) ligand is compound 1b
6en4  3.08  2018  IC50=5nM      // 6en4.pdf (BGZ) ligand is compound PB; Crystal is human SF3B core in complex with PB
5xfj  3.25  2018  IC50=6.0nM    // 5xff.pdf (6LF) kinase activity inhibition assay, IC50(W550M)=6.0nM
6c42  2.00  2018  IC50=6.13nM   // 6c42.pdf (85M) competitive assay, IC50(OP-1156)=6.13+/-0.06nM
6asu  2.32  2018  IC50=6.1uM    // 6apz.pdf (BVS) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 4-Me
5xff  2.70  2018  IC50=6.2nM    // 5xff.pdf (6LF) kinase activity inhibition assay, IC50(W550L)=6.2nM
5mxr  1.75  2018  IC50=6.2uM    // 5mxq.pdf (JTY) ligand is ANT-330 (62)
6f8b  1.30  2018  IC50=6.2uM    // 6f8b.pdf (CXH) ligand is compound 27; IC50 = 6.2 +/- 0.3 uM
5nuu  2.50  2018  IC50=6.3nM    // 5nuu.pdf (9A5) [Different protein in assay: protein in binding assay is from human] S-K1035
6q74  2.48  2018  IC50=6.3nM    // 6q6y.pdf (HKN) ligand is compound 16
6bik  1.90  2018  IC50=6.4nM    // 6bik.pdf (DTJ) Lanthascreen assay, compound 7
6cj5  2.80  2018  IC50=6.4uM    // 6cj5.pdf (F4G) ligand is compound 4
6dnp  1.71  2018  IC50=6.6uM    // 6apz.pdf (GZV) [Incomplete ligand] [Different ligand in assay: tautomer] ligand is PDKA-substituent 2-F-3-Me-6-F
5owt  2.20  2018  IC50=6.7nM    // 5nsx.pdf (F37) ligand is compound 8
6hf5  1.80  2018  IC50=6.7uM    // 5mxq.pdf (G1N) ligand is ANT-431 (76)
5ow8  1.90  2018  IC50=6.9uM    // 5ow8.pdf (AYN) [Nonstandard assay: Temp 37] ligand is compound 1
6b30  2.69  2018  IC50=60nM     // 6b30.pdf (CFG) [Different ligand in assay: Ligand in binding assay is racemic] ligand is compound 19
6dvo  1.98  2018  IC50=60nM     // 6dvl.pdf (HBV) Ligand is compound 4
6bmr  2.21  2018  IC50=60uM     // 6bmr.pdf (DZV) [Multiple sites: Src Homology 2 domains:IC50=60uM; phosphatese domain IC50 > 100uM] ligand is compound 2
6gxa  2.10  2018  IC50=60uM     // 6gx3.pdf (TB8) ligand is compound 13c, IC50 = 60 +/- 20 uM (schistosoma mansoni)
6euz  1.95  2018  IC50=65.6uM   // 6eut.pdf (C8Q) [Different ligand in assay: ligand in binding assay is racemic] ligand is compound 5
5nvc  1.60  2018  IC50=650nM    // 5nsx.pdf (9AN) ligand is compound 15
5wh5  1.80  2018  IC50=65nM     // 5wh5.pdf (R91) (R)-Zl-n-91
6cee  1.55  2018  IC50=65uM     // 6ce6.pdf (EYM) ligand is compound 33; IC50 = 65+/-9.7uM
5nwg  1.40  2018  IC50=660nM    // 5nsx.pdf (9CB) ligand is compound 41
5yjo  2.14  2018  IC50=67nM     // 5yjo.pdf (8W0) [Covalent complex] compound 21, IC50=67+/-17nM
6ay5  1.44  2018  IC50=69nM     // 5w0e.pdf (C3V) ligand is compound 17
6ax4  1.45  2018  IC50=6nM      // 6ax4.pdf (5-mer) [Incomplete ligand] ligand is 5b,IC50=6+/-0.5nM
6f4n  2.54  2018  IC50=6uM      // 6f4n.pdf (AKG) [Uncommon element] ligand is 2OG and Manganese (II) ION; IC50 = 6 +/- 1.4 uM
6fzx  2.10  2018  IC50=7.0nM    // 6fzx.pdf (EEK) ligand is compound 7; IC50 = 7.0 +/- 0.2 nM
6fod  2.50  2018  IC50=7.11nM   // 6fo7.pdf (E05) [Different protein in assay: X-ray(Danio rerio); IC50(human)] ligand is compound 2a
6g1w  1.90  2018  IC50=7.18nM   // 6g1u.pdf (E0Z) [Covalent complex] [Different protein in assay: X-ray(TcAChE); IC50(hAChE)] ligand is compound 16; IC50 = 7.18 +/- 0.29 nM
5zh4  2.60  2018  IC50=7.25uM   // 5zh2.pdf (9CC) ligand is compound 18,IC50=7.25+/-0.5uM
6mvx  3.46  2018  IC50=7.2uM    // 6mvv.pdf (K4D) ligand is Flecainide; IC50 = 7.2 +/- 0.4uM
6duf  1.96  2018  IC50=7.3nM    // 6c0j.pdf (K5C) mutant V106A/F227L; ligand is compound 25a; IC50 = 7.3+/-0.23nM
6gz9  3.10  2018  IC50=7.4mM    // 6gz9.pdf (TXC) ligand is valacyclovir
6b33  2.48  2018  IC50=7.5nM    // 6b33.pdf (CF7) compound 43
5wkm  2.25  2018  IC50=7.5uM    // 5wkj.pdf (N02/B6Y) [Covalent complex] ligand is compound 10e, protein source is Middle East respiratory syndrome-related coronavirus
6bh8  3.85  2018  IC50=7.6uM    // 6bh8.pdf (RDF) Ligand is compound phosphoramidon; IC50 = 7.6+/-1.1uM at [S] = 40uM
6g9m  1.86  2018  IC50=7.9nM    // 6g8x.pdf (ESW) ligand is compound 20
6mu1  4.10  2018  IC50=7.9nM    // 6mu1.pdf (JYP) IC50 = 7.9 +/- 2 nM
5nwc  1.50  2018  IC50=700nM    // 5nsx.pdf (9CE) ligand is compound 14
5nqr  2.20  2018  IC50=70nM     // 5nqr.pdf (958) ligand is TH1713
5xih  2.20  2018  IC50=70nM     // 5xig.pdf (86U) [Nonstandard assay: Temp 37] ligand is In-5,IC50=70+/-5.5nM
6afr  2.00  2018  IC50=70nM     // 6afr.pdf (9E3) ligand is compound 38,IC50=70+/-19nM
6fgy  1.54  2018  IC50=70nM     // 6fgy.pdf (D9W) ligand is compound 4
6mx3  1.36  2018  IC50=7300nM   // 6mx3.pdf (K5P) [Different ligand in assay: X-ray structure of 1 in STING protein is a symmetrical dimer] ligand is compound 1
5xii  2.17  2018  IC50=75nM     // 5xig.pdf (86X) [Nonstandard assay: Temp 37] ligand is In-6,IC50=75+/-6nM
6hth  1.95  2018  IC50=75nM     // 6hqy.pdf (GQN) ligand is compound 5; IC50 = 75 +/- 25 nM
6g92  1.99  2018  IC50=76000nM  // 6g8x.pdf (ERZ) ligand is compound 5
5vm6  1.50  2018  IC50=78nM     // 5vl2.pdf (9EG) [Multiple sites: ] ligand is TCC
6hm7  1.64  2018  IC50=79.4nM   // 6hm6.pdf (GDH) ligand is compound 44
6f6d  1.82  2018  IC50=79.4uM   // 6f6d.pdf (17-mer) ligand is peptide H3(17-33)A21M; IC50 = 79.4 +/- 0.1 uM
6b5j  2.97  2018  IC50=79nM     // 6b5j.pdf (CV4) ligand is compound 4
6dcg  1.45  2018  IC50=7nM      // 6dcg.pdf (G67) ligand is compound 20(MK-8353);
6fyl  1.95  2018  IC50=7nM      // 6fyi.pdf (3NG) ligand is CX-4945
6f8t  1.80  2018  IC50=7uM      // 6f6u.pdf (CZT) ligand is GEBR-4a; IC50 = 7 +/- 2 uM
6e0q  2.35  2018  IC50=8.0nM    // 6dcy.pdf (HKD) ligand is compound 33; IC50 = 8.0 +/- 1.1 nM
6ety  1.68  2018  IC50=8.9nM    // 6ety.pdf (BXK) IC50(8)=8.9+/-0.1nM
6bo6  2.80  2018  IC50=80nM     // 6bjq.pdf (E0V) in vitro inhibition assay, IC50(UNC4917)=80+/-1nM
6emh  1.76  2018  IC50=833nM    // 6ekd.pdf (BGE) Ligand is compound 38; IC50 = 833+/-139nM
5xpo  2.28  2018  IC50=84nM     // 5xpl.pdf (8BL) ligand is 5a,IC50=84+/-0.50nM
6ffi  2.20  2018  IC50=8nM      // 6ffh.pdf (D8B) ligand is compound 3 (M-MPEP); IC50= 8 +/- 2 nM
5w6e  1.90  2018  IC50=9.1nM    // 5w6e.pdf (0NY) IC50 = 9.1 +/- 0.5 nM. ligand is compound (S)-3
5xyy  1.70  2018  IC50=9.221uM  // 5xyx.pdf (P0F) ligand is compound 3, IC50=9.221+/-0.455uM
6ay3  1.39  2018  IC50=9.5nM    // 5w0e.pdf (C3J) ligand is compound 16
5ygi  2.18  2018  IC50=90nM     // 5ygi.pdf (T93) inhibition assay
6i3s  1.77  2018  IC50=90nM     // 6i3s.pdf (H28) ligand is compound 13
6ezh  2.60  2018  IC50=91.4nM   // 6ezg.pdf (C6H) [Different protein in assay: X-ray(Tetronarce californica); IC50(human)] ligand is compound 6a; IC50 = 91.4 +/- 12.7 nM
5yqn  1.60  2018  IC50=93.7uM   // 5yql.pdf (L55) ligand is compound 24b
6hsk  2.10  2018  IC50=93nM     // 6hqy.pdf (GOK) ligand is Quisinostat; IC50 = 93 +/- 8 nM
6ex0  2.78  2018  IC50=94uM     // 6ewz.pdf (C1Z) ligand is compound pppGpp; IC50=94+/-26uM
6hti  1.69  2018  IC50=97nM     // 6hqy.pdf (GQW) ligand is compound 6; IC50 = 97 +/- 16 nM
5wf7  2.50  2018  IC50=98.5uM   // 5wf7.pdf (A9G) ligand is GSK126
6axq  1.30  2018  IC50=99000nM  // 5w0e.pdf (C2Y) ligand is compound 6
6bto  2.05  2018  IC50>10000nM  // 6bsl.pdf (E8P) ligand is compound 9
6bqj  1.69  2018  IC50>1000nM   // 6bqj.pdf (Z1B) [Different protein in assay: protein in binding assay is genotype-1a] ligand is compound 16
6fh6  2.08  2018  IC50>1000uM   // 6fg6.pdf (D8Q) ligand is compound 1
6fh7  2.10  2018  IC50>1000uM   // 6fg6.pdf (EN2) ligand is compound 2
6ft7  2.02  2018  IC50>10uM     // 6ft7.pdf (E6Q) ligand is compound 8a
5yp6  2.20  2018  IC50>25uM     // 5yp5.pdf (4CX) ligand is 6, pIC50<4.6
5yp5  2.65  2018  IC50>25uM     // 5yp5.pdf (4CZ) ligand is 5d, pIC50<4.6
6gqm  2.00  2018  IC50>33.3uM   // 6gqj.pdf (F8H) ligand is compound 44
5o4t  1.50  2018  IC50>400uM    // 5mwg.pdf (9KT) ligand is compound 9
6bsx  1.65  2018  IC50>500uM    // 5yxh.pdf (E7S) ligand is compund 1
6di0  1.30  2018  IC50>6000nM   // 6di0.pdf (GJG) Ligand is compound 6; binding assay: microfluidic, off-chip mobility shift kinase assay
5o5h  1.85  2018  IC50>75uM     // 5mwg.pdf (9LK) ligand is compound 43
6f5m  2.70  2018  IC50~0.5uM    // 6f5m.pdf (CQH)
6boy  3.33  2018  IC50~1.8uM    // 6bn7.pdf (RN6) ligand is compound dBET6(4)
5ye8  1.85  2018  IC50~1mM      // 5ye7.pdf (8U3) ligand is compound 10
5uq9  3.00  2018  IC50~700nM    // 5uq9.pdf (8HS) enzymic assay
6b5m  1.79  2018  Kd<0.001nM    // 6b5l.pdf (15-mer) ligand is petide 21
6d59  1.70  2018  Kd<0.10uM     // 6d55.pdf (FVJ) ligand is compound 58; Binding assay: FPA
6fel  2.84  2018  Kd<0.4uM      // 6eww.pdf (8-mer) ligand is peptide pepS511
5zo7  2.60  2018  Kd<1nM        // 5zo7.pdf (5C5) ligand is PVEI0138
6fs0  2.25  2018  Kd=0.00017uM  // 6fs0.pdf (E4W) ligand is compound (Ra)-7
5mpk  1.90  2018  Kd=0.003uM    // 5eic.pdf (0BC) ligand is compound 13
6ma3  2.00  2018  Kd=0.005uM    // 6ma1.pdf (JAJ) ligand is compound 2a; Kd = 0.005 +/- 0.001uM
6ma5  2.00  2018  Kd=0.008uM    // 6ma1.pdf (J9V) ligand is compound 4a; Kd = 0.008 +/- 0.001uM
6ma1  2.75  2018  Kd=0.008uM    // 6ma1.pdf (JA4) ligand is compound 4a; Kd = 0.008 +/- 0.001uM
6d56  1.68  2018  Kd=0.009uM    // 6d55.pdf (FVM) ligand is compound 65; Binding assay: FPA; Kd = 0.009+/-0.0017uM
6eq8  2.19  2018  Kd=0.010uM    // 6epy.pdf (BQZ) Kd = 0.010+/-0.001uM
6cus   NMR  2018  Kd=0.013mM    // 6cus.pdf (IHP) ligand is compound IP6; Kd = 0.013+/-0.001 mM
6cks  1.72  2018  Kd=0.015uM    // 6ckr.pdf (F5Y) ligand is compound 35
5nlk  1.80  2018  Kd=0.035uM    // 5nlk.pdf (92E) ligand is compound 16
6eol  1.50  2018  Kd=0.037uM    // 6eog.pdf (BKH) ligand is compound 2h; Kd=0.037+/-0.0010 uM
6fa3  1.82  2018  Kd=0.038uM    // 5ocg.pdf (D1Z) ligand is Abd-6
6fyz  2.15  2018  Kd=0.039uM    // 6fyz.pdf (EBE) ligand is compound 16
6d55  1.68  2018  Kd=0.044uM    // 6d55.pdf (FWA) ligand is compound 64; binding assay: FPA; Kd = 0.044+/-0.0067uM
6ma4  2.00  2018  Kd=0.045uM    // 6ma1.pdf (JA7) ligand is compound 3a; Kd = 0.045 +/- 0.02uM
6fa4  2.02  2018  Kd=0.051uM    // 5ocg.pdf (D1W) ligand is Abd-7
5ygd  1.55  2018  Kd=0.054uM    // 5ygd.pdf (11-mer) [Nonstandard assay: Tem 20,PH=8.0] ligand is Piwi-R10me2s,Kd=0.054+/-0.018uM
6ckr  1.62  2018  Kd=0.05uM     // 6ckr.pdf (F5V) ligand is compound 32
6bh1  1.93  2018  Kd=0.06uM     // 6bgu.pdf (DQG) [Different protein in assay] ligand is compound N52; Kd = 0.06+/-0.01 uM
6epz  1.80  2018  Kd=0.072uM    // 6epy.pdf (MLB) Kd = 0.072+/-0.004uM
6chp  1.94  2018  Kd=0.075nM    // 6chl.pdf (F0Y) ligand is compound 11
6ht1  2.10  2018  Kd=0.077uM    // 6ht0.pdf (GQ5) ligand is compound 92
5mpn  1.23  2018  Kd=0.085uM    // 5eic.pdf (YE5) ligand is compound 19
6as8  2.10  2018  Kd=0.089uM    // 6aox.pdf (BTG) bio-layer interferometry experiment, Kd=0.089+/-0.4uM
5ypo  2.29  2018  Kd=0.08uM     // 5ypo.pdf (15-mer) [Nonstandard assay: PH=8] ligand is pSAPAP1-R2,Kd=0.08+/-0.01uM
6b2c  2.00  2018  Kd=0.094uM    // 6b1c.pdf (C9Y) ligand is 4b,Ki=0.090uM
5unp  2.92  2018  Kd=0.096nM    // 5unp.pdf (8FY) ligand is T-025
6fs1  1.60  2018  Kd=0.098uM    // 6fs0.pdf (E4Q) ligand is compound 4
5yj8  1.76  2018  Kd=0.104mM    // 5yj8.pdf (8W9) ligand is compound 1,Kd=0.104+/-0.002mM
6afl  1.60  2018  Kd=0.10uM     // 6af5.pdf (73H) [Covalent complex] ligand is 15,Kd=0.10+/-0.01uM(ITC),Kd=0.064+/-0.001uM(SPR)
6b1c  2.16  2018  Kd=0.111uM    // 6b1c.pdf (C9J) ligand is 4a,Ki=0.075uM
5ymx  1.35  2018  Kd=0.12uM     // 5ymx.pdf (GDP) Kd=0.12+/-0.03uM
6d5h  1.80  2018  Kd=0.12uM     // 6d55.pdf (FV7) ligand is compound 38; binding assay: FPA; Kd = 0.12+/-0.034uM
5ywx  1.74  2018  Kd=0.14nM     // 5ywx.pdf (93C) ligand is F092,Kd=0.14+/-0.010nM
6h7o  2.80  2018  Kd=0.14nM     // 6h7o.pdf (P32) [Incomplete ligand] [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is cyanopindolol
6d5e  1.75  2018  Kd=0.14uM     // 6d55.pdf (FVG) ligand is compound 47; binding assay: FPA; Kd = 0.14+/-0.009uM
6bgy  1.22  2018  Kd=0.15uM     // 6bgu.pdf (DLJ) [Different protein in assay] ligand is compound N46; Kd = 0.15+/-0.01 uM
6ajj  2.79  2018  Kd=0.16uM     // 6ajf.pdf (J9E) microscale thermophoresis assay, Kd(ICA38)=0.16+/-0.02uM
6cve  2.20  2018  Kd=0.16uM     // 6cve.pdf (CTP) ligand is CTP; Kd = 0.16 +/- 0.01 uM
5vk0  1.80  2018  Kd=0.18nM     // 5vk0.pdf (12-mer) PMI(8,12)-a, Kd(SPR)=0.18+/-0.19nM
6bgv  1.59  2018  Kd=0.18uM     // 6bgu.pdf (DQG) [Different protein in assay] ligand is compound N40; Kd = 0.18+/-0.02 uM
6ghh  1.90  2018  Kd=0.193uM    // 6ge7.pdf (TDA) ligand is C13, Kd = 0.193 +/- 0.031 uM
5ya5  1.89  2018  Kd=0.19uM     // 5ya5.pdf (6TD) ligand is HL-11
6fo5   .95  2018  Kd=0.19uM     // 6fnx.pdf (DZH) ligand is compound 17; Kd = 0.19 +/- 0.07 uM
6msy  2.00  2018  Kd=0.1uM      // 1zls.pdf (4-mer)
6mub  2.50  2018  Kd=0.1uM      // 1zls.pdf (5-mer)
6eq7  1.50  2018  Kd=0.1uM      // 6eq2.pdf (BS8) compound 11
6b1k  1.17  2018  Kd=0.213uM    // 6b1c.pdf (C9G) ligand is 3a,Ki=0.363uM
6bgw  1.64  2018  Kd=0.21uM     // 6bgu.pdf (DKS) [Different protein in assay] ligand is compound N41; Kd = 0.21+/-0.02 uM
6fa2  2.60  2018  Kd=0.220uM    // 5ocg.pdf (D2W) ligand is Abd-5
6bh0  1.99  2018  Kd=0.22uM     // 6bgu.pdf (DO1) [Different protein in assay] ligand is compound N51; Kd = 0.22+/-0.03 uM
6cqz  2.22  2018  Kd=0.23nM     // 6cqt.pdf (_VX) [Covalent complex] Ligand in binding assay is P(R/S) form
6cqt  2.27  2018  Kd=0.23nM     // 6cqt.pdf (_VX) [Covalent complex] Ligand in binding assay is P(S) form
6fsy  1.34  2018  Kd=0.247uM    // 6fsy.pdf (E5Q) Kd(ITC)=0.247+/-0.08uM
5y97  3.05  2018  Kd=0.25mM     // 5y97.pdf (LAT) ligand is lactose, ITC Kb = 4x1000 M-1
5z7j  1.98  2018  Kd=0.25uM     // 5z7j.pdf (36J) ligand is alpha-ZOL
6bh5  1.65  2018  Kd=0.25uM     // 6bgu.pdf (DNY) [Different protein in assay] ligand is compound N48; Kd = 0.25+/-0.02 uM
6d5g  1.92  2018  Kd=0.25uM     // 6d55.pdf (FVD) ligand is compound 43; binding assay: FPA; Kd = 0.25+/-0.057uM
6dq8  1.46  2018  Kd=0.26uM     // 6dq4.pdf (H6S) [Different ligand in assay: Ligand in binding assay is racemic, both R and S form can bind with protein] ligand is compound N49; Kd = 0.26+/-0.03 uM
6df1  2.30  2018  Kd=0.277uM    // 6dez.pdf (3-mer) Biolayer Interferometry assay, ligand is pY peptide
6bnt  3.20  2018  Kd=0.28uM     // 6bnt.pdf (15-mer) AP2M1: YMPMpS
6gfs  2.00  2018  Kd=0.291uM    // 6ge7.pdf (F15) ligand is C15, Kd = 0.291 +/- 0.117 uM
6f5u  2.07  2018  Kd=0.29mM     // 6f5u.pdf (CQN) [Nonstandard assay: pH = 5.2] ligand is bepridil ; Kd=0.29 +/- 0.06 mM
6ajh  2.82  2018  Kd=0.29uM     // 6ajf.pdf (9ZF) microscale thermophoresis assay, Kd(AU1235)=0.29+/-0.04uM
6nao  3.23  2018  Kd=0.2uM      // 5v8h.pdf (8ZP) ligand is compound PF-06928215
5xhz  1.32  2018  Kd=0.32uM     // 5xhz.pdf (11-mer) ligand is ARAP1; Kd=0.32 +/- 0.03 uM
5yyf  1.90  2018  Kd=0.33uM     // 5yyf.pdf (7-mer) ligand is XL-07i
6epy  2.04  2018  Kd=0.347uM    // 6epy.pdf (RAF) Kd = 0.347+/-0.42uM
5w4e  2.18  2018  Kd=0.349uM    // 5w4e.pdf (16-mer) [Incomplete ligand] Kd(FP)=0.349+/-0.036uM
5v37  1.42  2018  Kd=0.34nM     // 5v37.pdf (8WD) kon=6.1E+5, koff=2.1E-4
5y21  1.77  2018  Kd=0.34uM     // 5xvw.pdf (14-mer) Kd=0.34+/-0.08uM
5uc4  2.05  2018  Kd=0.35uM     // 5uc4.pdf (83S) Kd = 0.35 +/- 0.13 uM. ligand is compound 4
6f7t  2.60  2018  Kd=0.36nM     // 6f7t.pdf (12-mer) Kd = 0.36 +/- 0.04 nM
6ar2  1.55  2018  Kd=0.393uM    // 6ar2.pdf (10-mer) [Incomplete ligand] [Nonstandard assay: Temp 20 C] ligand is pT378-MST
5zia  2.60  2018  Kd=0.3uM      // 5zia.pdf (9-mer) ligand is V1088-7
6fbv  3.50  2018  Kd=0.3uM      // 6fbv.pdf (FI8) ligand is Lpm
6gf9  2.10  2018  Kd=0.411uM    // 6ge7.pdf (X90) ligand is C17, Kd = 0.411 +/- 0.129 uM
6bgz  1.69  2018  Kd=0.41uM     // 6bgu.pdf (DNV) [Different protein in assay] ligand is compound N47; Kd = 0.41+/-0.03 uM
5xjm  3.20  2018  Kd=0.43nM     // 5xjm.pdf (8-mer) [Nonstandard assay: with Fab4A03] ligand is s-AngII, Kd=0.43+/-0.06nM
5y53  1.60  2018  Kd=0.43uM     // 5xvw.pdf (18-mer) Kd=0.43+/-0.06uM
6ghp  1.95  2018  Kd=0.44nM     // 6ghp.pdf (EZ5) ligand is compound 3a
5ucj  1.69  2018  Kd=0.44uM     // 5uc4.pdf (KU3) Kd = 0.44 +/- 0.56 uM. ligand is compound 6b
5xo7  1.88  2018  Kd=0.44uM     // 5xo7.pdf (36J) ligand is alpha-ZOL
6cvf  2.30  2018  Kd=0.45uM     // 6cvf.pdf (CDP) Kd = 0.45+/-0.05uM; ligand is cytidine diphosphate
6d5j  1.75  2018  Kd=0.46uM     // 6d55.pdf (FV4) ligand is compound 29; binding assay: FPA; Kd = 0.46+/-0.078uM
6bgx  1.88  2018  Kd=0.47uM     // 6bgu.pdf (DKV) [Different protein in assay] ligand is compound N42; Kd = 0.47+/-0.05 uM
6bny  3.34  2018  Kd=0.4uM      // 5w5v.pdf (E0M) IC50 = 0.4 +/- 0.05uM. ligand is compound 9
6coj  1.40  2018  Kd=0.4uM      // 6coj.pdf (F8G) [Different protein in assay: Protein in binding assay is E105AA] ligand is COCHEA-CoA; Kd = 0.4+/-0.2 uM
6gvz  1.54  2018  Kd=0.4uM      // 6gvz.pdf (CHO) ligand is GCDCA
5yf1  2.40  2018  Kd=0.52mM     // 5yf0.pdf (8V0) ligand is carnosine,the binding assay is tested in the present of SFG.
6afj  1.48  2018  Kd=0.52uM     // 6af5.pdf (73G) [Covalent complex] ligand is 13,Kd=0.52+/-0.02uM(ITC)
6bgu  1.68  2018  Kd=0.53uM     // 6bgu.pdf (DKP) ligand is compound N9; Kd = 0.53+/-0.06 uM
6e8m  1.61  2018  Kd=0.53uM     // 6e8i.pdf (13-mer) ligand is peptide DnaJ-A1-pTyr381; fluorescence polarization assay, Kd = 0.53+/-0.08uM
5oxl  2.66  2018  Kd=0.56mM     // 5oxk.pdf (2-mer) Kd = 0.56 + 0.08 mM, ligand is Ala-Leu
6czi  2.30  2018  Kd=0.56uM     // 6czh.pdf (38E) ligand is compound DFHBI; Kd = 0.56+/-0.07uM
6er3  1.37  2018  Kd=0.57mM     // 6er3.pdf (2-mer) [Incomplete ligand] ligand is compound 3'SL; ligand in the crystal is Sia-Gal; Kd=0.57+/-0.05mM
6drx  3.10  2018  Kd=0.58nM     // 6drx.pdf (H8G) Ligand is compound LSD
6ce2  2.15  2018  Kd=0.5uM      // 6ce2.pdf (SVR) ligand is suramin; Kd = 0.5+/-0.2uM( ratio of MjTX-I/suramin = 1:1)
5vyy  1.79  2018  Kd=0.62uM     // 5vyy.pdf (9QY) Kd = 0.62 +/- 0.13 uM. ligand is compound 1
5ygf  1.70  2018  Kd=0.62uM     // 5ygd.pdf (9-mer) [Nonstandard assay: Tem 20,PH=8.0] ligand is Piwi-unme,Kd=0.62+/-0.07uM
6mwe  2.05  2018  Kd=0.63nM     // 6mwe.pdf (919) ligand is rebastinib; IC50 = 0.63 +/- 0.08 nM
6afi  1.65  2018  Kd=0.63uM     // 6af5.pdf (73D) [Covalent complex] ligand is 11,Kd=0.63+/-0.02uM(ITC),Kd=0.48+/-0.08uM(SPR)
6f6i  2.40  2018  Kd=0.65mM     // 6f5u.pdf (8PR) [Nonstandard assay: pH = 5.2] ligand is paroxetine; Kd = 0.65 +/- 0.07mM
6c91  2.90  2018  Kd=0.65uM     // 5vyy.pdf (EQD) Kd = 0.65+/- 0.02 uM. ligand is compound 3
6cv8   NMR  2018  Kd=0.68mM     // 6cus.pdf (I3P) ligand is compound I(1,4,5)P3; Kd = 0.68+/-0.06 mM
6gjn  1.70  2018  Kd=0.6uM      // 6gjn.pdf (F0Q) ligand is compound 15; Kd = 0.6 +/- 0.4 uM
6afh  1.65  2018  Kd=0.75uM     // 6af5.pdf (73F) [Covalent complex] ligand is 10,Kd=0.75+/-0.02uM(ITC),Kd=0.46+/-0.10uM(SPR)
6e5x  1.50  2018  Kd=0.75uM     // 6e5x.pdf (15-mer) [Different protein in assay: peptide used for bioassay is 549-571.] Kd(ITC)=0.75+/-0.095uM, peptide used for crystallization is 556-568
6fmj  2.45  2018  Kd=0.76uM     // 6fmi.pdf (DV5) ligand is compound 3; Kd = 0.76 +/- 0.02 uM (ITC)
6dkb  2.68  2018  Kd=0.7nM      // 6dkb.pdf (FKY) ligand is compound 10b
6mu3  2.33  2018  Kd=0.7uM      // 1zls.pdf (4-mer) ligand is synthetic oligomannoses 7
6eq3  1.80  2018  Kd=0.7uM      // 6eq2.pdf (BU5) compound 9
6cdm  2.41  2018  Kd=0.805nM    // 5tkj.pdf (8-mer) protein is vFP7.04, ligand is Fusion peptide
6ckw  2.06  2018  Kd=0.83nM     // 6chl.pdf (F6D) ligand is compound 51
6ge7  2.30  2018  Kd=0.867uM    // 6ge7.pdf (EW8) ligand is C19, Kd = 0.867 +/- 0.184 uM
5y6k  2.86  2018  Kd=0.86uM     // 5y6k.pdf (8R6) [Uncommon element] ligand is Fe-tracer,Kd=0.68 +/- 0.11 uM
5nwz  2.37  2018  Kd=0.8nM      // 5nud.pdf (9CT) [Covalent complex] Kd = 0.8 +/- 0.2 nM. ligand is compound 8
5w5v  3.65  2018  Kd=0.8uM      // 5w5v.pdf (ANW) IC50 = 0.8 +/- 0.1 uM. ligand is Amlexanox (1)
5muc  2.60  2018  Kd=0.913uM    // 5muc.pdf (AH2) ligand is compound 4
6e8k  1.71  2018  Kd=0.91uM     // 6e8i.pdf (13-mer) ligand is peptide IL2Rbeta-pTyr387; fluorescence polarization assay, Kd = 0.91+/-0.06uM
6afc  1.45  2018  Kd=0.93uM     // 6af5.pdf (72R) [Covalent complex] ligand is 4,Kd=0.93+/-0.05uM(ITC),Kd=0.46+/-0.14uM(SPR)
6f6n  2.15  2018  Kd=0.95mM     // 6f5u.pdf (SRE) [Nonstandard assay: pH = 5.2] ligand is sertraline; Kd = 0.95 +/- 0.25 mM
5oht  1.87  2018  Kd=0.96uM     // 5ohs.pdf (9VH) Kd=0.96+/-0.12uM
5uch  2.65  2018  Kd=0.97uM     // 5uc4.pdf (871) Kd = 0.97 +/- 0.03 uM. ligand is compound 2
5xwr  2.69  2018  Kd=1.04uM     // 5xwr.pdf (12-mer) ligand is SALL4,Kd=1.04+/-0.06uM
6cdo  2.10  2018  Kd=1.06nM     // 5tkj.pdf (8-mer) protein is vFP16.02, ligand is Fusion peptide
6f09  1.59  2018  Kd=1.07uM     // 6f09.pdf (13-mer) Kd = 1.07 +/- 0.03 uM
6epa  1.82  2018  Kd=1.13uM     // 6epa.pdf (BNQ) ligand is compound IGS-1.76; Kd = 1.13 +/- 0.35uM
5ovc  1.55  2018  Kd=1.1uM      // 5ovc.pdf (7-mer) Kd = 1.1 +/- 0.05 uM, ligand is CKAP
5umx  1.59  2018  Kd=1.1uM      // 5umw.pdf (RBF) Kd = 59.5 +/- 8.6 uM, ligand is riboflavin, protein is TnmS3
6b5i  2.60  2018  Kd=1.1uM      // 6b5i.pdf (CU4) [Nonstandard assay: Tem 30 C] ligand is CM121,Kd=1.1+/-0.28uM,IC50=0.54+/-0.15uM
6bu0  2.43  2018  Kd=1.1uM      // 6bty.pdf (IHP) ligand is compound InsP6; Kd = 1.1+/-0.2uM
6ey9  2.00  2018  Kd=1.24uM     // 6ei5.pdf (C4N) ligand is compound 40; Kd = 1.24+/-0.14uM
5ugm  2.10  2018  Kd=1.26uM     // 5ugm.pdf (8A7) Kd(Edaglitazone)=1.26uM, Kd(Edaglitazone+C9)=0.63uM
6f7c  2.00  2018  Kd=1.26uM     // 6f7c.pdf (CVT) compound 12
5yvx  1.59  2018  Kd=1.29uM     // 5yvx.pdf (9-mer) [Nonstandard assay: Temp 20, PH=8] ligand is H3K4me1,Kd=1.29+/-0.15uM
6fv4  1.97  2018  Kd=1.2mM      // 6fv4.pdf (16G) ligand is GlcNAc6P; Kd = 1.2 +/- 0.05 mM
6gw4  2.30  2018  Kd=1.2uM      // 6gvz.pdf (CHO) ligand is GCDCA
6f6s  2.29  2018  Kd=1.30mM     // 6f5u.pdf (CXQ) [Nonstandard assay: pH = 5.2] ligand is benztropine; Kd= 1.30 +/- 0.43 mM
6fmc   .90  2018  Kd=1.32uM     // 6fmc.pdf (DUE) ligand is compound 1; Kd = 1.32 +/- 0.08 uM
6fmf  2.81  2018  Kd=1.32uM     // 6fmc.pdf (DUE) ligand is compound 1; Kd = 1.32 +/- 0.08 uM
5wmt  2.75  2018  Kd=1.38uM     // 5vyy.pdf (9QY) Kd = 1.38 +/- 0.11 uM. ligand is compound 1
5zk8  3.00  2018  Kd=1.3nM      // 5yc8.pdf (3C0) ligand is NMS; Kd=1.3+/-0.9nM
6f7b  2.00  2018  Kd=1.3nM      // 6f7b.pdf (CVQ) Kd(kPCA)=1.3+/-0.94nM, kon=4.1E+5, koff=2.2E-4
6mnf  2.76  2018  Kd=1.3uM      // 1zls.pdf (7-mer)
5vb9  1.70  2018  Kd=1.3uM      // 5vb9.pdf (15-mer) [Nonstandard assay: Temp = 8] ligand is 18-902
5z68  3.00  2018  Kd=1.3uM      // 5z68.pdf (ATP) ligand is ATP,Kd=1.3+/-0.2uM
6eq2  1.80  2018  Kd=1.3uM      // 6eq2.pdf (BU8) compound 6
6bm5  1.50  2018  Kd=1.43uM     // 6bdy.pdf (SAM) ligand is compound AdoMet; Kd = 1.43+/-0.05uM
6cw4   NMR  2018  Kd=1.50mM     // 6cus.pdf (FGV) ligand is compound IP6; Kd = 1.50+/-0.35 mM
6ey8  2.16  2018  Kd=1.55uM     // 6ei5.pdf (C4T) ligand is compound 38; Kd = 1.55+/-0.052uM
5owf  1.91  2018  Kd=1.59uM     // 5owf.pdf (GLN) [Nonstandard assay: Temp 20, pH=8.0] Kd = 1.59 +/- 0.23 uM. Protein is L117K mutant
6mj7  1.41  2018  Kd=1.5mM      // 6mj7.pdf (ARG)
6ftp  1.80  2018  Kd=1.5uM      // 5om2.pdf (DM2) ligand is doxorubicin, Kd for S-conformation
6ced  1.70  2018  Kd=1.5uM      // 6ce6.pdf (EYA) ligand is compound 31
6cms  2.68  2018  Kd=1.5uM      // 6cmr.pdf (5OD) ligand is compound SHP099; Kd = 1.5+/-0.23 uM
5vm0  1.79  2018  Kd=1.60nM     // 5vl2.pdf (9EG) [Multiple sites: site 1: Kd = 1.60 nM, site 2: Kd = 1.10 nM.] ligand is TCC
6eog  1.20  2018  Kd=1.60uM     // 6eog.pdf (BKK) ligand is compound 1c; Kd=1.60+/-0.078 uM
5y80  2.50  2018  Kd=1.62nM     // 5y7z.pdf (IRE) [Multiple sites: two ligands in two binding sites respectively in the PDB structure] ligand is gefitinib,Kd=1.62nM(site1),Kd=285nM(site2)
6cdp  2.46  2018  Kd=1.64nM     // 5tkj.pdf (8-mer) protein is vFP20.01, ligand is Fusion peptide
6ajg  2.60  2018  Kd=1.65uM     // 6ajf.pdf (3RX) microscale thermophoresis assay, Kd(SQ109)=1.65+/-0.20uM
6b5r  1.78  2018  Kd=1.69nM     // 6b5l.pdf (15-mer) ligand is petide 21
5un1  3.60  2018  Kd=1.6uM      // 5un1.pdf (BMK) Kd = 1.6 +/- 0.3 uM. ligand is MK-801
6czf  1.95  2018  Kd=1.6uM      // 6czf.pdf (G4P) [Nonstandard assay: Mg2+]
6dxl  2.45  2018  Kd=1.6uM      // 6dxg.pdf (HG4) ligand is compound 2; Kd is apparent dissociation constant
6er4  1.30  2018  Kd=1.70mM     // 6er3.pdf (3-mer) [Incomplete ligand] ligand is compound 6'SL; ligand in the crystal is SIA-GAL-BGC; Kd = 1.70+/-0.14mM
5oyd  2.10  2018  Kd=1.78mM     // 5oyd.pdf (7-mer) [Covalent complex] Ki = 1.78 +/- 0.17 mM
5za2  1.50  2018  Kd=1.7uM      // 5za2.pdf (NXL) [Covalent complex] ligand is avibactam,ki(app)=3.4+/-0.2uM
5zk3  2.60  2018  Kd=1.8nM      // 5yc8.pdf (QNB) ligand is QNB,Kd=1.8+/-0.6nM
5mwh  1.65  2018  Kd=1.8uM      // 5mwg.pdf (UWX) ligand is compound 21
5om7  1.73  2018  Kd=1.8uM      // 5om2.pdf (DM2) ligand is doxorubicin, Kd for S-conformation
6avi  2.29  2018  Kd=1.94uM     // 5ugm.pdf (KNA)
6b1h  1.80  2018  Kd=1.9nM      // 6b1f.pdf (C8Y) [Covalent complex] ligand is compound 3,Kd=1.9+/-0.2nM,KPC-2-cocrystallized 3
6b1f  1.44  2018  Kd=1.9nM      // 6b1f.pdf (C8Y) [Covalent complex] ligand is compound 3,Kd=1.9+/-0.2nM,KPC-2-soaked 3
5mtw  1.84  2018  Kd=1.9uM      // 5mtw.pdf (13-mer) Kd(ITC)=1.9+/-0.2uM
6cdg  1.60  2018  Kd=1.9uM      // 6cct.pdf (6-mer) ligand is peptide PGLWKS; Kd = 1.9+/-0.1uM
6eyt  2.21  2018  Kd=1.9uM      // 6eyt.pdf (UDP) [Uncommon element] Kd = 1.9 +/- 0.5 uM; the ligand contains a Mn atom
5o3r  1.90  2018  Kd=10.1uM     // 5o3q.pdf (AMP) [Multiple sites: site 1: Kd = 10.1 +/- 1.1 uM; site 2: Kd = 7.4 +/- 0.3 uM; site 3: Kd = 244.9 +/- 9.8 uM.] Kd = 10.1 +/- 1.1 uM. ligand is AMP
6gnw  1.75  2018  Kd=10.20uM    // 6gnm.pdf (F52) ligand is compound 2,4,5-T
6aoy  1.80  2018  Kd=10.6uM     // 6aox.pdf (145) bio-layer interferometry experiment, Kd=10.6+/-4.6uM
6arm  1.50  2018  Kd=10.6uM     // 6aox.pdf (145) bio-layer interferometry experiment, Kd=10.6+/-4.6uM
6drt  2.12  2018  Kd=10.7uM     // 6drt.pdf (13-mer) Ligand is peptide KKEPEGLDFLFDA, Kd = 10.7+/-3.2uM
6f4x  1.69  2018  Kd=10.7uM     // 6f4w.pdf (FMC) [Incomplete ligand] [Multiple sites: site 1: Kd=10.7 +/-7.9 uM; site 2: Kd= 95.2 +/- 60.4 uM; site 3: Kd=3.10 +/- 6.22 mM] ligand is FA covalent with Pi
5oxn  2.20  2018  Kd=10.95mM    // 5oxk.pdf (2-mer) Kd = 10.95 + 2.22 mM, ligand is Phe-Ala
6ftz  1.67  2018  Kd=1000uM     // 6fty.pdf (E7E) ligand is compound 6
6ct7  1.90  2018  Kd=100nM      // 6ct7.pdf (11-mer) ligand is peptide N-terminal acetylated alpha-syn
5qap  1.79  2018  Kd=100uM      // 5qa4.pdf (AV7) ligand is compound 21a
5qam  1.87  2018  Kd=100uM      // 5qa4.pdf (GA6) ligand is compound 17
6bnk  3.20  2018  Kd=102nM      // 6bnk.pdf (AGH) ligand is compound KRN7000; Kd=102+/-16nM
6bef  3.21  2018  Kd=104uM      // 6beb.pdf (3YI) ligand is compound 3-formyl rifamycin
5os8  1.55  2018  Kd=105uM      // 5oqu.pdf (J27) ligand is compound 11
6fx1  2.10  2018  Kd=105uM      // 6fx1.pdf (8-mer) ligand is N-glycan 1
5umy  1.78  2018  Kd=108nM      // 5umw.pdf (TNN) Kd = 108 +/- 13 nM, ligand is TNM A, protein is TnmS3
5yvt  2.40  2018  Kd=109uM      // 5yvt.pdf (NAI) IDH3 in complex with Mg(2+) and NADH
6evq   NMR  2018  Kd=10mM       // 6evq.pdf (C05) Kd=10+/-3mM
5o22  2.10  2018  Kd=10nM       // 5o22.pdf (C3R)
6fkq  3.07  2018  Kd=10nM       // 5z5k.pdf (19-mer) [Different ligand in assay: Ligand in binding assay is hDraxin-22. 22-aa] ligand is hDraxin-22 peptide
5zw6  2.05  2018  Kd=10nM       // 5zw6.pdf (6-mer) Kd=10+/-2.2nM
5yft  2.21  2018  Kd=10uM       // 5yfj.pdf (RI2) [Nonstandard assay: PH=8] ligand is R15P,protein is D204N mutant
5xiw  2.90  2018  Kd=11.03uM    // 5xiw.pdf (LOC) ligand is colchicine; Kd=11.03+/-2.57uM
5nap  2.17  2018  Kd=11.12nM    // 5nap.pdf (DZ7) Kd = 11.12 +/- 2.88 nM. Ki = dissociation constant in lecture
5yz2  1.75  2018  Kd=11.3uM     // 5yz2.pdf (AMP) [Nonstandard assay: pH 8.0] ligand is AMP,Kd=13.2uM in SPR
6b5a  1.62  2018  Kd=11.4nM     // 6b59.pdf (CQS) [Different protein in assay: Protein in binding assay is CA IX] ligand is compound 29
5yc2  2.70  2018  Kd=11.4uM     // 5yc2.pdf (18-mer) [Different ligand in assay: Ligand in binding assay is Rap1 479-527] ligand is Rap1,Kd=11.4+/-1.2uM,IC50=50.9uM (Rap1 479-527)
6hmg  1.27  2018  Kd=11.5uM     // 6hmg.pdf (2-mer) ligand is compound 4; Kd = 11.5 +/- 0.9 uM
6hai  2.20  2018  Kd=11.6nM     // 6h96.pdf (FWW) ligand is compound 3
5yqx  1.82  2018  Kd=110nM      // 5yqx.pdf (E0K)
6bnl  2.60  2018  Kd=110nM      // 6bnk.pdf (QWV) ligand is compound AH10-7; Kd=110+/-13nM
5qa7  1.82  2018  Kd=110uM      // 5qa4.pdf (IQQ) ligand is compound 4b
5qan  2.30  2018  Kd=110uM      // 5qa4.pdf (M8Q) ligand is compound 19a
6fgf  2.80  2018  Kd=110uM      // 6fg6.pdf (EN2) ligand is compound 2
5o1c  1.32  2018  Kd=113uM      // 5o1a.pdf (9GZ) ligand is compound 34
5o1g  1.35  2018  Kd=116uM      // 5o1a.pdf (9GK) ligand is compound 55
6g9i  2.19  2018  Kd=118uM      // 6g95.pdf (CXX) ligand is clomipramine; Kd = 118 +/- 40 uM
6chn  2.03  2018  Kd=11nM       // 6chl.pdf (F1D) ligand is compound 9
5nn0  2.10  2018  Kd=11pM       // 5nn0.pdf (92H) [Nonstandard assay: pH = 8] Ki = 11.1 +/- 0.46 pM. ligand is (+)-3
5yc4  2.70  2018  Kd=12.1uM     // 5yc4.pdf (9-mer) ligand is H3K4me3
5nkn  2.20  2018  Kd=120pM      // 5nkn.pdf (LOC) [Different protein in assay: Protein in binding assay is D6.2] Kd = 120 +/- 20 pM, ligand is colchicine
5qaa  1.95  2018  Kd=123uM      // 5qa4.pdf (EAJ) ligand is compound 6a
6min  1.90  2018  Kd=124uM      // 6mil.pdf (8-mer) Kd = 124 +/- 41 uM
6glb  2.00  2018  Kd=129nM      // 6gl9.pdf (F48) ligand is compound 20; IC50 = 129 +/- 13 nM
6gfx  1.83  2018  Kd=12nM       // 6gfx.pdf (19-mer) ligand is compound 13a; Kd = 12 +/- 2 nM
5otr  1.52  2018  Kd=12uM       // 5oqu.pdf (AU8) ligand is compound 14
5ytu  1.90  2018  Kd=12uM       // 5yto.pdf (5FW) [Incomplete ligand] ligand is isoproterenol
6dq4  1.39  2018  Kd=12uM       // 6dq4.pdf (K0I) ligand is compound GSK-J1; Kd = 12+/-2 uM
5o9o  1.90  2018  Kd=13.00uM    // 5o9o.pdf (9PB) Kd = 13.00 +/- 0.01 uM. ligand is compound 7
6clv  2.30  2018  Kd=13.3uM     // 6clv.pdf (6MB) [Incomplete ligand] [Different protein in assay: Protein in binding assay is wild type] ligand is compound SMX + pterin; Kd = 13.3 +/-3.5uM
6e4u  3.27  2018  Kd=13.6nM     // 6e4t.pdf (HU7) ligand is compound M2; Kd = 13.6+/-0.4nM
6afg  1.50  2018  Kd=13.7uM     // 6af5.pdf (72V) [Covalent complex] ligand is 9,Kd=13.7+/-0.7uM(ITC)
6gy5  1.09  2018  Kd=13.7uM     // 6gy5.pdf (11-mer) [Incomplete ligand] ligand is DAPK1 peptide
5yfs  2.30  2018  Kd=13.8uM     // 5yfj.pdf (RI2) [Nonstandard assay: PH=8] ligand is R15P, protein is C135S mutant
6cfd  2.57  2018  Kd=13.9nM     // 6cfd.pdf (EZA) ligand is compound ADEP4
5xgl  3.44  2018  Kd=131.6nM    // 5xgl.pdf (17-mer) [Incomplete ligand] [Nonstandard assay: PH=5.0] ligand is alpha-conotoxin LvIA
5nwe  2.00  2018  Kd=13200nM    // 5nwe.pdf (G39) Kd = 13200 +/- 600 nM, ligand is oseltamivir carboxylate
5z99  1.49  2018  Kd=133nM      // 5yyb.pdf (SLB) [Nonstandard assay: pH 8.0] ligand is Neu5Ac,Kd=133+/-22nM
6el5  1.67  2018  Kd=133nM      // 6ei5.pdf (PU1) ligand is compound 68; Kd = 133+/-4.1nM
6gl9  1.70  2018  Kd=135nM      // 6gl9.pdf (F3W) ligand is compound 10; IC50 = 135 +/- 3 nM
6gji  1.60  2018  Kd=135uM      // 6gji.pdf (F1E) ligand is compound 8; Kd = 135 +/ -6 uM
5ylj  2.70  2018  Kd=139.3uM    // 5xiw.pdf (8X0) ligand is MIL, Kd=139.3+/-34.76uM
6gjl  1.16  2018  Kd=139uM      // 6gjl.pdf (F1Q) ligand is compound 10; Kd = 139 +/- 4 uM
6fnf  1.56  2018  Kd=13nM       // 6fnf.pdf (DXH) ligand is NVP
5oha  1.55  2018  Kd=13uM       // 5oha.pdf (9UW) Ki = 13 +/- 1.3 uM, ligand is 2-Thiohydantoin
6am8  1.83  2018  Kd=13uM       // 5vm5.pdf (TRP) Kd = 13 +/- 1 uM. ligand is L-Trp
5z7b  2.10  2018  Kd=13uM       // 5z7b.pdf (VNL) [Nonstandard assay: pH 8.0 ] ligand is vanillate,Kd=13+/-1uM
5yc3  2.60  2018  Kd=14.2uM     // 5yc3.pdf (9-mer) ligand is H3K4me2
6eqa  3.16  2018  Kd=14.2uM     // 6eqa.pdf (9-mer) A2-AAG
5qat  1.90  2018  Kd=140uM      // 5qa4.pdf (T7O) ligand is compound 24
5y6f  2.30  2018  Kd=141nM      // 5y6f.pdf (C2E) c-di-GMP, Kd=141+/-24nM
6fnj  1.24  2018  Kd=142nM      // 6fnf.pdf (DWT) ligand is NVPiso
5mo2  1.50  2018  Kd=143uM      // 5mng.pdf (D86) Kd = 143 +/- 11 uM. ligand is N-amidinopiperidine, direct ITC, Neutron diffraction (295K)
5mnn   .86  2018  Kd=143uM      // 5mng.pdf (MRZ) Kd = 143 +/- 11 uM. ligand is N-amidinopiperidine, direct ITC, X-ray diffraction (100K)
5mno   .96  2018  Kd=143uM      // 5mng.pdf (MRZ) Kd = 143 +/- 11 uM. ligand is N-amidinopiperidine, direct ITC, X-ray diffraction (295K)
6csr  1.62  2018  Kd=144nM      // 6csp.pdf (BHO) ligand is compound 1
5qah  1.95  2018  Kd=144uM      // 5qa4.pdf (EFX) ligand is compound 9b
6f5w  1.91  2018  Kd=149uM      // 6f5w.pdf (KG1) ligand is compound 5; Kd = 149 +/- 16 uM
5o1h  1.32  2018  Kd=14uM       // 5o1a.pdf (9GN) ligand is compound 60
6h2t  1.67  2018  Kd=15.2uM     // 6h1u.pdf (GLU) ligand is GLU; Kd = 15.2 +/- 5.7 uM
5y7z  2.80  2018  Kd=15.4nM     // 5y7z.pdf (IRE) [Multiple sites: ] ligand is gefitinib, 1:1 binding model
6bcy  2.30  2018  Kd=15.5uM     // 6bcr.pdf (13-mer) Kd(site3, T360)=15.5+/-6.6uM
5qai  1.90  2018  Kd=150uM      // 5qa4.pdf (VM7) ligand is compound 12a
6gu7  2.75  2018  Kd=1560nM     // 6gu2.pdf (FB8) [Different protein in assay: protein in binding assay is CDK1-Cks2] Kd = 1560 +/- 220 nM; ligand is compound AZD5438
5qb0  1.95  2018  Kd=159uM      // 5qa4.pdf (AVA) ligand is compound 35
6aox  2.10  2018  Kd=15uM       // 6aox.pdf (TF0) bio-layer interferometry experiment, Kd=15+/-0.8uM
6eq6  2.00  2018  Kd=15uM       // 6eq2.pdf (EV2) compound 1
6g36  1.46  2018  Kd=16.3nM     // 6g33.pdf (EKH) ligand is 5-chlorotubercidin; Kd = 16.3 +/ - 0.9 nM
5zuj  2.60  2018  Kd=16.5uM     // 5zuj.pdf (15-mer) [Different ligand in assay: ligand in binding assay is TIFA protein] ligand is TIFA mutant,Kd=16.5+/-0.7uM
6bd1  2.35  2018  Kd=16.5uM     // 6bcr.pdf (14-mer) Kd(site4, S366)=16.5+/-8.1uM
6czc  2.30  2018  Kd=16.5uM     // 6czc.pdf (TTP) ligand is TTP; Kd = 16.5+/-0.7uM
6fbw  1.45  2018  Kd=16.5uM     // 6fau.pdf (8-mer) [Covalent complex] ligand is 4.2f-2; Kd = 16.5 +/- 2 uM
5yba  2.06  2018  Kd=16.81uM    // 5yba.pdf (8-mer) [Nonstandard assay: NaCl=50mM ] ligand is Myb1,Kd=16.81+/-0.58uM
5o0j  1.81  2018  Kd=16.85uM    // 5o0j.pdf (8BR) [Nonstandard assay: Temp 37] Kd = 16.85 +/- 4.12 uM. ligand is 8-Br-AMP
6gu2  2.00  2018  Kd=1600nM     // 6gu2.pdf (F9Z) [Different protein in assay: protein in binding assay is CDK1-CyclinB] Kd=1600+/-300 nM; ligand is compound Alvocidib
5qax  2.31  2018  Kd=160uM      // 5qa4.pdf (Q92) ligand is compound 28
5mos  0.96  2018  Kd=163uM      // 5mng.pdf (D86) Kd = 143 +/- 11 uM. ligand is N-amidinopiperidine, direct ITC, Joint X-ray/neutron diffraction (295K)
5y94  2.00  2018  Kd=164nM      // 5y8c.pdf (8QC) ligand is 6j
6g0v  1.09  2018  Kd=166uM      // 6g0v.pdf (EGZ) ligand is TF mimetic 2
5yh8  2.12  2018  Kd=167.8nM    // 5yh8.pdf (8UX) [Uncommon element] ligand is Staphylopine.containing Ni2+
5n7b  1.70  2018  Kd=168uM      // 5n7b.pdf (6-mer) [Nonstandard assay: Kd = 133 (temp=15C)] glycopeptide 2* (temp=25C)
6cnk  3.70  2018  Kd=17.0nM     // 6cnj.pdf (NCT) Kd = 10.2-26.6nM; Receptor plus Fab
6g35  1.55  2018  Kd=17.5nM     // 6g33.pdf (EKK) ligand is 5-bromotubercidin; Kd = 17.5 +/- 1.3 nM
5qa8  2.50  2018  Kd=170uM      // 5qa4.pdf (JSX) ligand is compound 4c
5qar  2.10  2018  Kd=170uM      // 5qa4.pdf (QIU) ligand is compound 23a
5qa4  1.95  2018  Kd=170uM      // 5qa4.pdf (TI7) ligand is compound 3a
5qad  1.75  2018  Kd=170uM      // 5qa4.pdf (WVV) ligand is compound 8a
6fuh  1.37  2018  Kd=170uM      // 6fty.pdf (E88) ligand is compound 8
5qa6  1.95  2018  Kd=175uM      // 5qa4.pdf (AUV) ligand is compound 4a
6faa  1.97  2018  Kd=179nM      // 6fa5.pdf (ADP) ligand is ADP
6fa5  2.30  2018  Kd=179nM      // 6fa5.pdf (ADP) ligand is ADP; same as 6faa
6fac  2.05  2018  Kd=179nM      // 6fa5.pdf (ADP) ligand is ADP; same as 6faa
5o5a  1.60  2018  Kd=17uM       // 5mwg.pdf (9LN) ligand is compound 2
5orj  1.99  2018  Kd=17uM       // 5oqu.pdf (A4Q) ligand is compound 3
5vkf  2.75  2018  Kd=17uM       // 5vh0.pdf (NPY) Kd(Naphthalene)=17+/-1.4uM
6bj3  1.90  2018  Kd=17uM       // 6bj2.pdf (9-mer) ligand is peptide IPLTEEAEL(B35-HIV)
6fgg  1.10  2018  Kd=17uM       // 6fg6.pdf (D9B) ligand is compound 5
5od5  1.90  2018  Kd=18.3nM     // 5od5.pdf (95B) [Uncommon element] Kd = 18.3 +/- 4.9 nM, ligand is [FeIII(11)Cp*IrIII]
5nyh  1.65  2018  Kd=18.7nM     // 5lny.pdf (9EK) Kd = 18.7 +/- 0.5 nM. ligand is compound 2b
5zop  2.70  2018  Kd=18.8uM     // 5zop.pdf (12-mer)
5wew  3.18  2018  Kd=180nM      // 5wep.pdf (A81) Kd(FosA,KP)=180+/-30nM
5xsu  2.40  2018  Kd=180nM      // 5xsr.pdf (8E3) [Nonstandard assay: ] ligand is compound 31,Kd=180+/-44nM,IC50=244nM
6i8y  1.52  2018  Kd=180nM      // 6i8b.pdf (2OD) ligand is 35
6gu6  2.33  2018  Kd=1810nM     // 6gu2.pdf (1QK) [Different protein in assay: protein in binding assay is CDK1-Cks2] Kd = 1810 +/- 150 nM; ligand is compound Dinaciclib
6gjr  1.69  2018  Kd=184uM      // 6gjr.pdf (F0W) ligand is compound 9; Kd = 184 +/- 13 uM
5yhl  4.20  2018  Kd=18nM       // 5yhl.pdf (8VL) ligand is ONO-AE3-208-Br. Protein is EP4-i3d (A62L/G106R). Complex is EP4-Fab001-ligand
5ov8  1.80  2018  Kd=18uM       // 5mwg.pdf (AXN) ligand is compound 13
6dub  1.20  2018  Kd=18uM       // 5ubb.pdf (6-mer) ligand is peptide SPKRIA
6eq5  1.80  2018  Kd=18uM       // 6eq2.pdf (AX7) compound 4
6fse  2.70  2018  Kd=18uM       // 6fsd.pdf (E5K) [Different protein in assay: X-ray(Mus musculus); IC50(human)] ligand is compound 15
6cd8  1.60  2018  Kd=19.4uM     // 6cct.pdf (4-mer) ligand is peptide PSRV; Kd = 19.4+/-1.2uM
5nne  1.15  2018  Kd=19.5uM     // 5nnc.pdf (11-mer) [Different ligand in assay: Ligand in binding assasy is TOP2A] ligand is TOP2A
6evn  1.48  2018  Kd=19.7uM     // 6evm.pdf (9-mer) Ligand is peptide PPG-PAG-PPG; Kd = 19.7+/-0.7uM
6fba  2.00  2018  Kd=19.9uM     // 6fba.pdf (D48) ligand is 2,3-naphthalenediol; Kd = 19.9+/- 4.7 uM; Binding assay: Microscale Thermophoresis
5qas  1.90  2018  Kd=190uM      // 5qa4.pdf (CVF) ligand is compound 23b
5wa5  1.17  2018  Kd=192nM      // 5wa5.pdf (4K4) Kd(XMD11-50)=192+/-28nM
5odx  1.82  2018  Kd=195nM      // 5lny.pdf (9RZ) Kd = 195 +/- 78 nM. ligand is compound 3b
5z89  1.42  2018  Kd=195nM      // 5z89.pdf (EGC) [Incomplete ligand] [Nonstandard assay: incubation 2.5h] ligand is Triton,Kd=195+/-21nM, Protein is S95C
6bvb  2.00  2018  Kd=196nM      // 6bvb.pdf (19-mer) Ligand is peptide HIF-2alphaOH;Kd = 196+/-17nM
6e4w  3.35  2018  Kd=197.8nM    // 6e4t.pdf (HUG) ligand is compound M3; Kd =197.8+/-3.5nM
6e49  2.90  2018  Kd=19uM       // 6b8i.pdf (17-mer) PCNA-Pif1815 -831;+/- 0.5
6bed  2.75  2018  Kd=19uM       // 6beb.pdf (RFP) ligand is compound rifampicin; Kd = 19+/-5uM
5olk  2.45  2018  Kd=1uM        // 5olk.pdf (DTP) Kd = 1 +/- 0.2 uM. ligand is dATP. binding stoichiometry = 2
6bdy  1.51  2018  Kd=2.04uM     // 6bdy.pdf (SFG) ligand is compound sinefungin; Kd = 2.04+/-0.07uM
6mim  2.53  2018  Kd=2.0uM      // 6mil.pdf (10-mer) Kd = 2.0 +/- 0.3 uM; ligand is peptide H3K9cr
6hm4  1.77  2018  Kd=2.12uM     // 6hm4.pdf (15-mer) Kd = 2.12 + 0.64 uM
6aqf  2.51  2018  Kd=2.14nM     // 6aqf.pdf (ZMA) ligand is ZM241385,Kd=2.14+/-0.75nM
6e59  3.40  2018  Kd=2.15nM     // 6e59.pdf (L76) Ligand is compound L760735; Kd = 2.15+/-0.22nM
6gon  1.65  2018  Kd=2.16uM     // 6gnm.pdf (8PF) ligand is compound PFOA
6goo  1.80  2018  Kd=2.16uM     // 6gnm.pdf (8PF) ligand is compound PFOA; same as 6gon
6h96  1.55  2018  Kd=2.1nM      // 6h96.pdf (FWE) ligand is compound 1
5o3q  1.75  2018  Kd=2.1uM      // 5o3q.pdf (CMP) [Multiple sites: site 1: Kd = 2.1 +/- 0.6 uM; site 2: Kd = 12.6 +/- 2.5 uM; site 3: Kd = 76.2 +/- 11.9 uM.] Kd = 2.1 +/- 0.6 uM. ligand is CAMP
6b5t  2.22  2018  Kd=2.21nM     // 6b5l.pdf (15-mer) ligand is petide 29
5zoo  1.85  2018  Kd=2.23uM     // 5zoo.pdf (14-mer) ligand is SP1
6fi4  2.00  2018  Kd=2.2uM      // 6fau.pdf (8-mer) [Covalent complex] ligand is 3.2e(the Sequence Length of peptide in Literature is different from that in PDB ); Kd = 2.2 +/- 0.7uM
6fhu  2.00  2018  Kd=2.3mM      // 6fap.pdf (3-mer) ligand is compound H3 3-mer
6dki  2.11  2018  Kd=2.3nM      // 6dkb.pdf (GOD) ligand is compound 19
6gl8  1.40  2018  Kd=2.47nM     // 6gl8.pdf (F3Q) ligand is S55746
5zvw  2.29  2018  Kd=2.4nM      // 5zvw.pdf (6-mer) Kd=2.4+/-0.3nM
6bh2  1.45  2018  Kd=2.4uM      // 6bgu.pdf (90V) [Different protein in assay] ligand is compound N54; Kd = 2.4+/-0.4 uM
6c99  2.00  2018  Kd=2.4uM      // 6c97.pdf (EQY) [Different ligand in assay: ] ligand is compound UCB-303
6eq4  1.40  2018  Kd=2.4uM      // 6eq2.pdf (BSW) compound 8
6cdc  1.75  2018  Kd=2.5uM      // 6cct.pdf (4-mer) ligand is peptide PGLW; Kd = 2.5+/-0.1uM
5oua  1.67  2018  Kd=2.67uM     // 5oua.pdf (18-mer) Kd=2.67+/-0.35uM
6egw  1.74  2018  Kd=2.67uM     // 6egw.pdf (18-mer) Kd(18-mer)=2.67+/-0.35uM, microscale thermophoresis assay
6dkg  2.53  2018  Kd=2.6nM      // 6dkb.pdf (GO7) ligand is compound 13b
5vzu  2.70  2018  Kd=2.7uM      // 5vzt.pdf (17-mer) Kd = 2.7 +/- 0.4 uM, ligand is Cyclin D1
6chh  2.30  2018  Kd=2.7uM      // 6b1a.pdf (F0P) [Nonstandard assay: PH=8.0] [Different ligand in assay: ] ligand is compound 6,Kd = 2.7+/-0.2 uM,Entry 6CHH supersedes 6B1A
6faw  1.40  2018  Kd=2.7uM      // 6fau.pdf (8-mer) [Covalent complex] [Different ligand in assay: ] ligand is 4.2c-1
6f4w  2.29  2018  Kd=2.95uM     // 6f4w.pdf (FMC) [Multiple sites: site 1: Kd=2.95 +/- 0.98 uM; site 2: Kd=163.7 +/- 34.2 uM; site 3: Kd=5.23 +/- 1.22 mM] ligand is formycin A (FA)
6e2o  2.39  2018  Kd=2.9nM      // 6e2m.pdf (S0L) ligand is compound 3(GS-444217); Kd = 2.9+/-0.8nM
6boe  3.60  2018  Kd=2.9uM      // 5w5v.pdf (E0S) IC50 = 2.9 +/- 0.5 uM. ligand is compound 5a
5xsr  2.30  2018  Kd=20.3nM     // 5xsr.pdf (8EC) ligand is compound 13,Kd=20.3+/-3.0nM,IC50=17nM
5znp  2.80  2018  Kd=20.6uM     // 5znp.pdf (15-mer) ligand is H3K4me3
5moq   .93  2018  Kd=20.7uM     // 5mng.pdf (BAM) Kd = 20.7 +/- 2.8 uM. ligand is Benzamidine, direct ITC, Joint X-ray/neutron diffraction (295K)
5mng   .86  2018  Kd=20.7uM     // 5mng.pdf (BAM) Kd = 20.7 +/- 2.8 uM. ligand is Benzamidine, direct ITC, X-ray diffraction (100K)
5mnh   .93  2018  Kd=20.7uM     // 5mng.pdf (BAM) Kd = 20.7 +/- 2.8 uM. ligand is Benzamidine, direct ITC, X-ray diffraction (295K)
5mo0  1.50  2018  Kd=20.7uM     // 5mng.pdf (BAM) Kd = 20.7 +/- 2.8 uM. ligand is Benzamidine, direct ITC, same as 5MNG, Neutron diffraction
6bm6  1.50  2018  Kd=20.8uM     // 6bdy.pdf (SAH) ligand is compound AdoHcy; Kd = 20.8+/-0.2uM
6d28  1.75  2018  Kd=200nM      // 1qy5.pdf (NEC)
5qag  2.30  2018  Kd=200uM      // 5qa4.pdf (Q2R) ligand is compound 9a
6gjj  1.38  2018  Kd=200uM      // 6gjj.pdf (L36) ligand is compound 2; Kd = 200 +/- 5 uM
5yhe  2.47  2018  Kd=203.3nM    // 5yh8.pdf (8UX) ligand is Staphylopine,containing Co2+
6b3v  1.60  2018  Kd=203pM      // 6b3v.pdf (7DQ) [Nonstandard assay: ATP:Mg2+ = 1 mM] ligand is compound PZ-2891,Kd=203+/-0.05pM
5os7  1.66  2018  Kd=205uM      // 5oqu.pdf (A8Q) ligand is compound 4
5o55  1.45  2018  Kd=20uM       // 5mwg.pdf (9L5) ligand is compound 8
5o1b  1.43  2018  Kd=20uM       // 5o1a.pdf (9H2) ligand is compound 13
5qb1  1.80  2018  Kd=20uM       // 5qa4.pdf (F1C) ligand is compound 36
6fut  1.50  2018  Kd=20uM       // 6fty.pdf (E82) ligand is compound 13b
5zt1  3.11  2018  Kd=21.23uM    // 5zt1.pdf (AGS) [Nonstandard assay: PH=8.0] ligand is ATP gammaS,Kd=21.23+/-0.80uM
5znr  3.20  2018  Kd=21.3uM     // 5znp.pdf (17-mer) ligand is H3K27me3
6fmk  2.75  2018  Kd=21.6uM     // 6fmi.pdf (DV8) ligand is compound 4; Kd = 21.6 +/- 0.8 uM (ITC)
6cfc  2.04  2018  Kd=210uM      // 6cfc.pdf (BLG) Kd = 210 +/-28uM;ligand is Cj0843
6bbx  2.20  2018  Kd=215nM      // 5umw.pdf (D77) Kd = 215 +/- 27 nM, ligand is TNM C, protein is TnmS3
6hke  2.11  2018  Kd=21nM       // 6hke.pdf (MLT) ligand is D-malate; Kd = 21 +/- 2 nM
6dk1  3.12  2018  Kd=22.5nM     // 6djz.pdf (GM4) Ligand is compound (+)-pentazocine; Kd = 22.5+/-10.8nM
6g6y  1.80  2018  Kd=220nM      // 6g6y.pdf (EOK) [Different ligand in assay: ligand is a tautomer] ligand is K858-1, Kd = 220.0 +/- 4.21 nM
6g6z  2.80  2018  Kd=220nM      // 6g6y.pdf (EOK) [Different ligand in assay: ligand is a tautomer] ligand is K858-1, Kd = 220.0 +/- 4.21 nM
5qak  1.90  2018  Kd=220uM      // 5qa4.pdf (AV4) ligand is compound 14
6guf  2.65  2018  Kd=224nM      // 6gu2.pdf (23D) Kd = 224 +/- 14 nM; ligand is compound CGP74514A
6cwn  1.53  2018  Kd=226nM      // 6cwf.pdf (6LA) Ligand is compound 4,6-Pyr-beta-D-ManNAcOMe
5qab  2.15  2018  Kd=226uM      // 5qa4.pdf (XEV) ligand is compound 6b
5ndb  2.38  2018  Kd=22uM       // 5ndb.pdf (8TW) [Different protein in assay: Protein in binding assay is Y58C] Kd = 22 +/-7 uM
5o1d  1.36  2018  Kd=22uM       // 5o1a.pdf (9GW) ligand is compound 50
6bee  3.11  2018  Kd=22uM       // 6beb.pdf (RXM) ligand is compound rifaximin
5qa9  1.90  2018  Kd=230uM      // 5qa4.pdf (QKU) ligand is compound 5
5ork  2.14  2018  Kd=234uM      // 5oqu.pdf (A4T) ligand is compound 6
6elp  1.85  2018  Kd=236nM      // 6ei5.pdf (BA8) ligand is compound 14; Kd = 236+/-19nM
6g38  1.47  2018  Kd=239.2nM    // 6g33.pdf (TBN) ligand is tubercidin; kd is 239.2 +/- 10.0 nM
6gub  2.52  2018  Kd=23nM       // 6gu2.pdf (F9Z) Kd = 23 +/- 3 nM; ligand is compound Alvocidib
5uxn  2.20  2018  Kd=23uM       // 5uxm.pdf (TYR) Kd = 23 +/- 1 uM, ligand is Tyr
6g0q  1.40  2018  Kd=24.6uM     // 5nnc.pdf (11-mer) [Different ligand in assay: Ligand in binding assasy is GATA1] ligand is GATA1
6eq1  2.10  2018  Kd=24.6uM     // 6epy.pdf (STW) Kd = 24.6+/-2.4uM
5qae  2.10  2018  Kd=240uM      // 5qa4.pdf (Q4G) ligand is compound 8b
5qao  2.00  2018  Kd=240uM      // 5qa4.pdf (Z8R) ligand is compound 19b
6gfy  2.70  2018  Kd=244nM      // 6gfx.pdf (EXH) ligand is compound 14a; Kd = 244 +/- 6 nM
5oqu  2.32  2018  Kd=244uM      // 5oqu.pdf (A4B) ligand is compound 5
5o87  2.20  2018  Kd=245nM      // 5o87.pdf (NCT) Kd=245+/-20nM
6beb  2.55  2018  Kd=246uM      // 6beb.pdf (RFV) ligand is compound rifamycin SV
6f1j  1.25  2018  Kd=24uM       // 6f1j.pdf (EDG)  ligand is AraDNJ; Kd = 24+/-0.4 uM
5qac  2.00  2018  Kd=250uM      // 5qa4.pdf (U4J) ligand is compound 6c
6ahi  1.90  2018  Kd=252uM      // 6ahi.pdf (MET) Kd=252+/-55uM
6css  1.70  2018  Kd=25nM       // 6csp.pdf (FBJ) ligand is compound 4
6guc  2.00  2018  Kd=25nM       // 6gu2.pdf (SU9) Kd = 25 +/- 5 nM; ligand is compound SU9516
5n1p  1.45  2018  Kd=25uM       // 5n1p.pdf (8GK) [Different ligand in assay: ligand in binding assay is Zn-binding] ligand is comound 1
6egs  2.70  2018  Kd=260uM      // 6egs.pdf (UD2) ligand is compound UDP-GalNac;Kd = 260+/-50uM
6gjm  1.35  2018  Kd=266uM      // 6gjm.pdf (L36) ligand is compound 4; Kd = 266 +/- 3 uM
6guh  1.50  2018  Kd=26nM       // 6gu2.pdf (FB8) Kd = 26 +/- 3 nM; ligand is compound AZD5438
6fnq  1.75  2018  Kd=26uM       // 6fnq.pdf (AVJ) ligand is TMH; Kd = 26 +/- 4 uM
5ost  2.10  2018  Kd=27.3uM     // 5oss.pdf (AEZ) [Nonstandard assay: pH=6.8] Kd = 27.3 +/- 0.4 uM, ligand is compound 6
5oaj  2.47  2018  Kd=275nM      // 5o87.pdf (TKT) Kd=275+/-15nM, T53F, Q74R, Y110A, I135S, G162E mutant
5yyb  2.48  2018  Kd=277nM      // 5yyb.pdf (NGE) [Nonstandard assay: pH 8.0] ligand is Neu5Gc,Kd=277+/-58nM
6co4   NMR  2018  Kd=27nM       // 2nbk.pdf (18-mer)
5oax  1.20  2018  Kd=27nM       // 5oax.pdf (9Q5) Kd = 27 +/- 3 nM, ligand is compound 36
5wj6  2.45  2018  Kd=27nM       // 5wj6.pdf (B4A) [Nonstandard assay: pH = 8.5] [Different protein in assay: Protein in binding assay is F327W] Kd = 27 +/- 2 nM. ligand is UPGL00004
6gla  1.92  2018  Kd=27nM       // 6gl9.pdf (F4B) ligand is compound 11; IC50 = 27 +/- 1 nM
5oss  1.70  2018  Kd=28.3uM     // 5oss.pdf (AEZ) [Nonstandard assay: pH=6.8] Kd = 28.3 +/- 6.9 uM, ligand is compound 6
6gnp  2.02  2018  Kd=28.41uM    // 6gnm.pdf (F4Z) ligand is compound TC2P
6hsh  1.55  2018  Kd=28.4nM     // 6hqy.pdf (GOK) ligand is Quisinostat(QSN); Kd = 28.4 +/- 3.3 nM
5z95  1.20  2018  Kd=284nM      // 5z95.pdf (EGC) [Incomplete ligand] ligand is Triton,Kd=284+/-22nM
6miq  1.75  2018  Kd=28uM       // 6mil.pdf (8-mer) Kd = 28 +/- 2 uM; ligand is peptide H3K9bu
6evp  1.68  2018  Kd=29.2uM     // 6evm.pdf (9-mer) Ligand is peptide PPG-PEG-PPG; Kd = 29.2 +/- 0.7 uM
6aji  2.90  2018  Kd=29.5uM     // 6ajf.pdf (AY6) microscale thermophoresis assay, Kd(rimonabant)=29.5+/-3.4uM
5o0e  1.50  2018  Kd=29.6uM     // 5o0e.pdf (18-mer) Kd=29.6+/-10.0uM
5o5m  1.58  2018  Kd=5.86uM     // 5o5m.pdf (9LQ,18-mer) Kd(18-mer)=29.6+/-10.0uM, Kd(9LQ)=5.86+/-2.75uM
6em7  1.24  2018  Kd=29.6uM     // 6em7.pdf (18-mer) microscale thermophoresis assay, Kd(18-mer)=29.6+/-10.0uM
6ema  1.88  2018  Kd=29.6uM     // 6ema.pdf (18-mer) microscale thermophoresis assay, Kd(18-mer)=29.6+/-10.0uM
6eru  2.15  2018  Kd=29.6uM     // 6eru.pdf (18-mer) microscale thermophoresis assay, Kd(18-mer)=29.6+/-10.0uM
6esa  1.31  2018  Kd=29.6uM     // 6esa.pdf (18-mer) microscale thermophoresis assay, Kd(18-mer)=29.6+/-10.0uM
5nau  2.25  2018  Kd=29.86nM    // 5nap.pdf (DZ0) Kd = 29.86 +/- 1.12 nM. Ki = dissociation constant in lecture
5qaq  2.40  2018  Kd=290uM      // 5qa4.pdf (S1C) ligand is compound 21b
6cwi  2.16  2018  Kd=29nM       // 6cwf.pdf (6LA) Ligand is compound 4,6-Pyr-beta-D-ManNAcOMe; Solving co-crystal structure in C2 space group; same as 6cwh
6cwh  2.00  2018  Kd=29nM       // 6cwf.pdf (6LA) Ligand is compound 4,6-Pyr-beta-D-ManNAcOMe; Solving co-crystal structure in P1 space group
6cwf  2.25  2018  Kd=29nM       // 6cwf.pdf (6LA) Ligand is compound 4,6-Pyr-beta-D-ManNAcOMe; same as 6cwh
6ggv  2.69  2018  Kd=29nM       // 6ggv.pdf (ARG) ligand is ARG
6e83   NMR  2018  Kd=29uM       // 6e83.pdf (12-mer) Binding assay: microscale thermophoresis; Ligand is peptide H3; Kd = 29+/-7uM
6f9g  2.39  2018  Kd=2uM        // 6f9g.pdf (PUT) ligand is putrescine; Kd = 2 +/- 1 uM
6hd6  2.30  2018  Kd=2uM        // 6hd4.pdf (FYH) ligand is compound 6;
6fi5  1.70  2018  Kd=3.0uM      // 6fau.pdf (8-mer) [Covalent complex] ligand is 3.2d(the Sequence Length of peptide in Literature is different from that in PDB ); Kd = 3.0 +/- 0.6uM
5oa6  1.94  2018  Kd=3.10uM     // 5o9o.pdf (9PT) Kd = 3.10 +/- 0.02uM. ligand is compound 12
6hpg  2.00  2018  Kd=3.17uM     // 6hpg.pdf (8-mer) ligand is Hsp90; Kd = 3.17 +/- 2.09 uM
6gr7  1.40  2018  Kd=3.19uM     // 6gnm.pdf (F52) [Different protein in assay: X-ray(Sparus aurata), Kd(human)] ligand is compound 2,4,5-T
5zu0  2.76  2018  Kd=3.1uM      // 5zu0.pdf (SAH) ligand is SAH,Kd=3.1+/-0.2uM
5zzw  2.60  2018  Kd=3.1uM      // 5zzw.pdf (SAH) ligand is SAH,Kd=3.1+/-0.2uM
6g14  1.80  2018  Kd=3.26uM     // 6g0z.pdf (G4P) ligand is compound ppGpp
5xvw  1.85  2018  Kd=3.29uM     // 5xvw.pdf (14-mer) Kd=3.29+/-0.34uM
6af9  1.39  2018  Kd=3.2uM      // 6af5.pdf (ISN) [Covalent complex] ligand is compound 1(high concentration),Kd=3.2+/-0.08uM(ITC),Kd=2.0+/-0.5uM(SPR)
6afa  1.65  2018  Kd=3.2uM      // 6af5.pdf (ISN) [Covalent complex] ligand is compound 1(low concentration),Kd=3.2+/-0.08uM(ITC),Kd=2.0+/-0.5uM(SPR)
6grp  1.60  2018  Kd=3.34uM     // 6gnm.pdf (F4Z) [Different protein in assay: X-ray(Sparus aurata), Kd(human)] ligand is compound TC2P
6fe1  1.95  2018  Kd=3.3nM      // 6fe0.pdf (V14) ligand is VD11-4-2
6fhq  1.95  2018  Kd=3.4mM      // 6fap.pdf (DE5) ligand is compound Fr21; Kd = 3.4 +/- 0.5 mM
6h7n  2.50  2018  Kd=3.5nM      // 6h7n.pdf (FVK) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is xamoterol
6ekq  1.65  2018  Kd=3.5uM      // 5mwg.pdf (B0H) ligand is compound 42
5owa  1.95  2018  Kd=3.5uM      // 5mwg.pdf (B0H) ligand is compound 42, same as 6ekq
6gnr  1.40  2018  Kd=3.61uM     // 6gnm.pdf (6J3) ligand is compound Clonixin
5uxm  1.54  2018  Kd=3.6uM      // 5uxm.pdf (TRP) Kd = 3.6 +/- 0.8 uM, ligand is Trp
6fau  1.25  2018  Kd=3.6uM      // 6fau.pdf (8-mer) [Covalent complex] ligand is 4.2e-1; Kd = 3.6 +/- 0.6 uM
5vl2  1.90  2018  Kd=3.77nM     // 5vl2.pdf (9EG) [Multiple sites: site 1: Kd = 3.77 nM, site 2: Kd = 0.98 nM.] ligand is TCC
6a6w  2.60  2018  Kd=3.7uM      // 5yc2.pdf (17-mer) ligand is Sad1,Kd=3.7+/-0.3uM
6afd  1.48  2018  Kd=3.7uM      // 6af5.pdf (72S) [Covalent complex] ligand is 6,Kd=3.7+/-0.1uM(ITC)
5xs8  1.95  2018  Kd=3.86uM     // 5xs8.pdf (2-mer) [Incomplete ligand] ligand is Cdelta4S6S,Kd=3.86+/-0.243uM,ligand in PDB is incomplete
5mqx   NMR  2018  Kd=3.9uM      // 5mqx.pdf (APR) citated data, Kd=3.9+/-0.65uM
5yv5  2.10  2018  Kd=3.9uM      // 5yv5.pdf (18-mer) ligand is aP1,Kd=3.9+/-0.3uM
6aff  1.60  2018  Kd=3.9uM      // 6af5.pdf (72U) [Covalent complex] ligand is 8,Kd=3.9+/-0.2uM(ITC)
6mil  1.93  2018  Kd=3.9uM      // 6mil.pdf (19-mer) Kd = 3.9 +/- 0.5 uM; ligand is peptide H3K9bu
5y20  2.41  2018  Kd=30.4uM     // 5y20.pdf (7-mer) [Incomplete ligand] ligand is H3K4me3
5qa5  1.95  2018  Kd=300uM      // 5qa4.pdf (L5D) ligand is compound 3b
6gfz  2.30  2018  Kd=3080nM     // 6gfx.pdf (EXE) ligand is compound 13b; Kd = 3080 +/- 10 nM
5o1f  1.38  2018  Kd=30uM       // 5o1a.pdf (9GQ) ligand is compound 52
5o1a  1.44  2018  Kd=30uM       // 5o1a.pdf (9H5) ligand is compound 11
5vh0  2.06  2018  Kd=30uM       // 5vh0.pdf (8P0) Kd(pyrene)=30+/-2.0uM
6ami  1.97  2018  Kd=30uM       // 5vm5.pdf (TRP) Kd = 30 +/- 4 uM. ligand is L-Trp
6fhk  1.66  2018  Kd=31.15nM    // 6fhk.pdf (ADP)
5yl2  2.09  2018  Kd=31.69uM    // 5xiw.pdf (8WU) ligand is SKLB028, Kd=31.69+/-5.26uM
5qaf  2.15  2018  Kd=312uM      // 5qa4.pdf (S1D) ligand is compound 8c
6gbe   NMR  2018  Kd=318uM      // 6gbe.pdf (12-mer) Kd = 318 +/- 47 uM
5yqw  1.36  2018  Kd=31nM       // 5yqw.pdf (CBS) [Nonstandard assay: PH=8.0,Temp=4 C] Kd=31+/-8.3nM
6bau  3.80  2018  Kd=31uM       // 6bat.pdf (CYS) [Nonstandard assay: 100 mM Na+] ligand is cys,Kd=31+/-3uM
6g86  1.74  2018  Kd=32.2uM     // 6g84.pdf (16-mer)
5ybi  2.27  2018  Kd=322.48uM   // 5ybi.pdf (ANP) ligand is AMPPNP,Kd=322.48+/-12.60uM
5vqe  1.89  2018  Kd=32mM       // 5vqe.pdf (G2F) [Covalent complex] ligand is 2FGlc
5nud  2.50  2018  Kd=32nM       // 5nud.pdf (99K) [Covalent complex] Kd = 32 +/- 11 nM. ligand is compound 9
6fe0  1.91  2018  Kd=330nM      // 6fe0.pdf (V90) ligand is VD12-09
5qaj  2.00  2018  Kd=330uM      // 5qa4.pdf (VBC) ligand is compound 13
6eya  2.10  2018  Kd=33nM       // 6ei5.pdf (C4K) ligand is compound 35; Kd = 33+/-3.1nM
6h7b  1.89  2018  Kd=33nM       // 6h7b.pdf (14-mer)
5o1e  1.30  2018  Kd=33uM       // 5o1a.pdf (9GT) ligand is compound 51
5ovv  1.40  2018  Kd=33uM       // 5ovc.pdf (7-mer) Kd = 33 +/- 2.0 uM, ligand is ProSAPiP1
5yto  1.90  2018  Kd=33uM       // 5yto.pdf (946) [Incomplete ligand] ligand is SBL-1
6hoy  1.70  2018  Kd=33uM       // 6hoy.pdf (TSN) Kd = 33 +/- 6 uM
5ogb  1.80  2018  Kd=34nM       // 5ogb.pdf (9U5) Kd(DC360)=34+/-2.5nM
6ccu  1.75  2018  Kd=35.2uM     // 6cct.pdf (4-mer) ligand is peptide PHRV; Kd = 35.2+/-5.3uM
6q3q  2.00  2018  Kd=35.2uM     // 6hpg.pdf (8-mer) ligand is Hsp90; Kd = 35.2 +/- 6.85 uM
5qal  1.95  2018  Kd=350uM      // 5qa4.pdf (TVZ) ligand is compound 11b
5msb  1.30  2018  Kd=35nM       // 5llc.pdf (V13) ligand is compound 10
6fui  1.38  2018  Kd=35uM       // 6fty.pdf (E7W) ligand is compound 9
6hqy  2.50  2018  Kd=367nM      // 6hqy.pdf (GKW) ligand is PCI-34051; Kd = 367 +/- 40.7 nM
6mdq  2.15  2018  Kd=367uM      // 6mdq.pdf (TES) ligand is testosterone
6h8s  1.77  2018  Kd=37.7uM     // 6h8r.pdf (FSZ)
5w8j  1.55  2018  Kd=370nM      // 5w8h.pdf (9Y7) [Nonstandard assay: in the presence of NADH] ligand is compound 33
5yy4  1.59  2018  Kd=370nM      // 5yy4.pdf (9-mer) [Nonstandard assay: Temp 25] ligand is pep1,Kd=370+/-5.6nM
6g9u  1.75  2018  Kd=370nM      // 6fe0.pdf (ETK) ligand is VR16-10
5osl  1.95  2018  Kd=375uM      // 5oqu.pdf (A9K) ligand is compound 7
6ei5  2.20  2018  Kd=38.3nM     // 6ei5.pdf (B5Q) ligand is compound 62; Kd = 38.3+/-9.4nM
6cd9  1.55  2018  Kd=38.3uM     // 6cct.pdf (4-mer) ligand is peptide PSRW; Kd = 38.3+/-2.1uM
5yij  3.18  2018  Kd=381uM      // 5yij.pdf (NAI) MST assay, ligand is NAD+
6byk  3.00  2018  Kd=390uM      // 6byk.pdf (12-mer) Kd=390+/-13uM
6hk6  2.35  2018  Kd=393nM      // 6hk6.pdf (G8H) ligand is 9
6csp  1.24  2018  Kd=3nM        // 6csp.pdf (FBM) ligand is compound 2
6f08  1.90  2018  Kd=4.06uM     // 6f08.pdf (13-mer) ligand is SOS1pSer peptide; Kd = 4.06 +/- 0.17 uM; Fluorescence polarization assay
5o9r  1.70  2018  Kd=4.09uM     // 5o9o.pdf (9PK) Kd = 4.09 +/- 0.04 uM. ligand is compound 9
5ody  1.15  2018  Kd=4.0nM      // 5oax.pdf (9SK) Kd = 4.0 +/- 0.4, ligand is compound 37
6c3u  1.85  2018  Kd=4.0uM      // 5wep.pdf (NY2) Kd(FosA,KP)=4.0+/-0.6uM
6ma2  2.10  2018  Kd=4.1uM      // 6ma1.pdf (J9S) ligand is compound ent-1a; Kd = 4.1 +/- 3.0uM
6eyb  1.90  2018  Kd=4.22uM     // 6ei5.pdf (C3Z) ligand is compound 41; Kd = 4.22+/-0.097uM
5uci  2.70  2018  Kd=4.27uM     // 5uc4.pdf (874) Kd = 4.27 +/- 0.95 uM. ligand is compound 5
6g3a  1.43  2018  Kd=4.2nM      // 6g33.pdf (5ID) ligand is 5-iTU; Kd = 4.2 +/- 0.4 nM
6baw  2.70  2018  Kd=4.2uM      // 5vyy.pdf (D57) Kd = 4.2 +/- 0.22 uM. ligand is compound 2
6g15  1.65  2018  Kd=4.31uM     // 6g0z.pdf (C1Z) ligand is compound pppGpp
5ol3  1.58  2018  Kd=4.32uM     // 5ol3.pdf (18-mer) Kd(18-mer)=4.32+/-0.89uM
6erv  2.06  2018  Kd=4.32uM     // 6erv.pdf (18-mer) microscale thermophoresis assay, Kd(18-mer)=4.32+/-0.89uM
6erw  1.89  2018  Kd=4.32uM     // 6erw.pdf (18-mer) microscale thermophoresis assay, Kd(18-mer)=4.32+/-0.89uM
6cer  2.69  2018  Kd=4.39uM     // 6cer.pdf (TDP) [Covalent complex] ligand is compound ThDP; Kd = 4.39+/-0.23uM
6ap6  1.65  2018  Kd=4.3uM      // 6ap6.pdf (TLF) [Nonstandard assay: PH=8] [Different protein in assay: Protein in binding assay is WT] ligand is Tolfenamic acid,Kd=4.3+/-0.5uM,Ki=0.12+/-0.02uM
6afe  1.50  2018  Kd=4.4uM      // 6af5.pdf (72T) [Covalent complex] ligand is 7,Kd=4.4+/-0.3uM(ITC)
6an1  2.69  2018  Kd=4.5uM      // 6an1.pdf (BKY) [Incomplete ligand] ligand is AM-879,Kd=4.5+/-0.6uM,ligand in PDB is wrong
5o9y  1.57  2018  Kd=4.60uM     // 5o9o.pdf (9PN) Kd = 4.60 +/- 0.03 uM. ligand is compound 11
6b5o  2.19  2018  Kd=4.66nM     // 6b5l.pdf (15-mer) ligand is petide 29
5y24  1.92  2018  Kd=4.6nM      // 5y24.pdf (6-mer) [Nonstandard assay:  PH=8.0] Kd=4.6+/-1.4nM
6g39  1.45  2018  Kd=4.6nM      // 6g33.pdf (5ID) ligand is 5-iTU; Kd = 4.6 +/- 0.3 nM
6ap7  1.51  2018  Kd=4.6uM      // 6ap6.pdf (BNY) [Nonstandard assay: PH=8] [Different protein in assay: Protein in binding assay is WT] ligand is MNAB,Kd=4.6+/-0.5uM,Ki=0.16+/-0.02uM
6fav  1.40  2018  Kd=4.7uM      // 6fau.pdf (8-mer) [Different ligand in assay: ] ligand is 4.2f-1; Kd = 4.7 +/- 0.6 uM
6g0z  2.15  2018  Kd=4.84uM     // 6g0z.pdf (GDP)
6h1u  1.68  2018  Kd=4.8uM      // 6h1u.pdf (ASP) ligand is ASP; Kd = 4.8 +/- 0.6 uM
5oah  1.80  2018  Kd=4.9nM      // 5oah.pdf (95B) [Uncommon element] Kd = 4.9 +/- 0.4 nM, Ligand is [FeIII(AZOTO)]2-
6ezi  1.50  2018  Kd=4.9uM      // 6ezi.pdf (10-mer) Kd = 4.9 +/- 0.2 uM
5qaz  2.20  2018  Kd=400uM      // 5qa4.pdf (Q2S) ligand is compound 34
5qaw  2.20  2018  Kd=400uM      // 5qa4.pdf (TVC) ligand is compound 27
6b1x  1.45  2018  Kd=40nM       // 6b1f.pdf (C9D) [Covalent complex] ligand is compound 1,Kd=40+/-7nM,KPC-2-soaked 1
6b1y  1.80  2018  Kd=40nM       // 6b1f.pdf (CD7) [Covalent complex] ligand is compound 1,Kd=40+/-7nM,KPC-2-cocrystallized 1
5nze  1.69  2018  Kd=410nM      // 5nwe.pdf (G39) Kd = 410 +/- 20 nM, ligand is oseltamivir carboxylate
6csq  2.03  2018  Kd=410nM      // 6csp.pdf (F9P) ligand is compound 3
5orh  1.75  2018  Kd=41uM       // 5oqu.pdf (A4N) ligand is compound 2
6eu6  1.98  2018  Kd=41uM       // 6eu6.pdf (NH4) ligand is NH4+; Kd=41+/-24uM;Binding assay method is MST
6g37  1.48  2018  Kd=42.7nM     // 6g33.pdf (FTU) ligand is 5-fluorotubercidin; Kd = 42.7 +/- 2.8 nM
6b22  1.93  2018  Kd=42nM       // 6b1f.pdf (C8Y) [Covalent complex] ligand is compound 3,Kd=42+/-6nM,OXA-24/40-cocrystallized 3
6b1w  1.73  2018  Kd=43nM       // 6b1f.pdf (C8V) [Covalent complex] ligand is compound 2,Kd=43+/-5nM,KPC-2-cocrystallized 2
6b1j  1.60  2018  Kd=43nM       // 6b1f.pdf (C8V) [Covalent complex] ligand is compound 2,Kd=43+/-5nM,KPC-2-soaked 2
6gu3  2.65  2018  Kd=4400nM     // 6gu2.pdf (FB8) [Different protein in assay: protein in binding assay is CDK1-CyclinB] Kd=4400+/-3200 nM; ligand is compound AZD5438
5wep  3.50  2018  Kd=440nM      // 5wep.pdf (A81) Kd(WT)=440+/-50nM
6e4a  1.26  2018  Kd=44nM       // 6e4a.pdf (HRY) Ligand is compound 48(CN750); Binding assay: BROMOscan assay
6h77  2.10  2018  Kd=46.3nM     // 6h77.pdf (ATP)
6h78  2.70  2018  Kd=46.3nM     // 6h77.pdf (ATP)
5w2s  2.40  2018  Kd=46.5nM     // 5w2o.pdf (KMG) Kd(5g)=46.5+/-18.7nM
6mv3   NMR  2018  Kd=470uM      // 6mv3.pdf (WW7) ligand is W7; Kd = 470 +/- 50 uM
6hly  1.40  2018  Kd=47nM       // 6hly.pdf (G9Z) ligand is agropinic acid; Kd = 47 +/- 5.6 nM (fluorescence)
6hlz  1.89  2018  Kd=47nM       // 6hlz.pdf (G9Z) ligand is agropinic acid; Kd = 47 +/- 5.6 nM (fluorescence); same as 6hly
6hm2  1.74  2018  Kd=47nM       // 6hm2.pdf (G9Z) ligand is agropinic acid; Kd = 47 +/- 5.6 nM (fluorescence); same as 6hly
5ods  3.09  2018  Kd=47uM       // 5ods.pdf (18-mer) Kd = 47 +/- 2 uM
6exj  1.80  2018  Kd=47uM       // 5ovc.pdf (7-mer) Kd = 47 +/- 2.5 uM, ligand is SSRL2
6czb  2.40  2018  Kd=47uM       // 6czb.pdf (UTP) ligand is UTP; Kd = 47+/-1uM
5wij  2.04  2018  Kd=488nM      // 5wij.pdf (AQG) Kd(NU6140)=488+/-26nM
6f20  2.00  2018  Kd=49.5uM     // 6f1x.pdf (C9E) ligand is compound 1
5qb3  2.00  2018  Kd=49uM       // 5qa4.pdf (AVM) ligand is compound 40
6gue  1.99  2018  Kd=4nM        // 6gu2.pdf (FB8) Kd = 4 +/- 1 nM; ligand is compound AZD5438
5o1i  1.40  2018  Kd=4uM        // 5o1a.pdf (9GH) ligand is compound 70
6bj2  3.35  2018  Kd=4uM        // 6bj2.pdf (9-mer) ligand is peptide IPLTEEAEL(B35-HIV)
6gmq  2.76  2018  Kd=5.0mM      // 6gmn.pdf (F4K) Kd = 5.0 +/- 0.4 mM; Compound is MB756
5vnb  2.40  2018  Kd=5.0uM      // 5vna.pdf (10-mer) [Different protein in assay: Protein in binding assay is full-length] Kd = 5.0 +/- 2.8 uM
5yls  3.00  2018  Kd=5.13uM     // 5xiw.pdf (Y50) ligand is SKLB050,Kd=5.13+/-0.62uM
5tkk  1.55  2018  Kd=5.29nM     // 5tkj.pdf (8-mer) protein is vFP5.01, ligand is Fusion peptide
5xpi  2.20  2018  Kd=5.2uM      // 5xpi.pdf (8C3) ligand is NV01, Kd=5.2+/-1.2uM
6gzh  3.17  2018  Kd=5.4nM      // 6gzd.pdf (LCI) ligand is compound A86
6gzm  1.59  2018  Kd=5.5nM      // 6gzd.pdf (LCI) ligand is compound A86
6bcr  1.99  2018  Kd=5.5uM      // 6bcr.pdf (14-mer) Kd(site 2, T340)=5.5+/-1.8uM
6fdp   NMR  2018  Kd=5.5uM      // 6fdp.pdf (9-mer) Kd = 5.5 +/- 2.5 uM
6bw5  3.10  2018  Kd=5.6nM      // 6bw5.pdf (TUM) [Nonstandard assay: without MgCl2] Kd = 5.6+/-1.3nM
6cpw  1.85  2018  Kd=5.6nM      // 6cpw.pdf (F8V) ligand is compound 27
6et8  1.70  2018  Kd=5.6nM      // 6et8.pdf (BWH) ligand is compound albicidin; Kd = 5.6+/-0.2nM
6fc6  1.80  2018  Kd=5.6uM      // 6fc6.pdf (11-mer) ligand is peptide ETF; Kd = 5.6 +/- 0.8 uM
6b5q  2.16  2018  Kd=5.7nM      // 6b5q.pdf (5-mer) [Nonstandard assay: Temp 30] ligand is compound 38,Kd=5.7+/-2.0nM
6g34  1.76  2018  Kd=5.7nM      // 6g33.pdf (5ID) ligand is 5-ITU; Kd = 5.7 +/- 0.5 nM
5ot3  2.04  2018  Kd=5.86uM     // 5ot3.pdf (9LQ,18-mer) [Uncommon element] Kd(9LQ)=5.86+/-2.75uM,Kd(18-mer)>100uM
6ert  1.80  2018  Kd=5.86uM     // 6ert.pdf (BVZ) [Uncommon element] microscale thermophoresis assay, Kd(BVZ)=5.86+/-2.75uM
6bhv  2.30  2018  Kd=5.87uM     // 6bhv.pdf (DQV) ligand is compound BAD; Kd=5.87+/-0.62uM
6cf6  1.93  2018  Kd=5.8uM      // 6cf6.pdf (13-mer) ligand is compound RNF146; Kd = 5.8+/-0.6uM
5zla  1.70  2018  Kd=50.1uM     // 5zla.pdf (9F3) [Different protein in assay: Protein in binding assay is C387A/E210A] ligand is DFA-III,Kd=50.1+/-7.2uM
5zku  2.32  2018  Kd=50.5uM     // 5zku.pdf (9F3) [Different protein in assay: Protein in binding assay is E210A mutant] ligand is DFA-III,Kd=50.5+/-7.1uM; same as 5zla
6fdt   NMR  2018  Kd=50.5uM     // 6fdp.pdf (9-mer) Kd = 50.5 +/- 5.0 uM
6fug  2.21  2018  Kd=50uM       // 6fty.pdf (E85) ligand is compound 7
6fuj  2.25  2018  Kd=50uM       // 6fty.pdf (E8B) ligand is compound 10
6elo  1.80  2018  Kd=514nM      // 6ei5.pdf (BAW) ligand is compound 7; Kd =514+/-6nM
5nz4  1.36  2018  Kd=520nM      // 5nwe.pdf (G39) Kd = 520 +/- 30 nM, ligand is oseltamivir carboxylate
6gnm  2.24  2018  Kd=54.61uM    // 6gnm.pdf (27M) ligand is compound BP2
6f1n  2.09  2018  Kd=547nM      // 6ei5.pdf (C8W) ligand is compound 6; Kd = 547+/-7.3 nM
6bod  3.20  2018  Kd=55uM       // 5w5v.pdf (E0P) IC50 = 55 +/- 29 uM. ligand is compound 3
6mxe  2.47  2018  Kd=55uM       // 6mxe.pdf (K5S) [Different ligand in assay: Ligand in binding assay is a symmetrical dimer] ligand is compound 18; Kd = 55+/- 30 uM(first)
6df2  2.60  2018  Kd=57.2nM     // 6dez.pdf (3-mer) Biolayer Interferometry assay, ligand is pY peptide
6fjm  2.10  2018  Kd=576nM      // 6fii.pdf (DKN) Kd = 576 +/- 49 nM; ligand is Disorazole Z
5xmx  2.00  2018  Kd=57nM       // 5xmx.pdf (89L) ligand is compound 18, Kd=57+/-1nM
6fsd  2.70  2018  Kd=57uM       // 6fsd.pdf (E5H) [Different protein in assay: X-ray(Mus musculus); IC50(human)] ligand is compound 10
6g9b  2.26  2018  Kd=582uM      // 6g95.pdf (IXX) ligand is imipramine; Kd = 582 +/- 256 uM
5umw  2.27  2018  Kd=59.5uM     // 5umw.pdf (RBF) Kd = 59.5 +/- 8.6 uM, ligand is riboflavin, protein is TnmS2
5qay  1.70  2018  Kd=590uM      // 5qa4.pdf (X6P) ligand is compound 32
5ywy  3.20  2018  Kd=59nM       // 5yhl.pdf (7UR) ligand is ONO-AE3-208. Protein is EP4-i3d (A62L/G106R). Complex is EP4-Fab001-ligand
5v3h  2.69  2018  Kd=5nM        // 5v37.pdf (8WG) kon=5E+5, koff=0.003
6atv  1.75  2018  Kd=6.0nM      // 6atv.pdf (15-mer) [Nonstandard assay: pH 6.1, NaCl = 80mM] NaCl = 80mM:Kd=6.0+/-2.0nM,NaCl = 1M:Kd=1.0+/-0.3uM
5wmg  1.19  2018  Kd=6.1nM      // 5wma.pdf (6JF)
6d6u  3.80  2018  Kd=6.1nM      // 6d6t.pdf (FYP) Kd = 6.1 +/- 1.1 nM; Conformation A
6d6t  3.80  2018  Kd=6.1nM      // 6d6t.pdf (FYP) Kd = 6.1 +/- 1.1 nM; Conformation B
6g85  1.53  2018  Kd=6.1uM      // 6g84.pdf (16-mer)
6g84  2.47  2018  Kd=6.1uM      // 6g84.pdf (16-mer) Kd = 6.1 +/- 0.3 uM
5o9q  1.40  2018  Kd=6.2uM      // 5o9o.pdf (9PH) Kd = 6.2 +/- 0.1 uM. ligand is compound 6
5zo8  2.20  2018  Kd=6.3nM      // 5zo8.pdf (4C5) ligand is PVEI0021,Kd=6.3+/-1.8nM
5zo9  2.70  2018  Kd=6.3nM      // 5zo9.pdf (4C5) Kd=6.3+/-1.8nM,5zo8 and 5zo9 are same complex with different crystal structrue
6d1x  2.30  2018  Kd=6.3uM      // 6cyg.pdf (PA7) compound is NPCA, Kd=6.3+/-0.1uM
5zkc  2.30  2018  Kd=6.4nM      // 5yc8.pdf (3C0) ligand is NMS; Kd=6.4+/-0.1nM
5yc8  2.50  2018  Kd=6.4nM      // 5yc8.pdf (3C0) ligand is NMS; Kd=6.4+/-0.1nM; same as 5zkc
6dq5  1.89  2018  Kd=6.4uM      // 6dq4.pdf (H6G) ligand is compound N43; Kd = 6.4+/-1.6uM
5otz  1.46  2018  Kd=6.5uM      // 5oqu.pdf (AUT) ligand is compound 15
6arn  1.25  2018  Kd=6.5uM      // 6aox.pdf (BQY) bio-layer interferometry experiment, Kd=6.5+/-1.4uM
6g47  1.50  2018  Kd=6.60mM     // 6g47.pdf (SIA) ligand is 52SFK; Kd = 6.60 +/- 0.43 mM
6gmx  2.53  2018  Kd=6.7mM      // 6gmn.pdf (F7B) Kd = 6.7 +/- 0.8 mM; Compound is MB1200
5oxk  2.38  2018  Kd=6.82mM     // 5oxk.pdf (2-mer) Kd = 6.82 + 1.33 mM, ligand is Ala-Gln
6mjf  2.20  2018  Kd=6.88uM     // 6mjf.pdf (SAH) Kd = 6.88 +/- 1.13 uM; ligand is compound SAH
6ghj  2.26  2018  Kd=6.89mM     // 6ghj.pdf (3-mer) Kd = 6.89 +/- 1.35 mM
6fjf  2.40  2018  Kd=6.8nM      // 6fii.pdf (DKE) Kd = 6.8 +/- 0.8 nM; ligand is FcMaytansine  ?binding assay: fluorescence anisotrop
5ohy  1.77  2018  Kd=6.8uM      // 5ohs.pdf (9VH) Kd=6.8+/-0.2uM
6evo  1.55  2018  Kd=6.8uM      // 6evm.pdf (9-mer) Ligand is peptide PPG-PRG-PPG; Kd = 6.8+/-1.0uM
5niy  1.70  2018  Kd=60uM       // 5niy.pdf (GNP) [Different protein in assay: Protein in binding assay is FtsY deltaN1 (aa.220-493)] ligand is GMPPNP
5wik  2.60  2018  Kd=620nM      // 5wij.pdf (584) Kd(BI-D1870)=620+/-36nM
6fu4  2.45  2018  Kd=639nM      // 6fu4.pdf (HSM) Kd = 639 +/- 27 nM; ligand is histamine
6f8g  2.03  2018  Kd=65.5uM     // 6f8f.pdf (12-mer) Kd = 65.5 +/- 9.6 uM
5yyz  1.80  2018  Kd=66.2uM     // 5yyz.pdf (13-mer) [Nonstandard assay: Tem 15] ligand is PT318,Kd=66.2+/-9.0uM
5wou  1.55  2018  Kd=664nM      // 5wou.pdf (8-mer) ligand is Gukh peptide; Kd=664+/-129nM
6hlx  1.65  2018  Kd=67nM       // 6hlx.pdf (G9Z) ligand is agropinic acid; Kd = 67 +/- 10.6 nM (fluorescence)
6htg  1.94  2018  Kd=67nM       // 6hqy.pdf (T61) ligand is compound 4; IC50 = 67 +/- 10 nM
6f55   NMR  2018  Kd=68.6uM     // 6f55.pdf (15-mer) Kd = 68.6 +/- 5.7 uM
6c28  2.09  2018  Kd=68uM       // 6c28.pdf (WCA) ligand is compound pCC;Kd = 68+/-8uM;binding assay method: DSF
6ckc  2.80  2018  Kd=6nM        // 6ckc.pdf (F5J) ligand is compound 1; Kd = 6+/-2nM
6fni  1.47  2018  Kd=6nM        // 6fnf.pdf (DXH) ligand is NVP
5y2f  2.53  2018  Kd=7.0uM      // 5y2f.pdf (8L9) ligand is compound MDL-801
5tkj  2.12  2018  Kd=7.15nM     // 5tkj.pdf (8-mer) protein is vFP1.01, ligand is Fusion peptide
6fap  2.70  2018  Kd=7.1mM      // 6fap.pdf (D3H) ligand is compound Fr23; Kd = 7.1 +/- 1.9 mM
6fi1  2.70  2018  Kd=7.1mM      // 6fap.pdf (D3H) ligand is compound Fr23; Kd = 7.1 +/- 1.9 mM
5mwz  1.25  2018  Kd=7.1uM      // 5mwg.pdf (KGU) ligand is compound 36
6aro  1.20  2018  Kd=7.1uM      // 6aox.pdf (BS7) bio-layer interferometry experiment, Kd=7.1+/-2.3uM
6gw1  1.90  2018  Kd=7.2uM      // 6gvz.pdf (CHO) ligand is GCDCA
5xbt  2.50  2018  Kd=7.3uM      // 5xbi.pdf (C2E) Kd(FP)=7.3+/-0.5uM
6gzl  1.95  2018  Kd=7.3uM      // 6gzl.pdf (17-mer)
5y1u  2.14  2018  Kd=7.6uM      // 5y1u.pdf (12-mer) ligand is AEBP2,Kd=7.6+/-0.6umol/L
6cnj  3.40  2018  Kd=7.7nM      // 6cnj.pdf (NCT) Kd = 6.9-8.6nM; Receptor alone
6gwr  2.07  2018  Kd=7.9nM      // 6gwr.pdf (FEW) ligand is compound 5n
6cc9   NMR  2018  Kd=700uM      // 6cc9.pdf (EWS) O1 state
6ccx   NMR  2018  Kd=700uM      // 6cc9.pdf (EWS) O2 state
5qav  1.72  2018  Kd=70uM       // 5qa4.pdf (L43) ligand is compound 26b
5qb2  1.75  2018  Kd=70uM       // 5qa4.pdf (U3M) ligand is compound 38
5qau  1.75  2018  Kd=70uM       // 5qa4.pdf (V7V) ligand is compound 26a
6h0b  1.80  2018  Kd=70uM       // 6h0b.pdf (16-mer) Kd = 70 +/- 15 uM; ligand is glycopeptide 6
6g98  2.47  2018  Kd=710nM      // 6fe0.pdf (ER5) ligand is VR16-09
6guk  1.30  2018  Kd=715nM      // 6gu2.pdf (FC8) Kd = 715 +/- 15 nM; ligand is compound CGP74514A
5v5o  2.24  2018  Kd=72.4uM     // 5v5o.pdf (19-mer) Kd=72.4+/-10.0uM
6cct  2.40  2018  Kd=72.5uM     // 6cct.pdf (4-mer) ligand is peptide PTLV; Kd = 72.5+/-1.7uM
6fng  1.04  2018  Kd=73nM       // 6fnf.pdf (DWT) ligand is NVPiso
5o8t  2.20  2018  Kd=74.1nM     // 5o87.pdf (SY9) Kd=74.1+/-22.6nM; redundant to 5obg
5obg  2.00  2018  Kd=74.1nM     // 5o87.pdf (SY9) Kd=74.1+/-22.6nM
6cvv  2.41  2018  Kd=75uM       // 6cvv.pdf (ATP) ligand is ATP; Kd = 75+/-3uM
6h7f  2.26  2018  Kd=763nM      // 6h7f.pdf (FV8) [Uncommon element] ligand is preacinetobactin
5vrl  2.65  2018  Kd=77nM       // 5vrl.pdf (9JA) Kd = 77 +/- 31 nM. ligand is AN12855
5om3  2.00  2018  Kd=79.2uM     // 5om2.pdf (DXT) ligand is doxycycline, Kd for S-conformation
6c4u  2.60  2018  Kd=798nM      // 6c4u.pdf (9-mer) ligand is peptide Myc-pTBD; Kd = 798+/-60nM
5o9p  1.75  2018  Kd=8.06uM     // 5o9o.pdf (9P8) Kd = 8.06 +/- 0.07 uM. ligand is compound 10
6ap8  1.27  2018  Kd=8.0uM      // 6ap6.pdf (BNY) [Nonstandard assay: PH=8] [Different protein in assay: Protein in binding assay is WT] ligand is MNAB,Kd=8.0+/-0.4uM,Ki=2.40+/-0.42uM
6e86   NMR  2018  Kd=8.2uM      // 6e83.pdf (8-mer) Binding assay: microscale thermophoresis; Ligand is peptide H3K4ac; Kd = 8.2+/-2.4uM
6dik  1.93  2018  Kd=8.47uM     // 6dik.pdf (GKP) ligand is compound CA; Kd = 8.47+/-1.26uM
6dq6  1.59  2018  Kd=8.5uM      // 6dq4.pdf (H6J) ligand is compound N44; Kd = 8.5+/-1.7 uM
5ok6  1.30  2018  Kd=8.86uM     // 5ok6.pdf (14-mer) [Different ligand in assay: ] IC50=8.86+/-1.13uM
6e4t  3.40  2018  Kd=8.96nM     // 6e4t.pdf (HTV) ligand is compound 1; Kd = 8.96+/-0.11nM
6b67  2.20  2018  Kd=8.9uM      // 6b67.pdf (7-mer) ligand is MpSIpYVA,Kd = 8.9+/-0.3uM
6hpw  1.90  2018  Kd=807nM      // 6hpw.pdf (GKT) ligand is compound 20
5w7x  2.01  2018  Kd=80uM       // 5w7x.pdf (9-mer) APLF FHA/XRCC1pSpT-9 complex
6hrq  1.85  2018  Kd=81.7nM     // 6hqy.pdf (GM5) ligand is NCC-149; Kd = 81.7 +/- 7.0 nM
5var  1.83  2018  Kd=81.7uM     // 5var.pdf (92Y) Kd = 81.7 +/- 7.1 uM. ligand is compound 1a.
5y8y  1.87  2018  Kd=82nM       // 5y8c.pdf (8PX) ligand is 6i
6beh  3.00  2018  Kd=82uM       // 6beb.pdf (RPT) ligand is compound rifapentin
6agg  2.71  2018  Kd=85uM       // 6agg.pdf (AG2) [Nonstandard assay: Temp 20, PH=7.9] ligand is Agmatine,Kd=85+/-5.7uM
5om2  1.47  2018  Kd=86.7uM     // 5om2.pdf (DXT) ligand is doxycycline, Kd for S-conformation
6ce6  1.60  2018  Kd=8uM        // 6ce6.pdf (EYP) ligand is compound 1
5xhs  2.19  2018  Kd=9.01uM     // 5xhs.pdf (3-mer) [Incomplete ligand] [Nonstandard assay: PH=8.0] ligand is 6b, PHQ-SLL-MCM
5oci  1.62  2018  Kd=9.0nM      // 5lny.pdf (9R8) Kd = 9.0 +/- 3.9 nM. ligand is compound 1g
6chl  2.20  2018  Kd=9.0nM      // 6chl.pdf (EXJ) ligand is compound 3
5yy9  2.65  2018  Kd=9.1nM      // 5yy9.pdf (13-mer) Kd=9.1+/-3.8nM
5ovp  1.50  2018  Kd=9.1uM      // 5ovc.pdf (7-mer) Kd = 9.1 +/- 0.5 uM, ligand is CIRL
6fby  1.50  2018  Kd=9.3uM      // 6fau.pdf (8-mer) [Covalent complex] ligand is 4.2b; Kd = 9.3 +/- 2.0 uM
6emu  2.30  2018  Kd=9.4uM      // 6emu.pdf (SAM) [Different protein in assay: Protein in binding assay is wild type] Kd = 9.4+/-1.2uM
6fmi  2.80  2018  Kd=9.4uM      // 6fmi.pdf (DV2) ligand is compound 2; Kd =  9.4 +/- 0.3 uM
6fii  2.41  2018  Kd=9.5nM      // 6fii.pdf (SG9) Kd = 9.5 +/- 1.9 nM; ligand is spongistatin-1
5oa2  2.15  2018  Kd=9.80uM     // 5o9o.pdf (9PW) Kd = 9.80 +/- 0.07 uM. ligand is compound 8
6gzd  2.28  2018  Kd=9.8nM      // 6gzd.pdf (LCI) ligand is compound A86
6i8b  1.76  2018  Kd=9.9nM      // 6i8b.pdf (H7T) ligand is 35
6eln  1.60  2018  Kd=900nM      // 6ei5.pdf (P4A) ligand is compound 10; Kd = 900+/-17nM
6h41  2.75  2018  Kd=90nM       // 6h41.pdf (18-mer) Kd = 90 +/- 4.5 nM
6cze  2.30  2018  Kd=93uM       // 6cze.pdf (ITT) ligand is Inosine triphosphate; Kd = 93+/-8 uM
6fns  1.85  2018  Kd=93uM       // 6fnq.pdf (DY8) [Different ligand in assay: ligand is racemic] ligand is compound 3; Ki = 93 +/- 11 uM
5win  2.38  2018  Kd=94nM       // 5wij.pdf (SKE) Kd(JNJ7706621)=94+/-1nM
5w4s   NMR  2018  Kd=94uM       // 5w4s.pdf (12-mer) Kd = 94 +/- 3 uM. ligand is pHM
5yhg  2.03  2018  Kd=952.3nM    // 5yh8.pdf (8UX) [Uncommon element] ligand is Staphylopine.containing Zn2+
6bgg   NMR  2018  Kd=95uM       // 6bgg.pdf (12-mer) ligand is peptide CHD4;Kd = 95+/-10uM
6fam  1.13  2018  Kd=97.7uM     // 6fam.pdf (2-mer) [Incomplete ligand] [Different protein in assay: Protein in binding assay is BtGH99, which is closely related to BtGH99.] ligand is compound 1; Kd = 97.7 +/- 4.9 uM;
6bec  2.91  2018  Kd=98uM       // 6beb.pdf (RBT) ligand is compound rifabutin
5y6g  2.30  2018  Kd=99nM       // 5y6f.pdf (C2E) PilZ domain
6bxy  1.82  2018  Kd=9nM        // 6bxy.pdf (EEV) Biolayer interferometry, Kd=9nM
6bmi  3.90  2018  Kd=9uM        // 6bat.pdf (SER) [Nonstandard assay: 100 mM Na+] ligand is serine,Kd=9+/-1uM
6d50  2.50  2018  Kd=9uM        // 6d41.pdf (GCB) Kd = 9+/-2uM
6exi  1.92  2018  Kd=9uM        // 6exi.pdf (ADN) ligand is Ado
6gjy  1.29  2018  Kd>1000uM     // 6gjy.pdf (F1Z) ligand is compound 5
5nw8  2.09  2018  Kd>100uM      // 5nw8.pdf (18-mer)
5ous  2.21  2018  Kd>100uM      // 5ous.pdf (18-mer)
6eh2  1.76  2018  Kd>100uM      // 6eh2.pdf (18-mer) microscale thermophoresis assay
6em6  1.64  2018  Kd>100uM      // 6em6.pdf (18-mer) microscale thermophoresis assay
6bh3  1.70  2018  Kd>12uM       // 6bgu.pdf (DQJ) [Different protein in assay] ligand is compound N55
6evm  2.00  2018  Kd>1500uM     // 6evm.pdf (9-mer) Ligand is peptide (P)9
6gu4  2.73  2018  Kd>20000nM    // 6gu2.pdf (FC8) [Different protein in assay: protein in binding assay is CDK1-CyclinB] Kd>20000 nM; ligand is compound CGP74514A
6fty  1.67  2018  Kd>2000uM     // 6fty.pdf (E7H) ligand is compound 5
6cex  2.57  2018  Kd>20mM       // 6cex.pdf (NHE) ligand is compound NCT
6cf5  2.04  2018  Kd>20mM       // 6cex.pdf (NHE) ligand is compound NCT
5ok3  1.59  2018  Kd>300uM      // 5ok3.pdf (18-mer) peptide 9, MST assay
6fg6  2.40  2018  Kd>400uM      // 6fg6.pdf (D8Q) ligand is compound 1
5oul  1.34  2018  Kd>500uM      // 5oqu.pdf (AWE) ligand is compound 9
5oxm  2.30  2018  Kd>50mM       // 5oxk.pdf (2-mer) Kd > 50 mM, ligand is Asp-Glu
5o5f  1.30  2018  Kd>50uM       // 5mwg.pdf (9LT) ligand is compound 7
6cea  1.60  2018  Kd>720uM      // 6ce6.pdf (EYY) ligand is compound 23
6ew6  1.39  2018  Kd>829uM      // 6ew6.pdf (C0H) ligand is compound 1
5v1d  2.80  2018  Kd~0.2uM      // 5v1d.pdf (12-mer) ligand is P16 peptide
6cvd  1.78  2018  Kd~100uM      // 6cs8.pdf (4ME) ligand is compound fragment1; Kd ~ 100+/-20uM
6drg   NMR  2018  Kd~120nM      // 6drg.pdf (2VN)
5ypp  1.90  2018  Kd~23uM       // 5ypp.pdf (VAL) crystal form 1a
5ypw  2.30  2018  Kd~23uM       // 5ypp.pdf (VAL) crystal form 1b
5ypy  1.97  2018  Kd~23uM       // 5ypp.pdf (VAL) crystal form 1c
5np8  1.90  2018  Kd~24uM       // 5np8.pdf (93T) compound is CRT0063465
5nx9  2.30  2018  Kd~25uM       // 5nx9.pdf (AMP)
6b4h  2.17  2018  Kd~3nM        // 6b4e.pdf (IHP) ligand is IP6
6dlx  1.85  2018  Kd~480uM      // 6cs8.pdf (GXY) ligand is compound fragment1; Kd ~ 480+/-20uM
5w19  2.10  2018  Kd~5uM        // 5w19.pdf (9TD) ligand is OIA
6g33  2.05  2018  Kd~7nM        // 6g33.pdf (5ID) ligand is 5-iTU
6c98  1.85  2018  Kd~80uM       // 6c97.pdf (ER7) [Different ligand in assay: Ligand in binding assay is R/S form] ligand is compound UCB-84
6bw8  2.90  2018  Ki<1.0nM      // 6bw2.pdf (ECM) [Nonstandard assay:] ligand is compound 35;TR-FRET, Ki = 1.6+/-0.10nM in the presence of 1% FBS
6b2p  3.01  2018  Ki<1.3nM      // 6b2p.pdf (CJJ) ligand is compound 38
6c7r  1.50  2018  Ki<1nM        // 6c7q.pdf (EO4) ligand is compound 28
6dh3  1.91  2018  Ki<5pM        // 6dgx.pdf (017) ligand is compound DRV
6dgx  2.00  2018  Ki<5pM        // 6dgx.pdf (017) ligand is compound DRV; same as 6dh3
6dgz  1.99  2018  Ki<5pM        // 6dgx.pdf (A60) ligand is compound UMass6
6dh5  2.01  2018  Ki<5pM        // 6dgx.pdf (A60) ligand is compound UMass6
6dgy  1.95  2018  Ki<5pM        // 6dgx.pdf (K13) ligand is compound UMass1
6dh4  1.94  2018  Ki<5pM        // 6dgx.pdf (K13) ligand is compound UMass1
6e9a  1.22  2018  Ki=0.0012nM   // 6e7j.pdf (J0S) binding assay: Continuous Fluorometric Assay; ligand is compound 4a
6cdj  1.13  2018  Ki=0.002nM    // 6cdj.pdf (GR8) ligand is compound 5d
5xvg  2.10  2018  Ki=0.009uM    // 5xva.pdf (8FX) [Nonstandard assay: Tem 22 C] ligand is compound 31,Ki=0.009uM
6cdl  1.25  2018  Ki=0.012nM    // 6cdj.pdf (GR5) ligand is compound 5c
6h5x  1.80  2018  Ki=0.015nM    // 6h5w.pdf (FT8) ligand is Omapatrilat; Ki = 0.015 +/- 0.001 nM
6h5w  1.37  2018  Ki=0.016nM    // 6h5w.pdf (FT8) ligand is Omapatrilat; Ki = 0.016 +/- 0.004 nM
6dif  1.20  2018  Ki=0.019nM    // 6dif.pdf (TPV) ligand is compound 3
5web  2.25  2018  Ki=0.01uM     // 5w44.pdf (KU5) Ki = 0.01 +/- 0.04 uM, ligand is compound 10e
6gbx  1.72  2018  Ki=0.020uM    // 6gbx.pdf (S77) ligand is SEN177
5w92  2.30  2018  Ki=0.02uM     // 5w44.pdf (KU0) Ki = 0.02 +/- 0.02 uM, ligand is compound 8e
6cn5  2.30  2018  Ki=0.02uM     // 6cn5.pdf (F7M) Ligand is compound 8b
6dj1  1.26  2018  Ki=0.031nM    // 6dif.pdf (AB1) ligand is compound 2
5xva  1.85  2018  Ki=0.051uM    // 5xva.pdf (8FU) [Nonstandard assay: Tem 22 C] ligand is compound 30,Ki=0.051uM
5wb3  2.20  2018  Ki=0.06uM     // 5w44.pdf (GYA) Ki = 0.06 +/- 0.05 uM, ligand is compound 10j
5ykp  1.68  2018  Ki=0.09uM     // 5ykp.pdf (OVA) [Covalent complex] Ki=0.09+/-0.01uM,
6apv  1.99  2018  Ki=0.11uM     // 6aps.pdf (3L4) [Nonstandard assay: pH 8.4] ligand is compound 2,Ki=0.11+/-0.008uM,ligand is wring in PDB.
6bbs  2.00  2018  Ki=0.13nM     // 6bbs.pdf (BZ1) ligand is BZM
6czd  2.40  2018  Ki=0.14mM     // 6czd.pdf (ADP)
6bqh  2.70  2018  Ki=0.16nM     // 6bqg.pdf (E2J) ligand is compound RIT(ritaneserin)
6drz  3.10  2018  Ki=0.16nM     // 6drx.pdf (H8J) Ligand is compound methysergide
6g4z  2.84  2018  Ki=0.17nM     // 6g4y.pdf (ELW) ligand is compound 2f; Ki = 0.17 +/- 0.13 nM
5yr5  1.60  2018  Ki=0.18uM     // 5yr5.pdf (OVA) [Covalent complex] Ki=0.18+/-0.022uM,
6dge  1.91  2018  Ki=0.19uM     // 6dge.pdf (GBG) [Covalent complex] ligand is compound CI-NIL; Ki = 0.19+/-0.04uM
5y0g  1.54  2018  Ki=0.20uM     // 5y0f.pdf (8JL) [Incomplete ligand][Nonstandard assay: Temp 30] ligand is 16do,Ki=0.20+/-0.01uM
6ebe  1.88  2018  Ki=0.20uM     // 6ebe.pdf (J3V) ligand is compound 15; binding assay: Stopped Flow CO2 Hydrase Assay
6eda  1.88  2018  Ki=0.20uM     // 6ebe.pdf (J3V) ligand is compound 15; binding assay: Stopped Flow CO2 Hydrase Assay; same as 6ebe
6dar  1.88  2018  Ki=0.219uM    // 6d9x.pdf (G2J) ligand is compound 4q
5y0f  1.54  2018  Ki=0.21uM     // 5y0f.pdf (8JO) [Incomplete ligand][Nonstandard assay: Temp 30] ligand is 16dk,Ki=0.21+/-0.01uM
6b8y  1.65  2018  Ki=0.22nM     // 6b8y.pdf (D0A) ligand is compound 22,IC50=0.00055uM Ki app =0.22 nM
6aps  1.76  2018  Ki=0.22uM     // 6aps.pdf (SV2) [Nonstandard assay: pH 8.4] ligand is compound 6,Ki=0.22+/-0.03uM
5vja  2.46  2018  Ki=0.260uM    // 5vja.pdf (DUK) ligand is HS38
6ecz  2.21  2018  Ki=0.27uM     // 6ebe.pdf (J4D) ligand is compound 17; binding assay: Stopped Flow CO2 Hydrase Assay
6aqq  2.71  2018  Ki=0.28uM     // 6apw.pdf (BVY) [Different ligand in assay: although the ligand author wrote in literiture is 4c,actual ligand is 5c according to PDB] the ki data of 5c is 0.28+/-0.02uM
6bu3  1.15  2018  Ki=0.28uM     // 6bt6.pdf (3GK) ligand is compound 1; Ki = 0.28+/-0.09uM
5wdw  2.30  2018  Ki=0.29uM     // 5w44.pdf (8KU) Ki = 0.29 +/- 0.05 uM, ligand is compound 10k
6eeh  1.63  2018  Ki=0.29uM     // 6ebe.pdf (J4D) ligand is compound 17; binding assay: Stopped Flow CO2 Hydrase Assay
6e7j  1.30  2018  Ki=0.33nM     // 6e7j.pdf (HWY) binding assay: Continuous Fluorometric Assay; ligand is compound 4e
5w44  2.10  2018  Ki=0.36uM     // 5w44.pdf (GY6) Ki = 0.36 +/- 0.03 uM, ligand is compound 7a
6bc9  1.80  2018  Ki=0.37nM     // 6bbs.pdf (ETS) ligand is DZM
6dry  2.92  2018  Ki=0.37nM     // 6drx.pdf (H8D) Ligand is compound methylergonovine
6eeo  1.72  2018  Ki=0.37uM     // 6ebe.pdf (J6V) ligand is compound 16; binding assay: Stopped Flow CO2 Hydrase Assay
5wfm  2.25  2018  Ki=0.3uM      // 5w44.pdf (KU5) Ki =0.3 +/- 0.5 uM, ligand is compound 9k, protein is E119D
5wap  2.20  2018  Ki=0.3uM      // 5w44.pdf (KU9) Ki = 0.3 +/- 0.1 uM, ligand is compound 10i
5n9n  1.84  2018  Ki=0.41nM     // 5n9k.pdf (8QK) [Incomplete ligand] [Nonstandard assay: Temp 37] Kiapp = 0.41 +/- 0.02 nM, ligand is compound 4a, the ligand ID and structure in PDB is wrong
5wa6  2.25  2018  Ki=0.44uM     // 5wa6.pdf (KU7) Ki(FP)=0.44+/-0.03uM
6h36  1.85  2018  Ki=0.45nM     // 6h2z.pdf (FKE) ligand is compound 7a
5n9k  1.64  2018  Ki=0.46nM     // 5n9k.pdf (8QK) [Nonstandard assay: Temp 37] Kiapp = 0.46 +/- 0.09 nM, ligand is compound 5
5yr4  1.82  2018  Ki=0.46uM     // 5yr4.pdf (TN4) [Covalent complex] Ki=0.46+/-0.04uM,
6got  1.56  2018  Ki=0.4nM      // 6got.pdf (F6W) ligand is compound 5b
5wdc  2.10  2018  Ki=0.4uM      // 5w44.pdf (G2K) Ki = 0.4 +/- 0.2 uM, ligand is compound 9e
5wa7  2.20  2018  Ki=0.4uM      // 5w44.pdf (KU4) Ki = 0.4  +/- 0.2 uM, ligand is compound 9b
6f92  1.90  2018  Ki=0.4uM      // 6f90.pdf (MVL) ligand is Manl
6cbh  2.00  2018  Ki=0.51uM     // 6cb5.pdf (EWJ) ligand is compound 8n
6g3o  2.27  2018  Ki=0.58nM     // 6g3o.pdf (EL8) ligand is compound 37
6hh3  1.82  2018  Ki=0.58uM     // 6g1p.pdf (A1R) Ki = 0.58 +/- 0.12 uM; ligand is compound ADP-HPD
5y12  1.75  2018  Ki=0.59uM     // 5y0f.pdf (8JX) [Nonstandard assay: Temp 30] ligand is 16d,Ki=0.59+/-0.03uM
6h2z  1.94  2018  Ki=0.5nM      // 6h2z.pdf (FKE) ligand is compound 7a
6h34  1.55  2018  Ki=0.5nM      // 6h2z.pdf (FKK) ligand is compound 8b
6c8x  1.61  2018  Ki=0.5pM      // 6c8x.pdf (BVR) [Uncommon element] ligand is compound boronic acid 1; Ki = 0.5 +/- 0.3 pM
5w73  2.20  2018  Ki=0.5uM      // 5w44.pdf (GY9) Ki = 0.5 +/- 0.2 uM, ligand is compound 9f
5ou3  1.60  2018  Ki=0.61uM     // 5ou1.pdf (AUN) [Nonstandard assay: Temp 37] Ki = 0.61 +/- 0.05 uM. ligand is compound 3
5laq  2.40  2018  Ki=0.63nM     // 5g2b.pdf (6M5) pKi = 9.2, ligand is compound NPD-001(1)
6eea  1.63  2018  Ki=0.63uM     // 6ebe.pdf (J3V) ligand is compound 15; binding assay: Stopped Flow CO2 Hydrase Assay
6ays  1.70  2018  Ki=0.65nM     // 6ays.pdf (HT6) kinetic inhibition assay,  Ki=0.65+/-0.17nM (calculated from the time-equilibrated rates)
6apw  2.61  2018  Ki=0.67uM     // 6apw.pdf (BTV) ligand is 5o,Ki=0.67+/-0.06uM
6h33  1.58  2018  Ki=0.6nM      // 6h2z.pdf (FKQ) ligand is compound 7b
6eiz  1.85  2018  Ki=0.6uM      // 6eiz.pdf (FOH) ligand is compound 6; Ki = 0.6+/-0.2uM
5xvf  2.66  2018  Ki=0.710uM    // 5xva.pdf (8FR) [Nonstandard assay: Tem 22 C] ligand is compound 10a,Ki=0.710uM
6aqo  2.64  2018  Ki=0.77uM     // 6aps.pdf (45T) [Nonstandard assay: pH 8.4] ligand is compound 7,Ki=0.77+/-0.06uM
6b4d  1.20  2018  Ki=0.78uM     // 6b4d.pdf (53X) ligand is 1d,Ki=0.78+/-0.009uM
6bvh  1.93  2018  Ki=0.7nM      // 6bvh.pdf (14-mer) binding data cited from other reference
6c7q  1.51  2018  Ki=0.7nM      // 6c7q.pdf (EO1) ligand is compound 12; Ki = 0.7+/-0.3nM
5kw2  2.76  2018  Ki=0.81nM     // 5kw2.pdf (6XQ) ligand is compound 1
5ou1  1.78  2018  Ki=0.86uM     // 5ou1.pdf (AUQ) [Nonstandard assay: Temp 37] Ki = 0.86 +/- 0.03 uM. ligand is compound 1
6apt  1.80  2018  Ki=0.89uM     // 6aps.pdf (45T) [Nonstandard assay: pH 8.4] ligand is compound 7,Ki=0.89+/-0.07uM
5wfw  2.29  2018  Ki=0.8uM      // 5w44.pdf (GYA) Ki = 0.8 +/- 0.4 uM, ligand is compound 10j, protein is E119D
6c4d  2.52  2018  Ki=0.912nM    // 6c3e.pdf (EJP) ligand is compound 22
6b7h  2.82  2018  Ki=0.927nM    // 6b7h.pdf (CWY) ligand is 8p,Ki=0.927+/-0.225nM
6h7l  2.70  2018  Ki=1.07nM     // 6h7l.pdf (Y00) [Incomplete ligand] ligand is dobutamine
6hgz  1.86  2018  Ki=1.08uM     // 6g1p.pdf (AR6) [Different protein in assay: X-ray(Latimeria chalumnae);Ki and IC50(human)] Ki = 1.08 +/- 0.08 uM; ligand is compound ADPr
6f7q  2.60  2018  Ki=1.09nM     // 6f7q.pdf (CWQ) ligand is compound 11; Ki = 1.09 +/- 0.12 nM
6f90  2.40  2018  Ki=1.0uM      // 6f90.pdf (MVL) ligand is Manl
5mgi  1.50  2018  Ki=1.13uM     // 5ll7.pdf (6YV) [Covalent complex] [Uncommon element] [Incomplete ligand] competitive assay, IC50=4.72uM
5y13  1.75  2018  Ki=1.16uM     // 5y0f.pdf (8K0) [Nonstandard assay: Temp 30] ligand is 16c,Ki=1.16+/-0.07uM
6bqg  3.00  2018  Ki=1.17nM     // 6bqg.pdf (ERM) ligand is compound ERG(Ergotamine)
5od1  1.34  2018  Ki=1.1uM      // 5od1.pdf (9RQ) Ki=1.1+/-0.1uM
6bt6  1.05  2018  Ki=1.23uM     // 6bt6.pdf (3GK) ligand is compound 1; Ki = 1.23+/-0.27uM
5owh  2.30  2018  Ki=1.2uM      // 5owh.pdf (B0K) ligand is compound 8b, same as 5owl
5owl  2.23  2018  Ki=1.2uM      // 5owh.pdf (B0K) ligand is compound 8b, the crystallization conditions are different
5z1c  1.45  2018  Ki=1.38mM     // 5z1c.pdf (ZXI) [Nonstandard assay: Temp 37] ligand is IBA,Ki=1.38+/-0.09mM
5nps  1.68  2018  Ki=1.3uM      // 5npr.pdf (9-mer) Ki = 1.3 +/- 0.8 uM. ligand is peptide 1
5yic  1.90  2018  Ki=1.3uM      // 5yia.pdf (8VO) [Nonstandard assay: pH 5.0] ligand is KNI-10333, Ki = 1.3 +/- 0.18 uM
6dpx  1.90  2018  Ki=1.3uM      // 6dpt.pdf (H7G) enzyme inhibition assay
6ayt  1.85  2018  Ki=1.4nM      // 6ays.pdf (4EH) kinetic inhibition assay,  Ki=1.4+/-0.2nM (calculated from the time-equilibrated rates)
5wf3  2.25  2018  Ki=1.4uM      // 5w44.pdf (KU2) Ki =1.4 +/- 0.7 uM, ligand is compound 9k, protein is E119D
6g4y  2.65  2018  Ki=1.5nM      // 6g4y.pdf (ELZ) ligand is compound 1a
5nw7  1.85  2018  Ki=1.7uM      // 5nw7.pdf (9C2) ligand is 5PAHz
6gdg  4.11  2018  Ki=1.8nM      // 6gdg.pdf (NEC) ligand is NECA; Ki = 1.8 +/- 1.2 nM
6dj7  1.31  2018  Ki=1.9nM      // 6dif.pdf (G10) ligand is compound 5; Ki = 1.9+/-0.7nM
5nxp  1.25  2018  Ki=10.2nM     // 5nxg.pdf (9DH) Ki = 10.2 +/- 1.0 nM. ligand is compound 5
6f9r  1.85  2018  Ki=10.6uM     // 6f9r.pdf (D0W) [Covalent complex] ligand is compound SamAsp; Ki = 10.6 +/- 0.3 uM
6dhc  2.85  2018  Ki=10.9nM     // 6dhc.pdf (GHJ) ligand is compound 3a
5l8c  2.01  2018  Ki=100nM      // 5g2b.pdf (908) pKi = 7, ligand is compound NPD-039(9)
5mwy  1.75  2018  Ki=100nM      // 5mwp.pdf (YNU) pKi = 7.0 +/- 0.1, ligand is eplerenone
6eif  2.22  2018  Ki=104nM      // 6eif.pdf (B5T) ligand is compound AC12
5zag  1.95  2018  Ki=108nM      // 5za7.pdf (94I) ligand is compound 25,Ki=108+/-17nM
6en6  1.80  2018  Ki=11.45nM    // 6en6.pdf (BJ2) [Multiple sites: N-domain:Ki=11.45+/-1.37nM; C-domain:Ki=961.02+/-153.00nM] ligand is compound 16; same as 6en5
6cbg  2.00  2018  Ki=113uM      // 6cb5.pdf (EWG) ligand is compound 5
6dh6  1.97  2018  Ki=117.2pM    // 6dgx.pdf (017) ligand is compound DRV; Ki = 117.2+/-5.8 pM
6ej3  1.94  2018  Ki=1179nM     // 6ej2.pdf (B7T) ligand is compound 23; Ki = 1179+/-374nM
6iiu  2.50  2018  Ki=11nM       // 6iiu.pdf (A8X) ligand is Ramatroban; Ki = 11 +/- 4nM
5npr  1.85  2018  Ki=12.5uM     // 5npr.pdf (9-mer) Ki = 12.5 +/- 7 uM. ligand is peptide 6
6dh2  1.98  2018  Ki=12.8pM     // 6dgx.pdf (A60) ligand is compound UMass6; Ki = 12.8+/-3.1 pM
6mvu  1.49  2018  Ki=1290uM     // 6mvu.pdf (K4V) [Different protein in assay: Protein in binding assay is C295A mutant] Ki = 1290 +/- 270 uM; ligand is pNPA
6apu  1.84  2018  Ki=13.46uM    // 6aps.pdf (3L6) [Incomplete ligand] [Nonstandard assay: pH 8.4] ligand is compound 1,Ki=13.46+/-0.83uM,ligand is wrong in PDB
5ny6  1.10  2018  Ki=13.5nM     // 5nxg.pdf (R92) Ki = 13.5 +/- 1.1 nM. ligand is compound 3
6f9t  1.60  2018  Ki=13.8nM     // 6f9r.pdf (D0Z) [Covalent complex] ligand is compound Sampatrilat; Ki = 13.8 +/- 0.2 nM
6dh7  2.00  2018  Ki=131.3pM    // 6dgx.pdf (K13) ligand is compound UMass1; Ki = 131.3+/-8.2 pM
5za7  1.70  2018  Ki=1356nM     // 5za7.pdf (HMX) ligand is compound 5,Ki=1356+/-183nM
5oh3  2.10  2018  Ki=136uM      // 5oh3.pdf (9V2) Ki = 136 +/- 11.6 uM, ligand is Ethosuximide
6ee3  1.82  2018  Ki=137nM      // 6ee3.pdf (J4V) [Different ligand in assay: Ligand in binding assay is R/S form] ligand is compound 6k; Ki=137+/-11nM
5oh9  1.65  2018  Ki=137uM      // 5oh9.pdf (9UT) Ki = 137 +/- 15.9 uM, ligand is Thiazolidine-2,4-dione
5va9  2.55  2018  Ki=14.3nM     // 5va9.pdf (19-mer) Ki=14.3+/-4.2nM
5wf6  2.90  2018  Ki=14.7nM     // 5wf5.pdf (UKA) Ki = 14.7 +/- 0.7 nM. ligand is UK432097
6iiv  3.00  2018  Ki=140nM      // 6iiu.pdf (A90) ligand is Ramatroban; Ki = 140 +/- 24nM
6dh8  1.95  2018  Ki=146.2pM    // 6dgx.pdf (A60) ligand is compound UMass6; Ki = 146.2+/-10.7 pM
6g2m  1.37  2018  Ki=15.1nM     // 6g2m.pdf (O84) ligand is compound 6; Ki = 15.1 +/- 5.6 nM
6h7m  2.76  2018  Ki=15.8nM     // 6h7m.pdf (68H) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is salbutamol
5ylv  2.80  2018  Ki=150nM      // 5ylu.pdf (8WX) [Nonstandard assay: Tem 37] ligand is SCH28080,Ki=150+/-10nM
5wlt  1.57  2018  Ki=155.5nM    // 5wlt.pdf (86B) ligand is compound 23
5zae  1.73  2018  Ki=156nM      // 5za7.pdf (EAU) ligand is compound 22,Ki=156+/-20nM
6ej4  2.88  2018  Ki=158nM      // 6eif.pdf (B7W) ligand is compound AC15
5n9l  1.79  2018  Ki=15nM       // 5n9k.pdf (8QH) [Nonstandard assay: Temp 37]  ligand is compound 4b
5uzj  3.30  2018  Ki=165nM      // 5uzj.pdf (8UV) [Nonstandard assay: Temp 30] ligand is compound 8
5zaf  1.65  2018  Ki=166nM      // 5za7.pdf (28I) ligand is compound 23,Ki=166+/-34nM
6eij  2.42  2018  Ki=1680nM     // 6eif.pdf (B5Z) ligand is compound AC20
6euc  2.22  2018  Ki=168uM      // 6euc.pdf (RM0) reverse inhibition assay, Ki(17)=168+/-23uM
6ewk  2.22  2018  Ki=168uM      // 6euc.pdf (RM0) reverse inhibition assay, Ki(17)=168+/-23uM; redundant to 6euc
6ej2  1.46  2018  Ki=16nM       // 6ej2.pdf (B7E) ligand is compound 28; Ki = 16+/-7.6nM
6f9v  1.69  2018  Ki=171.9nM    // 6f9r.pdf (D0Z) ligand is compound Sampatrilat; Ki = 171.9 +/- 32.2 nM
5nxx  2.20  2018  Ki=17uM       // 5nxx.pdf (3Q7) [Uncommon element] Ki = 17 +/- 2 uM, ligand is Arsenobetaine. uncommon atom is As
5uzk  2.30  2018  Ki=180nM      // 5uzj.pdf (504) ligand is compound 35
5za9  1.62  2018  Ki=183nM      // 5za7.pdf (50I) ligand is compound 18,Ki=183+/-10nM
6g46  2.40  2018  Ki=185uM      // 6g46.pdf (ELH) [Nonstandard assay: pH=4.9] ligand is compound 4f; Ki = 185 +/- 75 uM
6m9t  2.50  2018  Ki=19.9nM     // 6m9t.pdf (J9P) [Multiple sites: site 1(high):Ki=0.02 nM ; site2(low):Ki= 19.9 nM] ligand is misoprostol-FA
6ee2  2.10  2018  Ki=195nM      // 6ee2.pdf (J1V) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 6i; Ki=195+/-11nM
5g5v  1.80  2018  Ki=199nM      // 5g2b.pdf (8Z4) pKi = 6.7, ligand is compound NPD-038(22)
5zkb  2.95  2018  Ki=2.0nM      // 5yc8.pdf (82F) ligand is AF-DX 384, pKi = 8.70 +/- 0.05
6f28  2.40  2018  Ki=2.15uM     // 6f28.pdf (CG8) ligand is compound 5c; Ki = 2.15 +/- 0.10 uM
6hx5  1.44  2018  Ki=2.2uM      // 6hwz.pdf (GXE) [Uncommon element] ligand is compound 2a; Se-containing ligand
5ll7  1.40  2018  Ki=2.43uM     // 5ll7.pdf (6YV) [Covalent complex] [Uncommon element] competitive assay, IC50=10.1uM
5ylu  2.80  2018  Ki=2.4nM      // 5ylu.pdf (HKT) [Nonstandard assay: Temp 37] ligand is Vonoprazan,Ki=2.4+/-2.3nM
6h7j  2.80  2018  Ki=2.4nM      // 6h7j.pdf (5FW) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is isoprenaline
6h29  1.46  2018  Ki=2.4uM      // 6h29.pdf (FK8) ligand is compound 1
6h37  1.90  2018  Ki=2.6nM      // 6h2z.pdf (FKQ) ligand is compound 7b
5wg9  2.30  2018  Ki=2.6uM      // 5w44.pdf (KU4) Ki = 2.6 +/- 1.3 uM, ligand is compound 9b, protein is E119D
6fnr  1.83  2018  Ki=2.6uM      // 6fnq.pdf (DYT) ligand is compound 8; Ki = 2.6 +/- 0.4 uM
5nxg  1.20  2018  Ki=2.8nM      // 5nxg.pdf (RA1) Ki = 2.8 +/- 0.3 nM. ligand is compound 6
6eip  2.56  2018  Ki=2015nM     // 6eif.pdf (B7B) ligand is compound AC23
6ee4  1.58  2018  Ki=202nM      // 6ee4.pdf (J4S) [Different ligand in assay: Ligand in binding assay is R/S form] ligand is compound 6m; Ki=202+/-27nM
6gg4  2.46  2018  Ki=205uM      // 6gg4.pdf (PHE) ligand is PHE
5wxo  1.64  2018  Ki=207uM      // 5wxf.pdf (12-mer) [Nonstandard assay: Temp 37] [Different protein in assay: Protein in binding assay is full length] ligand is upain-2-6-W3A,Ki=207+/-14uM
6ee6  1.50  2018  Ki=216nM      // 6ee6.pdf (J4P) [Different ligand in assay: Ligand in binding assay is R/S form] ligand is compound 6o; Ki=216+/-12nM
5nxi  1.16  2018  Ki=217.4nM    // 5nxg.pdf (9DE) Ki = 217.4 +/- 15.7 nM. ligand is compound 4
6bw2  2.75  2018  Ki=21nM       // 6bw2.pdf (ECY) ligand is compound 28
6cvx  1.78  2018  Ki=21nM       // 6cvw.pdf (FH4) ligand is compound 12c; Ki = 21+/-2.6nM
6fnt  1.90  2018  Ki=21uM       // 6fnq.pdf (AVO) [Different ligand in assay: ] ligand is compound 2; Ki = 21 +/- 3 uM
5wf5  2.60  2018  Ki=22.4nM     // 5wf5.pdf (UKA) Ki = 22.4 +/- 2.5 nM. ligand is UK432097
6eqw  1.99  2018  Ki=22.4pM     // 6eqv.pdf (5-mer) ligand is compound I3
5nzn  1.73  2018  Ki=220000nM   // 5nwe.pdf (G39) Kd = 220000 +/- 4000 nM, ligand is oseltamivir carboxylate
6cjv  1.55  2018  Ki=2200nM     // 6cjv.pdf (G2Y) ligand is Sucralose
6gg5  3.20  2018  Ki=222uM      // 6gg4.pdf (TRP) ligand is TRP
5yum  2.43  2018  Ki=223uM      // 5ypp.pdf (ILE)
6fmp  2.92  2018  Ki=2265nM     // 6fmp.pdf (8-mer) ligand is peptide 1(Ac-Asp-Glu-Glu-Thr-Gly-Glu-Phe-OH)
6djc  1.46  2018  Ki=232.8nM    // 6djc.pdf (CF6) ligand is compound MS645
6eqv  1.90  2018  Ki=238nM      // 6eqv.pdf (5-mer) ligand is compound I2
6fcl  1.50  2018  Ki=23uM       // 6fch.pdf (AMP) ligand is compound AMP; Ki = 23 +/- 6 uM
5wgp  1.53  2018  Ki=2400nM     // 5wg7.pdf (AUD) CA IX (mimic) in complex with Ace K
6dh0  1.90  2018  Ki=25.6pM     // 6dgx.pdf (017) ligand is DRV; Ki=25.6+/-5.6pM
6eis  2.36  2018  Ki=252nM      // 6eif.pdf (B6N) ligand is compound AC27
6fag  1.79  2018  Ki=255.1nM    // 6fag.pdf (EON) in vitro enzyme assay
6ea1  1.82  2018  Ki=257nM      // 6ea1.pdf (J0Y) [Different ligand in assay: Ligand in binding assay is a racemic mixture] ligand is compound 6d-a; Ki=257+/-14nM
6dpz  1.50  2018  Ki=259uM      // 6dpt.pdf (H7D) enzyme inhibition assay
6arj  1.92  2018  Ki=25nM       // 6arj.pdf (BW4) ligand is EZM2302,IC50=6 +/ -3 nM,Ki=25+/-3nM
6dh1  1.97  2018  Ki=26.1pM     // 6dgx.pdf (K13) ligand is compound UMass1; Ki = 26.1+/-3.7 pM
6g22  1.85  2018  Ki=27.7nM     // 6g22.pdf (2O2) [Incomplete ligand] ligand is compound 4; Ki = 27.7 +/- 2.7nM; ligand is not consistent with the descriptions in reference
6f3b  1.40  2018  Ki=273.3nM    // 6f3b.pdf (CJK) ligand is compound 5
6edr  2.40  2018  Ki=28.5uM     // 6edr.pdf (ZNA) ligand is compound S-NAD+; Ki=28.5+/-3.1uM
6eee  2.30  2018  Ki=28.9nM     // 6eee.pdf (J4V) [Different ligand in assay: Ligand in binding assay is R/S form] ligand is compound 6k; Ki=28.9+/-4.4nM
6ea2  1.35  2018  Ki=285nM      // 6ea2.pdf (J1G) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 6h; Ki=285+/-40nM
6aqs  1.57  2018  Ki=28nM       // 6aqs.pdf (IM5) ligand is DADMe-ImmG,Ki=28+/-1nM
5oh4  2.30  2018  Ki=28uM       // 5oh4.pdf (9UZ) Ki = 28 +/- 5.0 uM, ligand is Glutarimide
5yjb  2.96  2018  Ki=29nM       // 5yjb.pdf (8WC) ligand is congpound 1, a reversible LSD1 inhibitor with a Ki of 29 nM
6mi6  2.95  2018  Ki=29uM       // 6mi6.pdf (JSJ) Ligand is compond ADP-beta-S-SL; Ki = 29 +/- 6 uM
5wlv  1.40  2018  Ki=3.0nM      // 5wlt.pdf (42G) ligand is compound 12
5yia  2.00  2018  Ki=3.0uM      // 5yia.pdf (8V9) ligand is KNI-10343, Ki = 3.0 +/- 0.33 uM
6f29  2.60  2018  Ki=3.25uM     // 6f28.pdf (CGW) ligand is compound 2; ki = 3.25 +/- 0.30 uM
5v6y  2.80  2018  Ki=3.39nM     // 5v6y.pdf (16-mer) pKi = 8.47 +/- 0.21. ligand is S45W/K46L/Q50W/Y52F (AMmut)
5yib  2.15  2018  Ki=3.3uM      // 5yia.pdf (8VC) [Nonstandard assay: pH 5.0] ligand is KNI-10743, Ki = 3.3 +/- 0.35 uM
5nxv  1.10  2018  Ki=3.5nM      // 5nxg.pdf (9E2) Ki = 3.5 +/- 0.3 nM. ligand is compound 7
6d1u  2.05  2018  Ki=3.63uM     // 6d1u.pdf (20-mer) ligand is peptide AM2/IMD(29-47), peptide sequence is GPAGRQDSAPVDPSSPHSY; pKi = 5.44+/-0.06
6buu  2.40  2018  Ki=3.6uM      // 6buu.pdf (10-mer) Ligand is peptide GRPRTTSFAE
6cvy  1.80  2018  Ki=3.9nM      // 6cvw.pdf (FHD) ligand is compound 12d; Ki = 3.9+/-0.7nM
6flg  2.50  2018  Ki=30.1nM     // 6fky.pdf (8-mer) ligand is compound 33.2; Ki = 30.1 +/- 6.1 nM
6faf  1.99  2018  Ki=306.1nM    // 6f3b.pdf (D3B) ligand is compound 15
5mwp  1.82  2018  Ki=31.6nM     // 5mwp.pdf (ECV) pKi = 7.5 +/- 0.1, ligand is AZD9977
6fky  2.98  2018  Ki=320nM      // 6fky.pdf (8-mer) [Different ligand in assay: compound 15 is a diastereomer; compound 15.1:Ki = 320nM; compound 15.2: Ki=170 nM] ligand is compound 15
6d9x  1.83  2018  Ki=323uM      // 6d9x.pdf (FZM) ligand is compound F-1
6dne  2.96  2018  Ki=33.3nM     // 6djc.pdf (H1V) ligand is compound MS660
6eqx  1.99  2018  Ki=33.7pM     // 6eqv.pdf (6-mer) ligand is compound I1
5ny3  1.40  2018  Ki=33.9nM     // 5nxg.pdf (9E8) Ki = 33.9 +/- 2.7 nM. ligand is compound 9
5wxf  1.46  2018  Ki=33uM       // 5wxf.pdf (12-mer) [Nonstandard assay: Temp 37] [Different protein in assay: Protein in binding assay is full length] ligand is upain-2-6,Ki=33+/-10uM
6c5f  1.40  2018  Ki=33uM       // 6c5f.pdf (7L9) ligand is 4-CPPC; Ki = 33+/-0.7uM
6c7w  1.28  2018  Ki=3410nM     // 6c7w.pdf (LMS) ligand is compound 1
6f05  2.20  2018  Ki=34uM       // 6ezy.pdf (GTS) ligand is GSO3
6ceh  1.43  2018  Ki=36.5nM     // 6ceh.pdf (EZ1) ligand is compound 5e; Binding assay:Stopped flow CO2 hydrase assay
6exs  2.50  2018  Ki=362uM      // 6exs.pdf (C3H) IC50 = 362 +/- 21.8 uM
5ny1  1.10  2018  Ki=366.7nM    // 5nxg.pdf (9E5) Ki = 366.7 +/- 46.5 nM. ligand is compound 10
6eiq  2.30  2018  Ki=383nM      // 6eif.pdf (B6Z) ligand is compound AC24
5l8y  2.14  2018  Ki=398nM      // 5g2b.pdf (CVA) pKi = 6.4, ligand is compound NPD-937(16)
5oh1  1.70  2018  Ki=39uM       // 5oh1.pdf (9UQ) [Different ligand in assay: ligand in binding assay is DL-aminoglutethimide] Ki = 39 +/- 3.8, ligand is Aminoglutethimide
6c1s  2.31  2018  Ki=3nM        // 6c1s.pdf (EFV) ligand is compound 6
5yid  2.10  2018  Ki=4.0uM      // 5yia.pdf (K95) ligand is KNI-10395, Ki = 4.0 +/- 0.29 uM
6ayr  1.95  2018  Ki=4.1nM      // 6ayo.pdf (BIG) ligand is BTDIA,Ki=4.1+/-1.0nM,Ki*=0.75+/-0.20nM
6cb5  1.78  2018  Ki=4.3uM      // 6cb5.pdf (EV7) ligand is compound 8g
5yr6  1.75  2018  Ki=4.57uM     // 5yr6.pdf (TN4) Ki=4.57+/-0.34uM,
6das  1.80  2018  Ki=4.94nM     // 6d9x.pdf (G2D) ligand is compound 6b; Ki = 4.94+/-0.79nM
5nxo  1.20  2018  Ki=4.9nM      // 5nxg.pdf (9HK) Ki = 4.9 +/- 0.6 nM. ligand is compound 2
5nya  1.20  2018  Ki=415.6nM    // 5nxg.pdf (FB2) Ki = 415.6 +/- 56.5 nM. ligand is compound 1
6m8y  1.10  2018  Ki=415nM      // 1kdy.pdf (4-mer) covalent complex
5zaj  1.65  2018  Ki=42nM       // 5za7.pdf (32I) ligand is compound 27,Ki=42+/-2nM
6eab  1.85  2018  Ki=431nM      // 6eab.pdf (J2D) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 6j; Ki=431+/-10nM
5oh7  1.85  2018  Ki=43uM       // 5oh7.pdf (HYN) Ki = 43 +/- 10.7 uM, ligand is Hydantoin
5wxp  1.75  2018  Ki=443uM      // 5wxf.pdf (4-mer) [Incomplete ligand] [Nonstandard assay: Temp 37] [Different protein in assay: Protein in binding assay is full length] ligand is upain-2-12-W3A,Ki=443+/-51uM
6m9d  2.00  2018  Ki=45nM       // 1ke2.pdf (3-mer) covalent complex; incomplete ligand structure
6ex1  1.60  2018  Ki=49.4nM     // 6evr.pdf (N19) ligand is compound (S)-12; Ki(hCA IX) = 83.7nM
6ayo  1.67  2018  Ki=5.1nM      // 6ayo.pdf (C1Y) ligand is PDIA,Ki=5.1+/-0.6nM,Ki*=1.4+/-0.1nM. Ki = determined from the initial rates
5yie  2.10  2018  Ki=5.6uM      // 5yia.pdf (8VF) ligand is KNI-10343, Ki = 5.6 +/- 0.60 uM
6isd  2.40  2018  Ki=5.79nM     // 6isd.pdf (5BQ) ligand is sulcotrione
5za8  1.90  2018  Ki=508nM      // 5za7.pdf (27I) ligand is compound 14,Ki=508+/-9nM
6dm8  2.70  2018  Ki=52nM       // 6dm8.pdf (6AK) ligand is compound 2; Ki = 52+/- 9nM
5zah  2.98  2018  Ki=53nM       // 5za7.pdf (30I) ligand is compound 26,Ki=53+/-5nM
6hh5  1.95  2018  Ki=54.2uM     // 6g1p.pdf (A3R) Ki = 54.2 +/- 4uM; ligand is compound ADP-HPM
6m9c  1.80  2018  Ki=56nM       // 1ke1.pdf (3-mer) covalent complex
5nxw  1.10  2018  Ki=57.4nM     // 5nxg.pdf (RA9) Ki = 57.4 +/- 7.7 nM. ligand is compound 8
6g3q  1.01  2018  Ki=57.9nM     // 6g3q.pdf (FO9) ligand is famotidine
6eir  2.40  2018  Ki=575nM      // 6eif.pdf (B6H) ligand is compound AC25
5oh2  1.90  2018  Ki=57uM       // 5oh2.pdf (BAQ) Ki = 57 +/-11.6, ligand is gamma-Butyrolactam
5v3r  1.91  2018  Ki=5uM        // 5v3r.pdf (18-mer) Ki = 5 +/- 1 uM. ligand is peptide CHMP4CA232
6d2o  1.90  2018  Ki=5uM        // 6d2o.pdf (4MZ) ligand is compound 4MI; An Applied Photophysics stopped-flow instrument was used for binding assay
5oje  1.58  2018  Ki=6.1uM      // 5oje.pdf (VSK) Ki = 6.1 +/- 0.4 uM. ligand is compound (S)-2
6d1m  1.21  2018  Ki=6.3nM      // 6d1l.pdf (FQY) ligand is compound 3f
6ar9  2.28  2018  Ki=6.54uM     // 6aps.pdf (3L4) ligand is compound 2,Ki=6.54+/-0.2uM
6ayq  1.42  2018  Ki=6.5nM      // 6ayo.pdf (TDI) ligand is MTDIA,Ki=6.5+/-0.6nM,Ki*=2.9+/-0.1nM. Ki = determined from the initial rates
6hwz  1.64  2018  Ki=6.7uM      // 6hwz.pdf (GXE) [Uncommon element] ligand is compound 2a; Se-containing ligand
5z5f  2.10  2018  Ki=6.8mM      // 5z5f.pdf (FUB) ligand is arabinose,Ki=6.8+/-0.6mM
6cbf  2.30  2018  Ki=6.8uM      // 6cb5.pdf (EWD) ligand is compound 8a
6m8w  1.10  2018  Ki=600nM      // 1kdv.pdf (4-mer) covalent complex
5ou2  1.45  2018  Ki=609uM      // 5ou1.pdf (36Y) [Nonstandard assay: Temp 37] Ki = 609 +/- 3 uM. ligand is compound 2
5tig  2.70  2018  Ki=60uM       // 5tig.pdf (7DH) Ki = 60 +/- 10 uM, ligand is compound 9
6c3e  2.60  2018  Ki=63.1nM     // 6c3e.pdf (EJY) ligand is compound 10
6c7x  1.50  2018  Ki=65.2nM     // 6c7w.pdf (EO7) ligand is compound 2
5wa1  1.87  2018  Ki=67uM       // 5v3r.pdf (18-mer) Ki = 67 +/- 13 uM. ligand is peptide CHMP4CT232
5wdl  2.63  2018  Ki=683nM      // 5wdk.pdf (R33) [Covalent complex] Ki(GR-AOMK)=683+/-36nM
6g2l  1.48  2018  Ki=68nM       // 6g2l.pdf (EJ8) ligand is compound 5; Ki=68+/-22nM
6m9f  1.30  2018  Ki=6nM        // 1kdz.pdf (4-mer) covalent complex
6cvw  1.78  2018  Ki=7.1nM      // 6cvw.pdf (FH1) ligand is compound 12b; Ki=7.1+/-1.1nM
6b95  1.95  2018  Ki=7.1uM      // 6b8z.pdf (D0P) [Covalent complex] [Incomplete ligand] ligand is compound 2, Ki=7.1+/-1.1uM
6dak  1.60  2018  Ki=7.21uM     // 6d9x.pdf (G1Y) ligand is compound 4a
6dj5  1.75  2018  Ki=7.2nM      // 6dif.pdf (G52) ligand is compound 4; Ki=7.2+/-1.4nM
6f9u  1.90  2018  Ki=7.4uM      // 6f9r.pdf (D0W) ligand is compound SamAsp; Ki = 7.4 +/- 0.3 uM
6d1l  1.40  2018  Ki=7.6nM      // 6d1l.pdf (FQV) ligand is compound 3e
6dj2  1.36  2018  Ki=7.6nM      // 6dif.pdf (AB1) ligand is compound 3; Ki = 7.6+/-0.3nM
6dil  1.48  2018  Ki=7.6nM      // 6dif.pdf (TPV) ligand is compound 3; Ki = 7.6+/-0.3nM
5y0x  1.60  2018  Ki=7.75uM     // 5y0f.pdf (8JR) [Incomplete ligand][Nonstandard assay: Temp 30] ligand is 16di,Ki=7.75+/-0.09uM
6h38  1.70  2018  Ki=7.8nM      // 6h2z.pdf (FKK) ligand is compound 8b
6g2n  1.40  2018  Ki=72.0nM     // 6g2n.pdf (O84) ligand is compound 6; Ki = 72.0 +/- 6.4nM
6dpt  1.79  2018  Ki=77nM       // 6dpt.pdf (H7M) enzyme inhibition assay
6b59  1.64  2018  Ki=8.2nM      // 6b59.pdf (CQS) ligand is compound 29
6evr  1.50  2018  Ki=8.8nM      // 6evr.pdf (BZW) ligand is compound (S)-17; Ki(hCA IX) = 104nM
6dpy  1.91  2018  Ki=80uM       // 6dpt.pdf (H7A) enzyme inhibition assay
6eed  1.50  2018  Ki=812nM      // 6eed.pdf (J6A) ligand is compound 6o; Ki=812+/-64nM
6eaa  1.65  2018  Ki=818nM      // 6eaa.pdf (J1V) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 6i; Ki=818+/-45nM
6dai  1.63  2018  Ki=85.2uM     // 6d9x.pdf (G2V) ligand is compound 3h
5zc5  1.90  2018  Ki=88nM       // 5za7.pdf (09I) ligand is compound 19,Ki=88+/-33nM
6c0s  2.35  2018  Ki=89nM       // 6c0s.pdf (EEJ) ligand is compound 17
6fkz  3.30  2018  Ki=900nM      // 6fky.pdf (8-mer) [Different ligand in assay: compound 2 is a diastereomer; compound 2.1:Ki = 900nM; compound 2.2: Ki=135 nM] ligand is compound 2
6g3v  1.69  2018  Ki=922.4nM    // 6g3q.pdf (FO9) ligand is famotidine
5nzf  1.75  2018  Ki=94000nM    // 5nwe.pdf (G39) Ki = 94000 +/- 7000 nM, ligand is oseltamivir carboxylate
6b2q  2.88  2018  Ki=9nM        // 6b2p.pdf (CJJ) ligand is compound 38
5nxy  1.90  2018  Ki=9uM        // 5nxx.pdf (1Y8) [Uncommon element] Ki = 9 +/- 2 uM, ligand is Arsenocholine. uncommon atom is As
5wg7  1.45  2018  Ki>20000nM    // 5wg7.pdf (AUD) CA II in complex with Ace K
6eil  2.47  2018  Ki>2800nM     // 6eif.pdf (B6B) ligand is compound AC22
6b0v  1.29  2018  Ki>320uM      // 6b0v.pdf (C8G) [Covalent complex] [Incomplete ligand] ligand is ARS-107
6b0y  1.43  2018  Ki>64uM       // 6b0v.pdf (8ZG) [Covalent complex] [Incomplete ligand] ligand is ARS-917
6oi8  2.50  2019  IC50<15nM     // 6oi8.pdf (MQV) ligand is compound 14a
6hrp  1.12  2019  IC50<1nM      // 6hrp.pdf (GMQ) ligand is compound 2
6hrt  1.36  2019  IC50<1nM      // 6hrp.pdf (GMW) ligand is compound 3
6e3n  3.19  2019  IC50<2nM      // 6e3m.pdf (HNS) ligand is compound 7
6e3o  3.19  2019  IC50<2nM      // 6e3m.pdf (HNY) ligand is compound 13
6e3p  2.80  2019  IC50<2nM      // 6e3m.pdf (HO1) ligand is compound 20
6pz4  1.85  2019  IC50=0.0004uM  // 6pz4.pdf (P6J) ligand is compound 20(AM-6494)
6n6o  2.60  2019  IC50=0.0007uM  // 6n6o.pdf (KE7) ligand is compound 20
6nzf  2.39  2019  IC50=0.00092uM  // 6nze.pdf (L91) ligand is compound 23; IC50 = 0.00092 +/- 0.0004 uM; Binding assay is HTRF
6nze  1.96  2019  IC50=0.0013uM  // 6nze.pdf (L8Y) ligand is compound 5; IC50 = 0.0013 +/- 0.0005 uM; Binding assay is HTRF
6nzh  2.73  2019  IC50=0.0016uM  // 6nze.pdf (L9A) ligand is compound 40; IC50 = 0.0013 +/- 0.0007 uM; Binding assay is HTRF
6nzm  1.72  2019  IC50=0.001uM  // 6nzm.pdf (L9S) ligand is compound 50
6ocz  2.65  2019  IC50=0.003uM  // 6ocw.pdf (M6Y) ligand is compound A86; IC50 = 0.003 +/- 0.001 uM
6rfj  2.61  2019  IC50=0.004uM  // 6rfi.pdf (K1E) ligand is compound 13
6gva  2.15  2019  IC50=0.006uM  // 6gva.pdf (FCQ) ligand is 4.35; with a fragment of cyclin A2
6ocw  2.60  2019  IC50=0.007uM  // 6ocw.pdf (M6M) ligand is compound A85; IC50 = 0.007 +/- 0.003 uM
6ode  2.90  2019  IC50=0.008uM  // 6ocw.pdf (M9G) ligand is compound B6; IC50 = 0.008 +/- 0.002 uM
6mjw  2.41  2019  IC50=0.0102uM  // 6mju.pdf (JUJ) ligand is G150
6mck  3.77  2019  IC50=0.012uM  // 6mck.pdf (JDP) [Different protein in assay: Protein in binding assay is a truncation of p97 containing only D1 and D2 domains.] ligand is CB-5083
6qmr  2.00  2019  IC50=0.012uM  // 6qmr.pdf (J6T) ligand is compound 12; Binding assay is TR-FRET
6r0k  1.15  2019  IC50=0.012uM  // 6r0k.pdf (JNN) ligand is compound SS-208; IC50 = 0.012 +/- 0.002 uM
6s90  1.82  2019  IC50=0.013uM  // 6s90.pdf (L0Z) ligand is compound 3
6plg  2.93  2019  IC50=0.015uM  // 6plf.pdf (ONS) ligand is compound 15
6oir  2.03  2019  IC50=0.017uM  // 6oin.pdf (MNJ) [Nonstandard assay: Concentration of Ac-CoA is 0.4uM;] ligand is compound 62
6sfj  1.95  2019  IC50=0.018uM  // 6sfi.pdf (LBB) ligand is compound 77
6g9s  2.00  2019  IC50=0.01uM   // 6g9f.pdf (ET5) ligand is CPD4
6oqn  1.70  2019  IC50=0.01uM   // 6o6f.pdf (N0P) ligand is compound 7
6rmf  1.51  2019  IC50=0.01uM   // 6rmf.pdf (K9B) [Uncommon element] ligand is VNRX-5133, two different forms; contain B element
6uwv  1.47  2019  IC50=0.01uM   // 6uvp.pdf (QK7) ligand is compound 34
6k1s  2.60  2019  IC50=0.020uM  // 6k1s.pdf (CUX) [Covalent complex] ligand is 10
6nzg  2.43  2019  IC50=0.020uM  // 6nzg.pdf (L9D) [Covalent complex] ligand is compound 2; Covalently bound
6h4z  2.30  2019  IC50=0.023uM  // 6h4o.pdf (FQ5) ligand is 16a
6ncj  2.00  2019  IC50=0.024uM  // 6ncj.pdf (KJJ) ligand is 24
6sfi  1.60  2019  IC50=0.026uM  // 6sfi.pdf (LB5) ligand is compound 75
6mju  2.45  2019  IC50=0.0275uM  // 6mju.pdf (JUM) ligand is G108
6uwp  1.29  2019  IC50=0.028uM  // 6uvp.pdf (QKA) ligand is compound 32
6mdc  2.14  2019  IC50=0.036uM  // 6mdc.pdf (JEA) ligand is 1
6rfi  2.31  2019  IC50=0.037uM  // 6rfi.pdf (K1H) ligand is compound 4
6h4s  2.45  2019  IC50=0.038uM  // 6h4o.pdf (FQE) ligand is 16m
6ul8  2.68  2019  IC50=0.03uM   // 6sze.pdf (Q9J) ligand is compound 11
6n0q  2.04  2019  IC50=0.04uM   // 6n0p.pdf (K7S) ligand is 10
6o6f  1.60  2019  IC50=0.04uM   // 6o6f.pdf (LOD) ligand is compound 5
6hkn  2.33  2019  IC50=0.051uM  // 6hkm.pdf (G9E) ligand is 35
6mhd  2.16  2019  IC50=0.051uM  // 6mhb.pdf (JRD) [Covalent complex] ligand is 44
6mt0  2.20  2019  IC50=0.05nM   // 6mt0.pdf (JYG) ligand is 28
6hro  2.30  2019  IC50=0.05uM   // 6hro.pdf (GKZ) ligand is 118a
6qeg  2.08  2019  IC50=0.05uM   // 6qeg.pdf (K4K) ligand is compound S-11a; IC50 = 0.05+/-0.006 uM
6mdb  2.34  2019  IC50=0.067uM  // 6md7.pdf (JE4) ligand is 3
6h52  2.14  2019  IC50=0.068uM  // 6h4o.pdf (FQN) ligand is 34g
6akw  2.20  2019  IC50=0.06uM   // 6akw.pdf (8S3) HPLC-based assay, IC50(FB23)=0.06+/-0.04uM
6qef  1.79  2019  IC50=0.06uM   // 6qef.pdf (HZW) ligand is compound 11r; IC50 = 0.06+/-0.006uM
6sfk  1.80  2019  IC50=0.071uM  // 6sfi.pdf (LB8) ligand is compound 81
6qed  1.80  2019  IC50=0.074uM  // 6qed.pdf (HZK) ligand is compound 21
6h4y  2.38  2019  IC50=0.077uM  // 6h4o.pdf (FO8) ligand is 17e
6hgx  2.16  2019  IC50=0.077uM  // 6hgv.pdf (G3T) ligand is Morpholino-Talinolol
6r8r  1.27  2019  IC50=0.085uM  // 6r8p.pdf (JV8) ligand is compound 45
6qfe  1.67  2019  IC50=0.08uM   // 6qfe.pdf (J08) ligand is GSK144
6k9u  2.35  2019  IC50=0.090nM  // 6k9u.pdf (D4L) ligand is 3g
6h4r  2.14  2019  IC50=0.093uM  // 6h4o.pdf (FQB) ligand is 17f
6st3  2.43  2019  IC50=0.094uM  // 6st3.pdf (LUW) [Nonstandard assay: With HIF-1 alpha NODD substrates] ligand is compound 8; IC50 = 0.094 +/- 0.042 uM
6oim  1.65  2019  IC50=0.09uM   // 6oim.pdf (MOV) [Covalent complex] ligand is compound AMG 510; covalent complex
6h4t  2.38  2019  IC50=0.100uM  // 6h4o.pdf (FOW) ligand is 19a
6pgp  1.50  2019  IC50=0.101uM  // 6pgo.pdf (OHY) [Covalent complex] ligand is compound 9; covalently bound
6h4p  2.19  2019  IC50=0.102uM  // 6h4o.pdf (FQ5) ligand is 16a
6h4w  2.81  2019  IC50=0.107uM  // 6h4o.pdf (FQQ) ligand is 19d
6o8i  1.42  2019  IC50=0.10nM   // 6o8i.pdf (LTJ) Ligand is compound 5a;IC50 = 0.10+/-0.05nM
6q96  1.80  2019  IC50=0.10nM   // 6q96.pdf (HRE) ligand is compound 12; Binding assay is TR-FRET
6tel  2.19  2019  IC50=0.11nM   // 6te6.pdf (N4Z) ligand is compound 10
6qmt  1.80  2019  IC50=0.120uM  // 6qmr.pdf (J7B) ligand is compound 3; Binding assay is TR-FRET
6h4o  2.25  2019  IC50=0.128uM  // 6h4o.pdf (FQH) ligand is 18a
6d4t  1.54  2019  IC50=0.12uM   // 6d4q.pdf (FWS) ligand is 45; IC50=0.12+/-0.02uM
6oip  1.80  2019  IC50=0.12uM   // 6oin.pdf (MLS) [Nonstandard assay: Concentration of Ac-CoA is 0.4uM;] ligand is compound 34
6r8q  1.50  2019  IC50=0.12uM   // 6r8p.pdf (JV5) ligand is compound 39
6h4x  2.34  2019  IC50=0.131uM  // 6h4o.pdf (FNQ) ligand is 17b
6h51  2.21  2019  IC50=0.134uM  // 6h4o.pdf (FQK) ligand is 34f
6hcw  1.46  2019  IC50=0.13uM   // 6agt.pdf (FYB) ligand is compound 5, kinase-glo assay
6rrm  1.64  2019  IC50=0.143uM  // 6rrm.pdf (9JT) [Covalent complex] ligand is ebselen; IC50 = 0.143 +/- 0.014 uM
6p3p  1.61  2019  IC50=0.145uM  // 6p3p.pdf (NQJ) ligand is compound 65; Binding assay is FP
6q7w  2.82  2019  IC50=0.14uM   // 6q7u.pdf (HLQ) ligand is compound 20; IC50 = 0.14 +/- 0.04 uM
6h50  2.19  2019  IC50=0.156uM  // 6h4o.pdf (FO2) ligand is 34a
6npv  1.86  2019  IC50=0.16uM   // 6npe.pdf (KWP) ligand is compound 51
6qm7  2.80  2019  IC50=0.16uM   // 6qm7.pdf (J6E) [Different protein in assay: Protein in binding assay is from L.donovani] ligand is compound 8; IC50 = 0.16+/-0.01uM
6ten  2.21  2019  IC50=0.17nM   // 6te6.pdf (N5K) ligand is compound 11
6h0u  2.30  2019  IC50=0.17uM   // 6h0u.pdf (FKB) [Covalent complex] [Incomplete ligand] ligand is 12
6mhb  2.75  2019  IC50=0.17uM   // 6mhb.pdf (JR7) [Covalent complex] ligand is 18
6md7  1.96  2019  IC50=0.181uM  // 6md7.pdf (JE1) ligand is compound 7
6oko  2.10  2019  IC50=0.18uM   // 6oko.pdf (1FN) ligand is compound 9; Binding assay is HTRF
6rj2  2.00  2019  IC50=0.1uM    // 6rih.pdf (K52) ligand is compound 40
6t6a  2.80  2019  IC50=0.20uM   // 6t6a.pdf (MLW) ligand is compound 11
6mo2  2.80  2019  IC50=0.21uM   // 6mo0.pdf (JVM) ligand is compound 5
6k4x  1.17  2019  IC50=0.22uM   // 6k4t.pdf (D0U) ligand is ASB
6p14  1.93  2019  IC50=0.22uM   // 6p10.pdf (NKY) ligand is compound 4
6rtn  2.17  2019  IC50=0.234uM  // 6rmf.pdf (KJK) [Uncommon element] ligand is VNRX-5133, bicyclic form; Binding assay is fluorogenic assay
6d4v  2.02  2019  IC50=0.23uM   // 6d4q.pdf (FWM) IC50(compound 22)=0.23+/-0.02uM
6ind  1.87  2019  IC50=0.24uM   // 6im6.pdf (AKO) ligand is compound 16
6imt  1.48  2019  IC50=0.25uM   // 6im6.pdf (AK0) ligand is compound 15
6sal  1.61  2019  IC50=0.264uM  // 6sal.pdf (L3E) ligand is compound 25 (allosteric ligand FM26)
6duk  2.20  2019  IC50=0.26nM   // 6duk.pdf (JBJ) compound is JBJ-04-125-02, HTRF assay
6hkm  2.47  2019  IC50=0.27uM   // 6hkm.pdf (G92) ligand is 1
6ink  1.70  2019  IC50=0.27uM   // 6im6.pdf (AKU) ligand is 2
6oiq  1.75  2019  IC50=0.27uM   // 6oin.pdf (MLV) [Nonstandard assay: Concentration of Ac-CoA is 0.4uM;] ligand is compound 63
6te6  1.98  2019  IC50=0.27uM   // 6te6.pdf (N4W) ligand is compound 3
6mo1  3.00  2019  IC50=0.29uM   // 6mo0.pdf (I16) ligand is 8
6oio  1.70  2019  IC50=0.29uM   // 6oin.pdf (ML7) [Nonstandard assay: Concentration of Ac-CoA is 0.4uM;] ligand is compound 60
6nzp  2.35  2019  IC50=0.2nM    // 6nzp.pdf (LB7) ligand is compound 11; Binding assay is HTRF
6p5v  1.40  2019  IC50=0.2uM    // 6p5v.pdf (O37) ligand is compound 27; IC50 = 0.2 +/- 0.1 uM
6hx1  2.14  2019  IC50=0.303uM  // 6hv0.pdf (GXK) [Multiple sites: ] ligand is 2; site 2(ATP-site): IC50 = 1.60 +/- 0.91  uM; site 3(RNase activity): IC50 = 8.9 +/- 0.21 uM
6j6m  1.25  2019  IC50=0.30nM   // 6j6m.pdf (BA0) [Covalent complex] ligand is 31a
6ilz  3.26  2019  IC50=0.34uM   // 6ilz.pdf (AFU) ligand is 19
6mhc  2.00  2019  IC50=0.37uM   // 6mhb.pdf (JRM) [Covalent complex] ligand is 37
6mo5  1.85  2019  IC50=0.3nM    // 6mo4.pdf (JWP) ligand is 19
6nzq  2.11  2019  IC50=0.3nM    // 6nzp.pdf (LB4) ligand is compound 29; Binding assay is HTRF
6o6g  2.40  2019  IC50=0.3uM    // 6o6f.pdf (LOJ) ligand is compound 4
6ovc   NMR  2019  IC50=0.3uM    // 6o6f.pdf (N8J) ligand is compound 6
6rj5  1.89  2019  IC50=0.3uM    // 6rih.pdf (K5N) ligand is compound 39
6rni  1.54  2019  IC50=0.40nM   // 6rn6.pdf (KAQ) ligand is compound 10; pIC50 = 9.4
6suo  1.74  2019  IC50=0.40nM   // 6sq0.pdf (LVH) ligand is compound 6; pIC50 = 9.4
6npu  2.33  2019  IC50=0.40uM   // 6npe.pdf (KWV) ligand is compound 29
6bqd  2.14  2019  IC50=0.41uM   // 6bik.pdf (69G) compound 4
6ohd  2.50  2019  IC50=0.42nM   // 6ohd.pdf (MKP) ligand is compound 25, T-3220137
6iji  2.70  2019  IC50=0.44nM   // 6ijh.pdf (AEL) ligand is 2b
6ilq  2.41  2019  IC50=0.44uM   // 6ilq.pdf (AE0) ligand is 2
6aa4  1.90  2019  IC50=0.47uM   // 6aa4.pdf (MKS) IC50(alpha-mangostin)=0.47+/-0.033uM
6eb2  2.49  2019  IC50=0.48uM   // 6eb1.pdf (J3P) LEDGF/p75 Independent Integration Assays, IC50(6l)=0.48+/-0.01uM
6oa3  1.90  2019  IC50=0.4uM    // 6o9x.pdf (M0M) ligand is JA2131
6rj3  1.42  2019  IC50=0.4uM    // 6rih.pdf (K58) ligand is compound 15
6fe5  1.52  2019  IC50=0.50nM   // 6ety.pdf (D6E) [Different protein in assay: E424M inactive mutant] IC50(ZJ-43)=0.50+/-0.11nM
6npe  2.15  2019  IC50=0.50uM   // 6npe.pdf (KWD) ligand is compound 6; pIC50=6.3
6qhb  1.84  2019  IC50=0.50uM   // 6qh9.pdf (J2W) [Different protein in assay: Protein KLK5/KLK1 was used in binding assay;But all structures were based on KLK6] Ligand is compound 5
6inm  2.00  2019  IC50=0.51uM   // 6im6.pdf (AKU) ligand is 1
6n83  2.00  2019  IC50=0.54uM   // 6n7y.pdf (YL6) ligand is (R)-6g
6qs5  1.96  2019  IC50=0.57uM   // 4dgm.pdf (JGB) IC50=0.57+/-0.08uM
6g9f  2.35  2019  IC50=0.59uM   // 6g9f.pdf (NXL) avibactam
6mo0  2.70  2019  IC50=0.59uM   // 6mo0.pdf (JVJ) ligand is 9
6nzr  2.56  2019  IC50=0.5nM    // 6nzp.pdf (LAJ) ligand is compound 12; IC50 = 0.3 +/- 0.2 nM; Binding assay is HTRF
6h4v  2.15  2019  IC50=0.613uM  // 6h4o.pdf (FQN) ligand is 34g
6p8y  2.31  2019  IC50=0.638uM  // 6p8w.pdf (O5Y) [Covalent complex] ligand is compound 6; covalently bound
5z1t  1.42  2019  IC50=0.63uM   // 5z1r.pdf (EFN) Alpha Screen
6imo  1.55  2019  IC50=0.65uM   // 6im6.pdf (AJL) ligand is 7
5y7k  2.51  2019  IC50=0.666nM  // 5y7h.pdf (8VU)
6s88  1.59  2019  IC50=0.67uM   // 6s43.pdf (L0K) ligand is compound 16l; IC50 = 0.67 +/- 0.03 uM
6moo  2.20  2019  IC50=0.68nM   // 6mo4.pdf (A5F) ligand is ACHN-975
6h4u  2.21  2019  IC50=0.693uM  // 6h4o.pdf (FO2) ligand is 34b
5z1s  1.42  2019  IC50=0.69uM   // 5z1r.pdf (EFM) Alpha Screen
6gcx  1.55  2019  IC50=0.6nM    // 6gcr.pdf (EUW) [Covalent complex] ADP Glo kinase assay, IC50(5)=0.6+/-0.04nM
6i3u  2.09  2019  IC50=0.6nM    // 6i3u.pdf (H2E) ligand is 33,
6mod  1.85  2019  IC50=0.71nM   // 6mo4.pdf (JWV) ligand is 26
5zhm  2.76  2019  IC50=0.73uM   // 5zhj.pdf (9D3) compound 11, IC50=0.73+/-0.13uM
6dhu  1.63  2019  IC50=0.74mM   // 6dhu.pdf (GHM) compound 1(cocktail soak)
6die  1.78  2019  IC50=0.74mM   // 6dhu.pdf (GHM) compound 1, same as PDB 6dhu(single soak))
6sq0  1.77  2019  IC50=0.79nM   // 6sq0.pdf (LRQ) ligand is compound 8; pIC50 = 9.1
6ffe  1.76  2019  IC50=0.79uM   // 6ffe.pdf (D7Q) pIC50=6.1+/-0.04
5zxi  2.10  2019  IC50=0.7nM    // 5zxi.pdf (9LU) transactivation assay, EC50=0.7+/-0.2nM
6aej  2.80  2019  IC50=0.7uM    // 6aej.pdf (7YC) enzymic inhibition assay, IC50(cpd-7)=0.7+/-0.3uM
6d4q  1.71  2019  IC50=0.83uM   // 6d4q.pdf (FWG) IC50(compound 14)=0.83+/-0.04uM
6i0x  1.60  2019  IC50=0.86uM   // 6i0x.pdf (BFB) [Covalent complex] [Incomplete ligand] ligand is Cl-amidine
6gj7  1.67  2019  IC50=0.87uM   // 6gj5.pdf (F0B) ligand is 22
6npp  1.35  2019  IC50=0.89uM   // 6npi.pdf (KWG) ligand is compound VK-0497
6fzm  2.67  2019  IC50=0.917uM  // 6fym.pdf (EE5) IC50=0.917+/-0.086uM
6k4t  1.39  2019  IC50=0.95uM   // 6k4t.pdf (JKE) ligand is TSA
6n19  1.50  2019  IC50=0.96mM   // 6dhu.pdf (K8V) compound 11
6qxd  2.32  2019  IC50=0.96uM   // 6qxd.pdf (JKB) ligand is compound 25; IC50 = 0.96 +/- 0.21 uM
6uvy  1.71  2019  IC50=0.99uM   // 6uvp.pdf (QJP) ligand is compound 18
6d4s  1.63  2019  IC50=0.9uM    // 6d4q.pdf (FWV) IC50(compound 37)=0.9+/-0.06uM
6o9x  1.70  2019  IC50=0.9uM    // 6o9x.pdf (M0S) ligand is JA2-4
6p11  2.15  2019  IC50=0.9uM    // 6p10.pdf (SKE) ligand is compound 1; IC50 = 0.9 +/- 0.1 uM
6n17  1.64  2019  IC50=1.01mM   // 6dhu.pdf (K8Y) compound 10
6fv1  2.30  2019  IC50=1.08uM   // 6fv1.pdf (E8E) compound 11n, IC50=1.08+/-0.09uM
6oin  1.70  2019  IC50=1.0uM    // 6oin.pdf (MQJ) [Nonstandard assay: Concentration of Ac-CoA is 0.4uM;] ligand is compound CTX-0124143
6p12  1.94  2019  IC50=1.11uM   // 6p10.pdf (NKY) ligand is compound 4
6rjp  2.57  2019  IC50=1.1nM    // 6rjp.pdf (17-mer) ligand is peptide 138C7; dissociation-enhanced lanthanide fluorescence immunoassay
6d4r  1.34  2019  IC50=1.1uM    // 6d4q.pdf (FWY) IC50(compound 18)=1.1+/-0.1uM
6htc  2.80  2019  IC50=1.1uM    // 6htb.pdf (GQK) ligand is ONX-0914
6m88  1.90  2019  IC50=1.1uM    // 6m88.pdf (MYC) ligand is 1
6n82  2.00  2019  IC50=1.1uM    // 6n7y.pdf (YF7) ligand is (S)-6g
6c67  2.11  2019  IC50=1.2uM    // 6c67.pdf (5ID) enzymic inhibition assay, compound 2
6qfh  1.65  2019  IC50=1.38uM   // 6qfe.pdf (J08) ligand is GSK144; Protein is KLK6 TM (triple mutation)
6hx8  2.40  2019  IC50=1.3uM    // 6hx8.pdf (GXN) ligand is 10 (STX3451)
6q5b  2.22  2019  IC50=1.3uM    // 6q5b.pdf (NXL) ligand is compound avibactam; IC50 = 1.3 +/- 0.3uM;
6jjm  2.05  2019  IC50=1.40mM   // 6jjm.pdf (4-mer) [Incomplete ligand] ligand is GM2-GS
6i1r  2.80  2019  IC50=1.45uM   // 6i1r.pdf (C5P) ligand is CMP
6nss  1.97  2019  IC50=1.4nM    // 6npt.pdf (L0M) ligand is compound 6
5zee  1.74  2019  IC50=1.57mM   // 5zee.pdf (HAR) IC50(L-NOHA)=1.57+/-0.06mM
6rne  1.65  2019  IC50=1.58nM   // 6rn6.pdf (KA8) ligand is compound 8; pIC50 = 8.8
6mny  2.80  2019  IC50=1.5nM    // 6mny.pdf (JVP) ligand is 9a
6ahs  1.75  2019  IC50=1.5uM    // 6ahs.pdf (9YO) compound 24
6oah  2.20  2019  IC50=1.5uM    // 6n7y.pdf (M2V) ligand is (R)-6f
6szj  2.53  2019  IC50=1.5uM    // 6sze.pdf (M5W) ligand is compound 2a
6j5l  2.30  2019  IC50=1.6nM    // 6j5l.pdf (B9C) ligand is 10e
6jib  2.25  2019  IC50=1.6uM    // 6jib.pdf (BQF) ligand is 41
5znl  2.80  2019  IC50=1.7nM    // 5znl.pdf (9G6)
6jse  2.00  2019  IC50=1.7nM    // 6jse.pdf (C6R) ligand is 16
6qxa  3.41  2019  IC50=1.7uM    // 6qxa.pdf (GQB) ligand is compound 1, ATC
6n3n  3.01  2019  IC50=1.8nM    // 6n3l.pdf (KA4) ligand is 6d
6d4u  1.70  2019  IC50=1.98uM   // 6d4q.pdf (FWP) IC50(compound 27)=1.98+/-0.1uM
5z1r  1.62  2019  IC50=1.99uM   // 5z1r.pdf (EFL) Alpha Screen
6dih  1.78  2019  IC50=1.9mM    // 6dhu.pdf (GJS) compound 3
5zqr  1.75  2019  IC50=10.6nM   // 5zqr.pdf (9H9)
6itj  1.99  2019  IC50=10.8nM   // 6itj.pdf (AXU) [Covalent complex] ligand is 9
6jwa  1.78  2019  IC50=10.9uM   // 6jwa.pdf (5ID) ligand is 5-iodotubercidin
6njj  2.30  2019  IC50=1018nM   // 6njh.pdf (KR7) ligand is compound 28; IC50 = 1018+/-239nM
6nji  2.45  2019  IC50=102nM    // 6njh.pdf (KR4) ligand is compound 5
6oyh  2.95  2019  IC50=104nM    // 6oyh.pdf (NK4) ligand is carbacaprazamycin
6htd  3.00  2019  IC50=10nM     // 6htb.pdf (GQH) ligand is 4(LU-002c)
6ib2  2.10  2019  IC50=10nM     // 6ib0.pdf (862) [Covalent complex] ligand is 4a
6pyu  2.54  2019  IC50=10nM     // 6pyr.pdf (P5V) ligand is compound 4-2
6udx  1.70  2019  IC50=10nM     // 6ud2.pdf (Q57) ligand is compound 7
5zgg   NMR  2019  IC50=10uM     // 5zgg.pdf (9F6) AraTM assay
6g8l  1.37  2019  IC50=10uM     // 6g6x.pdf (11-mer) betaYAP5
6qh9  2.27  2019  IC50=10uM     // 6qh9.pdf (J2N) [Different protein in assay: Protein KLK5/KLK1 was used in binding assay;But all structures were based on KLK6] Ligand is compound 13; Ligand is racemer
6nvh  1.90  2019  IC50=11.1nM   // 6nvg.pdf (XL6) [Covalent complex] ligand is compound 1
6nvl  2.70  2019  IC50=11.1nM   // 6nvg.pdf (XL6) [Covalent complex] ligand is compound 1
6msn  1.59  2019  IC50=11.3uM   // 6msn.pdf (JYD) [Different ligand in assay: ligand in binding assay is racemic mixture] ligand is RS-2-thiomalate
6kzc  2.00  2019  IC50=11.46nM  // 6kzc.pdf (DZC) ligand is 9c
6ijl  2.35  2019  IC50=11.7nM   // 5yjo.pdf (A8U) [Covalent complex] compound 29, IC50=11.7+/-10.9nM
6e6w  2.35  2019  IC50=110pM    // 6e3m.pdf (HWJ) compound 22, IC50=110+/-10pM
6npm  1.60  2019  IC50=110uM    // 6npi.pdf (KVD) ligand is compound VK-0044
6f1w  1.86  2019  IC50=11nM     // 6f1w.pdf (CG5) kinase inhibition assay, IC50(31a)=11+/-1nM
6htr  2.60  2019  IC50=11nM     // 6htb.pdf (GQT) ligand is 13
6nel  2.00  2019  IC50=11nM     // 6nel.pdf (KKV) ligand is compound 11; Binding assay is endonuclease assay
6pf5  2.39  2019  IC50=11uM     // 6pf3.pdf (OED) ligand is compound 23; IC50 = 11 +/- 1 uM
6uhv  2.53  2019  IC50=120nM    // 6ufn.pdf (XS6) ligand is compound 5; IC50 = 120 +/- 20 nM; acetylpolyamine hydrolysis assay
6e4c  2.35  2019  IC50=120pM    // 6e3m.pdf (HRJ) compound 24, IC50=120+/-10pM
6g3c  1.60  2019  IC50=123nM    // 5wij.pdf (EKT) compound 2
6q6m  2.35  2019  IC50=128nM    // 6q6m.pdf (HJW) ligand is compound 1
6nem  1.95  2019  IC50=12nM     // 6nel.pdf (KKS) ligand is compound 29; Binding assay is endonuclease assay
6q9u  2.40  2019  IC50=1300nM   // 6q96.pdf (HRE) ligand is compound 12; Binding assay is TR-FRET
6ckl  2.68  2019  IC50=130uM    // 6ckk.pdf (DAN) IC50=130+/-10uM
6n5f  1.93  2019  IC50=138.8nM  // 6n3k.pdf (KJ1) ligand is 3
6hmp  2.04  2019  IC50=138nM    // 6hmp.pdf (GEW) ligand is 3
6k0j  2.35  2019  IC50=13nM     // 6k0j.pdf (CQO) [Nonstandard assay: in presence of 50uM ATP] ligand is LDN192960
6i0k  1.64  2019  IC50=13uM     // 6i0k.pdf (GZ8) [Different protein in assay: EcNadA] ligand is 4MP
6i0c  2.68  2019  IC50=140nM    // 5nuu.pdf (GZ5) R-K1035
5ovf  2.01  2019  IC50=140nM    // 5ove.pdf (AWT) KRASG12C  CSOS1cat interaction assay , compound 17
6m95  1.80  2019  IC50=140nM    // 6m95.pdf (J8S) ligand is 1
6mo8  1.80  2019  IC50=1430nM   // 6mo7.pdf (JWD) ligand is 12
6q9q  2.10  2019  IC50=145nM    // 6q96.pdf (HUE) ligand is compound 13; Binding assay is TR-FRET
6hmr  1.78  2019  IC50=147nM    // 6hmp.pdf (GE5) ligand is 2
6qg7  2.10  2019  IC50=149nM    // 6qft.pdf (6HL) ligand is compound 1k; IC50 = 149 +/- 30nM
6f7i  2.43  2019  IC50=14nM     // 6f7i.pdf (CW5) compound MLT-747
6q39  2.21  2019  IC50=14nM     // 6q37.pdf (HDQ) ligand is compound 49
6qad  2.50  2019  IC50=14nM     // 6qad.pdf (HUZ) ligand is compound 13; IC50 = 14+/-1 nM
6m8e  2.00  2019  IC50=14uM     // 6m8e.pdf (J8G) ligand is 11
6qri  2.40  2019  IC50=15.21uM  // 6qri.pdf (CV9) ligand is chivoA
6i8z  1.99  2019  IC50=15.8nM   // 6i8z.pdf (H82) ligand is BI-4464
6pya  1.71  2019  IC50=150nM    // 6pya.pdf (P57) ligand is compound IPI; IC50 = 150 +/- 16 nM
6mo9  1.80  2019  IC50=1542nM   // 6mo7.pdf (JVY) ligand is 16
6irt  3.50  2019  IC50=155.10uM  // 6irs.pdf (AUU) ligand is BCH
6skd  2.26  2019  IC50=1585nM   // 6skb.pdf (LH2) ligand is compound 12; pIC50=5.8; contain uncommon B element
6dtn  1.48  2019  IC50=158nM    // 6dtn.pdf (7-mer) IC50(4)=158+/-20nM
6rn6  2.40  2019  IC50=158nM    // 6rn6.pdf (K9Q) ligand is compound 3; pIC50 = 6.8
6hcu  1.62  2019  IC50=15nM     // 6agt.pdf (FYB) compound 5, kinase-glo assay
6iby  2.51  2019  IC50=15nM     // 6ibx.pdf (HAT) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 7
6ic6  1.90  2019  IC50=15nM     // 6ic6.pdf (H9B)
6jz0  2.86  2019  IC50=15nM     // 6jz0.pdf (CKO) ligand is 78
6iuo  2.30  2019  IC50=16.3nM   // 6itj.pdf (AWX) [Covalent complex] ligand is 11
6c9n  2.10  2019  IC50=16.5uM   // 6c67.pdf (SGV) enzymic inhibition assay, compound 3
6htp  3.00  2019  IC50=160nM    // 6htb.pdf (GQQ) ligand is 7
6pi1  1.70  2019  IC50=160uM    // 6phr.pdf (B3N) ligand is compound 7; IC50 = 160 +/- 90 uM
6ega  2.51  2019  IC50=165.1nM  // 6eg9.pdf (J8A) kinase binding assay, IC50(HG-12-6, unphosphorylated IRAK4)=165.1+/-2.52nM
6ohu  3.53  2019  IC50=165nM    // 6oht.pdf (CTX) ligand is compound  tamoxifen; IC50 = 165 +/- 13 nM
6s9d  2.67  2019  IC50=16nM     // 6s9b.pdf (L3Z) [Different protein in assay: Protein in binding assay is EGFR L858R T790M C797S] ligand is compound 6
6pf4  2.85  2019  IC50=16uM     // 6pf3.pdf (OF7) ligand is compound 5; IC50 = 16 +/- 1 uM
6g8j  1.47  2019  IC50=17.2uM   // 6g6x.pdf (11-mer) betaYAP3
6e3z  1.94  2019  IC50=17.4nM   // 6e3z.pdf (HRV)
5zef  2.01  2019  IC50=17.9mM   // 5zee.pdf (NVA) IC50(L-Norvaline)=17.9+/-0.2mM
6qmd  1.94  2019  IC50=170uM    // 6qmc.pdf (J6N) ligand is compound (R)-7
6e6v  2.25  2019  IC50=17nM     // 6e3m.pdf (HWA) compound 1, IC50=17+/-3nM
6q9s  2.40  2019  IC50=17nM     // 6q96.pdf (HRN) ligand is compound 14; Binding assay is TR-FRET
6s7s  1.70  2019  IC50=17uM     // 6s43.pdf (KZ8) ligand is compound 16h; IC50 = 17 +/- 3 uM
5zqp  1.99  2019  IC50=18.3nM   // 5zqp.pdf (9H3)
5y7h  3.00  2019  IC50=18.7nM   // 5y7h.pdf (8O3)
6uim  2.75  2019  IC50=180nM    // 6ufn.pdf (Q7Y) ligand is compound 8; IC50 =180 +/- 20 nM; acetylpolyamine hydrolysis assay
6oyz  3.62  2019  IC50=185nM    // 6oyh.pdf (NKM) ligand is capuramycin
6nrf  2.00  2019  IC50=18nM     // 6nrf.pdf (KYV) [Incomplete ligand] ligand is compound 103, UTT103; ligand structure double bond in different form
6nwc  2.35  2019  IC50=18nM     // 6nwc.pdf (L6P) ligand is compound 3CB
6q8p  3.00  2019  IC50=18nM     // 6q8k.pdf (HQB) Ligand is compound 9m
6pf6  2.50  2019  IC50=18uM     // 6pf3.pdf (OEJ) ligand is compound 15; IC50 = 18 +/- 2 uM
6pk7  3.10  2019  IC50=19.2uM   // 6pk4.pdf (CTP) assay at CTPS2 concentration = 300 nM
5zqo  2.06  2019  IC50=19.4nM   // 5zqo.pdf (9GX)
6skb  1.84  2019  IC50=19.9nM   // 6skb.pdf (LH5) [Uncommon element] [Different ligand in assay: ligand in binding assay is enantiomer] ligand is compound 17; pIC50=7.7; contain uncommon B element
6c9r  2.10  2019  IC50=196.5nM  // 6c67.pdf (ERJ) enzymic inhibition assay, compound 6, IC50=196.5+/-20.3nM
6f96  2.50  2019  IC50=19nM     // 6f86.pdf (D0K) compound 2
6qhr  2.52  2019  IC50=19nM     // 6qft.pdf (J3N) ligand is compound 1m; IC50 = 19 +/- 9 nM
6g8q  1.85  2019  IC50=19uM     // 6g6x.pdf (11-mer) betaYAP3.2
6o1g  2.20  2019  IC50=1nM      // 6bfp.pdf (7SD) compound 1
6ow7  1.45  2019  IC50=1nM      // 6ow2.pdf (N9Y) ligand is compound 9
6pyr  2.21  2019  IC50=1nM      // 6pyr.pdf (P5J) ligand is compound 2-10
6hrw  2.45  2019  IC50=1uM      // 6hrw.pdf (GNK) ligand is 1
6qff  1.64  2019  IC50=2.04uM   // 6qfe.pdf (J08) ligand is GSK144; Protein is KLK6 WT
6h4q  2.31  2019  IC50=2.06uM   // 6h4o.pdf (FO2) ligand is 34a
6edl  2.80  2019  IC50=2.0nM    // 6e0r.pdf (J4M) compound 1, HTRF assay
6jut  2.10  2019  IC50=2.1nM    // 6jut.pdf (C9O) ligand is 6k
6dha  1.88  2019  IC50=2.1uM    // 6dha.pdf (GFV) [Nonstandard assay: FITC-TRAP220 peptide] EC50=2.1+/-0.05uM, using FITC-TRAP220 peptide
6e5b  2.77  2019  IC50=2.2nM    // 6e5b.pdf (HUJ) [Covalent complex] [Uncommon element] IC50(compd 5, B5i)=2.2+/-2.4nM
6m8c  1.80  2019  IC50=2.2uM    // 6m8c.pdf (IRH) ligand is 6
6s7z  1.85  2019  IC50=2.2uM    // 6s43.pdf (KZN) ligand is compound 16j; IC50 = 2.2 +/- 0.2 uM
6hop  1.55  2019  IC50=2.38uM   // 6hop.pdf (FER) ligand is curcumin
6e3m  2.65  2019  IC50=2.3nM    // 6e3m.pdf (HOG) compound 18, IC50=2.3+/-0.4nM
6gcw  2.00  2019  IC50=2.3nM    // 6gcr.pdf (EUQ) ADP Glo kinase assay, IC50(7)=2.3+/-0.3nM
6c9p  2.00  2019  IC50=2.3uM    // 6c67.pdf (MTP) enzymic inhibition assay, compound 4
6m89  1.85  2019  IC50=2.3uM    // 6m89.pdf (QUE) ligand is 2
6ufn  2.70  2019  IC50=2.3uM    // 6ufn.pdf (Q6M) ligand is compound 2; IC50 = 2.3 +/- 0.2 uM; acetylpolyamine hydrolysis assay
6n3o  2.40  2019  IC50=2.4nM    // 6n3l.pdf (KA7) ligand is 6e
6r7d  2.35  2019  IC50=2.4nM    // 6r7d.pdf (JUQ) ligand is 1S,2S-12, AZ13690257
6ebw  2.46  2019  IC50=2.5nM    // 6e0r.pdf (J3Y) compound 9, HTRF assay
6qcj  2.01  2019  IC50=2.5uM    // 6qcd.pdf (XEG) ligand is compound catechin gallate; IC50 = 2.5 +/- 0.1 uM
6jmf  2.00  2019  IC50=2.6nM    // 6jmf.pdf (9FC) ligand is 4
6nvi  2.12  2019  IC50=2.6nM    // 6nvg.pdf (XL7) [Covalent complex] ligand is compound 3
6hys  2.60  2019  IC50=2.6uM    // 6hys.pdf (ADP)
6q7v  2.56  2019  IC50=2.6uM    // 6q7u.pdf (HLK) ligand is compound 11; IC50 = 2.6 +/- 0.8 uM
6p8x  2.11  2019  IC50=2.78uM   // 6p8w.pdf (O5V) [Covalent complex] ligand is compound 5; covalently bound
6peb  2.46  2019  IC50=2.7nM    // 6peb.pdf (OE4) ligand is compound 3, NVP-LTM976
6hgv  2.00  2019  IC50=2.8uM    // 6hgv.pdf (G3Q) ligand is talinolol
6hvw  3.00  2019  IC50=2.8uM    // 6htb.pdf (GVW) ligand is 43
6n7z  2.55  2019  IC50=2.8uM    // 6n7y.pdf (KF7) ligand is (S)-6d
6kzd  1.71  2019  IC50=2.95nM   // 6kzc.pdf (DZ6) ligand is 9o
6kdz  3.10  2019  IC50=2.9nM    // 6kdx.pdf (D79) ligand is 2; binding assay method is HTRF
6rz6  2.43  2019  IC50=2.9nM    // 6rz6.pdf (KNW) ligand is compound 11a, ONO-2570366; HTRF assay
6pgo  1.60  2019  IC50=20.1uM   // 6pgo.pdf (OJ1) [Covalent complex] ligand is compound 2; covalently bound
6im6  1.70  2019  IC50=20.7uM   // 6im6.pdf (AH3) ligand is 5
6njh  2.15  2019  IC50=203uM    // 6njh.pdf (KRD) ligand is compound 6
6jsz  1.53  2019  IC50=2090nM   // 6jse.pdf (C7O) ligand is 22
6e0r  2.30  2019  IC50=20nM     // 6e0r.pdf (HKJ) compound 7, HTRF assay
6r5f  3.25  2019  IC50=20nM     // 6ocq.pdf (JSW) ligand is compound 77
6m7h  1.60  2019  IC50=20uM     // 6m7h.pdf (KN9) ligand is KN95
6etg  1.28  2019  IC50=21.8uM   // 6etg.pdf (BWT) compound 6, FDH assay
5zqq  2.29  2019  IC50=21.9nM   // 5zqq.pdf (9H6)
6s9b  3.25  2019  IC50=2100nM   // 6s9b.pdf (L1H) [Different protein in assay: Protein in binding assay is EGFR L858R T790M C797S] ligand is compound 1
6prt  1.30  2019  IC50=2120uM   // 6prt.pdf (OWA) ligand is compound R-10; IC50 = 2120 +/- 270 uM
6hvv  2.70  2019  IC50=215nM    // 6htb.pdf (GT8) ligand is 39
5zcu  2.41  2019  IC50=2160nM   // 5zcu.pdf (PYV) IC50 for pyrabactin with RCAR3:PP2C complex, Phosphatase activity assay
5ovi  2.20  2019  IC50=21nM     // 5ove.pdf (AXH) KRASG12C  CSOS1cat interaction assay , compound 23
5qj2  2.82  2019  IC50=21nM     // 5qj2.pdf (JXS) compound 20, The Amplex Red (AR) assay to measure the inhibition of MPO peroxidase activity
6msc  2.36  2019  IC50=21nM     // 6msa.pdf (JY7) ligand is 23
6q7h  2.30  2019  IC50=21nM     // 6q6m.pdf (HL8) ligand is compound 9
6gjd  1.58  2019  IC50=22nM     // 6gjb.pdf (F0E) ligand is SCH-TCO
6ic0  2.60  2019  IC50=22nM     // 6ibx.pdf (HAK) [Different ligand in assay: ] ligand is 21; the code in literature and PDB are inconsistent(6ico & 6ic0)
6ibz  2.44  2019  IC50=22nM     // 6ibx.pdf (HAW) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 15
6qaa  1.90  2019  IC50=22nM     // 6qaa.pdf (HUN) ligand is compound 6; IC50 = 22 +/- 6 nM
6iup  2.00  2019  IC50=23.1nM   // 6itj.pdf (AX0) [Covalent complex] ligand is 10
6nyw  2.19  2019  IC50=230nM    // 6nyv.pdf (L8M) ligand is compound 4
6qw9  1.04  2019  IC50=230nM    // 6qw7.pdf (MK7) ligand is relebactam
5qj3  2.76  2019  IC50=24nM     // 5qj3.pdf (JXP) compound 24, The Amplex Red (AR) assay to measure the inhibition of MPO peroxidase activity
6f26  1.83  2019  IC50=24nM     // 6f1w.pdf (C9Z) kinase inhibition assay, IC50(31b)=24+/-4nM
6ps9  1.21  2019  IC50=24uM     // 6prt.pdf (Y17) ligand is compound 17; IC50 = 24 +/- 2 uM
6iar  1.84  2019  IC50=25.1nM   // 6iar.pdf (H8W) ligand is 4
6oa1  1.80  2019  IC50=25.7uM   // 6o9x.pdf (M0P) ligand is JA2120
6n3z  2.24  2019  IC50=259.3nM  // 6n3k.pdf (KC4) ligand is 4
6imi  1.46  2019  IC50=26.1uM   // 6im6.pdf (AH6) ligand is 6
6hvu  2.90  2019  IC50=260nM    // 6htb.pdf (GTW) ligand is 29
6qwa  1.06  2019  IC50=260nM    // 6qw7.pdf (MK7) ligand is relebactam
6s9c  2.73  2019  IC50=267nM    // 6s9b.pdf (L1K) ligand is compound 5
6huc  3.00  2019  IC50=26nM     // 6htb.pdf (GRT) ligand is 18
6nd3  2.36  2019  IC50=26uM     // 6nd3.pdf (BTL) [Covalent complex] ligand is betaine aldehyde; covalent interaction;
6hmb  1.04  2019  IC50=273nM    // 6hbn.pdf (3NG) ligand is THN27
6hv0  2.73  2019  IC50=276nM    // 6hv0.pdf (GUK) [Multiple sites: IC50 = 736  nM] ligand is 33
6n3l  2.61  2019  IC50=27nM     // 6n3l.pdf (KAV) ligand is 5
6nri  2.20  2019  IC50=27nM     // 6nrf.pdf (KYM) [Incomplete ligand] ligand is compound 83, UTT83; IC50 = 7.57+/-0.05
6udy  1.70  2019  IC50=27nM     // 6ud2.pdf (Q54) ligand is compound 5
5ovh  2.30  2019  IC50=280nM    // 5ove.pdf (AWW) KRASG12C  CSOS1cat interaction assay , compound 21
6knh  1.76  2019  IC50=280uM    // 6knh.pdf (CIT) ligand is citrate
5z5v  1.66  2019  IC50=287nM    // 5z5t.pdf (96X) alpha screen assay
6ke0  2.95  2019  IC50=28nM     // 6kdx.pdf (D7C) ligand is 5l; binding assay method is HTRF
6pf3  2.39  2019  IC50=28uM     // 6pf3.pdf (OE7) ligand is compound 14; IC50 = 28 +/- 6 uM
6hwu  2.30  2019  IC50=29.1nM   // 6hmp.pdf (GE5) ligand is 2
6q8k  2.29  2019  IC50=290nM    // 6q8k.pdf (FG9) Ligand is compound 10i
6kdx  2.44  2019  IC50=294nM    // 6kdx.pdf (D6X) ligand is 4a; binding assay method is HTRF
6m9l  2.45  2019  IC50=29nM     // 6m95.pdf (J9G) ligand is 10
6mhm  2.74  2019  IC50=29nM     // 6mhm.pdf (JRY) [Covalent complex] [Incomplete ligand] ligand is carmofur
6n3k  2.20  2019  IC50=29nM     // 6n3k.pdf (K9V) ligand is 1
6q6o  2.30  2019  IC50=29nM     // 6q6m.pdf (HKE) ligand is compound 2
6ibx  2.11  2019  IC50=2nM      // 6ibx.pdf (H9Z) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 29
6p1l  2.80  2019  IC50=2nM      // 6p1d.pdf (9LL) ligand is EAI045; crystal use EGFR(T790M/ V948R); assay use EGFR L858R/T790M
6npi  1.50  2019  IC50=2uM      // 6npi.pdf (60Q) ligand is compound VK-0064
6qfg  1.68  2019  IC50=3.01uM   // 6qfe.pdf (J08) ligand is GSK144; Protein is KLK6 SM (single mutation)
6qae  2.49  2019  IC50=3.0nM    // 6qae.pdf (HUK) ligand is compound 12; IC50 = 3.0 +/- 0.2 nM
6rpg  2.70  2019  IC50=3.0nM    // 6rpg.pdf (KDW) Ligand is compound 2b; IC50 = 3.0 +/-0.1nM; Binding assay is HTRF
5zma  3.18  2019  IC50=3.0uM    // 5zma.pdf (9FX) Phosphatase assay, IC50(9987)=3.0+/-0.3uM
6hs0  1.45  2019  IC50=3.16uM   // 6hrw.pdf (GNW) ligand is 5
6izq  2.45  2019  IC50=3.19uM   // 6izq.pdf (XJ2) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is 10
6dji  1.75  2019  IC50=3.1mM    // 6dhu.pdf (GOG) compound 4
6hs4  2.05  2019  IC50=3.1uM    // 6hro.pdf (GON) ligand is 118
6jsf  2.30  2019  IC50=3.3nM    // 6jse.pdf (C7X) ligand is 17
6q9o  1.21  2019  IC50=3.4nM    // 6q96.pdf (HU8) ligand is compound 10; Binding assay is TR-FRET
6ak4  2.80  2019  IC50=3.5uM    // 6aej.pdf (PD9) enzymic inhibition assay, IC50(entacapone)=3.5+/-0.8uM
6oag  2.30  2019  IC50=3.7uM    // 6n7y.pdf (M2Y) ligand is (S)-6f
6jsn  2.60  2019  IC50=3.8nM    // 6jse.pdf (C7O) ligand is 22
6mso  2.05  2019  IC50=3.8uM    // 6msn.pdf (JYD) ligand is RS-2-thiomalate
6mum  3.06  2019  IC50=3.9nM    // 6mul.pdf (K47) ligand is 2q, binding assay method is HTRF
6mzw  2.20  2019  IC50=3.9nM    // 6mzq.pdf (TZ0) [Covalent complex] ligand  i s TAS-120
6mzq  2.00  2019  IC50=3.9nM    // 6mzq.pdf (TZ0) ligand  i s TAS-120
6q9l  1.13  2019  IC50=3.9nM    // 6q96.pdf (HTZ) ligand is compound 9; Binding assay is TR-FRET
6nkp  2.03  2019  IC50=300nM    // 6njz.pdf (13-mer) Ligand is bA-WLA-YSKbio peptide
6hv5  3.00  2019  IC50=325nM    // 6htb.pdf (GQH) ligand is 4 (LU-002c)
6hvr  2.70  2019  IC50=330nM    // 6htb.pdf (GRW) ligand is 16
6r8p  1.45  2019  IC50=33uM     // 6r8p.pdf (JVB) ligand is compound 3
6gcl  1.95  2019  IC50=34.2uM   // 6gcl.pdf (EUE) ligand is inhibitor 3a (F020)
6ufo  2.68  2019  IC50=35.0uM   // 6ufn.pdf (Q6P) ligand is compound 3; IC50 = 35.0 +/- 0.1 uM; acetylpolyamine hydrolysis assay
6g8k  1.25  2019  IC50=35.4uM   // 6g6x.pdf (11-mer) betaYAP4
6phz  2.00  2019  IC50=350uM    // 6phr.pdf (FKS) ligand is compound 2; IC50 = 350 +/- 100 uM
6oht  3.20  2019  IC50=351nM    // 6oht.pdf (MKM) ligand is compound U18666A; IC50 = 351 +/- 12 nM
6n5h  1.72  2019  IC50=357.9nM  // 6n3k.pdf (AUB) ligand is 5
6a6k  2.90  2019  IC50=35nM     // 6a6k.pdf (9S6) ligand is compound 35.
6huu  2.80  2019  IC50=35nM     // 6htb.pdf (GTW) ligand is 29
6k1q  2.70  2019  IC50=35nM     // 6k1q.pdf (D2U) ligand is IRL2500
6qft  2.70  2019  IC50=35nM     // 6qft.pdf (J0B) ligand is compound 1b; IC50 = 35 +/- 3nM
6nrj  1.65  2019  IC50=36nM     // 6nrf.pdf (KYJ) [Incomplete ligand] ligand is compound 93, UTT93
6q9y  1.20  2019  IC50=3700nM   // 6q96.pdf (HRQ) ligand is compound 16; Binding assay is TR-FRET
6uii  2.65  2019  IC50=370nM    // 6ufn.pdf (SS9) ligand is compound 6; IC50 = 370 +/- 20 nM; acetylpolyamine hydrolysis assay
6n5c  1.95  2019  IC50=375nM    // 6n5c.pdf (KDJ) ligand is 1
6f86  1.90  2019  IC50=37nM     // 6f86.pdf (CWW) compound 5
6s9x  2.60  2019  IC50=381nM    // 6s9w.pdf (L1W) [Covalent complex] ligand is compound 15c; IC50 = 381 +/- 116 nM; No Ki data
6r7j  1.84  2019  IC50=39.8nM   // 6r7a.pdf (JUN) ligand is compound 14
6pht  1.80  2019  IC50=390uM    // 6phr.pdf (OKP) ligand is compound 1; IC50 = 390 +/- 100uM
6p1d  2.40  2019  IC50=39nM     // 6p1d.pdf (NQ1) ligand is DDC4002; crystal use EGFR(T790M/ V948R); assay use EGFR L858R/T790M
6hgy  2.20  2019  IC50=3nM      // 6hgy.pdf (G4B) ligand is 1
6ny4  2.33  2019  IC50=3nM      // 6ny4.pdf (Z3A) ligand is compound 22; IC50 = 3 +/- 1 nM
6ow2  1.70  2019  IC50=3nM      // 6ow2.pdf (NB4) ligand is compound 1
6pl3  3.00  2019  IC50=3nM      // 6pl2.pdf (OOD) ligand is compound 2a; Only IC50 data, no Kd
6rj6  1.98  2019  IC50=3nM      // 6rih.pdf (K5K) ligand is compound BI-4924
6fne  2.50  2019  IC50=3uM      // 6fne.pdf (DY5) compound is bragsin1, Liposomes and flotation assay
6s43  1.42  2019  IC50=4.0uM    // 6s43.pdf (KUE) ligand is compound 16b; IC50 = 4.0 +/- 0.1 uM
6e5g  2.43  2019  IC50=4.3uM    // 6e5g.pdf (HUY) [Covalent complex] FP inhibition: EC50=4.3+/-0.6uM
6imr  1.50  2019  IC50=4.3uM    // 6im6.pdf (AJX) ligand is 8
6tld  1.61  2019  IC50=4.44uM   // 6tld.pdf (NK5) ligand is compound 2b; IC50 = 4.44 +/- 1.52 uM
6fu1  1.55  2019  IC50=4.4uM    // 6fu1.pdf (E7Q) IC50=4.4+/-0.17uM
6m8b  1.80  2019  IC50=4.4uM    // 6m8b.pdf (KMP) ligand is 4
6dtx  3.33  2019  IC50=4.5nM    // 6dtw.pdf (H9Y) state RT kinetic assay, IC50(WT, compound 1)=4.5+/-1.2nM
6eb1  2.20  2019  IC50=4.65uM   // 6eb1.pdf (J3M) LEDGF/p75 Independent Integration Assays, IC50(6b)=4.65+/-1.3uM
6jsg  2.30  2019  IC50=4.6nM    // 6jse.pdf (C6U) ligand is 8
6mo4  1.84  2019  IC50=4.6nM    // 6mo4.pdf (JWM) ligand is 17
6gcr  2.30  2019  IC50=4.7nM    // 6gcr.pdf (EUW) ADP Glo kinase assay, IC50(6)=4.7+/-0.5nM
6oe3  2.90  2019  IC50=4.8nM    // 6oe3.pdf (M9A) ligand is compound Cmpd I; IC50 = 4.8+/-1.1nM
6hot  1.50  2019  IC50=40.1uM   // 6hop.pdf (CIY) ligand is Ferulic aldehyde
5ovg  2.30  2019  IC50=400nM    // 5ove.pdf (AWZ) KRASG12C  CSOS1cat interaction assay , compound 18
6qw8  1.10  2019  IC50=400nM    // 6qw7.pdf (MK7) ligand is relebactam
6uhu  2.80  2019  IC50=400uM    // 6ufn.pdf (Q7V) ligand is compound 4; IC50 = 400 +/- 70 uM; acetylpolyamine hydrolysis assay
6ib0  2.60  2019  IC50=40nM     // 6ib0.pdf (H8Z) [Covalent complex] ligand is 3a
6i0p  1.90  2019  IC50=40uM     // 6i0k.pdf (QAS) ligand is 6MPDC
6nk0  1.53  2019  IC50=410nM    // 6njz.pdf (11-mer) Ligand is bA-WLA-Yam peptide
6pic  2.03  2019  IC50=410uM    // 6phr.pdf (6XA) ligand is compound 4; IC50 = 410 +/- 100
6keb  3.20  2019  IC50=41uM     // 6ke5.pdf (D6C) ligand is Diltiazem
6pyb  1.80  2019  IC50=4200nM   // 6pya.pdf (P5G) ligand is compound DVT; IC50 = 4200 +/- 790 nM
6pdj  1.81  2019  IC50=42nM     // 6pdj.pdf (ODJ) ligand is compound 11
6nsp  2.31  2019  IC50=44.1nM   // 6npt.pdf (L0P) ligand is compound 9
6q37  2.21  2019  IC50=440nM    // 6q37.pdf (HE8) ligand is compound 23
6j10  2.30  2019  IC50=445nM    // 6j10.pdf (B4O) ligand is Ciclopirox
6e3g  2.10  2019  IC50=44nM     // 6e3g.pdf (HOJ) ligand is compound 3a. Displacement assay of boron-dipyrromethene (BODIPY)-labeled with apo ROR  t
6qme  1.81  2019  IC50=44uM     // 6qmc.pdf (J6Q) ligand is compound 12
6mep  2.89  2019  IC50=45nM     // 6mep.pdf (9VS) ligand is 7
6i0r  2.10  2019  IC50=45uM     // 6i0k.pdf (QAT) ligand is 5MPDC
6qw7  1.78  2019  IC50=470nM    // 6qw7.pdf (MK7) ligand is relebactam
6oco  2.58  2019  IC50=474nM    // 6oco.pdf (M5V) ligand is compound 6; HTRF assay
6mdd  2.05  2019  IC50=47uM     // 6mdd.pdf (JE7) ligand is 24
6agt  1.95  2019  IC50=4nM      // 6agt.pdf (9X0) compound 2, kinase-glo assay
6n9p  2.23  2019  IC50=4nM      // 6n9p.pdf (KHD) [Covalent complex] [Incomplete ligand] ligand is 6
6oyw  2.60  2019  IC50=4nM      // 6oyt.pdf (NKJ) ligand is compound 11
6qha  1.82  2019  IC50=5.01uM   // 6qh9.pdf (J2Q) [Different protein in assay: Protein KLK5/KLK1 was used in binding assay;But all structures were based on KLK6] Ligand is compound 6
6jt3  2.40  2019  IC50=5.0nM    // 6jt3.pdf (C83) ligand is 5; binding assay method is HTRF
6p5w  1.69  2019  IC50=5.1uM    // 6p5v.pdf (O0A) ligand is compound 1; IC50 = 5.1 +/- 0.6 uM
6a84  1.98  2019  IC50=5.3nM    // 6a84.pdf (9SU)
6nvj  2.30  2019  IC50=5.3nM    // 6nvg.pdf (XL5) [Covalent complex] ligand is compound 4
6dtw  2.74  2019  IC50=5.5nM    // 6dtw.pdf (H9Y) steady state RT kinetic assay, IC50(Y181C, compound 1)=5.5+/-1.1nM
6hzu  2.20  2019  IC50=5.5nM    // 6hzu.pdf (GYQ)
6m8a  1.75  2019  IC50=5.5uM    // 6m8a.pdf (LU2) ligand is 3
6hp9  1.96  2019  IC50=5.6nM    // 6hp9.pdf (GKB) ligand is 7c
6d4w  1.80  2019  IC50=5.6uM    // 6d4q.pdf (FWJ) [Different ligand in assay: ligand structure is incorrect] IC50(compound 35)=5.6+/-0.2uM, ligand in crystal structure is compound 29, IC50=0.68+/-0.05uM
6oyt  2.82  2019  IC50=5.9nM    // 6oyt.pdf (NJV) ligand is compound 4, GS-4997
6fff  1.67  2019  IC50=50.1nM   // 6ffe.pdf (D7H) pIC50=7.3+/-0.21
6r7k  1.54  2019  IC50=50.1nM   // 6r7a.pdf (JUH) ligand is compound 22
6rn7  1.66  2019  IC50=50.1nM   // 6rn6.pdf (K9W) ligand is compound 5; pIC50 = 7.3
6hy2  1.60  2019  IC50=50nM     // 6hy2.pdf (12-mer) ligand is CR20
5y7j  2.52  2019  IC50=51.7nM   // 5y7h.pdf (8OL)
6hva  2.90  2019  IC50=525nM    // 6htb.pdf (GQT) ligand is 13
6aa5  1.90  2019  IC50=52nM     // 6aa4.pdf (MKU) IC50(3-isomangostin)=52+/-1.2nM
6oz6  3.70  2019  IC50=52nM     // 6oyh.pdf (NKD) ligand is 3'-hydroxymureidomycin A
6hv2  1.71  2019  IC50=52uM     // 6hv2.pdf (5-mer)
6hou  1.80  2019  IC50=53.4uM   // 6hop.pdf (V55) ligand is Vanillin
6nrh  1.50  2019  IC50=55nM     // 6nrf.pdf (KYP) [Incomplete ligand] ligand is compound 63, UTT63; ligand structure lack one double bond
6kla  2.11  2019  IC50=56nM     // 6kla.pdf (DJX) ligand is 15a
6nrg  1.70  2019  IC50=56nM     // 6nrf.pdf (KYY) [Incomplete ligand] ligand is compound 55, UTT57; ligand structure lack one double bond
6s7k  1.55  2019  IC50=57uM     // 6s43.pdf (KYZ) ligand is compound 16a; IC50 = 57 +/- 3 uM
6imd  1.50  2019  IC50=58.5uM   // 6im6.pdf (AH9) ligand is 4
6imb  1.55  2019  IC50=58.5uM   // 6im6.pdf (AH9) ligand is 4
6q9w  1.55  2019  IC50=580nM    // 6q96.pdf (HRT) ligand is compound 15; Binding assay is TR-FRET
6hvs  3.10  2019  IC50=5900nM   // 6htb.pdf (GRT) ligand is 18
6hv4  3.00  2019  IC50=590nM    // 6htb.pdf (GQK) ligand is ONX-0914
5z1e  2.30  2019  IC50=5nM      // 5z1d.pdf (95U) [Covalent complex]  kinase activity assay, C218S mutant
5z1d  2.28  2019  IC50=5nM      // 5z1d.pdf (95U) [Covalent complex]  kinase activity assay, C276S mutant
6hcv  2.20  2019  IC50=5nM      // 6agt.pdf (FYE) compound 4, kinase-glo assay
6q7a  2.20  2019  IC50=5nM      // 6q6m.pdf (HKZ) ligand is compound 4
6rna  2.62  2019  IC50=5nM      // 6rn8.pdf (KA2) ligand is compound 5; Binding assay is FP
6p10  2.30  2019  IC50=6.0uM    // 6p10.pdf (SKE) ligand is compound 1; IC50 = 6.0 +/- 1.0 uM
6od6  2.00  2019  IC50=6.16nM   // 6od6.pdf (M7D) ligand is compound 13; pIC50 = 8.21
6jpj  2.64  2019  IC50=6.2nM    // 6jpj.pdf (FGF) ligand is FGF401
6qab  2.49  2019  IC50=6.2nM    // 6qab.pdf (HUQ) ligand is compound 10; IC50 = 6.2+/-3.4 nM
6qac  2.77  2019  IC50=6.2nM    // 6qac.pdf (HUT) ligand is compound 8; IC50 = 6.2+/-0.4 nM
6mul  3.09  2019  IC50=6.3nM    // 6mul.pdf (K4A) ligand is 1, binding assay method is HTRF
6rln  2.87  2019  IC50=6.3nM    // 6rln.pdf (K8K) ligand is compound 6; uses Promega ADP-Glo kinase kit to measure kinase activity
6rn9  1.90  2019  IC50=6.3nM    // 6rn6.pdf (K9Z) ligand is compound 6; pIC50 = 8.2
6qhc  1.87  2019  IC50=6.3uM    // 6qh9.pdf (135) [Different protein in assay: Protein KLK5/KLK1 was used in binding assay;But all structures were based on KLK6] Ligand is compound 1; Ligand is racemer
6uvv  1.63  2019  IC50=6.64uM   // 6uvp.pdf (QJV) ligand is compound 17
6hbn  1.59  2019  IC50=607nM    // 6hbn.pdf (FXB) ligand is THN27
6g8p  1.90  2019  IC50=61.2uM   // 6g6x.pdf (11-mer) betaYAP2.2
6d5w  2.48  2019  IC50=63.0uM   // 6d5w.pdf (FVV) Ras:SOS1:Ras complex
6ffg  1.59  2019  IC50=63.1nM   // 6ffe.pdf (D7B) pIC50=7.2+/-0.07
6qho  2.70  2019  IC50=631nM    // 6qft.pdf (J3H) ligand is compound 1a; IC50 = 631 +/- 87nM
6s55  2.09  2019  IC50=631nM    // 6s55.pdf (KW5) ligand is compound 36; pIC50 = 6.2 +/- 0.03
6oi9  2.06  2019  IC50=64nM     // 6oi8.pdf (MQM) ligand is 13f
6hor  1.80  2019  IC50=65.5uM   // 6hop.pdf (GJK) ligand is Feruloylmethane
6hv7  3.40  2019  IC50=6500nM   // 6htb.pdf (GQQ) ligand is 7
6eg9  2.41  2019  IC50=66.9nM   // 6eg9.pdf (0LI) kinase binding assay, IC50(ponatinib, unphosphorylated IRAK4)=66.9+/-2.37nM
6npt  2.19  2019  IC50=68.3nM   // 6npt.pdf (KWY) ligand is compound 1
6ijh  2.60  2019  IC50=68nM     // 6ijh.pdf (AEO) ligand is AF-399/14387019
6hzv  2.46  2019  IC50=6nM      // 6hzu.pdf (GYW)
6ic5  2.00  2019  IC50=6nM      // 6ic5.pdf (HB5)
6qxu  1.20  2019  IC50=7.0nM    // 6qxu.pdf (JKN) ligand is compound 5k
6dim  1.81  2019  IC50=7.2mM    // 6dhu.pdf (GJP) compound 2(cocktail soak)
6djd  1.78  2019  IC50=7.2mM    // 6dhu.pdf (GJP) compound 2, same as PDB 6dim(single soak)
6m8d  2.00  2019  IC50=7.2uM    // 6m8d.pdf (J8D) ligand is 7
6n7y  2.00  2019  IC50=7.7uM    // 6n7y.pdf (KFA) ligand is (R)-6d
6q9h  2.00  2019  IC50=7.8nM    // 6q96.pdf (HRH) ligand is compound 11; Binding assay is TR-FRET
6hrx  1.87  2019  IC50=7.9uM    // 6hrw.pdf (GO8) ligand is 2
6pys  2.19  2019  IC50=70nM     // 6pyr.pdf (P5J) ligand is compound 2-10; selectivity(alpha/delta) = 70
6huq  3.00  2019  IC50=72nM     // 6htb.pdf (GT5) ligand is 20
6uf0  1.96  2019  IC50=73nM     // 6uf0.pdf (Q5V) ligand is compound 13a; IC50 = 66 - 91nM;binding assay fluorescence anisotropy
6ic7  2.00  2019  IC50=78nM     // 6ic7.pdf (H9H)
6jjn  2.50  2019  IC50=78uM     // 6jjm.pdf (5-mer) [Incomplete ligand] ligand is SLeX
6skc  2.18  2019  IC50=79.4nM   // 6skb.pdf (LH8) [Uncommon element] ligand is compound 10; pIC50=7.1; contain uncommon B element
6psb  1.59  2019  IC50=79uM     // 6prt.pdf (Y18) ligand is compound 18; IC50 = 79 +/- 3 uM
6a1c  1.68  2019  IC50=7nM      // 6a1c.pdf (9NX) kinase assay
6mob  1.80  2019  IC50=7nM      // 6mob.pdf (JWY) ligand is DP-2976
6c9q  1.95  2019  IC50=8.0uM    // 6c67.pdf (5N5) enzymic inhibition assay, compound 5
6n4t  1.95  2019  IC50=8.1nM    // 6n4t.pdf (KD7) [Covalent complex] ligand is cpd-8
6jid  2.50  2019  IC50=8.3uM    // 6jib.pdf (BQC) ligand is 1
6fym  2.15  2019  IC50=8.55uM   // 6fym.pdf (EBB) IC50=8.55+/-0.8uM
6s8a  2.60  2019  IC50=8.5nM    // 6hve.pdf (L0N) [Different protein in assay: Protein in binding assay is L858R/T790M/C797S mutant] ligand is 19h; binding assay method is HTRF
6nvg  1.99  2019  IC50=8.5nM    // 6nvg.pdf (XL8) [Covalent complex] ligand is compound 5
6s89  2.70  2019  IC50=8.6nM    // 6hve.pdf (L0Q) [Covalent complex] [Different protein in assay: Protein in binding assay is L858R/T790M/C797S mutant] ligand is 19g; binding assay method is HTRF
6qg4  2.30  2019  IC50=8.6nM    // 6qft.pdf (J0E) ligand is compound 1h; IC50 = 8.6 +/- 2.9 nM
6a3n  2.60  2019  IC50=8.7nM    // 6a3n.pdf (9Q9) compound 2, IC50=8.7+/-0.3nM, enzymic assay
6uil  2.85  2019  IC50=80nM     // 6ufn.pdf (FKS) ligand is compound 1; IC50 = 80 +/- 10 nM; acetylpolyamine hydrolysis assay
6djj  1.74  2019  IC50=80uM     // 6dhu.pdf (GM7) compound 5
6sze  2.94  2019  IC50=80uM     // 6sze.pdf (M2B) ligand is compound 1
6hwv  1.70  2019  IC50=83.2nM   // 6hmp.pdf (GEW) ligand is 3
6moa  1.27  2019  IC50=83nM     // 6mo7.pdf (JW4) ligand is 42
6msa  2.06  2019  IC50=84nM     // 6msa.pdf (JY4) ligand is 17
6f8j  1.95  2019  IC50=86nM     // 6f86.pdf (CZ5) compound 4
6r49  2.21  2019  IC50=8mM      // 6r49.pdf (JSB) ligand is compound 39
6e6j  2.44  2019  IC50=8nM      // 6e6j.pdf (HWV) compound is ABBV-744, BD2 domain
6gjb  1.82  2019  IC50=8nM      // 6gjb.pdf (F0H) ligand is TCO-GDC-2
6hub  2.90  2019  IC50=8nM      // 6htb.pdf (GRW) ligand is 16
6nsq  3.05  2019  IC50=8nM      // 6nsq.pdf (KZP) ligand is compound 2l; IC50 = 8+/-1 nM
6i0b  2.38  2019  IC50=9.1nM    // 5nuu.pdf (9A5) S-K1035
6n4e  1.65  2019  IC50=9.9nM    // 6n4e.pdf (KCD) ligand is 1bv
6qwb  1.04  2019  IC50=910nM    // 6qw7.pdf (MK7) ligand is relebactam
6mo7  1.85  2019  IC50=9376nM   // 6mo7.pdf (JWA) ligand is 10
5zr3  2.50  2019  IC50=98nM     // 5zr3.pdf (9J0) alphascreen competitive assay, IC50(16d)=98+/-10nM
6f94  2.35  2019  IC50=99nM     // 6f86.pdf (D0H) compound 10
6n5g  2.60  2019  IC50=99nM     // 6n3k.pdf (KDS) ligand is 2
6i5i  1.60  2019  IC50=9nM      // 6i5h.pdf (H3E) ligand is 12h
6ocu  2.77  2019  IC50=9nM      // 6oco.pdf (M5D) ligand is compound 29; HTRF assay
6hrz  1.57  2019  IC50>100uM    // 6hrw.pdf (GO2) ligand is 4
6hry  1.84  2019  IC50>100uM    // 6hrw.pdf (GOE) ligand is 3
6uvp  1.56  2019  IC50>100uM    // 6uvp.pdf (QJJ) ligand is compound 3
6huv  3.10  2019  IC50>10uM     // 6htb.pdf (GT8) ligand is 39
6hvt  2.90  2019  IC50>1uM      // 6htb.pdf (GT5) ligand is 20
6n69  2.00  2019  IC50>50000nM  // 6n4e.pdf (KDV) ligand is 1a
6fv2  2.95  2019  IC50>50uM     // 6fv1.pdf (D03) compound 11a
6rnu  2.40  2019  IC50>99.2uM   // 6rnu.pdf (KBH) [Covalent complex] ligand is compound 2; TR-FRET assay
5zlf  2.85  2019  IC50~330uM    // 5ze6.pdf (B29) compound 69 for EcOPPS
5ze6  2.50  2019  IC50~450uM    // 5ze6.pdf (HJX) compound 70 for EcOPPS
6sd9  2.35  2019  Kd<0.8nM      // 6sd9.pdf (88Z) ligand is foretinib; pKd>9.1, then Kd<0.8nM
6sdc  1.67  2019  Kd<1.26nM     // 6sd9.pdf (88Z) ligand is foretinib; pKd>8.9, then Kd<1.26nM
6un3  1.90  2019  Kd<2.3nM      // 6un1.pdf (XT8) [Covalent complex] ligand is ticarcillin; FPA assay, Kd = Koff / Kon; covalently bound
6n9h  1.04  2019  Kd<55uM       // 6n9h.pdf (308) ligand is amantadine
6naf  1.92  2019  Kd<55uM       // 6n9h.pdf (308) ligand is amantadine; Expression System is different from 6N9H
6qgj  1.90  2019  Kd=0.001uM    // 6qfi.pdf (J1T) ligand is compound 14; SPR Kd=0.001uM, FP Ki=0.02uM
6mqe  2.46  2019  Kd=0.0051nM   // 6mqc.pdf (8-mer)
6r8o  1.36  2019  Kd=0.006uM    // 6r8l.pdf (JV2) ligand is compound 14
6h4d  2.90  2019  Kd=0.011uM    // 6h4d.pdf (GDP)
6i8m  2.10  2019  Kd=0.016uM    // 6i8m.pdf (H7W) ligand is (S)-13
6qyn  2.50  2019  Kd=0.024uM    // 6qxj.pdf (JL8) ligand is compound 10d
6qz8  2.15  2019  Kd=0.024uM    // 6qxj.pdf (JL8) ligand is compound 10d
6dyv  1.62  2019  Kd=0.026nM    // 6dyu.pdf (OS3) Kd(HpMTAN, 16)=0.026+/-0.006nM
6dyy  1.61  2019  Kd=0.028nM    // 6dyu.pdf (OS6) Kd(HpMTAN, 30)=0.028+/-0.010nM
6h76  1.50  2019  Kd=0.030uM    // 6h75.pdf (SLB) [Different protein in assay: ] ligand is Neu5Gc
6qyo  2.10  2019  Kd=0.030uM    // 6qxj.pdf (JLH) ligand is compound 18a
6maj  2.14  2019  Kd=0.034uM    // 6maj.pdf (JAV) ligand is WM-3835
6qmk  1.72  2019  Kd=0.035uM    // 6qmc.pdf (J8H) ligand is compound 21; has ITC Kd data
6dyw  1.45  2019  Kd=0.036nM    // 6dyu.pdf (OS5) Kd(HpMTAN, 32)=0.036+/-0.010nM
6qmj  1.86  2019  Kd=0.044uM    // 6qmc.pdf (J6K) ligand is compound 20; has ITC Kd data
6dyu  1.60  2019  Kd=0.055nM    // 6dyu.pdf (OS2) Kd(HpMTAN, 15)=0.055+/-0.025nM
6jb0  1.63  2019  Kd=0.058uM    // 6j9w.pdf (TRE)
6slg  1.33  2019  Kd=0.05nM     // 6slg.pdf (LHZ) ligand is compound 15, AZD0364; SPR pKd=10.3 for phosphorylated ERK2
5zyj  1.90  2019  Kd=0.061uM    // 5zyj.pdf (9ML) Kd=0.061+/-0.005uM, kon=7.78E+5, koff=4.82E-2, E16A(1S,2R)
6u5y  1.53  2019  Kd=0.069uM    // 6u5m.pdf (Q0M) ligand is compound 7k; Kd = 0.069 +/- 0.034 uM; Binding assay is FPA
6qyp  2.20  2019  Kd=0.070uM    // 6qxj.pdf (JL5) ligand is compound 13
6nfh  1.40  2019  Kd=0.07uM     // 6nfh.pdf (KLM) ligand is compound 1; binding assay is ThermoFluor
6rr0  2.18  2019  Kd=0.07uM     // 6qsz.pdf (12-mer) ligand is Ubp10 pT123 peptide
6qsz  2.50  2019  Kd=0.07uM     // 6qsz.pdf (16-mer) ligand is peptide Esc1-pS1450
5zyi  1.90  2019  Kd=0.086uM    // 5zyi.pdf (9ML) [Different ligand in assay: ] Kd=0.086+/-0.003uM, kon=8.73E+4, koff=7.54E-3
5zyl  1.80  2019  Kd=0.088uM    // 5zyl.pdf (9MC) Kd=0.088+/-0.002uM, kon=1.63E+5, koff=1.43E-2, E25A(1S,2R)
6p83  1.70  2019  Kd=0.08uM     // 6p83.pdf (O3Y) ligand is compound 1o
6qfq  1.60  2019  Kd=0.08uM     // 6qfi.pdf (J3E) ligand is compound 3; ITC Kd data
6nfi  2.41  2019  Kd=0.09uM     // 6nfh.pdf (KLP) ligand is compound 5; binding assay is ThermoFluor
6pi5  1.67  2019  Kd=0.11uM     // 6pi5.pdf (GUN) ligand is guanine; Kd = 0.11 +/- 0.02 uM
6pii  1.87  2019  Kd=0.11uM     // 6pi5.pdf (GUN) ligand is guanine; Kd = 0.11 +/- 0.02 uM; redundant to 6pi5
6u8l  1.57  2019  Kd=0.122uM    // 6u5m.pdf (Q1P) ligand is compound 6g; Kd = 0.122 +/- 0.04 uM; Binding assay is FPA
6qr0  1.59  2019  Kd=0.12uM     // 6qr0.pdf (JFB) ligand is compound 26l; Kd = 0.12+/-0.02uM
6fzf  1.95  2019  Kd=0.15uM     // 6fzf.pdf (14-mer) microscale thermophoresis, Kd(T475M,in presence of GW1929)=0.15+/-0.04uM
6efk  1.50  2019  Kd=0.16uM     // 6efk.pdf (6-mer) Ac-IEEVD, pKd=6.8
6fvl  1.98  2019  Kd=0.16uM     // 6fvl.pdf (6-mer) Kd(EcwtSC)=0.16+/-0.05uM
6np2  1.20  2019  Kd=0.16uM     // 6np2.pdf (SIS) ligand is compound sisomicin; Kd = 0.16 +/- 0.01 uM
5zyk  1.55  2019  Kd=0.18uM     // 5zyk.pdf (9MC) [Different ligand in assay: ] Kd=0.18+/-0.006uM, kon=8.66E+4, koff=2.07E-2
6ai9  2.09  2019  Kd=0.18uM     // 6ai9.pdf (PAZ) [Different protein in assay: protein in binding assay is WT] Kd(Cab2,PPA)=0.18+/-0.01uM
6qqz  1.70  2019  Kd=0.18uM     // 6qqz.pdf (JEB) ligand is compound 26g; Kd = 0.18 +/- 0.06 uM
5zhl  2.25  2019  Kd=0.19uM     // 5zhj.pdf (9D0) compound 15, koff=0.12, kon=6.45E+5
6kdi  2.70  2019  Kd=0.19uM     // 6kdh.pdf (2-mer) Ka=5.2x10 E6 M-1, ligand is dT(6-4)T DNA
6e23  1.66  2019  Kd=0.1nM      // 6dy7.pdf (HLJ) compound is C6
6iph  1.65  2019  Kd=0.22uM     // 6aec.pdf (DTP) [Nonstandard assay: in presence of Mn2+]
6idg  2.00  2019  Kd=0.22uM     // 6idg.pdf (2-mer) ligand is dT(6-4)T
6fvm  1.63  2019  Kd=0.25uM     // 6fvl.pdf (6-mer) Kd(EcM1SC)=0.25+/-0.09uM
6i17  1.56  2019  Kd=0.25uM     // 6i0z.pdf (GZW) ligand is 24
6mqm  3.48  2019  Kd=0.269nM    // 6mqc.pdf (7-mer)
6u8o  1.60  2019  Kd=0.289uM    // 6u5m.pdf (Q1G) ligand is compound 5n; Kd = 0.289 +/- 0.19 uM; Binding assay is FPA
6fzg  2.10  2019  Kd=0.28uM     // 6fzf.pdf (EDK) [Nonstandard assay: binding affinity for PPAR gamma and its peptide in the presence of EDK] microscale thermophoresis, peptide is not solved in the crystal structure. Kd(I290M,in presence of GW1929)=0.28/-0.09uM
6oja  1.55  2019  Kd=0.2nM      // 6dzx.pdf (MET) L-methionine
6n9l  2.01  2019  Kd=0.2uM      // 6n9l.pdf (ADP)
6phr  1.65  2019  Kd=0.2uM      // 6phr.pdf (SS9) ligand is compound 3
6qgk  1.80  2019  Kd=0.2uM      // 6qfi.pdf (J1Q) ligand is compound 2; SPR Kd=0.2uM, ITC Kd=0.2uM, FP Ki=1.3uM
6idz  2.71  2019  Kd=0.31uM     // 6icw.pdf (3-mer) ligand is alpha 2-3
6if0  1.80  2019  Kd=0.31uM     // 6if0.pdf (A59) ligand is D16
6qz6  1.90  2019  Kd=0.32uM     // 6qxj.pdf (JLE) ligand is compound 8b
6qz7  2.20  2019  Kd=0.32uM     // 6qxj.pdf (JLE) ligand is compound 8b
6pxc  1.60  2019  Kd=0.335uM    // 6pxc.pdf (14-mer) ligand is peptide p190RhoGAP phosphotyrosine; ITC Kd1=0.43uM, Kd2=0.24uM, we use mean value
6a73  2.45  2019  Kd=0.33uM     // 6a73.pdf (IHP)
6np3  1.15  2019  Kd=0.34uM     // 6np2.pdf (LLL) ligand is compound gentamicin; Kd = 0.34 +/- 0.01 uM
6ntj  1.90  2019  Kd=0.34uM     // 6np2.pdf (LLL) ligand is compound gentamicin; redundant to 6np3 
6qzb  2.00  2019  Kd=0.34uM     // 6qxj.pdf (JLK) ligand is compound 8d
6g2r  2.10  2019  Kd=0.35nM     // 6g2r.pdf (EJK) compound 6
6qi7  2.50  2019  Kd=0.35uM     // 6qi7.pdf (PLM) ligand is palmitic acid; Kd = 0.35 +/- 0.09 uM
6qr3  1.61  2019  Kd=0.36uM     // 6qr3.pdf (JE8) ligand is compound 26o; Kd = 0.36+/-0.05uM
6fzp  2.30  2019  Kd=0.38uM     // 6fzf.pdf (14-mer) microscale thermophoresis, Kd(WT,in presence of GW1929)=0.38/-0.09uM
6pfj  2.08  2019  Kd=0.39uM     // 6pfj.pdf (C2E) ligand is ci-di-GMP; Kd = 0.39 +/- 0.05 uM; FP assay
6mom  2.10  2019  Kd=0.3nM      // 6mom.pdf (JX4) ligand is NCGC1481
6n7d  1.78  2019  Kd=0.3nM      // 6n7d.pdf (KF4) ligand is 54
6iez  1.90  2019  Kd=0.3uM      // 6iez.pdf (A50) ligand is B16
6pek  4.20  2019  Kd=0.3uM      // 6pek.pdf (10-mer) ligand is peptide (EY)5; Kd = 0.3 +/- 0.1 uM; FP assay
6jki  2.59  2019  Kd=0.41uM     // 5wyq.pdf (SFG) Ki=0.41+/-0.07uM,SAM for substrate
6r4s  2.75  2019  Kd=0.41uM     // 6r4s.pdf (ATP) ligand is ATP; assay in the precense of Mn2+
6c8c  1.50  2019  Kd=0.42uM     // 6c8c.pdf (EQ7) compound is JH-RE-06
6u8b  1.26  2019  Kd=0.431uM    // 6u5m.pdf (Q1M) ligand is compound 6b; Kd = 0.431 +/- 0.08 uM; Binding assay is FPA
6sy7  2.75  2019  Kd=0.47mM     // 6sy7.pdf (AMP) ligand is AMP
6fzj  2.01  2019  Kd=0.47uM     // 6fzf.pdf (14-mer) microscale thermophoresis, Kd(M280I,in presence of GW1929)=0.47+/-0.08uM
6r7r  2.80  2019  Kd=0.47uM     // 6r7r.pdf (DAS) ligand is compound D-ASPARTIC ACID; Kd in presence of 300 mM NaCl; no D-aspartate binding in absence of NaCl
6idb  2.50  2019  Kd=0.4uM      // 6icw.pdf (3-mer) ligand is alpha 2-6
6u5m  1.80  2019  Kd=0.511uM    // 6u5m.pdf (Q0S) ligand is compound 7t; Kd = 0.511 +/- 0.050 uM; Binding assay is FPA
6j81  1.80  2019  Kd=0.51uM     // 6j81.pdf (B8X) ligand is E14 (this code is belong to literature 6iez )
6op9  2.50  2019  Kd=0.52nM     // 4otw.pdf (DB8) Bosutinib; Kd=0.52+/-0.06nM
5zys  1.78  2019  Kd=0.54uM     // 5zys.pdf (10-mer)
6p3w  2.54  2019  Kd=0.55uM     // 6p3w.pdf (7-mer) [Different protein in assay: Assay use Cyclin A, crystal use Cyclin A-CDK2] ligand is ORC1(233-240) peptide
6o3x  1.99  2019  Kd=0.56uM     // 6o3w.pdf (12-mer) ligand is peptide Sen1 NIM2; Kd = 0.56 +/- 0.05 uM
6qr4  1.52  2019  Kd=0.59uM     // 6qr4.pdf (JD8) ligand is compound 26n; Kd = 0.59+/-0.23uM
6nad  2.90  2019  Kd=0.5nM      // 6nad.pdf (KHY) ligand is 25
6dyz  1.62  2019  Kd=0.63nM     // 6dyu.pdf (OS2) Kd(HsMTAP, 15)=0.63+/-0.08nM
6r8l  1.64  2019  Kd=0.670uM    // 6r8l.pdf (JUZ) ligand is compound 16
6mkq  1.90  2019  Kd=0.686uM    // 6mkq.pdf (NXL) [Covalent complex] ligand is avibactam
6pi7  2.80  2019  Kd=0.68uM     // 6pi7.pdf (16-mer) ligand is compound PIWIL1-based peptide; Kd = 0.68+/-0.06 uM
6md4  2.24  2019  Kd=0.69uM     // 5ugm.pdf (BRL) two ligands: Rosiglitazone and OA, Kd(Rosiglitazone)=1.28uM
6hgi  1.52  2019  Kd=0.6uM      // 6hgd.pdf (C0R) ligand is Corticosterone
6aec  1.72  2019  Kd=0.71uM     // 6aec.pdf (ATP) [Nonstandard assay: in presence of Mn2+] Kd(MnrATP)=0.71+/-0.21uM
6j72  2.20  2019  Kd=0.74uM     // 6j72.pdf (GTP)
6ak5  1.70  2019  Kd=0.75uM     // 6aec.pdf (GTP) [Nonstandard assay: in presence of Mn2+] Kd(MnrGTP)=0.75+/-0.16uM
6hq7  2.46  2019  Kd=0.769uM    // 6hq3.pdf (PCG) dimer has two active binding site(positive co-operativity)
6hq3  2.79  2019  Kd=0.775uM    // 6hq3.pdf (CMP) dimer has two active binding site(negative co-operativity)
6a87  2.41  2019  Kd=0.7mM      // 6a86.pdf (2-mer) fucose(alpha1-6)GlcNAc, Kd=0.7+/-0.14mM
6oie  2.08  2019  Kd=0.7uM      // 6oie.pdf (19-mer) ligand is peptide H3K14cr; Kd = 0.7 +/- 0.1 uM
6p7p  1.67  2019  Kd=0.7uM      // 6p7p.pdf (3-mer) ligand is 3-mer nucleic acid cAAA
6dsp  1.37  2019  Kd=0.81uM     // 6dsp.pdf (PAV) Kd=0.81+/-0.13uM
6qyl  2.20  2019  Kd=0.83uM     // 6qxj.pdf (JLE) ligand is compound 8a
6qz5  2.00  2019  Kd=0.83uM     // 6qxj.pdf (JLE) ligand is compound 8a
6htn  1.55  2019  Kd=0.86uM     // 6htn.pdf (MFU) ligand is methyl-a-L-fucoside
6mlo  1.72  2019  Kd=0.8uM      // 6mku.pdf (ARG)
6n3f  2.10  2019  Kd=0.8uM      // 6n3e.pdf (4-mer) [Incomplete ligand] ligand is ULM5
6hm1  1.54  2019  Kd=0.91uM     // 6hm1.pdf (AO3) ligand is Allosamidin
6dz0  1.62  2019  Kd=0.94nM     // 6dyu.pdf (OS3) Kd(HsMTAP, 16)=0.94+/-0.12nM
6r8i  1.52  2019  Kd=0.94uM     // 6r8i.pdf (19-mer) ligand is FxxP motif model peptide SLPFTFKVPAPPPSLPPS
6jbb  1.95  2019  Kd=1.03uM     // 6j9w.pdf (SUC)
6jb4  1.63  2019  Kd=1.04uM     // 6j9w.pdf (MAL)
6mle  1.86  2019  Kd=1.0nM      // 6mku.pdf (ARG)
6qgf  1.34  2019  Kd=1.0uM      // 6qgf.pdf (J0T) Ligand is compound R; Kd = 1.0+/-0.03 uM
6uyx  1.70  2019  Kd=1.0uM      // 6uys.pdf (17-mer) ligand is peptide DAXX-SIM-PO4; Kd = 1.0 +/- 0.2 uM
6mbo  1.59  2019  Kd=1.13uM     // 6mbo.pdf (JDG) [Different protein in assay: protein in binding assay is G9a] ligand is 12a in space group P212121
6mbp  1.95  2019  Kd=1.13uM     // 6mbo.pdf (JDG) [Different protein in assay: protein in binding assay is G9a] ligand is 12a in space group P3121
6pka  2.25  2019  Kd=1.19uM     // 5vz2.pdf (7-mer) compound 16, Kd=1.19+/-0.1uM
6r9x  1.66  2019  Kd=1.1mM      // 6r8l.pdf (JW2) ligand is compound 8
6d9s  2.11  2019  Kd=1.1uM      // 6d9r.pdf (G4P) compound is (p)ppGpp
6o7g   NMR  2019  Kd=1.1uM      // 6o7g.pdf (12-mer) ligand is peptide H4K16ac; Kd = 1.1+/-0.2uM
6os6  1.33  2019  Kd=1.1uM      // 6os3.pdf (TRP) ligand is L-Trp; binding to CymD prenyltransferase-DMSPP
6a80  1.56  2019  Kd=1.26uM     // 6a80.pdf (CYS) [Different ligand in assay: ligand in binding assay is L-cystine (S)] ligand in crystal structure is different from the literature
6md0  1.95  2019  Kd=1.27uM     // 5ugm.pdf (OLA)
6mh1  1.60  2019  Kd=1.2uM      // 6mh1.pdf (JQP) ligand is compound V
6n48  3.20  2019  Kd=1.2uM      // 6n48.pdf (KBY) ligand is Cmpd-6FA
6r8w  1.40  2019  Kd=1.2uM      // 6r8l.pdf (JVH) ligand is compound 40
6iyv  1.50  2019  Kd=1.32uM     // 6iyv.pdf (2RG) [Covalent complex] ligand is ertapenem
6gj8  1.65  2019  Kd=1.36uM     // 6gj5.pdf (F0K) ligand is BI2852
6e22  1.60  2019  Kd=1.3nM      // 6dy7.pdf (HLS) compound is C3
6dz3  1.91  2019  Kd=1.3nM      // 6dyu.pdf (OS6) Kd(HsMTAP, 30)=1.3+/-0.1nM
6n0p  2.37  2019  Kd=1.3nM      // 6n0p.pdf (K81) ligand is 15
6k4r  3.11  2019  Kd=1.45uM     // 6k4k.pdf (AMP) binding assay method is microscale thermophoresis
6dz2  1.99  2019  Kd=1.4nM      // 6dyu.pdf (OS5) Kd(HsMTAP, 32)=1.4+/-0.1nM
6e1a  3.10  2019  Kd=1.4nM      // 6e1a.pdf (HL7) compound is 42 (M-89), Biolayer Interferometry assay, Kd=1.4+/-0.6nM, koff=2.9E-4, kon=2.3E+5
6h8c   NMR  2019  Kd=1.4uM      // 6h8c.pdf (19-mer)
6i5j  2.80  2019  Kd=1.4uM      // 6i4x.pdf (11-mer) ligand is GHR2_pY595
6i5n  1.98  2019  Kd=1.4uM      // 6i4x.pdf (11-mer) ligand is GHR2_pY595
6n3w  1.75  2019  Kd=1.56uM     // 6n3v.pdf (KBJ) ligand is 2
6bs3  2.30  2019  Kd=1.5uM      // 6bs3.pdf (ADP) Kd(BagAB, ADP)=1.5uM
6i14  1.73  2019  Kd=1.5uM      // 6i0z.pdf (GZN) ligand is 9
6n0m  3.30  2019  Kd=1.5uM      // 6n0m.pdf (K94) ligand is NV-5138
6rml  2.81  2019  Kd=1.5uM      // 6rml.pdf (15-mer) ligand is peptide 53BP1 pT670 phosphopeptide; Kd = 1.5 +/- 0.2uM; Binding assay is Fluorescence polarisation
6jan  1.77  2019  Kd=1.61uM     // 6j9w.pdf (MAL)
6aad  1.44  2019  Kd=1.62mM     // 6aac.pdf (9TU) compound is mTmdZLys
6ipj  1.98  2019  Kd=1.62uM     // 6aec.pdf (TTP) [Nonstandard assay: in presence of Mn2+]
6rqk  1.85  2019  Kd=1.6mM      // 6rqk.pdf (MVL) ligand is compound mannoimidazole
5zhn  2.65  2019  Kd=1.6nM      // 5zhj.pdf (9D0) compound 15, koff=2.18E-2, kon=1.35E+7
6stl  1.30  2019  Kd=1.6nM      // 6ssy.pdf (TAU) ligand is taurine
6inz  2.29  2019  Kd=1.6uM      // 6inz.pdf (2-mer) [Incomplete ligand] ligand is deltaHA
6mnc  2.40  2019  Kd=1.6uM      // 6mnc.pdf (J3Z) ligand is E1
6r4v  2.20  2019  Kd=1.74uM     // 6r4v.pdf (BFQ) ligand is compound ibandronate; Kd = 1.74 +/- 0.22 uM
6aan  1.51  2019  Kd=1.76mM     // 6aac.pdf (9TX) compound is mEtZLys
6i8t  2.10  2019  Kd=1.76uM     // 6i8m.pdf (H7Z) ligand is (R)-13
6aeh  1.64  2019  Kd=1.77uM     // 6aec.pdf (UTP) [Nonstandard assay: in presence of Mn2+] Kd(MnrUTP)=1.77+/-0.60uM
5zdb  1.97  2019  Kd=1.78uM     // 5zdb.pdf (AR6) Kd=1.78+/-0.05uM, crystal P21
5zdd  2.73  2019  Kd=1.78uM     // 5zdb.pdf (AR6) Kd=1.78+/-0.05uM, crystal P212121; redundant to 5zdb
5zdc  1.98  2019  Kd=1.78uM     // 5zdb.pdf (AR6) Kd=1.78+/-0.05uM, crystal P32; redundant to 5zdb
5zde  2.80  2019  Kd=1.78uM     // 5zdb.pdf (AR6) Kd=1.78+/-0.05uM, crystal P3221; redundant to 5zdb
5zym  1.90  2019  Kd=1.7uM      // 5zym.pdf (9M6) Kd=1.7+/-0.6uM, kon=1.01E+5, koff=1.68E-1, E25B(1R,2S)
6gge  1.25  2019  Kd=1.7uM      // 6gge.pdf (EYE)
6a9c  1.98  2019  Kd=1.8mM      // 6a9c.pdf (9-mer) P2
6d78  2.35  2019  Kd=1.8nM      // 6d78.pdf (9-mer) alpha-D26Y, beta-L98W, Kd=1.8+/-0.3nM
6mh7  1.74  2019  Kd=1.8uM      // 6mh1.pdf (JQY) ligand is compound IV
6ncp  2.76  2019  Kd=1.8uM      // 6ncp.pdf (5-mer)
6ipi  1.80  2019  Kd=1.95uM     // 6aec.pdf (DCP) [Nonstandard assay: in presence of Mn2+]
5zdf  2.50  2019  Kd=1.98uM     // 5zdb.pdf (AR6) T267K, Kd=1.98+/-0.02uM
6hol  1.40  2019  Kd=1.9uM      // 6hoi.pdf (15-mer) ligand is LIR peptide of ATG14
6uyy  1.60  2019  Kd=1.9uM      // 6uys.pdf (17-mer) ligand is peptide DAXX-SIM-PO4; Kd = 1.9 +/- 0.3 uM
5zhj  1.75  2019  Kd=10.1uM     // 5zhj.pdf (SAH) koff=7.75E-2, kon=7.7E+3
6o68  2.78  2019  Kd=10.3uM     // 6dgl.pdf (LO4) compound is cioglitazone
6p85  1.90  2019  Kd=10.3uM     // 6p83.pdf (O4V) ligand is compound 3
6jof  2.20  2019  Kd=10.4uM     // 5zhj.pdf (BWR) AZ51, koff=0.21, kon=2.01E+4
6haj  1.50  2019  Kd=10.6uM     // 6ha4.pdf (EVB) ligand is sclx8 which is bidentate-ligand model
6kjf  2.40  2019  Kd=10.8uM     // 6kjf.pdf (SIM) ligand is simvastatin
6haz  1.31  2019  Kd=100nM      // 6hax.pdf (FX5)
6ql3  1.35  2019  Kd=100nM      // 6ql1.pdf (V14) ligand is compound 25
6qrd  1.75  2019  Kd=100nM      // 6qrd.pdf (JEH) ligand is compound 29e; Kd = 100 +/- 24nM
6j3p  1.60  2019  Kd=105nM      // 6j3o.pdf (B8O) ligand is (R,R)-36n
6rih  2.15  2019  Kd=105uM      // 6rih.pdf (K4T) ligand is compound 9
6ha4  1.33  2019  Kd=107uM      // 6ha4.pdf (T3Y) ligand is sclx4
6iqg  3.00  2019  Kd=10nM       // 6iqg.pdf (17-mer) ligand is IgG-BP
6qrg  1.84  2019  Kd=10uM       // 6qrg.pdf (JET) ligand is compound 8; Kd = 10 +/- 1 uM
6pia  1.75  2019  Kd=11.0uM     // 6phr.pdf (XS6) ligand is compound 6
5zbz  1.31  2019  Kd=11.1uM     // 5zbz.pdf (SAU) N-terminal domain, microscale thermophoresis assay, Kd=11.1+/-0.9uM
6abk  1.58  2019  Kd=11.3mM     // 6aac.pdf (9VF) compound is TeocLys
6j0o  1.80  2019  Kd=11.9uM     // 6j0o.pdf (XAF) ligand is SC1(this code is belong to literature 6iez)
6jaq  1.95  2019  Kd=111.23uM   // 6j9w.pdf (GLC)
6fmn  1.36  2019  Kd=1120nM     // 6fmn.pdf (E4E) microsomal stability assay, Kd(compound 2)=1120+/-110nM
6d49  1.80  2019  Kd=118uM      // 6d49.pdf (FVP) Kd(P22)=118+/-41uM, crystal 1
6d4a  1.75  2019  Kd=118uM      // 6d49.pdf (FVP) Kd(P22)=118+/-41uM, crystal 1
6gjw  1.90  2019  Kd=11uM       // 6gjw.pdf (F2H) ligand is 5a
6i77  1.22  2019  Kd=11uM       // 6i74.pdf (H5Q) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 5
6pg5  1.99  2019  Kd=11uM       // 6pg3.pdf (OHV) ligand is compound 35; Kd = 11 +/- 1 uM
6nv7  2.13  2019  Kd=12.1nM     // 6nv7.pdf (L3J) ligand is inhibitor 2; Kd = 12.1 +/- 5.8 nM
6cf7  2.72  2019  Kd=12.2nM     // 6cf7.pdf (EZ7) JNJ4796
6dgr  2.15  2019  Kd=12.3uM     // 6dgl.pdf (GDY) compound is CAY10638
6i4x  2.69  2019  Kd=12.5uM     // 6i4x.pdf (11-mer) ligand is EpoR_pY426
6a05  2.20  2019  Kd=12.8uM     // 6a03.pdf (1YD) MST assay, Kd(3',3'-cGAMP)=12.8+/-1.1uM
6a30  2.79  2019  Kd=12.9uM     // 6a30.pdf (6-mer) [Different protein in assay: peptide used in binding assay is syb2(29-96)] Kd(syb2(29-96))=12.9+/-1.8uM
6e7u  2.27  2019  Kd=121nM      // 6e7u.pdf (HX7) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=121+/-5.1nM, Kd(PH=6.5)=78+/-3.0nM, chain BD: 363
6cjj  1.74  2019  Kd=125uM      // 6cjj.pdf (ADP)
6e7t  2.31  2019  Kd=129nM      // 6e7t.pdf (HYY) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=129+/-9.3nM, Kd(PH=6.5)+116+/-2.2nM, Chain BD: 363
6me1  1.97  2019  Kd=12nM       // 6mco.pdf (16-mer)
6pg9  1.75  2019  Kd=12uM       // 6pg3.pdf (OH1) ligand is compound 30; Kd = 12 +/- 1 uM
6qqv  1.71  2019  Kd=12uM       // 6qqv.pdf (JEW) ligand is compound 24d; Kd = 12 +/- 2 uM
6un1  2.26  2019  Kd=13.0nM     // 6un1.pdf (TJ7) [Covalent complex] ligand is temocillin; FPA assay, Kd = Koff / Kon; covalently bound
6jon  2.34  2019  Kd=13.2uM     // 6jon.pdf (DTP) ligand is dATP
6mjq  3.00  2019  Kd=13.3nM     // 6miv.pdf (JUD) ligand is 15p
6g6x  1.13  2019  Kd=13.3uM     // 6g6x.pdf (11-mer) betaYAP2
6n55  3.09  2019  Kd=13.4nM     // 6n53.pdf (UZ0) [Incomplete ligand] ligand is 2  AzUd
6n53  2.70  2019  Kd=13.4nM     // 6n53.pdf (UZR) [Incomplete ligand] ligand is 2  AzUd
6max  1.42  2019  Kd=13.6uM     // 6max.pdf (9TF) [Incomplete ligand] ligand is Purpurin
6op0  2.55  2019  Kd=13.8nM     // 6ooy.pdf (A7A) ligand is UCB-9260; Biopore assay
6jao  1.77  2019  Kd=13.8uM     // 6j9w.pdf (2-mer) ligand is Z9N-GLC
6tyz  1.51  2019  Kd=131nM      // 6tyt.pdf (16-mer) ligand is peptide hsAPLF KBM; Kd = 131 +/- 12nM; FP assay
6mt6  1.31  2019  Kd=133.0uM    // 6mt3.pdf (9-mer)
6klk  1.76  2019  Kd=133.2uM    // 6klk.pdf (URF) ligand is 5-FU
6dql  3.30  2019  Kd=13nM       // 6dql.pdf (8-mer) SIP-WT
6i68  1.85  2019  Kd=13uM       // 6i41.pdf (9-mer) [Different protein in assay: ] ligand is BRD3 fragment
6jdl  2.25  2019  Kd=13uM       // 6j7e.pdf (AGS) ligand is ATPgS
6qrc  1.73  2019  Kd=13uM       // 6qrc.pdf (JFE) ligand is compound 24b; Kd = 13 +/- 2 uM
6mja  2.35  2019  Kd=14.1nM     // 6miv.pdf (JTJ) ligand is 15o
6gga  1.55  2019  Kd=14.2uM     // 6gga.pdf (EY2) ligand is PK9284
6mjj  1.93  2019  Kd=14.3nM     // 6miv.pdf (JU4) ligand is 15m
6jfk  2.00  2019  Kd=14.4uM     // 6jfk.pdf (GDP)
6pg8  1.67  2019  Kd=140uM      // 6pg3.pdf (OGY) ligand is compound 16; Kd = 140 +/- 30 uM
6e7r  2.10  2019  Kd=147nM      // 6e7r.pdf (HYS) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=147+/-5.0nM, Kd(PH=6.5)=170+/-4.8nM, chain BD: 363
6qfw  1.20  2019  Kd=149nM      // 6qfu.pdf (JR8) [Uncommon element] ligand is cofactor 9; inculde uncommon Ir element
6qk8  2.92  2019  Kd=14uM       // 6qk8.pdf (8-mer) ligand is peptide pS481;Kd = 14 +/- 2 uM
6qre  1.93  2019  Kd=14uM       // 6qre.pdf (JCQ) ligand is compound 7; Kd = 14+/-1uM
6hah  1.45  2019  Kd=15.4uM     // 6ha4.pdf (FWQ) ligand is sclx6
6p84  1.70  2019  Kd=15.6uM     // 6p83.pdf (O3V) ligand is compound 2o
6nsv  1.31  2019  Kd=15.8nM     // 6efk.pdf (6-mer) Ac-LWWPD, pKd=7.8
6mt4  1.55  2019  Kd=150.5uM    // 6mt3.pdf (9-mer)
6q4q  1.45  2019  Kd=150nM      // 6q38.pdf (8-mer) ligand is Stapled Peptide P2-C4
6e1z  1.10  2019  Kd=150uM      // 6dy7.pdf (HLP) compound is C4
6ipl  1.64  2019  Kd=153uM      // 6aec.pdf (DTP) [Nonstandard assay: in presence of Mg2+]
6cd5  1.58  2019  Kd=156nM      // 5wa5.pdf (R4L) Kd(XMD17-26)=156+/-12nM
6pyd  2.00  2019  Kd=156nM      // 6pyc.pdf (P4S) ligand is compound MBG
6i62  1.65  2019  Kd=157.5nM    // 6i61.pdf (27N) ligand is Hydroxychlor (HPTE)
6nlj  1.65  2019  Kd=15uM       // 6nlj.pdf (KTV) ligand is analog 12; Kd = 11 +/- 1 uM
6qlr  0.97  2019  Kd=15uM       // 6qln.pdf (J4N) ligand is compound 6; Kd = 15+/-0.3 uM; Binding assay is fluorescence polarization
6jap  1.77  2019  Kd=16.02uM    // 6j9w.pdf (SUC)
6kmj  1.40  2019  Kd=16.3uM     // 6kmj.pdf (17-mer) ligand is H3K14Ac
6qxj  1.70  2019  Kd=16.4uM     // 6qxj.pdf (JKQ) ligand is compound 6a
6g2b  1.61  2019  Kd=160uM      // 6g24.pdf (EH8) Kd(compd 8)=160+/-26uM
6e3s  3.00  2019  Kd=167nM      // 6e3s.pdf (79A) microscale thermophoresis, compound is PT2385
6g7a  1.42  2019  Kd=167nM      // 6g5l.pdf (EOQ) Kd(9, FTSA)=167nM
6nfz  2.97  2019  Kd=16nM       // 6nfy.pdf (B49) ligand is compound sunitinib; Protein in crystal is at active state
6nfy  2.17  2019  Kd=16nM       // 6nfy.pdf (B49) ligand is compound sunitinib; Protein in crystal is at inactive state
6qts  1.11  2019  Kd=16uM       // 6qto.pdf (9-mer) ligand is peptide UVR8; Kd = 16+/- 1uM
6t1l  2.00  2019  Kd=17.1uM     // 6t1i.pdf (M7N) ligand is compound 3
6om2  2.77  2019  Kd=17.7nM     // 6om2.pdf (11-mer) ligand is proTGF-beta1 ligand peptide; assay use TGF-beta3 ligand peptide
6n54  2.42  2019  Kd=17.8nM     // 6n53.pdf (KEA) [Incomplete ligand] ligand is 2  AzCd
6g24  2.10  2019  Kd=1700uM     // 6g24.pdf (EH2) Kd(compd 3)=1700+/-700uM
6g2o  1.81  2019  Kd=170nM      // 6g24.pdf (EJE) Kd(compd BI-9321)=170+/-3nM
6e7x  2.58  2019  Kd=175nM      // 6e7x.pdf (T97) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=175+/-5.6nM, Kd(PH=6.5)=186+/-11nM, chain BD: 363
6ql2  1.30  2019  Kd=17nM       // 6ql1.pdf (EZL) ligand is EZA
6mkw  2.32  2019  Kd=17uM       // 6mku.pdf (HIS)
6qas  1.75  2019  Kd=18.1nM     // 6qas.pdf (34W) Ligand is compound PF-03814735
6t1j  1.97  2019  Kd=18.1uM     // 6t1i.pdf (M7T) ligand is compound 2
6miy  2.75  2019  Kd=18.5nM     // 6miv.pdf (JTV) ligand is 15a
6n3e  1.89  2019  Kd=18.9uM     // 6n3e.pdf (7-mer) [Incomplete ligand] ligand is ULM4
6i66  1.60  2019  Kd=182.5nM    // 6i61.pdf (H4Q) ligand is 4-sec-butylphenol
6iou  2.10  2019  Kd=184.2uM    // 6iop.pdf (SER) ligand is L-serine
6i78  1.15  2019  Kd=18uM       // 6i74.pdf (H5H) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 8
6seo  2.55  2019  Kd=18uM       // 6sen.pdf (17-mer) ligand is FAM181B(220-235) peptide; Kd = 18 +/- 1 uM
6mj4  2.00  2019  Kd=19.1nM     // 6miv.pdf (JTG) ligand is 15w
6ueg  2.00  2019  Kd=19.5uM     // 6uec.pdf (Q5G) ligand is compound 2
6jbe  1.75  2019  Kd=19.80uM    // 6j9w.pdf (GLC)
6qr9  2.42  2019  Kd=190nM      // 6qr9.pdf (JEE) ligand is compound 29c; Kd = 190 +/- 23nM
6qtq  1.30  2019  Kd=190uM      // 6qto.pdf (9-mer) ligand is peptide UVR8; Kd = 190 +/- 40 uM
6frj  1.40  2019  Kd=193uM      // 5n7b.pdf (6-mer) [Nonstandard assay: Kd = 141 (temp=15C)] glycopeptide 3*(temp=25C)
5zk7  2.12  2019  Kd=195.2nM    // 5zk7.pdf (14-mer) Kd=195.2+/-49.7nM, kon=3.4+/-1.6E+5, koff=5.8+/-1.4E-2
6poh  1.67  2019  Kd=1970uM     // 6pmf.pdf (OVG) ligand is compound 21; Kd = 1970 +/- 640 uM
6prg  2.35  2019  Kd=198.5uM    // 6prg.pdf (4-mer) ligand is stachyose; Kd = 198.5+/-23.0 uM
6qqw  1.80  2019  Kd=19uM       // 6qqw.pdf (JDQ) ligand is compound 24c; Kd = 19+/-1uM
6quv  1.48  2019  Kd=1mM        // 6quu.pdf (JJN) ligand is compound 15R
6r0x  3.13  2019  Kd=2.00nM     // 6r0x.pdf (8-mer) ligand is heparin, a kind of oligosaccharide; Kd = 2.00 +/- 1.17 nM
6bs5  3.10  2019  Kd=2.0uM      // 6bs3.pdf (ANP) Kd(BagAB, AMPPNP)=2.0uM
6n8x  1.49  2019  Kd=2.0uM      // 6n8x.pdf (KFY) ligand is PU-11-trans
6qge  1.16  2019  Kd=2.1uM      // 6qge.pdf (J1E) ligand is compound S; Kd = 2.1+/-0.1uM
6iiw  1.70  2019  Kd=2.2uM      // 6iiw.pdf (10-mer) ligand is PAF152-11
6n87  1.59  2019  Kd=2.2uM      // 6n7q.pdf (13-mer)
6pi6  1.65  2019  Kd=2.2uM      // 6pi5.pdf (OKM) ligand is 2-Hydroxyatrazine; Kd =2.2 +/- 0.2 uM
6jjz  1.65  2019  Kd=2.3nM      // 6jjw.pdf (18-mer) ligand is Dendrin peptide
6j0g  1.60  2019  Kd=2.3uM      // 5zxk.pdf (H6P) HMBPP, R351H, structure 1
6j0k  2.00  2019  Kd=2.3uM      // 5zxk.pdf (H6P) HMBPP, R351H, structure 2; redundant to 6j0g
6ets  1.33  2019  Kd=2.3uM      // 6etg.pdf (I1L) compound 1, Kd=2.3+/-0.9uM
6n3v  1.45  2019  Kd=2.45uM     // 6n3v.pdf (KB7) ligand is 1
6j3o  2.11  2019  Kd=2.4uM      // 6j3o.pdf (B4L) ligand is 12
6cse  3.24  2019  Kd=2.5uM      // 6cse.pdf (ALA)
6h1d  1.94  2019  Kd=2.5uM      // 6h1d.pdf (SAH) ligand is SAH complex with TRMT112
6agk  2.80  2019  Kd=2.66uM     // 6agk.pdf (9WR) compound is 4v
6ggd  1.40  2019  Kd=2.6uM      // 6ggd.pdf (EYB)
6t1o  1.90  2019  Kd=2.6uM      // 6t1i.pdf (M82) ligand is compound 6
6ak6  1.75  2019  Kd=2.76uM     // 6aec.pdf (CTP) [Nonstandard assay: in presence of Mn2+] Kd(MnrCTP)=2.76+/-0.47uM
6ikm  3.40  2019  Kd=2.7nM      // 6ikm.pdf (SPD) ligand Spermidine
6nfo  2.93  2019  Kd=2.7uM      // 5v8h.pdf (KKM) ligand is compound 19 not 20 as in paper
5zyh  1.95  2019  Kd=2.7uM      // 5zyh.pdf (9N0) [Different ligand in assay: ] Kd=2.7+/-0.5uM, kon=7.17E+3, koff=1.94E-2
6i12  1.65  2019  Kd=2.7uM      // 6i0z.pdf (H08) ligand is 5
6hk4  2.50  2019  Kd=2.81nM     // 6hk3.pdf (G8E) ligand is 4
6fvo  2.69  2019  Kd=2.84uM     // 6fvl.pdf (6-mer) Kd(MtM1SC)=2.84+/-0.7uM
6bs4  2.50  2019  Kd=2.8uM      // 6bs3.pdf (AGS) Kd(BagAB, ATPgammaS)=2.8uM
6sen  1.65  2019  Kd=2.8uM      // 6sen.pdf (17-mer) ligand is FAM181A(190-205) peptide; Kd = 2.8 +/- 0.2 uM
6mg5  1.80  2019  Kd=20.3uM     // 6mg5.pdf (6ZW) ligand is 1
6itq  1.53  2019  Kd=20.5uM     // 6itp.pdf (HCY) [Nonstandard assay: pH = 10.5] ligand is cortisol
6n93  1.70  2019  Kd=20.6uM     // 6n93.pdf (KGA) ligand is 8
6rmm  3.53  2019  Kd=20.6uM     // 6rml.pdf (15-mer) ligand is peptide 53BP1 pS366; Kd = 20.6 +/- 1.9 uM; Binding assay is Fluorescence polarisation
6ocq  2.79  2019  Kd=200nM      // 6ocq.pdf (M5J) ligand is compound 11; Binding assay is fluorescence polarization
6mlp  1.49  2019  Kd=200uM      // 6mku.pdf (HIS)
6pg6  1.68  2019  Kd=200uM      // 6pg3.pdf (OH7) ligand is compound 29; Kd = 200 +/- 10 uM
6i67  1.75  2019  Kd=201.4nM    // 6i61.pdf (H42) ligand is tetrahydro-2-naphtol
5z66  1.80  2019  Kd=206nM      // 5z66.pdf (VDM) microscale thermophoresis, Kd=206+/10nM
6ipm  1.72  2019  Kd=206uM      // 6aec.pdf (DCP) [Nonstandard assay: in presence of Mg2+]
6g6t  1.12  2019  Kd=20nM       // 6g5l.pdf (ENN) Kd(9, FTSA)=20nM
6nfn  2.63  2019  Kd=20nM       // 6nex.pdf (BCG) ligand is benzoylecgonine
6qfx  1.32  2019  Kd=20nM       // 6qfu.pdf (JR3) [Uncommon element] ligand is cofactor 10; inculde uncommon Ir element
6gj6  1.76  2019  Kd=20uM       // 6gj5.pdf (EZZ) ligand is 18
6iae  2.49  2019  Kd=20uM       // 6ia7.pdf (GTP)
6p86  1.80  2019  Kd=20uM       // 6p83.pdf (O4S) ligand is compound 4.1
6p8z  1.65  2019  Kd=20uM       // 6p8w.pdf (O5S) [Covalent complex] ligand is lead compound 1; non-covalent bound; NMR Kd data
6i96  1.85  2019  Kd=210nM      // 6i96.pdf (0UE) [Uncommon element] ligand is B-FoxA
6dyr  2.45  2019  Kd=218.6uM    // 6dyr.pdf (HJD)
6cq1  1.70  2019  Kd=219uM      // 6c3l.pdf (F8J) Kd(15a, NMR)=219+/-32uM
6ift  1.90  2019  Kd=21uM       // 6ift.pdf (SAM)
6nw3  2.35  2019  Kd=22.1nM     // 6nv7.pdf (L4J) ligand is inhibitor 1; Kd = 22.1 +/- 9.5 nM
6pl1  2.03  2019  Kd=22.2nM     // 6pl1.pdf (OOJ) ligand is compound 1b; SPR assay
6hq4  2.63  2019  Kd=22.4uM     // 6hq3.pdf (CMP) dimer has two active binding site(negative co-operativity)
6itp  1.57  2019  Kd=22.4uM     // 6itp.pdf (HCY) [Nonstandard assay: pH = 3.8] ligand is cortisol
6h9v  1.52  2019  Kd=220mM      // 6h9v.pdf (MFU) IAS373
6nk1  1.55  2019  Kd=220nM      // 6njz.pdf (14-mer) Ligand is bA-WLA-YRPKbio peptide
6e7m  2.70  2019  Kd=221nM      // 6e5s.pdf (RET) [Covalent complex] [Nonstandard assay: ] M5, Kd=221+/-18.0
6v5l   NMR  2019  Kd=224.17uM   // 6v5l.pdf (QPD) ligand is allosteric inhibitor E22; Kd = 224.17+/-42.9uM
6nsx  2.00  2019  Kd=229nM      // 6nsx.pdf (6-mer) ligand is peptide HSH155 ULM; Kd = 229 +/- 57 nM
6e1y  1.22  2019  Kd=22nM       // 6dy7.pdf (HLM) compound is C2
6g2c  1.76  2019  Kd=22uM       // 6g24.pdf (EHT) Kd(compd 9)=22+/-2.2uM
6ooy  2.50  2019  Kd=22uM       // 6ooy.pdf (A7M) ligand is UCB-6876
6pg7  2.45  2019  Kd=22uM       // 6pg3.pdf (OH4) ligand is compound 17; Kd = 22 +/- 6 uM
6qln  1.00  2019  Kd=22uM       // 6qln.pdf (J5Q) ligand is compound 3; Kd = 22+/-0.7 uM; Binding assay is fluorescence polarization
6jno  2.65  2019  Kd=233nM      // 6jno.pdf (WY5) ligand is 10
6mmq  2.02  2019  Kd=238uM      // 6mmq.pdf (CMP) [Nonstandard assay: Temp 25, pH = 8, NaCl = 20 mM, HEPES = 20 mM]
6i75  1.17  2019  Kd=23uM       // 6i74.pdf (H5T) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 2
6qlu  1.10  2019  Kd=23uM       // 6qln.pdf (J62) ligand is compound 7; Kd = 23+/-1.0 uM; Binding assay is fluorescence polarization
6qtr  1.37  2019  Kd=23uM       // 6qto.pdf (12-mer) ligand is peptide HY5; Kd = 23 +/- 10uM
6qto  1.27  2019  Kd=23uM       // 6qto.pdf (12-mer) ligand is peptide HY5; Kd = 23 +/- 7uM
6e91  1.80  2019  Kd=240nM      // 6e8p.pdf (J04) [Different protein in assay: protein binding assay is CA IX] compound is STX2484
6pge  1.76  2019  Kd=240uM      // 6pg3.pdf (OJM) ligand is compound 24; Kd = 240 +/- 10 uM
6nj0  1.83  2019  Kd=244nM      // 6nj0.pdf (KOY) ligand is analogue 5
6mmc  1.42  2019  Kd=244uM      // 6mmc.pdf (ADP) [Nonstandard assay: Temp 25, pH = 8, NaCl = 20 mM, HEPES = 20 mM]
6g5l  1.21  2019  Kd=24nM       // 6g5l.pdf (EM5) Kd(7a, ITC)=24nM
6iso  2.95  2019  Kd=25.1uM     // 4v1c.pdf (7-mer) ligand is H3K4Cr peptide; Kd=25.1+/-2.5uM
6p87  1.90  2019  Kd=25.4uM     // 6p83.pdf (O4P) ligand is compound 5
6p8a  1.80  2019  Kd=255uM      // 6p83.pdf (O4D) ligand is compound 8.1
6j06  2.65  2019  Kd=256nM      // 5zxk.pdf (99C) HMBPP-08
6q36  2.01  2019  Kd=25nM       // 6q2x.pdf (16-mer) ligand is peptide 9; IC50 = 16 +/- 5nM
6n5x  2.05  2019  Kd=25uM       // 6n5x.pdf (JEF) ligand is CI-MPR
6pgb  1.73  2019  Kd=25uM       // 6pg3.pdf (OJG) ligand is compound 31; Kd = 25 +/- 3 uM
6qe0  1.39  2019  Kd=25uM       // 6qdx.pdf (HZ2) ligand is BA2; Kd = 25+/-3uM
6pg4  1.60  2019  Kd=260uM      // 6pg3.pdf (OHG) ligand is compound 2; Kd = 260 +/- 20 uM
6poq  1.80  2019  Kd=2700uM     // 6pmf.pdf (OVJ) ligand is compound 16; Kd = 2700 +/- 920 uM
6np5  1.35  2019  Kd=27uM       // 6np2.pdf (9CS) ligand is compound kanamycin B; Kd = 27 +/- 0.5uM
6nti  2.30  2019  Kd=27uM       // 6np2.pdf (9CS) ligand is compound kanamycin B; redundant to 6np5 
6o9c  2.45  2019  Kd=28.5nM     // 6o9b.pdf (9-mer) ligand is S45F beta-catenin peptide
6pga  2.45  2019  Kd=28.9uM     // 6pg3.pdf (OGM) ligand is compound 32; Kd = 28.9 +/- 0.5 uM
6pid  1.55  2019  Kd=29.0uM     // 6phr.pdf (OKS) ligand is compound 5
6mm5  1.95  2019  Kd=29.1uM     // 6mm5.pdf (12-mer)
6i11  1.67  2019  Kd=29.3uM     // 6i0z.pdf (H0H) ligand is 3
6i10  2.10  2019  Kd=29.5uM     // 6i0z.pdf (GZK) ligand is 2
5znc  1.66  2019  Kd=29.9nM     // 5znc.pdf (QI9)
6mln  1.72  2019  Kd=29nM       // 6mku.pdf (ARG)
5zjf  2.60  2019  Kd=29uM       // 5zjf.pdf (9G9) compound is MA
6o5g  1.89  2019  Kd=2uM        // 6eeb.pdf (LMJ) Kd(isomalbrancheamide D )=2+/-1uM
6ia7  2.30  2019  Kd=2uM        // 6ia7.pdf (GTP)
6dgl  1.95  2019  Kd=3.05uM     // 6dgl.pdf (GEV) compound is darglitazone
6dgq  2.45  2019  Kd=3.09uM     // 6dgl.pdf (GBV) compound is CAY10506
6qtw  1.39  2019  Kd=3.0uM      // 6qto.pdf (11-mer) ligand is peptide CRY1; Kd = 3.0 +/- 0.3uM
6a5e  2.77  2019  Kd=3.21uM     // 6a5e.pdf (15-mer)
6c3n  2.53  2019  Kd=3.2mM      // 6c3l.pdf (EHY) Kd(7CC5, NMR)=3.2+/-0.1mM
6qr2  1.55  2019  Kd=3.2uM      // 6qr2.pdf (JQB) ligand is compound 26j: Kd = 3.2+/-0.3uM
6dgo  3.10  2019  Kd=3.36uM     // 6dgl.pdf (GD4) compound is troglitazone
5zxk  1.96  2019  Kd=3.3uM      // 5zxk.pdf (H6P) HMBPP
6fgc  1.50  2019  Kd=3.3uM      // 6fgc.pdf (D95) [Nonstandard assay: displacement titration of the GephE-artesunate complex with the GlyR beta dimer peptide]
6a06  1.79  2019  Kd=3.4nM      // 6a03.pdf (1SY) MST assay, Kd(2',3'-cGAMP)=3.4+/-0.07nM
6gfm  2.77  2019  Kd=3.4uM      // 6gfm.pdf (0O2) ligand is pppGpp
6i74  0.96  2019  Kd=3.4uM      // 6i74.pdf (H5Z) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 3
6om4  1.70  2019  Kd=3.58uM     // 6om4.pdf (7-mer) Peptide sequence is MRTGNAN; Competition FP binding assay
6dzx  1.68  2019  Kd=3.5uM      // 6dzx.pdf (MED) D-methionine
6gdy  2.04  2019  Kd=3.5uM      // 6gdy.pdf (AKG) [Nonstandard assay: in presence of Fe2+] Kd(2OG)=3.5+/-2.1uM
6t1n  1.95  2019  Kd=3.5uM      // 6t1i.pdf (M7Z) ligand is compound 5
6n3y  1.80  2019  Kd=3.65uM     // 6n3v.pdf (HHJ) ligand is TrpGc
6csf  3.30  2019  Kd=3.6uM      // 6cse.pdf (DAL)
6r1b  2.27  2019  Kd=3.6uM      // 6r1b.pdf (CH5) ligand is compound GPC; Kd = 3.6 +/- 0.5 uM
5zdg  2.59  2019  Kd=3.76uM     // 5zdb.pdf (AR6) T267R, Kd=3.76+/-0.47uM
6mli  1.88  2019  Kd=3.7mM      // 6mku.pdf (HIS)
6d8v  2.80  2019  Kd=3.8uM      // 6d8v.pdf (PBE)
6hgg  1.79  2019  Kd=3.8uM      // 6hgd.pdf (HCY) ligand is cortisol
6ott  2.55  2019  Kd=3.8uM      // 6ott.pdf (N7Y) ligand is ppApp
6mm2  1.04  2019  Kd=3.92uM     // 6mm2.pdf (ATP) [Uncommon element] ligand is ATP
6aaq  1.55  2019  Kd=3.9mM      // 6aac.pdf (9U9) compound is BCNLys
6qzr  2.30  2019  Kd=30.0nM     // 6qzr.pdf (11-mer) ligand is FOXO1 pT24 peptide; Kd = 30.0 +/- 3.0 nM
6p88  1.70  2019  Kd=30.2uM     // 6p83.pdf (O4G) ligand is compound 6
6sge  1.50  2019  Kd=30.8nM     // 6hxu.pdf (GTP) RHOB-GTP in complex with nanobody B6
6g25  1.43  2019  Kd=300uM      // 6g24.pdf (EHQ) Kd(compd 4)=300+/-21uM
6e7w  2.67  2019  Kd=305nM      // 6e7w.pdf (HXM) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=305+/-18nM, Kd(PH=6.5)=147+/-5.6nM, chain BD: 363
6q9t  2.68  2019  Kd=30nM       // 6hzx.pdf (15-mer) ligand is 4
6nco  1.71  2019  Kd=30uM       // 6ncn.pdf (KQP) ligand is 3
6qdx  2.10  2019  Kd=30uM       // 6qdx.pdf (HY8) ligand is BA4; Kd = 30+/-4uM
6nu1  2.25  2019  Kd=31.2uM     // 6nu1.pdf (CYS) ligand is cysteine; assay in presence of FBP ligand
6hk3  2.35  2019  Kd=31.4nM     // 6hk3.pdf (G8B) ligand is 5
6j7l  1.85  2019  Kd=31.4uM     // 6j7k.pdf (TYD) ligand is TDP
6jag  1.85  2019  Kd=31.5uM     // 6j9w.pdf (SUC)
6nyv  2.43  2019  Kd=312nM      // 6nyv.pdf (LBD) ligand is compound 1; Kd = 312+/-300nM
6qlq  1.08  2019  Kd=31uM       // 6qln.pdf (J4E) ligand is compound 4; Kd = 31+/-1.3 uM; Binding assay is fluorescence polarization
6mt5  1.55  2019  Kd=32.3uM     // 6mt3.pdf (9-mer)
6qau  2.48  2019  Kd=32.9nM     // 6qas.pdf (1FV) Ligand is compound MRT67307
6fpu  1.36  2019  Kd=321nM      // 6fmn.pdf (E48) microsomal stability assay, Kd(compound 4)=321+/-193nM
6poi  1.77  2019  Kd=326uM      // 6pmf.pdf (OVS) ligand is compound 25; Kd = 326 +/- 65 uM
6dn5  2.40  2019  Kd=32nM       // 6dn5.pdf (7-mer) Kd=32+/-4nM, kon=8.4E+5, koff=2.6E-2
6hhp  1.80  2019  Kd=32nM       // 6hhp.pdf (8-mer) with molecule 1
6dyo  2.84  2019  Kd=32uM       // 6dyo.pdf (LDP)
6ql1  1.42  2019  Kd=330nM      // 6ql1.pdf (V50) ligand is compound 14; Kd = 330 +/- 140 nM
6e7v  2.60  2019  Kd=331nM      // 6e7v.pdf (T88) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=331+/-29nM, Kd(PH=6.5)=171+/-6.6nM, chain BD: 363
6qrf  1.86  2019  Kd=33uM       // 6qrf.pdf (JF5) ligand is compound 3; Kd = 33+/-2 uM
6pvz  1.99  2019  Kd=341uM      // 6pmf.pdf (OZM) ligand is compound 28; Kd = 341 +/- 47 uM
6pyc  3.60  2019  Kd=35.8nM     // 6pyc.pdf (P4S) ligand is compound MBG
6q4e  1.06  2019  Kd=350uM      // 6q3b.pdf (HH5) ligand is compound 33
6e92  1.77  2019  Kd=35nM       // 6e8p.pdf (HZY) [Different protein in assay: protein binding assay is CA IX] compound is STX2845
6qfu  1.80  2019  Kd=35nM       // 6qfu.pdf (J0K) [Uncommon element] ligand is cofactor 7; inculde uncommon Ir element
6dkp  2.97  2019  Kd=36.4nM     // 6d78.pdf (10-mer) alpha-D26Y, alpha-Y50A,beta-L98W, Kd=36.4+/-7.1nM
6e5s  2.06  2019  Kd=367nM      // 6e5s.pdf (RET) [Covalent complex] M2, Kd=367+/-14.7nM
6c3l  1.46  2019  Kd=36uM       // 6c3l.pdf (EGP) Kd(15f, ITC)=36+/-5 uM, Kd(15f, NMR)=44+/-16uM
6np4  1.15  2019  Kd=36uM       // 6np2.pdf (TOY) ligand is compound tobramycin; Kd = 36 +/- 0.3 uM
6c5h  1.99  2019  Kd=370nM      // 6c5h.pdf (5-mer) ligand is PSBP; Kd=370+/-45nM
6m8q  2.49  2019  Kd=370nM      // 6m8q.pdf (JBG) ligand is 2; binding assay method is SEC CTID
6rtw  1.90  2019  Kd=370nM      // 6rtw.pdf (Y01) ligand is cholesterol-hemisuccinate(HS)
6u80  1.55  2019  Kd=37uM       // 6u5m.pdf (Q1J) ligand is compound 5g; Binding assay is FPA
6o3y  2.80  2019  Kd=38.4uM     // 6o3w.pdf (13-mer) ligand is peptide Sen1 NIM3; Kd = 38.4+/-5.0uM
6j1l  2.30  2019  Kd=380nM      // 6j1l.pdf (B6L) ligand is 27
6py0  2.20  2019  Kd=386nM      // 6pxz.pdf (RTL) ligand is retinol, Kd = 386 +/- 143 nM
6qaf  1.61  2019  Kd=38nM       // 6qaf.pdf (XC3) [Uncommon element] [Incomplete ligand] ligand is compound CB-1158; Crystal in PH=9.0, Kd in PH=7.4
6i65  1.50  2019  Kd=390.4nM    // 6i61.pdf (H3Z) ligand is  4-iso-propylphenol
6g5u  1.70  2019  Kd=395nM      // 6g5l.pdf (ENN) Kd(9, FTSA)=395nM
6qtx  1.95  2019  Kd=39uM       // 6qto.pdf (10-mer) ligand is peptide COL3; Kd = 39 +/- 0.4uM
6qzh  2.10  2019  Kd=3nM        // 6qzh.pdf (JLW) ligand is cmp2105
6g2s  2.20  2019  Kd=4.01nM     // 6g2r.pdf (EJN) compound 5
6ggb  1.32  2019  Kd=4.1uM      // 6ggb.pdf (EXQ) ligand is PK9318
6ggf  1.32  2019  Kd=4.1uM      // 6ggf.pdf (EXQ) ligand is PK9318
6aee  3.30  2019  Kd=4.28uM     // 6aee.pdf (9-mer) Kd(D1-D4)=4.28+/-1.53uM, Kd(D1D2)=3.84+/-0.38uM
6hzx  2.91  2019  Kd=4.2nM      // 6hzx.pdf (10-mer) ligand is 2
6n8y  1.55  2019  Kd=4.2uM      // 6n8x.pdf (KFY) ligand is PU-11-trans; redundant to 6olx
6olx  1.44  2019  Kd=4.2uM      // 6n8x.pdf (KFY) ligand is PU-11-trans
5zk5  2.25  2019  Kd=4.3nM      // 5zk5.pdf (16-mer) Kd=4.3+/-0.4nM, kon=6.6+/-0.1E+5, koff=2.6+/-0.5E-2
6n0j  1.79  2019  Kd=4.3uM      // 6n0j.pdf (K8S) ligand is CCG-222740
6os5  1.66  2019  Kd=4.4uM      // 6os3.pdf (TRP) ligand is L-Trp; Kd = 4.4 +/- 0.4 uM
6p7q  1.66  2019  Kd=4.4uM      // 6p7p.pdf (2-mer) ligand is compound 5'-pApA
6uyz  1.40  2019  Kd=4.4uM      // 6uys.pdf (17-mer) ligand is peptide DAXX-SIM-PO4; Kd = 4.4 +/- 0.2 uM
6pgc  1.81  2019  Kd=4.5uM      // 6pg3.pdf (OJJ) ligand is compound 37; Kd = 4.5 +/- 0.3 uM
6qls  1.05  2019  Kd=4.5uM      // 6qln.pdf (HRK) ligand is compound 9; Kd = 4.5+/-0.2 uM; Binding assay is fluorescence polarization
6u6w  1.20  2019  Kd=4.71uM     // 6u5m.pdf (Q0Y) ligand is compound 1; Kd = 4.71 +/- 1.59 uM; Binding assay is FPA
6qmu  1.98  2019  Kd=4.8uM      // 6qmu.pdf (ZCQ) [Covalent complex] ligand is compound 4-nitrocatechol; Kd = 4.8 +/- 0.04 uM
6fvn  3.14  2019  Kd=4.99uM     // 6fvl.pdf (6-mer) Kd(MtwtSC)=4.99+/-3.97uM
6qav  2.05  2019  Kd=4.9nM      // 6qas.pdf (HVH) Ligand is compound MRT68921
5zni  2.30  2019  Kd=40.3uM     // 5znc.pdf (YMZ)
6dzv  4.20  2019  Kd=400nM      // 6d9g.pdf (HJM) [Nonstandard assay: without the 15B8 Fab] [Different protein in assay: protein in crystal structure is dN72/C13 SERT] compound is ibogaine
6im4  1.93  2019  Kd=40nM       // 6im4.pdf (6-mer) ligand is AimP
6s07  1.04  2019  Kd=40nM       // 6s07.pdf (17-mer) ligand is peptide Abz-ATTPLCGPSRASILSGR; Kd = 40 +/- 10 nM
6u9v  2.90  2019  Kd=40nM       // 6u9v.pdf (GDP) ligand is compound GDP; Kd = 40 +/- 10 nM
6hgj  1.83  2019  Kd=41.6uM     // 6hgd.pdf (AS4) ligand is Aldosterone
5zjz  1.67  2019  Kd=42.5nM     // 5zjz.pdf (14-mer) Kd=42.5+/-0.5nM, kon=6.5+/-0.3E+5, koff=2.8+/-0.1E-2
6q38  1.74  2019  Kd=420nM      // 6q38.pdf (9-mer) ligand is Stapled Peptide P1-C4
6h4a  2.65  2019  Kd=42nM       // 6f7i.pdf (FNB) compound MLT-748, kon=2.8E+4, koff=1.1E-3
6h75  1.45  2019  Kd=42uM       // 6h75.pdf (SLB) [Different protein in assay: Protein in binding assay is A11N mutant] ligand is Neu5Gc
6mla  1.58  2019  Kd=42uM       // 6mku.pdf (ARG)
6o5u  1.40  2019  Kd=42uM       // 6np2.pdf (KAN) ligand is compound kanamycin A; Kd = 42 +/- 0.2uM
6k2n  1.80  2019  Kd=43.4mM     // 6k2n.pdf (3-mer) ligand is glycan
6qi4  1.78  2019  Kd=43uM       // 6qi4.pdf (FKW) ligand is compound 3b; Kd = 43 +/- 6 uM
6gj5  1.50  2019  Kd=440uM      // 6gj5.pdf (F0N) ligand is 15
6q6f  3.30  2019  Kd=445.9uM    // 6q6f.pdf (HJQ) ligand is HMS 101; MST assay
6mmo  1.86  2019  Kd=447uM      // 6mmo.pdf (AMP) [Nonstandard assay: Temp 25, pH = 8, NaCl = 20 mM, HEPES = 20 mM]
6q3z  2.00  2019  Kd=44nM       // 6q3y.pdf (HG8) ligand is compound 16k
5zk9  1.76  2019  Kd=45.2nM     // 5zk9.pdf (14-mer) Kd=45.2+/-0.6nM kon=6.2+/-0.2E+5, koff=2.8+/-0.1E-2
6hk7  3.20  2019  Kd=45.9nM     // 6hk3.pdf (G8N) ligand is 6
5ove  1.85  2019  Kd=450nM      // 5ove.pdf (AXE) compound 1
6hkx  2.80  2019  Kd=456.3pM    // 6hkx.pdf (GCE) ligand is Arry-520
6hky  2.75  2019  Kd=456.3pM    // 6hkx.pdf (GCE) ligand is Arry-520
6ajz  1.30  2019  Kd=46uM       // 6ajv.pdf (LOC)
6qat  2.77  2019  Kd=47.3nM     // 6qas.pdf (FE7) Ligand is compound hesperadin
6gy0  2.55  2019  Kd=47.9nM     // 6gy0.pdf (FGE) ligand is AZ3
6phx  2.00  2019  Kd=478.6uM    // 6phx.pdf (3-mer) ligand is raffinose
6g29  1.70  2019  Kd=47uM       // 6g24.pdf (EHK) Kd(compd 6)=47+/-11uM
6jad  1.90  2019  Kd=48.3uM     // 6j9w.pdf (2-mer) ligand is Z9N-GLC 
6ajr  1.34  2019  Kd=48.5uM     // 6ajo.pdf (URA) compound is uracil
6i64  1.91  2019  Kd=48.7nM     // 6i61.pdf (H48) ligand is bisphenol-E
6pg3  2.04  2019  Kd=480uM      // 6pg3.pdf (OHJ) ligand is compound 1; Kd = 480 +/- 30 uM
6oh3  2.75  2019  Kd=482uM      // 6oh2.pdf (NCC) ligand is compound CMP-Sia; Kd = 482+/-147uM
6i5p  1.81  2019  Kd=48uM       // 6i41.pdf (9-mer) [Different protein in assay: ] ligand is BRD3 fragment
6ior  2.50  2019  Kd=49.5uM     // 6iop.pdf (ASN) ligand is L-Asparagine
6nzk  2.80  2019  Kd=49.7uM     // 6nzk.pdf (MJJ) ligand is compound (9-O-Ac-Me-Sia); Kd = 49.7 +/- 10.7 uM
6qfv  1.45  2019  Kd=49nM       // 6qfu.pdf (J0N) [Uncommon element] ligand is cofactor 8; inculde uncommon Ir element
6sdd  1.93  2019  Kd=4nM        // 6sd9.pdf (353) ligand is BMS-777607; pKd=8.4, then Kd=4nM
6qqu  1.59  2019  Kd=5.0uM      // 6qqu.pdf (JF8) ligand is compound 25; Kd = 5.0+/-2.1 uM
6d08  2.10  2019  Kd=5.1uM      // 6d07.pdf (15-mer) Y26F/F50G-CBX1 and H3K9bn, Kd=5.1+/-0.4uM
6mqc  1.99  2019  Kd=5.22nM     // 6mqc.pdf (8-mer)
6d07  2.10  2019  Kd=5.2uM      // 6d07.pdf (15-mer) Kd=5.2+/-0.3uM
6qlp  1.08  2019  Kd=5.2uM      // 6qln.pdf (J3Q) ligand is compound 8; Kd = 5.2+/-0.3 uM; Binding assay is fluorescence polarization
6sfc  2.00  2019  Kd=5.2uM      // 6sfb.pdf (L9T) ligand is compound 3; Kd = 5.2 +/- 1.8 uM
6ajy  1.60  2019  Kd=5.3uM      // 6ajv.pdf (A0R) Kd(ISL 4-methyl ester)=5.3uM, ligand structure is inconsistent with the literature
6qtm  3.00  2019  Kd=5.57uM     // 6qsz.pdf (17-mer) ligand is Ty5 pS1095 peptide
6t1i  1.80  2019  Kd=5.5uM      // 6t1i.pdf (M7W) ligand is compound 1
6a03  2.60  2019  Kd=5.67uM     // 6a03.pdf (2BA) MST assay, Kd(c-diAMP)=5.67+/-0.49uM
6a9o  2.50  2019  Kd=5.7uM      // 6a9o.pdf (6B3) microscale thermophoresis assay, Kd=5.7+/-1.3uM
6gxg  1.60  2019  Kd=5.7uM      // 6gxg.pdf (FFN) 
6gxy  1.80  2019  Kd=5.7uM      // 6gxg.pdf (FFN) 
6iot  2.70  2019  Kd=5.7uM      // 6iop.pdf (ARG) ligand is L-arginine
6pu3  1.80  2019  Kd=5.85uM     // 6ofq.pdf (4-mer) ligand is peptide STSA; Kd = 5.85 +/- 0.56 uM
6jam  1.63  2019  Kd=5.95uM     // 6j9w.pdf (TRE)
6e4v  2.00  2019  Kd=508nM      // 6e4v.pdf (HWS) Kd(coprogen)=508+/-110nM
6q4g  0.98  2019  Kd=50uM       // 6q3b.pdf (HJK) ligand is compound 37
6mji  2.30  2019  Kd=51.5nM     // 6miv.pdf (JTD) ligand is 15s
6ghv  2.10  2019  Kd=52.0uM     // 6ghv.pdf (EZ8) ligand is 16
6k5r   NMR  2019  Kd=53.5uM     // 6k5r.pdf (12-mer) ligand is IE2-SIM1
6hp5  2.28  2019  Kd=53.8nM     // 6hp5.pdf (6-mer) ligand is AimP
6hks  2.19  2019  Kd=53uM       // 6hks.pdf (11-mer)
6q3y  1.20  2019  Kd=54nM       // 6q3y.pdf (HG5) ligand is compound 16i
6mlj  1.60  2019  Kd=55nM       // 6mku.pdf (ARG)
6i7a  2.20  2019  Kd=55uM       // 6i41.pdf (9-mer) [Different protein in assay: Protein in binding assay is D140N mutant] ligand is BRD3 fragment
6dys  2.30  2019  Kd=56.4uM     // 6dys.pdf (HJ1)
6i61  1.65  2019  Kd=569.0nM    // 6i61.pdf (H3W) ligand is Bisphenol-B
6hmy  1.60  2019  Kd=57.7nM     // 6hmy.pdf (6-mer) [Different protein in assay: Protein in binding assay is B-pentamer] ligand is hexaose
6qc0  3.50  2019  Kd=57nM       // 6qc0.pdf (14-mer) ligand is Cdt2 C-terminal PIP-box peptide; sequence is SSMRKICTYFHRKS;
6k5t   NMR  2019  Kd=58.2uM     // 6k5r.pdf (12-mer) ligand is IE2-SIM1
6iyw  1.60  2019  Kd=58.8nM     // 6iyv.pdf (IM2) [Covalent complex] ligand is imipenem
6nng  2.40  2019  Kd=59.4uM     // 6nng.pdf (DJ9) ligand is compound DJ95
6qqt  1.67  2019  Kd=59uM       // 6qqt.pdf (JCH) ligand is compound 24a; Kd = 59 +/- 17 uM
6eeb  1.96  2019  Kd=5uM        // 6eeb.pdf (J6P) Kd(malbrancheamide)=5+/-1uM
6ml9  1.69  2019  Kd=5uM        // 6mku.pdf (ARG)
6ms1  1.35  2019  Kd=6.0uM      // 6ms1.pdf (8-mer)
6a04  1.90  2019  Kd=6.18uM     // 6a03.pdf (C2E) MST assay, Kd(c-diGMP)=6.18+/-0.76uM
6t1m  1.85  2019  Kd=6.1uM      // 6t1i.pdf (M8K) ligand is compound 4
5zyg  1.80  2019  Kd=6.2uM      // 5zyg.pdf (9N3) Kd=6.2+/-2.7uM, kon=5.45E+4, koff=3.0E-1
6iht  1.57  2019  Kd=6.2uM      // 6iht.pdf (3-mer) ligand is His12
6oh2  2.58  2019  Kd=6.3uM      // 6oh2.pdf (C5P) ligand is compound CMP; Kd = 6.3+/-1.2uM
6j63  2.62  2019  Kd=6.43nM     // 6j63.pdf (NTD) ligand is NTBC (this code is belong to literature 6isd )
6nv9  2.13  2019  Kd=6.4nM      // 6nv7.pdf (L3M) ligand is inhibitor 3; Kd = 6.4 +/- 2.9 nM
5zjy  1.59  2019  Kd=6.6nM      // 5zjy.pdf (13-mer) Kd=6.6+/-0.7nM, kon=1.5+/-0.3E+7, koff=9.4+/-0.8E-2
6i97  3.35  2019  Kd=6.6nM      // 6i96.pdf (0UE) [Uncommon element] ligand is B-FoxA
6o2p  3.30  2019  Kd=6.6nM      // 6o1v.pdf (VX7) ligand is compound ivacaftor; Kd = 6.6+/-1.2 nM
6g8i  1.60  2019  Kd=6.71uM     // 6g6x.pdf (11-mer) betaYAP7
6ipk  2.15  2019  Kd=6.7uM      // 6aec.pdf (8DG) [Nonstandard assay: in presence of Mn2+]
6qqq  1.85  2019  Kd=6.7uM      // 6qqq.pdf (JDE) ligand is compound 14; Kd = 6.7 +/- 0.6 uM
6peg  2.00  2019  Kd=6.86uM     // 6peg.pdf (4FQ) ligand is compound L2-4048; allosteric inhibitor
6g2f  1.74  2019  Kd=6.8uM      // 6g24.pdf (EHW) Kd(compd 16)=6.8+/-2.6uM
6k3l  2.09  2019  Kd=60.1nM     // 6k3l.pdf (3NG)
6e8x  1.60  2019  Kd=605nM      // 6e8p.pdf (J0A) [Different protein in assay: protein binding assay is CA IX] compound is STX140
6mtu  2.14  2019  Kd=6083nM     // 6mtu.pdf (8-mer) ligand is pMCC
6i41  1.90  2019  Kd=61uM       // 6i41.pdf (9-mer) ligand is BRD3 fragment
6cn8  1.40  2019  Kd=63.4nM     // 6cn8.pdf (7-mer) Kd(rufomucin 1)=63.4+/-6.0nM, koff=1.08E-1, kon=1.71E+6
6dyn  2.10  2019  Kd=638.9uM    // 6dyn.pdf (HSM)
6pvy  1.74  2019  Kd=639uM      // 6pmf.pdf (OZG) ligand is compound 26; Kd = 639 +/- 87 uM
6sde  2.49  2019  Kd=63pM       // 6sd9.pdf (V0L) ligand is savolitinib; pKd=10.2, then Kd=63pM
6ssy  1.62  2019  Kd=649uM      // 6ssy.pdf (P7I) ligand is 2-AEP
6v1c  1.55  2019  Kd=65uM       // 6v1c.pdf (4A4) ligand is GlcNAc-alpha-1,4-Gal disaccharide
6dy7  1.90  2019  Kd=66.2uM     // 6dy7.pdf (HH7) compound is C1
6e7s  2.72  2019  Kd=66.3nM     // 6e7s.pdf (HZ4) [Nonstandard assay: PH=7.6] Kd(PH=7.6)=66.3+/-3.2nM, Kd(PH=6.5)=70.7+/-2.0nM, chain BD: 363
5zdp  2.71  2019  Kd=66.62nM    // 5zdp.pdf (9AU) koff=0.0914, kon=1.372E+6
6cyg  1.50  2019  Kd=67.5uM     // 6cyg.pdf (N5O) compound is NEoCA, Kd=67.5+/-3.5uM
6p9e  2.00  2019  Kd=67.6nM     // 6p9e.pdf (O6D) kd = 67.6+/-5.98 nM; ligand is compound A-552
6c5j  2.29  2019  Kd=68.5nM     // 6c5h.pdf (5-mer) ligand is PSBP; Kd=68.5+/-29nM, crystal form 1
6c5k  1.75  2019  Kd=68.5nM     // 6c5h.pdf (5-mer) ligand is PSBP; Kd=68.5+/-29nM, crystal form 2
6dya  2.56  2019  Kd=681nM      // 6dy7.pdf (HHM) compound is C5
6det  1.75  2019  Kd=6nM        // 6det.pdf (ARG)
6nu5  1.60  2019  Kd=7.04uM     // 6nu1.pdf (CYS) ligand is cysteine; Kd = 7.04 +/- 1.83 uM
6ntb  1.90  2019  Kd=7.07uM     // 6ntb.pdf (ATP) ligand is ATP. Kd = 3.92 uM  with 7mM CaCl2
5zqu  2.60  2019  Kd=7.0uM      // 5zqu.pdf (9HF) Kd(CBt-PMN)=7.0+/-1.2uM
6n7q  2.10  2019  Kd=7.0uM      // 6n7q.pdf (13-mer)
6r9s  2.00  2019  Kd=7.1mM      // 6r8l.pdf (JVN) ligand is compound 3
6miv  2.05  2019  Kd=7.1nM      // 6miv.pdf (JU1) ligand is 15q
6j9w  1.80  2019  Kd=7.46uM     // 6j9w.pdf (TRE)
6r9u  1.26  2019  Kd=7.5mM      // 6r8l.pdf (JVQ) ligand is compound 4
6qe5  1.61  2019  Kd=7.5uM      // 6qdx.pdf (SAH) ligand is SAH; Kd = 7.5+/-0.9uM
6o3w  2.10  2019  Kd=7.65uM     // 6o3w.pdf (14-mer) ligand is peptide Sen1 NIM1; Kd = 7.65+/-0.89uM
6i13  1.79  2019  Kd=7.6uM      // 6i0z.pdf (H0Q) ligand is 7
6aao  1.40  2019  Kd=7.8mM      // 6aac.pdf (9U0) compound is TCO*Lys
5zml  1.80  2019  Kd=7.8nM      // 5zml.pdf (16-mer) Kd=7.8+/-1.9nM, kon=2.2+/-0.3E+6, koff=1.6+/-0.3E-2
6jdi  1.95  2019  Kd=7.8uM      // 6j7e.pdf (AGS) ligand is ATPgS
6hoi  1.14  2019  Kd=7.95uM     // 6hoi.pdf (10-mer) ligand is LIR peptide of BECN1
6cyh  1.49  2019  Kd=708uM      // 6cyg.pdf (N5A) compound is NEaCA, Kd=708+/-88uM
6mku  1.73  2019  Kd=70nM       // 6mku.pdf (ARG)
6qr7  2.03  2019  Kd=70nM       // 6qr7.pdf (JEK) ligand is compound 29b; Kd = 70 +/- 29 nM
6n9t  2.58  2019  Kd=70uM       // 6n9t.pdf (13-mer) ligand is 7a
6fcj  2.49  2019  Kd=71.1nM     // 6fcj.pdf (D4W) Kd=71.1+/-4.33nM, kon=4.79E+5,  koff=3.38E-2
6qra  1.71  2019  Kd=710nM      // 6qra.pdf (JDK) ligand is compound 31b; Kd = 710 +/- 90nM
6qcg  3.40  2019  Kd=7200nM     // 6qc0.pdf (14-mer) ligand is Cdt1 N-terminal PIP-box peptide; sequence is MEQRRVTDFFARRR; Kd = 7200+/-200nM
6g27  1.65  2019  Kd=731uM      // 6g24.pdf (EHE) Kd(compd 5)=731+/-308uM
6qhg  1.48  2019  Kd=737uM      // 6qhg.pdf (MGT) ligand is m7-GTP; Kd = 737 +/- 47 uM
6st0  1.50  2019  Kd=7463nM     // 6ssy.pdf (LUQ) ligand is ACES
6rhe  3.10  2019  Kd=74uM       // 6rhe.pdf (5-mer) ligand is S-GlcNAc peptide; Kd = 74 +/- 16 uM; FP assay
6mtv  2.60  2019  Kd=7715nM     // 6mtu.pdf (8-mer) ligand is MCC
6nfg  2.76  2019  Kd=78uM       // 5v8h.pdf (KKP) [Incomplete ligand] ligand is compound 16
6gxq  1.96  2019  Kd=79.4nM     // 6gxq.pdf (FFZ) ligand is 37
6ios  2.35  2019  Kd=79.4uM     // 6iop.pdf (PRO) ligand is L-proline
6q92  1.50  2019  Kd=797nM      // 6q92.pdf (ABH) [Uncommon element] ligand is compound ABH; PH=7.4; B element contained
6dn6  1.59  2019  Kd=7nM        // 6dn5.pdf (5-mer) Kd=7+/-2nM, kon=5E+5, koff=3.2E-3
5oai  2.00  2019  Kd=7uM        // 5oai.pdf (B5K) [Different protein in assay: protein in binding assay is MDM2(1-118)] MST assay for compound (R)-6a
6n3x  1.10  2019  Kd=8.09uM     // 6n3v.pdf (KBD) ligand is 3
6j9y  1.63  2019  Kd=8.54uM     // 6j9w.pdf (MAL)
6nnr  1.05  2019  Kd=8.5uM      // 4knz.pdf (UMC) ligand is dUMP; Kd = 8.5 +/- 0.9 uM(without Mg2+)
6i76  1.20  2019  Kd=8.5uM      // 6i74.pdf (H5N) [Different ligand in assay: ligand in binding asssay is racemic mixture] ligand is 4
6qr1  1.67  2019  Kd=8.5uM      // 6qr1.pdf (JFT) ligand is compound 27g; Kd = 8.5 +/- 1.0 uM
6n0k  1.46  2019  Kd=8.6uM      // 6n0k.pdf (K8M) ligand is CCG-257081
6pl2  2.59  2019  Kd=8.74nM     // 6pl2.pdf (OOM) ligand is compound 1a
6kqi  3.25  2019  Kd=8.7nM      // 6kqi.pdf (9GF) [Different protein in assay: Protein in binding assay is wild type] ligand is CP55940
6qlo  1.18  2019  Kd=8.8uM      // 6qln.pdf (J5E) ligand is compound 5; Kd = 8.8+/-0.3 uM; Binding assay is fluorescence polarization
6agp   NMR  2019  Kd=8.9uM      // 6agp.pdf (GDP) [Nonstandard assay: in presence of GDP] Kd(Mg2+)=8.9+/-0.7uM
6kjd  2.30  2019  Kd=8.9uM      // 6kjd.pdf (LVA) ligand is lovastatin
6pml  2.00  2019  Kd=820uM      // 6pmf.pdf (OR4) ligand is compound 23; Kd = 820 +/- 140 uM
6fh3  1.85  2019  Kd=850uM      // 6fh2.pdf (RPI) Kd(pArg)=850+/-400uM
6i18  1.49  2019  Kd=85uM       // 6i0z.pdf (H0N) ligand is BDP-13176
6nm4  2.58  2019  Kd=87nM       // 6nm4.pdf (KS7) ligand is compound MRK-740
6ftf  1.09  2019  Kd=8nM        // 6ftf.pdf (7CI) Kd(7-CN-7-C-Ino)=8+/-2nM
6m87  2.61  2019  Kd=8nM        // 6m87.pdf (2M9) ligand is MPTS
6md6  1.68  2019  Kd=8uM        // 6md6.pdf (JSV) ligand is G6SG-OMe
6s57  1.82  2019  Kd=8uM        // 6s55.pdf (KVT) ligand is compound 15; SPR pKd=5.1
6s56  2.01  2019  Kd=8uM        // 6s55.pdf (KVZ) ligand is compound 9; SPR pKd=5.1
6ajv  1.45  2019  Kd=9.1uM      // 6ajv.pdf (HCC) Kd(ISL)=9.1uM, +DMSO in crystal structure
6ajx  1.89  2019  Kd=9.1uM      // 6ajv.pdf (HCC) Kd(ISL)=9.1uM, -DMSO in crystal structure; redundant to 6ajv
6cyi  1.76  2019  Kd=9.1uM      // 6cyg.pdf (N5O) compound is NEoCA, Kd=9.1+/-0.3uM
6j7e  2.40  2019  Kd=9.2uM      // 6j7e.pdf (AGS) ligand is ATPgS
6hbm  2.76  2019  Kd=9.6uM      // 6hbd.pdf (AHR) ligand is D-galactofuranose
6hgf  1.65  2019  Kd=9.6uM      // 6hgd.pdf (HCY) ligand is cortisol
6p89  1.40  2019  Kd=9.77uM     // 6p83.pdf (O4A) ligand is compound 7
6g2e  1.85  2019  Kd=9.7uM      // 6g24.pdf (EHH) Kd(compd 13)=9.7+/-2.3uM
6ncn  1.82  2019  Kd=900uM      // 6ncn.pdf (KJM) ligand is 1
6joe  2.21  2019  Kd=91nM       // 5zhj.pdf (BWR) AZ51, koff=1.17E-2, kon=1.28E+5
6qpl  1.60  2019  Kd=91nM       // 6qpl.pdf (JC5) ligand is compound 3; Kd = 91 +/- 4 nM
6hmt  1.10  2019  Kd=92nM       // 6hhp.pdf (8-mer) with molecule 2
6i0z  1.77  2019  Kd=92uM       // 6i0z.pdf (GZQ) ligand is 1
6qlt  1.15  2019  Kd=92uM       // 6qln.pdf (J5W) ligand is compound 2; Kd = 92+/-5 uM; Binding assay is fluorescence polarization
6hni  1.35  2019  Kd=94uM       // 6hni.pdf (TYR)
6i63  2.23  2019  Kd=98.6nM     // 6i61.pdf (2OH) ligand is bisphenol-A
6njz  1.90  2019  Kd=9800nM     // 6njz.pdf (17-mer) ligand is YSA-GSGSK-bio peptide
6hay  2.24  2019  Kd=98nM       // 6hax.pdf (FX8) ligand is PROTAC 1, ternary complex VHL and PROTAC 1 with SMARCA2
6hhr  2.00  2019  Kd=98nM       // 6hhr.pdf (G5E) ligand is 7
6rk4  1.43  2019  Kd=98uM       // 6rje.pdf (K5T) ligand is P4-G5; high-resolution set crystal
6afk  2.75  2019  Kd=999nM      // 6afk.pdf (9WO) compound 32, kon=2.11E+5, koff=0.211
6ooz  2.80  2019  Kd=9nM        // 6ooy.pdf (A6Y) ligand is UCB-5307; Biopore assay
6da1  2.00  2019  Kd=9uM        // 6da1.pdf (16-mer) [Nonstandard assay: PH=6.5] Kd=9+/-6uM, crystal: PH=7.3
6dat  2.35  2019  Kd=9uM        // 6da1.pdf (16-mer) [Nonstandard assay: PH=6.5] Kd=9+/-6uM, crystal: PH=8.5
6mlg  1.89  2019  Kd=9uM        // 6mku.pdf (ARG)
6quw  1.24  2019  Kd>1.5mM      // 6quu.pdf (JJQ) ligand is compound 9b
6i15  1.91  2019  Kd>100uM      // 6i0z.pdf (GZT) ligand is 11
6i16  2.00  2019  Kd>100uM      // 6i0z.pdf (H0B) ligand is 15
6ra1  2.00  2019  Kd>10mM       // 6r8l.pdf (JVQ) ligand is compound 7
6oxl  3.50  2019  Kd>3000nM     // 6oxl.pdf (7-mer) ligand is peptide NECAP; Binding assay is pulldown depletion assays.
6o9b  2.20  2019  Kd>400nM      // 6o9b.pdf (9-mer) ligand is beta-catenin peptide
6gzy  2.15  2019  Kd>400uM      // 6gzy.pdf (FHH) ligand is 5
6hov  1.85  2019  Kd>500uM      // 6hop.pdf (FER) ligand is Ferulic acid; binding assay method is BROMOscan assay
6ob0  2.81  2019  Kd~11uM       // 6oau.pdf (M3D) ligand is compound 2
6e13  2.35  2019  Kd~200nM      // 6e13.pdf (HKS) [Nonstandard assay: in presence of excess Zn2+] Cys-DOPA
6hck  2.70  2019  Kd~25uM       // 6hck.pdf (LEU)
6omu  1.41  2019  Kd~2nM        // 6omu.pdf (MZJ) ligand is compound evobrutinib
6oos  1.90  2019  Ki<0.005nM    // 6oos.pdf (017) ligand is compound DRV (darunavir)
6oot  1.82  2019  Ki<0.005nM    // 6oos.pdf (017) ligand is compound DRV(darunavir)
6oou  2.13  2019  Ki<0.005nM    // 6oos.pdf (017) ligand is compound DRV(darunavir)
6c2t  1.73  2019  Ki<0.9nM      // 6c2r.pdf (EGJ)
6oxq  1.89  2019  Ki=0.005nM    // 6oxo.pdf (F53) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 4; Ki = 0.005 +/- 0.002 nM
6ng0  2.05  2019  Ki=0.0064uM   // 6nfy.pdf (B49) ligand is compound sunitinib; Ki = 0.0064+/-0.0034uM at ATP=300 uM
6qgh  2.00  2019  Ki=0.007uM    // 6qfi.pdf (1XJ) ligand is compound 13, ABT-263; FP Ki data
6oxp  1.97  2019  Ki=0.010nM    // 6oxo.pdf (K2A) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 3; Ki = 0.010 +/- 0.03 nM
6o0k  1.62  2019  Ki=0.018nM    // 6o0k.pdf (LBM) ligand is venetoclax; Ki = 0.018+/-0.014 nM
5zg1  1.32  2019  Ki=0.019uM    // 5zg0.pdf (9C0)
6oxv  1.99  2019  Ki=0.020nM    // 6oxo.pdf (NF4) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 16; Ki = 0.020 +/- 0.002 nM
6oxw  1.98  2019  Ki=0.028nM    // 6oxo.pdf (NFJ) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 17; Ki = 0.028 +/- 0.003 nM
6ne5  1.85  2019  Ki=0.03nM     // 6ne5.pdf (KJP) ligand is compound 42; Ki = 0.030+/-0.02nM
6no9  1.71  2019  Ki=0.03nM     // 6no9.pdf (KUV) ligand is compound 16
6oxr  2.04  2019  Ki=0.048nM    // 6oxo.pdf (NJA) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 12; Ki = 0.048 +/- 0.04 nM
6p3t  2.50  2019  Ki=0.048uM    // 6p3t.pdf (NRS) ligand is compound 1, inhibitor SGT449; Ki = 0.048 +/- 0.003 uM
6oqc  1.80  2019  Ki=0.04nM     // 6o6f.pdf (N0S) ligand is compound 9
6d3x  1.80  2019  Ki=0.051nM    // 6d3x.pdf (14-mer) Ki=0.051+/-0.007nM,
6udv  1.35  2019  Ki=0.051nM    // 6ud2.pdf (Q51) ligand is compound 3
6hlb  2.00  2019  Ki=0.0538nM   // 6hlb.pdf (9-mer) ligand is 10
6oy1  2.00  2019  Ki=0.057nM    // 6oxo.pdf (NJ1) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 26; Ki = 0.057 +/- 0.004 nM
6oqb  1.60  2019  Ki=0.05nM     // 6o6f.pdf (N0J) ligand is compound 10 (AM-8621); Some data are Ki, some are IC50
5zg3  1.65  2019  Ki=0.061uM    // 5zg0.pdf (9C6)
6ud2  1.70  2019  Ki=0.062nM    // 6ud2.pdf (Q4D) ligand is compound 1
6nzt  1.40  2019  Ki=0.063nM    // 6nzt.pdf (L9P) ligand is compound 36, voxilaprevir;
6ndl  2.00  2019  Ki=0.065uM    // 6ndl.pdf (BQX) ligand is compound 7; Ki = 0.065 +/- 0.03 nM
6nzv  1.55  2019  Ki=0.067nM    // 6nzt.pdf (L9J) ligand is compound 12
6pvx  1.55  2019  Ki=0.068uM    // 6pvu.pdf (U5F) ligand is compound p5U; Ki = 0.068 +/- 0.007 uM
5zty  2.80  2019  Ki=0.075nM    // 5zty.pdf (9JU)
6jn6  1.60  2019  Ki=0.07uM     // 6j8q.pdf (BY0) [Incomplete ligand] ligand is MS19
5zg0  1.58  2019  Ki=0.082uM    // 5zg0.pdf (9C3)
6oxu  1.86  2019  Ki=0.095nM    // 6oxo.pdf (NE7) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 15; Ki = 0.095 +/- 0.005 nM
6p3u  2.55  2019  Ki=0.095uM    // 6p3t.pdf (NRY) ligand is compound 2; Ki = 0.095 +/- 0.005 uM
6p3v  2.50  2019  Ki=0.096uM    // 6p3t.pdf (NRV) ligand is compound 3; Ki = 0.096 +/- 0.010 uM
6n4b  3.00  2019  Ki=0.098nM    // 6n4b.pdf (KCA) ligand is FUB
6oxx  1.96  2019  Ki=0.098nM    // 6oxo.pdf (NF7) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 22; Ki = 0.098 +/- 0.008 nM
6oxs  1.99  2019  Ki=0.109nM    // 6oxo.pdf (NJ4) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 13; Ki = 0.109 +/- 0.007 nM
6udi  1.94  2019  Ki=0.10nM     // 6ud2.pdf (Q4S) ligand is compound 20; Ki = 0.10 +/- 0.01 nM
6oxt  1.86  2019  Ki=0.111nM    // 6oxo.pdf (NEJ) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 14; Ki = 0.111 +/- 0.008 nM
6ps0  3.40  2019  Ki=0.114nM    // 6prz.pdf (CAU) ligand is carazolol
6o0p  1.80  2019  Ki=0.11nM     // 6o0k.pdf (LBM) ligand is venetoclax; Ki = 0.11 +/- 0.03 nM
6me4  3.20  2019  Ki=0.12nM     // 6me2.pdf (ML2) ligand is 2-iodomelatonin
6oy2  1.99  2019  Ki=0.134nM    // 6oxo.pdf (NJJ) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 27; Ki = 0.134 +/- 0.007 nM
6ps4  2.60  2019  Ki=0.13nM     // 6prz.pdf (JRZ) ligand is ICI-118551
6d40  1.43  2019  Ki=0.14nM     // 6d40.pdf (14-mer) Ki=0.14+/-0.02nM
6q89  2.21  2019  Ki=0.14nM     // 6hb5.pdf (LSS) [Incomplete ligand]
6oqd  1.48  2019  Ki=0.14nM     // 6o6f.pdf (N0M) ligand is compound 8
6ps3  2.50  2019  Ki=0.166nM    // 6prz.pdf (CVD) ligand is carvedilol
6sbt  2.30  2019  Ki=0.166uM    // 6sbt.pdf (L5H) Ligand is compound 11; Ki = 0.166+/-0.011uM
6ixd  1.00  2019  Ki=0.16nM     // 6ixd.pdf (B0F) ligand is 2
6h9x  2.10  2019  Ki=0.18nM     // 6h9x.pdf (SSA) [Incomplete ligand] ligand is 15
6i9a  1.20  2019  Ki=0.1nM      // 6i9a.pdf (H8E) ligand is KYT-36
6udt  1.50  2019  Ki=0.1nM      // 6ud2.pdf (Q4V) ligand is compound 10
6ps1  3.20  2019  Ki=0.201nM    // 6prz.pdf (TIM) ligand is timolol
6ps6  2.70  2019  Ki=0.201nM    // 6prz.pdf (TIM) ligand is timolol
6cjs  1.90  2019  Ki=0.20nM     // 6cjj.pdf (2GJ) AUY922
6oxz  1.96  2019  Ki=0.216nM    // 6oxo.pdf (NJG) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 24; Ki = 0.216 +/- 0.011 nM
6n78  1.83  2019  Ki=0.21nM     // 6n78.pdf (KEP) ligand is 21
6n79  2.27  2019  Ki=0.21nM     // 6n79.pdf (KES) ligand is 20
6jij  2.65  2019  Ki=0.23uM     // 6jij.pdf (6-mer) [Covalent complex] ligand is N3
6saf  2.05  2019  Ki=0.23uM     // 6saf.pdf (L2Q) ligand is compound 25
6d19  1.45  2019  Ki=0.246uM    // 6d15.pdf (YKG) compound 9, Ki=0.246+/-0.047uM
6oxy  1.96  2019  Ki=0.283nM    // 6oxo.pdf (NG4) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 23; Ki = 0.283 +/- 0.024 nM
6cjr  1.80  2019  Ki=0.30nM     // 6cjj.pdf (E0G) SNX-2112
6o5t  2.10  2019  Ki=0.316uM    // 6d15.pdf (L8J) compound 16, Ki=0.316+/-0.015uM
6ftw  2.16  2019  Ki=0.32uM     // 6ftw.pdf (E6Z) pKi(8b)=6.5+/-0.2
6q54  1.40  2019  Ki=0.32uM     // 6q54.pdf (HJ8) ligand is compound 6b; Ki = 0.32+/-0.03uM
6pt3  3.30  2019  Ki=0.39nM     // 6pt2.pdf (OWY) ligand is DPI-287
6hoq  1.55  2019  Ki=0.41uM     // 6hop.pdf (FER) ligand is ferulic acid
6me3  2.90  2019  Ki=0.42nM     // 6me2.pdf (JEY) ligand is 2-pmt
6iql  3.50  2019  Ki=0.43nM     // 6iql.pdf (L74) ligand is L745870
6me2  2.80  2019  Ki=0.43nM     // 6me2.pdf (JEV) ligand is ramelteon
6o0m  1.75  2019  Ki=0.46nM     // 6o0k.pdf (LBM) ligand is venetoclax; Ki = 0.46 +/- 0.12 nM
6pvw  1.60  2019  Ki=0.48uM     // 6pvu.pdf (OZV) ligand is compound cp4pA; Ki = 0.48 +/- 0.03 uM
6hle  1.99  2019  Ki=0.491nM    // 6hlb.pdf (6-mer) ligand is 5
6ibl  2.70  2019  Ki=0.49nM     // 6h7k.pdf (H98) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is formoterol
6hza  1.90  2019  Ki=0.504nM    // 6hlb.pdf (5-mer) ligand is 2
6oy0  2.00  2019  Ki=0.504nM    // 6oxo.pdf (NJ7) [Different protein in assay: Protein in binding assay is I84V mutant] ligand is compound 25; Ki = 0.504 +/- 0.039 nM
6n77  1.64  2019  Ki=0.57nM     // 6n77.pdf (KEJ) ligand is 15
6orr  2.25  2019  Ki=0.5nM      // 6orr.pdf (N37) ligand is compound 10, Inhibitor NS1; pKi = 9.30 +/- 0.07
6udu  1.75  2019  Ki=0.5nM      // 6ud2.pdf (Q4Y) ligand is compound 8
6qgg  1.50  2019  Ki=0.5uM      // 6qfi.pdf (J1H) ligand is compound 1; FP Ki data
6hld  2.10  2019  Ki=0.618nM    // 6hlb.pdf (7-mer) ligand is 12
6pgx  1.36  2019  Ki=0.62nM     // 6pgx.pdf (OJ4) ligand is compound 8; Binding assay is stopped flow CO2 hydrase assay
6ggg  1.71  2019  Ki=0.63nM     // 6ggg.pdf (EYN) the order is wrong, this code appears in the first literature.(same as 6gev 6gg8)
6n7c  1.69  2019  Ki=0.67nM     // 6n7c.pdf (KF1) ligand is 56
6hzd  1.90  2019  Ki=0.68nM     // 6hlb.pdf (6-mer) ligand is 4
6n7b  1.81  2019  Ki=0.6nM      // 6n7b.pdf (KEY) ligand is 38
6j8r  1.58  2019  Ki=0.76uM     // 6j8q.pdf (BHU) [Incomplete ligand] ligand is MS01
6gg8  1.80  2019  Ki=0.79nM     // 6gg8.pdf (EY8) pKi=9.1, compound is (R)-36
6odz  1.30  2019  Ki=0.7nM      // 6odz.pdf (M8J) ligand is compound 5a; Binding assay is stopped flow CO2 hydrase assay
6c2r  1.96  2019  Ki=0.8nM      // 6c2r.pdf (EG7)
6hzb  1.90  2019  Ki=1.05nM     // 6hlb.pdf (5-mer) ligand is 3
6fz4  1.85  2019  Ki=1.12uM     // 6fz4.pdf (EC8) Ki(37)=1.12+/-0.14uM
6hzc  1.90  2019  Ki=1.17nM     // 6hlb.pdf (6-mer) ligand is 7
6pit  2.25  2019  Ki=1.19uM     // 6pit.pdf (12-mer) ligand is SRC2 peptide 6a; Ki = 1.19 +/- 0.041 uM; FP assay
6d3z  2.00  2019  Ki=1.2nM      // 6d3z.pdf (14-mer) Ki=1.2+/-0.2nM
6oe0  1.30  2019  Ki=1.2nM      // 6odz.pdf (M8S) ligand is compound 5c; Binding assay is stopped flow CO2 hydrase assay
6peu  1.95  2019  Ki=1.3uM      // 6peu.pdf (12-mer) [Different ligand in assay: ligand in binding assay is MBP-SGSLESTSLRLGFYGYDLQDAAALEHHHHHH] ligand is peptide GRLGFYGYDLQD; Ki = 1.3+/-0.1 uM; Binding assay is fluorescence polarization
6s1s  1.78  2019  Ki=1.45uM     // 6s1s.pdf (KRT) ligand is compound 3
6d18  1.35  2019  Ki=1.4uM      // 6d15.pdf (GTV) compound 6, Ki=1.4+/-0.2uM
6npf  2.57  2019  Ki=1.4uM      // 6d3q.pdf (KVM) compound is KSF
6pvv  1.65  2019  Ki=1.4uM      // 6pvu.pdf (5FA) ligand is compound p5A; Ki = 1.4 +/- 0.06 uM
6nt2  2.48  2019  Ki=1.5nM      // 6nt2.pdf (KZS) ligand is compound GSK3368715
6me5  3.20  2019  Ki=1.67nM     // 6me2.pdf (AWY) ligand is agomelatine
6jav  1.44  2019  Ki=1.72uM     // 6jav.pdf (BC0) ligand is PT
6mq3  3.57  2019  Ki=1.7nM      // 6byz.pdf (J22) compound 63
6eds  3.18  2019  Ki=1.7nM      // 6byz.pdf (J22) compound 63, in complex with glucagon
6o94  1.98  2019  Ki=1.8nM      // 6o8u.pdf (LRS) ligand is compound 17; Ki = 1.8+/-0.9nM
6q60  1.55  2019  Ki=1.97uM     // 6q54.pdf (HJH) ligand is compound 7a; Ki = 1.97+/-0.17uM
6jay  1.50  2019  Ki=1.99uM     // 6jav.pdf (JUK) ligand is DP
6hhj  2.30  2019  Ki=10.7nM     // 6hhj.pdf (G4H) [Covalent complex] ligand is 24b
6n92  1.70  2019  Ki=10.8uM     // 6n92.pdf (KFV) ligand is 7
6hr2  1.76  2019  Ki=100nM      // 6hax.pdf (FWZ) ligand is PROTAC 2, ternary complex VHL and PROTAC 2 with SMARCA4
6u26  1.53  2019  Ki=107nM      // 6u26.pdf (063) ligand is compound 16; FP assay
6oac  3.15  2019  Ki=11.1nM     // 6oac.pdf (M1J) ligand is compound 6(PQR530); Binding assay is LanthaScreen technology
6s4t  2.00  2019  Ki=11.2nM     // 6s4n.pdf (KVB) ligand is WAY-254011; pKi=7.95
6rvl  1.72  2019  Ki=1148nM     // 6rvf.pdf (KKE) [Uncommon element] [Incomplete ligand] ligand is compound 3a; ligand is hydroxylation
6ibs  1.37  2019  Ki=11uM       // 6ibs.pdf (HB8) [Uncommon element] [Incomplete ligand] ligand is 6
6r0v  1.60  2019  Ki=11uM       // 6r0q.pdf (JO2) ligand is compound 4b; Ki = 11+/-1.8 uM
6c9v  1.70  2019  Ki=120.2nM    // 6c67.pdf (ERS) enzymic inhibition assay, compound 7, Ki=120.2+/-0.9nM
6g9x  2.30  2019  Ki=120uM      // 6g9x.pdf (JKE) Microscale thermophoresis binding assay, compound is TSA
6hzy  1.70  2019  Ki=121uM      // 6hzy.pdf (GYZ) ligand is 39
6d1b  1.25  2019  Ki=123.7uM    // 6d15.pdf (FUJ) compound 2, Ki=123.7+/-3.6uM
6c85  2.40  2019  Ki=126uM      // 6c85.pdf (PLQ) enzyme assay, Ki=126+/-14uM
6hp0  1.88  2019  Ki=12uM       // 6hp0.pdf (GJT) ligand is 17
6r11  1.75  2019  Ki=12uM       // 6r0q.pdf (JOB) ligand is compound 5b; Ki = 12 +/- 0.7 uM
6r18  1.35  2019  Ki=12uM       // 6r0q.pdf (JOQ) ligand is compound 11a; Ki = 12 +/- 1.7 uM
6r1c  1.50  2019  Ki=12uM       // 6r0q.pdf (JOW) ligand is compound 12a; Ki = 12 +/- 2.0 uM
6i5g  2.00  2019  Ki=13.03uM    // 6i5g.pdf (PTG) ligand is 15d-PGJ2
6h14  1.86  2019  Ki=13.7nM     // 6h14.pdf (FW8) [Different protein in assay: The source of protein in binding assay is human] [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 6
6rw1  1.70  2019  Ki=1305nM     // 6rvf.pdf (KL5) [Uncommon element] [Incomplete ligand] ligand is compound 3b; ligand is hydroxylation
6gf3  2.40  2019  Ki=14.3uM     // 6gf3.pdf (EX5) ligand is 34
6iam  1.51  2019  Ki=140nM      // 6iam.pdf (12-mer) [Incomplete ligand] ligand is 4
6ovz  2.02  2019  Ki=140uM      // 6ovz.pdf (N9M) [Covalent complex] [Incomplete ligand] ligand is compound 1 and as a substrate of NDM-1, after a substitute it lose a phenyl and form a  covalent bond with the protein
6hb5  1.88  2019  Ki=1484nM     // 6hb5.pdf (YSC) [Incomplete ligand]
6hb7  1.90  2019  Ki=149nM      // 6hb5.pdf (Y3U) [Incomplete ligand]
6myn  2.74  2019  Ki=14nM       // 5w5q.pdf (K6Y) compound is (R)-7
6ox0  1.76  2019  Ki=14uM       // 6ox0.pdf (SFG) ligand is sinefungin; Ki = 14 +/- 1uM
6a8n  2.49  2019  Ki=15.3nM     // 6a8g.pdf (10-mer) Ki(muPA-SPD, IG-2)=15.3+/-0.5nM
6d17  1.45  2019  Ki=15.3uM     // 6d15.pdf (VKE) compound 3, Ki=15.3+/-2.5uM
6u7o  1.33  2019  Ki=15.5pM     // 6u7o.pdf (Q1D) ligand is compound 6
6gvi  2.90  2019  Ki=150nM      // 6gvf.pdf (FDW) ligand is 3j
6q35  1.40  2019  Ki=15uM       // 6ibs.pdf (HD5) [Uncommon element] [Incomplete ligand] ligand is 3
6s4n  1.90  2019  Ki=162nM      // 6s4n.pdf (KUW) ligand is AZ6; pKi=6.79
6s4u  2.81  2019  Ki=17.4nM     // 6s4n.pdf (KVK) ligand is AZ3; pKi=7.76
6hhg  2.30  2019  Ki=17.5nM     // 6hhg.pdf (G4T) [Covalent complex] [Incomplete ligand] ligand is 27
6hgs  1.55  2019  Ki=170uM      // 6hgq.pdf (5GP) ligand is GMP
6e6m  1.55  2019  Ki=1786.5nM   // 6e5l.pdf (8CB) compound CBDO at 350nm
5qqo  2.00  2019  Ki=17nM       // 5qqo.pdf (NRJ) compound 10
6mlw  1.90  2019  Ki=184uM      // 6mlf.pdf (JVA) ligand is 8
6szp  1.76  2019  Ki=18uM       // 6szp.pdf (M3B) ligand is compound 8a; Ki = 18 +/- 6 uM;
6ugz  1.31  2019  Ki=19.1nM     // 6ugn.pdf (Q71) ligand is compound 2h, SB4-208
6n94  1.75  2019  Ki=19.8uM     // 6n94.pdf (KGJ) ligand is 9
6d1h  1.25  2019  Ki=190.2uM    // 6d15.pdf (KED) compound 11, Ki=190.2+/-22.6uM
6mnp  2.20  2019  Ki=195uM      // 6efj.pdf (1CE) [Different ligand in assay: ligand structure is different from that reported in the literature] Ki(compound 7)=195+/-44uM,   -Lactamase Inhibition Assay
6rfn  2.29  2019  Ki=199.5nM    // 6gxq.pdf (K3W) ligand is 40
6gev  1.54  2019  Ki=2.00nM     // 6gev.pdf (EWN) pKi=8.7, compound is (S)-13
6nmb  2.30  2019  Ki=2.01mM     // 6nmb.pdf (AMH) ligand is compound TXA;Ki = 2.01+/-0.09mM
6jn4  1.90  2019  Ki=2.02uM     // 6j8q.pdf (BX9) [Incomplete ligand] ligand is MS22
6d3y  1.32  2019  Ki=2.0nM      // 6d3y.pdf (14-mer) Ki=2.0+/-0.3nM
6jaw  1.98  2019  Ki=2.18uM     // 6jav.pdf (BBO) ligand is NI
6u7p  1.13  2019  Ki=2.1pM      // 6u7o.pdf (B4R) ligand is compound 7
6prf  1.21  2019  Ki=2.5nM      // 6prf.pdf (7OA) ligand is compound 2, GRL-14213A; Ki = 2.5 +/- 0.5 nM
6mxc  1.99  2019  Ki=2.73uM     // 6mxb.pdf (5GP)
6hy7  2.26  2019  Ki=2.7uM      // 6hy7.pdf (13-mer) ligand is RgIA
6j8q  1.79  2019  Ki=2.7uM      // 6j8q.pdf (BHU) [Incomplete ligand] ligand is MS01
6o50  2.35  2019  Ki=2.8nM      // 6o4w.pdf (EBW) [Different protein in assay: assay use mouse AChE, crystal use human AChE] ligand is compound BW284c51;
6ouv  1.94  2019  Ki=2.8uM      // 6ouv.pdf (TDK) ligand is MAP; Ki = 2.8 +/- 0.2 uM
6qyk  2.30  2019  Ki=2.8uM      // 6qxj.pdf (JLB) ligand is compound 7a; FP binding assay
6i5y  1.90  2019  Ki=2.9nM      // 6hb5.pdf (YSA) [Incomplete ligand]
6h12  2.20  2019  Ki=20.8nM     // 6h12.pdf (FJK) [Different protein in assay: The source of protein in binding assay is human] [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 2
6q8c  2.31  2019  Ki=20.8nM     // 6hb5.pdf (LSU) [Incomplete ligand]
6nwk  1.65  2019  Ki=20nM       // 6nwk.pdf (DEX) ligand is DEX
6d3g  2.40  2019  Ki=20uM       // 6d3g.pdf (NXL) [Covalent complex] compound is avibactam
6r13  1.65  2019  Ki=20uM       // 6r0q.pdf (JOK) ligand is compound 7f; Ki = 20+/-2.6uM
6mlh  1.65  2019  Ki=213uM      // 6mlf.pdf (GPM) ligand is 7
6plf  1.70  2019  Ki=214nM      // 6plf.pdf (ONV) ligand is compound 1; Ki = 214 +/- 26 nM
6nyh  2.10  2019  Ki=21nM       // 6nyh.pdf (L8D) ligand is compound GNE684; Binding assay is RIP1-catalyzed hydrolysis.
6dd1  1.70  2019  Ki=22.3uM     // 6d15.pdf (M3Q) compound 14, Ki=22.3+/-1.3uM
6o5x  1.70  2019  Ki=22nM       // 6o48.pdf (0Q4) ligand is CA-p2; Ki = 22+/-3.4nM
6mll  1.86  2019  Ki=239uM      // 6efj.pdf (N1G) Ki(compound 7)=239+/-23uM,   -Lactamase Inhibition Assay
5yy6  2.40  2019  Ki=24.16nM    // 5xgk.pdf (94L) compound is Y13161, Ki=24.16+/-1.01nM
6qs1  1.80  2019  Ki=2430nM     // 6qs1.pdf (11-mer) ligand is peptide BPPb;
6a8g  2.53  2019  Ki=246nM      // 6a8g.pdf (11-mer) Ki(muPA-SPD, IG-1)=246+/-46nM
6g02  1.84  2019  Ki=24nM       // 6g01.pdf (EF8) [Nonstandard assay: PH=6.15] Ki(kinetic assay)=24+/-5nM
6gvx  2.24  2019  Ki=24nM       // 6gvx.pdf (TAK) ligand is dorsomorphin
6ugo  1.46  2019  Ki=25.8nM     // 6ugn.pdf (Q77) ligand is compound 2d
6mia  1.40  2019  Ki=2540uM     // 6efj.pdf (1CE) [Different ligand in assay: ligand structure is different from that reported in the literature] Ki(compound 6)=2540+/-410uM,   -Lactamase Inhibition Assay
6hax  2.35  2019  Ki=26nM       // 6hax.pdf (FWZ) ligand is PROTAC 2, ternary complex VHL and PROTAC 2 with SMARCA2
6mxb  2.19  2019  Ki=26uM       // 6mxb.pdf (XMP)
6k05  1.94  2019  Ki=275nM      // 6k04.pdf (CQF) ligand is 40
6ugq  1.31  2019  Ki=28.2nM     // 6ugn.pdf (Q7A) ligand is compound 2i, SB4-206
6p5o  1.49  2019  Ki=28.6uM     // 6p5o.pdf (O2Y) ligand is compound CMP; Ki = 28.6 +/- 8.8 uM
6e5t  1.55  2019  Ki=285nM      // 6e5l.pdf (HVJ) compound abn-CBDO, at 350nm
6gvf  2.50  2019  Ki=28nM       // 6gvf.pdf (FE5) ligand is 1
6jio  2.60  2019  Ki=28uM       // 6jio.pdf (BQ3) ligand is 3
6q8b  2.20  2019  Ki=29.5nM     // 6hb5.pdf (L3U) [Incomplete ligand]
6o9d  2.51  2019  Ki=2nM        // 6o8u.pdf (LTY) ligand is compound 5; Ki = 2+/-0.71nM
6s0e  1.90  2019  Ki=3.17uM     // 6s00.pdf (DAN) ligand is compound DANA. Ki = 3.17 +/- 0.41 uM
6oe1  1.45  2019  Ki=3.1nM      // 6odz.pdf (M8V) ligand is compound 5b; Binding assay is stopped flow CO2 hydrase assay
6h7d  2.40  2019  Ki=3.2uM      // 6h7d.pdf (BGC) [Nonstandard assay: pH = 5.5] ligand is glucose
6dd0  1.50  2019  Ki=3.3uM      // 6d15.pdf (P9T) compound 8, Ki=3.3+/-0.1uM
6o21  1.15  2019  Ki=3.48nM     // 6o21.pdf (14-mer) ligand is cycle peptide SFTI-FCQR(Asn14)[1,14]; Ki = 3.48+/-0.35nM
5qtt  2.23  2019  Ki=3.4nM      // 5qtt.pdf (QEY) compound is 17
6d3q  2.24  2019  Ki=3.4nM      // 6d3q.pdf (4NG) compound is SF2312
6o4w  2.35  2019  Ki=3.4nM      // 6o4w.pdf (E20) [Different protein in assay: assay use mouse AChE, crystal use human AChE] ligand is compound Donepezil;
6gbw  1.45  2019  Ki=3.51nM     // 5jfd.pdf (EU5) compound 6
6nxz  1.75  2019  Ki=3.5uM      // 6nxz.pdf (D49) ligand is compound 3; Ki = 3.5+/-1.7 uM
6ps5  2.90  2019  Ki=3.69nM     // 6prz.pdf (SNP) ligand is propranolol
6tl2  3.80  2019  Ki=3.6uM      // 6tl2.pdf (NJZ) ligand is compound Br-BIT; Ki = 3.6 +/- 0.7 uM
6n96  1.70  2019  Ki=3.8uM      // 6n96.pdf (LCV) ligand is 5
6otg  1.50  2019  Ki=31.4nM     // 6otg.pdf (4UY) ligand is compound 1; Ki = 31.4 +/- 3.9nM
6rfw  2.18  2019  Ki=316nM      // 6gxq.pdf (K1Q) ligand is 41
6d15  1.30  2019  Ki=32.9uM     // 6d15.pdf (TWB) compound 1, Ki=32.9+/-3.3uM
6d1d  1.40  2019  Ki=33.8uM     // 6d15.pdf (GTV) compound 6, Ki=33.8+/-3.8uM
6dl2  1.47  2019  Ki=33nM       // 6dl2.pdf (GUJ) Ki(FP, 3)=33+/-4nM
6d1g  1.15  2019  Ki=34.2uM     // 6d15.pdf (YKG) compound 9, Ki=34.2+/-8.0uM
6hgr  1.52  2019  Ki=350uM      // 6hgq.pdf (IMP) ligand is IMP
6gxb  1.35  2019  Ki=35nM       // 6gxb.pdf (FF5) ligand is compound 1
6o0o  2.00  2019  Ki=36nM       // 6o0k.pdf (F3Q) ligand is S55746; Ki = 36 +/- 12 nM
6ppy  2.00  2019  Ki=36uM       // 6ppw.pdf (OVY) ligand is compound NeuNAC oxime; Ki = 36 +/- 12 uM
6jax  1.70  2019  Ki=38.43uM    // 6jav.pdf (8-mer) ligand is (GlcN)8
6m7i  1.70  2019  Ki=386uM      // 6efj.pdf (J84) Ki(compound 3)=386+/-33uM,   -Lactamase Inhibition Assay
6g01  1.61  2019  Ki=39nM       // 6g01.pdf (EEW) [Nonstandard assay: PH=6.15] Ki(kinetic assay)=39+/-1nM
6dzy  4.10  2019  Ki=3uM        // 6d9g.pdf (HJM) [Nonstandard assay: in presence of 15B8 Fab and 8B6 ScFv] compound is ibogaine
6q30  1.50  2019  Ki=3uM        // 6ibs.pdf (HCH) [Uncommon element] [Incomplete ligand] ligand is 5
6ny0  1.40  2019  Ki=4.0uM      // 6nxz.pdf (LBA) ligand is compound 1; Ki = 3.5+/-1.7 uM
5qtu  2.53  2019  Ki=4.1nM      // 5qtt.pdf (QEV) compound is 17
6byz  2.96  2019  Ki=4.3nM      // 6byz.pdf (J18) compound 37
6n7a  1.33  2019  Ki=4.3nM      // 6n7a.pdf (KEV) ligand is 39
5ywg  2.60  2019  Ki=4.56nM     // 5ywg.pdf (92L) inhibition kinetic assay, Ki=4.56+/-0.82nM
6of5  2.30  2019  Ki=4.5uM      // 6of5.pdf (MFJ) ligand is compound 1; Ki = 4.5 +/- 1.9 uM
6pno  1.82  2019  Ki=4.8uM      // 6pnm.pdf (ORM) ligand is compound 3f
6a94  2.90  2019  Ki=40nM       // 6a93.pdf (ZOT) compound is zotepine
6o4x  2.30  2019  Ki=40nM       // 6o4w.pdf (AA) [Different protein in assay: assay use mouse AChE, crystal use human AChE] ligand is compound 9-aminoacridine
6md8  1.40  2019  Ki=4200uM     // 6efj.pdf (J84) Ki(compound 3)=4200+/-300uM,   -Lactamase Inhibition Assay
6mnv  1.65  2019  Ki=428uM      // 6mlf.pdf (JVS) ligand is 3
6gwe  2.30  2019  Ki=42nM       // 6gwe.pdf (FE8) ligand is P2
6hb6  1.92  2019  Ki=43.4nM     // 6hb5.pdf (YSU) [Incomplete ligand]
6rvk  1.58  2019  Ki=439nM      // 6rvf.pdf (R29) [Uncommon element] [Incomplete ligand] ligand is compound 2b; ligand is hydroxylation
6nwl  1.60  2019  Ki=43nM       // 6nwk.pdf (HCY) ligand is HCY
6pve  2.30  2019  Ki=43nM       // 6pve.pdf (OZP) ligand is compound 1a, inhibitor LL319; Ki = 43 +/- 5.0 nM
6d1a  1.25  2019  Ki=44.3uM     // 6d15.pdf (TWB) compound 1, Ki=44.3+/-7.3uM
6r1a  1.54  2019  Ki=45uM       // 6r0q.pdf (JP8) ligand is compound 20b; Ki = 45 +/- 15.7 uM
6s5k  1.60  2019  Ki=47.9nM     // 6s4n.pdf (KWE) ligand is AZ8; pKi=7.32
6efj  1.65  2019  Ki=477uM      // 6efj.pdf (O5E) Ki(compound 9)=477+/-40uM,   -Lactamase Inhibition Assay
6mey  1.42  2019  Ki=479uM      // 6efj.pdf (O5E) Ki(compound 9)=479+/-41uM,   -Lactamase Inhibition Assay
6rot  1.34  2019  Ki=483.63nM   // 5jfd.pdf (KDQ) compound 4
6c9s  2.23  2019  Ki=48nM       // 6c67.pdf (ERP) enzymic inhibition assay, compound 17, Ki=48+/-0.6nM
6r1d  1.10  2019  Ki=4uM        // 6r0q.pdf (JP5) ligand is compound 7d; Ki = 4 +/- 0.4 uM
6r1w  1.35  2019  Ki=5.0uM      // 6r0q.pdf (JPW) ligand is compound 16b; Ki = 5.0 +/- 0.5 uM
6o95  1.77  2019  Ki=5.1nM      // 6o8u.pdf (LSV) ligand is compound 41; Ki = 5.1+/-1.2nM
5qqp  2.08  2019  Ki=5.3nM      // 5qqo.pdf (NR7) compound 13
6o8u  1.80  2019  Ki=5.3nM      // 6o8u.pdf (LS7) ligand is compound 23; Ki = 5.3+/-2.1nM
6q2y  1.00  2019  Ki=5.5uM      // 6ibs.pdf (HCQ) [Uncommon element] [Incomplete ligand] ligand is 3
6mxd  2.96  2019  Ki=5.83uM     // 6mxb.pdf (IMP)
6ibv  1.40  2019  Ki=5.9uM      // 6ibs.pdf (H9E) [Uncommon element] [Incomplete ligand] ligand is 1
6ibk  1.99  2019  Ki=509uM      // 6ibk.pdf (YTW) ligand is 4
6o57  1.71  2019  Ki=514nM      // 6o48.pdf (2NC) ligand is compound p2-NC; crystal in space group P41; redundant to 6o5a
6o5a  1.67  2019  Ki=514nM      // 6o48.pdf (2NC) ligand is compound p2-NC; crystal in space group P61
6qwi  2.85  2019  Ki=51uM       // 6qwi.pdf (JJW) ligand is compound 4
6ugr  1.31  2019  Ki=533.6nM    // 6ugn.pdf (Q71) ligand is compound 2h, SB4-208
6mlf  1.75  2019  Ki=53uM       // 6mlf.pdf (JV4) ligand is 9
6d1j  1.15  2019  Ki=56.2uM     // 6d15.pdf (7SX) compound 13, Ki=56.2+/-4.3uM
6mdu  1.15  2019  Ki=56uM       // 6efj.pdf (N1G) Ki(compound 7)=56+/-8uM,   -Lactamase Inhibition Assay
6h13  2.80  2019  Ki=58.6nM     // 6h13.pdf (FJN) [Different protein in assay: The source of protein in binding assay is human] [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is compound 3
6s9w  2.30  2019  Ki=59nM       // 6s9w.pdf (L1Z) [Covalent complex] ligand is compound 16a; Ki = 59 +/- 4 nM
6pvu  1.49  2019  Ki=6.2uM      // 6pvu.pdf (P0S) ligand is compound cP6i; Ki = 6.2 +/- 0.1 uM
6pnm  1.82  2019  Ki=6.7uM      // 6pnm.pdf (XX0) ligand is compound 3d
6jn3  2.22  2019  Ki=6.85uM     // 6j8q.pdf (BX6) [Incomplete ligand] ligand is MS05
6hhi  2.70  2019  Ki=6.8nM      // 6hhi.pdf (G4N) [Covalent complex] [Incomplete ligand] ligand is 3b
6pvs  2.58  2019  Ki=6.8nM      // 6pve.pdf (P0V) ligand is compound 2a, inhibitor LL320; Ki = 6.8 +/- 2.3 nM
6a93  3.00  2019  Ki=6.9nM      // 6a93.pdf (8NU) compound is risperidone
6om8  2.45  2019  Ki=6.9uM      // 6om8.pdf (UDX) ligand is compound UDP-xyl; Ki = 6.9 +/- 0.6 uM
6pnn  2.10  2019  Ki=6.9uM      // 6pnm.pdf (OR7) ligand is compound 3b; IC50 = 0.16 +/- 0.02 uM
6gg3  3.72  2019  Ki=62uM       // 6gg3.pdf (ALA)
6e5l  1.17  2019  Ki=66.7nM     // 6e5l.pdf (HVD) compound abn-CBD, at 350nm
6hhh  2.70  2019  Ki=67.1nM     // 6hhh.pdf (G4Q) [Incomplete ligand] ligand is 30
6ugp  1.31  2019  Ki=685.5nM    // 6ugn.pdf (Q7A) ligand is compound 2i, SB4-206
6jn5  1.97  2019  Ki=7.08uM     // 6j8q.pdf (BXU) [Incomplete ligand] ligand is MS23
6o0h  3.67  2019  Ki=7.0nM      // 6o0h.pdf (LBG) ligand is compound NDI-091143; Ki = 7.0+/-0.8nM
6abx  1.70  2019  Ki=7.19mM     // 6abx.pdf (FLC) citrate
6n97  1.75  2019  Ki=7.1uM      // 6n97.pdf (KGP) [Different ligand in assay: Ligand in binding assay is racemic mixture] ligand is 6
6n95  1.80  2019  Ki=7.5uM      // 6n95.pdf (YXS) ligand is 4
6cjp  2.60  2019  Ki=7.7nM      // 6cjj.pdf (F5S) CMLD013075
6pm9  2.86  2019  Ki=7.9nM      // 6pm9.pdf (OQ1) ligand is compound 42, MK-8719
6h3q  1.31  2019  Ki=73.2nM     // 6h3q.pdf (FMH) ligand is 7c
6rvf  2.07  2019  Ki=730nM      // 6rvf.pdf (KKH) [Uncommon element] [Incomplete ligand] ligand is compound 2a; ligand is hydroxylation in PDB
6d1k  1.20  2019  Ki=741.3uM    // 6d15.pdf (M3Q) compound 14, Ki=741.3+/-53.1uM
6qxs  2.88  2019  Ki=74nM       // 6qxg.pdf (UFP) ligand is compound FdUMP
6o48  1.46  2019  Ki=75nM       // 6o48.pdf (0Q4) ligand is CA-p2
6ugn  1.41  2019  Ki=763.5nM    // 6ugn.pdf (Q77) ligand is compound 2d, SB4-205
6do1  2.90  2019  Ki=8.32nM     // 6do1.pdf (8-mer) logKi(S1l8)=-8.08
6jtc  2.39  2019  Ki=8.45uM     // 6jtb.pdf (C8O)
6d16  1.40  2019  Ki=8.4uM      // 6d15.pdf (FUJ) compound 2, Ki=8.4+/-0.4uM
6r4k  2.13  2019  Ki=8.5uM      // 6qwi.pdf (JSK) ligand is compound 10
6d1i  1.10  2019  Ki=81uM       // 6d15.pdf (T6Z) compound 12, Ki=81+/-12.8uM
6uh0  1.31  2019  Ki=853.1nM    // 6ugn.pdf (PX7) ligand is compound 2o, SB4-202
6r1k  1.94  2019  Ki=9.0uM      // 6r0q.pdf (JPB) ligand is compound 7c; Ki=9.0+/-1.5uM
6k04  1.25  2019  Ki=9.1nM      // 6k04.pdf (CQF) ligand is 40
6q8a  2.11  2019  Ki=9.8nM      // 6hb5.pdf (HQ5) [Incomplete ligand]
6ic2  1.15  2019  Ki=917.4nM    // 6ic2.pdf (BBJ) ligand is EPA
6gvh  2.74  2019  Ki=920nM      // 6gvf.pdf (FDH) ligand is 3e
6gvg  3.00  2019  Ki=990nM      // 6gvf.pdf (FCZ) ligand is 3a
6gxe  1.30  2019  Ki=9nM        // 6gxe.pdf (FFH) ligand is compound 2
6r0u  1.70  2019  Ki>40uM       // 6r0q.pdf (JO5) ligand is compound 5a
6r0s  1.55  2019  Ki>40uM       // 6r0q.pdf (JOH) ligand is compound 4a
6r12  1.74  2019  Ki>40uM       // 6r0q.pdf (JOT) ligand is compound 7b
6r1x  1.80  2019  Ki>40uM       // 6r0q.pdf (JPQ) ligand is compound 7a
